<SEC-DOCUMENT>0000950170-25-026076.txt : 20250225
<SEC-HEADER>0000950170-25-026076.hdr.sgml : 20250225
<ACCEPTANCE-DATETIME>20250225073030
ACCESSION NUMBER:		0000950170-25-026076
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250225
DATE AS OF CHANGE:		20250225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beam Therapeutics Inc.
		CENTRAL INDEX KEY:			0001745999
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39208
		FILM NUMBER:		25659408

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-327-8775

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>beam-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-25T06:34:58.4575+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:beam="http://beamtx.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4b150673-d530-4e27-b32e-c308166d6f5f" name="dei:EntityCentralIndexKey" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf">0001745999</ix:nonNumeric><ix:nonNumeric id="F_44bbdf39-75b0-4e2d-91b6-bc6f8fafd314" name="dei:AmendmentFlag" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_ec6c3e71-0f51-488b-b6fd-efcdd79ede09" name="dei:DocumentFiscalPeriodFocus" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf">FY</ix:nonNumeric><ix:nonNumeric id="F_662b40b3-87ec-4a96-b46f-86be6e3fcabb" name="ecd:TrdArrDuration" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" format="ixt-sec:durday">419</ix:nonNumeric><ix:nonFraction id="F_e956a4ad-eb1c-418b-a3ab-90753a35728e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_551a0859-97e0-4c44-b2cf-761c527698d6" name="us-gaap:CommitmentsAndContingencies" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_42995f5e-5cf3-4580-bb7b-2701972eab60" name="us-gaap:PreferredStockValue" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7662523a-3bfe-403c-87db-b8b2c549a337" name="us-gaap:PreferredStockValue" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0794c34f-35e0-41b4-bece-9a3a0619ac97" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_28208d39-9753-4125-b201-de2b195f562d" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_4ef95e1d-df40-47c3-9777-21876464c49e" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_b9f60852-435f-4678-a85f-62bd679a4179">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_f812e6fe-6a44-4c16-bfa9-574585f77a74" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550">http://fasb.org/us-gaap/2024#OperatingExpenses</ix:nonNumeric><ix:nonNumeric id="F_f65e9bb1-b2e1-469e-be73-4e76142cee9f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_b17f1931-4673-4c3e-986b-af325cf85498">P2Y</ix:nonNumeric><ix:nonFraction id="F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_892f3c97-c2f0-430b-9466-4813ae1bf322" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3745d23f-5fb4-4f44-b19b-06bb7321b4f1" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf">http://beamtx.com/20241231#JohnEvansChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_c09ed080-95c6-42cb-9d05-3689f0ee40cc" name="us-gaap:NumberOfOperatingSegments" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonFraction id="F_db2bac11-48f9-4a6a-b941-8a8d70caf457" name="us-gaap:NumberOfReportableSegments" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="beam-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_800475ef-859c-4969-8401-92e0526a5add"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80db0869-90aa-4f87-a32a-529c3993d14c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81012567-268b-4289-94b6-e8719b8246c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_813182af-346c-4681-a9ad-91dbab4005fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_814c73a2-13c5-4097-a2c8-bac30dd2d509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_817c79ea-b465-4bb1-8354-36977c68b051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81c512a2-b46f-4d8c-9387-3f1e58834fa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82c07a0b-8c7a-44a6-b246-a5568dfbfc60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82d42227-3e5c-4f52-9372-708bac5614fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82e2a9c0-7247-45b0-b901-8dec8be826ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8344d4f6-8b07-419a-b031-0646b3b208b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_836d03ea-dc4b-4efb-b811-4ce1b53f71f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_846e5021-b00e-430e-b479-dfc4350907cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85f101d5-687c-4b48-a5aa-3771ed3f1761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87adf2d6-df78-4402-8dd8-a6be3d79324e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87b2a2c4-113b-4df3-b4a2-5e89a5c1ea98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_886c80e8-4054-44c9-a88c-53a8d43b6e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a19511f-2844-4f6d-b5ed-8ff465336cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b3ff14f-8fb9-421a-a317-71af6ec52baa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">beam:CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f22ed6f-66b3-48a8-b7b5-ae4b554749dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f838b8f-003d-4c56-9981-96bf4aa3558f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fffa0c5-ef26-4f15-a702-c749a8609fd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9064c4c3-29b7-480d-8518-b5181173d660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91314f01-9991-4b7a-bf23-848ddb837575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93ba963b-981f-49c9-a3d3-fb183f09f550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93edf44d-3df4-4991-a2e7-7db1fdea70fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_943bbfdd-15ab-44cf-894a-0a745768d5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_946d0d92-ab51-4d13-aa91-deb5bafa88d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_946fe569-b5da-4993-a5e7-d60b0d8a7441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95f6702d-f704-4654-9cb9-17cb2a30898f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">beam:UponParticipationElectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beam:AssignedToCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_968b0854-5a99-4bae-a667-e1e1a12f2c18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96d19294-dd72-40a8-a259-c7e1d6e2f357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_979dd123-9531-40b9-b541-eec96ea77e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97a94644-ff61-46cd-95e9-1614d5a9b854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98297106-5ba9-49e4-9046-f4505117edac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_987488ec-2b63-4e33-9f1f-663eb101d201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98e22f9d-79ae-43bd-8044-17f44f41029a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98e29b92-f652-4c61-b122-e4d83608d91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9943b4f2-89ba-4814-ad32-f267e31916f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99cb6cd9-808d-43eb-9961-10066106286f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a16ff51-e500-41df-8c2c-d24921af54f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b047b26-6d29-4529-a19f-49dec29b0738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b3ddcbc-bcaa-4620-bd37-18182d7ee2a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bd424a3-b990-4948-a990-a2d46eaf923c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:ProductDevelopmentAndRegulatoryApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c33e7b3-8a93-4aa9-a157-7bb70a697ac5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d139695-ac25-4472-b259-92e6538cbf05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e0b9b06-588c-4f43-8b01-cd02f7537d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:SuccessPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e71c9b4-c135-4fae-b90c-ed325df0b8f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e824cf6-96ad-482c-938b-89bcefc2519a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eb93719-d476-49d6-a58e-2223125d2c02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f2e893f-35a5-44f6-bf6e-ed53809acd18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1582983-8e90-4aba-91dc-4e54d1f21245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2d5f9fc-a682-42df-9b5c-99526ad1bc2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3572b5b-a007-4ae4-b166-33e00788180a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a46bf662-b041-4823-abd8-67f3900593df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4d1b346-89bb-46d5-943f-3575e89e7f76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a65535bf-d336-4fc3-a256-1c5e23cda5be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6a0e0af-be42-49df-9199-a22238777a85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a88c5e15-481f-445a-947c-2cb1d21faaee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9e94ca6-e934-4ab8-aeb5-8d4b40f267a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa7b8d00-54cd-467a-afdf-694a607825bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab0bc947-ab71-4f35-bc58-9f7f62090216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab2d17df-4178-483f-b1be-0b511648abbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab6a3226-270a-448c-aa4a-011574bd549f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad3ad482-636a-4574-9008-c4bfd3d86594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad5b92a4-0e86-485f-829d-78650bd85771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae43c909-7d70-442f-bc98-6a2f16383942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af7898ba-b7e3-42e1-92b5-062444fe5f45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b047b3c6-6f6d-40d7-952c-100389cfdae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0b3e437-b9b5-409d-a425-2ab1467d81a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b17f1931-4673-4c3e-986b-af325cf85498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1a1acf3-c64f-4967-b7e4-958c7a788e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b377391a-9d98-4bd0-8cd9-4b1adecb8106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3cae63a-1abc-4394-a9ad-0e685d5f41a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b519bc91-9533-4dcb-a39c-d95a0025a438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b772f99d-0bbb-4fb9-9d12-6cd094a0084e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b83b237b-6d18-4327-8bbc-c9cdb6104ded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b942b8ee-cafd-4a43-b778-957590c7d5a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9f60852-435f-4678-a85f-62bd679a4179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba54c365-7b5b-490a-a13d-b7f791f97e43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc22551d-700b-4bc6-97af-b994c3ba0a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc54d5fa-e469-4984-8576-7bcd6d681ec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcb6c93c-f14e-4acc-a009-3920a219ed08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bef248b2-037e-41dd-b7a6-9d8e777e673c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf27e455-b39d-4609-980a-18b8f5630e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfa4765e-7ba8-440e-948f-ab1010661413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0afc77b-a8b0-40be-ba4a-78a824b97e4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2169fb1-18be-4514-9888-865d6522b536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2e860ef-951c-4824-addf-069a1f368442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c448f064-efee-4973-8a00-ca00db426a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4d3bfe7-33e4-4541-9d0a-0c3653425814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6a74e2e-8d45-4ca0-9483-c5961f7d2166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6e8ae6e-253b-496d-b53a-66bdfb253362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8171dae-98d5-431f-8a83-4520d464b7e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca386094-8a4e-4c31-bbb9-c0a598866d8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cad5e1f8-39af-4380-a00d-766ccfd05763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc9a65a2-a296-4a7c-ad5a-f2a43865bbed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccd6d443-83ef-4b86-af01-1073799931eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce201eb2-a040-4b8c-828b-f421220ff5bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ceb22f03-41f2-470f-b6af-1fe085c96885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf066df4-fc9e-41d6-925d-5f1920357b78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf2ed59c-a2d6-4c18-ba5c-2809399c54d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf6c0d45-c719-46d3-96bf-bf86ff65ea9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf84f853-64e7-4f6f-a1df-e90a15485b3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfa419f9-1c34-4353-b182-40b224d5ecee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfbe57c7-0589-40d9-95a3-4e571ea9c241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2b86f6d-7df8-4851-bf8a-c817cab8b129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2eb4314-6249-4e88-ab61-d2f3989cba46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d318bed9-9799-44fd-bb35-943b44e05e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4874037-4abb-4593-9198-ea79ea979323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d499c8ac-d8df-400b-8755-7d20c1c148c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5f96b32-a698-4369-8181-0a106fbfb45a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d654daf4-dddc-4c8c-bf67-b1fb10abf6ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d81129aa-e4b3-4b3a-b639-c6b46fd97eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d996319a-4fd9-4406-ad76-885120f0800c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d99e5c1a-0015-40a1-bf03-09c293ead256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9c08767-4f6e-47cc-be86-e673973ca8ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db09f235-a08f-4af4-a99c-599807b457f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:OtherPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db910110-c7b9-47bd-9b00-ef30f2e39bbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beam:FormerStockholdersAndOptionholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">beam:GuideTherapeuticsIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc200094-3ff1-4578-a977-4d4a2356f15b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd66f54e-6ff6-4a57-b80d-1a794bfab97f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de039678-b07d-4465-a92c-33cf16c0096f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e09975e5-fe39-42ca-9dd2-53a5844a5478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e09cf5f9-77a3-4eb4-b400-584b976cf70e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0cca600-4621-432f-b776-908bc8bb5ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0ec3d1c-7bc1-435c-aba5-b5b2222df11e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1810127-cbd6-4854-8acf-9b9986eb6b42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1d74f31-840b-44fe-a432-c3e0d8792431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">beam:ResearchPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e23b6999-779a-4b5c-abb4-d337cb7a4896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2c7432a-a6e2-4466-b4d0-b448e1cd2b34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2d79338-1ac4-4b79-83d8-f195b051536a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2e2c4ed-f4d9-44d7-bdf2-3812900f3384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e38cf897-c702-4909-b484-fcd5d6b3590c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e53934-eb8b-4bda-9434-0a170bb66af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e41e2e9a-3d40-4c73-9a6a-0d57206be6a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5221100-f194-45c9-83f5-e78d6eb47872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e52f1520-daf9-498e-8105-a8484d3187d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5a0c25d-1ed8-41b2-b186-af6d43e40731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e64b5f77-b749-4105-a5c5-6201bccd7330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e708f03e-b5c8-4b4c-851b-c790a40ee844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e772a7bb-81e7-41e0-b75e-c792428e3114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e772ddd5-a271-42f1-b38d-0e1d6248021c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e78edfaa-86d2-4b56-8b7f-1698cc8559cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e86d3ec5-e144-44e9-8637-dc263422e9d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8a4929a-82aa-4502-9781-741961c7ae2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8dda33f-8c82-42ac-b988-c7074b08349c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9cd4ea8-3457-4c9a-9f89-0bc504f1aa04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea4d3092-a838-4e9e-9f43-dfd61bbd3ac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaa2ddbc-9a2b-4667-a992-ede8aed104d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb90fc29-55a2-424a-aaa9-70b942a8d848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebd07b65-49d7-49db-9728-c7dfc9f5943d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eda2e163-7061-4ef9-bdb3-990396f121b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ede17f6b-07f6-4cb0-8a64-18644baafbc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandSeventeenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee6bd22e-01c2-4e00-93f7-c74415f012a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee6f8e30-6665-4a51-9ae1-dad612ace074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee767960-3dae-4bd8-8d2c-8f119f919035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eecadce7-cffa-42a7-a808-35c5ac47a667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef0903ad-79ab-4cc9-8a92-a1067bb62252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef90c8a2-4431-4529-a22a-71ad29ed2842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0410223-d81d-47a5-95ac-2348253d72de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f086de51-1e25-47ba-abfb-108a2b30d5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0a9d4a5-df6e-4595-9abe-cec53ac89acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1109e54-6e94-4d48-a4a5-64a3507c850d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f14e16da-1c53-4541-9a52-16820f10bad3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f24310ad-daa3-4d84-88fe-4f5f29e1c62b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2642d59-f792-41fa-8608-056dec1837ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3b3e1c3-33ab-45c8-9774-7e07c887e615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4879e76-4b06-44ba-bf62-86e70abf1d54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4b1ef06-ec54-4fed-af05-d4a7050c16b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f605087d-584c-49ce-a137-7ec63bdd3243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6e9e1b7-0f7e-4ca5-8405-404a9168b722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f70341dc-ca94-4cc2-9501-827588f59d28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f74446ed-1db8-4037-8b3c-5b97e15acbc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f791e745-de9c-42ed-8a7a-14e39c2a105f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7d01556-0db0-4405-b94b-9d3f9b6e51a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8810dbf-4f3c-4f86-9ff9-d0d332a94fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f89f6da8-621e-4376-b358-73a07809ea70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8bffd7e-bec1-4a21-84c9-e2e5a56dbf98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f91cd450-b36e-4a10-b341-9cb4a003d5a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb510e5f-fbb4-4322-a22a-8b7179089277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb6723fb-3691-4707-acfb-4ac88805b04b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc0f5107-4297-4f5b-b705-3f7c3b7a3888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd96341a-93d5-40cd-b881-5aa499e5c784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff00880d-6565-4225-b41c-28e680e96f39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01b2a6c8-36f9-4f72-bd42-832c0a6e6c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0246c702-b123-4f5d-b939-4edd1eea0949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-10</xbrli:startDate><xbrli:endDate>2021-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_033b016b-6895-4539-b361-157a3608f06c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0345315c-39e6-4913-8fb3-95c4a3fb15d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03458b68-88f0-4f4c-835b-84b7c3df3693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_034a8b22-6f57-47e9-bcaf-d420a86c3ac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:ProductDevelopmentAndRegulatoryApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0515efd6-8f8f-400e-9505-a0e0559e9790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_051ea08a-43d3-423d-856c-04c479177819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07957533-1268-4b9e-a1dc-14b0a90775cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_083cb9d5-4b38-4882-b265-50928e148535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a6ecb33-4df6-4c5e-a4a2-fb3d9efdf7cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b1904af-7fc2-4128-b51e-282e6a1495b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b791370-9688-483b-9d3b-52cc2807c2c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bc8b385-01b6-4b97-b455-c669606db4c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c39d71b-489e-44e9-a246-f57bf060b04f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dda2cef-a73d-4c05-8098-6cd82221208a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e6053bb-b35e-475a-bcae-f92658e7661a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e6c1574-d290-4081-9ab2-1ea6ba4e8324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ee731d4-613b-4c17-be22-2735e8f23bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0faad1e3-a733-4640-bd7e-1ccdf04dcbda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1032047d-f16a-438d-95bb-df888c1ca808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10b0f522-be77-400a-bec4-a92278231be3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1320b092-7bb5-4608-a1f8-382e3ea5a98a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13901643-aa76-4301-bdf7-ba774fec2028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13e504bd-d42c-4cb7-9480-fe49e29deb03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_141a0bab-6778-428c-9b18-6212d89a1a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_149701ae-170a-49a0-bd98-e2e011d76e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15adaf12-5523-4f2f-ab23-7a53126734cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17281164-6360-4131-bbca-c983bf53650c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17ab1823-a6d7-4de6-8f1b-d8443d01ce0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18b725ca-8307-4b02-bf86-cd5bacd75fe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1915376c-4402-4696-8764-c838f2eb80a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_199c64fb-9ab2-4c44-aa73-4ccf1cc07ee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19c18905-de30-4069-8f57-7d6b0794deab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a4862fd-f679-425c-8077-3914a663d90a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">beam:CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ab7b8fc-388e-483b-a455-4d344bf26d3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bb5d16d-4da2-4d42-b325-fdfab05f797f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1df55ac6-9859-4cab-9d1d-717a8ccaca01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e89bb30-0a11-458c-b317-6b5ebf170463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">beam:AmySimonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f14ed46-687f-4e31-ac5e-c38d1b43d86f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f91b334-6d1a-442e-9b9d-4fc20bb74482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2003a022-90cd-4bc2-bf5e-3e183c02ed3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a59809-dfb3-4b7d-8868-958dd1e18924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21ed1982-a773-41b3-9848-3a746c980eb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22bf2ac7-5934-477b-9c81-096c75b0a449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_231917f7-78a3-4fef-87ae-dc90b41b4c08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2319aab4-a1e3-430e-8e4d-7cceabb77d5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23ce121e-638f-43db-86dc-7ed74a544114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23df4ae1-062b-4bd7-b3e6-9c50a1bd7d4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23fc252d-db0b-4f39-ab2b-7b17b577a703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_244af9b5-ee40-4af4-8025-4f3676ba9ad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_257027f1-7dcd-416a-869c-74ce3e11938f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25de5467-3e1a-4a4d-82d0-cb68b684e458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26e65229-9380-4e02-a80b-356c8953d6fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">beam:AmySimonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c909485-c763-4bfd-87a0-49786aefa4fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e4a2701-d32c-4f02-930f-f0d27e58173d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f5b4752-7d3c-4f25-abd8-17c95208595a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3019e88f-46c3-46a0-aaa1-f470bb587e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30808f53-fe50-4e76-b73c-7f5690993b05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:EditasLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30db48d9-fd35-4524-9f25-e5f0967f30bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30e95c96-73e5-48eb-9598-acd156ccfd5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beam:FromTwoThousandSeventeenPlanSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3112c485-fa21-4803-9cf3-c428e7cc148a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31375b14-847b-4dfc-8fc0-3d961e512723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_324afbe2-466a-44bf-954d-9a90de220b99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3323b4d1-71fb-4439-a445-cda91d3bdbde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33491d05-f4b0-41eb-b082-0966c1c67aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34071179-b962-4e08-81ba-677a509604da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_349daa7a-ee95-4e81-a366-8d8ce431c2f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3565eb40-7e5d-4491-b679-204f6e71151e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36b8ac53-6fab-4279-8285-1a0366571ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">beam:ExploitationLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_383b09a9-52f2-47a2-9a87-2d0c4207c081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_388bb271-1237-4e73-bb59-50ed985c9182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_389b0c5f-dbe8-49a8-ab15-9087170a4b41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ab34109-c504-4c2d-b824-f10aa01d2eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ac29eac-6794-4f6c-aaeb-4e2937541c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3af7bef2-d1fd-4b29-805f-7afc562dc297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b9e7d95-7542-4a96-be2f-5ddf5efc044b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fe5e002-e81f-4070-850c-d91b8489178b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">beam:NonCashStockBasedCompensationExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40bf49b4-00ca-4786-9c26-7a8dce5bfd9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4199c4a6-3fa7-41c4-9f65-6bba20a54792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4229e173-9015-4f39-94ef-b11fa932f35a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43329f90-70ad-4d83-9eb9-e3326b1f696b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43ad7076-7bc9-411a-b3ab-a6ecbc89e42b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43ded48b-9f05-4004-ac86-baa2f80a25b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4560ba19-2a2b-4005-ab3c-d11d72951668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46319399-2d12-411d-8c34-596d176648f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46b2d578-5aad-4081-994e-51251d5c3c82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4768fad0-596a-43bc-a633-4ba916d5e2bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_480875b2-e64b-432b-b458-b70c8350f511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48270b1e-53eb-4dbc-9160-a5e56e9c41e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48e046f4-2f13-45b1-996e-dc68dffe5446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b443d77-d326-4c74-b2e0-a91039c22fd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c1fa6f3-850d-46e4-b180-0fdb4f170121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4caac963-d273-445d-aea2-8c8e7d840dbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d433f10-5951-4793-a073-4cde03a41826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:OtherPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e0928f3-a41c-46c8-adbf-38ad87f13f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f1eba65-fbc3-49e1-9877-736765296cdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f5d5cc2-830f-4657-be05-fa7964276c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50e72256-3be3-432c-b4b0-8c3fd8054073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51719419-8be3-40d6-b822-aac6d564e3b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_525cf13e-fad6-4e2f-9c9e-48ad51403c66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52f693f7-a425-4188-9db1-a96f66ed8a57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53ff89ee-a53c-493c-897d-5a1e22a591f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55e6ef57-9f81-41ee-995e-bf71d1163777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55ec542c-c4d2-4393-9e6b-a19e465465aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56abebc6-1481-4c6b-a7b2-1ce074ebc051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5770c0c0-0283-4886-822d-4ead5360cae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5857fee8-666a-476e-977c-4c0b45614d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_586c5528-76ab-4467-958c-e7217226efd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a05ec5d-cf56-49cb-b84e-2b325f31bc00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">beam:UponParticipationElectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beam:AssignedToPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bc0c4e6-20ab-442d-9c3e-39c7a8ea82c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bf0ef81-7ab5-4b17-86bb-38c4a75f4dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ca56256-2128-4152-ba15-ce38a36b87a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d64756d-a5a5-4436-8aa5-135287bdbf64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d6e5236-b729-4f30-be75-4efef352181c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f5bdd0f-e177-4378-a5c9-df51ce96de8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5faf1e6f-7db9-44a9-9e75-3c1cdc11b9ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beam:FormerStockholdersAndOptionholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">beam:GuideTherapeuticsIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6026a8e0-6d93-4439-a24e-e03c582cd8c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_610ac957-5c8d-4898-bdab-ead2ab364037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_614fab24-9c40-4e21-a14b-7243d9e14888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_623147d8-2cfc-43d4-ad7a-4b423fda8bc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6268b7c6-50cc-4b67-b26d-5fcdb3082e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-10</xbrli:startDate><xbrli:endDate>2021-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_640fc477-4635-473c-bec3-329a0998059a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:SuccessPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64b520ff-9453-43d5-8018-62b50616536e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66014777-6584-477d-9aa8-ffa7abbe1249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6605f422-e078-49c1-bb32-3b2f67d8c39b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66656a01-1fea-46c0-875c-123162651c9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6694c047-b444-4cf8-931a-d5e47d7fa960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_683f1b33-2bd8-4061-9079-5d7ad5b7fa98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ac8ef0e-3351-4f21-bad5-60d55bade8c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ae048e6-a4cd-4f07-9ad4-aadfd8ecf040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c230fe6-3e37-42ee-94d5-d6260b72323d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e43c27e-aca0-44b5-b3bb-27130f064fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ef5f0dc-2479-4c31-82d9-09b202c6d219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7171d6c3-3dec-4790-a576-1812c763d4fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72946174-54ef-42ee-b20d-174ccb0133a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75673cb0-aa17-46e5-a5b8-9bf245874d0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ac0159f-2dc4-4afb-bc22-e46e6ac8813f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b3060c0-eaf2-45d0-a198-e1f21e52d13b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bde4f21-b869-4f23-b886-c0c6dfff5351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d97cc6a-a7a9-4cdc-bdd8-2d91dd596f4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e7cb18e-69e1-417d-807d-8ec7e9b03e54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e896a77-237e-4692-a24d-3c3b46d3a2db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ed33382-7533-4a0f-94fc-b6c4d06ac455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fbcfe71-e126-4c16-a2f8-6d4074f3e339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:PerProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ff6fe20-72a4-4903-950c-bd6bf0d3b3c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ff8794b-8499-4caa-8e54-fbac240792c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ffb90b6-e3c3-4094-a911-c196df383847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001745999</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Option"><xbrli:measure>beam:Option</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Positions"><xbrli:measure>beam:Positions</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>beam:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Founder"><xbrli:measure>beam:Founder</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bf1014e-0ccd-404d-af29-1b34384a4999" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_dc0c8dc2-d2f4-4592-a141-e5bc70eda85c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span><ix:nonNumeric id="F_af5f6e3b-5fcc-44c7-8a18-95bc8aa01905" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a331820-0ed8-4009-912b-83e88eed5749" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dcd4091d-2ee6-438f-b93a-6b83815b6882" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentFiscalYearFocus" continuedAt="F_dcd4091d-2ee6-438f-b93a-6b83815b6882_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_dcd4091d-2ee6-438f-b93a-6b83815b6882_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e0c4486f-1a08-43b3-83ba-0a3e0968f615" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                 TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                  </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb595051-7e28-4082-9764-32fd53d11e9d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39208</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2249088-7d96-4298-ab5d-cecdef2c7175" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c1be5f43-9637-416a-888d-c7cdc0913e6e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5c5fb062-c857-472e-a850-274cce8e8f82" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-5238376</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">incorporation or organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Identification No.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_dd1594c9-8705-4036-a9c4-3c1497b7f7d5" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">238 Main Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0c94fcdc-f249-4e26-9196-4d11b4cb24ae" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_1cc19067-329e-4c07-8d08-9d0fde1c4b5d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5dbe5a2d-7142-42bf-be11-1488ca9df89b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02142</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Address of principal executive offices</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Zip Code</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0f13101-8a61-4af1-9689-ebfc71c73264" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4383e8f0-c008-4f3d-9fa1-88081209b664" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">327-8775 </span></ix:nonNumeric></span><span style="font-size:8pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;box-sizing:content-box;"/>
    <td style="width:33.333%;box-sizing:content-box;"/>
    <td style="width:33.333%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f9cd247e-055e-49c5-a1dd-8e4815e51956" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.01 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_58797ef7-100d-4ff6-9256-32dd64af3b99" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">BEAM</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_db5cc30b-8ff7-4d24-91a9-5a11f29f98b0" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c694744-4e82-48ab-ab6f-122ae9594188" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_008ce1bb-5ffe-466b-b8bf-1abf42f52cd4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2961eba2-08be-4739-93c1-14c106786635" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e5475a9-5e97-4b26-a332-40ab8a3b8b3d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.08%;box-sizing:content-box;"/>
    <td style="width:55.02%;box-sizing:content-box;"/>
    <td style="width:23.9%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_197e4bc3-dbce-41e2-b3b7-56c3534f5392" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d6dc1941-ff23-4c05-9275-df4e2787bcab" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7d8f11b2-2d21-41b6-8aa1-8404c856f977" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c0733452-49a2-4c17-b1e6-7999f409b7b3" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#8195; </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9f4f43ad-3593-41bf-bcdb-b0669a3fe98d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b).&#8195; </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a5ce4298-aef2-4dcc-baa2-c685638e0348" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant was </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_880c4ec0-a841-4ab9-a922-c44b20b165ad" contextRef="C_5f5bdd0f-e177-4378-a5c9-df51ce96de8d" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-7" format="ixt:num-dot-decimal">1.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> based on the closing price of the registrant&#8217;s common stock on Nasdaq on June 28, 2024, the last business day of the registrant&#8217;s most recently completed second quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of registrant&#8217;s common stock outstan</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ding as of February 18, 2025 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f10a84d-89a4-4dc2-a854-195b1eff52a7" contextRef="C_9f2e893f-35a5-44f6-bf6e-ed53809acd18" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,688,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_4b953154-a017-4a67-bc4f-cead06c830cd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant incorporates by reference into Part III (Items 10, 11, 12, 13 and 14) of this Annual Report on Form 10-K portions of the Registrant&#8217;s definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:82%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#forward_looking_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#trademarks"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">TRADEMARKS</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#market_and_industry_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">MARKET AND INDUSTRY DATA</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">RISK FACTORS SUMMARY</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="forward_looking_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;suggest,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;estimates,&#8221; &#8220;targets,&#8221; &#8220;projections,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of important risks, uncertainties and assumptions, including those described in &#8220;Risk Factors Summary&#8221; and in &#8220;Risk Factors&#8221; in Part I, Item 1A of this report. Unless legally required, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. These forward-looking statements reflect, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current expectations and anticipated results of operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the initiation, timing, progress and results of our clinical trials, including our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-301 for the treatment of glycogen storage disease type 1a, and our anticipated Phase 1 healthy volunteer clinical trial of BEAM-103;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the initiation, timing, progress and results of our research and development programs and preclinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop and maintain a sustainable portfolio of product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop life-long, curative, precision genetic medicines for patients through base editing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to create a hub for partnering with other companies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans for preclinical studies for product candidates in our pipeline;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to advance any product candidates that we may develop and successfully complete any clinical trials or preclinical studies, including the manufacture of any such product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to pursue a broad suite of clinically validated delivery modalities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to generate additional novel lipid nanoparticles that we believe could accelerate novel nonviral delivery of gene editing or other nucleic acid payloads to tissues beyond the liver and our ability to expand the reach of our programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to our competitors and our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected timing, progress and success of our collaborations with third parties, including any future payments we may receive under our collaboration and license agreements,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and our ability to identify and enter into future license agreements and collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to base editing technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop our delivery modalities and obtain and maintain approval for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully maintain a commercial-scale current Good Manufacturing Practice, or cGMP, manufacturing facility;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the United States and foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific and management personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the strategic and other potential benefits of our acquisition of any additional technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding the period over which we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact on our business of macro-economic conditions, as well as the prevailing level of macro-economic, business, and operational uncertainty, including as a result of geopolitical events or other global or regional events.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we use the terms &#8220;Beam,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Annual Report on Form 10-K, we mean Beam Therapeutics Inc. and its subsidiaries on a consolidated basis, unless the context indicates otherwise.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="trademarks"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRADEMARKS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use BEAM and other marks as trademarks in the United States and/or in other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="market_and_industry_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MARKET AND INDUSTRY DATA</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise indicated, information contained in this Annual Report on Form 10-K concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that the information from these third-party publications, research, surveys and studies included in this Annual Report on Form 10-K is reliable. Management&#8217;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors Summary&#8221; and &#8220;Risk Factors&#8221; in Part I, Item 1A of this report. These and other factors could cause our future performance to differ materially from our assumptions and estimates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="risk_factors_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS SUM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MARY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An investment in our common stock involves risks. You should consider carefully the following risks, which are discussed more fully in &#8220;Risk Factors&#8221; in Part I, Item 1A of this report, and all of the other information contained in this Annual Report on Form 10-K before investing in our common stock. These risks include, but are not limited to, the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts. Our product candidates are still in preclinical development or early clinical development and it will be many years before we or our collaborators commercialize a product candidate, if ever. If we are unable to advance our product candidates to and through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in the enrollment or treatment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If clinical trials of any product candidates we identify and develop fail to demonstrate safety, purity and potency to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the product candidates we may develop or the delivery modalities we rely on cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting clinical trials at sites outside the United States. The U.S. Food and Drug Administration, or the FDA, may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not tested many of our proposed delivery modalities and product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gene editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing, which could materially harm our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing genetic medicines, and in particular any novel genetic medicines we may develop, have changed frequently and may continue to change in the future.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genetic medicines are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop, or otherwise harm our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We contract with third parties for the manufacture and supply of materials for our research programs, preclinical studies and clinical trial and expect to continue to do so for at least a portion of our future research programs, preclinical studies, and clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are developing product candidates in the field of genetics medicines, a field that includes gene therapy and gene editing, in which there is little clinical experience, there is increased risk that the FDA, the European Medicines Agency or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for any product candidates we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, or if we or our licensors are unable to successfully defend our or our licensors&#8217; patents against third-party challenges or enforce our or our licensors&#8217; patents against third parties our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our rights to develop and commercialize technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties have asserted and may in the future assert that we, our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intellectual property landscape around gene editing technology, including base editing and delivery technology, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our activities rely on information technology in our own systems and those of our business partners. These systems are subject to a wide and growing variety of cybersecurity risks that may adversely impact our business activities or our ability to engage in various transactions to support our business activities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical research activities depend on the use and disclosure of personal data related to individuals participating in our clinical trials. The rules addressing this data are changing across the world, and these rules may adversely impact our ability to identify individuals for clinical trials or conduct our trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our owned and in-licensed patents and other intellectual property may be subject to priority disputes or inventorship disputes or we may be subject to claims that we have infringed, misappropriated or otherwise violated the intellectual property of a third party and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">usiness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, with the potential to dramatically increase the impact of gene editing. We are also pursuing a suite of delivery modalities, including both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> approaches, depending on tissue type. The elegance of the base editing approach, combined with a tissue specific delivery modality, provides the basis for a targeted, efficient, precise, and highly versatile gene editing system that is designed to be capable of gene correction, gene silencing, gene activation, gene modification, and/or multiplex editing of several genes simultaneously.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to advance a broad, diversified portfolio of base editing programs against distinct, genetically validated editing targets, as well as an innovative, platform business model that will expand the reach of our programs to more patients. Overall, we are seeking to build the leading integrated platform for precision genetic medicine, which may have broad therapeutic applicability and the potential to transform the field of precision genetic medicines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently prioritizing the lead programs in our hematology and genetic disease portfolios, each of which have the potential to provide differentiated therapies for significant patient populations with high unmet medical need:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-101 is a patient-specific, autologous hematopoietic stem cell, or HSC, investigational therapy designed to offer a potentially best-in-class profile, incorporating base edits that are intended to alleviate the effects of sickle cell disease by increasing fetal hemoglobin, which is expected to increase functional hemoglobin production and, in the case of sickle cell disease, inhibit hemoglobin S polymerization. In December 2024, we announced preliminary positive data from our Phase 1/2 clinical trial of BEAM-101, which we refer to as the BEACON trial. The adult enrollment target for BEACON has been achieved, and the first adolescent patients have cleared screening and enrolled in the trial. We expect to dose 30 patients in the BEACON trial by mid-2025. We also plan to present updated data from the trial in mid-2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-302 is a liver-targeting lipid nanoparticle, or LNP, formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype), which is most commonly responsible for severe alpha-1 antitrypsin deficiency, or AATD. AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease. We are evaluating BEAM-302 in a Phase 1/2 dose-escalation clinical trial and expect to report initial data from multiple cohorts in the trial in the first half of 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also continuing to advance our other hematology and genetic diseases programs:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Engineered Stem Cell Antibody Paired Evasion, or ESCAPE, is a potentially non-genotoxic approach to HSC transplantation, or HSCT, which combines antibody-based conditioning with multiplex gene edited HSCs. In our ESCAPE program, we expect to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody designed to suppress hematopoietic stem and progenitor cells that express CD117, by the end of 2025. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-301 is a liver-targeting LNP formulation of base editing reagents designed to correct the R83C mutation, the most prevalent disease-causing mutation for, and the mutation which results in the most severe form of, glycogen storage disease type 1a, or GSD1a. We are evaluating BEAM-301 in a Phase 1/2 clinical trial, with patient dosing expected to commence in early 2025. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations of nuclease editing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gene editing works by disrupting, inserting, or modifying genes in the natural context of the genome. Most established gene editing methods rely on a class of enzymes, called nucleases, to make a double-stranded break in the DNA at a targeted location. Nuclease editors have several significant limitations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First, there is a lack of predictability in genetic outcomes when altering gene sequences with nucleases. Nuclease editors can be effective if the desired outcome is to knock out or switch off the whole gene, but do not allow for precise control of the specific genetic outcome at the target site and its effects may vary from individual to individual.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second, there are potential toxicities associated with double-stranded breaks, such as activating the cell death response and/or genomic instability. In addition, if the double-stranded break occurs in the wrong place, the break can also lead to unwanted gene disruptions. Multiple edits using double-stranded breaks can compound this issue and lead to large-scale genomic translocations and rearrangements, potentially limiting the applicability of nuclease-based approaches in multiplex editing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third, while gene disruption with nucleases is efficient, making specific sequence changes to correct or modify genes remains largely inefficient. It also requires the simultaneous delivery of an additional DNA template containing the desired, corrected gene sequence, which needs to be positioned at the precise location where the double-stranded break has occurred. The requirement of an additional DNA template significantly increases the complexity of delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, nuclease editing does not allow for the correction of genes in non-dividing cells, further limiting their applications, given that the majority of cells in the adult body are non-dividing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base editors: A potential differentiated class of gene editors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our base editing technology is a differentiated therapeutic approach to gene editing, potentially capable of altering the human genome at the foundational level of genetic information &#8211; a single base &#8211; without making a double-stranded break in the DNA. The elegance and simplicity of this approach can be thought of as a &#8220;pencil,&#8221; where the error is erased and the correct letter is written.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our base editing platform offers meaningful advantages over established approaches in gene editing, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highly precise and predictable gene editing, designed to make only one type of base edit at the desired target location;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highly efficient and therapeutically relevant levels of gene correction, which are generally unachievable by nuclease-based editing methods;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad applicability in a wide range of cell types, including both dividing and non-dividing cells;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct chemical modification of DNA with no requirement for delivery of the corrected DNA sequence;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Avoidance of unwanted DNA modifications associated with double-stranded breaks, including gene disruptions and chromosomal rearrangements, such as translocations or deletions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The potential for permanent editing of genes, creating the opportunity for a life-long therapeutic outcome, including the ability to treat infants or young children since the edit will be passed on by dividing cells as the child grows;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiple applications, including gene correction, gene silencing, gene activation, gene modification and/or multiplex editing of several genes simultaneously</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preservation of natural regulation and a normal number of copies of the gene in the cell by modification of genes in their native genomic setting; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A versatile and modular product engine that can target a different gene sequence with the same base editor and a different guide RNA.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our base editing technology</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary DNA base editors have two principal components that may be fused together or incorporated into one another to form a single protein. The first component is a CRISPR associated protein. These proteins have been adapted and engineered to target specific genomic locations in human cells. The targeting ability of the CRISPR protein has been preserved, but the cutting ability has been modified such that the CRISPR protein does not make a double-stranded break in the DNA. The second component of our base editors is a human deaminase, a class of naturally occurring enzymes. Our Cytosine Base Editors, or CBEs, and our Adenine Base Editors, or ABEs, each use a different, engineered deaminase, which we have designed to act only on single-stranded DNA. The deaminase makes a predictable chemical modification, called deamination, of the amine group on either adenine (A) or cytosine (C) bases.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The deaminase in a CBE will convert an amine group of C, resulting in the formation of uracil (U), which is read by the DNA polymerase as a thymine (T) base. Once this strand has been edited, the intermediate DNA consists of an edited strand, containing a U at the target locus, and an unedited strand with a guanine (G) base. The U:G is a mismatch and in order to preserve the edit, we modify the CRISPR to cleave the unedited single strand of the DNA, referred to as nicking. Nicking is intended to increase the efficiency of editing by inducing the cell to use the newly edited strand, and not the unedited strand, as the template for repair, resulting in a U:A pair with minimal translocations. Upon DNA repair or replication, the U is read as a T, resulting in a T:A pair, thereby completing the permanent conversion of a C:G base pair to a T:A base pair. Analogously, when an ABE is used instead of a CBE, the conversion of an amine group of A results in the formation of inosine, which is read by the DNA polymerase as a G, which subsequently leads to an A-to-G change. As a result, an A:T pair is converted to a G:C pair. Because the DNA is double-stranded, by targeting the non-coding strand, we can also convert a T:A pair to a C:G and a G:C pair to a A:T pair in the coding strand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The modular and individual components of our base editors have the potential to be customized for specific diseases, potentially allowing us to create new programs with significant efficiencies in development. For instance, by changing the guide RNA and/or CRISPR protein, we can retarget base editors to different genomic locations based on their gene sequences. By changing the deaminase, we can retarget which base is edited (e.g., C or A). As a result, we believe our base editing technology is highly versatile, efficient, and scalable for the discovery of new drug candidates in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our base editing platform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the unique advantages of base editing &#8211; single base editing precision, predictable editing outcome, high editing efficiency, and the avoidance of double-stranded breaks &#8211; make it a compelling approach for a wide range of therapeutic applications. This includes gene correction, gene modification, gene silencing and gene activation, as well as multiplex editing of several genes simultaneously.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To complement our next-generation gene editing technologies, we are also making significant investments in a suite of delivery technologies designed to deliver gene editing or other nucleic acid payloads to the right cells and enable potentially curative therapy. These delivery technologies include </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modalities, such as electroporation, as well as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modalities, such as LNPs. In our pipeline, we have initially focused on applications of these technologies where their delivery capabilities have already been clinically-validated by third parties, such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> editing of blood stem cells and LNP delivery to the liver. Longer term, we are also investing in more innovative delivery options, including through our collaboration with Orbital Therapeutics, Inc., or Orbital, which is focused on next-generation mRNA and non-viral delivery technology. We have also developed critical enabling capabilities such as mRNA manufacturing and cell processing for autologous and allogeneic cell therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the critical importance of high-quality manufacturing and control of production timing and know-how, we have also established a 100,000 square foot cGMP manufacturing facility in Research Triangle Park, North Carolina. The facility is designed to support manufacturing for our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cell therapy programs in hematology and our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-viral delivery programs for liver and liver-mediated diseases, with the capability to scale-up to support potential commercial supply. For our initial clinical trials, we are relying primarily on our internal manufacturing capabilities, along with CMOs with relevant manufacturing experience in genetic medicines. We believe this investment will maximize the value of our portfolio and capabilities, the probability of technical success of our programs, and the speed at which we can provide potentially life-long cures to patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In summary, we believe that building an integrated platform combining our gene editing capabilities with advanced delivery and manufacturing capabilities will give us the flexibility to develop a sustainable portfolio, featuring rapid development of new programs and lifecycle improvements in our core programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our internal pipeline, the breadth and depth of our integrated technology platform gives us the opportunity to create a hub for partnering with other companies, which is an important part of our business model. We believe this model will help us to unlock the full potential of precision genetic medicine across a wider array of possible applications, including many outside our core areas of focus.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our overall goal with these platform activities is to continue expanding our access to the technologies and teams in genetic medicine that will maximize our long-term value creation and impact on patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our base editing portfolio</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing multiple programs through clinical development in parallel. Our lead programs are focused on sickle cell disease and AATD, and we are also advancing programs in other genetic diseases.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the status of our primary programs:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><img src="img43983261_0.jpg" alt="img43983261_0.jpg" style="width:720px;height:298px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LNP = Lipid Nanoparticle; HSC = Hematopoietic Stem Cell; ESCAPE: Engineered Stem Cell Antibody Paired Evasion; FcRN = neonatal Fc receptor</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pipeline does not include assets designated for partnering</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hematology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing hematology base editing programs in which HSCs are collected from a patient, edited using electroporation, a clinically validated technology for the delivery of therapeutic constructs into harvested cells, and then infused back into the patient following a conditioning regimen, such as treatment with busulfan, the standard of care in HSC transplantation today. Once reinfused, the HSCs begin repopulating a portion of the bone marrow in a process known as engraftment. The engrafted, edited HSCs give rise to progenitor cell types with the corrected gene sequences. We are deploying this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> approach in our BEAM-101 and ESCAPE base editing programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sickle cell disease, a severe inherited blood disease, is caused by a single point mutation, E6V, in the beta globin gene. This mutation causes the mutated form of HbS to aggregate into long, rigid molecules that bend red blood cells into a sickle shape under conditions of low oxygen. Sickled cells obstruct blood vessels and die prematurely, ultimately resulting in anemia, severe pain (crises), infections, stroke, organ failure, and early death. Sickle cell disease is the most common inherited blood disorder in the United States, affecting an estimated 100,000 individuals, of which a significant proportion are of African-American descent (1:365 births). Beta-thalassemia is another inherited blood disorder characterized by severe anemia caused by reduced production of functional hemoglobin due to insufficient expression of the beta globin protein. Transfusion-dependent beta-thalassemia, or TDBT, is the most severe form of this disease, often requiring multiple transfusions per year. Patients with TDBT suffer from failure to thrive, persistent infections, and life-threatening anemia. The incidence of symptomatic beta-thalassemia is estimated to be 1:100,000 worldwide, including 1:10,000 in Europe. In the United States, based on affected birth incidence of 0.7 in 100,000 births, and increasing survival rates, we expect the population of individuals affected by this disease to be more than 1,400 and rising.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are pursuing a long-term, staged development strategy for our base editing approach to treat hematological diseases that consists of advancing our lead </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> program, BEAM-101, in Wave 1, improving patient conditioning regimens in Wave 2, and enabling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editing with delivery directly into HSCs of patients via LNPs in Wave 3. We believe this suite of technologies &#8211; base editing, improved conditioning and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivery for editing HSCs &#8211; can maximize the potential applicability of our sickle cell disease programs to patients as well as create a platform for the treatment of many other severe genetic blood disorders.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 1: Ex vivo base editing via autologous transplant with BEAM-101</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are using base editing to pursue the development of BEAM-101 for the treatment of sickle cell disease. BEAM-101 is a patient-specific, autologous HSC investigational therapy designed to offer a potentially best-in-class profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin, or HPFH. The beneficial effects of the fetal form of hemoglobin, or HbF, to compensate for mutations in adult hemoglobin were first identified in individuals with HPFH. Individuals who carry mutations that would have typically caused them to be beta-thalassemia or sickle cell disease patients, but who also have HPFH, are asymptomatic or experience a much milder form of their disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-101 aims to alleviate the effects of sickle cell disease by increasing HbF, which is expected to increase functional hemoglobin production and, in the case of sickle cell disease, inhibit hemoglobin S polymerization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, which we refer to as our BEACON trial. The BEACON trial includes up to 45 patients ages 18 to 35 with severe sickle cell disease who have received prior treatment with at least one disease-modifying agent with inadequate response or intolerance. Following mobilization, conditioning and treatment with BEAM-101, patients are assessed for safety and tolerability, with safety endpoints including neutrophil and platelet engraftment. Patients are also assessed for efficacy, with efficacy endpoints including the change from baseline in severe vaso-occlusive events, transfusion requirements, HbF levels, and quality of life assessments.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trial&#8217;s Data Monitoring Committee and the U.S. Food &amp; Drug Administration have cleared the trial to enroll adolescents from 12 to 17 years old. The adult enrollment target for BEACON has been achieved, and the first adolescent patients have cleared screening and enrolled in the trial. We expect to dose 30 patients in the BEACON trial by mid-2025. We also plan to present updated data from the trial in mid-2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we presented initial data from the BEACON trial at the 2024 American Society of Hematology Annual Meeting and Exposition, or ASH. The presentation contained preliminary data as of October 28, 2024 from seven patients in the trial, with follow up ranging from one to 11 months. The presentation data included the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patients achieved endogenous HbF levels exceeding 60% and reduction in corresponding sickle hemoglobin S below 40% that was durable through the data cutoff date. A pancellular distribution of HbF was also observed after the elimination of transfused blood. Total hemoglobin levels increased rapidly with resolution of anemia in all patients after elimination of the transfused blood.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patients achieved the minimum target cell dose in either 1 or 2 cycles of mobilization (average: 1.4). The mean time to neutrophil engraftment was 17.1 days (range: 15&#8211;21), with a low mean duration of neutropenia (6.3 days). The mean time to platelet engraftment was 19.1 days (range: 11&#8211;34). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase and reticulocytes, normalized or improved in all patients following BEAM-101 treatment. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial safety profile of BEAM-101 was consistent with busulfan conditioning and autologous HSCT. The most common treatment-emergent adverse events were consistent with busulfan conditioning, including febrile neutropenia, stomatitis and anemia. One patient died four months after BEAM-101 infusion due to respiratory failure that was determined by the investigator to be likely related to busulfan conditioning and deemed unrelated to BEAM-101. No vaso-occlusive crises were reported post-engraftment.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 2: Non-genotoxic conditioning</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In parallel with Wave 1 development, we also aim to improve the transplant conditioning regimen for patients undergoing HSCT, reducing toxicity challenges associated with HSCT standard of care. Conditioning is a critical component necessary to prepare a patient&#8217;s body to receive the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> edited cells that must engraft in the patient&#8217;s bone marrow in order to be effective. However, today&#8217;s conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. As a potential alternative to genotoxic conditioning regimens in HSCT, we are advancing our ESCAPE program. ESCAPE aims to avoid toxicity challenges associated with currently available conditioning regimens for patients with sickle cell disease and beta-thalassemia ahead of autologous HSCT, by combining antibody-based conditioning with multiplex gene edited HSCs. ESCAPE may also have applications in other diseases of the blood and immune system where HSCT could deliver potential benefits but has been limited by toxicities associated with current standard of care conditioning regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have nominated a development candidate for our ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 designed to block binding of BEAM-103, allowing the edited cells to evade suppression by the antibody. We intend to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia, potentially building on the same regulatory, manufacturing, clinical and commercial foundations being established with BEAM-101. We expect to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103 by the end of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 3: In vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">base editing via HSC-targeted LNPs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also exploring the potential for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editing programs for sickle cell disease, in which base editors would be delivered to the patient through an infusion of LNPs targeted to HSCs, eliminating the need for transplantation altogether. This approach could provide a more accessible option for patients, particularly in regions where </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">treatment is challenging. In preclinical studies, we achieved </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">validation of our most potent HSC-directed LNP, demonstrating:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">durable, dose-dependent mRNA transfection in HSCs, resulting in fluorescent reporter expression in more than 40% of cells, maintained out to 16 weeks post-delivery;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efficient transfection of human CD34+ cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efficient transfection of nearly 20% of CD34+ HSCs in humanized mice and NHPs at a dose of 1.0 mg/kg.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genetic diseases</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LNPs are a clinically validated technology for delivery of nucleic acid payloads to the liver. LNPs are multi-component particles that encapsulate the base editor mRNA and one or more guides and protect them from degradation while in an external environment, enabling the transient delivery of the base editor </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Because only one dose of a base editing therapy may be needed in a course of treatment, LNPs are a suitable delivery modality that we believe is unlikely to face the complications seen with chronic use of LNPs, such as those observed when delivering oligonucleotides or mRNA for gene therapy. All of the components of the LNP, as well as the mRNA encoding the base editor, are well-defined and can be manufactured synthetically, providing the opportunity for scalable manufacturing. We are currently using LNPs to advance BEAM-302 and BEAM-301.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BEAM-302: In vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LNP liver-targeting for AATD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-302 is a liver-targeting LNP formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype) predominantly responsible for the severe form of AATD. AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease. The most severe form of AATD arises when a patient has a point mutation in both copies of the SERPINA1 gene at amino acid 342 position (E342K, also known as the PiZ mutation or the &#8220;Z&#8221; allele). This point mutation causes Alpha-1 antitrypsin, or AAT, to misfold, accumulating inside liver cells rather than being secreted, resulting in very low levels (10%-15%) of circulating AAT. In addition to resulting in lower levels, the PiZ AAT protein variant is also less enzymatically effective compared to wildtype AAT protein. As a consequence, the lung is left unprotected from neutrophil elastase, resulting in progressive, destructive changes in the lung, such as emphysema, which can result in the need for lung transplants. The mutant AAT protein also accumulates in the liver, causing liver inflammation and cirrhosis, which can ultimately cause liver failure or cancer requiring patients to undergo a liver transplant. It is estimated that approximately 100,000 individuals in the United States have two copies of the Z allele. There are currently no curative treatments for patients with AATD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 open label, dose escalation clinical trial of BEAM-302 at sites located in the United Kingdom for the treatment of AATD. The trial will evaluate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 initially in patients with AATD-associated lung disease. The study design includes a dose exploration portion followed by a dose expansion portion to identify the optimal dose to take forward in a pivotal study. We continue to progress enrollment and global site activation and expect to report initial clinical data from multiple cohorts in the trial in the first half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BEAM-301: In vivo LNP liver-targeting for GSD1a</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-301 is a liver-targeting LNP formulation of base editing reagents designed to correct the R83C mutation, the most prevalent disease-causing mutation for, and the mutation which results in the most severe form of, GSD1a. GSD1a is an autosomal recessive disorder caused by mutations in the G6PC gene that disrupts a key enzyme, G6Pase, critical for maintaining glucose homeostasis. Inhibition of G6Pase activity results in low fasting blood glucose levels that can result in seizures and be fatal. Patients with this mutation typically require ongoing corn starch administration, without which they may enter into hypoglycemic shock within one to three hours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 clinical trial of BEAM-301 at a select number of sites in the United States. The trial is an open-label, multi-cohort, single-ascending dose evaluation of BEAM-301 for the treatment of GSD1a in patients with the R83C mutation. Key endpoints of the trial include safety and tolerability, time to hypoglycemia during fasting, and changes from baseline in corn starch supplementation. In January 2025, we activated the first clinical trial site for the Phase 1/2 clinical trial of BEAM-301. We are continuing site activation activities and expect dosing to commence in early 2025.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our portfolio of precision gene editing technologies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have licensed a portfolio of three additional complementary gene editing technologies &#8211; prime editing, Cas12b nuclease editing and RNA base editing &#8211; for certain fields. Combined with base editing, we have assembled a broad and versatile portfolio of next generation gene editing technologies for the potential treatment of many severe diseases.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a license to prime editing from Prime Medicine, Inc. Prime editing may be able to achieve the rewriting of short sequences of DNA at a target location. Prime editing utilizes a CRISPR protein to target a mutation site in DNA and to nick a single strand of the target DNA. The guide RNA allows the CRISPR protein to recognize a DNA sequence that is complementary to the guide RNA and also carries a primer for reverse transcription and a replacement template. The reverse transcriptase copies the template sequence in the nicked site, installing the edit. As with base editing, prime editing does not cause double-stranded breaks in the target DNA, resulting in lower insertion and deletion rates than gene editing technologies that rely on double stranded breaks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have the exclusive right to develop prime editing technology for the creation or modification of any single base transition mutations, as well as any edits made for the treatment of sickle cell disease. Transition mutations (i.e., A-to-G, G-to-A, C-to-T, or T-to-C) are the largest single class of disease-associated genetic mutations and include all of our current targets for base editing programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a license agreement with The Broad Institute, Inc., or Broad Institute, that gives us access to the Cas12b nuclease family, which allows us to make &#8220;cut&#8221; edits, which may be appropriate for some applications that require a double stranded break, or to use the general gene targeting ability of Cas12b for other gene editing applications.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Broad Institute license also gives us access to RNA base editing technology, a two-part modular system using an RNA-directed CRISPR protein for targeting RNA strands and a deaminase for editing. This CRISPR protein, known as Cas13, is modified so that it cannot break the RNA strand, and is fused to a deaminase capable of making a single base edit at a specific target location within the RNA strand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collabora</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ti</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ons</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our collection of base editing, gene editing and delivery technologies has significant potential across a broad array of genetic diseases. To fully realize this potential, we have established and plan to continue to seek out innovative collaborations, licenses, and strategic alliances with pioneering companies and with leading academic and research institutions. Additionally, we have and intend to continue to pursue relationships that potentially allow us to accelerate our preclinical research and development efforts. We believe these relationships will allow us to aggressively pursue our vision of maximizing the potential of base editing to provide life-long cures for patients suffering from serious diseases.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into a four-year research collaboration agreement with Pfizer Inc., or Pfizer, focused on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the agreement, we will conduct all research activities through development candidate selection for three pre-specified, undisclosed targets. Pfizer may opt in to exclusive, worldwide licenses to each development candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization, for each such development candidate. We have a right to opt in, at the end of Phase 1/2 clinical trials, upon the payment of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Pfizer would share net profits as well as development and commercialization costs in a 35%/65% ratio (Beam/Pfizer).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Apellis Pharmaceuticals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2021, we entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of our base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, we will conduct preclinical research on six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs and will assume responsibility for subsequent development. We may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Verve Therapeutics and Eli Lilly and Company</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, we entered into a collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, a company focused on gene editing for cardiovascular disease treatments, and in July 2022, we and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, we granted Verve exclusive worldwide licenses under certain of our editing technologies for human therapeutic applications against a total of three liver-mediated, cardiovascular disease targets, including use of our base editing technology for each of these targets and use of certain of our gene editing technology for two of such targets. In exchange, we received shares of Verve common stock. In October 2023, we entered into a transfer and delegation agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights under the Verve Agreement, including our opt-in rights to co-develop and co-commercialize each of Verve&#8217;s base editing programs for cardiovascular disease, which consist of programs targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target. In addition, Lilly acquired the right to receive any future milestone or royalty payments payable to us under the Verve Agreement. Under the terms of the Lilly Agreement, we received a $200.0 million payment and are eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sana Biotechnology</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, we entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, pursuant to which we granted Sana non-exclusive research and development and commercial rights to our CRISPR Cas12b technology to perform nuclease editing for certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> engineered cell therapy programs. Under the terms of the Sana Agreement, licensed products include certain specified allogeneic T cell and stem cell-derived products directed at specified genetic targets, with certain limited rights for Sana to add and substitute such products and targets. The Sana Agreement excludes the grant of any Beam-controlled rights to perform base editing. Sana is conducting a first-in-human trial of SC291, its CD19-targeted allogeneic CAR-T cell therapy, in patients with various B-cell mediated autoimmune diseases. Sana is also conducting a first-in-human trial of SC262, its CD22-directed allogeneic CAR-T cell therapy, in patients with relapsed or refractory B-cell malignancies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orbital Therapeutics</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, we entered into a license and research collaboration agreement, or the Orbital Agreement, with Orbital, pursuant to which each of us granted the other licenses to certain technology controlled during the three years after entry into the Orbital Agreement that are necessary or reasonably useful for the non-viral delivery or the design or manufacture of RNA for the prevention, treatment or diagnosis of human disease. Our license to Orbital is for all fields other than our exclusive field and also excludes the targets and substantially all of the indications that are the subject of our existing programs. Our exclusive field consists of all products and biologics that function in the process of gene editing or conditioning for use in cell transplantation, or that act in combination with any such products or biologics. Orbital&#8217;s license to us is for all fields other than Orbital&#8217;s exclusive field. Orbital&#8217;s exclusive field consists of products and biologics that function as vaccines and also of therapeutic proteins, other than therapeutic proteins (i) that use gene editing, (ii) for use in conditioning, (iii) for use in regenerative medicine, (iv) for use as a CAR immune therapy, including CAR-T, CAR-NK and CAR-macrophage compositions, (v) for use as a T-cell receptor therapy or (vi) that modulate certain immune responses. The licenses are exclusive in each party&#8217;s exclusive field for three years and non-exclusive in those fields thereafter. We and Orbital agreed that for a period of three years after entry into the Orbital Agreement, subject to limited exceptions, we would not research, develop and commercialize, or grant licenses to research, develop and commercialize, products or biologics within the other party&#8217;s exclusive field.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prime Medicine</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2019, we entered into a collaboration and license agreement with Prime Medicine to research and develop a novel gene editing technology developed by one of our founders. Under the terms of the agreement, we granted Prime Medicine a non-exclusive license to certain of its CRISPR technology (including Cas12b), delivery technology and certain other technology controlled by us to develop and commercialize gene editing products for the treatment of human diseases. Prime Medicine granted us an exclusive license to develop and commercialize prime gene editing technology for the creation or modification of any single base transition mutations, as well as any edits made for the treatment of sickle cell disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries, including the genetic medicines field, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property. While we believe that our differentiated technology, scientific expertise, and intellectual property position provide us with competitive advantages, we face potential competition from a variety of companies in these fields. Within these industries, we will compete with existing large pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are several other companies utilizing base editing technology, including PerkinElmer, Life Edit (an ElevateBio company), Metagenomi, Revvity and Intellia Therapeutics. In addition, we face competition from companies utilizing other gene editing modalities and various other genetic medicines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the disease areas that we focus on, we are also aware of competing companies that have approved therapies, those with therapies in development, and others that may emerge in the future. For sickle cell disease, these companies include CRISPR Therapeutics, Vertex Pharmaceuticals, bluebird bio, Novartis Pharmaceuticals, Kamau Therapeutics, Fulcrum Therapeutics, Tessera Therapeutics, Cimeio Therapeutics and Agios Pharmaceuticals. For our AATD targeted therapies, these include Wave Life Sciences, Moderna, Korro Bio, Tessera Therapeutics and Arrowhead Pharmaceuticals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates. This may include other types of therapies, such as small molecule, antibody, and/or protein therapies.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, conducting preclinical studies and clinical trials and seeking approval for products than we do today. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We also compete with these companies in recruiting, hiring and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for clinical trials, obtaining manufacturing slots at CMOs, and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, particularly if they represent cures, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, and availability of reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our platform technology, our programs, and know-how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating any valid and enforceable intellectual property rights of others. We seek to protect our proprietary position by, among other things, exclusively licensing and filing U.S. and certain foreign patent applications related to our platform technology, existing and planned programs, and improvements that are important to the development of our business, where patent protection is available. Notwithstanding these efforts, we cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or patents that may be licensed or granted to us in the future will not be challenged, invalidated, or circumvented or that such patents will be commercially useful in protecting our technology. For more information regarding the risks related to our intellectual property, please see Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;Risks related to our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned and our in-licensed patents and patent applications cover various aspects of our base editing platform and our programs, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C-to-T DNA base editors </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-to-G DNA base editors</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-to-I RNA base editors, or REPAIR </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C-to-U RNA base editors, or RESCUE </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dual editing C-to-T and A-to-G DNA base editors</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRISPR/Cas12b systems for nuclease editing </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novel guide RNA sequences </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems and methods for increasing the specificity of base editing </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiplex base editing in immune cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Methods for evaluating base editing specificity </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therapeutic methods </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery modality </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have an option to license patents and patent applications relating to CRISPR/Cas9 systems. We intend to continue to pursue, when possible, additional patent protection, including composition of matter, method of use, and process claims, directed to each component of our platform technology and the programs in our portfolio. As of December 31, 2024, our wholly-owned patent portfolio consisted of eight issued U.S. patents, and 21 issued patents in jurisdictions outside the United States. We also have approximately 539 pending patent applications, including PCT applications, provisional patent applications and counterparts to the foregoing U.S. and foreign patents. In addition, Beam co-owns one issued U.S. patent and one issued patent in a jurisdiction outside the United States. We also have approximately 26 pending patent applications between the Broad Institute, Inc., UCL Business, Ltd., and Apellis Pharmaceuticals, Inc. The patents and patent applications outside of the United States were filed in numerous jurisdictions, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Korea, Singapore and South Africa. Many of our owned patents and patent applications are related to our DNA base editing technology, including claims to base editor variants with enhanced activities or novel properties, methods of using such base editors, methods of using such base editors for therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">indications, multiplex base editing in immune cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, guide RNAs that target base editors to therapeutically relevant DNA sequences, and methods for evaluating base editing specificity. Certain of our owned patents and patent applications are related to viral and non-viral delivery technologies. If issued as U.S. patents, and if the appropriate maintenance fees are paid, the U.S. patents would be expected to expire between 2039 and 2045, excluding any additional term for patent term adjustments or patent term extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our in-licensed patent portfolio consisted of approximately 64 issued U.S. patents, and approximately 265 issued patents in jurisdictions outside the United States. We also have approximately 350 pending patent applications, including PCT applications, provisional patent applications and counterparts to the foregoing U.S. and foreign patents. The patents and patent applications outside of the United States were filed in numerous jurisdictions, including Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, New Zealand, Russia and Singapore. The patents and applications from our in-licensed portfolio for DNA base editing include claims to novel base editors, claims to engineered deaminase enzymes (e.g., evolved TadA) used in the base editors, compositions including the base editor or engineered deaminase as a component, methods of using such base editors, including methods of using such base editors for therapeutic indications, and guide RNAs that target base editors to therapeutically relevant DNA sequences. The in-licensed patents and applications also cover various aspects related to the platform technology, including base editing systems that employ </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">S. pyogenes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cas9, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">S. aureus </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cas9, Cas9 PAM variants, inactive forms of Cas9, and/or Cas9 nickases, and systems for delivery of base editors. The patents and applications from our in-licensed portfolio for RNA base editing include claims to novel base editors, compositions including the base editor as a component, guide RNAs that target base editors to therapeutically relevant RNA sequences, and methods of using such base editors, including methods of using such base editors for therapeutic indications. The patents and applications from our in-licensed portfolio for Cas12b editing include claims to methods of using Cas12b to modify DNA (e.g., nuclease cleavage of DNA) and engineered and/or non-naturally occurring compositions including Cas12b as a component. The patents and applications from our in-licensed portfolio for delivery technologies include claims to novel lipid-based delivery systems and compositions, viral-based delivery systems and compositions, and methods of using such systems and compositions to deliver base editors. The patents and applications from our in-licensed portfolio for the balance of our platform include claims to compositions and methods for delivery of charged base editor proteins into cells, modification and improvements to the base editing systems including improvements to the nucleotide binding protein component, guide RNA component and base editing enzyme component of the base editing complex, methods for evaluating gene targeting and base editing efficiency and compositions and methods for prime editing. Our current in-licensed patents and patent applications, if the appropriate maintenance fees are paid, are expected to expire between 2034 and 2040, excluding any additional term for patent term adjustments or patent term extensions (or the corresponding foreign equivalent). For information related to our in-licensed intellectual property, see the subsection below titled &#8220;&#8212;Intellectual Property Licenses.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a nonexclusive license to conduct research activities and an option to exclusively license certain patents and patent applications directed to Cas9 and Cas12a from Editas, who in turn has licensed such patents from various academic institutions. In the case of Cas9, a number of the U.S. patents are subject to an interference declared by the Patent and Trademark office, and a number of the European patents are the subject of one or more oppositions. For more information regarding the risks related to our intellectual property, please see Item 1., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Intellectual property&#8212;Intellectual property licenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;Risks related to our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, or PTA, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened (e.g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if a patent is terminally disclaimed over a commonly owned patent having an earlier expiration date). In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent application related to the U.S. patent. Patent term extensions, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, are also possible for patents that cover an FDA-approved drug as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a PTE of up to five years beyond the expiration of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug, a method for using it, or a method of manufacturing it, may be extended. Similar provisions are available in Europe and certain other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if our products receive regulatory approval, we may be eligible to apply for PTEs on patents covering such products, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such PTE should be granted, and if granted, the length of such PTE. For more information regarding the risks related to our intellectual property, please see Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;Risks related to our Intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in this Annual Report on Form 10-K.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely on trade secrets, know-how, continuing technological innovation, and confidential information to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have implemented measures to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. For more information regarding the risks related to our intellectual property, please see Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;Risks related to our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely on trademark protection for our company name and related designs. As of December 31, 2024, our registered trademark portfolio contained approximately 33 registered/allowed trademarks and pending trademark applications in the United States and in certain overseas jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property licenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to a number of license agreements under which we license patents, patent applications, and other intellectual property from third parties. The licensed intellectual property covers, in part, CRISPR-related compositions of matter and their use for base editing. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these types of license agreements in the future. We consider the following license agreements to be material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with The President and Fellows of Harvard College</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2017, we entered into a license agreement with Harvard, as amended, or the Harvard License Agreement, pursuant to which we received an exclusive, worldwide, royalty-bearing, sublicensable license under certain patent rights owned or controlled by Harvard to make, have made, offer for sale, sell, have sold and import licensed products in the field of the prevention or treatment of any and all human diseases and conditions, excluding human germline modification and products for non-human animal and plant applications. We also received a non-exclusive, worldwide, royalty-bearing, sublicensable license to research, have researched, develop and have developed &#8220;enabled&#8221; products related to the Harvard patent rights which are not licensed products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensed patents are directed, among other things, to C-to-T, A-to-G, and C-to-G base editors, for the treatment of certain diseases and conditions and to base editing, more generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Harvard License Agreement, we are required to use commercially reasonable efforts to develop products incorporating the base editing technology covered in the licensed patents, in accordance with a development plan that we prepared and submitted to Harvard. The development plan includes certain development milestones that we are required to meet, as well as the timelines for the completion thereof, and we may update the development plan from time to time as we believe necessary, in our good faith judgment, for us to meet such milestones. If we are successfully able to gain regulatory approval in any country to introduce a licensed product into the commercial market in such country, then we are also required to use commercially reasonable efforts to commercialize such licensed product and make such licensed product reasonably available to the public. If we fail to meet any of the deadlines for the development milestones, then Harvard may, depending on the nature of the failure and the impacted milestones, either terminate the Harvard License Agreement or our licenses with respect to the applicable licensed product(s), subject to certain exceptions and opportunities for us to cure such failure. Additionally, we are required to meet development milestones for the development of a licensed product covered by certain sub-categories of licensed patents. Failure to achieve milestones with respect to such sub-categories gives Harvard the right to grant third parties non-exclusive licenses under such failed sub-categories.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licenses granted to us under the Harvard License Agreement are expressly subject to certain preexisting rights held by Harvard and certain third parties. For example, certain of the licensed patents were developed by employees of the Howard Hughes Medical Institute and were subsequently assigned to Harvard but remain subject to a non-exclusive license between Harvard and Howard Hughes, pursuant to which Howard Hughes received a license from Harvard under certain of the licensed patents for research purposes with the right to sublicense to non-profit and governmental entities. In addition, certain of the licensed patents claim or cover inventions resulting from research that was sponsored by the U.S. government, and the U.S. government retains certain rights with respect to such licensed patents under applicable U.S. law. Harvard additionally retains limited rights for itself and for other non-profit research organizations to practice the licensed patents for research, educational, and scholarly purposes. Furthermore, Harvard retains the right, beginning a certain period of time after regulatory approval of any licensed product in the U.S. or certain European countries, to grant third parties the non-exclusive right to develop, manufacture, have manufactured, import, have imported, offer for sale, sell, have sold or otherwise distribute or have distributed such licensed product or an equivalent thereof solely for sale on a locally-affordable basis in certain specified developing countries in which we do not have plans to seek regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the licenses granted to us under the Harvard License Agreement are exclusive, Harvard may grant a license to a third party under the licensed patents to research, develop, and commercialize a product directed to one or more particular targets, or a proposed product, in the field under limited circumstances. If a third party that is not a specified competitor of ours inquires with Harvard for such a license, and then attempts to enter into a sublicense agreement with us after being referred to us by Harvard and fails to do so after a certain period of time and presents to Harvard a proposal including certain information describing the proposed development and commercialization of such product, then Harvard may notify us of such proposal. If we are not researching, developing or commercializing such a proposed product, then we can notify Harvard as to whether we are interested in developing such proposed product, entering into a sublicense agreement with such third party to develop such proposed product, or entering into a sublicense with another third party to develop the same proposed product. If we inform Harvard that we are interested in developing such proposed product, then we will prepare a development plan, similar in scope to the development plan under the Harvard License Agreement, to develop such proposed product. If we inform Harvard that we are interested in entering into a sublicense agreement pursuant to which a third party would receive a sublicense from us under the licensed patents to develop such proposed product, then we will have a specified period of time to enter into such a sublicense agreement and provide reasonable evidence thereof. If we are not researching, developing, or commercializing such a proposed product, fail to provide a development plan, or fail to enter into a sublicense agreement with respect to such proposed product, in each case, within specified time periods, then Harvard may grant a license to the applicable third party under the licensed patents to research, develop, and commercialize such proposed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are permitted to further sublicense our rights under the Harvard License Agreement to third parties, provided that any such sublicense agreement with a third party must remain in compliance with and be consistent with the terms of the Harvard License Agreement, and certain rights granted to us under the Harvard License Agreement can only be sublicensed to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaboration partners who are working with us to develop one or more licensed products. In addition, any such sublicense agreement must include certain provisions to ensure our ability to comply with the Harvard License Agreement. We are also responsible for any breaches of a sublicense agreement by the applicable sublicensee, if such breach results in a material breach of the Harvard License Agreement, provided that if we cure the breach or diligently enforce our rights to terminate the sublicense, we will not be subject to termination by Harvard for the sublicensee&#8217;s breach, even if it resulted in a material breach of the Harvard Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In exchange for the licenses granted to us under the Harvard License Agreement, we initially issued to Harvard 101,363 shares of our common stock and subsequently issued 765,549 shares of our common stock pursuant to anti-dilution rights in the Harvard License Agreement. We are also required to pay to Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. Harvard is also entitled to receive potential clinical and regulatory milestones in the mid-to-high eight figure range, and to receive success payments based on increases in the fair market value of our common stock. If we undergo a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. We paid Harvard a total of $9.0 million upon the completion of our Series A and Series B financings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $15.0 million. We elected to make the payment in shares of our common stock and issued 174,825 shares of our common stock to settle this liability on June 10, 2021. We may additionally owe Harvard success payments of up to an additional $90.0 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the sale of licensed products by us, our affiliates or our sublicensees, Harvard is entitled to receive low single digit royalties on net sales of licensed products until, on a country-by-country basis, the latest of the expiration of (i) the last to expire valid claim of a licensed patent covering the applicable licensed product, (ii) the period of exclusivity associated with such licensed product in such country or (iii) a certain number of years after the first commercial sale of such licensed product in such country. We are entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country and certain increases in the event we, our affiliates or sublicensees bring patent challenges relating to any licensed patents (subject to an ability to delay and/or avoid such increases by diligently seeking to terminate and/or terminating the sublicense that has taken the applicable action). If we sublicense our rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and we receive non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to an amount in the first decile depending on the date in which such sublicense agreement is executed and the stage of development our licensed products at such time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Harvard is responsible for the prosecution and maintenance of all licensed patents, provided that we have customary consultation, comment, and review rights with respect to such prosecution and maintenance activities. We are responsible for Harvard&#8217;s documented out-of-pocket expenses with respect to such prosecution and maintenance, but if Harvard enters into a license agreement with a third party pursuant to which it grants such third party a license under the licensed patents outside of our field, then Harvard must use reasonable efforts to include a provision in such agreement that provides for an apportionment of prosecution and maintenance costs between us and such third party with respect to such licensed patents. If we choose to no longer pay for the prosecution and maintenance costs of a given licensed patent, then we will be relieved of such payment obligation, but our license with respect to such licensed patent will also terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Harvard License Agreement will remain in effect until the later of the last-to-expire valid claim of the licensed patents or the end of the last to expire royalty term. We may terminate the Harvard License Agreement at our convenience following written notice to Harvard. Either party may terminate the Harvard License Agreement for a material breach of the other party, subject to a notice and cure period. Harvard may also terminate the Harvard License Agreement in the event of our bankruptcy or insolvency or if we fail to procure and maintain insurance. Upon expiration or termination of the Harvard License Agreement, the licenses granted to us will terminate and all rights under the licensed patent rights will revert to Harvard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Editas Medicine, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, we entered into a license agreement, or the Editas License Agreement, with Editas pursuant to which we received an exclusive (even as to Editas), royalty-bearing, sublicensable, worldwide license under certain patent rights owned or controlled by Editas related to certain base editing technologies and CRISPR technology to develop, commercialize, make, have made, use, offer for sale, sell and import certain base editing products for the treatment of human diseases or conditions. The license we received is non-exclusive with respect to certain specified targets. Our licensed field excludes the use of certain gene editing technologies in certain fields of use that have already been licensed to other partners of Editas, provided that our licensed field may expand if the fields licensed to other Editas partners are reduced or are otherwise modified as a result of any termination, expiration, or amendment to Editas&#8217; agreements with such partners. In addition, we received a royalty-free, non-sublicensable, non-exclusive license under a separate set of patent rights owned or controlled by Editas to conduct research activities in our licensed field and for which we have an option to obtain an exclusive license from Editas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the patents licensed to us under the Editas License Agreement were licensed to Editas from Broad Institute and Harvard and certain of the patents for which we have an option to obtain a license were licensed to Editas from the Massachusetts General Hospital, or MGH. Accordingly, the licenses granted to us under the Editas License Agreement are subject to the terms and conditions set forth in each of the license agreements concerning the licensed patents between Broad Institute, Harvard and Editas, or the Broad/Harvard Head Licenses, and each of the license agreements concerning the patents for which we have an option to obtain a license between MGH and Editas, or the MGH Head Licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described above, Editas granted us an exclusive option to obtain an exclusive license under certain patents on a patent family-by-patent family basis. If we so exercise the option with respect to a patent family of such optioned patents, then we would receive an exclusive license to such patent family of the same scope as the other patents exclusively licensed to us under the Editas License Agreement. In order to exercise an option with respect to a patent family of these optioned patents we would pay an eight-figure option exercise fee, depending on the date in which particular option is exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Editas License Agreement, we are required to use commercially reasonable efforts to develop a licensed product in our licensed field in each of the United States, Japan, the United Kingdom, or U.K., Germany, France, Italy and Spain. If we are successfully able to gain regulatory approval in any country for a licensed product, then we are also required to use commercially reasonable efforts to commercialize such licensed product in such country. We also have sole control and responsibility over all regulatory activities with respect to the development of licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are permitted to further sublicense certain of our rights under the Editas License Agreement to third parties, provided that any such sublicense agreement with a third party must remain in compliance with and be consistent with the terms of the Editas License Agreement and the Broad/Harvard Head Licenses and MGH Head Licenses, as applicable. We are also responsible for any breaches of a sublicense agreement by the applicable sublicensee and are responsible for all payments due under the Editas License Agreement by operation of any such sublicense. Following the signing of the Editas License Agreement, we obtained the right to further sublicense our rights the licensed patents from Broad Institute and Harvard to third parties, provided that we comply with certain sublicensing requirements under each of the Broad/Harvard Head Licenses as if we were Editas, as well as certain other customary conditions. We have not obtained any such right from MGH allowing us to further sublicense our rights under the licensed patents from MGH to third parties and will require written consent in the event we wish to further sublicense such rights to a third party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the execution of the Editas License Agreement, we paid Editas an upfront fee of $180,000. We also issued to Editas 1,833,333 shares of our Series A-1 Preferred Stock and 1,222,222 shares of our Series A-2 Preferred Stock. In addition, if any of our commercial, regulatory, development or sales activities with respect to the licensed products triggers a milestone payment or sublicense income that Editas owes under the Broad/Harvard Head Licenses or the MGH Head Licenses, then we are required to pay Editas the full amount of such milestone payment or sublicense income, as applicable; provided that we will not pay Editas for any sublicense income due as a result of our payment of any option exercise fee to Editas. Aggregate milestone amounts under the Editas License Agreement could equal up to $68.8 million for each product developed and commercialized using rights related to certain base editing technologies and CRISPR technology; in the event we develop and commercialize products covered by claims from the additional patent families licensed or optioned to us under the Editas License Agreement, aggregate milestone payments could equal up to $74.0 million per product. The percentage of sublicense income we would owe under the Editas License Agreement ranges from none to amounts between 10% and 20%. In addition, we agreed to pay for a portion of the annual license maintenance fees and prosecution and maintenance costs that Editas incurs itself or owes under the Broad /Harvard Head Licenses and the MGH Head Licenses with respect to the licensed patents. The upfront fee, equity issuance, and option exercise payments we make to Editas under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Editas License Agreement constitute both consideration for the licenses granted to us under the Editas License Agreement and reimbursement for prosecution and maintenance costs for the licensed patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the sale of licensed products by us, our affiliates or our sublicensees, we are required to pay to Editas an amount equal to the royalty rates that it owes to Broad Institute, Harvard, or MGH under its applicable in-licenses, plus an additional low- to mid-single digit royalty on net sales of licensed products, depending on whether such licensed product is covered by an Editas-owned patent and based on the aggregate worldwide net sales of licensed products in a given calendar year. We are entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country and if Editas is entitled to receive any reductions or offsets in respect to its royalty payment obligations under the relevant Broad/Harvard Head Licenses or MGH Head Licenses, then Editas will use reasonable efforts to avail itself of such reductions, which in turn would reduce our royalty payment obligations under the Editas License Agreement. The royalty term expires on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the last-to-expire royalty term in such country under any applicable Broad/Harvard Head License or MGH Head License, and, if such product is covered by a licensed Editas-owned patent, (ii) the date at which such product is no longer covered by a valid claim of a licensed Editas-owned patent in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As between the parties, Editas is responsible for the prosecution and maintenance of all licensed patents, provided that we have certain information, comment, and review rights for certain of the licensed patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Editas License Agreement will expire on a licensed product-by-licensed product and country-by-country basis on the expiration of the applicable royalty term with respect to such licensed product in such country. We may terminate the Editas License Agreement on written notice to Editas subject to a specified notice period. Either party may terminate the Editas License Agreement for a material breach of the other party, subject to a notice and cure period. Editas may also terminate the Editas License Agreement if we challenge the validity of any of the licensed patents, subject to customary carveouts. Upon expiration or termination of the Editas License Agreement in its entirety or with respect to a family of patents, the licenses granted to us will immediately terminate in its entirety or solely with respect to the expired or terminated patent family, as the case may be; however, if we have the right to terminate the Editas License Agreement due to Editas&#8217; material breach of the Editas License Agreement, then in lieu of so terminating the Editas License Agreement, we can elect to reduce our royalty payment obligations under the Editas License Agreement by certain specified percentages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with The Broad Institute, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, our affiliate, Blink Therapeutics Inc., or Blink, entered into a license agreement, as amended, or the Broad License Agreement, with Broad Institute. In September 2021, Blink merged with and into Beam, such that Blink&#8217;s separate corporate existence ceased and Beam continued as the surviving corporation and the successor by merger to the Broad License Agreement with respect to Blink. Under the Broad License Agreement, and as further detailed below, we received certain rights to RNA base editing technology, including the RNA editor platforms RESCUE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and REPAIR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which use Cas13 linked to a deaminase to deliver single base A-to-I or C-to-U editing of RNA transcripts, respectively, as well as the Cas12b nuclease family of gene editing enzymes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More specifically, under the Broad License Agreement, Broad Institute granted us an exclusive, worldwide, royalty-bearing and sublicensable license under certain patent rights to the extent owned or controlled by Broad Institute (including via an interinstitutional agreement with the Massachusetts Institute of Technology, or MIT, and Harvard) comprising (i) certain patent rights claiming or disclosing novel CRISPR enzymes and systems (including those related to DNA cleaving) or systems, methods and compositions for targeted nucleic acid editing, in each case to exploit products covered by such patents, (ii) certain product-specific patent rights claiming or disclosing novel CRISPR enzymes and systems, methods and compositions for targeted nucleic acid editing, in each case to exploit base editor products covered by such patents and (iii) certain patent rights generally related to gene targeting to exploit base editor products covered by such patents, in each case to make, have made, offer for sale, sell, have sold and import certain licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Broad License Agreement, we have also been granted (i) a non-exclusive, royalty-bearing and sublicensable license under all patents exclusively licensed to us under the Broad License Agreement to make, have made, offer for sale, sell, have sold and import certain products in our field that were made, discovered, developed or determined to have utility through the use of such patents in a research or discovery program commencing before May 2021 or through the use of transferred materials from Broad Institute but that are not covered by the licensed patents and (ii) a non-exclusive, worldwide, royalty-bearing and sublicensable internal research license under all patents exclusively licensed to us. All licenses granted to us by Broad Institute exclude human germline modification, the stimulation of biased inheritance of particular genes or, with certain exceptions, traits within a plant or animal population and certain modifications of the tobacco plant and are subject to certain retained rights of Broad Institute, Harvard and MIT and the U.S. federal government. Broad Institute additionally retains limited rights for itself, Harvard and MIT and for other non-profit research organizations to practice the licensed patents for research, educational, and scholarly purposes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Broad License Agreement, we are required to use commercially reasonable efforts to develop licensed products in accordance with a development plan that Blink prepared and submitted to Broad Institute. The development plan includes certain development milestones that we are required to meet, as well as the timelines for the completion thereof, and we may update the development plan from time to time if we believe, in our good faith judgment, that such update is needed in order to improve our ability to meet such development milestones. We will not be able to delay such development milestone timelines without providing a reasonable explanation and plan to Broad Institute and provided further that Broad Institute&#8217;s approval of the explanation and plan in its reasonable discretion is required for any milestone timeline extension of more than a specified number of years. If we are successfully able to gain regulatory approval in any country to introduce a licensed product into the commercial market in such country, then we are also required to use commercially reasonable efforts to commercialize such licensed product and make such licensed product reasonably available to the public.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we are required to use commercially reasonable efforts to pursue the viability of the technology covered, claimed or disclosed in certain sub-categories of licensed patents and must initiate a discovery program for the development of a licensed product covered by a valid claim, or otherwise generally enabled, by the use of such sub-category of the licensed patents during a certain period of time following the execution of the Broad License Agreement and submit an updated development plan and development milestones reasonably acceptable to Broad Institute for such sub-category of the licensed patents within such period of time. If we fail to use commercially reasonable efforts to pursue the viability of such technology or to initiate a discovery program or to submit an updated development plan in the specified time period then the license under such sub-category of the licensed patents will terminate and, if such sub-category of the licensed patents consists of base editor patent rights, our rights with respect to gene targeting licensed patents shall convert to non-exclusive so that such rights may be licensed for use to such terminated base editor licensed patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad Institute, MIT, and Harvard also retain the right to grant further licenses under specified circumstances to third parties, other than specified entities, that wish to research, develop, and commercialize a product that would otherwise fall within the scope of our exclusive license grant from Broad Institute and Harvard pursuant to Broad Institute, Harvard and MIT&#8217;s inclusive innovation model. If, after a specified period of time, such a third party inquires with Broad Institute for such a license and presents to Broad Institute a proposal including information describing the proposed development and commercialization of such a proposed product, then Broad Institute may notify us of the request and the requester&#8217;s identity, and the nature of the specific proposed product, including the applicable gene to which the proposed product is directed. Broad Institute is not required to share any other information provided by the requester to us in connection with the inclusive innovation model. If we are not researching, developing or commercializing such a proposed product, then we can notify Broad Institute as to whether in good faith we are interested in developing such proposed product, entering into a sublicense agreement with such requesting third party to develop such proposed product, entering into a sublicense with another third party to develop such proposed product, or that we are not interested in any of the foregoing. If we inform Broad Institute that we are interested in developing such proposed product, then we will prepare a development plan, similar in scope to the development plan under the Broad License Agreement, to develop such proposed product and must commence the development program for such proposed product within a specified period. If we inform Broad Institute that we are interested in entering into a sublicense agreement pursuant to which the inquiring third party or another third party would receive a sublicense from us under the licensed patents to develop such proposed product, then we may enter into such a sublicense agreement and provide reasonable evidence thereof during the period. If we decline to conduct the foregoing activities or do not complete such activities within the specified period, which period is reduced by the period of time the requesting third party has previously negotiated with us, then Broad Institute may grant a license to the applicable third party under the licensed patents to research, develop, and commercialize such proposed product, and our license to such the applicable patent rights will, at Broad Institute&#8217;s election, terminate with respect to the gene that is the subject of the proposed third party product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are permitted to sublicense the licensed patents to affiliates and third parties, provided that any such sublicense agreement must remain in compliance with and be consistent with the terms of the Broad License Agreement. In addition, any such sublicense agreement must include certain customary provisions to ensure our ability to comply with the Broad License Agreement. We are also responsible for any breaches of a sublicense agreement by the applicable sublicensee and are responsible for all payments due under the Broad License Agreement by operation of any such sublicense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As partial consideration for the rights granted under the Broad License Agreement, Broad Institute received 1,940,000 shares of Blink&#8217;s common stock. The shares issued to Broad Institute were exchanged into 865,240 shares of our common stock in connection with our acquisition of Blink on September 25, 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Broad License Agreement, we are also required to pay Broad Institute an annual license maintenance fee ranging from the low- to mid-five figures to the low-six figures, depending on the particular calendar year. Broad Institute is also entitled to receive clinical and regulatory milestones totaling in the mid-to-high eight figure range, and to receive success payments based on increases in the fair market value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $15.0 million. We elected to make the payment in shares of our common stock and issued 174,825 shares of our common stock to settle this liability on June 10, 2021. We may additionally owe Broad Institute success payments of up to an additional $90.0 million.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also required to pay royalties in the low single digits for products covered by the licensed patents with such royalty reduced by a certain percentage for products enabled by the licensed patents or transferred materials, but not covered by the licensed patents. The royalty rate payable by us is subject to customary reductions and offsets on these royalties with respect to a product in a given country. The royalty term for a product in a country will terminate on the later of the expiration of (i) the last to expire licensed patent covering the applicable product, (ii) the period of exclusivity associated with such product in such country or (iii) a certain period of time after the first commercial sale of such product in such country. If we sublicense our rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and receive non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to an amount in the low first decile, dependent on the development stage of products under the Broad License Agreement at the time of sublicense execution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad Institute is responsible for the prosecution and maintenance of all licensed patents, provided that we have certain consultation, comment, and review rights with respect to such prosecution and maintenance activities of exclusively licensed patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Broad License Agreement will remain in effect until the later of the last-to-expire valid claim of a licensed patent covering our licensed products or the end of the last to expire royalty term. We may terminate the Broad License Agreement for its convenience following written notice to Broad Institute subject to a specified notice period. Either party may terminate the Broad License Agreement for a material breach of the other party, subject to a notice and cure period. Broad Institute may also terminate the Broad License Agreement in the event of our bankruptcy or insolvency, if we fail to procure and maintain insurance or if we, our affiliates or sublicensees bringing patent challenges relating to any licensed patents (subject to a cure period for us to terminate the sublicensee that has taken the applicable action).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Bio Palette Co., Ltd.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2019, we entered into a license agreement, or the Bio Palette License Agreement, with Bio Palette Co., Ltd., or Bio Palette, pursuant to which we received an exclusive (even as to Bio Palette and its affiliates), sublicensable license under certain patent rights related to base editing owned or controlled by Bio Palette to research, make, have made, import, export, distribute, use, have used, sell, have sold or offer for sale, and otherwise exploit products for the treatment of human disease throughout the world, but excluding products in the microbiome field in Asia. In addition, we granted Bio Palette an exclusive (even as to us and our affiliates) license under certain patent rights related to base editing and gene editing owned or controlled by us to research, make, have made, import, export, distribute, use, have used, sell, have sold or offer for sale, and otherwise exploit products in the microbiome field in Asia, subject to our right, in its sole discretion, to expand Bio Palette&#8217;s license (and the applicable royalty obligations) to the entire territory. Each party to the Bio Palette Agreement retains non-exclusive rights to develop and manufacture products in the microbiome field worldwide for the sole purpose of exploiting those products in its own territory. Each party agrees to certain coordination obligations in the microbiome field in the event that either party determines not to exploit their rights in such field.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Bio Palette comes into the control of any other patent right that is useful for the treatment, diagnosis or prevention of any human diseases or conditions and intends to grant a license under that patent right in certain defined fields and in certain defined territories, we have the exclusive right of first negotiation for an exclusive license under that patent right in those fields and territories. If we come into the control of any other patent right that is useful in certain defined fields and intend to grant a license under that patent right in those fields in certain defined territories, Bio Palette has the exclusive right of first negotiation for an exclusive license under that patent right in those fields and territories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Bio Palette License Agreement, if we form a Scientific Advisory Board, then Bio Palette will have the right to appoint two representatives to such board until the conclusion of the period ending five years after the effective date of the Bio Palette License Agreement. Additionally, we and Bio Palette agree to communicate with each other regarding potential base editing collaborations in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to use commercially reasonable efforts to develop a licensed product in the United States, Japan, the U.K., France, Germany, Italy and Spain. For any licensed product in our licensed field and territory that receives regulatory approval, we are required to use commercially reasonable efforts to commercialize that licensed product in the relevant country. Bio Palette is required to use commercially reasonable efforts to develop a licensed product in Japan. For any licensed product that receives regulatory approval, Bio Palette is required to use commercially reasonable efforts to commercialize such licensed product in the relevant country.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the patents licensed to us under the Bio Palette License Agreement were licensed to Bio Palette from Kobe University under a license agreement we refer to as the Kobe Head License. Accordingly, the licenses granted to us under the Bio Palette License Agreement are subject to the terms and conditions set forth in the Kobe Head License, which include provisions providing for certain rights to be retained by third parties including governmental authorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and Bio Palette are both permitted to sublicense the licensed patents to affiliates and third parties, provided that the applicable terms of the Bio Palette License Agreement and the Kobe Head License would apply to such affiliates and third parties. The sublicensing party is also responsible for any breaches of such terms by the applicable sublicensee and is responsible for all payments due under the Bio Palette License Agreement by operation of any such sublicense.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the execution of the Bio Palette License Agreement, we paid Bio Palette an upfront fee of $0.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the execution of the Bio Palette License Agreement, we issued to Bio Palette 16,725 shares of our common stock, with an agreement to issue additional shares of our common stock in the low six figures in the event that the referenced Bio Palette patent issues in the United States. Upon the issuance of a certain Bio Palette patent in the United States in June 2020, we made a milestone payment to Bio Palette of $2.0 million and, in July 2020, issued to Bio Palette 175,000 shares of our common stock valued at $0.3 million. We also agreed to pay a royalty at a fraction of a percent on net sales of products that are covered by the patents licensed by Bio Palette to us, and Bio Palette agreed to pay a royalty at a fraction of a percent on net sales of products that are covered by the patents licensed by us to Bio Palette. The royalty term for a product in a country will terminate on the later of the expiration of (i) patent-based exclusivity with respect to such licensed product in such country or (ii) regulatory exclusivity with respect to such licensed product in such country.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any intellectual property arising out of activities under the Bio Palette License Agreement will be owned by the party inventing such intellectual property. Bio Palette is responsible for the prosecution and maintenance of all patents licensed by Bio Palette to us, provided that we have customary consultation, comment and review rights with respect to such prosecution and maintenance activities solely with respect to national entries of a certain specified PCT application. We have the sole right to prosecute and maintain patents licensed by us to Bio Palette.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Bio Palette License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the applicable royalty term for each such licensed product and country. Each party has the right to terminate the Bio Palette License Agreement for convenience with respect to the license granted to such party subject to a specified notice period. Either party may terminate the Bio Palette License Agreement with respect to the license granted to the other party for a material breach by the other party, subject to a specified notice and cure period. Additionally, either party may also terminate the Bio Palette License Agreement in the event of the other party&#8217;s bankruptcy or insolvency or if the other party, its affiliates or sublicensees brings a patent challenge relating to any licensed patents (but, in the case of such a patent challenge by a sublicensee, subject to a cure period for such party to terminate its agreement with the sublicensee that has taken the applicable action).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacturing, packaging, labeling, storage, record keeping, reimbursement, advertising, promotion, distribution, post-approval monitoring and reporting and import and export, pricing and reimbursement of pharmaceutical products, including biological products. The failure to comply with the applicable regulatory requirements at any time during the product development process or post-approval may subject a sponsor for marketing approval to delays in development or approval, as well as administrative and judicial sanctions. The regulatory requirements applicable to product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by government agencies in ways that may have a significant impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions and compliance with applicable statutes and regulatory requirements, both pre- and post-approval, and obtaining reimbursement status will continue to require the expenditure of substantial time and financial resources. The regulatory requirements applicable to biological product development, approval, and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business. Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensure and regulation of biologics in the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, our candidate products are regulated as biological products, or biologics, under the Public Health Service Act, or the PHSA, and the Federal Food, Drug and Cosmetic Act, or the FDCA, the implementing regulations of the FDA and other federal, state and local statutes and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA must approve a product candidate for a therapeutic indication before it may be marketed in the United States. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products is referred to as a sponsor. A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of a clinical protocol and submission to the FDA of an investigational new drug, or IND, application for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current Good Clinical Practices, or GCP; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of a Biologics License Application, or BLA, requesting marketing of the biological product for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product and proposed labelling; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of the BLA by an FDA advisory committee, where applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements; to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity; and, if applicable, the FDA&#8217;s current Good Tissue Practice, or cGTP, requirements for the use of human cellular and tissue products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GLPs and GCPs and the integrity of clinical data in support of the BLA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of the application fee under the Prescription Drug User Free Act, or PDUFA, unless exempted; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the BLA, which may be subject to additional post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post-approval studies required by the FDA. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies and investigational new drug application</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before testing any investigational biological product in humans, including a gene editing product candidate, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are generally referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. With the passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the Public Health Service Act, or PHSA, that required animal testing in support of an NDA or BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative non-clinical tests, including cell-based assays, microphysiological systems, or bioprinted or computer models. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved drug or biological product to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved new drug application, or NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks or any issues surrounding chemistry, manufacturing and controls, or CMC, for the proposed product. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin. Preclinical or nonclinical testing typically continues even after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expanded access to an investigational drug for treatment use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no requirement for a manufacturer to provide expanded access to an investigational product. However, if a manufacturer decides to make its investigational product available for expanded access, FDA reviews requests for expanded access and determines if treatment may proceed. Expanded access may be appropriate when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, sponsors of one or more investigational products for the treatment of a serious disease(s) or condition(s) must make publicly available their policy for evaluating and responding to requests for expanded access for individual patients. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides an additional mechanism for patients with a life-threatening condition who have exhausted approved treatments and are unable to participate in clinical trials to access certain investigational products that have completed a Phase I clinical trial, are the subject of an active IND, and are undergoing investigation for FDA approval. Unlike the expanded access framework described above, the Right to Try Pathway does not require FDA to review or approve requests for use of the investigational product. There is no obligation for a manufacturer to make its investigational products available to eligible patients under the Right to Try Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human clinical trials in support of a BLA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified principal investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clinical trials conducted in the United States, an IND is required, and each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. Clinical trials must also comply with extensive GCP rules and the requirements for obtaining subjects&#8217; informed consent. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements, including GCP, or the subjects or patients are being exposed to an unacceptable health risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data monitoring committee, or DMC. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated checkpoints based on access to certain data from the study. Finally, research activities involving infectious agents, hazardous chemicals, recombinant DNA, and genetically altered organisms and agents may be subject to review and approval of an Institutional Biosafety Committee, or IBC, in accordance with NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, in patients, such as cancer patients. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Clinical trials are undertaken within an expanded patient population at multiple geographically dispersed clinical study sites to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety, purity and potency such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety or effectiveness after approval. Such trials are typically referred to as post approval or post marketing clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting post approval or post marketing clinical trials could result in withdrawal of approval for products. The FDA generally recommends that sponsors observe subjects for potential gene-therapy related delayed adverse events in a long-term follow-up study of fifteen years for integrating vectors, up to fifteen years for herpes virus vectors capable of establishing latency, up to fifteen years for microbial vectors known to establish persistent infection, up to fifteen years for gene editing products, and up to five years for AAV vectors. The FDA recommends that these long-term follow-up studies include, at a minimum, five years of annual physical examinations followed by annual queries, either in-person or by phone or written questionnaire, for the remaining observation period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan, or DAP, for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, actions plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law, because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. This action raises questions about the applicability of statutory obligations to submit DAPs and the FDA&#8217;s current thinking on best practices for clinical development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s, or ICH, recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information on a public registry maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH&#8217;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017. As of December 2024, the FDA has issued six notices of non-compliance, thereby signaling the government&#8217;s willingness to begin enforcing these requirements against non-compliant clinical trial sponsors. While these notices did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Violations may also result in injunctions and/or criminal prosecution or disqualification from federal grants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interactions with the FDA during the clinical development program</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the clearance of an IND and the commencement of clinical trials, a sponsor is given the opportunity to meet with the FDA at certain points in the clinical development program. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-NDA meetings as well as end of phase meetings such as end of Phase 2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. A Type D meeting is focused on a narrow set of issues and should not require input from more than three disciplines or Divisions of FDA. Finally, INTERACT meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical studies outside the United States in support of FDA approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our clinical development program, we are planning to conduct trials at sites outside the United States. When a foreign clinical trial is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the trials must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign trials are conducted in a manner comparable to that required for IND trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acceptance by the FDA of trial data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the trial is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the trial through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric studies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must submit a pediatric study plan, or PSP, within 60 days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and the FDA. The PSP outlines the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after FDA&#8217;s receipt of the study plan. The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements, under specified circumstances. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special regulations and guidance governing gene therapy products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that the procedures and standards applied to gene therapy products and cell therapy products may be applied to any CRISPR/Cas9 product candidates we may develop, but that remains uncertain at this point. The FDA has defined a gene therapy product as one that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and which are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or be transferred to cells</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior to administration to the recipient. The Center for Biologics Evaluation and Research, or CBER, at FDA regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Therapeutic Products, or OTP, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has issued numerous guidance documents regarding gene therapies. Although the FDA&#8217;s guidance documents are not legally binding, compliance with certain aspects of them is likely necessary to gain approval for any product candidate we may develop. The guidance documents provide recommendations and additional clarity as to factors that the FDA will consider at each stage of gene therapy development and relate to, among other things, the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies; and gene therapy products for the treatment of rare diseases. In addition, in November 2024, the FDA issued draft guidance to address frequently asked questions surrounding the development of cellular and gene therapy products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a gene therapy trial is conducted at, or sponsored by, institutions receiving any NIH funding for research involving recombinant or synthetic nucleic acid molecules, the trial must be conducted in accordance with the NIH Guidelines for Research Involving Recombinant DNA Molecules. Research conducted at such institutions that involves the transfer of recombinant or synthetic nucleic acid molecules, or DNA or RNA derived from recombinant or synthetic nucleic acid molecules, into human subjects must undergo review and approval by an IBC before it commences. Many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with cGMP and cGTP requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the NDA sponsor and any third-party manufacturers involved in producing the approved product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. Material changes in manufacturing equipment, location, or process post-approval, may result in additional regulatory review and approval. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with cGTP. These standards are found in FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. The manufacturing facilities may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. If a manufacturing facility is not in substantial compliance with the applicable regulations and requirements imposed when the product was approved, regulatory enforcement action may be taken, which may include a warning letter or an injunction against shipment of products from the facility and/or recall of products previously shipped.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Submission of a BLA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s CMC and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. The fee required for the submission of a BLA under the Prescription Drug User Fee Act, or PDUFA, is substantial (for example, for federal fiscal year 2025, this application fee is approximately $4.3 million), and the sponsor of an approved BLA is also subject to an annual program fee, set at $403,889 per eligible prescription drug product for federal fiscal year 2024. These fees are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the sponsor is a small business submitting its first human therapeutic application for review.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of the BLA within 60 days of receipt and must inform the sponsor by that time whether the application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#8217;s regulations for applications state that an application &#8220;shall not be considered as filed until all pertinent information and data have been received&#8221; by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to evaluate safety, purity and potency or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept a BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA may inform the sponsor of certain requirements for information when it accepts the BLA or by the 74</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day of the receipt of the BLA. Thereafter, the FDA may submit &#8220;information requests&#8221; to the sponsor in the course of the agency&#8217;s review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application for an investigational product that is a new molecular entity, and six months from the filing date for an application with &#8220;priority review.&#8221; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of a BLA to extend beyond the PDUFA goal date.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of FDORA, Congress clarified the FDA&#8217;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to FDA as well as other persons holding study records or involved in the study process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the NDA. This is because under certain circumstances, principal investigators at a clinical trial site may also serve as scientific advisors or consultants to a sponsor and receive compensation in connection with such services. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of safety, purity and potency of the investigational product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the FDA may refer the BLA, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the NDA sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the sponsor during the review process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s decision on a BLA</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent. To reach this determination, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety, purity and potency in the BLA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA typically requires a robust safety database and substantial evidence of the efficacy of the product. The term &#8220;substantial evidence&#8221; has been interpreted by the FDA to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that &#8220;If [the FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, the FDA may consider such data and evidence to constitute substantial evidence.&#8221; In December 2019, the FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. It has not yet finalized that guidance, but the FDA did issue draft guidance in September 2023 that outlines considerations for relying on confirmatory evidence in lieu of a second clinical trial to demonstrate efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, before approving an application, the FDA will determine whether the facility in which the product is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety. The approval process is lengthy and often difficult, and the FDA may refuse to approve a BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a Complete Response Letter, or CRL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond. For those seeking to challenge the FDA&#8217;s CRL decision, the FDA has indicated that sponsors may request a formal hearing on the CRL or they may file a request for reconsideration or a request for a formal dispute resolution. During the product approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population or indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including post-marketing clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast track, breakthrough therapy, priority review and regenerative advanced therapy designations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has several programs designed to expedite the development and approval of drugs and biological products intended to treat serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review designation, and regenerative medicine advanced therapy (RMAT) designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may grant a product fast track designation if it is intended for the treatment of a serious or life-threatening disease or condition, and nonclinical or clinical data demonstrate the potential to address an unmet medical need for such disease or condition. For fast track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of sections of a fast track product&#8217;s marketing application before the application is complete in some circumstances. Fast track designation may be rescinded if FDA believes that the product no longer meets the qualifying criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to aid sponsors in designing the clinical trials in an efficient manner. Breakthrough designation may be rescinded if a product no longer meets the qualifying criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With passage of the 21st Century Cures Act in December 2016, Congress authorized an additional expedited program for regenerative medicine advanced therapies. A product is eligible for RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. The benefits of RMAT designation include the benefits available to breakthrough therapies, including potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. RMAT designation may be rescinded if a product no longer meets the qualifying criteria.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of such condition. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and it shortens the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated approval pathway</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For drugs granted accelerated approval, FDA generally requires sponsors to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. Failure to conduct required post-approval studies with due diligence, failure to confirm a clinical benefit during the post-approval studies, or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product approval on an expedited basis. All promotional materials for product candidates approved under accelerated approval are subject to prior review by the FDA unless FDA informs the sponsor otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require (i) a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded; (ii) a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed); and (iii) use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, FDORA requires the agency to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe the FDA&#8217;s latest thinking on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety, purity and potency information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recall, seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates the advertising and labeling of prescription drug products, including biological products. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. In addition, the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, with passage of the Pre-Approval Information Exchange Act, or PIE Act, in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products. In addition, in January 2025, the FDA published final guidance outlining its non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This final guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After approval, some types of changes to the approved product, such as adding new indications or dosing regimens, manufacturing changes, or additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw product approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency or issues with manufacturing processes, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety signals; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recall, seizure, or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the sponsor to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from adequate and well-controlled clinical trials to demonstrate the product&#8217;s safety, purity and potency in the new indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for certain approved drugs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan drug designation and exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation qualifies a company for certain tax credits. In addition, if a drug candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, FDA cannot approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for the same condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gene therapy products present novel issues for assessing when two products are the &#8220;same&#8221; for orphan exclusivity purposes. In September 2021, the FDA issued a final guidance document describing its current thinking on when a gene therapy product is the &#8220;same&#8221; as another product for the purpose of orphan exclusivity. Under the guidance, if either the transgene or vector differs between two gene therapy products in a manner that does not reflect &#8220;minor&#8221; differences, the two products would be considered different drugs for orphan drug exclusivity purposes. FDA will determine whether two vectors from the same viral class are the same on a case-by-case basis and may consider additional key features in assessing sameness. While the guidance provides some additional clarity on FDA&#8217;s approach to assessing &#8220;sameness,&#8221; significant ambiguity and uncertainty remain as to how FDA will assess viral vectors in the same class, what differences in vector or transgene are considered minor, and what additional features may be considered.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or provide a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, or FDARA, in 2017, but have not yet been approved or licensed by the FDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the agency to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; It is unclear how this court decision will be implemented by the FDA. Although there</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of non-patent regulatory exclusivity in the United States. Specifically, the Best Pharmaceuticals for Children Act provides for the attachment of an additional six months of exclusivity, which is added on to the term of any remaining regulatory exclusivity at the time the pediatric exclusivity is granted. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data, even if the data do not show the product to be effective in the pediatric population studied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2010 Patient Protection and Affordable Care Act, or PPACA, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application for licensure of a biological product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. This 12-year exclusivity period is referred to as the reference product exclusivity period and bars approval of a biosimilar but notably does not prevent approval of a competing product pursuant to a full BLA (i.e., containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the product). The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity, and enforceability prior to the approval of the biosimilar.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state-regulated, to regulate the use of biosimilars.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent term restoration and extension</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A patent claiming a new biological product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for a single patent for an approved product as compensation for patent term lost during product development and FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date a clinical investigation involving human beings is begun and the submission date of a marketing application less any dime during which the sponsor failed to exercise due diligence, plus the time between the submission date of an application and the ultimate approval date less any dime during which the sponsor failed to exercise due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA approval of companion diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic device on issues related to co-development of the products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate. This guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic products, the companion diagnostic&#8217;s intended use/indications for use should name the specific group of therapeutic products, rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA previously has required</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee, which for federal fiscal year 2025 is $540,783 and the small business fee is $139,196.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A clinical trial is typically required for a PMA application and, in a small percentage of cases, the FDA may require a clinical study in support of a 510(k) submission. A manufacturer that wishes to conduct a clinical study involving the device is subject to the FDA&#8217;s IDE regulation. The IDE regulation distinguishes between significant and non-significant risk device studies and the procedures for obtaining approval to begin the study differ accordingly. Also, some types of studies are exempt from the IDE regulations. A significant risk device presents a potential for serious risk to the health, safety, or welfare of a subject. Significant risk devices are devices that are substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human health. Studies of devices that pose a significant risk require both FDA and an IRB approval prior to initiation of a clinical study. Many companion diagnostics are considered significant risk devices due to their role in diagnosing a disease or condition. Non-significant risk devices are devices that do not pose a significant risk to the human subjects. A non-significant risk device study requires only IRB approval prior to initiation of a clinical study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the Quality System Regulation, which covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal and state data privacy and security laws</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are multiple privacy and data security laws that may impact our business activities in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Any clinical trials we conduct will be regulated by Subpart A of 45 CFR 46, also known as the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. Moreover, new laws and regulations governing privacy and security may be adopted in the future as well.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to potential enforcement by the HHS, we could also be potentially subject to privacy enforcement from the Federal Trade Commission, or the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule, which the FTC also has the authority to enforce. The FTC is also in the process of developing rules related to commercial surveillance and data security. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate risk for a potential enforcement action, which may be costly. Finally, both the FTC and HHS&#8217;s enforcement priorities, as well as those of other federal regulators, may be impacted by the change in administration and new leadership. These shifts in enforcement priorities may also impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the United States to certain foreign countries. For example, in 2024, Congress passed H.B. 815, which included the Protecting Americans&#8217; Data from Foreign Adversaries Act of 2024. This law creates certain restrictions for entities that disclose sensitive data, including potential health data, to countries such as China. Failure to comply with these rules can lead to a potential FTC enforcement action. Additionally, the Department of Justice recently finalized a rule implementing Executive Order 14117, which creates similar restrictions related to the transfer of sensitive U.S. data to countries such as China. These data transfer restrictions, and others that may pass in the future, may create operational challenges and legal risks for our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, California has enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January 1, 2023, the California Privacy Rights Act, or CPRA, significantly modified the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, at least eighteen other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation and procedures governing approval of medicinal products in the EU and the U.K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, purity and potency, and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety, purity and potency of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-clinical studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trial approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014, or CTR, became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the EU, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond streamlining the process, the CTR includes a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or the Member States Concerned. Part II is assessed separately by each Member State Concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Member State Concerned. However, overall related timelines will be defined by the CTR.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific clinical site after the applicable ethics committee has issued a favorable opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials Directive, remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EU Clinical Trials Register (https://eudract.ema.europa.eu).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain a marketing authorization, or MA, for a gene therapy product under the EU regulatory system, a sponsor must submit an application via the centralized procedure administered by the European Medicines Agency, or EMA. Specifically, the grant of an MA in the EU for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC lays down specific rules concerning the authorization, supervision, and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety, and efficacy of their products to the EMA&#8217;s Committee for Advance Therapies which provides a draft opinion regarding the application for marketing authorization and which is subject to final approval by the EMA&#8217;s Committee for Medicinal Products for Human Use. The European Commission grants or refuses marketing authorization in light of that final approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an application for an MA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the Committee for Medicinal Products for Human Use, or CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conditional marketing authorization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In specific circumstances, E.U. legislation (Article 14&#8211;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional MA for Medicinal Products for Human Use) enables sponsors to obtain a conditional MA prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive; and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exceptional circumstances</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not, and will not in the future, have to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. Under these procedures, before granting the MA, the EMA or the competent authorities of the member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy. Except conditional MAs, MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for a period of eight years. This also applies to biosimilars. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. In addition, if a pediatric investigation plan is accepted, then a further year of market exclusivity might be obtained (or in the alternative a patent extension (SPC) of a further 6 months). For orphan medicinal products, the periods are separate and different in that there is a total of 10-year data exclusivity and if they have a PIP, there is a further two-year extension to that 10-year period. Even if a compound is considered to be a new chemical or biological entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this context, it should be noted that the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products was published in April 2023 and includes, among other things, provisions that would potentially reduce the duration of regulatory data protection. The European Parliament requested several amendments in April 2024. At this time, the proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry in the long term, if and when adopted.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Periods of authorization and renewals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, purity and potency, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the EU market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory requirements after marketing authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the EU, which mandate the methods, facilities, and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. The marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU under Directive 2001/83EC, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PRIME designation in the EU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU has a Priority Medicines, or PRIME, scheme that is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining a marketing authorization in the EU, sponsors must demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are provided in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan drug designation and exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a sponsor obtains a marketing authorization in all EU member states, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent term extensions in the EU and other jurisdictions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU also provides for patent term extension through SPCs. The rules and requirements for obtaining an SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the EU, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pricing decisions for approved products</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU provides options for EU Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product, or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals, and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel trade (i.e., arbitrage between low-priced and high-priced Member States) can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Data Protection Regulation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or the EEA, and the processing of personal data that takes place in the EEA, is subject to the EU&#8217;s General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, or Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. While we were not self-certified under the Privacy Shield, this CJEU decision has lead to increased scrutiny on data transfers from the EU to the U.S. generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the CJEU decision, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework, or DPF, in December 2022, and has now adopted an adequacy decision to permit data transfers from the EU to the United States going forward. This development permits data transfers at this point under this framework and more broadly has made international data transfers more straightforward, but these provisions are being</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenged in court. The recent election in the United States and the new administration may also impact whether the DPF remains an adequate data transfer framework. The continuing uncertainty around this issue may further impact our business operations in the EU.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 23, 2016, the electorate in the U.K. voted in favor of leaving the EU, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the U.K. and whether personal information can transfer from the EU to the U.K. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act of 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the U.K. that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the U.K., it is unclear whether transfer of data from the EEA to the U.K. will remain lawful under the GDPR. The U.K. government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the U.K. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the U.K. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the U.K., although this decision may be re-evaluated in the future. The U.K. and the United States also have agreed on a framework for personal data to be transferred between the U.K. and the United States, called the U.K.-U.S. Data Bridge. The U.K.-U.S. Data Bridge may be challenged in the future. Continuing uncertainty about these data transfers, including the possibility of future changes, may impact our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond the GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow the GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the regulatory framework in the U.K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK&#8217;s withdrawal from the EU, commonly referred to as Brexit, took place on January 31, 2020. The EU and the U.K. reached an agreement on their new partnership in the Trade and Cooperation Agreement, which entered into force on May 1, 2021. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency, or MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol, as amended by the so-called Windsor Framework agreed in February 2023. As of January 1, 2025, the changes introduced by the Windsor Framework resulted in the MHRA being responsible for approving all medicinal products destined for the U.K. market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#8217;s withdrawal from the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2024, a new international recognition procedure, or IRP, applies, which intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include the EMA and regulators in the EEA member states for approvals in the EU centralized procedure and mutual recognition procedure, as well as the FDA for product approvals granted in the U.S. The RR assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion or an MRDC positive end of procedure outcome is an RR authorization for the purposes of IRP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage, pricing, and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Sales of our products will depend, in significant part, on the availability of coverage and the adequacy of reimbursement from third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the United States, third-party payors include government authorities or government healthcare programs, such as Medicare and Medicaid, and private entities, such as managed care organizations, private health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Some third-party payors may manage utilization of a particular product by requiring pre-approval (known as &#8220;prior authorization&#8221;) for coverage of particular prescriptions (to allow the payor to assess medical necessity). Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain net price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular drug product or service does not ensure that other payors will also provide coverage for the drug product or will provide coverage at an adequate reimbursement rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors are increasingly challenging the price and examining the cost-effectiveness of new products and services in addition to their safety, purity and potency. To obtain or maintain coverage and reimbursement for any current or future product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our product. These studies will be in addition to the studies required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Thus, obtaining and maintaining reimbursement status is time-consuming and costly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As noted above, the marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and other third-party payors fail to provide coverage and adequate reimbursement. There is an emphasis on cost containment measures in the United States and we expect the pressure on pharmaceutical pricing will increase. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory approval from one or more third party payors, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we obtain appropriate approval in the future to market any of our current product candidates in the United States, we may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country because this is not yet the subject of harmonized EU law. Many countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval and others with &#8220;peg&#8221; their pricing to a basket of other countries. EU member states may approve a specific price for a product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Some member states, in addition to controlling pricing will monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare law and regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Food, Drug, and Cosmetic Act, or the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the so-called &#8220;federal sunshine&#8221; law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers and teaching hospitals to the Center for Medicare &amp; Medicaid Services within HHS for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-bribery, anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health care and other reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, which, among other things, includes changes to the coverage and payment for drug products under government healthcare programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal 2032 and lowers the payment reduction percentages in fiscal 2030 and 2031.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the PPACA brought by several states without specifically ruling on the constitutionality of the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical prices</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Seven states (Colorado, Florida, Maine, New Hampshire, New Mexico, Texas and Vermont) have passed laws allowing for the importation of products from Canada. North Dakota and Virginia have passed legislation establishing workgroups to examine the impact of a state importation program.&#8239;As of May 2024, five states (Colorado, Florida, Maine, New Hampshire and New Mexico) had submitted Section 804 Importation Program proposals to the FDA. On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian product importation. That state now has authority to import certain products from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. The state will also need to relabel the products and perform quality testing of the products to meet FDA standards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The Inflation Reduction Act of 2022, or IRA, further delayed implementation of this rule to January 1, 2032.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028 and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but does not apply to drugs and biologics that have been approved for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, the HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, CMS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations by February 1, 2025. While there had been some questions about the Trump Administration&#8217;s position on this program, CMS issued a public statement on January 29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 6, 2023, Merck &amp; Co. filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the Pharmaceutical Research and Manufacturers of America, Novo Nordisk, Inc., Janssen Pharmaceuticals, Inc., Novartis AG, AstraZeneca plc and Boehringer Ingelheim International GMBH, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal, and on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 483 team members employed with us full-time, of which 115 had a M.D. or Ph.D. degree. Of these team members, 202 were engaged in research and development activities, 51 were engaged in clinical and regulatory activities, 68 were in technical operations, 60 were in quality roles and 102 were in general and administrative roles. None of our team members are represented by a labor union or covered by a collective bargaining agreement. The human capital measures and objectives we focus on in managing our business are our employee retention rate and our internal engagement survey participation rate. We seek to maintain an annual retention rate of greater than 85% and a survey participation rate of greater than 90%.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our website address is www.beamtx.com, and our investor relations website is located at investors.beamtx.com. Information on our website is not incorporated by reference herein. We will make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an Internet site (http://www.sec.gov) containing reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors and others should note that we announce material information to our investors using one or more of the following: SEC filings, press releases and our corporate website, including without limitation the &#8220;Investors &amp; Media&#8221; section of our website. We use these channels, as well as social media channels such as X and LinkedIn, in order to achieve broad, non-exclusionary distribution of information to the public and for complying with our disclosure obligations under Regulation FD. It is possible that the information we post on our corporate website or other social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the &#8220;Investor Center&#8221; section of our corporate website and on our social media channels. The contents of our corporate website and social media channels are not, however, a part of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our financial position and need for additional capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net loss was $376.7 million, $132.5 million and $289.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, we had an accumulated deficit of $1.6 billion. We have financed our operations primarily through private placements of our preferred stock, proceeds from sales of our common stock and collaboration revenue. We have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance clinical trials of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research programs and our preclinical development of other product candidates from our research programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate preclinical testing and clinical trials for any other product candidates we identify and develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing approvals for any of our product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any medicines for which we may obtain marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further develop our base editing platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional personnel, including research and development, clinical, and commercial personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our product development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license products, intellectual property, medicines, and technologies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain and operate a commercial-scale cGMP manufacturing facility. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not completed any clinical trials of any product candidates and expect that it will be years, if ever, before we have a product candidate approved for commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a medicine or medicines with significant market potential. This will require us to be successful in a range of challenging activities, including identifying product candidates, completing preclinical studies and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing, and selling those medicines for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Because of the numerous risks and uncertainties associated with developing base editing product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our operating expenses to increase as we continue research and development activities, expand clinical trials, and seek marketing approval for product candidates. In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility of a collaborator. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We have in the past delayed, reduced and eliminated certain research and product development programs to decrease operating expenses. If in the future we are unable to raise capital when needed or on attractive terms, we may again be forced to delay, reduce, or eliminate programs or curtail commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, our cash, cash equivalents, and marketable securities were $850.7 million. We believe that our existing cash, cash equivalents, and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, our operating plan may change as a result of factors currently unknown to us, and we may need to seek additional funding sooner than planned. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of continuing to build our base editing platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of acquiring licenses for the delivery modalities that will be used with our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, manufacturing, and clinical trials for the product candidates we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of the product candidates we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing for and undertaking future activities, including product sales, medical affairs, marketing, manufacturing, distribution, coverage and reimbursement for any product candidates for which we receive regulatory approval to commercialize; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our license agreements and our collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional license agreements and collaborations on favorable terms, if at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any additional license agreements or collaboration agreements we obtain; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment of success liabilities to Harvard and Broad Institute pursuant to the respective terms of the Harvard License Agreement and the Broad Institute License Agreement, should we choose to pay in cash;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our contingent liabilities require cash expenditures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license products, intellectual property and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating and expanding our manufacturing capacity; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing a sales, marketing, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those product candidates are approved, we may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for years, if ever. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any additional fundraising efforts may divert the attention of our management from their day-to-day activities, which may adversely affect our ability to develop and, if approved, commercialize our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us on a timely basis, we may have to significantly delay, scale back or discontinue the development or, if approved, commercialization of our product candidates or other research and development initiatives. For example, in October 2023, we announced a portfolio reprioritization and strategic restructuring, including cost-reduction initiatives which resulted in the pausing or elimination of certain pipeline programs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and any future license agreements and collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain funding on a timely basis, we may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of capital. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted. The terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates we may develop, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, we have and may in the future enter collaboration and acquisition agreements, pursuant to which we are required to issue additional shares of our common stock in connection with future milestone payment obligations. These and other future issuances to our partners and collaborators may cause substantial dilution to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an early-stage company. We were founded in January 2017 and began operations in July 2017. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring and developing our platform and technology, identifying potential product candidates, undertaking preclinical studies and operating clinical trials. Many of our product development programs are still in the early clinical, preclinical or research stage of development, and their risk of failure is high. We have not yet demonstrated an ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale medicine, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes about 10 to 15 years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history, particularly in light of the rapidly evolving base editing and gene editing field, may make it difficult to evaluate our technology and industry and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a new business, we may encounter other unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never generated revenue from product sales and may never become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for the next several years, if ever. Our ability to generate future revenues from product sales depends heavily on our, or our collaborators&#8217;, ability to successfully:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify product candidates and complete research and preclinical and clinical development of the product candidates we or our collaborators may identify; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek and obtain regulatory and marketing approvals for any of our product candidates for which we or our collaborators successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launch and commercialize any of our product candidates for which we obtain regulatory and marketing approval by establishing a sales force, marketing, and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">qualify for adequate coverage and reimbursement by government and third-party payors for our product candidates for which we or our collaborators obtain regulatory and marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, maintain, and enhance a sustainable, scalable, reproducible, and transferable manufacturing process for the product candidates we or our collaborators may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain and operate a commercial-scale cGMP manufacturing facility;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products, and services to support clinical development and the market demand for our product candidates for which we or our collaborators obtain regulatory and marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain market acceptance of any product candidates we or our collaborators may develop as viable treatment options; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">address competing technological and market developments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement internal systems and infrastructure, as needed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiate favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations, licensing or other arrangements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, protect, enforce, defend, and expand our portfolio of intellectual property rights, including patents, trade secrets, and know-how; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoid and defend against third-party interference, infringement, and other intellectual property claims; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire, and retain qualified personnel. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if one or more of the product candidates we or our collaborators may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history, and we may never achieve profitability. To the extent that we continue to generate taxable losses, any unused U.S. federal losses generated after 2017 will carry forward indefinitely to offset future taxable income; any U.S. federal taxable losses generated prior to 2018 will carry forward for 20 tax years from the year of generation. Additionally, we continue to generate business tax credits, including U.S. federal research and development tax credits, which generally may be carried forward 20 tax years from the year of generation to offset a portion of our future tax liability, if any. Additionally, Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, limit a corporation&#8217;s ability to utilize tax attributes to the extent the corporation experiences an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change in ownership, measured by value, among 5% or greater shareholders over a rolling three-year testing period. To the extent a corporation experiences an ownership change, utilization of pre-ownership change tax attributes (e.g., net operating losses and general business tax credits) to offset post-ownership change taxable income or taxes, is subject to an annual limitation, generally calculated as the pre-ownership change equity value of the corporation, subject to certain prescribed adjustments, multiplied by the long-term tax exempt rate published monthly by the Internal Revenue Service. We completed a Section 382 study as of December 31, 2024, and determined that no historical ownership changes occurred since December 2021. In addition, we may have experienced additional ownership changes since December 31, 2024 and may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change net operating losses or other tax attributes to offset U.S. federal taxable income or taxes may be subject to limitations, which could potentially result in increased future tax liability to us. There may also be limitations on our ability to use net operating losses and business tax credits at the state level. Additional limitations on our ability to utilize our net operating losses and other tax attributes to offset future taxable income or taxes may arise as a result of our corporate structure, whereby net operating losses or other tax attributes generated by certain of our subsidiaries or controlled entities may not be available to offset taxable income or taxes of other subsidiaries or controlled entities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is also a risk that due to regulatory changes or other unforeseen reasons, our existing net operating losses or business tax credits could expire or otherwise become unavailable to offset future income tax liabilities. As described below in &#8220;Comprehensive tax reform legislation could adversely affect our business and financial condition,&#8221; the Tax Cuts and Jobs Act of 2017, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating losses that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. At the state level, there may also be periods during which the use of net operating losses or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, we may not be able to realize a tax benefit from the use of our net operating losses or tax credits, even if we attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to discovery, development, and commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Base editing is a novel technology that has only recently been clinically validated for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are early in their development and may never lead to marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focused on developing potentially curative medicines utilizing base editing technology. Although there have been significant advances in the field of gene therapy, which typically involves introducing a copy of a gene into a patient&#8217;s cell, and gene editing in recent years, including the approval of an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nuclease editing product for treatment of sickle cell disease, base editing technologies are new and early in their development. The technologies that we have licensed and are developing have not yet completed any clinical trials. The scientific evidence to support the feasibility of developing product candidates based on these technologies is both preliminary and limited, and base editing and delivery modalities for it are novel. Successful development of product candidates by us will require solving a number of issues, including safely delivering a therapeutic into target cells within the human body or in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> setting, optimizing the efficiency and specificity of such product candidates, and ensuring the therapeutic selectivity of such product candidates. Several biological steps are required for delivery of base editing medicines to translate into therapeutically active medicines. These processing steps may differ between individuals and differ based on the targeted tissue. These differences could lead to variable levels of therapeutic protein, variable activity, immunogenicity, or variable distribution to tissues further increasing the risk inherent in the development of base editing medicines. There can be no assurance we will be successful in solving any or all of these issues, or that we will be able to progress our preclinical studies or clinical trials in accordance with anticipated timelines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have only recently brought therapeutics to the clinic, and our future success is highly dependent on the successful development of base editing technologies, cellular delivery methods and therapeutic applications of that technology. While other gene editing technologies have progressed through clinical trials, they continue to suffer from various limitations, and such limitations may affect our future success. We may decide to alter or abandon our initial programs as new data become available and we gain experience in developing base editing therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in our initial indications or any other indication we pursue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development activities in the field of base editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent interference proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to our and our licensors&#8217; intellectual property rights, see the section entitled &#8220;&#8212;Risks related to our intellectual property&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts. Our product candidates are still in preclinical or clinical development and it will be years before we or our collaborators commercialize a product candidate, if ever. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts and our future success depends heavily on the successful development of our base editing product candidates and the results of our clinical trials, none of which have yet been completed. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and, if approved, eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing clinical trials in the United States is subject to acceptance by the FDA of our investigational new drug applications, or INDs, and finalizing the trial design based on discussions with the FDA and other regulatory authorities. Similarly, in the European Union, or EU, a CTA must be obtained from each member state&#8217;s national competent authority where the study is conducted, and a positive opinion of an independent ethics committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after we receive and incorporate guidance from these regulatory authorities, the FDA, European national competent authority, or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trial or change their position on the acceptability of our data, trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter requirements for approval than we currently expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. For example, in December 2022, with the passage of FDORA, Congress required sponsors to develop and submit a DAP for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. The implications of this action are not yet known.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in January 2022, the new Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. This regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one EU Member State will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a clinical trials portal overseen by the European Medicines Agency, or EMA, and available to clinical trial sponsors, competent authorities of the EU Member States and the public.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization of our product candidates we may develop will require additional preclinical and clinical development; regulatory and marketing approval in any jurisdictions where our product candidates would be marketed, including by the FDA for the U.S. market and the European Commission upon a positive benefit/risk assessment provided by the EMA in the EEA; obtaining or creating manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of product candidates we identify and develop will depend on many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies, IND/CTA-enabling studies, and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory clearance of IND applications, CTAs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful enrollment in, and completion of, clinical trials in accordance with all applicable current Good Clinical Practice guidelines, or GCPs, current Good Laboratory Practice guidelines adopted by the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, and other regulatory requirements from foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of marketing approvals and, where required, pricing and reimbursement decisions from applicable regulatory authorities; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of arrangements with third-party manufacturers for clinical supply and commercial manufacturing and, where applicable, commercial manufacturing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful development of our internal manufacturing processes and transfer to larger-scale facilities operated by either a contract manufacturing organization, or CMO, or by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent, trade secret, and other intellectual property protection and non-patent exclusivity for our medicines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of the products, if and when approved, by patients, the medical community, and third-party payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies and treatment options; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a continued acceptable safety profile of the medicines following approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing and defending intellectual property and proprietary rights and claims; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supplying the product at a price that is acceptable to the pricing or reimbursement authorities in different countries. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not successfully achieve one or more of these activities in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of the product candidates we may develop, or the delivery modalities we rely on to administer them, cause serious adverse events, undesirable side effects, or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not completed human clinical trials of any of our product candidates. Moreover, there have been only a limited number of clinical trials involving the use of base editing technology similar to our technology. It is impossible to predict when or if any product candidates we develop will prove safe in humans. In the genetic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia, serious blood disorders and death. There can be no assurance that base editing technologies, or components of our product candidates or methods of delivery, will not cause undesirable side effects, as improper editing of a patient&#8217;s DNA and other effects could lead to lymphoma, leukemia, or other cancers, other serious conditions or syndromes or other aberrantly functioning cells.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant risk in any base editing product candidate is that &#8220;off-target&#8221; edits may occur, which could cause serious adverse events, undesirable side effects or unexpected characteristics. For example, Erwei Zuo et al. reported that cytosine base editors generated substantial off-target edits, that is, edits in unintended locations on the DNA, when tested in mouse embryos. Such unintended edits are referred to as &#8220;spurious deamination.&#8221; We cannot be certain that off-target editing will not occur in any of our planned or future clinical studies, and the lack of observed side effects in preclinical studies does not guarantee that such side effects will not occur in human clinical studies. We have developed assays that can detect off-target edits, even when such edits occur at very low frequencies. Using these assays, we have observed off-target edits in our base editing product candidates. As the sensitivity of these assays increases, it is possible that we will continue to detect more such off-target edits. While we do not believe that the off-target edits we have observed to date have had a material adverse impact on the safety or benefit of our product candidates, if, in the future, we detect off-target edits for a product candidate that negatively impact safety or efficacy, our ability to develop the product candidate as a therapeutic could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is also the potential risk of delayed adverse events following exposure to base editing therapy due to the permanence of edits to DNA or due to other components of product candidates used to carry the genetic material. Further, because base editing makes a permanent change, the therapy cannot be withdrawn, even after a side effect is observed. In addition, Rees et al. and Grunewald et al. have reported that the deaminases we currently use in our C base editors and our A base editors for use in DNA base editing also cause unintended mutations in RNA for as long as the editor is present in the cell.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we and others have demonstrated the ability to engineer base editors to improve the specificity of their edits in a laboratory setting, we cannot be sure that our engineering efforts will be effective in any product candidates that we may develop. For example, we might not be able to engineer an editor to make the desired change or a by-stander edit could diminish the effectiveness of an edit that we make.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain of our programs, we plan to use LNPs to deliver our base editors. LNPs have been shown to induce oxidative stress in the liver at certain doses, as well as initiate systemic inflammatory responses that can be fatal in some cases. While we aim to continue to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: immune reactions; infusion reactions; complement reactions; opsonization reactions; antibody reactions including IgA, IgM, IgE or IgG or some combination thereof; or reactions to the polyethylene glycol from some lipids or polyethylene glycol otherwise associated with the LNP. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our current or future clinical trials. Many of these types of side effects have been seen for legacy LNPs. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to side effects and adverse events caused by our product candidates, the conditioning administration process or related procedures used in BEAM-101 and potentially other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates also can cause adverse side effects and adverse events. For example, a patient in our BEACON trial for the treatment of sickle cell disease died due to respiratory failure four months after busulfan conditioning and infusion with BEAM-101. While the investigator determined that the patient&#8217;s death was likely related to busulfan conditioning and deemed the event unrelated to BEAM-101, we cannot be certain of these conclusions, nor that other patients will not experience adverse events from the trial&#8217;s conditioning regimen or otherwise. Additionally, we are developing alternative conditioning regimens and we cannot predict if such regimens will be compatible with our product candidates. If in the future we are unable to demonstrate that such adverse events were not caused by the conditioning regimens used, or administration process or related procedure, the FDA, the European Commission, EMA or other regulatory authorities could order us to cease further development of, or deny or limit approval of, our product candidates using such regimens, processes or procedures for any or all target indications. Even if we are able to demonstrate that adverse events are not related to the product candidate or the administration of such product candidate, such occurrences could affect patient recruitment, the ability of enrolled patients to complete the clinical trial, or the commercial viability of any product candidates that obtain regulatory approval.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any product candidates we develop are associated with serious adverse events, undesirable side effects, or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we successfully develop a product candidate and it receives marketing approval, we are required to present a comprehensive, concise, and critical analysis of new or emerging information on the risks of the approved product and on its benefit in approved indications, to enable an appraisal of benefit-risk profile in a Periodic Benefit Risk Evaluation Report, or PBRER, according to an internationally harmonized standard. Additionally, the FDA or a comparable regulatory authority such as the EMA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, or similar requirement such as Risk Management Plan, or RMP, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. FDA, EMA, or other comparable regulatory authorities may require specific post-approval trials to be carried out to further characterize the clinical efficacy and/or safety of the product candidate. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we develop, several potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label or limit the approved use of such product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to conduct additional clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have only recently begun testing our proposed delivery modalities and product candidates in clinical trials and any favorable preclinical results, or initial clinical results, are not necessarily predictive of results that may be observed in later clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a high failure rate for drugs and biologics proceeding through clinical trials. Even if initial clinical trials in any of our product candidates are successful, these product candidates may fail to show the desired safety, purity and potency in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. Data obtained from preclinical and clinical activities are also subject to varying interpretations, and the FDA, EMA, or other regulatory authorities may disagree with our interpretations, which may delay, limit, or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such adverse events may cause us to delay, limit, or terminate ongoing or planned clinical trials, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in the enrollment or treatment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our collaborators may not be able to initiate or continue clinical trials for any product candidates we identify or develop if we are unable to locate, enroll, and treat a sufficient number of eligible patients in these trials as required by the FDA, the EMA or other analogous regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial. Enrollment may be particularly challenging for some of the rare genetically defined diseases we are targeting in our most advanced programs, as well as for some of our product candidates for pediatric populations, due to a number of factors, including small patient populations as well as screening and testing requirements that limit patient eligibility. In addition, if patients are unwilling to participate in our base editing trials because of negative publicity from adverse events related to the biotechnology, gene therapy, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene editing fields, competitive clinical trials for similar patient populations, clinical trials in competing products, or for other reasons, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of any product candidates we may develop may be delayed. Moreover, some of our competitors currently and may in the future have ongoing clinical trials for product candidates that treat the same indications as product candidates we are developing and may develop in the future, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Treatment of enrolled patients may also be delayed or prevented due to a number of factors, including the complexity of our trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial patient enrollment is also affected by other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">size of the patient population and process for identifying patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of the trial protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability and efficacy of approved medications for the disease under investigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of genetic testing for potential patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to obtain and maintain patient informed consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk that enrolled patients will drop out before completion of the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility and exclusion criteria for the trial in question; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of base editing as a therapeutic approach; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor patients adequately during and after treatment; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients, especially for those conditions which have small patient pools. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to successfully initiate, enroll, and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different standards for the conduct of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different standard-of-care for patients with a particular disease; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in locating qualified local consultants, physicians, and partners; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential burden of complying with a variety of foreign laws, medical standards, and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment and of gene editing technologies. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment or treatment delays in our clinical trials may result in increased development costs for any product candidates we may develop, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling or treating a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit, or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If clinical trials of any product candidates we identify and develop fail to demonstrate safety, purity and potency to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidates we identify and develop, we must complete preclinical development and then conduct extensive clinical trials to demonstrate their safety, purity and potency in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates we identify and develop, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulators on trial design and endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, institutional review boards, or IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective CROs and clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of any product candidates we may develop may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development or research programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in designing well-controlled clinical trials due to ethical considerations which may render it inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of any product candidates we develop may be larger than we anticipate; enrollment of suitable participants in these clinical trials, which may be particularly challenging for some of the rare genetically defined diseases we are targeting in our most advanced programs, may be delayed or slower than we anticipate; or patients may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, or independent ethics committees may require that we or our investigators suspend or terminate clinical research or clinical trials of any product candidates we develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of any product candidates we may develop may be greater than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of any product candidates we may develop or other materials necessary to conduct clinical trials of any product candidates we develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing, and delivery of any product candidates we may develop to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in or cancellations of clinical trials as a result of efforts by the Trump Administration to reduce research funding by the NIH of medical research;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites dropping out of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events associated with any product candidates we may develop that are viewed to outweigh their potential benefits; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption to the operations of the FDA, EMA or other relevant regulatory authority; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols or otherwise complying with additional requirements. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we develop beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of any product candidates we develop, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for any such product candidates we may develop or not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to changes in the way the product is administered; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a REMS or through modification to an existing REMS; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be sued; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product development costs will also increase if we or our collaborators experience delays in clinical trials or other testing or in obtaining marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we may develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we may develop, any of which may harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial, scientific and managerial resources, we focus on research programs and product candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. For example, in October 2023, we implemented a strategic restructuring to prioritize development of our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sickle cell disease programs, including BEAM-101, our ESCAPE conditioning strategy, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> delivery to hematopoietic stem cells program, as well as our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editor BEAM-302 in development for the treatment of alpha-1 antitrypsin deficiency. We also announced plans to explore partnership opportunities for continued development of select programs, including BEAM-201 and other potential </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies. While we may identify new collaboration partners who can progress some of these programs, we may not be successful in doing so in a timely manner, on acceptable terms or at all. We may otherwise fail to raise sufficient additional capital in order to progress these programs ourselves or we may determine, for internal resource allocation purposes or for other reasons, to abandon development of these programs. As a result, we could miss valuable opportunities to capitalize on the potential of the programs. We may also allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration or that does not prove to have viable commercial opportunities. Any failure to use our financial and human resources efficiently could harm our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are conducting clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting clinical trials with one or more trial sites that are located outside the United States. The acceptance by the FDA or other regulatory authorities of trial data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the trial is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the trial through an onsite inspection if deemed necessary. Many foreign</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional foreign regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural differences in medical practice and clinical research; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished protection of intellectual property in some countries; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate we develop in the United States or any other jurisdiction, and any such approval may be for a narrower indication than we seek.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if any product candidates we may develop meet their safety, purity and potency endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee, EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials, and the review process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS or an RMP. These regulatory authorities may require labeling that includes precautions or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we may develop. Any of the foregoing scenarios could materially harm the commercial prospects for any product candidates we may develop and materially adversely affect our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing approval by the FDA in the United States, or by the EMA in the EEA, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates we may develop in those countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our product candidates will be unrealized.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any product candidates we may develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of any of our product candidates we may develop will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Ethical, social, and legal concerns about genetic medicines generally and base editing technologies specifically could result in additional regulations restricting or prohibiting the marketing of our product candidates we may develop. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the limitation to our targeted patient population and limitations or warnings contained in approved labeling by the FDA, EMA, or other regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to offer our medicines for sale at competitive prices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product candidate is approved by the FDA, the EMA, or other regulatory agencies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public attitudes regarding genetic medicine generally and gene editing and base editing technologies specifically; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try novel therapies and of physicians to prescribe these therapies, as well as their willingness to accept a therapeutic intervention that involves the editing of the patient&#8217;s gene; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA, the European Commission, the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of competitive products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity concerning our products or competing products and treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient third-party coverage or reimbursement; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if any of our product candidates we may develop are approved, such products may not achieve an adequate level of acceptance, we may not generate significant product revenues, and we may not become profitable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our commercial readiness activities, do not yet have a sales or marketing infrastructure and do not have experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved medicine for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates we develop if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates we may develop on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our product candidates we may develop to segments of the patient population; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any medicines we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates we may develop or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. Moreover, the base editing and delivery technology fields are characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. We will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are several other companies utilizing base editing technology, including PerkinElmer, Life Edit (an ElevateBio company), Metagenomi, Revvity and Intellia Therapeutics. In addition, we face competition from companies utilizing other gene editing modalities and various other genetic medicines. Within the disease areas that we focus on, we are also aware of competing companies that have approved therapies, those with therapies in development, and others that may emerge in the future. For sickle cell disease, these companies include CRISPR Therapeutics, Vertex Pharmaceuticals, bluebird bio, Novartis Pharmaceuticals, Kamau Therapeutics, Fulcrum Therapeutics, Tessera Therapeutics, Cimeio Therapeutics and Agios Pharmaceuticals. For our AATD targeted therapies, these include Wave Life Sciences, Moderna, Korro Bio, Tessera Therapeutics and Arrowhead Pharmaceuticals</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates we may develop. This may include other types of therapies, such as small molecule, antibody, and/or protein therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or non-competitive. Our competitors also may obtain FDA, EMA, or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidates that we may develop and commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our potential therapeutic products involve editing the human genome. The clinical and commercial success of our potential products will depend in part on public understanding and acceptance of the use of gene editing therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing is unsafe, unethical, or immoral, and, consequently, our product candidates may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, gene editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns relating to the application of gene editing technology to human embryos or the human germline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not use our technologies to edit human embryos or the human germline, such public debate and heightened regulatory scrutiny could prevent or delay our development of product candidates. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any product candidates we may develop. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing gene editing technologies, even if not ultimately attributable to product candidates we may identify and develop, and the gene publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates. Use of gene editing technology by a third party or government to develop biological agents or products that threaten U.S. national security could similarly result in such negative impacts to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations that govern marketing approvals, pricing, and reimbursement for new medicines vary widely from country to country. Some countries require approval of the sale price of a medicine before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a medicine in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the medicine, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the medicine in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates we may develop, even if any product candidates we may develop obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to commercialize any medicines successfully also will depend in part on the extent to which reimbursement for these medicines and related treatments will be available from government authorities or healthcare program, private health plans, and other organizations. Government authorities and third-party payors, such as private health plans, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. For example, the Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact our business, including provisions that impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. We cannot yet predict the effect the IRA will have on our business and the healthcare industry in general.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasingly, third-party payors are also challenging the prices charged for medical products and requiring that drug companies provide them with predetermined discounts from list prices. Novel medical products, if covered at all, may be subject to enhanced utilization management controls designed to ensure that the products are used only when medically necessary. Such utilization management controls may discourage the prescription or use of a medical product by increasing the administrative burden associated with its prescription or creating coverage uncertainties for prescribers and patients. We cannot be sure that reimbursement will be available for any medicine that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved medicines, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, the EMA or other regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any medicine will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new medicines, if applicable,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the medicine and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for medicines may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved medicines we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize medicines, and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Due to the novel nature of our technology and the potential for any product candidates we may develop to offer therapeutic benefit in a single administration or limited number of administrations, we face uncertainty related to pricing and reimbursement for these product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our initial target patient populations are relatively small, as a result of which the pricing and reimbursement of any product candidates we may develop, if approved, must be adequate to support the necessary commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any such product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to any product candidates we may develop (e.g., for administration of our product candidate to patients) is also important. Inadequate reimbursement for such services may lead to physician and payor resistance and adversely affect our ability to market or sell our product candidates we may develop. In addition, we may need to develop new reimbursement models in order to realize adequate value. Payors may not be able or willing to adopt such new models, and patients may be unable to afford that portion of the cost that such models may require them to bear. If we determine such new models are necessary but we are unsuccessful in developing them, or if such models are not adopted by payors, our business, financial condition, results of operations, and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the cost of a single administration of the genetic medicines we are seeking to develop to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of any such product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of any product candidates we may develop will be paid by government authorities, private health plans, and other third-party payors. Payors may not be willing to pay high prices for a single administration. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination that use of a product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective, and medically necessary; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical, and cost-effectiveness data. There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates we may develop. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new product candidates such as ours. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any product candidates we may develop will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for any product candidates we may develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer. Because the target patient populations for many of the product candidates we may develop are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus a substantial portion of our research and product development on treatments for rare genetically defined diseases. Many of our product candidates we may develop are expected to target a single mutation; as a result, the relevant patient population may therefore be small. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product candidates we may develop, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product candidates we may develop, or may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations, and prospects. Additionally, because of the potential that any product candidates we develop could cure a target disease, we may not receive recurring revenues from patients and may deplete the patient population prevalence through curative therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully identify patients who are likely to benefit from therapy with any product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success may depend, in part, on our ability to identify patients who are likely to benefit from therapy with any medicines we may develop, which requires those potential patients to have their DNA analyzed for the presence or absence of a particular sequence. If we, or any third parties that we engage to assist us, are unable to successfully identify such patients, or experience delays in doing so, then:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop any product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we develop may require use of a companion diagnostic to identify patients who are likely to benefit from therapy. If safe and effective use of any of our product candidates we may develop depends on a companion diagnostic, we may not receive marketing approval, or marketing approval may be delayed, if we are unable to or are delayed in developing, identifying, or obtaining regulatory approval or clearance for the companion diagnostic product for use with our product candidate. Identifying a manufacturer of the companion diagnostic and entering into an agreement with the manufacturer could also delay the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these factors, we may be unable to successfully develop and realize the commercial potential of any product candidates we may identify and develop, and our business, financial condition, results of operations, and prospects would be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing in human clinical trials of any product candidates we may develop and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates or medicines that we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant time and costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any medicines that we may develop. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue clinical trials and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to regulatory and operational risks associated with our internal manufacturing facility.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an approximately 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina intended to support clinical and commercial production of certain of our product candidates and components thereof. We aim to follow cGMP processes necessary to release product for our clinical trials and to meet all requirements from regulatory agencies, including the FDA, to allow us to support research, clinical and, if approved, commercial production of certain of our product candidates and components thereof. However, we can provide no assurances that our facility will be able to support our intended internal manufacturing capabilities and/or needs or comply with regulatory agency requirements. Furthermore, while the design of our facility is based on current standards for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">biotechnology facilities, it was not pre-approved by any regulatory agency, nor has the facility been inspected by any regulatory agency such as the FDA. If we are unable to operate our facility at the intended capacity, or if our facility is determined not to comply with applicable regulatory requirements, we may be unable to manufacture our products or product candidates in a timely manner, which could significantly impair our ability to develop, obtain approval for, or commercialize our product candidates. Additionally, we have incurred substantial expenditures in constructing our facility, and expect to incur significant additional expenditures operating our facility in the future. To the extent our facility does not operate at capacity or comply with regulatory requirements, we may incur expenditures beyond those we currently contemplate, including costs associated with engaging third parties to meet our manufacturing needs or undertaking remediation efforts to bring our facility into compliance with regulatory standards. Any such delays, interruptions or increased costs arising from the operation of our manufacturing facility could materially harm our business, operating results, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or any CMOs and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and any CMOs and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Further, while we carry biological or hazardous waste insurance coverage, such insurance coverage may not be adequate to cover losses, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting requirements. These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in substantial fines, penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Genetic medicines are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop, or otherwise harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, insufficient inventory, or potentially delay progression of our potential regulatory filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. In addition, our product candidates we may develop will require complicated delivery modalities, such as electroporation and LNPs, each of which will introduce additional complexities in the manufacturing process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, the EMA, and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we intend to use novel technologies to deliver the base editor and guide RNA constructs of product candidates, however scientific evidence to support the feasibility of developing product candidates based on these technologies is both preliminary and limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also may encounter problems hiring and retaining the experienced scientific, quality control, and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall, or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our relationships with third parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on and expect to continue to rely on third parties to manufacture components of our product candidates we may develop, conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on and expect to continue to rely on third parties, such as CMOs, CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing, to manufacture components of our product candidates and to conduct our clinical trials. Any of these third parties may terminate their engagements with us at any time under certain criteria. If we need to enter into alternative arrangements, it may delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, EMA and other regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. In the United States, we also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we design the clinical trials for our product candidates, we rely on and expect to continue to rely on CROs to conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct preclinical studies and clinical trials also results in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs and other third parties do not perform preclinical studies and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of, or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We contract with third parties for the manufacture and supply of materials for our research programs, preclinical studies and clinical trials and expect to continue to do so for at least a portion of our future research programs, preclinical studies and clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on third-parties for the manufacture and supply of materials for a portion of our preclinical studies and clinical trials, and may continue to do so for future research programs, preclinical studies, clinical testing and for commercial supply of any product candidates that we may develop and for which we or our collaborators obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have built a manufacturing facility designed to support manufacturing for our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cell therapy programs in hematology and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-viral delivery programs for liver diseases in Research Triangle Park, North Carolina, we cannot be certain that we will be able to maintain cGMP compliance, expand our internal manufacturing capacity, or meet the planned manufacturing needs of our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to establish long-term supply agreements with third-party suppliers or to do so on acceptable terms. Even if we are able to establish long-term supply agreements with third-parties, reliance on third-parties entails additional risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing or supply agreement by the third party; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible inability of third-party suppliers to supply and/or transport materials, components and products to us in a timely manner as a result of disruptions to the global supply chain or other factors.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party suppliers may not be able to comply with cGMP regulations or other regulatory requirements outside the United States. Our failure, or the failure of third-party suppliers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we rely on various CROs to obtain non-human primates, or NHPs, for use in preclinical development work. While we believe we currently have access to a supply of NHPs adequate to meet our near-term needs, such supply may nevertheless be adversely affected by supply chain limitations. If we are unable to secure adequate supply of NHPs certain of our preclinical development efforts will be delayed, and the cost of conducting discovery projects and preclinical development activities may substantially increase. Such delays or cost increases could materially adversely affect our discovery and preclinical development activities and our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any medicines that we develop may compete with other product candidates and products for access to manufacturing facilities or supplies. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing drug components and drug product necessary for gene editing. Any performance failure on the part of our existing or future suppliers could delay preclinical or clinical development or marketing approval. We do not currently have arrangements in place for redundant supply of all drug components and drug products necessary for our gene editing product candidates. If any one of our current contract manufacturers or suppliers cannot perform as agreed, we may be required to replace that manufacturer or supplier. Although we believe that there are several potential alternative suppliers to support any product candidates we may develop, we may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As our drug development pipeline increases and matures, the increased demand for clinical supplies from our facilities and third parties may impact our ability to operate. We will require increased capacity across our entire supply chain. Furthermore, we rely on many service providers, including those that provide manufacturing or testing services, all of whom have inherent risks in their operations that may adversely impact our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion of our clinical trials and commercialization of our product candidates require access to, or development of, facilities to manufacture our product candidates at sufficient yields and, if approved, at commercial-scale. We have limited experience manufacturing any of our product candidates in the volumes that are necessary to support clinical trials and no experience manufacturing at volumes that are necessary to support commercial sales. Efforts to establish these capabilities may not meet initial expectations as to scheduling, scale-up, reproducibility, yield, purity, cost, potency or quality. In addition, other companies, many with substantial resources, compete with us for access to the materials needed to manufacture our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently utilize, and expect to continue to utilize, third parties to, among other things, manufacture raw materials, components, parts, and consumables, and to perform quality testing. If the field of base editing and other genetic medicines continues to expand, we may encounter increasing competition for these materials and services. Demand for third-party manufacturing or testing facilities may grow at a faster rate than their existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of such raw materials, components, parts, and consumables required to manufacture our product candidates. The use of service providers and suppliers could expose us to risks, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or non-renewal of supply and service agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspections of third-party facilities by regulatory authorities that could have a negative outcome and result in delays to or termination of their ability to supply our requirements.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on third-party manufacturers may adversely affect our operations or result in unforeseen delays or other problems beyond our control. Because of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals and facilities to manufacture our product candidates on a clinical and, if approved, a commercial scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in the production of our product candidates. A third-party manufacturer may also encounter difficulties in production. These problems may include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties with production costs, scale up and yields;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of raw materials and supplies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quality control and assurance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortages of qualified personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with strictly enforced federal, state and foreign regulations that vary in each country where products might be sold; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of capital funding.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, any delay or interruption could have a material adverse effect on our business, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have and may in the future enter into collaborations with third parties for the research, development, and commercialization of certain of the product candidates we develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have and may in the future seek third-party collaborators for the research, development, and commercialization of certain of the product candidates we develop. Under the agreements we have entered into and any agreements we may enter into in the future with any third parties, we have and will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations involving our research programs or any product candidates we may develop pose numerous risks to us, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators may not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our medicines or product candidates we develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators with marketing and distribution rights to one or more medicines may not commit sufficient resources to the marketing and distribution of such medicine or medicines. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates we may develop. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. Furthermore, even if we receive such payments, they will likely result in payment obligations under license agreements with our licensors, which could be substantial. If we do not receive the funding we expect under these collaboration agreements, or if the funding is substantially offset by payment obligations to our licensors, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates, we may develop we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development and research programs and the potential commercialization of any product candidates we may develop will require substantial additional cash to fund expenses. For some of the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, if approved, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or, if approved, commercialization activities at our own expense. If we elect to increase our expenditures to fund development or, if approved, commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to develop product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are exposed to risks associated with our minority interest in Orbital Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, we helped launch Orbital Therapeutics Inc., or Orbital, in collaboration with ARCH Venture Partners, with a goal of advancing ribonucleic acid, or RNA, medicines. In connection with the Orbital launch, we entered into a license and collaboration agreement, or the Orbital Agreement, with Orbital pursuant to which we and Orbital each granted the other licenses to certain technology controlled by it necessary or reasonably useful for the non-viral delivery or the design or manufacture of RNA for the prevention, treatment or diagnosis of human disease. In addition, concurrently with our entry into the Orbital Agreement, Orbital issued us 75 million shares of its common stock. ARCH Venture Partners is also a stockholder of Orbital, one of our directors affiliated with ARCH Venture Partners, John Maraganore, as well as John Evans, our Chief Executive Officer, are members of the board of directors of Orbital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a lesser degree of control over its business operations, thereby potentially subjecting us to additional financial, legal, operational and compliance risks. In addition, the controlling shareholders or management of Orbital may have business interests, strategies or goals that are inconsistent with ours. These risks include the possibility that Orbital or such other stockholders have economic or business interests or goals that are or become inconsistent with our economic or business interests or goals; are in a position to take action contrary to our instructions, requests, policies or objectives; subject us to unexpected liabilities or risks; take actions that reduce our return on investment; act in a manner that compromises our key licensed rights, or important intellectual or other rights that we own or license; or take actions that harm our reputation or restrict our ability to run our business. Furthermore, as a result of our ownership in Orbital, we may in the future be required to include Orbital&#8217;s financial information in our consolidated financial results. We have not previously included a minority-owned subsidiary in our financial statements and we would therefore be subject to increased risk in accurately representing and incorporating Orbital financial statements into our own, which could result in delayed filings with the SEC and the finding of a material or significant weakness, among others. This could result in harmful consequences to our business, including an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent and other intellectual property protection for any product candidates we develop and for our platform technologies, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our platform technologies may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in large part on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection of our base editing platform technology, product candidates and other technology, including delivery platform technology methods used to manufacture them and methods of treatment, as well as successfully defending our patent and other intellectual property rights against third-party challenges. It is difficult and costly to protect our base editing platform technology and protect candidates, and we may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates we may develop is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our proprietary position by in-licensing intellectual property relating to our platform technology and filing patent applications in the United States and abroad related to our base editing platform technology, delivery platform technology and product candidates that are important to our business. If we or our licensors are unable to obtain or maintain patent protection with respect to our base editing platform technology, delivery platform technology and product candidates we may develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours and our ability to commercialize any product candidates we may develop may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or any licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The field of gene editing, especially in the area of base editing technology, has been the subject of extensive patenting activity and litigation. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain, and we may become involved in complex and costly litigation. Our pending and future patent applications may not result in patents being issued which protect our base editing platform technology, delivery platform technology and product candidates we may develop, or which effectively prevent others from commercializing competitive technologies and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consistent policy regarding the scope of claims allowable in the field of gene editing, including base editing technology, has emerged in the United States. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, enforce and defend our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patent rights. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will be valid and enforceable and provide sufficient protection from competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own, or in-license, may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates we may develop will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned by us with third parties. For example, a patent application directed to our potential HBG1 and HBG2 product candidates is co-owned by us, the President and Fellows of Harvard College, or Harvard, and Broad Institute. At present, we do not have a license to the ownership interest of Harvard or Broad Institute. If we are unable to obtain an exclusive license to such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our rights to develop and commercialize our base editing platform technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have licensed and are dependent on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our base editing technology and product candidates. For example, we are a party to license agreements with Broad Institute, Editas, Harvard, and Bio Palette, and others, pursuant to which we in-license key patents and patent applications for our base editing platform technology and product candidates (the Broad License Agreement, the Editas License Agreement, the Harvard License Agreement and the Bio Palette License Agreement, respectively). These license agreements impose various diligence, milestone payment, royalty, insurance, and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate our license, in which event we would not be able to develop or market our base editing platform or any other technology or product candidates covered by the intellectual property licensed under these agreements. For example, under the Harvard License Agreement, we are required to meet certain development milestones for the development of a licensed product covered by certain sub-categories of licensed patents. If we fail to meet such milestones, our rights with respect to the sub-category of licensed patents will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our base editing platform technology and product candidates in the future. Some licenses granted to us are expressly subject to certain preexisting rights held by the licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. For example, certain licensed patents developed by employees of the Howard Hughes Medical Institute, or HHMI, and subsequently assigned to Harvard and licensed to us under the Harvard License Agreement remain subject to a non-exclusive license between Harvard and HHMI. The Editas License Agreement provides that our field of use excludes the use of certain gene editing technologies for the diagnosis, treatment, and prevention of human cancers through certain engineered T-cells, which are licensed to Juno Therapeutics, Inc. (a subsidiary of Bristol-Myers Squibb Company). If we determine that rights to such excluded field are necessary to commercialize any of our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Broad License Agreement, rights granted to us include certain patent applications directed to Cas12b or Cas13 that are limited to the United States. The co-owners of these patent applications include Broad Institute, Harvard, MIT, the State University of New Jersey, or Rutgers, Skolkovo Institute of Science and Technology, or Skoltech, and the NIH. At present, we do not have a license to the ownership interest of Skoltech. If we are unable to obtain an exclusive license to Skoltech&#8217;s, interest in such patent applications, Skoltech may be able to license its rights to other third parties, including our competitors, and such third parties could market competing products and technology. In addition, we may need the cooperation of Skoltech in order to enforce patents issuing from these patent applications against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, pursuant to our license agreement with Broad Institute and our license agreement with Harvard, under certain specific circumstances (in each case), Broad Institute or Harvard (as applicable) may grant a license to the patents that are the subject of such license agreement to a third party in the same field as such patents are licensed to us. Such third party may then have full rights that are the subject of the Broad License Agreement or the Harvard License Agreement (as applicable), which could impact our competitive position and enable a third party to commercialize products similar to our potential future product candidates and technology. Any grant of rights to a third party in this scenario would narrow the scope of our exclusive rights to the patents and patent applications we have in-licensed from Broad Institute and/or Harvard, as applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have complete control in the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, pursuant to each of our intellectual property licenses with Broad Institute, Harvard, Editas and Bio Palette, our licensors retain control of preparation, filing, prosecution, and maintenance, and, in certain circumstances, enforcement and defense of their patents and patent applications. It is possible that our licensors&#8217; enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, or may not be conducted in accordance with our best interests. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors from making, using, and selling competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us in jurisdictions where the consent of a co-owner is necessary to grant such a license may not be valid and such co-owners may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, inventions contained within some of our in-licensed patents and patent applications were made using U.S. government funding. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, such as timely reporting, an obligation associated with our in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents. For example, the U.S. government could have certain rights in such in-licensed patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may also exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such in-licensed U.S. government-funded inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations, and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event any of our third-party licensors determine that, in spite of our efforts, we have materially breached a license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more licenses under the applicable license agreement and such termination would result in us no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party in-license, or if the underlying patents under a third-party in-license fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our owned and in-licensed patents and patent applications may not provide sufficient protection of our platform technologies, our product candidates and our future product candidates or result in any competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have in-licensed a number of issued U.S. patents and patent applications that cover base editing and gene targeting technologies, as well as our delivery platform technology. We have applied for provisional patent applications or Patent Cooperation Treaty, or PCT, applications intended to specifically cover our base editing platform technology and uses with respect to treatment of particular diseases and conditions, and currently own three issued U.S. patents. We have applied for provisional patent applications or PCT applications intended to specifically cover our delivery platform technology but do not currently own any issued U.S. patents. Each U.S. provisional patent application is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the intentions disclosed in the associated provisional patent applications. We cannot be certain that any of these patent applications will issue as patents, and if they do, that such patents will cover or adequately protect our base editing platform technology, delivery platform technology or our product candidates, or that such patents will not be challenged, narrowed, circumvented, invalidated or held unenforceable. Any failure to obtain or maintain patent protection with respect to our base editing platform technology, delivery platform technology and product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our owned patents and patent applications and our in-licensed patents and patent applications contain claims directed to compositions of matter on our base editing product candidates, as well as methods directed to the use of such product candidates for gene therapy treatment. Method-of-use patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, providers may recommend that patients use these products off-label, or patients may do so themselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own, or in-license, may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. For example, while our patent applications are pending, we may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in interference or derivation proceedings, or equivalent proceedings in foreign jurisdictions. Even if patents do successfully issue, third parties may challenge their inventorship, validity, enforceability or scope, including through opposition, revocation, reexamination, post-grant and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review proceedings. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in-licensed patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we own or the patents and patent applications we in-license with respect to our base editing platform technology, delivery platform technology and product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in development, testing, and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given that patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we or our licensors were in the past or will be in the future the first to file any patent application related to our base editing technology, delivery platform technology or product candidates. In addition, some patent applications in the United States may be maintained in secrecy until the patents are issued. As a result, there may be prior art of which we or our licensors are not aware that may affect the validity or enforceability of a patent claim, and we or our licensors may be subject to priority disputes. For our in-licensed patent portfolios, we rely on our licensors to determine inventorship, and obtain and file inventor assignments of priority applications before their conversion as PCT applications. A failure to do so in a timely fashion may give rise to a challenge to entitlement of priority for foreign applications nationalized from such PCT applications. For example, the European Patent Office, or the EPO, Opposition Division, or the EPO Opposition Division, has revoked our optioned Broad Institute patent European Patent No. EP2771468 following a third-party challenge to its priority rights. The patent was revoked due to loss of priority. We or our licensors are subject to and may in the future become a party to proceedings or priority disputes in Europe or other foreign jurisdictions. The loss of priority for, or the loss of, these European patents could have a material adverse effect on the conduct of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be required to disclaim part or all of the term of certain patents or patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we or our licensors are aware, but which we or our licensors do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, our patents would be declared by a court, patent office or other governmental authority to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, that block our efforts or potentially result in our product candidates or our activities infringing such claims. It is possible that our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Those patent applications may have priority over our owned patent applications and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. The possibility also exists that others will develop products that have the same effect as our product candidates on an independent basis that do not infringe our patents or other intellectual property rights, or will design around the claims of our patent applications or our in-licensed patents or patent applications that cover our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Likewise, our currently owned patents and patent applications, if issued as patents, and in-licensed patents and patent applications, if issued as patents, directed to our proprietary base editing technologies and our product candidates are expected to expire from 2034 through 2045, without taking into account any possible patent term adjustments or extensions. Our owned or in-licensed patents may expire before, or soon after, our first product candidate achieves marketing approval in the United States or foreign jurisdictions. Additionally, no assurance can be given that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own or in-license currently or in the future. Upon the expiration of our current in-licensed patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our owned patents and patent applications and in-licensed patents and patent applications and other intellectual property may be subject to priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have an option to exclusively license certain patents and patent applications directed to Cas9 and Cas12a from Editas, who in turn has licensed such patents from various academic institutions including Broad Institute, we do not currently have a license to such patents and patent applications. Certain of the U.S. patents and one U.S. patent application to which we hold an option are co-owned by Broad Institute and MIT, and in some cases co-owned by Broad Institute, MIT, and Harvard, which we refer to together as the Boston Licensing Parties, and were involved in U.S. interference No. 106,048 with one U.S. patent application co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier, which we refer to together as the University of California. On September 10, 2018, the Court of Appeals for the Federal Circuit, or the CAFC, affirmed the Patent Trial and Appeal Board of the USPTO&#8217;s, or PTAB&#8217;s, holding that there was no interference-in-fact. An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims filed by different parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 24, 2019, the PTAB declared an interference (U.S. Interference No. 106,115) between ten U.S. patent applications ((U.S. Serial Nos. 15/947,680; 15/947,700; 15/947,718; 15/981,807; 15/981,808; 15/981,809; 16/136,159; 16/136,165; 16/136,168; and 16/136,175) that are co-owned by the University of California, and 13 U.S. patents and one U.S. patent application (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial No. 14/704,551)) that are co-owned by the Boston Licensing Parties, which we have an option to under the Editas License Agreement. In the declared interference, the University of California has been designated as the junior party and the Boston Licensing Parties have been designated as the senior party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the declaration of interference, an adversarial proceeding in the USPTO before the PTAB has been initiated, which is declared to ultimately determine priority, specifically and which party was first to invent the claimed subject matter. An interference is typically divided into two phases. The first phase is referred to as the motions or preliminary motions phase while the second is referred to as the priority phase. In the first phase, each party may raise issues including but not limited to those relating to the patentability of a party&#8217;s claims based on prior art, written description, and enablement. A party also may seek an earlier priority benefit or may challenge whether the declaration of interference was proper in the first place. Priority, or a determination of who first invented the commonly claimed invention, is determined in the second phase of an interference. The ten University of California patent applications and the 13 U.S. patents and one U.S. patent application co-owned by the Boston Licensing Parties involved in U.S. Interference No. 106,115 generally relate to CRISPR/Cas9 systems or eukaryotic cells comprising CRISPR/Cas9 systems having fused or covalently linked RNA and the use thereof in eukaryotic cells. On February 28, 2022, the PTAB issued a decision that the Boston Licensing Parties have priority of invention over University of California with respect to a single RNA CRISPR-Cas9 system that functions in eukaryotic cells. This decision is being appealed. There can be no assurance that the U.S. interference will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resolved in favor of the Boston Licensing Parties on appeal. If the U.S. interference resolves in favor of University of California, or if the Boston Licensing Parties&#8217; patents and patent application are narrowed, invalidated, or held unenforceable, we may lose the ability to license the optioned patents and patent application and our ability to commercialize our product candidates may be adversely affected if we cannot obtain a license to relevant third party patents that cover our product candidates. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to similar interferences in the future with the same risks as described above. For example, on December 14, 2020, the PTAB declared an interference (U.S. Interference No. 106,126) between 14 U.S. patents and two U.S. patent applications (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,889,418; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial Nos. 14/704,551 and 15/330,876) that are co-owned by the Boston Licensing Parties, which we have an option to under the Editas License Agreement, and one U.S. patent application (U.S. Serial Nos. 14/685,510) that is owned by Toolgen, Inc, or Toolgen. In the declared interference, the Boston Licensing Parties have been designated as the junior party and Toolgen has been designated as the senior party. On September 28, 2022, the PTAB issued an order suspending proceedings in the priority phase of the interference. We cannot predict with any certainty when a decision will be made. The 14 U.S. patents and two U.S. patent applications co-owned by the Boston Licensing Parties involved in U.S. Interference No. 106,126 generally relate to CRISPR/Cas9 systems or eukaryotic cells comprising CRISPR/Cas9 systems having fused or covalently linked RNA and the use thereof in eukaryotic cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 21, 2021, the PTAB declared an interference (U.S. Interference No. 106,133) between the same 14 U.S. patents and two U.S. patent applications (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,889,418; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial Nos. 14/704,551 and 15/330,876, co-owned by the Boston Licensing Parties) as named in the interference with Toolgen, and one U.S. patent application (U.S. Serial Nos. 15/456,204) that is owned by Sigma-Aldrich Co., LLC, or Sigma-Aldrich. In the declared interference, the Boston Licensing Parties have been designated as the junior party and Sigma-Aldrich has been designated as the senior party. On December 14, 2022, the PTAB issued an order suspending proceedings in the priority phase of the interference. We cannot predict with any certainty when a decision will be made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned patents or patent applications or in-licensed patents or patent applications or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions), or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our owned, licensed, or optioned patents, or such patent claims may be narrowed, invalidated, or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. In the event of loss of patent rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we or our licensors are successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of foreign countries do not protect intellectual property rights to the same extent as federal and state laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our patents and intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover, the initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into license agreements with third parties and may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including base editing technology, delivery platform technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In each of our license agreements, we are generally responsible for bringing any actions against any third party for infringing on the patents we have licensed. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of or base editing platform technology, delivery platform technology or product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights to third parties under our collaborative development relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or broaden what we believe to be the scope of the licensor&#8217;s rights to our intellectual property and technology, or increase what we believe to be our financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and commercialize our base editing platform, delivery platform, or other product candidates or we could lose other significant rights, any of which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. It is also possible that a third party could be granted limited licenses to some of the same technology, in certain circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates, and we expect to seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates and technologies. Although we have succeeded in licensing technologies from third party licensors, including Harvard, Broad Institute, Editas, and Bio Palette in the past, we cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, our agreements with certain of our third-party licensors provide that our field of use excludes particular fields, for example, the use of certain gene editing technologies for the diagnosis, treatment, and prevention of human cancers through certain engineered T-cells, which are licensed exclusively or non-exclusively to a third-party licensee. If we determine that rights to such fields are necessary to commercialize our drug candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our drug candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, there has been extensive patenting activity in the fields of gene editing and delivery technologies, and pharmaceutical companies, biotechnology companies, and academic institutions are competing with us or are expected to compete with us in the fields of gene editing and delivery technologies and filing patent applications potentially relevant to our business and we are aware of certain third-party patents, as well as patent applications that, if issued, may allow the third party to circumvent our patent rights. For example, we are aware of several third-party patents, and patent applications that, if issued, may be construed to cover our base editing technology, delivery technology and product candidates. In order to market our product candidates, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for product candidates we may develop and base editing and delivery technologies. We may also require licenses from third parties for additional non-base editing technologies, including additional delivery methods that we are evaluating for use with product candidates we are developing and may develop in the future. In addition, some of our owned patents and patent applications and in-licensed patents and patent applications are co-owned with third parties. With respect to any patents co-owned with third parties, we may require licenses to such co-owners&#8217; interest to such patents. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The intellectual property landscape around gene editing technology, including base editing and delivery technology, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The field of gene editing, especially in the area of base editing technology, is still in its infancy, and no base editing product candidates have reached the market. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field and in the field of delivery technology, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market, and sell any product candidates that we may develop and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our base editing platform technology, delivery platform technology and any product candidates we may develop, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the EPO. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our base editing platform technology, delivery platform technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patents and patent applications that, if issued, may be construed to cover our base editing technology, delivery technology and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. Our product candidates make use of CRISPR-based technology, which is a field that is highly active for patent filings. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover our base editing platform technology and product candidates and their use or manufacture. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our base editing platform technology and product candidates. For example, we are aware of a patent portfolio that is co-owned by the University of California, University of Vienna and Emmanuelle Charpentier, or the University of California Portfolio, which contains multiple patents and pending applications directed to gene editing. The University of California portfolio includes, for example, U.S. Patent Nos. 10,266,850; 10,227,611; 10,000,772; 10,113,167; 10,301,651; 10,308,961; 10,337,029; 10,351,878; 10,407,697; 10,358,659; 10,358,658; 10,385,360; 10,400,253; 10,421,980; 10,415,061; 10,428,352; 10,443,076; 10,487,341; 10,513,712; 10,519,467; 10,526,619; 10,533,190; 10,550,407; 10,563,227; 10,570,419; 10,577,631; 10,597,680; 10,612,045; 10,626,419; 10,640,791; 10,669,560; 10,676,759; 10,752,920; 10,774,344; 10,793,878;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10,900,054; 10,982,230; 10,982,231; 10,988,780; 10,988,782; 11,001,863; 11,008,589; 11,008,590; 11,028,412; 11,186,849; 11,242,543; 11,274,318; 11,293,034; 11,332,761; 11,401,532; 11,473,108; 11,479,794; 11,549,127; 11,634,730; 11,674,159; 11,814,645; 11,970,711; 12,123,015; 12,180,503; 12,180,504; 12,215,343, which are expected to expire around March 2033, excluding any additional term for patent term adjustment, or PTA, or patent term extension, or PTE, and any disclaimed term for terminal disclaimers. The University of California portfolio also includes numerous additional pending patent applications. If these patent applications issue as patents, they are expected to expire around March 2033, excluding any PTA, PTE, and any disclaimed term for terminal disclaimers. As discussed above, certain applications in the University of California Portfolio are currently subject to U.S. Interference No. 106,115 with certain U.S. patents and one U.S. patent application that are co-owned by the Boston Licensing Parties to which we have an option under the Editas License Agreement. Although we have an option to exclusively license certain patents and patent applications directed to Cas9 and Cas12a from Editas, who in turn has licensed such patents from various academic institutions including Broad Institute, we do not currently have a license to such patents and patent applications. Certain members of the University of California Portfolio have been or are being opposed in Europe by multiple parties. For example, European Patent Nos. EP2,800,811 B1, and EP3,241,902 B1, and EP3,401,400 B1 have been opposed, and notices of opposition have been filed by several third parties against European Patent No. EP3,597,749 B1, which patents are estimated to expire in March 2033 (excluding any patent term adjustments or extensions). The opposition procedure before the EPO allows one or more third parties to challenge the validity of a granted European patent within nine months after grant date of the European patent. Opposition proceedings may involve issues including, but not limited to, priority, patentability of the claims involved, and procedural formalities related to the filing of the patent application. As a result of the opposition proceedings, the Opposition Division can revoke a patent, maintain the patent as granted, or maintain the patent in an amended form. In April 2021, the claims of European patent EP3,241,902 B1 were revoked in their entirety by the Opposition Division, and that decision was not appealed. In November 2024, European patents EP2,800,811 B1 and EP3,401,400 B1 were revoked by the Boards of Appeal of the European Patent Office. It is uncertain how oppositions filed against EP3,597,749 B1 will be resolved. If this patent is maintained by the Opposition Division with claims similar to those that were opposed, our ability to commercialize our product candidates may be adversely affected if we do not obtain a license to these patents. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous other patents and patent applications have been filed by other third parties directed to gene editing, guide nucleic acids, PAM sequence variants, split inteins, Cas12b or gene editing in the context of immune therapy or chimeric antigen receptors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the large number of patents issued and patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement claims or lawsuit against us, and if we are found to infringe such third-party patents, we may be required to pay damages, cease commercialization of the infringing technology, or obtain a license from such third parties, which may not be available on commercially reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to commercialize our product candidates in the United States and abroad may be adversely affected if we cannot obtain a license on commercially reasonable terms to relevant third-party patents that cover our product candidates, delivery platform technology or base editing platform technology. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology, delivery platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defense of third-party claims of infringement of misappropriation, or violation of intellectual property rights involves substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, future patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful and could result in a finding that such patents are unenforceable or invalid.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents, future patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents, future patents or the patents of our licensing partners also are, and may in the future become, involved in inventorship, priority, validity or enforceability disputes. Countering or defending against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent owned or in-licensed by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our technology and/or product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conversely, we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). We are currently challenging, and in the future may choose to challenge, third party patents in patent opposition proceedings in the EPO or another foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates, base editing platform technology, delivery platform technology or other or proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, as discussed above, elements of the University of California patent portfolio are being opposed in Europe by multiple parties and we are participating in the opposition proceedings. The EPO Opposition Division, or the Opposition Division, has initiated opposition proceedings against European patents estimated to expire in March 2033 (excluding any patent term adjustments or extensions) and co-owned by the University of California. The opposition procedure before the EPO allows one or more third parties to challenge the validity of a granted European patent within nine months after grant date of the European patent. Opposition proceedings may involve issues including, but not limited to, priority, patentability of the claims involved, and procedural formalities related to the filing of the patent application. As a result of the opposition proceedings, the Opposition Division can revoke a patent, maintain the patent as granted, or maintain the patent in an amended form. It is uncertain when or in what manner the Opposition Division will act on the opposition proceedings of these European patents. If these patents are maintained by the Opposition Division with claims similar to those that are currently opposed, our ability to commercialize our product candidates may be adversely affected if we do not obtain a license to these patents. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology, delivery platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications are due to be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations, however, in which non-compliance can result a partial or complete loss of patent rights in the relevant jurisdiction. Were a noncompliance event to occur, our competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our platform technologies and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents. For example, in March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the United States transitioned from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; patent system. Under a &#8220;first-to-file&#8221; system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our technology or product candidates or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America Invents Act also includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, allowing third party submission of prior art and establish a new post-grant review system including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The effects of some of these changes are currently unclear as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions including PTE and PTA, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments PTE term of up to five years as compensation for patent term lost during the FDA regulatory review process. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a PTE, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain PTE or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patents for our technology and product candidates, we also rely on know-how and trade secret protection, as well as confidentiality agreements, non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed by or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may consume our time and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties have asserted and may in the future assert that we, our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. In addition, we regularly enter into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as research institutions, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners and other third parties in order to evaluate technology for potential development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we try to ensure that we and our employees, consultants, and advisors do not use the proprietary information or know-how of others, we have received and may in the future be subject to claims that we or these individuals have inadvertently or otherwise wrongfully used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties, including</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any such individual&#8217;s current or former employer. Also, we have in the past and may in the future be subject to claims that these individuals are violating non-compete agreements with their former employers. We may then have to pursue litigation to defend against any of these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make gene therapy products that are similar to any product candidates we may develop or utilize similar base editing technology but that are not covered by the claims of the patents that we license or may own in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our license partners or current or future collaborators, may fail to meet our obligations to the U.S. government regarding any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending, owned or licensed patent applications or those that we may own in the future will not lead to issued patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, or parts of our owned or in-licensed patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to may be held invalid, unenforceable, or narrowed in scope, including as a result of legal challenges by our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current or future collaborators to the same extent as the laws of the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its BLA does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product and the exclusivity period may be shared amongst multiple first interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws, or amendments to laws, which address pharmacy practices involving biosimilar products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our product candidates may have a material adverse impact on our business due to increased competition and pricing pressure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to regulatory and other legal compliance matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory requirements governing genetic medicines, and in particular any novel genetic medicines we may develop, have changed frequently and may continue to change in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing genetic and cellular medicines, and in particular any novel genetic medicine products we may develop, have changed frequently and may continue to change in the future. We are aware of a limited number of genetic medicines that have received marketing authorization from the FDA and EMA. Even with respect to more established products in the genetic medicine field, the regulatory landscape is still developing. For example, the FDA has established the Office of Tissues and Advanced Therapies (formerly the Office of Cellular, Tissue and Gene Therapies) within CBER to consolidate the review of genetic medicines and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Genetic medicine clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee, or the RAC; however, the NIH announced that the RAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same applies in the European Union, or EU. The EMA&#8217;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety, purity and potency of advanced-therapy medicinal products. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a genetic medicinal candidate that is submitted to the CHMP before CHMP adopts its final opinion. In the EU, the development and evaluation of a genetic medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for genetic medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to genetic medicines and cell therapy products may be applied to any product candidates we may develop, but that remains uncertain at this point.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product candidates we may develop or lead to significant post-approval limitations or restrictions. As we advance any product candidates we may develop, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of these product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA decides whether individual genetic medicine protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, that institution&#8217;s IBC as well as its IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of genetic medicine products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any product candidates we may develop. Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for genetic medicine products and require that we comply with these new guidelines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we are initially seeking to identify and develop product candidates to treat diseases using novel technologies, there is heightened risk that the FDA, the EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed clinically meaningful, we may not achieve these endpoints to a degree of statistical significance, particularly because many of the diseases we are targeting with our platform, including T-cell acute lymphoblastic leukemia, glycogen storage disorder and Stargardt disease, have small patient populations, making development of large and rigorous clinical trials more difficult. Further, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the EU and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe, and only a limited number of gene therapy products have received marketing authorization or marketing approval from the European Commission or the FDA. Some of these products have taken years to register and have had to address significant issues in their post-marketing experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments in post-marketing experience or in clinical trials conducted by others of genetic medicines or cell therapy products may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing non-viral genetic medicinal technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety, purity and potency of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing non-viral genetic medicine technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, ethical, social and legal concerns about genetic medicine, genetic testing and genetic research could result in additional regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that any product candidates we may develop are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of any product candidates we may develop under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance any product candidates we develop through clinical development, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product candidates we may develop or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we may develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we may develop, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale, import, export, and distribution, are subject to comprehensive regulation by the FDA, the EMA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biological product candidate&#8217;s safety, purity, and potency. Securing regulatory approval also requires the submission of extensive information about the product manufacturing process, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for certain biological products must contain data to assess the safety and effectiveness of the biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the EU also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Pediatric Committee. For any of our product candidates for which we are seeking regulatory approval in the U.S. or the EU, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for example, the court overruled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act, or the APA. Additionally, in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities and Exchange Commission v. Jarkesy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our ability to develop and market new drug products may be impacted by litigation challenging the FDA&#8217;s approval of another company&#8217;s drug product. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the Supreme Court reversed that decision after unanimously finding that the plaintiffs (anti-abortion doctors and organizations) did not have standing to bring this legal action against the FDA. On October 11, 2024, the Attorneys General of three states (Missouri, Idaho and Kansas) filed an amended complaint in the district court in Texas challenging the FDA&#8217;s actions. On January 16, 2025, the district court agreed to allow these states to file an amended complaint and continue to pursue this challenge. Depending on the outcome of this litigation, our ability to develop new drug product candidates and to maintain approval of existing drug products could be delayed, undermined or subject to protracted litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, with the change in presidential administrations in 2025, there is substantial uncertainty as to how, if at all, the new administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. The impending uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market and sell any product candidates we may develop in the EU and other foreign jurisdictions, we or our third-party collaborators must obtain separate marketing approvals (a single one for the EU) and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product candidate be approved for reimbursement before the product candidate can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the U.K. as a result of the withdrawal of the U.K. from the EU, commonly referred to as Brexit. The U.K. is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency, or MHRA, is responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain, or GB, and Northern Ireland). At the same time, a new international recognition procedure, or IRP, will apply, which intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include the EMA and regulators in the EU/European Economic Area, or EEA, member states for approvals in the EU centralized procedure and mutual recognition procedure, as well as the FDA for product approvals granted in the U.S. However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals may force us to restrict or delay efforts to seek regulatory approval in the U.K. for our product candidates, which could significantly and materially harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Physicians may nevertheless prescribe our products off-label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that any of our sales and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. For example, in January 2025, the FDA published final guidance outlining its non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This final guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use. In addition, under some relatively recent guidance from the FDA and the Pre-Approval Information Exchange Act, or PIE Act, signed into law as part of the Consolidated Appropriations Act of 2023, companies may also promote information that is consistent with the prescribing information and proactively speak to formulary committee members of payors regarding data for an unapproved drug or unapproved uses of an approved drug. We may engage in these discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission, or the FTC, and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDCA, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> suit is entitled to a share of any recovery or settlement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Qui tam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market any product for an indication that is not approved, we may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on such product, manufacturers or manufacturing processes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters or untitled letters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the product from the market;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on coverage by third-party payors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar restrictions apply to the approval of our products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the EU. and are also subject to EU. Member State laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast track, breakthrough, or regenerative medicine advanced therapy designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA&#8217;s fast track, breakthrough, and regenerative medicine advanced therapy, or RMAT, programs are intended to expedite the development of certain qualifying products intended for the treatment of serious diseases and conditions. If a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the product&#8217;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA fast track designation. A product candidate may be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A product candidate may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening condition, and preliminary clinical evidence indicates that the product candidate has the potential to address an unmet medical need for such condition. While we may seek fast track, breakthrough, and/or RMAT designation, there is no guarantee that we will be successful in obtaining any such designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track, breakthrough, or RMAT designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw fast track, breakthrough, or RMAT designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track, breakthrough, and/or RMAT designation alone do not guarantee qualification for the FDA&#8217;s priority review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review a marketing application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek PRIME Designation in the EU for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and where the sponsor intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek designation for our platform technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek designation for our platform technology as a designated platform technology. Under FDORA, a platform technology incorporated within or utilized by a drug or biological product is eligible to be a designated platform technology if (1) the platform technology is incorporated in, or utilized by, a drug approved under a BLA; (2) preliminary evidence submitted by the sponsor of the approved or licensed drug, or a sponsor that has been granted a right of reference to data submitted in the application for such drug, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one drug without an adverse effect on quality, manufacturing, or safety; and (3) data or information submitted by the applicable person indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring significant efficiencies to the drug development or manufacturing process and to the review process. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original BLA for a drug that uses or incorporates the platform technology. Even if we believe our platform technology meets the criteria for such designation, the FDA may disagree and instead determine not to grant such designation. In addition, the receipt of such designation for a platform technology does not ensure that a drug will be developed more quickly or receive FDA approval. Moreover, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, EMA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. In addition, disruptions may also result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, with the change in the presidential administration in 2025, there is substantial uncertainty as to how, if at all, the new administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. There is also uncertainty as to how other measures being implemented by the Trump Administration across the government will impact our activities and those of the FDA and its operations. For example, the potential loss of FDA personnel could lead to further disruptions and delays in FDA review of our product candidates. Similarly, efforts by the new administration to substantially reduce research funding by the NIH of medical research could have substantial direct or indirect impacts on our research activities and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emergency related disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future emergency-related disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for another product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s standards for granting orphan drug exclusivity in the gene therapy context are unclear and evolving. For example, in September 2021, the FDA issued final guidance describing its current thinking on when a gene therapy product is the &#8220;same&#8221; as another product for purposes of orphan exclusivity. Under the guidance, if either the transgene or vector differs between two gene therapy products in a manner that does not reflect &#8220;minor&#8221; differences, the two products would be considered different drugs for orphan drug exclusivity purposes. The FDA will determine whether two vectors from the same viral class are the same on a case-by-case basis and may consider additional key features in assessing sameness. In addition, in order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. Further, under Omnibus legislation signed in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the agency to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we may develop for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Food, Drug, and Cosmetic Act, or the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the so-called &#8220;federal sunshine&#8221; law under the Healthcare Reform Act, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state laws also requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of any product candidates we may develop, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the United States Congress enacted the 2010 Patient Protection and Affordable Care Act, or the PPACA. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been adopted since the PPACA was enacted, including aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act, or CAA, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the CAA delays the 4% Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of calendar year 2024. Triggered by the enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The CAA&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Act in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in June 2021, The U.S. Supreme Court dismissed a lawsuit challenging the constitutionality of the ACA after finding that the plaintiffs do not have standing to bring the litigation. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The regulation intends to boost cooperation among EU Member States in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prices of prescription pharmaceuticals have been the subject of considerable discussion in the United States. There have been several U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Seven states (Colorado, Florida, Maine, New Hampshire, New Mexico, Texas and Vermont) have passed laws allowing for the importation of drugs from Canada. North Dakota and Virginia have passed legislation establishing workgroups to examine the impact of a state importation program.&#8239;As of October 2024, five states (Colorado, Florida, Maine, New Hampshire and New Mexico) had submitted Section 804 Importation Program proposals to the FDA. Vermont has submitted a concept letter to the HHS. On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each drug selected for importation, which must be approved by the FDA. The state will also need to relabel the drugs and perform quality testing of the products to meet FDA standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The IRA further delayed implementation of this rule to January 1, 2032.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028 and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, the HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, CMS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations by February 1, 2025. While there had been some questions about the Trump Administration&#8217;s position on this program, CMS issued a public statement on January 29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at 2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 6, 2023, Merck &amp; Co. filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the Pharmaceutical Research and Manufacturers of America, Novo Nordisk, Inc., Janssen Pharmaceuticals, Inc., Novartis AG, AstraZeneca plc and Boehringer Ingelheim International GMBH, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. There have been various decisions by the courts considering these cases since they were filed. The HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal, and on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. This is increasingly true with respect to products approved pursuant to the accelerated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This may be increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants, principal investigators and any commercial partners we may have. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the EMA, and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, the EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the U.K. The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations, and failure to comply with such requirements could subject us to significant fines and penalties and other consequences, which may have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the U.S., EU, U.K. and other countries in which we may conduct business. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In recent months, the Officer of Civil Rights, or OCR, has been especially active in enforcing the HIPAA rules. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. Additionally, OCR is looking to amend the HIPAA Security Rule, which, if and when finalized, could create additional compliance obligations and risk for our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to potential enforcement by the HHS, we could also be potentially subject to privacy enforcement from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule, which the FTC also has the authority to enforce. The FTC is also in the process of developing rules related to commercial surveillance and data security. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate risk for a potential enforcement action, which may be costly. Finally, both the FTC and HHS&#8217;s enforcement priorities, as well as those of other federal regulators, may be impacted by the change in administration and new leadership. These shifts in enforcement priorities may also impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the U.S. to certain foreign countries. For example, in 2024, Congress passed H.B. 815, which included the Protecting Americans&#8217; Data from Foreign Adversaries Act of 2024. This law creates certain restrictions for entities that disclose sensitive data (including potential health data) to countries such as China. Failure to comply with these rules can lead to a potential FTC enforcement action. Additionally, the Department of Justice recently finalized a rule implementing Executive Order 14117, which creates similar restrictions related to the transfer of sensitive U.S. data to countries such as China. These data transfer restrictions, and others that may pass in the future, may create operational challenges and legal risks for our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">States are also active in creating specific rules relating to the processing of personal information. In 2018, California passed into law the California Consumer Privacy Act or CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the European General Data Protection Regulation, or GDPR, which is further described below, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions, including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; the sole responsibility of which is to enforce the CPRA and other California privacy laws, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, at least eighteen other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect over the next few years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2025 and beyond, including New Hampshire and New Jersey. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, Washington state passed a health privacy law in 2023 that regulates the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the laws in the U.S., there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the group of companies of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the EC to offer adequate data protection legislation. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the EU, or CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for international transfers of personal data from the EEA. This CJEU decision resulted in increased scrutiny on data transfers and increased our costs of compliance with data privacy legislation, as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which serves as a replacement to the EU-U.S. Privacy Shield. The EC adopted the adequacy decision on July 10, 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue has the potential to impact our business. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act of 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the U.K. and the EU have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the U.K. Data Protection Act of 2018 and the GDPR, respectively. The U.K. and the U.S. have also agreed to a U.S.-U.K. &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the U.K. to the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Switzerland has also approved an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which functions similarly to the EU-U.S. Data Privacy Framework and the U.S.-U.K. Data Bridge in relation to data transfers from Switzerland to the U.S.). Any changes or updates to these developments have the potential to impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the U.S. regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Social media platforms present new risks and challenges to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As social media continues to expand, it also presents us with new risks and challenges. Social media is increasingly being used to communicate information about us, our programs and the diseases our product candidates are being developed to treat. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations or other consequences. Further, the accidental or intentional disclosure of non-public information by our workforce or others through media channels could lead to information loss. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business including quick and irreversible damage to our reputation, brand image and goodwill.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to employee matters, managing growth and information technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth may depend on our ability to identify and acquire businesses or technologies, and if we do not successfully do so, or otherwise fail to integrate any new businesses or technologies into our operations, we may have limited growth opportunities and it could result in significant impairment charges or other adverse financial consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing to seek to acquire businesses or technologies that we believe are a strategic fit with our business strategy. Future acquisitions, however, may entail numerous operational and financial risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a reduction of our current financial resources;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions and in connection with future milestone payment obligations under such acquisition agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty or inability to secure financing to fund development activities for those acquired or in-licensed technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher than expected acquisition and integration costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption of our business, customer base and diversion of our management&#8217;s time and attention to develop acquired technologies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient resources to acquire businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger biotechnology companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors likely will have access to greater financial resources than we do and may have greater expertise in identifying and evaluating new opportunities. Furthermore, there may be overlap between our product candidates and the companies which we acquire that may create conflicts in relationships or other commitments detrimental to the integrated businesses. Additionally, the time between our expenditures to acquire or in-license new technologies or businesses and the subsequent generation of revenues from those acquired technologies or businesses (or the timing of revenue recognition related to licensing agreements and/or strategic collaborations) could cause fluctuations in our financial performance from period to period. Finally, if we devote resources to potential acquisition opportunities that are never completed, or if we fail to realize the anticipated benefits of those efforts, we could incur significant impairment charges or other adverse financial consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain our Chief Executive Officer, President and other key executives and to attract, retain, and motivate qualified personnel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on John Evans, our Chief Executive Officer, and Dr. Giuseppe Ciaramella, our President, as well as the other principal members of our management and scientific teams. Mr. Evans, Dr. Ciaramella and such other principal members are employed &#8220;at will,&#8221; meaning we or they may terminate their employment at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development, and commercialization objectives.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified scientific, clinical, manufacturing, and sales and marketing personnel will also be critical to our success. Our competitors may seek to use these transitions and the related potential disruptions to gain a competitive advantage over us. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. Additionally, this shortage of highly qualified personnel is particularly acute in the area where we are located.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founders, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The inability to recruit, or loss of services of certain executives, key employees, consultants, or advisors, may impede the progress of our research, development, and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our development, regulatory, and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the growth and advancement of our pipeline, we expect to increase the number of our employees and the scope of our operations in the areas of drug development, regulatory affairs, and sales and marketing. To manage our anticipated future growth in these areas, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an early-stage biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage any future growth, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage the future development and expansion of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our common stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock and subject us to securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has been, and in the future, may be, subject to substantial volatility. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above your initial purchase price. The market price for our common stock may be influenced by many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of existing or new competitive product candidates or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and results of preclinical studies and clinical trials for any product candidates that we develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or discontinuation of any of our product development and research programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or changing views regarding the use of genetic medicines, including those that involve gene editing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to develop additional product candidates or products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us, our insiders or other stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of any future market stand-off or lock-up agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects of pandemics and public health emergencies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry, and market conditions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining adequate internal financial and accounting controls and procedures to ensure that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. To comply with the requirements of being a public company, we have undertaken certain actions, such as documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act of 2002, or SOX, which requires annual management assessment of the effectiveness of our internal control over financial reporting and an annual report on and attestation to such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assessment by our registered public accounting firm. Notwithstanding such actions, we may not be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, or any disagreement with our auditors on whether we have maintained such adequacy, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our common stock price and make it more difficult for us to effectively market and sell our service to new and existing customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we have incurred and expect to continue to incur significant legal, accounting, and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have increased our legal and financial compliance costs and make some activities more time-consuming and costly. For example, as a public company it is more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment unless they sell our common stock for a price higher than which they paid for it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our fourth amended certificate of incorporation, our second amended and restated by-laws, and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our fourth amended certificate of incorporation, or our certificate of incorporate, and our second amended and restated by-laws, or our by-laws, and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our certificate of incorporation and by-laws include provisions that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that special meetings of our stockholders can be called only by our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our directors may be removed only for cause; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that no stockholder is permitted to cumulate votes at any election of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expressly authorized our board of directors to make, alter, amend or repeal our by-laws; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our certificate of incorporation and by-laws. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay for shares of our common stock, thereby depressing the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our certificate of incorporation, by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and by-laws designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides that, subject to limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our certificate of incorporation or our by-laws, (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our by-laws or (5) any other action asserting a claim against us that is governed by the internal affairs doctrine. Furthermore, our by-laws also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our certificate of incorporation and by-laws described above. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our certificate of incorporation or by-laws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. For example, the Court of Chancery of the State of Delaware recently determined that a provision stating that federal district courts of the United States are the exclusive forum for resolving any complaint asserting a cause of action under the Securities Act is not enforceable. However, this decision may be reviewed and ultimately overturned by the Delaware Supreme Court.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General risk factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public health emergencies or epidemics could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health emergencies or epidemics could materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. The extent to any such public health emergency may impact our business, results of operations and future growth prospects will depend on a variety of factors, including the duration, scope and severity of the emergency, the existence and extent of travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, the effectiveness of actions taken in the U.S. and other countries, and the availability of therapeutic interventions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some factors from public health emergencies that could delay or otherwise adversely affect the completion of our preclinical and clinical activities and, depending on the duration of the outbreak, the initiation of any future clinical trials, as well as our business generally, include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees, manufacturing sites, research sites and other important agencies and contractors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on the availability of preclinical and clinical trial sites, researchers and investigators, regulatory agency personnel, and materials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on our business operations by local, state, or the federal government that could impact our ability to conduct our preclinical and clinical activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on travel that could hinder our timelines;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption in global shipping affecting the transport of key materials;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of, or delays in receiving, key materials from our CMOs due to staffing shortages, production slowdowns or stoppages, increased demand from third parties for key materials and disruptions in delivery systems; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions to our third-party suppliers, including through the effects of facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, labor shortages, decreased productivity and unavailability of materials or components.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health emergencies may also have the effect of heightening many of the other risks described in this section titled &#8220;Item 1A. Risk Factors,&#8221; such as risks related to our need to raise additional funding, fluctuation of our quarterly financial results, and our ability to obtain and maintain regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent changes or future changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the Tax Act was signed into law. The Tax Act, as amended by the CARES Act, among other things, contains significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and, for taxable years beginning after December 31, 2020, the limitation of the deduction for net operating losses to 80% of current year taxable income in respect of net operating losses generated during or after 2018. Any federal net operating loss incurred in 2018 and in future years may now be carried forward indefinitely pursuant to the Tax Act, but can no longer be carried back. Similar rules and limitations may apply for state income tax proposes. In addition, beginning in 2022, the Tax Act eliminates the option to deduct research and development expenditures currently and generally requires corporations to capitalize and amortize them over five years (or 15 years for expenditures attributable to foreign research).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Tax Act, as part of Congress&#8217; response to the COVID-19 pandemic, economic relief legislation was enacted in 2020 and 2021 containing tax provisions, including the CARES Act and the Inflation Reduction Act, or the IRA, which was signed into law in August 2022, introduced a number of new tax provisions. The IRA in particular includes a one percent excise tax imposed on certain stock repurchases by publicly traded companies, which generally applies to any acquisition of stock by the publicly traded company (or certain of its affiliates) from a stockholder of the company in exchange for money or other property (other than stock of the company itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. Regulatory guidance under the Tax Act and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. Additional tax legislation may also be enacted in the future, which could have an impact on us. In addition, it is uncertain if and to what extent various states will conform to the Tax Act and additional tax legislation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, disruptions impacting global supply, the conflict between Russia and Ukraine and related sanctions against Russia, increasing inflation rates and interest rate changes. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model or our stock performance, or if our operating results fail to meet the expectations of the investor community, one or more of the analysts who cover our company may change their recommendations regarding our company, and our stock price could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal computer systems and those of our current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach through our information security program and relevant contractual agreements with our business partners, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other disruptions, including the possible loss of personal data. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data, as well as subject us to obligations and risks related to the potential loss of personal data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to counterparties and data subjects could be material, in addition to potential costs related to regulatory investigations in the United States or other countries. In addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our third-party vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Additionally, there are increased rules and regulations governing the use and development of artificial intelligence at the state, federal, and international levels, which creates potential compliance and enforcement risk. These developments could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d1e348d-9173-4aaf-9d04-f86b3ea67cf6" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb1990c6-962e-41c2-97e8-4e3521f28aae" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have certain processes for assessing, identifying and managing cybersecurity risks, which are </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51daa59f-1973-4980-a05c-eba86256dc3e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">built</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program/information technology function and are designed to help protect our information assets and operations from internal and external cyber threats</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and enhance our practices. We engage certain external parties, including consultants, independent privacy assessors, computer security firms and risk management, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. We consider the internal risk </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68b1c07a-a225-49f9-961f-c400f5d959ce" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">oversight</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> programs of third-party service providers before </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12856b45-07ac-4900-8750-2481f0847104" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaging</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> them in order to help protect our company from any related vulnerabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on an assessment using these processes, we do not believe that there are currently any risks from known cybersecurity threats that are reasonably likely to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c7acb74-b32f-42ca-abad-00b5eb744940" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affect</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> our company or our business strategy, results of operations or financial condition. For additional information, please see the risk factor titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;General risk factors, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in this Annual Report on Form 10-K.</span></p><div><ix:nonNumeric id="F_e5446588-ed38-4665-bd76-e3e60d00927e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bd386b1-2c59-4378-8b6a-a1e940470a34" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c647664f-b69f-421c-aa96-4553891e8eda" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_444e78b5-3c42-4df6-a59b-e5b95a4d306a" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fe47729-942b-451b-b2a7-e3526c58ff4b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cadbfb1-3016-4d18-b02c-3047e1dd7536" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d96ade00-0b44-4736-93bf-d5b6372b5ed1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President of Information Security</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9febebb2-0e2c-47a1-8301-e9246f76baee" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, IS&#8217;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ed948e5-23af-4c3a-9d56-dc35e6d6a310" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have leased approximately 130,258 square feet of office and laboratory space in Cambridge, Massachusetts under a lease that expires in 2034. Additionally, we entered into a lease agreement with Alexandria Real Estate Equities, Inc. pursuant to which we built a 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina intended to support a broad range of clinical programs, which lease expires in 2037. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;BEAM&#8221; since February 6, 2020. Prior to that time, there was no public market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 18, 2025, there were approximately 27 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph set forth below compares the cumulative total stockholder return on our shares of common stock between February 6, 2020 (the date of our initial public offering) and December 31, 2024, with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period. This graph assumes the investment of $100 on February 6, 2020 in our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any. The graph uses the closing sales price of our common stock of $18.75 per share on February 6, 2020 as the initial value of our common stock and not the initial offering price to the public of $17.00 per share. The comparisons shown in the graph below are based upon historical data. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img43983261_1.jpg" alt="img43983261_1.jpg" style="width:720px;height:597px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of equity securities by the issuer or affiliated purchasers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of our common stock during the fourth quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">served]</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ons.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Item 1A, Risk factors, in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information pertaining to fiscal year 2022 was included in our Annual Report on Form 10-K for the year ended December 31, 2023 on pages 115 through 126 under Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Position and Results of Operations,&#8221; which was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 27, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, with the potential to dramatically increase the impact of gene editing. We are also pursuing a suite of both delivery modalities, including both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> approaches, depending on tissue type. The elegance of the base editing approach, combined with a tissue specific delivery modality, provides the basis for a targeted, efficient, precise, and highly versatile gene editing system that is designed to be capable of gene correction, gene silencing or gene activation, gene modification, and/or multiplex editing of several genes simultaneously.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to advance a broad, diversified portfolio of base editing programs against distinct, genetically validated editing targets, as well as an innovative, platform business model that will expand the reach of our programs to more patients. Overall, we are seeking to build the leading integrated platform for precision genetic medicine, which may have broad therapeutic applicability and the potential to transform the field of precision genetic medicines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hematology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing hematology base editing programs in which hematopoietic stem cells, or HSCs, are collected from a patient, edited using electroporation, and then infused back into the patient following a conditioning regimen, such as treatment with busulfan, the standard of care in HSC transplantation, or HSCT, today. Once reinfused, the HSCs begin repopulating a portion of the bone marrow in a process known as engraftment. The engrafted, edited HSCs give rise to progenitor cell types with the corrected gene sequences. We are deploying this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approach in our BEAM-101 and ESCAPE base editing programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are pursuing a long-term, staged development strategy for our base editing approach to treat hematological diseases that consists of advancing our lead </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> program, BEAM-101, in Wave 1, improving patient conditioning regimens in Wave 2, and enabling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editing with delivery directly into HSCs of patients via lipid nanoparticles, or LNPs, in Wave 3. We believe this suite of technologies &#8211; base editing, improved conditioning and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivery for editing HSCs &#8211; can maximize the potential applicability of our sickle cell disease programs to patients as well as create a platform for the treatment of many other severe genetic blood disorders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 1: Ex Vivo Base Editing via Autologous Transplant with BEAM-101</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are using base editing to pursue the development of BEAM-101 for the treatment of sickle cell disease. BEAM-101 is a patient-specific, autologous HSC investigational therapy designed to offer a potentially best-in-class profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin, or HbF. BEAM-101 aims to alleviate the effects of sickle cell disease by increasing HbF, which is expected to increase functional hemoglobin production and, in the case of sickle cell disease, inhibit hemoglobin S, or HbS, polymerization.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, which we refer to as our BEACON trial. The BEACON trial initially includes up to 45 patients ages 18 to 35 with severe sickle cell disease who have received prior treatment with at least one disease-modifying agent with inadequate response or intolerance. Following mobilization, conditioning and treatment with BEAM-101, patients are assessed for safety and tolerability, with safety endpoints including neutrophil and platelet engraftment. Patients are also assessed for efficacy, with efficacy endpoints including the change from baseline in severe vaso-occlusive events, transfusion requirements, HbF levels, and quality of life assessments. In December 2024, we announced preliminary positive data from our Phase 1/2 clinical trial of BEAM-101, which we refer to as the BEACON trial. The adult enrollment target for BEACON has been achieved, and the first adolescent patients have cleared screening and enrolled in the trial. We expect to dose 30 patients in the BEACON trial by mid-2025. We also plan to present updated data from the trial in mid-2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 2: Non-genotoxic Conditioning</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In parallel with Wave 1 development, we also aim to improve the transplant conditioning regimen for patients undergoing HSCT, thereby reducing toxicity challenges associated with HSCT. Conditioning is a critical component necessary to prepare a patient&#8217;s body to receive the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> edited cells that must engraft in the patient&#8217;s bone marrow in order to be effective. However, current conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. As a potential alternative to genotoxic conditioning regimens in HSCT, we are advancing our ESCAPE program. ESCAPE aims to avoid toxicity challenges associated with currently available conditioning regimens for patients with sickle cell disease and beta-thalassemia ahead of autologous HSCT, by combining antibody-based conditioning with multiplex gene edited HSCs. ESCAPE may also have applications in other diseases of the blood and immune system where HSCT could deliver potential benefits but has been limited by toxicities associated with current standard of care conditioning regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have nominated a development candidate for our ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 designed to block binding of BEAM-103, allowing the edited cells to evade suppression by the antibody. We intend to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia, potentially building on the same regulatory, manufacturing, clinical and commercial foundations being established with BEAM-101. We expect to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103 by the end of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Wave 3: In Vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Base Editing via HSC-targeted LNPs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also exploring the potential for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editing programs for sickle cell disease, in which base editors would be delivered to the patient through an infusion of LNPs targeted to HSCs, eliminating the need for transplantation altogether. This approach could provide a more accessible option for patients, particularly in regions where </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">treatment is challenging.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genetic Diseases</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BEAM-302: In Vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LNP liver-targeting for AATD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-302 is a liver-targeting LNP formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype) predominantly responsible for the severe form of alpha-1 antitrypsin deficiency, or AATD. AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease. The most severe form of AATD arises when a patient has a point mutation in both copies of the SERPINA1 gene at amino acid 342 position (E342K, also known as the PiZ mutation or the &#8220;Z&#8221; allele). This point mutation causes Alpha-1 antitrypsin, or AAT, to misfold, accumulating inside liver cells rather than being secreted, resulting in very low levels (10%-15%) of circulating AAT. In addition to resulting in lower levels, the PiZ AAT protein variant is also less enzymatically effective compared to wildtype AAT protein. As a consequence, the lung is left unprotected from neutrophil elastase, resulting in progressive, destructive changes in the lung, such as emphysema, which can result in the need for lung transplants. The mutant AAT protein also accumulates in the liver, causing liver inflammation and cirrhosis, which can ultimately cause liver failure or cancer requiring patients to undergo a liver transplant. It is estimated that approximately 100,000 individuals in the United States have two copies of the Z allele. There are currently no curative treatments for patients with AATD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 open label, dose escalation clinical trial of BEAM-302 at sites located in the United Kingdom for the treatment of AATD. The trial will evaluate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 initially in patients with AATD-associated lung disease. The study design includes a dose exploration portion followed by a dose expansion portion to identify the optimal dose to take forward in a pivotal study. We continue to progress enrollment and global site activation and expect to report initial clinical data from multiple cohorts in the trial in the first half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BEAM-301: In Vivo LNP liver-targeting for GSD1a</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM-301 is a liver-targeting LNP formulation of base editing reagents designed to correct the R83C mutation, the most prevalent disease-causing mutation for, and the mutation which results in the most severe form of, glycogen storage disease 1a, or GSD1a. GSD1a is an autosomal recessive disorder caused by mutations in the G6PC gene that disrupts a key enzyme, G6Pase, critical for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining glucose homeostasis. Inhibition of G6Pase activity results in low fasting blood glucose levels that can result in seizures and be fatal. Patients with this mutation typically require ongoing corn starch administration, without which they may enter into hypoglycemic shock within one to three hours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a Phase 1/2 clinical trial of BEAM-301 at a select number of sites in the United States. The trial is an open-label, multi-cohort, single-ascending dose evaluation of BEAM-301 for the treatment of GSD1a in patients with the R83C mutation. Key endpoints of the trial include safety and tolerability, time to hypoglycemia during fasting, and changes from baseline in corn starch supplementation. We are continuing site activation activities and expect dosing to commence in early 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the critical importance of high-quality manufacturing and control of production timing and know-how, we have established a 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina intended to support a broad range of clinical programs. The cGMP facility is designed to support manufacturing for our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cell therapy programs in hematology and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-viral delivery programs for liver and liver-mediated diseases, with the capability to scale-up to support potential commercial supply. For our initial clinical trials, we expect to rely primarily on our internal manufacturing capabilities, along with CMOs with relevant manufacturing experience in genetic medicines. We believe this investment will maximize the value of our portfolio and capabilities, the probability of technical success of our programs, and the speed at which we can provide potentially life-long cures to patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial operations overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were founded in January 2017 and began operations in July 2017. Since our inception, we have devoted substantially all of our resources to building our base editing platform and advancing development of our portfolio of programs, establishing and protecting our intellectual property, conducting research and development activities, organizing and staffing our company, conducting clinical trials, maintaining and expanding internal manufacturing capabilities, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sales of our redeemable convertible preferred stock, proceeds from offerings of our common stock and payments received under collaboration and license agreements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an early-stage company, and the majority of our programs are at a preclinical or clinical stage of development. To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for the foreseeable future. Our revenue to date has been primarily derived from license and collaboration agreements with partners. Since inception we have incurred significant operating losses. Our net losses for the years ended December 31, 2024, 2023 and 2022 were $376.7 million, $132.5 million and $289.1 million, respectively. As of December 31, 2024, we had an accumulated deficit of $1.6 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our internal programs and collaborations as we continue our preclinical and clinical development of product candidates; advance additional product candidates toward clinical development; operate our cGMP facility in North Carolina; further develop our base editing platform; continue to make investments in delivery technology for our base editors; conduct research activities as we seek to discover and develop additional product candidates; maintain, expand, enforce, defend and protect our intellectual property portfolio; and continue to hire research and development, clinical, technical operations and commercial personnel. In addition, we expect to continue to incur the costs associated with operating as a public company.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these anticipated expenditures, we will need to raise additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We can give no assurance that we will be able to secure such additional sources of capital to support our operations, or, if such capital is available to us, that such additional capital will be sufficient to meet our needs for the short or long term.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, we entered into a collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, a company focused on gene editing for cardiovascular disease treatments. In June 2021, we entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of our base editing technology to discover new treatments for complement system-driven diseases. In October 2021, we entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, pursuant to which we granted Sana non-exclusive research and development and commercial rights to our CRISPR Cas12b technology to perform nuclease editing for certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engineered cell therapy programs. In December 2021, we entered into a four-year research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. In September 2022, we entered into a License and Research Collaboration Agreement, or the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orbital Agreement, with Orbital Therapeutics, Inc., or Orbital, a newly formed entity focused on advancing non-viral delivery and RNA technologies. In October 2023, we entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Verve Agreement, including our opt-in rights to co-develop and co-commercialize Verve&#8217;s base editing programs for cardiovascular disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not generated any revenue to date from product sales and do not expect to do so in the near future. During the years ended</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022, we recognized $63.5 million, $377.7 million and $60.9 million respectively, of revenue from our license and collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information about our revenue recognition policy, see Note 2 and Note 10 of the notes to our audited consolidated financial statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with our clinical trials, including contract research organization costs and costs related to study preparation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing materials for use in our preclinical studies, IND-enabling studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with investments in delivery technology for our base editors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with the discovery and preclinical development of our research programs, including under agreements with third parties, such as consultants, contractors and contract research organizations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in research and development functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost to obtain licenses to intellectual property, such as those with Harvard University, or Harvard, The Broad Institute, Inc., or Broad Institute, Editas Medicine, Inc., or Editas, and Bio Palette Co., Ltd., or Bio Palette, and related future payments should certain success, development and regulatory milestones be achieved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with the building of our base editing platform;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with regulatory filings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and research materials; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities, depreciation and other expenses which include direct and allocated expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our external research and development expenses support our various preclinical and clinical programs. Our internal research and development expenses consist of employee-related expenses, facility-related expenses, and other indirect research and development expenses incurred in support of overall research and development. We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the early phases of development, our research and development costs are often devoted to product platform and proof-of-concept preclinical studies that are not necessarily allocable to a specific target.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our research and development expenses will increase substantially as we advance our programs through their planned preclinical and clinical development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, intellectual property, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and direct and allocated facility related expenses and other operating costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future to support our increased research and development activities. We also expect to continue to incur costs associated with being a public company and maintaining controls over financial reporting, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income and expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income and expenses consist of the following items:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consists primarily of remeasurement gains or losses associated with changes in success payment liabilities associated with our license agreement with Harvard, dated as of June 27, 2017, as amended, or the Harvard License Agreement, the license agreement with The Broad Institute, as amended, dated as of May 9, 2018, or the Broad License Agreement, and settlement payment derivative liabilities associated with a settlement agreement with a research institution.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consists of changes in the fair value of our investments in equity securities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consists of remeasurement of the fair market value of the technology and product contingent consideration liabilities related to the acquisition of Guide.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consists primarily of interest income from our investments in fixed income securities as well as interest expense related to our equipment financings.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For discussion of 2023 results and comparison with 2022 results, refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,518</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,709</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(314,191</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,561</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437,381</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(69,820</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,525</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,813</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,288</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">479,086</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">554,194</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(75,108</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(415,568</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(176,485</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(239,083</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,272</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,228</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,093</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,592</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,148</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,094</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,676</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,418</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,865</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,324</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,459</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(376,703</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(131,161</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(245,542</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,366</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(376,742</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(132,527</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(244,215</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and collaboration revenue was approximately $63.5 million for the year ended December 31, 2024, compared to approximately $377.7 million for the year ended December 31, 2023, a decrease of $314.2 million. License and collaboration revenue recorded in 2024 represents revenue recorded under the Pfizer, Apellis and Orbital Agreements, as well as $27.0 million of revenue recognized from development and regulatory milestones achieved under our agreements with Lilly and Sana. In 2023, we recorded $377.7 million of total revenue, inclusive of license revenue related to the Lilly, Pfizer, Apellis, Orbital and Verve Agreements and $1.8 million of revenue recognized from development and regulatory milestones achieved under our agreements with Sana. The decrease in revenue is driven primarily by $216.4 million of up-front revenue recognized in the year ended December 31, 2023, from the transaction with Lilly (see Note 10) and the net change in activity amongst our collaboration agreements. Revenue recognized under the Pfizer and Apellis agreements relate to nonrefundable up-front payments and are recognized based upon a measure of progress using total actual costs incurred as compared to total estimated costs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $367.6 million and $437.4 million for the years ended December 31, 2024 and 2023, respectively. The following table summarizes our research and development expenses for the years ended December 31, 2024 and December 31, 2023, together with the changes in those items in dollars (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,473</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,178</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39,705</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,796</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,878</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,082</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility and information technology related expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,387</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,339</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,048</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,522</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,812</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,710</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense (income)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,383</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,174</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(38,791</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,561</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437,381</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(69,820</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease of $69.8 million was primarily due to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A $39.7 million decrease in external research and development expenses driven by a $29.6 million decrease in outsourced services, primarily due to the strategic reprioritization of pipeline programs, timing of manufacturing spend and fewer IND-enabling activities, partially offset by increased clinical activities. Also contributing to the decrease is a $10.1 million decrease in lab supply expenses due to the strategic reprioritization of pipeline programs and a shift of programs beyond research activities</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decrease of $38.8 million in other expense primarily due to decreases of accrued liabilities for estimated license fees associated with the Lilly transaction; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decrease of $11.1 million of employee related expenses due to the annualized impact of the higher number of research and development employees prior to our strategic restructuring in October 2023 and the severance related to the restructuring.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease was partially offset by the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase of $15.7 million in stock-based compensation from additional stock options and restricted stock units granted during the year; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase of $4.0 million of facility and information technology, or IT, related costs, including depreciation and the expense allocated to research and development related to our leased facilities.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are expected to continue to increase as we advance clinical trials for BEAM-101, BEAM-302, and BEAM-301, continue our current research programs, initiate new research programs, continue the preclinical and clinical development of our product candidates, conduct any future preclinical studies, and begin to enroll patients in and conduct clinical trials for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $111.5 million and $116.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease of $5.3 million was primarily due to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decrease of $16.9 million attributable to the settlement of a contingent liability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decrease of $0.4 million in insurance costs; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decrease of $0.2 million in other expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease was partially offset by the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase of $6.3 million in stock-based compensation from additional stock options and restricted stock units granted during the year; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase of $5.9 million in personnel related costs due to an increase in the number of general and administrative employees between December 31, 2023 and December 31, 2024, and increases in salaries and bonuses to existing employees.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we recorded $2.3 million of other income related to the change in fair value of the derivative liabilities as compared to $7.5 million for the year ended December 31, 2023, driven primarily by the decline in the price of our common stock. A portion of the success payments was paid in June 2021; the remaining success payment obligations are still outstanding as of December 31, 2024 and will continue to be revalued at each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we recorded other expense of $14.1 million and $18.6 million, respectively, as a result of changes in the fair value of our investments in Verve and Prime Medicine common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in contingent consideration liabilities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we recorded $1.6 million and $9.7 million, respectively, of other income related to the change in fair value of the Guide technology and product contingent consideration liabilities as a result of an update in project timelines and the expected probability of achievement of the milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net was $49.1 million and $46.7 million of other income for the years ended December 31, 2024 and December 31, 2023, respectively. The increase was primarily due to increases in interest income driven by increased market rates and growth of our investment portfolio.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded an income tax provision of less than $0.1 million for the year ended December 31, 2024 and a provision of $1.4 million for the year ended December 31, 2023, which reflects that we generated taxable income that was not fully offset by the use of tax operating loss carryforwards and tax credits. Our taxable income includes income recognized related to our license and collaboration agreements with Apellis, Pfizer, Lilly, Sana and Orbital in the year ended December 31, 2024. Taxable income in the year ended December 31, 2023 included income recognized related to the Lilly Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception in January 2017, we have not generated any revenue from product sales, have generated only limited revenue from our license and collaboration agreements, and have incurred significant operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and the clinical development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we filed a universal automatic shelf registration statement on Form S-3 with the SEC, to register for sale an indeterminate amount of our common stock, preferred stock, debt securities, warrants and/or units in one or more offerings, which became effective upon filing with the SEC (File No. 333-277427).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into an at the market sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we are entitled to offer and sell, from time to time at prevailing market prices, shares of our common stock having aggregate gross proceeds of up to $1.1 billion. We agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. There were no shares sold under the Sales Agreement during the year ended December 31, 2024. As of December 31, 2024, we have sold 13,769,001 shares of our common stock under the Sales Agreement at an average price of $62.75 per share for aggregate gross proceeds of $864.0 million, before deducting commissions and offering expenses payable by us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $850.7 million in cash, cash equivalents, and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to make success payments to Harvard and Broad Institute based on increases in the per share fair market value of our common stock. The amounts due may be settled in cash or shares of our common stock, at our discretion. We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from the sale of our product candidates for the foreseeable future. We anticipate that we may need to raise additional capital in order to continue to fund our research and development, including our planned preclinical studies and clinical trials, maintaining and operating our commercial-scale cGMP manufacturing facility, and new product development, as well as to fund our general operations. As necessary, we will seek to raise additional capital through various potential sources, such as equity and debt financings or through corporate collaboration and license agreements. We can give no assurances that we will be able to secure such additional sources of capital to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(347,246</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(149,195</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,007</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,840</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,736</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">276,448</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(154,503</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199,093</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2024 was $347.2 million, including our net loss of $376.7 million, decreases in accrued expenses and other liabilities of $57.7 million, deferred revenue of $36.5 million and operating lease liabilities of $13.0 million, and an increase in prepaid expenses and other current assets of $5.4 million. In addition, noncash items, including the amortization of investment discounts and premiums of $22.8 million, decreases in the fair value of derivative liabilities of $2.3 million and a change in the fair value of contingent consideration liabilities of $1.6 million, also contributed to net cash used in operating activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These uses of cash were partially offset by increases in accounts payable of $1.8 million and other long-term liabilities of $0.5 million, as well as noncash items, including stock-based compensation expense of $120.7 million, depreciation and amortization expense of $21.9 million, a decrease in the fair value of non-controlling equity investments of $14.1 million and a decrease in operating lease right-of-use, or ROU, assets of $9.7 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023 was $149.2 million, including $216.4 million of cash received under the Lilly transaction, increases in accrued expenses and other liabilities of $67.7 million, as well as noncash items consisting of stock-based compensation expense of $98.6 million, a decrease in the fair value of non-controlling equity investments of $18.6 million, depreciation and amortization expense of $20.0 million and changes in operating lease ROU assets of $9.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These sources of cash were offset in part by our net loss of $132.5 million, a decrease in deferred revenue of $159.6 million, a decrease in operating lease liabilities of $10.2 million, decreases in accounts payable of $7.6 million, other long-term liabilities of $0.2 million, increases in prepaid expenses and other current assets of $6.5 million and collaborations receivables of $0.1 million, as well as noncash items including amortization of investment discounts and premiums of $29.7 million, decreases in the fair value of derivative liabilities of $7.5 million and a change in the fair value of contingent consideration liabilities of $9.7 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, cash provided by investing activities of $185.0 million was primarily the result of net maturities of marketable securities partially offset by purchases of marketable securities, in addition to purchases of property and equipment of $8.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, cash provided by investing activities of $71.8 million was primarily the net result of maturities of marketable securities partially offset by purchases of marketable securities, in addition to purchases of property and equipment of $33.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2024 of $7.7 million consisted of proceeds from the exercise of stock options of $5.6 million and $2.6 million of proceeds from the issuance of common stock under our Employee Stock Purchase Plan, or ESPP, offset in part by net repayments of equipment financing liabilities of $0.5 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023 of $276.4 million consisted primarily of proceeds from equity offerings of $236.6 million, net of sales commissions, proceeds from the issuance of shares from the Lilly Agreement of $33.6 million, $6.1 million of proceeds from the exercise of stock options, and $3.0 million of proceeds from the issuance of common stock under our ESPP, offset in part by net repayments of equipment financing liabilities of $2.3 million and payment of equity offering costs of $0.6 million.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses are expected to continue to increase substantially as we continue to advance our portfolio of programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, our expenses will increase if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance clinical trials of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research programs and our preclinical development of product candidates from our research programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate preclinical studies and clinical trials for additional product candidates we identify and develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing approvals for any of our product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any medicines for which we may obtain marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, enforce, defend, and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further develop our base editing platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to hire additional personnel including research and development, clinical and commercial personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our product development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license products, intellectual property, medicines and technologies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain and operate a commercial-scale cGMP manufacturing facility.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our cash, cash equivalents, and marketable securities at December 31, 2024 will enable us to fund our current and planned operating expenses and capital expenditures for at least the next 12 months from the date of issuance of our accompanying consolidated financial statements. We have based these estimates on assumptions that may prove to be imprecise, and we may exhaust our available capital resources sooner that we currently expect. Because of the numerous risks and uncertainties associated with the development our programs, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements will depend on many factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of continuing to build our base editing platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of acquiring licenses for the delivery modalities that will be used with our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, manufacturing and clinical trials for the product candidates we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of the product candidates we develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, distribution, coverage and reimbursement for any product candidates for which we receive regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our license agreements and our collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we are a party to or may become a party to, including our agreement with Guide; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment of success liabilities to Harvard and Broad Institute pursuant to the respective terms of the Harvard License Agreement and the Broad Institute License Agreement, should we choose to pay in cash;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license products, intellectual property, and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating and expanding our manufacturing capacity; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact on our business of macro-economic conditions, as well as the prevailing level of macro-economic, business, and operational uncertainty, including as a result of geopolitical events or other global or regional events.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of capital. We have historically relied on equity issuances to fund our capital needs and will likely rely on equity issuances in the future. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise capital through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or, if approved, future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We can give no assurance that we will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional funding will be sufficient to meet our needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual obligations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease certain assets under noncancelable operating leases, which expire through 2037. The leases relate primarily to office space, laboratory and manufacturing space, and equipment. Aggregate future minimum commitments under these office and laboratory leases and equipment leases are $227.7 million as of December 31, 2024, excluding any related common area maintenance charges or real estate taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurements under the Harvard License Agreement and Broad License Agreement occurred and success payments to Harvard and Broad Institute were calculated to be $15.0 million and $15.0 million, respectively. We elected to make each payment in shares of our common stock and issued 174,825 shares of our common stock to each of Harvard and Broad Institute to settle these liabilities in June 2021. The remaining success payment obligations are still outstanding as of December 31, 2024. We may additionally owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are potentially obligated to pay certain milestone and success fees, non-royalty sublicense income fees, royalty fees, licensing maintenance fees, and reimbursement of patent maintenance costs under agreements we have entered into with certain institutions to license intellectual property. Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial and success payment milestones. These amounts are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known with certainty.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we agreed to pay Guide&#8217;s former stockholders and optionholders up to an additional $100.0 million in technology milestone payments and $220.0 million in product milestone payments, payable in our common stock valued using the volume-weighted average price of our common stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is received. These payments are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known with certainty.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we enter into contracts in the normal course of business with CROs, CMOs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical accounting policies and significant judgments and estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception, we determine whether contracts are within the scope of ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 606, or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of our license and collaboration agreements in Note 10 to our consolidated financial statements in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of our license and collaboration agreements in Note 10.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing of when services are performed and the occurrence of external costs associated with the programs under the collaboration agreements could impact how revenue is recognized in a certain period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP: If the license to our IP is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. We generally recognize revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of our license and collaboration agreements in Notes 9 and 10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, we evaluate the probability of reaching the milestones and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. To date, we have not recognized any milestone revenue resulting from any of our agreements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our agreements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no performance obligations are required of us, or following the completion of the performance obligation period, amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value measurements &#8211; Success payments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to make success payments to Harvard and Broad Institute based on increases in the per share fair market value of our common stock. Any amounts due may be settled in cash or shares of our common stock, at our discretion. The success payments are accounted for as a derivative under Accounting Standards Codification 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liabilities are marked to market at each balance sheet date with all changes in value recognized in interest and other income (expense) in the consolidated statement of operations and other comprehensive loss. We will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the success payment obligation. To determine the estimated fair value of the success payments, we used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the price per share at the time of success payment. A significant change in our stock price or volatility could have a significant impact on the value of the liability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued and prepaid research and development costs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses and prepaid research and development costs. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to vendors in connection with preclinical development activities and vendors related to development, manufacturing and distribution of product candidate materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple vendors that conduct and manage preclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period and adjust accordingly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $850.7 million, which consisted of cash, money market funds, commercial paper, corporate notes and corporate equity securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term marketable securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investment portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency rates. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and research, manufacturing and development costs. We believe that inflation has not had a material effect on our financial statements included elsewhere in this Annual Report on Form 10-K. However, our operations may be adversely affected by inflation in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Exhibits and Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of December 31, 2024, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on that evaluation of our disclosure controls and procedures as of December 31, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable assurance level.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes policies and procedures that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We continue to review our internal control over financial reporting and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in &#8220;Internal Control &#8212; Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our senior management has concluded that the internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, issued an attestation report on our internal control over financial reporting. See below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout our company. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the year ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the stockholders and the Board of Directors of Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Beam Therapeutics Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by COSO.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2024, of the Company and our report dated February 25, 2025, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_934830b7-5d2f-4bbf-b483-060e4eb77ef0" contextRef="C_13e504bd-d42c-4cb7-9480-fe49e29deb03" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table describes for the quarterly period ended December 31, 2024 each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a &#8220;Rule 10b5-1 trading arrangement,&#8221; or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
    <table style="margin-left:1.204%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:10.358%;box-sizing:content-box;"/>
      <td style="width:11.998%;box-sizing:content-box;"/>
      <td style="width:12.737%;box-sizing:content-box;"/>
      <td style="width:25.295%;box-sizing:content-box;"/>
      <td style="width:12.737%;box-sizing:content-box;"/>
      <td style="width:26.875%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(Title)</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Taken </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(Date of Action)</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading Arrangement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number of Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ea2f458a-6690-4c11-a365-e99f8875a3b3" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amy Simon</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_4f21b7c3-6c16-4160-b117-cc10b57f19e2" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_c4deaf70-8e35-4799-8c79-c8e9e5e2fb6d" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">November 7, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_64ea169c-6037-425e-9b93-0ceadf8bc389" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_662b40b3-87ec-4a96-b46f-86be6e3fcabb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Until </span><span><ix:nonNumeric id="F_69fe99c8-160a-4a2e-af0c-aa487cf6b9be" contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution.</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41427ba0-0518-415b-bdc6-7c2b7d24129b" contextRef="C_1e89bb30-0a11-458c-b317-6b5ebf170463" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">204,956</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosur</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Regarding Foreign Jurisdictions That Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 10 will be included in the sections captioned &#8220;Management and Corporate Governance&#8221; and &#8220;Executive Officers&#8221; in our definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a written code of business conduct and ethics, or Code, that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the Code is available on the investor section of our website at investors.beamtx.com. We intend to disclose on our website any amendments to, or waivers from, our Code that are required to be disclosed pursuant to SEC rules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 11 will be included in the section captioned &#8220;Executive Compensation" and "Director Compensation&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 12 will be included in the sections captioned &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 13 will be included in the sections captioned &#8220;Certain Relationship and Related Person Transactions&#8221; and &#8220;Director Independence&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ting Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 14 will be included in the sections captioned &#8220;Principal Accountant Fees and Services&#8221; and &#8220;Audit Committee Pre-Approval Policy and Procedures&#8221; in our definitive proxy statement to be filed with the SEC with respect to our 2025 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a list of the financial statements included herein, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Index to the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2. Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3. Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.141%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49.01%;box-sizing:content-box;"/>
    <td style="width:6.141%;box-sizing:content-box;"/>
    <td style="width:11.042%;box-sizing:content-box;"/>
    <td style="width:11.022%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amended Certificate of Incorporation of Beam Therapeutics Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/11/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017023004866/beam-ex3_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amended and Restated By-laws of Beam Therapeutics Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen stock certificate evidencing shares of common stock</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000119312521103074/d160079dex411.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registered Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-254946</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/01/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated April 24, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000119312521103255/d161815dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated April 1, 2021, by and between Beam Therapeutics Inc. and Jefferies LLC.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">04/01/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, between the President and Fellows of Harvard College and Beam Therapeutics Inc., dated June 27, 2017</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex105_865.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to License Agreement, between the President and Fellows of Harvard College and Beam Therapeutics Inc., dated December 12, 2017</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex106_866.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to License Agreement, between the President and Fellows of Harvard College and Beam Therapeutics Inc., dated March 27, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, between The Broad Institute, Inc. and Blink Therapeutics Inc., dated May 9, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex108_867.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to License Agreement, between The Broad Institute, Inc. and Blink Therapeutics Inc., dated September 4, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, between Editas Medicine, Inc. and Beam Therapeutics Inc., dated May 9, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex1010_868.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, between Beam Therapeutics Inc., The Broad Institute, Inc., the President and Fellows of Harvard College, and Editas Medicine, Inc., dated September 26, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex1011_159.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, between the President and Fellows of Harvard College, The Broad Institute, Inc., and Beam Therapeutics Inc., dated January 7, 2021.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/22021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, between Bio Palette Co., Ltd. and Beam Therapeutics Inc., dated March 27, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc. 2017 Stock Option and Grant Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.141%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49.01%;box-sizing:content-box;"/>
    <td style="width:6.141%;box-sizing:content-box;"/>
    <td style="width:11.042%;box-sizing:content-box;"/>
    <td style="width:11.022%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Incentive Stock Option Grant Notice under the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Qualified Stock Option Grant Notice under the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312519257401/d734398dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between Beam Therapeutics Inc. and its directors and officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/27/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000095017021001110/beam-20210630ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Letter Agreement between Beam Therapeutics Inc. and John Evans, dated June 9, 2021</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement between Beam Therapeutics Inc. and Giuseppe Ciaramella, dated January 24, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Beam Therapeutics Inc. and Sravan K. Emany, dated December 2, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Incentive Stock Option Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement (Non-Employee Directors) under the Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex1025_407.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001745999/000156459021013190/beam-ex1026_406.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Award Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc. 2019 Cash Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024053939/beam-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy, dated April 1, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">05/07/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000156459020039490/beam-ex101_197.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/12/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated April 14, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/28/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated November 17, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/28/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-ex10_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated August 24, 2021</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/28/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312521209865/d187752dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Sales Agreement, dated July 7, 2021, by and between Beam Therapeutics Inc. and Jefferies LLC</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/07/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017023004866/beam-ex10_35.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated December 7, 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/28/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.141%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49.01%;box-sizing:content-box;"/>
    <td style="width:6.141%;box-sizing:content-box;"/>
    <td style="width:11.042%;box-sizing:content-box;"/>
    <td style="width:11.022%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017023020090/beam-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Beam Therapeutics Inc. and Christine Bellon, dated January 24, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017023020090/beam-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Beam Therapeutics Inc. and Amy Simon, dated January 29, 2021</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312523140832/d481853dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to Sales Agreement, dated May 10, 2023, by and between Beam Therapeutics Inc. and Jefferies LLC</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024020622/beam-ex10_39.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC, dated June 23, 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/27/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024020622/beam-ex10_40.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC, dated March 31, 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/27/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024020622/beam-ex10_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No.14, LLC, dated January 1, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/27/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024053939/beam-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Addendum to Letter Agreement between Beam Therapeutics Inc. and each of John Evans, Giuseppe Ciaramella, Christine Bellon and Amy Simon</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">05/07/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024091242/beam-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to License Agreement between The Broad Institute, Inc. and Beam Therapeutics Inc., dated May 31, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">05/07/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.42#</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex10_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4 to License Agreement, between the President and Fellows of Harvard College and Beam Therapeutics Inc., dated December 1, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.43+</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000119312520014727/d221975dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Beam Therapeutics Inc. and Terry-Ann Burrell, dated January 24, 2020</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-233985</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/27/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries of Beam Therapeutics Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Deloitte &amp; Touche LLP</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="beam-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1745999/000095017024020622/beam-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clawback Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39208</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/27/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Portions of this exhibit have been omitted because the Registrant has determined they are not material and are they type that the Registrant treats as private or confidential.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BEAM THERAPEUTICS INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Evans</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">John Evans</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.12%;box-sizing:content-box;"/>
    <td style="width:1.1%;box-sizing:content-box;"/>
    <td style="width:46.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Evans</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="margin-left:6.6pt;text-indent:-5.4pt;padding-left:5.4pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">John Evans</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sravan Emany</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sravan Emany</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Bethany Cavanagh</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President, Finance, and Treasurer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Bethany Cavanagh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Graham Cooper</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Graham Cooper</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Fishman</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mark Fishman, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Chirfi Guindo</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chirfi Guindo</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carole Ho</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carole Ho, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Maraganore</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">John Maraganore, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Christi Shaw</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Christi Shaw</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kathleen Walsh</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Kathleen Walsh</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:94%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#roirpaf"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of independent registered public accounting firm</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> (PCAOB ID No. </span><span><ix:nonNumeric id="F_7e4cfc03-d7f9-4b1d-95e2-539397469fdf" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated balance sheets</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_or_co"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated statements of operations and other comprehensive loss</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated statements of stockholders&#8217; equity</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated statements of cash flows</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to consolidated financial statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="roirpaf"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the stockholders and the Board of Directors of Beam Therapeutics Inc.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d39d7afa-dcde-474b-bf6f-0f267f6daab1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Beam Therapeutics Inc. and subsidiaries (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and other comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2025, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Estimates &#8211; Refer to Notes 2 and 6 to the financial statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company incurred $367.6 million of research and development expenses, including accrued liabilities of $14.7 million as of December 31, 2024. As disclosed in Note 2 to the financial statements, the Company expenses research and development costs, which include external costs relating to preclinical, clinical, and process development and manufacturing activities, as incurred. Research and development activities performed by service providers are accrued and expensed based upon estimates of the proportion of work completed over the term of the individual arrangements. Estimates are determined by reviewing vendor agreements and purchase orders, and through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services. Amounts paid to these third parties in excess of recognized expenses are recorded as prepaid costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified auditing the estimates of the extent of work performed by research and development service providers as a critical audit matter because of the level of management judgment required and volume of such estimates made by management. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to external research and development expenses included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the design and effectiveness of controls over the estimation of accrued and prepaid research and development costs.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the accuracy and completeness of the underlying data used in the estimates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a sample of service providers performing research and development activities, we performed the following:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inspected the contracts and any amendments to the contracts with the service providers.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the appropriateness of the method used by management to develop the estimates of the costs incurred to date.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performed corroborating inquiries with the Company's research and development personnel and inspected information from the service providers, which may include the service providers&#8217; estimate of the costs incurred to date, to evaluate the progress of the activity. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inspected the evidence of payments to the service providers related to the research activities performed.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition &#8211; Refer to Notes 2 and 11 to the financial statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company recognized revenue of $63.5 million. As discussed in Note 2 to the consolidated financial statements, at inception, the Company determines whether contracts are within the scope of ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 606, or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. For performance obligations where revenue is recognized over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified revenue recognition as a critical audit matter because of the judgments necessary for management to estimate total costs to satisfy the applicable performance obligation under the contract. This required a high degree of auditor judgment when performing audit procedures to audit management&#8217;s estimates of total costs and evaluating the results of those procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to revenue included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the effectiveness of internal controls over revenue recognition, including management&#8217;s controls over the estimates of total costs to satisfy the performance obligation.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3510089492940902%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We made a selection of revenue contracts and performed the following:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We obtained and read the relevant contracts and other documents related to the revenue transactions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the Company&#8217;s accounting analysis for the applicable contract, including the application to the relevant authoritative guidance.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.3695252381001304%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the amount of revenue recognized, including when applicable, the measurement of progress for revenue that is recognized over time. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested management&#8217;s estimate of the total cost of fulfilling the performance obligation, including retrospective reviews of the changes in such estimates over time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1fe2d09-dade-4069-9c68-94ef81762473" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb300023-04d4-4646-b0dd-c7ad73d35713" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2018.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3190044-c871-4054-9fe7-2bbbe980ccae" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,967</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_983b3200-bba3-4b02-8884-235486765a52" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,895</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f57c6bf-9d2a-46ba-832d-5100ccacb22d" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d075d208-1bcb-45be-ad14-9937f2d0ef45" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753,981</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_457488d9-3d21-4bbe-ae43-5dc8d4c5952b" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,409</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38fe91a6-82a5-4a00-bc3d-5293be6aab4d" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7ae7aae-4986-41fd-839d-b0d363f0f18c" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">878,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2e24bf-879f-4319-90c4-f1a5ffc9e02d" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211,043</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_745ecb83-88bf-4b19-883a-d198c91479d3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,412</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a6e7e23-c59b-4d0d-aad7-de6bb6ddd414" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,960</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906f61c5-9fb6-4046-a70f-66291e9c78f8" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,144</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59cb8b4c-dd91-4ae3-ab2f-dfbb6b74a7b6" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dad4d5da-f7b7-40aa-a47f-7513ba68d7d8" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68441e87-c67c-4ba3-b119-b6fc1148e602" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,846</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23b8732c-26a6-40cf-b5aa-3ea04ff1fa61" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc611d42-9a1d-4bde-9636-c7fda1228fd4" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,146</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcd78204-2dd7-412d-9883-7a0f754e953c" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a7f4d83-f9ce-4148-b139-ae9edffbab31" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,459,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_072cc25b-a603-45ca-afd9-2d3d8812e506" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,871</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36cf8b8f-a35e-4ff7-a042-ef985e92f2f7" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d426e272-c409-4548-b984-7d40c1e10921" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,468</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb975ab-43f4-4a99-90d4-42739d76576c" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,664</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_029a9c1d-ac0d-49cc-aba9-e149a148fcd1" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4445a20f-fecc-4162-ad71-0c7a24738a33" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,800</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34a4970f-c7a0-4f2e-8bef-6d4d8ab2ea02" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,858</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99951552-0f02-4aea-976d-3e45303af05b" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,706</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858c36ba-1f4f-41aa-b64d-b14205cf9de5" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,469</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e1b7913-f5c8-4dc0-93a8-bd84cf2dcb19" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,778</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5707329b-fbea-4fec-a7bd-2b9f1df357f7" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,066</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19992275-94e6-4896-8b95-55a9cf677ac3" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205,565</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d998ec2-e5ed-49ac-8e51-865926c0fc69" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,956</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7711ae-eeb7-4772-bf5c-c3af070c04e3" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,911</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d87dade-a2a4-4906-8841-286c5749e6b8" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3147f957-b2d5-4fbe-8b07-e9648663c891" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ecfd229-dc6e-4d93-986b-aef7e817f38d" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,218</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_454735c0-ddc4-4e09-b735-bb232f2ea497" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,888</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52350987-1d5e-4c4b-99a7-e200daecb66b" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,404</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0af5c29f-0b7b-46fe-bcf4-064396a3204d" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">504</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3e9a5fb-8c97-44d9-bd77-c24df5c9ae04" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc13ace6-ee40-4fbe-958b-b11fe9d69d3a" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370,279</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e107c2e-2f03-46b4-8005-20f0e16bf753" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e956a4ad-eb1c-418b-a3ab-90753a35728e;"><span style="-sec-ix-hidden:F_551a0859-97e0-4c44-b2cf-761c527698d6;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (See Note 9, </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">License agreements </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">and Note 10,</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> Collaboration and license agreements</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d27ce24-ef5c-41cd-9fc2-ddce126e87ee" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_d19e0f68-a22e-4161-b6c0-01f6a09bbdf8" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c095feb8-171f-43e9-b4d3-f67d803d89c3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4a84875f-ec5e-4e82-a48f-c5483d358b73" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a250ec6c-b9a5-416f-bc27-852cb6f65a6d" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8e727fc7-337d-4655-9659-58f339b8d690" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6a55958f-6d98-441d-921a-dd622fa25efd" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cbcc3f97-9f6a-49e8-88a4-0fef08154a9a" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued or outstanding at December 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_42995f5e-5cf3-4580-bb7b-2701972eab60;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_7662523a-3bfe-403c-87db-b8b2c549a337;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aeca014-c41f-49fe-8200-0789230663b1" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_4c8e3247-5e00-44a6-9a2b-177fe79df242" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de534136-153b-4cca-97ff-271b31889631" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b351155-10d4-4597-ae43-c3eb0e4bfdbb" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51be6ef-77f7-47f8-b8e9-521e01ab614d" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7ae8805f-2e93-479f-b48a-443f3e4055d3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,633,069</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c119b8b0-bb6e-4d9d-93c0-c41858c03d0e" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_08d1f565-aa4b-48d1-b901-3d680d7e3a72" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,632,496</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and outstanding at December 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e0b69a4-4faa-4e17-a333-2156adc6d07f" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ed52d6-4f82-43a5-86e9-acb37c0615ae" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff48176-acf1-4588-8def-a9506cd59e4e" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,298,661</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea465c3-6546-4474-a7c5-a3ebd309395a" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive (loss) income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b8045f-cc59-4b53-8a74-24405b7cf625" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e54eded-2aee-4cf2-b91b-9082878df4a9" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b91bac6c-c558-4d25-bf2b-a50c3b138c0e" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,566,631</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc204c4-e500-44c3-9372-d2c7239aa206" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,189,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_623756a6-1225-4cf5-b193-ff4e633c4950" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733,545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a593ab-b134-4f58-93d4-4cd18a577a07" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">981,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e681f8-6dc4-411c-bdf7-c9244a9246ba" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a776b7-4496-4b0c-bb4e-5f2ad811697e" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,459,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_or_co"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ons and Other Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0794c34f-35e0-41b4-bece-9a3a0619ac97;"><span style="-sec-ix-hidden:F_28208d39-9753-4125-b201-de2b195f562d;"><span style="-sec-ix-hidden:F_4ef95e1d-df40-47c3-9777-21876464c49e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span></span></span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_961ac718-c840-4279-9338-017f28f3c5e5" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bacf522a-248d-42c6-a2e6-e93c2bb9e817" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377,709</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77bf99ca-a453-41df-94a2-956577c20eae" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1aac89-c9ab-4c80-bbfe-c62d0a6570be" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367,561</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e683d93-0856-4242-bb78-500ee4ebcb22" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,381</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88eeaa9d-ad7a-4c90-a40f-c127a02c8dd0" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e42be19-0dd5-4e95-902e-54725446eced" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,525</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37f8430a-09f4-4554-a44c-67f54c6412ed" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,813</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e82f064-ee60-4120-ab0c-f31b403be799" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,805</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723e3b9c-dbea-477b-8441-64214d07816d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479,086</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7e11d28-9d28-429f-a25c-79973e36c685" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554,194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7034d78a-e419-4b08-9499-e6b8d0e949c6" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">399,399</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cadaf4f-7f24-43a2-9b78-32f625b76426" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">415,568</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f64d9041-66c0-4652-962a-0e692f031027" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">176,485</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcae2e62-2052-4a62-8b8b-031281350092" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">338,479</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6579c0c4-2f33-4e4e-9b88-ef0f46992a7a" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80236f0f-c606-4b8f-baae-d746266b8810" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0f4dbe3-f6fe-4b12-8286-b97215368bb0" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,900</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0da24ee-2914-4baa-91b6-1e747cc80286" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,093</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31aa552f-4d9c-43dd-98ec-9d9eaad56c3d" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe425b4f-69b1-49e8-8af9-23507d0148b6" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1a30b8-0039-4a4e-9c5c-804359287ea6" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:ChangeInFairValueOfContingentConsiderationLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a05193-ee1e-4313-8805-82d40e736b63" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:ChangeInFairValueOfContingentConsiderationLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a3f848-ec6f-40d1-91b5-6fccc03d1c36" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:ChangeInFairValueOfContingentConsiderationLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e87161b-a921-4f2f-9142-03be6ce6b4c8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,094</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f48814ed-44cd-4068-a47b-dcd1d9fd6e69" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,676</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a560a27-bc39-4421-8795-7a28e1f17283" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,297</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc517c7b-6382-45cf-84ec-942daa134baf" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03e247eb-f677-43e8-9436-a1de4c1553dc" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,324</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec71f5b-a195-4de3-aba3-7187aba26a4e" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,301</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ef119d3-0491-47be-a1f0-430190dcc2fe" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b9c22b9-8f5b-426d-9816-54aec8068f4f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,161</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97a41643-8955-4f40-96e8-3de1a419d43c" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">260,178</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0afcf0-da0d-455f-8154-8d4c14d6d440" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7d2ce4c-d603-421b-bb0f-0cb49d001d02" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,366</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b00bd4-4f16-422b-88c7-e9cdbcc6e71a" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from equity method investment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_840629ee-93f0-4d88-93ca-c568f04cbd07" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5361321-3d04-4cd7-9dbf-ee220c5ee4ff" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a6969d3-7abe-44b4-8b0e-8c893c3df78e" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bca6614c-5e03-443c-a710-645d17124fb9" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3520d28-7eb7-4102-bd7f-4d96aa7e0fe8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46663c03-af6e-4b91-9a81-9647116f157c" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,034</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf29475-8bcb-4ace-be4d-03aa01b3a7c5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,380</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a509a4e6-be84-4bfb-a61c-2dc4e9550bab" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,667</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5912831-d824-47de-9d37-b6e9bbccbda9" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,493</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8986824f-b4a2-46e3-987e-18e310d584b7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">291,468</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e0d8ac5-ade0-4f80-ad2b-e97cf4a1a8a1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_81268497-ff0b-4096-b9f7-2e2b24428a75" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.58</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82ba624c-9082-44c3-92c1-c006e374dfc1" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f0ca9f84-1cce-4c5e-ac1c-470f11fae04f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.72</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd2b855-274c-4196-8dec-9b83e4f9c135" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8b845a68-2252-4117-a377-48f156d75fd7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.13</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5ceee0f-b1d7-4c30-bc7d-dcee61107851" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_444b29c3-5128-426a-a691-b64ba6acff09" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,313,008</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0d51ef6-168f-458d-89f4-5ec4c949dfe6" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1aaee27a-0e87-48e0-934d-6bfa04812cda" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">77,151,771</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c87a79-068a-40d3-97f0-5a8e4185a913" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_67983ac9-cecb-4cd0-bb0b-03370028a423" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">70,015,305</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_redeemable_conve"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.828%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.421%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.041%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d101455-4d70-409d-b40e-ba3dd314685d" contextRef="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,389,425</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5f5c16-4dfd-416b-868a-44210e5fae29" contextRef="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0940c46a-d0d7-40af-b02f-af266c51d6c6" contextRef="C_b83b237b-6d18-4327-8bbc-c9cdb6104ded" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594,378</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bb607ed-b1d8-47e8-b89d-580956ebda20" contextRef="C_199c64fb-9ab2-4c44-aa73-4ccf1cc07ee0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ef846c3-95da-4885-b0cc-e62acd966129" contextRef="C_b047b3c6-6f6d-40d7-952c-100389cfdae9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">768,274</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad3f971b-7274-42b2-99f8-349482d9a36b" contextRef="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">826,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of common stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53149ca-698e-4d55-8759-398d6169809b" contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,073</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64cb7b49-4e19-485a-8a65-d992a33baba6" contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b60e156-c9cd-49ba-b3aa-6379b3e8939c" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock from At-the-Market offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b26067aa-5ec7-49be-8ada-95845bdf4a05" contextRef="C_5ca56256-2128-4152-ba15-ce38a36b87a3" name="beam:StockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;million</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae85f23-68f3-4dcc-8af1-8b5d10eb4ea8" contextRef="C_ab6a3226-270a-448c-aa4a-011574bd549f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,909,103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e4cfece-c585-4d3e-92b6-b4aff804f4ee" contextRef="C_ab6a3226-270a-448c-aa4a-011574bd549f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25861e7e-abfa-4be6-8199-2f2755872a3d" contextRef="C_b519bc91-9533-4dcb-a39c-d95a0025a438" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,057</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95752352-6c51-4195-90cc-c0a360d63b3a" contextRef="C_5ca56256-2128-4152-ba15-ce38a36b87a3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,076</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ceaa00d-a100-40a0-bd40-4eeb2ea20b56" contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">424,303</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46b45046-870e-42bb-b0fc-01dfa035d6c9" contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6948ff-9022-47d4-b420-ad1c4645d9c2" contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba1cc0d6-b9b7-4e31-a483-5f96184a1b47" contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,321</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e93485d-96e5-41b2-b10e-9760dc317d61" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,321</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f24555-5cd8-425d-b69e-f07b45b5cfd0" contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">484,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_026fc019-f45d-4392-a5f4-151282fe996f" contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9cc4b1a-57d8-4378-bbcc-ac0d41751779" contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,727</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4ed3326-b2b6-42f5-8016-5bbb81ae0c09" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f520c86-f0b6-410f-922b-a6a0757a4164" contextRef="C_480875b2-e64b-432b-b458-b70c8350f511" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,380</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c66c3c-a080-4eac-9d74-97d87ae1a04b" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,380</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be01af30-4d0c-4c63-a700-0ce6a164b3a4" contextRef="C_17ab1823-a6d7-4de6-8f1b-d8443d01ce0c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_239ac0ca-056a-41db-8bf3-c7961b8063cc" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9d7b88c-0346-4949-a073-8ba75ee4c1e1" contextRef="C_9a16ff51-e500-41df-8c2c-d24921af54f7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">71,277,339</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a20c98e-1c71-4f2b-9bdd-756a62f9a092" contextRef="C_9a16ff51-e500-41df-8c2c-d24921af54f7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_792cd3ef-bbbf-4c6b-8f75-8cc4a547e578" contextRef="C_525cf13e-fad6-4e2f-9c9e-48ad51403c66" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,792,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629b21a0-5274-4ba3-94a9-3a83ce6dac98" contextRef="C_b1a1acf3-c64f-4967-b7e4-958c7a788e9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,430</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb12656-7601-47c0-b466-b0ad7f2e246f" contextRef="C_fb510e5f-fbb4-4322-a22a-8b7179089277" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,057,362</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a949ba63-5b2b-4f64-8e2d-899179293534" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733,474</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of common stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f571d8ec-f734-4435-be34-defa5edbc3d5" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85852a52-9ad8-4ef8-aa28-896a06365a6f" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9ef523-c499-4761-80a9-b6557e2527d2" contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,031</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb947d60-6f6b-437b-8f0b-16ef8f500b84" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock from At-the-Market offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e48c32e1-6287-4a84-b725-90a2ca9a827c" contextRef="C_c8171dae-98d5-431f-8a83-4520d464b7e9" name="beam:StockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;million</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ce4ecea-790c-420b-9fdf-693ce8399f3e" contextRef="C_f1109e54-6e94-4d48-a4a5-64a3507c850d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,952,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aaf8c17-633d-480a-bf11-02a9a9e688a1" contextRef="C_f1109e54-6e94-4d48-a4a5-64a3507c850d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03055012-9f22-4753-bd0f-bc9312c71ce1" contextRef="C_97a94644-ff61-46cd-95e9-1614d5a9b854" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,868</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e2b12bb-0d5f-4034-990a-404aba9b5e9b" contextRef="C_c8171dae-98d5-431f-8a83-4520d464b7e9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of unregistered common shares in connection with license agreement</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_809ecd34-63af-4ab4-938d-7ce65a6e28f0" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,004,811</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86c3e265-03cb-4809-a1c0-10d12c54f2e5" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_038ddae6-06ab-4664-b24c-b75197d2c5ba" contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78" name="beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,580</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf820045-b4d0-4d3b-9aca-97e6a1cd8e41" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70b2625f-5981-4839-9e8f-5bf0b2c7a9ae" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">469,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce5e818d-843c-4fc0-90bf-951b19f3934f" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1996443-fb7d-4f01-94f1-b254aa4d700d" contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_637e2bd5-f4f0-4a4c-9cb3-3cf2ee028c8c" contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114e6b40-47e5-4ea7-8e8d-7bbf3067afca" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b99294a-82cd-40bf-9067-e9af374887a8" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">797,709</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b010a2-f9d8-4275-a556-af3df1045a38" contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70777f3f-e18c-4641-bbc5-a8ca9b6b81aa" contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,123</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1aec229-43b5-4dbe-876d-f6f3da854cc5" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,131</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb211d9d-c04d-4380-a0b0-20c97dc3eebc" contextRef="C_ca386094-8a4e-4c31-bbb9-c0a598866d8d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,034</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_161392e1-523a-4da6-836f-c891dd6c78c2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,034</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3958dbba-d569-47b4-99ca-fe686f1dc1d1" contextRef="C_98e22f9d-79ae-43bd-8044-17f44f41029a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599791b1-780a-4dea-9ee2-a2179dcd8f03" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f68c79d2-cfb0-49e5-8563-0ccbe8345b9f" contextRef="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,632,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74339fc7-cab2-4d0a-a9d3-fea6198c1589" contextRef="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77c51b4c-41b3-4502-bdfe-04a5b5f798e0" contextRef="C_e8a4929a-82aa-4502-9781-741961c7ae2b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ecaf290-868a-4d3d-bb65-70c4a9b9b9cf" contextRef="C_ee767960-3dae-4bd8-8d2c-8f119f919035" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6774fb82-83cb-4f42-9178-f4e2a341a25b" contextRef="C_2c909485-c763-4bfd-87a0-49786aefa4fe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,189,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e08e29b5-9bdd-4ee1-a6e5-bfaea48dadb0" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">981,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of common stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44dcb3b-bd2f-4112-b8a8-22b23980e9d2" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,187</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7e53d9e-0073-44cc-8976-a7c18f0da797" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d38a5cc-f1c1-4dd2-bc22-d1c992b89420" contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,620</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_face1c7e-b876-4b72-8805-f171a1e83b7b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,621</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b74d103-c84b-4023-bd7e-7510d0a091fe" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,302,037</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b92b659-d5d3-40c5-b041-b898743a8b50" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68ba73b6-1954-42db-8ce8-2e3ac06e716d" contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c9d838e-a33a-4820-bf69-bcb3ebc280cd" contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,662</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_616144af-a07b-4890-9324-33c8780f2527" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,662</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2f5e7f-9186-46f9-a410-9c4223a8af56" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">563,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ab480f-dfaa-432a-a389-0d3706d3d318" contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbe31ff9-7e8c-40f9-b163-2c9ae31ce4c9" contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22d1abc2-54c9-49e0-97e6-4c1ad0e1b453" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb01451-ad6e-44df-92e0-4dbab3ae7d4b" contextRef="C_22bf2ac7-5934-477b-9c81-096c75b0a449" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a48f6c17-b42e-4eb3-81a5-9c2008fd4223" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feb2a95c-0cb1-4915-9b18-70699776c6bd" contextRef="C_d5f96b32-a698-4369-8181-0a106fbfb45a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ec005e-5503-4257-b02c-f0ec07b308c4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b16f9555-0f93-4516-b4c7-0f27b16fd809" contextRef="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,633,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f38da1f-4871-47a7-b587-57ed79caca75" contextRef="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b9ab1c-e21e-46a2-83a9-35fe57a84daa" contextRef="C_257027f1-7dcd-416a-869c-74ce3e11938f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,298,661</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6818badc-3f40-44eb-9cfb-81be1fcd2065" contextRef="C_7ff6fe20-72a4-4903-950c-bd6bf0d3b3c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95503965-c683-4ea6-a411-044912018a7c" contextRef="C_979dd123-9531-40b9-b541-eec96ea77e9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,566,631</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edf5e0aa-ab32-43bb-89c7-dbc0d1dd5c6e" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733,545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.588%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.838000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.838000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.838000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8f653c1-37d7-480b-bdd2-9c7384c62ce9" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fd84c4-588d-4cab-8628-786d4ece7b27" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af69aac9-b112-45e7-9177-dce2c818ced2" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from equity method investment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a960eb2-3c21-4138-8a46-2bc0d6c837d4" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c5fa620-6da6-4e8b-81cc-d0b0173ced9e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,925</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b8010fd-a05a-4354-bacc-96dd60e8af31" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,012</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38cb048e-86b8-4517-b2c6-ffa25f072cb8" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,147</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of investment discount (premiums)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b95c1c2b-32a5-4806-89b1-1afaec657c7b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,765</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33383bab-6a7a-4876-8b69-73cef1515677" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,743</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f536564a-dc4d-4389-812a-1fcd11f8ced1" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4667892b-a103-4336-a31a-61007d71344b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,662</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9d8ad0a-1b23-4027-aad1-bbb8edb561f4" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f2c4b10-aa3e-4707-b775-54ab38b731ae" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,321</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ed95c36-fa96-4d12-8d79-53bccffcce23" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24fc3a21-d4c6-45a2-80ae-80f05ed0911c" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,519</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d35a37f-51d3-4e98-84c2-17f37f235ed5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,430</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c7ac4b-8874-4fe5-b79b-389c44fc0a28" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f910c749-38dc-48c8-9166-dbb06c2474a3" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc8c0e99-6a7d-4839-a7db-b06c3f1bbdf5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,900</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe034a7-b7b8-4fab-b31c-beddfbe25808" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3ef6402-6bef-472b-adfa-1e58c19551dc" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c66c964-1b4d-4d95-99af-2fc70966f44b" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_451b7f38-40df-4306-9f5d-dc0bbd3ef470" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,093</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acc80e2c-4476-4699-9172-96f4ccaa035f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0024d7-4da4-472a-bae4-bab288094662" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5beee07d-2d0c-4e86-b27c-b317c002bfa9" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ee41d8-fc09-4659-b690-f16896b7cd93" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d843f73-3f0d-4cf6-8d95-50898ac0eaf1" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,473</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee035c98-070b-4350-a1fc-eabac2dff584" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,753</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb66d75f-cec7-438f-ae60-f772daee6608" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d995141-83a9-40aa-9de4-e58da44028c7" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,578</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1bce13-5a76-4a50-badd-acc66eb620ef" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b48fdca-7572-486e-af77-63be0175eb9d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cfaa52a-d2b9-4c84-8d7b-d771eaabb308" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,663</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_883481fb-387e-4bf7-a6be-86a1906ec7f5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,933</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58b09a55-0b8a-4ca2-8502-0f96e2a27a65" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,951</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5386273a-2462-4919-9b6d-ea91bf64e9a1" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,168</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e989f411-daeb-475a-ab8a-438ec8b51d44" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,430</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a410e70-d242-4634-b73a-03b15dea75e2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73346e14-a237-42dd-8e1c-35c2f8576610" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1fcd7d5-96b6-425a-95c0-da7be67227d1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b333598c-116d-4183-9b71-9d45beb80361" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,559</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6446095-ff4f-4110-b4f5-897d714b01b3" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9f1a2c9-de15-4567-ab13-fa109c1a577a" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7b56459-cbb8-450d-9e01-0ab387ea59b0" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3cca716-6a70-4f01-9ba8-4aeac1e38f9b" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,569</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76133740-3090-4b06-ae7d-9ec3c83b3cc8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">347,246</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba392b6b-354f-4bc2-aecf-11d751c5c215" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,195</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b32d310-2412-4715-bc54-7cda3ac7ccb7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da7fdcdc-71a6-4281-a69a-287d4db49979" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,946</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ae018a-cc5d-4868-a853-a8c85efda665" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad197a26-c5a1-400f-ba00-7fbd38d701ee" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,951</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b98e9cfb-0ff8-4c43-8389-200a1b67c854" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">486,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90ae732-e545-45d5-aa3e-6b92ba75fe50" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">984,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ac33bc9-8ee1-48f8-b762-5d64de94c389" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,616,999</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b34c6db3-12b0-45d9-91bb-7a3124f05efe" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">680,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9fdfbb5-9eef-4e10-85cc-b0b5f8529cf3" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,089,910</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17963743-86f9-4c18-84c5-f76e187f30eb" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,204,614</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4af9f77b-1f1d-47e1-9bae-5b2f7ee41a08" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,007</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3632afd8-0fc7-4def-9b96-58d9d029a071" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,840</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62c228cf-387c-403d-90c2-bf18bb8e6600" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">461,336</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common shares, net of commissions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70e8cdc4-1eeb-43d8-bb41-52c7bd7bb993" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,568</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948106ae-0e66-4b4a-962c-ca71600a15e7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,258</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9dfc6aa-a677-4c83-9f49-f7f93f04a97f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,621</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69438cd3-a782-4f4a-9897-e436bdd8135d" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c1bb1d1-fec5-48fa-9d0c-20a0a07feaae" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of equity offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_152fd852-10f9-46ef-9b9c-51acf01618cf" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e2e8fa0-daf0-41c3-abe9-fdd8c38d8700" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equipment financings, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2e64b8c-c7d9-4592-a50a-7dbf160fd203" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f3c7e3c-b05e-4ea6-a6db-d1a1aefe50ac" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,252</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd60e5b2-219b-4a24-82d5-4af72943376b" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f0c7efc-d23a-48eb-934b-769426064bdd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04a9c03-c01e-4da5-98ee-ad282692475a" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,131</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_915443cb-f40a-42aa-9f09-0435ef873064" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from private stock issuance</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1be4de33-9614-45a3-a3c1-a10015951f8d" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c138c4-9133-431c-8dc7-0bacb7242444" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_695fc62d-d00f-4f2f-ac3e-32833a4ad905" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">276,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_536298cf-c295-4411-8bdc-1b21b95f5bcf" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,590</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_533d6691-d55b-4f5b-a9c1-f9867ba70980" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">154,503</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc020acd-f8fc-4ebc-81ce-9c52f70b67fe" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,093</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ee3e085-041b-4c7c-9e22-d6a73293b0cc" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327,219</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash&#8212;beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58cc8fd-8f1a-4414-af30-5cd553e2a1e2" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,614</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8fd6899-b205-4199-bb45-bb6fe67155bc" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,521</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b8b2b64-c70c-4a35-a40b-4eaea54303c9" contextRef="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">572,740</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash&#8212;end of period</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c480c97d-92f8-4801-a431-b6ac5ef5f488" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,111</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae9b2fc8-2239-4805-8c44-f9239a1ddfc1" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,614</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff21952d-6640-4dbc-9ffb-2841ba0d69ae" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,521</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated statements of cash flows (continued)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eb49d16-1631-442b-8007-fe16cf19c447" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9815babd-9d19-4773-836d-95d9b1ec6345" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a9c5fe0-ec34-4bc5-9ccd-9ba2e441f25a" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of noncash investing and financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment additions in accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f8cab1-50df-4f2d-9d5a-d3baed1e1348" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">834</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb26d5e-c3c8-4938-bc18-ac16a0a3d2b2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee55a93-bec5-4481-8928-ee2d3fd0028b" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,783</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc188687-4604-4afc-aa60-a4423cc11923" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,626</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1dca42-ee84-49e9-a1c5-75e76e69d866" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,852</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4c86b4-93fc-4e41-a68a-081f1ceaf712" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,050</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash contribution of intellectual property to Orbital Therapeutics, Inc.</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bae97d6-a610-4fd1-80d8-04cd194549f5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ContributionOfProperty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,500</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5a5c839-f660-49d1-ba55-4668b9423e02" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_d5a5c839-f660-49d1-ba55-4668b9423e02_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc., which we refer to herein as the &#8220;Company&#8221; or &#8220;Beam,&#8221; is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam&#8217;s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and capital resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, research and development costs including preclinical studies and IND-enabling studies, organizing and staffing the Company, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company has established internal manufacturing capabilities. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into an at the market sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3f384d7-7dbe-43c5-931d-383a8583e33b" contextRef="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2" name="beam:StockIssuanceProgramAuthorizedAmount" unitRef="U_USD" scale="9" decimals="INF" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33459cfd-a5ff-4b7e-8484-7df53a449ceb" contextRef="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a" name="beam:CommissionRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e5a0644-e50f-42d2-b6fb-0a7ecb2214f8" contextRef="C_33491d05-f4b0-41eb-b082-0966c1c67aa3" name="beam:StockSoldDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold under the Sales Agreement during the year ended December 31, 2024. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa358fc-8cb0-4a0f-984e-ebf578276e44" contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028" name="beam:StockSoldDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,769,001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the Sales Agreement at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9d8bfd4-3531-4559-b0b5-4a41013add54" contextRef="C_9e824cf6-96ad-482c-938b-89bcefc2519a" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">62.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbc82e1c-70d6-41f1-9dc4-4973246faa15" contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028" name="beam:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">864.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting commissions and offering expenses payable by it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has incurred substantial losses and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cbe76bd-7ef2-49d2-9865-73c14d522ae4" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="9" decimals="-8" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion as of December 31, 2024. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d5a5c839-f660-49d1-ba55-4668b9423e02_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its cash, cash equivalents, and marketable securities as of December 31, 2024 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56f7a7a3-ffef-46ec-acc5-6cac5fafd596" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">850.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ummary of significant accounting policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_143c74b4-f470-4713-b5d8-465636728484" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_143c74b4-f470-4713-b5d8-465636728484_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><ix:continuation id="F_143c74b4-f470-4713-b5d8-465636728484_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or the FASB.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01b5cfee-b2d9-44d0-8b57-9762dc2bb135" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_74eb44aa-6202-47e3-a65a-e87647f71c80" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_74eb44aa-6202-47e3-a65a-e87647f71c80_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_1" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_74eb44aa-6202-47e3-a65a-e87647f71c80_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and other derivative liabilities, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_90684386-3502-4c4e-9068-932662bccc70" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and restricted cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents consist of checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company&#8217;s leases of its facilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b345ca2-a9ec-44c5-acdd-569a4a978fee" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true" continuedAt="F_5b345ca2-a9ec-44c5-acdd-569a4a978fee_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#8217;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.863%;box-sizing:content-box;"/>
          <td style="width:1.281%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.764000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.281%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.764000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.281%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.764000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5259621-683d-4b6d-9d64-ed92ab6233c9" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,967</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb63812-e1a8-4551-bda1-ccf0a11ec929" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,895</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eca6e81-bd62-40a2-a85a-b7c529a70d6f" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232,767</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dced7681-18c6-43d0-8a32-6a7725af6ca0" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,144</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c961afd-5f5a-4276-a14f-9b431a9d5e7a" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,719</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fa0db00-a2dc-42f1-92cd-9eb5bbfa4ef2" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,754</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21dcaccc-dda8-428a-bdc0-585497577f2c" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,111</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72bd56b-1172-4637-8b51-edefc3309eab" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,614</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d515b1d4-e881-40ae-9869-ac284a814d3d" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,521</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_5b345ca2-a9ec-44c5-acdd-569a4a978fee_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ad5b6e5-6b55-491d-8a1e-f4f71903af71" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies marketable debt securities as available-for-sale and includes such securities within marketable securities in the Company&#8217;s consolidated balance sheets. Available-for-sale securities consist of commercial paper, high-grade corporate notes, U.S. Treasury securities and government securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expensed over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in interest and other income (expense), net.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24f45953-875e-4d47-af8b-a95c8ba071fc" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true" continuedAt="F_24f45953-875e-4d47-af8b-a95c8ba071fc_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies investments in equity securities that have a readily determinable fair value as marketable securities in the Company's consolidated balance sheets. The Company&#8217;s marketable securities are stated at fair value. Typically, the fair value of these securities is based on a quoted price for an identical equity security. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records changes in the fair value of its equity securities in other income (expense), net in its consolidated statements of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f913852-72b7-44ec-97dd-a8646aee0cd7" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_4f913852-72b7-44ec-97dd-a8646aee0cd7_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><ix:continuation id="F_4f913852-72b7-44ec-97dd-a8646aee0cd7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b191257-0882-4c3a-9f66-97922a3f835c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees and indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae6b5c2f-3ddb-4b5f-afe3-50bf1e181241" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_757b5fe1-729f-467b-8447-f1e639e0a4d7" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_020b2356-9198-4d8d-934c-c7f54970f48c" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6c0ed05-d40c-4eaf-8b34-a0f553394016" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:EquityIssuanceCostsPoliciesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity issuance costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes incremental legal, professional, accounting and other third-party fees that were directly associated with its stock offerings as other non-current assets until the offerings are consummated. Upon consummation, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in-capital generated as a result of the offerings.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_2" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56f5b2ff-4a18-4462-a029-5c50eddd5965" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value of financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the valuation methods utilized during the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates transfers between levels at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96c9c6b5-a745-4eb3-add5-69dc87ea9637" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_520090f1-3535-43a2-a149-2142223fbd62" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"/>
          <td style="width:2%;box-sizing:content-box;"/>
          <td style="width:49%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Asset category</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_070bca50-cb9e-4ea4-8355-cb4b386540fa" contextRef="C_18b725ca-8307-4b02-bf86-cd5bacd75fe4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment and office furniture</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_5e4df37f-ead9-4737-9ce0-22e7d8b624ba" contextRef="C_eaa2ddbc-9a2b-4667-a992-ede8aed104d7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term</span></span></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in interest and other income (expense). Expenditures for repairs and maintenance are charged to expense as incurred.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_3" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_182da381-d124-4db0-a7e9-0d23075637d0" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (or asset groups) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32262e62-3b5c-484c-b40a-4d6d0c3cd40e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_658d13e1-b15c-4c89-a181-f0ffacce5ea0" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_34b64850-9cee-4a39-82a2-fbb623997f14" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d8b0ccd-6aa6-43c8-944e-30c3ba42f8ed" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DerivativesPolicyTextBlock" escape="true" continuedAt="F_3d8b0ccd-6aa6-43c8-944e-30c3ba42f8ed_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Freestanding financial instruments and derivatives</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to a license agreement between the President and Fellows of Harvard College, or Harvard, and the Company, or the Harvard License Agreement, and a license agreement with The Broad Institute, Inc., or Broad Institute, and the Company, or the Broad License Agreement, (see Note 9), the Company is required to make success payments to Harvard and Broad Institute based the achievement of specified multiples of the initial weighted average value of the Company&#8217;s redeemable convertible Series A-1 Preferred Stock and the Company&#8217;s redeemable convertible Series A-2 Preferred Stock, or together the Series A Preferred, at specified valuation dates, payable in cash or Company common stock. Subsequent to the IPO, the amount of the success payments is based on the market value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Beam&#8217;s common stock. Pursuant to a settlement agreement between a research institution and the Company, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381c458d-13fa-4050-93ef-5022a3c15063" contextRef="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e" name="beam:PercentageOfRoyaltyPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty through 2038. Any amounts due must be settled in cash.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3d8b0ccd-6aa6-43c8-944e-30c3ba42f8ed_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success and settlement payments are accounted for as derivatives under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liabilities are recorded at fair value at each balance sheet date with all changes in value recognized in other income (expense), in the consolidated statement of operations and other comprehensive loss. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations. To determine the estimated fair value of the success payments, the Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Series A Preferred, prior to the IPO, and the value of the Company&#8217;s common stock, subsequent to the IPO.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_271abee7-db84-4047-979b-794117265d55" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_271abee7-db84-4047-979b-794117265d55_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases and rent expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases using a right-of-use, or ROU, model, which recognizes that, at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty that the Company will renew.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay fees for operating expenses in addition to monthly base rent for certain operating leases (non-lease components). The Company has elected the practical expedient which allows non-lease components to be combined with lease components for all current asset classes. Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_4" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_271abee7-db84-4047-979b-794117265d55_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leasehold improvements are not unique and are retained by the lessor at the end of the lease. However, in the case of a space designed to be suitable for the Company&#8217;s specific real estate needs and if the Company is responsible for cost overruns, the Company is the accounting owner of the leasehold improvements and costs associated are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s real estate operating leases provide for scheduled annual rent increases throughout the lease terms. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full terms of the lease. Tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the ROU asset related to that lease at lease commencement.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47950677-72bb-49d4-bf45-89ddad81adcb" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:AssetAcquisitionsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fea7a073-3083-4293-a6f0-c33c68cc9a50" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may be required to make milestone payments to the former stockholders and optionholders of Guide Therapeutics, Inc., or Guide, in the form of its common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the consolidated statements of operations and other comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value is determined based on probability adjusted discounted cash flow model that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success or in the probabili</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ties as to the periods in which milestones would be achieved would result in a significantly higher or lower fair value measurement. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_72812e94-f23c-422d-8c30-1cc722f90adc" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_72812e94-f23c-422d-8c30-1cc722f90adc_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. The Company only applies the five-step model to contracts when it determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_5" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_72812e94-f23c-422d-8c30-1cc722f90adc_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP: If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Notes 9 and 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore consideration included in the transaction price is constrained. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_6" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_7"><div><ix:nonNumeric id="F_4204a2d4-28e8-4e54-a707-2941c6a485e5" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract balances</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as an account or other receivable. A contract asset is an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities, or deferred revenue, primarily relate to contracts where the Company has received payment, but it has not yet satisfied or fully satisfied the related performance obligations. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its obligations under these arrangements. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27443c21-39f5-40cb-8dd2-41b80c477e7e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true" continuedAt="F_27443c21-39f5-40cb-8dd2-41b80c477e7e_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the total deferred revenue for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 were as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"/>
          <td style="width:1.5%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.843%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.5%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.843%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e9711b0-6752-4af4-af46-25f624ff70d9" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,594</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58726e61-648b-4bde-a62b-8064c59fdbd9" contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338,153</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue from license agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts recognized in revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cba1d80-8fa7-4756-8856-c595d9e5f34e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,518</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc37a3ee-afbc-4dc2-83b5-333630320c3b" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,559</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12a2066-e608-4024-a6c7-5d33f6bf0bab" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,076</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c6dc34a-0009-46b8-9f38-fdfbba340242" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,594</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_27443c21-39f5-40cb-8dd2-41b80c477e7e_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10e8d96d-528e-4384-9c47-5b4b478c6e45" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting, and other contracted services. The cost of obtaining licenses for certain technology or IP is recorded to research and development expense when incurred if the licensed technology or IP has not yet reached technological feasibility and has no alternative future use. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dc01c3b-f851-4341-8b5d-7fe400204fc4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation program allows for grants of stock options, restricted stock awards and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and other comprehensive loss based on their fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards and restricted stock units.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation awards are subject to either service- or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The Company bases its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus, weighted with its own volatility for the period in which its stock has been publicly traded. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees and non-employees, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3300ec2-5570-45e9-b51b-d44d53ac7bac" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_7" continuedAt="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa0904e3-abdb-4651-903c-afbcb6275f73" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred. Due to the uncertainty about the recovery of the expenditure, amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and other comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f93b0390-d9c4-4ad2-99b4-e845e1ae306d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ConsolidationVariableInterestEntityPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable interest entities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii) the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc2969d4-b7a9-49cb-9875-e58a76931263" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b33c5d5c-594c-4298-aa3e-e10689e4841b" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fed40b4d-4b22-4017-ba5a-3215b87b3402" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net loss per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the dilutive net loss per share calculation, stock options and stock units for which the performance and market vesting conditions have been deemed probable, potential dilutive securities, unvested restricted stock, and common stock options are considered to be common stock equivalents, while stock options and stock units with performance- or market-based vesting conditions that were not deemed probable of meeting the applicable vesting conditions are not considered to be common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders was the same as basic net loss per share attributable to common stockholders, since dilutive common shares were not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3_8"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_24f45953-875e-4d47-af8b-a95c8ba071fc_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity method of accounting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship.
</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the equity method of accounting, the Company&#8217;s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company&#8217;s proportionate share of the investee&#8217;s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset&#8217;s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&amp;D, that has no alternative future use. To the extent a basis difference relates to IPR&amp;D and the investee is not a business as defined in ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or ASC 805, the Company immediately expenses such basis difference related to IPR&amp;D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee&#8217;s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company&#8217;s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company&#8217;s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding or commits to guarantee investee liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee&#8217;s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company accounted for its investment in Orbital under the equity method of accounting. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59411752-48c5-4e82-a539-98f7e64606ba" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_368bd464-a034-4238-90eb-ee8006040c63" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> carrying value related to this investment as of December 31, 2024 or 2023. Refer to Note 10 for further details.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79746371-c640-4857-ab8f-c65fe91fd1c1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_79746371-c640-4857-ab8f-c65fe91fd1c1_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment and geographic information</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><ix:continuation id="F_79746371-c640-4857-ab8f-c65fe91fd1c1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_307ef690-66e9-4f4c-8a4e-fc475bc7a86e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment operating exclusively in the United States</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0417dd4-76c0-4c9c-8f48-bb23fab3561d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, Segment Reporting (Topic 280). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard did </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55001df2-3c8f-45ae-9f55-faa5b227ab0f" contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s consolidated financial statements. The Company</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4bffbd2-0519-4a5c-bbe0-17a6f558be8f" contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the ASU as of and for the period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45326ddc-918f-40ab-a332-a91274f03709" contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the required disclosures are included in Note 17, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently announced accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The amendments in this update expand income tax disclosure requirements, including additional information pertaining to the rate reconciliation, income taxes paid, and other disclosures. This update is effective for annual periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db75f5f0-3325-498e-bd0a-b5220ed2ad35" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">roperty and equipment, net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bd02a4d-073b-44ef-8d2b-94a3c143a9b6" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c660713-95be-4d2e-a201-20b66c683172" contextRef="C_b9f60852-435f-4678-a85f-62bd679a4179" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,195</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e47516-4a30-4952-833c-f526ce1eea92" contextRef="C_23fc252d-db0b-4f39-ab2b-7b17b577a703" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adce0743-4d1d-4b1f-8d25-c795145cb904" contextRef="C_324afbe2-466a-44bf-954d-9a90de220b99" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d67e6046-2758-468f-a992-9fe899dcf6e8" contextRef="C_5d6e5236-b729-4f30-be75-4efef352181c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62e1ae65-43f2-4216-bac5-6b0db9c3a534" contextRef="C_9e71c9b4-c135-4fae-b90c-ed325df0b8f3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,836</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0878cb4d-1467-460c-a4b4-b3558855b4a8" contextRef="C_c6e8ae6e-253b-496d-b53a-66bdfb253362" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,836</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2f6690f-4c76-4e31-ae84-edc0e716e2d7" contextRef="C_817c79ea-b465-4bb1-8354-36977c68b051" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a13f1bd-6a76-4412-a098-eb59602737d3" contextRef="C_f91cd450-b36e-4a10-b341-9cb4a003d5a8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,163</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3efa2620-1d33-43b8-ab80-c3f0bffa1cd4" contextRef="C_91314f01-9991-4b7a-bf23-848ddb837575" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,530</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7acebb5-c079-4b3f-9d80-5a8e6ab44ed6" contextRef="C_23ce121e-638f-43db-86dc-7ed74a544114" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,283</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a029634e-9865-4662-be84-75d04e3df5bb" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,519</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70df8d28-97c1-4b55-be1f-d2bfe55b5a62" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,142</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df468e8a-af15-4870-99cb-adeea3fffb9a" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,107</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76556bed-923f-4ac8-84de-acb1149a2bda" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,182</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80508325-e0cd-409b-8bdf-4e6ba0dd81b2" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,412</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cefdf11c-bb46-4d2f-a96d-eed55a870f94" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,960</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c408378f-3003-42de-913e-8213f66cba25" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:SummaryOfDepreciationExpenseIncurredTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes depreciation expense incurred (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f6dbb18-c661-48e3-b256-743abde1d797" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,925</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9af18aa-f7e4-4a64-b6ec-196f51d06bcb" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e5359b7-a3d5-4f9d-903c-68eec6111542" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,097</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_accf629a-3000-48fb-ae43-47b15da39245" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_accf629a-3000-48fb-ae43-47b15da39245_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. f</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">air value of financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of cash equivalents, marketable securities, equity securities of Verve Therapeutics, Inc., or Verve, and Prime Medicine, Inc., or Prime, contingent consideration liabilities related to the Agreement and Plan of Merger, dated February 23, 2021, between the Company and Guide, or the Guide Merger Agreement, success payment derivative liabilities pursuant to the Harvard and Broad License Agreements and settlement payment derivative liabilities associated with a settlement agreement with a research institution.</span></p><div><ix:nonNumeric id="F_0e2e6776-6eac-47b2-a9b3-c37568cf00d8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_0e2e6776-6eac-47b2-a9b3-c37568cf00d8_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_631c7295-1e61-4671-9146-5a86c9a4413e" contextRef="C_bc54d5fa-e469-4984-8576-7bcd6d681ec9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60039823-cfab-4620-bff2-147440fe9bb6" contextRef="C_2f5b4752-7d3c-4f25-abd8-17c95208595a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d762b7d-341b-4201-90b5-95fdc76cbcde" contextRef="C_6e43c27e-aca0-44b5-b3bb-27130f064fd6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2825c44d-0543-49b9-ac08-596f7a9bcc79" contextRef="C_0ee731d4-613b-4c17-be22-2735e8f23bcf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3125b5d-1bfe-46da-9ad7-366854b47d03" contextRef="C_55ec542c-c4d2-4393-9e6b-a19e465465aa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f86804dc-27a2-45c6-bd62-2f8e5787c4d5" contextRef="C_9c33e7b3-8a93-4aa9-a157-7bb70a697ac5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53e2bf16-7d89-4ea2-b01a-53ecb5835b24" contextRef="C_bc22551d-700b-4bc6-97af-b994c3ba0a2e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,165</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce57ec33-4eb8-4652-97b1-a7f7142284bc" contextRef="C_683f1b33-2bd8-4061-9079-5d7ad5b7fa98" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,165</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dad72acd-3940-4961-a222-462cd6fff76f" contextRef="C_6ae048e6-a4cd-4f07-9ad4-aadfd8ecf040" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,165</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e139d71-8bc7-4771-972f-672ecbfde862" contextRef="C_383b09a9-52f2-47a2-9a87-2d0c4207c081" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd6182df-277a-4fc2-8899-248dc942354e" contextRef="C_ad3ad482-636a-4574-9008-c4bfd3d86594" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee0c7829-1991-4d08-9eae-c54b9492cbdd" contextRef="C_d2eb4314-6249-4e88-ab61-d2f3989cba46" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b5d48a-7a15-482f-a219-11567ec70655" contextRef="C_3b9e7d95-7542-4a96-be2f-5ddf5efc044b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2237745b-0766-4d08-8de4-f0ab7a6b9cc4" contextRef="C_2e4a2701-d32c-4f02-930f-f0d27e58173d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6beb34-8c6d-4655-9e87-e76073f6a528" contextRef="C_e5a0c25d-1ed8-41b2-b186-af6d43e40731" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8285e87e-1bbb-4651-a3e0-154ac9d4d2a7" contextRef="C_5d64756d-a5a5-4436-8aa5-135287bdbf64" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e803b05-0d53-4d08-8b9f-2d14929dbff1" contextRef="C_cf2ed59c-a2d6-4c18-ba5c-2809399c54d4" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66db8d5e-0c31-4e6e-ab0b-6b15d1eba612" contextRef="C_01b2a6c8-36f9-4f72-bd42-832c0a6e6c71" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b44ee6-1370-4614-b8b1-44298002532a" contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">850,559</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bb5b434-99f3-46a2-a3de-4c76eeda8c91" contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">850,559</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_534b2b6c-e292-4843-a68f-61053313425b" contextRef="C_81c512a2-b46f-4d8c-9387-3f1e58834fa0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,567</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_177e127e-3a44-4f09-853f-0aa894521442" contextRef="C_bf27e455-b39d-4609-980a-18b8f5630e5f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">560,992</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c191ff8e-7cdd-47db-8d93-601e1368c3c8" contextRef="C_3019e88f-46c3-46a0-aaa1-f470bb587e9d" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc774359-4b60-4f03-8f02-00a5e70414af" contextRef="C_66656a01-1fea-46c0-875c-123162651c9f" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a4d623-4355-4779-835f-f6242c8adf9e" contextRef="C_7e896a77-237e-4692-a24d-3c3b46d3a2db" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aaea7d2-00f4-4aee-93b0-ec59fbd3307a" contextRef="C_0e6c1574-d290-4081-9ab2-1ea6ba4e8324" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4a76e7b-66ec-4a62-af4e-8091959ae03b" contextRef="C_943bbfdd-15ab-44cf-894a-0a745768d5a3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6430b689-fe3a-4518-80c6-c44cc4a7f5a7" contextRef="C_3112c485-fa21-4803-9cf3-c428e7cc148a" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative settlement liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ee26cac-e4b4-435b-96c0-54b0a5d773c6" contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ca37b7a-6d79-4458-8822-6b76c94fd878" contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43bedee6-53e7-4e9a-a208-354915cbc11c" contextRef="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9aa96b9-946c-4978-b22e-03b1d880d6d3" contextRef="C_033b016b-6895-4539-b361-157a3608f06c" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7519ebeb-1da1-4bf6-ad04-610231404dcf" contextRef="C_e09cf5f9-77a3-4eb4-b400-584b976cf70e" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17e87756-98b7-428b-a3d0-9e597e54b426" contextRef="C_7d97cc6a-a7a9-4cdc-bdd8-2d91dd596f4a" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cfa3a22-a0d6-4681-9a11-ee8aa6934b48" contextRef="C_5857fee8-666a-476e-977c-4c0b45614d60" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_513173db-dd21-480b-a6c9-3357e85b4a39" contextRef="C_4c1fa6f3-850d-46e4-b180-0fdb4f170121" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4893eee0-e84a-4067-973f-632dd4ef27c7" contextRef="C_d499c8ac-d8df-400b-8755-7d20c1c148c7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07aff6af-b15b-4dd6-8fc4-c3d8ed41e25b" contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f37c32e-e32a-4213-b506-4bf11a72d493" contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ae78d3-e6d5-472c-812c-33bc52faef2a" contextRef="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_accf629a-3000-48fb-ae43-47b15da39245_1" continuedAt="F_accf629a-3000-48fb-ae43-47b15da39245_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0e2e6776-6eac-47b2-a9b3-c37568cf00d8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3bfdb3-6d3d-490b-8533-a2aa1fdabcac" contextRef="C_40bf49b4-00ca-4786-9c26-7a8dce5bfd9c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3642f5ac-672f-4b06-b39b-d5c65684a49e" contextRef="C_82d42227-3e5c-4f52-9372-708bac5614fc" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79efed45-0f0e-40e2-ae0d-1fae257a75c3" contextRef="C_d9c08767-4f6e-47cc-be86-e673973ca8ad" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8faca5b4-6cbd-40c5-ae6b-826a8091313d" contextRef="C_43ded48b-9f05-4004-ac86-baa2f80a25b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f035788f-ef96-4613-8df6-5d5a1eabc7a2" contextRef="C_52f693f7-a425-4188-9db1-a96f66ed8a57" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0854ce59-5ddf-4709-85f7-19c2a488a16c" contextRef="C_87adf2d6-df78-4402-8dd8-a6be3d79324e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aee8765-82dd-49d0-b115-82493c01282a" contextRef="C_98e29b92-f652-4c61-b122-e4d83608d91b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f8ac8c0-5ced-43d4-aa4b-c3c5a6a1180e" contextRef="C_e2e2c4ed-f4d9-44d7-bdf2-3812900f3384" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b2a2137-a88b-46f5-8b29-f4d8ad0f8b1c" contextRef="C_f8810dbf-4f3c-4f86-9ff9-d0d332a94fe0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e98fcc87-8d8b-480b-8210-44001ca9d87e" contextRef="C_8f22ed6f-66b3-48a8-b7b5-ae4b554749dd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23126ebf-c494-41d0-88d2-9cd3216ecfb2" contextRef="C_244af9b5-ee40-4af4-8025-4f3676ba9ad1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c7a797-aeb3-4c52-ad9e-e9447344c3a2" contextRef="C_85f101d5-687c-4b48-a5aa-3771ed3f1761" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ef896a4-10b0-41b7-9f0b-0039585f663c" contextRef="C_0345315c-39e6-4913-8fb3-95c4a3fb15d2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e79305b-2f7e-465c-b41e-78f894c42636" contextRef="C_c6a74e2e-8d45-4ca0-9483-c5961f7d2166" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75b6172a-0bad-4193-b163-7713a0be197c" contextRef="C_0faad1e3-a733-4640-bd7e-1ccdf04dcbda" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d09261-1970-4f7a-9c03-5525bea66026" contextRef="C_e64b5f77-b749-4105-a5c5-6201bccd7330" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caa621e8-250a-4df2-afe5-da6ad55fa9dd" contextRef="C_98297106-5ba9-49e4-9046-f4505117edac" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b6b0f6a-b141-4dc9-b1ed-0c7b0f35b33d" contextRef="C_bef248b2-037e-41dd-b7a6-9d8e777e673c" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5afb03e6-7304-4ac1-a0fa-7195ece77fdd" contextRef="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9a5c04c-6bad-4c88-9d66-cea880807cfa" contextRef="C_fd96341a-93d5-40cd-b881-5aa499e5c784" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7e935ad-1789-4d31-93dd-0cff3db0f824" contextRef="C_4199c4a6-3fa7-41c4-9f65-6bba20a54792" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">457,564</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cab34cb7-ff54-4df0-a018-100597f1710c" contextRef="C_388bb271-1237-4e73-bb59-50ed985c9182" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732,106</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6524a8ae-ba3f-4029-8c93-f1a5cecbdc9f" contextRef="C_5bf0ef81-7ab5-4b17-86bb-38c4a75f4dea" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a819a237-faa4-453c-a798-a9eb587c6b91" contextRef="C_25de5467-3e1a-4a4d-82d0-cb68b684e458" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a784c7-c80e-4db5-80f9-d3d0923fdb1a" contextRef="C_e38cf897-c702-4909-b484-fcd5d6b3590c" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e0ee0f7-c19e-47a0-8661-b3bbc1ac47f6" contextRef="C_cad5e1f8-39af-4380-a00d-766ccfd05763" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8011ed7-f118-4f68-b210-632bae220fd3" contextRef="C_2319aab4-a1e3-430e-8e4d-7cceabb77d5e" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f43ca85-a158-49d1-bc81-4f6ba3506edb" contextRef="C_e41e2e9a-3d40-4c73-9a6a-0d57206be6a7" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b2a0396-3b1d-446b-9b45-9f621ebbdb7d" contextRef="C_9064c4c3-29b7-480d-8518-b5181173d660" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1cb0b5c-66d7-4e51-87f9-741f51d267d3" contextRef="C_c2169fb1-18be-4514-9888-865d6522b536" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43d2eabe-bdbb-450f-8ac0-4bc14634e332" contextRef="C_8344d4f6-8b07-419a-b031-0646b3b208b4" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e604c95f-60a2-41a5-86f4-ffcda4910201" contextRef="C_fc0f5107-4297-4f5b-b705-3f7c3b7a3888" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3baebd44-13a3-47f0-b7e6-fd601a175b51" contextRef="C_cfa419f9-1c34-4353-b182-40b224d5ecee" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bbc38c6-b134-44ad-8628-97187e98651b" contextRef="C_e09975e5-fe39-42ca-9dd2-53a5844a5478" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31999806-d7bf-4c5c-a23d-06ee88b6c0d9" contextRef="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5169c164-9f9c-4a7e-92c5-9e42083a1983" contextRef="C_fd96341a-93d5-40cd-b881-5aa499e5c784" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4243f6fb-e107-4895-8571-c564b56777d2" contextRef="C_814c73a2-13c5-4097-a2c8-bac30dd2d509" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Commercial paper and corporate notes are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through using models or other valuation methodologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Marketable securities, excluding corporate equity securities, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, the Company held an investment in Verve consisting of shares of Verve&#8217;s common stock. As of December 31, 2024, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_873ba82d-5c8f-402c-aeff-20655bcabb5f" contextRef="C_36b8ac53-6fab-4279-8285-1a0366571ae4" name="beam:EquitySharesHeld" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">546,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Verve's common stock, the value of which is included in marketable securities in the consolidated balance sheet. The Company recorded the investment at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_912a1912-7477-4346-97ea-fc3058299704" contextRef="C_e9cd4ea8-3457-4c9a-9f89-0bc504f1aa04" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71c393b3-b39a-476f-90ab-7e0a24bd9157" contextRef="C_ef90c8a2-4431-4529-a22a-71ad29ed2842" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_cf70edb4-41fe-44f1-b0bc-9c990d9892cd" contextRef="C_ea4d3092-a838-4e9e-9f43-dfd61bbd3ac8" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a700ed9e-9a6f-47e6-93df-2b6e4fb7a8c8" contextRef="C_389b0c5f-dbe8-49a8-ab15-9087170a4b41" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, associated with changes in the fair value of Verve's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, Prime completed an initial public offering of its common stock. As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77a70a11-e2fd-41b3-8b65-fda17fe06ec4" contextRef="C_ee6bd22e-01c2-4e00-93f7-c74415f012a3" name="beam:EquitySharesHeld" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3f0291cd-f583-4bfb-980e-c442bec03249" contextRef="C_d81129aa-e4b3-4b3a-b639-c6b46fd97eeb" name="beam:EquitySharesHeld" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,608,337</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Prime's common stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46790ac3-87a0-4d90-bbde-da83e60299f6" contextRef="C_07957533-1268-4b9e-a1dc-14b0a90775cc" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5959b9bf-41aa-4214-bd23-9c5a1d5f5547" contextRef="C_f3b3e1c3-33ab-45c8-9774-7e07c887e615" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_95165160-0997-4e99-b6af-832e5dd31c81" contextRef="C_946fe569-b5da-4993-a5e7-d60b0d8a7441" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9566283-1040-4098-a5a2-7ae73f9f0618" contextRef="C_17281164-6360-4131-bbca-c983bf53650c" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">15.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, associated with changes in the fair value of Prime's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9634d241-0955-4143-9459-520985fd6173" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a962cc09-2a8c-4490-81ec-7cda2c31aa57" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,093</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7040ce9c-8e58-4f48-99d8-ecf5f2e78538" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5ea164c-7ed5-479c-a734-f44a0183e8e4" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payment Liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; As discussed further in Note 9, the Company is required to make payments to Harvard and Broad Institute based upon the achievement of specified multiples of the initial weighted average value of the Company&#8217;s Series A Preferred or, subsequent to the IPO, the market value of the Company's common stock, at specified valuation dates. The Company&#8217;s liability for the share-based success payments under the Harvard and Broad License Agreements are carried at fair value. To determine the estimated fair value of the success payment liability, the Company uses a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_accf629a-3000-48fb-ae43-47b15da39245_2" continuedAt="F_accf629a-3000-48fb-ae43-47b15da39245_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c72767de-daff-40f7-b28b-5fd4b7b71dfa" contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.17%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.922%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.822000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fccbfc9-232c-47f3-a38b-7dbd50a63cc7" contextRef="C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">24.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e761ec-4801-450c-972d-509d532d4a91" contextRef="C_ab0bc947-ab71-4f35-bc58-9f7f62090216" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">27.22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec30e141-956c-4d59-90d2-10477fd0b265" contextRef="C_f14e16da-1c53-4541-9a52-16820f10bad3" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">24.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b7654b-a101-450d-9e72-9b7e9c5092d2" contextRef="C_6026a8e0-6d93-4439-a24e-e03c582cd8c8" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">27.22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fed7c7f-48c7-4a13-af10-e505a99937c7" contextRef="C_e23b6999-779a-4b5c-abb4-d337cb7a4896" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34680c88-284d-4bf6-8d97-c1dc6538d8bf" contextRef="C_21a59809-dfb3-4b7d-8868-958dd1e18924" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e636aed5-d543-4144-9313-251c6af9ed04" contextRef="C_e0cca600-4621-432f-b776-908bc8bb5ba7" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f73c06a-72c4-46dc-b31a-de27bb338c2d" contextRef="C_d996319a-4fd9-4406-ad76-885120f0800c" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0dc6370f-1553-4618-baea-65cf3ae31dd5" contextRef="C_0a6ecb33-4df6-4c5e-a4a2-fb3d9efdf7cd" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_73b4f1be-921d-4fbf-914a-1deafbe6fde6" contextRef="C_813182af-346c-4681-a9ad-91dbab4005fb" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.49</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9548a7bb-f314-489e-8b4f-523742f7bbfd" contextRef="C_0e6053bb-b35e-475a-bcae-f92658e7661a" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_9cd1856e-b4fa-4b65-b32b-11d5534b3738" contextRef="C_f791e745-de9c-42ed-8a7a-14e39c2a105f" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.49</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8c602cae-8583-4496-9442-a8bd1f364ef0" contextRef="C_ff00880d-6565-4225-b41c-28e680e96f39" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_592f57f1-7527-4277-96b9-04cd41bcae0f" contextRef="C_de039678-b07d-4465-a92c-33cf16c0096f" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8362fca3-d290-471c-b1e2-e043140b9e3f" contextRef="C_f6e9e1b7-0f7e-4ca5-8405-404a9168b722" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_057755be-9831-458b-bf78-ce8a107a0af3" contextRef="C_6ac8ef0e-3351-4f21-bad5-60d55bade8c9" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.36</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The computation of expected volatility was estimated using the Company's historical volatility along with available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the estimated number, timing, and probability of valuation measurement dates in the calculation of the success payment liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e0746fa-cd60-42bc-b646-6e4528b97a30" contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d30ec21-34d7-4c96-88a1-ef1147cf04da" contextRef="C_b942b8ee-cafd-4a43-b778-957590c7d5a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f0a3a9c-0d96-4a74-b2d4-609b63c1fb8b" contextRef="C_e1810127-cbd6-4854-8acf-9b9986eb6b42" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,300</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1a038e0-6d56-4412-9ef1-253a79b16a68" contextRef="C_f7d01556-0db0-4405-b94b-9d3f9b6e51a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,300</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e912f13-934b-4d8a-ab3e-f0978aad4858" contextRef="C_46319399-2d12-411d-8c34-596d176648f2" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10f49dd5-d985-481c-8a24-dc0c66c099c3" contextRef="C_3ab34109-c504-4c2d-b824-f10aa01d2eaa" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a2ced5d-569e-4641-8dd5-46fce53e573d" contextRef="C_c0afc77b-a8b0-40be-ba4a-78a824b97e4b" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11da0d95-3536-45bd-a409-9978f38a4afb" contextRef="C_96d19294-dd72-40a8-a259-c7e1d6e2f357" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6327444-0ffb-421a-90ea-fdd8812521a8" contextRef="C_7b3060c0-eaf2-45d0-a198-e1f21e52d13b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_210f6138-6064-4291-b66c-6e4a56b75eee" contextRef="C_0bc8b385-01b6-4b97-b455-c669606db4c9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_483feeca-2f4b-40b2-b8bf-4262f6020958" contextRef="C_53ff89ee-a53c-493c-897d-5a1e22a591f0" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2ecdb94-f6a0-41d0-b0c7-d4730a0aa0f5" contextRef="C_0c39d71b-489e-44e9-a246-f57bf060b04f" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7175d282-9c6b-4c41-8d1f-d78f96b45d4f" contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e030dc9-a5b6-4f39-a4ae-bb0a93a51ee3" contextRef="C_1df55ac6-9859-4cab-9d1d-717a8ccaca01" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa0fff2f-5c86-438b-971a-c24eafce30c3" contextRef="C_b377391a-9d98-4bd0-8cd9-4b1adecb8106" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b68cf35a-b807-4925-a1ef-a638c8eb6155" contextRef="C_4e0928f3-a41c-46c8-adbf-38ad87f13f70" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Guide Merger Agreement, Guide&#8217;s former stockholders and optionholders are eligible to receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2926ebbe-68f5-4f1e-98bd-2589aa68ef75" contextRef="C_db910110-c7b9-47bd-9b00-ef30f2e39bbb" name="beam:PotentialMilestonePayableInFormOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in technology milestone payments and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_340c7990-e990-4d9d-b107-2f7a7a96c555" contextRef="C_5faf1e6f-7db9-44a9-9e75-3c1cdc11b9ce" name="beam:PotentialMilestonePayableInFormOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">220.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product milestone payments, payable in the Company&#8217;s common stock valued using the volume-weighted average price of the Company&#8217;s stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is achieved. As these milestones are payable with a variable number of shares of the Company&#8217;s common stock, the milestone payments result in liability classification under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs based on timing of achievement that were unobservable in the market. These contingent consideration liabilities are classified within Level 3 of the fair value hierarchy.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41979b49-4a5c-48db-9134-37fe5f64e078" contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a79768a9-40a2-45cf-b113-ca7b0ae4c491" contextRef="C_cfbe57c7-0589-40d9-95a3-4e571ea9c241" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a19b2256-fe4b-4bbe-a5d6-837d7f743182" contextRef="C_3323b4d1-71fb-4439-a445-cda91d3bdbde" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6375d8-8608-4b1d-8af4-2482d1ba3779" contextRef="C_21ed1982-a773-41b3-9848-3a746c980eb5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b7bb58e-9ac0-4990-a2f2-30053535e7bc" contextRef="C_1320b092-7bb5-4608-a1f8-382e3ea5a98a" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of Achievement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff457a60-22d1-48e9-8112-a73142a111d7" contextRef="C_e78edfaa-86d2-4b56-8b7f-1698cc8559cd" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec6dded-edf4-438e-828c-fc796225bf8d" contextRef="C_ba54c365-7b5b-490a-a13d-b7f791f97e43" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aaeb374-d5f0-4525-9a78-9f0c66645cdb" contextRef="C_d654daf4-dddc-4c8c-bf67-b1fb10abf6ab" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dafd800-235e-4347-9240-c5677e4b3bc9" contextRef="C_e8dda33f-8c82-42ac-b988-c7074b08349c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c780dd5-56cf-4d05-b6a9-7f6b6580ca0f" contextRef="C_bfa4765e-7ba8-440e-948f-ab1010661413" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d6da8f2-132c-494d-9f87-02c6b3e92314" contextRef="C_81012567-268b-4289-94b6-e8719b8246c6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b8b94f-c547-42ed-a833-7a1985d9bd07" contextRef="C_836d03ea-dc4b-4efb-b811-4ce1b53f71f4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of Achievement</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_287ed916-f38a-44f0-8c55-bb6415f4a6fd" contextRef="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_61f82e88-4fb1-4ed8-a6cc-32684bc1bfa0" contextRef="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f3ac817b-7931-4cde-8366-ca0d5afc983f" contextRef="C_23df4ae1-062b-4bd7-b3e6-9c50a1bd7d4f" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_14e0f7c1-b3d9-4c10-915b-f30e9a1ea775" contextRef="C_886c80e8-4054-44c9-a88c-53a8d43b6e0e" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2034</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9dde4dd0-e2f3-4473-a431-2295841f9857" contextRef="C_46b2d578-5aad-4081-994e-51251d5c3c82" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_115f282b-5c8c-4f47-ae0b-38add186326b" contextRef="C_b0b3e437-b9b5-409d-a425-2ab1467d81a1" name="beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45bf9145-6c94-499c-b418-86b222304e11" contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8587bb22-7d34-4431-9cdc-78032b6e131e" contextRef="C_1ab7b8fc-388e-483b-a455-4d344bf26d3f" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,025</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f46c7d6-87c8-4a35-bec0-dda4dd26e6a5" contextRef="C_a1582983-8e90-4aba-91dc-4e54d1f21245" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d57b3f66-e189-465e-9adf-b61de4bdf410" contextRef="C_d2b86f6d-7df8-4851-bf8a-c817cab8b129" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef829fbd-4ea5-4626-a117-8fa43e421bf0" contextRef="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,654</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e11b751-39a9-4968-936e-90348d4f70cd" contextRef="C_64b520ff-9453-43d5-8018-62b50616536e" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,086</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f87d4701-60a2-4f66-b183-490095437e0d" contextRef="C_82e2a9c0-7247-45b0-b901-8dec8be826ad" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9d622e-35cd-4a40-836c-13eba805bbf4" contextRef="C_f4879e76-4b06-44ba-bf62-86e70abf1d54" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f7a5498-fd7a-4729-b6bd-8f4853981328" contextRef="C_8b3ff14f-8fb9-421a-a317-71af6ec52baa" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_809ee891-bbf4-454c-a24e-de73926599e2" contextRef="C_9b047b26-6d29-4529-a19f-49dec29b0738" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,723</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6a068a-bbf1-4aec-837d-64c4dfbd8859" contextRef="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">875</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b74d03e2-68c0-487d-9839-b4691d922711" contextRef="C_55e6ef57-9f81-41ee-995e-bf71d1163777" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bb4b732-2e64-49d8-8d75-5d6c0cfcc7de" contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e67fea48-a79a-4e03-a2a8-31a72a60e1ec" contextRef="C_bcb6c93c-f14e-4acc-a009-3920a219ed08" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e976e0bb-8ffa-4219-a1ef-bce9a8f295df" contextRef="C_946d0d92-ab51-4d13-aa91-deb5bafa88d2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba941b04-48be-4baf-8ead-2f3685ac6f25" contextRef="C_ee6f8e30-6665-4a51-9ae1-dad612ace074" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative settlement liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; On July 19, 2024, the Company entered into a settlement agreement with a research institution pursuant to which, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0b807dc-7b74-4a17-8b9a-bc506a006b12" contextRef="C_f74446ed-1db8-4037-8b3c-5b97e15acbc4" name="beam:SettlementAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d69546d-d544-4a01-9e58-f8f98f2df09d" contextRef="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e" name="beam:PercentageOfRoyaltyPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty through 2038. Any amounts due must be settled in cash. The maximum amount of development and regulatory milestone payments under the settlement agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a97142b3-0f46-4fa3-abc2-d9a612e0ebe3" contextRef="C_75673cb0-aa17-46e5-a5b8-9bf245874d0a" name="beam:PotentialMilestonePaymentsDueUnderSettlementAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the maximum amount of sales milestone payments is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd3f5c1-9dd7-4140-955a-267dd5cce00a" contextRef="C_43329f90-70ad-4d83-9eb9-e3326b1f696b" name="beam:PotentialMilestonePaymentsDueUnderSettlementAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, per program. The Company paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06ed405b-c6c8-43a7-b443-7b8e428aadac" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:SettlementAgreementUpfrontPaymentPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment during the 12 months ended December 31, 2024. There was no material charge related to this settlement in the year ended December 31, 2024 as the settlement value was substantially accrued in prior periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_accf629a-3000-48fb-ae43-47b15da39245_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contingent settlement payments are accounted for as a derivative under Accounting Standards Codification 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the potential payments meet the definition of a derivative and are not subject to any scope exceptions. The derivative liability is recorded at fair value on the Company's balance sheet with changes in value recognized in interest and other income (expense) in the consolidated statement of operations and other comprehensive loss. To determine the estimated fair value of the liability, the Company applied a probability-based model, which utilized inputs based on the potential achievement and related timing of certain development, regulatory and sales-based milestones that were unobservable in the market. This derivative liability is classified within Level 3 of the fair value hierarchy above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82e0e483-e3f0-4fe1-85f3-8575095c38df" contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following assumptions were incorporated in the calculation of the fair value of the derivative settlement liability:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.315%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:19.424000000000003%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1718e12-0b40-4816-a6aa-ad4526c6003b" contextRef="C_19c18905-de30-4069-8f57-7d6b0794deab" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f89820-e15b-484c-99b9-2232e27b1f3e" contextRef="C_b3cae63a-1abc-4394-a9ad-0e685d5f41a5" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c085fb5-5bb4-4dd2-86d9-f8e7d81cfac7" contextRef="C_7171d6c3-3dec-4790-a576-1812c763d4fd" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_dee9feb2-3e38-4d6a-a57d-9174c322556f" contextRef="C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357" name="beam:SettlementPaymentsExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_aa8b2a6e-4e03-4cd9-9b5c-ffe134a45be5" contextRef="C_31375b14-847b-4dfc-8fc0-3d961e512723" name="beam:SettlementPaymentsExpectedAchievementYear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2038</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b087009-b359-4abe-a6a4-88a05df0aa62" contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true" continuedAt="F_8b087009-b359-4abe-a6a4-88a05df0aa62_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the derivative liability based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:24.485%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial recognition of derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c51422c0-52c8-4855-8466-ceed06b3e021" contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2101e174-80c4-4d48-b3e1-3d0cfb17374a" contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dedd18b-4af8-434e-9796-7e2de71a0610" contextRef="C_34071179-b962-4e08-81ba-677a509604da" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_8b087009-b359-4abe-a6a4-88a05df0aa62_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da562aee-863e-470f-8387-20592346a01a" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e001b8e4-efc0-409b-bca4-b2ef1b126bbd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf9482e-9b8f-4889-bfec-bf35c0391aa7" contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8df929e-3df1-4354-9fd5-c9db73c75367" contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfeb64d4-67d5-4a0f-b75f-db3e7e0bbcf6" contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07583d01-1d83-48f1-8b8a-ebfb8d142a58" contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,296</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df5b7273-59a8-4889-a7b8-fd5ab672f535" contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_007ec9e0-c081-4715-8e53-071218221084" contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b005122a-3530-4500-aead-e5a60569573a" contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c1b362-3561-40ed-ae87-80758cd84ec6" contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,165</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e32f43-b24c-4ff3-8876-d0da16e1e5df" contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbc2a2b6-4f2a-4d3b-a5f3-807367f9f96e" contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_628dfec0-68d0-4e7b-845d-aead31417928" contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_630ff11f-e1b1-4519-86be-e896db0573ea" contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaf21111-08ec-429b-b355-8d81dfe4cf2b" contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,552</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbf20026-a85b-4643-9ced-cfb29d550ea7" contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c04eaab5-9f2c-4344-b1bf-0b2e1633d68e" contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b053b573-4dfe-49fe-9a8b-9bdc6e0a5ddb" contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd895f93-37e6-4661-b3fc-b3f3affd1197" contextRef="C_ccd6d443-83ef-4b86-af01-1073799931eb" name="us-gaap:EquitySecuritiesFvNiCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e08c67d-8929-4b86-aa71-0834e105f068" contextRef="C_ccd6d443-83ef-4b86-af01-1073799931eb" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,781</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28cbe42b-88c4-477c-a877-8d74ef4c5023" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,094</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eed5524c-0619-41ac-a124-141bed51d61e" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afe16590-b229-481d-8ed2-c7dc51f992df" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5ae2b8-62b0-46f3-bd22-b1cdd329d822" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46c54763-4b83-4897-a0d1-11f0f3e64fe0" contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,054</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc3c38a-9ac0-4bd0-849d-2e5bf2e2f271" contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5259b11-a921-4a29-a545-a17ceaf748a9" contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9908d9b-2c38-49a8-bbc7-8fd591c2ac69" contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfc64b24-9367-4ec4-82a3-293467a71153" contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,462</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c5ee0b7-3dd5-49dc-8026-fe21221a5dd5" contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e9b5393-6689-406b-acc0-f7893a43e27e" contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2867f94e-6804-47b4-9ab2-d67570ddcaad" contextRef="C_10b0f522-be77-400a-bec4-a92278231be3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,805</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eadc572-e3dc-4416-9e07-a894ef2edfd8" contextRef="C_10b0f522-be77-400a-bec4-a92278231be3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d59a3642-c891-4d69-867a-1ea868641ab5" contextRef="C_10b0f522-be77-400a-bec4-a92278231be3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_651617f4-65f3-40d6-b0ca-664e969114cb" contextRef="C_10b0f522-be77-400a-bec4-a92278231be3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c02ffb35-6fd2-40fc-9c65-bc14271db73e" contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,181</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce4fc58-5f49-4a73-9995-20f77e86dd39" contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed98a4c9-327b-4fd8-92a0-4b556f479b55" contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_890f347e-0a7d-434e-ad1a-5fa2690963eb" contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44cee08b-45b0-412c-ad75-b26b52fc60e9" contextRef="C_f70341dc-ca94-4cc2-9501-827588f59d28" name="us-gaap:EquitySecuritiesFvNiCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee457d59-a644-4390-a652-f1e2d164f41f" contextRef="C_f70341dc-ca94-4cc2-9501-827588f59d28" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96ec037f-6485-4db0-846d-0bdb8812ff16" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a00ef8c-14d6-4249-af0a-8d137048ccff" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,077</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1557db56-e7fb-48b2-b4f8-3ae9cdcc2bd9" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b44c20-e327-4f33-8da0-39fedf926932" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753,981</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. At December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the balance in accumulated other comprehensive (loss) income was comprised solely of activity related to marketable securities. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7983b412-cc05-4148-a38c-af03529b3cb4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_507e26a5-9682-41c1-9b53-1e36b0f97a36" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c5ba7dce-9e31-4649-a8b1-564e8d42121a" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses recognized on the sale or maturity of marketable securities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive (loss) income for the same periods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05e202a7-f103-4a04-96f1-46a7c74a9b5d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:DebtSecuritiesAvailableForSaleMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">less than one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_feca2c7b-1271-48a2-b4a3-f6bcfeb96cc9" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24060028-e254-44ea-8ea7-4b86d490938f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contingent obligation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baf711e7-1e1a-4dee-b3b0-255c048cf152" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AccruedContingentObligationLicenseAgreementCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97513116-5d03-4f7d-a39d-7bc4649d2a60" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AccruedContingentObligationLicenseAgreementCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,280</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17fe8262-50d4-4a39-a6d0-2e37735daa77" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,572</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a6d31ef-279b-40ee-8120-634f257857f2" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,774</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff067f1-0516-4a21-a5d7-63141d37c282" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AccruedResearchCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,179</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01df4c2-3510-47f5-b960-1245bf1e7fd1" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AccruedResearchCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,804</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b66ba54f-ace1-4b97-86e0-b37fae154aef" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:AccruedProcessDevelopmentAndManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73d93495-870f-44ef-9436-ac3b54365ec9" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:AccruedProcessDevelopmentAndManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,697</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a751167-83de-4dbe-a5b5-b6a77f62be99" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,381</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_302c369b-a3f8-423f-967c-37c8617c46f6" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b3a1cb4-deae-4181-87b0-b8ace47755a0" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ad57fa-b44f-4663-a525-f6f3cdae0dbc" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9202d1ca-fcda-4a64-8304-5d57d8b213cc" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60608c01-505f-464e-8d71-f3e962e42683" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,664</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_584240fa-7f86-4a1e-86f5-af0f1151fcab" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_584240fa-7f86-4a1e-86f5-af0f1151fcab_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s operating leases are as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A February 2018 lease for office and laboratory space as amended, which commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e1cefa4-a730-433f-ab22-b459c98de3e9" contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9" name="beam:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e684ece9-4c2c-4112-adfc-e136e150b755" contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9" name="beam:OperatingLeaseTerminationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease is subject to fixed-rate rent escalations and provided for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_378596f9-1aa8-4387-b523-e75140fc4258" contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9" name="beam:LeaseholdImprovementsLandlordAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements allowances and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e8d81ab-4a76-40a6-b78d-72b566e5aa25" contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a term </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9093d581-eae3-487e-b39a-6beb9e3a5626" contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension option.</span></ix:nonNumeric></span></ix:nonNumeric></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An October 2018 lease for laboratory space as amended, which commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7fb3834-37df-4db2-bca4-1ffccd3fe134" contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c" name="beam:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2958ea3f-bad7-405f-a91b-ead7d0f1ef3d" contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c" name="beam:OperatingLeaseTerminationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f5e31ee-2195-491c-a4d2-acab1833c1bd" contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amended lease is subject to fixed-rate rent escalations and provides an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14d8c624-0e0b-48e2-be40-6f25c4353754" contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a8be18-4ea7-4cab-857b-8ad31785df68" contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c" name="beam:NumberOfOperatingLeaseRenewalOptions" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b7cb419-7945-4808-8a40-04cffa0dccf8" contextRef="C_87b2a2c4-113b-4df3-b4a2-5e89a5c1ea98" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> periods through December 31, 2029.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An April 2019 lease for office and laboratory space that was built over the course of 2020 and 2021. Pursuant to the terms of the original lease agreement, the first phase of the lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c985ce5b-af67-4704-8b5d-0486f0cd9051" contextRef="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24" name="beam:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (rent payments for the first phase began in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7411e56f-9dbd-4097-bfc2-63ca8a96abed" contextRef="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24" name="beam:OperatingLeaseRentPaymentsBeginMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the second phase of the lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0eadf4c7-0270-4904-a876-e11bc2c10e39" contextRef="C_1a4862fd-f679-425c-8077-3914a663d90a" name="beam:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (rent payments for the second phase began in</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d04855a-bbdf-4a97-82b6-4e12961b7453" contextRef="C_1a4862fd-f679-425c-8077-3914a663d90a" name="beam:OperatingLeaseRentPaymentsBeginMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> February 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The lease is subject to fixed-rate rent escalations and provides for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4f6fcc-3784-4a9b-9031-57d60590a20c" contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2" name="beam:LeaseholdImprovementsLandlordAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements and the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01c2769a-5211-402c-b45a-a7df1249cc50" contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6c4443c-ff8b-4fa7-a7fb-c8c4c13346cc" contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_456f9cc1-3530-4b4f-b182-cd8800f34326" contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2" name="beam:NumberOfOperatingLeaseRenewalOptions" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_912aca97-d565-4e5c-ac87-8859c105eafe" contextRef="C_d4874037-4abb-4593-9198-ea79ea979323" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company determined that it is the accounting owner of all tenant improvements. In August 2021, the Company executed an amendment to this lease to occupy additional space. The term of this lease runs concurrent with the term of the April 2019 lease through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12d817fe-be8c-465d-ba2d-3e7c930cc4cb" contextRef="C_987488ec-2b63-4e33-9f1f-663eb101d201" name="beam:OperatingLeaseTerminationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2034</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An August 2020 lease for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f63f1e3b-d4b1-400a-b5db-35cb865ef7f8" contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c" name="beam:AreaOfFacilityBeingBuilt" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square foot manufacturing facility in Research Triangle Park, North Carolina. Construction of the manufacturing facility began in 2020 and the Company began making rent payments in the fourth quarter of 2022. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf7e467c-2b1b-49d5-a8fb-cbea71ef7e96" contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease will terminate </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_417d6d67-4fe4-427a-9df0-95c26f9da074" contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the rent commencement date, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd85310e-a156-4c07-9ce3-f99ec54d1ec3" contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a" name="beam:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease is subject to fixed-rate rent escalations and provides for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_411e634a-98ea-4ae1-be1c-78e295b9b4e5" contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a" name="beam:LeaseholdImprovementsLandlordAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements and the option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4edcd284-e886-451c-b371-8d2459f36e79" contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb33461-75bd-4551-9d3c-eee0ea5cac3d" contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a" name="beam:NumberOfOperatingLeaseRenewalOptions" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f465d438-ee3e-4b3a-a646-335e810554fb" contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each, which were not reasonably certain of exercise as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></ix:nonNumeric></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e871320-68e7-4540-b5b3-932b9eea7914" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes operating lease costs as well as sublease income (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c35aad-d159-43bb-bff8-0e6e3cfb531a" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7441608-080d-4a38-b833-0970eda04d5f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,063</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebbb10e4-6a9c-4148-9235-143b419dfec8" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,536</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3903f3c6-aaff-4c49-9e0d-2d2df7292310" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc5e6cdf-e577-4757-9bf8-c10e5c283401" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,777</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff7f3ab-f20e-4ed8-b232-6ce1b1917f15" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,364</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd461b65-c74d-4097-ad10-3a97c23bdb9c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b6cf1a3-778f-43d1-8448-74fcd773d50e" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7dcc5e9-c977-47db-9f52-281df1cd66d5" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sublease income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b96090-c7de-426c-be22-6ab6258738e7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15900a62-ab62-4667-b65e-63be1f50d08c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,944</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_883b362e-9dfa-4b92-921c-375110484962" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,840</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a755a876-d64a-4394-80d3-ac1d1d09db58" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,888</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b75d439-65c4-4166-b24b-c6e2a6bfacfb" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:OperatingLeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease term and discount rate for operating leases:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"/>
        <td style="width:1.021%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.31%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.021%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.31%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8f129c96-f203-45f1-aa65-ae6a00137dcd" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bb26a70f-3018-4e65-984f-1082c42a610d" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_178516e1-080e-48bd-ad82-bcae3a09a441" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44aba235-c038-43b3-a941-5145706a94f3" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21221d7c-2e9c-45d9-80f6-1df2b5fe7db8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease costs included in the measurement of lease liabilities (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.022%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.364%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.945%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.945%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d914231-2534-4acb-885f-69e9a35506bd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,981</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ddfbb2-c9b0-426a-8134-551d2538ce34" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,603</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65393177-986e-45f5-93f2-f92f0758d135" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,052</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_741de03d-28ec-4a36-b218-a5255f7966ea" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,626</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0507bc04-4386-4070-99de-d336324745cc" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,852</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3857ef1e-a49f-443e-8206-32119712abdb" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:OperatingLeaseLiabilitiesIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_584240fa-7f86-4a1e-86f5-af0f1151fcab_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73778de1-a96f-4595-8906-b76d4642db9c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the future maturity of the Company&#8217;s operating leases for each of the next five years and total thereafter were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.757%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13dba810-fcd5-4d81-926a-0f1a6671eb72" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,360</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f32b9c85-de02-487b-a384-022fa3ef32b4" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,526</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2522fbc9-281a-483f-982a-150234e89d36" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca92ab7-610a-4588-ba63-68f28a13abc8" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db7efb20-6723-489d-8c71-272b3a4799b2" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a80ab5f2-28cb-44e1-af40-0eb460230fd3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44f1bcd-3424-429a-98e6-8306d397c018" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,731</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8d52e58-0f85-4e5e-b382-2ee793ca5519" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,306</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8081411-417d-4451-bec4-f346dd17d9b2" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73b1f2ea-d5e5-4071-8277-4e99cdfd1b66" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Strategic restructuring</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company announced updated portfolio priorities and strategic plans to restructure the Company to streamline its business operations. In connection with this portfolio prioritization and strategic restructuring, the Company reduced its employee headcount by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3696d7d-52a7-4d09-82f2-e09d990045ea" contextRef="C_26e65229-9380-4e02-a80b-356c8953d6fd" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Positions" decimals="0" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> positions, or about </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e94cbfbc-4809-4ade-a21a-9028c449e40c" contextRef="C_26e65229-9380-4e02-a80b-356c8953d6fd" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of its workforce. During the year ended December 31, 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d818483f-4518-4f68-afff-f6d4f5109094" contextRef="C_614fab24-9c40-4e21-a14b-7243d9e14888" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f812e6fe-6a44-4c16-bfa9-574585f77a74;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restructuring charges</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the consolidated statement of operations related to these actions. These charges included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bedb59b7-8570-4c63-b16c-9a14d1e46fad" contextRef="C_f2642d59-f792-41fa-8608-056dec1837ab" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of one-time termination benefits and contractual termination benefits for severance, healthcare, and related benefits and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a70f16e-c4c6-4d58-b634-be7443bf53f7" contextRef="C_3fe5e002-e81f-4070-850c-d91b8489178b" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of non-cash stock-based compensation expense. The workforce reductions were substantially completed as of December 31, 2023, however the severance and other costs are paid over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_900f0b83-4a55-4f9a-954e-0d5dfc19095d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the restructuring liability activity for the Company's workforce reductions for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 as recorded in accrued expenses and other current liabilities in the consolidated balance sheet are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.52%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.700000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses incurred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4190209f-b042-4e08-9431-46b646d97728" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,494</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27c3c261-65e9-4bbb-9268-6ac49eee46ed" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53e4dbca-d936-401d-8819-b8b3d3ea2459" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55593b1b-ac5c-40d5-8534-b9eb087af798" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:LicenseAgreementDisclosureTextBlock" escape="true" continuedAt="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has various license agreements related to technology used in its research and development activities. The license agreements may include up-front payments, option fees, ongoing maintenance fees, sublicense fees, royalty-based payments, milestone payments, success-based payments, and other payments. Option fees, when applicable, are recognized when exercised, maintenance fees, sublicense fees, and other payments are recorded as incurred based on the estimated amounts due or that will ultimately be paid. Contingent payments that are not required to be accounted for as a derivative are recognized as incurred. As the success-based payments due under the Company&#8217;s license arrangements are derivatives, the change in the fair value of the success-based payments are recognized in a separate line item in the statement of operations and comprehensive loss, as discussed further below. The total contingent obligations and non-royalty sublicense fees included in research and development expenses in the statement of operations and comprehensive loss were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22116ff7-3537-42eb-8a63-1589c5a26807" contextRef="C_66014777-6584-477d-9aa8-ffa7abbe1249" name="beam:ContingentObligationAndNonRoyaltySublicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf1db8a-67f7-4790-af8e-ef8552fb11c1" contextRef="C_7ff8794b-8499-4caa-8e54-fbac240792c1" name="beam:ContingentObligationAndNonRoyaltySublicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b53dcd7-088a-466f-98b8-7a6a310bdeaa" contextRef="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589" name="beam:ContingentObligationAndNonRoyaltySublicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value attributable to sublicenses and the related sublicense fees due under the Company&#8217;s license agreements may require estimates and other judgments related to contractual requirements, which creates uncertainty over the ultimate amount that would be paid under these arrangements. Contractual amounts due are accrued and if a contingency exists related to the interpretation of the amounts due under the license agreement, the Company recognizes a liability for the amount that is probable and estimable. When no amount within the range of potential payments is a better estimate than any other amount, however, the minimum amount in the range is accrued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_1" continuedAt="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Harvard license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2017, the Company entered into the Harvard License Agreement for certain base editing technology pursuant to which the Company received an exclusive, worldwide, sublicensable, royalty-bearing license under specified patent rights to develop and commercialize licensed products and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product, unless terminated earlier by either party under certain provisions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partial consideration for the rights granted under the Harvard License Agreement include success payments, which are further described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Harvard License Agreement, Harvard is entitled to receive success payments, in cash or shares of Company stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Company&#8217;s Series A Preferred at specified valuation dates. The success payments range from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc167149-9a1e-4f54-8edb-193dc9a060c6" contextRef="C_5bc0c4e6-20ab-442d-9c3e-39c7a8ea82c0" name="beam:SuccessPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aaa6863-9d0d-455b-ae5a-40511444cf81" contextRef="C_231917f7-78a3-4fef-87ae-dc90b41b4c08" name="beam:SuccessPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and have valuation multiples that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_418931c5-dc4b-47c7-b01e-22d7a44e996e" contextRef="C_846e5021-b00e-430e-b479-dfc4350907cb" name="beam:SuccessPaymentsValuationMultiples" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f816deb-e68e-49ef-bcca-6447d57cd902" contextRef="C_e0ec3d1c-7bc1-435c-aba5-b5b2222df11e" name="beam:SuccessPaymentsValuationMultiples" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the initial weighted average value of the Series A Preferred. Subsequent to the Company&#8217;s February 2020 IPO, the amount of success payments is based on the market value of the Company's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2824e27-149b-4af0-aa0f-be2160a76457" contextRef="C_9e0b9b06-588c-4f43-8b01-cd02f7537d2d" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e86c1cd-7818-49a6-9452-514a5d897868" contextRef="C_8f838b8f-003d-4c56-9981-96bf4aa3558f" name="beam:SuccessPaymentAmountDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company elected to make the payment in shares of the Company&#8217;s common stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_749b63d4-d745-4c56-9211-42a0c56e1810" contextRef="C_0246c702-b123-4f5d-b939-4edd1eea0949" name="beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">174,825</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle this liability on June 10, 2021. The Company may owe Harvard success payments of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de3fe6c-b507-42bb-b9b9-4222311c6dc6" contextRef="C_a2d5f9fc-a682-42df-9b5c-99526ad1bc2b" name="beam:AdditionalSuccessPaymentAmountDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">90.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66e685d3-a9b9-4187-8972-eaa886477f09" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock" escape="true" continuedAt="F_66e685d3-a9b9-4187-8972-eaa886477f09_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harvard success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e569513d-4514-4986-b742-af332cb833fd" contextRef="C_800475ef-859c-4969-8401-92e0526a5add" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7873a95-9262-4d95-b394-774172401882" contextRef="C_80db0869-90aa-4f87-a32a-529c3993d14c" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_925825da-a970-4a7a-b3b2-bae9c46b9761" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" escape="true" continuedAt="F_925825da-a970-4a7a-b3b2-bae9c46b9761_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.812%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.942%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.702%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.702%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Harvard success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf0efb9-f464-44db-8296-8eefda9cdb41" contextRef="C_623147d8-2cfc-43d4-ad7a-4b423fda8bc2" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab643287-d8ed-46e2-80be-a789ac690803" contextRef="C_c4d3bfe7-33e4-4541-9d0a-0c3653425814" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11c534bd-a147-4c47-b00b-ba9c4ab25e33" contextRef="C_a9e94ca6-e934-4ab8-aeb5-8d4b40f267a6" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f56f40ab-389d-49ed-a986-5ff89f684844" contextRef="C_db09f235-a08f-4af4-a99c-599807b457f1" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83d428f2-fe27-4a37-9c35-112722125b3c" contextRef="C_034a8b22-6f57-47e9-bcaf-d420a86c3ac8" name="beam:AggregateMilestoneAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. Upon determination that a Harvard Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company will monitor the Harvard Product Milestone payments for this arrangement on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent products are commercialized under the Harvard License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_2" continuedAt="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Broad license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, the Broad License Agreement was entered into with Broad Institute for certain RNA base editing technology including an RNA editor platform. Under the Broad License Agreement, Broad Institute granted exclusive and non-exclusive worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed product and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. Under the agreement the Company shall use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of regulatory exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product unless terminated earlier by either party under certain provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional consideration under the Broad License Agreement included Success Payments, which are further described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Broad License Agreement, Broad Institute is entitled to receive success payments, in cash or shares of Company common stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Series A Preferred at specified valuation dates. The success payments range from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50b22abb-5722-4d90-bd66-6c6fdf8216e5" contextRef="C_f24310ad-daa3-4d84-88fe-4f5f29e1c62b" name="beam:SuccessPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7427b8a7-abb8-4bf4-bbb2-d0c2bdddbb11" contextRef="C_9b3ddcbc-bcaa-4620-bd37-18182d7ee2a9" name="beam:SuccessPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and have valuation multiples that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_238f1621-ccca-4ec6-8682-7fba5017f5a4" contextRef="C_083cb9d5-4b38-4882-b265-50928e148535" name="beam:SuccessPaymentsValuationMultiples" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a754a0e8-b27d-4130-ba92-0aed7c8cc38c" contextRef="C_c2e860ef-951c-4824-addf-069a1f368442" name="beam:SuccessPaymentsValuationMultiples" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the initial weighted average value of the Series A Preferred. Subsequent to the February 2020 IPO, the amount of success payments is based on the market value of the Company&#8217;s common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3be84881-6bd2-4ef8-a6db-03750e19cb26" contextRef="C_640fc477-4635-473c-bec3-329a0998059a" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78ea51a7-e574-4259-9ea6-c43b738a4f03" contextRef="C_1f91b334-6d1a-442e-9b9d-4fc20bb74482" name="beam:SuccessPaymentAmountDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company elected to make the payment in shares of the Company&#8217;s common stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_392c996e-754b-4de8-b95c-f964b4263cc3" contextRef="C_6268b7c6-50cc-4b67-b26d-5fcdb3082e86" name="beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">174,825</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle this liability on June 10, 2021. The Company may owe Broad Institute success payments of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cdcb029-bf4d-4908-9e37-72d11cfcf449" contextRef="C_a65535bf-d336-4fc3-a256-1c5e23cda5be" name="beam:AdditionalSuccessPaymentAmountDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">90.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec991800-09be-464f-9a52-8f4c479809b1" contextRef="C_ad5b92a4-0e86-485f-829d-78650bd85771" name="beam:SuccessPaymentAmountDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> success payments were due to Broad Institute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_66e685d3-a9b9-4187-8972-eaa886477f09_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f705040d-0314-499f-9ee0-d01f59f4b107" contextRef="C_ad5b92a4-0e86-485f-829d-78650bd85771" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_212f386b-78cd-47ee-a4de-ac474be3377f" contextRef="C_e5221100-f194-45c9-83f5-e78d6eb47872" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_925825da-a970-4a7a-b3b2-bae9c46b9761_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.94%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b239a07b-4832-434b-bf68-2e70fb29d395" contextRef="C_2003a022-90cd-4bc2-bf5e-3e183c02ed3c" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f39d97f2-fe33-4810-9e27-5f523672c68d" contextRef="C_ebd07b65-49d7-49db-9728-c7dfc9f5943d" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1674553c-24d2-4438-b21b-f9d8ed429173" contextRef="C_ce201eb2-a040-4b8c-828b-f421220ff5bf" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b51c2b93-630f-4e49-91c6-e116fa65a9f4" contextRef="C_4d433f10-5951-4793-a073-4cde03a41826" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c04c0a93-3589-4a15-921f-edabe325f7eb" contextRef="C_9bd424a3-b990-4948-a990-a2d46eaf923c" name="beam:AggregateMilestoneAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs will be expensed as incurred. Upon determination that a Broad Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company monitors the Broad Product Milestone payments for this arrangement on an ongoing basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent products are commercialized under the Broad License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Editas license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71ff642b-c949-4500-9645-e8fb28ae6888" contextRef="C_30808f53-fe50-4e76-b73c-7f5690993b05" name="us-gaap:CollaborativeArrangementNatureAndPurpose" continuedAt="F_71ff642b-c949-4500-9645-e8fb28ae6888_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. More specifically, Editas granted to the Company a worldwide, exclusive, sublicensable, license (subject to certain exceptions and conditions) under certain intellectual property controlled by Editas for the use of base editing therapies for the treatment of any field of human diseases and conditions, subject to certain exceptions, or the Beam Field, and the licenses granted or to be granted under the Editas License Agreement, or the Editas Development and Commercialization License. Additionally, Editas granted to the Company a royalty-free, non-exclusive license under certain intellectual property owned or controlled by Editas to perform research activities in the Beam Field, or the Editas Research License. Editas provided the Company with an exclusive option to obtain an Editas Development and Commercialization License to three additional groups of intellectual property owned or controlled by Editas, on a group by group basis, during the specified option period, subject to certain exceptions. Pursuant to the Editas License Agreement, the Company will use commercially reasonable efforts to develop a product that includes the rights licensed to the Company within a specified period of time and to commercialize any such products that have received regulatory approval in certain specified countries.</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_71ff642b-c949-4500-9645-e8fb28ae6888_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional consideration will be due to Editas if the</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company elects to exercise its option to obtain an Editas Development and Commercialization License to any of the three categories of intellectual property underlying the Editas Research License, for a fee ranging from a mid-teen million dollar amount to a low to mid-eight digit dollar amount per group, depending on the timing of the option exercise. Additionally, the Company is required to reimburse Editas for certain payments Editas may be obligated to make under existing Editas license agreements related to the intellectual property being licensed to the Company, including (i) development, regulatory and commercial milestone payments and certain sublicense income payments due as a result of the Editas License Agreement and (ii) a percentage of the annual maintenance fees and patent fees due to certain of the Editas&#8217; licensors. In addition, to the extent any products are commercialized under an Editas Development and Commercialization License, the Company would be required to make royalty payments equivalent to the royalties that would be due from Editas to any applicable licensors of Editas related to the sales of such licensed products, plus an additional tiered low- to mid-single digit royalty, depending on whether such licensed product is covered by an Editas-owned patent.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license rights and option rights granted by Editas to the Company are subject to the terms and conditions of the underlying license agreements that Editas is a party to and under which Editas licensed rights or option rights to the Company and the termination of such in-licenses, as applicable. Unless earlier terminated by either party pursuant to the terms of the agreement, the Editas License Agreement will continue in full force and effect and will expire on a licensed product-by licensed product and country-by-country basis upon the later of (i) the last-to-expire royalty term under any applicable institutional license to Editas and (ii) the date at which such product is no longer covered by a valid claim of a licensed Editas-owned patent in such country. The Company has the right, at its sole discretion, at any time to terminate the Editas License Agreement in its entirety or on a group-by-group of intellectual property basis, upon ninety days written notice to Editas. Upon termination of the Editas License Agreement, all rights and licenses granted by Editas to the Company (including the rights to exercise options and obtain such licenses) will immediately terminate and patents within a group of patents will no longer be deemed licensed patents. Expiration or termination of the Editas License Agreement for any reason does not release either party of any obligation or liability which had accrued, or which is attributable to a period prior to such expiration or termination.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The option exercise fees under the agreement will be recorded as research and development expense, if and when the Company exercises such options. To date, no options have been exercised. The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. In addition, the Company is required to make certain development, regulatory and commercial milestone payments to Editas upon the achievement of specified milestones. To the extent applicable, sublicense income payments will be accrued for the amount the Company is obligated to pay under each applicable in-license as amounts are due to Editas. Lastly, to the extent products are commercialized under the Editas License agreement, the Company will accrue royalty expense for the amount it is obligated to pay, with adjustments as sales are made.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_7fe69c21-0377-473f-b7f0-71caf1e83316" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_7fe69c21-0377-473f-b7f0-71caf1e83316_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Collaboration and license agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eli Lilly and Company</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81a439d5-0b63-4b1e-84bf-6a26e8afd1ef" contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company&#8217;s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company&#8217;s opt-in rights to co-develop and co-commercialize Verve&#8217;s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21541175-e9cd-44fb-a325-0869236a66c4" contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1" name="beam:CollaborationAgreementUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million nonrefundable upfront payment and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1210aa96-0016-4539-82a3-ccf7f58dd359" contextRef="C_a46bf662-b041-4823-abd8-67f3900593df" name="beam:PotentialAdditionalProceedsFromTransferAgreement" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">350.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lilly does not opt-in to co-develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7fe69c21-0377-473f-b7f0-71caf1e83316_1" continuedAt="F_7fe69c21-0377-473f-b7f0-71caf1e83316_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">co-commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a licensed product, Lilly is obligated to pay the Company a percentage of any royalties received from Verve for sales of such product, subject to certain caps on a licensed product-by-licensed product basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ac88af3-6c92-40c3-bc02-a4d47078bba7" contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3" name="beam:CollaborationAgreementTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the effective date of the Lilly Agreement, Lilly has the right to request the Company to perform any critical research and development services, if Lilly reasonably determines that the Company is uniquely able to provide such services and other conditions are met, including that no other third parties can provide such services. The parties will negotiate an agreement governing the Company&#8217;s performance of such activity, if any, and the Company will be compensated for any services at approximately cost plus a margin. The Company has not been requested to perform any services and believes it is remote that Beam would be requested to provide any services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Lilly Agreement, the Company and Lilly entered into a Stock Purchase Agreement providing for the sale and issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d15ebeb1-a3d8-4334-8c36-832c0ccd542e" contextRef="C_051ea08a-43d3-423d-856c-04c479177819" name="beam:StockPurchaseAgreementShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,004,811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to Lilly for an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_775089ec-7863-4bb8-a29c-3f77d1184db5" contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3" name="beam:StockPurchaseAgreementAggregatePurchasePrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received the consideration under the Stock Purchase Agreement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e79215-0d92-4b1b-9a19-d22f105f8c06" contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3" name="beam:StockPurchaseAgreementAmountReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in October and the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a03673f-858e-417e-9447-d930ed56feed" contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1" name="beam:CollaborationAgreementUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in November 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lilly Agreement and Stock Purchase Agreement were negotiated at the same time as a package and have been accounted for as one combined contract. The Company accounts for the component of the arrangement to transfer common stock to Lilly under ASC 505, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the revenue component under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company first applied the guidance in ASC 505 to measure the fair value of the common stock issued and allocated the remaining consideration to the ASC 606 component of the arrangement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall ASC 606 transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d81b84c2-c89e-49cb-8052-d704aaa47e37" contextRef="C_051ea08a-43d3-423d-856c-04c479177819" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">216.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is comprised of the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_051a805a-35be-4277-a79a-16ac0dbc82c6" contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1" name="beam:CollaborationAgreementUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the residual value of the proceeds received in excess of the fair value of the common stock sold to Lilly of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50041fb5-373c-4211-82eb-6212b9aeb117" contextRef="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7" name="beam:CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the common stock issued to Lilly was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbfa2801-cd67-4e0f-af06-69b9f413876d" contextRef="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7" name="beam:CollaborationLicenseAgreementFairValueOfSharesIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as determined by management with the assistance of a third-party valuation specialist. There is no variable consideration included in the transaction price at inception. The Company will re-evaluate the transaction price at each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the collaboration rights and licenses to intellectual property have the same pattern and timing of transfer and are transferred as of the effective date of the Lilly Agreement. Lilly&#8217;s right to request research and development services represents an optional purchase in the agreement that does not constitute a material right. All other items promised to Lilly are immaterial in the context of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue for the performance obligation at a point-in-time in October 2023 as all requirements related to the performance obligation have been completed. Any consideration received related to Lilly&#8217;s optional purchase of the Company&#8217;s research and development services will be accounted for as a separate contract if and when the option is exercised in accordance with ASC 606. During the year ended December 31, 2024 the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58acf01-c610-4966-8ccd-f01ab7ca2e9c" contextRef="C_7ffb90b6-e3c3-4094-a911-c196df383847" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to the achievement of certain clinical, regulatory and alliance events. During the year ended 2023 the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b418873a-f422-4cb3-90bb-ee20b40c790b" contextRef="C_dd66f54e-6ff6-4a57-b80d-1a794bfab97f" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">216.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the Lilly Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0238d6-921e-48c0-a672-7f9420d45f28" contextRef="C_7ed33382-7533-4a0f-94fc-b6c4d06ac455" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred revenue related to the Lilly Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orbital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, the Company entered into a License and Research Collaboration Agreement, or the Orbital Agreement, with Orbital Therapeutics, Inc., or Orbital. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecae1b94-ca05-4fcc-bf82-d01b05198b73" contextRef="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ribonucleic acid, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In exchange for the licenses and services provided by the Company under the Orbital Agreement, the Company received a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by Orbital, and research and development support services as outlined in a research plan. Orbital also granted the Company an exploitation license to certain RNA technology and nonviral delivery technology controlled by Orbital. The exploitation license is exclusive in the fields of gene editing and conditioning and nonexclusive in all other fields other than vaccines and certain protein therapeutics. The Company also received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9783e5a-1972-448c-92ca-cd86bab3c753" contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960" name="beam:CollaborationCommonSharesReceived" unitRef="U_shares" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Orbital&#8217;s common stock at closing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research plan has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_004ddb36-d5c6-493b-9cfc-e202727bef3f" contextRef="C_e1d74f31-840b-44fe-a432-c3e0d8792431" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and can be extended for unspecified periods upon mutual agreement between the Company and Orbital. The exploitation licenses are exclusive for an initial research term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc4a86fd-ac54-490b-b200-05073dc0bf3d" contextRef="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a52ca89-d889-40e8-91bb-0d5d14504c79" contextRef="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a" name="beam:CollaborationArrangementExtensionTermDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which may be extended for up to two successive one-year periods</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by mutual agreement between the Company and Orbital. Either party may terminate the licenses granted to it under the Orbital Agreement for convenience on a product-by-product basis at any time by providing 90 days&#8217; prior written notice.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7fe69c21-0377-473f-b7f0-71caf1e83316_2" continuedAt="F_7fe69c21-0377-473f-b7f0-71caf1e83316_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the consideration received under the Orbital Agreement under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_434235fd-d29f-44aa-a5cf-18a9f762d7ee" contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.5</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which represents the fair value of the Company&#8217;s equity interest in Orbital&#8217;s common stock at inception. There is no variable consideration included in the transaction price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the research and exploitation licenses are not distinct from the other promises in the Orbital Agreement, and as such the Company determined that the licenses combined with the research and development services, know-how transfers, committee participation and materials transfer represent a performance obligation. The Company recognizes revenue associated with the Orbital performance obligation over time as it is satisfied during the term of the agreement, which is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e714273-5b6a-4cf8-9ce8-a5e1c5a4bc5c" contextRef="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31" name="beam:CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9eb9ca1-4c77-457c-8816-a8483d1b824a" contextRef="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f97b3dd2-ee3c-4873-849d-814663524706" contextRef="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue during the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f9e9713-d268-4838-a609-2e76d7937fb6" contextRef="C_d318bed9-9799-44fd-bb35-943b44e05e86" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue during the year ended December 31, 2022. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e1fbf0-4bba-4507-ba0b-18288f05addb" contextRef="C_72946174-54ef-42ee-b20d-174ccb0133a1" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current deferred revenue related to the Orbital Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam does not have a controlling financial interest in Orbital as Beam does not have the power to direct the activities of Orbital. The Company has significant influence over Orbital through its noncontrolling representation on Orbital&#8217;s board of directors and the Company&#8217;s equity interest in Orbital. Accordingly, the Company does not consolidate the financial statements of Orbital and accounts for its investment using the equity method of accounting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of the closing date in September 2022, the fair value of the Company&#8217;s investment in Orbital was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_655dc6ec-6627-4211-b023-1f21e111da98" contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the Orbital common stock was determined by management with the assistance of a third-party valuation specialist. In determining the fair value of the Company&#8217;s investment, the valuation specialist used an option pricing model backsolve approach based on Orbital's most recent funding of preferred stock. The valuation requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are level 3 inputs, include the anticipated holding period to an exit and liquidity event, the volatility of market participants (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d5bf57e-5ba8-4598-8001-f61156343b0c" contextRef="C_eecadce7-cffa-42a7-a808-35c5ac47a667" name="us-gaap:AlternativeInvestmentMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) and the discount for lack of marketability (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23f4ebd6-7df7-4015-b40e-e2eb93a53ecd" contextRef="C_7bde4f21-b869-4f23-b886-c0c6dfff5351" name="us-gaap:AlternativeInvestmentMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%). At the date of the investment, a basis difference was identified as the carrying value of the Company&#8217;s investment in Orbital exceeded the Company&#8217;s proportionate share of the underlying net assets in Orbital. The Company concluded that the basis difference was primarily attributable to Orbital&#8217;s IPR&amp;D assets. As Orbital did not meet the definition of a business due to substantially all of the estimated fair value of the gross assets being concentrated in the group of similar IPR&amp;D assets, the basis difference attributable to the IPR&amp;D with no alternative future use was immediately expensed as of the date of the investment. The Company&#8217;s proportionate share of the basis difference exceeded its carrying value of the equity method investment in Orbital and the equity investment balance was reduced to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b636dbd-2827-4f13-9e7d-514b0dffb59d" contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no commitment for the Company to provide financial support to Orbital. The Company recognized a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12ce6cf4-132a-4e17-8827-f628edb84384" contextRef="C_d318bed9-9799-44fd-bb35-943b44e05e86" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">25.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in association with the basis difference charge in the Company&#8217;s consolidated statements of operations for the year ended December 31, 2022 and did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c5b1885-4bb3-4c2c-b1d4-9ce96e66fbd9" contextRef="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:fixed-zero"><ix:nonFraction id="F_68dfefa6-9e13-43f3-b86f-ca60532bb924" contextRef="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:fixed-zero">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize a gain or loss from the equity method investment for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6684cdcb-13a9-4624-997a-01a0445f5893" contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company&#8217;s base editing technology to develop </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5066bd77-9fe7-4528-ad59-1e9ae1804d32" contextRef="C_5a05ec5d-cf56-49cb-b84e-2b325f31bc00" name="beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%/</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d95b8fe-67da-41d0-a967-4b547481f154" contextRef="C_95f6702d-f704-4654-9cb9-17cb2a30898f" name="beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of the Pfizer Agreement, the Company was entitled to receive a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a3ae732-cbdd-42c4-bc41-da88d7b16df9" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="beam:NonrefundableUpfrontPaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in consideration for the rights granted to Pfizer under the collaboration. Should Pfizer exercise its Opt-In Right for any of the three programs, the Company would be eligible to receive development, regulatory, and commercial milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_def5a21a-d980-4ddf-b2d6-7980ba99a8e9" contextRef="C_7fbcfe71-e126-4c16-a2f8-6d4074f3e339" name="beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">350.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per program, for potential total consideration of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8646665-de8c-4573-a0df-b0a4b97bef46" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="beam:PotentialConsideration" unitRef="U_USD" scale="9" decimals="-7" format="ixt:num-dot-decimal">1.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, plus royalty payments on global net sales for each licensed program, if any. If Pfizer does not exercise its Opt-In Right for a program, the Company&#8217;s rights in such program revert to the Company and the Company will be required to pay Pfizer earn-out payments equal to a low single digit percentage of net sales earned on such program for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50d314d6-7ce5-4cc8-89c8-3d0ef38711ad" contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535" name="beam:EarnoutPaymentPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period, if any. As the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61680f51-eb9a-4160-83f2-ef04fe0e2283" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="beam:NonrefundableUpfrontPaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront fee was not received by the Company as of December 31, 2021, the Company recorded a collaboration receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f65313-bc4b-4afc-a1c2-1e35e1e7e83f" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with a corresponding deferred revenue liability. The Company received the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ffb5126-55fc-466b-a5f3-e4f40ae004a1" contextRef="C_cf84f853-64e7-4f6f-a1df-e90a15485b3b" name="beam:CollaborationAgreementUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment in January 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the collaboration term, Pfizer has a one-time option to substitute a disease that is the subject of a specific program with one pre-defined substitute disease. The collaboration has an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a57eea9-f01d-4933-9a6b-dc5a203b16dc" contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and may be </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_572f0470-4144-4d2d-babe-7de7b8850457" contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535" name="beam:CollaborationArrangementExtensionTermDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extended for an additional year on a program-by-program basis</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pfizer may terminate the Pfizer Agreement for convenience on any or all of the programs by providing 90 days&#8217; prior written notice.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7fe69c21-0377-473f-b7f0-71caf1e83316_3" continuedAt="F_7fe69c21-0377-473f-b7f0-71caf1e83316_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Pfizer Agreement under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb0c2076-2e19-4a49-923d-d6e0b9e0a3f1" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is comprised entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that the licenses to its base editing technology, including the exclusive development and commercialization rights, are not capable of being distinct from the other performance obligations, and as such the Company has determined that the licenses combined with the other research and development services represent performance obligations and no up-front revenue was recognized for the licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling price of each performance obligation was determined based on the Company&#8217;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Pfizer Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue for each performance obligation as it is satisfied during the term of the agreement using an input method. The Company allocated the transaction price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97462d0f-5b47-439f-b7b3-45175f9a0bb5" contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to each of the three performance obligations, which includes each of the three base editing programs combined with the research and development services, licenses, and exclusive development and commercialization rights. Revenue is recognized using an input method based on the actual costs incurred as a percentage of total estimated costs tow</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#8217;s performance in transferring control of the goods and services promised to Pfizer and represents the Company&#8217;s best estimate of the period of the obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4adc3d2f-5a5f-4cb1-b932-b69d83f030f5" contextRef="C_e708f03e-b5c8-4b4c-851b-c790a40ee844" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15444090-60a8-4c54-b712-634076bd32fc" contextRef="C_51719419-8be3-40d6-b822-aac6d564e3b7" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eb1ab69-ab35-4abe-8515-21d58c3456b0" contextRef="C_4f1eba65-fbc3-49e1-9877-736765296cdd" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Pfizer Agreement, during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90ddf72f-3eac-43d7-90b3-de0c5164973b" contextRef="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2448249-eadb-49b3-b8ec-c391b1d9ac3d" contextRef="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current and long-term deferred revenue, respectively, related to the Pfizer Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sana Biotechnology</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, under which the Company granted Sana a license for non-exclusive rights to its CRISPR Cas12b nuclease system for the development and commercialization of certain engineered cellular therapy programs. In addition to the license, the Company performed an initial technology transfer following the effective date of the Sana Agreement providing Sana with certain know-how, as required under the Sana Agreement. This technology transfer occurred in 2021. Following the license transfer and completion of the initial technology transfer, Sana is responsible, at its sole expense, for the development and commercialization of therapeutic products which must contain either specified CAR antigen targets or pluripotent stem cell, or PSC, product types.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the license, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a2b50bf-924d-4c53-9c5c-5203f0fb7b0b" contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee" name="beam:LicenseAgreementUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sana in October 2021. In addition, the Company may be eligible to receive development, regulatory, and commercial milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697302bd-fd5c-47f2-8e5a-1b81b34539c7" contextRef="C_e2d79338-1ac4-4b79-83d8-f195b051536a" name="beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">65.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sana on any product candidate or product. The Company will also be entitled to receive royalties equal to a low single digit percentage of net sales on any product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a58a2c12-8f84-4092-af20-c834d3bdf1bd" contextRef="C_e86d3ec5-e144-44e9-8637-dc263422e9d7" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7125e19e-4f6b-4b74-88f6-e1a8df88d61b" contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee" name="beam:AdditionalFeePerAdditionalOptionRight" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c65892e-0c5d-420a-9b68-88b025d5b1df" contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee" name="beam:OptionRightsAggregatePotentialAdditionalConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days&#8217; prior written notice or upon 180 days&#8217; prior written notice after first commercial sale.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Sana Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b714876e-4554-4e4f-94ed-39ca11a16e0a" contextRef="C_c448f064-efee-4973-8a00-ca00db426a3e" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is composed entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7fe69c21-0377-473f-b7f0-71caf1e83316_4" continuedAt="F_7fe69c21-0377-473f-b7f0-71caf1e83316_5"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has identified a single performance obligation, which includes (i) the non-exclusive license granted to Sana under the Company&#8217;s patent rights and know-how and (ii) the initial technology transfer following the effective date, which occurred in 2021. The Company further concluded that the Option Rights, Replacement Right, and Genetic Target Nomination Rights did not grant Sana a material right. As the Company only identified one performance obligation, no allocation of the transaction price is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16be20aa-e5f3-47a8-9684-b8d08d3bca66" contextRef="C_1f14ed46-687f-4e31-ac5e-c38d1b43d86f" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Sana Agreement during the year ended December 31, 2024 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35554741-0691-4044-a649-566481c90ab0" contextRef="C_30db48d9-fd35-4524-9f25-e5f0967f30bf" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Sana Agreement during the year ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab4ee96c-793c-408c-9c6f-8c517e565aff" contextRef="C_82c07a0b-8c7a-44a6-b246-a5568dfbfc60" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue under the Sana Agreement for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Apellis Pharmaceuticals</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e996f6a-d4e1-40b2-9f3f-94785260743d" contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company&#8217;s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the collaboration, the Company is eligible to receive a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84c43dfe-ef3d-41ec-9d55-eff61a072fe3" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront and near-term milestones from Apellis, which is comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e74ba0c-052e-44e3-959a-90ada1836bd5" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:UpfrontFeeReceivableUponSigningContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received upon signing and an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c907d31-6c86-4ec8-83f8-56eaf06cc2e1" contextRef="C_cc9a65a2-a296-4a7c-ad5a-f2a43865bbed" name="beam:CollaborationAgreementFirstAnniversaryAmountReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment on June 30, 2022, the one-year anniversary of the effective date of the Apellis Agreement, or the First Anniversary Payment. Following any exercise of an Opt-In Right for any of the six programs, the Company will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a00a1180-17fc-4499-99b1-723cb27d6bfb" contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and may be extended up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ec338ed-ac29-4c6b-8b93-1aff6d470515" contextRef="C_dc200094-3ff1-4578-a977-4d4a2356f15b" name="beam:CollaborationArrangementExtensionTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on a per year and program-by-program basis. During the collaboration term, Apellis may, subject to certain limitations, substitute a specific complement gene and/or organ for any of the initial base editing programs. Apellis may terminate the Apellis Agreement for convenience on any or all of the programs by providing prior written notice. The Company received the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7f792c-4e76-4d1c-8a76-6536fc26e402" contextRef="C_4768fad0-596a-43bc-a633-4ba916d5e2bd" name="beam:UpfrontPaymentReceivedUnderTermOfAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment from Apellis in July 2021 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc796b5c-f7d5-4cef-8df6-07f010f7a525" contextRef="C_43ad7076-7bc9-411a-b3ab-a6ecbc89e42b" name="beam:CollaborationAgreementFirstAnniversaryPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million First Anniversary Payment in June 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Apellis Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc01ea83-f9bc-459e-bcfa-c5a99afc35a5" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is composed of the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d03eb5-a818-4cfa-af2f-e4f32f4deed0" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:UpfrontFeeReceivableUponSigningContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the First Anniversary Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af17ae79-8c52-44b2-a5ce-9cbe9d12e920" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:CollaborationAgreementFirstAnniversaryAmountReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation were material promises that were both capable of being distinct and were distinct within the context of the Apellis Agreement and represented separate performance obligations. Therefore, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_145cff8d-bb17-45a4-b29e-d9b9b5b345e3" contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf" name="beam:UpfrontRevenueRecognized" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any upfront revenue related to the license. The Company further concluded that the Opt-In Rights and option to extend the collaboration term did not grant Apellis a material right. The Company determined that the term of the contract is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa0b56df-0ba9-4916-8853-02364bc76394" contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as this is the period during which both parties have enforceable rights.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling price of each performance obligation was determined based on the Company&#8217;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Apellis Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue for each performance obligation as it is satisfied over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adf25162-2fd1-4793-97a3-ec3d87f3c0c5" contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf" name="beam:CollaborationArrangementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term using an input method. The Company allocated the transaction price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389068cb-37ce-4f03-aa7d-e759417d2bca" contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36" name="beam:CollaborationAgreementAggregateTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to each of the six performance obligations, which includes each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is being recognized using an input method based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#8217;s performance in transferring control of the goods and services promised to Apellis and represents the Company&#8217;s best estimate of the period of the obligation. For the years ended December 31, 2024, 2023, and 2022, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f9594d-6c1f-4603-8611-f7e22de6eb8f" contextRef="C_141a0bab-6778-428c-9b18-6212d89a1a93" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b46372b-6802-44d2-a9d5-b6aeaab39db1" contextRef="C_fb6723fb-3691-4707-acfb-4ac88805b04b" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c8818e-ecd2-4fc7-9ac1-df214717dac9" contextRef="C_8fffa0c5-ef26-4f15-a702-c749a8609fd3" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue, respectively, related to the Apellis Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, there is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_191991e1-356e-4bbb-8f3e-7f5097341b56" contextRef="C_a6a0e0af-be42-49df-9199-a22238777a85" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b9cf6ea-66fc-4e8f-8bb0-8cb2b913c5fb" contextRef="C_a6a0e0af-be42-49df-9199-a22238777a85" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current and long-term deferred revenue, respectively, related to the Apellis Agreement.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7fe69c21-0377-473f-b7f0-71caf1e83316_5"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Verve</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f77ad769-c099-4f4d-b792-b87affc2b5ec" contextRef="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a" name="us-gaap:CollaborativeArrangementNatureAndPurpose"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Verve Agreement, Verve issued the Company </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d23922f-402a-4a7e-a9fd-76d5ecf5ae20" contextRef="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648" name="beam:CollaborationLicenseAgreementSharesReceived" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock as partial consideration for the licenses granted, having a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0de72f5-505f-429b-8a4f-0a8bbe324b42" contextRef="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648" name="beam:CollaborationLicenseAgreementFairValueOfSharesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the Verve common stock was determined by management with the assistance of a third-party valuation specialist. In addition, to the extent certain clinical, regulatory, and commercial milestones were met with respect to licensed products, Verve was required to pay to the Company certain amounts, as defined in the agreement. Lastly, to the extent there were sales of a licensed product, Verve was obligated to pay the Company royalties, as defined in the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also purchased shares of Verve's Series A preferred stock during the year ended December 31, 2020. During June 2021, Verve completed an initial public offering of its common stock. In connection with Verve&#8217;s initial public offering, Verve effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e80aeb3-65b2-4d2e-b8e0-df0d100d33d0" contextRef="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74c8208e-8624-496d-85f8-c1dcf54d59d8" contextRef="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">9.2592</ix:nonFraction></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split and also converted all shares of its preferred stock into shares of common stock. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_89e43b90-38d0-487a-b27c-e605d0959c23" contextRef="C_36b8ac53-6fab-4279-8285-1a0366571ae4" name="beam:EquitySharesHeld" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">546,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Verve's common stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2e103987-f4d5-4d45-a755-95e86a345c20" contextRef="C_9eb93719-d476-49d6-a58e-2223125d2c02" name="beam:EquitySharesValueHeld" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management determined that the performance obligations associated with the Verve Agreement were the combined licenses and improvements related to the licensed technology. All other items promised to Verve were immaterial in the context of the agreement. The fair value of the shares issued by Verve to the Company were considered a fixed upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c056dc97-1e48-4ad9-a03e-2265a5086079" contextRef="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a" name="beam:UpfrontPaymentFairValueSharesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the form of non-cash consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company, Verve, and Lilly entered into a Side Letter Agreement whereby the Company agreed to delegate to Lilly certain rights and obligations existing under the Verve Agreement, including the Company&#8217;s rights and obligations to co-develop and co-commercialize opt-in products, the financial rights to milestone and royalty payments, and the right to participate on certain joint decision-making committees. The Company determined that the transfer and delegation of rights represents a modification of the Verve Agreement to be accounted for as if it were part of the existing contract in accordance with ASC 606. Prior to the modification, the Company determined that its performance obligations associated with the Verve Agreement at contract inception and subsequent modifications were not distinct and represented a single performance obligation, and that the obligation would be completed over the performance period of the agreement. Accordingly, the upfront payment was being recognized as revenue using a time-based proportional performance model over the contract term (April 2019 through 2038) of the collaboration, as license revenue. The milestone payments and royalties were considered variable consideration and were constrained up until the modification date as no milestones or royalties were achieved. Subsequent to the modification, management concluded that the Company does not have material ongoing obligations to Verve in the arrangement and that the remaining revenue under the agreement should be recognized at a point-in-time upon modification. Therefore, the Company recognized the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd32912-3553-4822-88e2-3fc6422bac00" contextRef="C_586c5528-76ab-4467-958c-e7217226efd0" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized revenue in October 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f2090fa-3819-46ab-a278-342371e94e0a" contextRef="C_48e046f4-2f13-45b1-996e-dc68dffe5446" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any revenue under the Verve Agreement during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecc61200-820d-4007-95fb-6d1ddf4949f0" contextRef="C_9eb93719-d476-49d6-a58e-2223125d2c02" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining deferred revenue related to the Verve Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. For each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a49b0d36-8b88-4ca2-9153-c798a0c8b70e" contextRef="C_0b1904af-7fc2-4128-b51e-282e6a1495b8" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65ca81fa-6007-4a86-8a94-867f85d4f9cb" contextRef="C_e2c7432a-a6e2-4466-b4d0-b448e1cd2b34" name="beam:CollaborationAgreementPerformanceObligationRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue, respectively.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2288cdd3-ed2c-4839-b0f4-3e8a78716f43" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into the Sales Agreement with Jefferies pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43a85743-a1e1-46f9-ac15-625e8b91aef7" contextRef="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2" name="beam:StockIssuanceProgramAuthorizedAmount" unitRef="U_USD" scale="9" decimals="INF" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b1c415-ed06-4d10-89e7-f6e202ab1274" contextRef="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a" name="beam:CommissionRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a09ea0c-cbc8-4607-bc94-04f1cf5d2387" contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028" name="beam:StockSoldDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,769,001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the Sales Agreement at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d527635-b4de-4964-83a8-1d66ed05b366" contextRef="C_9e824cf6-96ad-482c-938b-89bcefc2519a" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">62.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c7e09b1-5a77-46b8-9c87-2a05323fa992" contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028" name="beam:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">864.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting commissions and offering expenses payable by it.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7720f00f-8bef-4150-8891-7b2f85a9efbe" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock are entitled to one vote for each share of common stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The holders of the Company&#8217;s common stock shall be entitled to receive ratably dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_153cf094-54d8-41a9-bdf8-9a9b4ba0d8b4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_153cf094-54d8-41a9-bdf8-9a9b4ba0d8b4_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock option and grant plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2017 stock option and grant plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2017, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan, or the 2017 Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options, restricted stock or other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2017 Plan is administered by the board of directors. Stock options awarded under the 2017 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_960baca5-4eab-4eb8-ab3b-7358975ef94f" contextRef="C_ede17f6b-07f6-4cb0-8a64-18644baafbc3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the grant date. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2017 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 incentive plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2019 Equity Incentive Plan, or the 2019 Plan, and, following the IPO, all equity-based awards are granted under the 2019 Plan. The 2019 Plan provides for the grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of the Company&#8217;s common stock that may be issued under the 2019 Plan was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70dd9a9d-8ba5-4ea3-8cc1-af3799de2ca5" contextRef="C_3ac29eac-6794-4f6c-aaeb-4e2937541c74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,700,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, or the Share Pool, plus the number of shares of the Company&#8217;s common stock underlying awards under the 2017 Plan, not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc2966f4-0eec-4b1b-bec6-3316d4b7e72d" contextRef="C_30e95c96-73e5-48eb-9598-acd156ccfd5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,639,818</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, that become available again for grant under the 2017 Plan in accordance with its terms. The Share Pool will automatically increase on January 1st of each year from 2021 to 2029 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_286ccb63-4a74-46f3-801f-1807d51b0586" contextRef="C_0515efd6-8f8f-400e-9505-a0e0559e9790" name="beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe49dd5-2e03-42de-af30-f066cbd8ebc8" contextRef="C_aa7b8d00-54cd-467a-afdf-694a607825bb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,773,507</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares reserved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9467e893-3683-46e4-bc1a-a7da1e61ccf8" contextRef="C_aa7b8d00-54cd-467a-afdf-694a607825bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,591,110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b9cef1b-62aa-4005-b3a2-1069a588201e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations and other comprehensive loss is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27410327-f8ef-4072-b55a-8dec57c60b92" contextRef="C_66014777-6584-477d-9aa8-ffa7abbe1249" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb473ad5-586c-4a90-8138-e64df73c937e" contextRef="C_7ff8794b-8499-4caa-8e54-fbac240792c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,812</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f1c98c-1112-4287-9500-0aaa2a40c0f5" contextRef="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,004</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e3ed433-5284-4eee-9cdf-4bfb4198f672" contextRef="C_7e7cb18e-69e1-417d-807d-8ec7e9b03e54" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,139</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0397eb79-22a0-44aa-891b-2000a3cee6e4" contextRef="C_b772f99d-0bbb-4fb9-9d12-6cd094a0084e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fffb305-074f-4640-a46d-6bef80f8833a" contextRef="C_349daa7a-ee95-4e81-a366-8d8ce431c2f7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,317</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bdd3cd1-b3b5-466a-9f70-86d6c63a4ab1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,662</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9074c583-8071-4447-a334-c7ac38f0d3e3" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,647</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8247e627-e21e-4a1a-8818-9ebe46d65554" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9930b4a-669a-4b8d-a8fc-cc4fce70837e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.18%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2877ca76-fa4d-4e38-9908-2f3dc7798ecd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4226de45-9d44-44ac-8eac-15135c7729b1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">78.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5da5a547-f7bd-4a0b-bd12-50011e20c210" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d32e4086-7036-40bb-8e89-76b971a9f61f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">78.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8f8f710-f0f6-4b53-8b8f-6d7c18985a78" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">74.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac4fd5d-d886-4453-97fd-75f091b9231c" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">77.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc63bb90-f95d-44b7-86ca-0b3587d4fa79" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.02</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59c89284-6c49-4073-8f28-382fb36f3eb8" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.73</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f705649-66d5-478c-91e2-0222a92b93d2" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ad8fa37-6837-4e80-8a41-0def6d60ffa4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf705813-567e-4dbb-a427-0d63d9cc7dc2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be696168-e3e6-47cb-a0e4-d5e4a85050b2" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_69c3575c-e1e1-4eaa-b7db-0124cc38569f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bd8ab6d9-5383-4132-8c7b-cae0ece7cf00" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f052b868-c772-4acd-a2dc-5fa8cce184f8" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23ede3c0-01e5-4298-9849-34561f48de57" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of option activity under the Company&#8217;s equity award plans:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.664%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.844000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.664%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value (1)<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cecf07c-76c9-483a-8621-c54f9aa73d73" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,276,033</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd1db932-ca16-48d7-abde-ea665e8c2c94" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">42.59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c5ea3182-6a08-475e-b078-4c0d3a994820" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baa9a2cc-7982-4f4b-ba2c-d52f595678c8" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,653</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_646e21d6-3f6c-4a35-8db0-6eaf4b7bdbc5" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,678,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83e6e4b2-4014-4eba-bfea-7caacff8088c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acfe3e39-0c7c-4a11-b8cf-2ebe43de2da1" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">563,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5df6c86f-3469-4449-8ceb-1b78225b284f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07badd3f-cf68-4964-ba06-22ff9359bd76" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">785,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9209bb12-ed90-42a6-934b-e2831b50903f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">53.82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d01d0393-8554-4f84-a850-8d15c843f89e" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,605,542</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3963d3a3-895c-47d3-8f2f-32f916d3e877" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">38.62</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_37c78f52-55c2-401f-a299-9b4f97aa8ae8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c461051c-f398-4ec0-b745-ab993d057bf5" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,182</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede65ae9-dd4c-4fcb-ac49-940fbcc352c0" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,896,483</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b76be8b-9946-48ad-82fe-6c8ce9954ae2" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">40.70</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d8f19922-25d1-4bd8-b373-808dbd000c62" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fab758f9-ef71-41da-9a39-1f2dfefec80f" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,102</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing price of the common stock for the options that were in the money as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_153cf094-54d8-41a9-bdf8-9a9b4ba0d8b4_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted stock options to certain employees to purchase shares of common stock that contain certain performance-based vesting criteria, primarily related to the achievement of certain development milestones related to editing applications, and the closing price of the Company&#8217;s common stock following an IPO. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. The expense related to performance-based options was immaterial for the years ended December 31, 2024, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead8b19a-c7ea-4db1-b9f7-6f802b25de10" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59e5b8f-0305-4301-8507-9962892998b8" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d6e1962-3264-45b0-9106-66115e88c7e3" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">40.86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The aggregate intrinsic value of stock options exercised during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef08292f-6931-449d-85a2-b176387a6f52" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95dee046-e94f-4ab8-8d5b-328e8d7134fd" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ff8236c-9cf0-424a-aa49-b6fcb47836dc" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The weighted-average exercise price of stock options exercised for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01a15791-5d81-4625-8459-903231b02133" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e8a9c3b-0a2f-4df7-b90c-982e2b14df12" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c49cf9f3-b8c1-470f-855d-6ab358c360a8" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06a61528-b9e9-49eb-86e3-9e6dc49e145c" contextRef="C_f8bffd7e-bec1-4a21-84c9-e2e5a56dbf98" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">86.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c9ed83b-21e7-412d-8dc0-f98276c95837" contextRef="C_f89f6da8-621e-4376-b358-73a07809ea70" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued shares of restricted common stock during the years ended December 31, 2024, 2023 and 2022, which consisted only of restricted stock units. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted common stock issued generally vests over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f65e9bb1-b2e1-469e-be73-4e76142cee9f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9fa0e9e-64bc-4b40-9408-ad8c56db34f5" contextRef="C_1bb5d16d-4da2-4d42-b325-fdfab05f797f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, if the holders of restricted stock units cease to have a business relationship with the Company, any unvested restricted stock units will be cancelled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_263e61ce-df0d-4a76-b595-81ea928ebd01" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company&#8217;s restricted stock activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2858c2ca-037e-46a5-bd80-e93a947f8264" contextRef="C_610ac957-5c8d-4898-bdab-ead2ab364037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,927,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eb05e82-1bcc-4d7c-ba71-397bed2b5ee4" contextRef="C_610ac957-5c8d-4898-bdab-ead2ab364037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">40.89</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05e53c4f-ae9c-473e-9d4c-b04c8ec26ad7" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,233,688</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e57df5-80b6-464f-a0b8-e7a730258ceb" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">31.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb7aa6c8-153f-429b-a365-a75426a734e3" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,302,037</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97b6e302-f51a-4ed7-b6dc-b54a62816e76" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">39.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908ea98e-ecb8-4ed9-9b38-6e9099a8e42d" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">281,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16ead2a5-61c0-4d01-b10f-525bd225b13d" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">38.58</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2681448a-4723-4b0a-8db9-9293509ba498" contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,576,855</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf94488-2a7b-4d1b-9d8e-5b315b09f9d0" contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">36.98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of restricted shares that vested during the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ec8fde-5a38-4b93-96a8-2a11e08a9e70" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b4e330-34bf-47d9-a9d0-7754c020d44f" contextRef="C_ef0903ad-79ab-4cc9-8a92-a1067bb62252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a120620-7835-40e4-a7c4-976bac71e523" contextRef="C_ceb22f03-41f2-470f-b6af-1fe085c96885" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adbf76e8-83c1-4a22-8bd1-f8770713363d" contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_281f0e95-0513-4f95-b17a-2dc3e0014804" contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7a5a450-49d6-468f-8694-4ea4823f5cc3" contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2020, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company&#8217;s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db8fd3f-b093-4b02-a09c-f9f10695361f" contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e" name="beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and at a purchase price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868766e9-be88-4207-81af-afcfc1d61620" contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
The Company used the Black-Scholes option valuation model to estimate the fair value of the purchase right under the ESPP on the date of grant. The expected volatility is based on the historical volatility of the Company's common stock for a period of years corresponding with the expected life of the option. The risk-free interest rate is based on the U.S. Treasury yield curve at the time of grant for securities with a maturity period similar to the expected life of the option. The expected life is based on the term of the purchase period for the grants made under the ESPP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the straight-line attribution approach to record the expense over the offering period. Stock-based compensation expense related to the ESPP for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afbe6baa-794e-424f-8a4f-537ddf623084" contextRef="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379ca9b7-51ca-47b9-972a-697bb548b79f" contextRef="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c74fba1-afc3-495d-b3db-0c794bb0158c" contextRef="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28739a86-e1f5-4a1d-9765-ad971714648e" contextRef="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,187</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1484e0-5dc0-474f-9093-5bee167e10ff" contextRef="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc81d8d7-5c9e-4e33-b2cc-f768a7b4b68c" contextRef="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,073</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the ESPP during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 respectively. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a633fe-7870-45f4-995a-c96fd697392d" contextRef="C_03458b68-88f0-4f4c-835b-84b7c3df3693" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,928,706</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the ESPP.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_a66f09ba-ff94-4c8e-87e1-9f39f30f9702" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Net loss per share attributable to common stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As noted above, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span><ix:nonNumeric id="F_86e37b5d-9385-4263-8d44-e1f15289a302" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_86e37b5d-9385-4263-8d44-e1f15289a302_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_86e37b5d-9385-4263-8d44-e1f15289a302_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.648%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.058%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.058%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.238%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebba94cd-9894-483f-815e-670312511e31" contextRef="C_f4b1ef06-ec54-4fed-af05-d4a7050c16b7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,576,855</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5fbd4dc-eeca-4856-970d-8a75874edd0c" contextRef="C_a4d1b346-89bb-46d5-943f-3575e89e7f76" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,927,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018ea452-8292-4474-acc4-4f867397af68" contextRef="C_cf6c0d45-c719-46d3-96bf-bf86ff65ea9a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,692,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e713d30-7cd9-42a1-ac6a-47737fb13c88" contextRef="C_4caac963-d273-445d-aea2-8c8e7d840dbc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,605,542</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d202bcd-0b6e-4d1b-9eb7-f48779ca752b" contextRef="C_6ef5f0dc-2479-4c31-82d9-09b202c6d219" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,276,033</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74d95a38-3ca7-4694-80fa-748ef79bde05" contextRef="C_3af7bef2-d1fd-4b29-805f-7afc562dc297" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,548,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c500c60-94e6-4042-93b6-ced937a01db8" contextRef="C_e52f1520-daf9-498e-8105-a8484d3187d1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dadcba9-b1cd-4b09-a8d4-d27578b77953" contextRef="C_f0410223-d81d-47a5-95ac-2348253d72de" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,415</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91ab8676-8b8a-4f27-87ee-4ca9078963c4" contextRef="C_1915376c-4402-4696-8764-c838f2eb80a0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,906</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74d23dea-135f-4ea7-a225-48fe59015237" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,255,796</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_285ba502-9e3e-48a4-aa58-749261f4dc4a" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,276,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f94031e-f500-4954-99f3-7085fd294e61" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,287,117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66a30d6d-73ce-43f0-8947-2c9f175c1b82" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_66a30d6d-73ce-43f0-8947-2c9f175c1b82_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.75%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.603%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.603%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.603%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c85e7f0e-cdb3-443a-9380-3f310c74e586" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_502acaee-5bfa-424d-a1e1-959df59678a2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae07bcc4-27a1-4b9e-b3af-4fa8ff519fbd" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad258e0-5cd1-4abb-a23d-555d0921ce12" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cfeb4f6b-ddd1-4bc5-a2cb-8a1a40657300" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,313,008</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02c30249-1c15-4b98-b4d2-9071476ce4e2" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7d021a90-68a6-4b4d-a527-54ea5687a1f4" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">77,151,771</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5519ed4b-08b8-4544-8167-2b91769ecf6d" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3da5226b-2f92-4e2c-89eb-e91363db4244" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">70,015,305</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44bfa0df-7671-4738-a0f2-73077e14f60f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dfa10d44-9b12-4021-9874-31ee5dc751b7" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.58</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c245c48-4c74-4485-957b-25fd2950909c" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ea8cf1af-afaa-434e-8398-870d77c04d52" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.72</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cdf7c41-acf7-435c-96fd-bb8cc2f79b72" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c1f75c64-3bee-4fe6-a1dc-a8ca8ec29ba7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.13</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_66a30d6d-73ce-43f0-8947-2c9f175c1b82_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c2c9a564-ccf4-45d5-b951-945b11a696da" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_c2c9a564-ccf4-45d5-b951-945b11a696da_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25e10866-dcc0-43bf-a4f9-b50103ec41d0" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.683%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.045%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.045%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.225%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a6f2ab-0d2f-4df4-8b25-48867378df35" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f01cb4-44e4-41c6-bb43-137703300b38" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5874d93-a743-4dcc-bf5b-3ef5d5b77531" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e0221dc-7bee-4d12-ae9a-514af1a129f0" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00d93f6d-a02a-485c-9f26-24b13510838a" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c4e072a-b4fe-4f9f-9715-656158fed621" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d869033-168a-4a95-a6eb-f77a0c0de65e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c2de65-2050-40f2-a680-8a0b428fc912" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">18.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a20a1155-57b8-4953-9a38-b081c0863436" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible/ nontaxable permanent items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_000e0275-6d28-412e-b443-2ca6fabf8964" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3326e31b-39d0-45d0-8847-ebe57b121c93" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d90af441-d5b8-49c3-90ab-5e2a04fb3a49" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b06e858-652a-4f44-975b-42a635b141bd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">31.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6f5a0bb-2a59-4037-bc5e-c917fef04d8b" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">50.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6352d90c-00d6-47bb-a0ba-0bc7226b6d7f" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">32.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b94db3f-68b5-4e2e-8ebf-453f5a548c7c" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78b2f28d-b1fe-4cc7-b5b0-29fe2ded498f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5194ef4-1c28-4fa5-9a35-6f3ac9486f98" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6928f457-dd71-4b8c-bd53-8aa17d113b24" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c558f91-dc73-464d-831e-40bb3ab2e4e0" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,954</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00a2ada4-049d-40a5-b47d-ef522a6b76e5" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1af572ba-8887-4939-9322-a3978022a8f3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,554</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1700d334-2305-46ea-a014-670243f6c631" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,759</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599b1826-4c9a-4ae4-aa34-aad9695c6f65" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,868</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4652a2-18a0-4e1b-90b7-201c698220f3" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cac11c6-858d-4899-b796-77fb131a3197" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_250f60d6-fdf8-42d3-9f11-23179184f741" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,792</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a4ab80-6be6-4f0b-bfa6-3c0d0b3325ed" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,771</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66bc2874-62fa-48ad-acd6-253b2850b558" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,951</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e3b9e88-9c8a-419a-a7f7-9f0d0c655b71" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,218</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd52e91-16aa-4dec-9d8a-b27dd443b880" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dec5f6f-18b8-4b0a-b2fe-c28c25c63406" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc1c122-0df1-46bd-89bc-d306c65f92ce" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,917</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized Research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85dd4bbc-6ea8-47b9-882b-7c34a9b2ab18" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:DeferredTaxAssetsCapitalizedResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,954</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d54e0f7-ee51-4496-806c-a09f95c75474" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:DeferredTaxAssetsCapitalizedResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,721</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0ad3fce-ef1c-4cca-89f5-68fa520ea3cc" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="beam:DeferredTaxAssetsLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03cc47a4-62c5-47ff-bf11-26d585c9aa38" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="beam:DeferredTaxAssetsLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,179</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f500b97f-e96b-453b-8b47-0651ecff2523" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,738</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f0a0121-e53c-44ef-9761-4b80f20068f5" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">366,251</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROU asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9777b390-7167-4d2e-89a0-5af012657f52" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4409ad30-61a5-451d-9e05-6029b6826b8f" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eefd00a-8dd4-479a-9500-654aa4e13376" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3446b6f7-e00a-42a6-9888-9bcf663beccb" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20ebe273-256c-4dc0-9833-5cb9316e29e0" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,563</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d2a75c0-4593-45ff-937b-aef62d20f09c" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,415</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_709c7af7-b807-43f7-a868-61848d968ae3" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">438,259</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecbfc290-af13-4e0d-a595-7dcf4dd96089" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_892f3c97-c2f0-430b-9466-4813ae1bf322;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c2c9a564-ccf4-45d5-b951-945b11a696da_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, the Company recorded a current tax provision of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f7af6e3-de60-4bba-b6c3-39410ae7def0" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a2c1cd2-7df4-48c5-b765-6e8f11302fca" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_315e1c34-4503-4dc4-932e-8f3438b2b7ee" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of income tax expense, respectively, which reflects that Company generated taxable income that was not fully offset by the use of net operating loss carryforwards and tax credits. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets and has determined that it is not more likely than not that the Company will recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2024 and 2023. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34d182dd-e65d-4fad-b44d-eda92e556ad8" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2024 due to the increase in deferred tax assets, primarily due to increased capitalization of research and development expenditures in 2024. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac5a796b-ea98-41e8-83af-f202bb0aa746" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, limit a corporation&#8217;s ability to utilize tax attributes to the extent the corporation experiences an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change in ownership, measured by value, among 5% or greater shareholders over a rolling three-year testing period. To the extent a corporation experiences an ownership change, utilization of pre-ownership change tax attributes (e.g., net operating losses and general business tax credits) to offset post-ownership change taxable income or taxes, is subject to an annual limitation, generally calculated as the pre-ownership change equity value of the corporation, subject to certain prescribed adjustments, multiplied by the long-term tax exempt rate published monthly by the Internal Revenue Service. The Company completed a Section 382 study as of December 31, 2024, and determined that no historical ownership changes occurred since December 2021. The Company may experience ownership changes in the future as a result of shifts in stock ownership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3bf2a6a-ea32-49c0-a39a-bc7ead8b081f" contextRef="C_f086de51-1e25-47ba-abfb-108a2b30d5ee" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">181.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90f98c1b-871d-4f96-a95d-caaf4650f8cd" contextRef="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023. Additionally, as of December 31, 2024, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d37fc597-ccbd-432b-98c9-e847e5a25a8a" contextRef="C_f086de51-1e25-47ba-abfb-108a2b30d5ee" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">61.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11a74bab-ebec-48fb-aa4c-415c8e1db6be" contextRef="C_ae43c909-7d70-442f-bc98-6a2f16383942" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8841821b-6326-40de-a23c-2573e69e2eb2" contextRef="C_48270b1e-53eb-4dbc-9160-a5e56e9c41e4" name="beam:TaxCreditsExpirationStartingYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2043</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a19acfb-1a4b-44b7-9119-cb58cac46c71" contextRef="C_7ac0159f-2dc4-4afb-bc22-e46e6ac8813f" name="beam:TaxCreditsExpirationStartingYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba90ef04-9cf6-4532-b2d2-69a4541abfb4" contextRef="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4a0d936-9418-42fd-95e1-cda7a6d8e4f7" contextRef="C_4560ba19-2a2b-4005-ab3c-d11d72951668" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a114b0c-e353-43d1-855b-0c2deb7dd590" contextRef="C_d99e5c1a-0015-40a1-bf03-09c293ead256" name="beam:TaxCreditsExpirationStartingYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bbc7328-08d1-458e-9d80-981a66a0035a" contextRef="C_93edf44d-3df4-4991-a2e7-7db1fdea70fc" name="beam:TaxCreditsExpirationStartingYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, and 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5417ab5e-3ea1-475b-8f02-3b5a4bca8452" contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ab363a81-cbf1-4791-b6ad-5700d30db3f7" contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e49cbdfb-442f-4711-aae2-0c9b0a2fc4b4" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company filed income tax returns in the United States and the Commonwealth of Massachusetts in all tax years since inception. Tax years beginning in 2021 remain open to examination in these jurisdictions, as carryforward attributes generated in past years may be adjusted in a future period. The IRS has not made any assessments as of December 31, 2024.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_356e4b95-fb06-46f6-a8ac-699536edc790" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Related party transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orbital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 10, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company&#8217;s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Founders</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_038d932f-904a-4900-bf2e-6f436c195f75" contextRef="C_8a19511f-2844-4f6d-b5ed-8ff465336cef" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1237546b-23fb-46a4-8ded-71038f98964f" contextRef="C_9d139695-ac25-4472-b259-92e6538cbf05" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49a3f36e-58ce-40f6-b48a-c929553d8664" contextRef="C_af7898ba-b7e3-42e1-92b5-062444fe5f45" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, to its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f5f3ca-749b-45eb-a290-99a932353e06" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:NumberOfFounderShareholders" unitRef="U_Founder" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> founder shareholders for scientific consulting and other expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8adb4747-6c5c-4507-ba48-eceef1efabc9" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Employee benefits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2018, the Company established a defined-contribution plan under Section </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c3507cd-2b37-4cb4-8156-8c7647077d77" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:DefinedContributionPlanName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Beginning January 1, 2020, the Company made matching contributions equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a34df2e-9bdc-4764-b352-4c26350c20fc" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the employee&#8217;s contributions, subject to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f20b9c-84cd-4be7-899a-426b13af3c7d" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. The Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb51209-10dc-4a85-b5da-7b563dc9c713" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042fe0f9-60a1-4816-959f-94acbc5c9829" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6d2d43-314b-405b-93e2-2599f2187f18" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_c4cf81d7-7ea0-4bf5-8784-d5f9f4308bbd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_c4cf81d7-7ea0-4bf5-8784-d5f9f4308bbd_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Segment Data</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3745d23f-5fb4-4f44-b19b-06bb7321b4f1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM is John Evans, its Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c09ed080-95c6-42cb-9d05-3689f0ee40cc;"><span style="-sec-ix-hidden:F_db2bac11-48f9-4a6a-b941-8a8d70caf457;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment and the measure of segment profit or loss is consolidated net income (loss). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32c24534-43d2-431f-8f5b-72d4616ecdda" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal reporting of significant segment expenses is based on the functional classification. External expenses include costs from external manufacturing, clinical and research organizations, supply chain and logistics costs, consultants, and other vendors. Employee related expenses include, employee salaries and benefits costs, employee meal, travel and entertainment spend, along with payroll related taxes and other similar items. These functional costs exclude stock-based compensation, facility and information technology costs, depreciation and amortization, and other segment items.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c4cf81d7-7ea0-4bf5-8784-d5f9f4308bbd_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below provides information about the Company&#8217;s segment, including significant expenses, other segment items, certain other segment expenses, and a reconciliation to net income (loss):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2da578a-8b12-4aab-963d-11cdc0175806" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_e2da578a-8b12-4aab-963d-11cdc0175806_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a72b10b2-b2f8-4e28-8e63-9a715782c3bd" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_543e414b-4242-448a-8238-c89b1403ad84" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377,709</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0bf04fc-ebe0-4bc7-b865-7cecf0665825" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c81c6f-08c9-40db-867f-a3b16aaf2786" contextRef="C_f0a9d4a5-df6e-4595-9abe-cec53ac89acc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,189</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06b833a7-e4ab-467a-a8ab-38725ed73519" contextRef="C_56abebc6-1481-4c6b-a7b2-1ce074ebc051" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,063</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_821126a7-ab43-4eae-b878-c546e9e97541" contextRef="C_f605087d-584c-49ce-a137-7ec63bdd3243" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,380</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8a967fb-c695-41a7-93eb-add53e73c852" contextRef="C_0b791370-9688-483b-9d3b-52cc2807c2c4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,796</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e078c148-295f-48b3-88a3-b9294dc14f31" contextRef="C_99cb6cd9-808d-43eb-9961-10066106286f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,878</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0d6daf-08c1-4855-9563-18d3bb3ede1e" contextRef="C_6c230fe6-3e37-42ee-94d5-d6260b72323d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_805f61e5-2eb7-493d-bb18-6240f3c86fa2" contextRef="C_968b0854-5a99-4bae-a667-e1e1a12f2c18" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,115</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4737d07e-ba24-4731-a7f9-43491174d129" contextRef="C_e772ddd5-a271-42f1-b38d-0e1d6248021c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,016</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e73ee3e8-2c4a-48e5-8e6a-e875fc030bca" contextRef="C_5770c0c0-0283-4886-822d-4ead5360cae3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,885</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e7977d0-4a5b-471b-afd3-26597a4dcacc" contextRef="C_0b791370-9688-483b-9d3b-52cc2807c2c4" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,822</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e332c60-f72e-44ec-8d09-b388c5f0f772" contextRef="C_99cb6cd9-808d-43eb-9961-10066106286f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_917adf4f-0dee-4fd1-8b5f-4ddd4b02c6ae" contextRef="C_6c230fe6-3e37-42ee-94d5-d6260b72323d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,105</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility and information technology related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8124a67-5c45-47c3-8e04-493444fd0374" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="beam:FacilityAndInformationTechnologyRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,911</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcbf703c-5828-40bd-8525-9b6d4fb8d54e" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="beam:FacilityAndInformationTechnologyRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,804</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774cc520-8326-4ffa-b7b3-53fcd6d6318a" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="beam:FacilityAndInformationTechnologyRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,448</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6d2dadf-fcc1-4623-9ca0-32616898d25e" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,925</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6d7555-eb05-438d-8e31-9bde124c96ef" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5028870-1229-4a5e-be24-fc3078129e4f" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4c92d9-121c-48c7-b554-740932d2e6ec" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,662</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9f8721d-65c8-4733-81e6-c61aedb5f55f" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,647</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b61b28f3-5868-4811-81ae-e327c53d6de7" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aeca39d-8e77-4e60-ae5a-1f8b0e5988ae" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,094</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1590116a-1b61-4ed4-9451-90f488cac8d7" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,676</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76aef40e-d49b-498e-8c65-7d8d4d0c6d4e" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,297</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_761dfdc7-aeac-4bc2-a876-8943bf424e2f" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4c357d-7605-4f66-8864-8d34f6bdfa99" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,366</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f3eb217-223e-4761-9067-218832278eb0" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,410</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65bdfd14-acec-4493-b98e-5749a3b951f9" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,895</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bd9070b-aa56-4914-a319-6ba05e31c95d" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,821</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d34385f7-ea13-4fca-8853-eb5d4152cdd0" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,938</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bb536e2-e4a0-48b2-8daf-be90607ffd66" contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86684973-264f-4779-b577-d68d2b724916" contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_495a4a32-01ce-4520-a34b-43f2e3c1ce6e" contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Denotes significant segment expense</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e2da578a-8b12-4aab-963d-11cdc0175806_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Segment Items includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss from equity method investment</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone expense</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Sublicenses fees</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></div></div></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>beam-ex10_18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html>
 <head>
  <title>EX-10.18</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img245850697_0.jpg" alt="img245850697_0.jpg" style="width:161px;height:70px;"></p>
  <p style="font-size:10pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 25, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:68.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Sravan K. Emany 811 Cedar Terrace</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Westfield N.J. 07090</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Re: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Offer of Employment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Sravan,</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to offer you employment on the following terms:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__start_date__provided_that_you_satisfy"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Start Date. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provided that you satisfy the conditions described at the end of this letter agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), your first day of employment with the Company will be no later than December 19, 2024, or another date mutually agreed upon in writing between you and the Company. The actual day you begin employment will be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__position___your_initial_title_with_th"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your initial title with the Company will be Chief Financial Officer. You will report to John Evans, Chief Executive Officer. You will be expected to devote your full business time and your best professional efforts to the performance of your duties and responsibilities for the Company and its affiliates and to abide by all policies, practices and procedures of the Company and all codes of ethics or business conduct applicable to your position, as in effect from time to time. As this is a full-time role, it is understood and agreed that you will not engage in additional employment, consulting, or other business activities (whether full-time or part-time) without prior written consent from the Chief Executive Officer. Notwithstanding anything to the contrary in this paragraph, the Company provides consent for you to continue your current commitments as described on Exhibit A hereto. By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__location__it_is_understood_that_the_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Location. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is understood that the Company will not require you to relocate permanently to the Cambridge, Massachusetts area. You agree to perform the duties of your position and such other duties as may be assigned to you from time to time by the Company. You are generally expected to work from the Company&#x2019;s Massachusetts office, currently located in Cambridge, MA, two to three days per week on a consistent schedule. If there are important meetings in the office on days that you are not routinely on site, you are expected to be in the office on those days as well. While working remotely, you agree to only work from locations that allow you proper internet access to be able to do your job.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__salary___the_company_will_pay_you_a_b"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you a base salary at the rate of $575,000 per year, payable in accordance with the Company&#x2019;s standard payroll schedule. This salary will be subject to periodic review and adjustments at the discretion of the Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the Board of </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The base salary in effect at any given time is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__annual_incentive_bonus__for_each_cale"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Incentive Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For each calendar year of your employment with the Company, you may be eligible to earn a discretionary annual incentive bonus. Your initial target annual bonus will be 50 percent of your base salary. To earn an annual performance bonus for any particular calendar year of employment,</font></div></div>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.806%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) the Company and/or you must achieve applicable performance metrics, to be established, determined, and measured by the Board in its sole discretion, and (ii) you must remain employed by the Company on the date the bonus is paid. Nothing in this offer letter requires the Company to pay an annual bonus in any particular year. For your first year of your employment with the Company, if you remain employed by the Company through the date the Company pays an annual incentive bonus, your annual incentive bonus will be guaranteed to be an amount equal to your target annual bonus, without pro-ration.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__sign_on_bonus___the_company_will_pay_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sign-on Bonus. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you a one-time sign-on bonus in the gross amount of $325,000 which will be paid in the first month of employment, subject to your continued employment on the payment date. This payment will be subject to customary deductions and withholdings as required by law. You acknowledge and agree that, if your employment is terminated with Cause (as defined below) or if you resign other than for Good Reason (as defined below), in either case before the first anniversary of the Start Date, you will repay the gross amount of the sign-on bonus within thirty (30) days following the last day of your employment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__equity_awards___subject_to_approval_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to approval of the Board or the Committee, following your Start Date you will be granted the following equity awards (subject to your remaining employed on the date such awards are granted):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;" id="a__an_option__the__option_award___to_pur"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to purchase 160,000 shares of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;). The Option Award will have an exercise price per share equal to the closing price of the Common Stock on The Nasdaq Global Select Market on the last day of the first month of your employment. The shares underlying the Option Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will vest and become exercisable, subject to your continued employment on each applicable vesting date, as follows: 25% of the Option Shares will vest on the first anniversary of the vesting start date associated with the Option Award and the remainder shall vest thereafter in equal monthly installments each month following such date for the subsequent thirty-six (36) months such that the options would be fully vested with respect to the Option Shares on the four-year anniversary of the vesting start date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;" id="b__an_award_of_80_000_restricted_stock_u"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An award of 80,000 restricted stock units (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The RSU Award will be granted on the last day of the first quarter of your employment and will vest in four (4) equal installments on the anniversary of the grant date, subject to your continued employment such that the RSU Award would be fully vested on the four-year anniversary of the grant date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;" id="c__the_option_award_and_the_rsu_award_wi"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option Award and the RSU Award will be subject to the terms and conditions of the Beam Therapeutics Inc. 2019 Equity Incentive Plan (as it may be amended from time to time, or any</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successor to such plan, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as well as the agreement evidencing the applicable award. In the event of any conflict between the terms of this Agreement and the terms of the Plan or the applicable award agreement, the Plan or award agreement will control.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.3780291282799726%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__benefits__expense_reimbursement_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits; Expense Reimbursement.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;" id="a__you_will_be_eligible_to_participate_i"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will be eligible to participate in such benefits programs as the Company shall maintain from time to time in accordance with the terms of such plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;" id="b__in_accordance_with_the_company_s_poli"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Company&#x2019;s policies and procedures, you will be entitled to reimbursement of all reasonable and properly documented expenses incurred by you in the performance of your duties that are approved by the Company, including with respect to reasonable expenses related to travel to Cambridge, Massachusetts to work from the Company&#x2019;s offices. Your right to payment or reimbursement for business expenses and other amounts hereunder shall be subject to the following additional rules: (a) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (b) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (c) the right to payment or reimbursement shall not be subject to liquidation or exchange for any other benefit.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__representation_regarding_other_obliga"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation Regarding Other Obligations. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition of your employment, you will enter into an Employee Non-Solicitation, Confidentiality and Assignment Agreement between you and the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Employee Non-Solicitation, Confidentiality and Assignment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). You represent that if you are subject to any confidentiality, non-competition or other agreement that restricts your employment activities or that may affect the performance of your obligations to the Company under this Agreement, you have provided the Company with a copy of that agreement. You further represent that you have not used and agree that you will not use or disclose on behalf of the Company any trade secret or other confidential or proprietary information of any previous employer or any other party without that party&#x2019;s consent. The terms of the Employee Non-Solicitation, Confidentiality and Assignment Agreement will continue to apply regardless of any change of duties, position or compensation or benefits during your employment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__taxes___all_forms_of_compensation_re"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__entire_agreement__interpretation__en"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement, Interpretation, Enforcement and Amendment. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement, the Equity Documents and the Employee Non-Solicitation, Confidentiality and Assignment Agreement constitute the complete agreement between you and the Company, contain all the terms of your employment with the Company and supersede any prior agreements, representations, or understandings (whether written, oral, or implied) between you and the Company related to the subject matter of this Agreement. Except with</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respect to any Disputes arising under the Equity Documents, which will be governed by the governing law set forth therein, the terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance, or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be governed by laws of the Commonwealth of Massachusetts, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts regarding any Dispute or any claim related to any Dispute. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x2__termination_of_employment__severance"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment; Severance Benefits. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is understood that you are an &#x201c;at-will&#x201d; employee. Either you or the Company may terminate the employment relationship at any time and for any reason, with or without Cause or prior notice and without additional compensation to you, subject to the following:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;" id="a__the_company_may_terminate_your_employ"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company may terminate your employment with Cause upon written notice to you effective immediately, in which case you will not be entitled to receive any form of payment other than your earned salary (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;" id="b__you_may_terminate_your_employment_upo"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you may terminate your employment upon at least thirty (30) days&#x2019; prior written notice to the Company, in which case you will not be entitled to receive any form of payment other than the Accrued Obligations. In the event you provide the Company with the written notice contemplated by the prior sentence, the Company may unilaterally accelerate the date of termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;" id="c__the_company_may_terminate_your_employ"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company may terminate your employment without Cause upon written notice to you effective immediately, in which case you will receive the Accrued Obligations. In addition, subject to your entering into and complying with a separation agreement and general release in a form provided by the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that becomes fully effective (due to its timely execution and non-revocation) within sixty (60) days of the termination of your employment, or such shorter period of time set forth therein (such requirements, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which may, in the Company&#x2019;s discretion, include a one year post-employment noncompetition provision, then in addition to the Accrued Obligations, you will be entitled to: (i) payment of an amount equal to twelve (12) months of your then Base Salary as of the date of termination, such amount to be paid in equal installments over a twelve (12) month period after the date of your termination in accordance with the Company&#x2019;s usual payroll practices and periods, and (ii) provided you timely elect and remain eligible for coverage pursuant to Part 6 of Title I of ERISA, or similar state law (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), payment or reimbursement to you of an amount equal to monthly COBRA premiums at the same rate as the Company pays for active employees for you and your eligible dependents until the earliest of (A) twelve (12) months following the date of termination, (B) the date you become eligible for coverage under a subsequent employer&#x2019;s medical plan or (C) the date you become ineligible for COBRA, all subject to applicable COBRA terms and in compliance with applicable non-discrimination or other requirements under the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Patient Protection and Affordable Care Act, and the Health Care and Education Reconciliation Act (collectively the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;" id="d__in_the_event_that__within_the_change_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event that, within the Change in Control Period (as defined below), your employment with the Company is terminated by the Company without Cause or as a result of your resignation for Good Reason, then in addition to the Accrued Obligations, and subject to your compliance with the Release Requirements and in lieu of the Severance Payments, you will be entitled to: (i) an amount equal to twelve (12) months of your then Base Salary as of the date of termination, such amount to be paid in equal installments over a twelve (12) month period after the date of termination in accordance with the Company&#x2019;s usual payroll practices and periods; (ii) an amount equal to your target annual performance bonus amount for the year your employment terminates, payable within sixty (60) days following the date of termination; (iii) provided you timely elect and remain eligible for COBRA coverage, payment or reimbursement to you of an amount equal to monthly COBRA premiums at the same rate as the Company pays for active employees for you and your eligible dependents until the earliest of (A) twelve (12) months following the date of termination, (B) the date you become eligible for coverage under a subsequent employer&#x2019;s medical plan or (C) the date you become ineligible for COBRA, all subject to applicable COBRA terms and in compliance with </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable non-discrimination or other requirements under the Code, the Patient Protection and Affordable Care Act, and the Health Care and Education Reconciliation Act (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (iv) immediate vesting of the then unvested portion of any outstanding equity awards then held by you (together with the CIC Severance Payments, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In order to effectuate the accelerated vesting contemplated by (iv) in the preceding sentence, the unvested portion of your equity awards that would otherwise terminate or be forfeited on the last day of your employment will be delayed until the earliest of (A) the date on which both a Change in Control and the effective date of the Separation Agreement has occurred (at which time acceleration will occur), (B) the date that the Separation Agreement can no longer become fully effective (at which time the unvested portion of your equity awards will terminate or be forfeited) or (C) if the date of termination occurred prior to a Change in Control and no Change in Control has occurred, the date that is 31 days after the date of termination (at which time the unvested portion of your equity awards will terminate or be forfeited). For the avoidance of doubt, in no event will you be entitled to both Severance Payments and CIC Severance Payments, and if the Company has commenced providing Severance Payments to you prior to the date you become eligible to receive CIC Severance Payments, then the previously paid Severance Payments shall reduce the CIC Severance Payments.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;" id="e__for_purposes_of_this_agreement_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement:</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.778%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform your assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, for thirty (30) days after written notice is given to you by the Company describing such failure in reasonable detail; (iv) your gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in harm to the Company; or (v) your material violation of any provision of any agreement between you and the Company, including this Agreement or any agreement relating to noncompetition, non-solicitation, nondisclosure and/or assignment of inventions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means &#x201c;Covered Transaction&#x201d; as defined in the 2019 Equity Incentive Plan: Any of (i) a consolidation, merger or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#x2019;s then outstanding common stock by a single person or entity or by a group of persons and/or entities acting in concert, (ii) a sale or transfer of all or substantially all the Company&#x2019;s assets, or (iii) a dissolution or liquidation of the Company. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period beginning on the date that is 30 days immediately before the date of the first event constituting a Change in Control and ending on the 12 month anniversary of the first event constituting a Change in Control.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that you have complied with the Good Reason Process (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in your responsibilities, authority or duties; or (ii) a material diminution in your Base Salary; (each,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason Condition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the foregoing, a suspension of your responsibilities, authority and/or duties for the Company during any portion of a bona fide internal investigation or an investigation by regulatory or law enforcement authorities shall not be a Good Reason Condition. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean that (i) you reasonably determine in good faith that a Good Reason Condition has occurred; (ii) you notify the Company in writing of the occurrence of the Good Reason Condition within thirty (30) days of the occurrence of such condition; (iii) you cooperate in good faith with the Company&#x2019;s efforts, for a period not less than thirty (30) days following such notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to remedy the Good Reason Condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) you terminate employment within thirty (30) days after the end of the Cure Period. If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f)</font><div style="width:100%;display:inline;" id="f__the_severance_payments_or_cic_severan"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Severance Payments or CIC Severance Payments, as applicable, shall commence within sixty</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.769%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(60) days after the date of termination of your employment hereunder or, if later, the Change in Control, and shall be made on the Company&#x2019;s regular payroll dates; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the sixty- (60-) day period begins in one calendar year and ends in a second calendar year, the Severance Payments or CIC Severance Payments, as applicable, to the extent they qualify as &#x201c;non- qualified deferred compensation&#x201d; within the meaning of Section 409A (as defined below), shall begin to be paid in the second calendar year. In the event a regular payroll period is missed between the date of the termination of your employment hereunder and first payment date, the first payment shall include a &#x201c;catch up&#x201d; payment.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g)</font><div style="width:100%;display:inline;" id="g__in_the_interest_of_clarity__in_the_ev"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the interest of clarity, in the event your employment with the Company is terminated as a result of your (1) death, (2) disability, (3) resignation outside of the Change in Control Period, (4) resignation other than for Good Reason within the Change in Control Period or (5) termination by the Company with Cause, you will be entitled to the Accrued Obligations, but you will not be entitled to the Severance Payments, CIC Severance Benefits or any other compensation or benefits. Notwithstanding anything to the contrary in this Agreement, all severance pay and benefits</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.96%;text-indent:-0.015%;padding-left:0.013%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.806%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided to you pursuant to Section 12(c) or (d) of this Agreement (as applicable) shall be reduced and/or offset by any amounts or benefits paid to you to satisfy the federal Worker Adjustment and Retraining Notification (WARN) Act, 29 U.S.C. &#167; 2101 et seq., as amended, and any applicable state plant or facility closing or mass layoff law (whether as damages, as payment of salary or other wages during an applicable notice period or otherwise).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">h)</font><div style="width:100%;display:inline;" id="h__to_the_extent_applicable__you_shall_b"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.3780291282799726%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__timing_of_payments_and_section_409a_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Timing of Payments and Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;" id="a__notwithstanding_anything_to_the_contr"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, if at the time your employment terminates, you are a &#x201c;specified employee,&#x201d; as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6)-month period or, if earlier, upon your death; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe harbor set forth in Section 1.409A-1 (b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A of the Code (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;" id="b__for_purposes_of_this_agreement__all_r"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, all references to &#x201c;termination of employment&#x201d; and correlative phrases shall be construed to require a &#x201c;separation from service&#x201d; (as defined in Section 1.409A- 1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term &#x201c;specified employee&#x201d; means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-l(i).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;" id="c__each_payment_made_under_this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;" id="d__in_no_event_shall_the_company_have_an"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;display:flex;margin-top:11.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.3780291282799726%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x4__section_280g"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 280G</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Company and you (collectively, the &#34;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;) (i) constitute a &#34;parachute payment&#34; within the meaning of Section 280G of the Code and (ii) but for this paragraph, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be reduced to the extent necessary so that no portion of such Payments retained by</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you shall be subject to excise tax under Section 4999 of the Code; provided, however, such reduction shall only occur if after taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, such reduction results in your receipt on an after-tax basis, of the greatest amount of benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. In the event of a determination that such reduction is to take place, reduction shall occur in the following order: first, reduction of cash payments, which shall occur in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced; second, cancellation of accelerated vesting of equity awards, which shall occur in the reverse order of the date of grant for such stock awards (i.e., the vesting of the most recently granted stock awards will be reduced first); and third, reduction of employee benefits, which shall occur in reverse chronological order such that the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced. If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis.</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless you and the Company otherwise agree in writing, any determination required under this Section 14 shall be made in writing by a nationally recognized independent public accounting or consulting firm (the &#34;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accountants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required by this Section 14, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely in reasonable, good faith interpretations concerning the application </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Sections 280G and 4999 of the Code. The Company and you shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 14. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 14.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x5__indemnification__the_company_shall_i"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall indemnify you and hold you harmless to the fullest extent provided under the Certificate of Incorporation and the By-Laws of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney&#x2019;s fees), losses, and damages resulting from your good faith performance of your duties and obligations to the Company, subject to the limitations and conditions set forth therein.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;" id="x6__notices___any_notices__requests__dem"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to you at the last address you have filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Company&#x2019;s Chief Executive Officer. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to your Company email address or, in the case of Company, the Company email address of the Company&#x2019;s Chief Executive Officer, with confirmation of receipt.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;" id="x7__other__the_company_has_entered_into_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has entered into this Agreement based on your representations (oral and written) regarding your background and experience (including those pertaining to your education, training, qualifications, licensing and prior work experience) on all job applications, resumes or CVs you have submitted to the Company and in any interviews or discussions you have had with the Company. By</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">executing this Agreement, you specifically affirm that all information that you have provided orally and in writing is full, complete and accurate. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be conditioned on (i) your satisfactory completion of reference and background checks, if so requested by the Company, and (ii) your submission of satisfactory proof of legal authorization to work in the United States. You acknowledge and agree that this Agreement and certain payments hereunder may be subject to (i) any clawback, forfeiture or other similar policy adopted by the Board or Committee and as in effect from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and (ii) applicable law. You shall receive an opportunity to review the Clawback Policy, if any, and agree to take all required action to enable the enforcement of the Clawback Policy. For the avoidance of doubt, any action by the Company to recoup any compensation under the Clawback Policy shall not be deemed to give rise to &#x201c;Good Reason&#x201d; hereunder.</font></p>
  <p style="font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:center;" id="xsignature_page_follows_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[signature page follows]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:1.31in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.546%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.019%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date first written above, this Agreement will take effect as a binding agreement between you and the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:44.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:44.627%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEAM THERAPEUTICS INC.</font></p>
  <p style="margin-left:44.627%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.176%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ John Evans	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> John Evans</font></p>
  <p style="margin-left:44.627%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accepted and agreed:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Sravan K. Emany</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12/2/2024</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:24.63%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>3
<FILENAME>beam-ex10_42.htm
<DESCRIPTION>EX-10.42
<TEXT>
<html>
 <head>
  <title>EX-10.42</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENT NO. 4 TO LICENSE AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), effective as of December 11, 2024 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 4 Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), is entered into by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a corporation existing under the laws of the State of Delaware, having a place of business at 238 Main Street, Cambridge, Massachusetts 02142 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and Fellows of Harvard College</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Harvard</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each of Harvard and Licensee are a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; hereunder and collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="margin-left:1.107%;text-indent:6.816%;font-size:10pt;margin-top:9.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensee and Harvard have entered into that certain License Agreement dated as of June 27, 2017, as amended by that certain Amendment No. 1 to License Agreement dated as of December 12, 2017, that certain Amendment No. 2 to License Agreement dated as of March 27, 2020, and that certain Amendment No. 3 to License Agreement dated as of January 7, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="margin-left:1.107%;text-indent:6.816%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensee and Harvard desire to amend the Agreement to clarify the Parties&#x2019; respective obligations and rights regarding reporting under Sections 4.3 and 5.1 of the Agreement, and to modify certain terms relating to the Royalty Term and royalty rate for Licensed Products, subject to the terms and conditions of this Amendment No. 4.</font></p>
  <p style="margin-left:1.107%;text-indent:6.817%;font-size:10pt;margin-top:9.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGREEMENT TO AMEND</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms used but not defined herein shall have the meaning given to them in the Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.868%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement is hereby amended from the Amendment No. 4 Effective Date by adding a new Section 4.3.6 immediately following the existing Section 4.3.5, to read as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;4.3.6. With respect to the achievement of the first milestone under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to any Licensed Product for which a milestone payment is payable under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Licensee shall provide to Harvard, together with the notice of achievement of such milestone pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, containing the following information with respect to such Licensed Product: (a) General Description (Free text) of the Licensed Product, (b) Product/Program name, (c) indication for which the Licensed Product is being developed as of the date of the Product Report, (d) target cell type(s), (e) target Gene(s), (f) target base edit(s), (g) guide RNA sequence(s), (h) Base Editor version (for example, [**]), (i) Base Editor amino acid sequence, (j) delivery method (for example, [**]) and composition (specifically identifying whether [**] are used, provided that no chemical structures are required to be disclosed), and (k) nuclease cut profiling (yes/no, based on [**]). Harvard will</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide notice promptly to Licensee of any deficiency in the contents of the Product Report, and Licensee shall remedy any such deficiency within [**] days after such notice from Harvard. With respect to any Licensed Product that has already met a milestone under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 11, 2024, Licensee shall provide a retrospective Product Report for such Licensed Product within [**] days after December 11, 2024. For clarity, the information included in any Product Report shall be Licensee Confidential Information for the purpose of this Agreement. Notwithstanding the foregoing, with respect to any Licensed Product exploited pursuant to (i) a Sublicense granted under any of the agreements set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and any amendments or restatements of the agreements set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) further Sublicenses of such Sublicenses, to the extent permitted under this Agreement, or (iii) license agreements entered into pursuant to any agreement in clause (i) or (ii) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Sublicenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and each Sublicensee under such Existing Sublicenses, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Sublicensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Licensee will only be obligated to provide information required to be provided in a Product Report to the extent Licensee has access to, and the right to so disclose, such information, provided that Licensee shall use commercially reasonable efforts (but without any obligation to make any payments to such Sublicensees in connection with such request or agree to any concession with such Sublicensees) to obtain access to, and the right to disclose, such information, or to otherwise facilitate the transfer of such information directly between Existing Sublicensees and Harvard. With respect to any Licensed Product exploited by any Sublicensee, Licensee is permitted to facilitate the transfer of Product Reports directly between such Sublicensee and Harvard, which provision of the Product Reports by such Sublicensee shall satisfy Licensee&#x2019;s obligation hereunder.&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.973%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement is hereby amended by (a) adding a new Exhibit 4.3.6 thereto, as set forth in Attachment 1 hereof, and (b) adding a new Appendix A thereto, as set forth in Attachment 2 hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.993%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.2 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;4.4.2 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.31%;font-size:0;margin-top:12.15pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.047946764352057%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Licensed Product exploited pursuant to an Existing Sublicense, on a country-by-country basis, in each country in which such Licensed Product is Covered by a Valid Claim, royalties shall be paid on the sum of Net Sales of such Licensed Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Patent Rights Covering the applicable Licensed Product (or if the last Covering Valid Claim with respect to such Licensed Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid Claim; provided, however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date of such issuance to the expiration date of such Valid Claim); (b) the period of regulatory exclusivity associated with such Licensed Product in such country; and (c) [**] years after the First Commercial Sale of such Licensed Product in such country but only for so long as such Licensed Product is sold (such period, when used with reference to Licensed Products that are subject to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). During time periods when such Royalty Term is only in effect in a given country for a given Licensed Product due to clause (c) of the definition of Royalty Term in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then the royalty rate provided for such Licensed Product in such country shall be reduced by [**] percent ([**]%) from that set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above for such portions of the Royalty Term for such Licensed Product in such country.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.31%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.047946764352057%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Licensed Product exploited by Licensee or its Affiliates or pursuant to a Sublicense other than an Existing Sublicense, on a country-by-country basis, in each country in which such Licensed Product is Covered by a Valid Claim, royalties shall be paid on the sum of Net Sales of such Licensed Product until the later of:</font></div></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) the expiration date of the last to expire Valid Claim within the Patent Rights Covering the applicable Licensed Product (or if the last Covering Valid Claim with respect to such Licensed Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid Claim; provided, however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such issuance to the expiration date of such Valid Claim); and (b) [**] years after the First Commercial Sale of such Licensed Product in such country but only for so long as such Licensed Product is sold (such period, when used with reference to Licensed Products that are subject to this Section 4.4.2.2, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). During time periods when the Royalty Term is only in effect in a given country for a given Licensed Product due to clause (b) of the definition of Royalty Term in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then the royalty rate provided for such Licensed Product in such country shall be reduced by [**] percent ([**]%) from that set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, [**]% in the absence of any reductions for third party royalties permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and a minimum percentage of [**]% with the application of a full [**]% reduction for third party royalties permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for such portions of the Royalty Term for such Licensed Product in such country.&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.993%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;4.4.3 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Royalty Set-Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.31%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.047946764352057%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4.3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Licensed Product exploited pursuant to an Existing Sublicense, if the applicable Sublicensee obtains a license from a third party after arm&#x2019;s length negotiations to patent application(s) and/or patent(s) that such Sublicensee believes in good faith Cover such Licensed Product, then Licensee may offset [**] percent ([**]%) of any royalty payments due under such third-party license with respect to such </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent application(s) and/or patent(s) with respect to sales of such Licensed Product against the royalty payments that are due to Harvard with respect to Net Sales of such Licensed Products in such country; provided that in no event shall (a) the royalty payments to Harvard with respect to such Licensed Products be reduced by more than [**] percent ([**]%) of the amount otherwise due, (b) with respect to royalties paid to the third party solely on the basis of claims of pending patent applications of the third party (and no issued patent claim of the third party covers the applicable Licensed Product), such amounts shall only be offsettable in accordance with the foregoing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the Covering pending claim of the third party&#x2019;s pending application would meet the definition of Valid Claim set forth in this Agreement were such pending claim within the Patent Rights as of the Effective Date, and (c) the royalty offset provided in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be applied to any combination product for which an adjustment to Net Sales has been made in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, but to avoid doubt only as relates to royalties on patent applications and patents that would apply in the absence of the Other Active Components (third party patent royalties due solely because of the presence of the Other Active Components shall not be offsettable against adjusted Net Sales of a Combination Product).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.31%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.047946764352057%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4.3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Licensed Product exploited by Licensee or its Affiliates or pursuant to a Sublicense other than an Existing Sublicense, if Licensee, an Affiliate of Licensee or an applicable Sublicensee obtains a license from a third party after arm&#x2019;s length negotiations to patent application(s) and/or patent(s) that Licensee, such Affiliate or such Sublicensee believes in good faith Cover such Licensed Product, then Licensee may offset [**] percent ([**]%) of any royalty payments due under such third-party license with respect to such patent application(s) and/or patent(s) with respect to sales of such Licensed Product against the royalty payments that are due to Harvard with respect to Net Sales of such Licensed Products in such country; provided that in no event shall (a) the royalty payments to Harvard with respect to such Licensed Products be reduced by more than [**] percent ([**]%) of the amount otherwise due, (b) with respect to royalties paid to the third party solely on the basis of claims of pending patent applications of the third party (and no issued patent claim of the third party covers the applicable Licensed Product), such amounts shall only be offsettable in accordance with the foregoing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the Covering pending claim of the third party&#x2019;s pending application would meet the definition of Valid Claim set forth in this Agreement were such pending claim within the Patent Rights as of the Effective Date, and (c) the royalty offset provided in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be applied to any combination product for which an adjustment to Net Sales has been made in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, but to avoid doubt only as relates to royalties on patent applications and patents that would apply in the absence of the Other Active Components (third party patent royalties due solely because of the presence of the Other Active Components shall not be offsettable against adjusted Net Sales of a Combination Product). Notwithstanding the foregoing, during the period in which royalties are payable under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to Net Sales of a Licensed </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product solely due to clause (b) of the definition of &#x201c;Royalty Term&#x201d; as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the royalty payments to Harvard with respect to such Net Sales of such Licensed Product may be reduced by up to [**] percent ([**]%) of the amount otherwise due, to a minimum royalty rate of [**]%.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.993%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.4 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:11.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;4.4.4 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss of Market Exclusivity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:7.773%;text-indent:7.312%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any Licensed Product exploited pursuant to an Existing Sublicense, if a Loss of Market Exclusivity exists in a country with respect to such a Licensed Product, then the royalty rate for such Licensed Product in such country shall be reduced by [**] percent ([**]%) of the applicable rate determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.4.2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, provided that in no event shall the effective royalty rate applied to Net Sales of such Licensed Product in such country be reduced as a result of the application of the terms of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to less than [**] percent ([**]%) of the applicable rate determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.4.2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Once Loss of Market Exclusivity exists with respect to a Licensed Product in a country, it will be deemed to continue to exist thereafter with respect to such Licensed Product in such country unless Harvard requests in writing that Loss of Market Exclusivity with respect to a Licensed Product in a country be re-evaluated (which request may not be made more frequently than [**] in a Calendar Year), in which case the existence of such Loss of Market Exclusivity, and any corresponding reduction pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall depend on whether the criteria set forth in the definition of Loss of Market Exclusivity are still met with respect to such Licensed Product in such country. If it is determined that the Loss of Market Exclusivity no longer exists, the termination of the [**] percent ([**]%) reduction in royalty rate due to the absence of Loss of Market Exclusivity shall be effective only on a going-forward basis from the date of such Harvard request, and there shall be no recovery of monies or retroactive increase in rates for time periods prior thereto.&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.877%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1.6 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;text-indent:7.314%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;5.1.1.6	A Product Report for any Licensed Product for which Net Sales were generated during the applicable Calendar Quarter and for which Licensee has not previously provided a Product Report.&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.877%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement is hereby amended to add a new Section 5.1.1.7, which reads as follows:</font></div></div>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;5.1.1.7	A description of any substantive changes to the information in any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable Product Report provided to Harvard under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1.1.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding each applicable Licensed Product.&#x201d;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee hereby represents and warrants that, as of the Amendment No. 4 Effective Date, Appendix A as set forth in Attachment 2 hereof is a true, complete, and correct schedule of all Sublicenses (including amendments thereto) granted by Licensee and any Sublicensee to third parties under the Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:6.738%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.3493707990094506%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as specifically set forth in this Amendment No. 4, the terms and conditions of the Agreement (including all exhibits thereto) shall remain unchanged and in full force and effect. Licensee and Harvard hereby agree to be bound by provisions substantially identical to Sections 11.5 through 11.17 of the Agreement with respect to this Amendment No. 4, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutatis mutandis </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(which are incorporated herein by reference as they so apply); provided that references to the Agreement provided in Section 11.5 shall be read to apply to the Agreement as amended by this Amendment No. 4.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signatures Follow</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.741%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 4 to be executed by their duly authorized representatives as of the Amendment No. 4 Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.713%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:146.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.435%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRESIDENT AND FELLOWS OF HARVARD COLLEGE</font></p><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Jordan B. Grant		</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Title:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;text-indent:6.25pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:1.16%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BEAM THERAPEUTICS INC.</font></p><p style="margin-left:1.16%;text-indent:0;font-size:12pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.435%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Title:</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.053%;font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12/12/2024</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.87in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.741%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 4 to be executed by their duly authorized representatives as of the Amendment No. 4 Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.713%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:146.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.435%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRESIDENT AND FELLOWS OF HARVARD COLLEGE</font></p><p style="text-indent:0;font-size:12pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Name:</font></p><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0in;text-indent:6.25pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:1.16%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BEAM THERAPEUTICS INC.</font></p><p style="text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:12pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.16%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.435%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ John Evans	</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Name: </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">John Evans</font></p><p style="margin-left:1.16%;text-indent:0;font-size:12pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="margin-left:50.227%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12/13/2024</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.87in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>beam-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:29.773%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.463%;text-align:center;" id="beam_therapeutics_inc__insider_trading_p"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc. Insider Trading Policy</font></p>
  <p style="margin-left:1.28%;font-size:10pt;margin-top:2.85pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as amended and restated as of December 5, 2024)</font></p>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.877%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Insider Trading Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) provides guidelines with respect to transactions in the securities of, and handling confidential information about, Beam Therapeutics Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Applicable Other Companies (as defined below). The Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has adopted this Policy to promote compliance with U.S. federal and state securities laws that prohibit certain persons who are aware of material nonpublic information about a company from: (i) trading in securities of that company; or (ii) providing such material nonpublic information to other persons who may trade on the basis of that information, commonly known as &#x201c;tipping.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Subject to this Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy applies to transactions in the securities of the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as well as securities of Applicable Other Companies (collectively, with Company Securities, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Other </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are Partner Companies or Competitor Companies about which a person subject to this Policy possesses material non-public information that was learned in the course of providing services to the Company. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partner Companies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are companies with which the Company does business, or is evaluating doing business, including a supplier or a development or commercialization partner of the Company or any of its subsidiaries. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitor Companies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are companies listed in the &#x201c;Competition&#x201d; section of the Company&#x2019;s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.</font></div></div>
  <p style="margin-left:2.04%;text-indent:5.944%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Importantly, non-public information about one entity can be material to another entity. By way of illustration and not limitation:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.612264140718984%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-public information about the Company can be material to an Applicable Other Company. For example, the pending sale of Company assets could be material to a Partner Company or a Competitor Company whose prospects could be affected by the Company&#x2019;s asset sale.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.13%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.612264140718984%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-public information about an Applicable Other Company can be material to the Company or to another Applicable Other Company. For example, data from one Partner Company&#x2019;s clinical trial could be material to the Company or to another Partner Company or a Competitor Company with products that target the same indication or that use the same mechanism of action.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.868%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons Subject to the Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy applies to all directors, officers and other employees of the Company and its subsidiaries. The Company may also determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material nonpublic information about the Company or Applicable Other Companies. Any such other persons will be notified by the Compliance Officer (as referenced below) of the Board&#x2019;s determination. Collectively, the foregoing persons are referred to in this Policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div>
  <p style="margin-left:2.04%;text-indent:6.884%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy also applies to transactions by Other Covered Persons. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Covered </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are: (i) family members who reside with Covered Persons (including a spouse, a child,</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a child away at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), (ii) anyone else who lives in a Covered Person&#x2019;s household, (iii) any family members who do not live in a Covered Person&#x2019;s household but whose transactions in Subject</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities are directed by such Covered Person or are subject to such Covered Person&#x2019;s influence or control, such as parents or children who consult with a Covered Person before they trade in Subject Securities, and (iv) all corporations, limited liability companies, partnerships, trusts or similar entities controlled by a Covered Person or any person described in items (i)-(iii), unless the entity has implemented policies or procedures designed to ensure that the applicable Covered Person or Other Covered Person cannot influence transactions by the entity involving Subject Securities. Covered Persons are responsible for the transactions of Other Covered Persons and therefore should make them aware of the need to confer with the Covered Person before they trade in Subject Securities. Covered Persons should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for their own account.</font></p>
  <p style="margin-left:2.04%;text-indent:6.853%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the provisions in Sections 7 and 12 of this Policy are not applicable to transactions by the Company itself, transactions by the Company will only be made in accordance with applicable U.S. federal securities laws, including those relating to insider trading.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Subject to the Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy applies to transactions in Subject Securities, including common stock, options to purchase common stock, restricted stock units or any other type of securities that the Company or an Applicable Other Company may issue, including, but not limited to, preferred stock, convertible debt and warrants.</font></div></div>
  <p style="margin-left:1.107%;text-indent:14.554%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in this Policy is intended to limit the ability of a venture capital partnership or other similar entity with which a Director is affiliated to distribute Subject Securities to its partners, members or other similar persons. It is the responsibility of each affected Director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.897%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual Responsibility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and Applicable Other Companies and to refrain from engaging in transactions in Subject Securities while in possession of material nonpublic information about the Company or Applicable Other Companies, as applicable. Each individual is responsible for ensuring that he or she, and each Other Covered Person whose transactions are subject to this Policy, as discussed above, complies with this Policy. In all cases, the responsibility for determining whether an individual is in possession of material nonpublic information rests with that individual, and any action on the part of the Company, the Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. A Covered Person could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading &#x201c;Consequences of Violations.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration of the Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#x2019;s Chief Legal Officer or such officer as is designated by the Chief Executive Officer shall serve, in consultation with the Chief Executive Officer, as the Compliance Officer for the purposes of this Policy. In the absence of the Compliance Officer, another employee designated by the Compliance Officer (or, if the</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.741%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Officer is unavailable, by the Chief Executive Officer) shall be responsible for administration of this Policy. All determinations and interpretations by the Compliance Officer or his or her delegate shall be final.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.184%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:5.204%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is the policy of the Company that a Covered Person or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:5.204%;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Covered Person who is aware of material nonpublic information relating to the Company or an Applicable Other Company may not:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in transactions in Subject Securities of such company (including gifts of such securities), except as otherwise specified in this Policy under the headings &#x201c;Transactions under Company Plans,&#x201d; &#x201c;Transactions Not Involving a Purchase or Sale&#x201d; and &#x201c;Rule 10b5-1 Plans&#x201d;;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pass such material nonpublic information on to others or recommend to anyone the purchase or sale of any securities when such persons are aware of such information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclose such material nonpublic information to persons within the Company whose jobs do not require them to have that information, or anyone outside of the Company, including, but not limited to, family, friends, business associates, investors and expert consulting firms, unless any such disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assist anyone engaged in the above activities in contravention of this Policy.</font></div></div>
  <p style="margin-left:2.027%;text-indent:6.883%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not excepted from this Policy. The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company&#x2019;s reputation for adhering to the highest standards of conduct.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Material Nonpublic Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.622%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information is considered &#x201c;material&#x201d; if a reasonable investor would consider that information important in making a decision to buy, hold or sell securities. Any information that could be expected to affect the Company&#x2019;s or an Applicable Other Company&#x2019;s stock price, whether it is positive or negative, should be considered material to such company. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight.</font></div></div>
  <p style="margin-left:8.707%;text-indent:7.425%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">projections of future earnings or losses, or other financial guidance;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to previously announced financial guidance, or the decision to suspend</font></div></div>
  <p style="margin-left:15.373%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial guidance;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a pending or proposed merger, acquisition or tender offer;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a pending or proposed acquisition or disposition of a significant asset;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a pending or proposed joint venture or licensing agreement;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Company restructuring;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant related party transactions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:6.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in dividend policy, the declaration of a stock split or an offering of additional securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bank borrowings or other financing transactions out of the ordinary course;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment of a repurchase program for Company Securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in the Company&#x2019;s cost structure;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major marketing changes;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in management;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in or dispute with auditors or notification that the auditor&#x2019;s reports may no longer be relied upon;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending or threatened significant litigation, or the resolution of such litigation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant regulatory developments;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials, including the timing of and findings and data from such trials;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timelines for expected launches of new products or for new indications;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending bankruptcy or the existence of severe liquidity problems;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the gain or loss of a significant supplier;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:6.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of a ban on trading in Company Securities or the securities of another company; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2996616775973635%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity breaches or incidents, including investigations of such incidents.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.496%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonpublic Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Generally, information that has not been disclosed to the public is considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be</font></div></div>
  <p style="margin-left:8.707%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considered widely disseminated if it has been disclosed through the Dow Jones &#x201c;broad tape,&#x201d; newswire services, a broadcast on widely available internet, radio or television programs, publication in a widely available newspaper, magazine or news website, or public disclosure documents filed with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that are available on the SEC&#x2019;s website. By contrast, information would generally </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> be considered widely disseminated if it is available only to the Company&#x2019;s employees or only to the employees of the Company and an Applicable Other Company.</font></p>
  <p style="margin-left:8.693%;text-indent:7.388%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once information is widely disseminated, it is still necessary to afford the investing public sufficient time to absorb the information. As a general rule, information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:8.693%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is considered nonpublic until the end of the second full trading day after the information is released. For example, if the Company announces financial results after market close on Monday or before trading begins on a Tuesday, the first time a director, officer or employee can buy or sell Company Securities is the opening of the market on Thursday (assuming he or she is not aware of other material nonpublic information relating to the Company at that time). However, if the Company announces financial results after trading begins on that Tuesday, the first time a director, officer or employee can buy or sell Company Securities is the opening of the market on Friday (again assuming he or she is not aware of other material nonpublic information relating to the Company at that time). Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material nonpublic information.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.022%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions under Company Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The prohibitions in Section 7 of this Policy do not apply to the following transactions, except as specifically noted:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.53%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Exercises</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to the exercise of a stock option acquired pursuant to a Company equity incentive plan or to a transaction in which a person has elected to have the Company withhold shares subject to an option award to satisfy tax withholding requirements. This Policy does, however, apply to any sale of shares as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of or taxes associated with an option.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock and Similar Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to the vesting of restricted stock, the settlement of restricted stock units or similar awards, or to a transaction in which the Company withholds shares to satisfy tax withholding requirements upon the vesting of any restricted stock or the vesting or settlement of any restricted stock unit. The Policy does apply, however, to any market sale of restricted stock or other Company Securities received upon the settlement of any restricted stock unit or similar award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.452%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Policy does not apply to periodic purchases under a Company employee stock purchase plan, if such plan exists, that are made as the result of an election made at the beginning of the purchase period. This Policy would apply, however, to an initial decision to participate in the plan or a decision to increase the level of contribution in a subsequent purchase period. The Policy also applies to any sales of shares purchased under the plan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:15.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.874378447328947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Policy does not apply to purchases of Company</font></div></div>
  <p style="margin-left:8.707%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities in the Company&#x2019;s or its subsidiaries&#x2019; 401(k) plans as a result of periodic contributions made pursuant to payroll deduction. The Policy does apply, however, to initial elections to participate, and increases in the level of participation, in a Company stock fund and transfers in or out of a Company stock fund (including in connection with a plan loan).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.013%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions with the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any purchase of Company Securities from the Company or sales of Company Securities to the Company are not subject to the prohibitions in Section 7 of this Policy. In addition, nothing in this Policy is intended to limit the ability of any Covered Person or Other Covered Person to sell Subject Securities as a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable securities law.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Not Involving a Purchase or Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Transactions in mutual funds that are invested in Subject Securities are not transactions subject to the prohibitions in Section 7 of this Policy.</font></div></div>
  <p style="margin-left:8.68%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note that gifts of securities are considered &#x201c;sales&#x201d; for purposes of this Policy.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.052%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has determined that the following transactions present a heightened legal risk and the potential appearance of improper or inappropriate conduct. It is therefore the Company&#x2019;s policy that any person covered by this Policy may not engage in any of the following transactions:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.43%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Short sales of Company Securities (i.e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value and therefore might signal to the market that the seller lacks confidence in the Company&#x2019;s prospects. In addition, short sales may reduce a seller&#x2019;s incentive to seek to improve the Company&#x2019;s performance. For these reasons, short sales of Company Securities are prohibited. In addition, Section 16(c) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) prohibits executive officers and directors from engaging in short sales. Short sales arising from certain types of hedging transactions are also governed by the paragraph below captioned &#x201c;Hedging Transactions.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.485%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publicly Traded Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Given the relatively short term of publicly traded options, transactions in options may create the appearance that a director, officer or employee is trading based on material nonpublic information and focus such person&#x2019;s attention on short-term performance at the expense of the Company&#x2019;s long-term objectives. Accordingly, transactions in Company Securities that are put options, call options or other derivative securities on an exchange or in any other organized market, are prohibited by this Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.485%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a director, officer or employee to continue to own Company Securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company&#x2019;s</font></div></div>
  <p style="margin-left:8.707%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other shareholders. Therefore, directors, officers and employees are prohibited from engaging in any such transactions.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.43%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledged Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#x2019;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in Subject Securities, directors, officers and other employees are prohibited from holding Subject Securities in a margin account or otherwise pledging Subject Securities as collateral for a loan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;text-indent:7.53%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.0657046193599244%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standing and Limit Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Standing and limit orders (except standing and limit orders under Rule 10b5-1 Plans, as described below) create heightened risks for </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:8.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insider trading violations, similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a director, officer or other employee is in possession of material nonpublic information. The Company therefore discourages placing standing or limit orders on Subject Securities other than pursuant to Rule 10b5-1 Plans. If a person subject to this Policy determines that they must use a standing order or limit order, that person must contact the Compliance Officer for clearance to place the order.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.906%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:1.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this defense, a person subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Subject Securities that meets certain conditions specified in the rule (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If the plan meets the requirements of Rule 10b5-1, Subject Securities may be purchased or sold without regard to certain insider trading restrictions. To comply with this Policy, a Rule 10b5-1 Plan must be approved by the Compliance Officer and meet the requirements of Rule 10b5-1. A Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is not aware of material nonpublic information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.</font></div></div>
  <p style="margin-left:8.707%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans will be considered by the Compliance Officer on a case-by-case basis.</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Rule 10b5-1 Plan must be submitted to the Compliance Officer for approval at least five days prior to the entry into the Rule 10b5-1 Plan. No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.993%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy continues to apply to transactions in Subject Securities even after termination of service to the Company. If an individual is in possession of material nonpublic information related to a company when his or her service terminates, that individual may not trade in Subject Securities of such company until that information has become public or is no longer material.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.113%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Violations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic information to others</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">who then trade in the Subject Securities, is prohibited by U.S. federal and state laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities, as well as foreign regulatory authorities. Punishment for insider trading violations is severe, and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#x201c;controlling persons&#x201d; if they fail to take reasonable steps to prevent insider trading by company personnel.</font></p>
  <p style="margin-left:2.027%;text-indent:6.883%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, an individual&#x2019;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not the employee&#x2019;s failure to comply results in a violation of law. In addition to the formal sanctions summarized above, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&#x2019;s reputation and irreparably damage a career.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.163%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.935%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Assistance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Compliance </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.935%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officer.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.042%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All persons subject to this Policy must certify their understanding of, and intent to comply with, this Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.385%;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;margin-right:7.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout Periods and Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will notify certain individuals if they are subject to the additional blackout periods and pre-clearance procedures outlined in the Addendum to this Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.906%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the Company, the Compliance Officer or the Company&#x2019;s other employees will have any liability for any delay in reviewing, or refusal of, a trading plan submitted pursuant to Section 13, a request for pre-clearance submitted pursuant to the Addendum to this Policy or a request to allow clearance submitted pursuant to Section 12. Notwithstanding any such review or clearance, none of the Company, the Compliance Officer or the Company&#x2019;s other employees assumes any liability for the legality or consequences of such trading plan or transaction to the person engaging in or adopting such trading plan or transaction.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:29.773%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.528%;text-align:center;" id="certification"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.973%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have read and understand the Company&#x2019;s Insider Trading Policy (the &#x201c;Policy&#x201d;). I understand that the Compliance Officer is available to answer any questions I have regarding the Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:7.003%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since I have been an employee, officer or director of the Company, or otherwise subject to the Policy, I have complied with the Policy as in effect at such time.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.033673469387755%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I will continue to comply with the Policy for as long as I am subject to the Policy. Print name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:46.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:29.84%;font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.463%;text-align:center;" id="addendum_to_insider_trading_policy_of"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Addendum to Insider Trading Policy of</font></p>
  <p style="margin-left:29.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:28.537%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:7.011%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established additional procedures to assist in the administration of its Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in order to facilitate compliance with laws prohibiting insider trading while in possession of material nonpublic information and to avoid the appearance of any impropriety. These additional procedures are applicable only to the Company&#x2019;s directors, officers subject to Section 16 of the Securities Exchange Act of 1934, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">officers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and other persons who, because they are in a position to routinely become aware of material nonpublic information, are periodically designated by the Compliance Officer as being subject to these procedures. The Compliance Officer will notify those individuals who are subject to this Addendum. All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:6.951%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each person who is subject to this Addendum is responsible for making sure that he or she, and each family member, household member or entity whose transactions are subject to the Policy, as discussed in the Policy, complies with this Addendum. In all cases, the responsibility for determining whether an individual is in possession of material nonpublic information rests with that individual, and any action on the part of the Company, the Compliance Officer or any other person does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.022%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Directors, officers and other persons who are designated by the Compliance Officer as being subject to this Addendum, as well as their family members and other related persons and entities specified in the &#x201c;Persons Subject to the Policy&#x201d; section of the Policy, may not engage in any transaction in Company Securities at any time, even if not subject to a Blackout Period (as defined below), without first obtaining pre- clearance of the transaction from the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer at least two trading days in advance of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre- clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company Securities, and should not inform any other person of the restriction. When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic information about the Company, and should describe fully those circumstances to the Compliance Officer. The requestor should also indicate whether he or she has effected any &#x201c;opposite-way&#x201d; transactions within the past six months, and should be prepared to report the proposed transaction on an appropriate Form 4 or Form 5, if applicable. The requestor should also be prepared to comply with SEC Rule 144 and file a Form 144, if necessary, at the time of any sale. After receiving clearance to engage in a trade from the Compliance Officer, the requestor must complete the proposed trade within two trading days or make a new trading request. Notwithstanding receipt of pre-clearance, if the requestor becomes aware of material non-public information or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.013%;font-size:0;margin-top:3.75pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Trading Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Directors, officers and other persons subject to this Addendum may not engage in any transaction in Company Securities (other than as specified </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;font-size:0;margin-top:3.75pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below under the heading &#x201c;Exceptions&#x201d;) during a blackout period beginning the first calendar day of each fiscal quarter and ending after two full trading days following the public release of the Company&#x2019;s quarterly earnings during such quarter (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For example, if the Company announces financial earnings before trading begins on a Tuesday, the Blackout Period will end with the opening of The Nasdaq Global Select Market on that Thursday. However, if the Company announces earnings after trading begins on that Tuesday, the Blackout Period will end with the opening of The Nasdaq Global Select Market on that Friday.</font></div></div>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.013%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event-Specific Trading Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. From time to time, an event may occur that is material to the Company or an Applicable Other Company and is known by only a few directors, officers and/or employees. So long as the event remains material and nonpublic, such persons as designated by the Compliance Officer may not trade Subject Securities of such company. In addition, the Company&#x2019;s financial and/or operational results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Compliance Officer, designated persons should refrain from trading in Company Securities prior to the commencement of the Blackout Period. In that situation, the Compliance Officer may notify these persons that they should not trade in the Company Securities, without disclosing the reason for the restriction. The existence of an event-specific trading restriction period or extension of a Blackout Period will not be announced to the Company as a whole, and should not be communicated to any other person. Even if the Compliance Officer has not designated someone as a person who should not trade due to an event-specific restriction, no person subject to this policy should trade while aware of material nonpublic information.</font></div></div>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.062%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The quarterly trading restrictions and event-specific trading restrictions described above do not apply to those transactions to which the Policy does not apply, as described therein under the headings &#x201c;Transactions Under Company Plans,&#x201d; &#x201c;Transactions Not Involving a Purchase or Sale&#x201d; and &#x201c;Transactions with the Company.&#x201d; Further, the requirement for pre-clearance, the quarterly trading restrictions and event-specific trading restrictions do not apply to transactions conducted pursuant to approved Rule 10b5-1 plans described in the Policy under the heading &#x201c;Rule 10b5-1 Plans.&#x201d;</font></div></div>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.033%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Transaction Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each director or officer shall notify the Compliance Officer of the occurrence of any purchase, sale, gift, transfer, or other acquisition or disposition of securities of the Company as soon as possible following the transaction, but in any event within one business day after the transaction. Such notification may be oral or in writing (including by e-mail) and should include the identity of the covered person, the type of transaction, the date of the transaction, the number of shares involved, the purchase or sale price, and whether the transaction was effected pursuant to a contract, instruction or written plan that is intended either to satisfy the affirmative defense conditions of Rule 10b5-1(c) or to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S- K).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.935%;text-indent:7.163%;font-size:0;margin-top:3.95pt;justify-content:flex-start;margin-bottom:0;margin-right:4%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.118889404007624%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deemed Time of a Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of this Addendum, a purchase, sale, gift, transfer, or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it. For example, in the case of an open market purchase or sale, this occurs when the trade is executed, not when it settles.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>beam-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement No. 333-277427 on Form S-3 and Registration Statement Nos. 333-236582, 333-254378, 333-263067, 333-270079, and 333-277382 on Form S-8 of our reports dated February 25, 2025, relating to the financial statements of Beam Therapeutics Inc., and the effectiveness of Beam Therapeutics Inc.&#x2019;s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>beam-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO
<br>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
<br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, John Evans, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Beam Therapeutics Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(b)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(c)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(d)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(b)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"></td>
    <td style="width:3.52%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;text-indent:12pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2025</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.003in;text-indent:12pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Evans</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">John Evans</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>beam-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO
<br>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
<br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
 </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Sravan Emany, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Beam Therapeutics Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(b)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(c)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(d)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:95.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(b)</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.66%;box-sizing:content-box;"></td>
    <td style="width:4.54%;box-sizing:content-box;"></td>
    <td style="width:89.8%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"></td>
    <td style="width:3.34%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.66%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2025</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sravan Emany</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sravan Emany</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>beam-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO
<br>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with this Annual Report of Beam Therapeutics Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.6%;box-sizing:content-box;"></td>
    <td style="width:2.8%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.6%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Evans</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">John Evans</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>beam-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with this Annual Report of Beam Therapeutics Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.6%;box-sizing:content-box;"></td>
    <td style="width:2.8%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:46.6%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sravan Emany</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sravan Emany</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img43983261_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43983261_0.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &R!!8# 2(  A$! Q$!_\0
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MI_PK[6X?'EI>27-CH,D_]H^&?)C=U>[5LH$;9CK_ !"L[X%?\%-O&GQ6\8>
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M]N*Z3P#_ ,$Z/!_@2^\)A[R\UC3/#&@7_A_[!?PQR1WZ7DAEFE<X^1MQ. H
M&:I:=_P3<T6^T3P=H/B;Q7K_ (M\'^![F\N--T:\40@&; C5YHW$C>2N0A!'
M#<G%&H'+_%K_ (*)>(/#_P"P]X0^)GA[0]-N/$6J:L-'U;3+D.R6=Q'Y@N$4
M*0<AHSCGH1FMWX-?MW:A\:_VVE\"Z1I^GR>!YO#PU&'406-Q)<BWBG>,'.W:
MOG 'CBM"T_X)J^%M*TV;1M-U[5-/\)_\)5;^*K;1! )HK.5(FBDA21V+E)<Y
M)/(/UJY^S3_P3WT']E_Q)X>U32=>U/4YM"AU.';<6\<?VL7K(27(.1Y:HJJ!
MU YQ1J!Z7;_$N[U']I@^#(([=M-TWP\-7U%RI,T<TLYC@0'H 421CD<U\\^(
MOVT_BMX>A^*7BZVT?P9>>!?A7XB?2M0M"\T.J7%NFPO+&^3'N"OT.,XKZ/\
M 'PC3P;\5/&WBV6^DO;[QI+:%E>,*+&&VA$:0IR25)W-SW:O(?$'_!/&3Q)>
M>,;.;XE^(H?!_P 0-;.MZUX?M]/MXQ<L2N8?M.#(L9"X(&,BC4#GOBW^WOXH
M\)?\+2DT'0]/U+3_  =>:''97+P33"RM;^W$TMU<I%EG6/(X0=*PM5_X*&>+
M=*_9.O?&\-U\.]6NK7Q5:Z%%J=C)-)I\EO,3NFE@.)H73&2C<D#(!KUCQA^P
MG::SXG\8:WH_C/Q!X7U/Q)?:9J%K-IL: :2]A;^3'&%8XGC=2=R."#6!?_\
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M\;?L2WWB3Q3;^)](^(.IZ#XNN=#BT#7K\Z3;7EMXC@C^Z\]K*#&) ><COU%
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M=>'C0.6O9+S[1Y[.8"_D_,/D("YV]\T 67_:J^-'QA\<>.+KX4^%O!>J>%/
M&OGP_)9ZK<RQ:EKTT>W[0T+C$<*KN&W=G.*I?&/_ (*;Z;\$/B?\9?#/B6XT
M?1=0\%Z/9WOAFUEAEEDU&YFLO.>*1DRN%E*)U7@_C72>.?\ @G8VLZ_XN.@_
M$[Q=X/\ #?Q U!-6\2:+IT,)%[<C:9'@G/[RW\PJ-P3.:ZK4OV)]%U37?B[>
M2:I>;OBUI%KH\RR01RG25@LS:AXG;)=F4[CNQR!]: .]^ GCRZ^*?P+\&^)[
M^&&WOO$6BVNHW$4((CCDEB5V5<Y. 3@9-=+?G_09_P#KFW\JP_A-\/X?A1\+
MO#?A:WN9KRW\-Z;!IL=Q*H62=8D"!V X!.,X%;E^/]"N/]J)A^AH Y[X)G/P
M>\,_]@^/^M:/CO7IO"_@C6M3MU1KC3;">ZB5Q\K.D;, ?;(K-^"0Q\'?#/\
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M [8H ]0_94_:"U3X\ZU\4+?4[2QLX_ _C&Z\/6A@#!IH(8XV$DF2?F.\],#
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MZ.Q1BI ^<T_;C\%H/^03\2?_  B-5_\ C%#_ +</@MS_ ,@OXDC_ +D?5?\
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M!X"/V[_ H_YAOQ)_\(75O_C%(_[=O@21&5M,^)#*PP0? FK<C_OQ7O\ BC%
M'SOH7[:WP\\-Z+:Z?9Z3\2H;6SC$42?\(-J[;5'3DP9JU_PWAX%_Z!OQ)_\
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M_P#C%?0&*,4 ?/I_;N\"D_\ (-^)7_A":M_\8H_X;O\  W_0-^)7_A":M_\
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M&* /GS_ANSP+_P! WXE?^$)JW_QBD/[=7@4_\PWXE?\ A":M_P#(]?0F*,4
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M+M+OIHS+H"W! CN@Z92:$AXV#J<;2QXVF@#WZBD1Q(@92&5AD$=Z6@ HHHH
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M#^CZIJO_ !YVE[?Q0377.!L5B"V3P,=3Q7R-XV_8M^)'[6&I?&#Q%J?BB_\
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M7\H^P?W5HV#^ZM'^HN%_Y^2^Y!_K+6_E7XG]7'_#WW]F3_HMWP__ /!D*/\
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M_P!!6;6A,A7?>:*2B@DTM=_Y"]W_ -=6_F:HCK5S7F_XG-U_UU;^=50F*I;
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M_LO$_P C/SJHK]%?^(7O]IS_ )Z?#K_P=R?_ !FC_B%[_:<_YZ?#K_P=R?\
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M\5?] 32__!BW_P :H_MKQ5_T!-+_ /!BW_QJ@#IJ*YG^VO%7_0$TO_P8M_\
M&J/[:\5?] 32_P#P8M_\:H Z:BN9_MKQ5_T!-+_\&+?_ !JC^VO%7_0$TO\
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MVO%7_0$TO_P8M_\ &J .FQ1BN9_MKQ5_T!-+_P#!BW_QJC^VO%7_ $!-+_\
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M7_0$TO\ \&+?_&J/[:\5?] 32_\ P8M_\:H Z;%&*YG^VO%7_0$TO_P8M_\
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M_#/Q/?>!_#_@GRK>_N]-(BOM1NV02.3+]Y(T#*H5<$D$DG(Q\'_\/5/VE?\
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MY+_C1_P]4_:5_P"BZ?$S_P 'DO\ C1_J+B?^?L?Q#_6*E_(_O1_606P/_K4
MYK^3<_\ !5/]I0K_ ,ET^)O_ (/)?\:^@O\ @FY_P74^.'P<_:=\*V/CKQQK
MGC[P3XBU2WTW5+/6)/M4T"S.(Q-!(?F5T9E.,[6&01W&.(X)Q5.FYQFG97MJ
M73XBHRDHN+5S^DBBFH^Y:=7QI] %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%!.!0!Y_P"*/^1BNO\ ?_H*IU>\
M3KG7[D_[?]!5&M"6P)P**'&]=OOFB@DN:N<ZO=?]=6JO4VKOC5[K_KJ:AH N
M>'_^0W:_]=!76>+/$5OX0\+:EJUT=MKI=K+=S'T2-"[?H#7):&=FL6Y]'!KJ
M_&7AFW\:^$-4T>ZW"UU:TELYBO79(A1L?@30K<RYMAN_*[;GY _&S_@H5\7M
M2_9W_9_\<3?$[Q-X!LOCIXSURZO)M%T:/5KC1])4[;2V@M_+9I-BINR 6)=C
MR*QT_P""G'QBTW]BO]IRZTSXL:IXCD^&^M:##X9\2:GH$6DZ^D-U<PQW/FV+
M)G9\Q5"Z DD_A[E\%_\ @EK\0?BE^R]\'O"M]XPU;X4^./V9_$^KVNC:K%I,
M=['JUNTA%O=1+*=K1M"Z\D'D,,<5UGB+_@A==?$?P)\6I/&7QI\0>*/B%\6(
M]*@N_$TNCV\"Z?!I]PEQ"B6T9$;99 ,DC@#CKG[&GBLOA%1J6NGVOUT_#S/G
MI8?&2ES0;V[E7_@G;\?-2UKXI:UK'B#]H;XM>.-#\->&Y]3U+3/%?PZ_X1_3
MX4&PF<731)N:/!^4'D,37#?\$M?^"GGQ.^,W[6^H:7\2-6M[CPG\;M+O_$WP
MTME,/F:3#:7,L?V9PH!#/"%E ?+8 ]<5['XX_P""9'QW^+GPO\2^"_%G[5NO
M:WX=\4Z4^EW5O_PA]C;L(W*9*R1D-DHK+UY#G.:M>(_^"%7PI\+W?PWU[X60
MP_#'QM\.M5M=076[*W:X?5XXT,<UO<([X*RJ3DC&,FN7ZQE[<U4L^?167PV^
M2ZFD:.,Y8\OV>_4^$?@U_P %E?C9%^RW\;](USQ5=:E\2M8U.R3X;736T(D6
M*?49;*5% 4!C&8L\@XSS7WQ_P2T_;UB^(7[!GPTO/B5X^T/4_BQXFL[EX[&]
MU"VM+_69ENIXHDCBRN2Q0("%Q7#>!O\ @W\\+^%OB'\)O$-UXTO-2F^&%YK%
MX8VTY$753>W,US#OPWR_9Y)B5QG=M'2O:?V3/^"3WPO_ &<OA7\/])US0=!\
M=>*_AV'_ +*\3W^EQI?VY-S)<(4.24V-(<8/;/6GF6*RN=.U%.][Z+K:W7H:
M82CC(U+SVM979\O^ O\ @I%\=O 'Q&_:ZU3XI6ND:/>?"WP/I_B'1?"=E<+>
M6FB231S-&KS@#S9&Q&9,$KG('%3?LH_M ?M+ZQ\3M2^$M]\4-%\3>+OB%\([
M'XB^&=;U714BA\.7ES((Y8#' !YD2*V4W _,HSP37T_KO_!,_0_&?QN^/7BK
M7->O+_3/CQX<L_#E[ID<"I_9T<$4D7F1R9.YCOR,C *]Z\N^$G_!%G4O VC>
M+I->^.'C36?%6K>$;/P/X=\06%M'I=YX7TRT<20)'Y;8D?<J[BV-P!!ZYK+Z
MU@7!Z)-I=+ZV7Y.]^Y7U?$J2NVUKU&_\$=OVH_B%\7_BA\;/ _C;QM?>/+'X
M>:G:P:5J>LZ/'HNLS^9&WG%[10#]GWK^ZD8#<#U/;YY_X*'_ /!2_P"*'@3_
M (*F1_#_ ,"_$R'3M)M)M(L]/MX%M%T"VNVD,FHPZS<3#<K"W5V18G#  < Y
MK[<_8C_X)ZZC^S-\7O&WQ)\:_$35/B=\1?'5I9Z9>:K<:?%I\4=G:@B&,11<
M%N<LY.3_ #\+_:)_X('P_''Q+\0K&W^+6M:'\-_BAXE3Q;KGAP:%:75PFHA=
MOF6]XX\R)3Z#L<<C.71Q6!^N3G4MRM6VTOU:_3N34HXMX>,8_%?OK;H??G@G
MQCIGQ \*6.M:+J5CK&E:E$L]M>64RS6]PA_B1UX9?>M:O+_V-_V>+C]E+]FO
MPG\/9O$4_BC_ (16S%C%J$UG%:-)$K'RU\N/Y1M7"YY)QD\FO4*^;JJ*FU!W
M5]#V*<I.*YEJ%>?_ +1?PO\ $7Q1\&V</A/Q9>>#O$&DW\6HV=W&ADM[AH\Y
M@N8P1YD#@D,N0>A'2O0*^>_^"DWQMUSX$? _0]3T/Q WA:34O%.FZ5>:FMBM
MZUK:S.PE98F!#$*,@8SQ69H<OJ7_  3\USXS^(O%VN_$35O"MEJWB'P\N@6R
M^%=,:VC@*W"W"7<K2L6FF26.,J#A5 (YS70W_P  /C)\3#I=CXV^(.@6VC:-
M!/YB>'+*:UF\03O"\,9NR[D+$-Y9HH^&8#D# 'FWP$_;V/AKQ'\2$\0>//\
MA8G@WP7IMA>0ZN=%&E:D]Y<RM$MDMN=@E#'9MD"J SX)P.-OXI?\%)-4L;+3
M=/T'P3JMOXL7Q#I5EJ.E7$]I<,MC>2,J21R1S&-C(4:,?-\C#Y@.#0 [P?\
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M\5/"MEJ'AWQ%X\^&NHM8CQ!?Q?98)+*2S%S%=20Q AIT5MIC7"LP!.!FN?\
MBG^T#\6M,_8Q^%/BK1;S388=6M=#G\1ZU<L&OKAKBXMXVA@A"[%,GF$ER<!<
M@#)R/<?@Y^RU;_"CX4>*M(N/$&I>(->\;R7-WK>NWD:B:\N)H_+W"-<*B(@5
M50< *.:J^(?V1H?$/[*7AKX7MK<T,/AU-+07XMPSS?8I8I!\FX ;_* Z\9H
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MM$9F.TM;R<D]P !BN>A+*HJ*FTW&]]-'?MZ=#2I]>;?*FD[6\K?YG2?LY?\
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M<1A=H9L@@]!S7V >::$Q0!YS^R/\";C]F?\ 9\\/>![C4X]8?P^DL2WD=O\
M9UF5IGD7Y,D*0&Q@<<<5Z1110 4444 %%%% !1110 4444 1W47VBVDC_P">
MBE?S%>#Q_L:W"?L'S?!H:\GVB:PDLAJAM<J-]PTV[RR??;C->^44 ?.'BO\
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M_$)G\&O^BB_$;_OJV_\ C=?JOM]Q2[?>NC_6/,O^?S_#_(C^R<'_ "(_*?\
MXA,_@U_T47XC?]]6W_QNC_B$S^#7_11?B-_WU;?_ !NOU8V^]&WWH_UCS+_G
M\_P_R'_9.#_D1^4__$)G\&O^BB_$;_OJV_\ C='_ !"9_!K_ **+\1O^^K;_
M .-U^K&WWHV^]'^L>9?\_G^'^0?V3@_Y$?E/_P 0F?P:_P"BB_$;_OJV_P#C
M='_$)G\&O^BB_$;_ +ZMO_C=?JQM]Z-OO1_K'F7_ #^?X?Y!_9.#_D1^4_\
MQ"9_!K_HHOQ&_P"^K;_XW1_Q"9_!K_HHOQ&_[ZMO_C=?JQM]Z-OO1_K'F7_/
MY_A_D']DX/\ D1^4_P#Q"9_!K_HHOQ&_[ZMO_C='_$)G\&O^BB_$;_OJV_\
MC=?JQM]Z-OO1_K'F7_/Y_A_D']DX/^1'Y3_\0F?P:_Z*+\1O^^K;_P"-T?\
M$)G\&O\ HHOQ&_[ZMO\ XW7ZL;?>C;[T?ZQYE_S^?X?Y!_9.#_D1^4__ !"9
M_!K_ **+\1O^^K;_ .-T?\0F?P:_Z*+\1O\ OJV_^-U^K&WWHV^]'^L>9?\
M/Y_A_D']DX/^1'Y3_P#$)G\&O^BB_$;_ +ZMO_C='_$)G\&O^BB_$;_OJV_^
M-U^K&WWHV^]'^L>9?\_G^'^0?V3@_P"1'Y3_ /$)G\&O^BB_$;_OJV_^-T?\
M0F?P:_Z*+\1O^^K;_P"-U^K&WWHV^]'^L>9?\_G^'^0?V3@_Y$?E/_Q"9_!K
M_HHOQ&_[ZMO_ (W1_P 0F?P:_P"BB_$;_OJV_P#C=?JQM]Z-OO1_K'F7_/Y_
MA_D']DX/^1'Y3_\ $)G\&O\ HHOQ&_[ZMO\ XW1_Q"9_!K_HHOQ&_P"^K;_X
MW7ZL;?>C;[T?ZQYE_P _G^'^0?V3@_Y$?E/_ ,0F?P:_Z*+\1O\ OJV_^-T?
M\0F?P:_Z*+\1O^^K;_XW7ZL;?>C;[T?ZQYE_S^?X?Y!_9.#_ )$?E/\ \0F?
MP:_Z*+\1O^^K;_XW1_Q"9_!K_HHOQ&_[ZMO_ (W7ZL;?>C;[T?ZQYE_S^?X?
MY!_9.#_D1^4__$)G\&_^BB_$;_OJV_\ C=>X?L+_ /!O[\$_V'/BO;^.+.;Q
M%XR\3Z<Q;3+C6Y8VATQB,>9'$BJOF=<.V2,\8/-?= &.].W5C6S[,*L'3G5;
M3*AEF%@^:,%<:J!:=1NHW5Y)W!11NHW4 %%&ZC=0 44;J-U !11NHW4 %%&Z
MC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !0>
ME&ZD)XH X+Q-_P AVY_WOZ"J-7O$ISKMS_O?TJC6AF%%!.!10!=U@XU:Y_ZZ
MM_.J^=QJSK'.KW/_ %U;^=5]N* )]/+1WD6UMK;@ W]WWK;?P/>N>/$FMX]
M8N/_ !RL&Q;-[#_OK_.O0!\J_P"-3(J)SC>!K['_ ",FN=/6+_XBE_X02\_Z
M&/6_^^HO_B*W;;4[>]FFCAN(9I+=MLJ(X9HCZ,!T/UJ7=_D5+TT8SFT\"WVQ
M?^*DUL8_ZY'_ -DIP\#7P_YF36ORB_\ B*Z-FQ4%EJ5OJ2,UO<0S*KE"8W#
M,."#CN.XHL/38P_^$&O<?\C)K7Y1?_$4+X$O!_S,FM?^0O\ XBNBR?\ 9J'4
M-3M]+@\ZYN(;>($ O*X102<#D^IHY;L#"_X0:]4X_P"$EUK_ ,A?_$4K>!+X
M_P#,RZW^'E?_ !%;DFH6\=]';M/"MQ(I=(BX#NHZD#J0/6H;'Q'I^IZA-:V]
M]9W%U;_ZV&*96DB_WE!R/QJN5[I"YD9/_""7A'_(R:T/IY7_ ,12?\(#>_\
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MW_H9M=_.+_XBNEHH YL> [T/N_X2;7/_ "#_ /$4?\('>[]W_"3:YW_YX_\
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M>-OB+H/PTT*35/$>M:3H.FPG#W6H7<=M"IZX+N0,^V:X+_ANWX*_]%:^'/\
MX45I_P#'*UA0JS5X1;^3,Y581=I-([,^ [[_ *&;7/\ R#_\;IO_  @FH?\
M0S:Y_P"0?_B*X[_ANWX*_P#16OAS_P"%%:?_ !RD_P"&[O@I_P!%:^'/_A0V
MG_Q=7]4K_P C^YD_6*7\R^\[+_A!-0_Z&;7/_(/_ ,11_P ()J'_ $,VN?\
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M_P 5Z/;ZCI=]9ZEI]TN^&YMIEFAF'JKJ2"/H:SJ4:D-9Q:]47&I"7PM,Q_\
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MZ:B@#F?^$$U#_H9M<_\ (/\ \11_P@FH?]#-KG_D'_XBNFHH YG_ (034/\
MH9M<_P#(/_Q%'_"":A_T,VN?^0?_ (BNFHH YG_A!-0_Z&;7/_(/_P 11_P@
MFH?]#-KG_D'_ .(KIJ* .9_X034/^AFUS_R#_P#$4?\ "":A_P!#-KG_ )!_
M^(KIJ* .9_X034/^AFUS_P @_P#Q%'_"":A_T,VN?^0?_B*Z:B@#F?\ A!-0
M_P"AFUS_ ,@__$4?\()J'_0S:Y_Y!_\ B*Z:B@#F?^$$U#_H9M<_\@__ !%'
M_"":A_T,VN?^0?\ XBNFHH YG_A!-0_Z&;7/_(/_ ,11_P ()J'_ $,VN?\
MD'_XBNFHH YG_A!-0_Z&;7/_ "#_ /$4?\()J'_0S:Y_Y!_^(KIJ* .9_P"$
M$U#_ *&;7/\ R#_\11_P@FH?]#-KG_D'_P"(KIJ* .9_X034/^AFUS_R#_\
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MR#@C([@@CZTZXNH[.VDFFDCBAB4N[NP544<DDG@ >M $E%-AG2XA62-UDCD
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M'E9BD2YX1<#ZT >AT444 %%%!.T4 !.*,U^?/[</[2,B?M0ZKXBT>]\032_
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M]L_4-)_8#L_BY)HEI+KEWIT++IPF*VINY)UMP"_41>8P.3SM]Z /H,N N<C
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M7I6E[S]GB8Q(\LQ7H9'9OO'D  =J^#_(3^ZOY5]4_P#!;0_\;4_C5_V'%_\
M2>&OEBOW;**<88.FHJVB_(_.<9)NM*_=C?(3^ZOY4>0G]U?RIU%>E9'*-\A/
M[J_E1Y"?W5_*G4460#?(3^ZOY4>0G]U?RIU%%D WR$_NK^5'D)_=7\J=119
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M:R7>EN_3=$298_6-B/X:TO"?[/NK?'GPS\8M)T'X*^%]<U+6?'&O6MKXZO\
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MMDMX(1_LH@ %>;FW&$,5AI4*5-KF5M6=.#R*5*JJDY;=C8HHHKX,^D"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/2B@]*
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M,P?#?_H0O!W_ ()[?_XB@#:_X6UX5_Z&;P__ .#&'_XJC_A;7A7_ *&;P_\
M^#&'_P"*K%_X9@^&_P#T(7@[_P $]O\ _$4?\,P?#?\ Z$+P=_X)[?\ ^(H
MVO\ A;7A7_H9O#__ (,8?_BJ/^%M>%?^AF\/_P#@QA_^*K%_X9@^&_\ T(7@
M[_P3V_\ \11_PS!\-_\ H0O!W_@GM_\ XB@#:_X6UX5_Z&;P_P#^#&'_ .*H
M_P"%M>%?^AF\/_\ @QA_^*K%_P"&8/AO_P!"%X._\$]O_P#$4?\ #,'PW_Z$
M+P=_X)[?_P"(H VO^%M>%?\ H9O#_P#X,8?_ (JC_A;7A7_H9O#_ /X,8?\
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M;_\ 0A>#O_!/;_\ Q%'_  S!\-_^A"\'?^">W_\ B* -K_A;7A7_ *&;P_\
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M;P__ .#&'_XJC_A;7A7_ *&;P_\ ^#&'_P"*K%_X9@^&_P#T(7@[_P $]O\
M_$4?\,P?#?\ Z$+P=_X)[?\ ^(H VO\ A;7A7_H9O#__ (,8?_BJ/^%M>%?^
MAF\/_P#@QA_^*K%_X9@^&_\ T(7@[_P3V_\ \11_PS!\-_\ H0O!W_@GM_\
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M$]O_ /$4?\,P?#?_ *$+P=_X)[?_ .(H VO^%M>%?^AF\/\ _@QA_P#BJ/\
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M /0A>#O_  3V_P#\11_PS!\-_P#H0O!W_@GM_P#XB@#:_P"%M>%?^AF\/_\
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M(H VO^%M>%?^AF\/_P#@QA_^*H_X6UX5_P"AF\/_ /@QA_\ BJQ?^&8/AO\
M]"%X._\ !/;_ /Q%'_#,'PW_ .A"\'?^">W_ /B* -K_ (6UX5_Z&;P__P"#
M&'_XJC_A;7A7_H9O#_\ X,8?_BJQ?^&8/AO_ -"%X._\$]O_ /$4?\,P?#?_
M *$+P=_X)[?_ .(H VO^%M>%?^AF\/\ _@QA_P#BJ/\ A;7A7_H9O#__ (,8
M?_BJQ?\ AF#X;_\ 0A>#O_!/;_\ Q%'_  S!\-_^A"\'?^">W_\ B* -K_A;
M7A7_ *&;P_\ ^#&'_P"*H_X6UX5_Z&;P_P#^#&'_ .*K%_X9@^&__0A>#O\
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M?_BJ/^%M>%?^AF\/_P#@QA_^*K%_X9@^&_\ T(7@[_P3V_\ \11_PS!\-_\
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M/AO_ -"%X._\$]O_ /$4?\,P?#?_ *$+P=_X)[?_ .(H VO^%M>%?^AF\/\
M_@QA_P#BJ/\ A;7A7_H9O#__ (,8?_BJQ?\ AF#X;_\ 0A>#O_!/;_\ Q%'_
M  S!\-_^A"\'?^">W_\ B* -K_A;7A7_ *&;P_\ ^#&'_P"*H_X6UX5_Z&;P
M_P#^#&'_ .*K%_X9@^&__0A>#O\ P3V__P 11_PS!\-_^A"\'?\ @GM__B*
M-K_A;7A7_H9O#_\ X,8?_BJ#\6_"H_YF;P__ .#&'_XJL7_AF#X;_P#0A>#O
M_!/;_P#Q%'_#,'PW_P"A"\'_ /@GM_\ XB@"GJ>K6NLZC+=65Q;WEK,V4FAD
M$D;CIPPX-0T3^'-/\(W#:;I5C::;I]JVV&VMHEBBB!YPJJ !R3TH)P*J),AD
MDA1J*8[[VHJB37UG_D+7/_75OYU JY%6-9_Y"MQ_UT;^=5TZ4 6M#&-9MO\
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M+]I_3]5\1:AJ7B;Q=>>(+2QN[);^]TO7M&:2V17C%GAK6ZTU6+/O 4D9.<T
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M-?G39>*/B9XD^'OC[PGI,7B!H?@7JNN:A-=,TKR:W>_:))-,MD/WI4BC<S,
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M0>E 'D/[27[:/A']F>6WM-6DN;[5KJ,RQ6%FH:4)_?;) 53SC/7!P.#7C_\
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M[]X4_P"A7\0_]]1?_%5\";?<T;?<T?V;2#_B+/$7_/R/_@*/OO\ X>_>%/\
MH5_$/_?47_Q5'_#W[PI_T*_B'_OJ+_XJO@3;[FC;[FC^S:0?\19XB_Y^1_\
M 4???_#W[PI_T*_B'_OJ+_XJC_A[]X4_Z%?Q#_WU%_\ %5\";?<T;?<T?V;2
M#_B+/$7_ #\C_P" H^^_^'OWA3_H5_$/_?47_P 51_P]^\*?]"OXA_[ZB_\
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MVD'_ !%GB+_GY'_P%'WW_P /?O"G_0K^(?\ OJ+_ .*H_P"'OWA3_H5_$/\
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MGPJ;Q#+X/UFY76-<CM]%\8R:+>_9;VT%M;QPHUHD0E<RF-9#)Y3289ACC %
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M"]Z .F Q2%<US7_"S8O^@/X@_P#!>]'_  LV+_H#^(/_  7O0!T@3%.KF?\
MA9L7_0'\0?\ @O>C_A9L7_0'\0?^"]Z .FHKF?\ A9L7_0'\0?\ @O>C_A9L
M7_0'\0?^"]Z .FI"N37-?\+-B_Z _B#_ ,%[T?\ "S8O^@/X@_\ !>] '2[1
M2+'M[L?K7-_\+-B_Z _B#_P7O1_PLV+_ * _B#_P7O0!TNP4GE+D>PQ7-_\
M"S8O^@/X@_\ !>]'_"S8O^@/X@_\%[T =(8PWX4>5D=>,GCUKF_^%FQ?] ?Q
M!_X+WH_X6;%_T!_$'_@O>@#-^'O[/OA_X;?$7Q-XLL_[2O/$'BMU^V7=]=O<
M-%$A)2WA#<10JS,0BX&6)K2^('PFTGXDZIX?OM0^U1WWA?4$U+3KBWE\J2&0
M JRYQS&Z,4=#PRG%'_"S8O\ H#^(/_!>]'_"S8O^@/X@_P#!>] '2", 8QGG
M(XZ4['%<S_PLV+_H#^(/_!>]'_"S8O\ H#^(/_!>] '2[:3R\ONKF_\ A9L7
M_0'\0?\ @O>C_A9L7_0'\0?^"]Z %TSX3Z/IGQ2U+QDL<TVO:G90Z:TTLFX0
M6T;,PBC'\"EV+L!U;![5TM<S_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O0!T
MU%<S_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O0!TU%<S_P +-B_Z _B#_P %
M[T?\+-B_Z _B#_P7O0!TU%<S_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O0!T
MU%<S_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O0!TU-"8[G\:YO\ X6;%_P!
M?Q!_X+WH_P"%FQ?] ?Q!_P""]Z .D:)64CUIU<S_ ,+-B_Z _B#_ ,%[T?\
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M^@/X@_\ !>]'_"S8O^@/X@_\%[T78^5'2;*-E<W_ ,+-B_Z _B#_ ,%[T?\
M"S8O^@/X@_\ !>]%V'*CI-E&RN;_ .%FQ?\ 0'\0?^"]Z/\ A9L7_0'\0?\
M@O>B[#E1TFRC97-_\+-B_P"@/X@_\%[T?\+-B_Z _B#_ ,%[T78<J.DV4;*Y
MO_A9L7_0'\0?^"]Z/^%FQ?\ 0'\0?^"]Z+L.5'2;*-E<W_PLV+_H#^(/_!>]
M'_"S8O\ H#^(/_!>]%V'*CI-E&RN;_X6;%_T!_$'_@O>C_A9L7_0'\0?^"]Z
M+L.5'2;*-E<W_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O1=ARHZ391LKF_\
MA9L7_0'\0?\ @O>C_A9L7_0'\0?^"]Z+L.5'2;*-E<W_ ,+-B_Z _B#_ ,%[
MT?\ "S8O^@/X@_\ !>]%V'*CI-E&RN;_ .%FQ?\ 0'\0?^"]Z/\ A9L7_0'\
M0?\ @O>B[#E1TFRC97-_\+-B_P"@/X@_\%[T?\+-B_Z _B#_ ,%[T78<J.DV
M4;*YO_A9L7_0'\0?^"]Z/^%FQ?\ 0'\0?^"]Z+L.5'2;*-E<W_PLV+_H#^(/
M_!>]'_"S8O\ H#^(/_!>]%V'*CI-E&RN;_X6;%_T!_$'_@O>C_A9L7_0'\0?
M^"]Z+L.5'2;*-E<W_P +-B_Z _B#_P %[T?\+-B_Z _B#_P7O1=ARHZ391LK
MF_\ A9L7_0'\0?\ @O>C_A9L7_0'\0?^"]Z+L.5'2;*-E<W_ ,+-B_Z _B#_
M ,%[T?\ "S8O^@/X@_\ !>]%V'*CI-E*J[:YK_A9L7_0'\0?^"]Z/^%FQ?\
M0'\0?^"]Z0[(Z:BN9_X6;%_T!_$'_@O>C_A9L7_0'\0?^"]Z .FHKF?^%FQ?
M] ?Q!_X+WH_X6;%_T!_$'_@O>@#IJ*YG_A9L7_0'\0?^"]Z/^%FQ?] ?Q!_X
M+WH Z:BN9_X6;%_T!_$'_@O>C_A9L7_0'\0?^"]Z .FHKF?^%FQ?] ?Q!_X+
MWH_X6;%_T!_$'_@O>@#IJ*YG_A9L7_0'\0?^"]Z/^%FQ?] ?Q!_X+WH Z:BN
M9_X6;%_T!_$'_@O>C_A9L7_0'\0?^"]Z .FHKF?^%FQ?] ?Q!_X+WH_X6;%_
MT!_$'_@O>@#IJ*YG_A9L7_0'\0?^"]Z/^%FQ_P#0'\0_^"]J ,+Q9_R,5U_O
M_P!!6<3@58U?4?[6U*:X$-Q;^8V?+GC*2)QW':JYZ5H3(C)S11102=!JW_(4
MN/\ KHW\ZKU8U7_D*W7_ %U;^=5Z +FA\ZM;?]=!79A<5QFA?\A>V_ZZ"NTJ
M9%1#%&***DH,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HK@?VD/C]I_
M[.'PV;7KRSNM6NKJ[@TS2],M2!/JE[.X2&!">%+,<ECP ">V* .^Q1BO!5_:
M4^)7@/44C\=?#.WT^SU"QN[JTOM%U5M2M[.6"!IO(NSY2^5O"E5D&5+<=Q72
M?!;]K?PO\5O@HGBZZU'3=':QT>UU?7+5[CS/[$2> 3CS&P.-F2#CD T >K8H
MQ7G=M^UE\.+WXAVOA6+QEH;>(+P(8;/S_P!X[.GF*F>@<IA@A.X@]*=X1_:O
M^&_COQ%J&E:3XU\/7M]I<4L]Q$ET!LCB.)7#'"LJ$?,RDA>^* /0L48KS'P?
M^V=\*_'TE\ND^.O#UXVEV;ZC= 7&SR+9&56F;=C$>64;NASP33M._;'^&&J^
M$+S7X?&V@_V-87,5G<W3S^6MO++_ *M7# $;^=I(PW;- 'IF*,5R_P *_C3X
M5^-NBW&H>%-=T_7+.SG-K.]L^3!* "4=3@J<$'! X-<AKW[:_P -=(7Q)#!X
MLT>_U/PS975[<V4$V97%N"953C#E2,-M)VGKB@#U?%&*\5\,?M]?#/4_A1X1
M\5:QXHTGP['XQL4O;6VNYB9(@<;PV!PJ,=I<@+D=:Z37OVM_AIX:\:+X=OO&
MWAZUUIK<7?V:2Z&5A,?FB0G[H0Q@L&)P10!Z-BC%>;^%?VOOAGXUT/7-2TSQ
MKH-Q8>&K<76ISF;RULX3G;*VX#Y#@X8<$\ FH]#_ &R?A?XE\-ZOK%CXX\/S
M:;H,4<VHS_:-OV)78JGF*P#*6((4$9/& <B@#TS%&*YOX9?%SPW\9?#YU3PO
MK5CK5@LK0M);/DQ.,91U.&5AD<, >1724 &*,444 &*,444 &*,444 &*,44
M4 &*,49KP_PO^W%X9;5_%R^*;S2_"NFZ'XDN?#FE75S>;FUJ6VACDG9$VY^4
MN5"C<3M/?B@#W#%&*Y/3/CCX2UGX4MXYM=?TV?PBEL]XVJ+)_HZ1)D.Q..-N
MU@<\C!STK"^-'[2_A_X6>&MT6K:!-KVH:?\ ;](L+V_%JFH(61%;S,-M0M(B
MAL'E@!DT >DXHQ7&V?Q]\)2^#=*UR7Q!I"Z?K%Z-,MKA9]T4]WO9#"AQ\S!T
M<=/X"3@ U#\-?VE/ GQA\0WFD^&?%6CZWJ-BIDF@MILML#%2ZY^^@;@LF1GO
MS0!W&*,444 &*,44$X% !BC%>":Y^U1XR\;?$?Q7H?PO\$Z9XGM? ERMAK&H
M:IK']GQ2WA02-:VX$;EW567<S;5#-CFMZT_;4\%Z+X!\-ZOXTOE^'^H>(H&F
M&CZX3%?6I1]DF] ,A P_UAPI!!S@T >NXHQ7F_BS]K[X8^!O$?\ 9&K>-O#]
MGJ7V47OV=KD,WD&,RB7C(\LQ@L&Z8'6J,W[<?PE@\,V>L-X^\._V;J$TD%M.
M)RPF:/'F$ #.U=PRV-HSUH ]6Q1BO/O'/[5?PY^&NIZ39Z[XRT'3;C6XH[BR
M62Y!$T3D!)<C(6-B0 [$*?6N'\'?MX>'_B5XV?1=!DTEIK/Q?)X7NA>7YADE
M5(&D\^!=A$A9E91'D'"ELXQ0![SBC%>;:)^U_P##+Q'J>L6=CXW\/7-QH-O-
M=WJI<\1Q0Y\UP>CJF#N*%MN.<5?^%G[37@'XV:W=:;X3\6:-KU_8PK<306D^
MYEB;I(/[R9XW+D9XH [K%&*X/X@?M._#_P"%GC*U\/\ B+Q=HFCZQ>!&2VN9
M]K*KMM0N>D88\ N0#7'_  :_:[7XX_M+>-O!NBVFER:'X("07%]]L?[7<7)"
MEML/EA1$I8KNWY++P,'- 'MF*,444 &*,444 &*,444 &*,44'I0 AP!VI/^
M^:^0OVT_^"B>J?!SQ_-X3\(V=C)J%BJF^O;I3(L;L,B-%!'.,9)Z9Z=Z\._X
M>B_%;_GIH/\ X!?_ &5=M/ 59QYD?G>:>*&1X'$RPM24G*+L[1NK^I^EW_?-
M'_?-?FC_ ,/1?BM_STT'_P  O_LJ/^'HOQ6_YZ:#_P" 7_V57_9M8\__ (C#
MD']__P !_P""?I=_WS1_WS7YH_\ #T7XK?\ /30?_ +_ .RH_P"'HOQ6_P">
MF@_^ 7_V5']FU@_XC#D']_\ \!_X)^EW_?-'_?-?FC_P]%^*W_/30?\ P"_^
MRH_X>B_%;_GIH/\ X!?_ &5']FU@_P"(PY!_?_\  ?\ @GZ7?]\T?]\U^:/_
M  ]%^*W_ #TT'_P"_P#LJ/\ AZ+\5O\ GIH/_@%_]E1_9M8/^(PY!_?_ / ?
M^"?I=_WS1_WS7YH_\/1?BM_STT'_ , O_LJ/^'HOQ6_YZ:#_ . 7_P!E1_9M
M8/\ B,.0?W__  '_ ()^EW_?-'_?-?FC_P /1?BM_P ]-!_\ O\ [*C_ (>B
M_%;_ )Z:#_X!?_94?V;6#_B,.0?W_P#P'_@GZ7?]\T?]\U^:/_#T7XK?\]-!
M_P# +_[*C_AZ+\5O^>F@_P#@%_\ 94?V;6#_ (C#D']__P !_P""?I=_WS1_
MWS7YH_\ #T7XK?\ /30?_ +_ .RH_P"'HOQ6_P">F@_^ 7_V5']FU@_XC#D'
M]_\ \!_X)^EW_?-'_?-?FC_P]%^*W_/30?\ P"_^RH_X>B_%;_GIH/\ X!?_
M &5']FU@_P"(PY!_?_\  ?\ @GZ7?]\T?]\U^:/_  ]%^*W_ #TT'_P"_P#L
MJ/\ AZ+\5O\ GIH/_@%_]E1_9M8/^(PY!_?_ / ?^"?I=_WS1_WS7YH_\/1?
MBM_STT'_ , O_LJ/^'HOQ6_YZ:#_ . 7_P!E1_9M8/\ B,.0?W__  '_ ()^
MEW_?-'_?-?FC_P /1?BM_P ]-!_\ O\ [*C_ (>B_%;_ )Z:#_X!?_94?V;6
M#_B,.0?W_P#P'_@GZ7?]\T?]\U^:/_#T7XK?\]-!_P# +_[*C_AZ+\5O^>F@
M_P#@%_\ 94?V;6#_ (C#D']__P !_P""?I=_WS1_WS7YH_\ #T7XK?\ /30?
M_ +_ .RH_P"'HOQ6_P">F@_^ 7_V5']FU@_XC#D']_\ \!_X)^EW_?-'_?-?
MFC_P]%^*W_/30?\ P"_^RH_X>B_%;_GIH/\ X!?_ &5']FU@_P"(PY!_?_\
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M1]5PLFI[I-6OZ'M&*,445R'W 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
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M)CC624!=V 0 :^O_  %I5QH7@?1[&Z4+<V=C!!* =P#K&H;GOR#S6J,"EW4
M%%&ZC=0 44;J-U !2-RII=U!.: /F']KS_@G?;_M!>,O^$FT/5(M#UN>-8KM
M9H3)!=A1A6.,%6 P,\@@#CO7C/\ PZ&\8*?F\6>'_P +:7_&OT"P#WI#'G^*
MNRGCZT%RIGPN9>'&18[$2Q5>D^:6KLVKL_/[_AT1XN_Z&S0/_ :6C_AT/XO_
M .ALT'_P&EK] /+_ -JG;?>M/[2K=SA_XA/P[_S[?_@3/S]_X=#^+_\ H;-!
M_P# :6C_ (=#^+_^ALT'_P !I:_0+;[T;?>C^TJW</\ B$_#O_/M_P#@3/S]
M_P"'0_B__H;-!_\  :6C_AT/XO\ ^ALT'_P&EK] MOO1M]Z/[2K=P_XA/P[_
M ,^W_P"!,_/W_AT/XO\ ^ALT'_P&EH_X=#^+_P#H;-!_\!I:_0+;[T;?>C^T
MJW</^(3\._\ /M_^!,_/W_AT/XO_ .ALT'_P&EH_X=#^+_\ H;-!_P# :6OT
M"V^]&WWH_M*MW#_B$_#O_/M_^!,_/W_AT/XO_P"ALT'_ ,!I:/\ AT/XO_Z&
MS0?_  &EK] MOO1M]Z/[2K=P_P"(3\._\^W_ .!,_/W_ (=#^+_^ALT'_P !
MI:/^'0_B_P#Z&S0?_ :6OT"V^]&WWH_M*MW#_B$_#O\ S[?_ ($S\_?^'0_B
M_P#Z&S0?_ :6C_AT/XO_ .ALT'_P&EK] MOO1M]Z/[2K=P_XA/P[_P ^W_X$
MS\_?^'0_B_\ Z&S0?_ :6C_AT/XO_P"ALT'_ ,!I:_0+;[T;?>C^TJW</^(3
M\._\^W_X$S\_?^'0_B__ *&S0?\ P&EH_P"'0_B__H;-!_\  :6OT"V^]&WW
MH_M*MW#_ (A/P[_S[?\ X$S\_?\ AT/XO_Z&S0?_  &EH_X=#^+_ /H;-!_\
M!I:_0+;[T;?>C^TJW</^(3\._P#/M_\ @3/S]_X=#^+_ /H;-!_\!I:/^'0_
MB_\ Z&S0?_ :6OT"V^]&WWH_M*MW#_B$_#O_ #[?_@3/S]_X=#^+_P#H;-!_
M\!I:/^'0_B__ *&S0?\ P&EK] MOO1M]Z/[2K=P_XA/P[_S[?_@3/S]_X=#^
M+_\ H;-!_P# :6C_ (=#^+_^ALT'_P !I:_0+;[T;?>C^TJW</\ B$_#O_/M
M_P#@3/S]_P"'0_B__H;-!_\  :6C_AT/XO\ ^ALT'_P&EK] MOO1M]Z/[2K=
MP_XA/P[_ ,^W_P"!,_/W_AT/XO\ ^ALT'_P&EH_X=#^+_P#H;-!_\!I:_0+;
M[T;?>C^TJW</^(3\._\ /M_^!,_/W_AT/XO_ .ALT'_P&EH_X=#^+_\ H;-!
M_P# :6OT"V^]&WWH_M*MW#_B$_#O_/M_^!,_/W_AT/XO_P"ALT'_ ,!I:/\
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M1NH **-U&: /./%O_(R7G^__ $%9U:/BW_D9+S_?_H*SJT)D%%%%!)T>J?\
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M?_\ *C7L=% 'CF?V@/\ JC__ )4:,_M ?]4?_P#*C7L=&<4 >.9_: _ZH_\
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M: _ZH_\ ^5&C9^T!_P!4?_\ *C7LE&: /&]G[0'_ %1__P J-&S]H#_JC_\
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M +6G_/1/SH^UI_ST3\Z.5AROL>0;/V@/^J/_ /E1HV?M ?\ 5'__ "HUZ_\
M:T_YZ)^='VM/^>B?G1RL.5]CR#9^T!_U1_\ \J-&S]H#_JC_ /Y4:]?^UI_S
MT3\Z/M:?\]$_.CE8<K['D&S]H#_JC_\ Y4:-G[0'_5'_ /RHUZ_]K3_GHGYT
M?:T_YZ)^='*PY7V/(-G[0'_5'_\ RHT;/V@/^J/_ /E1KU_[6G_/1/SH^UI_
MST3\Z.5AROL>0;/V@/\ JC__ )4:-G[0'_5'_P#RHUZ_]K3_ )Z)^='VN/\
MYZ)^='*PY7V/(-G[0'_5'_\ RHT;/V@/^J/_ /E1KV%9UD/RLII](D\;V?M
M?]4?_P#*C1L_: _ZH_\ ^5&O9** /&]G[0'_ %1__P J-&S]H#_JC_\ Y4:]
MDHH \;V?M ?]4?\ _*C1L_: _P"J/_\ E1KV2B@#QO9^T!_U1_\ \J-&S]H#
M_JC_ /Y4:]DHH \;V?M ?]4?_P#*C1L_: _ZH_\ ^5&O9** /&]G[0'_ %1_
M_P J-&S]H#_JC_\ Y4:]DHH \;V?M ?]4?\ _*C1L_: _P"J/_\ E1KV2B@#
MQO9^T!_U1_\ \J-&S]H#_JC_ /Y4:]DHH \;V?M ?]4?_P#*C1L_: _ZH_\
M^5&O9** /&]G[0'_ %1__P J-&S]H#_JC_\ Y4:]DHH \;V?M ?]4?\ _*C1
ML_: _P"J/_\ E1KV2B@#QO9^T!_U1_\ \J-&S]H#_JC_ /Y4:]DHH \;V?M
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M>'](T;X=^)-2\8:Y9W6HOHK7-O!]CM+>41-<-<%C$T;N0(RI._.>,&N6TO\
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MQCK6B:6=$T5+32QIMII]NY4RR-'O<O/)L0,V0 %P% H ]K!S1110 444$X%
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MT%X__P"AZ\9?^#NY_P#BZY&BCZO2_E7W(/[+P?\ SZC_ . K_(Z[_AH+Q_\
M]#UXR_\ !W<__%T?\-!>/_\ H>O&7_@[N?\ XNN1HH^KTOY5]R#^R\'_ ,^H
M_P#@*_R.N_X:"\?_ /0]>,O_  =W/_Q='_#07C__ *'KQE_X.[G_ .+KD:*/
MJ]+^5?<@_LO!_P#/J/\ X"O\CKO^&@O'_P#T/7C+_P '=S_\71_PT%X__P"A
MZ\9?^#NY_P#BZY&BCZO2_E7W(/[+P?\ SZC_ . K_(Z[_AH+Q_\ ]#UXR_\
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M&N&1XV !45:\)_\ !-K_ (5_;Q:QX?\ &TVB>/8=;FUI=6L=%MX+!3/ EO-
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M?S\[J-U?T#?\0W7[-_\ S[^-/_!X_P#A1_Q#=?LW_P#/OXT_\'C_ .%'^NN
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MO_!F] '68H Q7)_\*FA_Z#WBK_P9O1_PJ:'_ *#WBK_P9O0!UA&:,?SKD_\
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M_P#0>\5?^#-Z/^%30_\ 0>\5?^#-Z .LHKD_^%30_P#0>\5?^#-Z/^%30_\
M0>\5?^#-Z .LHKD_^%30_P#0>\5?^#-Z/^%30_\ 0>\5?^#-Z .LH/-<G_PJ
M:'_H/>*O_!F]'_"IH?\ H/>*O_!F] '6 8H/-<G_ ,*FA_Z#WBK_ ,&;T?\
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M1P: ):*CN;R&RM7FFECAAC7<\CL%51ZDG@"FVNI6]\SK#<0S-&0'".&VD@$
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MQ ;*_P#H(G]T?\C^FC_A\/\ LU_]%=\)_P#?]_\ XFC_ (?#_LU_]%=\)_\
M?]__ (FOYEZ*/]1L-_/+\ _X@-E?_01/[H_Y']-'_#X?]FO_ **[X3_[_O\
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MC_V6R.O')K,D_P""</P4DE\-/_PK_15?P?8RZ;I#*'!LK:3?OB!W<H?,?@Y
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MCV-3^5_<'/'N>Y45X;_P\S_9[_Z+-\.?_!Y!_P#%4?\ #S/]GO\ Z+-\.?\
MP>0?_%4>QJ?RO[@YX]SW*BO#?^'F?[/?_19OAS_X/(/_ (JC_AYG^SW_ -%F
M^'/_ (/(/_BJ/8U/Y7]P<\>Y[E17AO\ P\S_ &>_^BS?#G_P>0?_ !5'_#S/
M]GO_ *+-\.?_  >0?_%4>QJ?RO[@YX]SW*BO#?\ AYG^SW_T6;X<_P#@\@_^
M*H_X>9_L]_\ 19OAS_X/(/\ XJCV-3^5_<'/'N>Y45X;_P /,_V>_P#HLWPY
M_P#!Y!_\51_P\S_9[_Z+-\.?_!Y!_P#%4>QJ?RO[@YX]SW*BO#?^'F?[/?\
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M_!Y!_P#%4G_#S+]GW_HLOPY_\'D'_P 53]C4_E?W!SQ[GN=%>&?\/,OV??\
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MCV-3^5_<'/'N>Y45X;_P\T_9[_Z+-\.?_![!_P#%4?\ #S3]GO\ Z+-\.?\
MP>P?_%4>QJ?RO[@YX]SW*BO#?^'FG[/?_19OAS_X/8/_ (J@_P#!33]GL?\
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M57M9]W]X<D>QPB_LO?#$G_DG'@?_ ,$EO_\ $4Y_V6_ABIX^'7@;_P $EO\
M_$5W.QO0_E1L;T/Y4>VGW?WARQ['"?\ #+OPQ_Z)SX&_\$EO_P#$4?\ #+OP
MQ_Z)SX&_\$EO_P#$5W>QO0_E1L;T/Y4>VGW?WARQ['"+^RY\,2W_ "3GP-_X
M)+?_ .(J7_AE;X8?]$Z\#_\ @DM__B*[=%;<.#U]*F(Q1[:?=_>'+'L<$/V5
MOAB/^:=>!_\ P26__P 12_\ #+/PQ_Z)SX'_ /!);_\ Q%=X/FZ49VL*/:S[
MO[PY8]CA1^RQ\,<_\DY\#_\ @CM__B*<O[*WPPS_ ,DY\#_^"2W_ /B*[P<T
MH'-+VT^[^\.2/8X;_AE;X7?]$W\"_P#@DM__ (FC_AE;X7?]$W\"_P#@DM__
M (FN\HI^UGW?WAR1['!K^RK\+L_\DW\"_P#@CM__ (FI/^&5OA=_T3?P+_X)
M+?\ ^)KN!UJ2E[2:ZO[PY(]C@C^RM\+@/^2;^!?_  1V_P#\32#]EGX7D_\
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M - 2W_\ B*] +*1U'YTZ)55>M'M)]W]X<L>QP#?LF_"T'_DF_@;_ ,$EO_\
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M_P"&5_AA_P!$Y\#_ /@DM_\ XBN\Q1BCVU3^9_>'+'L<'_PRO\,/^B<^!_\
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??_?(H^RQ_P#/./\ [Y%%% !]EC_YYQ_]\BBBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img43983261_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43983261_1.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" O8#D,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ-)%-/'X2\>?%GP;HGC&2""(S2SQ^$)M6/B9X%7:JS+I1B>>6"VC9KBX@BD
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MBSX"^(&KZ9I NK>R.JZAIOA/7]7O;+31>W=K:&^N8(K475S;V_F^;-&C>XT
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M=Q$S@'H=%>;_ !0^,?PA^"&@6?BOXT_%3X;_  A\+:AK%OX>L/$OQ0\<>&/
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M_17R!_P\)_8%_P"CX?V0/_$EO@Q_\VM=_P##;]K+]E?XR^)!X-^$'[2_[/\
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MO?AWXZ\+^-K2.WN%1X)Y+GPUJFIPI#,LD;12LX219$*,P92?2J "BO(/BO\
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MT5D=V\V51MQDC[=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#VCO\ U(_A!0!_",!(@28!U4NPCE 909(PC,$<8&^,21LP4[D#H3C<I/\
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M1M8^+?CF#2?#.AB9$W6_ACP3INI:;I,<[JD&E^&M#669XK>T>1?UY_X.=/\
M@F!X._X)Q?M:_ ZY^#.@C1_@+\:?V=?A_I7A9HK5;2 ?$7]G_P ,>&OA+\1H
M)(X]\<VJZSHMC\.OB-XCU RM/J?B;XA:U=W :9I+BX /]6CX9_$7PA\7_AQX
M ^+/P^U>#Q!X#^)_@KPM\0O!6NVI!M]9\)^,]#L?$?AW58"K,/*U#2-2L[I
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M/W8_X-;/^"UGQZ^&/[5_PR_X)[_M"_$[Q)\2/V<_CU,O@'X/-X]UW4_$&H?
M[XGP:?J5WX)T3P7J6H2WE_:^!_B#J,<7@FX\&;WT?2_$6I^&]:T--#B3Q*FM
M_P!67_!PA_P4&_8I^#W_  3(_:X^$GCWXQ?##Q9\4?CO\'/&?PB^%GP@\/\
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MKNR\*>!;::VMO%>C$>)O'45]-JFE>&O"/Y8_L*_\$&/^"G?_  4.\%6WQ4^
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MZ3H/QIUOQ%^S!XTLKAY+">:3XNV#Z%X-TVZ255*/;_&"Q^'=U/:W$6YGL&@
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MT71?#/A[Q9\5?$WAW[0'A6^\83>,/"_A%==M4CO]/L/#'BK0K:\6R\0:[:W
M!^&WPX_X-+_^"S'C_P &VWB[4_A/\)/AC<WNGPZE9^#/B/\ &OPK:^,I(KF2
M'[/;W-CX13QAI6D:@]K,+V;3M<UK3+VPCCFLM2@LM7C;3:_+;]I7]C/_ (*)
M_P#!(KXW^#Y_C/X&^+/[+'Q4M+FYUGX5_%?P1XL-MIVLR:=Y2W6I?#7XQ?#3
M7;W0]0O;*WO+-]8TS2/$:>(-"@U.SMO$NE:5->I:O_MT5^=G_!5C]A;P)_P4
M3_83^/O[-7B_0+'5?$6M>"=<\2_!S69[59]1\%?&WPQI&H:C\-/%.CSIMN[:
M2/7Q#H^MPV4]O)K7A36/$'ARXE^PZQ=(X!^"?_!M;_P<%>)_^"@33?L3_MCZ
MMI,O[6'@[PK+KGPM^)T%M%I3?M#^#?#=F\OB>U\1:=;K%I=O\6O!^GQ)KFH2
MZ+#9V?C3PJFJZZNC:=?^%=?OM9_H _X*Q?\ *++_ (*6?]F ?MD?^LZ_$:O\
M9O\ 8[_:)\5?L@_M7?L^?M+^$[O4M.U[X&_%[P3X_>/3Y&M[O4-)T#7;27Q1
MX:G4M'YMCXH\-_VQX8UBQF(AOM+U6]L;D&&XD4_[*W_!4[4K'6?^"3__  4;
MUC3+A;O3=5_X)Y?M>ZEI]TBR(ES8WW[-OQ"NK2X5)4CE59H)8Y%61$D4, Z*
MP( !_B1Z5JNIZ%JFFZWHNH7ND:SH]_9ZKI.JZ;=366HZ9J>GW$=W8:A87ML\
M=Q:7ME=0Q7-K=021S6\\4<L3JZ*P_P!BK_@@5_P5/TO_ (*E_L,>%O&GBG5+
M(_M*_!4:3\*_VE-$C:W@N[WQ;8Z6AT#XH6^GPB+R-"^+&CVSZ_$\%K;Z;:>+
M+3QIX:TU7@\-^8W^1'\"?@9\2_VDOBCX=^#'P>\/R^+/B5XOM/%$WA/PM;/M
MU#Q)?>%O".N^,I]"TA C_:M=U;3_  ]>6&@V'R#4=9N+&P,T N?.C_2G_@B'
M_P %.?$W_!*G]NSP/\8=2N=6E^!OCB2#X6?M->#K9;B8ZG\,-8U.W^T>)K32
M K_:/%WPQU:.W\9>'5CACU&]33]9\(Q7EE8>+-6:0 _U,_\ @M;_ ,HC_P#@
MHU_V:!\</_4)U2O\P3_@V]_Y3:_L$?\ 90/B#_ZH_P"*%?Z;_P#P6&\3>'O&
MG_!&O]OKQCX2UK3?$?A3Q9^Q)\6O$WAGQ#HUW#?Z1KWA[7OAU>:IHNM:5?V[
M/;WNFZIIMU;7UC=P.\-S:SQ31,R.I/\ F0?\&WO_ "FU_8(_[*!\0?\ U1_Q
M0H _M=_X.F/^"3_[;7_!3_\ X86_X8Y^'/A_X@?\*/\ ^&G/^%B_V[\1/ _@
M'^R?^%E_\,]_\(C]E_X3/6]&_M;[?_P@'B?S_P"S?M/V'[%#]L\G[9:^;_(A
MK/\ P:J_\%I] T?5==U/]G?P##INBZ;?:MJ$R?M!_!.9XK'3K66\NY%AB\:M
M+*T<$,C+'&K2.0%12Q /^N97G_Q9_P"25_$O_LG_ (R_]1S4J /\&+PSX>U7
MQ=XC\/\ A30H$N=;\3ZWI7A[1[:2:*VCN-5UJ_@TW3X)+B=XX+=);NYAC::9
MTBB5C)(ZHK$?T1_\0G__  6U_P"C<OA__P")$? __P";>OPA_9Z_Y+]\#O\
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M^"=_[ ?Q#N_A_/X"ED\-?M+_ +0_@G4;G3_'MOX[MIYH]<^#7PQ\16;17'A
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M !(CX'__ #;U_JW?!?XN>"/C[\(?A?\ ''X::HNM_#WXP?#_ ,(?$OP5JJ[
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M?N_$-]$]U)<>+_BOXTC&O>+M9$10FTL[O6-0\2:[<;HXX+&VO;F1XXXV=?\
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MF\2? +XE^&="CO);6WNIU;4]>U?3=+MMD#AKJ\A5BJDL/],'_A_Q_P $;?\
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M'>EOH7Q!T3Q'IU@TJ0R76FP65\(8X[J-: /P#_X//?\ E%!\+_\ L]_X1_\
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M#I6K:W\)-"^*.M^,+C3I94$=X]C#\6?#%G=36K-'%+NMIF::(I#X5_P?*?\
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M:E8Z/I.GV^K:XUQ?ZGJ=U%96%E K:$JF:ZNIXH(@S*"\B@D#FOUMH _R1?\
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M33:9J=I/( ?0]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >2_'VPU/5/@3\:M,T65H
M-9U'X2_$>PTF=$$KPZG=^#M9M["58V>-9&CNI(G5&D0.0%+J#N'^$=X!U.PT
M3QWX*UG5%#:9I'BWPYJ>HJ55PUA8:Q9W=XI1GC5P;>*0%6D16'!=02P_WRZ_
MQ-/^"O7[#?BO_@GG_P %!_VC/V<]=TB:P\*67CC5O''P;U06LUOIOB7X*>/-
M0O/$'PZU32Y9 8KK^S=(N?\ A$]>^RRSV^G^+O#?B+1O.>739< '^V1')'-'
M'+%(DL4J+)%+&RO')&ZADDC=25='4AE92592""00:?7\]_\ P0 _X+$_ S_@
MH?\ L@_!SX9^(?B-X;T3]LOX.?#_ $#X=_%SX4:_K=E8^,?&<O@32;/0;;XO
M^#-.O)+6X\6>'?&NEV5CK_B*70K>X_X0_P 47^J:!JD-O:1Z)J6L_K?^U[^V
M;^S;^PG\%O$OQZ_:?^*/AOX9^ _#UC?S6::KJ-DGB7QKK%G937MOX.^'GAJ6
MY@U/QKXTU586CTSP[HD5Q=R?/=W7V33;:\OK8 ^H:^>OVN;#4M5_91_:=TS1
MRRZOJ/[//QIL-*9 2ZZE>?#?Q+;V)4*K,6%U)$5 5B3C"D\'_(,^)?\ P6B_
MX*$^+_V[/CY^UU^SI^T/\>/@?XA_: ^,6H>+-'^&?@CQUK6J^'(]#,UKX=^&
M'@37/ <@N_!/Q!N/"?@K3/"_A"U_MGPC?QZG)I:2PV$9N! O^NY^QQIO[0L'
M[)?[/]E^V#X@L/&G[2]Y\(O"%U\?-4MM \.:!IT_Q'UK18-1\7:*NB>%['3_
M  PD&@W][/X;>72--L=-U,:8VH16-JEX;= #_#Z^ VMZ1X9^.7P9\2>('@BT
M'P_\5_AWK>MR74DD5M'I&D^+]'O]2>XEA5Y8X$LK>9I9(D:1(PS(K, #_O0
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MXD@M[>W@^&VF10P00Q*L<,,,:K'%%&JI&BJB*%  ]A_X,\_V:8_C'_P50O\
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MEAK%OYHU3PQ9^&MMU<6MK9L@![3_ ,&KVA_LG^&?^"B=_P#M/_M=_M#?L\?
M7PC^S)\--;USX:CX]?&3X;?"I/%OQB^(L5UX&T)O#MG\1/$>@1^)8/"?@R[\
M?:YJ-UI2WTGACQ ?!-Y.MI<W^FW _IE_X.?OB]_P3=_;P_X)I:]<_"+]NW]B
M'XC?M _LW>._#OQA^%OA/P5^U3\!_$WCGQ?I=Q+_ ,(=\2O!'AO1-&\=ZAK&
ML3ZEX2UZ3Q;%HFE65SJ&L:SX$T*SM(GF9(W_ )6O@-_P:Y_\%9_VBO@K\*_C
MUX#^'OPDL? WQC\!^&?B3X+A\7_%S1_#GB.7PGXQTJVUSPY?:KH5Q837&ES:
MGH][9ZC':7#_ &B.WNH?/2.4O&GK7_$(=_P62_Z$KX ?^'VT+_Y64 > ?\&T
M?[='_#$/_!53X+?\)'K7]E?"7]IK=^S'\3_M,_EZ9;?\+&U/3/\ A6OB*Z\Y
MELK+_A'_ (K:=X-^WZ[<^7_9'A/4?%>;F"TO+WS/]-O_ (+#_P#**#_@I'_V
M9!^TY_ZI_P 6U_C<_M7?LN?&_P#87_:.^(7[-/QXT:/P?\9/A!K&D6^OVNCZ
MLFHV44NJ:)I/BSP]K6@:[9>7'?:?J>B:QI.L:5J-MY;&*YB8K#/&\:?ZA5O^
MW%#_ ,%#O^#8;]H[]I6^U"VO?B#JO_!.W]I?P/\ &B&!D$MG\9?AU\(O%WA+
MQ]/<6J_\@]/$VI:<GCC2;%FD:'P]XJT9C+*)!*X!_E5?!WX1_$+X^_%CX;?
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MTVTUC0/$7A[6[*;3=8T36M)OXI['4]*U33[FXLK^PO()K:[M9I8)XWC=E/\
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M3KB2;;;QS.O^<O\ \&[.EZGK'_!:C]@&TTF22.ZA^+&OZI*T40F8Z9H?PO\
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M?!+*YU+P3\1O VN+J&EW+Q16WB3P5XF@:XMVL]2E@;]+_P#@V]_Y3:_L$?\
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M_P#PLO#G_P LJ /\P3_B#;_X*X?]#'^R!_X>7QM_\Z"O]"O_ ().?LN?$O\
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MTR3:SI_[.?PJ:^C=C\B7&GF>+2KJ*(E8;BPDCDVW"SHO]R'_  :6:7J>G_\
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ME1]MUCP!K?B33K SQRK9:O)8WQ@DELT2@#_0U_X//?\ E%!\+_\ L]_X1_\
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M_(U?\$U/^Q?_ &L__3C^SG0!_(_^Q3_P2[_;M_X**:1\4]<_8S^ UW\:]/\
M@J_A2/XE&P^('PI\'7F@2^-XO$<WA>*VTOXB^.O"&J>(I=5C\)>(&6+PO9ZU
M):?V?MOEM6NK(7/@_P"TM^R?^TE^QQ\1I?A+^U%\%O'_ ,$/B"EA#JUMX>\>
M:'/I;:OHUQ)+!!KGAW4U,VC>)]"EN;>YLTUOP[J.IZ4U[:7ED+O[7:7,,7]S
M'_!C7_R*O_!2O_L8/V3/_3=^T97]+W_!:O\ X)3_  ]_X*O_ +'GB?X37EKH
M^B_'SP#;ZKXV_9H^)E["D,_A3XC06.?^$9U;4XXWNX_A_P#$>*UM_#/C:S"W
M5O;(VD^+8=.O=<\):(L8!_GF_P#!"[_@AC\#O^"L^IW>J>-_V\/ ?P\N/ 6J
M1ZG\0_V9/ _AC6;_ /:,OO!%MJ%O;S:MI^H^-(?#O@[2=%U<316\?C;PK9?%
MW3?#=W>6-GXCTBTU2\M].;_4V_9C_9E^"7['7P,^'W[.'[.W@>Q^'GPA^&.D
MRZ3X5\-65Q>W\D?VN]NM5U;5=5U;4[B[U76]>U[6;Z_UG7-:U2[N;_4]4OKJ
MZN)F:0!?\27X8_$O]IC_ ()U_M8Z7XY\'W7B/X)?M-?LR_$W4M/O;#4(##J7
MAOQAX2U.[T+Q7X-\5:49#:ZMHU_Y.I^&O%6A7+7&E:]HMW?Z?/\ :+&\)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&G3O$EN7C$5[9^!_#5LWQ?T;89$2XB\2?#O1C%*D[V\EW91"]?\ V'** /\
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MOP7\<]/\;7?@:RL+N+PW>^(]<^&5SH=OJ)O-0LBDFI0:1J<ML(Q(&6SFW%2
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M+T_1-$TC3H$M=/TK2-*M(;#3=-L;:(+%;V=C900VMM!&JI#!$D: *H%:E%%
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MUL-+\.Z;'+_I5T4 ?Q'?\&CW_!/3]M;]A_XB?MOZK^UG^SE\1/@3IWQ$\%_
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MVHK;X.V:WNHFW?5)O!USIT/PULM$NM08R/XCGMH=#G+?;6U)H6\\_P!5W_!
M7_@UX^*7P8^,7@#]MS_@I!HFB>&M<^&NHV?C#X)?LOP:II/BG5K/QS83-/X>
M\?\ QFU/2)-3\-60\*3I:^(O"/@;0=7U;4'\1II6I>+[_0V\/W?A'6_[U:*
M"BBB@#\_/^"KOPP\?_&K_@FI^W+\)/A5X6U3QQ\2?B-^S)\6_"'@?P?HD<<N
MK^)?$VN>$]0LM)T;38YI88GO+^[EC@@626-#(X#.HYK^ S_@@5_P1^_X*:?L
MS_\ !7']CWXX?'G]C3XQ?"_X3>!-:^+-QXO\=^)],TJ#0M AUOX!?%7PSI,E
M_+;ZO<S(M]KVM:5I<&R!R;J^@5@JDLO^GM10!_-Q_P '1?\ P3\^+7[?/_!.
M[P_IG[/7PVUGXI?';X)?'?P/\1/"/A'PQ#:S^)]>\,ZY8:Y\/?&^CZ7%>7%M
M%)!%!XIT;Q;J48FCD^S^#EF4LL#QR?R(?\$6_P#@@Q_P40\.?\%0?V._'_[4
MO['_ ,4_A-\#?A-\4X/C%XM\;>-M.TB#0;'4_A1H^J^/? 6GSK!JMW+<RZW\
M1=!\):/';K!(A6]DEG'V>*6O]3:B@#^=_P#X.>?V6OVA/VP/^"8T_P (/V9O
MA1XJ^,OQ,;]H'X3>)U\&^#K>VN=8.@:):^+DU;51%=W5I%]EL7OK19V\[<#/
M'M5LG'XC_P#!IW_P34_;O_8H_;+_ &CO'W[5G[,7Q,^!W@[Q7^S)-X0\.^(/
M&]CIUKI^K^)F^*GP]UE=&M'L]2O7:\.EZ7J%Z%:-$\BTE._("G^]BB@#S;XP
M_"#X9_'_ .%OCWX*?&3P;HWQ!^%OQ.\,:IX.\<^#=?@:?2]>T#6+=K>\M93$
M\-U:7,>Y+K3M4T^XM-5TC4H+35=)O;+4K.UNH?\ -O\ ^"FG_!H1^U[\$_&O
MB3Q]_P $\_L_[47P*U+4KN_T?X8ZKXE\/>&/C[\.M,D62Y.EW_\ PD]UX<\)
M?$S2]-Q]CT_6?#6KVGC'4]\,,_@-I(9M4N_]-FB@#_$N?_@FO_P5X^'=TWA*
MU_85_P""AOAQKK5KVS@TSP]^SE^T0NE:QJT,)^V'2)M \(RZ1K\C6EF9#>:3
M/?Q7-E;+/'/+:QJX^SOV/?\ @VA_X*Y?M:^(=%AU#]FGQ#^S)\/KR[CCUWXD
M?M0QR_"== M!*!/(GPRU>(_&/6KUX%G:P@T[P"=-FN(XH=2UK1X+F*\K_8#H
MH _(G_@D-_P1S_9R_P""1/P5U'P3\+I[OX@_&3XA1:/=?'#X]>(K"+3_ !#X
M_P!2T=+IM.T?1=&BN+VV\&^ - GU#47\/>%;2]O[D/=S7_B#6M?U9Q?)]3_\
M%(/ 'C+XK_\ !/#]O3X6_#GP]J'B[XA?$K]C#]J/P!X$\*:2D<FJ^)_&7C'X
M'^.?#OA?P]ID<LD44FH:UK>HV.FV222QQM<W,:O(BDL/L^B@#_+5_P""(_\
MP1N_X*@?L]?\%5?V+_C/\:_V+/C-\.?A9X ^)VHZQXR\;>(M,TF'1?#VF2^!
MO%FG1WNH2P:Q<3)"]]>VEL#'#(?,G08P21_J5444 ?QY_P#!TQ_P1)\>?MS^
M$OA[^V-^R!\-+OQS^U+\-3IGPY^)?@'PO'91:_\ %[X2ZE?F/P]J]G#<S6L.
MI>*_A;KE])M#2Q75_P"!M=U?[3=30^#M"L5_G[_X(4_\$=O^"G7[.'_!6/\
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M9M1L!:7=K\25\5:O964%LL%MX>UK0D0EMV/U0_X-2/\ @C/^TY^RC^T?\?\
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MT4 ?XPO_  X(_P""R7_2/;]H#_P3Z'_\O:/^'!'_  62_P"D>W[0'_@GT/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)>'?'^LZ/JNGK:JUUX(O;16O!?V[0@']@]%%% !1110 4444 %%%% !1110
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M;^_EM-)TV\N([*QMY[RZ>,06T,LTB(WP)_P2R_X*;?#/_@JW\#OB=^T3\'?
M7B_P'\-O!G[0/C'X)>%!X[N=,/BGQ=I_A'P9\.O%1\::IHVCO>6/A4ZK/X[F
MLK7PZFM^(9K>STNWO[K5$NM1FTO3 #],**_#']GO_@HG^W%\3O\ @L5^TE^P
MK\0/V2O^$+_8^^%'@_Q1KGPX_::_X5O\7M+_ .$YU?1[?X:2Z7IG_">ZW>R?
M"_5_[0D\6>)4\C0;2.ZF_L+%N0UG?[OW.H **** "BBB@ HHKF?&NMW'AGP;
MXM\26D,-Q=>'_#.O:W;07&_[/-<:3I5W?PPS^4\<GDR26ZI+Y;H^QFV.K8(
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ME+>0Z5XPOK^ ZUIVJ0_VA:VADB>V\Z"7^A*@ HHHH **** "BBOPY_X+]_\
M!4?XO?\ !)+]CGX:_M'?!;X??#?XD^*?&O[2_@[X)7^A?%!/$[Z!::!XD^%O
MQE\=W6K68\*:]X=U$:Q!J/PVTJSMS->RV7V*_P!0$EJ\YMIH #]QJ*_'+_@B
M7_P5K\$?\%<OV34^+2Z;H'@?X\_#G61X+_:%^$^AW=W-8^$?$MP+J[\->)/#
MB:I<7.L3>!/'NAP-J7AV\OYKE[75M/\ %'A634=3O?"U[J%Q^QM !17\X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPI_X*U?\'/WQ\\!1?M9_"/\ X)'_ +/>J?LKZM:W?B3P?X)U;4==T/XU^+_
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M"UU+X!^._#N@^--;OFM]?;3Y;3P)J.H?$#XA:7<W\,MM8QW-AKY6>*6WN'0
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M<WC6EGLALM(T:P\R)]5\1^(M5N+#P_X:T:&1;C6-?U/3M,MR)KI#7\F'PO\
M^"WO_!?'_@HU9>(?BM_P2V_X)4_!Z']FS3]9U*S\+_$+]ICQ;*MUXWC\/W%S
M#/9Z%KVM?&G]G;PKKFHZCJ&G3:)K-OX*@\7Z1X0U66[T'5/%T%Y9/KD.A_P>
MM_$WQ'X<_8%_9E^%VDW&JV6A_$S]J2/6?%4UC<75M8ZG9_#OX:>,)M+\.ZT(
M'2"^LKG6?%-GXBMM-O1+ VJ>%;#4XXOM6DV\T/!?LQ_\%=_^"P?[.O[.OP.^
M!/PI_P"#='XW'X<_"7X5>!O 7@^[TO5?B9:6FL:+X<\.Z?IUMXB:/3O@:UI-
M>^)3"_B#4[Z.6=]2U/4KO49[FZN+J6XE /T6_P"":?\ P7J\?_'#]K74?^";
MG_!2;]EK4OV)/V[PVI7'@G0[>2]G^%OQ.M=-T2Y\1/I^BW>M:GJ=]I>L7^C:
M=JFK>$;[3M>\;>"?'NEZ?<R:#XPCU1]-T;5/8/\ @O;_ ,%<_BQ_P21^'O[+
MGCGX7^ /A=XY@^-GQDU7X?>-)/B?'XLDL_#GAK2M$L]8N-8T8>$]?T*?[?$D
MT[2?;3?6YBC4);%\[OY4_P#@I7X\_P""Q/\ P4:_:B_8A_:JC_X(F?M/_LW?
M%']CGQA;:W;^+O!OAGXD>--=\;:-IGC[P7\0/"FD7M]<?#GPC>:7#X%US0/$
M]]H2P7%ZCS^.M<;R[9B6G_2C_@]Y_P"36?V'O^R__$3_ -5U;T ;>C?\' 7_
M  6?_:A^.VF?$3]@?_@EQ:_$7_@GAXD^,VB_"CX=_%#X@_"?XZOK_C[0M9\;
MVO@=/B1J'Q,\/>*-.\,>%-%&HP7%YK6I:9\./%_ACX3VUQJNE>.M4UW4-(-]
M;_J9_P %@?\ @NS;?\$]?BW\*?V-/V:?V?M<_:]_;P^.-CI&H^#?A'HUY?6W
MA[PIIOB75;W1O"USXH.A66I>(=?\1>)K_3-2DT;P-HD>EW"Z)97/B7Q#XD\.
M:9+H?_"0?M!^R[\+-#^!W[-?P ^#?AK3]-TO0OA;\&?AIX"TVQT>UALM-B@\
M+>#M'T8O:VT$4,:+<26CW+MY:O-+-)-+F61V/X*_\%4/VZ/^",'_  2X_;(\
M'_M4?&GX)-\6?^"FNH^%1<>"[7X/:3<:Y\8K/PKKGA>3X4V.J>++[5O%&B>
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MS:9XA\)^*])N]"\0Z'J$096DLM5TB_N[&Z165FAG<*RM@@ ^9OV"?VX_@?\
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MKVTVN74VCW5];74VF6UTH!_0?XO_ ."YW_!:S_@G'KO@?QG_ ,%B_P#@F/\
M#CP[^RYXN\2V^AZS\9/V3]:AUR\\$RZW ES9V5Y]G^.GQJ\(2:SIMS+<:=I_
MAWQCKOPXE\71Z==+H'B'5);*34]2_J8N/VDO!OC#]D;5/VM/@CK.C^/O!&K_
M +/^L_';X9:NPNAH_B;1QX!O/&OAPW\"/::C:1W:16UMJVGR-9:KITWVNPN4
ML[^WECB_C[_;0_X*>?\ !9#]M;]E']H#]E'Q_P#\&[7Q[T_PS\=_A?XH^'\N
MNO<?%#7IO"6LZI8N_A3QUI^CWGP3M+;4-8\!^*[?1?&6B6\MW:*VL:%8D7=L
MP$\?W9_P0H^&7[47P/\ ^""/[0WP0_:N^$'Q4^"?C3X4I^U]H/@SP?\ %OPY
MK7A?7)OASXB^&=M\1K#6-&TO7(H;@>&[GQ=XW\9V-M/;1BS?5=-UB./]]%<
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M)+WQ!JGBGQ-<>'?$_B[PW:V'BJY6?5;ZPT[5+_5M+T^[U.TM;>4 _&3X6?\
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MBRTA(=9N8-1>"W6/4YHYA=-]I^)/^"NW_!Q_^T1X4G_:4_8-_P""/WP]TO\
M9)N(=1\5> ;C]H"_36OC?\1? $5@;C0]?M?AS:?M$?!KQGJ2^)-.ECU_2-.^
M'WP_\5+JTEQIUCX5\2^*K*&2\USYA_X.I?AYH?Q=_P""IW_!$OX3^)K2WO\
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M/-5E5U=9H-)\;>*M!U.XML*;J"TDMEDB:42)_/#_ ,&>'[$OACPM^R3\2?\
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M9(\>?\&_O[0?P\_X2+Q)X$\8^$_B99VOQ,\8:O\ #WQ3X)\3V&K'6]%T._\
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MGQ]^R9\$YX5_:$_:R^($'CG6[:QTWPSJ5S9^/==\ 3>$?%V@>';VRU_6!%X
M^$-O=Q:FWB_7+2^\<_:Y/ BW<VD_U"5^&_\ P;S?L7_LQ_LB?\$S_@7JW[.7
MBOP[\6+W]HKPGH'QH^+/QUT6U:&7XC^.M9L6BNM$3[7%#JNE^'_A3.=0^'FB
M>%-3@T^_T&]TC7[K7-(TWQCK?BI9OW(H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;QQP6MI:PQ6]O"B111HBJH /X=?^"\'_ "LL?\$+?^Q@_9;_ /6R/$E??_\
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M>\,?"3XE?%OQ9X^\1Z9]IN+[1O#-K#X=6XU2VL3+J4MN9[<_V&_\,F_LL?\
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M?#=;>&T'P_E\)Z#)X(%I;WR:I!;#PH^GG01;P:E''J,,(L/+COHTNT5;A%D
M!_.U\>/'>B?$O_@U'OO&6@:M!K5EJ7_!)CX:V=W>P>4!'K^@?!OPAX=\5:;<
M) /(BO\ 1?$^E:OHVI6\.8;?4+"Z@B9DC5CW_P#P:L?\H.?V1O\ L8/VD?\
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MEE,,36>HZ9J$-Q97UK*.)+>Y@EB<<,A% '\^_P#P:L?\H.?V1O\ L8/VD?\
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M3J%['J5^=<U_3]/M]5U8WVHQ17]X;^[N#<WL<=U-OG19  ?YL7Q9_;.^*O\
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MHT^."PU[48?!WB!/#/QP\#:,Y\7:#K>C:-KOA_1-0T9+"'Q+_HBUR'CCX?>
MOB=X?N?"7Q*\$>$/B%X5O'22\\,^./#6C>+/#]U)&DD:27.BZ]9:AIL[I'-*
MB/+;,RI+(H(5V! /Y$_^"D7_  =5?LQZS\!M2^#G_!)CQ+\2/VCOVS/C9;P^
M!OAEK'AGX)?$?1K3X5:IX@W6EUXAM_#OQ-\"Z/K'CWXA:?;LT7@GPMX>\*>)
M-!N=>GMM4UK4)M/TF31-;_=+_@GU\)/VX/%/_!-C0OAY_P %+/BM>>.?VJ_C
M)\/?'UG\3;YO#/PVT*?X9Z/\0M-U'0O#/@'[/\+?#WA7PWK>L>$/"L^GW7B3
M5IHK_4+OQC?:_9MK^J:=9Z;=5]@?"7]D#]DOX!:U<^(_@3^R[^SM\%?$-ZM\
MEYKWPE^"?PU^'&M7::G+YVI+<ZIX.\,Z-?3KJ$W[V^66=Q=R_O)Q(W-?1- '
M^<7_ ,$%?^"H_P *O^"$_C3]L7_@F_\ \%-=&\>? ^YLOCM+XTTGQ]:^ _%G
MB[2=/\4VNBZ5X!\1KJVA>&=*U/Q;>>$?%?A[PKX/\6_#[Q?X7T#Q!IFOZ+)=
MWB-]DO='N+O@/^#C7_@KCIG_  5K_9TTGP_^Q9\+?B?K/[$7[*GQ;\+>.?C7
M^TQXY\,W/@OPWXF^-?B[1=;\!?"SP-X.TG5)(]4SIWA_Q=XTU2\MM7@M?$FH
MB^DOW\-Z+H>@0:QXD_T0OC#^S%^S7^T/#:V_Q_\ V>?@;\<[>Q6%+*#XP_";
MP%\38;1+:=[FW6UB\:Z!K:6ZP7,DEQ"L2H(IW>5 LC,QW+;X$_!"S\ V7PHM
M/@W\*K7X6Z9+%/IOPVMOAYX1@\ Z?/;N98)K+P=%I"^';26&1FDBD@TZ-XW8
MNA5B30!\%?#?P+KWQ1_X(G^ OAGX6LYM0\3_ !$_X):^%O OARPMU#W%]KWB
M[]DRQ\/Z19P(S(KS7.H:A;PQ*S*&=U!90<C^2G_@U7_X*T?LV?LB?#R7_@E[
M\??#_P 7/!G[2WQ@_;?UJW\#0R>"H?\ A&(M<^(7AKX6_#.U\)^,KG4=9TS7
M_!_BC1/&?@;5=.UK3=1\/,+<7>G0Q2S:D;VPM/\ 04T[3M/TC3['2=)L;/2]
M*TNSMM.TS3-.MH++3].T^R@2VL[&QL[9(K:TL[2VBCM[:VMXXX(((TBB1(T5
M1XQ=_LO_ +-%_P#$F+XRWW[._P "[WXP0:I::Y!\5KOX2> +GXDPZU8>7]AU
MB+QS-X??Q1'JEGY,7V34$U07=OY4?DS)L7 !_&K_ ,$^/^5Q/_@I)_V2#XH_
M^F_]FJO,_C1JOQ,_X-P/^"Y7QY_;9\:?"WX@_$?_ ()P?\%"]1\5:KXS\>^!
M] @U ?#[Q9\5/&8^).NZ$[JNG:/8>,_AS\1[?Q#=^&/"FHZGIL?C'X1>(Y7T
M2ZU'Q-INI6^B?W7Z=\+OAGI'C'4OB+I/P[\"Z9\0=9AEM]8\=:=X1T"R\8ZM
M;SBV$\&I>)[;3XM;OH9A968EBNKZ5)!:6P=2((MF_P"(_#/ASQCHFH>&O%WA
M_1/%/AS5HD@U7P_XCTJPUS1-3@CFCN(X=0TK4[>ZL+R)+B&&=([F"1%FBCE4
M!T5@ ?R*?\%%?^#IC]B/QA^RKX_^$'_!-[Q=\6?VC/VP?V@?"&K?"/X3:'X&
M^$7Q@\$ZK\-_%/Q$TZY\,IXO>^\5^$O#.K:OXO\ "L.HS:GX(T3X<V?B^\UC
MQK!H-E++9:7+?:G:>W^ OV<O^"S_ .S;_P &^M_9> ?VC?C/XG_X*C0PW'Q_
MU1/B+XAL_P!H;XA6OA74=6L9=7_9Q\/:A\<K'XB1VGB#0?@]:1SZ=H?AZ W-
MM\6[/4M \&WX?6?[4O?Z"OA;^QW^R-\#O$MQXS^"G[+/[.7P?\87<EW-=^*_
MA;\$/AE\/_$MU+J%HEA?RW&N^$_#&D:I-)>V,<=E=O)=,US:(EM,7A54'T;0
M!_('_P $Y?\ @Z\_89U']FWP#X%_X*0?$KX@_L_?M;_"WPU9> _C'J'BGX+?
M$GQ7H_Q+\9>% -#OO&FE+\'?!'BN[T'6_$\=G'K/B[PWXC\)^"8/#OBRYUS1
M](MKG1[/3;RZ_+CX-W?@#_@LU_P<F_ G]L3_ ()T? K7_AG^RS^R^? 7C#]H
M+X]2^ D^'^C_ !'\6_#S4O&7B:]\6^(+*Q2""'Q?\6AKOA3X5:%H6I2/X\US
MPMH,_C3Q'I=II6GZU;Z)_=/\6OV)OV,_CYK4WB3XZ_LC_LQ_&GQ%<&U:?7OB
MU\!/A5\1M:G:Q1X[(S:IXQ\*:S?2&SCDDCM2\[&W21TAV*[ ^V>!/A[X!^%O
MAFP\%_#+P/X/^'7@[2O,_LSPGX$\,Z+X1\,Z=YS^9-]@T'P_9:?I=GYKDO)]
MGM8_,<[FR>: .PKS_P"+/_)*_B7_ -D_\9?^HYJ5>@5'-#%<12P3Q1SP3QO#
M-#,BR1312*4DBEC<,DD<B,4='4JZDJP()% '\,__  8^_P#) ?V^?^RP?!?_
M -0OQG6__P &I'_)_7_!>;_LO_@G_P!7/^UO7]H?@?X7?#/X8V^H6GPU^'?@
M7X>VNK307&JVW@?PCH'A.WU*XMD>*VGU"'0-/T^.\FMXY9(X);E9'B21TC95
M=@7>$_AC\-O >H:_JW@;X>^!_!FJ^*KA+OQ1J?A/PGH/AW4/$EW%/>7,5SK]
MYH^GV=SK%Q'<ZA?W"3:C)<2)/?7DJL)+F9G /QY_X.0O^4)7[>__ &3_ .'W
M_J\/A?7SK_P0H^!_AO\ :9_X-L_@-^SEXQN[K3O"OQY_9_\ VM?@[XAU.P@M
MKC4=)TCXD_&K]H'P??:OID-XKVS:II,&L/J.F&92D=_;6\A(V@C^BSQ)X8\-
M>,M$U#PSXP\/:'XK\-ZM''#JGA_Q)I-AKNB:E%#/%=11:AI.J6]U87D<5S!!
M<1I<6\BI/#%,H$D:,&^&/"OACP3H5AX7\&>'-!\(^&M*6=-+\.^&-'T_0="T
MU+JZGO;E;#2=*M[2PLUN+VYN;N=;>WC$MU<3W$@:661V /X%/^"0'_!3 ?\
M!OEXD^-W_!*O_@K/X-^(/PC\(:'\5?%'Q(^!GQ\T7P'XF\7^!]8T;6S9:+K%
M]IEIX=TN\\3>*/AEXPFT"V\7^#/%'A31?$>H:;K&J^)?#7BW3M'U&U-EI/K?
M_!3O_@LMX^_X+"?$+]GK_@G5_P $(_&?[05UXUUOXK:+\0_BQ^UG\/%^+OP
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MD:KIUY$T%W8:EIM]%/9WUE=0N\-Q:W4,L$\3-'+&R,00#^0:]\":Q_P<I_\
M!N!\,;#PYXCTRY_:X^$=WH,RR:QJ"VUE?_M3_LYZ+J7@S5]-\67L@:+3I_C;
M\+/&%UK]I=/-#I^@ZE\4O#^JZ@ZZ=I=W;'X4_P"":?\ P<Z7?_!/#X8^$?\
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MK^JZGKNN_L]_ _6M;UK4+W5M9UG5OA/X"U'5=6U74;F2\U#4]3U"\T":[O\
M4+^[FFNKV]NII;FZN99)YY))9&8W_#G[/'P \':BNL>$?@;\'O"NK($":IX<
M^&?@K0]1013PW486]TS1+6Y41W-O!<(!* D\$,RXDC1E /X$/!7P6_X*$_\
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M'?VB:3_P3R_8!T'Q#_PENA?L-_L>Z+XK\A+7_A)M)_9F^"VG>(?LT:LB6_\
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MN?#^JZII]U?:-<17UK;7L<VG3VTD=W;P7*L)H8W4 [BOX@_^#,W_ )RO?]G
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M?RS_ /!LG_P4_P#VQO\ @I5H/[<%]^US\0-"\>7/P3^(OPK\/?#Q]$\!>#/
MPTG2O%%G\2YM9@ND\(:-I"ZJ]Q)X;TDQS:B+B6W$#B%T$\P?^IB@ HK\L/\
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MN[[9:6%]IW@OX$?$K1)W<S%&CU_QMX@UE%'V'6KB,0+;Q@']PU%?Q0?LE_\
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M/]K;5_\ @G3_ ,$-_@18?M"?&C1-7U[P?XX^/FLZ$OB[PSIGB#0M372M?O\
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M&]@BNK.]L[J)X+FTN[:=)(;BVN(7>&>"9'BFB=XY$9&(-FB@#S3X7?!?X._
M_1+[PS\%?A/\-/A!X;U/59-=U+P_\+O GA?X?Z)J&MS6EGI\VLWVE>$]*TFP
MN]5EL-/L+*34+BWDNWM+&SMFF,-M"B>ET44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;]K3X-3S3,B *TLLTTTTDA!>26661B7D<D _1#_@ME_P6W_:#_9P_:.^%/\
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MEAM?$_@KQ-8Z3XI\.W,L4UO'J^DV@N[>YLVN+:;_ $5*_A#\&_\ *\9\6?\
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M^PG\9M-T2><75QHMG\3?VC/V8?&<&C7-P(X1/<Z2FM#3[B411;YK:1O+3.T
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M .";]A^S5X0U)X/B?^V[XYMOAS'9V3N-5C^#W@6;2_%OQ3O[(0EI)!JVI2>
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M^]W_ !"X_P#!"C_HQG_S9G]L/_Z(*@#^=7_@O9^V)\+O^"]WQA_9 _X)U?\
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M)\%Z6OAP7^D6>O\ C_5](:3QFS>*=>T/P1X$\*_V+XJ\6IX@T75[FQT_Y/\
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MM:L]#\0ZQ;^*]<TME*7'AOP_K3S%+>*:1/Y@/^"Z>G77_!+'_@NG_P $\_\
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M/2+*,EC'::;IEE:V=LA8E8844DXS71T ?P1_\%4?^5O'_@F5_P!B_P#LK_\
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M?M2?!R_LET3Q!?Z?;Z3JK7EC;7-[:K87<YN+2WGN8@\,4CK_ &Q44 ?Q8_\
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M  O\-7\-[#;ZC;16?PZT#0_$KZ5>00/I6N^,/$4/E>9)-+-_1310 5_GY?\
M!1SX2_&+_@DO_P ')'P8_P""A?P2^%7Q+\5?L\?M+:CI'C_XSK\,_ 7B;Q;I
MEG8>.'?X7?M2:!J5IX<TR_-UKK1/:_';3X;X(EYXM\2:3/:2F?3)3:_Z!M%
M'\<7_!?7_@DU^V+-^UI\(_\ @LY_P2MMM0\0?M1?":S\-S?%'X;>%8[*_P#%
MOBZ+P'I%SI7AWXA^#=&O+E8_B))J7P_?_A5WC[X96/GZGXM\'6FAV?AK1M;N
MKW7;6;YT\,_\'D7Q ^$6@#P?^VQ_P2_^*WP^^..C0C2=5MO#?BK6? &AZ]XI
MM[2)[F-O _Q8\!Q>+?A_'+<RIG1I]?\ B!?V%K+%*UY>.RQ'^ZBB@#_._P#C
MO\3/^"K/_!U'XV^#GP%\+?LA^)/V'/\ @GIX'^(FG?$'Q]\3?&O_  DFN:=?
M:GIUG?>';GQ'/X_\3>&/AOIGQ1\2:!HFKZ[!X*^%/PY\+J-+UKQ(U[X[UVXT
MRVT_Q-H']$/_  <%_ 2'P5_P;X?M%_LX? CP7XEUS2/AM\/OV//AA\-?!7AW
M3M5\5^)/^$0^&G[2G[.>BZ-8V]GIMM=ZIJLND>%O#RSWUQ';.XM;&ZOK@)%'
M*Z_T/T4 ?YR?_!,O_@X4_:F_X)T?L.? C]C'_ASC\?\ XQ?\*3T_QO8?\+(_
MX6%\1?A[_P )-_PF/Q-\:?$;S?\ A#_^&3_'']C?V=_PF']C[/\ A*=6^V?V
M=_:&^U^U_8;7["^)/_!?K_@NA^W'X3_X5-_P3Z_X(Y_&;]GKQCXZ@?11\;/%
MFG>/?BG9^%X;QKZTDU;0/&?CSX/? OX+^!-16: V]IXA^(MUX@T2RFM;X+9F
M_-O<:;_=510!_-E_P;R_\$2O$_\ P3!^'_Q)^.O[3FN:=XV_;@_:4B@7XCZC
M9:PWBJU^&?@L:J_B.3P#:^,IS)<>+/%/B?Q(]OXI^*GB:&XN-(U;7]*\/Z9H
MT^J6GAK_ (2GQ-^2'[17PR^*7_!6[_@Z2^$_A+Q-\-O'T/['/_!/N6R9_$7B
M'P7XDT[P%XHE^ EZGCOQE)!>ZKIL/A_7!XY_:)UC0OAE>FSOIX=?\ Z!9:C$
M+BWMC"?[O** "OR&_P""ZW[#C?\ !0+_ ()B?M*?!+0]&_MGXH>&_#)^-/P1
M@AMA<ZG)\6/A/#=>)=%T714((35/'FB)XC^&<4QVK';^-KEF>-<R+^O-% '\
MJ/\ P:I_&_XA?&;_ ()L^,/V-/VG/ACXXTC6OV8]>U/X>6&D?%GP'KVB:=XX
M_9Z^+L&N:UX:TDIXLTNSA\2VNB:H/B%X(U32X8[NVT?PE:^#M/N_+M]1M(3^
M7OBW]AS_ (*A?\&VW[77Q5_:7_X)N?"76/VT_P#@GE\:KR?5?B+\!M'T_P 0
M>(?%'@KPSI.H7^K:/X=\7:1X?BUGQMI>L?#JQUC6K'P/\</#.E^*]&D\/G4)
M/B9X>@:8:7>?WX44 ?YD?_!77_@MK\!O^"MOP[^$/@J+]B_]O[X0?M?? +5_
M$WBCX/V7PR^*>A6.A>%O&'C2U\)V":OXBT^U^&VJ^-?&(AU70+>QT2;2O#/P
M^\1Z9\\NC^)8'U[4](7XFUB/]L*[_:6_X)[?'+_@Y!\)_MQ7/[$W@NTMO"G@
MO6_'WPUN;N^U'0]'NKG7M.\*>/+*]&B:]'/XGUBTTN_^+>H>);'4_C_X_P#A
MMH*Q65OK[66@ZIH_^MK7#?$GX8_#?XR>"M>^&WQ<\ ^#/BA\//%-I]@\2^!O
MB!X9T;QAX1UZS$B3+;:OX=\066H:3J$4<T<<\2W5I+Y4\<<\>R6-'4 Y#]GO
M]H'X(?M1_!_P9\<OV<_B+X7^*GP=\<6-Q<>$/&GA"X>71KZ'3+ZYT?4+$V\\
M%I?:3J6BZI87FCZOH>J6-AJVBZG976F:E86=Y;30)[17F'P8^"_PK_9W^%_@
M[X+?!+P/H7PV^%?P_P!,?1_!G@?PU;O:Z)X?TV6]NM1FMK&*66>;$^H7UY>W
M$LTTLT]U<SSS2/)(S'T^@#^$7_@\N\ _%;Q/\4?^"8/BKX:?"CXA?%%/ ;?M
M'ZUK%KX&\)>)/$:6KP>(OV<]1L++4[O0-'U@:0VJC2[N.TENH&+B"YEAAN!;
M2H.]_P"(NS]J;_I!+\?_ /P^OQ%_^@DK^WVB@#_.N_;-_:>_X+<_\''/ASPK
M^R-\%/\ @F[XQ_9 _9BOO%_ASQ?\0O%?Q/F\7V_AG5[C0YU_LF\\8?&_XA>
M/A=HNI^&/"^H/-XG7P/\-O NJ^-M2O[73YEM-=;3K6UD_I1_;#_8KL/V.O\
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MB#Q5X@\)?#SQQX1L[F[U*7PEKVE_$/3-9\,:1'_P@NO>$K*]\.26^F_WQ44
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MD3WVL>$6UB6WM]2G\+?$7X96.N^(/"(G\;1:3X1^,'AHQWL/BFRUVS(\)_Z
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M/ 6LZY\5?'-EIU^E],FAI\./ FI>(CI@TT7WA][RXOM+_LXHH _EF_X-M?\
M@D[^T7^Q[IW[1/[<_P"W?)>#]L_]M;5!JNN>'-=NK+4_%_@;P9J?B&_\>^([
MSQUJ=A++:P_$#XK>-]4M_$?BOPU!).GABT\,>&+2\FM?$%SK^B:-\:_\$SOA
M?\2]#_X.PO\ @J'\0=;^'?CK1_ 6O?";XVV^A^-]4\):_I_A#6;BZ^('[,\U
MK!I7B6[T^'1M1FN8;&]E@BL[V9YH[.Z>-66WE*?VQT4 ?R9?\'#O_!,#]J[Q
M_P#'']F/_@K7_P $Y=#OO%O[77['S:''XM^&NFW#W.L^/O 'P^\0ZIX]\(ZC
MX3\-&ZLAXMU31;_5_%_ASQEX"T^X;7_B3X.\56^B:+:7]]H\6DZKXS;?\'@O
M@/2/ %CX.\<?\$V_VR=*_;1ET5('^"-MH6C6?@#4O%GV1(8Q8^*=7O8?BO::
M+?:O<:>$MS\%-4U*QM-02W675+J&"74/[,Z* /XZ/^"#'_!-S]M;XB_MS_'W
M_@MS_P %-/"&I?#'XW?&NU\3Z?\  [X+>*-.O-+\7>#],\916.A7GB+5?#6L
M3S>(OAWH/@CX:Z-8_![X7^#_ !/(WBR?PE>ZU?\ B6SLEMM!O]?SO^"S_P#P
M3Y_;B_96_P""D'PN_P""XO\ P2V^$\_QH\=:/I%IHW[3_P  _#.GZMKGB'QF
M]AX;NO M[XEB\!^'I[37O'?AKQO\.&TGPGXFT?P<E_XM\.^*O#>@_$"PTC4Y
MKC5-5T#^RBOY'O\ @JM^UA_P5<_X)9_\%+] _;.\-^&_C-^U5_P2B\?^%_#]
MM\3O@9X M(]=TOX2^(=,\$P> M;EFNU\,ZQJ7PTNI?$%OI'Q-\/:M<7=AX(\
M;:SJ6K^%=5U'3]4N3=V@!YUK7_!=G_@JA^WWX"O_ -FO]@S_ ()"?M&? G]H
M?XCP7_P[\3_M ?&^Y\5Z?\&_V;[S4+:>Q\1>)Y?%6I?#+P+ID7B/P[IDL^H^
M'IO%.IZ#J&G:W!:/:>!_'-_%;>&M5^:O^#)30=3\.V?_  5(TK5)!=76D_$'
M]FC0;O48FFEMKW4]%B_:,MM1D@GN$CFF!D>.?=-&DQCN(GE1'DVU[W\8_P#@
M\"^"GQ?^'VK?#'_@G#^R!^V-\8?VO?'V@:AI'PN\-^+/AEX+?2/#GB34;:_L
M;77;K0?AE\0_BSXN\;W_ (9N?L>N1^$]'\-1:7KT#0V5WXKTAFNU@_1'_@VE
M_P""7OQ<_P"":W[%'BZ;]I'3K;1/VCOVFOB.GQ7^('A:.\M-3U'P%X:T[0[7
M1/ G@;Q'JMA=7NGZEXGL_,\2^*M=>PNYK;3;WQD^@,\UWH]W=7(![M_P<._L
M3Q_MR?\ !*?]I'P5I&DIJ?Q,^#FB#]I'X1%85GO5\8?!ZSU#6]:TK38\;Y=1
M\8?#>?QWX(T^%)(@VH^)+*60NL'EO_.=_P &G?PT^*W[;'[6/Q__ ."IO[1\
MK>)=4^!_P1^#'[%OP=URZMI1:7'B'PM\)_!'@CQ%KFGM(\JP>)M!^$W@;PM%
MXHGADCM]5U3XU>)-3%G#)?E(/8/^"PG_  <*?&/XB^)OVM?^".W[(/[%_P 6
MM1_:G\9^,/'_ .R@/&T&L+XDEU7P?K=Q?>$]<\4?#GP7X8T==?FU3QIX-NY9
M-&U#5-2TW3O!EMK+Z_>7>I+I 67^DS_@CE^P.O\ P37_ .">?P"_9=U7^RKC
MXCZ/HU]XW^->K:.ZW%EJWQA\?WK^(?&26]^@5=6L/##W%CX$T/5_*@;4O#OA
M/1[I[>W:0Q( ?I]1110!_##_ ,%//A5\4-=_X.PO^";OQ!T3X;^/M9\!:)H/
M[,2:SXWTKP?XAU'PAI#V/C_XO37RZGXEM-.FT:P:SBN;>6Z6ZO8C;QSPO,$6
M5"WK/_!Q1\,OB3XS_P""P_\ P0@\2>#_ (?>./%?AWPG\=_AY=^*M?\ #7A/
M7M=T7PU:P_M1?!:_FN?$&J:7875CHUO%8VMS>RS:C/;1QVEO/<LPAAD=?[1:
M* "OXG?^"-'PO^)?AK_@YJ_X+*^.?$?P[\=>'_!/B70?VDT\.>,-;\):_I7A
M;Q ]]^U)\'+^R71/$%_I]OI.JM>6-M<WMJMA=SFXM+>>YB#PQ2.O]L5% '\6
M/_!:/]B_]M7]A+_@IQ\._P#@NY_P3O\ A1JOQT@32--T/]K#X)^%;#5]6UF_
MM]-\(I\.];UK4/"_AFTN-;U7P%XT^&UGH]IK&M:-IFMWOP^\<^%K'XB:M87-
MI(+G3[GC#_@Z%^)7[;_P^U#]F7_@EY_P3_\ VL-4_;D^)NE3>!%U+QWHGAF+
MX>?L^ZMXDMIM.O/B'<>(O"WB#6KV^3P;;7(UG3M7^(&C?"[PSI5Y%!KGB.6?
M2M,GT;5_[0J* /XG_P#@S9^"/Q:^!?AK_@I/X5^+?@CQ=X1U>W^+GP3TJWOO
M$OAOQ)H5EXFG\/6'QBTW5=4\.W?B32M)N-;TUKHQS+?109:*[M9+A(7N%2O-
MOVT_V5/VY_\ @AW_ ,%:/B;_ ,%;/V'O@)XK_:B_8\_::O\ Q'JW[3WPB\&2
MZGK7B;0-7^*OB$>*_B=I&JZ1H]AK?B/1=&G^(=I#\3/AS\1M-\/:OX;\)7]]
M+X"\20:=HC6\'B7^ZFB@#^*GX]?\'7VI_M!?#'Q)\"_^":7[!'[:/B3]M+QS
M8W?@;P_'X]^&GA^ZTKX5^(]=M!!'XGT_0?ASXK^(7B/QAKVA65S)JNCZ7XAT
M7P5HUM>QV6L:]/>:):7NEWWZG_\ !';X%?M0?\$R?^";GQ!^+O\ P4W^/OQU
M^+_Q:U&#5?C5XU\(^+_B;\1_VA=2^"?@+1/#L3^'O@[X!T?4M9\4_;_']]>/
MJU_XDTWP LMMXE\:>(M.\,V,^NC0=.U>^_H'HH _A?\ ^"6/[,'[1/\ P6J_
MX*I?$K_@L'_P4!^%?C#X>? 7]G'Q59>&/V0/V?/B5H&KZ5;6VO\ AN0ZS\/+
M&UTGQ#964NI:#\(K?4(?B'XM\00V%IIWC/XY>)+2^TQAI>A^(/#-BO\ P67_
M &0OVC_^"2__  4N^%'_  6O_P""<WPY\2^,_"7Q8\9S:!^UM\$/ FBZUK%I
MK/B;Q*/M/C<ZUH?AVQU&YB\%?'C1K&YU*^UHZ;=P^"_C7HMIXU:1M8U_PY:V
M_P#<_10!XS^SQ\<_!W[2_P #_AA\>O -KXBT[PI\4O".F>*M-T?Q?H=]X9\7
M>'Y;Q&BU3PSXK\/ZC''=Z/XF\,ZO!?Z!K^GN)([;5M-O([:XNK80W,OLU%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %:WLK.UDNY;6TMK:74+D7M_+;P10R7MX
M+:VLA=W;QHK7-R+.SM+03S%Y1;6MM '\J")%LT44 1"" 3M<B&(7+Q1P/<"-
M!.\$3R210M*!YC11R32O'&6*(\LC* SL3+110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_@D3_P &T_[*'[;G_!'!OVFOBJ/B _[5G[0NA_&;7_@?XFTSQ=J>BZ#\*I/
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M=D( /U>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OXT?\ @[:^!/\
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MD5T='C\2W-GX<U/3I+VT\+6GB!HM<G#ZZ\1N(KC]LJ /\H?_ ()U?M=_'O\
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M0RZUJO@?6KG6]%T[<UQJ_B/PUH^B6DJS:B-_\D7_  3V_P"#F'QO_P $X/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)
M\3?^K ^&%?TG5_-C_P $=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_-C_P1T_Y.:\=?]D)\3?^K ^&%?TG5_-C_P $=/\ DYKQU_V0GQ-_ZL#X
M84 ?TG4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)\3?^K ^&%?TG5_-C_P $
M=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)
M\3?^K ^&%?TG5_-C_P $=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_-C_P1T_Y.:\=?]D)\3?^K ^&%?TG5_-C_P $=/\ DYKQU_V0GQ-_ZL#X
M84 ?TG4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)\3?^K ^&%?TG5_-C_P $
M=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)
M\3?^K ^&%?TG5_-C_P $=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M46I^ M7\0R3>+7BU*_\ #,GB3X1Z;>_$>#76BMY+/3_$D6GRFV_M'_X-FO\
M@MG\7/\ @J/\-_B[\&?VHXM"O_VCOV<].\':R_Q&\/:-;>';?XO?#WQ3+J>D
MKX@U[P_I21:!I'C7PYKNE1V?B)_#]CH?A_5K3Q!H5SI6@V-Q;:N7_D"^"?\
MP<=_$/X?_M^^,O\ @I%X^^!6E^._CWK_ /P3VTG]D--$@\42Z;X)U[XKZ-K_
M ,.[B+XQ>)2^G3:K:>&]4LO!=SKVM^"=*:>]N-;O#H5AXBTW3;H:WIO](G_!
MH-_P38^/'[.W@G]H3]N']H7P3JOPRO\ ]IG2O"7A'X->"?$>B2^'?$MU\-],
MU&^\8:_\0KO0YS#/HWASQIK-_H%IX,L;W3["[NM-\,WFNP0/H&LZ!>7H!^CG
M_!T5^WEJG[$__!+KQ[X<\$7SV7Q4_:XUL_LT>$[RVN9+>^\/^$_%?A_6]3^+
M/BNW,313@V_@+2]1\(6=U:W,-WI?B#QQH&K0^8MC*A\C_P"#2[]A#3/V6?\
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M+XI\0ZO:6-A<0'7=/DL_"]VWA9]&.J7X!A?\&C\%[?\ _!:G5;O39%EL;3X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2S2,WIU%% !7A_B?]F/]FSQMXRMOB+XS_9[^!WB[X@V4IGL_'7B?X3^ M?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUZ_L(;JYCA!F>"!Y)5B!D9 @)J#P'\5OA=\4[6\OOAA\2? /Q'LM/:W2_O/
M?C'P[XOM;%[N,S6J7EQX>U'48;9KF$&6W69T,T8+QAE!-?YD_P"SO_P;&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^;'_@CI_R<UXZ_P"R
M$^)O_5@?#"OZ3J_FQ_X(Z?\ )S7CK_LA/B;_ -6!\,* /Z3J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD7BOXK>)99?$WQ.\3B1RUQ+:ZIXSU75_[&2ZEGEL/#T.D:2DIMM/@5/\_?\
MX-L_@/X[_P""HW_!:3XM?\%"OCS:MX@TSX'^)O%7[4OC6ZF6:XT:7X]?%77]
M<M_@UX6M/,^>RL?"=VWB;QOX0M8)8;?28OA/HNEQP#3@MJ?]/F@ HHHH ***
M* "BBB@ K_*]_P""JOPK\7_\$#/^"^?@G]J[X&:"^F?"/Q;X]L/VIOA9H.G%
M+?2]0\$>.;_4?#_[1'P3B\HP6NFV37FH>/\ POIFEPF/^PO WBSP9-&\<OD2
MK_JA5_-/_P '3W_!/M?VTO\ @F?XN^*?A'1O[0^-'[%EQJ?Q[\&O:VL4NI:I
M\-[>QAM?CKX42X9'N(K&3P/9Q_$,VMFK7&IZW\,] TV-<73, #^AKX5?$WP5
M\:_AC\._C%\-M:A\1_#WXJ^!_"OQ%\#Z_;JR0ZSX2\::'8^(O#VI)%(!)#]L
MTK4;6=H)56:!G:&5%D1E'?5_'-_P9S?M]R?'7]C#XA?L2^.-::\^('[(/B)-
M7\ )>W#R7FI_ 7XH:CJ6JZ;:6[W,\US>_P#"!?$"+Q3I-TT8BL]&\/>)/ 6C
MV\4<<<8/]C- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7\V/_!'3_DYKQU_V0GQ-_ZL#X85_2=7\V/_  1T_P"3FO'7_9"?
M$W_JP/AA0!_2=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^!8/C7\6TFMQ;:F?B3\9=GCG5M+UE% 5]2\%:/J>@_#DR*/FL_!MF"TC*99
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7\V/_  1T_P"3FO'7_9"?$W_JP/AA7])U?S8_\$=/^3FO'7_9
M"?$W_JP/AA0!_2=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1%9W=V"HB*"S,S,0%50"68D  $DX%?BE\0/^#BW_ ((O?#+XG7OPD\4_MU>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH:=_:5_P1:_X)C?$3_@C;^RY\5O@_P#%C]K6Q_: ^'EUXLOOBYH-K'\-]1\
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ME)(QX9_X)HQ&1!*^N_M;R)$642/'%I_[-ZRR*A.YDC::)9& *HTL88@NH/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2STS4K&.:&'_ %"XXXX8XXHHTBBB18XHHU5(XXT4*D<:* J(B@*JJ JJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8[B/2/B+>K"F+N6VE_U'J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K^;'_@CI_P G->.O^R$^)O\ U8'PPK^DZOYL?^".G_)S7CK_ +(3
MXF_]6!\,* /Z3J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC\$?!+PQJOC^Q\DPO;_%#XA+/\2/BC#('/FR&W^('BWQ';1RS!)7@AB+0VX
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MM:3X8^'TMAJ4LC,%L_B"6D5Y;J*2( _T=J*** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?S8_\ !'3_ ).:\=?]D)\3
M?^K ^&%?TG5_-C_P1T_Y.:\=?]D)\3?^K ^&% '])U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\?\ ]FK7?$7B#0OM$ES'$5:WTC1/B]X9TZ"XC@FN]3\26%M%BZEBMI_].F@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^;'_@CI_P G->.O^R$^
M)O\ U8'PPK^DZOYL?^".G_)S7CK_ +(3XF_]6!\,* /Z3J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M M%,I(&:Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYL?^".G_ "<U
MXZ_[(3XF_P#5@?#"OZ3J_FQ_X(Z?\G->.O\ LA/B;_U8'PPH _I.HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\
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MOM*U;3II[2YC66.6VN$63SK2\@N+.ZCANK>:&/Y^_;!_;X_8\_8$\%Z/X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^H:;9R^?#X=\7^0VD_$#P>9?,E\RX\%^/-,\2>$[QO-D_P!+T:?]X_WC]9T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8\,^#K7Q+/#K5UX1TKQYKVB7?Q-^.'QJ\0:%!)X;\">&+:Q\/>%K%=(AU+6
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M /X+N6__  4<\._"'4_&O[.'COX_?$/XS?#/6[>6XL/!/B_0OCIH_BR+XR?
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MK^;'_@CI_P G->.O^R$^)O\ U8'PPH _I.HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-Y;W>HW<5MI?P[^*OB'4[E9+JTMU0 _U):*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OYL?^".G_ "<UXZ_[(3XF_P#5@?#"OZ3J_FQ_X(Z?\G->.O\ LA/B;_U8
M'PPH _I.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?S8_\ !'3_ ).:\=?]D)\3?^K ^&%?TG5_-C_P
M1T_Y.:\=?]D)\3?^K ^&% '])U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM*\4NF:K:ZAHNH:GIMY^LO\ Q"X_\$*/^C&?_-F?VP__ *(*C_B%Q_X(4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5RJHUO'KMUX%U79*7NK"UDA-O+_%/_P2>_8+M/\ @I-^WU\"_P!C77/B#?\
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MHHH **** "BBB@ HHHH **** "OYO_\ @Z+_ ."@A_8C_P""9?C;P)X0UO\
MLSXT_MBW&H_L^^ EM;AH=4TOP3JNF&?XV>,+;RIK>YCATOP)<-X/@U"TF6ZT
MGQ+\0?"]_&KK"^/Z0*_ROO\ @KA\:O'O_!?+_@NIX!_9$_9ZU1M6^%/@3QXG
M[+?PAUBP!O\ 1+;0O#FK7>L?M$?'V58/,BN]'CETCQ3XACU*S>1-8^''P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5_-C_P $=/\ DYKQU_V0GQ-_ZL#X85_2
M=7\V/_!'3_DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\@?\%"?^3!?VX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\"_M0_\ !++_ ()V?MGW.HZI^TQ^QW\#/B=XGU9#'J/CZX\'
M6OACXH74938(Y/BIX)?PU\1@D8R853Q0JPN3)"$D^:OOJB@#^0KX_?\ !F5_
MP35^(UY=ZK\#_BE^T?\ LYWEQYGV?0;/Q-X?^*W@.QW,&B\G3?'>AMX[E\L%
MD/VKXES^8FS[LBO))^4WQ5_X,?OC7ITT\GP0_;X^%OC&W>9WMK/XJ_!GQ9\-
M9K:W>Y7R[>?4O"/C#XKI?36]HS[[R/2M.2\N8EVV-C%<'[-_HG44 ?YA"?\
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M++=27U_IO[/>N76@Z8(99)9[VSU/1X;R*+S1=S+:*\/^GE10!_F$-_P=!_\
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MQ_P23_X(M_\ !OS_ ,%1?A9\/],\,?MG?MI:'^US:?#KPYJ/QM_9\O\ XB?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K^;'_@CI_R<UXZ_P"R$^)O_5@?#"OZ3J_FQ_X(Z?\
M)S7CK_LA/B;_ -6!\,* /Z3J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M$-MX;_8N^ VK:AJ/C#QO8WSPE]*U#XFPR>)_%/A]KR,>1XX^*'A_P\S;%ME
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M[X<)IL4P*VUWKGBK0+V[MWBG?2K67[1;6P!_2%7X@_\ !R%_RA*_;W_[)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRI''&BEGDD=B%1$4%F9B%5022 ":_%/X@?\ !Q;_ ,$7OAE\3KWX2>*?VZO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-XON;3PS>Z5(+?X;Z?K)M]>NBWBR2*.6WO?V4H _D"_X@J?^"67_ $7S]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?PR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:SIEW'\LUI?6-Q#/&2$D0.8YHXY4>-0#LZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?S]1\>>#S-I_A[XEJYFN]5,VA>.#<7=SX@\00:)_5?0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-C_P $=/\
MDYKQU_V0GQ-_ZL#X85_2=7\V/_!'3_DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3[4=K>]L;F&8)-'%<0,S07,,-Q')$G<4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5_-C_P $=/\ DYKQU_V0GQ-_ZL#X
M85_2=7\V/_!'3_DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME>76A>.#<W,WBG6;/0@#^J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+X5^&4$2PA?#_P /O"NE>$]''E(2L9_L_2+<E%)"G(!/4^HT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M^+W_  7 _P""17P__P""M7[)^H> XTT;PS^TG\*XM8\6_LU?$^_A"+HWBJ>U
MA.J> ?$M["C78^'GQ)CT^PTGQ&L:W!T74[3P_P",;>PU*Z\-1Z7?_P >O_!N
M#_P5W^('_!-']I/Q+_P2G_;Y?6/AW\)-=^*&K^"?##_$"86<O[+W[0KZW+I>
MK>&M:N;B9[72OA?\1=>8PZU>)<R^'O#7C"6P\;036GA_Q)XTU]O]*NOXV_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *_FQ_X(Z?\ )S7CK_LA/B;_ -6!\,*_
MI.K^;'_@CI_R<UXZ_P"R$^)O_5@?#"@#^DZBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM;\0>!OV:O >J-%MGMXO#FGK\3_BI9I,R9>WU"7Q+\'Y2L3JHFTEO.5V$)B
M/[V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#6O6,VFZQHVK6%PK17-E?V5Q-!-&P#!7W(R2*KK_ )3_ .WY\"?C1_P;)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%K2)X-1T_6+6Z;Q-I?B7PY<6VBOK<6F^);FZTKV']G[_ (*X_P#!4#_@@O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?PG_\ !TM_P0>'
MC33?%_\ P5$_8U\(26WQ#\.0R>)?VM_A?X3LGCE\8:)IZ"6Z_:#\)Z;IT0E3
MQEX;BB%U\5[:U0+XAT&"3XA'[-KVA^*;OQ7_ '85'-#%<12P3Q1SP3QO#-#,
MBR1312*4DBEC<,DD<B,4='4JZDJP()% '\G7_!LU_P %THOV_?A59_L<_M/>
M+8W_ &S?@MX7C_X1SQ/K=XHOOVD/A9H-O';IXI6YG?S-2^*G@JS2"V^(MJ[2
M:CXETP6OQ#@?49I?&O\ PC_]9-?YD?\ P<"?\$D/BC_P2$_:I\&_\%./^"?<
MFN_#SX$:Q\3]-\8Z?<>!H6C?]E7XXS7YO8-%^S)#-8P_"#Q]>-<Q^%+/4+>;
MPU:R7NJ_"G7+$:/>^%K+Q#_:5_P1/_X*Z_#+_@K;^RO8?$.S_L?PG^T5\,X=
M'\+_ +2GPDLKAA_PC/B^YM9?L/C/PQ:W4\VH2_#7XB+87^J^$KFXDNI-*N[7
M7/!U]J.I:GX8O-2O0#]DJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FQ_P""
M.G_)S7CK_LA/B;_U8'PPK^DZOYL?^".G_)S7CK_LA/B;_P!6!\,* /Z3J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A/BE\1?#'P?\
MAE\1?BWXVO!IW@WX6^!/%WQ%\6Z@2H%CX8\$^']0\3:]>$NR(!:Z5IEW.2[*
MH"99E&2/\U+_ (-4_AUXG_;4_P""U'QQ_;@^)$)OM3^&/A3XW_M!:]JDBM>1
M/\9OVCO$M_X0M+5Y)0H5[O0O'7Q3U>UNI TBRZ''Y<*NXFMOZX_^#GK]I@?L
MU_\ !'']I6.RO39>)_V@I_"7[,_A8B41"Z/Q/U1[GQW9'!#RBY^$/AKXCKY4
M>2Y ,H-NLU?G-_P9=_LSCX;_ + GQT_:8U32S::[^TQ\>7T'1;]X"IU3X:_
MK13H&AW,,[JIDBB^(GB[XL:>Z1;HEET\YD:7?'" ?V/4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYL?^".G_
M "<UXZ_[(3XF_P#5@?#"OZ3J_FQ_X(Z?\G->.O\ LA/B;_U8'PPH _I.HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!^!G_  7V_P"",7A#_@K%^S3)?^"+'1O#_P"V/\$M*U75_@%XYNC!I\?B
MJU(>_P!7^"GC74W55?PEXQF0R:!J%XX'@GQDUIKMO/!HVH>+]/UW^6K_ (-H
M?^"SOB_]ACXT7?\ P2B_;PO-9\#?##5/B+K/@OX4:O\ $,2Z3??LV?'.;7;G
M3]>^%?C(:J\4N@_#[QOXI^T6Z&?R[/P+\1+F6^O(X-!\6>(M9T'_ $B*_BG_
M .#IK_@A4/VC/!OB'_@I#^R9X-,WQ_\ ASH NOVDOAUX<L-UY\:/AKX=L%C3
MXD:+86B;[[XF_#?1[01ZW:)%+>>-? -E'':.=>\'Z3I7B8 _M8HK^-O_ (-=
M?^"ZO_#7'@#1O^"??[5WC(W/[47PJ\.-'\$O'_B._>34_C_\+/#MB7?0-6U"
M\=GU7XL_#72K8F^N)9CJGC?P/;Q>(IXK_7/#/C36]0_LDH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO
MX0_^"]G_  7L_P""F_[,/_!3,?L%?L$VV@Z+_P (]X=^$VG:7I6A?![3/C1\
M5OC)\2_B[H.E^)-/T?1]%UO2?$S2;5\0:'X:\+^%?"?AL:[J.LQZC<W&HZM_
M:VF:7HX!_=Y17^:)_P /7O\ @\"_Z-@_:_\ _%5^M?\ S@J/^'KW_!X%_P!&
MP?M?_P#BJ_6O_G!4 ?Z7=%?Y</Q5_P"#A3_@Y:_9,OO!7B+]J/P?XS^$.B>(
M=5NAX<TK]H[]A.T^#WASXA2:!]BN=;T33[_6?AW\/]:U:*UM[^P_MI/"FOV6
MJZ?;ZA:RB]L7N;>9O]*;]ECXPWG[0W[,7[./Q_U#1[;P]?\ QR^ WP@^,-]H
M%E-+<6>AWGQ,^'WA[QK<Z/:7$Y,T]MIDVMO9033$RRQ0(\A+L: />**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FQ_X(Z?\
M)S7CK_LA/B;_ -6!\,*_I.K^;'_@CI_R<UXZ_P"R$^)O_5@?#"@#^DZBBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_%#Q)IDUO+\5_$-K*(X;WPSI%Q;_  RMY(;VROKGXEZ5?0W%K_:]X7\*^&/
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M2R_Z1I_L ?\ B&_[.O\ \[FC_AT[_P $LO\ I&G^P!_XAO\ LZ__ #N: /\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?S8_\ !'3_ ).:\=?]D)\3?^K
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M3?AQX.@O)F_TE[3QH8UD\JXNE?\ 53_@\Q_:?/PI_P""<WPN_9NTK4/LVO\
M[5GQTTM=7LO,9/[0^&/P/M(/'?B7:J.ID:U^(NH_!YR)%> 122[U$I@8?9__
M  :Q?LP']F[_ ((\? W6M2T_[!XK_:7\3>./VE/$J-&PDDM/&5_;>%?A[,)9
M$222WOOA3X'\"ZQ$H40QRZK<>095=KB< _HLHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\'?^"[?_!%/X=?\%;OV
M?TN?#:Z#X(_;"^$.DZA<? ;XJ7T1M;/6+5WDU"]^#_Q'O;6":[N_A_XFNS+-
MI=^8KN]\ >)[D^)=&AGL+_Q;H'BC]XJ* /\ ,E_X(6?\%K/C'_P1Z^/FO_\
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M4K;:;H^C:9!;6-C:QY9S'!"GF2O)/*7FED=NTH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYL?^".G_)S7CK_
M +(3XF_]6!\,*_I.K^;'_@CI_P G->.O^R$^)O\ U8'PPH _I.HHHH ****
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M,?"-G@+]D\,> O#6F>%= MMJY \C2M)M(L D#9@<5_F3_P#!#W2]1_X*F_\
M!R1XQ_:]\2V5SJ'A/PG\0_C[^VI?VEY$Y72=(L]6G\+_  ,T,7#B+R)?!WB;
MQS\,VTV*1)+NXLO",L;QG9=74'^HY0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>,-2CTW2=/@7Y(+:$8DO-5UC4K@QV&B:!H]K?Z[KVJ3VNE:+IU_J5U;6LO\
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M63P+I]UJFCZ;X^O?Z[*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUEY(](\)>!_CG\,/%GB;59(HVEECTW0=!\4:AJM\\<2/+(MK:2LD:L[ *I(
M/I*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"Y-'\1ZCJ?D0V,WC0>--*L-R:)+M_<^@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA5\&_C%XE1_+N3;%K;Q)J'@G0O!-VC,LLL;6OBB826T0N$W1W%DUU]Y^%/\
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M_B"7_A&O#MOKVD+<1Z!#I<VI>(?%;P6NLVB>%M2TV[_N"_9(_P""%7_!,?\
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M4/&=O<:-\0-8TKPU=37$R>#-,T/5CK&J7$%Q-K-_J"?Y]WQ-_P""7'_!2/\
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MY//8B+8^[:0#I:_FQ_X(Z?\ )S7CK_LA/B;_ -6!\,*/^&S/^"GO_0L>.O\
MQ'N/_P"8ZC_@CI_R<UXZ_P"R$^)O_5@?#"@#^DZBBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@BT'2 X-GJ+Z=(S%ID^T 5_5)_Q'%_"O_I';\0/_ !([PY_\Z"OP#_X+Q?\
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M=I]K;V-A86-O%:65C96D26]K9V=K;I'!;6MM!''#;V\,:10Q(D<:*BJHM44
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MMO!?QO\ "2(C/<MJ'@>\O;@>(--LD"&[\4> M3\7^#X'EBMG\0B\+VT?Z;T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%?FI\;O^"Q__!+']G75-8T'XM_M
MZ?LT:'XE\/:A=Z1XA\):#\2]%^(7C+P_JUA+-!?:3KO@_P"',GBSQ-HVJ6<]
MO+#=:=J6E6MY;RA8Y8$>2)7\(_9J_P"#@[_@DU^UW^T/X2_9@^ 7[3=QXO\
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M_P"&9-<OK/P+)%H5[XG^%>DZ+\(]>\5MX>NIH-3\9>'=:(U#43=S7=U_F'_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5!%GI&EV=N"%4$1Y"@<4 =W1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.GQO\
MV/?V2?VF=0T75OVD?V6_V<_V@M5\-6<VG>'-3^-_P1^&?Q7U#0-/N)VN;BQT
M6\\>>&-?N=*LY[EWN)K:QD@@EG9I71I&+'PO_AT[_P $LO\ I&G^P!_XAO\
MLZ__ #N:^_Z* /@#_AT[_P $LO\ I&G^P!_XAO\ LZ__ #N:T=(_X):_\$R/
M#^JZ=KN@_P#!.?\ 81T36]'O;;4M)UC2/V1/V?M-U72]1LIDN+._T[4++X>P
MW=E>VD\:3VUU;313P3(DD4B.H8?=U% #41(T6.-51$541$4*B(H"JJJH 55
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MXKX]\#:CI7P2_P""JWPQO_$46E7H\-W_ .TC\+/#,&A?$#0;RRGDL;R7XO\
MP6C33=)UF>RO-PUS5?AVGA;5M+M;&:&W^&WB;69',@!_H3T5X!^S9^U5^SE^
MV'\,],^,7[,/QE\!_&SX<:KY<:>(O VMPZC_ &9?/!'<MHOB72)!!KOA'Q);
M031/?^&/%6F:-XAT[S$6_P!,MG8+7O\ 0 4444 %%%% !1110 4444 %%%%
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M+=[>0:KX7;Q/\#G>RCM8I)+_ $4:#<S&3:7TJ;4;FW2?^YK_ ((S?LU?MO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M--9Y81^T'^SOK=KK+6EC96H>>^O?$GACQGX%T!I-UAX\%\L<R?MC_P $W/\
M@\J^#WQ!_L'X:_\ !2CX9_\ "DO%<OV;3_\ AH;X/:9K?B?X2ZC.=D7V_P ;
M?#?S-9\?^!-P4/<WWA2Y^(VGW5W-),=(\+Z9%MB /[C**\L^#7QQ^#7[1/@'
M1_BG\!OBGX ^,7PXU]"VD>-OAMXKT7QCX;NY$"FXM!JFA7E[;0:C9,XAU'3+
MEX=1TVZ#VE_:VUS')$OJ= !1110 4444 %%%% !1110 4444 %%%% !1110
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MTZZAL]7\2^#/!6NW&H>&M>T.6'Q#HU[X7@NK">+3-0MX;NQU'1[Z\_U#H/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OYL?\ @CI_R<UXZ_[(3XF_]6!\,*_I.K^;'_@CI_R<
MUXZ_[(3XF_\ 5@?#"@#^DZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S$
M_P#@Y[^,'B__ (*(?\%J/@I^P'\'[XZTGP=?X8_LU>%K&!YKW2Q\=?C]X@T#
M6_'FL81EBA33[37/AUX5\2E"BV,_P_U#[;=(+606W^D)^T;\<_!G[,?P!^-/
M[17Q#G\CP1\$/A?XW^*7B8+,D-Q=:5X(\.ZAX@N--L6=9/,U35OL*Z7I-M'%
M-/=ZE>6EK;P3SS1Q/_G#_P#!K/\  _QC^W]_P6(^.7_!0;XS0'Q!)\$T^(7Q
M]\3:M/%/<:?=?M"?M&:WXET?PG;,D_F0K%9Z5J?Q2\4Z*)9GETS4/">B2VD.
MZ".XM0#_ $D/@C\(_"'P!^#7PG^!?P_M/L'@;X-_#?P3\+O!]H4C1X/#7@/P
MWIOA?15F$*)&UP=/TNW>YD51YL[22G+.2?4*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK^%_\
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MO]3\0:Q8^'_#^@^'] TJ&XU'6-:UK6=1L[*UM;>(0V\;SZEJ=S8:18:AJ%H
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M\,_'[2)+O_A4&N1^:[);_P#"93:CJWPMO8K2*.35-7\4^#;K4;@6?AN/R_\
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M;P9IUGJ=SXBT2UN/]%;1-?LH+BZU+0=7L[( _3NBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OP$_X*/?\&W?_  3?_P""A[ZY
MXVE\ /\ LT?'_53<WC_&OX!V&D^''U[5Y]TGVWXC_#IK9? _CPW%RWVC5M5-
MAH/CK4L"+_A.+6.OW[HH _RW_C/_ ,$1O^"['_!$7Q[K/Q]_88^(OQ!^*GP]
MTAVO+WXF_LEW>KSZ[>Z!IDDMS:Q?&G]F34SK-YX@TR"&&;5-3TO^P_C!\/=&
MAA%SJVOQNJ$?H'^P;_P>A^+?#LNE_#O_ (*4?L\/XA^Q2PZ3J'QR_9YM+;0_
M%-M-;R&TN+OQM\%/%&I6>B:A>^<?M&M7_@WQ=X4CL4MKB+2OA_>W$D5I'_H.
MU^6?[=O_  1?_P""<?\ P46M]2O_ -H[]G/PM)\2;^#RX/CE\.$7X;_&JRF5
M62WN;KQOX;AMY/%Z62R3"RTCXAV'C+P[;O/),FC>>5E4 ]H_8X_X*4_L,?M^
M^'XM<_9-_:4^&WQ7O/L7V_4O ]IJS>'_ (I>';=0HEE\2_"OQ3#HOQ T.VBE
M+0KJ-_X=BTF[DCD;3[^\A7S3]R5_G'_MA?\ !FW^U?\ !+7)OBG_ ,$WOVD]
M/^+I\.Z@NN^%/ GQ$U./X*?';0KJTE>338?"OQ-TBY@^'?B+Q!:R)!,FNZE<
M_!NWB=I&@AB>"/[1\D^ O^"Y/_!P9_P1[\4:9\)OVT?!OCWXB^%--N8]+L_"
MG[:W@'Q%JM]J]K;10+=3_#_]HO1[K2O$GC24V=MY=GK<_CKXG>&;:9;F<:9=
M3?:U< _U)J_B?^//_!ZC^SC\,?C%\1OAU\-OV+_BE\5_!_@;Q=KOA+2_B+J7
MQ9\-_#UO&!\/:E<Z3=:]IWA,^"?&%UINAZE=6DMWH1U/5X]7N=)EL[G5M(T/
M4);G2;/V7]CW_@\E_P"">WQECL-$_:M^'GQ4_8]\63+$MWKGV.[^.?PD$K%8
MCY7B7P'H=G\1K:220F8PW?PF^P6EN3YVMRM&S-_/1_P:L? _]F?]J?\ X*C_
M +6_AO\ :!^#7P1_:%\"R_LY?%/QGX,\,_&SX;>!_BCX;37#^T!\(X[+Q+H'
MA[Q_HFM6%MKD?AW5M5@BU.SLHM3@TG4=2M_-CM;J[1P#]5O^(XOX5_\ 2.WX
M@?\ B1WAS_YT%'_$<7\*_P#I';\0/_$CO#G_ ,Z"OZO?^'3O_!++_I&G^P!_
MXAO^SK_\[FC_ (=._P#!++_I&G^P!_XAO^SK_P#.YH _ 7]@K_@[P_9Z_;,_
M:K^#G[+?BO\ 9+^)WP1O_CIXTT3X:^!_',?Q(\-_$G1[?QYXJO8]+\*Z9XDT
MJ+POX*U'3=)UK5Y[72%UC37UN6ROKZT:ZTM-/-WJ%G_7S7^8Y^W#\&_A#\!?
M^#MW]E?X9_ SX5_#?X+_  XT?]J?_@G9=Z1\/_A/X'\,?#KP1I5WK"_"+4]6
MN=-\*>#]+T?0;&XU34KJYU#49K6PBDO;ZXGN[EI;B621O]..@ HHHH ****
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M9/V!?^5S;XP_]G/_ /!0#_U3GQQKPH_\$BO^#H__ ()LH)?V;/&/QQ\0>!=
M.V*V_93_ &GF\8^!IQ!EK=$^!7BCQ!X;UW78F1)&MTD^$5_% ,PS"WEN8H9_
MR#_9>_X*,?M*?L$?\%7)OV]OV@_AEJGQ/_:;\$?$+XQ2_'+X;_%&UG^#7B?6
M?'?Q"\)^,/AY\0K3Q+9:9X3B;P'XKL+CQ-J5Y+9_\(48-/UBT%O=:$8C+  #
M_:,HK^5G]C#_ (.[?^"9/[2-QI?ACX\Q_$']B_QY?F. O\4+%?&OPEGOIF58
M[2Q^*O@:UN+BPB7+M<:KX]\$> =%MU0;]1+.JU_3;\./B?\ #;XQ>$-*^(/P
MD^(/@CXH^ ]>B\_1/&OP[\5:%XT\)ZQ#A6,FF>(O#=_J6D7R .I9K:\E"[AN
MQD4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%5[N[M+"UN;^_N;>RL;*WFN[R\NYH[:UM+2VC:
M:XN;FXF9(8+>"%'EFFE=(XHT9W954D %BBOECP7^W-^Q;\2/C!%^S[\._P!K
M/]G#Q]\<IK'5=1B^$O@KXU?#OQ5\07MM#MY+S60/"VA>(;_5_M6E6$,^I:A8
M?9?M]II5M=:I/;)I]M/<Q_FG_P %F/\ @N[\"O\ @CI;_"OP]XS^$WCWXX_%
MOXQZ=X@U_P (^!?"VJZ9X.\/V'ACPS<VNG7^M>*O'6KV>L#33=ZM?06&DZ=H
MWAGQ'>W M]2NK]-+@M[$ZF ?N)JNJZ9H6EZEK>M:A9:1HVCV%YJNK:KJ5U#9
M:=IFF:?;R7=_J%_>W+QV]I965K#+<W5U/)'#;P122RNJ(S#_ "A/CYH7[1O_
M  <\?\%>_P!I?5/V>KDQ> ?AO\*/B5<_!:Y\1PW46@^'/@I\%=+U>R^$.BW2
MW$EL-$UGX_?%?6-+NKZ*XN)9/#6L?%'Q#K/V?4]'\(SV1]>_X*&?\';W[77[
M:_P#^,/[-/PZ_9]^%'[-OPV^-OAB^\"^+?$%CXM\:?$?XLVO@?698$\2>'M%
M\7G_ (0'PK:#Q7HJ7WA3Q%>77P[OFN/#.MZQ:Z;#I6I3VFK6/]*'_!LI_P $
MX_&O[/W_  2$^)/Q4T%=5^"G[7?[>GACQ]XB\,_$#QAX8>+6?AMX;T[1_%?@
MS]FC64T*\C6YO_#-K=7MU\;]+6>&$^)-.\=6;[9].32I2 ?!7_!GU_P4J@\-
M>$_CE_P3)_:'\30>"]0^$EWXC^,OP.;QY?Q>'5T30I]<BT[XW_"ZY?7);"#2
M+GPSXSOK+QYINBRYU&>X\4_$B[N5AM]$")_:E\,_VL?V6?C3XV\0_#3X.?M+
M? #XL_$;PEI[:MXJ\ ?#/XR?#KQYXV\,Z4MU#8MJ?B'PKX6\1ZKKNBZ>M[<V
M]FU[J5A;6PNIX;<R>;*B-_CT_P#!47_@E!_P4!_X)S>(_"7C_P#;CT[3]<U+
M]HOQ)X]UBT^*>B_$.3XIGQ=XVTV]L-9\8W'C'Q1<(NK+XNUR;Q)'XA\[Q$1J
M7B03:KJ$<UW<:?J_V7^U;_@W7_X-]OAG^S3XL^ 7_!4^P_;+N?CXGC?X-W/B
M/X1^#O 7P\;X?^$=/L/BUX*O-"UM/B!K&J>,/%.K>)]3T/3];U#2;GPBFB^$
M_P#A&/&NCM/J5WJ=UIRV%H ?LK_P5"_X+V?L(_\ !)_Q;X:^&'Q]G^*GCWXR
M>+/",7CK3?A3\%O".D^(O$.G>$[_ %34=$T;7_$NL>+O%'@?P=HECK&JZ-K4
M-I9_\)'>>(3;:/>7YT$VL^E/J7\X_P 8/^#X7P[!+/9_ '_@G]K6J0><YMO$
M?Q@^.ECH4HMT8B-9_!?@OX?>(T::="'=H_'RI:,AC5+T2>;%_5+^W!_P1N_X
M)T?\%&OB1X%^+?[7W[/L/Q.\?_#[PZ?!VC>(+#X@?$WX?7E_X034K_6;7PQX
MBD^''C#PG)KVDZ;K&JZGJ>E+?2/=Z;<:EJ4=G=PVFHWUM<;OP7_X(^_\$M_V
M?3:3_"K]@C]EW1M4L'MI+#Q)KWPE\+^/_&%C+:9,,MEXT^(=EXJ\66DNXB26
M2WUF-[B6.&6X:62&%T ,+2?VO/VA_P!IW_@DTO[:/[(WP4;1?VE_BO\ LL7W
MQ;^"7P1^(\JZBD7Q#O\ P]<WFB: ]S,?"]OXGL[VZA:\\%WMW_PC=AXQM+CP
M_=7RZ+9:O,EM_!A<:7_P>+?MG7-_&\?_  4*\(+JMS=-/:_VGX>_8;TZ,-?B
M26VM_M%_\ ;:SL/-(BAA26.UGTW?"GG::TJM_J$0PQ6\44$$4<$$$:0PPPHL
M<4,4:A(XHHT"I''&BA$1%"HH"J  !4E '\A'_!O/_P $J_\ @L#^QC^T3\5/
MCO\ M^?M!ZE/\.O&_P +[WPC)\$==^..N?'KQ%XL\<W?B+0]9TGQKK5]-J.N
M>$O#4GA2TL=;MK?6-*\1:IXAU23Q!>Z9)!;Z5/=W$_T/_P %5O\ @V2^!G_!
M4?\ :Y7]K7Q#^TS\4_@WKNL^"O#'@_QUX1T'PGH'C/3-</@VRETK0=6\-:AK
M>KZ:_@Z4Z5]DMM6T\Z?K^GW]S:-J5O#I][?7\MS_ $X44 ?RF?"#_@SI_P""
M2?P\DL[GX@7_ .T[\>KB*83WMEX_^+NE^%]"O/EC4VD5K\(/!7PXURTL3Y;.
M%_X26>_#SS?\3(Q^1';_ -//A[X8_#SPI\-=#^#?A_P7X;T[X4^&_!.F?#?1
M/AZFDVD_A*Q\ Z/H<'AK3?""Z)=1SV,WA^U\/VT.CKIMS%-;2:>@MIDDC+ ]
MU7Y2?MW_ /!;#_@FY_P3IAU;3/VA?VBO#=W\3],AF9/@1\+#%\2_C1<WD<?F
MQ:=J'A#P_<O;>")KU WV&_\ B9K'@C0KID=$U?>-M 'Z%?#?X'_!7X-VKV7P
MA^$'PN^%5E)%) ]I\-_A_P"$_ UJ\$LL<\L+V_AC2=+B:*2>&*:2,H4>6*.1
M@712-7XD_%/X8_!KPGJ'C[XO_$;P'\*O NDX_M7QI\2?%_A_P-X3TS<DDJ_V
MAXC\3ZCI>CV>Z.&:0?:;R/*12./EC8C_ #N/VOO^#Q/]L[]H/Q'/\)/^";?[
M.=A\&D\2WKZ'X1\7^*=$_P"%[?M#^(;B8/\ 8KGPOX L+&Z^'/AS69U+!_#]
MUH/Q>P81+:ZOEF6/YM^%W_!OA_P7B_X*R>,K3XV?MT_$'Q5\)=+U)FN8O&'[
M9GCGQ-KGQ&M=,O)=]QIW@;X$:4VK:[X*AM92##X1\2V?PAT6WMT8:<J)'##(
M ?U4?M=?\'9?_!)W]FN74=!^&GC'X@?M=^-K-98%T_X"^%MG@>VU%-_EPZG\
M3_B!=>$/#EYILBHK-J_@&+X@1)YT2I;RR+<I;_SB?';_ (/%/^"C/[0WB5/A
M[^PW^RW\-O@[<:[<O:^'K==&\4?M-_&R]E562 :-"NG^&?!DDLX)N)].?X5>
M(98I!###J#Q0SR7O[S?L<?\ !G[_ ,$TO@"FFZ[^T;JWQ+_;-\<6H22YA\9Z
MI<_"SX3+=)&@2XT_X=?#S58?$4@6?S9)+/Q5\2_%NEW"&"&;3BL<IN/Z1_@-
M^RQ^S3^RUX=/A3]F[X!?![X%>'WBCBNM.^%/P[\*^!DU/RMI$^LS^'M+L+O6
M[V1D66XU#5Y[V^NI\SW-Q+,S2$ _S73\"?\ @[E_X*4[G\9W?[;OAWPGKBB7
M5;;Q_P"-]"_8E\ RV-UNQ-?_  SCU'X*6^LV)R&BLM+\":Q(L<B3V]B+<^:/
M5OAI_P &7'_!1;QW<QZY\<_VG?V7OAR^K21W6I#2]9^*?Q<\:6\DD[)=MJT,
MW@;P;H%U?+"HN(C9>-M2AN=\<<U[:OYAC_TQZ* /\K7_ (+&?\&U&D_\$EOV
M)]"_:BN/VOM1^/'BO4?C'X)^%M_X2A^"=M\-O#UO'XOT'QCK4NIVFIO\4?'6
MI3OI<GA9+.-)K6!=12[:Z:/3FC%J?L#_ ()2_P#!JM\ /^"AO[ '[//[8WC+
M]JSXP_#OQ+\:--\>WVI^#?#/@OP5JFAZ*_@_XK>._AY;1V%_JLRW]PMY9>$;
M;49S<*#'=7D\4?[J.,U_2_\ \'1/[(_[0/[8_P#P2UUCP+^S7\.-?^+?Q!\
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M9R_^B6H _P!+NBO\FWXS?MM_\'&G_!*+]IWX'Z!^V/\ M*_M"^$_&FOKX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKG?$_B_PGX)TZ/6/&?BCP[X1TB6^L],BU7Q/K>FZ!ITFI:C
M+Y&GZ='?:K<VEL]]?3D0V=HLIN+J4^7!&[\4 =%1110 4444 %%%% !1110
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M,'@SXP?&WXQVGPJF\?\ PR_9Q\;_ !$\5Z!JWB[QYKMOJOPL^'GC^'Q;X/\
MA[_PD/Q+EU"]T;Q5IVFC1M<T_3[?Q5X:U/3O$4]]K%[;6 !^H/\ P2)^&7[*
M/_!2#]L?]M#]NC_@L/\ M&_ 7X9_#GQ=H?Q@6"Q^,OQ@\!_#"]^(GQP^-^A:
MSIEQ+\*])\;^(+/4-6L_V>? NN2:SX:LO#UG?W7@KQ1??!=](0R6%O;UZ-_P
M;S?\%(OAW_P2,_X*+?'_ /9?^-_QY\#:[^QO\7]4\1^"-3^.?AC6AXC^$UOX
MZ^&%YK4_PE^-^B:EHCZTL/A'X@>'Y-4\,:D;.$W4+>+?"=SXJELH?!=VEG^I
MGQ>_X-/_ -BB?PK^RQX0\8_\%)_ G[,'Q9^&GP$T'P9^T'X0URU^'GB^3XA_
M%._U#Q/X\U_QCX4E\3?%GX<:SX1L%\0^+-9TNQLM2T?Q5#J'@[P]H"6G]C7-
MO?7=S^2'_!9;_@VGNO\ @F9^R9X9_;#^"G[2>H_M3?#&/QOHWA?XGRGX=:7X
M3C\%:#XQ4V7@SQ[9:MH?C?QAI^L>&K[Q4MGX0U&0FV>WUCQ-X7^RM=0W=XUH
M ?Z?VM_''X.>'?@S?_M$ZQ\3O ]I\"--^'[_ !6NOBZ/$>EW/P^_X5LNB#Q(
MGC>V\46EQ/I5]X;N-"9-5LM4L;FXMK^SEAELGN!/"'_%J?\ X.B/^"%5O/-;
MR?MSQ-)!+)"[0?LV_M>W4#/$Y1C#<VWP!FMKB(LI,<]O++!,F)(I'C96/'_\
M$9M6_98_X*C?\$$_@]^SKJ>@W$GPXLO@4?V-_P!H#P)8^(KZ/Q#X=\;_  _T
M/3M&US4K76EDEN]+U+Q+;S^'OC!X3=3<0:1:^*=%LW@D2PN+!?BO_B"I_P""
M67_1?/V__P#PZ?[.O_T*M '[H?L4_P#!87_@F]_P41\;^)?AI^Q[^T[H/Q9^
M('A+PZ?%NL^#;KP+\6/AIXC_ .$9COK33;K7-)TKXM^ O =WXCTW3K_4-.M=
M7N?#D>JQZ/+J6FC5#9C4+,SP_MI_\%C/^";'_!/+Q[H/PN_:^_:@T'X4?$7Q
M)X=A\6Z9X,M/ ?Q:^)?B"/PW<WEW866L:QIWPD\ ^/)O#EGJ-UI]]%I;^(ET
MIM4^QW4FGK<Q6\KI\K_\$R?^#>+]A#_@E3\:_$/[0?P%\2?M"_$3XGZYX&U/
MX>6>L?'3QSX%\1VGA;P[KFHZ3J6N#PWI7P_^%_PRL4U'5Y-$TZVN=1UJ+6KF
MWL8[BUTUK&.^OOM,'_!3'_@W9_8*_P""I_QOT?\ :(^.OB#]H3X<?%/3_!NE
M>!=6UKX%^.O _AVT\7Z)H-Q?3:"_B72OB%\,/B=8-J6CQ:A<V-MJ&APZ'/<6
M MK;4C?"RLV@ -?1O^#E+_@B'KMI:7ME^WIX,@AO7>.%-9^%G[0/AV[1DN'M
MB;NP\0?"73+ZP0R1LRR7UM;QO;E+M&:UECF?]?[?XS_"2Z^$,'[0$'Q+\#M\
M#KGX?Q?%:'XN/XFTB'X=M\,YM!7Q1'X];Q=-=1Z)%X3/AQAK;:Y+>)IZ:9F\
M>=807'\D-]_P9._\$[9-4>73?VH/VTK31C+ 8["^U[X&ZAJBP*D8N8WU>W^"
M>F6CRRR"9H)ET2-+=)(TD@N3$TDW](FM_P#!//\ 9YUG_@GU/_P336W\7Z=^
MSF_P!M?V=K:6S\0J_CVR\)V.A0:/8^((O$=W87%G-XOM[NV@\0M>76C3:+<:
MRC+/H3Z1(^DD \#T/_@NM_P1\\0R7$5A_P %$?V8[=K9$DD.N>/[;PQ&RR,R
MJ+>7Q+!I,5VX*DO':O-)$I5I%164GZ[_ &=?VX_V-OVNKOQ!IW[+_P"U%\!_
MCWJWA2WAO?$^A_"OXH>$?&6O^'].N9(H+75=8T#1M5NM9T[1[NYE6TM-8NK&
M+3+J]6:RM[N2ZMYX8_Y#_$'_  8_?L^7)B_X17]O;XRZ,HEG,P\0?!SP3XF,
MD#%?LT<3:=XM\)"&6(!_/F=9TN"RF."VVD/^G'_!'[_@VO\ A/\ \$F?VE?$
MG[3VG?M.^/?CQXQU+X8:W\,/#VB:EX!TCX<>']"L?$^KZ'JFOZOJ,6G>*O%=
MYXBOY8O#NGV.E6\MSING::D^H7=Q:ZE>OID^D@'] GQ)^/WP)^#5]H&E_%_X
MU_"3X5:GXKE,'A;3OB3\1_!W@:^\2S+-';M#H%IXGUG2[C6)1<310&/3H[EQ
M-+'$1O=5.%:?M3_LQ7]W;6%A^T;\![V^O;B&TL[.T^+WP^N;N[N[F18;>VMK
M>'Q"\T]Q/,Z10PQ(\DLCJB*S, ?YM_\ @MW_ ,&U'B?_ (*N?M1Z7^U3X#_:
MZMOA+KUM\)- ^&E_\//'OP[U+QMX<2;PA?Z]?Z->^&?$&C^+=%N_#>E:L=?N
M&UK2)/#^LF#5EO=>M;JZ?5Y=-L_Q#_X@AOVI_P#H^#]G_P#\-[\1?_CU '^C
MY17YG:]^P;\0U_X)/3_\$Z/!_P"TCXNT_P")-E^R)8_LW:+^TK>0ZA:^()->
MTOP/;>%8_%%W966KW&L:;H>J-:MIEQI=GK][K&E^%+M]/M=:OM1MH]0F_@XG
M_P"#+K_@JOHDLNK:'\?/V%;B]TF5M0T@Z;\5_P!H#3-;EN;&3[18/8RS_LSV
MMGI^IM+%$]O))J\$%K=;&.H(B?:  ?Z?%%?Q]_\ !OC_ ,$0?^"E?_!-O]I_
MXD_&C]K+]H[P5JGPK\1?"34_ =O\'OA_\4?B'\2+7QEXKU'Q!X<U72_%7B*R
M\4^&?#/AW1!X.L]'U*'2-6M!J?B.:77+[38/[-T>[U0ZED?\' 7_  1#_P""
MH?\ P4=_:S\&_&']E;]H[P39?!/2?A/H/A.U^$WCSXL?$/X:VW@+QAI&JZY<
M:[JVD:-X9\->)?#VN?\ "7P:I97MSXED-CX@\RT.@W\#Z5H^ASS ']C=%?YA
M=K_P:>?\%R[2YM[JU^._P%L[JVGAN+:[@_:;^+T,]K/#(LD-S#-#\,A-%+!(
MJRQRQ$2QNH:,[P*_O UC]C7]HOQ5_P $FY/V&?$7[3^MC]I[4?V1;+X&ZS^U
M)87OB1M2NOB9#X)MM#O/%T^L/=6WC/4M,U'487TS5]?N+FW\7ZUH=S>:Q=I#
MKU[+"H!WW_!2O]O+X;?\$YOV.?CA^T]XZU+0IM:\ ^"-0N?ASX&U'4X+;4/B
M'\2M6DBT#X?^$[&P6XCU2[L=4\7ZEI,7B&\TR"XET/PXFL:[,@MM+G9?\X/_
M ()._P#!&WXC?\%J?@O_ ,%.OVQ?BCXQO]8^-4]AXD'P$U.]UJ&TOO'O[7/B
M/6[?XQ^*O$?BN$2Q"'PUJ]I;1?#B6\O[6?0VF^*^OZMIL0UKX?0"U_(_]H[_
M ()H?'SX ?M_V?\ P3A'C#X3?'G]I75?&_P[^';_ /"C/$'C/Q/X,A^(GQ0&
MD7&E^%+_ ,1>-? ?@+4QJ^C0Z_IMSXSN5T.;2O#AFO(;_4S>:5K-OI_^@9_P
M06_X-ROC7_P2>_:5\8_M,?&']J+P;X_OO$?P;UGX60_"_P"$>B^*[3PS>7/B
M'Q+X9UZXUKQ1XC\5#1Y]7M- 3PO$FB:9%X3MI9M2U5]2DU&P32?L6L@'Y-_\
M&N?_  6Q^"?['_P;^-W["/[?GQ=TWX&>&?A3XHU'X@? KQ!\28]9L[?1SK^L
MRV/Q:^#<\$.GW-QI.HZ1XS:+QQHFBRVGVV[U#Q/\16G,7]EV\!_HW\6_\'1?
M_!#[PG=160_;+E\3733P13KX2^ O[1VL6MI#/%YHO)=4;X36ND7,$0*I/%IM
M_?7T4K>6UGO24)_%_P#\'8'_  3>M?V/_P#@H!:_M2>#/#EQ;_ +]MJXU3X@
M:E#HRQ6-OX>^.FCW%D?C/X>AN3:7UOIUQXV_M#3/B?IEYJ$4WV[7/%?C&&QT
M^:P\,RQ+^\7[&O\ P::?\$?/VA/@9\&_VE_#7Q^_;*^+_P /_C'X$\-?$3PL
ML_C_ .$7A/2)M&\1Z?8:DNDZSIOAWX-R>(-.\0Z+<B^T'Q'81^+HY=+U.'4=
M+F@@U#3S.H!_45^T3^WK\"O@!^PEXW_X*%QZC??%/X"^&?@WI7QJ\-7_ ,.X
MAJ%Y\0_#/BJUTF3P,OAS[;]DCME\576OZ';K>ZL+.WT2"^EO]9%I!87@C_B=
M^+'_  ?"?$^^,]O\#/V / 7A8(0MKJWQ8^./B'QZ;D8D)FG\/>#_  %\./L1
M+-"HMX_$^H "&1OM1-PJ6O\ >AX*_9V^"?@#X >&?V6O#_PW\,2?L_>$OAAI
M?P:TOX5^(-/C\6>%;GX9Z3X>B\+0^$]?L?$_]KCQ1IUYH4(LM9_X2)M4GUT2
MW4VL2WMQ=W,LOC/PN_X)Q_\ !/SX)/;S_"/]B']D[X=W]K(LT6L>%/V??A7I
M.OF:.X-S%-/XAM_"RZY=303$-;2W6H326RQPQ0-'%#"B '\__P#P;L_\%Q/V
M]?\ @K)\:OC]X6_:1_9V^&/AGX,^!_AS%XP\+?&;X,^"OB/X5\&Z#X]@\3>%
M?#\7PBUC4O&GC;Q_8^(-:\5:!K.L^--,6WUBPU;28O"&O&YMKW3=4TV/1OE[
M_@NI_P $]?\ @X=_:^_;O\2C]CKXI?$&/]AO7/"'@&R\!Z#X'_:GT+X$>!O!
M=S!X3T?3O'UA\3_ D/COPAXG\;>(;[QW!XH\2VGB)?"OCE(O"NN:3HECJ-LU
MC/HUM_;3:VMM8VUO965O!:6=I!#:VEI:PQV]M:VUO&L4%O;P1*D4$$$2)%##
M$BQQQJJ(JJH GH _S6/@[_P99_MY_$'6K+7?VFOVL?V>OAE9ZO>177B";P<W
MQ(^.7Q!A@:55NVO+?6M ^&?AR[U9HE=H3%XWU"U8&!I;T,988O[X_BO^PK^S
MU^T#^QS8?L-_M!^&]1^,WP0@^'7P^^'FI1^+-<U2T\6ZROPTL]"B\,>+Y_%G
MAVYT;6;#QK;ZGX=T[7I=<TFYL9)]3%RDT4FG7EW8S_8E% 'XF?!;_@W/_P""
M,'P+FMKWPW^PK\-/&>IV\YN7OOC3K/COXY0W<H=B@N?#WQ7\5>+?"/D1QE(1
M9V_AZWLY4C62XMYKEYIY?UR^&GPE^%7P7\,0>"?@[\,_A]\)_!MK*\]MX2^&
MG@SPYX$\,6\\BHCS0:#X6TW2M*AE=(XT>2.T5V6-%)(50/0:* "BBB@ HHHH
M **** /S=_X*N?\ !.?PW_P5-_8W\8?LD^)/BGXC^#2:_P")_!_C+1O'OA[1
M+7Q4NF:]X,U,W]A%KWA*[U30(_%&@7,<URESI,?B'0+@7JZ?J,&J12:>L4_\
MDO\ Q Q_]91?_-)O_P KBO[_ "B@#^ /_B!C_P"LHO\ YI-_^5Q1_P 0,?\
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MO[0/PO\ $5KHD5MX0T#Q%J$4\VB^&];OQ/<6D-F(["2-[E9Y((I0#LH_"O\
MP=W?\$T,G2V_;C\4^$M"P8(=)U+0/V\/ -OH]ODEK70&F^/$'A?0V@#RSH=)
M\.3:=&\ES<1Z=<J\L?9>%?\ @[[_ ."O?P)U2T\,?M$_L_\ [/7C"YM_*.HV
MOQ"^#_Q0^$/Q!NHXYQ+,T4FB^.]#T"QDEMIQ 9&\ 7,416RG6$D7*7O]D_\
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M/$3WFDZ:9)K4?&#]F[6=/FU7Q%8VELD^H:G:W7@OXH> =$MXGGU'Q"@57/\
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M*:]')/I/C#P-K5Q;*EO+KO@;Q=IVM^$M:DMT6VFU+1[F>UW6LL+L ?4E%%%
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M-!\/Z99:-HNE646?*L]-TO3H+:QL;6/)\NWM8(HDR=J#)K8H _C+_P""4?\
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M%,DDCACDEED2**)&DEED94CCC12SR2.Q"HB*"S,Q"JH)) !- #Z_S9/V!?\
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M,FSY5]HOB#0KN^TK4K5R&7SK2ZE0.KQL0Z,H .THHHH **** "BBB@ HHHH
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M81R(QZSP=\5OA?\ $3X>:;\7?A]\1_ ?COX4:UHMSXDT;XF^#/%WA_Q3\/\
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M:1QW?B.YL/#UM+*T>F0-!^W5]_P>K?\ !+F&*\%A\ ?V];VZBCN/L2S?#/\
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M1+>ZO#%(+6WFODEN#&XB1RC8_$O_ (+*_P#!7;]E_P"!'_!,_P#:I\<_ /\
M:'_9F^./Q<UWX?Q_#/P!X&\)_$_X7_%F6YU3XN:I8?#ZX\1ZCX.T;Q#K*ZKH
MOA'0O$.K>+;F'5;"ZT&^;1H--U2VO+6_:SN0#_-D_8 _X*BZK^Q=^VC\2_\
M@H/\0?@]IO[5'[47B.R^)&N?#[7?B-XNNM!\*>$_C-\7-4GF\;_&+Q3I>CZ)
M=ZQXQU&30-5\6:!IOA[2]=\&10'QA?ZHNM0SZ9IT!_335/\ @\#_ ."P^H>(
M)]9M-7_9JT/3I;IKB/PGI?P/\[P_;0M)"XL8+G6_%NL>*FM46)X5>Y\2W%Z8
M[F8O>/*MO+!^EG_!J5_P1X_9,^./PP\2_MR_ME>#?A1\<=4\8>*?$GPV_9W^
M!7Q5L_#'C/PC#HWAC-AXY^)WB+X;^)8K_3/%^MZEKJZGX6\)6NM:7?V'ANW\
M->(/$$=E<ZMJ6AZEX?\ [.O^'3O_  2R_P"D:?[ '_B&_P"SK_\ .YH _P Z
M+]O7_@Y7_P"'H'_!/[Q=^R/^V)^Q?X.3XPC7?#GCKX7?'WX,_$/4O#GAWP5\
M0_"UP8[#7E^%?C70/&VJPIJ?AZ_\4>$O$2VWQ/N$O]#\6:BMA:Z3=VMI<5^V
MW_!EM^WAXJ\<?#+X_P#_  3T\9_VIJFF_!2,?'OX,:PZ3W%CH/@SQMXB@T;X
MD> YK@A;;3K6V\=ZEI?C3PW9CS+C4K[QGX]N'9(=-A2OI3_@XS_X((_LA^,?
MV%/B3^U+^R!^SW\*/V<OCA^RCX0U;XFZIHWP*^'7A?X8>#/BC\(O#@?5_B7I
M/BSP?X%T?2- G\1^%O#$>J^-?#GB]-*;6V&@7/A;4;J;2=4M;C0^H_X,Y?C;
M\-_BE_P3Q^(G@32_A7\+O _Q@^ _Q9_X07XA^-_ O@#PKX2\5?%[P3KNF2>+
M_A9XK^)^O>'M&TJ]\8^*=$?4_&_@:VU+79M3U'^Q/"NFWMU?3ZAJE_+( ?UU
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?EW_P6/_X*#:-_P3._X)_?&[]I8W5A_P +
M(72A\.O@+HM\(95\0_'#QS;7MAX)C^Q3CRM2L/"R0:I\0O$>GLT;7?A3P;KT
M,,@N'A5OU$K\7O\ @M;_ ,$<_#?_  6.^"?PL^%FJ?'SQ'^S[KWPB^(.H>._
M#?BC3?!%K\2O#VH'6=!ET'5=.\1>")_%?@2>_G6W^SRZ-JMGXNTV726.H126
MNH0ZDZP '\GO_!I-\._V8? OC?\ : _X*2?M@_M-_ +PA\7M;U+7/A/\&='^
M,GQO^'/AOQ\TWB%[;Q'\:?C#J&E>,/$]GK@O/%-Q?:9X,T'Q%+#%=7D(^)L$
MCSVNJ1RR?V[^./VR_P#@F7\3?#>H>#?B3^U9^PG\0?"&K)Y>J>%?''QS_9_\
M6>&]2C 90FH:'KWBB_TN\0*[#;<VLBX9AC#'/\=__$#'_P!91?\ S2;_ /*X
MH_X@8_\ K*+_ .:3?_E<4 ?D1_P<T_L>?L.? G]IOX7?M'_L ^,?V7M>^!OQ
MPTB33/B#\%?V>?B'\/-8\-?#7XJ^"&MC<W%KX-^&?B$CP5X)^)OA2YL)K&ST
M&STS3K/Q+X<\97$5QI\VKZ7 ?[BO$E_\1/V_/^""OA%_^".7C/2/V;?%GQ'_
M &;?AQH'P'L-)\1W7ARX^&FE^!+K1/#7Q$^ VB^/K19[[P7XUT33?"_B_P"$
M6G>.HY(I],\2VL>K+K^AK,/%FF?SV?\ $#'_ -91?_-)O_RN*_K&_P""27_!
M-3PU_P $H_V/M&_92\.?%KQ/\;'A\<^+OB)XA\>>(]$M_"EO>^(O%PTNWN[3
MPOX-M]9\2)X1\-6UEHFGM%HS^)=?FEUB;6=9GU-Y=6:WMP#^ C1/^"K'_!R1
M_P $4M=T_P %_M9Z%\6O&7PYLKZ/3[71OVR/">I_&3P!KCAT1[3P7^TQH&L/
MKNKS06D#6^GV&@?&?7-"TM6BD?P]*H2)_P"UK_@AO_P6S\*_\%E/AA\7=67X
M)Z[\#?BK\ -1\":=\2O#O]O#QGX#U6W^(EKXJD\+ZYX+\7MI.@7LCW<O@?Q(
M-8\,:MHT5[X=5=,\O5_$$%]]MB_;S7_#^@^*]%U3PWXHT32/$GAW6[*?3=:T
M#7]-L]8T75].ND,=S8:II6HPW-C?V5Q&3'/:W<$L$R$I)&RDBO,O@G^SM\ ?
MV:O#>J^#?V=O@C\)?@1X2UWQ%J'B[6O#'P?^'GA+X;Z!J_BC5([:"_\ $.I:
M1X/TG1["]UBXM+*QL&U"Y@DN4T[3]/TV.1+&PL[>  ]3M]8TF[U#4=)M-4TZ
MZU72!:G5M,M[VVGU#2Q?P_:+$ZC912M<V0O(/W]J;F*(7$/[R'>GS5HU_G)_
M\%(/^#=W_@L1^SY^V!\;?V\?^"?OQN\<?'.Z\>_$;QE\4K7Q%\-_BYK/PU_:
MT\,VWBG5+GQ%J6@ZW:ZAJWAZT\>V.DBX7P_I\/@SQ?K6J^*],L;>%_A_ID<B
M:2OO'_!&;_@X+_X*K:I^W1\&_P#@FU^W]\$/$7Q5U_QYXF/@C5/$/B3X2:Q\
M)_VF?A2(M-NKA?%GCSP_8:3H&@:_X'\,6FFR:AXPO]:\#Z)XCM]$34_$][XP
MU2:Q.GWX!_?I17E_Q%^-_P %_A!>^$--^+7Q>^%_PNU'XA:M/H/@&P^(OC_P
MIX)O?'&NVL45Q=:+X0M?$NK:9/XEU:V@G@FGT[18[V\ABFBDDA5)$8^H4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_*K\;?^#/C
M_@E;\:?BU\0?BRGCG]K[X4R?$3Q7K?C"\\ _"OXE?"&Q^'OAW4?$&H7&J:C9
M^$].\;? /QUXATO1OMMU/)9:7=>)]0M]-A=+*P%M8P6]M%_5510!_(%_Q!4_
M\$LO^B^?M_\ _AT_V=?_ *%6C_B"I_X)9?\ 1?/V_P#_ ,.G^SK_ /0JU_49
M^TG^T=\&_P!D7X&?$C]H_P#: \96G@'X0_"C0#XB\9>)[NVO+XVEK)>6NEZ=
M8:?IFFP76I:OK>NZUJ&FZ%H&C:;:W&H:OK6I6&FV4$ES=1H?)OV%?V^?V8_^
M"COP,@_:&_93\<S^-?  \2ZQX+UJ'5=&U#PWXG\)^,-"BL;O4?#7BGP]JD<=
MWI>IKIFJZ1K%L5:XL[_1]7TW4;&[N+>Z5P ?C?\ L9?\&J7_  31_8G_ &CO
MAG^T]X-\6_M2_%;QY\(?$%IXP\!:)\:?B'\,=7\%:/XRTJ07&@>*Y-)^'WP6
M^&^J:AJWAV^2/4M&CO\ 7+C2H-2@M[R?3;F:VMVB_I:HHH **** "BBO/M0^
M+7PJTGQSI'POU7XF?#[3/B7X@BFGT'X=ZAXS\.67CG6X+>U-]<3:1X2N=2CU
M_4HH+)6NYI+/3YDBM5-PY6(%Z /0:*_-;_@IG_P5;_9-_P""3_PI\*_%+]J+
M4?'%X_Q US4/#OPY^'OPQ\,6_BCQ]X[U31K6TOM>&CVVKZQX8\+:?8Z#97]C
M<ZKJ?B?Q5H%A']MLK2UGN]1O+6RF_DF^/O\ P>_7#?;]._9<_80ACPTHTSQC
M\??BP\^Y.1 U_P##;X=^'[?8W225;?XK2#K"C_\ +:@#_0"HK\>_^")__!0C
MX[?\%//^"?\ HG[3_P 9?@[H/P.^)>I^,O'?@C3AH>F^*(OAMX[M?#=OI4FD
M_$WP1H_B;5;[Q"G@V\U'5KOPY<V$WBO7&?7/"/B%+7Q"T;QQV?\ %K\4/^"#
M'_!SO^VU\2?&&E_M4?&._P!3T"]\0ZM:KXJ^-'[94.N?!K4].N;RX9]0\'?#
M/X::MX\O?"?@Z]$TMQ8>&8/A/X4DLK><PMX7L9#);@ _T;- _:'_ &?_ !7X
M^F^%'A;XY_!WQ+\4K:SNM1N/AMH'Q-\%:SX^@T^QQ]NOIO!VG:W<^(HK.SR/
MM5R^G+#;Y'G.F17Y_P#_  4S_P""T7[$/_!)]/ -A^U#K_C[4?&WQ.TW6=<\
M%_#7X4^#XO&'C35- T&ZMK#4-=NAJFL^&/#&AZ6=1NTT^PFU_P 3:7)JUW#J
M":7#>+I6J/9_@+_P2%_X-/OB)^PI^UQ\%_VQ_P!H3]K?PIXG\3?!+4]8\0Z%
M\*_@?X4\30Z/K&OZGX9U;PY;G6?BAXLO/#NJMX>M8M:O6U30;7X=0R>([8)8
M7.JV-C/>VUS_ $>_M]?\$F?V$/\ @II+\-[W]L+X-2?$+6/A/_;<'@GQ!HOC
M3QMX U^PTKQ&UC+K6@WNK>!]>T&ZUC0[RZTVQO8M/U5[M=,O8IKG2'L)-1U0
MWH!_+K\8_P#@]_\ @GIC74'[/W[!OQ3\;HSO'9:K\8_B]X2^%K0Q[6\NZNM
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M9@M[>W@18H8((8O@\L<,,,:K'%%&JI&BJB*%   /)_\ @X+_ .""^E?LR_\
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M\#_#,LI56?3KJ?7W^,7B+4+&)B\1O;#4_#-[>JB7"1Z87:U7^FS]@G_@E_\
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MTZZ^'6FZE$49[CPI\#+62\\$6ULTL45Q:CQ[/\2M:TVX0R:=K]L'9:_I3HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"-^#5O;0:?HQGAEMKCQEXNO_#?@FRND^PW7B&/4I[.QNO\ /X_:L_X+)?\
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M? 9TZ&U\2+YWAR+P)X_CO8--L;G5-32S\2>&_B-IE[+JFLS>*--\1WEUJ?\
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M;PI<PZ]HXTJUF\,Z_'J%TNG6E_XETN3395U[[;8?S,_\0.GQ4_Z2)?#_ /\
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MO&\YH5,3?&_7?@[+%'L"W+-<012+;, L3W0:U'YN>.O^#X;X+Z?K5I!\-/\
M@GS\4/%OAU[J%+[5?'7Q[\*?#O6K:R::1;BXM- T#X;?%"QO;J*W$4L-G-XE
ML(9YGD@>^MTB6YF_2WX4?\&AG_!&[X=F$^+_  ;^T%\>/*W;Q\5_CMK6CBYR
MT;#SO^%':3\&2NT(R+]G-OE9I"VYA$T7Z?\ P>_X(J_\$G/@3<V-_P##G_@G
M]^S'!JFERQW&EZUXS^&ND_%37],NX;B&Z@O].U_XJ#QIK-CJ-M/!&]KJ-K?1
M7UL Z07$<<LJ. ?H!\)_B+I'Q@^%GPT^+7A^PUC2]!^*/P_\&_$71-,\0VB:
M?K^G:1XV\.Z;XETVPURPBGN8[+6+.SU.&WU.TCN;A+:]CGA2>54$C=EJ:ZDV
MFZBNCR6<6KM8W:Z5+J,<TNGQZD;>06,E]%;O'<2V:71B:ZC@DCF> .L3JY5A
M= "@*H"JH 50   !@  <  < #@"EH _S.OB3_P $T/\ @[V_:.^(/C6R^)/Q
M/_:/_L-_%&MZ?>:G%^W9X*^'OP8U1EU">,ZKX3^&G@WXOZ&D/AF^L-9N;C2)
MK/X9:>(]",FB26MG>67]AP\WI/\ P9^_\%@?C+?1>(/C=^T%^S)HEZRR///\
M0OC3\8?B3XOCDGC9V6,Z3\*O$.ES;IH8$O';Q7#A626$7AB,8_TZ:* /\[;3
M/^#'GXQ/X?U>[UW_ (*#?#BR\3V^B:M<Z'H>A_L_>)-;T;5?$,"2MHFD:AXC
MU+XJ^&;K1]*U-EA34M=A\.:O<Z.9':WT'65B'F_SF_\ !.;]AW]E/XJ?MT^)
M?V(_^"FGQA^)_P"Q=XDL?$.J_#S2/$5E%X-L-(TOXP^&=<GTC5?AI\0M6\96
M-]I?A,^(6CFM_"OC)WGT$:U8VVEW45W%XFTR_L_]GNOYJO\ @MA_P;@_ ?\
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MS76NP?"F>RB\#:A>S2237-UJ:_"[6O MEK6HWLLEYJ^MV>I:O<.9+\X_>V@
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M0WPMT?3['PQH7@^WM]*L/!DWC3Q-HOV3Q3%\1;;XB:SJ&CZAKWBQ6OK'5Y]
MT'P[J@\(VO@>! #_ % K_6M&TNXTZTU/5M,TZZU>Y^Q:3;7]_:V=QJEY\O\
MHFG0W$L<E[<_.G[BV667YU^3YAGYH_;,_;5_9O\ V ?@7KO[1G[4WQ!@^'?P
MQT34=.T**^73-4UW6O$/BC64NGT7PGX6\/:+:WNJZYXAU9+&]FM[.UM_*MK&
MQU#5M2N+#2--U"_M?\R?_@E+_P $'OVS_P#@L7I?A[]M*;]M7P%X6\$:'\59
M/"GB[X@>)?'GQ1^)G[47@_Q;X)O]'UN9K#09M)MK"WU^UTK4])\4^&;S5?BQ
MH[>7JNAZA!@S7)L_]+O]M+]@[]G'_@H'^SG>?LO_ +4WA?4OB#\.+G4O#'B"
MVOH]9GT3QGHWBSPDS#2/&.A>)M+CM[C2/$AM[C4].O[RT@2WU'2-<UW1KNTE
MTO5KRSD /Y9?C_\ \'LW[(/A3[;9?LU?LC_'GXSWT'F0V^J_%+Q-X*^!WAJY
MFY5+RS.B-\8_$5U8KE9!%J&A:#>S[6@>.SW+<#]C?^"$'_!8?Q+_ ,%A?@7\
M8OB3XR_9^D^!GB3X/?$RR\$W$NB:UJ/B?X>>,=-U_1FU_29O#NO:KIFDWJ>)
MO#\$<EAXST%H;R&RBNO#6O0:@D?BD:)HFQ\!/^#<G_@C/^SX+&XT#]B3X>_$
M?6K3R7GUOX]ZGXJ^.9U.>%0HGOO#'Q*UO7_ *>9C,UKIOA#3]/E8DM9G-?L=
MX%^'_@/X7^%M+\#_  S\$^$?AWX*T..2'1?!_@7PWHWA'PMH\4TTEQ-%I?A_
M0++3])T^.6XEEGD2TM(5DFDDE8%W9B ?Y]O_  4-_80_X.JOVO?VROVAO!6C
M>,OC G[-5[\6/&[?#"Z\"_M.^!_@G^SS_P *>O-=NI_A]$?"6A_$+POX@UW^
MSO"EWI&GZE:>(?"GB7QFFJP:D^JOJ%S'>:E+WW_!-W_@T*_:K^#_ .U!\!OV
MG_VLOVJOA?X87X/?%CP5\:I/!OP*N/&WC?QWXD\0^"/$MCXOTS1-2\?>*] \
M"Z9X;;4M9T^W7Q#K.F6/C&:2Q>^MM/?[5=Q:K:?Z 5% 'Q9^VQ_P3N_8T_X*
M+>"?"?P]_;+^"&D_&CPOX%\13^*O!\-SXH\>^!]9\.ZW=V#:;?SZ7XK^&GBK
MP9XKMK/4[,Q1:KI"ZW_8^JO9Z;/J-A=7&EZ=+:^?? #_ ()'?\$R?V7C8W/P
M1_8:_9O\)ZUI@1=/\7ZE\-=#\=>/[14VG$'Q$^(,/BKQU&':..28#Q#B>6**
M6;S)8HW7]%** &1QQPQQQ11I%%$BQQ11JJ1QQHH5(XT4!41% 554!54    "
MGT44 %%%% !1110 4444 ?%OCO\ X)M_\$[/BCXNU[X@?$S]@C]BWXB^//%6
MHW&K^*/&WCO]EKX&^+O%WB35KN1I;O5->\2>(/ NH:SK&HW4K-)<7NH7MQ<S
M2,SR2LQ)KDO^'3O_  2R_P"D:?[ '_B&_P"SK_\ .YK[_HH ^ /^'3O_  2R
M_P"D:?[ '_B&_P"SK_\ .YKTGX3_ + 7["/P&\9V'Q'^!O[%/[)/P8^(>EP7
MMKIGCSX3_LX?!SX=>,].MM1MI++4+>P\4>$/!NCZY9P7]G--:7L-O?1QW5M+
M)!.LD3LA^MJ* "BBB@ HHHH **** "L[5]'TGQ!I6IZ#K^EZ=KFAZU87>E:Q
MHVKV5MJ6E:MI>H026M_INIZ=>Q3V=_87MK++;7=G=0RV]S!))#-&\;LIT:*
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M262:EX=\7>#M=TOQ-X8U_3I&=([_ $77]%NKW2M4LG>-T2ZL;N>!F1U60E2
M 2>+O%6@>!/"GB?QOXKU&+1_"W@WP]K7BKQ+J\Z320Z7H'A[3;G5]9U&:.WC
MEG>*QTZSN;F1(8I9F2(K'&[E5/\ D%:S_P %(/V>OVRO^"W0_P""@_\ P4$M
M/B)??LOZ3\7$\;:%\+?"'AO3?&7B _#GX3PO'\ /A-<:#J?B'0=!&CSW6D^&
M+[XI,M\ECKTEQXWG2R>\\2-(O^F/_P %N/V@?B#^R[_P2F_;9^-WPKFT:V\?
M>%OA(NC^'KSQ!H.D^*-*L)/B!XM\-?#B_P!1N/#NOVFHZ!K4NG:5XMOKZRTW
M7],U30KJ^M[:+6=*U/36NK"X_P J+]C?_@C%_P %,?\ @HE\+=9^/'[(?[-4
M7Q;^&.E^/-:^'FJ^)H/BW^SW\-X;7QMHND^'_$.KZ+%X<^(WQ/\  NM".TTK
MQ7H-TEW8Z(=$=;\6ME=R3VEY;VP!_??_ ,1DG_!(_P#Z%S]K_P#\,UX)_P#G
MOU\"?\%/O^#CO_@C#_P4=_8>^/'[)OBCP[^U?8ZIX^\*RW_PU\4:A\%?!;Q^
M!_B[X8<:[\-O%IEA^+4MY#8V'B:SL[/Q''8;+O4_".H>(=#5Q#JDRM_-[_Q"
MX_\ !=?_ *,9_P#-F?V//_H@J/\ B%Q_X+K_ /1C/_FS/['G_P!$%0!^V_\
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MLLT)OE2!)[G^:+_@D?\ #/\ X)._'OXD_$;]KC_@MS^W!'=>(=8\=:EJ>E_
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M^+IA\$?\)1XBT.*S.N:A//<::(]>TO69QI*E85-R;Q 7NI37W-^SY_P;$_\
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M>QG:UU"PDN+.1WLM5TRZ1[35-(OX[75-,NT>UO[2VN$:,>OT %%%% !1110
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MO?\ !,K_ )1N?\$^?^S(/V4/_5#> : /M^BBB@ HHHH **** "BBB@ HHHH
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M;R%+BTO;*[MWDM[JTNK>2.>VN8))(9X9$EB=D96-NO\ .I_X-^_^"C?[5O\
MP3+_ ."@MU_P1-_;]U'5;?P'J_C^3X0_#?3O%FL2ZLGP-^,^J(-2^']AX UR
M<N]_\'OCR=2TFU\-:1:AM'?7/%_@WQ?X<CT6TUKQ:=9_T5J "BBB@ KY5_;
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MX6T^Z\0>*/!'@>;P./$$_P#8-CK<.KP^)- %CK4-OJOAN:PFL["2W_#S3_\
M@O'_ ,&YG[&\TG_#$?\ P2$NO'OBK2[AAI_CGQ]\,/A#X8NY%1FE271?B?\
M$+7_ (U_%RRM99T@=[>YT+2262*62V=[2!: /VU_X-T/^"PW[?G_  55U+]H
MS4/VKOV>_ OA#X5^#+'PSJWPN^,_PK\!^/O O@2\\1ZEJ-[:^(/A<EQXV\6^
M-[?QE?6FEMIOB"RN]'UM=2\-6=O<P^*6U+_A)/#\UG^<?_!9G_@WW_X*\?\
M!1[_ (*"_$WQ]X,_:6^'&M_LG^,!X4U#X::3\6_BSX]\->%?A%I6E>'='TZ_
M\$6_PF\,^%O&5JE_9:Y::MJUIKNA:3)#XJFU#^W=?U#3-<U#488/C;Q)_P '
MKW[7/B;QCX5T?X%_L%_ ?P_H5UX@TS3O^$'\2>,/B;\5?&.O:;/?6]M;^&?"
MNK^#[?X66>G^(+VW;^S=,OO^$'\06Z7TUO*GAN[1/[/F_P!$?P#XCU+QCX$\
M%>+M8\+ZOX'U?Q3X2\.>(]5\%^( HU[PAJ6N:/9ZG?>%];"I&HU?P_=74NDZ
MD%C11>6DP"*,* #^%W]FK_@R+\%Z9J&BZY^UQ^VUK?BRSAN[*XUGX=? /X:V
M_A."YM[>5);NQB^*7CG7?$-[+!J";K0RP_##2;NTC#3PW#S3(+3^I']L3]K+
M_@D-H/PWUW]G_P#;=_:"_8EU+P%$FGZ5K_P.^-'Q$^%_C2_DD\+3V\^FI=_"
M_5=3USQ5=:CX>OK&SN+:]&A2ZCI>IPVLZW$%^T+M^A_Q!\)#Q]X"\;^!3KFM
M^&!XT\(>)?"1\2^&KLZ?XC\/#Q'HU[HYUSP_?J"UCK>D_;/M^E7:@FVO[>"8
M E*_@@^'W_!CUKLWB74KCXN?\%#=-C\*P:U=_P!G6OP^_9_O+WQ+K^A><3:W
M6I:KXF^*5GIWA;6KF(E[NU@TGQG9VTV5COKQ3Y@ /U%T_P#X. ?^#:_]AFU;
M3OV6M#\$I=Z9;BV>R_9+_8UO/ UW.TD;P3H_B?Q'X*^$>CZY=3P*KW^IGQ+?
MB_:Y+7.H7-VUXL?QM\8?^#WS]G721=Q_ #]A?XU>/R5E2QO/C#\3_ WP@".7
M*07%WIW@K2OC@9%1")Y;.'5(C*ZFT2^A#_;8_K_X/?\ !FM_P2N\!"TNOB9X
MT_:E^.NHJL1O[3Q)\2?#'@GPK<21N&?[%I?PX\">&_$UE#.H\N2.X\;:C*JD
MF&XB?#C]5?@__P $"?\ @CA\#OLS>#/^"??P#UJ6TW&.?XMZ1K?Q[E:1L$RR
MGXXZY\0UDD#*'B++MMVYMEA&  #^+SQ__P 'I7_!1;QM?_V/\$OV6OV6/!#Z
ME<>5I]OK.C?%SXL>*P!*LL4%A+I_Q!\#Z5=7311M#.\OA2Z66)Y7@MK641RQ
M?97_  2G_P""K/\ P<F_M:_MY?L\:;\3_@QXYUK]DWQ-XSLM,^-KZU^R)9_"
MCX0>&OAM=2/!XG\9P_&.^\$:-JUAXK\-6&GZMJ/A#0U^(5TGBGQ!:OX>_P"$
M>UIYH[:T_NQ^'GP>^$GPBT_^R?A1\+?AS\,-*\M8?[,^'G@CPSX*T_RE6%%B
M^Q^&],TVV\M4M[=%3R]H6"%0 (D"^C4 >7_&_P"'2?&#X+_%[X2R7,-G'\4?
MA?X_^'3W=RDDEO:IXV\*:MX::YG2(&5X8%U,RRI&#(R*P0;B*_QLO^">G_!,
M>U_;3_;.^(7[!7Q8_:#TG]D#]H?0['XA>'/AOI'Q&^'E[XF\/>/?CM\.=7?3
M-7^"/B#5;;Q=X9U+P#K%U#8Z]>V&L1Z'XOEO'\/7^D66@7>N7>C:=JG^T[7\
M9O\ P<'_ /!N?\1/VL?B<_\ P4$_X)U/9>'OVK+)](UGXH_"FRUZ'P)>?%77
M_"HMV\.?%+X9>,I[_3-+\*_&/2(]/TRVU"UU+4=!TKQ5'IMAX@M-?T?QCIUV
MOC, _+SP3_P9"?M/7[ ?$?\ ;F^ WA1,2;F\$_#3X@_$!@PG@6(!==U'X:!@
M]LUS+(2ZF*>*"W598[B2ZMO0/B;_ ,&5W@+X,_#SQM\6?BE_P5OT;P-\./AS
MX8UGQEXW\8>(?V,H[#1?#GAGP_8S:EJVJZA=2?M<X2"TM+>238@>:9PD%O'+
M/)'&WS-X,_X.8_\ @NY^P1HB? []KW]F;1O'_BSPBEEHUOXF_:C^!OQ9^'OQ
M5EB2Z?3-._MK6_"VN> ]#\9Q7K+!::=XEE\/7.J^(Y434;GQ'K]Y>RWEQYU\
M3?BW_P '$7_!R+JVB_!ZV^$>N?#']E^ZUZUO=6T[PUX&\5_ ?]E33I=-U$!=
M<^(WQ(\;W6M^(_BI?>')8X+]/!D'B3QO=VNIZ?'K'A7X=VNKQ^<H!^;W_!$K
M_@D#8_\ !77]KOXG?!M/B5XU\ _ 3X1> =?\>>*/B_IG@?39->NX[CQ'9>&?
MAIX<DT.\U[4M$\->)O&[7>H>(FTZ;6?$,5II7A'Q59V=WJ,EK'J2_P!=]I_P
M9*_L():VR7_[6O[6]S?);PK>7%HOP<LK6>[6-1<36UG-\.;^:TMY9@[PVTM_
M>R01LL3W=RR&9_WS_P""1'_!*CX-_P#!)3]ERR^!GP\OQXV^(GBN_M_%_P =
MOC)=Z9_96J?$[QXMI]CADMM-:[U!]!\&>%[)Y-(\%^%TO[J/3+.2_P!4O)[S
MQ#K^OZGJ'ZI4 ?SJ?\$Q?^#:G]C3_@E]^TI#^U1\-OBM\?/BO\2=(\'>)/!_
MA.V^)VK>"(?#?AF/Q=;)IOB#7(-.\&>#/#5WJ>LSZ)]JT6S_ +3U&XTJSL]4
MU*<Z7<:D=-O],_HKHHH _+[_ (*R_P#!*_X/?\%;_P!F[0?V>?BYXX\<?#5/
M!OQ.T'XL>#/&_@,:7=ZEI/B71]%\1>%[FVU+1M;@GTW6M'U3PWXLURTEM6>Q
MN[74#INI6U\$LKBQO_YE=5_X,>?@K-?32:)_P4%^*.G::PB\BTU7X"^$]9OH
MB(D$QFU&T^)&A6\XDF$DD033+<Q1,D+&9T:>3^ZNB@#^!W6_^#&KP[<7$+>&
M_P#@IAK6DVJP[9X=;_9%L?$%Q)<;W/FPW-A^TIX9CAA\LHGD/:7#[U>3[1M<
M11^7ZG_P8Y?$>*ZNTT?_ (*->";^R1F%C<:G^S-KNDW5P@7*-=V=K\;=:BLF
M9\JRPWU^$7Y@[D[!_H944 ?YN.K?\&1?[7T-C+)H?[:7[-NHZD&C$-IJWA'X
MGZ+8R(9%$S2ZA9Z;KT\3)$6>-5TR82R!8V>%6,J?T(_\&]G_  0I_:%_X) ^
M*OVC?%OQM_:-\$_$FT^,OA_P7X=T3X<_"9O&9\$VEQX;U'4M2N/&WB5O%VD^
M'FG\5017@T+05L-&<6>D7^N&YU.8WT%K:_T^T4 %?S7?\'%?_!/#_@IK^WWX
M+_9PTO\ X)]_',> M"^'NM^/[KXO_##_ (6UXC^#;>-M0UVW\*IX$\6?VYH4
M(LO$:>#XM+\5V#:-KU_9C36\21ZAHT%]/=:@;/\ I1HH _S Q_P0>_X.BO!F
M=#\*?%;XL/H\1^T1OX1_X*$S:-HK3W #SF*QU'XH>'KI9PP"W$CZ9&LCC*2S
M+AZ7_AR1_P '5W_15/C_ /\ BQZW_P#GUU_I]T4 ?Y@G_#DC_@ZN_P"BJ?'_
M /\ %CUO_P#/KKR'X_\ _!%3_@Y:TOX(_%?7OCAXF^-GCOX0>%? 7B;QE\2/
M"6L?MTV'Q&L-9\(>#-+N/%6M0OX#N/BWJP\6SP6FCR7ECH,&EZA?:C?6UM;Z
M=9W%^]M$W^JS3)(XYHY(I8TEBE1HY8I%5XY(W4J\<B,"KHZDJRL"K*2"""10
M!_#%_P &1?QTTB]^ _[:?[,]WXTTO^W_  W\6_!_QST#X=2QVEMK7]C^-?!U
MAX!\7>-;"5E2]UG3/MO@'P3H6L)$UQ;>&KH:$;@6DGBJT^V_W05_F\?\%3/^
M"/W[=7_!&3]M.[_X*;?\$E]-\8WGP(_MW6?&EQH?PTT:;Q=K7P!776>[\;_#
MCX@?#FULKIO%O[.NKI)=MI.IKINIZ3X7T*./1_%[Z%J/A[PUXMU_WKX2?\'P
M>JV7@?3;/XZ?L 67B+XD6EM%%JVO_"KXZR^$?!FNW26\8EO;+PKXL^'7C+6O
M#$4UT)"NGR^+O%9AA93_ &A*RE6 /MS_ (.:_P#@B=\0OVT_&R_\% 3^US\/
M_A!\$OV;?V:-5L/B9X.^+%IXNO+3POH_@35_%GC;4?$7PQM_#EO?V.K^)/'$
M.N0Z*_AF]BT&^UCQ!I'AZQMM<U$ZG966C_R+_P#!#[_@ASXO_P""S7BCX^VE
MO\=1^SIX#^ FA>";C5?'<OPGF^+']O>+/']_KT>A>$['1#\1/AE!;F/2/"OB
M#5]3U-=>O9+ 0Z5;2:4RZQ#=0?=_[2'_  4'_P""O?\ P<]?$+1/V4/V<?@2
M?AO^S=:>)]&U'Q+X!\"W/B"\^&6@W$-W'=:5XU_:B^/>IZ39VNI67A=UFU30
MM"LM#\-6%]<VEI<>'_AWXH\<V.C7!_OX_P""3'_!,_X7_P#!*G]CWP?^S3X"
MOD\5>*[B]G\<_&GXF26:65W\2OBQKEE86NO:Y';8\VP\.:5::=IWAKP;H\KR
MS:;X9T?3SJ$][K=SJ^IWX!_-U\/O^#(?]E'39HV^*O[;G[0OC.W$BF:+X?>
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M\;0>#M+U;4M+TS6-2T_6;?2+;3]/U?6K\:'JD\6D_9X[>6Y_6*OQW_X*>_\
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M!TK[5'>7/A3Q+&9=)\;>!M3N(E2.75_ WC+3M=\):K)&HAFO]'GFMR]O+$[
M'U51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>2?'OXW?#S]FO
MX*?%7]H#XLZTGA_X;?!OP%XG^(OC356\MYH-!\*Z5<ZM>06%O))%]NU>_6V7
M3]%TN)Q<ZKJUU9:;:*]U=0HW\;G_  1'_P"#H#XS?MU_\%"]>_9>_:U\.?"K
MP)X ^/9\3O\ LNR>$-*O])U'P1XQT1[G6M!^%?BGQ!J&KW5OXK3Q7X-M=3M;
M3Q#=VNGZC>^/]+TS2],LDM_%EKI6E ']OU%%% !1110 4444 %%%% !1110
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MPR7'B/QYX7^&>N:+X<USQ[+%J!UWQ7I-[K<]YXD%Q)K&K 'Q?^TC_P '2/\
MP1M_9UFU/2[/]H;7_P!H3Q3I,MS#=>&?V<?A[X@\=)*]N65?[.\>^(AX*^$6
MK)<2H\<$NF?$6[B^59IW@MI8)Y>*_P""6'_!RU^SK_P5-_:YUW]D_P "?L^?
M&#X2:G)X%\1^//A[XP\:ZMX9UVV\5V7A%[&37]*\2:/X7^U)X&U1=.OO[1TJ
M7^V_$NC:@+*]L)]6T[4Y=(M-6^:_@;_P9H?\$POAWJ1U;XO?$+]IC]H5DO9I
M(?#NN^-_#OPY\'MIWFLUK:WMM\.?"VC>,Y[U(B(KN_M/'>GP7)426^FV&2M?
MT ?LA_\ !-+]@W]@O^T)_P!D?]E[X7?!?6M6TA/#^K>,=%TR]USXAZMH*7%O
M=G1-5^)/C"_\1>/M2TB6\L[2^N--OO$D]G=7UI:WMS#+=6T,R '\V?\ P<%_
M&3_@XBTW]K7PE\%?^";G@GXWVO[+GBKX7>']0TOQO^S5\+=/\3ZMJGCF6\U:
MW\76WQ-^+E[X;U;4OA3JND3):1:%IMGXC\%Z)J7A^?3M6%UK&JM?KI'X9^'?
M^#:?_@X#_;LUO2/%7[9OQ<B\&K+>P:I)K/[6/[4GB+XU>,=,MICS>Z-H/@/4
M?C&MKJJ6<S_9-&U'6_"KV^[^SKZXT=EECA_T_** /A[QA^PE\,/CG^P/X=_8
M&_:PU/7/VB? Y^!_PK^$OQ*\;>(+_4=%\9?$;Q%\,=&\*I;?%:XU6SU*[U/2
M/&U_XS\)V'C]+Q=4OWM]?P+N?4[<W"77^:5_P<3_ +'_ /P3F_81_:!^$'["
M'[!?PQU&'XPZ3IUIXV_:&^)OC7XJ^*O%^NQ:G\0_LJ?"CX1A/$?B"S\"^$Q8
MZ!-)X[\1ZA#X=T^[N]+\6^!)+O7TMK+5(9?]9:O\TK_@Z=_X)B?LG?LV?'CX
MF_MH^(?VW/&4?QW_ &NO$EUXV^'_ .R!'\%=)\=ZW?:C8V6EZ5XG\2ZM\5O^
M%O>#1X!^$=A<VJ66D7E_\//%&M)>RP>&] L/$T6E:S?Z* ?UK_\ !*";_@F?
M_P $T?V'/@K^S'X<_;0_8D;QIHOANT\0_&WQCI/[17P0CN/B!\9_$<2ZIX[\
M0WFHKXOBO=5T^QU6XD\->#WU)Y;G3?!&A^'=(#".Q5:^M_VC?VC?^"8'[4WP
M&^+O[.?Q<_;+_8_UKX;_ !H\ >)?AYXNLE_:6^"8NDTOQ)IL]@=2TN>7QC*+
M'7=$N)(-9\/ZFB&?2M;L-/U*V*7%K$Z_Y+7[(G_!'?\ X*9?MW>&D\;?LM?L
MA?$OXB^!)WN([#X@:M<^$?A?\/=9ELS*EY%X>\>?%SQ+X$\(^(Y;.6"2VNXM
M"UG49+6["V=PL=T\<+<1^V)_P2]_;_\ V Q8W/[7/[+?Q*^#^AZG>+ING^-;
MJ#1?&'PWO=4=6>/2+;XG?#W5_%OP]FUB6-))H=)3Q,=1G@CEGBM7AC=U /Z(
M?^#<']KZ?_@EY_P5N^+W_!.WXD_$[PAXT^!W[1?C^[^"&F?$#P=XFTGQ%\-M
M5^-'A'5M1@^ WQ/\):WI.I:KI<NA?%S3=0N/!<<6GW#75W?>./!(UZ: ^%)(
M+?\ TXJ_S(/^"*__  ;P_LC?\%'/"GPX_:G^&?\ P4S\:7R_"CQYX-N_CK^S
MY9?LR:;\./C'\//%.EW-MX@B\/0^.A^T;XYL],TOQ =/N9O GQ2T[P;K&G:O
M:6EY-%I6G>)M%U_P[H7^F_0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%?CU_P5J_X+6?LG_\ !(WX?Z5??%N;4?B1\<O'&G7.H?"S]G7P1?6=OXS\
M5V5O--9MXG\2ZO>1W.G_  _^'T&I0OI\_BK5K6_O;^ZAOK7PGX<\57VDZO9V
M/\<UK_P<K_\ !PA^V/K.K^*_V*/V,8[[X=:7>36\6E? /]D;XQ?M&_V=##<V
M[FW\6>-5'BVVO-6C$D=G=W.FZ3X2M&CN4,>CVETT4] '^D]17^>I^RO_ ,'?
MG[7?P'^+MG\'/^"K_P"R;!I^DQ7=K8^)O$W@+P!XO^#'QR\ P74@7^W/$7PE
M\?ZG<:-XQMH2DGF:5I8^&]ZEMYUS:3ZM=6L>F7O]YOP&^/?P=_:?^$?@?X\?
M +X@>'_BA\)/B/HZ:YX.\:^&KB2;3=4LO.EM;F&6&XBM]0TO5M+U"WN]*US0
MM7L[#6]!UFROM'UG3['4[*ZM(0#UZBBB@ HHHH **** "BBB@ HHHH *Y7QO
MX%\$?$SPIKG@/XD>#O"OQ \#^)[&33/$G@SQOX>TCQ7X4\0Z;,09=/USP[KU
MG?Z1JUC*54R6E_9W%NY4%HS@5U5% '\H7[=O_!HA_P $Z?VF/[5\6?LRZAXJ
M_8C^)EYY]PL'@:*7X@?!/4+Z7+F74?A1XHUBTO\ 0U+)'#;6WP]\<^#-"L(F
MFE_X1R^F9=O\S?B;_@CW_P '''_!&/7M6\=_L<^+/BAXZ^'UE?/J]]K?[&'C
MG6/B#X<UY;78]E/XZ_9D\1:=;Z[XKO$MB6N[>]^$_CC0=/D@NX1K-S;?9[J[
M_P!2&B@#_*(_:<_X.;?VY/VE?V'OVB_^"?/[:/P.^'/B'Q9\2M!T+P7=_%K1
M]+UWX-?$CPEJWA?QMX9\7W=QX]^'3VFK>%-<U2XN?#7]ESZ=H.C_  OBTY;P
MW#6T\EJ;>Y_4;_@UV_X+3?\ !.S]A3]C#QW^RY^UK\;;WX*_$?7_ -I7QW\5
M=!U+7/A]X]U_P/JGAKQ+\/?A1X=L(CXI\$^'O$]OH^IQ:AX*ULW47B.#1;%8
M19^1J%Q/=I /Z'/^#F?X#_!#QE_P2,_;'^+?BWX._"[Q-\5OAYX(\!7G@'XG
M:]X"\+:K\0_!-U-\8?AYI4\WA+QK>Z5-XE\.O<Z5J.HZ7=?V1J=H+G3=0OK"
M<26EW<0R?RD?\$&_^#>3]CW_ (*S_P#!/CQK\>_B]\2/CU\+_C%X9_:4^(GP
MKT;6_ACK_@MO"=SX:T'X?_"/Q+I0\0^$?%W@CQ#/J%U;:CXQUS=/HWB+PW+/
M%):QSR2"V&\ _OS^#7_!2C_@GQ^T*MHOP5_;8_9<^(U_>1V\L?A_P]\</AW-
MXMA%V0MLE]X-N-?M_%>F33N?+CM]1T:UG:4-%Y?F(Z+]HVEW:7]K;7]A<V][
M8WMO#=V=Y:31W-K=VES&LUO<VUQ"SPSV\\+I+#-$[QRQNKHS*P)_S<_VD_\
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M<GBKP=:^-K36O"6I>$=(\,S?VGJTGAV7P]XAB72M&_M9[_Q  ?UL45_F"?\
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M?L_^"?$.I7-EX)UCQ7XALH-+\3:;);SZ(NH77VO3[.\LKG\.O^"87C;_ (.
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MV\;&UTVWMH"R0110HWEY6*..-2$15&]7^<A\4_\ @]\_:6U9;H?!+]A;X&>
M&9)!9/\ %/XH>/OB^L,A@=8I+J+PEI/P/-RBW)CFDAAFM&>!7MEG21Q=I\T'
M_@X,_P"#ES]K\K'^S3\,/%NFV^LHYM$_99_8;U+XD0M:W4,=T'L=2\<^$_C;
M=0P1V,4\T6H)J EM[.:XOC>*T%O=VH!_J#5SGBGQCX1\#Z5)KOC7Q3X<\'Z)
M"6$VL>*=<TSP_I412&6X<2:AJUU:6B%((9IV#3 K#%+(<)&[#_,=;]E7_@\$
M_;)$C^)->_;G\.Z'JC.^I6OBO]H_PK^RYX>,1>*\VZAX"A^(_P ,);JW6>Y@
M\BQM_"5YY,L86&TC73)?L?2^%?\ @ST_X*U?&O5H?%/[0?[0_P"S?X2N[D+#
M?7OC3XK?%;XM_$&*(7*L0$TWX>WVAW<2QRW=RB-X]B+7)CB,:"YFN;< _O9^
M)7_!67_@F'\(/M,?Q"_X* _L@:'?V?F_:M#@_:!^&>O>)X?)^T"3?X5\.>(M
M7\2<26MQ N-*.^ZB:T3=<E8C\ ?$K_@Z)_X(E?#?[3;Q_M=W'Q"U6U\W.D_#
M7X+?'#Q'YWE_:%'V;Q!=?#W2?!D_FRVYABV>)CGSK>X;993+=5^!OPT_X,=(
MA]EN_C%_P42D?_4_;?#_ ,-/V<5CQ_QZ27'V7Q?XI^+\N[/^GVD/F^!UQBTU
M!\YFTP??_P -/^#+O_@F/X6^RW7Q$^,O[7_Q2U"+R?M5G)XY^&/@KPO=[/LC
MRXTWP_\ ">3Q+;^?+#=QG9XS?R[&\$*?Z;;1ZBP!_)3_ ,'(7_!4']F+_@JC
M^UE\$OBU^S%'\2H_!'PT^!:?"[7[SXB>$M/\*:C?:W#\2O&_B5K[0M-MO$6M
M2W.E2Z1KUA+;S:D^DWAG:2WN+&W:-B/,O^"1W_!P#^U]_P $E8M2^'?@[3]!
M^._[,VO:W<^(-5^ WQ%U'4M)@T/6[Q5&H:_\,/&6FKJ-]\/=7UEH;=];M)-)
M\4^$]2=9[V?PNVN3_P!M)]&?\')'_!-3]DG_ ()L?ME_LN?!;]E+P3KWA/P-
M\0?@5H7C7QE:^)?&_BGQMJ&N>)9_BIXP\)W.H27_ (CU*\DL%N='T.QCDLM)
M6PL%G\Z:&UB:3"_Z$WAK_@A!_P $>/"<8CTO_@GC^S7=*+2WL@?$W@MO&DGD
MVRJL;F7QC?:[*UVP4?:+\N;ZZ8LUU<S,S$@'\HGCS_@^/\:WWAC6K/X8?\$W
M_"WA;QG/9.GAWQ'X\_:BU;Q[X8TS46C_ '=SK7@OP]\"/AOJNN644I^>RL?'
MWAV>XC7Y;^V9_D_C-_;%_;)_:'_;T^/7BW]I']I[Q]>?$'XG>+?(L_M+00:;
MH7ACPWI\D[:'X+\&>'[-4T_PWX1T".YN$TS2;)-TEQ<7NKZI<ZEKVJ:MJM__
M +)UE_P21_X)6:?9VUC!_P $UOV"I(;6&.")[[]D3X!:G>.D:A5:YU#4O %W
M?WDQ S)<7ES/<2MEI978DG^<[_@[9_91_9;^"_\ P2R\/^,/@[^S9\ OA-XM
ME_:M^$FC2>*?AI\'/AWX$\1R:1>^#OBM/>:4^M^%O#FE:F^FW<]G9S7-BUT;
M6>6UMI)8G>"(H ?SV_\ !//_ (.J?C__ ,$\_P!CGX+?L<^"_P!E/X/?$/PS
M\%[#Q=8Z9XQ\4>-/&NF:[K0\7_$+Q;\0[N2_L=)A_L^W-I?>+;K3[=;<D-:6
MD#RLTSR$_4FK_P#![;^W#->O)H7[(7[*>FZ<4C$=KJ]]\7=;O5D"@2L]_9^-
M] @D1WRT<:Z;&T2X1I)2-Y_IH_X-OOV=_P!G_P ;?\$5OV(/%'C/X&?!WQ=X
MEU70?C,^J>(O$_PR\%:]KNI/:_M(?&*RMFO]6U71+N_O&M[*VMK2!KBXD,5K
M;P6\96**-%_?+3?@G\&=&L;?3-'^$?PQTK3;162UT_3? 7A6QL;9'D>5UM[2
MUTF*"%6ED>1ECC4-([N068D@'^:KXP_X/0O^"C'B=6L$_9;_ & Y_#\B0/+H
MWC#X;_'3Q@LMY#(T@N&<?M#:%9%%/E&")M+:6"1&D%R^]5C^*_B1_P '!?QL
M_:3$NB>)?^"4O_!''QOK]UNN?[2MOV#=?\7^,$AA5OM#6=[KGQ?\37UFI5QY
M]Y910W<:?*EW$CR!_P#6WT?0M$\.V?\ 9WA_1M*T+3_-DG^PZ/IUIIEGY\NT
M2S?9;*&"#S9 BB239O?:NXG QJT ?XFOQ$^/&H?$MY;C5_\ @E3^RCX>O'):
M.Z^'?PP_;%^&R6[ML!:+2O!'[2^AZ#(-J;1%=:3<0(6=TB64^8/DG5_AI\3_
M !SK%M:^$?V:?$GAN\N7D%MH'@3P;\8=:>[81&1HX;?Q9KGC;59O)CBDFQ#<
M[POFO(6C0;/]X"B@#_(E_8"_X*;_ /!:'_@FA\#K_P#9[_96_9_\2^'_ (>Z
MOX_U_P")VLKXM_92\?>,M;U3QGXCTKP]H.H:G/J>K696VB&A^$_#NEV^GZ;;
M6.GQ0Z8MTUM)J5WJ-[>?;W_$1A_P<CZQ_P 2C2_A#J"ZGJG_ !+M.;2?V'/$
M5YJJW]]_HUFVF6EQHFH6]UJ N)8S96T]A?0SW/EQ2V=RC-"_^GY10!_E3>*O
M^"K?_!U;XI\::;XX$'[;OAN^TBU@M+'0?"O["\6D^"]D$YN3+J7@U_@'=^'O
M$%U/.S-/=^(K#5KAX"+ 2)IT<5G'P/B+_@Y=_P"#@WX27"Z=\4OC1J/AO4"W
MDBV^)?[(?P1\'WS2D.P46S_!WPPQEVQN0@@^ZCG9\K$?ZR]4=2TS3=:L+G2]
M8TZQU;3+V/R;S3M2M+>_L+N+<&\JYM+J.6WGCW*K;)8W7<H.,@&@#_)3_P"(
ML#_@MK_T<;\/_P#Q'?X'_P#S$5P!_P"#H[_@NN22/VY H))"C]F;]CW"@GH-
MW[/S-@=!N8G'4D\U_IW?%[_@DM_P3&^.XN'^*7[!/[*7B+4+M0EQXAM/@GX%
M\+^+I(Q.UR(SXS\(Z/H/BL1B=Y9?+7653=/<_+BYG$GY;?%__@TR_P"",'Q/
M^U2>&?@U\5O@3>7?G/+>_"#XY^/)MEQ/*96N+73?BW>?%?0K+824AL[328=,
M@BQ'%8HJJ% /X7H/^#H?_@N]=3PVUM^W!+<7-Q+'!;V\'[,7['TT\\\SB.*&
M&*/]GQI)999&5(XT5G=V"J"Q K[PM/\ @IA_P>,:[96TVG^!?V][S3]8M89+
M+4+'_@E=X"CM;JSU")6MKVSU:V_8_CB2WG@F2>WU&"ZCC6-DN8KA5"R#]=/B
MC_P9 ?LZ:M>B3X+?MX_&OP!I_P!I9S:_%'X1^!?B_>FS,\3) +_PGXD^!\ N
M5MA-$UW_ &<8GGDBN!9)'$UM-_8_^S)\!O#7[+?[.GP,_9M\&ZKKFN^%/@/\
M)_ 7PE\.ZUXENEO-?U?2/ /AK3?#5CJ6KS1JD OKV#3DN9X+2*"QM6D^RV%O
M;V<,$$8!_F[?\-*_\'DG_0N?M_\ _B)_@;_YS=?@Q^UE\>_^"D'@3]O"T_:#
M_;"UGXH^ _V]_AOK/PJ\=P>(_B9X$\/^#_B%X9U?P3I6@ZG\*-<N?!S>&-,T
M!!IVD:=H%]I*WGAR6UU&TBMY[R&]6:1I/]N*O\5+_@K7\7_VO?'7_!3CX_\
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MY]\T ?>5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5_-C_P1T_Y.:\=?]D)\3?^K ^&%?TG
M5_-C_P $=/\ DYKQU_V0GQ-_ZL#X84 ?TG4444 %%%% !1110 4444 %%%%
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M:OX]1M88(].U>U34;VQ_EX_X*"?\%*/^"3WQ3_X)B_"GX2_L*?L$?!+]FO\
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M:V7Q3I_@_P 2_">UM=;"P7;:IIUG/Y-A=W,=C'=78TV6[U, _H,_X-T_C/\
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M?AE,/$'BC4-*\1Z7X,BB?QA_:EYX+U*PM[2[:&Z\:3KIL>D2VX!YA_P<Q_\
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M!86WC]?@U\-;0W.RZ(B-[X=^)7Q7F$!D2R4W L#($N+J06K-9Q1WWYZ_'/\
MX,@_C1ILNH77[-/[='PO\902>?+I6A?'/X8>*_AI+:?,WV:QU#Q7X!U7XLIJ
M&$">?JMMX,TS<S-Y>C*%&_XNN/\ @S$_X*P0:S#I<7Q-_8BO+&1H5?Q';_%S
MXO+HUN)5R[S07?[/MKXA9;8_),(-!G=F&;=9UPQ /[@O@O\ \%U/V%/BW^P!
MIO[?&M_$?PG\%-$U/PC\0]8LO@U\:OB/\// WQ/U3Q9\.K_Q!HEYX&\.65_X
M@\GQ3?>)=?\ #\FG>#]0T&.]36$U"Q,ME8ZDFHZ38?P^_%C_ (/,/^"I_C:7
M5[;X<_#_ /9.^"^DW%Q?#0[C0OAMXU\9^+M+L)YXWL4U'6/'GQ*UOPMK&J6$
M$9@>_@\!Z/87C3W$SZ+$3;QVWU#\&O\ @R*_:GU>]LF_:%_;5_9_^'^G"8MJ
M,?P:\&?$7XP7KVZ70 ALI_&]G\#8(YKFR#,;F>WE2QNF"?9-0B0O)^[OP7_X
M,_/^"1WPZ\+)I7Q,TWX]_M ^)I?+EO?%GC;XN:IX+$4X0++#HF@_":T\"V-A
MIKL/,CM]8F\1ZC$25;6)EP  ?Y8LNH0^(==U?6?%>IW\5QJY\1:S=W^FZ397
M]Q=^(KJTU#4=/BDL'U+0K2UL-6\1-9V>JWUO.SZ'I=W>:K8:/K=Q86^A:ADL
MMI]DC=9[DWYN9UFMFM8EM$M%BMS;3QWPO&FEN99FNHY[5M/ABMXH;>:.\N7N
M9(+3](_^"O/[,7P0_8X_X*8?M8?LS_ /7M0U3X+?"[XFVND^%WG_ +0U34_"
MUGJ_AOP]XDUOP,]UKMZNH>(+OX;ZSK6J^!UU;4=2\[7W\.KJ%S?F2\DN*_H.
M^''[4_\ P9N^"/#>@V%_^P;^UMXRU^T\.:)I6N^)_&[?$O5M4\1:G86%O#J'
MB#4-(B_:]?PCH^KZS>QS:AJ,'A/2=)T>"XN);72K6VTR.VMHP#^.:ZMO"B:/
M%/9:UXAN-?9XA/IEUX8TVTT>.,H#,T6N1>+;V]F>-\K%&_AZ!9D =Y("3&/1
M?V=OBSI_P(^.WPC^,^J_#[PU\5],^%_Q \,^.+_X9>,VF7PAX^M?#NJ6^I3>
M$O%"VZ2RS>'M=2 Z=K-LL4BW6GSW%M)&\<KJ?[6-&_X*F_\ !HS\-M%OKCP9
M_P $N?%GBG4[#3Y)=*TCQE^SIX$\:/JM]:>;=6-C/JWQ,^-GBI+=;RZ*V]U?
MW@N<6S;;B*[@ACM3_,1_P2A^.O[._P %O^"K_P"RI\;/C1\.-.?]G?3_ -H&
M0ZGX(UJ\'BC2? >A>.XM?\)^"];U6]U:Q:7Q-I_P<UGQ-X=\:7L]UIZWNN0>
M#I&6U2\NDC !_H9?\$3/^"=G_!)O]I_]B+X#?MK6?_!*+X'_  A\9?%>W\7Z
MI=^"OBO9^*/VA=*L+WP_X[\3^%X?$_@NZ_: U#QC*WA7Q(FC1^)_!\PTNT.C
MV5_:6>DSW5KIEAK%Y_2KX-\"^"/ASH5OX6^'O@[PKX$\,V;,]IX=\&^'M(\+
MZ%:NR1QL]OI&B6=CI\#-'%$C-%;J2D4:DE44#I+>WM[.W@M+2"&UM;6&*WMK
M:WB2"WM[>!%BA@@AB58X888U6.**-52-%5$4* !-0!_ E_P5<_X(L?\ !P3^
MVE^WK^T%XF\"_M #7OV6?&?C&75?@U;ZA^U%XA\ _#'P3\.IA#;>'/ LOPAL
M+J:[TC7?"VFR/;>)M1TKP7>V7BC58M5\2C5M2U+6YXW^:/A'_P &1/[6&M_9
MS\=OVV?V>_AJKJ[7*_"GP)\1OC5+;GS4$2(OBT_ >*X8P%WF/G1)%.BPQ-<1
MN;E/](2B@#^,?X1_\&4/[!?ALP7/QI_:A_:D^*MY [.UKX-'PR^$OA^\!"JL
M5[8W?A#XE:\8ER[G[!XIT^8R>4?.$<<D<_ZK?!C_ (-GO^"+/P5:VN[']C70
M_B/K5NT#2:S\9_'WQ+^)ZW9MP#&+GPMXB\6R^ =K/ODG2V\(6Z71D,5RLMO'
M;PP_O%10!X+\'_V5?V8/V>X8H/@)^SE\"/@G%"CQQI\)?A'X ^'6U98O(E&?
M"'A_2&8S0DQ3,Q+3(2LI<$Y]ZHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OE7QQ^PG^Q#\3O$LOC3XD
M_L;_ +*OQ"\8SZB-8F\6>./V>?A'XL\2S:L(6MQJDNNZ]X0U#5)-1%N[P"]>
MZ-SY+M%YNQBI^JJ* .7\&^"/!?PY\.:;X/\ A[X0\+^!/"6C0BWTCPMX-T#2
M?#'AS2K=0 (--T31+2QTRQA   BM;6)   %X%=1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '(P?#_P':^+9_']MX)\(V_CNZT]
MM)N?&L'AO1H?%MQI3RB=],G\21V2ZS-I[3@3-927K6S2@2&,N :ZZBB@#\]_
M^"H'_!//P%_P5"_9!\;_ +)/Q"\?>,?ACI?B?6_"OBK2?&W@M;:\OM%\2^#-
M635M&EU30+Z6WT[Q5H$LHEAU+P_?7-F)]\-]8:AIFL:?INI6G\1'QC_X,B?V
MJ-#%U)\ ?VV?@%\3%0![6#XM^ ?B#\%9YAD%X7?PC+\=X$E5-RPN66*>4+YI
MLXW9XO\ 1_HH _R]/^'./_!U!^Q/F3X!>//C]JWAG26N79/V</VVH'\,W"11
MBVC+?#/Q-\2/!>JZ]'<0(CVEJW@'47B,%N\MM:W4-J%5_P#@J)_P=F?L<++;
M_%KP9^U9JOAG2GE\ZZ^,_P"Q/H_C7PM(\,D&GR2#XJ:3\)8+[4HA(MLH\CX@
M7-HSW,-TBE]2$]U_J%44 ?YI'PX_X/3_ /@H/X*OFTCXZ_LI?LP>/7TV9K>^
M@\.6?Q7^#_BGS%GB>2'4I=5\:?$32[>ZCA^T6ZB'PM9*FZUEEMY'MYQ>_!'_
M  6Y_P"#A+Q=_P %B_A-^SW\'M"^!6M?LX>%OASXP\6>./B)X+@^*C?%'1_B
M+XSN[#2] ^'6IVU[;^"?A]*J^$M*N?&PAL+_ $"ZE2\\7NMM>2_8Q//_ *KW
MQ'^"'P7^,=LME\7?A#\+_BI9I"MNEI\1_ 'A3QQ;);I)+*D"P>)])U2)84EG
MFD6(($62:5PH:1R?X!O^#O#_ ()6?"#]GKP%^S-^UI^R-^S?\+/@I\+[+7_&
M'PK^/6E?!'X8^$_AWX;L?$7B:/0=6^%7BK6='\%:7I5A%!J0T;QAX:FU&:PA
ML+34SX>L!,NH^(8H[H _ME_X)O\ [$?PX_X)Y?L9_!#]EGX<Z+IVG?\ ""^$
M-+N?B#K=G!;K?>//BUJ^GV=U\1O'FN7L,:R:EJ.O^(A<BTEN'G.F>'K30_#M
MB\>CZ)IMM;_3?Q/^,OP@^"6AVGB;XS_%7X;?"+PW?ZC'I%CXA^)_CGPQX!T.
M]U:6">ZBTNTU;Q7JFDV%QJ,MM:W-Q'90W#W+P6\\JQ&.*1E^$_\ @DA_P47^
M%_\ P4U_8I^$_P ?O!7B/3[WX@V?AO0O"/[0/@M;BU77?AY\:='TBT@\8Z5J
MNFP,)+;2=<U".?Q-X+U)H((-<\)ZIIE]'%:W8O\ 3K#XW_X+N_\ !#P_\%E_
M"O[/Z:-^T5=_ 3QI^SQJ/Q%FT-=3\%2^/_!'BS2_B=%X*CURWU?2;7Q1X5U#
M1M;TV;P+I$^D>(+*YU*,VDVJ:7>Z-/\ ;+/4=* /PC_X/'OV7/@%\1O@5^S[
M_P %'O@SJW@+7/'^C?%'3/V=?BCXK^'^M:)K,7CKP?XJ\+>+_%'@#4_$&HZ#
M->6E_J/@+5_ 6LZ!I5_)=)J+Z9XN.FW#WEAH>E0Z1_4__P $8OVD/%7[6W_!
M+3]B/X]>.]3GUSQSXK^"6CZ#XU\07<YN;[Q+XO\ AIJFK?"WQ/XGU*<JH?5?
M$FM^"[[7=5VJJ+J.H7*1JJ*JC_)T_P""G/\ P3:UG_@FE^TO9_LK7W[0GPC_
M &D/B9+H^FW_ (CT?X)6WC*YU/P-J.N7:)X=\'^--/UC0K6UM?&FN6K6VKVG
MA?1M6U[4[73[O2[G5(+#^UM(%]^Q?PX_X)L_\'8'[$'@;PWI7P(M/VN_!WPP
MTS3UOO#_ ,//A'^U5X(\6^#?#[:Y,-4U"TM_@?9_%O5H-%U-K_49)]91/ 4#
M/?R7L\D\[PW<L8!_J=45_E^#_@L=_P '6'[)BM_PN_X=_M#ZIH&EJ9S)\?/V
M"[2VT$VRF:^N9#XZ\,_";P1J&K6NUY1/=/XOOA910&T@N+-+0PQ>J?#?_@];
M_;V\*W']F?&[]DK]E[QY+ILSV-\G@_\ X6Q\(M>:6T$-O.FI'6_&7Q/L+?5!
M<PWAO?L^A6-LDLL<,6F6HM76< _TKZ*_('_@B_\ \%9]#_X+ ?LS>+/C[IOP
M-\2_ 36/ /Q/U#X6>*/">J^)5\=^';W5;+PYX>\3PZKX0\=Q>&O""ZY92Z?X
MCM8M1L+GP[IFI:'?QM;W,=U9W.G:E?\ Z_4 %%?(WQS_ &_?V'OV8O'6B_#+
M]HW]KK]G+X%?$#Q!I,.OZ5X1^+7QB\!^ -;FT&YN;FSM-=N+/Q/KFFOIVBWE
MW97UK9:MJ/V33[VXL;Z&UN)I+.Y6+U/X:?M&_L]?&@0M\'?CQ\&?BPMPI>W;
MX:?%#P1X[$Z".ZE+PGPMKFJB51%97DA9-P$=I=.3M@E* 'LU%%% !1110 44
M44 %5;ZQLM3LKS3=2L[74-.U"UN+&_L+ZWBN[*^LKN)[>ZL[RUN$D@N;6Y@D
MDAN+>:-XIHG>.1&1F4VJ* /PX_;<_P""%_\ P18^+_@7XA_%KX^?LG?";X-Z
M=X*\*>)_'OC3XM_!@ZC\ +SPQH?AS2;[7O$_C'6;?X77/A[PIKTNGZ5:7^I7
M]SXN\+^)5F\J2YFMY[I8Y%_@9_X-_P#_ ()Q_#;_ (*)_P#!6J[UCPEX0\5C
M]B#]E_QOJGQ]U;2_B-=Z?XAUV]\&Z3XPO&_9Z^%7CO5],TK2="UGQ+XPU:TT
MJY\7VT.CV&F:_P"%O"'Q"BM;6!?)6OZC/^#Q#_@HE?\ P!_9'\!?L+?#S4KJ
MQ\>_M@75WK?Q+U"S:6&32?@%\/\ 5-/FOM%^TIY4D5Q\2?'!TC26-M-+'<>%
M?"_C;1=5MQ:Z[;&7^1O]@C_@O;\8O^"6G[*UY^S]^Q'\$_A+I'Q%^(_BJ]\?
M_';]H?XP:;JWCCQ9XH\0&(Z7X6\/^!?">DZYX=T#PQX2\!^'(+;3],B\4W/C
MLZMKFI^,/$Z:;X=?Q+_9.F@'[X?\%NO^#=O_ (*^?M;?MG?M!?M(_!GXG^$?
MVDOA1\5]?L-<\%_#76?BZ_PZ\3^!_#>FVUE9Z#\-1X1\<-H_PS33/!<5JD.C
M:MI_BY%UM8Y?$.J6=AXCU+4(Y?P+_P""5_[:O_!:7]DC]ISPQ_P3_P#V*/%?
MBV/QR/CSKVB^(?V/_&^F>"->\%WWCWPOJ$ME\5?#^O0^-+*[G\$:?:V/A;6)
M?'VM>"_$/AF\TG3='U;Q/%JMK<Z?)JD?VI\*/^#QS_@JUX+\56>I_$C0OV:O
MC-X4^T#^UO"NK_#'4O!5Y-9-,\DL>B^(_!'BG2I=*U!8G6WM;W5-,\1V<*1Q
MO<Z5>RF1Y/S[_P""B7_!3/X._&__ (**?"+_ (*C_L,^"_'_ .SC\=YI?AW\
M5?C'\._%L>AZGX;\._M(?#?4+6"X\0>#/%/AS4K9/'?@+X@^'=,T&'Q5%K7A
M;P3J>NZM!XON]>T-X_%DJJ ?Z8__  6N_P""F?B'_@D_^Q5<?M0^$_@M/\</
M$5_\4?!7PLTG0KG4;_1_"7AJZ\76?B'5#XN\>ZOI=AJ%_I_AJUM_#,^AVAAC
MMAJ/BW7_  QHS7]FVIH[?RM?#_\ X/C?$< @M_BG_P $Y]$U0L%%SJ_P_P#V
MEK_0A"5BG+-!X<\1?!;Q&;D3S_9HUCD\4VAM8A/,9+QS'"/[8OV1/VC/A;_P
M4"_8Y^"G[2'AW0]/U7X<?M$?"_2?$U_X/\16EIKEEIU[>QR:9XT\":]:WMM)
MI^JS>$O%EAKOA/52UO+8WEYH]Q+ );:2-VY+Q_\ \$R/^"<7Q3\]_B)^P3^Q
MSXONYS(SZIK7[-GP>NM<C>9[>2>2VU[_ (0]=9LY;@VMNMQ+:7\,EQ'"D4S/
M$-A /F'_ ((^_P#!9#X'?\%AOA;\3_'7PJ^'GC[X3^*?@SXFT#PU\1? GCJ;
M2=5^Q_\ "7:?J>I>%M9\/^)]#E^PZYI.K0Z)K5M(MQ8Z/JNGW^DW4=UI:V4^
MF:AJ'SE^T%_P<[_\$EOV:?CY\2?V=/B)\5/B7=^.?A'XYU3X<>/]3\(?"+Q1
MXF\(Z)XO\.W[:3XKTI-9M!'/J;^%-9AO]&UN32M.O4&I:9?V^G'41'$\W[ _
MLT_LB?LQ_L<>#=6^'W[+7P,^&_P)\':_X@NO%6O:'\.O#=EH-OKGB*[BBMI-
M7UF>!3>:I>16=O;Z?9/?W-P-.TVVM=-L%MK"V@MX_P @OVI_^#8__@D]^UO\
M:OB;\?\ QY\,?B7X0^)/Q?UW6/%_CV_^&'Q5UWPSH^K>./$4\][K_C6+PYJ-
MOK^BV&OZWJ=S+K&K+96<&CZAK$MQJ5UI,MU>W\EV =C\%_\ @Y6_X(O_ !U\
M:^$OAQX3_;#M="\;^.?$EAX4\,Z-\0OA!\<O 6G7NL:K<6]GI<=YXU\1_#>S
M^'NA6^H7ES':07/B#Q;I<2S_ "SM"'B:3];?V@?VC_@/^RI\--4^,?[1_P 6
M? WP7^&.C7=CIU]XS\?Z]9Z#I']J:I(T6F:19O<N)]4UG47CE^PZ/ID%YJ=V
ML-Q);VLD=O,R?SB>!O\ @SX_X)0^!/BEX ^)UIXH_:XUV'P#XCT/Q,/AYXC^
M+'P\N_ 7BV[T'4TU2WL_%BV'P9TSQI+IEW-%!!J%KX?\:>'GGM8%BCFA:6Y>
M?]<_^"KG_!+OX.?\%:OV9M,_9N^,?C/QU\/+3PO\3/#_ ,7/!?C3P!)I4FJZ
M'XR\/Z#XI\*QMJ&E:W9WFFZ[HM]X;\:^(["[TV0V,ZW-Q9:A:ZA;S6(28 YC
M0_\ @N;_ ,$@?$,$UQ8?\%$_V6[>."40NNN?$K3/#,[.4#@PVWB0:3<W,6T@
M&>WBE@#YC,@D5E'WA\!_VD/V?_VH_!+?$C]F_P"-/PO^.G@*/5+G0[CQ;\*?
M&_A[QSH=CKEE#;W%YH>I7WAV_OXM,UJUMKRSNKC2=0-MJ$-K>6=S);+!=6\D
MG\8^M_\ !CW\"I[B)O#G[?WQ:TJU6';/#K?P/\'>(+B2XWN?-BN;#QYX:CAA
M\LHGD/:7#[U>3[1M<1I_0;_P1F_X(V_#7_@CI\)_BU\/O!7QA\8_&[Q%\9_&
M^C^+O%WB_P 3:#I_@^PM[;PQI%QI'AK1="\):;JNNPZ>+./4=7N=3U2?6KZ[
MU>>]A1UM+73K.W0 ^U?B?_P4+_8$^"7C75_AM\9_VXOV/_A'\1?#QM1K_@'X
MG_M+_!?P#XUT,WMK#?68U?PKXK\:Z3KNFF[LKB"\M1>V$!N+6>&XBWQ2H[4/
M /\ P4?_ .">'Q6\7:'\/_A=^WI^QA\2?'OB>^ATSPUX)\ _M1_ _P 8^+O$
M.I7#!(-/T/PWX>\<ZCK.K7T[D)#:6%E<7$K$*D;$@5_+=^VA_P &;WAG]J?]
MJS]H#]I3PI_P4&\0_"_3_CU\5_&_Q>OO ?B;]FN#XJZAX<\0_$3Q#J'BSQ)I
M]MXWA^/_ ,.FU31HM<U6^&A0W7A>WOM.TC['I]Y?:K<6TFHW/E_P8_X,E_#W
MPW^+GPS^(?BO_@I)XB\5^'? OCKPOXOU;PUX2_99A^'?B77+;PWK%IK']FZ)
MXZG_ &C_ !M'X3U"ZDLXXX->_P"$4UZ33F/VB'3Y9DC*@']N?Q,^*GPP^"W@
MS5_B/\8_B/X"^$WP]\/I%)KWCSXF>,/#W@/P9HD<\JP02:OXH\4ZCI6AZ:DT
MSI#$UY?0K)*ZQH2[ 'X]_P"'L7_!++_I)9^P!_XF1^SK_P#/&KQK_@LG_P $
MK= _X*\_LH:/^S1K/QJ\0_ :_P#"WQ;\+?&#POXZT?PK%X^TM=<\.Z#XM\*S
M:7XH\"S^)_!@\2:1>Z!XVUPVJVWBK0KW2M=BTG58[NZM+6^T?5/Y9_\ B!C_
M .LHO_FDW_Y7% ']U?PB^.'P6_:!\(I\0/@+\7_A=\;O <E_<Z4GC;X1>/\
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M/^"@WB'X7Z?\>OBOXW^+U]X#\3?LUP?%74/#GB'XB>(=0\6>)-/MO&\/Q_\
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M/_@L]\9#?6NB_'#P%^SYH^J*3+HGP-^#O@_2C%:SKOCCT[Q-\2;;XF>/=-0
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M1\&O$-S;1&"WN-<^&'@C5IX("YD,,,M_H=Q)%$9&9S&C*A<EB-Q)H _R%_\
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M3H]VMO/$L]M#=":VA]6T'_@[S_X(VZQ_9W]H>,_V@?"OVTH+G^WO@3K=Q_9
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MQ>^%<]W)&J2*UJZ>(O@+K]B()&=9'9+)+D/#&([A(S+'+Y9K/_!D[_P3IGO
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MFRBUBPM]5TZR.LZ!+?6$7B#1CJ&B2W]BE^UW#_#?J?\ P8__ !!TR+4;^?\
MX*0_#NVT?3X[N[FU/4_V<M;TV*WTVT62:2_U%G^-,UK81Q6L9N+LO>2V]JJR
M%KF2.,RD ^&O^":WQ6^'G_!&_P#X.,O$?P/^&WQ_\">+?V+?B3XYUGX):M\2
MK?XD^$==^'>J_!?XJ>'+/X@?!C7-=^(-AK<W@DZ[\+?%=]X'TOQ=XJ>\@>RF
MTGQ[I+1:,=8U&RA_T9O^'A/[ O\ T?#^R!_XDM\&/_FUK_(@_8W_ ."7U[^W
MC_P4KO?V OV;?CAI?C;P58^)/BC _P"U+!X"OSX*D^'/PNT_5I;KXLIX/M?$
M]W>IX4\6ZQ9:3H?@T3^)H9=3N?%WA5KR73I=2DM+;^F+_B!T^*G_ $D2^'__
M (CCXC_^>_0!_=V/VL_V5V 9?VF/V?BI ((^,OPY(((R""/$F"".01P17;>"
M/C1\'?B9?7FE_#?XL?#3X@ZGI]H+^_T[P1X[\+>*[ZQL3-';B]O+30=5O[BV
MM#<2Q0"YFC2$S21Q;][JI_SSO^((;]J?_H^#]G__ ,-[\1?_ (]7Z@_\$>O^
M#6CXQ?\ !.+]NGX:?MA_$G]L3PGXQTSX5Z/XYAT_P#\+/"'BK0I_&U_XT\&:
MYX)_LOQ;K.N:K!!!X5TZ#7Y/$$UA#I^J2ZGJ^D:1 RV42/=H ?V=U5OKZRTR
MSN=0U*\M=/L+.&2XO+Z^N(K2SM;>)2TL]S<SO'#!#&H+22RNB(H)9@!FK5?E
M5_P6:_X)Z>./^"GW["?CK]E#X>?&-?@KXHU_Q9X'\866NZC;:I>^$?$H\&:N
M=2/@SQY9:+/%J4_A?4Y'BU-9+6*_?3_$6B^']5.F:@M@UM( ?HK_ ,+9^%?_
M $4OX?\ _A9>'/\ Y94?\+9^%?\ T4OX?_\ A9>'/_EE7^<)_P 02_[?7_1U
MW[('_@1\9_\ YUU'_$$O^WU_T==^R!_X$?&?_P"==0!_H]_\+9^%?_12_A__
M .%EX<_^65=-HGB3P[XFMYKOPWK^B^(+6WF^SSW.B:I8ZM;PW&Q)?(FFL)[B
M..;RY$D\IV5]CH^W:P)_S7O^()?]OK_HZ[]D#_P(^,__ ,ZZN9UO_@RB_P""
ME=O<0KX;_:1_8:U:U:'=/-K?C3X^>'[B.XWN/*AMK#]GGQ-'-#Y81_/>[MWW
ML\?V?:@ED /].&BOY'?^#>7_ ((!?MD?\$F/C[\8OC+^T3^TC\)O$?A;Q]\+
M)?AY8?!OX">(?B5XD\)>(-:F\3>&=?T_Q_XWN_'W@/X:VMOK/A"ST76=$\-V
M^G>&]7OC;^+M7D'B'3+1KW2M7_KBH **_ /_ (.#?^"6?[6'_!5?]G+X2_"'
M]ECX^^#?A'=^"OB1J?B?Q_X,^)OB7Q[X4^&WQ0T'4O#[Z5IYU_4OA[X5\<ZI
M=:IX/NA<RZ'I.H^%;[1[R/Q#J\]Q=V%W9V33_P ?X_X-&?\ @M9X;']AZ!\<
M/V9VT?328+!O#W[1/QBTW16AR9"VGV-Y\(-(N;:!G=SY<^F6<F\NQA&[<P!_
MI^5S_BSQ1HW@CPKXF\:>([K[#X>\(^']9\4:]>[&D^QZ-H&G7.JZI=>6GS2?
M9[&TGEV+\S;-HY(K_,D_XA-O^"XJ?.GQN^ 6Y/F79^TQ\6%?<O*[2?AFH#9
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MPBBNM4MM(T<7.]='@6'_ $8Z "BO\YW]H[_@]/\ VO-"^)'Q#\)?!/\ 8O\
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M 2RN[,Z5<VFIV<]I=07O\_O_ !"!?\%H?^CQ_P!D#_Q(7]JW_P"AGK_2[HH
M_P T3_B$"_X+0_\ 1X_[('_B0O[5O_T,]9>K_P#!G'_P6!\26T>G>)?VK_V+
M-<TP7$5PUGJ_QR_:@U>V26,,BW,=G?\ [,;V[7$4<DHB8F-@'9!(BNQK_3/H
MH ^"O^"8'[&%S_P3T_8,_9Q_8ZO_ !G;_$'5O@OX3UJPU[QA96,NF:=K7B3Q
M?XU\3_$+Q))I-E<,UU!HMIKWBW4=/T7[81>R:5:6<MZB74DR+]ZT44 %%%%
M!1110 4444 %%%% !1110 4444 %?Y^G_!Y?_P $VO%][XE^%G_!37X8>%WU
M?PI9^%-&^!_[2PT?3YGG\/7>F:S?S_"GXE^(&M=[R:5K4&NS_#75]9N/LL.D
MW.C?#W2O-FDUN 6W^@77*^.? W@SXF^#O$_P\^(OA7P_XY\!^-=#U+PSXO\
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MQ!JUS'9Z5H?A_0K"XU36=8U.\F*Q6NGZ9IUK<WM[<RLL<%M!)*Y"H37YU_L
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MT/A/_P $7_VK?V,_CM^P _C3X*^'/B+I_B/QAX.L%\:^)?%U_P##GXT?L_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\0W2P1:E_8[_  PU>?3=,\/^%-/\.>$-%T^75+PQV&A+?2R?;M1OGD_4(_\
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M"![O^O7_ ((9?\$2=(_X(S_#_P".NCR?M ZK\?\ QS^T)K?P]U7Q9JJ^"?\
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M+?'?P'XD\/:5\3O".EQ(8X/$6I:[\0XA;21VECXHATZSL[6WR/C!_P %*O\
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M/CU2^NTMYYX%N;JZEF6&:6(.$D=3W-%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?GA_P %-_\ @FE^S[_P50_9HU3]G'X^1:MI
M*VFL0^,OAG\2/"[01^+OA=\0[#3M1TS3O%.C+<AK+5K&:PU6_P!*\1>&-55M
M,U_1[R:+?I^L6NC:YI'Z'U_&G_P=L_LO_MZ>(/AY\(/VO_V/?B5^T0GP]^%/
MA[6_ W[1WPF^#'Q"^)NE6VG>'%U<^,O"7QHN/ /@W5[?2M3T[P[?)K6E>/\
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MOK61)$N[!8[34FO(#&Z3PB:%E.2*_P!2^O\ )%_X.OR1_P %M?VC""01\/\
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MQGXP_LN_L^_ ?]G?Q7^PY\-OBCX9^ ?P@^%?P8T'7= ^-/BCX;:_KOASX6>
MM%\"Z?J>LG4? ?Q+T]-<U:#0[74;V:RLH+"&:6X@@T_8\4D7\E?[1/Q0\-_&
MSX]?&3XP^#_A9X4^!_A;XH?$OQGX\\/_  ?\"O(_@[X::3XJU^^UFR\%^&B]
MM8QKHV@0WBZ?8QV>FZ1IL4,*Q:5HNBZ:EII5G_I=_P#$/+^P'_P5 _X)C?\
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M\.I]-OI)Y/ OQ)USPZWC/Q-XYL]2DTN;PO9:'\1_%OB*XN_LD6NQOX-DUR5
M#^Q']M7_ (*+_L6_\$\/!^D>-?VP?CUX4^#^G^)7OXO"6BWMOK?B7QMXQGTR
M*.2_3PKX#\'Z5K_C#7(+)I[2#4-2L]&?2-*GOK"/5=0L?MENTG\F?[5__![-
M\&O#FH3:%^Q;^R-XT^*$4-PD;_$+X_>*;'X9Z-*D,V+A]'\ ^#4\;:[JMG?0
M BQOM9\5>$+ZT9EEO- D*FV/[E_\%;O^"!/[,?\ P5Z^)?P4^*OQ@^)_Q?\
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MU'7+ZSTN&ZU:_6W@6\OY;BX$,0DV+Z%10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8=0UV'POJ=T?%^LZW=^.$T^S\(_VM444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<W"K*/X81^UQ_P 'D7P('V";PG^WOKL$#1PS//\ L7>!?V@8VC*MJI,NNQ_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\?O_!Z%\2OB
M=X/_ .";7P7\$>$;S4=+^'WQ9_:F\,^'_BQ<V%P\,.MV'AKP%XY\;>#_  ;K
M$:_+=:1J'BC0;?QAY#@!=9\!Z+.&!A"O_-!^Q+_P3[_X)R?M5?M9_P#!$_\
M9Q\):A%X\\/_ +6'['?[4>J?MD7^B>-;U_&_AK]IK0O@U^T)K\%K?V5EK$K>
M"=5^$WB+PSX*U7P/X>FLM.TOQ!H.C>'_ !)K6CZUIWB[49-6_P!+']MS]BSX
M#?\ !0/]FWX@_LM?M'>'+G7OAQX_MK.0WFDW::9XJ\(>)='NDU#PUXW\%ZVU
MO=?V-XI\-ZE%'=6-Q);7FG7]J]]H.OZ;K'AO5]9T?4/\PW]L[_@AW^V9_P $
MU?\ @IG^SS^S1^PE\=/%7QA_: ^,/@/XD?&C]FGQ9\--2D_9_P#C!H^E_#_P
MY\0M8\7:%-KDOC2TTJP\50>"/!OBJ".YT3QC;0>-;:232H-*L;K6X_#S ']R
M7_!"K_@B7\3O^"-]I\=]'US]L>/]H/P/\;V\)ZI_PK2Q^$%_\/M"\$^-/"4N
MKV0\:Z1K%]\5/&@O=0\3>'-2M='\16L/AG1);I-$\/"YU34(="L$7^+;P9X-
M@_X+^_\ !R7XW\(_'SQ'XHU+X#:E\6OC+;?8_#NJ2VEQI7[-O[.&F>*8/AYX
M*T"[0!/#EGXS'AWPW8^)-2TB.UN_[9\;^)_$]G(FOWYO6_H?_P"#8[_@N1^T
M]^V?\4/BA^P%^W3=S^+_ (W?#+P-K/CWX>_%75_#]IX7\<ZOIW@KQ/IGA;Q_
M\./BKIME#IEG>>+_  Y<>(=&N]!U:'0--U>XT_2O%5OXQGU#6+6SOKK^??\
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M*Z?]"]\=O_$6]$_^=%0!_2=17\V/_#1?_!73_H7OCM_XBWHG_P Z*C_AHO\
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M@>1)$!GL;RZMGW(V8IG P2"/QE_X:+_X*Z?]"]\=O_$6]$_^=%7$?$?XB?\
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MW5S=2[=\\\LC,YZ'_AHO_@KI_P!"]\=O_$6]$_\ G14 ?TG45_-C_P -%_\
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M17\V/_#1?_!73_H7OCM_XBWHG_SHJ/\ AHO_ (*Z?]"]\=O_ !%O1/\ YT5
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M4?\ #1?_  5T_P"A>^.W_B+>B?\ SHJ /Z3J*_FQ_P"&B_\ @KI_T+WQV_\
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MJ/\ AHO_ (*Z?]"]\=O_ !%O1/\ YT5 '])U%?S8_P##1?\ P5T_Z%[X[?\
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M7OCM_P"(MZ)_\Z*C_AHO_@KI_P!"]\=O_$6]$_\ G14 ?TG45_-C_P -%_\
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M.HK^;'_AHO\ X*Z?]"]\=O\ Q%O1/_G14?\ #1?_  5T_P"A>^.W_B+>B?\
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M4(C@2.)._P#^&B_^"NG_ $+WQV_\1;T3_P"=%0!_2=17\V/_  T7_P %=/\
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MI.HK^;'_ (:+_P""NG_0O?';_P 1;T3_ .=%1_PT7_P5T_Z%[X[?^(MZ)_\
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MG_0O?';_ ,1;T3_YT5 '])U%?S8_\-%_\%=/^A>^.W_B+>B?_.BH_P"&B_\
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MG_0O?';_ ,1;T3_YT5 '])U%?S8_\-%_\%=/^A>^.W_B+>B?_.BH_P"&B_\
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M3_YT5'_#1?\ P5T_Z%[X[?\ B+>B?_.BH _I.HK^;'_AHO\ X*Z?]"]\=O\
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M?#/QUJFMZ';6.N/9:EJ']F^+=#\7:!XSU+PG:0Z/??K-_P ')?\ P72\;?\
M!+#P-\._@/\ LRVV@3?M9_'OPUK?BJQ\8^(["RU[2_@A\-;#4'\/6OCN/PGJ
MD$^D^)O%OB?Q!;ZWIO@:SUVWU'PK93^$_$.I>)M'UFWM[+1-5 /ZCJ*_S(_B
M'_P4,_X.G_\ @FMX/^"O[<G[6/BOQ/J_[/\ \:O$/AB>'PM\6M%_9]\5^#?$
M#:_H]SXJT3P-XT\(_#ZQM_'OP.O?%7A?3+O5+.VT63X=:Y9M;76FWDMGKEKJ
M^A+_ '__ /!.;]N/X>_\%&_V-O@I^U[\.-.F\/Z9\4?#]R?$?@R[ODU&_P#
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M9G1]$\,ZEX6M=,N_$7A_PMN\6>*XK35[W-^&W_!=+_@M;_P1P_;0\(_LZ_\
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MN]:\0>&["[OHM&M+UJ /Z?**_P S3PI\;/\ @[Q^.'[.%W_P4<\$?%#XMR?
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M/_@MK_P5'^.6J_M&_'GQ9^QO\&9_B!X<^$WP8U#XP?$/4O@CHLWCKXM'PO\
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M' _[<U]^WI/_ ,$N/^"J42^+?B5K?CSQG\)O#'Q(O?#/@WPK\0_AQ\:O!/\
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MX#&G^$O'O@;QI/IUUH.@ZU:V.NZQ<^(O$7A74]*\6:EX-NBL !_>K17X*?\
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MJ5A;?B5^VQ_P7/\ ^"K_ /P4H_X*(>+/V O^"-VH7'@#P5X.\8>-/"/AW7_
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MV>M6VNZ)KNJKXM\->&-%EN=4 /[O:*_S2O$G_!7+_@X4_P""'/[2GPK\*_\
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M=/\ &?\ PSK\1M%\-Q>)[BUL="TGXG?"S0;"_P!:^'FFZ]>ZA:>'=0GL]/\
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MPN[?P_J>M>*O%-EJM[IZV>GV3)-?6ME:P3EVD!2!  I!) /[BZ*** "BBB@
MHHHH **** "BBB@ HK^*W_@OS_P<!_M4_ ?]K'0O^"87_!,;3;(_M(ZA=_#K
MP]X\^)L/A+2?'GC2P^)/Q1?2[[P3\'/A3X4\5V&J^"[C7]5T/7O"]SKOB77=
M%\1);OXJBT/1K?1=<TF]U>V_(/XK?\%)_P#@YF_X(I_%KX3^/_V^==U?XE?#
M/XLWMQ>?\('\4[[X2?$CX:>.8='G@G\3^#]-\?\ PH2^U/X5^-].L-1%SIMM
MH^LZ; @EM-3D\.>+_#^EW.FT ?Z9U%?,?[&/[5WPR_;C_9;^"?[6'P?FN6\
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MG_!$GX^Z]\$/BU\/OB+9_M#^-_ 7[,7A[QA\-O&_A[QMX?GOO$'B"#Q=\1=
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MQI\E[%;^,_BD_@/PKH\FE6=_??9?$OC#4$L;UO#^@7.HV=7_ (.4=5B^+_\
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M".ZLKLZ;*/#7@B/4A<6&K:!XQL(8+J7\'_\ @R7_ .3^OVK_ /LT"X_]7/\
M"ZO]%O\ :%_Y(#\<?^R/_$S_ -0O6Z_SI/\ @R7_ .3^OVK_ /LT"X_]7/\
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MB'4X=/GT_P /:1\#KOQWH<OA!946TMH]'L;:_NO!=_;6LUM:M%:Z5+#':QM
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M4 %%%% !7^:]_P 'JOPH\?\ A_\ ;M_9._:#U+2=2U7X2^+?V:-.^&6AW5Y
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MEUO7O$%[I4L]OHD/A"QU;6]*O_OO_@R@_P"4;G[2O_9[_BW_ -4-\ :_3_\
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M/B3X[L)R);9[NWU+4K&17%C(O]%__!;/_@KE\/O^"1G[*DGQ.N=/TKQK\?\
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M$_9R\<Z%\,_V*?V7?!WQ8UC6/"_CWQM??$+QGI^HIXCN[GPCHWQD^(&O^'_
M]QK%QX7TKPFMT-&TSP/X!EM[:YU[7[G5M9U6R-E=>'O]&W]C[P?^SQ_P3S_X
M)<?"_3?A3\1--^+'[.O[,W[,6M?$6W^+6@ZGI>H:3\3/#OA_PYKOQ2\<?$?2
M+[2;W5M'CL?&FJS>(_$]E;6&HZE8Z9#J<=A!>7D-HLTGXF?\'B.K?LW2_P#!
M+?P_!\0;SP9<_''4OC;\/;[]F59);&X\:SW*SN_Q,U#PV;<2ZJ?!A^',NHIX
MINU:/PP^K7'@F/4IFUR;PI%+^(7[,_[37Q0^ G_!G5^T_P#\)CK^I1CXO?M*
M^./V9?V<(M1N[QH1\+_BAJOPV/Q*T#1Q<-MCTV9K7]IF\-II^;,W\NHM*OF/
M?@ 'Z)?\&:GPT\2_$73O^"CO_!03XA0)?>+?V@/CKHWP_MM=DB=)&UK31KWQ
MC^+36DDC,\MIKNM_%KP++.6,@6XT&-!(94G _J*^'_\ P2\_X)^_"C]I$?M>
M_#3]E7X6^!OVDO[6\:Z\_P 6/#%AJ6D:_<:W\1M,U/1_'.KW=K::G'HEYJ7B
M>PUK6(]5O;O2IKB>?5=2O1(E]?7-Q+\5_P#!M]^SH_[-G_!&[]C?0]0L!9>)
M/BKX.U?]H;Q)*8O(DOV^-_B+4O'7@^ZFC(W^;!\,M1\"Z86<LTB:<C_(K+%'
M^!7_  ="_P#!?WQ/\,-7\8_\$S/V*O%UQH?C-]-;1/VK_C3X<NIH-:\,0ZU9
MQR/\#?A]JMJZ2Z?X@O=)ND?XF>);!_M>CVE_!X+TFZMM:;Q2-* /AC_@ZP_X
M*8_#/_@H%\=_@%_P3N_8^MS\:;_X)?%75H/%GC+PA$NN6?C;X]^,AI_@#P]\
M*OAC/9%_^$@'AR2XU+3?$&JV+7.FZWXJUBRTC2)&'AJZN]0_LI_9H_X)+?L[
MP?\ !,W]C;]A;]L[X,_#3X^0_L_?#;PC<:YHWB>S?7?#^C_&*YTZ]U+QWK'A
M34%EM+R-(O$7B7Q1I6GZM:R6DU_H5S+#)%%:W]Q:'^?'_@WE_P""<?\ P39_
MX)^^&_"O[7W[6O[8O[%WB[]MWQ1H:W_AGPK>?M)_ [4O#?[+VBZ[9 /HVC!O
M&$D.I_&2[T^XEL?&GC.*22T\.1W%YX-\%N;--=\3^+_ZGOVO?^"BW[,'['?[
M&7C?]N7QA\0O#GCGX,>'=&>?P?J/PW\1Z'XL@^+/BR\O;G1?#/@;X?:SH][?
M:+K.L^(O$EM+HPNH+R73M%2UU;5M:GL]+T/5;FU /!OVJOVI/V$_^"#/[!]A
M>#0-%^&GPH^'UGXA\._L^?L\^$-1N9/$7Q$\<ZWJ6L>+W\$^"8=;O=5U1H[_
M ,1:WJ&N>*_$VHS7>F>%--OKO5M1D*BPT^[_ (VO^#1O]F?XJ_M+?\%&OVC?
M^"F/B[0;71_AWX"L?BE8'5K2WN++2]7^/?[0.IIJVH^&O"L#[HI]-\)^!M3\
M3WVOI]IEET1?$7@>"2*7^VDN+?\ -KX<ZU\5/^#D?_@H_J_Q2_;Q_:O^$O[+
M'[/'@..UO-:;QE\5/!?@+1/A;\*+K5;A]%^#'[.N@_$'5[&V\0>/O$YL[EM:
M\87MC?P6L\.H>.?&RZA-%X9\&:W_ *5O[$GB7_@F[\&/AS\-?V/OV(/C+^R_
M/X<\%:%<V7@SX6_"?XT?#;QMXLU2/3[:;5?$7B._L-!\3ZKXE\4^(=0,=]XB
M\7^)[Z.]U+4+N2^U?5;MB9)% /T"HHHH **** "BBB@ HHHH **** /\??XT
M_MH:9\#O^#BK]HK]LSXB_#[6/C-%\%/V^_VB]?\ "OPYTR]M;/4O%'B#X6>*
MO'G@SX"Z+_:=S;:FFFVNG>)?#_P].H:E9:?J]_I>FZ=<WFAZ5JNI6UCIUS^^
M?Q _X.7/^"GW[.WQ'^%-[_P5<_X)+?#SPQ^S=XZ\3VOBGP;I&K?!GXJ?#[X@
M65MIED;2]USX>>(OC+XM\8^"->\>^%=.UQ-1ET>]\/\ A?5GCU*?2;K5?"5C
MK\&HZ?\ D)\??#/@G]A7_@Z>UGQ!^TA:Z?H7PFTS_@I/HW[0VJ:QXA@A/AO1
M? 'QM^(-I\8_"_C:=Y(C:MH/@D>.=.UB]N(TE_LUO#5] ^;W3YHU_JK_ .#Q
MCXB?!MO^"4_P]\/:OXA\)ZGXW^(/[1_PQ\2?!2SAO=.U+5=7M=%\,>,+OQ1X
MO\+_ &<W,TWA^S\(ZV=/U+Q#9.FEJ/%6B:?-?&77=.MKT _9W]IW]OCX3^'/
M^"0_QH_X*!_ +Q'8:A\.?^&0?%7Q-^".JV$5OIT*:[KG@VXT?X8Z%<V$+%-"
MU/3O'NHZ'X6UO1"/M7AW5[6^TB:V%[826P_%O_@S9_9N'PW_ ."9'Q%^.6L:
M>(]2_:D_: \77^F7OEM$=1^&_P )],L?AIHT!F&))1:>/K7XL*)$<1QFX,<:
MI,DSO_/Y\;OCAXW^!W_!G[^R#\%-<U"2TNOVM_VK/'^D^&-!GCN+"^'P+\"_
M&SXH?%W6+XQ3,7N;.;XK^$?"^I6\BQP6]YIGBW3KN'S8&2>[_OV_X)9?LZ/^
MR;_P3F_8N_9\N]/72]=^'G[//PY@\9V*Q& 0?$3Q%H<'B_XDDQ-\ZM-X^\0>
M))W,@$C/*SR!9&8  ;^SQ_P3-_X)Z_L5?$KQ1\?OV;_V8OA+\ /B!JW@?7_!
MWB?QIX,M[WP[9KX#U37-%\8:]I<^G2ZJ?#&E:2=6\+:)J4L]MIEF;"WTF"V@
MGMM-22V;_/-_X.#?VV+#_@MW_P %,OV=?V3/V#-&;XNZ'\*;K5O@5\,/%^D1
M_P"@_%OXJ?$CQ'I=SX_\4Z%J0!2/X2^&[3PQH-M;>++^.'2QIOAWQ?X[6[?P
M?>:=J+?8O_!RK_P7A\=_M$?%GQ;_ ,$KOV(/%4>D_"G3O%D?PI_:&^*6D:[;
M:'<?&;XA/JRZ#K/P>TCQ-?76G:?H7PC\,ZXQT/QUK<^H6EGXZUFTU*PN;^'X
M=:;<3^,_U\_X(0_L*?\ !+#_ ()1> HOBK\3/VX_V(_BG^W!X^\/"Q\=?$:W
M_:1^"]YX9^%>BZ@1/>?#7X/F\\56]W;V#@06_B_QI<0P:SXRNK79##H_AU8-
M&(!^Y?BC_@E/^Q)\:/V=?V7?V?/VH?V?_AS^T#HW[*GP=\(?"/X:ZCXTTZ]D
MO?#FF^'_  -X3\$ZM+X=U*QO-.U;2H?$5KX.T*?4H;>ZB%Y+I&CW%RCW.E6$
MEO\ *7_!6W_@HG^RY_P18_X)^1>!?#EMX?TGQQ/\'9_@7^QK^SMI,[WUW<CP
M[X/M_!'A>^N[&]N[C48/A;\+M..D7GBW7]6NR]];6=KX<M;^]\5>(-,@N?HG
M_@I]_P %4O@-_P $U_V)=2_:^US5-#^)O_"7V.DZ9^SCX2\,^(;.[L?CIXV\
M7Z+-KO@R'0/$FE?VE8GP/+H<4OC'7O&=D;W3[;P?9376E?VKJVHZ!I6K?YW?
M["_P3N?^"^/[<WQ$_;&_X*L?ML?"+X._!GPUXBTR'QEIWC/XR>!OA9XI\8V,
M27.I^'/@+^S[X7\7>((&\&?#;PU8SPKXA\30Q73Z7::JTMM<:]X^\2ZQXDT\
M _8G_@RC_8N^(&D:O^U#^WSXI\/W6C> ?$_@VR_9M^$6L7R20-XTG7Q9I'C?
MXL:AI,$B(UQH?AW4O"7@+1!K,?F6-YKTFNZ/;3-?>'-8AMO] "ODG]EOXI?L
M.CPOX6_9V_8Z^+7[-.M^&_A5X&MK;PQ\)O@/\3_AUXM;P?X!T"?3M&6]3PYX
M/\0ZMJ-MHUI?ZKIEKJ&N7L+"XUC6+:34K^?5-5$ES];4 %%%% !1110 4444
M %%%% &)XFTJYUWPYX@T.SU.YT6[UG1-5TJUUFR"&\TFYU&PN+2#4[02!D-S
M82S+=0!P4,L2!@1D5_E\_P#!KQ\??A;_ ,$W?^"J_P"T/\%_VV]=\/\ [._B
MKQ+\*?'?[.[>(/BCJ-IX4T3PC\8?!/Q4\':KJ'@3Q-XCUFXLM%\-V^OQ>%-=
MAL]5U:ZM]/OM=T?0=+MKDW&LV2S_ .I#7\6GQY\&?\&X7_!>S]NS4_@=<ZQ\
M9OAC^V\FG^*=+\1_$/X?Z%>_L^Z]\0M;^'%Q:Z!JG@KQ /BEX.\0>$_&_P 2
M/#-K8W$6GO=^ KCQ-=>']#O;)==U#2] L+&R /PH_P"#O;]L/]F3]JC]MKX"
MZ!^SE\1_!'Q@G^"'P.O_  K\2/B#\.M;TSQ7X1.O^)?&-]XCTOP78>+M$N[W
M1->N_"^G-)?ZJ='N[RSTG4/$T^CW-T-9LM6T_3OZ<?VF_P!KW7/A+_P:7>$?
MC#K.I[_'?Q-_X)S?L^_ 33[O>%O]8UOXU>"O!7P0U;4X9&*XU:'PKKOB#Q;<
MS1&-HI=-N[BU5'CA0?R%?\'&/[''[!7[!OQP_9F_86_80T"^UGQUX#\&^+_&
M?Q^\3ZAXB7XB?%+Q-X[^+FN^&M-^'W@CQKJ^G06T=OKGAWPWX'_M70_ 6CZ#
MH5CI&G^/K76;;1VU+QCJ-]J'[*_\''FD^./@A_P3$_X(C?\ !)'P]&D_Q6\5
M:=\(]+\4^&[&9%N;_P 9_!7X2>"?@WIVGWOV171[#Q-\2_B]K5W; >;%=ZGX
M=^U(LTU@LB@'[G?\&R_[(GA;X=?\$0?A)X6\?^%M,UJQ_:\'Q=^+OQ3\+ZQ8
MQW6D^*/#/Q6O;OX?Z/INK6TRA=1TSQ%\&/"G@R*]@F3RI;:_FM1YD 623]3/
M@+^PW_P3X_X)MV/QC^,/P'^"_P )?V6=#U_PG8:C\:/&NG:A>>'/"\7@[X<)
MXAURWU+7[C7];GT#P]I/AZ+6]=U"_P!0MH],22!T;5)[B'3K 6GTS\"?A/X9
M_9V^ WP=^!WAEX;?P?\  [X2^ /A9H4SK':01^'OAOX0TGPII]Q*"WEP+_9^
MCQ33%W(3+L[G!8_YJ7_!<[_@M+\4/^"O7[4.D?\ !/C]CKQ_X?\ !7[&MO\
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MTV#5]0\0Z$ ?*'_!RK_P5$^ ?["G[ OQ8_9%TV_T?7/VB_VLO@CXN^"7P_\
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M>>_L_P#3,^!7QI_9A^)>BGPA^S/\6O@1\0O#WPST7PYHC>&?@9X^^'_BW2/
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MM_#<_F!_P:I_LZ/\ O\ @C?\$-=O]/73O$/[1OC;XF?M"Z[$8BD\MOXBUY/
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MFT8SW,OCL>*X]>:3Q6?$$0_:3_@J=YO[>_\ P=7?\$[/V/+7R]9\$?LI:?\
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M&)_"7A\^%=!U#2&MY;2?3]1LO#SW&CK>6<MO*VFWE]8L?LE[<P2?QZV'F_\
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MO%_8FM)I%SIG]H:O!!I$6JW6EVEQ>6UQ>VC'^7_]F+_@AS_P;:_M>?"C4O\
M@I;\*?&_QST_]E?PQ=^.-?\ 'OPJ\:_&>R\'_#+X>0^ =;OY_$6E?$/3;_PY
M-\9_"5A'IVFB_P!,L+OXN6]QJ?@[5M(U.SEF_M.RN: /YQ/^#;7XJ1K_ ,'
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MTMOK7QT^+=WK.N:7IWB[XP:]HD@@T;PM8:A<'2[C5K/X?^$[JWM;OQ3XRU@
M]N_X)SV7CK_@M_\ \'*$O[;?A7X?:AX0^$?@#X[^%_VL/&$MVGR>!? 'P'M_
M#FC? G1_$-]8.=-G\>>-=:\#^ +#4-+LKR5;R^E\8:U9+?Z)X?U.5/Z4_P#@
M\;_:-/PH_P""6_AWX'Z=>&/6/VI?C_X$\)ZG8ABGVCP#\+DO/BWKMV2,EQ:>
M-O#/PRMC#@!QJ)E+CR-DGZ3_ /!+WP)_P25_X)V_!'P-^R?^R;^U-^RSXF\3
M^)]9T2V\3>)K?X]_!K7/BW^T!\6=:>VT:TU35K?1?%<^H:OK.JZA<Q:-X,\&
M:-!-9Z):7%IH.@64D\UQ/??SR?\ !PB)?VZO^"]W_!);_@G)8LNN>$?!-QX*
M\:_$C28U\^*RM/BG\2E\4_%FVO+/E9[K3_@7\$=)UZ-9U$'V35T0RQQS73*
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M !?\9[N"^> (MUJ?AEXYMYTZ$1@'],GQY_X)>?\ !/[]I[XOZ5\?OCS^RO\
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ML(XXH[&:+59+N.6S2*-+9U:%8T5 H .VHHHH **** "BBB@ HHHH *_RU_\
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M(O\ @VV,O[<G_!:O_@K9_P %,;V'^T_"UC?>*O"/PXOKN-F6RL/C?\5+RY\
M#3IWVB:^\._!WX+1>&[N2,?N['7E,L4 O[=:_K/\1_\ !+S_ ()^^+/VE-(_
M;#U[]E7X6W?[3>B>-M$^(]A\9H+#4]-\8MXY\.(D>B>)=0N=+U.RM-8U+3DA
MMEA?5[.^C865AYL<G]GV7D?B9_P9]_LYO\'_ /@D\OQ;U*P$&M?M2_'CXE?$
MNUO)8?*O)/!?@E]-^#7AW3Y 0KFRAUWX?>--;TYI%S+'XCEN(F>UGMVKSO\
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MJOI%U>"T3Q#;^'M0N[5K[3M*FMP#^?SP'\//B]_P<B_M@?MT?\%*_C_I.O\
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M6-)TGQ'/X@\?WWA_4K_P!##\/I]5O)KRPU/3'M+6-]421)85F7_5AH ****
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M#"9F5=H_V8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OXJOVW_ /@T+\4_MO?M=_M$?M9^,?\ @IG<:%K'QY^*GBGQ]!X8
MN?V1)?%#^"_#>HWK0>#/ 47B.;]J;1GURS\!>#[70O!UAJG]C:.E[8Z';SQZ
M1ID;I8V_]JM% '\ ?_$#'_UE%_\ -)O_ ,KBOJOXR?\ !J?\9_$7["'[+W[
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MS97UG<1O!<VL\L,J-&[*=JB@#^#3]I?_ (,I=.U;XL>(O%G['7[:9^%7PO\
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MQ1_Q Q_]91?_ #2;_P#*XK^_RB@#^:3]M+_@A'\3_P!KS]MS_@F+\<=9^/\
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MLO\ :ECYOVF/Z/HH _ '_@AC_P $,?\ ARY_PU%_QE%_PTG_ ,-)_P#"DO\
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M,&J_M+:G_P -3_\ #27_  T1I_PEL/(_X4?_ ,*>_P"$/_X5=<_$:X\WS?\
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M"#7/!NJ1>-$L8M-T-/&^B^+K<C1=/M8]8\->)+FTLY8/S;_9,_X,M?A/X/\
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MXMTGP[I_B;P#K7@#QAK^H!M;\6:Q8:UXATCQ!J[7&J'PO8:[JFKZY>_UGT4
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M/A32ULY=;:R=KY[9M0N?RX_X@8_^LHO_ )I-_P#E<5_?Y10!_*=^QS_P;?\
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M?9?MW]F_\)%HM[H_V_[%]IL_MGV/[9]H^R_:[7[1Y?D_:8-_FKV%% '\X/\
MP1"_X-]_^'-GQ4^.'Q,_X:W_ .&C?^%S?#_P]X%_L3_A0O\ PJ#_ (1O^P?$
M;Z__ &I_:7_"Z/BA_;'VO?\ 9/L/V#2_(QY_VR;/DC^CZBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _(+_@I?_P7 _87_P""4GBGX<^ _P!IW5_B7J?C_P")V@7O
MB[0?!/PI\$0^+M;L?!]IJ-UHT?BG7IM7UWPMH>G:5J.M6&I:3ID2:Q<ZK>7>
MFZ@Z::+2TENE_+__ (C)/^"1_P#T+G[7_P#X9KP3_P#/?K^>'_@]?_Y21_LU
M?]F0>$O_ %?/Q^K^H;P__P &I7_!%&_T'1+ZZ_9T\?O<WND:;=W#C]H;XW('
MGN;.&:5@B^-@J!I'8A5 50<   "@#Q?_ (C)/^"1_P#T+G[7_P#X9KP3_P#/
M?K[2_8'_ .#CW_@F[_P45_:(\/?LN?!/4OC1X5^+OC+2O$6I>!]*^+/PXL/#
M.E^,IO"FA:EXJU_1M%UCP]XL\7VL6LV'A?1M9U\6VM?V1;W=CI5Y'97=S?B&
MRF\L_P"(3_\ X(E?]&Y?$#_Q(CXX?_-O7\>/_!+#X.> OV>/^#L+0O@-\*]+
MN=$^&GP;_; _;=^&7@'1[S4]0UJ[TOP?X)^%?[1/A[P]87.KZK<7>IZG/::5
MI]K!+?ZA<W%Y=.AFN9I)7=R ?ZIE%%% !1110 4444 %?YJ__!QY_P %:O\
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MZ;J?BR[TC6->MM"M7L[2\D:^FT?0-9U!$:-4^SZ?<$N&"JW^LC7\<7_!Z_\
M\HW/V:O^SW_"7_JAOC]0!_,[^S1^U;_P=-?MC?#J?XM_LP_%O]M3XT?#:V\2
M:GX0G\8>#;CPC=:1%XFT:UTV]U31FDN[6SE^V65IJ^F3S*(B@2\A(=B2!_5K
M_P $JO%__!8;X??\$S/^"H?C[_@I5K/Q\\._'/P1\,_BAXO_ &>O$'Q?;1$\
M2Z%9^&O@!XPUI-9\*OI226Z1Z7XOLK*]#7,;E;^",[&0%3=_X,V_^41_B/\
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M7-K#X2\$^'5\(^(M:\ WFM>)-7%Y#;7?A-I;4 _L$HK_ #&?A]^W7_P<R?\
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MHOX)>&-1N(=)\5Z1JNF$ZSX*\7:MIDT6IZ3-+;0ZE(\:6]]##-#_ !=_L/\
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M_#V"]3X Z#<^(O'7_"MY/#?CYO$S3:?:Z=JDJZ"-53PV-0N#;!([DV"F53(
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M'AH^*/B3;:!K?Q6\>>-M1,MA8:EJ6BPKHQU2*ZU'3?#?@S2;DVJZ^N_M<?\
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MW[7/_8O_ +-W_K,OPCK^YW_@Z(_;0_:=_84_X)V^ ?C'^R=\6=7^#?Q+U?\
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M?_!5K_@HI\=O^#@;X??LQ?%[]K;XL>/O@#JGQG_;.T#4/A9KVHZ9-X7NM&\
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M6=G9O>MKWAK7--\96-JT9%A:^ _$]SYA^V;5_N^K_(T_;]\&>)_^"%7_  <
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MPUSQ+8K<+>Z]XAD.IW%W?'Z9_P"#M90G_!%GXO(I8A/B]^S^H+N\CD+\1=-
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M]X;DCN];CUS0/V5;#6-'\3Z]H5S;/%<Z7I.G?!^ZAUW2KW36\/:3JNC1JUJ
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M"=(FFFM-,?5=;\"&RTO4+BST'Q9JEAK^J6]A? '^G517\\O_  ;U?\%JIO\
M@K?^S_XUTGXN:1X9\(_M7_L^W7A_3/BGI7A<R6>@?$'PIXBLYD\+_%OPWHMW
M))/HO]K:GI6N:)XO\.6=SJ6G>']<L;'4+:ZT_2_%VB:'IOY%_P#!P+_P<M_&
MG]FSX^Z[^P/_ ,$X9-)L?BWX)O-.\/\ QF^.]QX8TWQYK&B>/]6B1D^$WPF\
M'Z[IFL>&;_Q!I$=]ID'B?Q-K&D^(VB\0W=UX1T?0['5]$O-5E /[CJ*_R[O'
M]]_P=[_LR_"L_MN_$3QM^V?HGPWT'35\8Z\=:\?_  R^(Y\)^'([6UN)=?\
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M (;\1:4;_4M.M],U;4?W,H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_:7[XL_^KM\94 ?ZO5?R>_\ !UI_P55^+?[ 7[.WP&^#W[+WQ1U?X6?M%_M
M>/\ 4?$EQXO\+2VG_"1^%O@Y\,;2$Z^UNUQ;W::9/XP\8^(O"FE6%W-%B_TG
M1?&-E;*[0W$EM_6%7^3/_P %4?B1XI_X+=?\' J? KX8:Q<:AX'NOC1X+_8M
M^$.K6/\ Q,+/0?AG\//$E]I_Q+^)-IM1H[O01X@N?BM\7!=1V[2-X7FM8BER
M;2,R 'ZD_P#!LO\ \%U/VN/C'_P4$?\ 98_;@_:0\:_&GPI^T5X UC1_A)>?
M$*[TJ8^$_C'X&BN?&&DV>GWT&G6)L[3QIX0M?&6BSVK3$ZMXE@\&V4"27)@C
M?_1/K_)3_P""\_[)FH?\$=?^"PGA7XF_LO:6OPZ\":FWPB_:O_9K%C#.VE^%
M?$GA+5+6Q\3>'FG1X8[QM/\ BAX&U?7;S2@\;Q^&/%NAVMXLD5XMQ=?ZE'[)
MO[1O@G]KS]F;X%?M._#N5&\'_'+X8>$?B-I=J+A;J;19O$.DV]UJWAF_F1$4
MZOX4UHZCX:UJ,(A@U;2KV!D5HR  ?@3_ ,'&_P#P7<\2?\$I/!GP^^"'[.FC
M^'M<_:W^.GAS5O%>E:YXNTX:SX7^#?PRM;ZZ\.1>/;K0&N[6/Q'XM\0>(K75
M=/\  &E7ZWOAF&Y\+>(M5\66>H6=C8>'O$?\KGPG7_@[W_;7\'6G[3OPJ\;?
MMLZMX$\7V=MXHT#6[;XL_##]G;PWXGT:X2*[T[6O WPLUKQ9\*;'6?#>JV\T
M-UI5UX/\$W.AZY92+/I[7MHV\_HI_P 'G_[ 'QE\5^.?@5_P41\ ^%=5\7_"
MWPA\(K/]GSXTW6APWNIW/PV;0_'/C3QQX%\6^(-/@@E.G>$/$$_Q"\0Z#=>)
M-R:9I>N:?H^G:M):W7B'1OMWA/\ P3F_X/'/%O[/OP?^%7P!_;#_ &7!\5M
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MDE4>)?V3_C/:_P!I7?A"PFX@U*ZC^#?CG6/ $U\L<EM;>,M$NYOLB7.FFUB
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MNI2^%/B;-%!XR:WT^1Q ;KX??$E=-TV_FMQJUA>(PLIO]/S]F[]GKX6_LH?
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M=&2X=+.7QW\(O%'AW6?".N36Y;RIIM-\+>(_B1I<1$9F1=?=ED6)94D_T\:
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MR_%2;X8>%Y/B$OBFRDBMY+3Q&OBYM7&MVKP0O;ZF+J)HHV0HO\;_ /P=4_\
M!5?_ (*!_L$?MA_L[_#C]D3]I/Q-\%?!7C+]FJ'QMXET'1/#/P]URWU7Q2WQ
M1\?Z$VKS7'C#PAXBOH9CI.D:=9>3:W4%KLM4?[/YSR2/_3KX(_;F\*?L^_\
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M/VC/"LWB>\AU?3HY9+6WGT7QIXL\+Z#JEQ9)XK\$Z@R6]C0!_J(5_(O\&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH[2*'4/ZRZ* "O\ )%_X.P/^4VO[1O\ V3_]G?\ ]4?X(K_6ZK_+\_X.:/V
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M=U8"4W-OX?U9-;O/#&A6,]S+?V'@O3M#TR[O;J\M);N7^!/QK_P36_X++_\
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MFL='UNSMIY1_.!_P75^!G_!1;X$?M>> M*_X*??M ^'_ -H?]I'QW^SOX/\
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M\*O^"A)1A(T3VFES> M5@\0ZG#(L<I6XTGP]+JFIVWR@&XM(P9(03,G\P?\
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M_$OC#_@U&\7Z[XU^'OCOX3^-9/V>/V#--\:_#7XF>$=?\">./!/C'P_^T?\
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M^*OCA\+/&,:^'_%&L>'/A3\0OC?^S-\:_#'AV75KSP=XQU"X^&-YIWB?X?\
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M.I:O=>$?%'A+7?@WJ6DP>++_ $$7_BJW\.^(/!/CJXM1IWB#Q%9W44[2NEH
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MJL&HVNA_&KX<^'=-U'Q%X UJRFT_1=0OTU*/1AI.OVTH\#^.M:TMY[^^ /\
M1[_:CUK]@GPWK/PHUS]M34OV1]!UU+WQ5IGP/UW]J&X^#VF:C#J=[%X?O/&F
ME_"S6/BNT,T&IZA;Z7X8O/$>G>%+I+V_M])T>ZU"":'2[62W^FO"&L^$/$'A
MG1M6\ ZKX;UOP;<V:IX>U/PA?:7J7AFXT^T=[-%T:]T66;2I;.VDMY+55L9&
M@A>!X %:-E7_ "UOB;\ /^#@#_@XS_:%^$5S^T#\ ?'7PT^'7@6S&D^'O&/C
M3X.>)OV?/V<?A'X5\67VDMXV\9>'QX]%OK'Q&\2:PNDZ3>ZUIWAG5O''C'4H
M=,T.QMK73/#]G:&Q_MX_;:_9N^+?["O_  0B\>_LR?\ !.I?C3>_&+X!_ SX
M9^!_@QJ/P,T3Q'?_ !P\3>);+XE>!Y/'/C#P_H?P^M+_ %^7Q3XS%[XS\6^*
M8/#UI*D2ZQKTBI'I\<I0 _=6BOY.?^#6WQ+_ ,%5/$6@_MKM_P %.[;]MBWO
MK35_V?A\&/\ ALCPI\7?"]R]I/9_&0^/O^%?+\5M'TB2]@6:+P?_ ,).=#$Z
M6\AT :B8VFLM_P#6-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC;7/!&C^(_$FF^']0NM5TSQ2KV7AO7XKO6_"&CZ=?:<+&]N+VT_A\_X@J?\
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M?/&OP>^(WQG^!_P7^%7C;X0>%O$?@FU\0?":/QK'>>+/"NMZM9:[INC>)?\
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MFBW?C'3?"NGP>%_$7A?4M:TK^W=(T#PS+X7CNO$:7^GZY^!7PM_X*H_\'/\
M^QK\/?"7[.A\ ?M7V.F>'M/T_P '_#RR^.'[$>N^+/'NF:=9MIEMH^BZ)XD\
M<?"N7Q+XIAM;2&#2]'CUVZ\3F+3-02UL&$4>CM9 'P!_P5H_X)^>//\ @AO_
M ,%"O"/PY^$_Q[UCQ/J>C>%_ ?[2?P)^+>CV]OX0^(/A:UNO%_BG2_#Z:Y9Z
M7J>HPZ?XN\,>)? .II_:%J]M8:_8I8:S%I6FP:E+I%I_;;_P<-_%[6OV@O\
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M%U#I[6MI$D<LUQ=S0P6\,T\L<3_Y/_[$-]_P<K?\$XO"OCCP5^QE^RI^W_\
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M/"-CX'\>OX4T/Q),-3T;3(=3U"YEN_S4/_!*3_@IEKWPY^(OQYC_ &!?VFM
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M/X9^!KFZL=/O[OPIX*37-;FEUK4+6WOO$OB+6M9U9[:QTO\ L72-* /X#O\
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MW\']?>XL=&A^(>J06UI=^*?#-_>>'YO$.N:9+XLT36=1\:ZY>Z7JWXJ>#_\
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MQ;IK>C>-M4\,_&VPOM'E<P6]V\.J:AJ&B7=RDPC7Q!I.J6MQ,ES:W.S]6_\
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M$RP0WFK:-:^-]5M5N3(LMMX:U#RH6E030?ZAM?YX/_!HE_P4H_9Z^#FN3?\
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MZ+I?AYM6_M/XI_LU^.-8LLZ/HNF6?V'3M0M--'V;[0+,74UQ/* ?UQ?MH_\
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M86.***-52.-%5$10J@* *_KB_P"#R3_E$?X<_P"SO_@U_P"H3\7Z_G5^#G[
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MACXYN]9UK^P]#@N;G5/&7Q(\>Z[J.JC1])M[F235=:BTC28&ACLX  ?P\?\
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M)X:_LP:T@7[!-\05\(#Q@FHEM:/BM?$'_$W'[&?\&U'_  ;Q_&/]D3XHV_\
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MI:7#/)!JVAZ@=L/F&", _<:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /F3PI^Q?\ LG^ _P!HKQ3^UMX(_9\^
M%?@[]I+QSX7U+P=XU^,7A?PGIN@>,?%VA:SJFC:SJT?B:\TJ*UM]<U34M0\/
M:))>^(M3MKGQ%<P:;:V,NJM8)]F/TW110 4444 %%%% !1110 4444 %%%%
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M^(EM+O0/#W@RRO)K[Q9K/BRTAL=6_K4_X+^_\%'/^"A?_!.+P+^SGX\_82^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\:?$+Q MX^@^!/"?B/QEK::="ESJ#Z1X7T>\UO4EL;>6:WBGO&LK&86T,EQ
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M^*9/$\&K66I'1OA-XI2*V@\,7D3WLFE0&Y2.[FGM0#]':*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX<USX6E=6\*?%+36U&[O-0T;68M0^+FHO!IL]LVBOIWV2>VU']'/^"/'[?\
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M;*./29?$?B'X5^./'%E?ZE-; /JW@KP;XBEM[G6=+>_KV;_@[?\ B]X[\4>
M_P#@GU_P3?\ A_KMUH4G[>_[3-EI'C:>Q4L]]X>\#>)OAKX9\,:!J*!LSZ7?
M_$#XL>'O%*VJ1L]QJ7@&Q)ECCB>&Z\T_X/-;8ZW\*/\ @FWX1LG$FN^)/VJ/
M$]MI-@B2S7-V6\-^'-,=X+>!))IQ%>:QIL+)"CRM)=PI&CNX%,_X.44;P_\
M\%=_^#>+QOK<<DGA&#]J7PXDZW,8736;PS^TW^S!J_B"/[05D!D?3-6TX7D;
M1,(K<6[A9/,90 ?U/>"OV#OV1/ 7[*UC^Q1HGP$^',G[,]KX);P'>_##4?#6
MEWFC^(-*N-,ETS4]4\1O]FBN-7\7:W]HN]3UGQC/*/$M]KM[=:ZVIIJDINA_
M,?\ \&SWB[5OV5OVV/\ @K;_ ,$@+C5M0U3X<_LX?'7Q=\6?@##J][->:GIG
M@J/QS)\./$ FEN09##K?AR;X+ZW+;VWE65OK]UXBU%8YKG7KBYD_LIK^*O\
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MUM](N[:.Z\2>)K6?2--N-7\4Z]J=QJ\FJ)::8]K^,G_!R)X.^&/P _X*K?\
M!&WX]?LMZ9H/@C]N?XD_M!6MMXRMO "VGA_7_B9X93XG?"CPUX(U3XC6^B)%
M<WLWBG4?%'CWX<C7=5M+B\\=>&+OQ)X7U&YU;2_"<%A8?T+_ /!7'_@LI^S=
M_P $F_A/;ZKXZD'Q-_:*\>V%PGP-_9K\+ZC"OC3QWJ+RR6%IKWB%XHKV?P9\
M.+75%-KJ/BR\L+F?4+B"[TCPEI7B+78)M.A_)O\ X(^_\$IOVI/C[^U3<_\
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MNKR?79/A]X2UK6%_MG4]"L==O[W6/$WBS5?+UOXB^+9I?$6KQ6ME:>'=%T,
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MK;Q2P^#-3\,W>N6>LSPW=EY=OK.FZKI%A_'7_P $>?\ @I+\6_@[_P %;O\
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MJ/\ PB'P_P#CCIL9TKQ'JVE:3=Z]=>$SJMSI_A7Q+X>\67.BZ?J&IZ+8>)_
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M8%5IRBH!^Z5?QA?\'D/_ "2W_@FG_P!G?ZC_ .H[HU '[1_\%#?^"U_[._\
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MOI'@[6;'6O%+VCVW@PZOX.L= \8:B]OHGA[Q!?Z]?Z3I6I?G1_P7,_Y6%_\
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M[4-)5-/N/[1U#P-=ZM:_9U'E6=];P2YGCD)_%CXW_P#!SW\*(_CWX]_9X_8
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M.U\8?#O4D\X&[7XTBUV;"TD?7_\ !SS^VB?'_P#P3K_98_9<_9AU0^+?'?\
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MB3_@KG_P;!:O\>?@7=_L$:K^WG^P]XT^+NH_&#2/CE\)[7Q9%JFZ_P!!\/\
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M7+KX?^)=%N/#EN+2Z?3K[QCXD\"7]]);R1WNE:1"!='Y?_X/5-&D\1_L^?\
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MZG6)?A]\,OAU\-[GPKX8FNW!=++3O%/C/QYK*P0%(YI-;1YQ(]O#Y0!]W?\
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M;MUN()8T]VH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M00QZ?#JFJ^$;+Q9:PW//@:]U"UDL);'_  ;Q_L+_ +6FO?M.?MB?\%GOV\?
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M;7$23V]Q;SHT4T$\,JM'-#-&S1RQ2*R2(S(ZE200#^-SX,?M:?ME_P#!=?\
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MB?Q;\//&_@#P_K^A^#;.(ZEXGTK5_%=EI(O]>71=%U/^H&B@#^1_PI_P=I_
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M;P6T<D]Q=2);PQPI)<W<\ES=W#K&JJT]U<RRW%Q,P,DT\DDLC-([,0#^9O\
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M-:\,CQO^T[^T9I^F^(X-+O6L96U'0;B_T_Q)I,-P\$5Q<6=FSL;>7<WY-_\
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M0"22=.N0  .22> !R3TK?HH _C[_ .#+OPYXA\,_\$Y?VD;+Q'H6L^'[R?\
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M =1TGX3_  \^+GP[\6?LO>"_@GX$^*]C\2-(\,6WA^_\2:_X4UBRBF^'.O\
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MR[D@B=BD+W5P\:JT\I::@#^-S_@DUX;\1:?_ ,'._P#P6JUR_P! UJQT34_
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M6(JYM[B>$L8YI%::@#^7/_@K]^V#_P %.?\ @FG^WE^S]^V-X4T?XJ?M)_\
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M)8K".]N)TLXY$M;9)$MUC5UMX%8$11A?[&+/XR_"#4-#\6>)[#XK?#:^\->
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M:^-_#/CK1[>X<.4@GU/POJ>J644SB.0K%).KL$<A2%;&EKOQ(^'?A?Q%X?\
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M[2Y^QW>N_#+QSX8\>:-:WF9!]EN-3\*ZIJME#<YBE'D23K+F.0;/D;'\S?\
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M-_&WA'P<_B34H]&\.IXJ\2:-X>?7M8E*+%I6BKJ][9G5-2D,D8CL;$3W3F1
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M.]N83_87Q ^*6O6FEZE\15>*RM='UN;PIX*FTVQC\"7=QJ7Y8?\ !+#]F?\
M8,_X*L:)XT_X*6?\%S?VQOA=\7?C1\6_'GC'1_A7^S?\2/VL]/\ @SX5^$7P
MX\+>(;FPM/+\'Z7\2/!OCC0M+E\16^M6_@KP3::KIO@RV\*6L.NZKI_BS5O%
MEQJ%C^P?P"_;DO?^"^'_  0>_;*^&6CZ?Y?[<OAO]G'X@?"3XS?!_23%HFJ:
MI\<=)\(:GJ_PZUS0=,N)+=M/\)_&_7/#4$5C:W:VUGHGB%O%_@B:YN;?PR^J
MWOY'_P#!N9_P3(_X(A?\%'_V,AH?[0_[-^F>,?VYO@AXO\<>&_CYHNI?'_\
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M\(_^",'[??[-U]XNM_C7X5TCQ]\/OB1\:K'P;:?!&34]3T?QAIWA ^!_'O\
MPFQ^(^A?$#6-;\.:_P##;3=<L['PCK#>*;M]$LM8O(M8M)-3 /RP^-O_  0!
M_P""2G[;'P+TSX@_\$,/C1\&_@W^U5\-=>\&^*/ /Q1^%G[6?Q1^(7ABTM;#
MQ#I,&LP?$B)/&/Q?\>>!]>TK0I]2U7PSKF@:/X>\6KXUM=$L/$5ZVE7MU-9_
MUW_ 31?BQX;^!_P@\._'CQ%X=\8?&SP_\,_!&B?%KQ=X1%^OACQ9\1M)\-Z=
MI_C'Q/H,>J6.FZC#I?B#7[>_U>TM[RPM;BWBO%@DB4Q\_P 4/_!8/_@W#_85
M_80_9>^,W_!03]C7X_\ QL_8S^)O[/VCQ>-_ ^@3?%6]UOP7JWB%-3M+31/!
M'@KQ+J\EI\8?#OCCQ1>W<>B^%-33XE>(R=5FLHI]&FB:ZNT_I4_X(:?M+?'#
M]K[_ ()4_L@_M!?M'3:CJ/QB\;^#O%UEXJ\1ZKIUEI-_XSA\%?$[QOX#\.>.
M;BPT^TT^UCE\9>%_#.C>(I;F'3[.#4YM0DU6SCDL;ZUN9P#]9*_B!_X*+2_$
MO_@MG_P7CM?^".=[\5_&WPX_86_9)^'ME\6/VC= ^'VI2:'JWQ,UZR\+>#_%
M6LWT\EQ:WEAJM]9Z[\3_ (=_##PV=?TZ\TKP9N\9>+]&L]1U*]@BO?[?J_B9
M\%>*/#G_  3R_P"#O#]H?6OCO>VWPY^%W_!0O]F^ST3X)?$'Q;=6.F^%M9\3
M>)M'^!FM2VL_B2^FBL]*>^^*GP)\>?#W3;"XNHI[C7=2\)63VN-<T>60 ^C/
MV\O^#5[]D./]GW_A+O\ @EGX)\5_LO\ [;WPAN='\5_!KQSH_P >_BU)#XRU
MW2M5M9[K2?%>M>/_ !QXF3POJ,]E+JE]H/B[PC)X7O\ 1]=73H;F6Y\.0)I$
M/Z)?M5_"?_@L1\9?^"//A'X*?"_QA\)_ /\ P4C\8^!?!'@?X]?$6S^(M]X2
MT^RT^RMKZV^)/B7X9^,O"_A&XM-+^(GCVVTS2+4/I^G^&]'\--XN\477AG7M
M+NM"T"YE^V/^"E7[>/PX_P"";W[&_P 9/VJ_B#/H5[>>!O#5Y#\-O FL:^N@
M7'Q4^*FI026W@;X=Z3<1VFI:@T^NZPT+ZK=:9I.J3Z%X:M=;\2W-F=-T:]FB
M_F<_X+;?\%E?VO!_P0W_ &1/VF_A%X"\7?L2_$?]OWQ\FCZVV@>/-1\5>,?A
M?\&QH_CWQ)H0\+?%*P\+?#C5-#\5?%W0-"\'>*](U_2_#>G:II7@K4O$>F:9
M*NJ-;:[:@'T1\-O^#:;_ ((A?LY?L\^![']O2Q\-^*_CM=^#=/U/XM_'/XM?
MM9_$SX1IJ7Q!U72?M'B[4_#6FZ1\6?A_X,MO#=CXBAUN;PV=8T/6=0DL;0/X
MBU37;B.\E?X%_P"#:GQ#X6_9U_X+-?\ !2K_ ()\_LL?M")\?/V#--^$GB/X
MV?";7;#QIIOQ \,7NL^$OB/\$/#N@:UX;\1^'9V\(ZAJ=MX=^,GB#P1XW\3^
M%[2SMO'-[X.T"_ND$.BZ7;6?Z(_LS_\ !K'_ ,$B_#'PP\)?&;]HO6/B#^V3
MXCUKP5I7Q-\=_&GXD_'CQ3X=^&WBV?4] M_$FJ>/-,;X;ZWX)9/ 5Q'+)KVE
MS^*/%WBEY-":&7Q!K^MP-<SS?E)_P0"\8?LIZC_P<M_\%"?^&,M"\+>&OV8+
MG]E?XL> ?@?I_@I(K?PA?:)X#^*G[)VC7GB#PN6F>74M$\7:AX*\0^+M-U-I
M+F_UFSUA-;O7EFNKN< 'V%_P2EU73]"_X.=_^"Y6MZM<K9Z7H_PP\6ZKJ5VZ
M22):Z?I_Q#^"MW>7+1PI),ZP6\,DK)%')(P4JB,Q"GY7_P""7W[(VC_\',/[
M2?[6/_!1S_@I'KWC_P"(/[-WPP^+-S\&/V9?V8M'\<^)_!/@SP]IG]G0^+)?
M#^I7'A/4=+UW1-,\*>"O$'@*?4'\%>(-"UKQUXYU_6_$?B76/)L8[#5_I7_@
ME_X9L?&O_!R]_P %X?!NIO+'IOBWX.^//#.H20-MG2QU[QS\&M*NWA8$%95M
M[N1HVR,. <CK6[_P:$?$W2O@1X!_;A_X)B?&6ZL? /[5GP._:S\9?$'5/ACK
M]S8:;X@UK1K[P7X'^&'BF?PQ;/*EQXIM_"'B+X1RS:[?::E[!8Z3XI\*ZB+E
M],U>PD !ZS\8O^" /Q,_8:_;>_95_;)_X(8PQ?!W3]/\;V^A_M6?L_>./C/X
MI?X6>*_A8][ITFL""Z\>W_C+Q)JNG>)='G\2:9J_AF[O-?'AW6SX7\6_#VT\
M-:MH<4J>6?\ !<S_ )6%_P#@@+_V/_A+_P!7YHM?L+_P5Q_X+*:+_P $S_%/
M[*_P?^'7P<T_]JS]IG]J+XK:;X)\-?L[:5\3O^%>>+(?"&K1W6@Z?XS?4[/P
M/\1YM/\ [2^(>H^%/#?AZSU7PW#;>)D?Q2=,OA)X<U"6T_$__@XI\8Z)\!_^
M"TO_  0?_:.^+-Y!X.^#GA;XA:>/%GCR_P#M1\.>';?PC\</A_JOC._OM16S
M&;+POHOBO2];U)DA^TIIC-<M:Q@J" ?V4?%G_DE?Q+_[)_XR_P#4<U*OY0O^
M#*G_ )19?'S_ +/_ /BG_P"LZ_LJU_1U^W)^U!\%_P!ES]COXY_M _%KQWX9
M\/?#_0/A'XQU33-0O==TZU3QEJ>H>%=0/A;POX0EDF9=?\1>--0GL=)\+Z;I
M2WMSJU]J%JEI#,KYK^<7_@RI_P"467Q\_P"S_P#XI_\ K.O[*M 'AO\ P:U2
M>/(M1_X+Q2_"RU\-WWQ.B_:-23X<V7C*]OM-\(7GCQ)_VD&\(6OBK4=+L=3U
M*P\-W'B :=%KE[IVFZA?6NF/=3VEC=W$<=O)ZO\ LA_\&WOPC\2:'\8?VI/^
M#@'Q/:?M,_M4?$WXD^);Z^US5?VE/B/X1^%/@_P3:K#-H,FF^)O!_B;X4ZK-
M>WAM]>O;71KR]L?"GA'P>-%\.Z)X0T<Z+=W$OP%_P1'_ &B?&?[)/[+/_!S+
M^TK\.-*@UCX@_!CX@Z]XY\#VMY8'5=,@\6Z5_P -''P[J^MZ8LULVH>'M U:
M2TUWQ%9K<VS7.AZ;J$2W$!<2IW7_  1@_P""*7[-/_!8K]E[1O\ @I%_P4C_
M &AOV@?VP?CE\6/'_P 2M&UKPE??&;5--T+X:VW@KQGJ.@6GA'Q!-IB-XTM-
M;U*QLK3QA8:-I'B;PMX7T/P/XK\):;X?\*6=I;PZG?@'S#\5?AE^Q7_P2U_X
M+\?\$OI_^"07[1/AC4? O[1?QI^&_P $?VC?@M\/OCU'\<_#O@/2?B1\7O!W
MPM\2>$_$VK0^*O$^NOI7BWPAXZ_X2+PYX5^(^N>(=7T#QIX-MO&5C=KY6APZ
M7[[_ ,'37[!7[)WAK]NK_@FA\5]$^%/V+Q_^W7^T_K/A;]JG7O\ A.OB3<_\
M+3T+PSK'[,7@71+'^R[OQC<:+X(^Q>%?$.L:7]J^'.G>$+RY^V?;KNXN-1M[
M6\@^8_\ @I=\)_\ @F;^QQ_P7%_X(W?LR_L!?#GP#\/IO@+^UC^SMXB_:6'@
MOQ/KGC2^MO%GB/\ :<^$5QX;\'^._''C/Q-XI\2WOC#PGX=\*:AJU]I&N^()
MV\/6/C"P,J6ESJ%_&OZI?\'9=Y9Z)^T1_P $,?%&LW5MI?ASP]^UMX[O-=US
M4)XK33-(LX?''[*VHS76H7D[I!:6T-AIFH7<T\SI%%;V=Q+(ZI&QH ^GO^"Q
M7Q(^%7_!O)_P2#U7X:?\$W? T_P)USX[_&T?#3X92V?C/QUX\O?AQXF^(7AS
M6O%/Q)^*MCK'Q2\5>,O$4FIV?A#X>S:%X>C367M=!\6^(?#NNVNFO;Z??P3_
M "#^R1_P1A_X-_%_9]T/6?V\?VK_ ($?M2_M?_%7P[9^,OCG\8O&W_!0.+1-
M9TCXD^++2UUKQ+IWA2W\)_&CPW!>1Z!K<CVW_"1^/+3Q7XI\27MM?ZAK-['I
MNL2^&[3W'_@\E^ ?B[XL_P#!-SX/_&_P-HM]XLTC]G?]H?0?%/C_ /LN9KC3
M=)^&7Q#\'^(O",OC#4([6:-[G3;;QK-\/]#^V64C36=OXIEO0\-@M[=V_J7[
M%W_!"[_@W$_;I_9K^%?[37P-_9$T?Q-X.^)'A71]7O+33?VJ_P!K>^U'P5XJ
MGTVSN/$WP^\6VUI^T5<-HWC#P;JEQ-HNOZ1=,)[>ZM_.B:>RN+6ZG /C3_@B
MK\>$_P""?_\ P5\^+?\ P1I^''[4-K^UY^PW\4/A[>_%K]CGQC%\2_#/Q)?X
M7:QHOA:]^(FO^!K+6O"MW<^&X%N-'L_'VF>,=%T#['876N^#O#WC;3_#_AN;
MQ-XHLI/$/A/\$H?^#E?_ (+-_MNZM^U;XM\:ZC_P3^_X)S>(9OA7\+?@;X3\
M6:KX5TKQ+J]_XN\6>!_#&H3W.F-%?6$7Q(7X7?$+XB>/O$6CWNG>-B!X(\&6
M>M6?A_3K2*P^VO\ @G[\,_\ @W]^'7_!9^Y_9B_X)^?L4_%"\_:B_9>\+^//
M%EW^U9X"^.7QA^)'P$^'-Z?!$W@OXA:-K+^-?VE_$-IJC00?$&;X2ZA<?\*^
M\3V=K\0M=71(X;673[O7M(^=O^#>/QCX?_8*_P""O7_!7S_@F_\ 'K4K7P-\
M3OBU\8-*\?\ P(/B:>'1XOB/HW@KQ9\5=:L;70;S5W@O-=UKQY\,OB_X(^(?
MA#2(6GO+SP_I7BJ^CCDDM+K !\W?\'%O_!"[X$_\$^OV(_&G[3'_  3QO/B'
M\#/A)JWB?X6^ /VL/V<I/BGX]\<?#'Q]X2NO&-C+\-O'L*_$37_%GB>3Q7X/
M^*__  C-NMKJ/B#4;);'Q+=WF@CPZEIK5GXF_L>_X)._\HLO^":?_9@'[&__
M *SK\.:_%_\ X.[/VJOA9\)?^"4_C;]FW6_$NDM\6_VJO'7PGT#P/X'BO+*7
MQ(_AKX:_%#PI\7O%?CB;2FN$OK;PKI+_  _T[PS<ZVD$L/\ ;WBC1M+4,;N>
M2V_:#_@D[_RBR_X)I_\ 9@'[&_\ ZSK\.: /O^OX-O!OPP\3_P#!R]_P6&_;
M)\-?M)^.O'^C_P#!-;_@F]XMG^&_A3X&> ?&VI^'])^(GC&V\:^,_!/A+7-6
M,.R*'4?B<? /Q&\:^+_%VEV<'C#0?"=IX1^&^C:OIRR0^)(/[R:_AT_X-Y?'
M>@?L&?\ !7/_ (*[?\$W?C_>1?#CXD_%WXSV/Q#^ $'C"^L=,/Q&T?PAXN^*
M>JZ=::%J-]<(_B+7?'_PO^*W@3XA^$-(M&EU"]\/Z3XKO#;BYLKV"  ZS_@K
MG_P0!_9[_8'_ &9O%O\ P44_X))7OQ2_8U_:0_8[TU_BI=6W@WXQ_$WQ3HOC
M7X>Z;=62>/UGO?B9XI\:>(],U;0O#1U#7DLK;76\(^*M%LM=\'^)_"NKQ:[9
M7ND?:W[3_P"VC=?\%"?^#63XU_M=ZKI5EH?B?XK?LC^)(O'.DZ:X.FVGQ#\!
M?$=OAMX_?3(B3)::1?\ C#P?K.J:+8SM)<6>CWUA!--<.AN)?KS_ (.+?VP_
MA;^R=_P2A_:OTOQKXFTJS\=?M'?";QK^SG\)?!37UBOB3QIK_P 6-'E\$^(;
MG1M*N)DN+K3/!?A37]6\5>)-2BC,&F6-A#"91JFI:1:WGY#?#?X"^.?V=?\
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M;:RUWQ'X0^(_P.U6R\/>++VS_MVQ^'OC36-#FN;ZZN]1NM3_ *#O^#;P!?\
M@B5^P0%  _X0#XA'   RWQQ^*+,>.[,2Q/4DDGDU^0/[:O\ RN2?\$P?^S0-
M1_\ 4&_;MH _L]K^+'_@\X\5^*? ?P6_X)S^.? MV=/\;>#/VKM?\5^#K\6M
MG?&R\4^'?"FE:QX>NQ8ZA!<V%X;;5K.TF%K?6UQ9W!3R;F"6%WC;^TZOXO\
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M5]'')):76 #YN_X.+?\ @A=\"?\ @GU^Q'XT_:8_X)XWGQ#^!GPDU;Q/\+?
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MOA;P_P"&=$O/%'AL> -7U?P]X$FN_#&F>-K3Q?>Z:T\6MM>W'Q7)_P $"?\
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M6Q<V6@S0G2--U#4@_P!CL[B:, ]THHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\S/^"?W_  2?_9>_X)L>.?VH_B#^SQJ'Q4O=>_:[\6>%
M_&7Q53XC>+-'\2Z?;ZOX1UCXEZWI2^$[?2_"WAR32+-KSXK>*!=PWMQJSS0Q
MZ4B31-:3/=:W[ G_  2X_9I_X)OZY^TEX@_9[OOB=>W_ .U/\0K'XE_$P?$3
MQ3I/B2W@\1Z=>>+;VW3PO'I?ACPZVE::9O&>L"2VNY-4E9%LU%RIAD:;]':*
M /SM_P""E/\ P3%_9O\ ^"JGP;\&? S]IR^^)=AX*\"?$W3_ (L:)+\+O$^E
M>%-;?Q1IOA7Q7X/MX[Z^U?PUXHMY]*.D^,M7:2TCL8)FNULYA=*D+PS?;?BS
MX;^!/'_P]UOX4^/_  KH7CKX=>)_#%SX-\4>#_%^EV.O^'_$OAF]L#IE]H^N
MZ5J$$MCJ5E?69:&Z@N+=HI0Q.P'&.WHH _EXU7_@TE_X)F2^-?$VI^$?B7^V
MK\,_A)XRU*?5/$W[-7@/X_:=9?!;4W9+:*UTR>/6OA_KGQ#O-%MXDN@\.L^/
MM7U=FEM$M-;L;.S:RNOTL_9+_P"",7[#G[#W[7?C_P#;)_9G\(^*?AMXX^('
MP*T']GBZ^'6F:YIG_"GO#WP^\/V/P>LX)?#GA@>'X_$">*=4F^"?A76/$7B;
M6_%VN:CXB\0ZKXMU[6'N]4U^6Y@_5NB@#X!_X* _\$Q?V-/^"FOPWT[X<_M9
M_"NV\7/X;ENKGP'\0M!O'\,_%+X<W=^;?^T9?!?C:RB>]LK+51:6G]L^'=2A
MU;PKK<EGI]QK&@W]UIFFSVGXY>%_^#2?_@F]:^+/#.J_%3XR?MS_ +1/@#P5
MJ4EYX5^"/QD_: T2\^&&G64R6QETAH_ _P -O!'C2WLS/"Z[O#WC+P[+-8-!
M9W[7TL$EY<?U%T4 ?G;^VA_P3'_9T_;;_92\,_L3^,=2^)/P;_9L\,7?A%K?
MX;_LY:[X;^&&CZEH7@&V\KP;X)U6VE\'^(;63P-X=O(M/UJP\,V5M8V']N:)
MH.IW"SSZ/8>3]2?LW?L[_";]DSX%?"_]G'X&>%[?P?\ "GX0^$]/\(>#]$A*
MRSK9V0>6[U35KP1Q/JOB+Q!J<]]K_B;6[A/MFM^(-3U+5KQGNKR9C[=10!^5
M/P=_X(\?LF_L]_M^?$__ (**_!#4_B_\+_C!\:4\1+\5_AYX4\9:+:_ GQVW
MBZWLY_$LVN> +CPC=:B9]7\7V%K\2)Y;+Q19M#X]275;(VVGW5WI,_RQ^V-_
MP;:?\$YOVN/C-KW[1FDQ_&O]D[XZ^)Y;S4_$GQ _9(\?Z7\+SXE\3WUR;R[\
M6:WX;U7PGXM\.)K^JW9:X\2:EX<T_P -W_B:YFNM4UF[NM?N9-9K]_:* /Q)
M_P""?G_!O_\ \$^O^"=WQ6O?V@O .E?%;XZ?M&7$FJ2:?\>OVG?'-A\2OB%X
M;.N026NM2^&8]#\,>"?!^EZMJ=I--8W/BP^%+CQM_9ES?:4GB9--U35;6^^E
M_P#@HS_P2C_8N_X*E^ _#O@O]J_X?:EJVJ>!Y-4F^'7Q-\$:]/X0^)WP^EUM
M+:/6$\/>((H+[3[W3=36SM)+WP[XKT7Q)X8N+NTL]1DT5M2LK.[M_P!'Z* /
MYA/"'_!IS_P3HM->\/7_ ,:/C/\ MT_M3^%O"&I:?>>%OAI\??VA=-U+P+IE
MC80VL;:2UIX ^'OP^UI;6_%N;6^_LG7-&1]*6UTZWAMS;S75W_2QX/\ !_A3
MX?>%/#7@3P+X<T3P?X*\&Z%I7ACPGX4\-:99Z-X>\-^'-#LH=-T;0]$TC3XH
M+'3-*TO3[:WLK"QM(8K>UMH8X88U1% Z.B@ KX _X*!_\$Q?V-?^"F_PVT_X
M<?M9?"RW\6/X<DN[GP%\1/#]XWAGXJ?#>\U#[/\ VC-X*\:V<,MY96>J?9+0
MZQX=U2#5_">N266GW&LZ!?W.F:;-:??]% '\SGPH_P"#4S_@FSX'^)?A;X@_
M%7Q[^UW^UGI'@*\BN/ WPI_::^-&A>,/A;H4%N()[:PN-!\(_#SP)J6LZ;;Z
ME&]TVB7^MGPSJ=HMMI>OZ#K%LE^VI?MQ^U]^Q/\ LU?MU?L_:]^S)^TM\-M-
M\<_"36FTN[M-'MY[KP_J7A+7- 21/#GB;P1K>BRV>H^%O$'A])I[?3[W2YHH
MI--NM0T+4K:_\/ZKJNE7OU710!_,!X'_ .#3W_@G_P"%[*W\%^*/VC/^"A?Q
M4^!MEJ$5[9_LZ>-_VEM,T[X--#]NBU*[TZ]T'X=_#?P+JC6MW>0J3-I6LZ-J
M,<>)?MTFI)'J2_HG\&O^")_["G[.'[:/@[]N+]G;PEXJ^!GQ"\&_"F/X-6_P
MU^&>K:#H'P0UWP7'X6D\)A?$W@IO"UWJ^JZU/;1Z1K.H:X/%5M?ZOXG\.Z1X
MAU>2_P!2.JS:G^ME% 'YQ? #_@EQ^S3^S=^W!^TO_P % ?A[??$Z;X[?M6Z3
M=Z-\3[3Q'XITG4O 5O:7NM>&=>F/A;P_:^&-.U'29A?>$]+"/>:]JBK UU&4
M9IDDB^=OV_\ _@@=_P $^O\ @HA\3;#X[?$;P[\2/@I^T):K"E]\>OV9/&.G
M?"WXE>)5M+./3]-F\5SW_AGQ;X7\1:MI=C%#8:?XFU+PQ-XJATNWM-%;7)-%
MLK+3K?\ ::B@#\//V ?^#?G]@O\ X)^_%\_M(>&W^,O[1/[2D<%Q'I7QS_:?
M\>6/Q%\8>%)M1TZ?2]9NO"%GHOAKPAX<TJ_U.PN;C3_[=U#1]:\66.E2SZ79
M>(X;2^U-+_[<_;^_X)R?LH?\%,?@U;_!']K#P#<>*_#VCZTOB;P;XDT#5[KP
MSX\^'_B86LMC)KG@_P 360D>SFN[":6RU/2]2M=5\/:Q;^0-7T:^>RL)+7[G
MHH _FG_9?_X-4O\ @F3^S;\7O!GQ=UG6/VC_ -I5_ACJO]K_  O^&_[1_P 1
M/"'BSX4>"KV*\34[&YA\'>$/AOX%CUU[+5E;45T[Q#>ZEX8O9TM9=3\.7MU;
MO=7'ZN?\$Z?^";W[/?\ P3 ^#?CCX&?LVWOQ%OO!7Q ^,?B7XXZ[+\3/$FE^
M*-;3QIXK\*^"/!^J16%]I/AWPS;V^B+I/@#0FM;&2QN+B*[>_F>]E2XCAM_O
MRB@#\Q_V*?\ @DI^R3^PE!^UCI_PILO'/C/0_P!M+Q//XG^.?AKXPZUH'CCP
MYK+7B>-(=2T"PTB#PIH=K'X8U:S\>^(;#5-'U9=9COK"6&UFE,:S"?\ ,"7_
M (-1/^"?7A_Q_P"*?%?P2^/O[?G[-'@[QM>FZ\3_  ;^!/[1VF^&?AW?6L;F
M6TT5;C7/AUXE\>7.C6TDDP6WU_QIK]U'%((K"]T_9N;^G>B@#\ =<_X-H/\
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MVC6^HZQK-[J'W[10!^;7[!__  2M_9?_ ."=^I?M-ZE\"I?B-K1_:T\=6_Q
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M+_\ @DG^RQXV_P""DWP__P""J.LZA\5U_::^&WAY/#7AZPLO%VC0?"]].C\
M>*_ANK:CX5D\*3:O<W/_  CWC'5G,L7BBV0ZBMG<^6(H7MIOT^HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img245850697_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img245850697_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !L /0# 2(  A$! Q$!_\0
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MT9>R]K]DZVBBBOH3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=?98=4T^:?[OE0W2N_\ WS0!N45@^(/%.C^%K/[3K.J6.EVK''FWUPL*;O\
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MP?\ H-?:GP#_ .2/>$_^O%* /0:^:/V]O^2-6'_8:M__ $5<5]+U\T?M[?\
M)&K#_L-6_P#Z*N* /!/V=_\ D2[[_L(/_P"BHJ*/V=_^1+OO^P@__HJ*B@#]
M#=@K(_X1G2AKS:S]BC_M1HO*^T[?GVULT4$\I\]>.?C]<1W$FGZ!:^7)G8]U
M,K;_ /@,7\+?[U>A_"SPA<:!HSWFJS27.N:AMN+N6X^=T_NQ?\!J?4?AEX?U
MGQ-:ZU);JMY;G<XC7Y)?[NY/\_=KLWB7]X:9YU&C5]K.K5ES?RENO+IOV<?A
MK<3-+)X-TUI';>[;6KU&O'?%.I_$+PMI=UJUS?:*UK;LOR0J[O\ ,VQ?X/\
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MC_A)9+&:XW?N_L.[9M_VMZ)5'X:^*;KQ9I^J3WOE^9;ZA+:IY:_PJJ__ !5
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CEXA>VZC9(HQC[G%%=WH_@[2-#T^*SM+*-((Q\JD9HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>beam-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-25T06:35:00.2878+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://beamtx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:beam="http://beamtx.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails2" id="DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails2">
        <link:definition>100020 - Disclosure - Guide Acquisition - Summary of Transaction Price Determined and Allocated (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails2">
        <link:definition>100030 - Disclosure - Leases - Summary of Future Maturity of Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails2" id="DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails2">
        <link:definition>100040 - Disclosure - Leases - Summary of Future Minimum Payments Related to Equipment Financing Obligations (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100050 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss">
        <link:definition>100060 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" id="StatementConsolidatedStatementsOfStockholdersEquity1">
        <link:definition>100070 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100090 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>995465 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995485 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>995495 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>995505 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995515 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995525 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1" id="DisclosureStrategicRestructuring1">
        <link:definition>995535 - Disclosure - Strategic Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisition" id="DisclosureGuideAcquisition">
        <link:definition>995545 - Disclosure - Guide Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>995555 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>995565 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995575 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan" id="Role_DisclosureStockOptionAndGrantPlan">
        <link:definition>995585 - Disclosure - Stock Option and Grant Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>995595 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995605 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>995615 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>995625 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData" id="DisclosureSegmentData">
        <link:definition>995635 - Disclosure - Segment Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995645 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995655 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995665 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995675 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>995685 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>995695 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995715 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables" id="DisclosureStrategicRestructuringTables">
        <link:definition>995725 - Disclosure - Strategic Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionTables" id="DisclosureGuideAcquisitionTables">
        <link:definition>995735 - Disclosure - Guide Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables" id="Role_DisclosureLicenseAgreementsTables">
        <link:definition>995745 - Disclosure - License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables" id="Role_DisclosureStockOptionAndGrantPlanTables">
        <link:definition>995755 - Disclosure - Stock Option and Grant Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>995765 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995775 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables" id="DisclosureSegmentDataTables">
        <link:definition>995785 - Disclosure - Segment Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>995805 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails">
        <link:definition>995825 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails">
        <link:definition>995835 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails">
        <link:definition>995855 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails">
        <link:definition>995865 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai" id="DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai">
        <link:definition>995885 - Disclosure - Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails">
        <link:definition>995895 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails">
        <link:definition>995905 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails">
        <link:definition>995915 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails">
        <link:definition>995925 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails">
        <link:definition>995935 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails">
        <link:definition>995945 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>995955 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995965 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995975 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1">
        <link:definition>995985 - Disclosure - Accrued Expenses and Other Current Liabilities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails" id="Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails">
        <link:definition>996005 - Disclosure - Leases - Summary of Operating Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails" id="Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails">
        <link:definition>996015 - Disclosure - Leases - Summary of Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails">
        <link:definition>996025 - Disclosure - Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails" id="DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails">
        <link:definition>996035 - Disclosure - Leases - Summary of Future Maturity of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails">
        <link:definition>996045 - Disclosure - Leases - Summary of Future Minimum Payments Related to Equipment Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails">
        <link:definition>996055 - Disclosure - Leases - Summary of Future Minimum Payments Related to Equipment Financing Obligations (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails" id="DisclosureEquityMethodInvestmentAdditionalInformationDetails">
        <link:definition>996065 - Disclosure - Equity Method Investment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails" id="DisclosureStrategicRestructuringAdditionalInformationDetails">
        <link:definition>996075 - Disclosure - Strategic restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails" id="DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails">
        <link:definition>996085 - Disclosure - Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails" id="DisclosureGuideAcquisitionAdditionalInformationDetails">
        <link:definition>996095 - Disclosure - Guide Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails" id="DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails">
        <link:definition>996105 - Disclosure - Guide Acquisition - Summary of Transaction Price Determined and Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>996115 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails">
        <link:definition>996125 - Disclosure - License Agreements - Harvard License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails" id="Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails">
        <link:definition>996135 - Disclosure - License Agreements - Harvard License Agreement - Success Payment Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" id="Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails">
        <link:definition>996145 - Disclosure - License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails">
        <link:definition>996155 - Disclosure - License Agreements - Broad License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails" id="Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails">
        <link:definition>996165 - Disclosure - License Agreements - Broad License Agreement - Success Payment Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" id="Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails">
        <link:definition>996175 - Disclosure - License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails">
        <link:definition>996185 - Disclosure - License Agreements - Editas License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails">
        <link:definition>996195 - Disclosure - License Agreements - Bio Palette License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>996205 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>996215 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails" id="Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails">
        <link:definition>996225 - Disclosure - Stock Option and Grant Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>996235 - Disclosure - Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails" id="Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails">
        <link:definition>996245 - Disclosure - Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails" id="Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails">
        <link:definition>996255 - Disclosure - Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails">
        <link:definition>996265 - Disclosure - Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>996275 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>996285 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails">
        <link:definition>996295 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails">
        <link:definition>996305 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996315 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>996325 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>996335 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails" id="DisclosureSegmentDataAdditionalInformationDetails">
        <link:definition>996345 - Disclosure - Segment Data - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails" id="DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails">
        <link:definition>996355 - Disclosure - Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="beam-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails2" xlink:href="beam-20241231.xsd#DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails2" xlink:href="beam-20241231.xsd#DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails2" xlink:href="beam-20241231.xsd#DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" xlink:href="beam-20241231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="beam-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="beam-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="beam-20241231.xsd#DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="beam-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails" xlink:href="beam-20241231.xsd#DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails" xlink:href="beam-20241231.xsd#DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="beam-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails" xlink:href="beam-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:href="beam-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails" xlink:href="beam-20241231.xsd#DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#axisDefault" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:href="beam-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="beam-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="beam-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails" xlink:href="beam-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails" xlink:href="beam-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails" xlink:href="beam-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails" xlink:href="beam-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureEquityMethodInvestmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureStrategicRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureGuideAcquisitionAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="beam-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="beam-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="beam-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="beam-20241231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="beam-20241231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:href="beam-20241231.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:href="beam-20241231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="beam-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="beam-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1" xlink:href="beam-20241231.xsd#DisclosureStrategicRestructuring1" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisition" xlink:href="beam-20241231.xsd#DisclosureGuideAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="beam-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock" xlink:href="beam-20241231.xsd#DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="beam-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="beam-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="beam-20241231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:href="beam-20241231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData" xlink:href="beam-20241231.xsd#DisclosureSegmentData" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="beam-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="beam-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="beam-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:href="beam-20241231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="beam-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables" xlink:href="beam-20241231.xsd#DisclosureStrategicRestructuringTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionTables" xlink:href="beam-20241231.xsd#DisclosureGuideAcquisitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables" xlink:href="beam-20241231.xsd#Role_DisclosureLicenseAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="beam-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="beam-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables" xlink:href="beam-20241231.xsd#DisclosureSegmentDataTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails" xlink:href="beam-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails" xlink:href="beam-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai" xlink:href="beam-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1" xlink:href="beam-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails" xlink:href="beam-20241231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails" xlink:href="beam-20241231.xsd#DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails" xlink:href="beam-20241231.xsd#Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="beam-20241231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails" xlink:href="beam-20241231.xsd#DisclosureSegmentDataAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementPaymentsExpectedAchievementYear" xlink:label="beam_SettlementPaymentsExpectedAchievementYear"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SanaBiotechnologyMember" xlink:label="beam_SanaBiotechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryAmountReceivable" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentFairValueSharesReceived" xlink:label="beam_UpfrontPaymentFairValueSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsInterestPercentage" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerIncMember" xlink:label="beam_PfizerIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInFairValueOfContingentConsiderationLiabilities" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" xlink:label="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonCashStockBasedCompensationExpenseMember" xlink:label="beam_NonCashStockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="us-gaap_InvestmentIncomeDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndITRelatedExpensesMember" xlink:label="beam_FacilityAndITRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndInformationTechnologyRelatedExpenses" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPalettePatentMember" xlink:label="beam_BioPalettePatentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalResearchAndDevelopmentExpensesMember" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardInstituteMember" xlink:label="beam_HarvardInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfRentedSpace" xlink:label="beam_AreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificFoundersMember" xlink:label="beam_ScientificFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SalesMilestoneMember" xlink:label="beam_SalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfOperatingLeaseRenewalOptions" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OrbitalTherapeuticsIncMember" xlink:label="beam_OrbitalTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalSuccessPaymentAmountDue" xlink:label="beam_AdditionalSuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTerminationMonthAndYear" xlink:label="beam_OperatingLeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToCompanyMember" xlink:label="beam_AssignedToCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExploitationLicensesMember" xlink:label="beam_ExploitationLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfUpfrontFee" xlink:label="beam_PaymentOfUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OfficeAndLaboratorySpaceMember" xlink:label="beam_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationCommonSharesReceived" xlink:label="beam_CollaborationCommonSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenueRecognized" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesOwed" xlink:label="beam_NonRoyaltySublicenseFeesOwed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonrefundableUpfrontPaymentReceivable" xlink:label="beam_NonrefundableUpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GrossProceedsFromIssuanceOfCommonStock" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerformanceBasedStockOptionsMember" xlink:label="beam_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PercentageOfRoyaltyPayments" xlink:label="beam_PercentageOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseAnnualRent" xlink:label="beam_FinanceLeaseAnnualRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePayableInFormOfCommonStock" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncludingTwoThousandSeventeenPlanSharesMember" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock" xlink:label="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesTable" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GiuseppeCiaramellaMember" xlink:label="beam_GiuseppeCiaramellaMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsMember" xlink:label="beam_SuccessPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfDepreciationExpenseIncurredTableTextBlock" xlink:label="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockOptionsAndRestrictedStockMember" xlink:label="beam_StockOptionsAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChristineBellonMember" xlink:label="beam_ChristineBellonMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerMember" xlink:label="beam_PfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseFeeMember" xlink:label="beam_LicenseFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPaymentPaid" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementShares" xlink:label="beam_StockPurchaseAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPayments" xlink:label="beam_SuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementUpfrontPaymentReceived" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockShares" xlink:label="beam_ObligationToIssueCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTerm" xlink:label="beam_CollaborationArrangementExtensionTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfMilestoneAmount" xlink:label="beam_PaymentOfMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ApellisPharmaceuticalsIncMember" xlink:label="beam_ApellisPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfFounderShareholders" xlink:label="beam_NumberOfFounderShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedProcessDevelopmentAndManufacturingCosts" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesPaid" xlink:label="beam_NonRoyaltySublicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquityIssuanceCostsPoliciesPolicyTextBlock" xlink:label="beam_EquityIssuanceCostsPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UponParticipationElectionMember" xlink:label="beam_UponParticipationElectionMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalFeePerAdditionalOptionRight" xlink:label="beam_AdditionalFeePerAdditionalOptionRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseCommencementMonthAndYear" xlink:label="beam_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationCurrent" xlink:label="beam_AccruedContingentObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:label="beam_DebtSecuritiesAvailableForSaleMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockBasedCompensationMember" xlink:label="beam_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FromTwoThousandSeventeenPlanSharesMember" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceCosts" xlink:label="beam_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LabEquipmentMember" xlink:label="beam_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAgreementUpfrontPaymentReceived" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockReceivedMember" xlink:label="beam_CommonStockReceivedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseCommencementMonthAndYear" xlink:label="beam_SubleaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedLiabilitiesForLicenseFees" xlink:label="beam_AccruedLiabilitiesForLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalGeneralAndAdministrativeExpensesMember" xlink:label="beam_ExternalGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsValuationMultiples" xlink:label="beam_SuccessPaymentsValuationMultiples"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontRevenueRecognized" xlink:label="beam_UpfrontRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedResearchCosts" xlink:label="beam_AccruedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EarnoutPaymentPeriod" xlink:label="beam_EarnoutPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DefinedContributionPlanName" xlink:label="beam_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryPaymentReceived" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonStatutoryOptionsMember" xlink:label="beam_NonStatutoryOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsCapitalizedResearch" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssetsSoldForLeaseback" xlink:label="beam_AssetsSoldForLeaseback"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SravanEmanyMember" xlink:label="beam_SravanEmanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesIssued" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DepreciationMember" xlink:label="beam_DepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AmySimonMember" xlink:label="beam_AmySimonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockIssuedMember" xlink:label="beam_CommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived" xlink:label="beam_StockPurchaseAgreementAmountReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsLeasingArrangements" xlink:label="beam_DeferredTaxAssetsLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FounderShareholdersMember" xlink:label="beam_FounderShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseholdImprovementsLandlordAllowance" xlink:label="beam_LeaseholdImprovementsLandlordAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfFacilityBeingBuilt" xlink:label="beam_AreaOfFacilityBeingBuilt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentObligationAndNonRoyaltySublicenseFees" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationLicenseAgreementCurrent" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseMember" xlink:label="beam_InterestAndOtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TaxCreditsExpirationStartingYear" xlink:label="beam_TaxCreditsExpirationStartingYear"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseAreaOfRentedSpace" xlink:label="beam_SubleaseAreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialConsideration" xlink:label="beam_PotentialConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchPlanMember" xlink:label="beam_ResearchPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockValue" xlink:label="beam_ObligationToIssueCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementInitialTerm" xlink:label="beam_CollaborationArrangementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputProbabilityOfAchievementMember" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentAndRegulatoryMilestonesMember" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAgreementDisclosureTextBlock" xlink:label="beam_LicenseAgreementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseNet" xlink:label="beam_InterestAndOtherIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseRentPaymentsBeginMonthAndYear" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProceedsFromTransferAgreement" xlink:label="beam_ProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementTermOfContract" xlink:label="beam_CollaborationAgreementTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesReceived" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratorySpaceMember" xlink:label="beam_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsTable" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_WorkforceReductionMember" xlink:label="beam_WorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveMember" xlink:label="beam_VerveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputFairValueOfCommonStockMember" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeeRelatedExpensesMember" xlink:label="beam_EmployeeRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesPurchasedUnderEquityMethod" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadInstituteMember" xlink:label="beam_BroadInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiability" xlink:label="beam_SuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToPfizerMember" xlink:label="beam_AssignedToPfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssembledWorkforceMember" xlink:label="beam_AssembledWorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTermAndDiscountRateTableTextBlock" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommissionRate" xlink:label="beam_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificConsultingAndOtherExpensesMember" xlink:label="beam_ScientificConsultingAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerProgramMember" xlink:label="beam_PerProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EditasLicenseAgreementMember" xlink:label="beam_EditasLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InsiderTradingArrAbstract" xlink:label="beam_InsiderTradingArrAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersFoundersAndConsultantsMember" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseOffsetAmount" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" xlink:label="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OptionRightsAggregatePotentialAdditionalConsideration" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTermDescription" xlink:label="beam_CollaborationArrangementExtensionTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesValueHeld" xlink:label="beam_EquitySharesValueHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentAmountDue" xlink:label="beam_SuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPayment" xlink:label="beam_SettlementAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementAggregateTransactionPrice" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived1" xlink:label="beam_StockPurchaseAgreementAmountReceived1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceProgramAuthorizedAmount" xlink:label="beam_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssetAcquisitionsPolicyTextBlock" xlink:label="beam_AssetAcquisitionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseLiabilitiesIncreaseDecrease" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPaletteLicenseAgreementMember" xlink:label="beam_BioPaletteLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherPaymentsMember" xlink:label="beam_OtherPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInCollaborationReceivable" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AggregateMilestoneAmount" xlink:label="beam_AggregateMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ComputerEquipmentAndSoftwareMember" xlink:label="beam_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentReceivedUnderTermOfAgreement" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveLineItems" xlink:label="us-gaap_RestructuringReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TerryAnnBurrellMember" xlink:label="beam_TerryAnnBurrellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontFeeReceivableUponSigningContract" xlink:label="beam_UpfrontFeeReceivableUponSigningContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementSharesReceived" xlink:label="beam_CollaborationLicenseAgreementSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsAmortization" xlink:label="beam_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CorporateEquitySecuritiesMember" xlink:label="beam_CorporateEquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockSoldDuringPeriodSharesNewIssues" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherOperatingIncomeExpenseAbstract" xlink:label="beam_OtherOperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JohnEvansChiefExecutiveOfficerMember" xlink:label="beam_JohnEvansChiefExecutiveOfficerMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination upfront consideration paid in common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of consideration paid to former stockholders and optionholders in common stock, as part of a business combination, excluding purchase price adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Upfront Consideration paid in Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PrimeMedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prime medicine Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PrimeMedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Medicine Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PrimeMedicineIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Medicine Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone liabilities projected year of achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which achievement is expected to be attained for contingent consideration liability milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Expected Achievement Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent Consideration Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementPaymentsExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Payments Expected Achievement Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementPaymentsExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which achievement is expected to be attained for settlement payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementPaymentsExpectedAchievementYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement payments expected achievement year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SanaBiotechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sana Biotechnology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SanaBiotechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sana Biotechnology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative liability measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement first anniversary amount receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement First Anniversary Amount Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount receivable on the one-year anniversary of the signing date of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guide Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentFairValueSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment fair value shares received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentFairValueSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Fair Value Shares Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentFairValueSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of shares received as an upfront payment as part of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-The-Market .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At-The-Market</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The interest rate on finance leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Interest Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability payments interest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of contingent consideration liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of change in Fair Value of Liabilities based on Level 3 inputs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions to deferred revenue from license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase From License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Freestanding Financial Instruments and Derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonCashStockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash Stock Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonCashStockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Stock Based Compensation Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonCashStockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Cash Stock Based Compensation Expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FacilityAndITRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facility And IT Related Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FacilityAndITRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facility and IT related expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FacilityAndITRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility And Information Technology Related Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facility and information technology related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense related to facilities and information technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of common stock purchase price lower of the fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering price discount rate at start of the offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPalettePatentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio Palette Patent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPalettePatentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bio Palette Patent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPalettePatentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio Palette Patent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Research And Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External Research And Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses recognized on sale or maturity of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time Termination Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One-time Termination Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard Institute</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard Institute.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square feet of office and laboratory space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of area rented under an operating lease, in square feet.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Rented Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of investment in debt and equity securities measured at fair value (available-for-sale).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities held, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities and Equity Securities FV-Ni</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific founders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Founders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Founders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease renewal options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease Renewal Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, number of renewal options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OrbitalTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orbital Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OrbitalTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orbital Therapeutics, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OrbitalTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orbital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OrbitalTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Orbital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Shares Issued Proceeds In Excess of Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The residual value of proceeds received in excess of fair value for shares issued as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amounts recognized in revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalSuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional success payment amount due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalSuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Success Payment Amount Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalSuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The remaining amount of success payments that may become due as part of a licensing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, termination month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Termination Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, termination month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties for unrecognized tax benefits since inception</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of milestones the Company may be eligible to receive.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development regulatory and commercial milestones receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory and Commercial Milestones Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assigned to Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assigned to Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assigned to company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExploitationLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exploitation licenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExploitationLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exploitation Licenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExploitationLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exploitation Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to acquire Guide, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equipment financings, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paydown of principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual percentage increase in shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationCommonSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Common Shares Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationCommonSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares received at closing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationCommonSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of common stock received as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Transaction Price Determined and Allocated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement performance obligation revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Performance Obligation Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock (See Note 11, Redeemable convertible preferred stock)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable convertible preferred stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable convertible preferred stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial recognition of derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense incurred for non-royalty sublicense fees owed to licensor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-royalty sublicense fees owed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Royalty Sublicense Fees Owed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and related benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonrefundableUpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable upfront payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonrefundableUpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonrefundable upfront payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance-based stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PercentageOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PercentageOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of royalty payment due, contingent upon certain milestones, as part of a derivative settlement liability, as a percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PercentageOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of unregistered common shares in connection with license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Unregistered Common Shares In Connection With License Agreement 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of unregistered common shares issued during the period in connection with a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseAnnualRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease annual rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseAnnualRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Annual Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseAnnualRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual rent amount under a financing lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Phase of Lease in January 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commencement Of Second Phase Of Lease In January Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commencement of second phase of lease in January two thousand twenty one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payable in form of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of potential milestones payable in the form of common stock as part of a business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payable In Form Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Including 2017 Plan Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Including Two Thousand Seventeen Plan Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Including Two Thousand Seventeen Plan Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the success payment liability arising from a licensing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Success Payment Liability Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GiuseppeCiaramellaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Giuseppe Ciaramella</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GiuseppeCiaramellaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Giuseppe Ciaramella [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GiuseppeCiaramellaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Giuseppe Ciaramella</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Broad License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Broad license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broad License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broad Institute</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Depreciation Expense Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of depreciation expense related to physical assets used in the normal conduct of business and not intended for resale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Depreciation Expense Incurred Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockOptionsAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">stock options and restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockOptionsAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockOptionsAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Quoted Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement aggregate transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChristineBellonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Christine Bellon</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChristineBellonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Christine Bellon</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChristineBellonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Christine Bellon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Fee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for upfront payment of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued For Upfront Payment Of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued for upfront payment of acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock to redemption value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash acquired from Guide</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Agreement Upfront Payment Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount paid during the period for an upfront payment as part of a settlement agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement agreement upfront payment paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale and issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares available for sale and issuance as part of a stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash&#8212;end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash&#8212;beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amounts representing interest at 8.76%</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amounts representing interest at 8.76%</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of stock converted upon the conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of net profits and development and commercialization costs assigned to the specified party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profits as well as development and commercialization costs percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Profits and Development and Commercialization Costs Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of success payments payable upon achievement of specified stock value targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Maturity of Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of the business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum exercise price per share of stock options, as a percentage of the fair market value of common stock on the date of grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Exercise Price Per Share Of Stock Options On Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price per share of stock options on fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, cost to recognize over a weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment received as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to issue common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of stock the Collaborator is obligated to issue to the Company if the Company elects to extend the collaboration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation to Issue Common Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Transaction Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration arrangement extension term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangement extension term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Extension Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of milestone amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Milestone Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PaymentOfMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ApellisPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Apellis Pharmaceuticals, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ApellisPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Apellis Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ApellisPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Apellis Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ApellisPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Apellis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) from equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial and follow-on public offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Payment of equity offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfFounderShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of founder shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfFounderShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Founder Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfFounderShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of founder shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jeffries LLC Amended Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jeffries LLC amended sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jeffries LLC Amended Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for process development and manufacturing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Process Development And Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Process development and manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount paid during the period for non-royalty sublicense fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Royalty Sublicense Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonRoyaltySublicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-royalty sublicense fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquityIssuanceCostsPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for equity issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquityIssuanceCostsPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuance Costs Policies Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquityIssuanceCostsPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of restricted shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares converted upon the conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UponParticipationElectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon Participation Election</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UponParticipationElectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upon Participation Election [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UponParticipationElectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upon participation election.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in operating lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees, officers, board of directors and consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees Officers Board Of Directors And Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Officers, Board of Directors and Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option and Grant Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LillyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lilly Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LillyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lilly Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LillyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lilly Agreement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining unrecognized revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalFeePerAdditionalOptionRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional fee per additional option right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalFeePerAdditionalOptionRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Fee Per Additional Option Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AdditionalFeePerAdditionalOptionRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of fee per additional option right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution to 401(k) Plan as a percentage of employee's eligible earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of redeemable convertible preferred stock to redemption value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Value of common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, offering period, start date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The commencement date of the first offering period of a share based payment plan, in YYYY-MM-DD format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities for license fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contingent Obligation Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contingent obligation current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contingent obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, before tax, of unrealized loss on investment in debt and equity securities measured at fair value (available-for-sale).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities held, Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Loss Before Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturity dates of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Describes the period of time in which investments will reach maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregated purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Aggregate Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate purchase price of a stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Two Thousand Seventeen Plan Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">From 2017 Plan Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From 2017 plan shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of equity securities held by the Company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Shares Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity shares held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity shares held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases and Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimate of Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs incurred in a stock issuance transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity instruments issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount received as upfront payment under a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommonStockReceivedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommonStockReceivedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease, commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The month and year in which a sublease will commence.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Commencement Month and Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedLiabilitiesForLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities for license fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedLiabilitiesForLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities For License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedLiabilitiesForLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities for license fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Verve Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Verve Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Verve Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liability accrued for minimum amount in range of loss based on settlement offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExternalGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External General And Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ExternalGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External General And Administrative Expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales Agreement, with Jefferies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jeffries LLC Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jeffries LLC sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jeffries LLC Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsValuationMultiples_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The valuation multiple applied to the initial weighted average of the specified class of stock, used to determine success payment targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsValuationMultiples_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payments Valuation Multiples</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentsValuationMultiples_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payments, valuation multiples</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alternate investment, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GuideTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Guide Therapeutics, Incorporated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GuideTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guide Therapeutics Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_GuideTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guide Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares excluded from computation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EarnoutPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earn-out payment period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EarnoutPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnout Payment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EarnoutPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earn-out payment period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan name.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accrued restructuring, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accrued restructuring, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fully diluted equity interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount received as payment for the first anniversary of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement First Anniversary Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement first anniversary payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonStatutoryOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-statutory options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonStatutoryOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Statutory Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NonStatutoryOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Statutory Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MilestoneExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MilestoneExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MilestoneExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense recognized during the period for achievement of a milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssetsSoldForLeaseback_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets sold for leaseback</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssetsSoldForLeaseback_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The sale price of assets sold to a leasing company for leaseback.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Current Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claims outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability accrued for loss based on settlement offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award weighted average remaining contractual life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Life [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SravanEmanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sravan Emany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SravanEmanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sravan Emany [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SravanEmanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sravan Emany [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in fair value of equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of non-controlling equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of non-controlling equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity securities recognition amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration license agreement fair value of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration License Agreement Fair Value Of Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of shares issued as part of a collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability for Uncertainty in Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution to 401(k)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Discount for Lack of Marketability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-sale, Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restructuring Liability Activity for Company's Workforce Reductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AmySimonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amy Simon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AmySimonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amy Simon</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AmySimonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amy Simon</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase agreement amount received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Amount Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount received as part of a stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility of Market Participants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Total Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, before tax, of unrealized gain on investment in debt and equity securities measured at fair value (available-for-sale).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities held, Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Gain Before Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Payments Related to Equipment Financing Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for success payment liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued to satisfy success payment obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FounderShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder Shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FounderShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder Shareholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FounderShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration of Product Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Of Product Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration of product liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the principal and interest portions of a finance lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Principal And Interest Portions Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal and Interest Portions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in employee headcount, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FormerStockholdersAndOptionholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former Stockholders and Optionholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FormerStockholdersAndOptionholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Former stockholders and optionholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FormerStockholdersAndOptionholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Stockholders and Optionholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseholdImprovementsLandlordAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements landlord allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseholdImprovementsLandlordAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseholdImprovementsLandlordAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Landlord Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfFacilityBeingBuilt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing facility, number of square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfFacilityBeingBuilt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The area of a facility being built for future lease, in square feet.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AreaOfFacilityBeingBuilt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Facility Being Built</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent obligations and non-royalty sublicense fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Obligation And Non Royalty Sublicense Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of contingent obligations and non-royalty sublicense fees included in research and development expenses during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent obligations and non-royalty sublicense fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs Included in Measurement of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the lease costs included in the measurement of lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Costs Included In Measurement Of Lease Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Nondeductible/ nontaxable permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondeductible/ nontaxable permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contingent Obligation License Agreement Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of liability recognized arising from contingent consideration in a licensing agreement, expected to be settled within one year or the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contingent obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other income (expense).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Other Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest and Other Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Transaction Price Allocated [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination transaction price allocated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Derivative Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TaxCreditsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which specified tax credits begin to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TaxCreditsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credits Expiration Starting Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TaxCreditsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits expiration starting year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for success payment liability, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for success payment liability, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for success payment liability, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued to satisfy success payment obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseAreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease area of rented space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseAreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of space to be subleased, in square feet.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SubleaseAreaOfRentedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Area Of Rented Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential aggregate consideration that may be received as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to issue common stock value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of stock the Company is obligated to issue to the Collaborator if the Company elects to extend the collaboration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ObligationToIssueCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation to Issue Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration arrangement, initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangement initial term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Initial Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement Input Probability Of Achievement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Of Achievement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of investment discount (premiums)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for licensing arrangements with third parties, which includes, but is not limited to, success payments and milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Guide Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of interest income and income (expense) related to nonoperating activities classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expense Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic and diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted - average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen stock option and grant plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Stock Option And Grant Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent payments beginning month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The month and year in which the rent payments will begin under an operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Rent Payments Begin Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, merger agreement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in employee headcount, positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from potential future development-stage upfront payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of proceeds the Company received as part of a transfer agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares, net of commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement term of contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General And Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of shares received as part of a collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration license agreement fair value of shares received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration License Agreement Fair Value of Shares Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease liability payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease Liability Payments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities included in marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_WorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Workforce Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_WorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workforce Reduction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_WorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Workforce Reduction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to acquire Guide</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Value of shares issued for upfront payment of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Verve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Verve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_VerveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Verve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-sale, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Under Equity Award Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input fair value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Fair Value Of Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment and office furniture.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment And Office Furniture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment and Office Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeeRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Related Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeeRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeeRelatedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee related expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased under equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares purchased under equity method.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Purchased Under Equity Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broad Institute</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broad Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BroadInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Broad Institute.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">In-process research and development charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense In Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of unregistered common shares in connection with license agreement, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Unregistered Common Shares In Connection With License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of unregistered common shares issued during the period in connection with a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period over which revenue is expected to be recognized as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Performance Obligation Revenue Period For Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement performance obligation revenue period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of liability incurred for success payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payments liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Data</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Option Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share of stock sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToPfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assigned to Pfizer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToPfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assigned to Pfizer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssignedToPfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assigned to Pfizer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jeffries LLC Sales Agreement and Amended Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jeffries LLC Sales Agreement and Amended Sales Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jeffries LLC Sales Agreement And Amended Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black-Scholes Option Valuation Model to Estimate Fair Value of Purchase Right Under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Variables Included in Calculation of Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assembled Workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assembled Workforce.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assembled Workforce [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments received from (made to) related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Term and Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the lease term and discount rate for an operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term And Discount Rate [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The commission rate the Company agreed to pay for all shares sold under a Sales Agreement, as a percentage of gross sales proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commission Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificConsultingAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific consulting and other expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificConsultingAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Consulting And Other Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScientificConsultingAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Consulting and Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Per Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PerProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Per Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of contingent consideration liability for technology and product milestones incurred by the acquirer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred Technology And Product Contingent Consideration Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business combination liability for milestones at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology and product contingent consideration liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to acquisition related in process research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D Guide Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation In Process Research And Development Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EditasLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Editas License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EditasLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Editas License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EditasLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Editas License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments due under settlement agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments Due Under Settlement Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of milestone payments that may become due under a settlement agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InsiderTradingArrAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Insider Trading Arr Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_InsiderTradingArrAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insider Trading Arr Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligations, leased back equipment term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees, officers, founders and consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees Officers Founders And Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Officers, Founders and Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount allowed to purchase common stock using payroll deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum annual amount of funds that employees can contribute through payroll deductions to purchase shares as part of share based compensation plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Payroll Deduction Yearly Limit Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other, payable within one year or the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense offset amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense offset amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Offset Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the change in fair value of the success payment liability arising from a licensing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Change In Fair Value Of Success Payment Liability Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Fair Value of Success Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of potential fee for additional option rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option rights aggregate potential additional consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Rights Aggregate Potential Additional Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October 2020 Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October Two Thousand Twenty Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2020 Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The description of the extension term of a collaboration arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Extension Term Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationArrangementExtensionTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration arrangement extension term description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees and Indemnifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesValueHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity shares value held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesValueHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Shares Value Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_EquitySharesValueHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares of equity securities held by the Company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution to 401(k) Plan as a percentage of employee's contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment amount due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Amount Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of success payment due as part of a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of the business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContributionOfProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution of Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContributionOfProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash contribution of intellectual property to Orbital Therapeutics Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of transactions costs incurred by the acquirer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Cost Of Acquired Entity Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Agreement Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment the Company has agreed to pay upon signing of a settlement agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SettlementAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement agreement upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon conversion of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issuable upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement aggregate transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate transaction price of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Aggregate Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Financing Lease, Residual Value of Leased Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plus: residual values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of investment in debt and equity securities measured at fair value, classified as available-for-sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities and Equity Securities FV-Ni Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase agreement price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Amount Received1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockPurchaseAgreementAmountReceived1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Purchase Agreement Amount Received1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average exercise price of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds of shares authorized under ATM sales agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of shares authorized to be issued under a stock issuance program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Program Authorized Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional proceeds from potential future development-stage payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Additional Proceeds From Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for asset acquisitions, both as part of a business combination and not as part of a business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisitions [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized cost of investment in debt and equity securities measured at fair value (available-for-sale).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities held, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities and Equity Securities FV-Ni Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the estimated useful lives of property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) in operating lease liabilities related to right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities arising from obtaining ROU assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPaletteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio Palette License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPaletteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bio Palette License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_BioPaletteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio Palette License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Collaboration receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in amount due within one year (or one business cycle) as part of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Collaboration Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Product and Service [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment value of stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 250,000,000 shares authorized, 83,633,069 and 81,632,496 issued and outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AggregateMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AggregateMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_AggregateMilestoneAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount the Company is obligated to pay upon achievement of specified milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Development and Regulatory Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Development and Regulatory Approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product Development and Regulatory Approval.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Nature and Purpose</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 9, License agreements and Note 10, Collaboration and license agreements)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted - average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reportable Segment Net Revenues and Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement rights and obligations, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Rights and Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease liability payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease Liability Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration of Technology Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Technology Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Of Technology Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration of technology liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received under term of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received Under Term of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment received under the terms of an agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative settlement liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Harvard</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commencement of first phase of lease in October 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commencement Of First Phase Of Lease In October Twenty Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Phase of Lease in October 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TerryAnnBurrellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Terry-Ann Burrell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TerryAnnBurrellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Terry-Ann Burrell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_TerryAnnBurrellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terry-Ann Burrell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontFeeReceivableUponSigningContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront fee receivable upon signing contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_UpfrontFeeReceivableUponSigningContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront fee receivable upon signing of a collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of stock received as part of a collaboration and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CollaborationLicenseAgreementSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration License Agreement Shares Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable convertible preferred stock, Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable convertible preferred stock, Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CorporateEquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CorporateEquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_CorporateEquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Equity Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_RegulatoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_RegulatoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_RegulatoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of outstanding common stock held by the Company as part of a license and collaboration agreement, as a percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaboration Agreement Outstanding Common Stock Held Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration agreement outstanding common stock held percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock sold during period shares, new issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new shares sold, but not necessarily issued, during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Sold During Period Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherOperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Operating Income Expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherOperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_OtherOperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payment Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_SuccessPaymentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JohnEvansChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">John Evans Chief Executive Officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="beam_JohnEvansChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">John Evans Chief Executive Officer [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" xlink:to="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PrimeMedicineIncMember" xlink:to="beam_PrimeMedicineIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" xlink:to="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DerivativeLiabilityMember" xlink:to="beam_DerivativeLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SettlementPaymentsExpectedAchievementYear" xlink:to="beam_SettlementPaymentsExpectedAchievementYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SanaBiotechnologyMember" xlink:to="beam_SanaBiotechnologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementFirstAnniversaryAmountReceivable" xlink:to="beam_CollaborationAgreementFirstAnniversaryAmountReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_UpfrontPaymentFairValueSharesReceived" xlink:to="beam_UpfrontPaymentFairValueSharesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AtTheMarketMember" xlink:to="beam_AtTheMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FinanceLeaseLiabilityPaymentsInterestPercentage" xlink:to="beam_FinanceLeaseLiabilityPaymentsInterestPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PfizerIncMember" xlink:to="beam_PfizerIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ChangeInFairValueOfContingentConsiderationLiabilities" xlink:to="beam_ChangeInFairValueOfContingentConsiderationLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" xlink:to="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NonCashStockBasedCompensationExpenseMember" xlink:to="beam_NonCashStockBasedCompensationExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeDividend" xlink:to="us-gaap_InvestmentIncomeDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FacilityAndITRelatedExpensesMember" xlink:to="beam_FacilityAndITRelatedExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FacilityAndInformationTechnologyRelatedExpenses" xlink:to="beam_FacilityAndInformationTechnologyRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BioPalettePatentMember" xlink:to="beam_BioPalettePatentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTermOfContract" xlink:to="us-gaap_DerivativeTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ExternalResearchAndDevelopmentExpensesMember" xlink:to="beam_ExternalResearchAndDevelopmentExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_HarvardInstituteMember" xlink:to="beam_HarvardInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AreaOfRentedSpace" xlink:to="beam_AreaOfRentedSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ScientificFoundersMember" xlink:to="beam_ScientificFoundersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SalesMilestoneMember" xlink:to="beam_SalesMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NumberOfOperatingLeaseRenewalOptions" xlink:to="beam_NumberOfOperatingLeaseRenewalOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OrbitalTherapeuticsIncMember" xlink:to="beam_OrbitalTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" xlink:to="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AdditionalSuccessPaymentAmountDue" xlink:to="beam_AdditionalSuccessPaymentAmountDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OperatingLeaseTerminationMonthAndYear" xlink:to="beam_OperatingLeaseTerminationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" xlink:to="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AssignedToCompanyMember" xlink:to="beam_AssignedToCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ExploitationLicensesMember" xlink:to="beam_ExploitationLicensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PaymentOfUpfrontFee" xlink:to="beam_PaymentOfUpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OfficeAndLaboratorySpaceMember" xlink:to="beam_OfficeAndLaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationCommonSharesReceived" xlink:to="beam_CollaborationCommonSharesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementPerformanceObligationRevenueRecognized" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NonRoyaltySublicenseFeesOwed" xlink:to="beam_NonRoyaltySublicenseFeesOwed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NonrefundableUpfrontPaymentReceivable" xlink:to="beam_NonrefundableUpfrontPaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_GrossProceedsFromIssuanceOfCommonStock" xlink:to="beam_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PerformanceBasedStockOptionsMember" xlink:to="beam_PerformanceBasedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PercentageOfRoyaltyPayments" xlink:to="beam_PercentageOfRoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FinanceLeaseAnnualRent" xlink:to="beam_FinanceLeaseAnnualRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" xlink:to="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PotentialMilestonePayableInFormOfCommonStock" xlink:to="beam_PotentialMilestonePayableInFormOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IncludingTwoThousandSeventeenPlanSharesMember" xlink:to="beam_IncludingTwoThousandSeventeenPlanSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock" xlink:to="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="beam_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_GiuseppeCiaramellaMember" xlink:to="beam_GiuseppeCiaramellaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BroadLicenseAgreementMember" xlink:to="beam_BroadLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="beam_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPaymentsMember" xlink:to="beam_SuccessPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock" xlink:to="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockOptionsAndRestrictedStockMember" xlink:to="beam_StockOptionsAndRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ChristineBellonMember" xlink:to="beam_ChristineBellonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PfizerMember" xlink:to="beam_PfizerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LicenseFeeMember" xlink:to="beam_LicenseFeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" xlink:to="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SettlementAgreementUpfrontPaymentPaid" xlink:to="beam_SettlementAgreementUpfrontPaymentPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockPurchaseAgreementShares" xlink:to="beam_StockPurchaseAgreementShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" xlink:to="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPayments" xlink:to="beam_SuccessPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="beam_NatureOfBusinessAndBasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementUpfrontPaymentReceived" xlink:to="beam_CollaborationAgreementUpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ObligationToIssueCommonStockShares" xlink:to="beam_ObligationToIssueCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="beam_BusinessCombinationTransactionPriceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationArrangementExtensionTerm" xlink:to="beam_CollaborationArrangementExtensionTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PaymentOfMilestoneAmount" xlink:to="beam_PaymentOfMilestoneAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ApellisPharmaceuticalsIncMember" xlink:to="beam_ApellisPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NumberOfFounderShareholders" xlink:to="beam_NumberOfFounderShareholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_JeffriesLlcAmendedSalesAgreementMember" xlink:to="beam_JeffriesLlcAmendedSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedProcessDevelopmentAndManufacturingCosts" xlink:to="beam_AccruedProcessDevelopmentAndManufacturingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NonRoyaltySublicenseFeesPaid" xlink:to="beam_NonRoyaltySublicenseFeesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ContingentConsiderationLiabilitiesMember" xlink:to="beam_ContingentConsiderationLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EquityIssuanceCostsPoliciesPolicyTextBlock" xlink:to="beam_EquityIssuanceCostsPoliciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_UponParticipationElectionMember" xlink:to="beam_UponParticipationElectionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="beam_ChangeInOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" xlink:to="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LillyAgreementMember" xlink:to="beam_LillyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AdditionalFeePerAdditionalOptionRight" xlink:to="beam_AdditionalFeePerAdditionalOptionRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OperatingLeaseCommencementMonthAndYear" xlink:to="beam_OperatingLeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedContingentObligationCurrent" xlink:to="beam_AccruedContingentObligationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:to="beam_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:to="beam_StockPurchaseAgreementAggregatePurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockBasedCompensationMember" xlink:to="beam_StockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FromTwoThousandSeventeenPlanSharesMember" xlink:to="beam_FromTwoThousandSeventeenPlanSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EquitySharesHeld" xlink:to="beam_EquitySharesHeld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockIssuanceCosts" xlink:to="beam_StockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="beam_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LabEquipmentMember" xlink:to="beam_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LicenseAgreementUpfrontPaymentReceived" xlink:to="beam_LicenseAgreementUpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CommonStockReceivedMember" xlink:to="beam_CommonStockReceivedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SubleaseCommencementMonthAndYear" xlink:to="beam_SubleaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedLiabilitiesForLicenseFees" xlink:to="beam_AccruedLiabilitiesForLicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_VerveTherapeuticsIncMember" xlink:to="beam_VerveTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ExternalGeneralAndAdministrativeExpensesMember" xlink:to="beam_ExternalGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_JeffriesLlcSalesAgreementMember" xlink:to="beam_JeffriesLlcSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPaymentsValuationMultiples" xlink:to="beam_SuccessPaymentsValuationMultiples_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_UpfrontRevenueRecognized" xlink:to="beam_UpfrontRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_GuideTherapeuticsIncorporatedMember" xlink:to="beam_GuideTherapeuticsIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedResearchCosts" xlink:to="beam_AccruedResearchCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EarnoutPaymentPeriod" xlink:to="beam_EarnoutPaymentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DefinedContributionPlanName" xlink:to="beam_DefinedContributionPlanName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementFirstAnniversaryPaymentReceived" xlink:to="beam_CollaborationAgreementFirstAnniversaryPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NonStatutoryOptionsMember" xlink:to="beam_NonStatutoryOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_MilestoneExpense" xlink:to="beam_MilestoneExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DeferredTaxAssetsCapitalizedResearch" xlink:to="beam_DeferredTaxAssetsCapitalizedResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AssetsSoldForLeaseback" xlink:to="beam_AssetsSoldForLeaseback_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SravanEmanyMember" xlink:to="beam_SravanEmanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationLicenseAgreementFairValueOfSharesIssued" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DepreciationMember" xlink:to="beam_DepreciationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AmySimonMember" xlink:to="beam_AmySimonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CommonStockIssuedMember" xlink:to="beam_CommonStockIssuedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockPurchaseAgreementAmountReceived" xlink:to="beam_StockPurchaseAgreementAmountReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DeferredTaxAssetsLeasingArrangements" xlink:to="beam_DeferredTaxAssetsLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" xlink:to="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FounderShareholdersMember" xlink:to="beam_FounderShareholdersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" xlink:to="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FormerStockholdersAndOptionholdersMember" xlink:to="beam_FormerStockholdersAndOptionholdersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LeaseholdImprovementsLandlordAllowance" xlink:to="beam_LeaseholdImprovementsLandlordAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AreaOfFacilityBeingBuilt" xlink:to="beam_AreaOfFacilityBeingBuilt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ContingentObligationAndNonRoyaltySublicenseFees" xlink:to="beam_ContingentObligationAndNonRoyaltySublicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" xlink:to="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedContingentObligationLicenseAgreementCurrent" xlink:to="beam_AccruedContingentObligationLicenseAgreementCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_InterestAndOtherIncomeExpenseMember" xlink:to="beam_InterestAndOtherIncomeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="beam_BusinessCombinationTransactionPriceAllocatedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TaxCreditsExpirationStartingYear" xlink:to="beam_TaxCreditsExpirationStartingYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SubleaseAreaOfRentedSpace" xlink:to="beam_SubleaseAreaOfRentedSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PotentialConsideration" xlink:to="beam_PotentialConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ResearchPlanMember" xlink:to="beam_ResearchPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ObligationToIssueCommonStockValue" xlink:to="beam_ObligationToIssueCommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationArrangementInitialTerm" xlink:to="beam_CollaborationArrangementInitialTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_MeasurementInputProbabilityOfAchievementMember" xlink:to="beam_MeasurementInputProbabilityOfAchievementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DevelopmentAndRegulatoryMilestonesMember" xlink:to="beam_DevelopmentAndRegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LicenseAgreementDisclosureTextBlock" xlink:to="beam_LicenseAgreementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_MergerAgreementMember" xlink:to="beam_MergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_InterestAndOtherIncomeExpenseNet" xlink:to="beam_InterestAndOtherIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" xlink:to="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OperatingLeaseRentPaymentsBeginMonthAndYear" xlink:to="beam_OperatingLeaseRentPaymentsBeginMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ProceedsFromTransferAgreement" xlink:to="beam_ProceedsFromTransferAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementTermOfContract" xlink:to="beam_CollaborationAgreementTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationLicenseAgreementFairValueOfSharesReceived" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LaboratorySpaceMember" xlink:to="beam_LaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="beam_FinanceLeaseLiabilityPaymentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_WorkforceReductionMember" xlink:to="beam_WorkforceReductionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_VerveMember" xlink:to="beam_VerveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_MeasurementInputFairValueOfCommonStockMember" xlink:to="beam_MeasurementInputFairValueOfCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:to="beam_LaboratoryEquipmentAndOfficeFurnitureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EmployeeRelatedExpensesMember" xlink:to="beam_EmployeeRelatedExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NumberOfSharesPurchasedUnderEquityMethod" xlink:to="beam_NumberOfSharesPurchasedUnderEquityMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BroadInstituteMember" xlink:to="beam_BroadInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ResearchAndDevelopmentExpenseInProcess" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPaymentLiability" xlink:to="beam_SuccessPaymentLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AssignedToPfizerMember" xlink:to="beam_AssignedToPfizerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:to="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AssembledWorkforceMember" xlink:to="beam_AssembledWorkforceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OperatingLeaseTermAndDiscountRateTableTextBlock" xlink:to="beam_OperatingLeaseTermAndDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CommissionRate" xlink:to="beam_CommissionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ScientificConsultingAndOtherExpensesMember" xlink:to="beam_ScientificConsultingAndOtherExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PerProgramMember" xlink:to="beam_PerProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" xlink:to="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" xlink:to="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EditasLicenseAgreementMember" xlink:to="beam_EditasLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" xlink:to="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_InsiderTradingArrAbstract" xlink:to="beam_InsiderTradingArrAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="beam_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EmployeesOfficersFoundersAndConsultantsMember" xlink:to="beam_EmployeesOfficersFoundersAndConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="beam_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ResearchAndDevelopmentExpenseOffsetAmount" xlink:to="beam_ResearchAndDevelopmentExpenseOffsetAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" xlink:to="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OptionRightsAggregatePotentialAdditionalConsideration" xlink:to="beam_OptionRightsAggregatePotentialAdditionalConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationArrangementExtensionTermDescription" xlink:to="beam_CollaborationArrangementExtensionTermDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_EquitySharesValueHeld" xlink:to="beam_EquitySharesValueHeld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPaymentAmountDue" xlink:to="beam_SuccessPaymentAmountDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_NatureOfBusinessAndBasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" xlink:to="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SettlementAgreementUpfrontPayment" xlink:to="beam_SettlementAgreementUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="beam_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationAgreementAggregateTransactionPrice" xlink:to="beam_CollaborationAgreementAggregateTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" xlink:to="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockPurchaseAgreementAmountReceived1" xlink:to="beam_StockPurchaseAgreementAmountReceived1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockIssuanceProgramAuthorizedAmount" xlink:to="beam_StockIssuanceProgramAuthorizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:to="beam_PotentialAdditionalProceedsFromTransferAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AssetAcquisitionsPolicyTextBlock" xlink:to="beam_AssetAcquisitionsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OperatingLeaseLiabilitiesIncreaseDecrease" xlink:to="beam_OperatingLeaseLiabilitiesIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_BioPaletteLicenseAgreementMember" xlink:to="beam_BioPaletteLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OtherPaymentsMember" xlink:to="beam_OtherPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_IncreaseDecreaseInCollaborationReceivable" xlink:to="beam_IncreaseDecreaseInCollaborationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_AggregateMilestoneAmount" xlink:to="beam_AggregateMilestoneAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:to="beam_ProductDevelopmentAndRegulatoryApprovalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ComputerEquipmentAndSoftwareMember" xlink:to="beam_ComputerEquipmentAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="beam_FinanceLeaseLiabilityPaymentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_UpfrontPaymentReceivedUnderTermOfAgreement" xlink:to="beam_UpfrontPaymentReceivedUnderTermOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveLineItems" xlink:to="us-gaap_RestructuringReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_HarvardLicenseAgreementMember" xlink:to="beam_HarvardLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" xlink:to="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_TerryAnnBurrellMember" xlink:to="beam_TerryAnnBurrellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_UpfrontFeeReceivableUponSigningContract" xlink:to="beam_UpfrontFeeReceivableUponSigningContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CollaborationLicenseAgreementSharesReceived" xlink:to="beam_CollaborationLicenseAgreementSharesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_DeferredTaxAssetsAmortization" xlink:to="beam_DeferredTaxAssetsAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_CorporateEquitySecuritiesMember" xlink:to="beam_CorporateEquitySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_RegulatoryMember" xlink:to="beam_RegulatoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" xlink:to="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_StockSoldDuringPeriodSharesNewIssues" xlink:to="beam_StockSoldDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="beam_OtherOperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_SuccessPaymentLiabilitiesMember" xlink:to="beam_SuccessPaymentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="beam_JohnEvansChiefExecutiveOfficerMember" xlink:to="beam_JohnEvansChiefExecutiveOfficerMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="beam_AccruedExpensesAndOtherCurrentLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherOperatingIncomeExpenseAbstract" xlink:label="beam_OtherOperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInFairValueOfContingentConsiderationLiabilities" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseNet" xlink:label="beam_InterestAndOtherIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="beam_ChangeInFairValueOfContingentConsiderationLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="beam_InterestAndOtherIncomeExpenseNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="beam_OtherOperatingIncomeExpenseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_OtherOperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceCosts" xlink:label="beam_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="beam_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseLiabilitiesIncreaseDecrease" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInCollaborationReceivable" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="beam_OperatingLeaseLiabilitiesIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ContributionOfProperty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="beam_IncreaseDecreaseInCollaborationReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="beam_ChangeInOperatingLeaseRightOfUseAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AmySimonMember" xlink:label="beam_AmySimonMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GiuseppeCiaramellaMember" xlink:label="beam_GiuseppeCiaramellaMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SravanEmanyMember" xlink:label="beam_SravanEmanyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TerryAnnBurrellMember" xlink:label="beam_TerryAnnBurrellMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChristineBellonMember" xlink:label="beam_ChristineBellonMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_AmySimonMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_GiuseppeCiaramellaMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_SravanEmanyMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_TerryAnnBurrellMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_ChristineBellonMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAgreementDisclosureTextBlock" xlink:label="beam_LicenseAgreementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="beam_LicenseAgreementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquityIssuanceCostsPoliciesPolicyTextBlock" xlink:label="beam_EquityIssuanceCostsPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssetAcquisitionsPolicyTextBlock" xlink:label="beam_AssetAcquisitionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="beam_EquityIssuanceCostsPoliciesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="beam_AssetAcquisitionsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfDepreciationExpenseIncurredTableTextBlock" xlink:label="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTermAndDiscountRateTableTextBlock" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_OperatingLeaseTermAndDiscountRateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock" xlink:label="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" xlink:label="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockSoldDuringPeriodSharesNewIssues" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GrossProceedsFromIssuanceOfCommonStock" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ApellisPharmaceuticalsIncMember" xlink:label="beam_ApellisPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommissionRate" xlink:label="beam_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SanaBiotechnologyMember" xlink:label="beam_SanaBiotechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceProgramAuthorizedAmount" xlink:label="beam_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerIncMember" xlink:label="beam_PfizerIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived" xlink:label="beam_StockPurchaseAgreementAmountReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProceedsFromTransferAgreement" xlink:label="beam_ProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementUpfrontPaymentReceived" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementShares" xlink:label="beam_StockPurchaseAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcAmendedSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="beam_NatureOfBusinessAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockSoldDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_GrossProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_ApellisPharmaceuticalsIncMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_CommissionRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_SanaBiotechnologyMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockIssuanceProgramAuthorizedAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PfizerIncMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="beam_NatureOfBusinessAndBasisOfPresentationLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_PotentialAdditionalProceedsFromTransferAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_ProceedsFromTransferAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_CollaborationAgreementUpfrontPaymentReceived" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementAggregatePurchasePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesTable" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PercentageOfRoyaltyPayments" xlink:label="beam_PercentageOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="beam_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="beam_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="beam_PercentageOfRoyaltyPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ComputerEquipmentAndSoftwareMember" xlink:label="beam_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LaboratoryEquipmentAndOfficeFurnitureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" xlink:label="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LabEquipmentMember" xlink:label="beam_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LabEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CorporateEquitySecuritiesMember" xlink:label="beam_CorporateEquitySecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="beam_CorporateEquitySecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseMember" xlink:label="beam_InterestAndOtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesPurchasedUnderEquityMethod" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentAndRegulatoryMilestonesMember" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SalesMilestoneMember" xlink:label="beam_SalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePayableInFormOfCommonStock" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPayment" xlink:label="beam_SettlementAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PercentageOfRoyaltyPayments" xlink:label="beam_PercentageOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPaymentPaid" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_EquitySharesHeld" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="beam_InterestAndOtherIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_PrimeMedicineIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_NumberOfSharesPurchasedUnderEquityMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_DevelopmentAndRegulatoryMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_SalesMilestoneMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PotentialMilestonePayableInFormOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_TitleOfIndividualAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_SettlementAgreementUpfrontPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PercentageOfRoyaltyPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_SettlementAgreementUpfrontPaymentPaid" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputFairValueOfCommonStockMember" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputFairValueOfCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputProbabilityOfAchievementMember" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputProbabilityOfAchievementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputProbabilityOfAchievementMember" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementPaymentsExpectedAchievementYear" xlink:label="beam_SettlementPaymentsExpectedAchievementYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputProbabilityOfAchievementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="beam_SettlementPaymentsExpectedAchievementYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CorporateEquitySecuritiesMember" xlink:label="beam_CorporateEquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="beam_CorporateEquitySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:label="beam_DebtSecuritiesAvailableForSaleMaturityPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="beam_DebtSecuritiesAvailableForSaleMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationCurrent" xlink:label="beam_AccruedContingentObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationLicenseAgreementCurrent" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedResearchCosts" xlink:label="beam_AccruedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedProcessDevelopmentAndManufacturingCosts" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="beam_AccruedContingentObligationCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="beam_AccruedContingentObligationLicenseAgreementCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="beam_AccruedResearchCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="beam_AccruedProcessDevelopmentAndManufacturingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfRentedSpace" xlink:label="beam_AreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OfficeAndLaboratorySpaceMember" xlink:label="beam_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseCommencementMonthAndYear" xlink:label="beam_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratorySpaceMember" xlink:label="beam_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseRentPaymentsBeginMonthAndYear" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTerminationMonthAndYear" xlink:label="beam_OperatingLeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfOperatingLeaseRenewalOptions" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseholdImprovementsLandlordAllowance" xlink:label="beam_LeaseholdImprovementsLandlordAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfFacilityBeingBuilt" xlink:label="beam_AreaOfFacilityBeingBuilt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssetsSoldForLeaseback" xlink:label="beam_AssetsSoldForLeaseback"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseAnnualRent" xlink:label="beam_FinanceLeaseAnnualRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AreaOfRentedSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_OfficeAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseCommencementMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LaboratorySpaceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseRentPaymentsBeginMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseTerminationMonthAndYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_NumberOfOperatingLeaseRenewalOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_LeaseholdImprovementsLandlordAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_IncreaseDecreaseInOperatingLeaseLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AreaOfFacilityBeingBuilt" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AssetsSoldForLeaseback" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_FinanceLeaseAnnualRent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseLiabilitiesIncreaseDecrease" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="beam_OperatingLeaseLiabilitiesIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsTable" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="beam_FinanceLeaseLiabilityPaymentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="beam_FinanceLeaseLiabilityPaymentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsTable" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsInterestPercentage" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="beam_FinanceLeaseLiabilityPaymentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="beam_FinanceLeaseLiabilityPaymentsInterestPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="beam_FinanceLeaseLiabilityPaymentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OrbitalTherapeuticsIncMember" xlink:label="beam_OrbitalTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="us-gaap_InvestmentIncomeDividend"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="beam_OrbitalTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentIncomeDividend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_WorkforceReductionMember" xlink:label="beam_WorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonCashStockBasedCompensationExpenseMember" xlink:label="beam_NonCashStockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="beam_WorkforceReductionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="beam_NonCashStockBasedCompensationExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveLineItems" xlink:label="us-gaap_RestructuringReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveLineItems" xlink:to="us-gaap_RestructuringReserve_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePayableInFormOfCommonStock" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_PotentialMilestonePayableInFormOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssembledWorkforceMember" xlink:label="beam_AssembledWorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationTransactionPriceAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="beam_AssembledWorkforceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationTransactionPriceAllocatedAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseFeeMember" xlink:label="beam_LicenseFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentObligationAndNonRoyaltySublicenseFees" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedLiabilitiesForLicenseFees" xlink:label="beam_AccruedLiabilitiesForLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_LicenseFeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ContingentObligationAndNonRoyaltySublicenseFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AccruedLiabilitiesForLicenseFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsMember" xlink:label="beam_SuccessPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesOwed" xlink:label="beam_NonRoyaltySublicenseFeesOwed"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherPaymentsMember" xlink:label="beam_OtherPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentAmountDue" xlink:label="beam_SuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalSuccessPaymentAmountDue" xlink:label="beam_AdditionalSuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPayments" xlink:label="beam_SuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsValuationMultiples" xlink:label="beam_SuccessPaymentsValuationMultiples"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AggregateMilestoneAmount" xlink:label="beam_AggregateMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_SuccessPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesOwed" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_OtherPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_ProductDevelopmentAndRegulatoryApprovalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentAmountDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalSuccessPaymentAmountDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentsValuationMultiples" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AggregateMilestoneAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsMember" xlink:label="beam_SuccessPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesOwed" xlink:label="beam_NonRoyaltySublicenseFeesOwed"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherPaymentsMember" xlink:label="beam_OtherPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesPaid" xlink:label="beam_NonRoyaltySublicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPayments" xlink:label="beam_SuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsValuationMultiples" xlink:label="beam_SuccessPaymentsValuationMultiples"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentAmountDue" xlink:label="beam_SuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalSuccessPaymentAmountDue" xlink:label="beam_AdditionalSuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AggregateMilestoneAmount" xlink:label="beam_AggregateMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_SuccessPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesOwed" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_OtherPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_ProductDevelopmentAndRegulatoryApprovalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentsValuationMultiples" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentAmountDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalSuccessPaymentAmountDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AggregateMilestoneAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EditasLicenseAgreementMember" xlink:label="beam_EditasLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_EditasLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPaletteLicenseAgreementMember" xlink:label="beam_BioPaletteLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPalettePatentMember" xlink:label="beam_BioPalettePatentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfUpfrontFee" xlink:label="beam_PaymentOfUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfMilestoneAmount" xlink:label="beam_PaymentOfMilestoneAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BioPaletteLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_BioPalettePatentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PaymentOfUpfrontFee" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PaymentOfMilestoneAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OrbitalTherapeuticsIncMember" xlink:label="beam_OrbitalTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerProgramMember" xlink:label="beam_PerProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToCompanyMember" xlink:label="beam_AssignedToCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UponParticipationElectionMember" xlink:label="beam_UponParticipationElectionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProceedsFromTransferAgreement" xlink:label="beam_ProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerMember" xlink:label="beam_PfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockIssuedMember" xlink:label="beam_CommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToPfizerMember" xlink:label="beam_AssignedToPfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchPlanMember" xlink:label="beam_ResearchPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SanaBiotechnologyMember" xlink:label="beam_SanaBiotechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockReceivedMember" xlink:label="beam_CommonStockReceivedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExploitationLicensesMember" xlink:label="beam_ExploitationLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementShares" xlink:label="beam_StockPurchaseAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ApellisPharmaceuticalsIncMember" xlink:label="beam_ApellisPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived1" xlink:label="beam_StockPurchaseAgreementAmountReceived1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveMember" xlink:label="beam_VerveMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived" xlink:label="beam_StockPurchaseAgreementAmountReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationCommonSharesReceived" xlink:label="beam_CollaborationCommonSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementInitialTerm" xlink:label="beam_CollaborationArrangementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTermDescription" xlink:label="beam_CollaborationArrangementExtensionTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialConsideration" xlink:label="beam_PotentialConsideration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontRevenueRecognized" xlink:label="beam_UpfrontRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonrefundableUpfrontPaymentReceivable" xlink:label="beam_NonrefundableUpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementUpfrontPaymentReceived" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenueRecognized" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAgreementUpfrontPaymentReceived" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementAggregateTransactionPrice" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontFeeReceivableUponSigningContract" xlink:label="beam_UpfrontFeeReceivableUponSigningContract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryAmountReceivable" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentReceivedUnderTermOfAgreement" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryPaymentReceived" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalFeePerAdditionalOptionRight" xlink:label="beam_AdditionalFeePerAdditionalOptionRight"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OptionRightsAggregatePotentialAdditionalConsideration" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EarnoutPaymentPeriod" xlink:label="beam_EarnoutPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementTermOfContract" xlink:label="beam_CollaborationAgreementTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTerm" xlink:label="beam_CollaborationArrangementExtensionTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockValue" xlink:label="beam_ObligationToIssueCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockShares" xlink:label="beam_ObligationToIssueCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesReceived" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesIssued" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementSharesReceived" xlink:label="beam_CollaborationLicenseAgreementSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseOffsetAmount" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentFairValueSharesReceived" xlink:label="beam_UpfrontPaymentFairValueSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesValueHeld" xlink:label="beam_EquitySharesValueHeld"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="beam_OrbitalTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_PerProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="beam_AssignedToCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="beam_UponParticipationElectionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ProceedsFromTransferAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PfizerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="beam_CommonStockIssuedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="beam_AssignedToPfizerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="beam_ResearchPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PotentialAdditionalProceedsFromTransferAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_SanaBiotechnologyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="beam_CommonStockReceivedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="beam_ExploitationLicensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_ApellisPharmaceuticalsIncMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAggregatePurchasePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PrimeMedicineIncMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_VerveMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationCommonSharesReceived" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementInitialTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementExtensionTermDescription" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PotentialConsideration" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontRevenueRecognized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonrefundableUpfrontPaymentReceivable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementUpfrontPaymentReceived" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenueRecognized" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_LicenseAgreementUpfrontPaymentReceived" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementAggregateTransactionPrice" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontFeeReceivableUponSigningContract" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementFirstAnniversaryAmountReceivable" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontPaymentReceivedUnderTermOfAgreement" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementFirstAnniversaryPaymentReceived" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalFeePerAdditionalOptionRight" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_OptionRightsAggregatePotentialAdditionalConsideration" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EarnoutPaymentPeriod" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementTermOfContract" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementExtensionTerm" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ObligationToIssueCommonStockValue" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ObligationToIssueCommonStockShares" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesReceived" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesIssued" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementSharesReceived" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ResearchAndDevelopmentExpenseOffsetAmount" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontPaymentFairValueSharesReceived" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EquitySharesHeld" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EquitySharesValueHeld" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardInstituteMember" xlink:label="beam_HarvardInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadInstituteMember" xlink:label="beam_BroadInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GrossProceedsFromIssuanceOfCommonStock" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceProgramAuthorizedAmount" xlink:label="beam_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommissionRate" xlink:label="beam_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockSoldDuringPeriodSharesNewIssues" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiability" xlink:label="beam_SuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="beam_PrimeMedicineIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcAmendedSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="beam_HarvardInstituteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="beam_BroadInstituteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_GrossProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockIssuanceProgramAuthorizedAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_CommissionRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockSoldDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_SuccessPaymentLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersFoundersAndConsultantsMember" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificFoundersMember" xlink:label="beam_ScientificFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockOptionsAndRestrictedStockMember" xlink:label="beam_StockOptionsAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonStatutoryOptionsMember" xlink:label="beam_NonStatutoryOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerformanceBasedStockOptionsMember" xlink:label="beam_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncludingTwoThousandSeventeenPlanSharesMember" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FromTwoThousandSeventeenPlanSharesMember" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_EmployeesOfficersFoundersAndConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_ScientificFoundersMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_StockOptionsAndRestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_NonStatutoryOptionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_PerformanceBasedStockOptionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_IncludingTwoThousandSeventeenPlanSharesMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_FromTwoThousandSeventeenPlanSharesMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsAmortization" xlink:label="beam_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsCapitalizedResearch" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsLeasingArrangements" xlink:label="beam_DeferredTaxAssetsLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="beam_DeferredTaxAssetsAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="beam_DeferredTaxAssetsCapitalizedResearch" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="beam_DeferredTaxAssetsLeasingArrangements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TaxCreditsExpirationStartingYear" xlink:label="beam_TaxCreditsExpirationStartingYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="beam_TaxCreditsExpirationStartingYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificConsultingAndOtherExpensesMember" xlink:label="beam_ScientificConsultingAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FounderShareholdersMember" xlink:label="beam_FounderShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OfficeAndLaboratorySpaceMember" xlink:label="beam_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfFounderShareholders" xlink:label="beam_NumberOfFounderShareholders"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseAreaOfRentedSpace" xlink:label="beam_SubleaseAreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseCommencementMonthAndYear" xlink:label="beam_SubleaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PrimeMedicineIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="beam_ScientificConsultingAndOtherExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_FounderShareholdersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_OfficeAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_EquitySharesHeld" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_NumberOfFounderShareholders" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_SubleaseAreaOfRentedSpace" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_SubleaseCommencementMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SubleaseIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DefinedContributionPlanName" xlink:label="beam_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="beam_DefinedContributionPlanName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalResearchAndDevelopmentExpensesMember" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalGeneralAndAdministrativeExpensesMember" xlink:label="beam_ExternalGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeeRelatedExpensesMember" xlink:label="beam_EmployeeRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndITRelatedExpensesMember" xlink:label="beam_FacilityAndITRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndInformationTechnologyRelatedExpenses" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockBasedCompensationMember" xlink:label="beam_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DepreciationMember" xlink:label="beam_DepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_ExternalResearchAndDevelopmentExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_ExternalGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_EmployeeRelatedExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_FacilityAndITRelatedExpensesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="beam_FacilityAndInformationTechnologyRelatedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_StockBasedCompensationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_DepreciationMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" xlink:label="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" xlink:label="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceCosts" xlink:label="beam_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="beam_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_StockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="beam_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OctoberTwoThousandTwentyPublicOfferingMember" xlink:label="beam_OctoberTwoThousandTwentyPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseLiabilitiesIncreaseDecrease" xlink:label="beam_OperatingLeaseLiabilitiesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInCollaborationReceivable" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_OctoberTwoThousandTwentyPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="beam_OperatingLeaseLiabilitiesIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ContributionOfProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="beam_IncreaseDecreaseInCollaborationReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="beam_ChangeInOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AmySimonMember" xlink:label="beam_AmySimonMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GiuseppeCiaramellaMember" xlink:label="beam_GiuseppeCiaramellaMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SravanEmanyMember" xlink:label="beam_SravanEmanyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TerryAnnBurrellMember" xlink:label="beam_TerryAnnBurrellMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChristineBellonMember" xlink:label="beam_ChristineBellonMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_AmySimonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_GiuseppeCiaramellaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_SravanEmanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_TerryAnnBurrellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="beam_ChristineBellonMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTermAndDiscountRateTableTextBlock" xlink:label="beam_OperatingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" xlink:label="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" xlink:label="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCostTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_OperatingLeaseTermAndDiscountRateTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="beam_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockSoldDuringPeriodSharesNewIssues" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GrossProceedsFromIssuanceOfCommonStock" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ApellisPharmaceuticalsIncMember" xlink:label="beam_ApellisPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommissionRate" xlink:label="beam_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SanaBiotechnologyMember" xlink:label="beam_SanaBiotechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceProgramAuthorizedAmount" xlink:label="beam_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerIncMember" xlink:label="beam_PfizerIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived" xlink:label="beam_StockPurchaseAgreementAmountReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProceedsFromTransferAgreement" xlink:label="beam_ProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementUpfrontPaymentReceived" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementShares" xlink:label="beam_StockPurchaseAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_NatureOfBusinessAndBasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcAmendedSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockSoldDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_ApellisPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_CommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_SanaBiotechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockIssuanceProgramAuthorizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PfizerIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_PotentialAdditionalProceedsFromTransferAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_ProceedsFromTransferAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_CollaborationAgreementUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="beam_StockPurchaseAgreementAggregatePurchasePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="beam_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SummaryOfSignificantAccountingPoliciesTable" xlink:label="beam_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PercentageOfRoyaltyPayments" xlink:label="beam_PercentageOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="beam_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="beam_PercentageOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ComputerEquipmentAndSoftwareMember" xlink:label="beam_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="beam_LaboratoryEquipmentAndOfficeFurnitureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LaboratoryEquipmentAndOfficeFurnitureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LabEquipmentMember" xlink:label="beam_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CorporateEquitySecuritiesMember" xlink:label="beam_CorporateEquitySecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="beam_CorporateEquitySecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseMember" xlink:label="beam_InterestAndOtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesPurchasedUnderEquityMethod" xlink:label="beam_NumberOfSharesPurchasedUnderEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentAndRegulatoryMilestonesMember" xlink:label="beam_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SalesMilestoneMember" xlink:label="beam_SalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePayableInFormOfCommonStock" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPayment" xlink:label="beam_SettlementAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PercentageOfRoyaltyPayments" xlink:label="beam_PercentageOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" xlink:label="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementAgreementUpfrontPaymentPaid" xlink:label="beam_SettlementAgreementUpfrontPaymentPaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_EquitySharesHeld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="beam_InterestAndOtherIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_PrimeMedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_NumberOfSharesPurchasedUnderEquityMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_DevelopmentAndRegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_SalesMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PotentialMilestonePayableInFormOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_SettlementAgreementUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PercentageOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="beam_SettlementAgreementUpfrontPaymentPaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputFairValueOfCommonStockMember" xlink:label="beam_MeasurementInputFairValueOfCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputFairValueOfCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiabilitiesMember" xlink:label="beam_SuccessPaymentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_SuccessPaymentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationLiabilitiesMember" xlink:label="beam_ContingentConsiderationLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract" xlink:label="us-gaap_DerivativeLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputProbabilityOfAchievementMember" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" xlink:label="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_ContingentConsiderationLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputProbabilityOfAchievementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MeasurementInputProbabilityOfAchievementMember" xlink:label="beam_MeasurementInputProbabilityOfAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SettlementPaymentsExpectedAchievementYear" xlink:label="beam_SettlementPaymentsExpectedAchievementYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="beam_MeasurementInputProbabilityOfAchievementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="beam_SettlementPaymentsExpectedAchievementYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DerivativeLiabilityMember" xlink:label="beam_DerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="beam_DerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CorporateEquitySecuritiesMember" xlink:label="beam_CorporateEquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="beam_CorporateEquitySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfRentedSpace" xlink:label="beam_AreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OfficeAndLaboratorySpaceMember" xlink:label="beam_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" xlink:label="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseCommencementMonthAndYear" xlink:label="beam_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LaboratorySpaceMember" xlink:label="beam_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" xlink:label="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseRentPaymentsBeginMonthAndYear" xlink:label="beam_OperatingLeaseRentPaymentsBeginMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OperatingLeaseTerminationMonthAndYear" xlink:label="beam_OperatingLeaseTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfOperatingLeaseRenewalOptions" xlink:label="beam_NumberOfOperatingLeaseRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LeaseholdImprovementsLandlordAllowance" xlink:label="beam_LeaseholdImprovementsLandlordAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="beam_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AreaOfFacilityBeingBuilt" xlink:label="beam_AreaOfFacilityBeingBuilt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssetsSoldForLeaseback" xlink:label="beam_AssetsSoldForLeaseback"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseAnnualRent" xlink:label="beam_FinanceLeaseAnnualRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AreaOfRentedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_OfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_LaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseRentPaymentsBeginMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_OperatingLeaseTerminationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_NumberOfOperatingLeaseRenewalOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_LeaseholdImprovementsLandlordAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AreaOfFacilityBeingBuilt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_AssetsSoldForLeaseback" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="beam_FinanceLeaseAnnualRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsTable" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="beam_FinanceLeaseLiabilityPaymentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:label="beam_FinanceLeaseLiabilityPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsTable" xlink:label="beam_FinanceLeaseLiabilityPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FinanceLeaseLiabilityPaymentsInterestPercentage" xlink:label="beam_FinanceLeaseLiabilityPaymentsInterestPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="beam_FinanceLeaseLiabilityPaymentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="beam_FinanceLeaseLiabilityPaymentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_FinanceLeaseLiabilityPaymentsLineItems" xlink:to="beam_FinanceLeaseLiabilityPaymentsInterestPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OrbitalTherapeuticsIncMember" xlink:label="beam_OrbitalTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" xlink:label="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="us-gaap_InvestmentIncomeDividend"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="beam_OrbitalTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentIncomeDividend" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_WorkforceReductionMember" xlink:label="beam_WorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonCashStockBasedCompensationExpenseMember" xlink:label="beam_NonCashStockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="beam_WorkforceReductionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="beam_NonCashStockBasedCompensationExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FormerStockholdersAndOptionholdersMember" xlink:label="beam_FormerStockholdersAndOptionholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfTechnologyLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfTechnologyLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" xlink:label="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentConsiderationOfProductLiabilitiesMember" xlink:label="beam_ContingentConsiderationOfProductLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" xlink:label="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialMilestonePayableInFormOfCommonStock" xlink:label="beam_PotentialMilestonePayableInFormOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_FormerStockholdersAndOptionholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="beam_ContingentConsiderationOfProductLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_PotentialMilestonePayableInFormOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MergerAgreementMember" xlink:label="beam_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GuideTherapeuticsIncorporatedMember" xlink:label="beam_GuideTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:label="beam_BusinessCombinationTransactionPriceAllocatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssembledWorkforceMember" xlink:label="beam_AssembledWorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationTransactionPriceAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="beam_GuideTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="beam_AssembledWorkforceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="beam_BusinessCombinationTransactionPriceAllocatedAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="beam_BusinessCombinationTransactionPriceAllocatedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseFeeMember" xlink:label="beam_LicenseFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ContingentObligationAndNonRoyaltySublicenseFees" xlink:label="beam_ContingentObligationAndNonRoyaltySublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedLiabilitiesForLicenseFees" xlink:label="beam_AccruedLiabilitiesForLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_LicenseFeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ContingentObligationAndNonRoyaltySublicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AccruedLiabilitiesForLicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsMember" xlink:label="beam_SuccessPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesOwed" xlink:label="beam_NonRoyaltySublicenseFeesOwed"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherPaymentsMember" xlink:label="beam_OtherPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentAmountDue" xlink:label="beam_SuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalSuccessPaymentAmountDue" xlink:label="beam_AdditionalSuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPayments" xlink:label="beam_SuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsValuationMultiples" xlink:label="beam_SuccessPaymentsValuationMultiples"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AggregateMilestoneAmount" xlink:label="beam_AggregateMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_SuccessPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesOwed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_OtherPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_ProductDevelopmentAndRegulatoryApprovalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentAmountDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalSuccessPaymentAmountDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentsValuationMultiples" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AggregateMilestoneAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardLicenseAgreementMember" xlink:label="beam_HarvardLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_HarvardLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsMember" xlink:label="beam_SuccessPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesOwed" xlink:label="beam_NonRoyaltySublicenseFeesOwed"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OtherPaymentsMember" xlink:label="beam_OtherPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonRoyaltySublicenseFeesPaid" xlink:label="beam_NonRoyaltySublicenseFeesPaid"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProductDevelopmentAndRegulatoryApprovalMember" xlink:label="beam_ProductDevelopmentAndRegulatoryApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPayments" xlink:label="beam_SuccessPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentsValuationMultiples" xlink:label="beam_SuccessPaymentsValuationMultiples"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentAmountDue" xlink:label="beam_SuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalSuccessPaymentAmountDue" xlink:label="beam_AdditionalSuccessPaymentAmountDue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AggregateMilestoneAmount" xlink:label="beam_AggregateMilestoneAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_SuccessPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesOwed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_OtherPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonRoyaltySublicenseFeesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_ProductDevelopmentAndRegulatoryApprovalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentsValuationMultiples" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_SuccessPaymentAmountDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalSuccessPaymentAmountDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AggregateMilestoneAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadLicenseAgreementMember" xlink:label="beam_BroadLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BroadLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EditasLicenseAgreementMember" xlink:label="beam_EditasLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_RegulatoryMember" xlink:label="beam_RegulatoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_MilestoneExpense" xlink:label="beam_MilestoneExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_EditasLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_RegulatoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_MilestoneExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPaletteLicenseAgreementMember" xlink:label="beam_BioPaletteLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BioPalettePatentMember" xlink:label="beam_BioPalettePatentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfUpfrontFee" xlink:label="beam_PaymentOfUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PaymentOfMilestoneAmount" xlink:label="beam_PaymentOfMilestoneAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_BioPaletteLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_BioPalettePatentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PaymentOfUpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PaymentOfMilestoneAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OrbitalTherapeuticsIncMember" xlink:label="beam_OrbitalTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LillyAgreementMember" xlink:label="beam_LillyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerProgramMember" xlink:label="beam_PerProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToCompanyMember" xlink:label="beam_AssignedToCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UponParticipationElectionMember" xlink:label="beam_UponParticipationElectionMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ProceedsFromTransferAgreement" xlink:label="beam_ProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PfizerMember" xlink:label="beam_PfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockIssuedMember" xlink:label="beam_CommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AssignedToPfizerMember" xlink:label="beam_AssignedToPfizerMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchPlanMember" xlink:label="beam_ResearchPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialAdditionalProceedsFromTransferAgreement" xlink:label="beam_PotentialAdditionalProceedsFromTransferAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SanaBiotechnologyMember" xlink:label="beam_SanaBiotechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommonStockReceivedMember" xlink:label="beam_CommonStockReceivedMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExploitationLicensesMember" xlink:label="beam_ExploitationLicensesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementShares" xlink:label="beam_StockPurchaseAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ApellisPharmaceuticalsIncMember" xlink:label="beam_ApellisPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAggregatePurchasePrice" xlink:label="beam_StockPurchaseAgreementAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived1" xlink:label="beam_StockPurchaseAgreementAmountReceived1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveMember" xlink:label="beam_VerveMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockPurchaseAgreementAmountReceived" xlink:label="beam_StockPurchaseAgreementAmountReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" xlink:label="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationCommonSharesReceived" xlink:label="beam_CollaborationCommonSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementInitialTerm" xlink:label="beam_CollaborationArrangementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTermDescription" xlink:label="beam_CollaborationArrangementExtensionTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PotentialConsideration" xlink:label="beam_PotentialConsideration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" xlink:label="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontRevenueRecognized" xlink:label="beam_UpfrontRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonrefundableUpfrontPaymentReceivable" xlink:label="beam_NonrefundableUpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementUpfrontPaymentReceived" xlink:label="beam_CollaborationAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementPerformanceObligationRevenueRecognized" xlink:label="beam_CollaborationAgreementPerformanceObligationRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_LicenseAgreementUpfrontPaymentReceived" xlink:label="beam_LicenseAgreementUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementAggregateTransactionPrice" xlink:label="beam_CollaborationAgreementAggregateTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontFeeReceivableUponSigningContract" xlink:label="beam_UpfrontFeeReceivableUponSigningContract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" xlink:label="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryAmountReceivable" xlink:label="beam_CollaborationAgreementFirstAnniversaryAmountReceivable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentReceivedUnderTermOfAgreement" xlink:label="beam_UpfrontPaymentReceivedUnderTermOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementFirstAnniversaryPaymentReceived" xlink:label="beam_CollaborationAgreementFirstAnniversaryPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AdditionalFeePerAdditionalOptionRight" xlink:label="beam_AdditionalFeePerAdditionalOptionRight"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OptionRightsAggregatePotentialAdditionalConsideration" xlink:label="beam_OptionRightsAggregatePotentialAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EarnoutPaymentPeriod" xlink:label="beam_EarnoutPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationAgreementTermOfContract" xlink:label="beam_CollaborationAgreementTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationArrangementExtensionTerm" xlink:label="beam_CollaborationArrangementExtensionTerm"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockValue" xlink:label="beam_ObligationToIssueCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ObligationToIssueCommonStockShares" xlink:label="beam_ObligationToIssueCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesReceived" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementFairValueOfSharesIssued" xlink:label="beam_CollaborationLicenseAgreementFairValueOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CollaborationLicenseAgreementSharesReceived" xlink:label="beam_CollaborationLicenseAgreementSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseOffsetAmount" xlink:label="beam_ResearchAndDevelopmentExpenseOffsetAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_UpfrontPaymentFairValueSharesReceived" xlink:label="beam_UpfrontPaymentFairValueSharesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesValueHeld" xlink:label="beam_EquitySharesValueHeld"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="beam_OrbitalTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_LillyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="beam_PerProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="beam_AssignedToCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="beam_UponParticipationElectionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ProceedsFromTransferAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PfizerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="beam_CommonStockIssuedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="beam_AssignedToPfizerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="beam_ResearchPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PotentialAdditionalProceedsFromTransferAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_SanaBiotechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="beam_CommonStockReceivedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="beam_ExploitationLicensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_ApellisPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAggregatePurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PrimeMedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_VerveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_StockPurchaseAgreementAmountReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationCommonSharesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementInitialTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementExtensionTermDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_PotentialConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_NonrefundableUpfrontPaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementPerformanceObligationRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_LicenseAgreementUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementAggregateTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontFeeReceivableUponSigningContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementFirstAnniversaryAmountReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontPaymentReceivedUnderTermOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementFirstAnniversaryPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_AdditionalFeePerAdditionalOptionRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_OptionRightsAggregatePotentialAdditionalConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EarnoutPaymentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationAgreementTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationArrangementExtensionTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ObligationToIssueCommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ObligationToIssueCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementFairValueOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_CollaborationLicenseAgreementSharesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_ResearchAndDevelopmentExpenseOffsetAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_UpfrontPaymentFairValueSharesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EquitySharesHeld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="beam_EquitySharesValueHeld" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_HarvardInstituteMember" xlink:label="beam_HarvardInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" xlink:label="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BroadInstituteMember" xlink:label="beam_BroadInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AtTheMarketMember" xlink:label="beam_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_GrossProceedsFromIssuanceOfCommonStock" xlink:label="beam_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuanceProgramAuthorizedAmount" xlink:label="beam_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_CommissionRate" xlink:label="beam_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockSoldDuringPeriodSharesNewIssues" xlink:label="beam_StockSoldDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SuccessPaymentLiability" xlink:label="beam_SuccessPaymentLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" xlink:label="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="beam_PrimeMedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcAmendedSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="beam_HarvardInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="beam_BroadInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="beam_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockIssuanceProgramAuthorizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_CommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockSoldDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_SuccessPaymentLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" xlink:label="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockOptionsAndRestrictedStockMember" xlink:label="beam_StockOptionsAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersFoundersAndConsultantsMember" xlink:label="beam_EmployeesOfficersFoundersAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" xlink:label="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NonStatutoryOptionsMember" xlink:label="beam_NonStatutoryOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificFoundersMember" xlink:label="beam_ScientificFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PerformanceBasedStockOptionsMember" xlink:label="beam_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncludingTwoThousandSeventeenPlanSharesMember" xlink:label="beam_IncludingTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FromTwoThousandSeventeenPlanSharesMember" xlink:label="beam_FromTwoThousandSeventeenPlanSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" xlink:label="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_StockOptionsAndRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_EmployeesOfficersFoundersAndConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_NonStatutoryOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_ScientificFoundersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_IncludingTwoThousandSeventeenPlanSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="beam_FromTwoThousandSeventeenPlanSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="beam_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="beam_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_TaxCreditsExpirationStartingYear" xlink:label="beam_TaxCreditsExpirationStartingYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="beam_TaxCreditsExpirationStartingYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_PrimeMedicineIncMember" xlink:label="beam_PrimeMedicineIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ScientificConsultingAndOtherExpensesMember" xlink:label="beam_ScientificConsultingAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FounderShareholdersMember" xlink:label="beam_FounderShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_OfficeAndLaboratorySpaceMember" xlink:label="beam_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EquitySharesHeld" xlink:label="beam_EquitySharesHeld"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_VerveTherapeuticsIncMember" xlink:label="beam_VerveTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_NumberOfFounderShareholders" xlink:label="beam_NumberOfFounderShareholders"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseAreaOfRentedSpace" xlink:label="beam_SubleaseAreaOfRentedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_SubleaseCommencementMonthAndYear" xlink:label="beam_SubleaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="beam_PrimeMedicineIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="beam_ScientificConsultingAndOtherExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_FounderShareholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="beam_OfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_EquitySharesHeld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="beam_VerveTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_NumberOfFounderShareholders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_SubleaseAreaOfRentedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="beam_SubleaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalResearchAndDevelopmentExpensesMember" xlink:label="beam_ExternalResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ExternalGeneralAndAdministrativeExpensesMember" xlink:label="beam_ExternalGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EmployeeRelatedExpensesMember" xlink:label="beam_EmployeeRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndITRelatedExpensesMember" xlink:label="beam_FacilityAndITRelatedExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndInformationTechnologyRelatedExpenses" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_StockBasedCompensationMember" xlink:label="beam_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DepreciationMember" xlink:label="beam_DepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_ExternalResearchAndDevelopmentExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_ExternalGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_EmployeeRelatedExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_FacilityAndITRelatedExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="beam_FacilityAndInformationTechnologyRelatedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_StockBasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="beam_DepreciationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_JohnEvansChiefExecutiveOfficerMember" xlink:label="beam_JohnEvansChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="beam_JohnEvansChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="beam_AccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="beam_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="4" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset" xlink:label="us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="beam_ChangeInFairValueOfContingentConsiderationLiabilities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="beam_InterestAndOtherIncomeExpenseNet" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInFairValueOfContingentConsiderationLiabilities" xlink:label="beam_ChangeInFairValueOfContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_InterestAndOtherIncomeExpenseNet" xlink:label="beam_InterestAndOtherIncomeExpenseNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="beam_ResearchAndDevelopmentExpenseInProcess" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="beam_ChangeInOperatingLeaseRightOfUseAssets" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="18" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="20" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="21" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="beam_IncreaseDecreaseInCollaborationReceivable" order="22" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="23" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="25" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ResearchAndDevelopmentExpenseInProcess" xlink:label="beam_ResearchAndDevelopmentExpenseInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="beam_ChangeInOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_IncreaseDecreaseInCollaborationReceivable" xlink:label="beam_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNi" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:to="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" xlink:label="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="beam_AccruedContingentObligationLicenseAgreementCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="beam_AccruedContingentObligationCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="beam_AccruedResearchCosts" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="beam_AccruedProcessDevelopmentAndManufacturingCosts" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationLicenseAgreementCurrent" xlink:label="beam_AccruedContingentObligationLicenseAgreementCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedContingentObligationCurrent" xlink:label="beam_AccruedContingentObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedResearchCosts" xlink:label="beam_AccruedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_AccruedProcessDevelopmentAndManufacturingCosts" xlink:label="beam_AccruedProcessDevelopmentAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" xlink:label="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" xlink:label="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" xlink:label="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="beam_DeferredTaxAssetsAmortization" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="beam_DeferredTaxAssetsCapitalizedResearch" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="beam_DeferredTaxAssetsLeasingArrangements" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsAmortization" xlink:label="beam_DeferredTaxAssetsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsCapitalizedResearch" xlink:label="beam_DeferredTaxAssetsCapitalizedResearch"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_DeferredTaxAssetsLeasingArrangements" xlink:label="beam_DeferredTaxAssetsLeasingArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="beam_FacilityAndInformationTechnologyRelatedExpenses" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="9" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="beam-20241231.xsd#beam_FacilityAndInformationTechnologyRelatedExpenses" xlink:label="beam_FacilityAndInformationTechnologyRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="beam_InterestAndOtherIncomeExpenseMember" name="InterestAndOtherIncomeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedResearchCosts" name="AccruedResearchCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_CommonStockReceivedMember" name="CommonStockReceivedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ContingentConsiderationOfTechnologyLiabilitiesMember" name="ContingentConsiderationOfTechnologyLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" name="TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_CollaborationAgreementFirstAnniversaryPaymentReceived" name="CollaborationAgreementFirstAnniversaryPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_AssignedToCompanyMember" name="AssignedToCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_AdditionalSuccessPaymentAmountDue" name="AdditionalSuccessPaymentAmountDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ChristineBellonMember" name="ChristineBellonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementFirstAnniversaryAmountReceivable" name="CollaborationAgreementFirstAnniversaryAmountReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_DeferredTaxAssetsCapitalizedResearch" name="DeferredTaxAssetsCapitalizedResearch" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_CollaborationArrangementExtensionTerm" name="CollaborationArrangementExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_SuccessPaymentAmountDue" name="SuccessPaymentAmountDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability" name="StockIssuedDuringPeriodSharesSuccessPaymentLiability" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_DerivativeLiabilityMember" name="DerivativeLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_HarvardInstituteMember" name="HarvardInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ContingentConsiderationLiabilitiesMember" name="ContingentConsiderationLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_NonCashStockBasedCompensationExpenseMember" name="NonCashStockBasedCompensationExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_UpfrontFeeReceivableUponSigningContract" name="UpfrontFeeReceivableUponSigningContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ChangeInOperatingLeaseRightOfUseAssets" name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ExternalResearchAndDevelopmentExpensesMember" name="ExternalResearchAndDevelopmentExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementPerformanceObligationRevenueRecognized" name="CollaborationAgreementPerformanceObligationRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LaboratorySpaceMember" name="LaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockSoldDuringPeriodSharesNewIssues" name="StockSoldDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_JohnEvansChiefExecutiveOfficerMember" name="JohnEvansChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_IncludingTwoThousandSeventeenPlanSharesMember" name="IncludingTwoThousandSeventeenPlanSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CorporateEquitySecuritiesMember" name="CorporateEquitySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ContingentObligationAndNonRoyaltySublicenseFees" name="ContingentObligationAndNonRoyaltySublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember" name="EmployeesOfficersBoardOfDirectorsAndConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ObligationToIssueCommonStockValue" name="ObligationToIssueCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" name="AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_LicenseFeeMember" name="LicenseFeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" name="NumberOfSharesIssuedForUpfrontPaymentOfAcquisition" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_FinanceLeaseLiabilityPaymentsLineItems" name="FinanceLeaseLiabilityPaymentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_TwoThousandSeventeenStockOptionAndGrantPlanMember" name="TwoThousandSeventeenStockOptionAndGrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AreaOfFacilityBeingBuilt" name="AreaOfFacilityBeingBuilt" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_SravanEmanyMember" name="SravanEmanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" name="CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_OperatingLeaseRentPaymentsBeginMonthAndYear" name="OperatingLeaseRentPaymentsBeginMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_PaymentOfUpfrontFee" name="PaymentOfUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" name="ContractWithCustomerLiabilityIncreaseFromLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" name="AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_MeasurementInputProbabilityOfAchievementMember" name="MeasurementInputProbabilityOfAchievementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_DeferredTaxAssetsLeasingArrangements" name="DeferredTaxAssetsLeasingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_FinanceLeaseLiabilityPaymentsTable" name="FinanceLeaseLiabilityPaymentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_EmployeesOfficersFoundersAndConsultantsMember" name="EmployeesOfficersFoundersAndConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_NonRoyaltySublicenseFeesOwed" name="NonRoyaltySublicenseFeesOwed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_AssetAcquisitionsPolicyTextBlock" name="AssetAcquisitionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" name="CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SettlementAgreementUpfrontPayment" name="SettlementAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_BioPaletteLicenseAgreementMember" name="BioPaletteLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_NonStatutoryOptionsMember" name="NonStatutoryOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedContingentObligationCurrent" name="AccruedContingentObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_OptionRightsAggregatePotentialAdditionalConsideration" name="OptionRightsAggregatePotentialAdditionalConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationLicenseAgreementFairValueOfSharesIssued" name="CollaborationLicenseAgreementFairValueOfSharesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_SettlementPaymentsExpectedAchievementYear" name="SettlementPaymentsExpectedAchievementYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_TaxCreditsExpirationStartingYear" name="TaxCreditsExpirationStartingYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_LicenseAgreementUpfrontPaymentReceived" name="LicenseAgreementUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_EquityIssuanceCostsPoliciesPolicyTextBlock" name="EquityIssuanceCostsPoliciesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_UpfrontPaymentReceivedUnderTermOfAgreement" name="UpfrontPaymentReceivedUnderTermOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_OctoberTwoThousandTwentyPublicOfferingMember" name="OctoberTwoThousandTwentyPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" name="IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock" name="SummaryOfPrincipalAndInterestPortionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_OperatingLeaseLiabilitiesIncreaseDecrease" name="OperatingLeaseLiabilitiesIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ContingentConsiderationOfProductLiabilitiesMember" name="ContingentConsiderationOfProductLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_UpfrontRevenueRecognized" name="UpfrontRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_StockBasedCompensationMember" name="StockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedContingentObligationLicenseAgreementCurrent" name="AccruedContingentObligationLicenseAgreementCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_AssignedToPfizerMember" name="AssignedToPfizerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_OperatingLeaseTerminationMonthAndYear" name="OperatingLeaseTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_ExploitationLicensesMember" name="ExploitationLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockPurchaseAgreementAmountReceived1" name="StockPurchaseAgreementAmountReceived1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LaboratoryEquipmentAndOfficeFurnitureMember" name="LaboratoryEquipmentAndOfficeFurnitureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AssetsSoldForLeaseback" name="AssetsSoldForLeaseback" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_BusinessCombinationTransactionPriceAbstract" name="BusinessCombinationTransactionPriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" name="CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SubleaseAreaOfRentedSpace" name="SubleaseAreaOfRentedSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_FacilityAndITRelatedExpensesMember" name="FacilityAndITRelatedExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedProcessDevelopmentAndManufacturingCosts" name="AccruedProcessDevelopmentAndManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_AdditionalFeePerAdditionalOptionRight" name="AdditionalFeePerAdditionalOptionRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable" name="DevelopmentRegulatoryAndCommercialMilestonesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ObligationToIssueCommonStockShares" name="ObligationToIssueCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_ProductDevelopmentAndRegulatoryApprovalMember" name="ProductDevelopmentAndRegulatoryApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AccruedLiabilitiesForLicenseFees" name="AccruedLiabilitiesForLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_MergerAgreementMember" name="MergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_PotentialMilestonePaymentsDueUnderSettlementAgreement" name="PotentialMilestonePaymentsDueUnderSettlementAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" name="LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_InsiderTradingArrAbstract" name="InsiderTradingArrAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" name="CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_OrbitalTherapeuticsIncMember" name="OrbitalTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AssembledWorkforceMember" name="AssembledWorkforceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_OtherPaymentsMember" name="OtherPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_TerryAnnBurrellMember" name="TerryAnnBurrellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_PerProgramMember" name="PerProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_GiuseppeCiaramellaMember" name="GiuseppeCiaramellaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_MilestoneExpense" name="MilestoneExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_VerveMember" name="VerveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_UponParticipationElectionMember" name="UponParticipationElectionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SuccessPaymentsValuationMultiples" name="SuccessPaymentsValuationMultiples" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_EarnoutPaymentPeriod" name="EarnoutPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_IncreaseDecreaseInCollaborationReceivable" name="IncreaseDecreaseInCollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_BioPalettePatentMember" name="BioPalettePatentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SubleaseCommencementMonthAndYear" name="SubleaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ProceedsFromTransferAgreement" name="ProceedsFromTransferAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ResearchAndDevelopmentExpenseInProcess" name="ResearchAndDevelopmentExpenseInProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_SalesMilestoneMember" name="SalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockPurchaseAgreementShares" name="StockPurchaseAgreementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_OperatingLeaseCommencementMonthAndYear" name="OperatingLeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" name="AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_EditasLicenseAgreementMember" name="EditasLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" name="BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_BroadInstituteMember" name="BroadInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_DefinedContributionPlanName" name="DefinedContributionPlanName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_NumberOfSharesPurchasedUnderEquityMethod" name="NumberOfSharesPurchasedUnderEquityMethod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_AggregateMilestoneAmount" name="AggregateMilestoneAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_NonRoyaltySublicenseFeesPaid" name="NonRoyaltySublicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_SuccessPayments" name="SuccessPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_InterestAndOtherIncomeExpenseNet" name="InterestAndOtherIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LeaseholdImprovementsLandlordAllowance" name="LeaseholdImprovementsLandlordAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_StockPurchaseAgreementAggregatePurchasePrice" name="StockPurchaseAgreementAggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_DebtSecuritiesAvailableForSaleMaturityPeriod" name="DebtSecuritiesAvailableForSaleMaturityPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_FormerStockholdersAndOptionholdersMember" name="FormerStockholdersAndOptionholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SummaryOfDepreciationExpenseIncurredTableTextBlock" name="SummaryOfDepreciationExpenseIncurredTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_UpfrontPaymentFairValueSharesReceived" name="UpfrontPaymentFairValueSharesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_PaymentOfMilestoneAmount" name="PaymentOfMilestoneAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" name="LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_OtherOperatingIncomeExpenseAbstract" name="OtherOperatingIncomeExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CommonStockIssuedMember" name="CommonStockIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_FinanceLeaseLiabilityPaymentsInterestPercentage" name="FinanceLeaseLiabilityPaymentsInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_SanaBiotechnologyMember" name="SanaBiotechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationArrangementInitialTerm" name="CollaborationArrangementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_OperatingLeaseTermAndDiscountRateTableTextBlock" name="OperatingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_FounderShareholdersMember" name="FounderShareholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementAggregateTransactionPrice" name="CollaborationAgreementAggregateTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ScientificFoundersMember" name="ScientificFoundersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SuccessPaymentLiabilitiesMember" name="SuccessPaymentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_JeffriesLlcSalesAgreementMember" name="JeffriesLlcSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" name="AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_GuideTherapeuticsIncorporatedMember" name="GuideTherapeuticsIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ScientificConsultingAndOtherExpensesMember" name="ScientificConsultingAndOtherExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockPurchaseAgreementAmountReceived" name="StockPurchaseAgreementAmountReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_MeasurementInputFairValueOfCommonStockMember" name="MeasurementInputFairValueOfCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_PercentageOfRoyaltyPayments" name="PercentageOfRoyaltyPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_PotentialConsideration" name="PotentialConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ResearchPlanMember" name="ResearchPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" name="JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_PrimeMedicineIncMember" name="PrimeMedicineIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationCommonSharesReceived" name="CollaborationCommonSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_CollaborationArrangementExtensionTermDescription" name="CollaborationArrangementExtensionTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_LillyAgreementMember" name="LillyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_NumberOfOperatingLeaseRenewalOptions" name="NumberOfOperatingLeaseRenewalOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_ApellisPharmaceuticalsIncMember" name="ApellisPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_BroadLicenseAgreementMember" name="BroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_PfizerMember" name="PfizerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementUpfrontPaymentReceived" name="CollaborationAgreementUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_SuccessPaymentLiability" name="SuccessPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_EquitySharesHeld" name="EquitySharesHeld" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock" name="BusinessCombinationUpfrontConsiderationPaidInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ExternalGeneralAndAdministrativeExpensesMember" name="ExternalGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_HarvardLicenseAgreementMember" name="HarvardLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_DepreciationMember" name="DepreciationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost" name="BusinessAcquisitionCostOfAcquiredEntityTransactionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_FinanceLeaseAnnualRent" name="FinanceLeaseAnnualRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_VerveTherapeuticsIncMember" name="VerveTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_RegulatoryMember" name="RegulatoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" name="IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_FromTwoThousandSeventeenPlanSharesMember" name="FromTwoThousandSeventeenPlanSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_ChangeInFairValueOfContingentConsiderationLiabilities" name="ChangeInFairValueOfContingentConsiderationLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock" name="ScheduleOfSuccessPaymentLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_SettlementAgreementUpfrontPaymentPaid" name="SettlementAgreementUpfrontPaymentPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_FacilityAndInformationTechnologyRelatedExpenses" name="FacilityAndInformationTechnologyRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_NonrefundableUpfrontPaymentReceivable" name="NonrefundableUpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_PfizerIncMember" name="PfizerIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AreaOfRentedSpace" name="AreaOfRentedSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_SuccessPaymentsMember" name="SuccessPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_EquitySharesValueHeld" name="EquitySharesValueHeld" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage" name="NetProfitsAndDevelopmentAndCommercializationCostsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="beam_StockIssuanceProgramAuthorizedAmount" name="StockIssuanceProgramAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_PotentialAdditionalProceedsFromTransferAgreement" name="PotentialAdditionalProceedsFromTransferAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" name="TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" name="ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_CommissionRate" name="CommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_StockIssuedDuringPeriodValueSuccessPaymentLiability" name="StockIssuedDuringPeriodValueSuccessPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_WorkforceReductionMember" name="WorkforceReductionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_NumberOfFounderShareholders" name="NumberOfFounderShareholders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_BusinessCombinationTransactionPriceAllocatedAbstract" name="BusinessCombinationTransactionPriceAllocatedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_EmployeeRelatedExpensesMember" name="EmployeeRelatedExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" name="AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_PotentialMilestonePayableInFormOfCommonStock" name="PotentialMilestonePayableInFormOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_ResearchAndDevelopmentExpenseOffsetAmount" name="ResearchAndDevelopmentExpenseOffsetAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="beam_CollaborationLicenseAgreementFairValueOfSharesReceived" name="CollaborationLicenseAgreementFairValueOfSharesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" name="EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_JeffriesLlcAmendedSalesAgreementMember" name="JeffriesLlcAmendedSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationLicenseAgreementSharesReceived" name="CollaborationLicenseAgreementSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" name="BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="beam_AmySimonMember" name="AmySimonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="beam_CollaborationAgreementTermOfContract" name="CollaborationAgreementTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873700960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BEAM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Beam Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001745999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,688,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5238376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">238 Main Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-8775 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant incorporates by reference into Part III (Items 10, 11, 12, 13 and 14) of this Annual Report on Form 10-K portions of the Registrant&#8217;s definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Beam Therapeutics Inc. and subsidiaries (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and other comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2025, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538868872832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 281,967<span></span>
</td>
<td class="nump">$ 435,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent', window );">Marketable securities</a></td>
<td class="nump">568,773<span></span>
</td>
<td class="nump">753,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">27,409<span></span>
</td>
<td class="nump">21,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">878,149<span></span>
</td>
<td class="nump">1,211,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">111,412<span></span>
</td>
<td class="nump">124,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">104,865<span></span>
</td>
<td class="nump">112,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,103,824<span></span>
</td>
<td class="nump">1,459,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">47,468<span></span>
</td>
<td class="nump">111,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative liabilities</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">108,858<span></span>
</td>
<td class="nump">68,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">13,469<span></span>
</td>
<td class="nump">12,778<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">182,066<span></span>
</td>
<td class="nump">205,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">147,956<span></span>
</td>
<td class="nump">159,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liabilities</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">33,218<span></span>
</td>
<td class="nump">109,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long-term portion of derivative liabilities</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">370,279<span></span>
</td>
<td class="nump">478,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 9, License agreements and Note 10, Collaboration and license agreements)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 250,000,000 shares authorized, 83,633,069 and 81,632,496 issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,298,661<span></span>
</td>
<td class="nump">2,169,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,566,631)<span></span>
</td>
<td class="num">(1,189,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">733,545<span></span>
</td>
<td class="nump">981,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,103,824<span></span>
</td>
<td class="nump">$ 1,459,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities measured at fair value, classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873879552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">83,633,069<span></span>
</td>
<td class="nump">81,632,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">83,633,069<span></span>
</td>
<td class="nump">81,632,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873894976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 63,518<span></span>
</td>
<td class="nump">$ 377,709<span></span>
</td>
<td class="nump">$ 60,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 367,561<span></span>
</td>
<td class="nump">$ 437,381<span></span>
</td>
<td class="nump">$ 311,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">111,525<span></span>
</td>
<td class="nump">116,813<span></span>
</td>
<td class="nump">87,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">479,086<span></span>
</td>
<td class="nump">554,194<span></span>
</td>
<td class="nump">399,399<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(415,568)<span></span>
</td>
<td class="num">(176,485)<span></span>
</td>
<td class="num">(338,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OtherOperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">23,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of non-controlling equity investments</a></td>
<td class="num">(14,093)<span></span>
</td>
<td class="num">(18,592)<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ChangeInFairValueOfContingentConsiderationLiabilities', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">9,740<span></span>
</td>
<td class="nump">18,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_InterestAndOtherIncomeExpenseNet', window );">Interest and other income (expense), net</a></td>
<td class="nump">49,094<span></span>
</td>
<td class="nump">46,676<span></span>
</td>
<td class="nump">15,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">38,865<span></span>
</td>
<td class="nump">45,324<span></span>
</td>
<td class="nump">78,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes</a></td>
<td class="num">(376,703)<span></span>
</td>
<td class="num">(131,161)<span></span>
</td>
<td class="num">(260,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(1,366)<span></span>
</td>
<td class="num">(3,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(376,742)<span></span>
</td>
<td class="num">(132,527)<span></span>
</td>
<td class="num">(289,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (376,667)<span></span>
</td>
<td class="num">$ (129,493)<span></span>
</td>
<td class="num">$ (291,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (4.58)<span></span>
</td>
<td class="num">$ (1.72)<span></span>
</td>
<td class="num">$ (4.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (4.58)<span></span>
</td>
<td class="num">$ (1.72)<span></span>
</td>
<td class="num">$ (4.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted - average common shares outstanding, basic</a></td>
<td class="nump">82,313,008<span></span>
</td>
<td class="nump">77,151,771<span></span>
</td>
<td class="nump">70,015,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted - average common shares outstanding, diluted</a></td>
<td class="nump">82,313,008<span></span>
</td>
<td class="nump">77,151,771<span></span>
</td>
<td class="nump">70,015,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ChangeInFairValueOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ChangeInFairValueOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income and income (expense) related to nonoperating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OtherOperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OtherOperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873272816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>ATM Offering</div></th>
<th class="th">
<div>ATM Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>ATM Offering </div>
<div>Additional Paid-in Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 826,738<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 1,594,378<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
<td class="num">$ (768,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,389,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,076<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 108,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">84,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(289,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">733,474<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">1,792,554<span></span>
</td>
<td class="num">(2,430)<span></span>
</td>
<td class="num">(1,057,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,277,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">3,032<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,938<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 235,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,952,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1', window );">Issuance of unregistered common shares in connection with license agreement</a></td>
<td class="nump">33,600<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">33,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement', window );">Issuance of unregistered common shares in connection with license agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">98,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">6,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(132,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">981,329<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">2,169,798<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="num">(1,189,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,632,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">120,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">563,349<span></span>
</td>
<td class="nump">563,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(376,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(376,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 733,545<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 2,298,661<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="num">$ (1,566,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,633,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of unregistered common shares issued during the period in connection with a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of unregistered common shares issued during the period in connection with a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870012112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in a stock issuance transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538874617440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (376,742)<span></span>
</td>
<td class="num">$ (132,527)<span></span>
</td>
<td class="num">$ (289,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,925<span></span>
</td>
<td class="nump">20,012<span></span>
</td>
<td class="nump">14,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of investment discount (premiums)</a></td>
<td class="num">(22,765)<span></span>
</td>
<td class="num">(29,743)<span></span>
</td>
<td class="num">(9,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">120,662<span></span>
</td>
<td class="nump">98,647<span></span>
</td>
<td class="nump">84,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">9,668<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
<td class="nump">8,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(2,272)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(23,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liabilities</a></td>
<td class="num">(1,592)<span></span>
</td>
<td class="num">(9,740)<span></span>
</td>
<td class="num">(18,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of non-controlling equity investments</a></td>
<td class="nump">14,093<span></span>
</td>
<td class="nump">18,592<span></span>
</td>
<td class="num">(20,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,349)<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="num">(7,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="num">(7,578)<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(57,685)<span></span>
</td>
<td class="nump">67,663<span></span>
</td>
<td class="num">(16,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(12,951)<span></span>
</td>
<td class="num">(10,168)<span></span>
</td>
<td class="nump">12,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_IncreaseDecreaseInCollaborationReceivable', window );">Collaboration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(36,518)<span></span>
</td>
<td class="num">(159,559)<span></span>
</td>
<td class="num">(35,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">473<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="num">(2,569)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(347,246)<span></span>
</td>
<td class="num">(149,195)<span></span>
</td>
<td class="nump">22,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(8,946)<span></span>
</td>
<td class="num">(33,732)<span></span>
</td>
<td class="num">(48,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(486,439)<span></span>
</td>
<td class="num">(984,338)<span></span>
</td>
<td class="num">(1,616,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">680,392<span></span>
</td>
<td class="nump">1,089,910<span></span>
</td>
<td class="nump">1,204,614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">185,007<span></span>
</td>
<td class="nump">71,840<span></span>
</td>
<td class="num">(461,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,568<span></span>
</td>
<td class="nump">108,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of stock under ESPP</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Equipment financings, net</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(2,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">7,736<span></span>
</td>
<td class="nump">276,448<span></span>
</td>
<td class="nump">111,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(154,503)<span></span>
</td>
<td class="nump">199,093<span></span>
</td>
<td class="num">(327,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;beginning of period</a></td>
<td class="nump">444,614<span></span>
</td>
<td class="nump">245,521<span></span>
</td>
<td class="nump">572,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;end of period</a></td>
<td class="nump">290,111<span></span>
</td>
<td class="nump">444,614<span></span>
</td>
<td class="nump">245,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions in accounts payable and accrued expenses</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseLiabilitiesIncreaseDecrease', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="num">$ (1,626)<span></span>
</td>
<td class="nump">$ 3,852<span></span>
</td>
<td class="nump">41,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Non-cash contribution of intellectual property to Orbital Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_IncreaseDecreaseInCollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_IncreaseDecreaseInCollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseLiabilitiesIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in operating lease liabilities related to right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseLiabilitiesIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956232048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (376,742)<span></span>
</td>
<td class="num">$ (132,527)<span></span>
</td>
<td class="num">$ (289,088)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538874138240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table describes for the quarterly period ended December 31, 2024 each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a &#8220;Rule 10b5-1 trading arrangement,&#8221; or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
    <table style="margin-left:1.204%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:10.358%;box-sizing:content-box;"></td>
      <td style="width:11.998%;box-sizing:content-box;"></td>
      <td style="width:12.737%;box-sizing:content-box;"></td>
      <td style="width:25.295%;box-sizing:content-box;"></td>
      <td style="width:12.737%;box-sizing:content-box;"></td>
      <td style="width:26.875%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(Title)</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Taken </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">(Date of Action)</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading Arrangement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number of Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amy Simon</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adoption</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(</span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">November 7, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_662b40b3-87ec-4a96-b46f-86be6e3fcabb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Until </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 31, 2025</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution.</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204,956</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares</span></p></td>
     </tr>
    </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=beam_AmySimonMember', window );">Amy Simon</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Amy Simon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 7, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">419 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">204,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=beam_AmySimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=beam_AmySimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869932752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have certain processes for assessing, identifying and managing cybersecurity risks, which are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">built</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program/information technology function and are designed to help protect our information assets and operations from internal and external cyber threats</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and enhance our practices. We engage certain external parties, including consultants, independent privacy assessors, computer security firms and risk management, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. We consider the internal risk </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">oversight</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> programs of third-party service providers before </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaging</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> them in order to help protect our company from any related vulnerabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on an assessment using these processes, we do not believe that there are currently any risks from known cybersecurity threats that are reasonably likely to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affect</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> our company or our business strategy, results of operations or financial condition. For additional information, please see the risk factor titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under Item 1A., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk factors&#8212;General risk factors, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in this Annual Report on Form 10-K.</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President of Information Security</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, IS&#8217;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have certain processes for assessing, identifying and managing cybersecurity risks, which are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">built</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program/information technology function and are designed to help protect our information assets and operations from internal and external cyber threats</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President of Information Security</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, IS&#8217;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vice President of Information Security</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, IS&#8217;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870764208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam Therapeutics Inc., which we refer to herein as the &#8220;Company&#8221; or &#8220;Beam,&#8221; is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam&#8217;s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and capital resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, research and development costs including preclinical studies and IND-enabling studies, organizing and staffing the Company, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company has established internal manufacturing capabilities. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into an at the market sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold under the Sales Agreement during the year ended December 31, 2024. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,769,001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the Sales Agreement at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">864.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting commissions and offering expenses payable by it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has incurred substantial losses and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion as of December 31, 2024. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its cash, cash equivalents, and marketable securities as of December 31, 2024 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">850.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870964576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ummary of significant accounting policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or the FASB.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and other derivative liabilities, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and restricted cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents consist of checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company&#8217;s leases of its facilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#8217;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.863%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,967</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,895</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232,767</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,144</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,719</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,754</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,111</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,614</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,521</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies marketable debt securities as available-for-sale and includes such securities within marketable securities in the Company&#8217;s consolidated balance sheets. Available-for-sale securities consist of commercial paper, high-grade corporate notes, U.S. Treasury securities and government securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expensed over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in interest and other income (expense), net.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies investments in equity securities that have a readily determinable fair value as marketable securities in the Company's consolidated balance sheets. The Company&#8217;s marketable securities are stated at fair value. Typically, the fair value of these securities is based on a quoted price for an identical equity security. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records changes in the fair value of its equity securities in other income (expense), net in its consolidated statements of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees and indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity issuance costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes incremental legal, professional, accounting and other third-party fees that were directly associated with its stock offerings as other non-current assets until the offerings are consummated. Upon consummation, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in-capital generated as a result of the offerings.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value of financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the valuation methods utilized during the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates transfers between levels at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:49%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Asset category</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment and office furniture</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in interest and other income (expense). Expenditures for repairs and maintenance are charged to expense as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (or asset groups) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Freestanding financial instruments and derivatives</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to a license agreement between the President and Fellows of Harvard College, or Harvard, and the Company, or the Harvard License Agreement, and a license agreement with The Broad Institute, Inc., or Broad Institute, and the Company, or the Broad License Agreement, (see Note 9), the Company is required to make success payments to Harvard and Broad Institute based the achievement of specified multiples of the initial weighted average value of the Company&#8217;s redeemable convertible Series A-1 Preferred Stock and the Company&#8217;s redeemable convertible Series A-2 Preferred Stock, or together the Series A Preferred, at specified valuation dates, payable in cash or Company common stock. Subsequent to the IPO, the amount of the success payments is based on the market value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Beam&#8217;s common stock. Pursuant to a settlement agreement between a research institution and the Company, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty through 2038. Any amounts due must be settled in cash.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success and settlement payments are accounted for as derivatives under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liabilities are recorded at fair value at each balance sheet date with all changes in value recognized in other income (expense), in the consolidated statement of operations and other comprehensive loss. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations. To determine the estimated fair value of the success payments, the Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Series A Preferred, prior to the IPO, and the value of the Company&#8217;s common stock, subsequent to the IPO.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases and rent expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases using a right-of-use, or ROU, model, which recognizes that, at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty that the Company will renew.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay fees for operating expenses in addition to monthly base rent for certain operating leases (non-lease components). The Company has elected the practical expedient which allows non-lease components to be combined with lease components for all current asset classes. Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leasehold improvements are not unique and are retained by the lessor at the end of the lease. However, in the case of a space designed to be suitable for the Company&#8217;s specific real estate needs and if the Company is responsible for cost overruns, the Company is the accounting owner of the leasehold improvements and costs associated are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s real estate operating leases provide for scheduled annual rent increases throughout the lease terms. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full terms of the lease. Tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the ROU asset related to that lease at lease commencement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may be required to make milestone payments to the former stockholders and optionholders of Guide Therapeutics, Inc., or Guide, in the form of its common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the consolidated statements of operations and other comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value is determined based on probability adjusted discounted cash flow model that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success or in the probabili</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ties as to the periods in which milestones would be achieved would result in a significantly higher or lower fair value measurement. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. The Company only applies the five-step model to contracts when it determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP: If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Notes 9 and 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore consideration included in the transaction price is constrained. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract balances</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as an account or other receivable. A contract asset is an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities, or deferred revenue, primarily relate to contracts where the Company has received payment, but it has not yet satisfied or fully satisfied the related performance obligations. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its obligations under these arrangements. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the total deferred revenue for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 were as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338,153</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue from license agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts recognized in revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,518</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,559</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting, and other contracted services. The cost of obtaining licenses for certain technology or IP is recorded to research and development expense when incurred if the licensed technology or IP has not yet reached technological feasibility and has no alternative future use. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation program allows for grants of stock options, restricted stock awards and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and other comprehensive loss based on their fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards and restricted stock units.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation awards are subject to either service- or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The Company bases its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus, weighted with its own volatility for the period in which its stock has been publicly traded. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees and non-employees, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred. Due to the uncertainty about the recovery of the expenditure, amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and other comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable interest entities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii) the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net loss per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the dilutive net loss per share calculation, stock options and stock units for which the performance and market vesting conditions have been deemed probable, potential dilutive securities, unvested restricted stock, and common stock options are considered to be common stock equivalents, while stock options and stock units with performance- or market-based vesting conditions that were not deemed probable of meeting the applicable vesting conditions are not considered to be common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders was the same as basic net loss per share attributable to common stockholders, since dilutive common shares were not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity method of accounting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship.
</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the equity method of accounting, the Company&#8217;s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company&#8217;s proportionate share of the investee&#8217;s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset&#8217;s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&amp;D, that has no alternative future use. To the extent a basis difference relates to IPR&amp;D and the investee is not a business as defined in ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or ASC 805, the Company immediately expenses such basis difference related to IPR&amp;D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee&#8217;s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company&#8217;s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company&#8217;s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding or commits to guarantee investee liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee&#8217;s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company accounted for its investment in Orbital under the equity method of accounting. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> carrying value related to this investment as of December 31, 2024 or 2023. Refer to Note 10 for further details.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment and geographic information</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment operating exclusively in the United States</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, Segment Reporting (Topic 280). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s consolidated financial statements. The Company</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the ASU as of and for the period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the required disclosures are included in Note 17, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently announced accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The amendments in this update expand income tax disclosure requirements, including additional information pertaining to the rate reconciliation, income taxes paid, and other disclosures. This update is effective for annual periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872663152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">roperty and equipment, net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,163</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,519</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,142</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes depreciation expense incurred (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,097</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871287568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. f</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">air value of financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of cash equivalents, marketable securities, equity securities of Verve Therapeutics, Inc., or Verve, and Prime Medicine, Inc., or Prime, contingent consideration liabilities related to the Agreement and Plan of Merger, dated February 23, 2021, between the Company and Guide, or the Guide Merger Agreement, success payment derivative liabilities pursuant to the Harvard and Broad License Agreements and settlement payment derivative liabilities associated with a settlement agreement with a research institution.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">850,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">850,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560,992</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative settlement liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">457,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732,106</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Commercial paper and corporate notes are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through using models or other valuation methodologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Marketable securities, excluding corporate equity securities, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, the Company held an investment in Verve consisting of shares of Verve&#8217;s common stock. As of December 31, 2024, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">546,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Verve's common stock, the value of which is included in marketable securities in the consolidated balance sheet. The Company recorded the investment at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, associated with changes in the fair value of Verve's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, Prime completed an initial public offering of its common stock. As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,608,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Prime's common stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, associated with changes in the fair value of Prime's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,093</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,592</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payment Liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; As discussed further in Note 9, the Company is required to make payments to Harvard and Broad Institute based upon the achievement of specified multiples of the initial weighted average value of the Company&#8217;s Series A Preferred or, subsequent to the IPO, the market value of the Company's common stock, at specified valuation dates. The Company&#8217;s liability for the share-based success payments under the Harvard and Broad License Agreements are carried at fair value. To determine the estimated fair value of the success payment liability, the Company uses a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.17%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.822000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.49</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.49</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.36</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The computation of expected volatility was estimated using the Company's historical volatility along with available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the estimated number, timing, and probability of valuation measurement dates in the calculation of the success payment liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,300</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,300</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Guide Merger Agreement, Guide&#8217;s former stockholders and optionholders are eligible to receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in technology milestone payments and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product milestone payments, payable in the Company&#8217;s common stock valued using the volume-weighted average price of the Company&#8217;s stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is achieved. As these milestones are payable with a variable number of shares of the Company&#8217;s common stock, the milestone payments result in liability classification under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs based on timing of achievement that were unobservable in the market. These contingent consideration liabilities are classified within Level 3 of the fair value hierarchy.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of Achievement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of Achievement</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2034</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative settlement liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; On July 19, 2024, the Company entered into a settlement agreement with a research institution pursuant to which, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty through 2038. Any amounts due must be settled in cash. The maximum amount of development and regulatory milestone payments under the settlement agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the maximum amount of sales milestone payments is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, per program. The Company paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment during the 12 months ended December 31, 2024. There was no material charge related to this settlement in the year ended December 31, 2024 as the settlement value was substantially accrued in prior periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contingent settlement payments are accounted for as a derivative under Accounting Standards Codification 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the potential payments meet the definition of a derivative and are not subject to any scope exceptions. The derivative liability is recorded at fair value on the Company's balance sheet with changes in value recognized in interest and other income (expense) in the consolidated statement of operations and other comprehensive loss. To determine the estimated fair value of the liability, the Company applied a probability-based model, which utilized inputs based on the potential achievement and related timing of certain development, regulatory and sales-based milestones that were unobservable in the market. This derivative liability is classified within Level 3 of the fair value hierarchy above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following assumptions were incorporated in the calculation of the fair value of the derivative settlement liability:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.315%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.424000000000003%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2038</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the derivative liability based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.485%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial recognition of derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870592624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,491</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,552</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,094</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,054</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,462</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151,805</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,181</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,077</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753,981</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. At December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the balance in accumulated other comprehensive (loss) income was comprised solely of activity related to marketable securities. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses recognized on the sale or maturity of marketable securities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive (loss) income for the same periods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">less than one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873204544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contingent obligation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,280</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,697</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,381</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870774464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s operating leases are as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A February 2018 lease for office and laboratory space as amended, which commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease is subject to fixed-rate rent escalations and provided for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements allowances and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a term </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension option.</span></span></span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An October 2018 lease for laboratory space as amended, which commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amended lease is subject to fixed-rate rent escalations and provides an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> periods through December 31, 2029.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An April 2019 lease for office and laboratory space that was built over the course of 2020 and 2021. Pursuant to the terms of the original lease agreement, the first phase of the lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (rent payments for the first phase began in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the second phase of the lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (rent payments for the second phase began in</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> February 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The lease is subject to fixed-rate rent escalations and provides for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements and the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company determined that it is the accounting owner of all tenant improvements. In August 2021, the Company executed an amendment to this lease to occupy additional space. The term of this lease runs concurrent with the term of the April 2019 lease through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An August 2020 lease for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square foot manufacturing facility in Research Triangle Park, North Carolina. Construction of the manufacturing facility began in 2020 and the Company began making rent payments in the fourth quarter of 2022. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease will terminate </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the rent commencement date, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease is subject to fixed-rate rent escalations and provides for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in tenant improvements and the option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each, which were not reasonably certain of exercise as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes operating lease costs as well as sublease income (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,777</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sublease income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,840</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,888</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease term and discount rate for operating leases:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"></td>
        <td style="width:1.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.31%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.31%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease costs included in the measurement of lease liabilities (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.022%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.364%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.945%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.945%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,603</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,052</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the future maturity of the Company&#8217;s operating leases for each of the next five years and total thereafter were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,731</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873102608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Strategic Restructuring</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Strategic restructuring</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company announced updated portfolio priorities and strategic plans to restructure the Company to streamline its business operations. In connection with this portfolio prioritization and strategic restructuring, the Company reduced its employee headcount by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> positions, or about </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of its workforce. During the year ended December 31, 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f812e6fe-6a44-4c16-bfa9-574585f77a74;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restructuring charges</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the consolidated statement of operations related to these actions. These charges included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of one-time termination benefits and contractual termination benefits for severance, healthcare, and related benefits and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of non-cash stock-based compensation expense. The workforce reductions were substantially completed as of December 31, 2023, however the severance and other costs are paid over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the restructuring liability activity for the Company's workforce reductions for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 as recorded in accrued expenses and other current liabilities in the consolidated balance sheet are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.52%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses incurred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870588336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_LicenseAgreementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has various license agreements related to technology used in its research and development activities. The license agreements may include up-front payments, option fees, ongoing maintenance fees, sublicense fees, royalty-based payments, milestone payments, success-based payments, and other payments. Option fees, when applicable, are recognized when exercised, maintenance fees, sublicense fees, and other payments are recorded as incurred based on the estimated amounts due or that will ultimately be paid. Contingent payments that are not required to be accounted for as a derivative are recognized as incurred. As the success-based payments due under the Company&#8217;s license arrangements are derivatives, the change in the fair value of the success-based payments are recognized in a separate line item in the statement of operations and comprehensive loss, as discussed further below. The total contingent obligations and non-royalty sublicense fees included in research and development expenses in the statement of operations and comprehensive loss were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value attributable to sublicenses and the related sublicense fees due under the Company&#8217;s license agreements may require estimates and other judgments related to contractual requirements, which creates uncertainty over the ultimate amount that would be paid under these arrangements. Contractual amounts due are accrued and if a contingency exists related to the interpretation of the amounts due under the license agreement, the Company recognizes a liability for the amount that is probable and estimable. When no amount within the range of potential payments is a better estimate than any other amount, however, the minimum amount in the range is accrued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Harvard license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2017, the Company entered into the Harvard License Agreement for certain base editing technology pursuant to which the Company received an exclusive, worldwide, sublicensable, royalty-bearing license under specified patent rights to develop and commercialize licensed products and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product, unless terminated earlier by either party under certain provisions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partial consideration for the rights granted under the Harvard License Agreement include success payments, which are further described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Harvard License Agreement, Harvard is entitled to receive success payments, in cash or shares of Company stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Company&#8217;s Series A Preferred at specified valuation dates. The success payments range from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and have valuation multiples that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the initial weighted average value of the Series A Preferred. Subsequent to the Company&#8217;s February 2020 IPO, the amount of success payments is based on the market value of the Company's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company elected to make the payment in shares of the Company&#8217;s common stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,825</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle this liability on June 10, 2021. The Company may owe Harvard success payments of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harvard success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.812%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Harvard success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. Upon determination that a Harvard Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company will monitor the Harvard Product Milestone payments for this arrangement on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent products are commercialized under the Harvard License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Broad license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, the Broad License Agreement was entered into with Broad Institute for certain RNA base editing technology including an RNA editor platform. Under the Broad License Agreement, Broad Institute granted exclusive and non-exclusive worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed product and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. Under the agreement the Company shall use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of regulatory exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product unless terminated earlier by either party under certain provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional consideration under the Broad License Agreement included Success Payments, which are further described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Under the Broad License Agreement, Broad Institute is entitled to receive success payments, in cash or shares of Company common stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Series A Preferred at specified valuation dates. The success payments range from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and have valuation multiples that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the initial weighted average value of the Series A Preferred. Subsequent to the February 2020 IPO, the amount of success payments is based on the market value of the Company&#8217;s common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company elected to make the payment in shares of the Company&#8217;s common stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,825</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle this liability on June 10, 2021. The Company may owe Broad Institute success payments of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> success payments were due to Broad Institute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.94%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs will be expensed as incurred. Upon determination that a Broad Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company monitors the Broad Product Milestone payments for this arrangement on an ongoing basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent products are commercialized under the Broad License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Editas license agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. More specifically, Editas granted to the Company a worldwide, exclusive, sublicensable, license (subject to certain exceptions and conditions) under certain intellectual property controlled by Editas for the use of base editing therapies for the treatment of any field of human diseases and conditions, subject to certain exceptions, or the Beam Field, and the licenses granted or to be granted under the Editas License Agreement, or the Editas Development and Commercialization License. Additionally, Editas granted to the Company a royalty-free, non-exclusive license under certain intellectual property owned or controlled by Editas to perform research activities in the Beam Field, or the Editas Research License. Editas provided the Company with an exclusive option to obtain an Editas Development and Commercialization License to three additional groups of intellectual property owned or controlled by Editas, on a group by group basis, during the specified option period, subject to certain exceptions. Pursuant to the Editas License Agreement, the Company will use commercially reasonable efforts to develop a product that includes the rights licensed to the Company within a specified period of time and to commercialize any such products that have received regulatory approval in certain specified countries.</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional consideration will be due to Editas if the</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company elects to exercise its option to obtain an Editas Development and Commercialization License to any of the three categories of intellectual property underlying the Editas Research License, for a fee ranging from a mid-teen million dollar amount to a low to mid-eight digit dollar amount per group, depending on the timing of the option exercise. Additionally, the Company is required to reimburse Editas for certain payments Editas may be obligated to make under existing Editas license agreements related to the intellectual property being licensed to the Company, including (i) development, regulatory and commercial milestone payments and certain sublicense income payments due as a result of the Editas License Agreement and (ii) a percentage of the annual maintenance fees and patent fees due to certain of the Editas&#8217; licensors. In addition, to the extent any products are commercialized under an Editas Development and Commercialization License, the Company would be required to make royalty payments equivalent to the royalties that would be due from Editas to any applicable licensors of Editas related to the sales of such licensed products, plus an additional tiered low- to mid-single digit royalty, depending on whether such licensed product is covered by an Editas-owned patent.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license rights and option rights granted by Editas to the Company are subject to the terms and conditions of the underlying license agreements that Editas is a party to and under which Editas licensed rights or option rights to the Company and the termination of such in-licenses, as applicable. Unless earlier terminated by either party pursuant to the terms of the agreement, the Editas License Agreement will continue in full force and effect and will expire on a licensed product-by licensed product and country-by-country basis upon the later of (i) the last-to-expire royalty term under any applicable institutional license to Editas and (ii) the date at which such product is no longer covered by a valid claim of a licensed Editas-owned patent in such country. The Company has the right, at its sole discretion, at any time to terminate the Editas License Agreement in its entirety or on a group-by-group of intellectual property basis, upon ninety days written notice to Editas. Upon termination of the Editas License Agreement, all rights and licenses granted by Editas to the Company (including the rights to exercise options and obtain such licenses) will immediately terminate and patents within a group of patents will no longer be deemed licensed patents. Expiration or termination of the Editas License Agreement for any reason does not release either party of any obligation or liability which had accrued, or which is attributable to a period prior to such expiration or termination.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The option exercise fees under the agreement will be recorded as research and development expense, if and when the Company exercises such options. To date, no options have been exercised. The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. In addition, the Company is required to make certain development, regulatory and commercial milestone payments to Editas upon the achievement of specified milestones. To the extent applicable, sublicense income payments will be accrued for the amount the Company is obligated to pay under each applicable in-license as amounts are due to Editas. Lastly, to the extent products are commercialized under the Editas License agreement, the Company will accrue royalty expense for the amount it is obligated to pay, with adjustments as sales are made.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for licensing arrangements with third parties, which includes, but is not limited to, success payments and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870596832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Collaboration and license agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eli Lilly and Company</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company&#8217;s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company&#8217;s opt-in rights to co-develop and co-commercialize Verve&#8217;s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million nonrefundable upfront payment and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lilly does not opt-in to co-develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">co-commercialize </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a licensed product, Lilly is obligated to pay the Company a percentage of any royalties received from Verve for sales of such product, subject to certain caps on a licensed product-by-licensed product basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the effective date of the Lilly Agreement, Lilly has the right to request the Company to perform any critical research and development services, if Lilly reasonably determines that the Company is uniquely able to provide such services and other conditions are met, including that no other third parties can provide such services. The parties will negotiate an agreement governing the Company&#8217;s performance of such activity, if any, and the Company will be compensated for any services at approximately cost plus a margin. The Company has not been requested to perform any services and believes it is remote that Beam would be requested to provide any services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Lilly Agreement, the Company and Lilly entered into a Stock Purchase Agreement providing for the sale and issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004,811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to Lilly for an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received the consideration under the Stock Purchase Agreement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in October and the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in November 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lilly Agreement and Stock Purchase Agreement were negotiated at the same time as a package and have been accounted for as one combined contract. The Company accounts for the component of the arrangement to transfer common stock to Lilly under ASC 505, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the revenue component under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company first applied the guidance in ASC 505 to measure the fair value of the common stock issued and allocated the remaining consideration to the ASC 606 component of the arrangement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall ASC 606 transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is comprised of the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the residual value of the proceeds received in excess of the fair value of the common stock sold to Lilly of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the common stock issued to Lilly was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as determined by management with the assistance of a third-party valuation specialist. There is no variable consideration included in the transaction price at inception. The Company will re-evaluate the transaction price at each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the collaboration rights and licenses to intellectual property have the same pattern and timing of transfer and are transferred as of the effective date of the Lilly Agreement. Lilly&#8217;s right to request research and development services represents an optional purchase in the agreement that does not constitute a material right. All other items promised to Lilly are immaterial in the context of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue for the performance obligation at a point-in-time in October 2023 as all requirements related to the performance obligation have been completed. Any consideration received related to Lilly&#8217;s optional purchase of the Company&#8217;s research and development services will be accounted for as a separate contract if and when the option is exercised in accordance with ASC 606. During the year ended December 31, 2024 the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue related to the achievement of certain clinical, regulatory and alliance events. During the year ended 2023 the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue related to the Lilly Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred revenue related to the Lilly Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orbital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, the Company entered into a License and Research Collaboration Agreement, or the Orbital Agreement, with Orbital Therapeutics, Inc., or Orbital. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ribonucleic acid, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In exchange for the licenses and services provided by the Company under the Orbital Agreement, the Company received a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by Orbital, and research and development support services as outlined in a research plan. Orbital also granted the Company an exploitation license to certain RNA technology and nonviral delivery technology controlled by Orbital. The exploitation license is exclusive in the fields of gene editing and conditioning and nonexclusive in all other fields other than vaccines and certain protein therapeutics. The Company also received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Orbital&#8217;s common stock at closing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research plan has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and can be extended for unspecified periods upon mutual agreement between the Company and Orbital. The exploitation licenses are exclusive for an initial research term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which may be extended for up to two successive one-year periods</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by mutual agreement between the Company and Orbital. Either party may terminate the licenses granted to it under the Orbital Agreement for convenience on a product-by-product basis at any time by providing 90 days&#8217; prior written notice.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the consideration received under the Orbital Agreement under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.5</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which represents the fair value of the Company&#8217;s equity interest in Orbital&#8217;s common stock at inception. There is no variable consideration included in the transaction price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the research and exploitation licenses are not distinct from the other promises in the Orbital Agreement, and as such the Company determined that the licenses combined with the research and development services, know-how transfers, committee participation and materials transfer represent a performance obligation. The Company recognizes revenue associated with the Orbital performance obligation over time as it is satisfied during the term of the agreement, which is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue during the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue during the year ended December 31, 2022. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current deferred revenue related to the Orbital Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beam does not have a controlling financial interest in Orbital as Beam does not have the power to direct the activities of Orbital. The Company has significant influence over Orbital through its noncontrolling representation on Orbital&#8217;s board of directors and the Company&#8217;s equity interest in Orbital. Accordingly, the Company does not consolidate the financial statements of Orbital and accounts for its investment using the equity method of accounting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of the closing date in September 2022, the fair value of the Company&#8217;s investment in Orbital was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the Orbital common stock was determined by management with the assistance of a third-party valuation specialist. In determining the fair value of the Company&#8217;s investment, the valuation specialist used an option pricing model backsolve approach based on Orbital's most recent funding of preferred stock. The valuation requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are level 3 inputs, include the anticipated holding period to an exit and liquidity event, the volatility of market participants (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) and the discount for lack of marketability (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%). At the date of the investment, a basis difference was identified as the carrying value of the Company&#8217;s investment in Orbital exceeded the Company&#8217;s proportionate share of the underlying net assets in Orbital. The Company concluded that the basis difference was primarily attributable to Orbital&#8217;s IPR&amp;D assets. As Orbital did not meet the definition of a business due to substantially all of the estimated fair value of the gross assets being concentrated in the group of similar IPR&amp;D assets, the basis difference attributable to the IPR&amp;D with no alternative future use was immediately expensed as of the date of the investment. The Company&#8217;s proportionate share of the basis difference exceeded its carrying value of the equity method investment in Orbital and the equity investment balance was reduced to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no commitment for the Company to provide financial support to Orbital. The Company recognized a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in association with the basis difference charge in the Company&#8217;s consolidated statements of operations for the year ended December 31, 2022 and did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize a gain or loss from the equity method investment for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company&#8217;s base editing technology to develop </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%/</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of the Pfizer Agreement, the Company was entitled to receive a nonrefundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in consideration for the rights granted to Pfizer under the collaboration. Should Pfizer exercise its Opt-In Right for any of the three programs, the Company would be eligible to receive development, regulatory, and commercial milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per program, for potential total consideration of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, plus royalty payments on global net sales for each licensed program, if any. If Pfizer does not exercise its Opt-In Right for a program, the Company&#8217;s rights in such program revert to the Company and the Company will be required to pay Pfizer earn-out payments equal to a low single digit percentage of net sales earned on such program for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period, if any. As the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront fee was not received by the Company as of December 31, 2021, the Company recorded a collaboration receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with a corresponding deferred revenue liability. The Company received the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment in January 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the collaboration term, Pfizer has a one-time option to substitute a disease that is the subject of a specific program with one pre-defined substitute disease. The collaboration has an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and may be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extended for an additional year on a program-by-program basis</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pfizer may terminate the Pfizer Agreement for convenience on any or all of the programs by providing 90 days&#8217; prior written notice.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Pfizer Agreement under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is comprised entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that the licenses to its base editing technology, including the exclusive development and commercialization rights, are not capable of being distinct from the other performance obligations, and as such the Company has determined that the licenses combined with the other research and development services represent performance obligations and no up-front revenue was recognized for the licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling price of each performance obligation was determined based on the Company&#8217;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Pfizer Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue for each performance obligation as it is satisfied during the term of the agreement using an input method. The Company allocated the transaction price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to each of the three performance obligations, which includes each of the three base editing programs combined with the research and development services, licenses, and exclusive development and commercialization rights. Revenue is recognized using an input method based on the actual costs incurred as a percentage of total estimated costs tow</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#8217;s performance in transferring control of the goods and services promised to Pfizer and represents the Company&#8217;s best estimate of the period of the obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Pfizer Agreement, during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current and long-term deferred revenue, respectively, related to the Pfizer Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sana Biotechnology</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, the Company entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, under which the Company granted Sana a license for non-exclusive rights to its CRISPR Cas12b nuclease system for the development and commercialization of certain engineered cellular therapy programs. In addition to the license, the Company performed an initial technology transfer following the effective date of the Sana Agreement providing Sana with certain know-how, as required under the Sana Agreement. This technology transfer occurred in 2021. Following the license transfer and completion of the initial technology transfer, Sana is responsible, at its sole expense, for the development and commercialization of therapeutic products which must contain either specified CAR antigen targets or pluripotent stem cell, or PSC, product types.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the license, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sana in October 2021. In addition, the Company may be eligible to receive development, regulatory, and commercial milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sana on any product candidate or product. The Company will also be entitled to receive royalties equal to a low single digit percentage of net sales on any product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days&#8217; prior written notice or upon 180 days&#8217; prior written notice after first commercial sale.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Sana Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is composed entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has identified a single performance obligation, which includes (i) the non-exclusive license granted to Sana under the Company&#8217;s patent rights and know-how and (ii) the initial technology transfer following the effective date, which occurred in 2021. The Company further concluded that the Option Rights, Replacement Right, and Genetic Target Nomination Rights did not grant Sana a material right. As the Company only identified one performance obligation, no allocation of the transaction price is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Sana Agreement during the year ended December 31, 2024 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue under the Sana Agreement during the year ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue under the Sana Agreement for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Apellis Pharmaceuticals</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company&#8217;s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the collaboration, the Company is eligible to receive a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront and near-term milestones from Apellis, which is comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received upon signing and an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment on June 30, 2022, the one-year anniversary of the effective date of the Apellis Agreement, or the First Anniversary Payment. Following any exercise of an Opt-In Right for any of the six programs, the Company will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and may be extended up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on a per year and program-by-program basis. During the collaboration term, Apellis may, subject to certain limitations, substitute a specific complement gene and/or organ for any of the initial base editing programs. Apellis may terminate the Apellis Agreement for convenience on any or all of the programs by providing prior written notice. The Company received the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment from Apellis in July 2021 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million First Anniversary Payment in June 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the Apellis Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The overall transaction price as of the inception of the contract was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is composed of the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the First Anniversary Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation were material promises that were both capable of being distinct and were distinct within the context of the Apellis Agreement and represented separate performance obligations. Therefore, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any upfront revenue related to the license. The Company further concluded that the Opt-In Rights and option to extend the collaboration term did not grant Apellis a material right. The Company determined that the term of the contract is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as this is the period during which both parties have enforceable rights.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling price of each performance obligation was determined based on the Company&#8217;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Apellis Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue for each performance obligation as it is satisfied over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term using an input method. The Company allocated the transaction price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to each of the six performance obligations, which includes each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is being recognized using an input method based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#8217;s performance in transferring control of the goods and services promised to Apellis and represents the Company&#8217;s best estimate of the period of the obligation. For the years ended December 31, 2024, 2023, and 2022, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue, respectively, related to the Apellis Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, there is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of current and long-term deferred revenue, respectively, related to the Apellis Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Verve</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Verve Agreement, Verve issued the Company </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock as partial consideration for the licenses granted, having a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fair value of the Verve common stock was determined by management with the assistance of a third-party valuation specialist. In addition, to the extent certain clinical, regulatory, and commercial milestones were met with respect to licensed products, Verve was required to pay to the Company certain amounts, as defined in the agreement. Lastly, to the extent there were sales of a licensed product, Verve was obligated to pay the Company royalties, as defined in the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also purchased shares of Verve's Series A preferred stock during the year ended December 31, 2020. During June 2021, Verve completed an initial public offering of its common stock. In connection with Verve&#8217;s initial public offering, Verve effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2592</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split and also converted all shares of its preferred stock into shares of common stock. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">546,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Verve's common stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management determined that the performance obligations associated with the Verve Agreement were the combined licenses and improvements related to the licensed technology. All other items promised to Verve were immaterial in the context of the agreement. The fair value of the shares issued by Verve to the Company were considered a fixed upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the form of non-cash consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company, Verve, and Lilly entered into a Side Letter Agreement whereby the Company agreed to delegate to Lilly certain rights and obligations existing under the Verve Agreement, including the Company&#8217;s rights and obligations to co-develop and co-commercialize opt-in products, the financial rights to milestone and royalty payments, and the right to participate on certain joint decision-making committees. The Company determined that the transfer and delegation of rights represents a modification of the Verve Agreement to be accounted for as if it were part of the existing contract in accordance with ASC 606. Prior to the modification, the Company determined that its performance obligations associated with the Verve Agreement at contract inception and subsequent modifications were not distinct and represented a single performance obligation, and that the obligation would be completed over the performance period of the agreement. Accordingly, the upfront payment was being recognized as revenue using a time-based proportional performance model over the contract term (April 2019 through 2038) of the collaboration, as license revenue. The milestone payments and royalties were considered variable consideration and were constrained up until the modification date as no milestones or royalties were achieved. Subsequent to the modification, management concluded that the Company does not have material ongoing obligations to Verve in the arrangement and that the remaining revenue under the agreement should be recognized at a point-in-time upon modification. Therefore, the Company recognized the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized revenue in October 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any revenue under the Verve Agreement during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining deferred revenue related to the Verve Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. For each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872663920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into the Sales Agreement with Jefferies pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,769,001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the Sales Agreement at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">864.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting commissions and offering expenses payable by it.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Company&#8217;s common stock are entitled to one vote for each share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The holders of the Company&#8217;s common stock shall be entitled to receive ratably dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869779744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option and Grant Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock option and grant plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2017 stock option and grant plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2017, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan, or the 2017 Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options, restricted stock or other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2017 Plan is administered by the board of directors. Stock options awarded under the 2017 Plan expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the grant date. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2017 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 incentive plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2019 Equity Incentive Plan, or the 2019 Plan, and, following the IPO, all equity-based awards are granted under the 2019 Plan. The 2019 Plan provides for the grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of the Company&#8217;s common stock that may be issued under the 2019 Plan was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,700,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, or the Share Pool, plus the number of shares of the Company&#8217;s common stock underlying awards under the 2017 Plan, not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,639,818</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, that become available again for grant under the 2017 Plan in accordance with its terms. The Share Pool will automatically increase on January 1st of each year from 2021 to 2029 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,773,507</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares reserved and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,591,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations and other comprehensive loss is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,139</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,317</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.18%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of option activity under the Company&#8217;s equity award plans:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.664%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.844000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.664%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value (1)<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,276,033</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,678,145</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">563,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">785,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,605,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,896,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing price of the common stock for the options that were in the money as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted stock options to certain employees to purchase shares of common stock that contain certain performance-based vesting criteria, primarily related to the achievement of certain development milestones related to editing applications, and the closing price of the Company&#8217;s common stock following an IPO. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. The expense related to performance-based options was immaterial for the years ended December 31, 2024, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.86</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The aggregate intrinsic value of stock options exercised during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The weighted-average exercise price of stock options exercised for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued shares of restricted common stock during the years ended December 31, 2024, 2023 and 2022, which consisted only of restricted stock units. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted common stock issued generally vests over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f65e9bb1-b2e1-469e-be73-4e76142cee9f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, if the holders of restricted stock units cease to have a business relationship with the Company, any unvested restricted stock units will be cancelled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company&#8217;s restricted stock activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,152</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,233,688</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.05</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,302,037</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,948</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.58</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576,855</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of restricted shares that vested during the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2020, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company&#8217;s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and at a purchase price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
The Company used the Black-Scholes option valuation model to estimate the fair value of the purchase right under the ESPP on the date of grant. The expected volatility is based on the historical volatility of the Company's common stock for a period of years corresponding with the expected life of the option. The risk-free interest rate is based on the U.S. Treasury yield curve at the time of grant for securities with a maturity period similar to the expected life of the option. The expected life is based on the term of the purchase period for the grants made under the ESPP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the straight-line attribution approach to record the expense over the offering period. Stock-based compensation expense related to the ESPP for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,187</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,073</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the ESPP during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 respectively. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,928,706</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the ESPP.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956184992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Net loss per share attributable to common stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As noted above, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.058%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.058%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576,855</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,692,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,605,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,276,033</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,548,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,255,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,276,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,287,117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.75%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,313,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,151,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,015,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.72</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873328944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.683%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.045%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.045%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.225%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible/ nontaxable permanent items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,954</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,554</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,759</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,792</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,218</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized Research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,954</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,721</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,738</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">366,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROU asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,259</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_892f3c97-c2f0-430b-9466-4813ae1bf322;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, the Company recorded a current tax provision of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of income tax expense, respectively, which reflects that Company generated taxable income that was not fully offset by the use of net operating loss carryforwards and tax credits. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets and has determined that it is not more likely than not that the Company will recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2024 and 2023. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2024 due to the increase in deferred tax assets, primarily due to increased capitalization of research and development expenditures in 2024. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, limit a corporation&#8217;s ability to utilize tax attributes to the extent the corporation experiences an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change in ownership, measured by value, among 5% or greater shareholders over a rolling three-year testing period. To the extent a corporation experiences an ownership change, utilization of pre-ownership change tax attributes (e.g., net operating losses and general business tax credits) to offset post-ownership change taxable income or taxes, is subject to an annual limitation, generally calculated as the pre-ownership change equity value of the corporation, subject to certain prescribed adjustments, multiplied by the long-term tax exempt rate published monthly by the Internal Revenue Service. The Company completed a Section 382 study as of December 31, 2024, and determined that no historical ownership changes occurred since December 2021. The Company may experience ownership changes in the future as a result of shifts in stock ownership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023. Additionally, as of December 31, 2024, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2043</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, and 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company filed income tax returns in the United States and the Commonwealth of Massachusetts in all tax years since inception. Tax years beginning in 2021 remain open to examination in these jurisdictions, as carryforward attributes generated in past years may be adjusted in a future period. The IRS has not made any assessments as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956331488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Related party transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orbital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 10, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company&#8217;s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Founders</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, to its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> founder shareholders for scientific consulting and other expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870603552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Employee benefits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2018, the Company established a defined-contribution plan under Section </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Beginning January 1, 2020, the Company made matching contributions equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the employee&#8217;s contributions, subject to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. The Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873648640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Data</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Segment Data</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3745d23f-5fb4-4f44-b19b-06bb7321b4f1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM is John Evans, its Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c09ed080-95c6-42cb-9d05-3689f0ee40cc;"><span style="-sec-ix-hidden:F_db2bac11-48f9-4a6a-b941-8a8d70caf457;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment and the measure of segment profit or loss is consolidated net income (loss). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal reporting of significant segment expenses is based on the functional classification. External expenses include costs from external manufacturing, clinical and research organizations, supply chain and logistics costs, consultants, and other vendors. Employee related expenses include, employee salaries and benefits costs, employee meal, travel and entertainment spend, along with payroll related taxes and other similar items. These functional costs exclude stock-based compensation, facility and information technology costs, depreciation and amortization, and other segment items.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below provides information about the Company&#8217;s segment, including significant expenses, other segment items, certain other segment expenses, and a reconciliation to net income (loss):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,189</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,380</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,878</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,016</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility and information technology related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,094</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,366</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,895</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,821</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Denotes significant segment expense</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Segment Items includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss from equity method investment</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone expense</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Sublicenses fees</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869406064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or the FASB.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and other derivative liabilities, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and restricted cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents consist of checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company&#8217;s leases of its facilities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#8217;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.863%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,967</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,895</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232,767</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,144</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,719</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,754</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,111</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,614</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,521</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Debt Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies marketable debt securities as available-for-sale and includes such securities within marketable securities in the Company&#8217;s consolidated balance sheets. Available-for-sale securities consist of commercial paper, high-grade corporate notes, U.S. Treasury securities and government securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expensed over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in interest and other income (expense), net.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Corporate Equity Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies investments in equity securities that have a readily determinable fair value as marketable securities in the Company's consolidated balance sheets. The Company&#8217;s marketable securities are stated at fair value. Typically, the fair value of these securities is based on a quoted price for an identical equity security. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records changes in the fair value of its equity securities in other income (expense), net in its consolidated statements of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity method of accounting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship.
</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the equity method of accounting, the Company&#8217;s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company&#8217;s proportionate share of the investee&#8217;s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset&#8217;s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&amp;D, that has no alternative future use. To the extent a basis difference relates to IPR&amp;D and the investee is not a business as defined in ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or ASC 805, the Company immediately expenses such basis difference related to IPR&amp;D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee&#8217;s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company&#8217;s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company&#8217;s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding or commits to guarantee investee liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee&#8217;s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company accounted for its investment in Orbital under the equity method of accounting. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> carrying value related to this investment as of December 31, 2024 or 2023. Refer to Note 10 for further details.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and Indemnifications</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees and indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had not experienced any losses related to these indemnification obligations, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquityIssuanceCostsPoliciesPolicyTextBlock', window );">Equity Issuance Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity issuance costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes incremental legal, professional, accounting and other third-party fees that were directly associated with its stock offerings as other non-current assets until the offerings are consummated. Upon consummation, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in-capital generated as a result of the offerings.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value of financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the valuation methods utilized during the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates transfers between levels at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:49%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Asset category</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment and office furniture</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in interest and other income (expense). Expenditures for repairs and maintenance are charged to expense as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (or asset groups) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Freestanding Financial Instruments and Derivatives</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Freestanding financial instruments and derivatives</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to a license agreement between the President and Fellows of Harvard College, or Harvard, and the Company, or the Harvard License Agreement, and a license agreement with The Broad Institute, Inc., or Broad Institute, and the Company, or the Broad License Agreement, (see Note 9), the Company is required to make success payments to Harvard and Broad Institute based the achievement of specified multiples of the initial weighted average value of the Company&#8217;s redeemable convertible Series A-1 Preferred Stock and the Company&#8217;s redeemable convertible Series A-2 Preferred Stock, or together the Series A Preferred, at specified valuation dates, payable in cash or Company common stock. Subsequent to the IPO, the amount of the success payments is based on the market value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Beam&#8217;s common stock. Pursuant to a settlement agreement between a research institution and the Company, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty through 2038. Any amounts due must be settled in cash.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success and settlement payments are accounted for as derivatives under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liabilities are recorded at fair value at each balance sheet date with all changes in value recognized in other income (expense), in the consolidated statement of operations and other comprehensive loss. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations. To determine the estimated fair value of the success payments, the Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Series A Preferred, prior to the IPO, and the value of the Company&#8217;s common stock, subsequent to the IPO.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases and Rent Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases and rent expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases using a right-of-use, or ROU, model, which recognizes that, at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty that the Company will renew.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay fees for operating expenses in addition to monthly base rent for certain operating leases (non-lease components). The Company has elected the practical expedient which allows non-lease components to be combined with lease components for all current asset classes. Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leasehold improvements are not unique and are retained by the lessor at the end of the lease. However, in the case of a space designed to be suitable for the Company&#8217;s specific real estate needs and if the Company is responsible for cost overruns, the Company is the accounting owner of the leasehold improvements and costs associated are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s real estate operating leases provide for scheduled annual rent increases throughout the lease terms. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full terms of the lease. Tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the ROU asset related to that lease at lease commencement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AssetAcquisitionsPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent consideration liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may be required to make milestone payments to the former stockholders and optionholders of Guide Therapeutics, Inc., or Guide, in the form of its common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the consolidated statements of operations and other comprehensive loss.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value is determined based on probability adjusted discounted cash flow model that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success or in the probabili</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ties as to the periods in which milestones would be achieved would result in a significantly higher or lower fair value measurement. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. The Company only applies the five-step model to contracts when it determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP: If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Notes 9 and 10.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore consideration included in the transaction price is constrained. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract balances</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as an account or other receivable. A contract asset is an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities, or deferred revenue, primarily relate to contracts where the Company has received payment, but it has not yet satisfied or fully satisfied the related performance obligations. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its obligations under these arrangements. Upfront payment contract liabilities resulting from the Company&#8217;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the total deferred revenue for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 were as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338,153</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue from license agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts recognized in revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,518</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,559</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting, and other contracted services. The cost of obtaining licenses for certain technology or IP is recorded to research and development expense when incurred if the licensed technology or IP has not yet reached technological feasibility and has no alternative future use. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation program allows for grants of stock options, restricted stock awards and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and other comprehensive loss based on their fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards and restricted stock units.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation awards are subject to either service- or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The Company bases its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus, weighted with its own volatility for the period in which its stock has been publicly traded. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees and non-employees, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred. Due to the uncertainty about the recovery of the expenditure, amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and other comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable interest entities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii) the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net loss per share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the dilutive net loss per share calculation, stock options and stock units for which the performance and market vesting conditions have been deemed probable, potential dilutive securities, unvested restricted stock, and common stock options are considered to be common stock equivalents, while stock options and stock units with performance- or market-based vesting conditions that were not deemed probable of meeting the applicable vesting conditions are not considered to be common stock equivalents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders was the same as basic net loss per share attributable to common stockholders, since dilutive common shares were not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment and geographic information</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment operating exclusively in the United States</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, Segment Reporting (Topic 280). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have a material impact on the Company&#8217;s consolidated financial statements. The Company</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the ASU as of and for the period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the required disclosures are included in Note 17, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently announced accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The amendments in this update expand income tax disclosure requirements, including additional information pertaining to the rate reconciliation, income taxes paid, and other disclosures. This update is effective for annual periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AssetAcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions, both as part of a business combination and not as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AssetAcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EquityIssuanceCostsPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EquityIssuanceCostsPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871285536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#8217;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.863%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.281%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,967</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,895</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232,767</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,144</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,719</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,754</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,111</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,614</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,521</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Life of Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:49%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Asset category</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment and office furniture</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term</span></span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Changes in Total Deferred Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the total deferred revenue for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 were as follows (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338,153</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue from license agreements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts recognized in revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,518</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,559</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,594</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873649664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,163</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,519</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,142</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SummaryOfDepreciationExpenseIncurredTableTextBlock', window );">Summary of Depreciation Expense Incurred</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes depreciation expense incurred (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,097</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SummaryOfDepreciationExpenseIncurredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation expense related to physical assets used in the normal conduct of business and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SummaryOfDepreciationExpenseIncurredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538866622384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,786</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">850,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">850,559</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,567</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560,992</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative settlement liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,689</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189,670</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">457,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732,106</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Harvard</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Success payment liability &#8211; Broad Institute</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration liability &#8211; Product</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,523</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">Summary Of Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,093</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,592</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember', window );">Success Payment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Variables Included in Calculation of Estimated Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.17%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.822000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.49</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.49</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.36</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of change in Fair Value of Liabilities based on Level 3 inputs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Harvard</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broad Institute</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,300</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,300</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Variables Included in Calculation of Estimated Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of Achievement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of Achievement</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2034</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of change in Fair Value of Liabilities based on Level 3 inputs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Technology Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">875</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Variables Included in Calculation of Estimated Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following assumptions were incorporated in the calculation of the fair value of the derivative settlement liability:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.315%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:19.424000000000003%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestones</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Projected Year of achievement of settlement payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2038</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of change in Fair Value of Liabilities based on Level 3 inputs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in fair value of the derivative liability based on level 3 inputs (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.485%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial recognition of derivative liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873066672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Securities Held</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,296</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,165</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,491</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,770</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,552</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,781</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,094</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,773</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s marketable securities held at December 31, 2023 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,054</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,289</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,462</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151,805</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,181</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate equity securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753,377</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,077</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753,981</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870975776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contingent obligation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,280</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,697</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,381</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871240144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Operating Lease Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes operating lease costs as well as sublease income (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,295</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,777</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sublease income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,840</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,888</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseTermAndDiscountRateTableTextBlock', window );">Summary of Lease Term and Discount Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease term and discount rate for operating leases:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"></td>
        <td style="width:1.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.31%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.31%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock', window );">Summary of Lease Costs Included in Measurement of Lease Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the lease costs included in the measurement of lease liabilities (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.022%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.364%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.945%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.945%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,603</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,052</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining ROU assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Maturity of Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the future maturity of the Company&#8217;s operating leases for each of the next five years and total thereafter were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,731</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the lease costs included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the lease term and discount rate for an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873043536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Liability Activity for Company's Workforce Reductions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the restructuring liability activity for the Company's workforce reductions for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 as recorded in accrued expenses and other current liabilities in the consolidated balance sheet are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.52%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses incurred</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued restructuring balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46539001957296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock', window );">Schedule of Success Payment Liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harvard success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,900</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,500</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,600</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock', window );">Schedule of Change in Fair Value of Success Payment Liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.812%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Harvard success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.94%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Broad Institute success payment liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in fair value of the success payment liability arising from a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the success payment liability arising from a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871288432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations and other comprehensive loss is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,139</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,317</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.18%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under Equity Award Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of option activity under the Company&#8217;s equity award plans:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.664%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.844000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.664%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value (1)<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,276,033</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,678,145</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">563,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">785,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,605,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,896,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing price of the common stock for the options that were in the money as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes the Company&#8217;s restricted stock activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,152</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,233,688</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.05</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,302,037</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,948</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.58</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576,855</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956191936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.058%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.058%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576,855</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,692,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,605,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,276,033</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,548,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,906</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,255,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,276,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,287,117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.75%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.603%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,313,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,151,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,015,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.72</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872668224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.683%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.045%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.045%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.225%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible/ nontaxable permanent items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the Company&#8217;s deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,954</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,554</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,759</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,792</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,218</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized Research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,954</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,721</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,179</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,738</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">366,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROU asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,259</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_892f3c97-c2f0-430b-9466-4813ae1bf322;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870968368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reportable Segment Net Revenues and Loss</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,189</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,380</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,878</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,016</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,885</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility and information technology related expenses*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,647</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,094</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,366</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,895</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,821</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Denotes significant segment expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Segment Items includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of non-controlling equity investments</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of contingent consideration liabilities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss from equity method investment</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone expense</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Sublicenses fees</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870200912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,566,631,000<span></span>
</td>
<td class="nump">$ 1,566,631,000<span></span>
</td>
<td class="nump">$ 1,189,889,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,700,000<span></span>
</td>
<td class="nump">$ 850,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember', window );">Jeffries LLC Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockSoldDuringPeriodSharesNewIssues', window );">Stock sold during period shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,769,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember', window );">Jeffries LLC Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.75<span></span>
</td>
<td class="nump">$ 62.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember', window );">Jeffries LLC Sales Agreement | Maximum | ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CommissionRate', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockIssuanceProgramAuthorizedAmount', window );">Aggregate gross proceeds of shares authorized under ATM sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember', window );">Lilly Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementAmountReceived', window );">Stock purchase agreement amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementUpfrontPaymentReceived', window );">Collaboration agreement upfront payment received</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementShares', window );">Sale and issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementAggregatePurchasePrice', window );">Aggregated purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember', window );">Lilly Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialAdditionalProceedsFromTransferAgreement', window );">Additional proceeds from potential future development-stage payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment received as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commission rate the Company agreed to pay for all shares sold under a Sales Agreement, as a percentage of gross sales proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of the business and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialAdditionalProceedsFromTransferAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialAdditionalProceedsFromTransferAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockIssuanceProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares authorized to be issued under a stock issuance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockIssuanceProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate purchase price of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received as part of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares available for sale and issuance as part of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockSoldDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares sold, but not necessarily issued, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockSoldDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869434528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 281,967<span></span>
</td>
<td class="nump">$ 435,895<span></span>
</td>
<td class="nump">$ 232,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="nump">12,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 290,111<span></span>
</td>
<td class="nump">$ 444,614<span></span>
</td>
<td class="nump">$ 245,521<span></span>
</td>
<td class="nump">$ 572,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538867814624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Claims outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PercentageOfRoyaltyPayments', window );">Percentage of royalty payment</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PercentageOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payment due, contingent upon certain milestones, as part of a derivative settlement liability, as a percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PercentageOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871235648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory Equipment and Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property and equipment, estimated useful life</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873736848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 178,594<span></span>
</td>
<td class="nump">$ 338,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts recognized in revenue</a></td>
<td class="num">(36,518)<span></span>
</td>
<td class="num">(159,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 142,076<span></span>
</td>
<td class="nump">$ 178,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871432496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 183,519<span></span>
</td>
<td class="nump">$ 175,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(72,107)<span></span>
</td>
<td class="num">(50,182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">111,412<span></span>
</td>
<td class="nump">124,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">101,195<span></span>
</td>
<td class="nump">100,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">71,788<span></span>
</td>
<td class="nump">61,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">4,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">3,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,530<span></span>
</td>
<td class="nump">$ 5,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956253248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 21,925<span></span>
</td>
<td class="nump">$ 20,012<span></span>
</td>
<td class="nump">$ 14,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873751312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 181,296<span></span>
</td>
<td class="nump">$ 285,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">850,559<span></span>
</td>
<td class="nump">1,189,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative settlement liability</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">14,935<span></span>
</td>
<td class="nump">13,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">281,786<span></span>
</td>
<td class="nump">435,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">181,296<span></span>
</td>
<td class="nump">285,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Corporate Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">100,165<span></span>
</td>
<td class="nump">23,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">164,770<span></span>
</td>
<td class="nump">152,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | U.S Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">114,761<span></span>
</td>
<td class="nump">271,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Corporate Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities included in marketable securities</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">21,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Consideration of Technology Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Carrying Amount | Contingent Consideration of Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">850,559<span></span>
</td>
<td class="nump">1,189,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative settlement liability</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">14,935<span></span>
</td>
<td class="nump">13,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">281,786<span></span>
</td>
<td class="nump">435,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">181,296<span></span>
</td>
<td class="nump">285,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Corporate Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">100,165<span></span>
</td>
<td class="nump">23,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">164,770<span></span>
</td>
<td class="nump">152,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | U.S Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">114,761<span></span>
</td>
<td class="nump">271,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Corporate Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities included in marketable securities</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">21,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Consideration of Technology Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Contingent Consideration of Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">289,567<span></span>
</td>
<td class="nump">457,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">281,786<span></span>
</td>
<td class="nump">435,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 1 | Corporate Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities included in marketable securities</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">21,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">560,992<span></span>
</td>
<td class="nump">732,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">181,296<span></span>
</td>
<td class="nump">285,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 2 | Corporate Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">100,165<span></span>
</td>
<td class="nump">23,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 2 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">164,770<span></span>
</td>
<td class="nump">152,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 2 | U.S Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">114,761<span></span>
</td>
<td class="nump">271,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative settlement liability</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">14,935<span></span>
</td>
<td class="nump">13,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 3 | Consideration of Technology Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Level 3 | Contingent Consideration of Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Harvard | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Harvard | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Harvard | Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Broad Institute | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Broad Institute | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Broad Institute | Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=beam_CorporateEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=beam_CorporateEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538866322720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities recognition amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,093)<span></span>
</td>
<td class="num">$ (18,592)<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SettlementAgreementUpfrontPayment', window );">Settlement agreement upfront payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PercentageOfRoyaltyPayments', window );">Percentage of royalty payment</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SettlementAgreementUpfrontPaymentPaid', window );">Settlement agreement upfront payment paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember', window );">Verve Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities recognition amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,500)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember', window );">Verve Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquitySharesHeld', window );">Equity shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_PrimeMedicineIncMember', window );">Prime Medicine Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities recognition amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600)<span></span>
</td>
<td class="num">(15,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_PrimeMedicineIncMember', window );">Prime Medicine Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquitySharesHeld', window );">Equity shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608,337<span></span>
</td>
<td class="nump">1,608,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember', window );">Technology Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePayableInFormOfCommonStock', window );">Potential milestone payable in form of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember', window );">Product Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePayableInFormOfCommonStock', window );">Potential milestone payable in form of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=beam_DevelopmentAndRegulatoryMilestonesMember', window );">Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePaymentsDueUnderSettlementAgreement', window );">Potential milestone payments due under settlement agreement</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=beam_SalesMilestoneMember', window );">Sales Milestone | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePaymentsDueUnderSettlementAgreement', window );">Potential milestone payments due under settlement agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EquitySharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of equity securities held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EquitySharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PercentageOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty payment due, contingent upon certain milestones, as part of a derivative settlement liability, as a percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PercentageOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialMilestonePayableInFormOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestones payable in the form of common stock as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialMilestonePayableInFormOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialMilestonePaymentsDueUnderSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments that may become due under a settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialMilestonePaymentsDueUnderSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SettlementAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment the Company has agreed to pay upon signing of a settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SettlementAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SettlementAgreementUpfrontPaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid during the period for an upfront payment as part of a settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SettlementAgreementUpfrontPaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_PrimeMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_PrimeMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=beam_FormerStockholdersAndOptionholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=beam_FormerStockholdersAndOptionholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538867153088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Other income (expense)</a></td>
<td class="num">$ (14,093)<span></span>
</td>
<td class="num">$ (18,592)<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869719376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details) - Success Payment Liabilities<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputFairValueOfCommonStockMember', window );">Fair Value of Common Stock | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Success payment liability measurement input</a></td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">27.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputFairValueOfCommonStockMember', window );">Fair Value of Common Stock | Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Success payment liability measurement input</a></td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">27.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Success payment liability measurement input</a></td>
<td class="nump">0.78<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility | Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Success payment liability measurement input</a></td>
<td class="nump">0.81<span></span>
</td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (years) | Minimum | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Success payment liability, term</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (years) | Minimum | Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Success payment liability, term</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (years) | Maximum | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Success payment liability, term</a></td>
<td class="text">4 years 5 months 26 days<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (years) | Maximum | Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Success payment liability, term</a></td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputFairValueOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputFairValueOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873638768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details) - Success Payment Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember', window );">Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember', window );">Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_SuccessPaymentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873678704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details) - Contingent Consideration Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="nump">$ 12,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(1,592)<span></span>
</td>
<td class="num">(9,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Technology Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">6,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(4,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Product Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(717)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871387008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Technology Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear', window );">Milestone liabilities projected year of achievement</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Product Milestones | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear', window );">Milestone liabilities projected year of achievement</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Product Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear', window );">Milestone liabilities projected year of achievement</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Discount Rate | Technology Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Discount Rate | Product Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Probability of Achievement | Technology Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Probability of Achievement | Technology Milestones | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Probability of Achievement | Technology Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Probability of Achievement | Product Milestones | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember', window );">Probability of Achievement | Product Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurement input</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which achievement is expected to be attained for contingent consideration liability milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputProbabilityOfAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputProbabilityOfAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538866596096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details) - Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SettlementPaymentsExpectedAchievementYear', window );">Settlement payments expected achievement year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SettlementPaymentsExpectedAchievementYear', window );">Settlement payments expected achievement year</a></td>
<td class="text">2038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability measurement input</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability measurement input</a></td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember', window );">Probability of Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability measurement input</a></td>
<td class="nump">0.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SettlementPaymentsExpectedAchievementYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which achievement is expected to be attained for settlement payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SettlementPaymentsExpectedAchievementYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputProbabilityOfAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=beam_MeasurementInputProbabilityOfAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873052976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details) - Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Initial recognition of derivative liability</a></td>
<td class="nump">$ 5,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 5,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=beam_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871559184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis', window );">Marketable securities held, Amortized Cost</a></td>
<td class="nump">$ 568,094<span></span>
</td>
<td class="nump">$ 753,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes', window );">Marketable securities held, Gross Unrealized Gains</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes', window );">Marketable securities held, Gross Unrealized Losses</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi', window );">Marketable securities held, Fair Value</a></td>
<td class="nump">568,773<span></span>
</td>
<td class="nump">753,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">181,095<span></span>
</td>
<td class="nump">285,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">181,296<span></span>
</td>
<td class="nump">285,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">100,175<span></span>
</td>
<td class="nump">23,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">100,165<span></span>
</td>
<td class="nump">23,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">164,491<span></span>
</td>
<td class="nump">151,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">164,770<span></span>
</td>
<td class="nump">152,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=beam_CorporateEquitySecuritiesMember', window );">Corporate Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities, Amortized Cost</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">21,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, Fair Value</a></td>
<td class="nump">7,781<span></span>
</td>
<td class="nump">21,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">114,552<span></span>
</td>
<td class="nump">271,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 114,761<span></span>
</td>
<td class="nump">$ 271,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities measured at fair value (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain on investment in debt and equity securities measured at fair value (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss on investment in debt and equity securities measured at fair value (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt and equity securities measured at fair value (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=beam_CorporateEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=beam_CorporateEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46539024460848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gains or losses recognized on sale or maturity of marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DebtSecuritiesAvailableForSaleMaturityPeriod', window );">Contractual maturity dates of investments</a></td>
<td class="text">less than one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DebtSecuritiesAvailableForSaleMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the period of time in which investments will reach maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DebtSecuritiesAvailableForSaleMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873583376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AccruedContingentObligationLicenseAgreementCurrent', window );">Accrued contingent obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and related benefits</a></td>
<td class="nump">21,572<span></span>
</td>
<td class="nump">21,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AccruedResearchCosts', window );">Research costs</a></td>
<td class="nump">11,179<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AccruedProcessDevelopmentAndManufacturingCosts', window );">Process development and manufacturing costs</a></td>
<td class="nump">3,525<span></span>
</td>
<td class="nump">4,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">3,381<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">7,811<span></span>
</td>
<td class="nump">28,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 47,468<span></span>
</td>
<td class="nump">$ 111,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AccruedContingentObligationLicenseAgreementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a licensing agreement, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AccruedContingentObligationLicenseAgreementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AccruedProcessDevelopmentAndManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for process development and manufacturing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AccruedProcessDevelopmentAndManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AccruedResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AccruedResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872194032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>Option</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,865<span></span>
</td>
<td class="nump">$ 112,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseCommencementMonthAndYear', window );">Operating lease, commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseTerminationMonthAndYear', window );">Operating lease, termination month and year</a></td>
<td class="text">2034-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend the lease for two terms of five years each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a term extension option.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NumberOfOperatingLeaseRenewalOptions', window );">Operating lease, number of renewal options | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_LeaseholdImprovementsLandlordAllowance', window );">Leasehold improvements landlord allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | First Phase of Lease in October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseCommencementMonthAndYear', window );">Operating lease, commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseRentPaymentsBeginMonthAndYear', window );">Rent payments beginning month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | Second Phase of Lease in January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseCommencementMonthAndYear', window );">Operating lease, commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseRentPaymentsBeginMonthAndYear', window );">Rent payments beginning month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratorySpaceMember', window );">Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseCommencementMonthAndYear', window );">Operating lease, commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseTerminationMonthAndYear', window );">Operating lease, termination month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The amended lease is subject to fixed-rate rent escalations and provides an option to extend the lease for two additional two-year periods through December 31, 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NumberOfOperatingLeaseRenewalOptions', window );">Operating lease, number of renewal options | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseCommencementMonthAndYear', window );">Operating lease, commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NumberOfOperatingLeaseRenewalOptions', window );">Operating lease, number of renewal options | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_LeaseholdImprovementsLandlordAllowance', window );">Leasehold improvements landlord allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AreaOfFacilityBeingBuilt', window );">Manufacturing facility, number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease will terminate 15 years from the rent commencement date, December 2022. The lease is subject to fixed-rate rent escalations and provides for $20.0 million in tenant improvements and the option to extend the lease for two terms of five years each, which were not reasonably certain of exercise as of December 31, 2024. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AreaOfFacilityBeingBuilt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The area of a facility being built for future lease, in square feet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AreaOfFacilityBeingBuilt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_LeaseholdImprovementsLandlordAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_LeaseholdImprovementsLandlordAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_NumberOfOperatingLeaseRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease renewal options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_NumberOfOperatingLeaseRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease, commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseRentPaymentsBeginMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The month and year in which the rent payments will begin under an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseRentPaymentsBeginMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseTerminationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease, termination month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseTerminationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=beam_LaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538866752880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 21,649<span></span>
</td>
<td class="nump">$ 22,063<span></span>
</td>
<td class="nump">$ 19,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">6,295<span></span>
</td>
<td class="nump">5,777<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 36,944<span></span>
</td>
<td class="nump">$ 36,840<span></span>
</td>
<td class="nump">$ 22,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538867969968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46539024255120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 24,981<span></span>
</td>
<td class="nump">$ 22,603<span></span>
</td>
<td class="nump">$ 19,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OperatingLeaseLiabilitiesIncreaseDecrease', window );">Operating lease liabilities arising from obtaining ROU assets</a></td>
<td class="num">$ (1,626)<span></span>
</td>
<td class="nump">$ 3,852<span></span>
</td>
<td class="nump">$ 41,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OperatingLeaseLiabilitiesIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in operating lease liabilities related to right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OperatingLeaseLiabilitiesIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956272576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Maturity of Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 24,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">22,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">23,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">23,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">22,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">112,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted lease payments</a></td>
<td class="nump">227,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(66,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 161,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538874085216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Option Pricing Model | Volatility of Market Participants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternate investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Option Pricing Model | Discount for Lack of Marketability | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternate investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538871150560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic restructuring - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>Positions</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in employee headcount, positions | Positions</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in employee headcount, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Operating Expenses<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=beam_WorkforceReductionMember', window );">Workforce Reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=beam_WorkforceReductionMember', window );">Workforce Reduction | One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=beam_WorkforceReductionMember', window );">Workforce Reduction | Non-cash Stock Based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=beam_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=beam_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=beam_NonCashStockBasedCompensationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=beam_NonCashStockBasedCompensationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873064592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveLineItems', window );"><strong>Restructuring Reserve Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued restructuring, Beginning balance</a></td>
<td class="nump">$ 4,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">$ (4,495)<span></span>
</td>
<td class="num">(1,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued restructuring, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870606992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Guide Acquisition - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember', window );">Guide Therapeutics, Inc. | Merger Agreement | Technology Milestones | Maximum | Former Stockholders and Optionholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePayableInFormOfCommonStock', window );">Potential milestone payable in form of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember', window );">Guide Therapeutics, Inc. | Merger Agreement | Product Milestones | Maximum | Former Stockholders and Optionholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialMilestonePayableInFormOfCommonStock', window );">Potential milestone payable in form of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialMilestonePayableInFormOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestones payable in the form of common stock as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialMilestonePayableInFormOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=beam_FormerStockholdersAndOptionholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=beam_FormerStockholdersAndOptionholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873629120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ContingentObligationAndNonRoyaltySublicenseFees', window );">Contingent obligations and non-royalty sublicense fees</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 43.5<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ContingentObligationAndNonRoyaltySublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent obligations and non-royalty sublicense fees included in research and development expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ContingentObligationAndNonRoyaltySublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869704688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Harvard License Agreement - Additional Information (Details) - Harvard<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentAmountDue', window );">Success payment amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability', window );">Issuance of common stock for success payment liability, Shares | shares</a></td>
<td class="nump">174,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPayments', window );">Success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Minimum | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentsValuationMultiples', window );">Success Payments, valuation multiples</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AdditionalSuccessPaymentAmountDue', window );">Additional success payment amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPayments', window );">Success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Maximum | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentsValuationMultiples', window );">Success Payments, valuation multiples</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Success Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Other Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Product Development and Regulatory Approval | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AggregateMilestoneAmount', window );">Aggregate milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AdditionalSuccessPaymentAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amount of success payments that may become due as part of a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AdditionalSuccessPaymentAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AggregateMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount the Company is obligated to pay upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AggregateMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued to satisfy success payment obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPaymentAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of success payment due as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPaymentAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of success payments payable upon achievement of specified stock value targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPaymentsValuationMultiples">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation multiple applied to the initial weighted average of the specified class of stock, used to determine success payment targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPaymentsValuationMultiples</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementNatureAndPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature and purpose of collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementNatureAndPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_SuccessPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_SuccessPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_OtherPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_OtherPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_ProductDevelopmentAndRegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_ProductDevelopmentAndRegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46539001957296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - Harvard License Agreement - Success Payment Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873533424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">$ (2,272)<span></span>
</td>
<td class="num">$ (7,500)<span></span>
</td>
<td class="num">$ (23,900)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember', window );">Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="num">$ (3,800)<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869400352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Broad License Agreement - Additional Information (Details) - Broad Institute<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentAmountDue', window );">Success payment amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability', window );">Issuance of common stock for success payment liability, Shares | shares</a></td>
<td class="nump">174,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Success Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company&#8217;s IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Other Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#8217;s licensed products at such time.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPayments', window );">Success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Minimum | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentsValuationMultiples', window );">Success Payments, valuation multiples</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPayments', window );">Success payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AdditionalSuccessPaymentAmountDue', window );">Additional success payment amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Maximum | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_SuccessPaymentsValuationMultiples', window );">Success Payments, valuation multiples</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Maximum | Product Development and Regulatory Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AggregateMilestoneAmount', window );">Aggregate milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AdditionalSuccessPaymentAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amount of success payments that may become due as part of a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AdditionalSuccessPaymentAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AggregateMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount the Company is obligated to pay upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AggregateMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued to satisfy success payment obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPaymentAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of success payment due as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPaymentAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of success payments payable upon achievement of specified stock value targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_SuccessPaymentsValuationMultiples">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation multiple applied to the initial weighted average of the specified class of stock, used to determine success payment targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_SuccessPaymentsValuationMultiples</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementNatureAndPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature and purpose of collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementNatureAndPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_SuccessPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_SuccessPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_OtherPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_OtherPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_ProductDevelopmentAndRegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_ProductDevelopmentAndRegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956242160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements - Broad License Agreement - Success Payment Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538962994832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">$ (2,272)<span></span>
</td>
<td class="num">$ (7,500)<span></span>
</td>
<td class="num">$ (23,900)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember', window );">Broad Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,700)<span></span>
</td>
<td class="num">$ (11,900)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538956260448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Editas License Agreement - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_EditasLicenseAgreementMember', window );">Editas License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. More specifically, Editas granted to the Company a worldwide, exclusive, sublicensable, license (subject to certain exceptions and conditions) under certain intellectual property controlled by Editas for the use of base editing therapies for the treatment of any field of human diseases and conditions, subject to certain exceptions, or the Beam Field, and the licenses granted or to be granted under the Editas License Agreement, or the Editas Development and Commercialization License. Additionally, Editas granted to the Company a royalty-free, non-exclusive license under certain intellectual property owned or controlled by Editas to perform research activities in the Beam Field, or the Editas Research License. Editas provided the Company with an exclusive option to obtain an Editas Development and Commercialization License to three additional groups of intellectual property owned or controlled by Editas, on a group by group basis, during the specified option period, subject to certain exceptions. Pursuant to the Editas License Agreement, the Company will use commercially reasonable efforts to develop a product that includes the rights licensed to the Company within a specified period of time and to commercialize any such products that have received regulatory approval in certain specified countries.Additional consideration will be due to Editas if the Company elects to exercise its option to obtain an Editas Development and Commercialization License to any of the three categories of intellectual property underlying the Editas Research License, for a fee ranging from a mid-teen million dollar amount to a low to mid-eight digit dollar amount per group, depending on the timing of the option exercise. Additionally, the Company is required to reimburse Editas for certain payments Editas may be obligated to make under existing Editas license agreements related to the intellectual property being licensed to the Company, including (i) development, regulatory and commercial milestone payments and certain sublicense income payments due as a result of the Editas License Agreement and (ii) a percentage of the annual maintenance fees and patent fees due to certain of the Editas&#8217; licensors. In addition, to the extent any products are commercialized under an Editas Development and Commercialization License, the Company would be required to make royalty payments equivalent to the royalties that would be due from Editas to any applicable licensors of Editas related to the sales of such licensed products, plus an additional tiered low- to mid-single digit royalty, depending on whether such licensed product is covered by an Editas-owned patent.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementNatureAndPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature and purpose of collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementNatureAndPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_EditasLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_EditasLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538860124672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,858,000<span></span>
</td>
<td class="nump">$ 68,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,218,000<span></span>
</td>
<td class="nump">109,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,076,000<span></span>
</td>
<td class="nump">178,594,000<span></span>
</td>
<td class="nump">$ 338,153,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,561,000<span></span>
</td>
<td class="nump">437,381,000<span></span>
</td>
<td class="nump">311,594,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain (loss) from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,518,000<span></span>
</td>
<td class="nump">377,709,000<span></span>
</td>
<td class="nump">60,920,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember', window );">Verve Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquitySharesHeld', window );">Equity shares held | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember', window );">Lilly Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementShares', window );">Sale and issuance of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementAggregatePurchasePrice', window );">Aggregated purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockPurchaseAgreementAmountReceived', window );">Stock purchase agreement amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company&#8217;s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company&#8217;s opt-in rights to co-develop and co-commercialize Verve&#8217;s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementUpfrontPaymentReceived', window );">Collaboration agreement upfront payment received</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">216,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementAggregateTransactionPrice', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementTermOfContract', window );">Collaboration agreement term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember', window );">Lilly Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialAdditionalProceedsFromTransferAgreement', window );">Additional proceeds from potential future development-stage payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember', window );">Lilly Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue', window );">Fair value of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationLicenseAgreementFairValueOfSharesIssued', window );">Collaboration license agreement fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company&#8217;s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementInitialTerm', window );">Collaboration arrangement, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementExtensionTermDescription', window );">Collaboration arrangement extension term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">extended for an additional year on a program-by-program basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_PotentialConsideration', window );">Potential total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NonrefundableUpfrontPaymentReceivable', window );">Nonrefundable upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementUpfrontPaymentReceived', window );">Collaboration agreement upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">134,300,000<span></span>
</td>
<td class="nump">48,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementAggregateTransactionPrice', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EarnoutPaymentPeriod', window );">Earn-out payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_PfizerMember', window );">Pfizer | Assigned to Company | Upon Participation Election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage', window );">Net profits as well as development and commercialization costs percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_PfizerMember', window );">Pfizer | Assigned to Pfizer | Upon Participation Election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage', window );">Net profits as well as development and commercialization costs percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_PfizerMember', window );">Pfizer | Maximum | Per Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable', window );">Development regulatory and commercial milestones receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember', window );">Sana Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_LicenseAgreementUpfrontPaymentReceived', window );">License agreement upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementAggregateTransactionPrice', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_AdditionalFeePerAdditionalOptionRight', window );">Additional fee per additional option right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_OptionRightsAggregatePotentialAdditionalConsideration', window );">Option rights aggregate potential additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember', window );">Sana Biotechnology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable', window );">Development regulatory and commercial milestones receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember', window );">Sana Biotechnology | License Agreement Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $15.0 million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $30.0 million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days&#8217; prior written notice or upon 180 days&#8217; prior written notice after first commercial sale.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember', window );">Apellis Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company&#8217;s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementInitialTerm', window );">Collaboration arrangement, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_UpfrontRevenueRecognized', window );">Upfront revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementAggregateTransactionPrice', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_UpfrontFeeReceivableUponSigningContract', window );">Upfront fee receivable upon signing contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementFirstAnniversaryAmountReceivable', window );">Collaboration agreement first anniversary amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_UpfrontPaymentReceivedUnderTermOfAgreement', window );">Upfront payment received under term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementFirstAnniversaryPaymentReceived', window );">Collaboration agreement first anniversary payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember', window );">Apellis Pharmaceuticals, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementExtensionTerm', window );">Collaboration arrangement extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_VerveMember', window );">Verve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Remaining unrecognized revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_UpfrontPaymentFairValueSharesReceived', window );">Upfront payment fair value shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-9.2592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquitySharesValueHeld', window );">Equity shares value held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_VerveMember', window );">Verve | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_VerveMember', window );">Verve | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationLicenseAgreementFairValueOfSharesReceived', window );">Collaboration license agreement fair value of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationLicenseAgreementSharesReceived', window );">Number of common stock received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationCommonSharesReceived', window );">Common stock shares received at closing | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition', window );">Collaboration agreement performance obligation revenue period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized', window );">Collaboration agreement performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationAgreementAggregateTransactionPrice', window );">Collaboration agreement aggregate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain (loss) from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (25,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Research Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementInitialTerm', window );">Collaboration arrangement, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Exploitation Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementInitialTerm', window );">Collaboration arrangement, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CollaborationArrangementExtensionTermDescription', window );">Collaboration arrangement extension term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">which may be extended for up to two successive one-year periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Option Pricing Model | Level 3 | Volatility of Market Participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternate investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember', window );">Orbital | Option Pricing Model | Level 3 | Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternate investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_AdditionalFeePerAdditionalOptionRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fee per additional option right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_AdditionalFeePerAdditionalOptionRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementAggregateTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate transaction price of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementAggregateTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementFirstAnniversaryAmountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable on the one-year anniversary of the signing date of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementFirstAnniversaryAmountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementFirstAnniversaryPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received as payment for the first anniversary of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementFirstAnniversaryPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which revenue is expected to be recognized as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementPerformanceObligationRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementPerformanceObligationRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The residual value of proceeds received in excess of fair value for shares issued as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment received as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationArrangementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangement extension term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationArrangementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationArrangementExtensionTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the extension term of a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationArrangementExtensionTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationArrangementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangement initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationArrangementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationCommonSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock received as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationCommonSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationLicenseAgreementFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares issued as part of a collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationLicenseAgreementFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationLicenseAgreementFairValueOfSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares received as part of a collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationLicenseAgreementFairValueOfSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CollaborationLicenseAgreementSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of stock received as part of a collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CollaborationLicenseAgreementSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones the Company may be eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EarnoutPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earn-out payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EarnoutPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EquitySharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of equity securities held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EquitySharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EquitySharesValueHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares of equity securities held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EquitySharesValueHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_LicenseAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received as upfront payment under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_LicenseAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net profits and development and commercialization costs assigned to the specified party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_NonrefundableUpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_NonrefundableUpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_OptionRightsAggregatePotentialAdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of potential fee for additional option rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_OptionRightsAggregatePotentialAdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialAdditionalProceedsFromTransferAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialAdditionalProceedsFromTransferAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_PotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential aggregate consideration that may be received as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_PotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate purchase price of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received as part of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares available for sale and issuance as part of a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_UpfrontFeeReceivableUponSigningContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront fee receivable upon signing of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_UpfrontFeeReceivableUponSigningContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_UpfrontPaymentFairValueSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares received as an upfront payment as part of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_UpfrontPaymentFairValueSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_UpfrontPaymentReceivedUnderTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment received under the terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_UpfrontPaymentReceivedUnderTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_UpfrontRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_UpfrontRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementNatureAndPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature and purpose of collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementNatureAndPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beam_AssignedToCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beam_AssignedToCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=beam_UponParticipationElectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=beam_UponParticipationElectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beam_AssignedToPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beam_AssignedToPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=beam_PerProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=beam_PerProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_VerveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_VerveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ResearchPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ResearchPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ExploitationLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ExploitationLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872684512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">The holders of the Company&#8217;s common stock are entitled to one vote for each share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember', window );">Jeffries LLC Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockSoldDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,769,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember', window );">Jeffries LLC Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share of shares issued</a></td>
<td class="nump">$ 62.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember', window );">At-The-Market | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,952,703<span></span>
</td>
<td class="nump">1,909,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember', window );">At-The-Market | Jeffries LLC Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_StockIssuanceProgramAuthorizedAmount', window );">Aggregate gross proceeds of shares authorized under ATM sales agreement</a></td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_CommissionRate', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_CommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commission rate the Company agreed to pay for all shares sold under a Sales Agreement, as a percentage of gross sales proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_CommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockIssuanceProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares authorized to be issued under a stock issuance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockIssuanceProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_StockSoldDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares sold, but not necessarily issued, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_StockSoldDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=beam_JeffriesLlcSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=beam_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538869110064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,662,000<span></span>
</td>
<td class="nump">$ 98,647,000<span></span>
</td>
<td class="nump">$ 84,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.13<span></span>
</td>
<td class="nump">$ 27.88<span></span>
</td>
<td class="nump">$ 40.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.94<span></span>
</td>
<td class="nump">$ 7.69<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, cost to recognize over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, cost to recognize over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of restricted shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,600,000<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="nump">$ 53,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense, expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beam_TwoThousandSeventeenStockOptionAndGrantPlanMember', window );">2017 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,773,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Plan | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Annual percentage increase in shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Plan | From 2017 Plan Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,639,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,928,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,187<span></span>
</td>
<td class="nump">130,403<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Common stock, shares description</a></td>
<td class="text">In February 2020, the Company&#8217;s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company&#8217;s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount', window );">Maximum amount allowed to purchase common stock using payroll deduction</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of common stock purchase price lower of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum annual amount of funds that employees can contribute through payroll deductions to purchase shares as part of share based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beam_TwoThousandSeventeenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beam_TwoThousandSeventeenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beam_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=beam_FromTwoThousandSeventeenPlanSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=beam_FromTwoThousandSeventeenPlanSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beam_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beam_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538877397552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 120,662<span></span>
</td>
<td class="nump">$ 98,647<span></span>
</td>
<td class="nump">$ 84,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">73,523<span></span>
</td>
<td class="nump">57,812<span></span>
</td>
<td class="nump">52,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 47,139<span></span>
</td>
<td class="nump">$ 40,835<span></span>
</td>
<td class="nump">$ 32,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873487952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">76.20%<span></span>
</td>
<td class="nump">76.30%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">78.50%<span></span>
</td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">77.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870010208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2023</a></td>
<td class="nump">8,276,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,678,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(563,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures</a></td>
<td class="num">(785,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">9,605,542<span></span>
</td>
<td class="nump">8,276,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December 31, 2024</a></td>
<td class="nump">5,896,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2023</a></td>
<td class="nump">$ 42.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">9.94<span></span>
</td>
<td class="nump">$ 7.69<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures</a></td>
<td class="nump">53.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">38.62<span></span>
</td>
<td class="nump">$ 42.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of December 31, 2024</a></td>
<td class="nump">$ 40.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted average remaining contractual life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of December 31, 2024</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 37,182<span></span>
</td>
<td class="nump">$ 51,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of December 31, 2024</a></td>
<td class="nump">$ 36,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award weighted average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538868803296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2022 | shares</a></td>
<td class="nump">2,927,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued | shares</a></td>
<td class="nump">1,233,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(1,302,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(281,948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2023 | shares</a></td>
<td class="nump">2,576,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested as of December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 40.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued | $ / shares</a></td>
<td class="nump">31.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">39.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">38.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested as of December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 36.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538867998544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">12,255,796<span></span>
</td>
<td class="nump">11,276,600<span></span>
</td>
<td class="nump">9,287,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">2,576,855<span></span>
</td>
<td class="nump">2,927,152<span></span>
</td>
<td class="nump">1,692,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">9,605,542<span></span>
</td>
<td class="nump">8,276,033<span></span>
</td>
<td class="nump">7,548,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">73,399<span></span>
</td>
<td class="nump">73,415<span></span>
</td>
<td class="nump">45,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873531312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (376,742)<span></span>
</td>
<td class="num">$ (132,527)<span></span>
</td>
<td class="num">$ (289,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted - average common shares outstanding, basic</a></td>
<td class="nump">82,313,008<span></span>
</td>
<td class="nump">77,151,771<span></span>
</td>
<td class="nump">70,015,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted - average common shares outstanding, diluted</a></td>
<td class="nump">82,313,008<span></span>
</td>
<td class="nump">77,151,771<span></span>
</td>
<td class="nump">70,015,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (4.58)<span></span>
</td>
<td class="num">$ (1.72)<span></span>
</td>
<td class="num">$ (4.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (4.58)<span></span>
</td>
<td class="num">$ (1.72)<span></span>
</td>
<td class="num">$ (4.13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46539001834640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible/ nontaxable permanent items</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.10%)<span></span>
</td>
<td class="num">(50.90%)<span></span>
</td>
<td class="num">(32.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538872654784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 48,954<span></span>
</td>
<td class="nump">$ 3,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">87,554<span></span>
</td>
<td class="nump">56,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">12,868<span></span>
</td>
<td class="nump">17,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">38,815<span></span>
</td>
<td class="nump">48,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative liabilities</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">2,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="nump">21,218<span></span>
</td>
<td class="nump">20,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">30,508<span></span>
</td>
<td class="nump">30,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DeferredTaxAssetsCapitalizedResearch', window );">Capitalized Research</a></td>
<td class="nump">180,954<span></span>
</td>
<td class="nump">137,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">44,096<span></span>
</td>
<td class="nump">47,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">468,738<span></span>
</td>
<td class="nump">366,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU asset</a></td>
<td class="num">(28,649)<span></span>
</td>
<td class="num">(30,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1,563)<span></span>
</td>
<td class="num">(5,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(438,259)<span></span>
</td>
<td class="num">(329,357)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DeferredTaxAssetsCapitalizedResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DeferredTaxAssetsCapitalizedResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538870983648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 108,900<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties for unrecognized tax benefits since inception</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 32,700<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_TaxCreditsExpirationStartingYear', window );">Tax credits expiration starting year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 181,500<span></span>
</td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 61,700<span></span>
</td>
<td class="nump">$ 41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_TaxCreditsExpirationStartingYear', window );">Tax credits expiration starting year</a></td>
<td class="text">2043<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_TaxCreditsExpirationStartingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which specified tax credits begin to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_TaxCreditsExpirationStartingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873199360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Founder </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_NumberOfFounderShareholders', window );">Number of founder shareholders | Founder</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,319)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_FounderShareholdersMember', window );">Founder Shareholders | Scientific Consulting and Other Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payments received from (made to) related parties</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember', window );">Verve Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_EquitySharesHeld', window );">Equity shares held | shares</a></td>
<td class="nump">546,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_EquitySharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of equity securities held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_EquitySharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_NumberOfFounderShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of founder shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_NumberOfFounderShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_FounderShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_FounderShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=beam_ScientificConsultingAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=beam_ScientificConsultingAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538963028480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_DefinedContributionPlanName', window );">Defined contribution plan name</a></td>
<td class="text">401(k)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution to 401(k) Plan as a percentage of employee's contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution to 401(k) Plan as a percentage of employee's eligible earnings</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer matching contribution to 401(k)</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_DefinedContributionPlanName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan name.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_DefinedContributionPlanName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538873671760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Data - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">John Evans Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46538859990288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 63,518<span></span>
</td>
<td class="nump">$ 377,709<span></span>
</td>
<td class="nump">$ 60,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">367,561<span></span>
</td>
<td class="nump">437,381<span></span>
</td>
<td class="nump">311,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">111,525<span></span>
</td>
<td class="nump">116,813<span></span>
</td>
<td class="nump">87,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beam_FacilityAndInformationTechnologyRelatedExpenses', window );">Facility and information technology related expenses</a></td>
<td class="nump">55,911<span></span>
</td>
<td class="nump">53,804<span></span>
</td>
<td class="nump">41,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,925<span></span>
</td>
<td class="nump">20,012<span></span>
</td>
<td class="nump">14,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">120,662<span></span>
</td>
<td class="nump">98,647<span></span>
</td>
<td class="nump">84,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">49,094<span></span>
</td>
<td class="nump">46,676<span></span>
</td>
<td class="nump">15,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(16,895)<span></span>
</td>
<td class="num">(46,821)<span></span>
</td>
<td class="nump">33,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(376,742)<span></span>
</td>
<td class="num">(132,527)<span></span>
</td>
<td class="num">(289,088)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=beam_ExternalResearchAndDevelopmentExpensesMember', window );">External Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">115,189<span></span>
</td>
<td class="nump">155,063<span></span>
</td>
<td class="nump">112,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=beam_ExternalGeneralAndAdministrativeExpensesMember', window );">External General And Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">25,115<span></span>
</td>
<td class="nump">40,016<span></span>
</td>
<td class="nump">25,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=beam_EmployeeRelatedExpensesMember', window );">Employee Related Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">98,796<span></span>
</td>
<td class="nump">109,878<span></span>
</td>
<td class="nump">89,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 34,822<span></span>
</td>
<td class="nump">$ 31,305<span></span>
</td>
<td class="nump">$ 28,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beam_FacilityAndInformationTechnologyRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to facilities and information technology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beam_FacilityAndInformationTechnologyRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beam_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=beam_ExternalResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=beam_ExternalResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=beam_ExternalGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=beam_ExternalGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=beam_EmployeeRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=beam_EmployeeRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MUMZYUZLX-\G4^;]G3]M+,C<)X0N58_P!"G*IVE:&4W.GM NV>B9[W,XX]F$
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ML)UI[<,O!+5?"+;<8O3(<2JHSMPLQ.QBK2;?'K<SLGUXAJ#V#,%VORZ(-=M
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M(R^6J\\F"GZSQF+QT+FHZ5QX<0_+Z4,=5QK=1-0/2#*,'EYAL.]R O^A[V3
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M(Q0V/\"4U(9@,L,J]T\&P?30)A$NJ"LZ+QV!TSNZ(#89:]UV &9.F#US8E9
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M=D?"B)L+TH*&9/45&Q5T'I(ALC$D))%*T?49N:M>S6G7H+R);5'UZ;=@3H+
MV4&,0..2(2%KF(W/[M/5H(: 5O_@Q3UP%MUN"2P)#N,]=!C1:SS'?\[NS?/8
M7[.S9Z>+YT^>PE\7YX\7SYX_QN_.SQ9/GSR]-]S?9XO3BPOX]^GI\^P4+GE\
M<>\33>=KUA&&?_YH<7IZBH^\N%@\.;W [RX>+QZ?G68_$4/3/A5NV2E/E&+Z
M5*NO*M"/H#C)D,W> 3P5E/<Q<-^QST6+BW+TJ%BV]A;97#.H^?'K=QVTQY@
M,Z*5\6:W \\!M?@^!PNT(!D^WK1Y@3S1 O>A )(3M\A^/?D(W(TFI@<?ULX9
M9K=IKEQ;D^J+O]Q&"IJ(5=Z"Y2M0XM=YV8*EJWH7Y:ZOX8%5^0=<L0'E(?:Y
M\61A>475H>UW:#.<*FG4^:W;8GA[A1XI?':T/?0+J+*:UH#,!/A7H-.]+"\Q
M%.@$]!%1"?/SV<>%(7=EOT-%A9X$RA),H_2D*;N@J-"W!4D#'P$I!YH?P@U
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M@< 1RJ=X/63M!Y''V+@/54HJD^0_Y50;#E\"49@CW6E%'07\ZGU*]*]Q8WC
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MXTL2-1?0,,4,>47NS##S6*MQH29++5C_&=QR:A=\4OXZ#;_>X:3@5\&OD]Q
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M(]:+^J%K]C@D CM=LZ,_MP[DL<4+X/=UTW3Z 1^ [UPD\E[_#U!+ P04
M" #,.UE:^/#9U30#   ?!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6R555&/VS8,?L^O(+QBZ '"V9*=.+DE >ZN+3J@+8*VVS ,>U!L)A9J2ZXD
M7Z[[]:7L7"X9T@Q[D4F)_/A1-*GYSM@OKD+T\-C4VBVBROOV)HY=46$CW;5I
M4=/)QMA&>E+M-G:M15GV3DT=BR29Q(U4.EK.^[V57<Y-YVNE<67!=4TC[;<[
MK,UN$?'H:>.CVE8^;,3+>2NW^ G];^W*DA8?4$K5H';*:+"X642W_.8N"_:]
MP>\*=^Y(AI#)VI@O0?FU7$1)((0U%CX@2/H\X#W6=0 B&E_WF-$A9' \EI_0
MW_2Y4RYKZ?#>U'^HTE>+:!I!B1O9U?ZCV;W%?3[C@%>8VO4K[ ;;C"(6G?.F
MV3N3WB@]?.7C_AZ.'*;)#QS$WD'TO(= /<M7TLOEW)H=V&!-:$'H4^V]B9S2
MH2B?O*5317Y^N;)47^N_@=0EO/[:J99NW#/X@'X>>PH0S.)B#W8W@(D?@'$!
M[XWVE8/7NL3R%" F9@=ZXHG>G;B(^ J+:T@Y Y&([ )>>D@W[?'2_TB7P:J6
MVI]F#7_=KIVW]*/\?2[W 3D[CQR:Y\:ULL!%1-WAT#Y@M/SY)SY)?KG .SOP
MSBZA_]\R700[3S6]AA4<1\'G*)J&P^KL&12&^M-Y,!OP%<+&U-3F2F_AI=*T
M8SI']N[J9D25Q&:-MJ_FL3)ZA]15E:E+4$UKS0,&8 <O@"><\=FXEQ+&IY/1
M.[D^BIUSED^G,.%LDF>C-YW5RG<6>X8;]1AD!QF;II-A'=V;INT\A7W&2!G/
MD[!.4CK65/YN&!=$G\@4Z!P(-DX3&#,Q34>?C9=U.#EW&7R:LC&? <_'C&>"
M,B-O611=T]728TGC@BZ\4+*/\!)RP7B2PQ6)XY"@@*O1^7L>:D 7P3G+J,U(
M$AF;31+X?'+K7JYKW$]8]0^E?Q(1'VF6.Z3<BLY:XO/O(OV)TNZ;][1&H?U"
M#Z9A$53,,Z@O0' V$Z%>(F')P#)CR2R'<QT0'PVM!NVV'\V.?JA.^V%^'78/
MT_]V&'K/YL/3\5[:K=(.:MR0:W*=CR.PPS@>%&_:?@2NC:>!VHL5O6!H@P&=
M;XSQ3TH(<'@3E]\!4$L#!!0    ( ,P[65JZA0Q4N0X  ((R   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;.5;68_;.!)^]Z\@>GIF$T!Q6Y>/S@%T
MKIDLDDUCDIG%8K$/M$2WN9%$A9*ZX_GU6U6D3LON8V8/8!_:NLABL5CUU<>2
M^MF-TE^*K1 E^Y8F6?'\9%N6^?G961%M1<J+J<I%!D\V2J>\A$M]=5;D6O"8
M.J7)F3>;S<]2+K.3%\_HWJ5^\4Q592(S<:E94:4IU[N7(E$WST_<D_K&S_)J
M6^*-LQ?/<GXE/HGRE_Q2P]59(R66J<@*J3*FQ>;YR85[_C+ ]M3@5RENBLXY
MPYFLE?J"%^_BYR<S5$@D(BI1 H?#M7@ED@0%@1I?K<R39DCLV#VOI;^EN<-<
MUKP0KU3R5QF7V^<GRQ,6BPVODO)G=?.3L/,)45ZDDH)^V8UIZ\]/6%05I4IM
M9] @E9DY\F_6#IT.R]F!#I[MX)'>9B#2\C4O^8MG6MTPC:U!&I[05*DW*"<S
M7)1/I8:G$OJ5+]YRJ=FO/*D$4QOV5F8\BR1/V+NL*'4%UB^+9V<E#(3-SR(K
M]*41ZAT0ZGKL@\K*;<'>9+&(^P+.0,-&3:]6\Z5W5.)K$4V9[SK,FWG!$7E^
M,VV?Y/FW3_NU+*)$%946!?O[Q1JF#9[RC[%)&Y'!N$B,GO,BYY%X?@+A40A]
M+4Y>_/"=.Y\]/:)PT"@<')/^T'4Z*G1<Y6#*-@Q'NZY'VS2CR78T]GDKV"N5
MYCS;_?#=TG,73XL#+<LM+QG7@J6"HYUC!M>;SA 0G!#@4:6US*XPR&3!(@6!
M7Y0X?L2++1-?*PG-4: # :"_B)*O$\$*["=+*> VMBEWG5O8^U><%FJK>2ZJ
M4D;0\%T631VFM'GH,)[%[%(#V+ /(I81F*G3AAXXJ% )ZH$"1K<8!!*P))*O
M96+&TR+A)4RP5#!KP2ZNM!!H!#-"PC/4Z(/05T([+*:F;\5:5X"'S//)O<')
MUZ*\$2(C$=;$).#'"D8EG? )75EA[4@.X&L4B:)@.=_1T* H6 [!KZ=J7NFB
MXO#<ZOH3U]=<QS302ZUXS-[+"-"W,XN"'A:B+!,SJUN&X$6AP!MPEC>RW,(J
M=_KRQC;V&7H@U]&6?$>6%1IW2FZV40DD#_0-6O,"Q<!-#=U0\TW/6\NC?@DJ
M"3N/KJ;K'4O$M4A(%YD-Q6XE+#:HMD//!2P2Z1IL7N,1>T0]5%6 V.+Q^>05
MUWJ'ZE+4OB?!KCUZ]NA/+D@5:-SW[O,)8*?861]GFPIDLE/F+5UGL9P?.*.9
M>D_;LPF8(!6:YIR#X^NFR2W'R8>QV#K?E^?"X-YJWAQK.8-KZ*AS!:$B6*9*
M,+4[FSGN/&R.3;_^]>27Z2=8?4V0T8MI=QXXB\6L.38"^M=&P(_J6NB,W*PK
MPH6F<[<Y-B+ZUQW=]Z%E :9W>[]#2WY69>MQIVP9SIPP7/7.O.7*"><+. OG
M,V>U\CHK^+[US\FG04S7OKLSK=VG3?B>,M]9S6:=XYYOU,_N(-4 P3L;D((%
M3@@RS>_0@>CNY'4+!9U@;R6'3C +[.]0 MT%H]\"M*UZGT6TS52BKG8L )<+
M.F[8:+6:WT?BI59Q%95L[H?T-Q0']^RZ=N'CE('CK*!YYV3,[/;A_SZF^?\1
M3 O\T)DO5P?.]C'MKM#D+4,'(JLYUI(&UWO0!!DX],+ZT/3J71[!I=!SW&#1
M'!M0Z5\?PR5OX4+3L#DV*O2OC^(2$(CE(AP<;H$FD Y -%_,!N=!N !X"N!L
MX<,D9O,_ )Y@"0B6ZN-8G-"S!\ 3N [(-+_[X )W'P@NKN,O7/L[E$MW'P(Q
MT#'T[.^(T- ;!QKT1K][,@HTYN$P#AL=1L)19E%2Q9:J0? /63<Q^"@!GY$;
MV3:KD<"BU"C K$7$*R"2T&!'8JA!S*H" >5KI9 A6F5R#:P3M;$;=GN_F+*]
M,$? BP8A?$Q)[TY*H@*HELSRRLY:02?DW$#?K;*'M'38S58"A<5>0E*W6,+6
MIDQV2-MEUEZM<;]%6,:+6C$M8#+H1[0W,/N2CK*P+8I%*70*&Q388VRUJJZV
MUHJIBD52X"!&6^QA/# 5@.,Q.C)XT)2-@FCK& =V5M_0.7"<Z##T./]/UK^G
MU5]7M+?%87:PRRF8P,K(R%X"!\4$[/1V?UN1X,X,IG MBI+0$&9OMK9VIXSB
M82+%ENO.QK>A"Q%$#ZA5E"KZ,F47U&)O]/Z@Z@8G&@9S9P798"#X3WV1IF=#
M6,PZR ZJ@+JCNW9FF0G.0B72[(G7'+;*$33#NM:T6VK .H'2,;F_Z)IC4%+8
M(,F=NBR524+5OPQSSV(Z;^^,FZ"S ##=7)"#);M]):XR^9M H<$T' SC3V?-
M'1C#N(;XEM-N.KZ_)W05<?9VU1%$QE5KR+X5QM9J"AF3?8Q*A</!")YCBQ_0
M*$\$"B97@_5!K*W6B8Q UD9HZV.RO*,_-7-@8Y[E0D9>.KZ_Z/@6*3+0MTX7
ML,1H[<7 VFXP]>I;=UZT5=<3C)BP<^N_O&IC5A@MA=AB.DRJL I#P"E8RD=6
M\<=XH])8=(M!=JF.#WP$W0T&#;<%?R-CO-DSQH2,04N/'C;Y.*[<*7N$FZ+9
MRF?V8NF$L O&"V]&#+%F@9>6!;[?(U3@?+$LH@K8+ !VI>U0["^0+-BJ[WD2
M:W0P-6V*="G_(FI^6>"-_2I8RRZQ^@_ GRMC.1Y!^KHV^UL$7EALD_;2*BEE
MGH@FL=2A=$/O"-"3@?SS*W%\@_<)X@UD7( W"(@]U%AI+.]![OI:B;9R]^[R
MHYFDI5!C4O?@&H*IU;A-6XB_Q72TN-LRV8VM0%+8/C%F&50="P:D4NA[5!:1
M.L >4P[+PZ",:A,O"03,ERF%TOXV>5C];+3N^P%P#1B37E/ 3:X3Q0H)"S=,
MWKN:4]A,3R%3E156LU5G\0FG+"\Q!D%3"USGA'T!V@L6D+31'\9Q\P#<0PL*
M$1N#<9,;>1+5JMEI'C/!,1\^9![:2-<=!YTF/92[V\7D[0!7.G#^",D[^0Z%
M>3!=XC[06TP];W@]>?,-,11=5*$!R/T62_8]@S;PX\+/8L6^;]NAG[!'A-&/
MV6PZ\]D3R!G!"L_G<![:<Y_._7E]?X[GG[<F"59E8VPQHL -<(=V 0P3[,?:
M%@B9 F^ Q>_TXXF"EJ;<?<UE0@@N,_-JE3+16E4EB1H74'L:(0OX*XC0-D$#
MJ2TU1QB.2 N$#HQ3SL#:4N'^J@3 LIJ*GKD@-U5I;NKM0 UX',N2DFD/.;N.
MV7?!K,)EA^:@479EB'.NU;K&"U"V2XSI)9!Y;X!H<\3+#P;S>#+$#)]%$F.)
M!%*F&T]T1^*@C5];U:HW(V.Y;R3U$0\X%$N,]O23EY;@CI3>, 96SHQJ(RO'
MIR-D11^+%\V$.I-YQ'QG":T>T]G"GBVH1/OXV$!^KQ@S-P/-4-:A@5Q2YS&=
MN?;,<X+;!@HZQ6A3.CYE2^IV:]6DNS7]I4DHA]Y\T?VV0 IAA4"# ;-5"70V
M-5)%GM[<P;UB(J\D.A D5/ A@5O**L<KWD8#1"+:9];A]N@/;9$H1<<K5=8A
M%(99>MZ@4VXK0/L]'#RSL#!*"L9X<0M  !55*I[L\0Q*3(=XAI&%]4AZ7(KL
M2<P-FJ!<"Q_ =VF4&]4\@58%BD8V8)@(QC,&CDF91)+R',")9M3.%DB8)4\Q
M;1V@8=%Y;A:E-H1].UBG20LV_:WN;9:R]&A_@: _D#4T=LMNZ@)&9%S1\)B+
M3Z]8L)PY^+D NFPE"P+33A64;;1*V1O#FPF@"G&WM\8'N8\U9#_?K'=D52K&
M\R[.6B9&3*6F+15FCM^(2A"&-=AFL!J-U^6Q]*J>>$B5=6HDUAD-O[S_U Y4
MA/QC%:%_/TVZB_[GDTX5^$/KH'4-M[WU()*$WYZH"A3X&0/'!9A 5G/@.+GL
MI]2+SKIYT,Q#1H/-X>BU1^SV3Y/L*6$->\Z\.?Z$^+/$+C,_,#?HW+U?IGV8
MF5NW3'Y'RKWK4MTM!\\=M $> W^)T ^9;NX?2HV!,P\#2HBA,UO.Z6SE+(([
MY&#S6N'4O@F =.$LO(/CX,L<RN_NPB9BVB[?EG[QS>@IO="D%SRPJK>]IZVS
M[L>,_;D"<NFNQDJ$T$=HBD!,EO?^O*/W$0H!EH,S%M^L0QD"JT4"G-'L(Q(N
M4V*,6(/:\&O<$?<^D\%A8Z"@*5+MNG0,_@>I%<;(,;%1J7=$&4CV50X@WOFP
MA>J(;MA)WYC2Z\)!AQHT&:7C[DVE($:G5GGS(5#4O,F0OS5P]?+-Q8<G[LPS
MVS:\\&?>"-9V1VJ^D!*ZY&"4SD!8?[I"-%1Z9QAYP2$ ZAPQPCPX0FN";P7!
MYKBQTFK'DW+7O&@ -%A"OD8KIXA:!964T@IT6-=>1&",KXX,?J?\&^RJ4]L!
M51W:HM5R+#^W1811UY+%8'G,3,O1D6G^8X.0%#]L9>#^%/+JE>9IOX28<VFD
M#YQBZ#:=:J'K04*F;R$/5 QI!,AHF.0S="R(*"P600@ O^U_42:+KAULVL.]
M[N%R9#&TGB46\  K224$'XP& <ZC2%=F_0RG,\3/UBLZ#KC__9=)\R  38VY
M%L,6O:CS79BE4:8-&N<3#!W##JD Z\8MW5JZH=,!)\.A?Q+QE=E9FNGD"EBJ
MJ4[7&J3X!;,)M@W5VTQ4]71 4:AIIDJ</&9%0_)W#/)PCMOB2-#NP,YZY+LV
M6T*T+R'V/F3LEP%Z[S'VZKZF4Z<LC;!&@%J8V#A8T=U_8P(+63;5*)B*R;%%
M1PR6!;38XO?4.!U5%/>LK!VHI!'#1U,\G(KV5K1+1PU V !H".LM:'<8[(H[
M\UMZUS>^]@]BLUC9N19#3MO67>[':O?7)CZ>S<\G!XAJRT!UAX$.F>:PTCT"
M #[[_@D+@E&Z>8?N@%4+PS>7OY=OCJ[;'\,O;Z.-G:\Q)N]LS=^&=[U\H]J%
MCK>8CS,^UUO>QNW,MW1CWYB?=?XO(,5J"?[W Q('6'#S+P+-W>8?+"[,_Q6T
MS<U_9WR 9 1<">RW@:ZSZ2(\8=K\QX.Y*%5._V6P5F6I4CK="@[3Q0;P?*,@
MPNT%#M#\V\F+?P%02P,$%     @ S#M96DVPFE'<!   B0L  !D   !X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULM5;=;]LV$'_/7W%PBZ(%!%NB),M)DP!)
MO]:' D73=@_#'FCI;'&A1)>DXGI__>XH67'7Q-B [44B[^-WGR3O?&OLK:L1
M/7QO=.LN)K7WF[/9S)4U-M)-S09;XJR,;:2GK5W/W,:BK()2HV<BCN>S1JIV
M<GD>:!_MY;GIO%8M?K3@NJ:1=G>-VFPO)LED3_BDUK5GPNSR?"/7>(/^R^:C
MI=UL1*E4@ZU3I@6+JXO)57)VG;%\$/BJ<.L.UL"1+(VYY<W[ZF(2LT.HL?2,
M(.EWAZ]0:P8B-[X-F)/1)"L>KO?H;T/L%,M2.GQE]*^J\O7%9#&!"E>RT_Z3
MV?Z"0SPYXY5&N_"%;2^;D\6R<]XT@S+M&]7V?_E]R,.!PB)^1$$,"B+XW1L*
M7KZ67EZ>6[,%R]*$QHL0:M FYU3+1;GQEKB*]/SE!VEOT<NE1KC!LK/**W3G
M,T_0+# K!YCK'D8\ I,(^&!:7SMXTU98_0@P(Y]&Q\3>L6MQ%/$UEE-(DPA$
M++(C>.D8:!KPTD?PWK=WZ#RUDW<1O,:E!]E6\.9;I_SN('3X[6KIO*5F^?VA
M+/0VLH=M\ $Z<QM9XL6$3HA#>X>3RV=/DGG\\D@$V1A!=@S]GY?J.$P^A0,D
M=Q_YYQIA930=4]6N86"'LZK^)+8G]BO3;&2[>_9D(9+BI:-&? BH1EV!])3E
M$ILEVK&,\%RUA&,Z1[EW+\Y.KAIC/:%7A.P\O+/&N>'[5BH+7Z7N\(2L-FA+
M)35LY(;PGD*R2*+X-*>52&+Z/H=3>#'0Q>F<5.S&6.D16N/)I22.HZ3(Z9^2
M;)*D)!UH\_SDR_1F"I_I1G.=W1W&D<RS*#M-0"Q.62EF'2(51=SKO#-W:%MN
MJ1^TDBS*<P$BS4E+S%F+2,4\.? *^[X[4"NB8I% R*QX.?X#]>2S\13[4\CG
M"XHZH]4B+4+42;X(<3.G*-+_OX;I?U=#L<BC..=H1!X/T81@F$$Y_ZF((HVR
MN8!Y.J:'*+DX5L$\B19Q#EDZYQ;)N!:YB)*L.%9!4201-1*D8D%:Z9S5 BW+
MCY90D#'JL;_7L">/12SR-$H++A^U<-&7,2O2$#GS3LDREU&.>2TYKV;U2*64
M UG]02\%2=(CO=>3X=$C+;J)&M4U+MQWLBPM[CF5<J7IZ$($;PC<,^)N"E</
MG5Q6#N6/0A,MI99MB:#X72V[IM.2[1OB6?*W(:,UO]QW",\UM<(+DB0RPE:Z
MGJ\<R3NC4>_8E_ Z<SXM]E#!I0?BG7)R+ 'QIS4D+W7(TIHF$ >4 +9'>;%8
MFG4;6*8-3CM)2"2P#_7QG'(>66.'TCI ?M)^SLEP'H;,"%Y$0.%),NUH*(@.
MCQLEN^(V9K>T=$ZM=L!DJE:H ,U+?1K^33+W;CI)&SI4RE1]?D:KM=&5HREE
M^4.#DZ$R"/!FJWP--0TO0*U1*0_?.LJHWX7 :LG:'BV-'ER4FJX$W^>?.&UH
M&[)+C5W6LEV'AF"/!BBJ\FT(JPW)5OXG7WIW2YH=^,TER_?5J:3O?95:!U!U
M_X2#)!<T.K[2)#5SV]<*I@^]L[.#\8@NH748 KD-*?/]I#12QSGSJA^O[L7[
M(95>SC6WF<85J<;3(I]0D&'PZS?>;,*PM32>1K>PK&E61LL"Q%\9NLJ&#1L8
MI^_+OP!02P,$%     @ S#M96GU5O^?W @  C 8  !D   !X;"]W;W)K<VAE
M971S+W-H965T,38N>&ULK55M:]LP$/Z>7R'<438P]4L<VTV30-)U;+"RT.[E
MP]@'V3['HK+D27+3_ON=[,3-( T,]L6ZD^YY[CF]G&=;J1YT!6#(4\V%GCN5
M,<W4\W1>04WUA6Q X$HI54T-NFKCZ48!+3I0S;W0]V.OIDPXBUDWMU:+F6P-
M9P+6BNBVKJEZ7@&7V[D3./N).[:IC)WP%K.&;N >S+=FK=#S!I:"U2 TDX(H
M*.?.,IBN(AO?!7QGL-4'-K&59%(^6.=3,7=\*P@XY,8R4!P>X1HXMT0HX_>.
MTQE26N"AO6?_T-6.M614P[7D/UAAJKF3.J2 DK;<W,GM1]C5,[%\N>2Z^Y)M
M'QLE#LE;;62] Z."FHE^I$^[?3@ I/XK@' '"#O=?:).Y7MJZ&*FY)8H&XUL
MUNA*[= HC@E[*/=&X2I#G%DL\URU4)";)SQF#9I049 OI@)%KENE0!CRF=&,
M<688Z)EG,*=%>OF.?]7SAZ_P!R&YE<)4FMR( HJ_"3P4.R@.]XI7X4G&]Y!?
MD''@DM /HQ-\XV$'QAW?^!6^-7VF&=]5WFT'Y9K\7&;:*+PSOX[5W#-&QQGM
M.YKJAN8P=_"A:%"/X"S.SX+8OSJA-QKT1J?8_\.)G>0_KCZ^(/N\<)A7=GGS
M75[^DO=?PW.)[UP;(DN",:24'-L%$QORE@F<D:U&O'XW'>'Q0YTAB[T"A\YH
MGQ&I#")M!IEQMJ'=\W]#SL_2, BOT(K&;ICZHYNZX?(9 !&U%=D'6IT*.#5(
ME8& DAE-PL"=)*$=DB0:W>&V4)57"-2X& 1ND%R22S?UH]%:R1RTQL[PB!VO
MJ:T,2UE3T99XGUIEJ^J!8W<23DCDQI>)Q96(0P64DQ+ KH[3 +]1G([Z\TW<
M- A(F+IQ%(R^2H.16$QB(] (4$<<1^38'?,..D0-:M/U0;OKK3!]LQAFAU:[
M[#O,2WC?IV^IVC"A"8<2H?Y%,G&(ZGM?[QC9=/TFDP:[5V=6^+L 90-PO932
M[!V;8/@!+?X 4$L#!!0    ( ,P[65KEJ&H\M08  ',1   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;+U86V_;.!9^]Z\@/+.#!E!MW2S;:1(@[>Q@
M9S&S#9IV!HO%/M 2;7,KBUZ2JI/Y]?.=0UFVDS3MHL"^R*1T+M^YD[[8&?O1
MK97RXFY3-^YRN/9^>SX>NW*M-M*-S%8U^+(T=B,]MG8U=ENK9,5,FWJ<QG$Q
MWDC=#*\N^-V-O;HPK:]UHVZL<.UF(^W]:U6;W>4P&>Y?O-.KM:<7XZN+K5RI
M6^4_;&\L=N->2J4WJG':-,*JY>7P.CE_G1,]$_RFU<X=K059LC#F(VU^KBZ'
M,0%2M2H]29#X^:3>J+HF08#QWT[FL%=)C,?KO?2?V';8LI!.O3'U[[KRZ\OA
M;"@JM91M[=^9W=]49\^$Y)6F=OP4NT";@+ALG3>;CAD(-KH)O_*N\\,1PRS^
M#$/:,:2,.RABE#]*+Z\NK-D)2]201@LVE;D!3C<4E%MO\56#SU_]HF"2NQA[
MR*(WX[+C>QWXTL_P):GXU31^[<1?FTI5IP+& -$C2?=(7J?/2OQ1E2.1)9%(
MXS1_1E[66Y:QO.Q9R\2_KA?.6P3_WT\9&43D3XN@@CAW6UFJRR$RWBG[20VO
M?O@N*>)7SP#,>X#Y<]*?<?VS?$^CFHY$9_#;K;+2ZV8EZO#B_5J)-V:SE<W]
M#]_-TF3ZR@GSD$A:):032U.C3-VY(,JT>"6NQ4]J85O4*^*2S (YR*PPRZ4N
MP=14HI8+ W$&1 R,)$E4+A(C$KNU+M>B-!N\*%4E="-^E1:O6!ZQ>V61V=(#
M!C[>JJU7FX6RE AS,6+\0:UV:!Z+_Z"@A3=BJ>]4]1)Z%;I#XX5RI:PEU;IC
ML5MK/FE 8+3?BV*4H(#JFGH!U'C52##I#9$I8//@(N,E4 8!DI$)=>>[)F2V
M)'UT<$XCWI;>!*PGSOE?/7*]M;HF(?,G/(+*Z!TRZ1S2"?L6Q]"F,XFXV$RH
M[KU-=OB=$;*J-!')FK8O[Y6T NFC3>5 ;4V[6A\@=@4\/W'2D75?ES]^+;W8
MP6>+5M=>($"6@96FM6 W2](1,R\6R4C<X'U+\80A1$@.=$1'&V/U2A/\H%RN
MK.* 1_QUJ:WS8KN60?#!_I, '>(,O2_8K5MY']*&'?5 TD*M).?9=;M"%V>8
MXBP$%Z1.E88B\06M?Y=-5WK@_HS6$U&]VJ.J35-Q]LU5Y+HJ2K-1_L4RZHS\
MBMSJX[3$;!:46DXHB>H8';<MC-E0$:H*J:$]64'B9(F<:+B3F5VC**VHC)_"
M-1(_GX0CA'^O0MVILO50 /]Q<1%/2">H"JBQ,V79;N^/:X(S-L#E=L'1[%EL
M"S\B0&5KV;T[[==]ANXC_Z@^]F5U%,4L%Z<UU1L2'_E4BB2.HSB.<;QIJ:<O
MC?$X+S3M$B.PM>0GK'2M_3V%[QWF!S?C]U;+9E4K<2/MQTC\PUC@?".MP?21
M(WBIP11MPTFJ0_T9J7T*]B5Z[.;P=2,_$L]I0E,V416AQJ&;X/L03TKAXP3>
M:0YPUR)%,ND29VG-AD6PW'TA<1PK$$8GC33]]LG2UT0\BO\/-;$?'#N%N#8(
M*P[A#BFXJ.]%J:S'"9RXD,BVU(Y'#K8/.W/>V1TF/47!0X+J3N7Z#_7H< !/
M.K+ 03,<+]E5G=L:>%F)%QPZTSI8Z<[.!_]DS'PP/-$_8/UX9!R!P=LG%<&A
M253D<UJD45QD6"3S:)(5@]^ D-$>TQ=1.I^(232=3D4>944^N%TC?5]RA1T3
MSKDPPC.+IX/;!V;PZ2A]U?^^$$F4H2;/!N^-1Z5_+[(BFN=Y6,SR.""<S69?
M\N@AR R*DJ'2CCN7X#3C@?C@3'8^.(G=B2-_Y]L&DE1B-.+RA%R@&]C!E:SG
M!2?/F9B/)N@+H^PQVRF*Z2@3?\&SP/.K+0J^A0OKM@I3BYL#OK4V%!^R,)#6
M"!XU"0T!WYXSI71KL:3CJFA==\Q[=*Y%A/)H/DM"J(JX2Z9X\CC[CM'!2L==
MC5J*6?C.M^_>?D#^.P6#*3F*M,!,SZ+9)!5Y J&QN/:/*ZX[9[3HE-0UJ6&B
M3W9=](LG<S*+1V+'T*!Q'+<&[BR<G_B*EK"DKLD]XG">?^1M/DFR;[(BIEU!
M[IFD!:VGF/)1,IG2>D;K;)H/^# .FB2?#MX?%"4)7A73P8=FGTK]H;1O[&DZ
MC:99,OA%.=PLT!9YSFJ0XOKBX<FBB+*XZ.OL8?\Y#@RB5R11#O1/W<#&1Q?A
MC;(KON[3_ 6N<"?NW_;_*%R'B_2!//P=@3L*#HTTQI=@C4?3R5#8<,4/&V^V
M?*U>&(]+.B_72E;*$@&^T^3=;TA!_S_+U9]02P,$%     @ S#M96N)!.[4V
M!   )@H  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULG59-;^,V$+WG
M5PRTVVT+.)8M*]DD:QMPDBVZAT6#;#\.10^4-+:(4*1*4G&\O[XSE/RAUC&P
MO=@D-?/FS>-PR.G:V"=7(GIXJ91VLZCTOKZ)8Y>76 DW-#5J^K(TMA*>IG85
MN]JB*()3I>)D-+J,*R%U-)^&M0<[GYK&*ZGQP8)KJDK8S2TJLYY%XVB[\"A7
MI>>%>#ZMQ0J_H/^M?K TBW<HA:Q0.VDT6%S.HL7XYC9E^V#PN\2U.Q@#9Y(9
M\\233\4L&C$A5)A[1A#T]XQWJ!0#$8V_.\QH%Y(=#\=;])]"[I1+)AS>&?6'
M+'PYBZXB*' I&N4?S?IG[/*Y8+S<*!=^8=W:IF2<-\Z;JG,F!I74[;]XZ70X
M<+@:O>*0= Y)X-T&"BSOA1?SJ35KL&Q-:#P(J09O(B<U;\H7;^FK)#\_I['P
MN)(Y/*+SMLE]8Z5>36-/X&P2YQW0;0N4O (T3N"ST;YT\%$76/0!8F*UHY9L
MJ=TF)Q'O,1_"9#R 9)2D)_ FNU0G 6_R"EXO01"ZH)05)5_ @DM#>HD._EQD
M9$6U\M<Q"=H Z?$ ?'YN7"URG$5T0!S:9XSF[]Z,+T<?3M!/=_334^C?LE,G
M@8[3O!K"/H#M*?5)PR^Y-QE:WHG) 'R)<&>J6N@-R:A-HW,2L:F+(&9MK%\:
M)0W45AK;RLIJNQU^K81VX,U!(.RATB?Z@*)B[B"]@ZQQ-'0.J!T1#!UH-V1F
MN=&Z.^!KZ4M"D>X(A:^B[0$]&KTT^VE9+!I.BD-C52NS0822FEY.V7K(*/&Z
MMN9%4E] M8'Q:$11G0S$!F LB(Q:( D&WX%9!AQN3]1%<QS"?:LL1]R@L(!\
M9( *'BN6N2OZR;\YY6:EY5>R? N7P_?4#I3BK B_OV-Y*>R*5)<Z )!&CM1H
MM\=Y^J.NZMEM+R8AM&>!I"<?AZ%?!I5_#=,]9JZ:HN-P<<C!:#SWU+#!HZ5.
MU2J>H<8E9\_2$Y%PMAJACAN1/.#PF4A120U8<.7+7%@:L_^68P_T+8R&R2$/
M;?1Y+EQ)J9K\Z9Q[-H>NZ!YS;3Q\X3&&U/;;TFYZJ\8:J2)=0[U :"^%HBUF
M!(4<7C@.<V2W2K-F\D'T71J!I*$E2Q".21-T+20M!EM2C H"O9 JX+)S?SN5
M%)E4TF_:.XP'+-1!;7SOCJ>Q-3M19"FGPZ5E^:OD>S*W#0T[D=PA_\9:KIPM
M(?E*C65"A<S;9P7G*YB+HA> NSE;5'R&SA9=G'ZN6U?A_\,TH:U^]^8J&2<?
MSCYNR5$Y,JD"+@?I=7KV(#9<VPY^@/'@^OH:?OSV.!.*DQ+:Q2%:6/@_:.F>
M-1R[!>*#N[M".F+\0G$0^DQ[C>]6=X^@17OW[\W;%]1G.J&2=EWADEQ'P_<7
M$=CV5=).O*G#2R SGMX58<@]#2T;T/>E,7X[X0"[I^'\'U!+ P04    " #,
M.UE:.YT9@C02  "O30  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6SM
M7&V3V[81_NY?@;EF6F>&IY-TY]A.;,^<[63B3MW<Q$DSG4X_0"0D(:8(!B M
MJ[^^NXL7@B"I>XD3IU-_L4]\60#[\NSN Y)/]DJ_-5LA&O9^5U;FZ<FV:>HO
MS\Y,OA4[;F:J%A6<62N]XPW\U)LS4VO!"[II5YXMY_,OSG9<5B?/GM"Q*_WL
MB6J;4E;B2C/3[G9<'YZ+4NV?GBQ._('OY6;;X(&S9T]JOA%O1/-C?:7AUUF0
M4LB=J(Q4%=-B_?3D<O'E\PN\GB[XAQ1[$_W-<"4KI=[BCU?%TY,Y3DB4(F]0
M H?_WHD7HBQ1$$SC%R?S) R)-\9_>^G?T-IA+2MNQ M5_B2+9OOTY-$)*\2:
MMV7SO=I_*]QZ'J"\7)6&_F5[=^W\A.6M:=3.W0PSV,G*_L_?.SW<Y(:ENV%)
M\[8#T2Q?\H8_>Z+5GFF\&J3A'[14NALF)RLTRIM&PUD)]S7/_B9ST+!@EQLM
M!"B[,4_.&I"+9\]R)^.YE;&<D+%8LM>J:K:&?5T5HN@+.(,)A5DM_:R>+X]*
M?"GR&3M?9&PY7UX<D7<>5GE.\LXGY'VG-[R2_^'H"!E[H2JC2EEPZQ=5P:ZT
M,+!V>T"MV3>RXE4N><G>P$&K%_:ORY5I-+C1O\=49"=P,3X!#*TO3<US\?2D
MQK'T.W'R[,]_6GPQ_^K(\B["\BZ.2;^A$8_+>#QC7@P/8M@/6P'JVM6\.K M
M-^P=UU*UAI7#2[4H054%:Q1K1+ZM5*DV!]8:."0K)ND*([C.MZ3R0KP#1*CQ
M7AN:LI'"S&C$$>D[?@ Q>=D6@K7UZ5J#P[&:'^ALQE1-IEL+@3^JC9+5AB$F
M-0(M*=P9TZZ\;'M JP,OF\,I!G81R=O)4D#L52(Z9MH\%\8,KL75J&8K=#@V
M8]_%\]EO!;A97</0?%4*N$,+4$:N-N"3((K.B_="YQ(D9S>9]W#,(%1#"#(P
M%6BKU1K^MO.%V<#U#%8E=V0GOE,MWE>T@BD-)WD#V%.6#/",+BD/;(7KE\4,
M0Z8!E8I(Z?8.'+52#8S\2RNU-3_<Q?,<I<-OR!LX&PX&U_(=1PQ.UQ]-=L8N
M#<US7-DTV19 1M-%SC/__*='R\7#KR*OU)K#9#N]=&.#[O#.?(L7H&/BKS67
M&ER[1$VLCPV?3!QNY\R(FFM0%\.( C\7.R_6>.Q J9!&->&+(>/E,'4MMIC=
M0"&E,FA46)\T /HXYKK59-\5YDT;%HUJ )'RSA0*O&(3":U4=>H\.G49'SPT
MZ<E %.]KO,/<;05L+T _G['SV1(#J"2P_8Q=G,\>=+_QUL_8<O;0'R(/P<$.
M,"?#!*80!@E [%:P?)\$Z-]S>SO\M<QP$;6@G%X>K'ZL!7G3:+EJ&PPU],9.
M$7;>.)3'JE1)-W2O/BPYUP^A9:+H_+DM-@-X1 MB'FG!FNYF!R7[K02KY%!=
MH9@6 $ W" 8'IMZY2?GH=/'KXE:U9>&CM5M!$@HVC/W(<?RC7T/(ZA:C$28O
MU^#8P='R SB&- G&;S%\&J'!";K$B4=CP9TR!\K+8AUW485044J^DJ6$97O?
MB!<K#:NU6I%]<;)6[_!KQGY")*V4OWPOFZWS9-("SK!6 *T-IO80U1+'7(D&
M%A.,B$-A;7!PAK02,[95>X@7;2</]9C<M3L_7&\H%&HU.F/?<@V)LQCJ@+VJ
MV%];@(WE?/&PKQ"!NJ5P=<KV0@;)GI3D/(7 GHE"HN7B/%RWVK0<5:B<ER7:
M%Q!(:'PP-0 %QG2&!7590#TJH@QD,UC(FQ"S.))?F;4W!J9<2T).U#;36!L;
M'-NAC4>0'28]7H+=O8@"C5NT>6/#B".H?8 I>?T,)C2&A<.YS'J5$-F/H@#*
MFV@9)6J2&U61;XHU&*:_ZN$:,87DF+0IVZ/#DF%B4*Y+#K@)4L 5Z#9!?CF4
M1=&QX03PFQ8B5>D#UAU: 3)VCM3-%^!+OQ4-";=_3DG=<L!X% UGQH2O50EI
M"M4.F7,;9DJP$ ;VHQ$*XXAOQZQ^H_&"FN'8.RY+#_8X3$U^T:\D(99VX-E@
M^P)QM9&E!26.,>]P"Y*?U ')[LO/W26&@H;.QO.UCI0C,..Z^6 I&<AP0B!S
M2E6@6._*"&[<& 5F0$ EPP]%8&$&0D *[SS8RN+KQB'K6FK3Q%8UO"2H&YM2
M6T%A:T@?T./@T.#]I<1" S!'NI)2P^R2N &]2^S$(12NX+RTE8B!2'0Z\U#M
M0FL#,(CBNPPP#6"^L'=55U1;6ZC"].3KH4*8'/([UK6V,GKC;KKR<$[Y>O$5
M^_'ZD;-P2F+ET<BFM''M '%D1J"+G)LM6L9L86(&->V! 5J&_&T&<[3Z#<5W
M6[ORF^=;":'M2ZH.*'>8U^O2BK.Y59*2]\0K(#2#H_&-Z->I:8GR!IP#9%QB
M1[L65/Y#-'7#X,W67 66&#9(TD6Z# 8]U@Y*M0>S>2C50#,<V0?*>C"%S]AB
M'I_'R*;0[<;I%D:!'8E^P"#5"L+'B[G_^\8K'ZX476%EH)X2-LV-Z><;L=(M
M!R2!&G+.7EU]E\7E!5HDU04X1J^!<C@Y9H6_&(I"N)#\H)\SI.GU2 1^@\'@
MA'?(HG6PTF$'JBACJN_3B?NS*[K<1P[V["L!15'DDK9#Z\'?_87%J0JP&C-A
M!;ZO#>K)K7 Z=A&AEO9NCR0HD-M#S5Z4Z]N*1"^ZOW("ME(78[=;U$,O1LLX
MG!@"J MD,Y$22=2/X'!P"U$]$!(OK>9OHN2XAJ+>&8R%1"G"-2]S'-"E$RH;
M7&$,)601FQJN$  ,4,% %,'(C^>G!?05M1N$D+W*\0P2$M@F1>B?>CCX] S+
MRM><G'R11=I*_(WM((NVVMDQ=W0!55U1"1]-E/H[O[#@20 "$0;TO9[8U\CC
M*1FZT4'['8*.+24.)MN6&(,=RN+A1?9H^> V=V,?" 5^20YEH@9#N0)\,:<.
M<]&?/K9W8*V@@$' PMAM3; (X%=@V0U520DJ>3Q/5=*52+8UM30X=3QCTT]M
MU>^)_(3NDPNKUH!ZS.=?WNOUS?&/>Q-+B.1"XYX]GL\1\K,E_'^#23N^ (MH
MA'FXC)#]%@S++=?W3^((OAYP!/>0(R"*@-B!>R_"Z/V1;Z*%^VR1G</Z/Z>_
MS[-'X>_%,IO3C^^H%!E4'.,] HP1QJ6>LL+VVU>F"=E'"3(H$G1_VJC3'33U
M:RQ'UG+3:ILRX10S\KT_A$4'V**P*&$M &5@50!8(&*,)"-38_V&5O6EF]<&
M*"KIEP PC<C;0)C'L\Z5:6*ZL5MM1!<D=3-6'LJY4&,I8"J,$DR%>3J.JU-E
M%V\;4/&&$@!6(@\?S!Z'0L16K)0!>D1S-=Y.!+K74'[U\[]R(EZ'TP"M/;0A
M%JP41/IXET?M(<^B2I_$*9%A!W)=ZJ/55T'Y[O(A&=T1/J!V[(6P^NDK%#W4
M$CO8#IBI?J!)O:(K45#9ULNJ#3A)(3>R<5TV5EZ@Y0H*(9(^\*ZXEO:K ;&V
M(W0$V7H-D&R<MR*(!-'4#3E^S]:<@[Q.U.L&8@*TA;E*'P:FB8D_VGX8D!#(
MF_0XB)&!;M*_T!1MI6)[)\\S)OR*F6)HP8H*:SNR_D1+0I5@CKM4UL>HT>ZU
M8%D?/' "6UASSX !.PK5KKJ# _"@PDKZPHK&BN;;$5@XR?>(#*YR<*RQG6(<
M>A-9>H3U:>QP6.U:OW*(F6Z+#'8\B+RR"8E@RM\(]7M:Q1.Q[>N<CF4,>S0.
M,R^M@-#K&[<'X(9)MBY^Q"[/%]JV\K-[)-. TB,SP3)4A?5Z$BS!J+1<]1=[
M'8??#TF2 .60;)+V83BC@#%6*\AC=ARR4ZS?82/-ILC365*+?GS=B T8J:HM
MD>H9OF!D7'GDE!!;_HIH<\[T=MX2/EDV8RDF<W1,\7-K&K?Q8QR,XIIVO #U
M/M>*3U"ZMO9>/+)+L1<.46//39_EI5'MU:\J Y$/4=4C=[__^^4DP6LY%&H9
M[85X#=Q;0Z[#EF06\2$3,\H&@WL2)Q"P89NI.W)K1M9\2);XCT42=RKN_*&7
MDK8<-U@_D<:?2./;D,;18CXN?_Q!Z./+KD_N,\CM=0#5;6*GI.^'8HIOC(P?
MAB^..8K?DS;^1!/W:>+?E!8>9:3N1@ZG7G@=26RO_S44L0UOT\0L\1%2=RIP
M(Y;XXS*ZQS7RZ_C<U#I_>%XWG?#_+;^;*N*N/.\E73GR\%*EAC))V^.6^ T8
MXW2)QYCCCDV]=XUF>L3I1?; T<=??&3Z^+K%_EH:^39:03IY$=')#SLZ>4%\
M^QWHY'3\WY-6QO).(D+HC\@PIPKX7V6:[3I^*YYYLIK]#5CFI'_X1#C_>L)Y
MJICZL'3S-9W-)]KYCT$[>P[XMM3S!,+\7L2SXYQ-Y- ?C7(^!H?_ X3SUU!V
M\I&GT(>,\^@SQ'QX9^@3G>@1U=#$W.G7HI#0KL"J7E7YC&ZV9V;L*GJ\^+A
M=\8SR_WGM#J*F "[MN"-D\_M,_;A? 3S&)XE]B$4,QI?4P"+./!5>^QG"7<I
M59:V?K"SL.;I:(_68&9YK7#3U![,D9^];M(\)IPC&CKAGKWZ[\/QGUVB\6N
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M&K6C/[<")J;Q CB_5JKQ/W" \(VV9_\%4$L#!!0    ( ,P[65I(75Y<%Q\
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M/L *6U#>8#H6#H7)4)TJUK6IS.H!$*-7(*OXJ7W53^LF")3+ )F[.:O6!$;
M%PE_.$ZC"H60X#C+ONL;!5JY4J"G:X5$:<R#K+H'L94/+ KP#[FHE%@\V-DF
M9R=Z^,DLQ\%ZF?.)>*5J]:H&5 (<6Z^A[A6_O)4-L(C>XN^ >ASJ'P;D2;2=
M4@U2$$FM._@K8J\4^79])8C@"Y#2T_DIKJ]"4M:F!HL)X--Z^NVR 17O%DH
MZ%8H@%?C[Q&N^BW^]4)<7,7# 5=N30>?HE*UJ+2<B0,>MQTX!0&/_=8N"=:P
MK933RTY*"]!5NI#5#&9= 4=VIF'1!T[0H+F!B^]QG+EXN[14+@W@K3:=DY%'
M"(<,/ 7"4/8%""H/!DNWM&)^ [@3GI-B"\,@O6!1 #?AFGA% Q0>ZX#3C>4+
M%+)6 FOAZVT/"LI/"6+P#_!J"&*W?KEMD>A#"(\7#\?Y,Y1K#;@ QX8ATZ:D
M:?0'\:!DTS(@N "U7"KRG$1)?+4<5[K\8"W;7%Q^[D$X$E0@=E2#_B1AH6A
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MM\V$W>S\#O?+*.ZTH2^FFF<.=A@Y0L&4HV>N5GIC=_2VL[3=R.O92*W2,0H
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M-$_NMEFR%3M5W69(.K&V(XRV4."/)LZS=89769D@R$"!D6V:URBKLA\X>NT
M?) 465+W;Y2HL(82\1VLU**N3OI %KN\VDL)$=5ZG252X:KSAP.'W&;:7$$#
M0*:&!2+!FL 4:*\[8S*MFQC:T\J[1B5;9##9IBF?-5V=6C^IB@(N9)U=\G;O
M-DC$\@"43-=2P;#5GD4<AVV<*=J8C D-2OP@%D)^WF&:\#VQES%%?%W+8332
MN):N>"-5C7;12;2A8V/C) %BJYA\?0NW9^5&9&R=DJRS@.VH5L22'%6K*H?W
M- $Q<IQ"/%:)4VHYB'R;OA]@W K*T>L_.8.7XNT?35;OZ8%=]3!WE_8)XN[
M[AR]D2REM^^O/^!YG@O)0BY7#%8VT1!MX\K# "RMM;\,;UO/ZON*XJ'D-[?Q
M#IB69#'7I*)6-ZX+DM*41X5"C\U54V8T92<5,PG*96.337XN)T[GL<7_K](R
MKD(GS8JF$&534#)\545A0%Q#PEZL3(&>CHFX0WJBSNH,0=V+T%EXGN-YGEVI
MRPIN3>*ZHH3>Y8WFA]^D%RN1[RFAK!-/U*J#H-?D7?DYD=!\YLS#I1/Y4:<7
MF[>2$(U0W<99'J]R7&VH="F?3"Z=@H&,V%92J93#?)?56X'@"V!!8?W>&XO7
MR/6X =%!<B7L(U0K""8A'-I,7#9@B\+7G+<R!M83N(BUJ@JB!3X9@>]E"V&Y
MU-KX[$GV%)HVBK*.*K'UWC=YE7((F9.R6[LI25X9)%XU&@"D->G,B%T4,D6]
M2-A#I2-Y(OB,Y+5#LH=2\TD&)4\JE4IR&*.:M>P+$ JK4XM0&655!:X-=Q'J
M<L3XCISGBE=LP4 =0['$" K%-DZ%CXQ=A,[,6[2*67)CBMYW9DO?\?TVGP>I
M0DNNF[I1@_YU$K2XP=BRA\^QX= &:-!/<"VQ(F43K6A6C]$!>?54WF)?L6/N
MQA1%E@#DG*_;]H9F0A!L9>FV11 65'F6Q@:M\$52V"W8\JBXIP8&FT@Q);>T
M'X$TA%US/](6OC4B28*K1F..?OIL\@]N@<R$1XZ>L*/Q$=)',/EXSJ!'@OR.
M88_$;('2#.@B '9,)^_.VSE=.'ZX%%//B<*9" ,G]!>37ZH:H_5#?GXD_,!S
MYG-::1DY\^D"%]'4"5%E8Q9 11PCJ(6];W3??%_G,9:Y2;953K7%(RZ1D@E5
M0%&E,C?9.!+8=K4[-/HO]]U;*,[MYK;*84I.77<Q=P/Q^%(L(G<F'M-M*/@N
MHKLIOG"WP,/'D]]YTR;3R_@6[@2K4)G^=+E6DO@%\2(4*7$1,74]R!2AN\ T
M$;C! K.[Q=.,NBQ"L<]DG@K/!;H_'G_U@ZFH.5>8(CT5<Q*-CY ^(G;L@!!P
M(75M/&XWSR9+^WTMV=V7UE&S-'2$FP$3(/UL\G<#-ZT'^HM7FXV2&Q@]^3!$
MO/H(+$(1.<%B[G@A9>@T<&=+L7 Y27UG/@LG[VQ( V>^B!Q_.A,!O._!%8#C
MC!+FB9C-0R><+L53L727TPEVVFN9U?QJ$<V<(%K@U2QTH^ A=:9BZ<R]F3.;
M!B*,7.3PPO5%B&J(@G9)T\'.0-_,B99S9QJQ-9Z[\,2<K0GGCH\0/?&?FJQO
M_4,IHC+ 02)NX[QA>HK^E30Y0TIL.GB:K==(),*^E:SOI#0U(JT/"*H3V7:3
M0><>[DW:1D//1^-'#:KE>.U,[M]WS)O-FA@J]V?-IX4XJJ9#]RV@K\UQQ:*]
M));)=VR,'G;[D[ZY'M,FXNXTLY4PX(46H%KVGRCD@\IBATQ'[F=HJ$H:'UMR
M"$Z0 3<+V^);F4,L+3)@40T'Z.%D-&5> ^PV!_>PC/=>E]_+$?K"I4W&]0=7
M?$3GVA#YH\:\?AB!@:D5T6Q"0N)-6)*2Y,@[XU"0$I1B&IMAFV!#H@UGIT8%
M2E%, )C0G@^XLN*2@&8#'SJB8;LQ.3;G(CWC($2DP("L$4<T>^]6I"$^)>W5
MX'+"4KLOL!&I*7(;@%"[U['L -2*6&9'JOI@F5SL:4 7N6./M+Y@NEV0?DB:
MO*L*LR&51QV%D]_BF2V!P*QZ=]@<^CVL6,>9LE6_:_<M77R/>EK:J-;BKU'#
M85O0DP%D(9C9(Q$LW"CB]PQ1T5SP)HPZ"UI_OG<?0*@C#64'Q=^H8ZLB\)+"
MED,J*XJNU]Y;?8/0G?9#CK4^<O<Q1)[3_5MB;!6GKL.N7;CSI=5TYLZG1XX]
M0Y@=>S1AI$5SL(O6; RG'3'7_W\.ZSVIB%KT^=R4A'?'NV]38)GF&DCLX)5A
MQ%9N=4L'4<?^0V)F%6\/:/->?>::!7@&B -[BM#I8+\^1'Z[I>U1?+"['Z'>
MMZ=WCQYL>U7F^X.%!H<'(W5'"EA-+?F'#/*E;AW3^Z&^J\A]O"4TFKKB73O)
ML>=, K056'9H\4 1-!AJ;Y"TA:^Q0K?WXX!2X+;9KL/OUJ'46/9]H,_(YNTP
M IP0M.6Y3-T#2F@8("*O3_:CXR,8RP^?36Y,)#O2._FUU>4T)P#'=I8!"-0L
ML'BSG+PWKO:=( R=.< H]%UO-OG-R'F"%Z&'+4I(M"U<$ML;4KH@\IWE-*)W
M(.?10PJ Z3LS,,QH-F,>YBZC X ;X/!!N(RMS#7L&O\;PH5 A2'"^>&@U"UN
MA""<9Q#NU0G".L2.<8D^$O.H1\LC)'F010R Y2@?V"4'@$(>XCS3DI')'#1^
M/>0H2;\#DI=;]O8%(&1.3"V#M-O,ZY9#7MOCVI_D2O$Y$!SG_?GGM?>LS@=T
M;V^NKUN\ZL)U>_YDAEUM@<0E>73\4;=\U4@[)L]CBNG0T5S>,%D:_B9@#VPO
MVWFC8T\*6YYM,F)U0RX^/LH:K4.;J1BA2YN$8(G*RI9*15N7/HJ6C9'V]*0@
MN-K%"K[,=JS9V04-GUQC>Z/-J7VV:DQ<5-5LMI"R5P X,'8HT9X[-ZM_PRP2
M&M.^"M4:&]@6>8:UR0JPBAF?I?(Y")G1K=^1AH@. :S%@%!SQ,;DD[ #4/I)
MUCV$/'P,:.CU.E-HX+6*.3QIO&\G'_B,?RHR4^PF@S?TK99$)KN\LLAOQ)?@
MKB?$GQ)B5G(GP^;-YS'G#F/87(,8YCB&MD*6U/>N&?FD6XS/_@=G#9P-UD*F
MQIC O+>G[H<'-  ?2]G-M"VZ?Z7H['<X:AR,OQSMM,:MW2!Z4BF"W<H<$G0-
MN%,BS]:=1<851LMSQSZ'FO[JWF "G4TW@")SVI,TBDA S0/@P]X#YI1+8@ V
M7[0W(WUBI%Q-3_:M]AK9G,>J!8<'E1T/.%21CY<.@V97&OT*I*%(*@\B.=[[
M-]J2##I<I+A?T@_)L-44,'<^ D(ZD^=60Z>TG1'4B+A1G"B++SKS'>WQ.<^^
MB.B+,UL4-QSU[_[6MF_?G=VW/SF@Q7XX<_QH@<7\T'.FGEEOX3G>(FS9QT&5
M?"L!^:*-R(F3>V)OD;/PYJ>/YD^<R7,*G/JSPM7@'R:%5!O^'PW56U/6YL\F
MW=/NKSJOS#]4^N'F?SX_QVJ#/:G(Y1I3L6^<71A0:6_J:L?_5UE5=5T5?+F5
M2%5% _!^755U>T,+=']@>OE?4$L#!!0    ( ,P[65HQAEVS900  (8*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U6;6_;-A#^[E]QT(:A 31;
M+Y8E>[:!),VP 6MG-.V*8=@'6CI;1"12(ZDXV:_?D;)5NW",8.@7FY1XS_/<
M"T\WWTGUH$M$ T]U)?3"*XUI9J.1SDNLF1[*!@6]V4A5,T-;M1WI1B$KG%%=
MC:(@F(QJQH6WG+MG*[6<R]947.!*@6[KFJGG&ZSD;N&%WN'!![XMC7TP6LX;
MML5[-)^:E:+=J$<I>(U"<RE X6;A78>SF[$][P[\P7&GC]9@/5E+^6 WOQ8+
M+[""L,+<6 1&?X]XBU5E@4C&/WM,KZ>TAL?K _K/SG?R9<TTWLKJ,R],N? R
M#PK<L+8R'^3N%]S[DUB\7%;:_<*N.YLD'N2M-K+>&Y."FHONGSWMXW!DD 4O
M&$1[@\CI[HB<RK?,L.5<R1TH>YK0[,*YZJQ)'!<V*?=&T5M.=F;YGO+^F]0:
M&E1P7S*%<&V,XNO6L'6%8"3<RKJF^-T;F3^4LBI0Z?G($+=%&.5[GIN.)WJ!
M)XS@G12FU' G"BQ. 48DNE<>'93?1!<1WV(^A#CT(0JB\06\N(]$[/#B%_#N
MF!)<;#6L^DC\=;W61E'A_'W.X0YN?![.7J:9;EB."X]NBT;UB-[RA^_"2?#3
M!;'C7NSX$OHW3-MEGC >@N6J#ES:<;&ON/*.2Q]QP;4&(0T6P-;R$7V@!F(1
MN"PT< &[DN<EF!*MT(:)9[KBC51& P-Q8'P%CP\-L0C#654]0\&KUEYST)BW
MBAN.&DI&^S6B 'S*JY:J#S9*UHZ; !N"=PU";CIS>B_.N*RM 5> FPUU%$W=
MIJT*P@5&Y#\>B(?PL41J+%*1RY9AY_J"#<,C*FIS(-IZ3:C$=O#&XFN@CJD-
M$P75(+2:#*R_K,K;BAG2+TUIVP_/B:^X*/05N>'.&="L[@3W.>@C9%]O9$4]
MV^KI0WRJF6)O2UM8);8U%F#[;"U;84[]86:?>D!1^/\K_*_P:HTYH\A1=5DG
M+"]QU/M$N2HH&>5!G&9LG]#9@ J6-%!;09<@:BT#VUIL?XGM3S3X)!Y16X'D
M-<G)[=(I@,A/THF?)0FMIE'JATD$H3^91GX63@>_'X5"-M9;;7UH6I67%+83
M9V#J3X+$3\819'Y$H$$<0TK[S(^GT>#N?K6"-*;UU/Z-PP3&B3\-)H./TE!^
MPLB/DL1/IQ,(0V<_"0+"C#(2%:8NV5_RVH6S^R#S?U&?2\HW*SK".K[N;Z@)
MF%*VFJ"IDJCRL#$'.&([ N\JZFHV^!.9VG]!+B;J?5O393-2S09]]_H>WD!,
M\4@ILE=N%\:4MBC=[Z)LZ@=9!E>#MR@D?6H[^\]?W]\7;ZU_)E19Y,=A[ =!
M!JFMBM!/TQ#2P _"Q(^#9'#27(^ASZ%9F>-ADAWT#].#*^-A&,/5N0_+Z&@V
MH*!LW02DB8I"VHT)_=-^R+KN9HLOQ[L)[1U36TZE6^&&3(-A2C.-ZJ:>;F-D
MXR8-:E8TM[AE28,B*GN WF\D]9']QA+TH^?R/U!+ P04    " #,.UE:B#+5
M-ML(  #K%0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R=6-MNVT@2
M?==7-#07Q  CB:0NM&,;<)P9;(#-3& GNP^+?6B1+:D37C3=3<N:K]]3U21-
M1;(3[(M(D5W5=3EUJIJ7N\I\M1NEG'@L\M)>#3?.;2_&8YMN5"'MJ-JJ$F]6
ME2FDPU^S'MNM43)CH2(?1Y/)?%Q(70ZO+_G91W-]6=4NUZ7Z:(2MBT*:_5N5
M5[NK83AL']SI]<;1@_'UY5:NU;URG[<?#?Z-.RV9+E1I=54*HU97PYOPXNV4
MUO."?VFUL[U[09XLJ^HK_7F?70TG9)#*5>I(@\3E0=VJ/"=%,..O1N>PVY($
M^_>M]M_9=_BRE%;=5OF_=>8V5\-D*#*UDG7N[JK=/U3CSXSTI55N^5?L_-HX
M'HJTMJXJ&F%84.C27^5C$X>>0#)Y1B!J!"*VVV_$5KZ33EY?FFHG#*V&-KIA
M5UD:QNF2DG+O#-YJR+GK]V5:%4I\DH_*7HX=--+S<=I(O_72T3/2820^5*7;
M6/%;F:GL4,$8IG3V1*T];Z,7-;Y3Z4C$82"B231]05_<^1>SOOB[_HEWVJ9Y
M96NCQ']NEM89(.*_IWSV&J>G-5*57-BM3-75$&5@E7E0P^M??PKGDS<OV#OM
M[)V^I/V[^7A9.IR.1*/!D09Q@\))JS+5N99<!=5*N(T2NELDU",*W"J!!]O:
MJ4S45I=K7K52F3(R%]9)5[O*[/MR1CK<5+SP%K*RW/_Z4Q*%BS=6J-5*<;D=
M"6@KI!6K*@<;V(O!C26+D'15+)6AQ \H\93]F'ZBP>]'-K">*!Q-Q"^'E\&]
MXRUZ 0A$"6+#%JTK2U6JE79B 8$P'L6XF0[ND$9ITHV098:2?@!5;4$\CLU.
MC<JTLV(Z6H@P@=AT% W^J CO-7Q<YFHL2A2!?)2X%UL%KBA)6#M56/%*A*.Y
M.,,U&LWX&HX2<3:XW<AR3<:*!YG7/CF2HB++5&%5'(Y"7CZ;C,[Y)HZP^=G@
M4^7@QX3]?BUHE;]&N'[:^#Q69(!MD_UM=D!:RL"K!B,2!?&4$_$*)KE-55L$
MPYY=#$XG!X^?E$#<*H=T_D'!1@3@#B"$8K,BE<;LT3QVTF16_"RF27 ^F^(F
MQO7\QT*?+((99&;S8 &1FS0U-39N@&M9M(*C1H11D,P3$2Z".)D_F6B@MZR5
MB),@"6=DPN(\PFNC'R2C%-6Q1(DX#6UQL%B$(H)UX>"WOVKM]AQ2;.63%(5!
M%"8(0C!+%H.;HC)._^U?Q7@V2>AR'BX&MW*KD2K]-RSHW R3"?L?QHM@$86#
M?RJTE&[_O9A.@\GY7$P70;@X;W*='8=:3.=P(L9>\WD0P=*[/S_[5P2T))A/
M&\Q,@B0FU'PTE!=L0,%2<,M'&8OG"U[)$H,_.8S :#";QQY^P10A.X.AUEX\
M@]4I AO-6I2>!_%LT0'U9\&XB][T[M!/&9A[Q 1D0:5TP %,_H$G ;*7B"#H
M0YE9S9"81)-$;!K ;$WUH&W#<SDLAI LL?,$95+H/,>K '_#T;3]RQL C;TG
MD#WFQP![VJUGM7P?B-U&(YT8(6B^X'U<9]T:)$,LQ1EC5FCUT:H=BJVLG%C5
M>;['9BO*VG+/_M4  [8OOU='9'2O0D;B@RPQ0W%.-]"O?*+( FC=5E8SSDFL
M5&L/>O6@,T4)7"(-M$\-WN#UF.X VQ:2/\ B+2I)/VV?*0<:1'/*O,L@7.V=
M1KD0W+\BACXW])#7]-.[0R8XQ^L2Y<.O&N+N2.W$]B.!=B(I3QC)#O%"1O4P
M0Z$_B678<03$%H+QB/GUE!C2:ZB0,\HCX#5)P-DMG,"GK":KNW[9KJ=W)QP)
M &2-&5DC2(W4TPYI2RM=0S?/<2A#%_C R&-;,W[8B<4,+>;0!T3@)H,^/($8
MBN#>S]8@S23BW>,D;A/TO@0&L [<Y]GWMLH8W.%Y,@^HX\B"2S\ '@H@!*5<
MF6UEV*X.9BT*$8/:Z9SA0(%RSN@EYA7;QE0].J8!;H&='HZ!T81S@B=34#1Y
M4^U0H7:CMR+E/ASP\_!-4[I4F,@+ Y@,%6M$!NYXR,XFU.53[(:20W%I;)MV
M[;Q3'8@"X:R-#RA%'"0BBPJ5-OM%@ );I7:#%KRI<DPH@/<#G@#$Z,9^##-*
MO2:B%/"5Z8#\J3+D\<!O^9+71^XVL>P@A$GV];>+OHWS*S5:CX(3W-2TX"9T
M8DD#)'/O$T&=498:J@,;N9.;]9F2.H0?X$ <MEY^ =)(AR3"+FMLPZ!A!X)>
MUE*9IW7.S">M)[]3KBG?V#DI+6![\0OZ6Z;HFSC=DB*;(ABD.ON"HQG5& PL
MP#9ZFVN?9]*4(\>OB0&;!J**K?-CZ[9>YAJGM0Q$B',3#&Y$CJKE'@<+G2I?
MKBV-T2"2*W:NK3TN/>OJ;$\.?S-,-XW4\\(A)9>5V&@<+XU&R(X  DTI-]9,
M()D@ATXK-(:'1A5RW\/;"57:=Y55343DZ\ES-)F+E2O':V!,^O5)G-G\E#\=
M'W]+\=3'PR3$F-WKY.W@_]V62K&5S,,5Z9EC:N]&A).&'+'AL_$_-G,>XC1Q
MPLIF&(D.WWY 6Y#I!L.!<P=EY5.)X&L$%B<DP\XQ64_;T0E#XN'L\EQ@3\9S
M&N*,]*RAX?EAL/\O0Z/6T(5X-N?!"TD'DNNR+5*> GG<05LZQ&DW3UBQQ'$!
MNZ,BP*FL&HU2YCS_PX4JU<P@.XUE==D)^A[=32*,Y.ZX=7IL/#1APZ.?<+U9
MI-P_&0+2>[(#P'QA;U^5FBLG55MR]W"KE<XATS]^*Y1?V57CYU*3BWQD;N9)
M+PUBVF'^@^='"=4\+K V/[HW5O0LZ%XMU5J799?E*(0!])&0BK"D&E./$G3D
M.Y"W"?/0E]IHFVD_57!%]8NTWXV>9FRB9HGH^7V)C9:J86C_5K;4TW5.(MR[
M^R8=&$IEIC@3-'Y9R[S^7#6/3GWD&?<^P!7*K/DS(U%*73K_+:Y[VGW)O/$?
M\)Z6^\^@'Z1!X"Q.+RN(3D:+V5 8_VG1_W'5EC_G <.N*OAVH^" H05XOZHJ
MU_ZA#;KON]?_ U!+ P04    " #,.UE:21A/+#H#   J!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6R556V/TS ,_BM60?!E6KMN!Z=CFW1W@. #
M<#K>/B ^I*W;1N2E).[M]N]QTJ[LI&,2TM3%B?WXL1T[ZYUUOWR+2'"OE?&;
MI"7J+M+4ERUJX>>V0\,GM75:$(NN27WG4%312*LTS[(7J1;2)-MUW+MQV[7M
M24F#-PY\K[5P^RM4=K=)%LEAXU8V+86-=+ON1(.?D;YV-XZE=$*II$;CI37@
ML-XDEXN+JU70CPK?).[\T1I")(6UOX+POMHD62"$"DL*"(+_[O :E0I 3./W
MB)E,+H/A\?J _C;&SK$4PN.U5=]E1>TF.4^@PEKTBF[M[AV.\9P%O-(J'[^P
M&W27K%SVGJP>C9F!EF;X%_=C'HX,SK-_&.2C01YY#XXBR]>"Q';M[ Y<T&:T
ML(BA1FLF)TTHRF=R?"K9CK:WJ 1A!3?"T1Z^.&&\B/GRZY08/VBEY8AU-6#E
M_\!:Y/#!&FH]O#$55@\!4B8VL<L/[*[RDXBOL9S#<C&#/,M7)_"64[3+B+?\
M[VCAQV7AR;'T\[' !]C5X["A<2Y\)TK<)-P9'MT=)MMG3Q8OLE<G2*\FTJM3
MZ/]9HI-8CS-=G,WAX*2+3N@X,Y]<(4DHN/1\W7WI9,%ZTL!'2PB+; ;4(EQ;
MW0FSAU9X\+(QLI:E,,1ZM>K1E CV#MT,BIZ@LNC!6(*2;XNS:C:YH-;9OFE!
M4E PXSD'T?  B(0-B=C-_!N-GGLHK' 5V!HJZ;C;K?,@3'7,Z]F3\WSQ\I4'
M_-U+#E :0H8+_ XX<_AR%$>P/[ 2#D$H;V-R)',G"X+)*R4*ZP8^05_)DJ<5
MZS8.D0<7Q=U6W"%H'A*R4\A66K/ZP%BC+M#Y.;RU/7<,T^9)$VGO4;"$H8V
MFR#J38T0O\L(SHL<'E9 BPJ9Z3X0\"$I3R&;+WEV<!ZMF45Q=1 CR(.=&6?:
M=QB'I=K/0JRA&EP91*@'GN!;SDEK5>3,+P/X4K*[4/105!^BY9H%<,O<'.!]
M%U+#H3[6$.G1_-+HFCBE/2/UAH91-NU.#\'E,/_^J@^OR ?A&LF75F'-IMG\
MY5D";IC,@T"VB].PL,2S-2Y;?LS0!04^KRU?ZU$(#J;G<?L'4$L#!!0    (
M ,P[65H@\6BE.P,  "P'   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;(U566_;, S^*X1W8 .R^$C:%5T2H&DWK ,&%.V.AV$/LLW$6G6XDIPT_WZ4
M?"P!VF OMDB1GSZ2(C7;:G-O*T0'CU(H.X\JY^KS.+9%A9+9L:Y1T<Y*&\D<
MB68=V]H@*X.3%'&6)*>Q9%Q%BUG0W9C%3#=.<(4W!FPC)3.[)0J]G4=IU"MN
M^;IR7A$O9C5;XQVZ[_6-(2D>4$HN45FN%1A<S:.+]'PY]?;!X ?'K=U;@X\D
MU_K>"]?E/$H\(118.(_ Z+?!2Q3" Q&-APXS&H[TCOOK'OU3B)UBR9G%2RU^
M\M)5\^@L@A)7K!'N5F\_8Q?/B<<KM+#A"]O6=D(G%HUU6G;.)$NNVC][[/*P
MYW"6/..0=0Y9X-T>%%A>,<<6,Z.W8+PUH?E%"#5X$SFN?%'NG*%=3GYN\5'6
M0N\088D*5]S96>P(UF_&10>Q;"&R9R#2#+YJY2H+'U6)Y2% 3'P&4EE/:ID=
M1;S"8@R3= 19DDV/X$V&("<!;_(,WBTZ;I"NDAO"A%\7N76&+L7OIR)N\:9/
MX_E&.;<U*W >42=8-!N,%J]?I*?)AR-LIP/;Z3'T_RO)<8CT= P#3-Z'?*TH
MH>G9"%R%<*EES=0.T#J6"TXWJ 3F[S-!E>\**JCA>1,ZIQ9,04.U-7#7-=,T
M2=_<OP6]"EC7RJ%13, M;E U'KS$$6@3=CO;&T(9P[=#!11Z@\8"$P*P(VQA
M6VF0?B)U=/S%Y[*10&,"F"K!IYP72%/AH>DJ:\,&X>BMA9H9QPM. 9+>:8]#
MY!G4V@3Z+6].*J4:XEU0,FC0L'93>4N#[QQ[]!W/[9A*L>9*<;6&+XP\S [:
MVYD<)E.R$NGCBLJ;[B?1 E&EDXC,20*O^LSU,;]^<9:E[S_80Y\1S<K\#Z7<
MNS'?]B$+Y'O:0J#@:YX+/ B@3?+_4"*$EY"-)Y1?(4@S"N+)/]&GU*N27@6K
MKJ@[9%0V] T/U*XH<TIPW[+A.VG=:951G6R-8?Z*W?BI%HGW)IA$LPYSVF>C
M4:X=9H-V> HNV@GXS[Q]1[XR0[6R('!%KLGX_4D$IIW-K>!T'>9AKAU-U["L
MZ#E#XPUH?Z6UZP5_P/! +OX"4$L#!!0    ( ,P[65H@D:II=P8  -4.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(U7;6_;MA;^[E]!>,.P%FRL
M-\MRF@1HTW;KQ7I;-'<;AF$?:.G8(DJ1+DG9<7_]/8>4'>>ER8# $:GS\O Y
M;^+9UM@OK@7P[+I3VIV/6^_7IY.)JUOHA#LQ:]#X9FEL)SPN[6KBUA9$$Y0Z
M-<F2I)QT0NKQQ5G8^V0OSDSOE=3PR3+7=YVPN]>@S/9\G([W&Y_EJO6T,;DX
M6XL57('_??W)XFIRL-+(#K231C,+R_/QJ_3T=4'R0> /"5MW],SH) MCOM#B
M?7,^3@@0**@]61#X;P.7H!090AA?!YOC@TM2/'[>6W\7SHYG60@'ET;]*1O?
MGH^K,6M@*7KE/YOMKS"<9TKV:J-<^&7;*)O-QZSNG3?=H(P(.JGC?W$]\'"D
M4"7?4<@&A2S@CHX"RC?"BXLS:[;,DC1:HX=PU*"-X*2FH%QYBV\EZOF+*U@A
MQ9Z1\MG$HT7:G]2#]NNHG7U'.\W8!Z-]Z]A;W4!SV\ $H1SP9'L\K[-'+;Z!
M^H3E*6=9DA6/V,L/Y\N#O?R)\WV&M;%>ZA7[^]7">8O9\,]#YXW6BH>M486<
MNK6HX7R,)># ;F!\\=,/:9F\? 1K<<!:/&;]R5@\KIW.3MBQ!?:_%MBEZ=9"
M[RA/4=PQZ1US4<@Q+ J/,IC4$A?+L-B*'9.:;5M9M_C@P6JAU [KC_B#AJ$=
MH6LI%+Z-/8&*"PU86/5*V""[P>)!V<4NV*Q;"4N&?<2*$($&:AF*NA-?P')F
M++O\^.8#9]XP@>YVW^#(#:H%/[H&'C0.^HZC>,,0GZF%!_3K3&]K<"?'9__I
MARI+9R]=\$% _V-:S=YN!.D3'Y<!WMMKJ'OJ$.SC<BEKL.R6%?2LL4E%!H>C
M( (F\(\Y/)6"HQ,2K,B86."+@?&P381T(%QO@3C?OUI;LY2>J%#&.8)9HWFC
M9".(=8WM6>K:=,!^)H%G S@Z4N\0UCT!BF*(;M^L(+I&&J$6+B!$?TB4"_OD
M239@W2#\PIL76!\]DK\15A+S(5D$^]H+3 **<4R:;0LABL=119L+[/[!^1 :
MBK59WN&G%FOIT<6=J.US;N"/I(DFN=(2PR*0JCUE<(V3B<Z.0*@Q-_N$7O8Z
MM'PT4BOA7%"DC1.,\F#]1EG7JF\P28W#R"ZMZ?#=((0Q[Y?$A$48'(U)C9;4
M$%X'PF*1X$ 46GZ+^<!QNJW7R$_=XD ,@LJL)')>N^B"![IQ9N!1A@0V"-JR
M#>C&6&3A;;=69@>4SRH$_RY6SF OX@26G(08QP5H+'-_<'20PGQ36%U6;"""
M!R+9(\) I$/S#4)1!LG>2M^RM=A9H]0!@1?7@X^(U<E.HF,L!NABW-QMV@.9
M<!VIQ2%6?WD10X092H<);'&&Y$HE_2Z8/NXG'NI6&Z1NMS], ]AQL2'$64YE
MWU%Z?!LL'6$;TN,&&XM5N* O$$K\#2:[N^7N)F/O-HW!&A^XIW0\SL5]:/A#
MSC'4D>4[+V^4PCF094P)(F(XN[E?S:>COS#;AC'+<$A"MT"+."A'-"AI6N;T
MDXU^P]Z%QH?"5@J/%GL5M670/; ?69GS:5KA0SZ;\5DRIZV$S[-D]'F?U:3>
MH((RZUN81X<*LD^)/F=I.N5I-6?I=,J3,L=UQO,J&7TWPY^S><5G\Y*ER9Q7
MLXI5<SXM9J-?,+/M4'BBP<\@22,\=.O[P%9/"S]G&2)+IZQ(>)*6M*JJZ6.X
M\H)764:$Y\F4915/D^GHW;](W_NFD(QYFK)ISJND8$7*BZ(:O7DLO5F68G30
M+:'-6%KP%$FY^DY9L13ERC(C+LMBQJJ"YUDZ>D\U#\X?E<H^Q5@QY\F\8,_H
ML>3EK R/&+UL/F//4#7(81?8'X/E&%6>ER7+>9$FHX_WLY^E):_F4S*(M83F
M\IS/\PK-_??>K/J17L]*/BLR%E=IGO%I-AM6&>9!4J$N>X[)KXW'^GUD)+ (
M9_\U]#[ &9JG.V54W%GY$@>_T"N:.-B')#9@H?HPDW$4RDU,&*S)!8686NQ3
M:MKH%UC(GCHG]0GXVE-N2+U!UN,7UU,F2!U5"?1^*,>0/H3C-_I0B ,K>NK
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MMH,M4DX%?+V 9>8K%":KNMK*B?CCF^/ISSWG>#Y+]V_39K-(\/_)>R#8N[1
M2)EP/L%,@*EXC/C &%.9'7R<Q_.,2YS1]6>LPXST ,%%>]E[G(^P:8F:-V[Y
M!3=5Q#J,M:U*MP=>4W\!@R-\3>@._'L#.C3H T4. R+Z 2FU?$+$OU*  RT-
M'!,V&AA NV=)43N'8Z."";*U0$1)F5$A?9"&TP%^ O:=VMTCZ(%[L/:#P!>
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M_NEIS/JV2-QJ!0,!_BT #X'!H]BB6"3&^%(?!P!R*:H]0H!L3".'0?962Q8
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MX9@\S@X[(HWI-'F/?V6T2XTD-:!+W_BU7$D&)!E=F[1>LX:D:)/2G&BSS1O
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M:]^[UOH@:LIA-Z1SA(.-;MF)RN^E9,T-LMB:P;*8S1*8N]8SBZS3FX[V/I+
M;W)(:LRXI,V5\)4H*R$1:>B2CDL%C7X9U^@-%S=Z9'T9.&N-!MLSJT2^:CV;
M+X.EF[/U'C_M91D( M\*3WHS0"35 #-#;KK)<#,%E]:[EJRIS;;)U#EXH2\P
M9:Q6VP=?2]PJ3U ]OBF-G1@#?-"*ER.[Q%$&:N@[-GNG:#3.@S=NG9>DAV@]
MT7\FY\]?+*Y>XF6>EY<O%N=7EP^NI9*K82]?'U@\ZY%SE1Z1^N^#ZR#Y3;*^
MCO(HN7RVN#I_D3R&/\^O7BZNKEXFCQ^\YP"R@>[IQ>+L^3,#YYR8"8VH+^8;
M2'^RQ_O.'.]D1^IO&=#B"SO'#OQ\1/NQ0T-$=X V;7B3&EPR$V.WY\0PTH6S
M9X" 6D/7R[-WNBJ[ W=9:[MX'UI:F(M]M6BD"*WML#EH07/:3G%XP4/98?TO
M.W3#+=KX#.R]+_SC;Z5K/5VP9M-QF6FYK)>LI[WL.,^/*J^4$=@Z1<,W*(81
MW81R3'$')W+Y<XC,LVPXO)5/Y/"R#]&*5PX,6=-:^, 57H3,T9*../V^>1"E
MU42%7ICW?<=765GIX?MC@"#KW1$.[!SOD2Z'6+HP">GQ3>_C5[NGI 51X^**
MKV'M7#:]/)IL-KTV]"J_F.]53MV23M[0KKPUN#_*-(X9:DA&HR6#4S3'H8ET
MJW6OI*;5J=YMQ-WH.?.;[JG7RU'X%[PK(M,:L]YO'6@90#$_\F"4NH5/"X_R
M]T+P%0+EB?_&\@]_M<3I=-.-R96-W"(26K,_/W^QB [@A#MBV:]"CW9X^E3_
M"$YX-+KL[+;LQRPG6AWCEBYK:$H-"W#_?!E!1(2YS6GOWZD5^<+CVA-MK:"Z
M3G!]ORE2V(*;Y:8B&W;GO6[D@N*R&^S39A];A*/3-P3K<$<PZW &0^2&]X-7
M1$9E49CFTDA,*TH,CL?Y(R@^28CZ+GI=PYU&DG<A0N4DB:/^,@Y>7\,J;9EI
M66*$FXHEIGI5IHNQ+^#:8!^9)A2.J7F/;0H0Y]GB87+PT.ZOEOV:R(5F!@1O
M*3UP3YT$_5V (7R)ORJ0TI'BV[>%5W[,KO=6[Q=Y8('$(YH<;R:-UQ?(!GB3
M*_2.#+DQDKI$<4BZC9."8V\Z^;I7O601 =E&FIA2#A-HX&E2$.?7J:)?\)=N
MK0O%0)97:QZ1=Q,QC7"(XZY"ISIJ'C8#R#N43,\7.?F0HH,MTD]6M>NU!F&1
M3RG\?AQ2*,  ZK&U6RI&ET))6)[/K NYJAX\1> -:,-536J3_7%% 1VQ/5EE
MHB:Q=!H=&,=+CI27N2<OZ<V!"CIJDS7FHBR]Z],T _1*<YNN-6N@7TS%'1^P
M 7.SI-N(4(WJ@!SQ?I!EA]J3MHST5\I@KWNS!C47!2%]V52X?<:["7E%?&]#
MIG&Q\9U!)Y]<5>NB\FQ#UYB3P=7T35?[QG0Q%@3DBL^P:T0J-=02AMMFRC7U
M[-): @4%._KF_5O@R^EJ11WKI2O#FZY OS>&KT^3\[/GB^0&;]04=4R", FU
M3_2+&<%4[F(2B\-#.@TYFS0]+AK-X6UD$GVN84-@57@CK#3\U/1GP_&\9P).
M 0SRM/"F"NK2EI84R(S+TJAM<TK7"P$]8Q]PZGMB#A3O3N%]GZ"ZJ(/FY],;
M>+BF[)3HNG9ILB57QNV930Y/?IH'F'X8R ZD#K)/YG+;1"YWL7C/].^NKM0#
M% 5FJ"25M'[/*:PAY.^B+%+V7F!A"I6B^:>K<E!P/=DI ]!DY:1[.$.SEU3O
M.4LBM-2_.- )/VWG70Y'O<YVU'6!G3[QBY,0A.V[ 0#+2BD@HN-;Y87>>06<
M"H^?@\4\L'0X"_$ID<Q9[)=XU_EDOJX,/;+"?1S2<-N7BKK0E'WA7=H>S&&@
M1S0'-A S3+=I6KF3W?8?$HG,IR@JP)^MWIT[YM#S_6*^0[LO</B@=/@>7>43
MO0Z.'<P3M9/!>DB,5=V2K49WGJE_WDB+01-"/^9H=A_=V1+Y^I%N0VIY#!&'
M+?_QX7T_Y95>@N][U4Z4B&@J164VSKOAT#6& O;B6 )X%:/2%H>S$JOLR.-9
MK;2%7%_+X1W@N]TVZFFF:F%<.>G;@D_>*\(WR:#C*"XWECP"?!J@\):+;^0U
MGCI- 3OG[V>S[)\B,=Y<X09&ZC_;V1;&U%4YO&=<L:Q7Y1,+C:.0Z6U3U;?:
M>[W?55+K37VBN/?DV),=*?CE-(=#AR>(D+>66+5"<L3K(QP$CYO: >;B^/1D
M/O;6D6""^,">C_ZV]0F H^D(>K[+2-YEDAK2A#"H =YG;K!R7IW5\'R,+6Y]
MB!W[0:N;Y5*AV?W%?!_Z#]P#X=?TZP1?.NKU%E^?$J<^E !/35U/K[JM5Q7$
MGXFO^+LOEYP6*JTIY-91O:*GGRO6]RF,NQ-+AJIV,%O9F-CY#*R]\O->XQ%V
M?3*PT<5BP_F'MY+[T!7,SL8/&3O<HV42GI)+P<AC1&D1?/4MC0X_D!6]$ /6
ME>P9IU43[O6R S#TR[Q--I)ZJWKQT5^B*@@Z J=!NHF=)#\OF$9.^GZ%5O*^
M1QCZRYDRZ0(KR<RDC!$60TP3_HJ1^(Z/D>9K8_T(#DV0$M3^DEK-%6G 8.->
M>'3<[FNJ1&F21:DH=F;DZ5')X^@M!ZT)4!<#)Z!*5;N.$3DY)/T1<4?>'7@I
MM60P6A[+.%\=AL"?,/ G"/R)R8N2YX&W<5N\R'@405-@0 M;;4E*KER_M>64
M"-B,J[/_TLWQ*:-Z=!HD!][8V40GWT=FN9]Q*4>W X&.&*6U$7YZ737: @XL
M2,V:+XQJM)X^-UQNENV&7M<7\QVJWT9*YT] N:/,]UL&(?(?^8KR 5>$M7)
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M 9L(;O;U $K+)1N*G7\:$\4-;!WC_VJ<'./"3^B:&,20U]]M7;UV;UU1X&"
M%M\_Q&(\_RWF6V/G_E?7%P^?P)OA\=??[4!L_)S6:W1K%6X%KYZ=/K]ZR%X
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MXR_@^4YK][KP!H97>_TO4$L#!!0    ( ,P[65HR%G@79P@  $$C   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;,U:6V_;N!)^]Z\@O.DB ;2Q2%V=
M)@&:I#TMT*!!DW:Q.-@'1F)B;2712U))?7[]#JFK;5GV>MNS?;!X$3F<(6>^
MF:%U^LS%%SEC3*&O69K+L_%,J?G)9"*C&<NH/.9SEL.;!RXRJJ I'B=R+AB-
MS:0LG1#;]B<93?+Q^:GINQ'GI[Q0:9*S&X%DD654+"Y8RI_/QGA<=WQ,'F=*
M=TS.3^?TD=TR]6E^(Z U::C$2<9RF? <"?9P-GZ%3RYPH">8$9\3]BP[=:1%
MN>?\BVZ\B\_&MN:(I2Q2F@2%XHE=LC35E("//RNBXV9-/;%;KZF_,<*#,/=4
MLDN>_IK$:G8V#L<H9@^T2-5'_OR650)YFE[$4VF>Z+D::X]15$C%LVHR<) E
M>5G2K]5&[#*!5!.(X;M<R'!Y114]/Q7\&0D]&JCIBA'5S ;FDER?RJT2\#:!
M>>K\#4T$^DS3@B'^@-XD.<VCA*;H72Z5*&#[E42'=_0^9?+H=*)@13UO$E74
M+TKJ9 -U3- US]5,HM=YS.)E A-@M>&7U/Q>D$&*5RPZ1@ZV$+&).T#/:>1W
M##UGJ_P6>I_0^R1-5,(DNF94%H+%"#3G(XL*(9+\$5U0F4@+?<KYO63B26\+
M[-2\4'H,AYU+$VJ4[;_O81WT3K%,_MZW;253;C]3VA)/Y)Q&[&P,IJ978N/S
MGW_"OOUR0&2W$=D=HGY^"Y8=%VEYX!N._Y64#$Z>YG%W5_HD&5RK7Y*[&4,/
M/ 5 T'NJC'(A6 \ZA9HAI5]KOIYJOG3/)<_F-%_\_%-(</!2HH>&5]KRFG9.
M\'Z!4O;$M$&I69*ODITE3% 1S1:(*@1:Q;)[)AK-0H=F!B\DD)5')Z-+*L1"
MLVMV[+TAC*N25*4S*K<-!LL98G\6"2RE+>AD!%; %F"WXHL6LP":Z "1$%M!
MZ&^H&4G)R[8V@BW(F# RS^D<N*V';"E'UV9=HZU2Z[+9H)-U>A@6)U._*6LZ
M*VV8*.9<4,50SA5L-;9M"_M>4S;SEMNC3\>WQ^A.&--:=%A!V'>M(+";LB&P
MW"X)_(<_,9%K:%HB@6&HCYNR(;'<[O"N#T@ML1' UN.EY^I.WG'5:MP!"CW;
M\KSI4HV$4\OS ZAYOFU-IZ1S@AU;&MT64<2DA*U?&%EJW5V4H_%+])8"Q(@8
MYCO6U+8[Y9INU.]VH'HA.(T-OB>J@&UP+0]HEL]5!3*]HRLF0).U]]16JE*V
M0MFS7-NMGJL43"]L>J[ >/0T@$F9Q&![!B?7V;MCT2SG*7]<(!=4SNVH8</5
MU/\[%&\$CXM((=_QS&^5'/15Y]J%CP,$BC.%X9U*W[97+W]\3'/^+YCF.I[E
MA],-M75,VQ6:2.A98%E-65-:::]!$W$LCWAUT<Q::@[@DD<L[ 9-V8#*<GL(
METB 8:C7E T+R^U!7"+8"@-OI=@"34 =@,@/[)6ZZP4 3R[4 @>$L/UO $]P
M! :6ZK+/3LR[/> )5 =HEL]U<('>/<$%6TZ J^<J7=.[#\3 1(]4SQZB'ND'
M&JV-3K?2"S3ERX$ T&L"0&\X "PS,/3A 7T !!&PVQ'/&#I\_162/<F.= =$
MO!#]7@&JW'%T.:.P$1+ZNQ$CS&^U]G6IM;>MUKYE:=P7,0XRMW/$6.61R?]@
M)6ZD2"HI6"U%4DL1 [.*HZB28ATX 8^C ?N;@21KZ/D;HZ+*:Y:P=F3B1P.X
M\""C#_W,':!#[3OLJ8.J1FAY$"SH!K&-(0T<M=\<M;_EJ$M[NZGL;4LP/TAL
MS[0D:%@-?L1,+/@.(H>-R.'.F=AGT.4R:@#C2PNM5:!PES2-BK24! :]!E3,
M0$?CCAGV"36X["XF]M1P\\P$,]I;F4=<FT^TS)KN8@U[Z[%.[2UT2+.*\7*#
M5S"A0#UQ9=)H*;[9K3%ZLV+R60;,2\6C+^A01QER1H6Q3>(>A]J3D>"8D-7V
M2.-DI,5\XGH#C"L(0O0"P1AX8'@$4_2B':>8R-#A0B/&$;*/;0?]@MQC=ZKK
M/M2]JNZ8NN/7_;ZN#RC:M%&TZ<Z*5J*@/L7EY+]K<_J>RQA<%03":#"M7L@8
M7'AW-!>5U<+B1KD:)M>1>D!;-C'>"]X]V&UR_TT:AXSO'EW0%()TUA=B:TV9
M6K:)@::68TJ =4<'*8U '6$.(6D+8=21J055+3"IV-'00LY2T.67"]F:UJ:%
ML&'GR-1P52.0FVU9R.TDG66*"*FNF3:@E=AN+Q_M0;WLA%B72R'6%C\U3'9/
MU,:=.U/\([JJBJMO+#5II2;_CK<:7O??<5?1MN#?^*9./G&ML4M!2BR;;*#M
MVLM9724RX@4P\%%'I1A<@O8N&\H1+'I?IR4@PZMHE@ $&H D,(QHSZ*'0TG:
M4D_[H_11!A)79]K$UP]//T(]Q7;<LL/4\2 ,M'?P>/"^^WNZI^&5OX%_VD]U
M6A'2?^"H=E6_W3R7;^ESU:7KA-JA@'_PG4T.Q;5\SS5NQ+/LT#>UJ16X.WBN
M,ND^J/)D"*JL@&Q<1U]U&*^(@\I]F2QIF]/2]X8'YKK/7']LT=3VKQ,\_-])
MYRJT5LA%K]KM\;?(=JAN$WSL_9 .:H_4?KO4;:Z+MR2[W\U![9$7+X,(E;+(
MYGK=O^>BUM$E'KZ,/QEM\#JM.Q$==[+J-F@'_'6HW:Y01=L2H.H%)"]NK^_8
M83K89U ZCW#0)-MK SR8HG]7Y[''Y< _=!Z=XVVO&;^-L]CF SH7CZ-W.6P6
M30WGC[I>JF0O=Y"(!'X_?&,2;@/J\F^C/DV8=+YJR)AX--]N2&24N/S H>EM
MO@]Y57X5T0XO/RZYIN(Q =-+V0-,M8\# "I1?J]1-A2?FV\D[KE2/#/5&:,@
MKAX [Q\X5W5#+]!\-7/^%U!+ P04    " #,.UE:Y^HCKHP#  !D"   &0
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M=WK7:!D7QI&R!5*_;A,3+3&V3<P9/I-;M>1T2ZXU6R/3@*Z@@,H!RQ1U6Q+
M#+ED2KM=[CH]TQ6)^$2CR]!=NBM6A**IH[1&:5M"[J;)PT7(*)P2//>%D#+!
M)#&I!R/3Z&+,E: 99H:=2:DJ:3N3)L[+7#>NS/[!-((W<'AP$?6BR\[-AAR7
MGE0.YR?Q(.[,V)IFGC5P!+V3P6  Q_\>IT]Q8D([VT;SBO]!BY]9PZ[R#;>F
M3XEZX6>LH?.D,ZH'4:MMQ_BDGE[/YO4;<,OT@M.M"YR3:_?TW5D NIZK]<*J
MI9]EJ;(T&;U8T%.$VAG0_EPINUFX .WCEOP"4$L#!!0    ( ,P[65J:(2[8
M.P,  &$)   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,56;6_;-A#^
M[E]Q4(<B 8SHQ7:2I;:!V%W0 BUFU%V+H=@'6CK)1"E2(ZDXZ:_OD9(5=W#4
M=!O0+R*/O'OXW.GARW2G]&>S1;1P5PII9L'6VNHJ#$VZQ9*9,U6AI)E<Z9)9
M,G41FDHCRWQ0*<(DBL[#DG$9S*=^;*7G4U5;P26N-)BZ+)F^7Z!0NUD0!_N!
M=[S86C<0SJ<5*W"-]H]JI<D*.Y2,ER@-5Q(TYK/@.KY:3)R_=_C <6<.^N R
MV2CUV1FOLUD0.4(H,+4.@5%SBTL4P@$1C;];S*!;T@4>]O?H-SYWRF7##"Z5
M^,@SNYT%EP%DF+-:V'=J]PK;?#S!5 GCO[!K?:, TMI85;;!Q*#DLFG975N'
MIP0D;4#B>3<+>98OF67SJ58[T,Z;T%S'I^JCB1R7[J>LK:993G%V_H:G5&&$
MZT(C4K&M@9/W;"/0G$Y#2PLXMS!MP18-6/((6)S 6R7MUL!O,L/L6X"0F'7T
MDCV]1=*+^!+3,QC%0TBB9-R#-^K2'7F\T2-XO^N"2?Z%.44,8:FD48)GK!&(
MS&"ET5 1F@&5PPV73*:<"5C38%N@3]<;8S7IZ:]C)6H(C(\3<'OLRE0LQ5E0
MN;7T+0;SY\_B\^A%3WKC+KUQ'_I\37LVJP4ZZNLZ3=$86+%[1QO><+;A@MO[
M8Z1[88^3?K]%R)6@7<UE =9IIMW:_ L:L#2]5&7%Y/WS9Y=)?/'"T'1#J6HI
MB3TE M+PBNE;IC,XX9*B56WHAYC3JP%I ,L-:J^#0V.PCW@<]Q<8#7^-(FHG
M0SJGX'\GO="*9?!:&LMM;;&7_,")V"EY-/AG6%\&X^&DS>"<VAZ53#J53)ZL
MDN66R0*!6-\PKN$#$_6/JZ=_N2?4'.\J?PJ1N.@T=6ZY5J6?2CN"SLH=R=L]
M23?R[S3U)S+=GE)P_!>Y3S)X*,^W*S]%>2<0#T?TQTY]?S2\[/IQ,HR\\3-+
M\SWE_M<2_8C$7:GB@U)=/)0J]OOW])CLPX-KKT1=^,O=0*IJ:9L;L!OMW@_7
MS;7YX-X\/MXR77!I0&!.H='9!4E:-Q=Z8UA5^4MTHRQ=R;Z[I3<0:N= \[E2
M=F^X!;I7U?PK4$L#!!0    ( ,P[65JEJ(4CN 4  +T-   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;(U7VV[;.!!]]U<,W L20)8EZNHT,>"TW6X?
MN@V:IL5BL0^T1-M")-$E:;O>K]\94G:<7<?-BT12P^&9X9E#ZG(CU;U>"&'@
M9U.W^JJ_,&9Y,1SJ8B$:KGVY%"U^F4G5<(-=-1_JI1*\M).:>LB"(!TVO&K[
MXTL[=J/&EW)EZJH5-PKTJFFXVEZ+6FZN^F%_-_"EFB\,#0S'ETL^%[?"W"UO
M%/:&>R]EU8A65[(%)697_4EX<9V1O37X5HF-/F@#13*5\IXZ'\NK?D" 1"T*
M0QXXOM;BK:AK<H0P?G0^^_LE:>)A>^?]-QL[QC+E6KR5]?>J-(NK?MZ'4LSX
MJC9?Y.9WT<63D+]"UMH^8=/9!GTH5MK(IIN,")JJ=6_^L\O#<R:P;@*SN-U"
M%N4[;OCX4LD-*+)&;]2PH=K9"*YJ:5-NC<*O%<XSXULCBWOXO'0I:DOXH'AK
MX*;F+9Q]Y=-:Z//+H<&5R'Y8=%ZOG5?VA->0P2?9FH6&]VTIRL<.A@AQCY/M
M<%ZSDQ[?B<*'*/2 !2P^X2_:QQU9?]%3<2^X$H-KW,\2;O@6:69@HC#VN;#M
MOR93;11RYN]CT3O?\7'?5$<7>LD+<=7'0M%"K45__/I%F 9O3B"/]\CC4]['
MMZY\0,[ ;MY@:H-X*QLL5,WM1K[_26UQ#/I)Y\>A'RY3'"XCW#)8G(54N,_
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MWN>50;%J2P+"S2,2.?[D'LM2+XA(-F+F)R/(?*L<H9<F4:\K%V!>FN5>&"?
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MV73;BTXO%)!M)H!823B[G?[X2D# .%@Q[6EN8CYT'@F]X@A>E-DC90]\2XA
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M']> ,Q#&0+]?<JY>&F: YJ)Y]@]02P,$%     @ S#M96N:YO[_5 @  C@D
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M UT5_ZJ#JO %=Z[0EF_?S.V!";0;8-]G2N&FXVIX?00;_P-02P,$%     @
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M_PX/S\@)N^4(+5]X@J^O[M\F*ZF$WN_?^PK6\ WZ^4P/N)-KG,+8T8=<@MB
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M1'@^05V?,R8W)_D-JNW1\7]02P,$%     @ S#M96LIZO;_, P  S@\  !D
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M:W-H965T<R]S:&5E=#4S+GAM;,U736_;.!#]*X2V6+3 )A+U93MK&ZB=#39
M@PV2ICT4>Z"EL464(KTD9;?_?DE)D25;=EK$AUYLB9IY?/.&&LV,MT)^51F
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MX%<6A!J@O7,XBO?I'1IUA.ZR\W?L_)/L[J5(BT2_4!!.@_SLF3X76C?D78.
M?\$. 9^U13@76E?!79. S] EU!C= QOM?X-[K.(P&!XYUKL^ 9^G4< ]/<
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M+824=@]C#XI]DXC)DB?)20O[^$FR8Z?#T:!=H"^Q)>L>G7MU[),[V CY4ZT
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M;HJ1]]DC.2QHQ<VMW'R'1H]S,)-<NU^R:6P#CV25-K)LP.A!R43]I8]-'/8
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M4X77>1CV@(FA'2Q>LZ@0O_PX6OR=YELJ5CPR]_)*7ZNQ*J&6!Y3F06D^E!9
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M4JX@?E\5!7]<D!7L7RES^7]02P,$%     @ S#M96L8WC#0' P  [ D  !D
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M@4R357>+JB%HJ4_;!17R[-:/F;R.(:8 <GQ)J=@UU 3-!2_Z!U!+ P04
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M,QJU<Z#SE5)V;[@QT$W]]#=02P,$%     @ S#M96E'WCT33 @  P <  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULK55M3]LP$/XK5H8FD 9Y;0>L
MC43)IB&!0'1L'Z9]<!.GL7#LS'9:]N]W=M+0EU#U U\:W_F>Q_><Z[O14LAG
M51"BT4O)N!H[A=;5I>NJM" E5F>B(AQV<B%+K,&4<U=5DN#,@DKF!IXW=$M,
MN1./K.]!QB-1:T8Y>9!(U66)Y;\)86(Y=GQGY7BD\T(;AQN/*CPG4Z*?J@<)
MEMNQ9+0D7%'!D23YV+GR+Y.!B;<!/RE9JK4U,DIF0CP;XR8;.YY)B#"2:L.
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M=: TMYDZPH'K!>KYDC'Y-M"G2O^G(/X'4$L#!!0    ( ,P[65J49/#D2 0
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MVK(8=<5&BY6=%G.A<?;898)?!R"- 3Y?"*%W&W-!];T1_@902P,$%     @
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M6.94PZGDOUAJLJEWX)$4%K3DYE*NOD$3SY[E2R37U3]9-;8#CR2E-E(T8/1
ML+Q^TH=&AS7 </0*(&@ P5L!80,(WPH8-8!1I4P=2J5#3 V-)DJNB++6R&8;
ME9@5&L-GN=WV*Z-PEB'.1%]+E@(Y3NY*IEFU$Y_)<9I63<K)>5YGEIW8CL%0
MQO4G-+FYBLGVUB>R15A.KC-9:IJG>N(;=,D2^TFS_$F]?/#*\C$DNR0<[I!@
M$(PZX*=OAX<=\+@??@;S71*$%7RX"?=1QU;,H!4SJ/C"5_A.2HTC6F_H^?L[
MCI%S T+_Z1*HIAQU4]I3?Z0+FL#4PV.M0=V#%WW\,!P/OG3)Y9(L=D2V(678
M2AGVL4>G,C<L7T)N2"*QR*2@ZBSDC,X91VFA,]UJUG'%:DO>?30<AKBW]^LJ
MO30*]FW^K!O%O?[]8_2C-OI1;_3UJ;S.,.@"2L,2O8-'$7/]B5R 6H(BQTL%
M(*P\3^0:DBR77"X?R07C@#4#D]":T@<F2H$M6R(1=&5D<IM)CF)J@@>6_"BL
MILU(EYR];KXW.5V2Q8[(-K9GK]V>/??G?,^EE"[)8D=D&U*.6RG'O9D^DP:3
MF.&K1CRG+BGH(YUSL*\6^_8A<H$U0 C46-L$[A*W=Y'WBNN2+!Z_+$@#^VNK
MS89L^ZUL^PX+Q$S)M$R,\^K0Z^-[57=)%CLBV]B;@W9O#MQ7AP.74KHDBQV1
M;4AYV$IY^#^J0^\B[Q77)5E\^/)+).BH#O[:![Z]C5U0M62Y)AP6"!SL[F,)
M5_4-I^X8653?_'-I\ 91-3.\%(*R!CB_D*ALT['7B/::&?T%4$L#!!0    (
M ,P[65HJ*T(4RP(  # (   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM
M;*U6WV_:,!#^5ZRLFCII)2$);=5!)"";5JG5JE;='J8]F.1(K#IV9AMH__N=
MG9!!"Z@/O!#_N.^[N^^2.X8KJ9YT"6#(<\6%'GFE,?65[^NLA(KJGJQ!X,U<
MJHH:W*K"U[4"FCM0Q?TP",[]BC+A)4-W=J>2H5P8S@3<*:(75475RP2X7(V\
MOK<^N&=%:>R!GPQK6L #F,?Z3N'.[UAR5H'03 JB8#[RQOVK=&#MG<%/!BN]
ML28VDYF43W9SG8^\P 8$'#)C&2@^EC %SBT1AO&WY?0ZEQ:XN5ZS?W.Y8RXS
MJF$J^2^6FW+D77HDASE=<',O5]^AS<<%F$FNW2]9M;:!1[*%-K)JP1A!Q43S
MI,^M#AN _OD>0-@"PM> > \@:@'1>P%Q"XB=,DTJ3H>4&IH,E5P19:V1S2Z<
MF Z-Z3-AR_Y@%-XRQ)GDAF580R#C0@%@.8TF9V2<Y\Q6A7)R+9I7R];H- 5#
M&=>?T.3Q(26G)Y_("6&"W#+.T4 /?8,A66(_:]U/&O?A'O?]D-Q*84I-OHH<
M\FT"'W/I$@K7"4W"@XPI9#T2]3^3, CC'0%-WP^/=L#3]\/# ]E$77DBQQ?O
MX;L'#51E):$B)RDL\3.M;95V*7V0R;:/*UW3#$8>]@<-:@E>\O%#_SSXLDNE
M8Y*E1R+;4C#N%(P=>[1'06P(G,ZDHK:_D+%25!3N17>2;NY_F!(4,2459!OT
M^P8YR;6!2O_9)7Q\3.&/298>B6Q+^$$G_.#@JSO%[YJAMJBLG'%6N!ZBG>I"
MBC,E7R@W+SAO\++I07. G2VD\7/I_-@QMDRB'GY<RTW9WMK$46^P;92^-0I[
M%YU-DZ6_T4LK4(6;29ID<B%,TX6ZTV[LC5VW?W4^P7'83*__-,TLO:6J8"@%
MASE2!KT+C$LU\ZG9&%F[CCV3!ON_6Y8XTD%9 [R?2VG6&^N@^Y.0_ -02P,$
M%     @ S#M96D$8)RIY"   RB\  !D   !X;"]W;W)K<VAE971S+W-H965T
M-S N>&ULS5IK;^.V$OTKA%L462"Q+27.8YL8R$:W:(JF#3:[]WXH[@=:&MO$
M2J1+4G%<],=W2.II*TI<,$ 6R-J6R,/A&7)F#J7+M9#?U!) DZ<LY>IJL-1Z
M]7$T4O$2,JJ&8@4<[\R%S*C&GW(Q4BL)-+&=LG04CL>GHXPR/IA>VFOW<GHI
M<ITR#O>2J#S+J-Q\@E2LKP;!H+SPF2V6VEP832]7= $/H+^N[B7^&E4H"<N
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MTP#OSX70Y0\S0/7Z_O0?4$L#!!0    ( ,P[65K60<*79P(  %8&   9
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M2T#3*E.$8G6(L,)A5_ E$L9:LYF!%=.B=?B$F;2/E="[1.-4>$-BG4- _9D
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MUZA']>/N;?1[JI8<+#!E"U@Z'IY#3%/N!6_WQ<C<OO(\E\;(S'Y<,9HPA0_
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MG8>Z1D39,Y43Q1>VBYARI7L2.\QTFPG"&.C]&>=J/3$?J!O7Z ]02P,$%
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M1R5?42!<<=1$.H-Q0\ 'B\9+-OKJ7(4'DO G<1SL)CQ92C9B4^TCTW&4T.6
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M-Q%E..GVXT/\OR+K#0YH'BVJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%I(:=T
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M"JTE=ELZ4\VKK:J_SOU4?IU[MFW_A*]UR]Y-+IO>76CF.I-V5G'5;BJ>8GE
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M+:HK-W_)Y6W ^3R3-PR)6DE(4@[C?TGFHMHV-8[/-QWHV=#V_OL2+\H'0>7
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M+=OWNOQ1QY&^\''$/C5^L)S.<@;+F2QGL9S-<@[+N2SG;;CV\XC>XL4^VW#
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M+I P%PGSD# ?"0M L)Z\G*V\'!V]&?3>+6K9A+OR8D_R-5,)1DL\53!(F-O
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M[VD3\T98FFD+:O8>:9%I')QI7&A#/"C-A]("%*TOB\Y%MO0NLKQ;I)ZWE'*
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M)**PT93>^5B?&Z)J7:J)XJ6]S-]QI5L#.\QUNP?"&.CW&\[5X\1\H&D@%S\
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MIB>IV=[4L;SNIJKL?.A2&4FLQ0D:C2<SE)7[>^%620CPGE#AO@&I]A:PHU%
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ML&RJFQNLA$'9 'R_DM(\=VR"KK9.?P!02P,$%     @ S#M96HK&=E,B!
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M- B] .]'G*O]A=Z@[LJ]7U!+ P04    " #,.UE:S4K-=0D#  "6"@  &0
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MO:'>]**J@JJ&XJ6M"Q9<Z2K#/N:Z< 1A O3[C'.U;9@!FE(T_@=02P,$%
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MUKF82.B2)I.Z*[.I:7JZH;/6%Q!VD1MSN1&,8S$W AB6!W. <2P+R_,_S6>
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M3*!W1KTS@=X9]<X$>F?4.Q/HG5'O3*!WGASV)M [H]Z90.\&]6X(]&Y0[X9
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MH<AJ*+*N*;*N*;*N_Z>LWX=A_X_CYV?:V:9_S<_FOQS=_ 102P$"% ,4
M" #,.UE:!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( ,P[65IWXV[D[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,P[65J97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ S#M96F)M8B:^"@  ^SH  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,P[65JH&<2G
ME 8  !H<   8              " @0$3  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " #,.UE:B'+)I^D"   %"@  &
M@('+&0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ S#M9
M6D:@@X-O!@  3!L  !@              ("!ZAP  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( ,P[65H+ZS\.N H  ,UN   8
M      " @8\C  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" #,.UE:!<NG4F$"  "Q!0  &               @(%]+@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ S#M96G9/'(F+"0  CB\  !@
M             ("!%#$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( ,P[65HE#HR : (  (L&   8              " @=4Z  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #,.UE:E&#<:8H$  "=
M#0  &               @(%S/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ S#M96E9.UZ6W"0  %"P  !D              ("!,T(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #,.UE:K?NZ
ML@,)   (%@  &0              @($A3   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( ,P[65J@EYZANR<  +"%   9
M  " @5M5  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MS#M96OCPV=4T P  'P<  !D              ("!37T  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " #,.UE:NH4,5+D.  "",@  &0
M            @(&X@   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( ,P[65I-L)I1W 0  (D+   9              " @:B/  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ S#M96GU5O^?W @
MC 8  !D              ("!NY0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " #,.UE:Y:AJ/+4&  !S$0  &0              @('I
MEP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,P[65KB
M03NU-@0  "8*   9              " @=6>  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ S#M96CN=&8(T$@  KTT  !D
M     ("!0J,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" #,.UE:2%U>7!<?  #4?0  &0              @(&MM0  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,P[65ICX-$B P0  ' )   9
M              " @?O4  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ S#M96@1&!KJ_#   S"0  !D              ("!-=D  'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #,.UE:,89=LV4$
M  "&"@  &0              @($KY@  >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    ( ,P[65J(,M4VVP@  .L5   9              "
M@<?J  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ S#M9
M6DD83RPZ P  *@<  !D              ("!V?,  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " #,.UE:(/%HI3L#   L!P  &0
M        @(%*]P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( ,P[65H@D:II=P8  -4.   9              " @;SZ  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ S#M96O-![=M.,@  >[4
M !D              ("!:@$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " #,.UE:[6N=2I,$  #6"@  &0              @('O,P$
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,P[65HWMZRU
M6@,  ,$'   9              " @;DX 0!X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ S#M96C(6>!=G"   02,  !D
M ("!2CP! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #,
M.UE:Y^HCKHP#  !D"   &0              @('H1 $ >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,P[65H<DFI; 0,  &\&   9
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M970S-RYX;6Q02P$"% ,4    " #,.UE:,3&*:R,$  "\"0  &0
M    @('K7 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M ,P[65I_ N;(B 0  /L)   9              " @45A 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ S#M96LHD[,Q!!   )PD  !D
M             ("!!&8! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " #,.UE:4I3C.&8&  !C,   &0              @(%\:@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,P[65KQ=RQDYP(
M &P)   9              " @1EQ 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ S#M96H!-B519!   =!8  !D              ("!
M-W0! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #,.UE:
MYKF_O]4"  "."0  &0              @(''> $ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,P[65J7Z=%3QP(  #D'   9
M      " @=-[ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ S#M96A7B8G/E P  [A,  !D              ("!T7X! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #,.UE:XR?N]XX"  #&!@
M&0              @('M@@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( ,P[65H\Z^';;PL   IN   9              " @;*% 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ S#M96GP R00=
M!P  A4   !D              ("!6)$! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " #,.UE:5MS]'\("   .!P  &0
M@(&LF $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,P[
M65IS!/RXH@0  "H=   9              " @:6; 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ S#M96LIZO;_, P  S@\  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( ,P[65K+N01+/ 4  )P>   9
M  " @3NT 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MS#M96KP)6:?0 @  (P@  !D              ("!KKD! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " #,.UE:B@V@2B,#   S"0  &0
M            @(&UO $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( ,P[65K':;Z&X0D  %YF   9              " @0_  0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ S#M96L8WC#0' P
M[ D  !D              ("!)\H! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    " #,.UE:@[:MM5@"   !!@  &0              @(%E
MS0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( ,P[65I1
M]X]$TP(  , '   9              " @?3/ 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ S#M96MJ/C;CM @  ( @  !D
M     ("!_M(! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,P[65HJ*T(4RP(  # (   9              "
M@7GE 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ S#M9
M6D$8)RIY"   RB\  !D              ("!>^@! 'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    " #,.UE:UD'"EV<"  !6!@  &0
M        @($K\0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0
M   ( ,P[65J='JZE"@,  +X*   9              " @<GS 0!X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ S#M96CJ#^JM_"   <B\
M !D              ("!"O<! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q0
M2P$"% ,4    " #,.UE:]_%>^&P"  !<!@  &0              @(' _P$
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( ,P[65H>;/B0
M# ,  ,0*   9              " @6," @!X;"]W;W)K<VAE971S+W-H965T
M-S4N>&UL4$L! A0#%     @ S#M96O@TF/1#!@  =1$  !D
M ("!I@4" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #,
M.UE:32\CSZLI   #,@( &0              @($@# ( >&PO=V]R:W-H965T
M<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( ,P[65JXMSP87 4  'PB   9
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M970X,BYX;6Q02P$"% ,4    " #,.UE:A_O\[2\#  !6"@  &0
M    @(% 4P( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    (
M ,P[65J\=>!/\ ,  -$2   9              " @:96 @!X;"]W;W)K<VAE
M971S+W-H965T.#0N>&UL4$L! A0#%     @ S#M96K'^=P]B P  T@L  !D
M             ("!S5H" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"
M% ,4    " #,.UE:E[W_N7 #  !G"P  &0              @(%F7@( >&PO
M=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( ,P[65J*QG93(@0
M &0.   9              " @0UB @!X;"]W;W)K<VAE971S+W-H965T.#<N
M>&UL4$L! A0#%     @ S#M96LYG%M\J!   "10  !D              ("!
M9F8" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4    " #,.UE:
M!W2>VK #  "A#P  &0              @('':@( >&PO=V]R:W-H965T<R]S
M:&5E=#@Y+GAM;%!+ 0(4 Q0    ( ,P[65K-2LUU"0,  )8*   9
M      " @:YN @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%
M  @ S#M96K5QWR(] P  MP<  !D              ("![G$" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " #,.UE:!B2<@7\%  #4&0
M&0              @(%B=0( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+
M 0(4 Q0    ( ,P[65K<2G/X20,  *P4   -              "  1A[ @!X
M;"]S='EL97,N>&UL4$L! A0#%     @ S#M96I>*NQS     $P(   L
M         ( !C'X" %]R96QS+RYR96QS4$L! A0#%     @ S#M96IG;ZBN?
M!@  RSP   \              ( !=7\" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ,P[65H<1N&VJP(  "LV   :              "  4&& @!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,P[65K-'F2\0 (
M 'HT   3              "  22) @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !D &0 <QL  )6+ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>381</ContextCount>
  <ElementCount>462</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Other Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Strategic Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1</Role>
      <ShortName>Strategic Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Stock Option and Grant Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan</Role>
      <ShortName>Stock Option and Grant Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Segment Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData</Role>
      <ShortName>Segment Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Strategic Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables</Role>
      <ShortName>Strategic Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995745 - Disclosure - License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables</Role>
      <ShortName>License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Stock Option and Grant Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables</Role>
      <ShortName>Stock Option and Grant Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Segment Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables</Role>
      <ShortName>Segment Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai</Role>
      <ShortName>Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Leases - Summary of Operating Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Leases - Summary of Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Summary of Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Leases - Summary of Future Maturity of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Maturity of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Equity Method Investment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails</Role>
      <ShortName>Equity Method Investment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Strategic restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails</Role>
      <ShortName>Strategic restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails</Role>
      <ShortName>Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Guide Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Guide Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996115 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996125 - Disclosure - License Agreements - Harvard License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Harvard License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996135 - Disclosure - License Agreements - Harvard License Agreement - Success Payment Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails</Role>
      <ShortName>License Agreements - Harvard License Agreement - Success Payment Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996145 - Disclosure - License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails</Role>
      <ShortName>License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996155 - Disclosure - License Agreements - Broad License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Broad License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996165 - Disclosure - License Agreements - Broad License Agreement - Success Payment Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails</Role>
      <ShortName>License Agreements - Broad License Agreement - Success Payment Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996175 - Disclosure - License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails</Role>
      <ShortName>License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996185 - Disclosure - License Agreements - Editas License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Editas License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Stock Option and Grant Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails</Role>
      <ShortName>Stock Option and Grant Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996235 - Disclosure - Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails</Role>
      <ShortName>Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996255 - Disclosure - Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails</Role>
      <ShortName>Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996265 - Disclosure - Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996275 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996285 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996295 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996305 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996315 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996345 - Disclosure - Segment Data - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails</Role>
      <ShortName>Segment Data - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="beam-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996355 - Disclosure - Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails</Role>
      <ShortName>Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="beam-20241231.htm">beam-20241231.htm</File>
    <File>beam-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img43983261_0.jpg</File>
    <File>img43983261_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="918">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "beam-20241231.htm": {
   "nsprefix": "beam",
   "nsuri": "http://beamtx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "beam-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "beam-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 370,
   "keyCustom": 92,
   "axisStandard": 36,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 54,
   "hidden": {
    "total": 19,
    "http://fasb.org/us-gaap/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 1,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 381,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 951,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 918,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100050 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss",
     "longName": "100060 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
     "longName": "100070 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100080 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c8171dae-98d5-431f-8a83-4520d464b7e9",
      "name": "beam:StockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8171dae-98d5-431f-8a83-4520d464b7e9",
      "name": "beam:StockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100090 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_13e504bd-d42c-4cb7-9480-fe49e29deb03",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_13e504bd-d42c-4cb7-9480-fe49e29deb03",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "995465 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995485 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments",
     "longName": "995495 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities",
     "longName": "995505 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995515 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995525 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1",
     "longName": "995535 - Disclosure - Strategic Restructuring",
     "shortName": "Strategic Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements",
     "longName": "995555 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "longName": "995565 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock",
     "longName": "995575 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan",
     "longName": "995585 - Disclosure - Stock Option and Grant Plan",
     "shortName": "Stock Option and Grant Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "longName": "995595 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995605 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "995615 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits",
     "longName": "995625 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData",
     "longName": "995635 - Disclosure - Segment Data",
     "shortName": "Segment Data",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995655 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995665 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995675 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "longName": "995685 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables",
     "longName": "995695 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995715 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables",
     "longName": "995725 - Disclosure - Strategic Restructuring (Tables)",
     "shortName": "Strategic Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables",
     "longName": "995745 - Disclosure - License Agreements (Tables)",
     "shortName": "License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables",
     "longName": "995755 - Disclosure - Stock Option and Grant Plan (Tables)",
     "shortName": "Stock Option and Grant Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "995765 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995775 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables",
     "longName": "995785 - Disclosure - Segment Data (Tables)",
     "shortName": "Segment Data (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "995805 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_23c34874-bdc1-42e6-b9e3-2958be00d4e1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails",
     "longName": "995825 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_18b725ca-8307-4b02-bf86-cd5bacd75fe4",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18b725ca-8307-4b02-bf86-cd5bacd75fe4",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails",
     "longName": "995835 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Changes in Total Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_149701ae-170a-49a0-bd98-e2e011d76e53",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails",
     "longName": "995855 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)",
     "shortName": "Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:SummaryOfDepreciationExpenseIncurredTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:SummaryOfDepreciationExpenseIncurredTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
     "longName": "995865 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_4b443d77-d326-4c74-b2e0-a91039c22fd7",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1032047d-f16a-438d-95bb-df888c1ca808",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)",
     "shortName": "Fair Value of Financial Instruments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f74446ed-1db8-4037-8b3c-5b97e15acbc4",
      "name": "beam:SettlementAgreementUpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai",
     "longName": "995885 - Disclosure - Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)",
     "shortName": "Fair Value of Financial Instruments - Summarizes Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
     "longName": "995895 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
     "longName": "995905 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_0bc8b385-01b6-4b97-b455-c669606db4c9",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f7d01556-0db0-4405-b94b-9d3f9b6e51a6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
     "longName": "995915 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_9b047b26-6d29-4529-a19f-49dec29b0738",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d2b86f6d-7df8-4851-bf8a-c817cab8b129",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
     "longName": "995925 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821",
      "name": "beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821",
      "name": "beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
     "longName": "995935 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357",
      "name": "beam:SettlementPaymentsExpectedAchievementYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357",
      "name": "beam:SettlementPaymentsExpectedAchievementYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
     "longName": "995945 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_6605f422-e078-49c1-bb32-3b2f67d8c39b",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6605f422-e078-49c1-bb32-3b2f67d8c39b",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
     "longName": "995955 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995965 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995975 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "beam:AccruedContingentObligationLicenseAgreementCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "beam:AccruedContingentObligationLicenseAgreementCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ccb1a659-fef4-488d-b02f-e973d39dbbf9",
      "name": "beam:OperatingLeaseCommencementMonthAndYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails",
     "longName": "996005 - Disclosure - Leases - Summary of Operating Lease Costs (Details)",
     "shortName": "Leases - Summary of Operating Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails",
     "longName": "996015 - Disclosure - Leases - Summary of Lease Term and Discount Rate (Details)",
     "shortName": "Leases - Summary of Lease Term and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:OperatingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:OperatingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails",
     "longName": "996025 - Disclosure - Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details)",
     "shortName": "Leases - Summary of Lease Costs Included in Measurement of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails",
     "longName": "996035 - Disclosure - Leases - Summary of Future Maturity of Operating Leases (Details)",
     "shortName": "Leases - Summary of Future Maturity of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
     "longName": "996065 - Disclosure - Equity Method Investment - Additional Information (Details)",
     "shortName": "Equity Method Investment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails",
     "longName": "996075 - Disclosure - Strategic restructuring - Additional Information (Details)",
     "shortName": "Strategic restructuring - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_26e65229-9380-4e02-a80b-356c8953d6fd",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "U_Positions",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_26e65229-9380-4e02-a80b-356c8953d6fd",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "U_Positions",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails",
     "longName": "996085 - Disclosure - Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details)",
     "shortName": "Strategic restructuring - Schedule of Restructuring Liability Activity for Company's Workforce Reductions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_149701ae-170a-49a0-bd98-e2e011d76e53",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
     "longName": "996095 - Disclosure - Guide Acquisition - Additional Information (Details)",
     "shortName": "Guide Acquisition - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "longName": "996115 - Disclosure - License Agreements - Additional Information (Details)",
     "shortName": "License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_66014777-6584-477d-9aa8-ffa7abbe1249",
      "name": "beam:ContingentObligationAndNonRoyaltySublicenseFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "beam:LicenseAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_66014777-6584-477d-9aa8-ffa7abbe1249",
      "name": "beam:ContingentObligationAndNonRoyaltySublicenseFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "beam:LicenseAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
     "longName": "996125 - Disclosure - License Agreements - Harvard License Agreement - Additional Information (Details)",
     "shortName": "License Agreements - Harvard License Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_8f838b8f-003d-4c56-9981-96bf4aa3558f",
      "name": "beam:SuccessPaymentAmountDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f838b8f-003d-4c56-9981-96bf4aa3558f",
      "name": "beam:SuccessPaymentAmountDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails",
     "longName": "996135 - Disclosure - License Agreements - Harvard License Agreement - Success Payment Liability (Details)",
     "shortName": "License Agreements - Harvard License Agreement - Success Payment Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_800475ef-859c-4969-8401-92e0526a5add",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
     "longName": "996145 - Disclosure - License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)",
     "shortName": "License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_623147d8-2cfc-43d4-ad7a-4b423fda8bc2",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "beam:ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
     "longName": "996155 - Disclosure - License Agreements - Broad License Agreement - Additional Information (Details)",
     "shortName": "License Agreements - Broad License Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_ad5b92a4-0e86-485f-829d-78650bd85771",
      "name": "beam:SuccessPaymentAmountDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ad5b92a4-0e86-485f-829d-78650bd85771",
      "name": "beam:SuccessPaymentAmountDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
     "longName": "996165 - Disclosure - License Agreements - Broad License Agreement - Success Payment Liability (Details)",
     "shortName": "License Agreements - Broad License Agreement - Success Payment Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_ad5b92a4-0e86-485f-829d-78650bd85771",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
     "longName": "996175 - Disclosure - License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)",
     "shortName": "License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2003a022-90cd-4bc2-bf5e-3e183c02ed3c",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
     "longName": "996185 - Disclosure - License Agreements - Editas License Agreement - Additional Information (Details)",
     "shortName": "License Agreements - Editas License Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_30808f53-fe50-4e76-b73c-7f5690993b05",
      "name": "us-gaap:CollaborativeArrangementNatureAndPurpose",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_30808f53-fe50-4e76-b73c-7f5690993b05",
      "name": "us-gaap:CollaborativeArrangementNatureAndPurpose",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "longName": "996205 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3e53934-eb8b-4bda-9434-0a170bb66af3",
      "name": "us-gaap:CollaborativeArrangementNatureAndPurpose",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "longName": "996215 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
     "longName": "996225 - Disclosure - Stock Option and Grant Plan - Additional Information (Details)",
     "shortName": "Stock Option and Grant Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "996235 - Disclosure - Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)",
     "shortName": "Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_66014777-6584-477d-9aa8-ffa7abbe1249",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
     "longName": "996245 - Disclosure - Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)",
     "shortName": "Stock Option and Grant Plan - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails",
     "longName": "996255 - Disclosure - Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details)",
     "shortName": "Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_149701ae-170a-49a0-bd98-e2e011d76e53",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails",
     "longName": "996265 - Disclosure - Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)",
     "shortName": "Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_610ac957-5c8d-4898-bdab-ead2ab364037",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_610ac957-5c8d-4898-bdab-ead2ab364037",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "996275 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "996285 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails",
     "longName": "996295 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails",
     "longName": "996305 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4371d-f11f-4b07-a378-d85c1e344ff3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996315 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "996325 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:NumberOfFounderShareholders",
      "unitRef": "U_Founder",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:NumberOfFounderShareholders",
      "unitRef": "U_Founder",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails",
     "longName": "996335 - Disclosure - Employee Benefits - Additional Information (Details)",
     "shortName": "Employee Benefits - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:DefinedContributionPlanName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:DefinedContributionPlanName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails",
     "longName": "996345 - Disclosure - Segment Data - Additional Information (Details)",
     "shortName": "Segment Data - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
     "longName": "996355 - Disclosure - Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)",
     "shortName": "Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf",
      "name": "beam:FacilityAndInformationTechnologyRelatedExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beam-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2023-07",
        "label": "Accounting Standards Update 2023-07 [Member]",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1027"
     ]
    },
    "beam_AccruedContingentObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedContingentObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Contingent Obligation Current",
        "documentation": "Accrued contingent obligation current.",
        "terseLabel": "Accrued contingent obligation"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AccruedContingentObligationLicenseAgreementCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedContingentObligationLicenseAgreementCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Contingent Obligation License Agreement Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a licensing agreement, expected to be settled within one year or the normal operating cycle, if longer.",
        "terseLabel": "Accrued contingent obligation"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities for license fees",
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued Liabilities, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "beam_AccruedLiabilitiesForLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedLiabilitiesForLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities for license fees",
        "label": "Accrued Liabilities For License Fees",
        "documentation": "Accrued liabilities for license fees."
       }
      }
     },
     "auth_ref": []
    },
    "beam_AccruedProcessDevelopmentAndManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedProcessDevelopmentAndManufacturingCosts",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for process development and manufacturing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Process Development And Manufacturing Costs",
        "terseLabel": "Process development and manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "beam_AccruedResearchCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AccruedResearchCosts",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r192",
      "r783"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r101",
      "r199",
      "r778",
      "r825",
      "r829"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r24",
      "r596",
      "r599",
      "r683",
      "r820",
      "r821",
      "r1193",
      "r1194",
      "r1195",
      "r1204",
      "r1205",
      "r1206",
      "r1208"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "beam_AdditionalFeePerAdditionalOptionRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AdditionalFeePerAdditionalOptionRight",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional fee per additional option right",
        "label": "Additional Fee Per Additional Option Right",
        "documentation": "The amount of fee per additional option right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1027",
      "r1353"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r1204",
      "r1205",
      "r1206",
      "r1208",
      "r1290",
      "r1354"
     ]
    },
    "beam_AdditionalSuccessPaymentAmountDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AdditionalSuccessPaymentAmountDue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional success payment amount due",
        "label": "Additional Success Payment Amount Due",
        "documentation": "The remaining amount of success payments that may become due as part of a licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r236",
      "r237",
      "r238",
      "r239",
      "r250",
      "r314",
      "r315",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r398",
      "r399",
      "r403",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r640",
      "r641",
      "r653",
      "r654",
      "r655",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r730",
      "r731",
      "r732",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of redeemable convertible preferred stock to redemption value",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r123",
      "r128"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r481"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AggregateMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AggregateMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate milestone amount",
        "label": "Aggregate Milestone Amount",
        "documentation": "The aggregate amount the Company is obligated to pay upon achievement of specified milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1088",
      "r1098",
      "r1131"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1091",
      "r1101",
      "r1134"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1126",
      "r1135",
      "r1139",
      "r1147"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r516"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Alternate investment, measurement input",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "beam_AmySimonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AmySimonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amy Simon [Member]",
        "documentation": "Amy Simon",
        "terseLabel": "Amy Simon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from computation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "beam_ApellisPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ApellisPharmaceuticalsIncMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apellis Pharmaceuticals, Inc",
        "documentation": "Apellis Pharmaceuticals, Inc.",
        "label": "Apellis Pharmaceuticals Inc [Member]",
        "verboseLabel": "Apellis"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AreaOfFacilityBeingBuilt": {
     "xbrltype": "areaItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AreaOfFacilityBeingBuilt",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing facility, number of square feet",
        "documentation": "The area of a facility being built for future lease, in square feet.",
        "label": "Area Of Facility Being Built"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AreaOfRentedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AreaOfRentedSpace",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet of office and laboratory space",
        "documentation": "The amount of area rented under an operating lease, in square feet.",
        "label": "Area of Rented Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "beam_AssembledWorkforceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AssembledWorkforceMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assembled Workforce",
        "documentation": "Assembled Workforce.",
        "label": "Assembled Workforce [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AssetAcquisitionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AssetAcquisitionsPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisitions",
        "documentation": "Disclosure of accounting policy for asset acquisitions, both as part of a business combination and not as part of a business combination.",
        "label": "Asset Acquisitions [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r160",
      "r194",
      "r227",
      "r267",
      "r276",
      "r301",
      "r305",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r584",
      "r588",
      "r645",
      "r772",
      "r887",
      "r981",
      "r982",
      "r1027",
      "r1055",
      "r1245",
      "r1246",
      "r1307"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r200",
      "r227",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r584",
      "r588",
      "r645",
      "r1027",
      "r1245",
      "r1246",
      "r1307"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r1015"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AssetsSoldForLeaseback": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AssetsSoldForLeaseback",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets sold for leaseback",
        "documentation": "The sale price of assets sold to a leasing company for leaseback."
       }
      }
     },
     "auth_ref": []
    },
    "beam_AssignedToCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AssignedToCompanyMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assigned to Company",
        "label": "Assigned to Company [Member]",
        "documentation": "Assigned to company."
       }
      }
     },
     "auth_ref": []
    },
    "beam_AssignedToPfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AssignedToPfizerMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assigned to Pfizer",
        "label": "Assigned to Pfizer [Member]",
        "documentation": "Assigned to Pfizer."
       }
      }
     },
     "auth_ref": []
    },
    "beam_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market [Member]",
        "documentation": "At-The-Market .",
        "terseLabel": "ATM Offering",
        "verboseLabel": "At-The-Market"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale, Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Available-for-sale, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Available-for-sale, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r372",
      "r771"
     ]
    },
    "beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities measured at fair value (available-for-sale).",
        "terseLabel": "Marketable securities held, Fair Value",
        "label": "Available For Sale Debt Securities and Equity Securities FV-Ni"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain on investment in debt and equity securities measured at fair value (available-for-sale).",
        "terseLabel": "Marketable securities held, Gross Unrealized Gains",
        "label": "Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Gain Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss on investment in debt and equity securities measured at fair value (available-for-sale).",
        "negatedLabel": "Marketable securities held, Gross Unrealized Losses",
        "label": "Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Loss Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt and equity securities measured at fair value (available-for-sale).",
        "totalLabel": "Marketable securities held, Amortized Cost",
        "label": "Available For Sale Debt Securities and Equity Securities FV-Ni Amortized Cost Basis"
       }
      }
     },
     "auth_ref": []
    },
    "beam_AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities measured at fair value, classified as available-for-sale.",
        "terseLabel": "Marketable securities",
        "label": "Available For Sale Debt Securities and Equity Securities FV-Ni Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale, Fair Value",
        "verboseLabel": "Marketable securities",
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r372",
      "r616",
      "r765",
      "r1015",
      "r1019",
      "r1218",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r402",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "beam_BioPaletteLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BioPaletteLicenseAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio Palette License Agreement.",
        "label": "Bio Palette License Agreement [Member]",
        "terseLabel": "Bio Palette License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "beam_BioPalettePatentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BioPalettePatentMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio Palette Patent.",
        "label": "Bio Palette Patent [Member]",
        "terseLabel": "Bio Palette Patent"
       }
      }
     },
     "auth_ref": []
    },
    "beam_BroadInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BroadInstituteMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Broad Institute",
        "label": "Broad Institute [Member]",
        "documentation": "Broad Institute."
       }
      }
     },
     "auth_ref": []
    },
    "beam_BroadLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BroadLicenseAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Broad License Agreement",
        "documentation": "Broad license agreement.",
        "label": "Broad License Agreement [Member]",
        "terseLabel": "Broad Institute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r570",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r570",
      "r1005",
      "r1006"
     ]
    },
    "beam_BusinessAcquisitionCostOfAcquiredEntityTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions costs incurred by the acquirer.",
        "label": "Business Acquisition Cost Of Acquired Entity Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, merger agreement date",
        "label": "Business Acquisition, Date of Acquisition Agreement",
        "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total transaction price",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r12"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of equity instruments issued",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2"
     ]
    },
    "beam_BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessCombinationConsiderationTransferredTechnologyAndProductContingentConsiderationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration liability for technology and product milestones incurred by the acquirer.",
        "label": "Business Combination Consideration Transferred Technology And Product Contingent Consideration Liabilities",
        "verboseLabel": "Business combination liability for milestones at fair value",
        "terseLabel": "Technology and product contingent consideration liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration liabilities",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r1197"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r144",
      "r575",
      "r618",
      "r619",
      "r620"
     ]
    },
    "beam_BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone liabilities projected year of achievement",
        "documentation": "The year in which achievement is expected to be attained for contingent consideration liability milestones.",
        "label": "Business Combination Contingent Consideration Liability Expected Achievement Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability measurement input",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liabilities",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r144"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guide Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r571"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Other liabilities assumed",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total transaction price",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "beam_BusinessCombinationTransactionPriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessCombinationTransactionPriceAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Business Combination Transaction Price [Abstract]",
        "documentation": "Business combination transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "beam_BusinessCombinationTransactionPriceAllocatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessCombinationTransactionPriceAllocatedAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price allocated",
        "label": "Business Combination Transaction Price Allocated [Abstract]",
        "documentation": "Business combination transaction price allocated."
       }
      }
     },
     "auth_ref": []
    },
    "beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "BusinessCombinationUpfrontConsiderationPaidInCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination upfront consideration paid in common stock",
        "documentation": "The aggregate amount of consideration paid to former stockholders and optionholders in common stock, as part of a business combination, excluding purchase price adjustments.",
        "label": "Business Combination Upfront Consideration paid in Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent Consideration Liabilities",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment additions in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash acquired from Guide",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r190",
      "r964"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r149"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r110",
      "r224"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r110"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r185",
      "r235",
      "r314",
      "r355",
      "r356",
      "r357",
      "r363",
      "r364",
      "r398",
      "r403",
      "r551",
      "r561",
      "r562",
      "r572",
      "r573",
      "r577",
      "r591",
      "r592",
      "r604",
      "r605",
      "r640",
      "r641",
      "r654",
      "r678",
      "r679",
      "r730",
      "r731",
      "r818",
      "r819"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r185",
      "r314",
      "r355",
      "r356",
      "r357",
      "r363",
      "r364",
      "r365",
      "r398",
      "r403",
      "r551",
      "r561",
      "r562",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r590",
      "r591",
      "r592",
      "r593",
      "r604",
      "r605",
      "r606",
      "r609",
      "r640",
      "r641",
      "r654",
      "r678",
      "r679",
      "r730",
      "r731",
      "r818",
      "r819",
      "r1178"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r249",
      "r360"
     ]
    },
    "beam_ChangeInFairValueOfContingentConsiderationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ChangeInFairValueOfContingentConsiderationLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement.",
        "label": "Change In Fair Value Of Contingent Consideration Liabilities",
        "negatedLabel": "Change in fair value of contingent consideration liabilities",
        "terseLabel": "Change in fair value of contingent consideration liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease right-of-use assets.",
        "label": "Change In Operating Lease Right Of Use Assets",
        "terseLabel": "Change in operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "beam_ChristineBellonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ChristineBellonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Christine Bellon",
        "documentation": "Christine Bellon",
        "label": "Christine Bellon [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r227",
      "r255",
      "r256",
      "r259",
      "r261",
      "r269",
      "r270",
      "r354",
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r438",
      "r439",
      "r442",
      "r445",
      "r453",
      "r645",
      "r835",
      "r836",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r875",
      "r896",
      "r918",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1170",
      "r1200",
      "r1209"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r269",
      "r438",
      "r439",
      "r440",
      "r442",
      "r445",
      "r451",
      "r453",
      "r835",
      "r836",
      "r837",
      "r838",
      "r998",
      "r1170",
      "r1200"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "beam_CollaborationAgreementAggregateTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementAggregateTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement aggregate transaction price",
        "documentation": "The aggregate transaction price of a collaboration agreement.",
        "label": "Collaboration Agreement Aggregate Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementFirstAnniversaryAmountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementFirstAnniversaryAmountReceivable",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement first anniversary amount receivable",
        "label": "Collaboration Agreement First Anniversary Amount Receivable",
        "documentation": "The amount receivable on the one-year anniversary of the signing date of a collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementFirstAnniversaryPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementFirstAnniversaryPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount received as payment for the first anniversary of a collaboration agreement.",
        "label": "Collaboration Agreement First Anniversary Payment Received",
        "terseLabel": "Collaboration agreement first anniversary payment received"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which revenue is expected to be recognized as part of a collaboration agreement.",
        "label": "Collaboration Agreement Performance Obligation Revenue Period For Recognition",
        "terseLabel": "Collaboration agreement performance obligation revenue period for recognition"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementPerformanceObligationRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementPerformanceObligationRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement performance obligation revenue recognized",
        "documentation": "The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement.",
        "label": "Collaboration Agreement Performance Obligation Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement Shares Issued Proceeds In Excess of Fair Value",
        "documentation": "The residual value of proceeds received in excess of fair value for shares issued as part of a collaboration agreement.",
        "terseLabel": "Fair value of common stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementTermOfContract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term of contract",
        "label": "Collaboration Agreement Term of Contract",
        "documentation": "Collaboration agreement term of contract."
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationAgreementUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationAgreementUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement upfront payment received",
        "documentation": "The amount of upfront payment received as part of a collaboration agreement.",
        "label": "Collaboration Agreement Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationArrangementExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationArrangementExtensionTerm",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration arrangement extension term",
        "documentation": "Collaboration arrangement extension term.",
        "label": "Collaboration Arrangement Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationArrangementExtensionTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationArrangementExtensionTermDescription",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the extension term of a collaboration arrangement.",
        "label": "Collaboration Arrangement Extension Term Description",
        "terseLabel": "Collaboration arrangement extension term description"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationArrangementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationArrangementInitialTerm",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration arrangement, initial term",
        "documentation": "Collaboration arrangement initial term.",
        "label": "Collaboration Arrangement Initial Term"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationCommonSharesReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationCommonSharesReceived",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Common Shares Received",
        "terseLabel": "Common stock shares received at closing",
        "documentation": "The number of shares of common stock received as part of a collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationLicenseAgreementFairValueOfSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationLicenseAgreementFairValueOfSharesIssued",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration license agreement fair value of shares issued",
        "label": "Collaboration License Agreement Fair Value Of Shares Issued",
        "documentation": "The fair value of shares issued as part of a collaboration and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationLicenseAgreementFairValueOfSharesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationLicenseAgreementFairValueOfSharesReceived",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of shares received as part of a collaboration and license agreement.",
        "terseLabel": "Collaboration license agreement fair value of shares received",
        "label": "Collaboration License Agreement Fair Value of Shares Received"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CollaborationLicenseAgreementSharesReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CollaborationLicenseAgreementSharesReceived",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock received",
        "documentation": "The number of shares of stock received as part of a collaboration and license agreement.",
        "label": "Collaboration License Agreement Shares Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r165",
      "r177"
     ]
    },
    "us-gaap_CollaborativeArrangementNatureAndPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementNatureAndPurpose",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Nature and Purpose",
        "terseLabel": "Agreement description",
        "verboseLabel": "License agreement description",
        "documentation": "Description of nature and purpose of collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CollaborativeArrangementRightsAndObligations": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementRightsAndObligations",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement rights and obligations, description",
        "label": "Collaborative Arrangement, Rights and Obligations",
        "documentation": "Description of rights and obligations under the collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "beam_CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commencement of first phase of lease in October 2020.",
        "label": "Commencement Of First Phase Of Lease In October Twenty Twenty [Member]",
        "terseLabel": "First Phase of Lease in October 2020"
       }
      }
     },
     "auth_ref": []
    },
    "beam_CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Phase of Lease in January 2021",
        "label": "Commencement Of Second Phase Of Lease In January Two Thousand Twenty One [Member]",
        "documentation": "Commencement of second phase of lease in January two thousand twenty one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r423",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "beam_CommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CommissionRate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commission rate the Company agreed to pay for all shares sold under a Sales Agreement, as a percentage of gross sales proceeds.",
        "label": "Commission Rate",
        "terseLabel": "Commission rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 9, License agreements and Note 10, Collaboration and license agreements)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r152",
      "r774",
      "r874"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "beam_CommonStockIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CommonStockIssuedMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued",
        "documentation": "Common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1204",
      "r1205",
      "r1208",
      "r1290",
      "r1351",
      "r1354"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "beam_CommonStockReceivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CommonStockReceivedMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Received",
        "documentation": "Common stock received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r875"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Milestone payment shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r875",
      "r893",
      "r1354",
      "r1355"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Milestone payment value of stock issued",
        "terseLabel": "Common stock, $0.01 par value; 250,000,000 shares authorized, 83,633,069 and 81,632,496 issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r776",
      "r1027"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefits",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r206",
      "r208",
      "r213",
      "r766",
      "r790",
      "r791"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r167"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r969"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r69"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ContingentConsiderationLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ContingentConsiderationLiabilitiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Liabilities",
        "label": "Contingent Consideration Liabilities [Member]",
        "documentation": "Contingent consideration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ContingentConsiderationOfProductLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ContingentConsiderationOfProductLiabilitiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Product Milestones",
        "terseLabel": "Contingent Consideration of Product Liabilities",
        "label": "Contingent Consideration Of Product Liabilities [Member]",
        "documentation": "Contingent consideration of product liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ContingentConsiderationOfTechnologyLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ContingentConsiderationOfTechnologyLiabilitiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration of Technology Liabilities",
        "verboseLabel": "Technology Milestones",
        "label": "Contingent Consideration Of Technology Liabilities [Member]",
        "documentation": "Contingent consideration of technology liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ContingentObligationAndNonRoyaltySublicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ContingentObligationAndNonRoyaltySublicenseFees",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent obligations and non-royalty sublicense fees",
        "label": "Contingent Obligation And Non Royalty Sublicense Fees",
        "documentation": "The amount of contingent obligations and non-royalty sublicense fees included in research and development expenses during the period.",
        "verboseLabel": "Contingent obligations and non-royalty sublicense fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Total Deferred Revenue",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Deferred revenue",
        "terseLabel": "Deferred revenue liability",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r467"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining unrecognized revenue recognized",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r467"
     ]
    },
    "beam_ContractWithCustomerLiabilityIncreaseFromLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ContractWithCustomerLiabilityIncreaseFromLicenseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to deferred revenue from license agreements",
        "label": "Contract With Customer Liability Increase From License Agreements",
        "documentation": "Amount of increase in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term portion of deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r467"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfChangesInTotalDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts recognized in revenue",
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ContributionOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContributionOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of Property",
        "terseLabel": "Non-cash contribution of intellectual property to Orbital Therapeutics Inc.",
        "documentation": "Value of property contributed in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion of preferred stock",
        "verboseLabel": "Common stock issuable upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r49",
      "r93",
      "r126",
      "r448"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Notes",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1004",
      "r1015",
      "r1028",
      "r1043",
      "r1348"
     ]
    },
    "beam_CorporateEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "CorporateEquitySecuritiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Equity Securities",
        "documentation": "Corporate equity securities.",
        "label": "Corporate Equity Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r433",
      "r440",
      "r689",
      "r710",
      "r770",
      "r966",
      "r968"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r1243"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r1243",
      "r1244"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r1202"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1158"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1158"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1160"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1160"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1162"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1160"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1153"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1155"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1157"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1157"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1158"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1161"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1159"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1156"
     ]
    },
    "beam_DebtSecuritiesAvailableForSaleMaturityPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleMaturityPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity dates of investments",
        "documentation": "Describes the period of time in which investments will reach maturity.",
        "label": "Debt Securities, Available-for-sale, Maturity Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "beam_DeferredTaxAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DeferredTaxAssetsAmortization",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization.",
        "label": "Deferred Tax Assets Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "beam_DeferredTaxAssetsCapitalizedResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearch",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Capitalized Research",
        "terseLabel": "Capitalized Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Derivative liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "beam_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Leasing Arrangements",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "ROU asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer matching contribution to 401(k)",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution to 401(k) Plan as a percentage of employee's eligible earnings",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution to 401(k) Plan as a percentage of employee's contribution",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "beam_DefinedContributionPlanName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DefinedContributionPlanName",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan name",
        "label": "Defined Contribution Plan Name",
        "documentation": "Defined contribution plan name."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfDepreciationExpenseIncurredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r267",
      "r281",
      "r305",
      "r981",
      "r982"
     ]
    },
    "beam_DepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DepreciationMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Member]",
        "documentation": "Depreciation.",
        "terseLabel": "Depreciation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Success payment liability",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r100",
      "r147",
      "r148",
      "r201",
      "r968"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liabilities",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "totalLabel": "Derivative Liability, Total",
        "terseLabel": "Derivative settlement liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r616",
      "r617",
      "r630",
      "r644",
      "r857",
      "r858",
      "r859",
      "r860",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r888",
      "r890",
      "r891",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r968",
      "r1294",
      "r1295",
      "r1296",
      "r1352"
     ]
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "Current portion of derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Long-term portion of derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Success payment liability measurement input",
        "verboseLabel": "Derivative liability measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620"
     ]
    },
    "beam_DerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DerivativeLiabilityMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Member]",
        "documentation": "Derivative liability.",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Term of Contract",
        "terseLabel": "Success payment liability, term",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freestanding Financial Instruments and Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r70",
      "r71",
      "r72",
      "r75",
      "r231",
      "r248"
     ]
    },
    "beam_DevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestones [Member]",
        "documentation": "Development and regulatory milestones.",
        "terseLabel": "Development and Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestones the Company may be eligible to receive.",
        "terseLabel": "Development regulatory and commercial milestones receivable",
        "label": "Development Regulatory and Commercial Milestones Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DirectFinancingLeaseResidualValueOfLeasedAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectFinancingLeaseResidualValueOfLeasedAsset",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Financing Lease, Residual Value of Leased Asset",
        "terseLabel": "Plus: residual values",
        "documentation": "Amount of residual asset covered by residual value guarantee under direct financing lease. Excludes guarantee considered to be lease payments for lessor."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option and Grant Plan",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r483",
      "r511",
      "r512",
      "r514",
      "r1008"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084",
      "r1127"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r252",
      "r255",
      "r259",
      "r260",
      "r261",
      "r266",
      "r568",
      "r581",
      "r613",
      "r614",
      "r767",
      "r792",
      "r972"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r255",
      "r259",
      "r260",
      "r261",
      "r266",
      "r568",
      "r581",
      "r613",
      "r614",
      "r767",
      "r792",
      "r972"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r263"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r262",
      "r264",
      "r265"
     ]
    },
    "beam_EarnoutPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EarnoutPaymentPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earn-out payment period",
        "label": "Earnout Payment Period",
        "documentation": "Earn-out payment period."
       }
      }
     },
     "auth_ref": []
    },
    "beam_EditasLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EditasLicenseAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Editas License Agreement.",
        "label": "Editas License Agreement [Member]",
        "terseLabel": "Editas License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r1012"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r526",
      "r554",
      "r1012"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r1012",
      "r1203",
      "r1280"
     ]
    },
    "beam_EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentAcquisition",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to acquisition related in process research and development expenses.",
        "terseLabel": "IPR&amp;D Guide Acquisition",
        "label": "Effective Income Tax Rate Reconciliation In Process Research And Development Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "negatedLabel": "Nondeductible/ nontaxable permanent items",
        "terseLabel": "Nondeductible/ nontaxable permanent items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1203",
      "r1280"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1012",
      "r1203",
      "r1280"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1203",
      "r1280",
      "r1281"
     ]
    },
    "beam_EmployeeRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EmployeeRelatedExpensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Related Expenses [Member]",
        "label": "Employee Related Expenses [Member]",
        "documentation": "Employee related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and related benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, cost to recognize over a weighted-average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense, expected to vest",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Outstanding Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "beam_EmployeesOfficersBoardOfDirectorsAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EmployeesOfficersBoardOfDirectorsAndConsultantsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, officers, board of directors and consultants",
        "label": "Employees Officers Board Of Directors And Consultants [Member]",
        "terseLabel": "Employees, Officers, Board of Directors and Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "beam_EmployeesOfficersFoundersAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EmployeesOfficersFoundersAndConsultantsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, officers, founders and consultants.",
        "label": "Employees Officers Founders And Consultants [Member]",
        "terseLabel": "Employees, Officers, Founders and Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r182",
      "r210",
      "r211",
      "r212",
      "r232",
      "r233",
      "r234",
      "r237",
      "r244",
      "r246",
      "r248",
      "r268",
      "r359",
      "r366",
      "r399",
      "r454",
      "r549",
      "r550",
      "r564",
      "r565",
      "r566",
      "r569",
      "r580",
      "r581",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r601",
      "r612",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r654",
      "r657",
      "r683",
      "r788",
      "r820",
      "r821",
      "r822",
      "r845",
      "r918"
     ]
    },
    "beam_EquityIssuanceCostsPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EquityIssuanceCostsPoliciesPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity issuance costs.",
        "label": "Equity Issuance Costs Policies Policy [Text Block]",
        "terseLabel": "Equity Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r560",
      "r1174",
      "r1175",
      "r1176",
      "r1285",
      "r1286",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of fully diluted equity interest",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Collaboration agreement aggregate transaction price",
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Carrying value of equity method investment",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r286",
      "r305",
      "r350",
      "r1188",
      "r1225"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Equity Securities",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r78",
      "r352"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity securities, Fair Value",
        "totalLabel": "Equity securities, Amortized Cost",
        "terseLabel": "Equity securities included in marketable securities",
        "verboseLabel": "Equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r642",
      "r965"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity securities, Amortized Cost",
        "terseLabel": "Equity securities, Fair Value",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummarizesOtherIncomeExpenseIncurredDueToChangesInFairValueOfCorporateEquitySecuritiesHeldDetai",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of equity investments",
        "negatedLabel": "Change in fair value of non-controlling equity investments",
        "terseLabel": "Change in fair value of non-controlling equity investments",
        "verboseLabel": "Equity securities recognition amount",
        "totalLabel": "Other income (expense)",
        "netLabel": "Other income (expense)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r1224"
     ]
    },
    "beam_EquitySharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EquitySharesHeld",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of equity securities held by the Company.",
        "label": "Equity Shares Held",
        "totalLabel": "Equity shares held",
        "terseLabel": "Equity shares held"
       }
      }
     },
     "auth_ref": []
    },
    "beam_EquitySharesValueHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "EquitySharesValueHeld",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity shares value held",
        "label": "Equity Shares Value Held",
        "documentation": "The value of shares of equity securities held by the Company."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1088",
      "r1098",
      "r1131"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r644",
      "r996",
      "r997"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "beam_ExploitationLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ExploitationLicensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exploitation licenses.",
        "label": "Exploitation Licenses [Member]",
        "terseLabel": "Exploitation Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ExternalGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ExternalGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External General And Administrative Expenses [Member]",
        "documentation": "External General And Administrative Expenses."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ExternalResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ExternalResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External Research And Development Expenses [Member]",
        "documentation": "External research and development expenses.",
        "terseLabel": "External Research And Development Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_FacilityAndITRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FacilityAndITRelatedExpensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility And IT Related Expenses [Member]",
        "documentation": "Facility and IT related expenses.",
        "terseLabel": "Facility And Information Technology Related Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_FacilityAndInformationTechnologyRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FacilityAndInformationTechnologyRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility and information technology related expenses",
        "documentation": "Amount of expense related to facilities and information technology."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r630",
      "r1015"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r630",
      "r1015"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r1019"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Variables Included in Calculation of Estimated Fair Value",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r1019"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r631",
      "r1017"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r631",
      "r1017"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r629",
      "r630",
      "r632",
      "r697",
      "r698",
      "r699",
      "r996",
      "r997",
      "r1002",
      "r1003",
      "r1004",
      "r1015",
      "r1019"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r631"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r996",
      "r997"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r620",
      "r1015",
      "r1295",
      "r1300"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r996",
      "r997"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r627",
      "r628",
      "r629",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r764",
      "r1015",
      "r1020"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r470",
      "r475",
      "r617",
      "r630",
      "r697",
      "r1002",
      "r1003",
      "r1004",
      "r1015"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r470",
      "r475",
      "r617",
      "r618",
      "r630",
      "r698",
      "r996",
      "r997",
      "r1002",
      "r1003",
      "r1004",
      "r1015"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r617",
      "r618",
      "r619",
      "r620",
      "r630",
      "r699",
      "r996",
      "r997",
      "r1002",
      "r1003",
      "r1004",
      "r1015",
      "r1019"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r631"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r631"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of change in Fair Value of Liabilities based on Level 3 inputs",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r626",
      "r631"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r620",
      "r1015",
      "r1295",
      "r1300"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial recognition of derivative liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1299"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r631"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Beginning Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r631"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r629",
      "r630",
      "r632",
      "r697",
      "r698",
      "r699",
      "r996",
      "r997",
      "r1002",
      "r1003",
      "r1004",
      "r1015",
      "r1019"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1300"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "beam_FinanceLeaseAnnualRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FinanceLeaseAnnualRent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease annual rent",
        "label": "Finance Lease Annual Rent",
        "documentation": "The annual rent amount under a financing lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance Lease, Liability, Total",
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Payments Related to Equipment Financing Obligations",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1304"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "beam_FinanceLeaseLiabilityPaymentsInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FinanceLeaseLiabilityPaymentsInterestPercentage",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate on finance leases.",
        "label": "Finance Lease Liability Payments Interest Percentage",
        "terseLabel": "Finance lease liability payments interest percentage"
       }
      }
     },
     "auth_ref": []
    },
    "beam_FinanceLeaseLiabilityPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FinanceLeaseLiabilityPaymentsLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease liability payments.",
        "label": "Finance Lease Liability Payments [Line Items]",
        "terseLabel": "Finance Lease Liability Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_FinanceLeaseLiabilityPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FinanceLeaseLiabilityPaymentsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease liability payments.",
        "label": "Finance Lease Liability Payments [Table]",
        "terseLabel": "Finance Lease Liability Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amounts representing interest at 8.76%",
        "terseLabel": "Less: amounts representing interest at 8.76%",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equipment financings, net",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Paydown of principal",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r436",
      "r451",
      "r602",
      "r637",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r789",
      "r990",
      "r1015",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1028",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1291",
      "r1294",
      "r1295",
      "r1296",
      "r1298",
      "r1300"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r729",
      "r733",
      "r960"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r960"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1135"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1135"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1135"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1135"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1135"
     ]
    },
    "beam_FormerStockholdersAndOptionholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FormerStockholdersAndOptionholdersMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Stockholders and Optionholders",
        "documentation": "Former stockholders and optionholders.",
        "label": "Former Stockholders and Optionholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_FounderShareholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FounderShareholdersMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder Shareholders.",
        "label": "Founder Shareholders [Member]",
        "terseLabel": "Founder Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "beam_FromTwoThousandSeventeenPlanSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "FromTwoThousandSeventeenPlanSharesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From Two Thousand Seventeen Plan Shares [Member]",
        "terseLabel": "From 2017 Plan Shares",
        "documentation": "From 2017 plan shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r898"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "verboseLabel": "General And Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "beam_GiuseppeCiaramellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "GiuseppeCiaramellaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Giuseppe Ciaramella",
        "label": "Giuseppe Ciaramella [Member]",
        "terseLabel": "Giuseppe Ciaramella"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r395",
      "r397"
     ]
    },
    "beam_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds from issuance of common stock",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Current Carrying Value",
        "terseLabel": "Claims outstanding",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "terseLabel": "Guarantees and Indemnifications",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "beam_GuideTherapeuticsIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "GuideTherapeuticsIncorporatedMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guide Therapeutics, Incorporated.",
        "label": "Guide Therapeutics Incorporated [Member]",
        "terseLabel": "Guide Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "beam_HarvardInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "HarvardInstituteMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Harvard Institute",
        "label": "Harvard Institute [Member]",
        "documentation": "Harvard Institute."
       }
      }
     },
     "auth_ref": []
    },
    "beam_HarvardLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "HarvardLicenseAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Harvard",
        "documentation": "Harvard license agreement.",
        "label": "Harvard License Agreement [Member]",
        "terseLabel": "Harvard"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061",
      "r1084"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r117",
      "r1016"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r118"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "beam_IncludingTwoThousandSeventeenPlanSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IncludingTwoThousandSeventeenPlanSharesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Including 2017 Plan Shares",
        "label": "Including Two Thousand Seventeen Plan Shares [Member]",
        "documentation": "Including Two Thousand Seventeen Plan Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r794",
      "r974",
      "r1211",
      "r1213",
      "r1214",
      "r1215",
      "r1216"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain (loss) from equity method investment",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Loss from equity method investment",
        "negatedLabel": "Loss from equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r102",
      "r154",
      "r267",
      "r283",
      "r305",
      "r350",
      "r785"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r408",
      "r622",
      "r626",
      "r631",
      "r815",
      "r817",
      "r903",
      "r960",
      "r1018",
      "r1321"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r408",
      "r622",
      "r626",
      "r631",
      "r815",
      "r817",
      "r903",
      "r960",
      "r1018",
      "r1321"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r526",
      "r527",
      "r537",
      "r545",
      "r1012",
      "r1283"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r526",
      "r527",
      "r537",
      "r545",
      "r1012",
      "r1283"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r522",
      "r526",
      "r533",
      "r534",
      "r535",
      "r538",
      "r544",
      "r555",
      "r557",
      "r558",
      "r559",
      "r840",
      "r1012"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "negatedLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r175",
      "r247",
      "r248",
      "r267",
      "r284",
      "r305",
      "r525",
      "r526",
      "r556",
      "r795",
      "r1012"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r523",
      "r524",
      "r538",
      "r539",
      "r543",
      "r547",
      "r834"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "beam_IncreaseDecreaseInCollaborationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IncreaseDecreaseInCollaborationReceivable",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Collaboration receivable",
        "terseLabel": "Collaboration receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) as part of a collaboration agreement.",
        "label": "Increase Decrease in Collaboration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r1197"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "beam_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Change in operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1180",
      "r1197"
     ]
    },
    "beam_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "terseLabel": "Change in operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1126",
      "r1135",
      "r1139",
      "r1147"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "beam_InterestAndOtherIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "InterestAndOtherIncomeExpenseMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other income (expense).",
        "label": "Interest And Other Income Expense [Member]",
        "terseLabel": "Interest and Other Income (Expense), Net",
        "verboseLabel": "Interest and Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "beam_InterestAndOtherIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "InterestAndOtherIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income and income (expense) related to nonoperating activities classified as other.",
        "label": "Interest And Other Income Expense Net",
        "terseLabel": "Interest and other income (expense), net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r221",
      "r222"
     ]
    },
    "us-gaap_InvestmentIncomeDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeDividend",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend received",
        "documentation": "Amount of dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of investment discount (premiums)",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r179",
      "r317",
      "r319",
      "r638",
      "r639",
      "r1316"
     ]
    },
    "beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of unregistered common shares in connection with license agreement, shares",
        "label": "Issuance Of Unregistered Common Shares In Connection With License Agreement",
        "documentation": "Number of unregistered common shares issued during the period in connection with a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of unregistered common shares in connection with license agreement",
        "label": "Issuance Of Unregistered Common Shares In Connection With License Agreement 1",
        "documentation": "Value of unregistered common shares issued during the period in connection with a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_JeffriesLlcAmendedSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "JeffriesLlcAmendedSalesAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffries LLC Amended Sales Agreement",
        "documentation": "Jeffries LLC amended sales agreement.",
        "label": "Jeffries LLC Amended Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "JeffriesLlcSalesAgreementAndAmendedSalesAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffries LLC Sales Agreement and Amended Sales Agreement",
        "documentation": "Jeffries LLC Sales Agreement and Amended Sales Agreement.",
        "label": "Jeffries LLC Sales Agreement And Amended Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_JeffriesLlcSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "JeffriesLlcSalesAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales Agreement, with Jefferies",
        "terseLabel": "Jeffries LLC Sales Agreement",
        "documentation": "Jeffries LLC sales agreement.",
        "label": "Jeffries LLC Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment and office furniture.",
        "label": "Laboratory Equipment And Office Furniture [Member]",
        "terseLabel": "Laboratory Equipment and Office Furniture"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LaboratorySpaceMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory space.",
        "label": "Laboratory Space [Member]",
        "terseLabel": "Laboratory Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1179"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1179"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1026"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1303"
     ]
    },
    "beam_LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Costs Included in Measurement of Lease Liabilities",
        "documentation": "Tabular disclosure of the lease costs included in the measurement of lease liabilities.",
        "label": "Lease Costs Included In Measurement Of Lease Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LeaseholdImprovementsLandlordAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LeaseholdImprovementsLandlordAllowance",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements landlord allowance",
        "documentation": "The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Leasehold Improvements Landlord Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r675"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Financing obligations, leased back equipment term of contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r676"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r676"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases and Rent Expense",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease, description",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Maturity of Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1304"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, option to extend term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r227",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r585",
      "r588",
      "r589",
      "r645",
      "r873",
      "r973",
      "r1055",
      "r1245",
      "r1307",
      "r1308"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r153",
      "r780",
      "r1027",
      "r1201",
      "r1226",
      "r1301"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r189",
      "r227",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r585",
      "r588",
      "r589",
      "r645",
      "r1027",
      "r1245",
      "r1307",
      "r1308"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfContingentConsiderationLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfTheDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1292"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "beam_LicenseAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LicenseAgreementDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for licensing arrangements with third parties, which includes, but is not limited to, success payments and milestone payments.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement Terms",
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "beam_LicenseAgreementUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LicenseAgreementUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement upfront payment received",
        "label": "License Agreement Upfront Payment Received",
        "documentation": "The amount received as upfront payment under a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LicenseAndCollaborationAgreementOutstandingCommonStockHeldPercentage",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of outstanding common stock held by the Company as part of a license and collaboration agreement, as a percentage.",
        "label": "License and Collaboration Agreement Outstanding Common Stock Held Percentage",
        "terseLabel": "License and collaboration agreement outstanding common stock held percentage"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LicenseFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LicenseFeeMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fees",
        "documentation": "License Fees.",
        "label": "License Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_LillyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "LillyAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lilly Agreement.",
        "terseLabel": "Lilly Agreement",
        "label": "Lilly Agreement [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability accrued for loss based on settlement offer",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r1173"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Facility",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Debt Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains or losses recognized on sale or maturity of marketable securities",
        "label": "Marketable Security, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r477",
      "r517",
      "r620",
      "r726",
      "r814",
      "r816",
      "r830",
      "r865",
      "r866",
      "r926",
      "r928",
      "r930",
      "r931",
      "r940",
      "r958",
      "r959",
      "r989",
      "r998",
      "r1007",
      "r1019",
      "r1020",
      "r1024",
      "r1025",
      "r1038",
      "r1247",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "verboseLabel": "Discount for Lack of Marketability",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term (years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "beam_MeasurementInputFairValueOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "MeasurementInputFairValueOfCommonStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input fair value of common stock.",
        "label": "Measurement Input Fair Value Of Common Stock [Member]",
        "terseLabel": "Fair Value of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Volatility",
        "verboseLabel": "Volatility of Market Participants",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "beam_MeasurementInputProbabilityOfAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "MeasurementInputProbabilityOfAchievementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of Achievement",
        "documentation": "Measurement Input Probability Of Achievement [Member]",
        "label": "Measurement Input Probability Of Achievement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r1019"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r1019"
     ]
    },
    "beam_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Guide Merger Agreement",
        "documentation": "Merger agreement.",
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "beam_MilestoneExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "MilestoneExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone expense",
        "label": "Milestone Expense",
        "documentation": "The amount of expense recognized during the period for achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r477",
      "r517",
      "r620",
      "r726",
      "r814",
      "r816",
      "r830",
      "r865",
      "r866",
      "r926",
      "r928",
      "r930",
      "r931",
      "r940",
      "r958",
      "r959",
      "r989",
      "r998",
      "r1007",
      "r1019",
      "r1020",
      "r1024",
      "r1038",
      "r1247",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "beam_NatureOfBusinessAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NatureOfBusinessAndBasisOfPresentationLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Line Items]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_NatureOfBusinessAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NatureOfBusinessAndBasisOfPresentationTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Table]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r112",
      "r155",
      "r187",
      "r204",
      "r207",
      "r212",
      "r227",
      "r236",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r257",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r568",
      "r581",
      "r614",
      "r645",
      "r787",
      "r895",
      "r916",
      "r917",
      "r1053",
      "r1245"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r240",
      "r241",
      "r242",
      "r243",
      "r252",
      "r253",
      "r258",
      "r261",
      "r581"
     ]
    },
    "beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NetProfitsAndDevelopmentAndCommercializationCostsPercentage",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net profits and development and commercialization costs assigned to the specified party.",
        "terseLabel": "Net profits as well as development and commercialization costs percentage",
        "label": "Net Profits and Development and Commercialization Costs Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "beam_NonCashStockBasedCompensationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NonCashStockBasedCompensationExpenseMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash Stock Based Compensation Expense",
        "label": "Non Cash Stock Based Compensation Expense [Member]",
        "documentation": "Non Cash Stock Based Compensation Expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1092",
      "r1102",
      "r1126",
      "r1135"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "beam_NonRoyaltySublicenseFeesOwed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NonRoyaltySublicenseFeesOwed",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense incurred for non-royalty sublicense fees owed to licensor.",
        "terseLabel": "Non-royalty sublicense fees owed",
        "label": "Non Royalty Sublicense Fees Owed"
       }
      }
     },
     "auth_ref": []
    },
    "beam_NonRoyaltySublicenseFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NonRoyaltySublicenseFeesPaid",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid during the period for non-royalty sublicense fees.",
        "label": "Non Royalty Sublicense Fees Paid",
        "terseLabel": "Non-royalty sublicense fees paid"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "beam_NonStatutoryOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NonStatutoryOptionsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-statutory options.",
        "label": "Non Statutory Options [Member]",
        "terseLabel": "Non-Statutory Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "beam_NonrefundableUpfrontPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NonrefundableUpfrontPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable upfront payment receivable",
        "documentation": "Nonrefundable upfront payment receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "beam_NumberOfFounderShareholders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NumberOfFounderShareholders",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of founder shareholders.",
        "label": "Number Of Founder Shareholders",
        "terseLabel": "Number of founder shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "beam_NumberOfOperatingLeaseRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NumberOfOperatingLeaseRenewalOptions",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease renewal options.",
        "label": "Number Of Operating Lease Renewal Options",
        "terseLabel": "Operating lease, number of renewal options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1212"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r1212"
     ]
    },
    "beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NumberOfSharesIssuedForUpfrontPaymentOfAcquisition",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued for upfront payment of acquisition",
        "label": "Number Of Shares Issued For Upfront Payment Of Acquisition",
        "documentation": "Number of shares issued for upfront payment of acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "beam_NumberOfSharesPurchasedUnderEquityMethod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "NumberOfSharesPurchasedUnderEquityMethod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares purchased under equity method",
        "documentation": "Number of shares purchased under equity method.",
        "label": "Number of Shares Purchased Under Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ObligationToIssueCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ObligationToIssueCommonStockShares",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligation to issue common stock shares",
        "documentation": "The number of shares of stock the Collaborator is obligated to issue to the Company if the Company elects to extend the collaboration.",
        "label": "Obligation to Issue Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ObligationToIssueCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ObligationToIssueCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligation to issue common stock value",
        "documentation": "The value of stock the Company is obligated to issue to the Collaborator if the Company elects to extend the collaboration.",
        "label": "Obligation to Issue Common Stock Value"
       }
      }
     },
     "auth_ref": []
    },
    "beam_OctoberTwoThousandTwentyPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OctoberTwoThousandTwentyPublicOfferingMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2020 Public offering.",
        "label": "October Two Thousand Twenty Public Offering [Member]",
        "terseLabel": "October 2020 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "beam_OfficeAndLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OfficeAndLaboratorySpaceMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space.",
        "label": "Office And Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time Termination Benefits",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r974",
      "r1211",
      "r1213",
      "r1214",
      "r1215",
      "r1216"
     ]
    },
    "beam_OperatingLeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OperatingLeaseCommencementMonthAndYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, commencement month and year.",
        "label": "Operating Lease Commencement Month And Year",
        "terseLabel": "Operating lease, commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1026"
     ]
    },
    "beam_OperatingLeaseLiabilitiesIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OperatingLeaseLiabilitiesIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Increase (Decrease)",
        "documentation": "The increase (decrease) in operating lease liabilities related to right-of-use assets.",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets",
        "verboseLabel": "Operating lease liabilities arising from obtaining ROU assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfFutureMaturityOfOperatingLeasesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities",
        "terseLabel": "Lease liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsIncludedInMeasurementOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r671"
     ]
    },
    "beam_OperatingLeaseRentPaymentsBeginMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OperatingLeaseRentPaymentsBeginMonthAndYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payments beginning month and year",
        "documentation": "The month and year in which the rent payments will begin under an operating lease.",
        "label": "Operating Lease Rent Payments Begin Month And Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "beam_OperatingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OperatingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Term and Discount Rate",
        "documentation": "Tabular disclosure of the lease term and discount rate for an operating lease.",
        "label": "Operating Lease Term And Discount Rate [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_OperatingLeaseTerminationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OperatingLeaseTerminationMonthAndYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, termination month and year.",
        "label": "Operating Lease Termination Month And Year",
        "terseLabel": "Operating lease, termination month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r1026"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r1026"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "beam_OptionRightsAggregatePotentialAdditionalConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OptionRightsAggregatePotentialAdditionalConsideration",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of potential fee for additional option rights.",
        "terseLabel": "Option rights aggregate potential additional consideration",
        "label": "Option Rights Aggregate Potential Additional Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "beam_OrbitalTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OrbitalTherapeuticsIncMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orbital Therapeutics, Inc.",
        "label": "Orbital Therapeutics, Inc [Member]",
        "terseLabel": "Orbital",
        "verboseLabel": "Orbital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r145",
      "r831",
      "r832"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liability accrued for minimum amount in range of loss based on settlement offer",
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13",
      "r146"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13",
      "r146",
      "r205",
      "r208",
      "r244"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Noncash Income (Expense), Total",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "beam_OtherOperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OtherOperatingIncomeExpenseAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income Expense.",
        "label": "Other Operating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "beam_OtherPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "OtherPaymentsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Payments",
        "label": "Other Payments [Member]",
        "documentation": "Other Payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1090",
      "r1100",
      "r1133"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1093",
      "r1103",
      "r1136"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1093",
      "r1103",
      "r1136"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PaymentOfMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PaymentOfMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of milestone amount.",
        "label": "Payment Of Milestone Amount",
        "terseLabel": "Milestone payment paid"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PaymentOfUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PaymentOfUpfrontFee",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of upfront fee.",
        "label": "Payment Of Upfront Fee",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Tenant improvement allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r108"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r1196"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial and follow-on public offering costs",
        "negatedTerseLabel": "Payment of equity offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r216",
      "r318"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "beam_PerProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PerProgramMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per program.",
        "label": "Per Program [Member]",
        "terseLabel": "Per Program"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PercentageOfRoyaltyPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PercentageOfRoyaltyPayments",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Royalty Payments",
        "documentation": "The amount of royalty payment due, contingent upon certain milestones, as part of a derivative settlement liability, as a percent.",
        "terseLabel": "Percentage of royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-based Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PfizerIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PfizerIncMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pfizer Inc",
        "documentation": "Pfizer Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PfizerMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer",
        "label": "Pfizer [Member]",
        "documentation": "Pfizer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "beam_PotentialAdditionalProceedsFromTransferAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PotentialAdditionalProceedsFromTransferAgreement",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional proceeds from potential future development-stage payments",
        "label": "Potential Additional Proceeds From Transfer Agreement",
        "documentation": "The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_PotentialConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PotentialConsideration",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential aggregate consideration that may be received as part of a collaboration agreement.",
        "terseLabel": "Potential total consideration",
        "label": "Potential Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PotentialMilestonePayableInFormOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PotentialMilestonePayableInFormOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payable in form of common stock",
        "documentation": "The amount of potential milestones payable in the form of common stock as part of a business combination.",
        "label": "Potential Milestone Payable In Form Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "beam_PotentialMilestonePaymentsDueUnderSettlementAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PotentialMilestonePaymentsDueUnderSettlementAgreement",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments due under settlement agreement",
        "label": "Potential Milestone Payments Due Under Settlement Agreement",
        "documentation": "The amount of milestone payments that may become due under a settlement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r438"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r875"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r438"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r875",
      "r893",
      "r1354",
      "r1355"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r775",
      "r1027"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "beam_PrimeMedicineIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "PrimeMedicineIncMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prime medicine Inc.",
        "label": "Prime Medicine Inc [Member]",
        "terseLabel": "Prime Medicine Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares, net of commissions",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private stock issuance",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r1219"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuances of stock under ESPP",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "beam_ProceedsFromTransferAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ProceedsFromTransferAgreement",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from potential future development-stage upfront payments",
        "label": "Proceeds From Transfer Agreement",
        "documentation": "The amount of proceeds the Company received as part of a transfer agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ProductDevelopmentAndRegulatoryApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ProductDevelopmentAndRegulatoryApprovalMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Development and Regulatory Approval",
        "label": "Product Development and Regulatory Approval [Member]",
        "documentation": "Product Development and Regulatory Approval."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r728",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r962",
      "r1000",
      "r1037",
      "r1038",
      "r1039",
      "r1042",
      "r1044",
      "r1241",
      "r1242",
      "r1250",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r728",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r962",
      "r1000",
      "r1037",
      "r1038",
      "r1039",
      "r1042",
      "r1044",
      "r1241",
      "r1242",
      "r1250",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r204",
      "r207",
      "r219",
      "r227",
      "r236",
      "r244",
      "r247",
      "r248",
      "r354",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r568",
      "r581",
      "r583",
      "r586",
      "r587",
      "r614",
      "r645",
      "r768",
      "r786",
      "r844",
      "r895",
      "r916",
      "r917",
      "r1013",
      "r1014",
      "r1054",
      "r1195",
      "r1245"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r675"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r168",
      "r171",
      "r172"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r191",
      "r784"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r675",
      "r769",
      "r784",
      "r1027"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r168",
      "r171",
      "r782"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumPaymentsRelatedToEquipmentFinancingObligationsParentheticalDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r675"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful life",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1238"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r469",
      "r477",
      "r506",
      "r507",
      "r508",
      "r517",
      "r620",
      "r700",
      "r709",
      "r726",
      "r814",
      "r816",
      "r830",
      "r865",
      "r866",
      "r926",
      "r928",
      "r930",
      "r931",
      "r940",
      "r958",
      "r959",
      "r989",
      "r998",
      "r1007",
      "r1019",
      "r1020",
      "r1024",
      "r1025",
      "r1038",
      "r1047",
      "r1239",
      "r1247",
      "r1295",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfContingentConsiderationLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r469",
      "r477",
      "r506",
      "r507",
      "r508",
      "r517",
      "r620",
      "r700",
      "r709",
      "r726",
      "r814",
      "r816",
      "r830",
      "r865",
      "r866",
      "r926",
      "r928",
      "r930",
      "r931",
      "r940",
      "r958",
      "r959",
      "r989",
      "r998",
      "r1007",
      "r1019",
      "r1020",
      "r1024",
      "r1025",
      "r1038",
      "r1047",
      "r1239",
      "r1247",
      "r1295",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "beam_RegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "RegulatoryMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory",
        "label": "Regulatory [Member]",
        "documentation": "Regulatory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r476",
      "r687",
      "r688",
      "r773",
      "r781",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r892",
      "r894",
      "r925"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received from (made to) related parties",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r687"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r1306"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r899",
      "r900",
      "r903"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r476",
      "r687",
      "r688",
      "r773",
      "r781",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r892",
      "r894",
      "r925",
      "r1306"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r688",
      "r690",
      "r841",
      "r842",
      "r843",
      "r901",
      "r902",
      "r903",
      "r922",
      "r924"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r433",
      "r440",
      "r689",
      "r710",
      "r770",
      "r967",
      "r968"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1279"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1279"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r960",
      "r981",
      "r1315"
     ]
    },
    "beam_ResearchAndDevelopmentExpenseInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseInProcess",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "verboseLabel": "In-process research and development charge",
        "terseLabel": "Research and development expense",
        "label": "Research And Development Expense In Process"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ResearchAndDevelopmentExpenseOffsetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseOffsetAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense offset amount",
        "documentation": "Research and development expense offset amount.",
        "label": "Research and Development Expense Offset Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "beam_ResearchPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ResearchPlanMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research plan.",
        "label": "Research Plan [Member]",
        "terseLabel": "Research Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1086",
      "r1096",
      "r1129"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1087",
      "r1097",
      "r1130"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1094",
      "r1104",
      "r1137"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r1189",
      "r1199"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Unvested Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuring1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r407",
      "r410",
      "r415"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in employee headcount, positions",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in employee headcount, percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Expenses incurred",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r411",
      "r412",
      "r1240"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r412",
      "r413"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1172"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringScheduleOfRestructuringLiabilityActivityForCompanysWorkforceReductionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accrued restructuring, Ending balance",
        "periodStartLabel": "Accrued restructuring, Beginning balance",
        "label": "Restructuring Reserve",
        "totalLabel": "Restructuring Reserve, Total",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r413"
     ]
    },
    "us-gaap_RestructuringReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r128",
      "r779",
      "r824",
      "r829",
      "r839",
      "r876",
      "r1027"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r232",
      "r233",
      "r234",
      "r237",
      "r244",
      "r246",
      "r248",
      "r359",
      "r366",
      "r399",
      "r549",
      "r550",
      "r564",
      "r565",
      "r566",
      "r569",
      "r580",
      "r581",
      "r594",
      "r597",
      "r598",
      "r601",
      "r612",
      "r654",
      "r657",
      "r820",
      "r822",
      "r845",
      "r1354"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r267",
      "r277",
      "r278",
      "r299",
      "r305",
      "r309",
      "r311",
      "r313",
      "r465",
      "r466",
      "r728"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Balances",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r961"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r961",
      "r970"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued and sold",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of common stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock sold",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share of shares issued",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "beam_SalesMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SalesMilestoneMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestone [Member]",
        "documentation": "Sales Milestone.",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SanaBiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SanaBiotechnologyMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sana Biotechnology",
        "documentation": "Sana Biotechnology."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r478",
      "r1173",
      "r1207"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Marketable Securities Held",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Transaction Price Determined and Allocated",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "beam_ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in fair value of the success payment liability arising from a licensing agreement.",
        "label": "Schedule Of Change In Fair Value Of Success Payment Liability Table [Text Block]",
        "terseLabel": "Schedule of Change in Fair Value of Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r1012",
      "r1280"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r560",
      "r1174",
      "r1175",
      "r1176",
      "r1285",
      "r1286",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r645"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r645"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1293"
     ]
    },
    "beam_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Estimated Useful Life of Property and Equipment",
        "documentation": "Tabular disclosure of the estimated useful lives of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r675"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r899",
      "r900",
      "r903"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Liability Activity for Company's Workforce Reductions",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r119",
      "r120"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reportable Segment Net Revenues and Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity Under Equity Award Plans",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r135"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option Valuation Model to Estimate Fair Value of Purchase Right Under ESPP",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r122",
      "r125",
      "r127",
      "r128",
      "r196",
      "r197",
      "r198",
      "r269",
      "r438",
      "r439",
      "r440",
      "r442",
      "r445",
      "r451",
      "r453",
      "r835",
      "r836",
      "r837",
      "r838",
      "r998",
      "r1170",
      "r1200"
     ]
    },
    "beam_ScheduleOfSuccessPaymentLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ScheduleOfSuccessPaymentLiabilityTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the success payment liability arising from a licensing agreement.",
        "label": "Schedule Of Success Payment Liability Table [Text Block]",
        "terseLabel": "Schedule of Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ScientificConsultingAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ScientificConsultingAndOtherExpensesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific consulting and other expenses.",
        "label": "Scientific Consulting And Other Expenses [Member]",
        "terseLabel": "Scientific Consulting and Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ScientificFoundersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ScientificFoundersMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific founders.",
        "label": "Scientific Founders [Member]",
        "terseLabel": "Scientific Founders"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r267",
      "r272",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r313",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r396",
      "r409",
      "r414",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r977",
      "r981",
      "r982",
      "r991",
      "r1041",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r859",
      "r861",
      "r863",
      "r927",
      "r929",
      "r932",
      "r941",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r963",
      "r1001",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1040",
      "r1047",
      "r1250",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r980",
      "r988"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r977",
      "r985"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Data",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r288",
      "r290",
      "r291",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r313",
      "r975",
      "r978",
      "r979",
      "r981",
      "r983",
      "r986",
      "r987"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r290",
      "r291",
      "r305",
      "r981"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographic Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r308",
      "r311",
      "r976",
      "r977",
      "r984"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "verboseLabel": "Series A Preferred Stock Shares",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191",
      "r1248"
     ]
    },
    "beam_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SettlementAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SettlementAgreementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement Upfront Payment",
        "documentation": "The amount of upfront payment the Company has agreed to pay upon signing of a settlement agreement.",
        "terseLabel": "Settlement agreement upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SettlementAgreementUpfrontPaymentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SettlementAgreementUpfrontPaymentPaid",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement Upfront Payment Paid",
        "documentation": "The amount paid during the period for an upfront payment as part of a settlement agreement.",
        "terseLabel": "Settlement agreement upfront payment paid"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SettlementPaymentsExpectedAchievementYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SettlementPaymentsExpectedAchievementYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Payments Expected Achievement Year",
        "documentation": "The year in which achievement is expected to be attained for settlement payments.",
        "terseLabel": "Settlement payments expected achievement year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage increase in shares authorized",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "documentation": "The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Common stock, shares description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of common stock purchase price lower of the fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Common stock offering price discount rate at start of the offering period",
        "documentation": "Discount rate from fair value on offering date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Issued",
        "verboseLabel": "Issuance of restricted common stock",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested as of December 31, 2023",
        "periodStartLabel": "Unvested as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested as of December 31, 2023",
        "periodStartLabel": "Unvested as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of restricted shares vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares available for future issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares for future issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodStartDate",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, offering period, start date",
        "documentation": "The commencement date of the first offering period of a share based payment plan, in YYYY-MM-DD format.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period Start Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable as of December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable as of December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeitures",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of December 31, 2024",
        "periodStartLabel": "Outstanding as of December 31, 2023",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding as of December 31, 2023",
        "periodEndLabel": "Outstanding as of December 31, 2024",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount allowed to purchase common stock using payroll deduction",
        "documentation": "The maximum annual amount of funds that employees can contribute through payroll deductions to purchase shares as part of share based compensation plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Payroll Deduction Yearly Limit Amount"
       }
      }
     },
     "auth_ref": []
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePricePerShareOfStockOptionsOnFairMarketValueOfCommonStock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum exercise price per share of stock options, as a percentage of the fair market value of common stock on the date of grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Exercise Price Per Share Of Stock Options On Fair Market Value Of Common Stock",
        "terseLabel": "Percentage of exercise price per share of stock options on fair market value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "beam_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualLifeAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award weighted average remaining contractual life.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Life [Abstract]",
        "terseLabel": "Weighted average remaining contractual life (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average exercise price of stock options",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable as of December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price per share",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Price per share of stock sold",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1026"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r225"
     ]
    },
    "beam_SravanEmanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SravanEmanyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sravan Emany",
        "label": "Sravan Emany [Member]",
        "documentation": "Sravan Emany [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r186",
      "r267",
      "r272",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r313",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r396",
      "r401",
      "r409",
      "r414",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r977",
      "r981",
      "r982",
      "r991",
      "r1041",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r227",
      "r255",
      "r256",
      "r259",
      "r261",
      "r269",
      "r270",
      "r354",
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r438",
      "r439",
      "r442",
      "r445",
      "r453",
      "r645",
      "r835",
      "r836",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r875",
      "r896",
      "r918",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1170",
      "r1200",
      "r1209"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r97",
      "r98",
      "r182",
      "r210",
      "r211",
      "r212",
      "r232",
      "r233",
      "r234",
      "r237",
      "r244",
      "r246",
      "r248",
      "r268",
      "r359",
      "r366",
      "r399",
      "r454",
      "r549",
      "r550",
      "r564",
      "r565",
      "r566",
      "r569",
      "r580",
      "r581",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r601",
      "r612",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r654",
      "r657",
      "r683",
      "r788",
      "r820",
      "r821",
      "r822",
      "r845",
      "r918"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r859",
      "r861",
      "r863",
      "r927",
      "r929",
      "r932",
      "r941",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r963",
      "r1001",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1040",
      "r1047",
      "r1250",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r268",
      "r657",
      "r728",
      "r833",
      "r856",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r875",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r894",
      "r897",
      "r898",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r918",
      "r1048"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r478",
      "r1173",
      "r1177",
      "r1207"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r268",
      "r316",
      "r657",
      "r728",
      "r833",
      "r856",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r875",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r894",
      "r897",
      "r898",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r918",
      "r1048"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSegmentDataScheduleOfReportableSegmentNetRevenuesAndLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock based compensation.",
        "terseLabel": "Stock Based Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "documentation": "Costs incurred in a stock issuance transaction.",
        "label": "Stock Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockIssuanceProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockIssuanceProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds of shares authorized under ATM sales agreement",
        "documentation": "Amount of shares authorized to be issued under a stock issuance program.",
        "label": "Stock Issuance Program Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to acquire Guide, Shares",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49",
      "r94",
      "r97",
      "r128",
      "r435"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under ESPP, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued and sold",
        "terseLabel": "Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs, Shares",
        "label": "Number of common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128",
      "r835",
      "r918",
      "r943"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock, Shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanSummaryOfOptionActivityUnderEquityAwardPlansDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of common stock options, Shares",
        "negatedLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128",
      "r492"
     ]
    },
    "beam_StockIssuedDuringPeriodSharesSuccessPaymentLiability": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesSuccessPaymentLiability",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for success payment liability, Shares",
        "verboseLabel": "Issuance of common stock for success payment liability, Shares",
        "label": "Issuance of common stock for success payment liability, Shares",
        "documentation": "Number of shares issued to satisfy success payment obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to acquire Guide",
        "verboseLabel": "Value of shares issued for upfront payment of acquisition",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r97",
      "r98",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r97",
      "r98",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs",
        "verboseLabel": "Value of common stock shares issued",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128",
      "r845",
      "r918",
      "r943",
      "r1054"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r97",
      "r98",
      "r128"
     ]
    },
    "beam_StockIssuedDuringPeriodValueSuccessPaymentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSuccessPaymentLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for success payment liability",
        "documentation": "Value of stock issued to satisfy success payment obligation.",
        "label": "Stock Issued During Period Value Success Payment Liability"
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockOptionsAndRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockOptionsAndRestrictedStockMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "stock options and restricted stock.",
        "label": "Stock Options And Restricted Stock [Member]",
        "terseLabel": "Stock Options and Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockPurchaseAgreementAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockPurchaseAgreementAggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated purchase price",
        "label": "Stock Purchase Agreement Aggregate Purchase Price",
        "documentation": "The aggregate purchase price of a stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockPurchaseAgreementAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockPurchaseAgreementAmountReceived",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase agreement amount received",
        "label": "Stock Purchase Agreement Amount Received",
        "documentation": "The amount received as part of a stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockPurchaseAgreementAmountReceived1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockPurchaseAgreementAmountReceived1",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase agreement price",
        "label": "Stock Purchase Agreement Amount Received1",
        "documentation": "Stock Purchase Agreement Amount Received1"
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockPurchaseAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockPurchaseAgreementShares",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale and issuance of common stock",
        "label": "Stock Purchase Agreement Shares",
        "documentation": "The number of shares available for sale and issuance as part of a stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_StockSoldDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "StockSoldDuringPeriodSharesNewIssues",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sold during period shares, new issues",
        "documentation": "Number of new shares sold, but not necessarily issued, during the period.",
        "label": "Stock Sold During Period Shares, New Issues",
        "verboseLabel": "Shares issued and sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r97",
      "r98",
      "r114",
      "r877",
      "r893",
      "r919",
      "r920",
      "r1027",
      "r1055",
      "r1201",
      "r1226",
      "r1301",
      "r1354"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r226",
      "r437",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r452",
      "r454",
      "r603",
      "r921",
      "r923",
      "r947"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "verboseLabel": "Reverse stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "verboseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "beam_SubleaseAreaOfRentedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SubleaseAreaOfRentedSpace",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease area of rented space",
        "documentation": "The amount of space to be subleased, in square feet.",
        "label": "Sublease Area Of Rented Space"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SubleaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SubleaseCommencementMonthAndYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease, commencement month and year",
        "documentation": "The month and year in which a sublease will commence.",
        "label": "Sublease Commencement Month and Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r1026"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r692"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r692"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r692"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r693"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPaymentAmountDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPaymentAmountDue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success payment amount due",
        "label": "Success Payment Amount Due",
        "documentation": "The amount of success payment due as part of a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPaymentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPaymentLiabilitiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success Payment Liabilities",
        "label": "Success Payment Liabilities [Member]",
        "documentation": "Success payment liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPaymentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPaymentLiability",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability incurred for success payments.",
        "label": "Success Payment Liability",
        "terseLabel": "Success payments liability"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPayments",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of success payments payable upon achievement of specified stock value targets.",
        "label": "Success Payments",
        "terseLabel": "Success payments"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPaymentsMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success Payments",
        "label": "Success Payments [Member]",
        "documentation": "Success Payments."
       }
      }
     },
     "auth_ref": []
    },
    "beam_SuccessPaymentsValuationMultiples": {
     "xbrltype": "pureItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SuccessPaymentsValuationMultiples",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation multiple applied to the initial weighted average of the specified class of stock, used to determine success payment targets.",
        "label": "Success Payments Valuation Multiples",
        "terseLabel": "Success Payments, valuation multiples"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SummaryOfDepreciationExpenseIncurredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SummaryOfDepreciationExpenseIncurredTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Depreciation Expense Incurred",
        "documentation": "Tabular disclosure of depreciation expense related to physical assets used in the normal conduct of business and not intended for resale.",
        "label": "Summary Of Depreciation Expense Incurred Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SummaryOfPrincipalAndInterestPortionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SummaryOfPrincipalAndInterestPortionsTableTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the principal and interest portions of a finance lease.",
        "label": "Summary Of Principal And Interest Portions Table [Text Block]",
        "terseLabel": "Summary of Principal and Interest Portions"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "beam_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "beam_TaxCreditsExpirationStartingYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TaxCreditsExpirationStartingYear",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The year in which specified tax credits begin to expire.",
        "label": "Tax Credits Expiration Starting Year",
        "terseLabel": "Tax credits expiration starting year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock to redemption value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock (See Note 11, Redeemable convertible preferred stock)",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Redeemable convertible preferred stock, Ending Balance",
        "periodStartLabel": "Redeemable convertible preferred stock, Beginning Balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r515",
      "r777"
     ]
    },
    "beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingShares",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted upon the conversion of convertible securities.",
        "label": "Temporary Equity Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Shares",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "beam_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock converted upon the conversion of convertible securities.",
        "label": "Temporary Equity Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering Value",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Redeemable convertible preferred stock, Ending Balance, Shares",
        "periodStartLabel": "Redeemable convertible preferred stock, Beginning Balance, Shares",
        "terseLabel": "Preferred stock outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "beam_TerryAnnBurrellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TerryAnnBurrellMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terry-Ann Burrell",
        "label": "Terry-Ann Burrell [Member]",
        "terseLabel": "Terry-Ann Burrell"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1305"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Summary Of Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r436",
      "r451",
      "r602",
      "r637",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r789",
      "r1015",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1028",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1291",
      "r1294",
      "r1295",
      "r1296",
      "r1298",
      "r1300"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "beam_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan Member",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "beam_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "beam_TwoThousandSeventeenStockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "TwoThousandSeventeenStockOptionAndGrantPlanMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureStockOptionAndGrantPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen stock option and grant plan.",
        "label": "Two Thousand Seventeen Stock Option And Grant Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r236",
      "r237",
      "r238",
      "r239",
      "r250",
      "r314",
      "r315",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r398",
      "r399",
      "r403",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r640",
      "r641",
      "r653",
      "r654",
      "r655",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r730",
      "r731",
      "r732",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureGuideAcquisitionSummaryOfTransactionPriceDeterminedAndAllocatedDetails",
      "http://beamtx.com/20241231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCalculationOfEstimatedFairValueOfSuccessPaymentLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInFairValueOfSuccessPaymentLiabilitiesBasedOnLevel3InputsDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBioPaletteLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsBroadLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsEditasLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementChangeInFairValueOfSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLicenseAgreementsHarvardLicenseAgreementSuccessPaymentLiabilityDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r412",
      "r413"
     ]
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRevenueExtensibleList",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue, Product and Service [Extensible List]",
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Government Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1002",
      "r1317"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1002",
      "r1004",
      "r1015",
      "r1317"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties for unrecognized tax benefits since inception",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r1011"
     ]
    },
    "beam_UpfrontFeeReceivableUponSigningContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "UpfrontFeeReceivableUponSigningContract",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront fee receivable upon signing contract",
        "documentation": "The amount of upfront fee receivable upon signing of a collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_UpfrontPaymentFairValueSharesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "UpfrontPaymentFairValueSharesReceived",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment fair value shares received",
        "label": "Upfront Payment Fair Value Shares Received",
        "documentation": "The fair value of shares received as an upfront payment as part of license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_UpfrontPaymentReceivedUnderTermOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "UpfrontPaymentReceivedUnderTermOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received under term of agreement",
        "label": "Upfront Payment Received Under Term of Agreement",
        "documentation": "The amount of upfront payment received under the terms of an agreement."
       }
      }
     },
     "auth_ref": []
    },
    "beam_UpfrontRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "UpfrontRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront revenue recognized",
        "documentation": "The amount of upfront revenue recognized.",
        "label": "Upfront Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "beam_UponParticipationElectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "UponParticipationElectionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upon Participation Election",
        "label": "Upon Participation Election [Member]",
        "documentation": "Upon participation election."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r164",
      "r166",
      "r169",
      "r170"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r1019",
      "r1296"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r1019",
      "r1296"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Model",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r1026"
     ]
    },
    "beam_VerveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "VerveMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verve.",
        "label": "Verve [Member]",
        "terseLabel": "Verve"
       }
      }
     },
     "auth_ref": []
    },
    "beam_VerveTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "VerveTherapeuticsIncMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verve Therapeutics, Inc.",
        "label": "Verve Therapeutics Inc [Member]",
        "terseLabel": "Verve Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares used in net loss per share attributable to common stockholders, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted - average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r261"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://beamtx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted",
        "verboseLabel": "Weighted - average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r261"
     ]
    },
    "beam_WorkforceReductionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beamtx.com/20241231",
     "localname": "WorkforceReductionMember",
     "presentation": [
      "http://beamtx.com/20241231/taxonomy/role/DisclosureStrategicRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce Reduction",
        "label": "Workforce Reduction [Member]",
        "documentation": "Workforce Reduction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 3.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/460/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0000950170-25-026076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-026076-xbrl.zip
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MQ\ZKY3:$Y$+Q\\.GL^FO3/GYI'[X:VTYO[M\<TQW^4"8GAYY<5>+R8?NB9]
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MG[%$KK.39NT;&:$6?(3A'UM2.3F3KQJ!F4A65Z($X)4%E:O)EK 9/UP0ZIQ
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M)]A7MG)Y/?MZY=#/>E/&EL!/P$ZXU*^6%?IC3[Q9&VN)Z%(>MBYP+QR4+<'
M\8W*)ET44R,;$00,9"1]$:"XIO@?ETC79HH==M;<YZXD&M<AV$V?-9D6L[4)
M-,HZK!(S)-L2=)U]45Y[&X;M*=SDLJ.A^&([:Y3(L. [:M#=JJVBL15OG1DI
M:;;BJC,7#"OV:]0\7XQTO-V[,V 0>).)#IMJ3YF]Y:C8?&6&N<4E&83;? O%
M^CQN>]!0:<4!67H,Z/=U21-YFZT#*JE(_2?*)!TG0P6B*B4$[,,.6AFH#(FM
M]-IE2&I3V,UIMNGL9]HFL_=KM) Q(*CFHU&A4!@W&S:4(APAACF*!OY:U: W
M1FNEQ/&1':-5_*#N@6)J@8J+*7XU(?B1B!)C; U<,^RQV-8A-W93O6-71F&)
M'?>2*/].O4L:]<EAE<U^B]UG,]=^K)WN)-Q2.,R;KKU1T+ SE^5$D+3R@(F]
M"IDV&-MP.98UR'&AIR_/CKB926V/JLKN$TTM@=/%R/!RV1$5FK/D5!PO2;:_
M,U9O%QWO!3;:I((,KO@>(Y0H,XQ7NM%7#\$H76IMT=IAY^N,NZQS;/[>Z-:<
M<0!E5*DK2U!\E6975R%Y7:#&K- IHN2&#8'OO$UN1\8]&I5,M6 ZJQQ'C,ZR
MUQ%"]9@I:=?&C4]]=/?C9TPL'\<JQ&@PEL)@6;;\:%)L'SR)+!EG$EFMAY6E
MOR3,IR63AJ)-:XWMM(D:'/LW4&QJH$BW8%Q21@^;(KDH\SR?)/'\]!27#='#
MUTO&H'CX,TT9*A_>G[;[[6@RG3 Q4;9O26O==+$->@W0?4HQ4>N(D$(S4F,4
M()7808><:DW>YSKL[*K;\;&?!L=&W92R29W%[&R);3QIY\ YRLS@-D*K)EAG
M#.4V;#;CBU:B;+B$]?QT[P:)I2UYVPI4KY\WTQO,FR5TV624$1D(SBL#.28-
MT>D<=(U(9KAA*M=L@OABJW.WY*>EUM#:#JG*$D*#%4I.22H^HBLJ69>'Q2\#
M-VL/9GW''8_.4'+;A7V;M)P,^!QA NL\>V*5-5ON*8,JU2O7-:(:UA.[]I#R
M59'OUC<@;8E0Z)I5V0 FFX 1#C&AG(766]"E-(MUV($8@Q)JA @5(CO;I4)&
M4\"%$&7ZJ0%J##2H:>7&!:[KKZIZNZ'JXA@9<+E:8/7H9#Z=+/<IHU%B[%0U
M!&L\N(0*4B8'B%BZB[54NY=5[^MT0'RFD)VN#UM+R-[=-/990E:RZM5D\!X%
M$3H48F6(JF3&AZDE-ZSJ' VSCZ S2U.Q!)8]]NKEG\(NF!& WWK-W6=GAXUA
M#5!N-4(4LGEEL76P$GMTBO%F1NR@:T/T%%TRPQ9=W(;]]E5M-#2D@V6U'S0#
MZ)ZAM&(A9QG(V+719=B"P!&W@HY@V!OIV$,!%64,:BT,Q3 PSZ3@7&&-PEAL
M5)+>_P/G[?U(ZI6*N],1\)O2#7^^+NHYO>('()I>NC*ST<]LJ9;;'TX@7.'7
M9R"_*9U H31CB*]<&1F24I!ME^XPY[3O2AL<EH%NE\-MW]6CT!-9!2$(W$2O
M&:>0AH8M,&M44G'8X-BH2&!;E(HAYJ# -B3I1$N0FJF0NM:Y9\TV?M@9YNNZ
M>+6>')VLY&N5B)/CYG0@9WM%IWNY]B9%0Q5;)=:SO:.D:")@DGT'OGJL+F((
MPT:]AFH^V_G8E;V8UR2O?Z785J[7Y#]/WGE'[W]^"G_D74F%[*S1=K.?[XQ;
M^BS1ZBJ+;PTQ8V%(++UH*%D#K4(L)1CCA_5R/@*)?V..84HLUQL8N:<1D9Y5
M31*==%9VM)@,: Q"U-A,IF;2N%/\!LWN;,=T=645HF7**&*7L[L(6;H,NRF8
MF( EC[>N;L26]VO(F-Y0M* KIUG76FA)-V"4X2$SW !C73+>MFC:N--UQ^K5
MVXV2["J%1NR$:9+,6RP(6'H!K43PK&J>AB7@SA?G;L?OZ@IS8\<8VFH7KL\L
M4U@(*E4O%0D9Z[#%5M<I%O]PO>07*A7?3;R</6>5R3L()%,-FDN 0NG@T'H5
M:_)JV#3;[F)C.^UQ'T%':T<Z- 3-"H 5@I.0F3>@0S*J:U6P#1M1'6&4RY=?
M;_6)!9X7]_RT?ZFIZ9NT6S+\6K&;W% 6WK3D(*7.%JS[SOZ6KF'<,NXOSJ9?
MLLIU!,-G@C/-9^@QLT.NNW1+J03*,_JL.MF(P_+&*E9R<K:H]J?90I+%@EW8
MX;YJ^IY.Z05_71HU)M/3"@::4I]L;F'YE5N1#.(E-OW?L_D_^VQ>Z3>2<O6_
M3G+NJ3&TQ;(NL6"M!..D;SS'Z""2X*<4*>AALQ)C)_DV&=%Q*6:* 5Q1_(]C
MK[+T8%CF*2KV+W7SPR;Y;HN11N*CHJDS"['KR_Y2IP;8%7O&#J/RJNI0ADUJ
MW><SM,GAB?0_O^U8?_BZ'IXT:H_FLR-QH4Z69USS$.=3)MKB&<V?'^!<1GY\
M\ 2[C./O"#LX80/7&39$!4[E*J7&#KPQ)M92=.[#.LUC#Y7YFH8F]< *(\4F
M^S<KN%P)4-O(N*$&6UJS[+V,RD5[$U7;S<Z$'HC=RQ)!]<CN9D4OZYD\JPJ'
M68=4HADVT;<_CN=&(<H.(R\?.^+AEUO_O2//*2KK=*M048+/M1K(GF\DF>A3
MZCXW,VS+SD<'!-V,.6@].N<"HUO=2F*]Q78I%5O!EQQ)>ZRE;MU?NJYEOK*C
MZ_,>/K1*50&F$&51=H2"30-6RCU8UWT=+@6YRQJM?=4^61,3 !HQ@'>&F3UA
M1-".;*X&M?)]-"H/9='V:1GOK9G^'$%I2GL?0+7"[JX V9)=@=QLSR60USCL
MRL)QU_5M< =L3TDS;3JXSB;:]10@]YZAJ6:M86S5:1_&[^Y^;]=0 [9OPS.[
M1<")L5[#!,%H]N%M#%"L3Q MJIA4)HS#"M7&V@[W-#Z;2N\M$A29X.'0R';L
MFH$,>?2!-64>UJ_<)>FV%.?,NC;G%8N/5 \RKN:?I&*H%H=*V>9Q6&JLU9)]
MJ=",#0+-+P[:&U57O%;D.W391.TL8Y-57T(J4<>L4C9QV*36FD6 O]$2)U-J
MYTFMO8%V)41C>P$;,JNRJ")@Y5\=UI22\D6Y8<M4_LP_O'],AX>3Q;,#G!]A
M704:\/#FAAJJZBQB$9S)4<K/"I0H_>T]5ELB6J;EJ%0<=S_&P',TOQR,'\>(
MM!S8K"-DMNC@5&U0V"\%C^AR)E_C7BR/OO6Z=LM%I#KEW*'9R)I2;&ENJ4-P
M/6)01G4[7.A]T%C3"(Y85XI12H/@9;2&,1Z*TQ5,HI 4Y=!M'I6:MWGPKS /
MOALQ4;H8##4QR)?]DCT:*,T92-94A8%"C<.V&V\B>JKW#W9]RBUM=&/:C002
M&XPZ\<E8;)0L^F1\PBX7P]%L6;JH-4V$*KMA3<_N&ALWG]+]7(W,ZCB 5NMH
MY'<._2R-;&U1.A0(*3-P\<PXQ08-VK.S'F1%8!BVX_D&.^Q?JI%A:)]]DTK2
M,FMK7\%FF7.2M87495JJKPYM+]JW8>M4QV7SKW1)\C Q!.'J5$*29E\ETWLJ
M(VE?(+D2JVW=ACQL8?V?CV_]=3(EF=YZ)1OX[(2A-BYH._-;MZ9X,!5C('19
M2!.)[6O%#NSU*$RACKCG1!SRLXCQT_ESFK^2$<R7.R-7'UU>M"9=N2]EF.-L
M_N;^\?%\]NHOA_7O$*E]4H!BK>*[<=C.:T^]!;9R24;2*UD5+,O*%2GO,^68
MAZWIV)U3L*9.6MW6XVF51WVUCC8:BN%&" -YS7YI0G"VL<MJ;(/D0P7EJHM9
MQYCTL"[K+J?.7441:E.Z(F8?O15<$F03?);VO%9!NZ(PJQC]N$.OQF[KWZ1"
M3[:6+/G&(OO24C)03/#@53:)M$M^#R9"K_R##T[[8Y0A#=;/YM1I/E^OI7HC
M(CM6@F-/U3D&JL7*X*'5W@I/,EK- #O8+3,*Z7&\+=S;ST'M +?>IK\&%Y2B
MLW+L_<4N^SFT25 8"H%)A@)JEWT9SAD<9-?>CNK95&$\:J."')*87;MJ!BK@
M3:TFJ5C-]KM#/]OL_MGH@K/XRAE:^D*S"G8E?34Q>)*]/$7&(^4(Q7D/-80<
M5&C%U6&]CL$J;K84SJPVMZ@+RQG[(,Z13(UW ;J/I:N@BG+#]JG>R&&;>RKG
MK:&IU &C;0Q'E8>D<H)06S+&:*/2L!MMUVH2/#JBN0QD>(;\6O9&N"DH;TN1
MWC(6[NA1 N$$/;,;FRB&H(>CRJV3\%4["3N"G!2J]M%!,UEFKB49.5T,:,)0
MT%&R9EC(.6ZJ>@3[/'1:>I.Q2J)H=7,0M)6E39J!-AD#)K+J3]W84H?%<>-R
M\,:AP2T+_PD+=\2FR0J&M.""4U"DSUK7VKIRK98V'%H9?<S#UU0BM'E],T#1
M\@:] :VL42XVZ#I(&C@UR)Z=@]932E57V9^Y!_(UKHGX6A2U5D5US^"BT*J-
M3K%;2=4!9F-B,E87&K8$[J.3%=]JQA?S%7'V<*ZB-MF&KA*[,6P\'<D8+=(6
M0JO)H;.MC#=:<&L52/L92-.LHXO*!F(IGD$0$Q-U3V"3(4OH,8\;2!NX9?[Z
M,0^Q%&(Z?F-*?LGPS\W99J!M5CHXQO,HJS$LBU-I7::=QN@Z5;[:L'CCST(7
M_TZ]2^7,D\,J"]H67[!9R>U"(9%7KC2IGJ[@:HF075+0R64RN5%16S?VUU?=
M6NW@33F-JF"!$&,"9U*%7/1JQ)MI*:/&<3L#1IRFLR,#[')4&@ET9%SK,DH4
M(B<9[Z:T;C&0'X'?MZ2R/3;L?#KO5WVMI@,6_BFBM]J$:%G^!WCX 98PZ&B2
M9NL&P0:&VMJR<2L5H>9D2_<V>'5;P+M7.2 =D;4UGQ%#8Z^VD31RZ (M.?:<
ME*XT+D6'F5,W@F3* A3/HIBLS$0KTJ4O0XMK\P5KBYZ1RZAT7&LBY)F;\,XX
M2#[Z^:PO_\#]F:*@L_8VABI3OPW[NIDE+K)*K<FF;J@DA>,V3'U\2?,'IZK>
M3%'+N0;7RVFRW%7GQ->SLFREZUI5I'%'@Z^I,N_7>G)TLK**3Y<'-)?CYG0@
M9WLEIG!VM%UQTYL4MZI3EG6"9*7((60V<#Y";*&HF-GBC;N4=G_B-P^8(J]0
MFA0O#MD;?8PN!=,;]! S.["^0E(Q@LW:80BV935L[/$)DY\D=C9G,'N"AU*J
M=-5<\E?JBCU861,_>'LF?>U/^^J;CZ?_CM,3UN:7>D]?_,$'OWDZW1C[K&_=
MG_8N_=_3]@2+S&^:L9DY9M][NU9$Y[4C3*>'VHV,P]%88DF]@DV)3NO]46K$
M7;/.E6Y"L\.6KNS-T)E1X\T;G&:M2_%-A\:,@XQ&9,9=L<9#;QV+\CWF."P?
M?60P__7VW?[EU;ZREG?=NO=8 ^3DLRS*E$8BW2"RJY]JQ8IJ'R8?WJ0=7.-@
M';*AY&Z@92-&IWO(5#)@5J6'5HOUPVTE&&.&ZQ<!N"-H#TJY%/:4%&H-SJ?*
MYD1'",53Z3HJ%X9+YU!M]QY/V^35I#$&OIS#.7KS?'*T/VM==->.F@L04NS@
MR,I^3$]0;6JZ.-M2&-:6_YG6?(Y3_'$R6UZ@OILI.CWK8JV#T#2"<ZQA<\D,
MS'HUJI3H7!IV\M^FFQ8^-_PCBSPV(E)&*8NKD?>R/<&5*G%Q%BE+.MFJ##4[
M;'YC *(,(%9&H\])96@R1M.5V""ED"#[)&.'=<KC=BE=/X#WC!T?^OOLD*'&
M&AACAYAV"$S_>6IF@R4$1E/3.1G *)D +0-?DTM@,;I0F7VI##LTZ;: <?\#
M2AL$H<;X9"U[ANAD<QV1A5(9CF)C%-J\<O&VG'H75"G=8(W@,R-,%V.!7!.;
MXQQJ]$6AV_O9^SM).HX <*S..O8(,:&4GU&'%)&@U:P*FQ)7Q^U0NN$C<P?A
M#D36Q"A-HLXJ@D2N063$A.Q5QN:'5<=?02O\9][2C6^_-+9:EZ*#TF1OM*$
M)3,C&W;?"BG5'&T]&[&SW!P_/&E9=1ZLS,:VK4 *K4*D%AUZY[0>UG6]YIKF
M55_AJJ#V\92_R@*]V!_GS;;ND&37C2G@2HM0+#-JKEZAYE_;N-/ !G;>OHC;
M]$EPX09/R#6V5^--@U84\W*W67H9"L2B8_$Q8MQ^X](743FK J:#V6%[?"1;
M($ZM]MYH'.>PY^*!2%J6L3M(RGBA5XBA8,:V#SGZC\_9N'8W^2VTVS]HYXJ+
MIA2HG368<Y5!GE4-%"N=%'7I>=SA2R-V_JUV[:UG,%:';J8.T?BH3.P:8I,$
MF0Q)22$S1G65+&F=&;J.2L5U TNM3015R+"J27L\_0F/)\N_7!LT3NC/-_(N
M1,E9(AL+=OZ3:0IJ";*2RY'SP\:'!M368Z3"OBI#$2AX8S*P+I$!+<H )D:G
MUH>:LK<M]*UO;;BN,K;K-]._LR#GLY1QTJ&D6D#57*0;,TD61L:BY-;XD]C&
M4\8[J+X:8.R!2<5$$P.$+@L1/1,I$;-"JST3&:^K';9K9!MC/C[)#U\K;+\^
M&OAX<^(I/RY?'- O./\GW<R9):9FE5WR4&.00IG>)(_$S)EC"D@=71\V4S!,
M*_>6+" Y-%%I:%;&R72V@-FJ#ETU$\DG'>UP>XMNYVK>/%"W2:^D>W;_/6.3
M9H6EC0<L+8&.-7NCDL]^6 .X!DO_PNKGS:FQ>'0R;;<,? ,9N.JJO9Q.-S:2
MN4/1[%:'7E3MQMANPZ@,/$CXZFK)]N6(U.<0QBJ=*4G"-%29B,T0!A$U=!=5
M*3Y%ROM@++_:B;T;X>(];[2S*JG4O85.7D(>["B6R'8R=A\8I6=;U+#UP']&
MEH=MLL3%5]%W8%4K+K4,O5G/'CZ?.PO*(=]5#K%;58:+Q8S8C+6;N69,O6JR
M\Z [$3O#GJU[%H\8J>CJ@J]QV+$OFUBK8&^PW?A* :M5E'W- :(E5DB)"F2?
M$V!MVH=:^\"5H%+2\2L>7:Y(NC1SYM?)E)9$T]/@#T-5N> KDB]MBF?>&36Q
MNH-'\]G1I;MXSG(SE=N0ZSYG^+R=XJ-MU2J_93J=KV8D/HOIM#95@HH=&>.[
MI"SDVBU49Q+%6K4;=S+[4'KTMA;Z5H%K&WW1#I*+DMWK%5*O+*DM!TU>FVB&
MK<W;SHR,H13H"#Z'<=@+R5A065;D2F<3[QIDS*J1,:KD8;N\UI_S]@3+Q8=[
M([O6V.*:AJ@[RZZ3NEK'[D5MF'6SI94V+/BZ'=>V_MULM>-XF'RDM8ZY5C&J
M<T7FN+,K450RTDT:JJXA(@YKB49<4K(C:^%4U#IF*#D8J:M*D'1!V<2!GDFI
MW%ZLCKR)0V59OAIB1"#VV9DT20/:$""U5,E974T?;M#:.6E.6ZTO*C*>S.I*
MV5[5@C_3E)7P(=OY^^UH,ITLEO,5I1Z^/A8O9LORMIO!W]8'3\4IB.0;8X"L
MH<C,8*-<#\2BZ/6P&&#- ,SEX>W/3MA/QL4Z89C/I:<"9=:DY^I0DS="SU 2
M5F\A=&1,9YB4R20/&A7+JH\:Q]V9L/%)%VM?^=I[5/Y.\U?TXH#5Q?$J&[WU
M7/0F]7BL036;P'<*#)2819#_ #8H(E\K41S.Q(J3_)ROV$ZD"O*4/WZAY<&L
M/9Z^HL7R+==<_BO1.^KAZ;Q(E\3U"'<-+EJ0Q.'8@#R0.-OL=)W'6U1W/M7\
MQ>P9S?ML?O1H-E^-!5F\Y[>PS3F<\;V>N@2K*-H76/*2US9 ?.AF>G5LLD5E
MS.!-9\ 7T4#&%,$T59U1L:JT#VV#XU9&W.R&QG&T:DJEF"A;/FR4Z@@+I7AF
M:T4M)U^S'G=2YJ@[[V]C^[N-J*1<5/4=6J$D"Q038-$>LDI1=BJZXH95S8,B
MNA&J2+!8I]E^5Z\<N&H:E,2:L&N%J'0SA,/!OY$2CB,,_!R"C:K)A!5"S,Q&
M/51 )'8YR60;O=,U#NMH;JMR8YP*!^RQD.Q$T%TF1)L,2;$BC]BK#T;*R(8-
MU=WG,[3)X8F\\[?(].'K>GC2J$E]R^G&Q+,\SGG;%'M4J_H6!KP?/,&?;/1[
M>BRGNIGAO9(IMNR!)9*]*\P!"ID.OK7NJ5?EW#Z4#.ZC=W7SVL?&\;5J(MV1
M&(Y&#RZH *AB@4K)L-U!E^VP)06C#EX>(?=7T:+J&7KRLBK$>4@]!-#$U,56
M6MG^\)T]>5.=/"EE@)+F-Z6B@N15A99U22YE'=.P:GVU">VD+D]$X_PT6TA=
MC41.V?VZ) *_SJ8_X>)@99]9Y5,3H\^G6@G">@FY3[LC@7F7[N-_S^;_[+-Y
MI=^HG<Z"O)%HWJG272[,S:HBN)AD4J0)#!A3J^1+;WG8E2)[C1/VOR=WF'"5
MTZH7+1N*=&!44$J#G+L#8G]'9[8I2,/-E-IE7FL_08*35>4. ]B.$9RNTL+&
M] ZEH%'H7<PW.LZN]T]#;%Z3WZPXNS,FDXX6LM+^=+YM=B2M^^SD9&NZ'7?L
MQ+7FV_Z"TY..9T#K$=8OL7)2@4KKE^&D36DI:TWN64%4*&N,DSU=2DK\]U!T
M#SD,"]#7+:U>5:/^,N%_EK//7ZV^RZZ("#JO9\:N'/IY#((MJL@(N]3,9DPC
M%(L%,% M-65R9E@&&612Q[OAU74'S9K-#9IUME%SJ3 $4:RYE7* E7VG@FAZ
M4FC\N"O2]MIMDAI FM>)C+]E@NT?)AH'?/B@"NH,!F51A%(R\\I6:%JW:++7
M(8SI-9T7B_Y,LY?L]1R(HCFS'<OC^;U?[N_!NP]69YOYW3<^IY.93:E:!SZ'
MIF,(+O5A?9DQ1@[?)N//&*F8YF,"CP(W5=*0V84 KXW7S5=;QRT^&W#;RR?O
M5]DH"^\\"[0C7HXA=6Q*M"""LZ4R*+8R_!6S#LV3*<..2AL1&6MQ6M9>P1 W
M1L7N3?(.DI$4;:T-LDSOK596EVM%J@U;'K07R/BKP:=)I2BCR"DXQJ>606IQ
M/D&)JB;K5?=ZV"+4O5D2NYOB),>Z017-,,5*X6!C3<\:7@%Z\H%R=7K<7K53
MLKS U_=/E@>S^63YCO ]X$\7K.)_$HTPWW:0<T>IF$3*A>[ =&UE7X"@SB!+
M?D-JO9-W;B^GS:Y*P6\FQ8ISML4H,]L#6V7986J()2YK97,UIK=AZT(W'A7Z
M/!.WP7(V5W7'T*W4\+#W%HBIHI,"U5MQ74>ES; F;D#O[3;!.1Z#(]8<+#03
MV5 XWP )#:2:*+;D%)O^41G\AI:C[\C^-&=MU^+;>PTN9BN%N\P2M9&RZ'0R
MPR$&B?Z<*:FG\^<,#2;U2NF-(/:S,./&5->F^YSVE%M(99/8+C)C5)F<GP!;
MZ6 3MA09<_:H1N.606/46]+KY#MZ[< W*W!2!O<J0M"^^]ZRB:EN/?UYO8?7
M&WSXKJE@\-"+K'3(Q-Y/8F@=9=VQ-SG4MI=QRF=]\E_;P,XC!!RZ;[Y6!AZR
MJ,H%'Z&03(S#F(,S,50W;,!A%R3;CN!X1=$8'\ 6LA+1JU!D9%^JMK>DO&-$
M,"H5'DVF.!4'\_%4>@;>TN&M/S0_GK%O0]=J]AHFVNIUU-GI#&E%&]6"-(<;
M8/P>F@^.;!DV0+!SI;:;?)DWOC(6(M9B3"TGW9VY9@+'*(EML[(U#(>IKQL@
MW\&R:[-!H3(]9 :KC&.-!W9R$N16-& ./01J"?VP0O4UU&)]YBV-&;[9I%&P
MO:=,!.AE+6+F?U*.#3QJ,@9]UOVK],,V8IF^V%*P 1QZ[RE09]2=>](RHID@
M9T]0>M1-ZV!C'%81[D>@>]QBHIUQ7/6./8SJFF%?(TL?1BB .A/[?_Q_XPX[
MNC6]>VIZ-QAA\P$+E1I .]&855@W%L:FE51T_(GRPZ8&+\#]CR>+R90-[//3
M4UQ62P]?+VG.N/[#HU//^OQO9IVCCU%5_E]0)K&KG5( ]K0;>W#LM]F@*M*P
M89#KD/8OIJI_@:FV.X@T^N1C)TH05DMO8F"D$R.#YZJ*\T&[%H:%S/N!=&XK
M,W=NFU*HWIL$,<BH>1<8U_M4@:+1T1A&^FU8'M]U^9>567]KFQRU*:V$2O!P
M@]I]8$>^%BC)$9ABC>]6,YP8CF)7>KV>LY.,_+R7J/7[\6PJLUSYV\>GPX$.
M:9TY/6M=>%6]2?-CF17[SL@-AN23EU-J+V9KQ98WPIE[EN=A=JJ. ABUT@^,
M;7*U!#;7B(DPF3HDMVVW\^<V%G3.'5V1A($B%IG6HR.D4 K85!U&WUVC??#,
MOUH8LE\,OZ7 >$4?))-M-,,@I[V!@MI#)9M0-O'$<5?./3\IC-DG.'\C<SR>
M]E7IX67[MGQQ0*>#R6ZFAU:IHBR^,KEW*47L4!@#0=&F&.=[+W'8 1RCI4U'
M(&<++OK0 #UZV64:("'_I"U[*+&TTL.PI3VWYF0S4?&SJ,19 <ZI;'RA$IQ-
MNM4MD#?,OR6:+-/ %!22'EKJU)F;==+#%LL/N"]YD^:^^]*:ZD Z1G V)M8V
M-4/K7E?*H5':>L7G==E2,3A)FWEX[)I"A]@*LZ7##%G8TE9=6]6ZY#K<HDAQ
MWUY,E@)O'D_;Y-6DG9S/B%DQX:/9_(CF*^1S,#ML-%\PSYZV7YS]OBFM-7!,
M]3R$?[^R/"XF;]>BKF[HYQ.^B7?FBIYKV+:)$,LGS7S;B//Q"\U?TOS+.!UZ
MM>'3;D(0@S(!$RD(+=NSK>W&$9"RU2=36ZK##6RZT?M[UKZ)C^]A/^/'JQ]?
MW//3OO[*TV&,9= *:_81?$T-7,H)2L,"A,U@L<$I.VRMS_T_<-[>'U^ZFA,_
MJ:SX]HP2KB/[M) KN[N.6!FA=@6B<;9ETBZE817&[6C^?P1CM8LM@:F],NIL
M#K!%!%><L;UA*G78V5Y#Q/X&"'8'$U*)-8!7E6E80H1B0@/?:RM6)4-IWVOT
MM["5>[0N6"W>E%;K\,X[AWX6[SC5JQ.',U@/+MH*A:H%:S*JG)/R>;A$R5_T
M3%]%6K==TYO5-:YXHWJ'[+RTUS4/2>D$P12O@@[>AN$<]3UPD_>BR'I'",4U
M3]@CZ& 8E^B2(!-C%:VJ](>0;GU8J/]G.N/)Y/#PS<9=T8W;T\]GFEW4(H6@
M&-:R60L^.39KL4%&3- [1BR%M''#[O ['?YV0<@GLXIOPV:77)>/ES3?3,L3
ME._.&" 595]XU5"*Y;,7TP-[,-7F85.JZZCW!_PN7JUJER\.N:%T##X@7UEW
M0IF[HB!%S_J</5'V9+RN>>M[&#= QU$REF-,2O^:NF9"R*XJQTZV<[+BOC,@
ML1J!88J++7;,XU7?[]DFN"N=\BI?VJ?R681+MNMB+9C2V(*PNP)9Q0R^16R^
M".6&#56NU:[W*<-!]EGW?:T*"&NBK@BLE3EWW3 28@:&H)KW_!.E.BRX_3IS
M=-M/17\\^_>Q(\17D&S3"YIO>PG:C@('2,HE"H"N-A83%=D'E/P&MMX2U:[<
M<'9Z2'7_R=M$S:WMN7&VIW1GHV[0M>R&+RQ4**5J+?FJR3K7^]:+TG?W\-58
MU5FC6+(1G)$)(XX-;V._595HK+'##F5<JZGZ;%#P;[1:%W&C>Z@#.5M-),"*
M"IPK'HHM!4S43&,57&_#)DW'V/Q^NV3ZUBR\E:;NNVH5C&.'VE6K(9F6V7<O
M?*$:FM'#NB0W= ;[CD!W=S+,38%5U;%:;;*9BQG!)9_0,\\U.]Q(F3T+CKUK
M///ZFXGSAC831\T0,$B92*,J[6VR5BD&T$F;&H-M;#U'H_(GULD^F\_*6;C@
M:;]?#R9LP;YT7.+ZJ:'M122&,3G1>$S(AH9D290SBAW]GAO8$F).6'5U-Z.3
M29S\V?S-\V.L6\[LZK1VLO[TT,W8C&BR"_R6P3OJIVX5HX8&_*=:B]+6XJW-
M&%($?8B6*02(6BH(R;,9D/J<THWS*;JFABL>O&XQV*7J"A;4W^BEK%)D<?QE
M<L@$92]K=\'A#>3_(^B\AK2_>^AG23OFXF0'O(N)F:;+IB;E&_206/*U5[8-
MF_\7??V.!+_X8_;B8':RP&G[=3(E%O'I%:S_[(0]8UR0?/5&(OZ(56F?.Y@F
MB!][@5*E3(?U@62JDK;#T?/*V*>?:?:2M>^!;$P^$\'E\?S>+_>W*7@[*+R)
MQ:H@(R$)NP'GFY)!M0E(=Z/)FZ;ML 54-S)M^'EV?(,]7+$T.DTCIR!# ?C<
M12:&5E5#Z[U[.^X<V$T$).TF3/BNT. &'-^/'2%Q2)D!\ANKG$W=A;S[%=)Z
M0?5@.OG/DW?NX?W/3Z-ES^9\WNG+7V:-MKV:8V,%1[$9&4*F(#*P68W>A2QM
M-F2M"1D3V7$GT@]82+X3=--RK#4@(.-6V219H31IEVQ9M^9SZ&Y8%V<(U;BQ
MYIN5/I@=SEZ^N=WF>X,S29%B+3H1!-EYZ'1L[![*/U0CY:(L^6%';:W5N?$7
M$\MO9,U_I)0#Q@C&1@(7LI&I(@ULM<6%9M&T85V/H;3H@'KJM@'ARZO(U%)J
MC"-7/=NRF"]YU!"J06M2ZZB'K6,?@UMNI_1\(49MUMID('IKF5&5M(UW1M"A
MNJ8"5N>WOL%Y&XQZK=;=<:C12^T4-9 VLD];!S;"/4%H3D77+7NEP]7H;*]P
M_B^&2#RC.7_Z<HY?9%C<?HW>C[V'3D9!-.C 964A>R6.<2A=-5OLN#.#UAUN
M7.O)T<FJ"O;I\H#F<MR<#N1LK^@4YN^/V/<4LRN07)8(!B+[4MY!+U@-2WXV
M==C@[O"M\#L*2O5>LBH!B!TH<"H[P*PU5)U#ZS;9Y(:-*^[2KN[$$SZ93D[I
M]OL_3B/9%Y0Y.@5[9['_U6?GYSC_Z/QW.<D'3GC,Q[QWNK.;XA^O>;9GL],!
MK8L/W^'%Q]<\[5FCP8=/>O;A-4^Y^,_^_OE.EO-[\L%USR5%O.\_\AE7K#Z\
MYAD?S4ZFC>8??N"S#Z]YRM_Y1QD,R6RW8.DY8HZK^&!V>(CSQ:H*^>)BJT'$
M=/D4OYX<T:J$[-W[F2QFSNAX[_?G#_[L=M[[OOSQ 4UG1Y/IATZ[[IN[<HJ[
M5^_^+][&\P?OO=PU'X9_F;R^QW<V.YFSIW?ZZP%A6ZD4OOP/_W+GSO?\WSN+
MY9M#UH['V-ID^A*6L^-[ZEL_F7[W7S!A"KZ^!_8[OGTXH,G+@^799\=G,L)7
M.%Q%];XKL]>PF/P7G^)>F<WY,L!_^8YO__C\"IWUA1Q"][0Z7GYWA/.7?-K5
M];Y;?=;Q:'+XYMX+5J:+.[_2'W=^FQWA]/S ,ELN9T=\K"@=P,/)R^F]0^I+
MN<;B&*?GE_GC@%D(%E)%>(^Q#/PQQ^/O+EV;+_UG5UM]]D]:U;[?FS)F6CW\
M'Y.V/+C7)TM8:;VI7/7_^E<=U'??WY6+\SL]OO1>+Y[Y[%7(0YIOC3]>WFFS
MDW)(WUU^W1>WM-F74TFV;EWS]9CMO9XK+^:+/6^='<[F]_Y5K?[GNX\__1^G
M[%UFA^TR,<+&WL?OOSY^\?#!G><O[K]X^/S_9^]=F-M&LC31OX*HG=JUXQ)J
M/B72WIX(69)=FBI+6DF>OMTW;BB20))$&P18>$AF_?H]C\Q$ @1EV1(E2L)$
M3)=%$D B\^3)\_C.=_2T;.5(G6;1]%1<'!U\.3^^/#ZZ</9/#IVC__?@M_V3
M3T?.P>GGS\<7%\>G)\U*;G(EVP\V%?\0Z0Q^E,51RSG<.=AQNNU!?[2!U7NX
M(:]=/;4*>/J]Z[=_-8>)6I:'/$_,6:[O[*1Q&/CZ=PE- 8[A^1\\WQO!8\O^
M\,%FY./I^6>G3M1_X&GP;F!!PF/(3 X\,E$_7G7'DTZ[TY=NVT/RB7;?=\6D
M.W([XUX?W'/1![?Z%T>YBN=R@FY]SQ,]T9Z,W,EP,''[LC]PAY/=7;<C17M/
M^&-_[$U^<2*!3KLO@W>'L9>C\X0N];9.<:?M_FY$KC11_[D!'?-PXVYTS'/1
M,76^SOW$:/1@T_$&*_"=TTB^?7AA?[A1/J8UM%V>*;YM)L#OK-O=(L]BO0=Q
M<'A[>!?\N1N*99RKG_"3.NWV#FQ%]7L/0S.+5+Y+Y4(@24]YT])UO^#CX?F)
M?OAUD :<EGZGKU<_@E_Y9K;H<?U?[<B">D4.+?QMS26CW>]=\[__EB750:GP
M!@E [4+=P!N[XT2*K^_H?UW\H&;<Y4!*NQ-$[Z\E=M86H9(-^*:J3ML84U$?
M)2K.0I<^00#%OM7_NI#36#I?CIV+Y1PVYO]JI2)*W10.MLDZD\#WVM[0][JN
MW\6"U0&"H#K]CBL'8V^O+7TQ''@/91+L1U$N0N[D^(LSB9.YR/[^2P#OETH/
M-$D<CD48QADL_D^JSCMNN-%>?_?]=PP "A%E_LN3F)]6\'>:W/V3DR_[?SCG
M1V>GYY?.V9?SBR_[)Y?.Y:D#WODEN.!.I^><GCN=P1O_K7/ZT;G\[<BQ''?C
MM.\?7.+7G5&O7[<D6BO ?U'W;>,1\?0&S$L-#WR,$R>;26<2I+#MG*44B2,C
M7_HEOZE>X8G)8+(K>V-L1..Y_;ZWYPY%9^B.0.$-A6AW1NW!0RF\,\K!'7%F
MKJ3QWOGPB3N'I\SP,M<72Q=?PY51G8*_VP2N4?$=T>MUAMVV"^H<&6;;(W?4
MZ8[=84\.AU+Z@[W^O;V^@SQ)$/-)"_)/>)&[OO3*^VZ-D!U*C_/%F&-]+%_Q
MX8;?^EX,X2>ER??\?GO4\=VNE+MNOS><N.-13[B[XV%OV!F,=X?#[D/MGT*<
M/L(G*=\VB'+I[V=W'<M59UL%#'/XWS-"OB]P/[RB:@X)L_(#:[J]\^C8LV6_
MW7\^_[#BP\W2Z?E6JZLM=_<W;,LU[G[C[C^*NR_;7K\_W)VX'=$&6[ W[H$9
M.!9N6_1D>[0+IW+GP:S?RP2&0\"3[7#Y^XW+OQ&7__)\_^3BF'S[!W7[G8]P
M ?[.>L#9T?GQZ:'S\?STLU/]O\O3!SWA[G9LK?Q?$ZQX"<&*A\MC8(54D"+<
MV/D8P"$/2@>=RMM-^>\]?HUVGXP'HT%[T''W9!<]_6'7'>WM]MU>=^(/>GZG
M(T?^?;7[$4&9\57X3;9TVMOMCML;==O#1_/='R'UU:1YMRS-6__&ULOU?S+(
MTNWV1^WAT-WS1^"0=T=#5XP'ONM)SY>3KK?7V;NWF<8;^5Q.J=@_RI#VYT$W
M\W=?_NY+^T&*N6,S$#G'D;?S:%O[ =_DN8/\'@[,\N;HF_ R$D@GGCB%(#HB
M==*%]+"FQW>"R FRU#F8B01>9@.0A0:>\TSU]@LRCY]G_&?0_O$ T/>ON24
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M7^J<#W;OZFH_TG8>[T4T\_2;H0&E/S$HO3/<:0]_@M1SL-/N_OAEW=[.Z">
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M-^G#2X3ISQ)V/KV)N@TB\UK5V24H'#&=PB&'.FU.S(J*>U6IH^N8_$7TB+'
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M8[W8V>N3DKO\[*3+.4AVBF=:QC41UHQH0K82D99200[E\)8.F,D&R4ON&UZ
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MVEW+HJ&TLFDYAFC%7;PX97#NZO['3<PT[<21![^Q#L2Q?19K-G?.1U7-@]7
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MQ\:UH8B7Q%ZV\'KQ-(S'Z)WR9D<Z0]T/@IL^LS,TR2-/O6)QD<TB SJEI<,
MGF!L:\TP\#>S8 R.FW6;"YB:$-S.1.$_=ISCR#F4GIR/8>*Z[6Z?3R\X*G.B
MFE\DJJ%NLBR:S13,UZCNSF8XB,[?NE56#1B7%@#]TM1( ]>(>H_2*\!/#DY/
M^!+5'=['DFNK_91R:5'/J5_#(V%AL?$[1PT+#!\<:0F2=/AQ*%-/%NI012(\
M4-G4E1NF6T8Z0,@/8WY@<J)Y-*6VW#[BB'OM4O.KZ@O@VL\#WX69'+#O2GYK
M"%N1-+E,<43Y@@T6BT%</Q-O:F[0 &4:_;QY_=QK=UD_DR]IA<#" #MB1"**
M&8,;,D7+'R=G+=R+<V5<K!CN,)]3VB!UJAF&XV8P8*NA'%'ND+O(9!&]?O=W
MAP@>P/_+^!EOSH)__8M"I>A$O[64Z#Q.*38UCR/"RJ4+I(I 7Y3L(O05<1LN
M9L+M.,1DDRP7*;%NL1OL<>W[_O[EX0[]+X>.47V"GL1]:EEP!*'@,P)L+17[
MX[:9B!G*L$AOMDSA,".]0E.J-;()9JE.S3A7Q0J +K-4*2H;%Q284'-\*V%1
M(JD8@"N40DNM:/<9YF=&S+>V>BMH1%!ASD0XP96\3?&\.LN?M+>B@U*>G-V.
ME,&SMYO[J7$/&C.[4>.;D=8CK&N0E#ZY0,/Y ,W ?9#:<>POG3-!28.C:Y'J
MEB9'%P?[9T<MW<VH,);A,2XIV?@;AQ,XM01R#S8XQP[0F,F*[BCP^66!!J9P
M94IJ%I_MCH4J.>9L >XA\D2+N)Z),<+OX%XI6:2XN7B,>O>T=.M2UGBF&-/H
M3-B&(LQF2^<Z#G.8&%DMQ+#,T5Z+>,-@D.[!8:>S!V=(%'LAV=QZZ*7#"\NM
ML*BDSDM13 7P'ICO(A-<.1$P7+J(GM%"TU"1%QD]V[1K:53#HUAXG7H+#TRY
M'[?D;%OM?-@[,$8:ER:3/88UQR)$XTX=@RY:2I0@U!8=-9[03IOYE!6)YN%2
M%@K=4EER%+K$-A;3<.GAKD/8-29TC?N-!J+3$:2=/ET<=L0M=E>G:G>5=89*
M8^J &AAEE+FUW':JJ$![ .[#9N!=-W8#_WX.\.]! _]^7?#OEXN<_ /)HH5A
M18IR#(45ROX5(\H^V7ENL!B^$CD4J-<D7VAB3*3CT<P=E*HFVF].0:MC*A)9
MGG!5$+ZHSNTSOFO'^8RGF TXJ@/.&)(#4:#+&"F$K#^"8I1ZY=(6\Y5_78L^
MLM!B5#%8@+=T9\(=Y\26 P/8TCEV.Z\4%@*T\9S@%DO+1XR76.RG8%8)[ZM*
MHC*8CO.O0;0*HKN98= ZS!@-R\@(4VE&QH99W9JEP9#36%K-7Q5AHP:&:5H8
MSKM_C; >#<%C& B#FU.ND:^XF<4*X,&X-M5A7F 39RL/K4BZ8]-)VD!/*F]6
M1@=2^TVN.P8K3J=+,'%]C8D$BDT59?/EBO_7+%H76*7H:]E"D]7.!(-+KOHH
MIFGL<1:81*9V[Z<6M%!A;532FK-$4F0S'2Z5&F]#N@I6-: *2A)C<LAUU]&6
MD;A:=1-[7IX8?4@T9)C\4&3!ZD<HQ!18H^0Y<O%%-\S+1]M!JUW4,LYG'<#D
MW!R[$/6OR_%81);FS-^$$&!$2U$<5CTJ1/%T,:PJS;M25,-T:J6?PPV3!-L+
M4<>C5BE$0EI03V49<&&=JBKR42#"*+%313.]9EDG3CR*'&FD6;'R%4U(N=("
MM*80TD85:06J6D*EMI-J3FMU5"<2^7-3%@3"H)H;@Z!G+)BJEI_SDS:^K #<
M$2V_W8P7C]@,&?HP*H5O"8_14J+4<TN/2HNZ'KB.GR$8(U6 .FW*HQ!EJBB?
M-;(653Q+$GG+;L0D*>U(>+9B2"GZ>'WG#:QSWT+JIJJ%,;5.41*OI^2Y(^]>
MS,;Z&$2HJ%HK%CZ(B4PKQSROI\9J:O@F:2N,!=.A3)4P&-;$PJ&$<AZV$@P2
MK095J^LIR$-4L,#/Q;^9- 09LR@ZJLX'SO-3L)6[^!3/>TZ*<>..VP?+!'SG
M[%LVP;IZ%.-9P!6O&(.ZIL:'C?9:.)V!49J\1[E!@FT(6)!G8]"C6,]R&*FN
MZE%[8()&B48N80E*:/?^M0GMB)J\\[Y2*J0__:DB(0MNKMAP<+>J'9F5:HB4
M@X$/ 9FF5\.YH@!X^_T"$=QAB_["P9CS1R8)$@'!*9VPV6.:W?,I',HLD_2#
MFP3+$Z/7=5AL[2:Q2H/BZGXQJ&1";J1V]XQJ!UL[J%&V>*OM15193I,*;_)=
MFY'HW[B&Q2YCLTL<R_)H9[4HC$80(N3#HAR2G0W3BEQ'6E2<0]OB[YM$;B/8
MCR'814VF.F.UT:*8XL"VH% MFAB%*6A78[&KB08W?I70=7G$.%K:(^-E-8I1
MB5$WPMX(^X91"U395 ZN4:*>V)@I,J>]25+5JR6_QG'%;;+JR38BW(CP9D7X
MD- :ZTOU,=K&4<ZX%);#H(P=9;3<*.8H,%'#1H8;&=ZL#.]?QX&OR]1-E@9E
MT);FN^>C"AU=S?0P.^TLB>=Q"H,,5S(P.I552=;P9I'T1[,?FOVP^?XT1?"5
MLN0R@5MHBA3%3T 1]!93[>B@8$S]&O((+1GF8RCXLNS0HTJGVWN%0N4%[SS5
MS6#(4% #U,19QCF:-;,@]!.$0P:X82DJAWXK%;-C/@DIM(B/GZ MMC&D*_'H
M%M3GHME+S5[:\%XRF?UR[JAR1-R/1N2G640:Z6^D?Z/2?X:5P,FU\08T=%!U
MP=:,X@*\@P3-H2BG FWT>6/B?"BPA89'CKSA\7+%T[ QBD&"CT+DF$:_I#+#
M'?$>G]>(?2/VFW4H+'(I:D\7^[EJS$'])B05LA7EM88VT21KR\"9@F4N%7-I
M\PZJ[6-=IWD 'ZVX]3E!#&[)EK]B_(#-::GY%._&:UFT@1LCHT=*.2809<3.
M4,L<33Y"E!-8'H^V3,0%Q? G)5X-!$#Q6G(NG\NUS:,8S, 4E;8C;E^3FENH
M83-UAB\6N@&M+"I(T<50(%X+ZTMG1>%WPVG", =R('A@M=R9N#?5X-00"NZ.
M!1^""(P;*X9++\]*=S"_-:2;% @PV*+*K0W Z8Z@>!YX2JA;:TIULT![N6F:
M^9TMGDX+I:^.<$P@$N:NX/A4K,D'RPSKQZ1#>)XCOB_SEWXXLAK![_O(2U+S
MLWWZF51<K[9V:]D+N$(CJDF4[70G]^7A4@.6LF*6S,28.]%\4JVPE4NM#6V:
M(@5UK:H39D' 3R0ZF/D"GRL#$G>AWO?-_EOJE::GZ<W!6UJ"E6*#IHCNF171
M[39%=$T1W3.T <HZD!*0H*HYI :_NL8.[8BAMM7:Q#EHJ?IEIGE4^#_397WB
MP#'A!:'SYHM-8Y-@A8*B"$!;0_%TX8,)@I?-EO28-Y=O%:_S*<?YX%K6W,5A
MR70*+=,F+T&V/T1UXXVQMQ4X<*D"@"OJ!;Y%RT:N"^=+I:H'SO]<'51P91Z5
MKM4<M=-<L#K_I >*T_CEW2<^0N=!"C.!P7SJ2N@H0IW86 ,F=,G=]1B\;YWU
MU$-0:J;$8A!L*JFQJ /G$&F_B7!,638P0U'@(79RQSGA?^"P;*JW$BNUAEMX
M9,QHXY@(WL!A*1748"&+NBJ2-PC5*,\L)Z*SRJCUEQR!-?![#!$G<B&"I"),
ML"CO0#C@"T6D 6LUIW)U.R^RXWP!4X:6F^_B\/U"<TKCT[X8N2,)NUQYU*5Z
ME"I(&B\5]-]$M8OP-V^'5$DX[!-8;[*?Z.G$+XYW,Q_M./N18.J_D$CWT2"-
MT,3!09'!C#5(.#B^WX>CELJ%EAZTLOOVJ^0!I:T71&1;_,"^^Z1_F^9C=CNQ
M( +KB9C;%L8,*L_]I(I/X+WP*AX#T8SLO[OD28"'*:6A9-'Y].Y 3<8'R4Q2
M>A1(L%RV79D_Q)C8)&9Q!,J*@J5:CFYD45YE-)191WXJ+@U[Q_KY_'DQ4!5/
MLF_]N@"[6US=<4E\&!PV815JRB@M][/.@ZEGET7N;K!GP;_["\22*-,,N[AB
ML"K#WJEV! 4C3ZV&$J#R"AY<TDQVY;!1HP%'(JTNI3O.1W*(P=ZC2BA4,KI1
M,T4X==Q&!_/++I\1^42J0ZKTSDC;:(>.*FXLP]MB'1HME^/"KJR,Q?:L*D]E
M'<%M/5*M^M_(G>E.RSD@Y^UM137<W(*]+M<J5'G92PSNA.A'FCC->$<##5(O
MU@@27!H_R:=V-U>M&W/L#?M\")X?/PZF4?#/9HHV6"+ EDOP)];46A4 %<X@
M7:IBEZ\4E.Z*9;S<>,9DY73RFXBJ3:.42<'3J M+A(U,65,/K ="L2!$<)."
M!%,ML'HLJ&1\&5=80ZFNS"KJN&-:3M6G*,OAD'+6TC $EA*7%D_]SS<\>(UG
M8:P,4BYHA;T;X4 9UYQI,OO:]E"&I)],)5U1;!U93#<]UT2_=1UG2NVF[.":
M^D7YZ;J3.8.K4;*\ /N!+\-8V9+4:P 5G(9E4&"6=DBI[BQ/.(6G&+!UB+=^
M7$I8M[R;RS;VP+$;"FGXF<2&\TG,O.&5K;O=,ZSZY6S]#/]Q<E9P0"Z"!:5]
MBT: BN,V1!25EROKS=;12G^C+V5O U.K&%CP6KN]G^HS&*(_N.0PBN:""Y=N
MT62$7,4@P9V;E$>^W>NO=M@V+;]]Q(W#./8+VG]6?DA/6&@U5I#TUX[S1PQG
M-1B[,IF75;EJ$\ A#&K04O1]L8#5BQ6\439+L.B5Y YF! QJM<G9G3E-QCCG
MJ&NU;0"7'T?>#N5FU-=68,&2S^JI-%?N#'GPUP$>[:O*>TFTA4HJTUC[3%CF
MC2U(,/%"AT-0Z5-IY)&>4NYG22A;5%=@_("'P_T)T  J^C!09 !</!PN'%(<
MVE('S2M-!1]BZRZ6/C/UP1SQG-H"17O5_3.G%EQU4QX;#B6KCT.&?17X!U^C
M^,:=Q3=6PU-<\E)=K=-IMUOPXDX*#R(B3.P]^.GS6>6!$PPNJX*9<]"#(@%Q
MN$P"0>;XF4B^MIP3&/O,.1 P*/!G55[97)>N<-\BNWCE*6C.P$YY'4IO^/"A
MJVT0;'MSE[H852C-MW^A'ZH;X M=Z)ISQBPW[F1V5TS# E?EBWPK!&B05N:L
MH2.9J+3<?&%KBB*^2.RXB8?_Q"_!6Z5H'\J3;E90)MPM_#+D0>2000#'1,!(
M!;[PNZV:P2PG8#V-^>#SJ8I(FNK8\I5(YYL$FL2WIN5UM8%JX1IR*G NO@48
M/J7I08IA:9K%F>9V= R4ALB43O'8!LO@V4^3 6<XGL_5IG-% "1=2&:&,A /
M#$?J5F%EOK*U?;E?<^P /(PTG\-PEZ50+"&+J%L?G\VU??J8YYXC5A4OOV2)
M<4:4&T983<@)^;A6>%FFD$.)(NQX,B/95K'EE"%((8D4D[4J0J!$K>5,I%#W
MQ09QOAUMU_'@HK<B[?F)])9>2$UX08*DB7JP+4QM@?GWSST-]"+L48N/D3KK
MV$JQ\)@UX:*?<:[=EXO,=+&TI-K*-1@!1^E+M?C9I4M%P@?!<&.N@0)'.&+Z
M(Q)XCG)1M^B((VW:)<+MI.SFC"XS>:I2%\Y5C<O-.6ECS&2X4*FG/ J1X)03
M&>C4F'/GUH:6CO"2.$U5U!>.O201I'X7\"DU#EI7D@++A(WDLQ1UK-D; N$"
M>#UY?*]9IV+V).8FJ-S_51L-F/37LD6!;]9T@:)JI/XZ4K5<U6I5\ FH'*]2
M,(<.0:ELU97E+7JXFH,9[X='H(OQ G5$<WF>*K30W<>CU;-Q&R:VJND:!.0S
M0T#N-0C(!@'Y0DM%C.7YBD\^W2^.;'TR%71Y:]$O7,67C<-KF^78X57@N8G6
M#\YPN;$TQ_M,/+FNZ2R>8MB\D%U$.R)>#*K4J)JLM&JSNM=LO5 0--;H)D8F
ML(L(#U)<T!EX5I97CJ&)(I12935\K,D+YE,G3;R__P+_Z/=&PUYWMW/5WOGW
M8OH+,I/6?EZJ&-SKMA??WJLCH#L:PA]PA#P3K,O#A>PPW?1WYP_J>GIB=3U]
M3\WO_N[\5FK^9CKMO5>MZMXY/]*'[[WST3L_@;M&,HX$9I8^>@Y89N"EQ<DV
MQC&?BT9XN%<_4[YT45:FP13(I6&ZHI$777:$G]&<;=Q>^,WD$NXCU1L?YK.3
M\TU:+U;^IX+?*PP(CNI@RTZZ&%/FS%%&W5V$=J1;&@S+O3M6 306S,(I8!96
M5,J 6LNL: :AAP4M69)[%++,8F<F$HS/2U^3UJN8.<9RN11WC/UZZ+<4A%?=
M_8JS7Y0[EB9R"E,;V214NG4U!3C&>9J'$Z&J*A#([(N$ZA8\0?B#NN:I3A;[
M8JFJ>!*IAL:WH$D=PU,C:NV\($H(&A?:VJJ4@>)[6#8,8I;$-PQ24WE]2BA'
M!%B*8,$F&2.MB0J</\!'65U7.=Z<(&4NE>*4VIDRQ:*5 :KO8I&:/HN^7(3Q
MDD$500.,^7%=9-"I*@:O^M9V2)158]S:C?F:[?>+5:\(U8OJ&UIT<V>HD?D%
MEN4(5@M+J^2^U'Z^Y1SM_G=+H^;',A/.-(S'*OJH8,&FARG=+BWZFK)Y@$3J
MSF_C"RJVF4Y!J6 8G;00AB9;"/T,D!(#-&0>2D4A,);4CDB/6O?/H((=Y0:F
M,]"$3A[Y%'57>HN<%&SR$7];PAAW')X=?8=XS"I3W1;T92H5Z,H/J-7,''-(
M$FNST).%OR3Q"]OU89&<!Z*E)W@AX+,W'NJ0]"W.U83#C(B0 XW_52).:@IB
M,A%!"+=FO<P]4ZD9E1YCV:\-TJ(%+*:3XZAN*;F*4*W/EXB^O,"I1_7/W=(X
MG8?8L#DMB8;3% 4T*16J*W[D$AAX02<61XL3RN[N3Q+\RMV?2_H'VH(8<G3>
M=-[U=@?..$BR6?H6*[LRX<)28K06YXOS(.Q]KWT1#\XPX6%/B;]8+M4<\Y1;
M\@J2D7O,]J!A19B(R"-/]9J DSQ6HNHSC"F(TMR02*L6U?:18@EWP2&!9Q<<
M4 $2Z<H%UDI&&?W4?C4"PET>?KALE5:MW+B7CP2S^V(XBB)%@%J*FV3%(U.L
M,W26("H[X$1Q>)Y/(WR8@Z\#WY/9H62+LP8)G&DMO!;K73G*4LBD3GS""U!"
MBTM>:7[YH$12#U\J@%>ZG(-?AG6$WLIK4\&/$2LNJ>J\T^)U$R>ACXDF.Y&$
M7ROA<XYR$"Y)D-<:X3452BS%N.HH6>71M7?V\$[ZD2Q[+54>1M6LA&[/$SCH
MD&2*;VTU5*>BL(75!=K:%-:3EZ7%4Z]*&$N8#GA^JP]/I_YI 3YQJU,HKR59
MK$RR19ZD.=N0)A&&BEE,91D@@%4TF51F]TIAFMT9AXDHC:O ,4T51U043G:I
MN7$N8AW>;.S"'Y5A9>:UC$%(-LD_$#"*_R3T!IF#RJ6I<V-2<TFW5928X ^V
M>ST>"N+WD.M1VAM,?:R=5$ZS4N\\V"OD8R'$0!]?UW!N8*F#68S>*NK!5!R5
MDM^ZK,U^MEY[Z9>7')?W6:SJ5J$ES1JB"M2K2RNHYQX-OA+JKX">K'0$1757
ME[ I$D,%(,\N)S(X&X.<T(&0(OP MV=,"IF3RM#2.9VR3=FP*#UW#,&PP1 T
M&(*MSPG\Y#G -LP[YT@5@I9.5CPLK1*E(I+*9ZXVAEYQ[$M9^1QC+U-)Q&S[
MJT;!92BPB2O6'BTUI]9.<0FQ.:F#R]6<(2U[G3#JK<KQIKKWI:XVL2N,J,$@
M!;<+U/H8K@+MXC*](IR5$R*^*(@S2R^J_ V.MA=43O. &(XYHD=EUW'&\/AP
M"6[K HPL.']32:F!DL]+<H4EHW!S2O'K( ([W!.9E6(K%/GX[>SC;QPZ&,,)
MC!$6+-$CY]GP-?.%.A12O<'X8XL!D?,%V.F:!TK'%;D.G7KF6E&=&XJM$"<H
M!@0R9LFL>QT>W[']\2S&% 6\7_$,1D_&>>@KPICE0B5G5-0)7F.N7/^52$B\
MQM11Y@WS?.)3"9A"]\=1M3C]9 =9T/(JZC($#-!#LJL0HV-%)(FJ>95DON+=
M7Z0' K8G$4AT38QOBL1,RV#=ZHR7=I2(A- @MCE 5"%&JP\O6B%(HJ+2+%)X
M1?V3\3>S8!R4Y/E",W %?Y%$ON9U55H=7;I<1;"=LQE.:.=OW4KE5)G=%?9C
MJB!+ G0.UYP0D8I@*KL?UOP6F2P1ZBDV/96=.C@]X6&P K0_*>A2N$JL/[#<
M'220Z0SQX]Y T4:Q$U,GJ*@X2&<@3":XIK!W@,,OIV,%MC\4:4:<RNI:EWD$
M:0JGYI=!)'SY9X[[))'I M2?9'9F.,+@F +-@_5J.BL\C]&I^TO3W%;][,HH
MB@A-\;:)5"NCF;:*M>$GLM>HBNW4MW":43(JM>+'D<PQB3X+0NYPBIR!H<S*
MV=ZSTG,)"6@_7$N#>IH1CKKG<7<8HL>A,+NFX\=-KA;L6J2Q&WMP18JI9/B0
M%+X5QK?;G,$WH&A4FTH.0^GR:<Q;!1,]4_/O8?&[G>Z@.WJ*0/(V: CBW<9=
M1I&)O?>I<R@RX7R.*7N/2W<0S^?8<EN:TL$O.Q<HUK'O_$\Q7[QW#I$;;-]'
M)DD*_N)2T39#FLV$3WRUE6&?RBB),4#A@\!2QBMED>AT\=O.'N5I0"^$/JL"
M-ECX*MH=BC -15"I"<-;RDU(I5^4.;)A4SRLV$RE$:9P,DFS$_EA; 69L5-X
M3><[8L>/8:_WVL7]U&]+F@N;:02^VVUW!XQMP$V$CH?A*X41Y0M&K/@X\305
MQ7PA!86^P2O-/QQ'SB&H:VI? O/0I[R3FCM:(BX#+L]>:144!RU>[)ATZT7L
M!9*U10$P<_:C"(D0/TO%0X]HB6\Z$L$<ZA?*1E=#4!G[F%AOZ40!Q88D?QC"
MQ3%Q:=>IE\7T!L,6#X2&BJHO6A$A&K72JHPIPI,O43R"="&UF(;=TH%#)<IF
M:<V0Z.'JZ%1[09]$3??TIC_+9C;K/E91&K-!:6.T"! /1BZ].;1!EWI2DG6P
MV_Z5L[Y2.P!!Q" QM*F81);-N9*=/Y:X-?IP,?N<L-/\/"'8O:Z5H) %;@0O
MS^+)!/^-#+LPQ@@M0R)!]?'4"L"Q5*EK'"+>BY1U/.8.$P[%-MD;XOUM8'3*
M0-$@#-B*<=FYUR^L_1^?RZK!(U:L FD<FJ<KA 9ZZJ6YI,=7'SV3JX]O>C U
M>_P)]CBA=9!+/)]K"XU]KYB9[U6OC@Z>H>!Z(EL '8RV4^2\$5C\.Y7OG,Y.
M_RT?:G,IB.J(#CS+;[%<%=JNG;V=#NSO9>J\(1Y.N,= I=NZG;<MS2Z/*H-N
MZ>=)T3V-;PL6H'#>[.[TZ#YUSZ]SE/CIHY6G=]33>_@FS:YL=N5&=^7O$HG#
M$OAMJB/#X3(-2O0#&-&EIN*XY9*<PL8SL<A,##D4'L+&'%_.ECYAN'5E8((9
MX3R,O25!O[BK(($+,=ZAL0/54ZM Q)MPD8ER-'NBV1./$-S0_J$*AJE$4"F"
MB?I;(<U62C)6PW3E_-2E.B0L=+&1<!=$-J%@H?"1>UT'M3CE<J<GVKMW(L<)
M#MTZK!" 1_F.+%#$BPI_>AH592E^0 &[/%&^HK(EBSQ<I,)K"M^+5G< 9V.,
M !8-AS4&MD3@'WFZJN=%D:"+$Y76"8.O#/8.#:)U[73Z$F;)=_+(^K4>VHYS
M$E?C@HP/YRG$VA9JA@$>.LRV%;M\92T:[Y,S[[Z#68Z0733.XF]<#F66Z!7G
M3HZ+BGK>H(PPL#/@S#5'@?& 4IKJ("P<,P89U*$H5<&G.BBI^&(:*YP8-=+1
M[8%P33"L[<UP+!$F/*PNC9R8A4M6RL9VG /[L91M-^RC1:O"2&*]EV!^W 4V
M^TEDD9<W46$J0";E0)D3>L/M!@9N(_Q6%<QQ"0UW^(2C5SL3.OZW.O>E(CW3
M\&JL,[.P(#O.;_$-)E):7!=H+JY'\&)A#A$+PR&DN[5@.\98PRNPW9- #D>*
M>ZJ2%DX_E43/+G)1HAI@(1]U*K% C2'1BS'K?.S4*YL2P)BWP4VUL!2/,56_
MIO"/._IOD[O&U@YWVC?895-2.R9Q#0<=-Z6L'5!ILZH7KZ?06($TB)GN054V
M'+A3C2$"%*K*W^6"C=(PN%&7:>Q@^ )5[:69 6P76P C2J3FAK## .QUN0Z!
M/)G":IYC->:22+29[YPTBT=@#MV3H%A41JG A" HP^1@,$2EBSV,0*R;^M5B
MU]KY?^Z%("_F4-2$XM@'B7D+1 D29CH$F>H/)9I6.3:>/6C$<9.]F]BI0KRH
MUY!"@Z3OM#78HV9HN$W<@\-.9P^MV=@+Z0J]>3COIR[H4VVXS5!,&M>@"3+=
M]=NN!<=MA2D;8QV_,3@XK*O^\ F!$]Q&!7.9R >;R14XU]N6LPB)"]T0+2*4
M"^\-5_'P;;C%F'@(QX$BKYO8[VSX9&:R<G[ \Z^%+XD95Q?A*:-<3PAE'1G1
M1JJ1J43-[4O314M6X12ZJY8K=_@R]*?<&(MG&?8RUH?%R)=:(B]M%4 4YCHW
ME+_@M(!R4)VV)%7_6X3F)91$)3O+7A^AWQ7>!58'#J'9TKF.PQPF!(LDR_@7
M:]KU-$KN!%E*OV[#-FSH_)XY%'_40/$;*/Z+#BOTWF%!\GT]L,=C[7DF<[M2
MU@ 6NLOY-DG];M)7"A/ZAT58"'9 R."U<FD=&CC;';38^AK54M>'-9!LNY>I
M[J/*!0%C0\+$=J_-GJ0A&R(J(M)@>U&-JQ%P50G;*I 0NI6Q5*C4*DL2&'TQ
M7#O#GD_$LF(JT-FMU1T/!/,0,&DTD7ASBZ>2Z]_BIET>XD:H,I<\5#1/V5W>
M;N':QAYY!>@9:714J :I'_#T0 IV;:.G6>Z;MHL:=+#=\[V-I<F*($UM+DX*
MI;KC"ATF[ _P8=*"[3HG=C3::0UNL,G4;D8L%6ZO17 ABR&(6M QQ$T:9""?
M "4JJ4F8@_9FA+?*"B8V-Y%NY4<T,X@8Q' CD_O-1:"QNW%.P8/.+B@9^37E
MM*(NYG_?P!6:3;#136":LI<E'M$\.=S).3CL]?\?%?Q[!B=?EFR5'?L>HXO-
M'F[V\!/MX8B9"KM\^/!>)DX8;)>(^YO0=// XPC[R6_@]V!).B-HX9+.3MN9
M3__V=?K:T"UWFOA/E48$FPV#;'&*CAQF!G'<A1C9)D6^M;&\[INL;T_Y:+<
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MD[DA6[[S@+:\;:V?#WL'5M\GT\4&7@IT$1?D,J6@M@.,,3FA"(]B+C.?LA'
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M>V9HFY%"A'9?EFV@915D%$3R-5F(5V4M74))WCO!6D:3DDC"]DEA4 C0P?8
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MI1.5C@OH3P]'8&&SE'1AI(>KLW6HODPL@*9LW_>.XN"=<O>?"SK<-1J]H!J
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MZ+:\<N8]'!R<S.<%G0<<IE_RQIW>Z>C"'9'BLKA%"_P%VB7_D^I^S^[=?XQ
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MW)'5,+WOZ'HB<Y]F42@B2*4$P]4#&BO,0Y30:\PP&>RYG "EG2')[9[B?J"
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M&)[G#O5;HQ\HB/KB;681LM\"_]J40"!1('=X-@AQ2FNN:=E.%C5^4-7NBBD
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M$<-,/ZQS \\>J/[(,O2<AY8/9D8F.C<S\+AN^GM;?M"/!QH:&.A6PKPR$#?
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M-IVGM7;OU,X)[(,^.=Z5XUWYHG=E6E!$)3$%W5GO:C>BT*2U17VGY(S)' ;
M'E <MRZ7BC$A4XYN"R3_B]^>9A92 FLRO1N:*V!#%N;=N$!5=R@1%>-Y^%JQ
M/>U.X#Z*Y8CROQ4H__M'E/]7A/(_*JNCLOH\A\Q'$P@A0]HG4/>:* E"\4!5
MCIG]@'31ZY^RP&A 80$$"[PR<3?8ZYGX+U S&K71YMS3HQ=S/.Q?VI=G%]RC
MD:?.:="X,27>3PS1V;!I1#13Y%(LT&*:7)9\5A#.#<07$VD9O%HWTI#>H@KB
MN":NA&]?&.*:V5!X )U3W)5$6.!"QZ1! 0[:_WSQZGB%CE?HRX?#5GD38M_;
M71D"G$I.T<--@^?"A):_GF>V=VK(D,O5&4BP ]I0@4-W63?%T!6*$$1F@-1?
MENKW%_AV:)8M*&G+GJ?PACKT=;-76=K9\HN!O"+HU?'Z':_?%[Y^8H5I3>6O
MYV*W(2VJ#%54#$.$"N"Z(.J/@%HY'M'C$?W"1]2D$GTB442HE=MT8IV'L2HF
M47X_ KB.W'])G[5&_QLD'Q9Y*V2E"0T(U8SY[NF^ PWW:EFY<8!+A)N.9]R=
M&-_1%&Q+D,\4WX;XMH6#/9$O XBJ06P[SF7AQC=MM=TVC$O&87C;$]!,YT(U
M4A<F8_69(&J0[MPPJA#IG UXV<VSD?OE A\%8_.)%//.S&7/>FFER(Y\RR72
M46II\O/;5UD,>=.D]YK76>QBI_'0?A)H#WZ0)K2/,N8H8_XZ&4.X;FA#)Q\Z
M+U:(/3EJ=YH$(RA8T9K;G%[]GW]]Q=E=YV6U'N)$>:I+=?4"ZB/O<JYI7@$/
M'Y3U\68<;\:7]L^$^2&N\^1<46&9GUXYI3-IRA7^!'3>.Z>$1L^)[E.A>:^>
MOGM^3ME=KFO]4"Q7"-31^3^>Y.-)_J(GF82XN#L PFN@.HA3G^+D2+*MZ P0
M\KAH)ZX_B NX G>M^1:H9!23.LI'K\OV_>@9D9V$&,C+4O.UHS<$U"\N-[@^
MKY^]?,,V&BFE>""*#/*X!4'KNUF?;KM;7PFP^1-AWJ\,$,OBK;8ES*WL^^H
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M[KE;M]%N%^"L7W7&9/8^JN!-.!A+5;[Z\B8OJ3;45ZNZ>7+:L?:EJ]9"D(9
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M#->DO'(.M/.<G6'E+M7*>;H+[B$/JR2DWB0:M..64NI-_MJ%G0%*P5TU).Y
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M[<V!XHM0#R*%'P4;6/ /SV\P62#;KI(>G<\LN#\E(D,,YPL4M6NE^.\:$<5
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M,PFFX%L)"?P5$(SA:/74?_9;/)-^._SKEVSL7OBJD/9LUI%"Y=84>"*MNW&
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MIE!41E77-F9D?2';T93.;B2SQ2R1G*,@QR5B!5U4X,_T;SOZBFVYU-5ONIA
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M7V+Y2(C4C"QHSFR?E8-R[I H, .*D$CGF<C(9!'5?3"'(>.DD&N<7Y+J312
MQ(!Y]\3H%*822U7JYJF-\.\=/AXV$XM*#O/"PGQ/;%7&8KMZZPCN"8%- +4P
MN&+@7%-4TYX'G^9_G#2/F]C$BCB86U&QF%4+'=TFN,QDB"!4;8/Z3#BKKZG2
MNT,DB9P#+"-V6^:6V^0*148$,:",T?OEN]$FKS[%0F2N$,%2ARD.FYIA;GC<
MM7)D]705"<&Q'#)+UL&H9QJBOB-,%]W 5&5BP7U(MGMR(6!*#VQ#860?UHF_
MQ8$[M9XT&4!Y.1&()1A@+72T?( A<T_JT=/;( .!]\\',DU3%_&M_GZI(\]Z
M"\>'TC?+(1&?!L00X3:F^R:2NV+R30%\VS;A#*^!"(4)^4/4P =JVY^3J+>$
MBA^NZ W2@LBD>ZNF]_2C-+U[K7^<U-]LQ+L((B?X#X.>R74+8EV\4R:,+*V3
M$<2+31 S'9WQ?I.=,FBER1ZJWKIS?I,E><CB5=7^\*"UVJX18T%V.;S22WGR
M-[]7:/RNZ(P+"]3@140L.",H75;O=+2;Z]IG&-+1A9+I7GS\\Q,?9\+HWZX\
M[BE$/S7A\6QWC0F/A\$[+ _#7SY:?ORS5A__+&3'[[(G]\^T W\8_RN/S=."
MH1U2>D12=?\NZM?/;@+_\.P+?:#8G?CPR')MUU(G>O3M0P@9K(W_?Q+.OU5S
M8Y2*R#1N5ZN#$.V6TQ0R'AT]YK>+R<O#IX?2>84?%B6<Y^".I-I:NC3O+'!R
MP;HN)/IS66%W%I"IXDKU31X?#;XW7U5U3.-XMA3WM2??RM=@8. 5\_,A)&GM
M!'GR('[ ^DD@XBQNPY$];3I=%3R?RD_!/^$7T$M5E\;SD@VHA.=1"U0ZT((C
M#R*6FN%#ZRN!A6,:Q;F+/#+M*48V,NVJ^SK7?1CC?J8UB#8+7R<;S;*9;^EF
MAK>@3\-R6":$S*I^:S./I]U(*\"DM90#_EY)OGRELR"!V[:]*F]\P4N_Q4Q&
M5Y9OQ9>J2!2,JD91U\(OF-T#*JA6BP/\[-O'7RG\;><=!M_Y[L%7>X:U3QTF
M]F@/$]O#Q#X/5^DD)FQ>)#60+]@5>17.D.MR%G8,\M(+ OJK<$9=7Q_.PH&Y
M>7<8(KZI.VZ@:<1PQ8HZ]NWPK54S+[3SSC[8N<L<^C&W9+O[.H#/&87&[$;4
M?QD!(LJJ:AYAC'K6Q=O2Y=_RRTU!R"9PI0LP3D_YQQ,YYEZ+'$SXQG/DYX\>
M'/QU.OFO;;!7)<)S^7/G__Y?T\FI4O/V__KMP5\C2J2P:K^V+#>D^Y#/2_T:
MX,-MF!8"MBY=9V"DL7UXK[B/CQT]OK>X;\F+9^^$&#<2J'=-0VDYI 0:$%\C
MC(.7)>*L$EX'1X-H)^*QF!3!0P@C'>HD+?#K\"BG[KF0.0.##!MQGIV*8Q-^
MB/X"81!2IB^#KX&YNW>QV5Q^__776#5=.3\\;Z[NFPZ!U  Y!E2L?'>C-:FT
M$I*.Z]25@'*U'BN0,ZO56AT$K]-[Q0BWQ\/O(]:[\>XOS!JD^0UK^())O[#K
M-5-R74:P7EJ??AD@2>Z,4*<U2SKYK3 ;&?"Q4>Z%[[EVEVS*X (4UKJ5 &W-
MK"6NE6@_4J'9.-M23H:W4-AQ>K7$(%,8\KA+6$-GG&C#H+RZB9SQ=;G*":"Z
MA@1SU(.+GXBZ/O\?G_P_J_IMN7A1YV4$Z-^5"%/:IEA,*<%3O@OO0KZI]F8@
M[MH;8.:S!45HA3]I9+&AX)NX6G@3/GNN9X$@K5^G+O7G(?Y\P:Z6X)5UE11*
MM#';W_@:?=K=QJSX8#XH[$ZSD \,5] ,%=]@0!;"O3BZ=C1-AY9JAMFN#&\3
M.%7T3;CPU*]3$^^3$%<>3VH +*9$AJP=[S.R5I2!:,<J&;Z\8G/PQ]%U(49:
MMUMW^W7&%Y8 @C:.>TE*8+%=>_?1N3>R_S&I%B+R=E3\G[;JWOX?@.C"BKJK
M3O +U,".3@XGK\/#3I[+P_Y3\[A/%W[<HOY(ML?_W6SM^$3!"=G FPBMEKIN
MF-DNQ[T19;V(G,.S$E6#37->TJY*\_9J92?HT E3A\YJ [<:!7]^BBUR(@-)
M!C)Y?IHQ%%%&N 2=(!.E0W*CY:S%!]@CGH8E.-,$Z>T,=CB+EI/4/CX!#91(
M/&?UKOX8,=\(WP/X\&F6IZ-+RS9IH(LDB4F'5]HP>(+&MTTJT')N=5NT@,;C
M:J4(7=2L',#-C/EZ35>YF;_5KP/%'QY"^5(^<+[5T,L4 WX1EIFD),,Z/IR<
M."+N'5?$MS5Q&K[^MD;%&OHBG9#!B!^7$!(SD)E?*2TR%&[M<&8]'\C>8A$.
MG*XD%(3,W7Z _U6GRQ<@5_>GV^C77#%.6143F99_;&'!FB*EU#+'CFGB?'\.
MW8$)_\C]\/<RXD-@ 1;DK"&O!(K:#:!/JG&&_UR*9^[@E8U\TSYJ,'.X[5U9
M,K<A<$D%Z*(S!Z37%O10J5?K&AE\YTL&>[_)!US+C+MF*9UB,@F'$^0(D>O!
MOTE$])>'WSPY_&:R%GFVZ>0O1P^/#Q_;OSDU?SG^]KO#H_BK7,%-J'A'ZI]"
M\$A>"Y ?*0,)Y?T(A[FU:HHZ5CBAUUNQ/R8P%[[SEZ/#)Y.9/ J7&]]>+%,I
M&8!4@%01SHJ*@DIMIKJT),19^QCKDOE)#B%.YJG@ILN%4JV!<JP;/<(%PK5B
MR=%R7,$;V9;I^8)/TBA!D+2A"*VNN&BL#2IX2C!]HP7;WN;R(@6RT?S,$TME
M:9&$-QJLB%NVI74JQ\U^K:M,0$2K+83,PDBZVQJJ]+\E 8M'TQ_Y\'AQEAA+
M8S!JTX,R$6Q8M-Y  <R"O"R>X?N['*/NA<+W0N%_S,I2RNT$P]C TW;&J@_>
M3P7"O7;]?DG^&4LRGCA8@/&4LIZ>F( /#Q$7K<<;I4[8$94F]DR-7?:'7;KQ
M^W6]7]=_S+HV%!7)-\,+YA)F8\L\:Y(:&.+]BMVOV#]WQ0K5)7'[R=8:43?#
MD9[7$'7R=AE@^/9Q^:>X8[^6]VOY3U[+EN.9(A1DQW6)0@48,$+87]8+[7H@
M&WK$R1+!NQ7[&Y;:YF:"XL&R656-?7ZDCTTJ#F&\40^]2;%G+\^)"!5]BW;%
M_2[8[X)_A0^22 JL/]19[IT*ITRE=%MR'5CUD*VS@^!QOX[WZ_A/7L=1OX:*
M#"LTB<15+4B<#+-4U<NV"/_>DJA(F7;!?U0)\3E6OO87E[NU?(?[9K_2]RO]
M3U[I21M#I+]8Z4;JND1LB)I_\"F N-BOQ?U:_)/7HBATN:1$V78-T( >N[.K
MKC2-;H*I7YL%3M?9K^']&O[3"QZ+5+G%6HQHDZE),5E39-9PH,0E*ETV7/;Q
MEZ*]=BD@,^=*NZVP7^;[9?YG+_.Y4!R1K.9 -34\;\-8<F.:G&#9#)&#J$*^
M.?QFOV[WZ_9?DJ:3,A_M=,E>>G,6#D#&4T[F/[T\<R3ZL,#A)\%M?8!UW7>1
M?Q)=Y(_W7>3[+O)/$D!IB#Q WRU/*AV_(T@;1ZGD,ZXP@9Y$U/3?9Z6)8E7+
MB;1>S=BF%E&:Q?!RN0Z63W]9LUMC;&+25['V@-B5M,!1!CB*D+.(LEO=-6$5
MV2G'SHEMH8ECGWR+7@>QN#$-I^S<"6PH^;<DI*7J9!P3HW3<=MHVD#+5(DV>
MQ"A4LYQY/$<RDUQYJU JJ6UO6J:1,E(X2^-\&F'D6&$TL25F5Y+$(BXTS"T:
M9#*Y;=E7L[-OD/T,OI!HBK&A_&-2FWJ=L#@Z&0DN4E!?IL_JH!/>2N1E0E=S
M^"-A+1BYXU#KPH&>>EB_UR#'F[IO"D7/IC1TJU8>T(6288[;R0IM^I.RYFIS
M;:PYBGOR8SDOT#IKRA/;L/;  [>K6R4X"&AXW!AWDJYW4AUGB;>164$_,E9A
M;1*H2BDNO4/O-EH=Q%@J*%U!KYR7DEV@7KW$[S^@4S< \[(GB>,V_LI3FUP8
M'Y 'Z[-T8?>2V;U- -@>825VRG]'6@/6A-@T%5Z\4E@WY.HTB7Z;O9A<6\>1
MW @#@ XKWY[$CEC)!>&S4)NOA#38'@@XY:(B SP;/:8)JY_!N/JD4_^7O7=K
MCN-(L@;_2CWLFLV8)=&2>GJFYY/9F$$4U:W9ID2CI)79OF551:%2S,JLSJP$
M6/WK-_RX>X1'7@!0$D! C!>) *KRZN'AE^/G",Y9F[VC 2S6^XL@LXCDSL1#
MSSUD_,\<,N:0\0\\*X7= :-P9G;!%N5W0[-EVO_==#M*G"GO.'0L8K:_49>]
MQI3&AG$JD&0OA+\4GM,1J44#XK:Q!YXI=49 (_ABL.5-@D]UUQ]MGOP3&.5\
M@ 1'<A.S@Q*?L(*=>%Z(-W],U,0]]UY<D;)SCR)I#6]G82R6_]J$92,%# XZ
M%P/?,<GM"+Y(<95<,K."C,80;8PZ8^@S4# ]SQ3',(KQ)[ &Y6SFN%(!.OM?
M<20[XTTC=,0+$$G,RR27NUA=;C8MN)5JCC6C3XJ<]+=[)S!_4KN$:4P"28R8
MB!DA \=XG!%ELID2::CW3.2X5'<"Z;(ZI^W*2/?<TT/!W8G%3@T:#C71W_@
M]PHRFH9XR4&Y1</MKCOT(5*'S-3]/:]UJM[H_'W6]_"JGZ"7NCS-37_"TLI^
M7^"_I)Q=^84?V<1XX>"E]LX_7TY;P>GP?_WU+Y_%.5989J KB+.&%4.D?\4Y
M:"4YMB<N9=""67*Q\(]B;(;5/LG+4P5V%D1\?UI]_@5) YSVWJS_KOP]Z5E\
MJM(P SOSR)616IY\@O#5&-J&H3',#GR3FH>*:X#;GG$&1$VG[*]T6A"Y(]>4
M@$'N,;DO/*JM.SIF.@+_OER4*>;D,<[<-OL$VF96AM7LH52C&:IZFU%CV38_
MNFURJP.X!! #,"8A4@/X@,<'1MW9;TQ;XG /XDO:]("01P@5\T1<MN6/8LO]
MQ@=)!<?@*"<+=9?"&L72H6M$]EPLC2H7JY!3G76L;C95FQNSLR)2BQEJ7A%Y
M13RF=_>G.I9LM\R?J^).+>4X''CPT%MY9$THUN_0IH[.E?)HGE+QS0_BR8&/
M7>73*+^ .BK_R2+DB3ZN,\Q\]X567UCD.:^2O$H>:Y44JQ,5<:Z4'_^$#JI?
M.D;Z1@B"I5^=G7PVWR=COHF3ETKYECF\3^4[_$ZX]F:1->-2-V$CJ#Z\VY55
M=VO%VE:K"]99(B;NJ03M+=7[!/SB0S('V2<C.:4=@/%\8%YA>84]1F+!D#4%
MR"AH/RB&6?$!0P.8*;FR=3ZP=8X@66;Z&IT,A>S'ROZ"[:9V2V7[*$$J#;&
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M2[ RH:F.5N[#D/JT5UVMSNH%6-"&#R%9<D1C&*)>UG*FF.A9@X>3DK"K3!7
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M4+J+5=;T<0;]AJWWSUN<!61V6$)K?SSIIA &0Q2Q1)ZJ1^3D/6X94):AGBP
M$YKNL)V[*LD3TG=B#(%[FZ'HUJ/O0L]ZHE&-17Q&X-_[N^U9&2-P#*CB+=VN
MCQ1X<\&3\"\Z4CF)YJ;"0JOTCLE#AY<N;)OB[O0/=*_0:'S:FNL9*_K,L*)_
M^2QC13-6]%EN^U_;$F 4SAO7:M+LLK.3*!;<8Y+ ;EP?I^-%3 5TDKA7HNWQ
MVX9DS0813\?3LLD@(L?RCA9#N(F?&JBU_7 *W;WVJ$M@_/E7 YV7VT$&!U,U
M4$O#-SIW579;&SR;+F )8BO1QM7 B.L.4;OCCG'@WHG*JR"%T+"GSKVT;W&4
M+[Z<-"!X,YPYLK1CG_2>]Y37W,=1=4KJ]?1N9Z92>(YFCH+?BI*.!$@7J<ZJ
M4\BV&(&Z)EB 6QSP&[$_3Z_#J./,J9=+97B)3&T2;R=MM1DB-2W?PK?4/JLK
M 4=.+W/^9$@Y301L"]@L]8:@N$6-H)T3 EQ3>.X=$=?3]V5W,)CW9V)USVE1
M/E"KY*X5MY3MSD@XW9[IPH+F:N4C(0T6R"*46I2('R>@#09U%1N)O)7*V-QN
MU%KVLD*5GEGF1(M(W2**63P.RW8.@"EJ<@=*L5(5K((_PP_CGL^B)/(,@J?+
M'&H19!)GJ-@7Z>7UHF,+$Q?**6J(5<(M-VTJDL:D\BGSW<S\A:E#::<UF65F
M/SAMFN:M]XFL\I?TJAKT$F>*A--H<01>CR2)<0)<;;)JK@G@SV1&_K"HNG3#
M55*.PC[S[7=?2PV(P'-UK,7C2@BXYQ];+"U3@W_H>Q0VA!*53QS1L/,3YQ>K
M'RK_O,BC%7I['.#Z%^'ODU!6_G)>_>0O9O7RQ\O5P2?^9..\MU+IG=:&*VE=
M,=X;:*G09FWT7IEN#ZM93G]FW*S U CF7O6JVJTM*QI=H3"<JH['JI'U7:+8
M'DJ&[K2GFB.ML>IT<D^[<O,I+26,C_-4V(U#Q9A>)'/912#UU5!QU5T1<KU;
ML-8B4BH$([W-P.XF7.!FBU\^Y57G(HD"]D<N0U8HZU(;6;I-S%^FBI,:G*:N
M BY?AE[PW9!,RD8G;B*V?A%+E*>R2%>XH%3#T;W%8QBIEP9:Q%32#J0=UT&O
MC_5_3)9ZSVX(-5$/QQ8(S*[:0&G;WCW$)S26QL!4PCS!P4!>AD]D&2:863-H
M,Z.E<VQK:O4&0/"XS\=XX>0H8J*N*3>"W4#P=1CJJQ"0&0ND[6% -"9+4JOQ
MP0V$M<.Z[''A^G"L\K=/QH<-QV^[</B1PL7LHP56Q*:D"E),SU(,#UGU+U)"
MX6W%'( K/.Y]2:L(FZ.=E/JBB!OML>Q[&A/TA_CFZ^_?>N_TLFVX QDZU/VQ
M17W'QH7<XEGS8.37EV_BG;W94]C_YQFO$GL64NHY5M?M25:SEG$8_12B"\)K
MQ_:YQIO:V:[+AHL!!T>IK+\^2)]#3H9?+$V%:$X"HI]M!<B_8JJ\U1S#F_3/
MB<I-5+N^FDB/\2.Z?"$OU3#* -G]OX-/4F2PC9I=S5;G8^2Y:EB#)K#WVYW?
M7(SA#"<ZG9BMSBI.')=_TOYT/S5U]<[?=-N;(VS;S2#\E'R&,8L/O:7P:1^^
M-!J?@6G(YS78.5 7)>H_NM^ZO*&N&@P1MQ$ %#R#6FU.4LN0P2C,60CQ?>,X
MD8*9(,##(*"_ Z[?\)$8KDX/1J_-9W+^<9;-0$"@+_X+$WA_*7@]P12=3%J^
M>N\V ^*K[ZFH;^[[C?\D%!-7/W;#X4@[5SC@YWI _\NO80S8;5_QR"5=^[<$
M[.FE?(HV8WQ[_F6 3<B';?WX'2(&H&&"&[?V!Q5P*S'CINU: M7RPF6D$J.R
MB "Q^91;]-\P?@-O.KPM>"L6I[Y9O=05^2.OR+?!"Z_^[=5/_[[ZKEW]Y<__
M^:<O/OO\/V"V!Q?[K/,9@E#R>$>RX5A)1O+'9_J:^X[7M,0_^]R?X4^O7M+K
MK7JS%:R(]8]&!'N\\]U9L6H]@0,/9GU+&/<O\?:2.$3QGF/9 ;)$[8/Y/"Z]
M#7()6R?Q5MM2_5X]E+^O 1C9;@("G>OTJ[-G-SSRX6 RBFD.]N&6N^(\J/+J
MI]5KWF:08$I)I0$V/.XG@!#(UD$PG=K9O2L)T 2-&#U(+$822D!*J!B&&KVQ
M;TU/XP<P41>3&^I!+D / WN"]XCB,\/3?1WP5Y=7]$8XHR0Z-&1X=G)M]*QT
MTRQF@OO**1AJ_,1B40RCV)M/V1^\O']Y3,M8&ITD&,Z%%&))H/?+>\@V"G'T
M+S[0[&D3Y.(%*@)+%XAD;:UB*Y3[1/RHJ;;H.L7PGHI7B$D$JZ0G(^MA.(**
M+%0:9&+K3T"]E323U7/PRX(R(2KP-AQ<R:O++Z4F(B34A)]C*%PB7\.Z-@51
MC)4;W2S15?#)IOMRM1ZJ&O?#OB-2(+;=5=G(2V165-N B,\WM'U^C/74!:RN
M?^%!H]E.AM@";=MP$9?A.!,\_,Z'ANT-F>%33O8R46PFBOU]+(M@>XJ%5C*=
M,-ULBZV]_Y/H1X4Z#(=@M"!+ -LFI9B"ZKY_>OGCY0M''5!&&\M?$E>;A9RS
MO3^*O5N2@]J5G:H_>3L=-2V\U0J-Q,%'W@CH"!E 1<P$;,LH'=HU0@'5]CNI
M'$%MA9F*I+13QW]9UEK+ FEY>3ST=A#ZU:9,IK*SXO@YZB[N-7+@ R]9+;2
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M-_>;DDJ[_$OXC73;YB0<6U[/:4 D]:/;$;?Z,MW6E>_X,OTUN03Y$CWP5!^
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M3PNC8X0"!QE2NT4REMS+N.OL]P'OM@E]4&VHULZ4[B1]31F%5E#'N?<"-0G
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MB*D_).0]<4<V0C+YIJ":Q@E3PMC(#8?R3)?7,_,] 2H[H']X@F4LQK2PY4S
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MJ]O6I^K _9:U)=;2VFDA?*'1NTEE510.I4!SB[QA)GE[/GOB5PS'CE0C4YE
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MT:_675MNZ1_$H>6W+H!M 5]U>;8J6_%C6S&R89\S.":"(&-E6)H_/N82=][
MO4D3T3B/'?IL9@W"%4IT_ ^;8/Z2F-R4N(X$VNW#+&H@R%^RG6<[?_B(Q,CS
MF:H39>@^NTC4ZBOJ 3 ^QF4WG,WS4<S3UM$4.'M+'0WUJ^.Q[4X)N6!JY^;[
M "_&>%F+6;;:F>T\V_D#VSE X@L$\!1Z;+ORIN!R/B;/"D$'C'A9@Z>FF/M
MLUBCX*-95<3N::,3\?585T",O7WU^@<>]NK:X6I/E59$-]I%\T_+O:]XF=!G
M\_+(R^,QHA0*.+Q99F/+QO:@QF8E7LH#"3X E46P@./ 3-ZY_^DOXLT,NQKK
MY-Q4=;WRP5@;Q+QN:S[.2^K<V6WL[BJA]A>KGYV*7[QKVIO5S=[A&.!='YT
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MTL!F$,P6B)5=NQF0N$U82]5EC0U184!!)P%$6MZOX6361LM#BYV3/&Z F;>
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M:^+!/?G='U! ;X9E!VC"N'<T:AW13Z%U=/]>4K;I;-./X*RIUNL_V$B'%[Q
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MJ*[I^W@5 7.;2"%RT?^4DA?HY6"2<W!Q8#$."F^(C2S*?.?1N=NE7W9%8($
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M8?HMF]!P@8B!-Q@I3X>Z,V<>&1F4E\2#+XFA(;KNWKE&F,W1F9 :_X2,>T,
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M0[TK:&QUS/9!.D:"[CGS8I6^,DY ?4NH3 G$:$Z]8>UH9R2GUT8T4!Q+#PZ
M>".AE8EH#G'?ALL;L2D#3TGNSD:/D!BBJYI1_9E34;#K+BSN;N3@[B>'](Q,
M\R'XYXU8VPA+982E&G_P;3>8$2=O5WN_3L#$'H+]B]5K_][)L_,L=<*_@3W9
MA\G^K^=HMMZW5Z[>LK*&-U\2N?:;VK]$SH=LG,Y!=CTF\2B6UHOL(3010S([
M[G#<EWT%];U9J6+L4W"_6(5VY8U%QA9,"@M [(HD/F6OT@TT-<L$5<LR-8?R
M%^K4I # D" 5BN(A5O[%SX#PI&K-DS495MO56]+%N5B]"7R9U@% :T[@!=X3
ME%MW !-$3R0L(K)E5 :5#LA6T96W!5)<U35K7[(X>1(!R],29:?PF8(?'*'R
MN-(O M/%"!]D]M+KF;)_/%RB0NC7Q4",RI M'(,&)Z'Y)^D)! =G.:AKXB<9
MF]QM=L9OED!3S2DZYA !V[%)J!/X76!0+0;KB**89!_$[\) I9:M?8"/H?5Y
M\BN_&D5C56S0'_"J*P^D?24@S@#KFHP6APU4:%<Z)\J;E$I@I(G<#N^/?M^T
M6R"C??T)2MQF7_DW4W;*]ZG?2!09DL/3L0%'HS*_ZYR*%N(TV4019="X#@DE
M*3A0K,\;J$3(\\1/9\O;\<9U[ZKF57V@S>H?U<ZM7OG/K_[-W^BKVI'[^JK2
M(M7YWXO5:T<5K*8]5,7JK;N^5BG=;[&C5"71QBN%SDP2-]E91)YL>NU\5PF7
MU:'=E@9@>DTZC12+A4\F@BI^._.[ENPRNDA*PC^&?0IPZI5<&E8]^?_RAOX9
MI^TA49<L;4;$&Z%B)1KB80K);'39D&2<=<+&Y -0SKMN\C')GLC(U[[:O*-\
MD1R'W$5AEBQ?E6Y9+]]^^\.;M\D[*%;_K]_<W?O5F\1_^=^OZ\&M*?WR;JQ8
M?><C7)^%]=//_3_EH1Q&Q_QFJ#?=<!C]]D?2]NO*T6]?>EOW-F1_B6=P>44R
MFZ/3\4V3C[B\_/'K2 R</&0'=\>W_#.]"QCN#QO,&OA/O&ZWQ$;I+[WMNG;U
M%=W?W+7Q99"FZ]Z5V_&E?,).YO+V^"Y).ZRL:1KA(9;D122+PKVO>E4=,EQ>
M%%>/TB@NMF!6K;PN_=ZQKL<A8]AKXDIL>7N,NX^LF-&.2 =7N)#F=CLQNWM(
M'P64L]H@>Z#3^>BTF:RVBLJ.]SC]@50-#ZV/N8<:F>FI6K=;AD?_B4F;3H[O
MC[_[*>]QK\V I811@'#-Q>RAW%36I%=*KUG<;]6-*DY49FI<A[JI5.-,ZE23
M.+(C75Z3?:=%-0PT>1_I6!=<(BK.Z):C;"O]*:*EA<;]U51/N;A=0E*2C;&0
MEMO&J VE!53Q?"9*^THG-<'-/X>JKQ)IZS2J+=*0MHA\DFR79/+;H6>U5JL\
M[P,VFHU%O2,^L[7CS;,A,  +9+#D:\D+PC_J&&6/BC$^/I6/4-F$9M>HMW)E
M=SV4:VC'%DEIM.GFDF&8"<\[$1:JIO)/UPY7MZ91,",._9/4RVWC):C ]R2'
M3+S>(#KRR>0*(W?IIW_Z)-Q?,8UUF9@:[[@IKP3R%9".R;5,S<??_TFL5?$L
M'8G>*VGS;BHZF_ C D%)A'$3KM"T.WIJ,426R#"&KH(D&-^G@X8MNA(LWQ@4
M;E4BE%XR\<<U+*,R,8=;MIFEC2I4X@KIJFKMK>"UOW,W;%T0G$,T[9*9]P*'
MP'<#3=BIT*P-WXJ#1%AT]ZB+F'H(_UH4_)JM6Q00G_W^NO>[R0D>SSO3%TG]
MZ?O1PX--FEWO#D4$NR>R(YVY*%[K4IE2EW/+SAH*G6/-PO&;3JP[E*\.J@\K
M,T%2B]7 74>QT4V+FH87J\N@B$BMB<2BY5%RC6VN%BQO!58=]IZ91S'X9=!2
M3D2+BNY6WLW,]/VHIV''O.ZE'4]ZB'WBV3[E0"%)+TNJ\8M926W$+\^J"Q.Y
MYM%O]K2W-%=QBI4+;ATU/;@1Q6:*A!6F3IGG53E;#J5308)<LF$*Z/J-MRQ4
M<'#D7D ?Y%7;L;$)%::===Z'N#=T8>_XDEPP2#BEDN0?YC9T05@_8KQ@J-9,
MK1*=#[RG]YEXX2?=9\MPS6<&U_S/SS)<\P\$UWS*6])'Z'-?;GVH28 :;A5!
MK.VH/<9)'=,D88ND_E5CTAM.;QMW53*H8U7Y; 4MIFF$U^Y"!8*W"Q/'CR.>
MK*G^C"*C[Y,W:'GM8^^:21YB@\#'"/O!GV:% K_C*"0DBQ.&D:#2/F\MB:JK
M&"AU=L3J!PJMO<MNMFK1J;8L7<W 7,R)[6LA0OMA1\#1-,1+NF-\,UH"O%B]
M&4MJ"**K:G;UX #1\(F #Q0J17,E9ZXHT*>$LJ" 7Y7>"=IT\ &BJ+VCLM.[
M?PYH_15+)<5 XE5*'69Z\_*<Y#9GQ.9';B2]K9+_&%?_"#GBFJZEZFQ:"K#(
M!?J"OF3[*H<CO<0X,*G3DJ&C+!FCZ+!+$4@4%V1^V2$+C]RPB;Z"??5W9T3^
M^=65&^#)&&:F&0%J%+'B'$^&\#UH PDE34T\2 2Q\PNO*KN5^$+YG%8&P_/R
MUU*J_80"]9,.@C\E[Y?DA:G[B/WZBG"+ZU\DAY-5M'5KS%'ZM\\AGB/= K-U
M>EOW;M1G2MN!*P[L")0:.<WSL+*/QUH:\U-G%J_&?YK]E3NLNW,;P+CJD;L#
MQ;*?<K)_69_V*-I&@"J\!.F'VK(.O13J8=_C<2H?XX>^>TZU9>MA," Q!=&E
MS.,WC -C'[O2L4>J'1I(D9Q--30TB@N[P='['ZI 1.Z>,GZ(ZY8*O%T//?.Z
MM<MX0O:DN/8..T753>YB$0XWXYR3./*>R,.PD>%I]EH2M&V3WF]L0I\XVK'X
MO;:]FZF0H!2WBS@N[=A0/R0"#>87)+IW3O@^86KUJ3KXRR>1K1,CZK6&LGR+
MU1;U_+/M$<6"#,YLR=73NFC5T&P%X6&B?: EI19"<4C$FD^RB<($9<:(\;I#
M_T<:4BAJQZ3@]G+GK3<GP[Q=E*1)!&AVX7W=5K:/?*D,8=PZ?A2,I4CL:T&9
M_6+UTUSP&/VMC_1* S_' C#KT" 7UU4 %A/TA7%;MME&Y3;$!\WJIXL?+E9-
MR07G5>\V0Q=?K8"@:MLVP^6'!<RQFDQ6Y&CB^:3TR@P\KJ[> X@]QPDLR <3
MGB0KO:/*P)7=*XJ$6WQ,%T&LCCSUT_F=K?3[Z 9<?PZS1-Z?$GF$M[_0HM'M
M1=#HNI/D L#SB98H=[?!!.>S<' 3\ ":P&)5A72GK07M$(G<F)FA:VKY$I+:
M.S.!\ W-"7UA_:< 3/DGVKQE'TCV&26%E>8$V!,#<:NT^"JL%DJT^+K=%KC"
M0\F!&!^]""T.7AG7E;]>HI]MJ<WL7UF_0LDW(6PUX[4;:N.:!T+9P557-GHV
M,)[2Y?CW+,? ,T/NR\6["7&M7LN!>G9V,=-;JAI ?I.M78?"$'?PY?+BK.>O
MZS)VO'A$CE:8]E^G+YGWS/A\68TMU WUQ15^O:.#U'"_,J9(>$<3HPKQ(Y\>
M%Q]"XQ0"$$DR0TT#43A/YM1<U:FAWW%F6DY^A5($G=8T3[!RF4<<.=] D X#
M#98V.CD'0D#BB]F&NHJ\0"MK!^!0%;K"*2M;.QS'3)<4RS(J"3W$>W!W.\,Q
M?X^QQ*5WG8.')^*'OT_-9!H11*>:P"H!V5@HH7)K^R1Q*F_94X_-.-EX>/;K
M-0 V236LKI,J%J\7.^82)1]'$81@?8HPZL)_6QWKLDFF8I+)EXO5W^8/SHE1
MC&.8@RJB*.?/XI,# NW(%)V+4Q H[N'VCN59$@8[0Y,^,N@M^&N[I-,<@''J
MY+G3\T9D;VY=@'"<_?@ONAL=-*2A>=6\I"-_X.U*5G\ZN</QQ*!6W1=X''\M
M2IN,K1,5&<TIRP.YL2EGV"XP?L/5F\<T(EBF@WS;[$2 ]ZU3];G+#8[ZQ6=?
M?($X\MNWESI'X/HPBT#.I^KCWH \,1:@-9"T$PCCK_B/4WJ(>", *1-09ET%
M5(3?P6B%=,,5,MK7N"W_&M[02OFZH+^V-_']I0E>I$U+O_<5GB8?(NP" ,ZY
M#NZ61OY>X#7SF646"%DBEY?;000ZN(+O_Z@3,,F GH9$9KZ@A;%V*$7AQW!M
M= 4R?4C1O-;,)3/>E?TI#.#K^RMTW+ \RU:)"E<WU"Y%G_%E'$MB3A1H9*3B
MIWRD<=ZM"2*QLY?'?_+OI0,>\N? Y$S2 =ZU^HOG;5J*4["OMY>\+F'JXW*5
MFO+<8JL:%3O_E"NAW_)+]Y\#IFWJ0L(LB^*<M+\GIL.H'RZB:&<I&?IBB^!O
ME6SFQDBQ9+>.B0G03:$7[8@& 3*_VZI'--7S5D)4-'+F"YHS<?7DI 6%/'!F
MA!$^T;HMM+UB(E#7['F4FLMW[*,,3%8<)4'[" ?,WM-']F%<0.@MY$8QRXUY
M,[_A0J) KJL^1V2KSV-H^[GKC(C*<-_PQ]*:C-D!T:KW-L,QM;7U6=>QOB<K
M/^N7B/?C6TH)1MPKU:F?G"3PL82M86C$;V'3P4:@!*==@A1.EB\>O#ZV="^9
MB1BD&!>":L6,C<.=+5YT>CB:S=<C%?$U!?VCA9,+C>N%WZ/LW\V.$T%P@FKH
MXAH0Y,-,C)V.BBP'V$25,;D1B#F%QT(U]=[^3';F+1+;-PE>(^08LYMH_I*$
M@_>H)-WWPG-F\#3NG2<YU<F9L858H;>3(#,%F7I&[J;7L6Y9_7)\@;"RW2%(
M8(Q!1\&6'8]*<V.CSK[F$")*Q[^^O$L@'AHXLE&L?FIP[A].L0G&0 /GWXS2
M<NPFRAU!Q\(OZEIX.Q)7HP[A6%:\H54<%&XP]T6.B;C84 B0//\:K,^H3/2G
M)!:]<VR>.H9E[:;42A>8@/6)PVQ6,:V@P0]*:YC\WE->E!D^^]S@LY]G^&R&
MSS[+33',](48-*KGMNR[H^L.$ ;Y\('X_8\^"RD;U%W2R+ +R+MKX4/WIF6
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M$WY(>9T#MQXTF+,7.IO!3NU3B@ 3LY5M -&*8^JV:2>8P1ORF72,K@A/"3]
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MK6Z;+S7*@\8T![@ ^+OES38XX'Z]7CN_F4G^K30J\8]S9OUX']W,^C\^NZT
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M.YF#)V8.-%!N 90!AS$R[Q8JME4(+(Q/^:4S0ELH.]R3^PS]15L^JGU<Z#8
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MP%#KKQE2O.%^5C_+(L:*XD%WX')?5S>X'-0&*JC$[U6\'H,^0-B[(_SP:N4
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M.OP%[R2_QZX7\+*T.G='%Y8/8&+!'Q8UZE0K.(;'@!8S.) FA85=G2O"2E2
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M_<71JG\S0&4JNUWK9Z##'&L[^^"V<E8M%$L"<<@:4")P\$7L/:I0+C![5J^
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M8(>2H\:84FK5FY=0]<46589%OI?B(;'=>9M&=E812U+>37TE8A+&.EG;;2@
M)39 ^SKFJ]+;%J6_IR(GY\FTZ&P"D1N./S/35:B:Q&'#@;6/F;:AW16&MC#0
MR7=XA+Z#Q"_^=<7MG[BAQAH8M!4)#."U#X,!0R<]5H707G?:E8& &XIL>/,B
M<(.6'/SZNNRHZ2)A25K#$C)")LC/A.T76W\X$1B&F)K@TS L"0J\CP+G&>&"
MV H@\Q0\J0T>;,PP-@S, '382H7S9B#E-%-6J>AU@$P0: C0>( J*BB**,A^
M^Z\6P7ZCO4\Y8%$ 0P%V_,HD%P2]*H.9-\Z<(G0"!;EMDAF(Q%"B1HP#OBL"
M<>3,:F"7#OS-9& N';$A(P"1\B7W23Q]MKB-;NTP;O'76VT%ELG@!LHSI6DB
M2_(59;KS-YY,VB,Q:3]QYV/'5LVOU"VW7G+K0(C@\;SLR+5!]T7!*%DS$E+%
M.\V&]R+;*V%I3AP.,E,Z@,QAR:XQYQ=B;T6B%-WF1[,W08><6>%,6F)5WK$J
M%&1B$7;G)W^C!G27/S1OO)_3BJ,LH@"I3VHW=#C?BW&M.HXA]FC5B66#9G#L
M'-)CIA":'=S.^ 21:1S5OJO+MO4.;/3^@Y-$ECORD'@01[-?DZ23WP/7(<7'
M7Z;+9.]N?3T__>!C1NYXSJHRZ'V8, M@<-*' ,9Z"%&)J=FO/K&^&"EL*=J9
M]Y FLAXNV<4P!MX)W#;%-ELNA3>X="/!!MM#5/4V33ZV5,OV51)>DZU\)+;R
M1[^U&B3()$0S$#U?.1M&9$-=%ELVL$&$.%+'*L?(9F%7'2\H[FWW*XIV(%^G
M=6J98#-A-"6.TM'L>Y:2&-DEDG)JJ,,N; ^*PPP"-=TAK$$A_@O]&1^97 V,
M?6#ER^+N.:<".V3M2IA> #^&A5ZH8V&SNPKAS12W F6!JB9$M:O<K:UC@AT^
M&__.B -+-JQ!"7- *L:JD(2N%@O]6R'3B)V$**@&C\#J+T&XDTE&S2- ]S7C
M/C<KLG+<\/>A]I96S LG7Z(B!W4FC3I36=Z<2R=339D&R$NM,8%&OZ41[DR(
M".7:WI<C66]A.-!I,>YW![?C$6(30,C&6\:%R'<,NHT=BW<U ,=;0B$3&70I
MR_F8[>,$&GUBH-'SYQ-H= *-/DG_),J&7U6WG(XIUQ";8(@$I13M*\FPDP%1
M9;?14I<A/X+^$#\D?Q&0%,KI5HB9EP->>(G,.;6&A0OUM0K[0=#S@8:*ZZ;=
M8*UTHZIK!H?4QJ 4% ZRF:+Q.,9H@D=^@>725#T.]SOUV.S*<NAIM*N6?#0+
MCF)G2%%#Z&2C(9FVL3Q\V3+)4:Y)",([;LZYW.KC)6['/U$GO(0,5I'W4.F@
M"=B'0!_QKV__ZQCO[G\XR>H =LD0R#E^ZU\.3@Q^^9\.4@88+_VK;&^ARQ28
M:-P5U4'Y=_28WR(8XX?:+\--OP%/;2/Z@=9GDA9(]F>YL]=V6''3O;FGO]7@
MZCL1M[0F,'UI;D3Z*19)1A/0=MR7%77\LY!;*"+DB@>L-,B72?TIO3?F)<**
MS1;O0M8EP4T$2.H03*&<62DE6(*A&"DH.^XMGS?:&:J4(O&311E9=.KPB"(8
M'&4\H@F+@'NV0KF0*X<[FD(\;_@%L6]8QENP>NZJH90ED=WB0M(&+^FXH@2H
M0#9M%"%';F&:MJSXF?".%9:2SC;@LA=/5>-'[;T^YM/S#P [0S@4MM\X ND^
M0-$![+;5 DI!Y8$6CN5F)Q&CTCDHTP.RSGB#S V)$ZK\R7AQOSH!CV/6.>?7
MJ/. 3DK&-L:)4#&,%')(XS4N4CJDZ+22PU#@.UCT,BP:0X'1<<]+%F0A,$!=
MH0@5,/K<A!2$R+:'Y1^5'KKH>TA'JJIWA#8QK;BVY7LWPG*RN(_CV:4!/:H,
MP*L+4'+#;YA4<<EZ*I[8&-;AIL@M"JAQ*.8NPZ.?:YW8:[T39YL]RY*UJ(PK
MEP+/$K^TF'WO;UGZ[1/[QE4S>UNNW&;C#'P+8J\<#5"(,I!&85^@(7U?'WMP
M_15FD)[CWWQ;0["#U+KX3&-_%2]]\&=%5YG'SUV$:TY8L_Z;L'UD)AS60 ?E
MF188#T">L[IRB#((6LZL/%R(HC,<Q5W?$A@A5/VL26QJ=#7';2@9-/.5(F.G
MB8SPFGLD<&&J=$3XM$/7@"OUF&A5PH41?C@E]=OQCAGZE#;]F#1L+*A\BZQ6
M3*"\YZ2RZM#A723[):AECRX&W526'F/M('AA.V$WL;[0/!<[4CN$2%R>,3R8
M7-,[9,_F0#C3M,S'G,;OZ8O'(6&($L9 [YL-6(K-9^",W&:;NPEE]G5!3 ?9
M(SG(R-0$LZ!.2YJ "OF$$$;T@IK-[Z"DB2%%9;/8'LIR.TXNX2?\*FDAQ&>D
MJ)X*,*2[BD03C''X? %,HMJ#LD C\0ES*?I=T 4.*DM)Y_^D1,D\8]> -6&;
M(Z83'T QH5'R*\H4YM'ZN2HD^A"F6I7&>"GDR9:I#"&SO@'0\\$WE5@\^>Q@
MIT=BA0H2ER3&OYH[L([_ZJ_\RIO]"" )OV:,^P!9M7_]^(-D2BZU[@A4E7[[
MT"L0*QO!.>C5'&"*I:!HWAM5Z(99,X%-VQO"^ C?,^87R+9A_XT(AQAJ!*N=
M,[:DA0F_ (P23ZB%(@T)VPG6S9R"1=1]BHM:: @#W> <COX6;M5BJX'<QT$E
MTN%Y\?[9W._?3DB'8'';2?WOOFXRO)^SOY:66,G?\%L?Z6R:U;,?MW##=_Z8
MN[Q$74M_./]-N6(='0/<>A',"9H2GAG6XB3I'^OL#EN;)#&7I9%5_'R:"M."
M^BA9KBX!W%$A=<HNL4T @CVMZMZ9?5<DN@<1-7%^O,AKE=GE/""FV%<<1)+F
M#:32>R20E+PWYI@26]*/%!#&YS@T#.0*[IW('@"=$VPT[DL)UEAT8:>P][%[
M"_]1TSH:+?%VCD]+(8%+ N(HB+.5G#=E=WQR"4L(?GH1@F#4.78JK9%!7$8)
M>^D#RO6(T(@&T:M&K3_^\)ZB.[PZW JRZTQ !I/WWY!L)\&[7_K-%4:S[SXT
MJP_-;1.N")]^!P4[1D2^-QA2_TWX FR%H#KSTP__^AR5([GP1]6)Y,O"UE>,
MU8628I!\;ZP,!(BP3RL")6:X<@];!]('RI5[M!34$3R3LS=C2VXJ"$UV^H^
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MV9C[D O/F<_4)"[G?!RS1$N8N_S"S0F[ :UUX)O2==1?+D!7DFE?+9C/!T;
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M*UV@V'O9;,L5SCHVXVN-,B\Q;Y0.S&M,J#T8\;!GIFT=,]QHN.+V<B_F*0@
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M=G$@5VJ68=\9TY;+R,,+NJV:541&="\?5N$;T"X4$FVF?I!*E'S4@CDP8[(
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ML>UB+8.O(]1CN>7F6;+H.8P@(T  V,K4_( L(:BKAHSI]V8WU0UADU!KN]U
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M*M-698IH$WN+$]DN<K@X&K:&K,CQ<R@S2I%P>9@_("O O%RX=36?5>PH4.F
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M>$/%"B8C:SS&XX)@L/Q5'4@XBA4"$N]5SYCW:L,I7#@;S=X5#((?)'QOZZ>
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M==W_$CF?UT5+PESU^[<_'\U^ZKU9:_PI^Y^C=T>$WA#A080CQ-722/MM"&/
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M+*F >0 E&25.'9D$AB!B/8>P[!9;\#F" [,P/SU >%1&> +C/7$PWO$$QIO
M>$\R!12=7* <XXTGQ@?O^AO($P#=CC^3VWZ%WAR='LB]PNRWW;RY,2ES6Y@/
M2*1JI#3)S4CE!U?SY;@^%*X'%="VLU<(]:GHX&5P'QPS<("$0V8KM3C(-4AH
M9]+VC&U/$J8$C2KH[/1.["7WX6*?-YUZT-@T1U30(G>[/ -!R-):8A&E86K
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M[J&#42!;>,]:$35%09AVIXL7N-]671-6FC9E=IM[+[;A,H-SR1]!K#0CS,?
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M320S/G#_B[O E8SD>NJH,L",W2HDS-C]Y:?X53GE/V$9?\!IY[O%G)J2#)H
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M,MGI[#PEO:9B#\L4+XRU+8=B&N522)UI-(',LR&WLJQ<R60NFJX*2>FV.Y"
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M%_,$2H,_HMH<55H.ISBD8IS\92R,4 ID[(8@4TSE:E11DU),J&YFQ<=QC5,
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M+9U'S#>M$4E@0SK:X7?BR7EE?:LTO>=MU^TVK/5KR\3$\+X]?WY6N./>P^D
M1C<4]]K@6 L/%P@P"F^.*;QO'B4:30GS"6W=,R*4#5 S_XRNV2(CX^+[R;_
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M<4$NT41#'T;$%3NA7/"[1/DYM9P'&@!$@6W'#>G0*XAER6( :5&'S7L*4F)
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M]6)[ZV+[><4;=K5NV,F?<+@:U3'=8-NTL&%F01(SEBW/BT80')K/E!L.=/:
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M+8?4VOT>-,\;W$-5JU(&_@>;NF*) 3KG8#Z0^U.3T8Y;C,UP6BV.G2#.R_Q
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M-DU$^H)8DAHB!$567"54<L$\0>LU7V(C;XE:46(';UXOTS()UC#!J;18;8^
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M[E/!6B&A 19V4!-SVAHQ&F]X#^YI2Q!(73G+Y42EDO(D13DZ1J[!CJG+B+H
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M-AF&W01)D$0K,J=EE'H/D5R;X5ZF)9BZLFOHDV44?Y2H D@"95!B,#5#PV.
M=MRB%H,5?HQQ]!RVP*!8#'1P J,"\4>$EA;K95K5Q$68!,P6/V#P![Z6^\$
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MG9:F Z>F+C756[*ER#1BHC7WE;L55;NG((AJ00H2Z%%*V>PPRUP?"+1;;$X
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M?JR2T3U.PP$H8HP4_ L#_V_ %>?4'EA++QWG^9V\^@%H/-,2X%]OPN#ENS!
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MVZRP<S@^9.VNFS4LMRR&A&'K'*+#5F&:LP.O1BOQOE&7LP\5I:Q4\L%P 7Y
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MPON_CNM"6 7[IB#7E<N?7\MW41YMO3Q]^'>WT;'SWOAER%J9:9YLU!KL_IR
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M'H$H/!" 5"(N**HX39HZVX.\4OUIM"H:'"3^2JY(=/<E&^IA'M>J6<$+[C/
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MA_;_[NBQ_@4/Z@7_K[_597<C2,(?N\+/H_CC18F]?0>B91?T?_U:UO$>&7J
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M&S)R/-VQY\'B:74V85O<D*[/W0[C+97](TH"0;VU](X/^!]*?X)^=[P)WME
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MT_&P,? !I?(U+*#22-Q*2W4=2*@ ',NIQ@3_8E8S/&"LBQ2(D(B-(9) MO!
M6MZ8N@5@MPM\+8V>R?N1@/.IUG0K/)^H9=X97E47F<<A[&&D[HP)9HI^_E3O
M7</Z)!VXD50P!= CA4,0 M4C+_ZE")G"ZT=X8-2.Q7&(O0O@;>Z\9*2(50R/
M*W.$0HTU?"0FPZ5J,^&%S+N;GCNI3@8W.5+YOH5I K(CGFDAE&_QS#HT;F[:
M^2QS$)9C\6^YG +S&(<IP;C#!1FIZD2Z$@\2\NP8H5V4BF%4J);GC#8V']Z
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MJG$Q.>O2S4NRAY@9TQN5TZ"0Y"P%&^_L^S-\@]L_O_'YL2#J@/]%\ .BY^&
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MB>H>;;RY@^L>B?AH$]:V:-S1O_M%#YM9T#/V[AGMMAI7TO/IJ@7]9L'@=E<
M-JG@NLW3XW-5^5JWKM8Q;.L(>UIB[K97]29$5_6Y."^Y=)N7;*W=K'!]HR2#
M'2L(WWW"-]UJ6EG7IZXBAAM3A4HX,?VP&<]S)R?>@/QF_''C)9NR[2W'<)<E
M]2QIU:JB]-OEI!V/A6A'M#]1/_<GEA]NXGBUTG&%]?'-&O!F*ME503G/K^/R
MMB#ZD4+U1YM)3JE2</T\/E'.NJ=D7'Z3+Z>Y+G:N>>9CI>#KI[A()?-I>RPJ
MVZR&&EQWUEV7P^_LZ;Y^8/NNZ/3]&)^GWBEW*%#^J?G3O:O47_!E'SG=P-&<
M6"06HJNG&Q!EP09EP(J4#=6*"<T[.MW@Y_*+GMCS^S2=UQ%BH_]VYQ??CGZ=
M%P=+HY]^>G.%K[MC@0\*NQ/SLL>C.GA> ,4X$!$%""44>!(CA )/S2.7FG:%
MZI_FJU"R)\C^KFA1%9F_E:C4A;/+)BUO-'\AJD]/.[:&J^-C/X7'OCD(HG80
MK68^W9M*KU=[F]I85]!!S7UG*>&$#IS0L<O5<)S0<403.OKK1?L_#^.3I\[U
M\I)W:-?JYIS+6Z=;KX\:^]?JJ+&^/MZ7-WO/>_U4OUL?W?:VM6>O+_40 .RI
M*;YNN[#FEXV;Q7H2P_NZB6'4G+4C5E=KQ)M_K89]/NH$J!-XLI_1P\\5.1^9
M0K2GIM^WK-.&)[<#Y'HW]>50PM[YY?HE5XL2S\@?-Z^O!PNZBR8]WXQ6WUBE
M/8=^];ZO5L>W+Z]"IW>3S2%"SS?O7[^HO"K>7@-1^AFG_(\W@YKU?:ZBFC]]
MY'WTF=SA33N\A3TS8I?K.\%;^I\_+1=WL;".94W!OG?AW[\M"I-$6)-&;O_/
M_:1Q8^UM%5777]P3D=Z]UMO1-:$EA'Z7%FU'ZOJ-*X?>2O1JK+W^U6(=?[?O
MOC^P-@=BDEW#Y65$2WVYI0I.ZU_^_!7[J@NK7:5KF])"U=L:XHTV^MD;N^XL
MZP]<Z;C>N/D_?O&GO]3-F_O$ZX LWWO?_X0M5X1.^*E8$_GAZ?B!(S_L%]&?
M"-_:Q&D[?@O%UW/XDOAMEWBM_.61(4@OEE)V\X0739-NS<DX9"AWH&IR#YGZ
M7J/=Z[K[-&/[[8.+']!VZ*SHK$,&W)';[LL#H2\O9)UP(/2PQ:_5$:[MB=?+
MZ\W-R*G(J<BI:#MT5@0<.FM_ J!-)6CW6*>]V=H&-UM_R;UWUU%$=&N0 MEL
M^UI_.[G;GS",@,DUJSG2H?Y0!RF]<],[,U8?ZAP/,?VI4_3#K#>;#]-VMZ'Y
M<*/]H1]HZP<_=^K?ZQU%/RS6XR=76XH\IY80(2 834$0*<#FI(%Y[Y,U) 27
M[FXI4CX+KFF$3&D&X8D&Q[6!:&2@B0N1,]]L*;ILX#?G+IY7=GDQB_5_7EU3
MRXOE2[=8U&.<_N&FE^6++F>3U;?\_5]_?_M]B5W*$RR?4CXNIC Y=]/FSU]!
M^==JBOV?OYJ\7SZ?79Y#G"]A_8JO_L(,'5NE-_N"-G?\EQ-UQ2=F+.3[4P09
M\OTP^-X:[CDC!+QWO'(W V., ,:E,$HKZ22[R_=46$VH2T U<2"L*^^.UD!B
MB5 :M4KRH'PON!P;*Y'ON^/[W2O8F, =*H'[FUO\.ZV;N%.X7+3'D?2#7E',
M!V6[84:,)Z/A.DL=2A(&-K*BQ\H[,)Q%J!,M2[X6/&/Q,3F;3^[\^8MW;C*M
M9/+#?/&VB/+WR2_?7M%*D?8JZ\L/U[_ZX=W/D_6B6T>Z+I49:\U1UX?LE4C]
M@[+=,$%V,M0?B9:1$0/4!P]"^@0N4@'6<IU9)"D+^9CTK2_4KR4?6T.1^@^9
MTN&:W*%3NC>+=.$FL3UQ:]:DFW.-PZW^IG[0,&K]T^\5Z3WO[!6&.YKR9.(%
M(;4P)EK@D=&2]M5X(0D.,@8319!6,M_%\MZ:J%ZM>*J$"*\K2:WVGG0;&3 ]
M%L0>.C! %WX*%]YE-RBJ#4(5U>8P:L--3I8Z!88Y"<+59<; (TAFN4_*.2^V
M"I.[+"X^H=K0,3U\)\EIN?"AUQ[94R:J[#@2U5]7)P9@3CK4**$OMNM]#'#:
M"N^U2]H5M1;6*! T1S#<QCJ&GBN>2:8F=)%/[D/+C3;C$FT<6LS1TP9F**3S
M4P/9R= Y*5D6$SZ#T;90,Z<6+ FB,+63.0>;R'8GR2X)VS[HG(X9I6,BL#]D
MX(N$^TRUAIA+O5G,+\K=?V@7^^H^O(MZ6-MX-$O+?M C:O"@;(<:W&L-UD*F
MX T'8WQ-CXH&&\,=1&I-L%1H&[<.]=IMB6Y%*V^F;K9<-_&TS/)SZDR2BR +
MRE"0A^QXR.Z#LMTP078R[$Z<2CHQ#D%:#R*2",Y%73A3>:]BC(**;I;$]L_N
M3(RM(LCNPU[JPG3K]M/Y)37+Q234,Y+JY)-^\".*\*!LAR+<:Q&V1&5%@P2;
MO0)!A *G20:EF*7)!FVRZ2+%NJ:2NN_]Y_DL=+N -:9"H/P.V>60UP=ENV&"
M[&1X7=K@C1<!8K04A$L<G&<98BZYE=?"::^Z2*[VSNN:8EL"KF(=VO2=>NSK
MB[1PR_*RT32Y)HW:FX-YALOR#VP01$E&23Y&28XNBBBC@ZR]+JF6<^"$SJ E
MY=XI$W7L)-6ZHI>?*KO\4N_V=?Y[D]I.DZX*GD2,C<*Y8H/V/*3W0=ENF" [
M&7I71@B:C(:@="A4[3AX2BUXE0.EPB1%.AD?^23T3MG8"(7TCNM91Y5XM>-!
M,,,:G 2?UBY/W*A]0!EGW!O-60"F7%T0"QF\+*D:3XZ4;(MFIV@G6=KUONS.
MJZ9TS.3!5\/09W$.",H+0A7EY=8NX:!*8B<86%?T0OB8P"JN(.@<'67,Y-A)
MT^,^Y86-Z>%SP]/RV4-/J,3!'[L._L!L<^#A 'O&*K?$^64]/J)OY#*<PX5V
MMNH)Q091&T8$L!@U",HB6&,X:$>REB)9R3N<(-)9KDD)'QO6LWRSWUX[L##^
MCC$QYSPQN*+('(_(6*>SB$55L@VIB(PPX"FWX))-,6?O/-^J;^X^UZ0SD1'2
MCC5%D>E]WKE9M;P/NX](1H]SU?+WE2G]?!J_P+%_FC@_F;;'B[2#4)KE//S[
MK'Q&6C3__5^&4?UM.QQE^6$'[\ ,\Y:ARI.L?_GS5^RKO1FM']ISJ" *;7<H
MVZ&S(N#06;NSW>Y%>@R6NDIZUH,41]/K&.DY$BL2Z\') 8FUI[9#9T7 H;,>
M,@KJ]HP2/$SSRY_FBQ#* UDVHPOWH9YNB^T* UI)ZHOMAK-*U&-:?HJYBYJ%
MP*0'IP@'(8,#EZ,%%GDTAK(DR=9HD)W:#-:D\F;%*=V.N.=CH_$,[*&T$_3%
M4$CO2._'3N]<A6R\R86@98)"S(6JB6"0LC4R6999UITL\.^3WNE8T8.?+=D7
MSSN&!G+,RG;*RA:7*8[2ZC#7U6+_O-W#'+;+W/V@613U0=ENF)'CR6AY%$PE
MIAD$06Q)U6JSGC4"=!2DY%V46/:HS<@^N?/G:YI9'QG=;,Z,7@OZC6:CCK1=
MZ+%0!L5]R!Z(-#\HVPT39"=#\\9[JZ7S('@6()RM9TW&\A/3W);L2VJUM?'G
M2U*V@]!\/?%*J8-W;!^3"^+2VO"2N$U#TL5\T7K\/!<G6DS>N>7D7<+\#87]
MX*R"PKZ_I39FG0TE%W.!Q"+2(8#SSD(JZNVH,#G$3H9)?7_%*#=TO-N*K!D+
M@@><#=KMD-L'9;MA@NQDN%T((1TC&7(JM"ZH8N"BID""=DQH;AS?.IQXEW6V
M)^!V2L8&R1V7VS!3V\K4<BJ_C*-%>I=FE]@7B3J..GYD.LZ%JZJ<H>@V 9%9
M N-3!A5%-,ZSY+;G]N^2H[TLGU"_^9^3Y=G+RZ;<?UIL%/U#UWINQD;B$MN@
M'1!9?E"V&R;(3H;EK;622LF 9,+J>9@.K%81>!*2$^XRD;Z+;.T)65Z9L28'
MG\-[3/Z'ZVM'D;6M3M7<+*WM,@0)Y?Q0<GY:8[UQ%/\ANVZD"5QY!S2+DL11
MY\ K47B<"D9DR#8FV?UYG/M*^?A8J(.?E(W>^Q3>B_-W$:H#@2H*31$:G:C7
MEG+(,A@0,1"PW)F23!H1,HO!4]O]R:#[$AHVUOK@I<73\MY#KR;BZ2^[GOZ"
M^_2&'27TQ7:]CP%.6^&E)IHSZR'[5-0ZIP!.^PC,VTQCYE)O[[G?)97<7P>0
M86.BL)@\:'=#3A^4[88)LI/A=&JM94Q+L"(I$,8J,-Y*D-+9D)76+G32W[DW
M3F=$CJ62R.G#7B#<9]XUQ,3JIWFU3UJ<XSH?BG O6 %%>&\BS**U)@4&2::Z
M@<X%,$E2,$I:I@+)06V53CM<H^O\Z&PJ]-A*S+,&[7U(\8.RW3!!=C(4[Y+6
MM.9,*7D-0FL&/LL H39E:A*(2)WD64]&\=*.+<79Q -?_\*TZTZ?9?FIO*@N
M9I5?-I/8>E/Q8ES:0GD^-$&@/.\Q S,ZNIC ,2>*U!(%Q@@*S*@@M;!)>=-%
M!O;=93.9I:9Y.3_WDUE++=>4\_(FX^Q1NL>4HW /VB^1_ =ENV&"[&3(GU.A
MLY4:/(L21/9U;W1A\V25,$KQ8.S6_*I=<K,^D#\;:\:1_'&Q[)BRMNO%,IQJ
M@LK=-X9 Y=[??O<4<F3,0@PJ@8B6@S7*@TM9)T-UYB;N?:I)YQK-^9C1@V\^
M0!<<F*&0YT\-9"?#\T(*S64@$&,0(!*QX,LOP'O&66:ISK;:^UR3[@MQQ(Z-
M0:+'-;1#F_XILC$\#0"UNC<\@5J]OUUBC$MBC08:Z\FL07BPUNFBNX1$EX)7
M:FL&66>G 72NT7(L")[N,VC/0WH?E.V&";(CI/?__B_#*$,8XMK0D+.1]O@_
MS#D&*DJG-0$'YU<=,&\A+LO ; ;BM0>A<@(?L@"B!+?*<49$)VM)+2'M-64Y
M?,*";HL3$E%A$*JH,#<5)O%DG<P>3+ :A(@6?-0: A.Q:(]UB8A.]H#M6V&8
M/?BBU6FY+8Y&'%[BN1J-B(GG,,."OMBN]Z)_VI(> ^7E Q6D),AJZX"5QH,O
M^6"R4=G(7<<C$;MJ,M1DS/3!9^FCGPW,4$CFIP:RDR%SF2C1@25@F7 0R@LP
MA$A@))-$"VUKV?4LQ([(7&@SY@:'(/9B[>X^:#XB#QO&VMWM!P!-"C!Y#V>3
M6#*XYS_\*UFIG' 1DJ?U&/D2(CGN/%A2?,IQJ9E)=Y_BUH=(21TQTH+5B=3.
M(@&>A0Q:T2"95M9$M5?:>#D_/Y\LS\L_FI&;Q98*)G7W9BBN//KZ;4JCG^?+
M-++CT092NUQ+^_+GDY(^3L*7]%U."CTW:>1^6Z2TNLC'7,6#OK-:H;UE2L8'
MN.71R_ETZOQ\/:2E7LUTRPI[-\(W5_QQ[_\\G'L'1[3[#0;+0ZI_^?-7[*N]
M&:T?P<VA@FJTW:%LA\Z*@$-G[<YVNZ^0G&2XOI<XZ.UR'OY]-I_&M&C:YE']
M[2C]YW*R_/ <^17Y]> <@?S:4]NALR+@T%D/&0P]?M_!S88-^I3M(O0XVD7>
M+#;SJIH:1HU'?]A[W>HC)T)%ID-B E*=3RYHB&!S8'7T0J),):-3ZF))^^J&
MV[#QC5N\7KQ=NF6*_W#3R_0F+=Z>N46ZO4!2?JRO+Z]J7N<7YVE1L/1]+0$N
MFO6KKQ=-?OSYAX^NVE.;2%8&'&.IW**BX%4@0&A6CECO8]Z:]KK+0L^3W&)U
MCWL6?CZR$K0W,*W8Z,(M1N_JS7V[_]KS_<\V$"MS\J8\IPI%GBQX$3EDI:,A
M/!J[?:#9X^';/IKFQ>7R;+XHO!-O/=.F_>/=!_?I%;V/S$%Q1A@M,Z10]U8G
MP\ )DR%(87CDTGC=R0KEGF^.R7%Y_O7_]P:XJ]L8N:N;'+>K"0<"L6.2I* "
M>.MD):@,/C -1K+@55;2J4[VHMSWG']LFLLO?L9UK:X^YQHO-&GVL?LR23.=
M@P;.=02AI 2KI 5I,N?6FZ@LV1=^]WE?RDEIRTV JE<F1'D*EE%7-%,QELO3
M3'EOS^OUY;)9%JP6J.WGYH(/@6>K2QB@Z@-(!HQQ DA.F1@JA;-;/6Y=/;0.
M;VXV?PC9](N.)BUF1_/%:'YMB)%;CKY/(9W[M!AQ.AXQPD3+5G=_R\>C\BD7
M*=0I&5,\.A![UK!G[2D2_,_TL0AF2XQ: C@9,@<A32''NN>4%<JTFB7GBQV?
M<K+#KOT*B&\D4231HP59KTE4*\4DXPZXSR45)CR T=&#-YZ5=-BZDF(@B0X(
MWX?>XXA%Z]T:8N>S0U>LA4O!$2H@B)I)V\('AA$"1!O+.%&*^ZWS6W:; E_O
M]NG+U2*8Q)G0(%.Y*R&< NN8+[FUSDG;F)E@W4P_WO?]8:WZ]CI$>0B"<@54
M<@\B! =6YUP2 >HY-<8JWC5PGZA0K3R7E$H)E$114AQ;KC()#H$G3Y+P.?JM
M(:"/A.P>JM1D"&7J0Y6H)?5)I0R%A.J!QMF4T"M9D(R6QU526-K-N*2M)[Q3
M'?>AN-4N&4-D<<%D2VJN;08O3$&CX)DG0:2,G:P>;=W5[H7.[5LS?*PX'Q-U
MW^[>P^#V@&LI@5);DH):8UF=$1/!\D!JL&"D"81'LK6>W0D5[16HQ$2:I9+@
MG"C24?X%WA(*/"I#HD[<Z:YC@CT E1:@LK&PJC= 75?<*UZQY([5HL%FTZ=6
M+7I"0;&)>&7K,='9%1I-M.H]Y\"H5"X&%8G.'<<(;0[6T5YQP^]C6W2TP3@:
MLOF@;#=,D)T,FW.1HF11%38W# 1W$HPJ>:P+GNM %)6NZ_2@4S:GR.:]F/J!
MBQ"'6H1X46ZYXMY-1Q=N$LO-C(*[J+,D^D&EJ->#LAWJ=:_UVN4L#-6J"'2F
MM7G*@(DI@[.2J!"E3:*3[2G7K/*FD,J/LY<K2NEJ@O*863-6ZK[5,/2ZP7@=
M4ON@;#=,D)T,M9ODA)*!@Y*BY&-""W ZR,+5R4=.++>RDXT&^Z9VJNQ8'WY$
M_C%Y'3:'#3 O"^'R_'):>XA&\_84MC _+Y]SEF9-/0?ZZ^F\:;X936;EUZD?
M5(MZ/BC;H9[W6L^%]88(F2$$:4O:)3D85T2="4&DUR$K)CM)U:Z)ICWZYN5-
MFOFQI9>?"M7\G):O\Z_N?4<ZKW!X_K#]$,E^4+8;)LA.ANQ-DB+%%(&YE$"$
MS,!;6B=\&V:TB5DXVTGR=ABR/_R9FL?DA[C,-NQT+J8\"9-E/R@6=1Q/3'Q:
M&.)!IYL'\/6!FOIK:.'J@*0@I0$1F02?F0<G2>"><A.VF_IW22U_24LWF:7X
MRK67VMP@P>]7'/CP *,ICZ3\])E(@XZE4F/%#[XR.!R^N(VWAT/KFSX1!Q[F
M?5*818U#C?N,QA$?&!%!0)+MMN_ P7+-(+*@&;?.,:*ZR*@/H7'4V+$Q!R^@
M#H<O.M6X0Z^FXG'BNQXGWGSTB W,Q3%.P3CEE..4CTSB8%Q+Y1105I)D$7+)
ME*GED+-(BO,@K-P:N;M+IGSS\)]7+2-U5'K7G(^E./C9MNBRF 6CNB!445UN
MS<LA3MIZD+.GO&Z(EZ;DJ'7B4XC4.*FU([J+''5OZF(-'7.&B>A)+?]B_KEK
M_CF=.#^93I;UO/,Z_@;ST2.,&-@S5ODGSB_]-/6.@':MA/WAP,'#%UCU9,*'
M3),R-!M0,92@@=)00H&L(5@FA"O_47YKQ\\NR>E/U[3U8A;W%DS0,25\;-C!
M>\6&Y,\#RP'N&!,3UA.#*\K/\<B/84YKY34(8565DB(_7B20F;EH*%56=S+[
MY\GD1T@[UA3EYT#Y;/E?5^ZQ_?$!]Z'*/Q]^)VJ31M[US%V<YOIZ/G4!JY?6
M3WY>-TA/PI?DBV=IY$+=\>EF'\JK1[/YLB:-B_+KXG_E9;\MVHD]B^5HGD?+
ML]2DZFIMU:-M,LZ3F9N%2;OJ67YQ7CZW>?:87HS]W_3H!CHJ".+DW2A,7=-4
M%_LMP=HQZL65SRK/KKY@?1?_U]8'WC\'_FV>IO<0)XO4>N_S<G^7Y[-OXZ2Y
MF+H/S^M?M[SNF2SN4R]K74=9_>)_+YOE)'_87&'[5DBS^.W%O&FWP#]?I*FK
MHVJ+S[ZO!JJW>.6^[_?MD$\&X@<]O1_@B=#UH*L1MYBF &7]WXJKLZNRV=JX
MD]ET,BO7M2SN]-Q=+N??WOY#>>:K7Z]@V-;.7"ZV?^ZFO[L/S;=?_>D*L/=J
M0D73#81N(:TG@/JRB'CUW:RS1W:/0FR>6'^]Z/?58_0E(-D/D+]+[GQ4Y*!\
M8[HL 40S^G$6'D7D>[_DNSS^%$^OC4EO"N"_KF7O7_.+8K[J7^7'Q;_"O*_/
M^N5- 7][=?U5X5^O;J'7S[U<?5O6;G<6CFYM+1S5786]OOA#@+:GIOAZ,BL1
MY?RR*0^S&8_2^Y#J@MK9*OJ,HP+%S;_.YY<%H-_@D_WDD_V,AGXNDWF$A-;[
M;;.J^];6VI#F=E!=[Z:^'$JH/+]<OV3U3924-/./F]>'>E#519.>-ZDD(86I
M-E999:3M^[ZZNTKY;M),VE3^P_/-^^]9?EQ]G=3/C.)_O!D(K>]S%0G]Z2/O
MH\^8H3N\;8>WD&=:"7+]?Y[H:_$&!W6#GUBN-Y]<K;^/-.Y?PM\.X1]0HMK'
MTK Y$(WNMSB/EKIMJ8+3^I<_?T7)5T=EMIU#E@=9]?]+;M&,7LUBNGWP$2)R
M3]U02*_]>$1HJ=WHE77"KITV1PZ9?^NI<_N$YX ,W7M7[WB3PY"MB72P-SK@
M2 >#IX/3LB62P=[(@"& #Y:I[6UNPCZWJ>QY ?[V4X$F!9B\A[-)C&GV_(=_
M$6U%X"(#EXF H%Z 3R&!==P11:T+5M]]M%L?P@PC)G(+5DM>/J0. F.$0DS,
M4RNS5"Q^]D-$RE8F&B%F4:Y$UTDK6FM@U&@EE C"IKVV)_XT*4AN5FM3[;I"
M\;9VN7>T2._2[/)Z//ZG_J?;QM*>@NK0BG\,(UR'T\-\VOW)5E$7-#403.4E
MI@O-<6Z 4)V9R3S(M#5 GX=*G]E"-C*#2$*"R4H!38YH%WWT(6]/@&I)YH?%
M_/QE^;!Z$?^<+,]>7C;%%&GQZGV87M;'\*)I4OE_L<.YRGPL*9Z4,Y2M,'TQ
M%)(_DO^QDW]))K)DS $3)A;R#PH<2PJ2Y8%Y;Y.A6Z,5+/?.*N[!FKHWT@8+
MCD<.V5/#,[%9UF$_?2%_KO58DX//7NB+8PZ3_?OACR@(* C'+@A:^VQM<.!$
M6^J(&:QP#*Q44NO 2'+;NQ6EBRY3!E*R\I[,,CA??M).<LJ4YB+X_@B"(F/+
M".I!]SL3OWS2SL.;2W9I)NEY<:E3;UYO?)C]-DKO+VJ9KWG^^$)]SPTXJ#6D
M'LM*[]<UT79/T@V&SHJ 0]OUSG;HK @X=-9A-UC@N9"/>YJ_I":Y13AKFQ=B
M>I>F\XNZZ7L'WSC!1X&%2RR8'VF]4CKJ7# 6@G4>1# $O,\)@F*1."4U\5OU
MRMVZ%U8$]&(6O[^FGU>K6DM72U5*CZ4Z^)F,Z'D#,Q32^ZF![&3H725E>+0<
MB)$*!!.LT+LV( E)220?/&/=]"?LG]X%UV-ND-X'[7E([X.RW3!!=C+T;DQ*
MSMD(+FI7HG=+P F2(5"F'6'!Q+AU;MQNW09/$+U3.I;VX&.1C\GS#GV$SXF4
MASIU]+^F6:HSEVNASL7RJDFS7+3#6K%6=ZQJ?UH'B^%9@(>L]R7!?*(62(P2
M1+(2+&$)I-!,"J%22+&+>M^:QDK \.(6B74;,] :,S \=O8D_!=/\4&H#@2J
M*#5%:KC.1G#B@-@L0$@I2G(J BB=I0A*4+8M-;O4'I]*:M384(Y2<PK^BU*#
M4!T(5%%JJM0DPS)1 E)2=4H-(^#J07&94R\(]TE;VT4=]&FDQNBQ(9C4]+Q4
MVFU3(YYVONMIY_.MG5N/+)2>R*/ D*+OG(0AQ2$W<C.>N+<!HD\.A-8>C! 4
ME&!41*(-59T42J\VGJYCB*:K;AEMQ\0HC").P6,Q7T6H#@2J*"YU;)1.E$9F
MP-;_"&9+[LED@)*FZB([*BBS-3-PE]+HOL1%2C&FA^_508]%<4%Q0:BBN-S*
M7 @741L'25 +PI,B,\):2,J;2%+Y.:@NBJ'[$A=N[;C\?Q27?M<_']\J>@0#
MSKL=,#]OFE%>S,]'UR>)X]SXH2A\7VS7>_T^%77^^C''E3]"_VFH6BXRZ,P$
M"%ZG3]8]?YQEQ:372K M_7]4Y?+'69B?I\I>#X\ FO(,RD^?*V)2.98*1\_?
M"YZ'X^2;?O@X"LF@;(="<N)"DI6(EM0U+Q4(""6+D"CF@"1E62:<$M;)</LG
M$!*JU5B8@_?4],6U44A02%!(4$B>2DB"2RPI!HP4#1&N_&2\\5 DA!G*)2%V
M:PK)HRJ2^Q,2SLU8Z(,7)_OBVIT*R>X]F#@'O[,Y^,NSM!A-6O\9?;WNJ/P&
M9^'CQ-Z'Z15.[#TUVZ&S(N#060=B.W16!!PZZR%GX>.$K4.G."_/W.RW5'*<
M47:3Q>B=FUZFT3R/8EI,WK7;.4?3B?.3Z60Y>?1FLA-Y0%@>Q?+HX,NC'QFA
M++4-) A@F?/:&I' >F,@99*%LI8Y[;IHI_C^BG[^ZB:S6KM\/;O^W<]IV5%[
M)1LSS;!^.63?.[HH'D'6/Y"=#,$;PKC*=6JR(@J$-QF\<PFB%HHI5;B>;@U1
MWJ7-X:D(7H\EP?.9!^U[2/"#LMTP078R!%\#]>A386>54R%XRL PH\!;S:CD
MRGC?R93\)XO@^=@BPQ]V]Q,>:=G7,EYY4_NJQ7PZG=2I4/^YG"P_E->]2\VR
M'EN!)3T," ; 21@0#+CCT9/HF$@)F*6BA!S.@:6^%@"UT"&4E--TL@?K54MN
M;U.X7+2K%3^\^WFR"3XZ[Z$78V(//@"Y+RZ.+?0H*"@H*"A/)"B<.E=2T:(+
MT080/$:P)@6PT2;GHE2!=S),_TD%Q8REQ:4H%!04%!244Q64CY0LDV#2BPS*
M>EJH.QDPKJ0&C$NB(Z'"^$YF.'5#]Y^N5I(QPVKE8:N5V'38UVIE?45Y<WE1
M_;&9Q/7@)VQ!Q&A@6*R$T<#^.E0\=9QX X1P"\+5%L0@ Q@B>,F@C$[N4=5$
MG]SY\Q5#_3C[H?#3/RH]O<XOK\CIY4UN^NF:FCI/"3$C'+I78B(X*-L-$V0G
M0_V)."*IY9 232 XY6 ,*5S.HB!)<^45?TS=KS_4;\=:8)HX:*]$ZA^4[88)
MLE.B?IZ-,)""*C1.(JT]!!)4#B$0'FG@CZH!]H?ZJ1E;<O#31([)+;&A<7@E
MPA\KF:5F.7*S.)K?.X=I/)JE)98#CS4P.*TC)_"0F ,&%R09317UX"RCJT#!
M4L&@'I:M0E)>!//HDN*&T5[,8CM7;C66<7U<3'?[(80=$SR,[#2<%P\C0Z@.
M!*JH,[6111A#18H@1"C_(<J $]I##)%&FZ-*RCZZ?OE4.J/&2N.)RB?AO*@S
M"-6!0!5UIAYZY:0BCFGPH;9(B)+4&&TE:,=,HIEJ9K;6R;ZX6/I$.D/EF%F-
M.M/O@FFW/97L*:MR[#@*IK_.EV[ZD4KI(XND)_(X,*CH.R]A4'' H"(&274H
MV:KBAH&0(8,1==.=8-$YRH5WN8M=W#_/9_/;1]>L8XJN3M0V8Z,.?O@9.BXF
MKJ@Q"%74F%L+<3PQH9.'K+0&P9,I\L(5.!J3"%1*'D,7&[OWK3%"CCG#1;B3
M<%S4&(3J0*"*&M,V>P1-L_1%5*P$$1,'YQT'38TN/S#E1.IB-_F^-4:;,2<4
M-:;?A=''=Y+NL_ VQ$+GSVDYFLZ;9N13\8^T*78NW?N=-H<?@7E1\/O.&RCX
M1SV/C*9,J2TY)Q&6@M ^E> BDY+ $FI)#('EK9!BE]+H]4G>/RSFYZNM*9?E
MFM='?<]GS7<M)ZY>]VMEQ+]-9O/%9/GAQFKM[4]9#;WY6UJ>S<M?KL8"=WY4
MN%9C30X^,',XM#.<"6B8&R-F42I1*A]V@)RW@3%OB]B5%%PP54=W4@52N!0,
M42:+K57$72J\ Y9*RNF8*LSL42I1*H\6LRB5*)6?D4JKG:!*<#!62A!9$+ J
M&> QT?(7&P7?6@S=I5 ]8*EDBHRI-BB5!Y'*0[<)G\CF_4ZIYLUB_F[25)(I
MCH6U\T%&.7VQ7>]C&(Q0]GRP4R0NATP@.A)!2)G!4"G 1!&HB"H*L766Y.YU
M[Q)YK%?0OTNS5*ZOJX9@>^CXH2\./9Q$NB\60_E ^4#YV%$^LHXL)!$@*E*2
M548]>$\RD."%C8302%AWM>!]R0<=<W7P.0A]\6E4$%005!!4D"=2$*,](3X*
M$)FJHB#,@S%!0[*AY!%!)4U==R72O24@8T%QV'<_*I0X^?70%<JZA##*B_GY
MYK#Z\W85X<:9]5BI'$J@,)R%D=Z'$K@>>_T #*,,H7R,4,8N&(3J0*"*K(M0
M/A(H(^LB5 <"U1-CW8,5U@11S*8$EM=];-&8\E-P$*0RF8C@(]'=]QX^5=>@
M',O#'\(^'+X8?-/@$51_]K*%'@MIPPPNV#-6V2+.+_TT'0U=_.' <<876!4C
MC>X.=I1<4<XH\$@$B! UV.@SI,08"3(ED;L9*YJ6U\'&7G:WBX.?U7X*+''H
M37MWK(JI,^(6U0W5[:,G<2BKZF08[7P"(;P XTD"$TS)IWG,VFQ-AMEIH.D^
MU:W(\UBRGIW!<9PL@>J&ZC9$W**ZG:*Z^>"4HB* 3+6!7_  3E,"2LA(-64B
M^ZWS#'<:I;I/=6/&CHGIV1[RXV0)[-$\DA[-O\^*P:?EFN/H-S>9C;ZNU>1O
M1H48RE7].RU=16V3PN5BLISLM+7\!)_0\&.;/B]BX:+W8,*9CQ2*N60D,@,Z
M>0V"$@8^ZI(@1ZN<TXGD9+HH%+>'6;Z<GY<+/TNS9O(NK6*/%^_<9%J)K403
M30DXWE[1VXOXOY>KI>H2J+S.O[KW;^:+>N4OELO%Q%^V=/CK_(U;E)=T-?T=
M3[ Z"=?'#!RA.A"HHDH5E1)**1Y*-NRR2B"\I6"=*?]10E.J,I6ZDQ.LAJ%2
M?$PX'H-U$MZ/0H50'0A43TRH#C;>Q65FA2XIEP\>1/EL\$E$(-PY0CUW.L@N
MJL.]D<('UIO'W&#S\5!JS=A\W#59W/)4;$,><'QRG(M4N)1]BL&*D\0ZD50)
M48PH>7OVX!0-P&(0R98$W#O?177YGCAE$X/LHRE9*6S;PK:M@]L5M:Z?N$6M
M.T6M"])29CB%:%C1.AT3V,@U>)6L]R'XZ+;:MG:I43^AUE%FQ\+V['C)X^0,
MU#K4NB'B%K7N%+7.6*.*RF7PPC$0*O&B8#H!-8E3$J41OI-!%D^H=<S2L5#8
ML#R<(O+C&Y:/H-ZYEPD6HXNT*-Y[?EX<OCESBS0>>==,PLC-XBA.II?+%+&\
MC&%(?R@%PY!3#$-L(M&X(,'%1$I(84CYB7E(5H<L''7&T2[*RZ]<>XG-F[1X
M6^GPNTJ&MP.0\F.*;Y=NF9K7^<5Y6A00?3^?3MVB:=]R%9Z0F^$)>VAT\I$P
MK,1-1E@-10D]"&(5>)LUL,0\$X(9I[=Z ;JX_^]7$O"D%A#/Y'W!&49K6)G
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MY67#7B]6Y/7SY;E/B]>Y#16:U]?<M1UKK?CM9A!!=HJ>A!">V<!!4F9 ,.7
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MI-\F3>&T%*\ZNMIE]-%D5GU[EE:4\/MD>3::3@K_-6GD?END=%X^K1_\C"'
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M9,I?5 8N7 3A@ZF#Z3W$8)R5FF3C\];(N?;PJ->7RV;I9M7ZCSY:RM"Q*A&
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MFC?-SVGY.O_JWK^9+^J5O5@N%Q-_N71^FGZ=OW&+<OT=%:JUQ"KU@'T496!
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M'NQ34\F/NP:+[.K]X:0%D%'ST9U]F:1<K^#BG7H)[W&Q,-A1<=L?H.6GYIV
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MZ(FT576X+EZ7UM_;9V3)HI+K&PR"2P22@6/MGO6!BHU5<EKUZOD0]Z9$FP\
MC[UA4==)RW72>NQJ,M=)ZP5UTFKURQU>GP=&$1X5? B^>9J5O6.Y+T+W/%ZS
MJ"F)D&V;T58'8[;K9H5P@=.V\%AX!N#7JOQLJM4Q3+FN.YSV0)V030$M*BY;
M ]OO*2SOE263U$U0CU&V.!@L3>LG&RA,J \4JC%IQ[=H:D(Q>](^G5%C3% 9
M3BANK:]N?(I>K>96.1R=U9:2_G.MKNRGF/];*5NJ;T.R@,,E*#6V9O;2UO:W
M=K<TT655F.+$-HNA'FB>6_E3&]Z[^ZW/S(]3%J8Q"2-D-LDTP8](%@9Q' @I
M97(0ZQ,S7"X7:B/1Y5=X"E@+D,CN[ZWWRSF][N?"=_=D9E7=#IL#7JL]BEO4
MM$49[Y*5 K7)FI776MJV&-9GCGTRX*)W;:5O_[&Q-N9S,(&NKN=W( BP\PI(
ML"Y5RYJ/'+;_IFE#<8-]S&SZ#&;8:-UF)I45"#GL:+8:Y2<MUR#B0(!=>+^.
M7R$:;S905MMTFY7I0-&T(U(F$VH.PDC;9@@@=)4I:Z_7:'S6;8+>'?9!0)VJ
M-7P73=N#KEW#9LZ*$<5=^4S?4N/B:![W2(0LDCP@/-.2,"8CPJ52)(HSSGB6
MI+G6!\G5@#>OUEC%LEL,_886Z4/#P ]9]*M37WXSJ;_SN05]FRF*J <J#?KJ
M[\LMK;;)WSI2D%"+W>E5(Q=WXU?VZFNM;>(;GK(J5Z8'EHW!-3Z9^KK\O.@T
MD>%%!IH.,E6?V/RM.;I<U[#6^KLWXS0D^]__TV3&C@PJ,\716$QCFQW-#3R<
M@"5>KIM#[)92W[_P_](>;WA_6>LWM75MZ98:;-]]<]XW_2*&4S&QCYE-^GK3
M7F5TZ'"V@+UUE%RD<?B7H<W5O%QK=/WUWK/I19#21Y_\Z!/]"S 8_/Z_$RS!
M/?B+?O!NY.P6BS6^BQ0DZ-Z!=3O%[[U3:K=6._*A%(L'3IK=#3[I25PD3YU]
M]+5;LG^ZR<O<%2 Y_/X_OJ%@QSUUBW8\SQ&W[, -W!^TI\-JE2/3VQ0V\\@4
MZ.3CA"2!DX_WRL?@Z>)Q/!_+O\#Q6,:$Z&:T38'GCRM L<+OR(1XSS9W0\BF
ML-'GP-2O99\<FQ^<S4/'YH[-)[9/CLT/SN:!8_-)F$K&&[]WTNO3S**'#"?^
M*EOI&><Y/_&][(T,/H[LGS;F>5+)2T='KZ>,(CXYV3U\BW:/$3\R);V:N=\B
M"J(L#BB)TU 1)F)%,A4SHE46<!$'82BS0[5IV8X,7Z[>\:K"LIK_S>=K?:@Q
MX"F=9?'^'BTOFLV>7_8X.?VB",C)Z2G*Z2P7<9C2@&C*4^Q&BUU .252YCZG
M5,LLV)+3E&6)3[DF-/$Y81GWX9PL)3K0/J4JB75T4CG-PFB69OO[S[YH-G-R
MVLEI)Z=?G)SVM>2Q3E$ZQP%A/B8RIA$G(I%1D''L^YQO#>((9<C2A,$YDA(6
MZ)B(3(<DR*)4:-]73-.3ZM-A,$N</GTJ%U4;SG<NJL<QZJ_[<_@=D$X-2+\<
M-3AK&7 \$ONJ<,O+QF E-1@W@,$TE3@Q 3L-\3 @,4^2(.)Y+/E64=;C>J,/
MRZ]^*6W/^7M&JWT=[*8SRM@$0/<A$2;'E$[N.[GOY/Y)Y7XBLYCR7)$H!XN+
MX6A#3EE.,L%"RC,5Z80?PD=V=+F?T,S)_7-F2B?WG=QW<O_9Y'[.?25\G_!
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MC"&74:XAGF.3]*S5:A8KC*&H0?>T,7D]GV/^7O<JT (T+KR*+VJP[X" ^T?
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M-5/J93=< '/US-A)^Y*&X-B!;(V!Z<[5,C@>/1RV,Z2=^\B;;1YY/<"J N
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MQGVYCSNP_*X5<R._U4B'FS7CC>N5YJH1E'FS-[SNFR0UXM(TO\-?[YIF\Z[
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MS],,P>K[*-B#N]**(:%9K:XQG;J<R ?3GM7Y3%']_KE:ED#WY9 ^9-MF;5+
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M(RTCQ'R58N*WA7W+J]X.W+Y6L>?:\%K&Q.4TE.V,8M#F(V,GK7<\RT9>:C7
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M= ;M.O;?-C9I_>+>&2[)JWX>2Z/#]5NK21.K#-V::;RN[^LR]DK_WK2Q^5#
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MR)FG*B+K+4:<Y\,=<PY111A.6/(4)& T8/20B (8#1@]?(RN;7/I2^ S "D
M*0 I *E!\]DPLN!A#_!9LN!G5U=Q7CO57]OK. >% PKGA*P5T#/ 7H!-@$U#
M9![ )F OP"; IB$R#V 3L!=@$V#3$)D'L G8"[ )L&F(S /8!.PUL";6T-WG
M8&W3H>G=T.('RD.A//1LZ 0"!XP$ @<"!P)W:HP$= *! X$#@1L<G4#@@)%
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M0!,O""U3U[G,:B!HCPS3"K%$HM":\63W9Z\]L0:@VEP(J4 #@ 8 #0 : #3
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MD5&9()*B+2B-D5;"(T(9D50*XLU> 2  -  T /3 Z00 _0+K\P"DAD$4 "D
M*0"IX? 9@!2 %(#428+4':XNMSQ(RE#V=P7B2AFDF4@H2<JIUS8D$W==716U
MD58I1)F*V=4U%%G* V*>.2X#LS0X<'5/&Z"/-G( =@0?<4?PZ_G,AM'WTV8Q
M7BP7$;0Q:.,3,N5>C!)FUD:K0@DP)XZXC1$9YC"*7ICD F-8[8T=P%%Z(A1'
M@9K2=%H39*RCB$0KG>51,[HW^_>9E3"_$*"$ARE:@,N#I=/PF>?%X'+D5LFH
M')(R^HS+,CLZB4>DL2%&&!LQVVL%;3AS+H6 B+ .<>X3TH9;A*WB0DD=A&6
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MDPSVWN2?8D#8J_PY$X[MC]]V,5&N'468E:04$D*V\:U$)NBHE(I2,0![ 'L
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MR6'PY*"3XEI& T:14H^+1C N"V#"L$B]XUK;V^3 :(K4&@9.:W0AJ.=@C3#
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M&[M)2(V;]]9(6$TQ&T"2WDNKA_=OP]&Z801$/$<>M#3:>\9 1UZB.#D%&V(
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M13-9#4@=SJKP)P)2>;5$#M 2&8K\ZJ;Q$,V)N\E>.QL58PFX#!&$$Z04C0U
M>?+.$.E][K5=RL)HF[0"X0G^$-Z5#K,,C$JZ-)BE4?8:\PQZT_B$Z_M[,;W
M"7P0CL)0A%79HK+%2V$+D[63PAK(43L0FEGPRD<P2 F26T,Y,SW7T/.<J<AX
MD+<@&'7@.-6@J<LJ!<F\<P?&%O+^WFXO< )7MJAL4=FBLD6?+8A-R5@*Q8D
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M+1/,)$ZI&,H&!B$G5-<-C$%.LHK0@Y73\)7GQ2 T(3H%BQ@;B*$@-)5@DN1
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MK/#MF9L7,<^6'#WIC!,4MALW ?'A7<?U91A6ET("_Z,;RTFG[:-Y[UDZINX
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MD]_A*MN+07R"^,YIRL"T]2!(2F H(Z"XR$QJ(W5^4A[Z'A!?ZRUTT:V3L&[
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M!H\1NU O9%EB0/_2DCZ$VE]ZX(;_]/587]^1^ >WL%^) 7;VV@?1S[;7RQ_
M7;I9R-MW^.T@QG^1%$N_V"I)'#[X^Q:VP=W6Z_8_): I?J@1X-]Y3@3YVX41
M:Y(%7T\=_'\>M-&Q]_0#&1.'[=3"ARQ%S5A735% 1=UBB1XY 1]V76'J];^
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M2PN]%TPE_"*]7J'S#B/OB(+9M978A!2.F*Y*S7VDO5.CT>$A7QM<\UQSR,_
MZ:)6I)IJ PX4CK;.94IRGC"24"X3(_),I ,< ^%$+)1P)(IB<-1T K_)!25Y
MJAR7,DX2X>XPF<*HH9^VAQ&5'NE\G8OOU4^/V(75FXXV\A'PBOU ,K:QJGUB
MIFO A,*CLMP>* <<%\-E8**DL>'$9#RIF(=1L+R9C. ?E@H:[3)<Q'BJLX@1
M11EZ^8DA*H]SPJTQU%H9Y3O5Z7\@73YZD@1U$C3&'YZF?6[\:UTRU>/&0/TN
M&W[\]<-]?)CQN6 C]^8>P598 F@WFX6W LI.;=FJ2L?2R!=XTCY?8V4?J-A&
M- ZL+'CV]L8'J)8SK#A!(H$U< ;",C<V=C;5X!Q&V%FA%/"A CX$1S&F5*=F
M&+B4S"0N=^!5IH+!E<:17(&3F><)2Z6A2K-^L.%]0Y)GB<W[^36/SD5NGFPZ
M<)K:5"0F)M)O(Q49 97'B)52B)1GF8L&>(*/[G%N1P,?D#Q_8E[VH?W.#UGR
MB_4[OZ2GUR;7JZFVVVM8OR^,W2?J=BV^?NEL+;R^\S[*:EN"CBV_?WTC=-/L
M@C]U@F[R;0?HLHMO/+'W=;W@>&8"/W@@\&N<9_LP@AS&=7F--+EOQN]Q!_R.
M893L:6?Y=ONP_A^U_M=_>Q)*V;'G^HZ![N,_WV^#2M.)/_V)?_QDA>G$GP6<
M^/- .U\<O_"9.W(@K-3Z;T]A^^<A'HZJP^G$BNPYF(0OSGH/)]#CH3.?S46O
M$/YR?Q35)FF>4,P<)903GHN4J(PS(ET<,ZU$'+O!\"\113Q+L+HOR37\)LV)
MX!$E.;,1QE$3H.=NM<)/#2S2!UFLL4['_N;:#_<'_I\.I1W/\^AP//45G[%O
M+78F ?V*F&<2T.,3T"X362SS!&<R,L(-_*7BG),LXS1C(':%&)11BLBH2(!8
MSB,I"7<B(S)FDB0LUW&>QX9R_<(".IFS24!_(W3EHV;I<I8(EAA)9)Y%A,M,
M C\BK)2TN>:IRK-TT!CPC"S=CQX]\>.RPY3'2-P]Y"VFQ-TP<5>A-F(+,E98
MPV6^->$1.)=O/,>79!>"LJ<FP=@WSKI%%SE_ZF+/YQVS:'K'YSUR//G,,#7A
M%)-;SCNM-]'J"0D1+'X\%>'&$(\_;1[D_WADS)\],F8O)_(2?#H&<K]D^N/,
M1/"KWZY)*!\Y2_U(NCU_:.<KE=K/&*)W^OF28R#_)!8FL3!&OCRY6'A\#<LD
M%B:Q,(F%5RX6V"061NKSG:CD;1I5O6^G?FS2'_W4Q_%+Y*:)U<?1FO<GCL^*
M?T]9KG&:(_\*:SB^>T[+[G/*^*2+K%,Y<3SEA'.CB&!Y2H2USLA<&\4'6?F4
MQ91G1A"FG28<80"DR23ABK,8?B649H>K1/Z7+)9_797E;\OVLU_MYDCE(70>
M'Z,\Y(T?].]'<M GQ7)>Q)L4RZ18*L4B5<IC)C)BA#6$IY81$2E+9"9RJ=,\
M$E&\JU@T-[%R-B-Q;$$9)9PBBJPDD8[3).8L$92_E&*)YV)2+)-BF13+6?';
MI%A>G6*A5(,N4(9(<$((UQRQHB-%%'@K7"J6V'B@6&1N<ZYE2FP>@V*12A!I
M54*$ 9\E<BS-9/IB'@N;1Y-F.9UF>42]^YAKMD\^7.0W/WMEU*-%GHDM=Z Q
MP26IXSB/(A:Y0;QQ$"W8SI@X)W*7"BXXWQ4H1D6Y8W%"9"0<8C5S^$VN29+G
M(LH43S)'7Q'N<CL$[$;>-I%I/R%VB<-TZ]%3USBMUR[]?"]GPRS8HJ[U7ZR^
MP!$BUX69.1SRXHK+[3J TL-7L[+X6G^$HUQN[!+E48T$CI)U:>3:(_?VH0H]
M*'1Y@Y.*L,"_'E)4Q\M7;G<@VLT:J*RWFWJ00G?5>E7Z26456*QJW[8S_'=G
M,!;.<UE570[^ =6XF1UL8UCG*@Q$;TG90BA> HDO/1#S68SY$+'A3#A&'"*6
M<QEG.,DE(92RC#'*$A7K 0!HS*50C)'4)?";S.9$:>D(W"F2(M6QU/TQ'^]K
MHOQ2+&RY@54&^,0C0<YFR45^%M")LS"4S&-Q=Z?E(?/N@^2^KLE5>J3SFH,_
M5;=HJ F,^[$'(8K0H3<+ZX=XUWTY>'Y6..-N4<.I>TAQ'#)W'PBYY_]E<_RJ
MRYO5M6"BS0!O.'@X[@[G"_2/%"JG,*@;)[Z5AT:^;7;E0@L6C\<MR)GE)8@)
M4UP6FVJ0(LXV "HO[2;<?2!?;&=&5?TV<-LP]*\:>.Y<:3=E):^PTZFYM1]X
MAR+*ZDT8Z3- 6,?1B+-+D(I +>3P]>U@:[J#W N<%C68,XFC,7MC)O<\Z"&S
MVOP2 V9\&(]7SXW?&:%9XKQ*4LVB[ Z3AUU<(<J^W_T#H[X\)C_Z0C+PF)^E
MV!LW-^^K#US %;QS;P,;[6%66]5^.% ?'N*^J"'N_;,ZZY7MF#I8Y%?4#150
MN.\_JY?8/7H'H'?W#/;<A,?AW(&+%K#]?E#YQQDV;Q0('L]I98/LV!ZE%Q;
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M-^_\]>OX2;%,BF52+$>HM(YSDV=^AG<<@W:A$<EQFG?B$A:G&=.I,(-"/F5
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MT0=L!9ZTIO/0Z_+ZATJ6N[.BRHW7M]5TJ=I( %$)N^,[!H-A\3[<H!GGC-:
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MZ51YBGYOX&SC+8R\+6=?UL4&7@W(LX%GMJ2MTN([C'ZW9P@635<2#&(;!X7
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MX5A3J9:]'4^<A&:J1O V#G;5AUA%QFJUKA?%$LO*!@X\J(["QRO@UAAHNZ?
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M(OYQ!=*L[$79RNJCQX37V#R*^%Q0.NX06WBU0\A#:'^O<)'(;\!Z@1N#3.Q
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MW%I'Z",<!C!($;_A#% ;PARML\%M\/)<(DQI "@W53ION]R=[E<!REUO?9%
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MEQH^37<&W-64  U1\W>367LQ\3$#L.XV934E01,._H2#/SH<?#'AX$\X^!U
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M_O"D>^'Z.U#[!U95#5Z&0TS"*:Y3!@&/HD$*V!W4/1D+8WAQ/"FE#2"209@
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MJ?.X:/H.NU,/62Z5H*MC$L-?[N_(?=* H=K"F%<3DQYKL5W,ZDE\1<^"V7O
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M+/L"=*/X]B3TL(CQNIOX>&/:E'1YTTQS>5M;_&);JDB41?MZU/:3E(V0AUP
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M#.8V(94\19R #>P$@5VM:926<"/<)\K4GJ9I&0^IV1T\T#*C=CX$"9+"6TW
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M\"N=02: 5RI]P(9;C#4_&B#SN/""QYK=SA74C]U<X:7"2Z\$LL)+A9>SERV
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M+9'"3"*.G0.\U08IZ8PBUB1)TE#DX.QXJRO>5KRM>%OQ]N%ZUNNDDR(8)9Q
MSSK!D'8Z(1F4)]IH894^1ZO# /&6/X6>?2J\E=;S%$1 00/H<@YR8%0*2 D
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M4Q@..RKO3)DU,=9&CKGN!>E.S:Q5,*I@]$(8WRHJ?0Z5J%/21>V0,3Q34MN
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M0Y.ZNGZUP_GY=#C_M:M>JZ7^0ROU[\OZ[8OCW1?NG^M4YPONZ]\]I#KT =T
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M#UD'?9#44V^LD!QYGSCB(@CDC"# QL(18J61P?Y&WDW8\D\&L2MNN<[E^/!
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MAD4;J)"GR5F<G@!G'=&"X<YYQ:A&6(,B<*$C,D'GUK/$2FDQ9N*.3+L84LX
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M[0+UFIN^5%R])%V7E[>OZCC?%Q]_"O!)3[R7/4G&<O8ED.VPCI5G4E*<Y7Z
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M8T:M[K3,/_7XYSSR@7@U];8ZUK1;Q<,S,VD=0XC[QV3 IWV;-[P=2 03A\Z
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M2P8P\  ,DG+HO<E8/&I58>0B]K<WD1^\!G[NAD]!%D*J!LX.K)*/29SO!*8
M()^9&QMF"ZZB?,LTM-*#.E5[]CTF2ZY2I_Y25K%GZR_290(B;W$[@4G@)KIP
M=T'FAC>1E\">AB^29(]7D'H*BNJ4ZBTL<Q"8IK%9?9ZH]N<ZC%TY^IU8QG2
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MT@0\Y5:Y@2QD;OB$DGH4=>=JIO/ -" 'XF?V#*S69]Y+@%XU*8A[4IA5E_2
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M N!EH![RS_/L+L[^CK)[-Y#"&7:M;M&*!/G@1-F]"CDDTXSHZTV'AWV'60-
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M.S.T9Q)3;B&ZX?XECN3!<HTB"U%"-9*"=5)(-6O9XQ+Q^^4'80ZW8GDHKKY
M]!7RJ7UTN\OY;JF'--UJ\M$8(V\/'SIW 78>@7[+1]NH<'@$'O-O+MRV)(T0
M XR2S$-?*C.HF&2>X?T431HJ]O9UP9&!%O(F8OI*V3:5E+:N+3,!EWV#[_IH
M Z_>'.#<8FNF-1H4NY)<GD2H #CL5LU%:T&;49=X>GVB0 Z><Q)"C(\(.SO)
M)S?S7KB_'/\=)1X),B,_2I9M/-U)X_.IY'K9,-(HBYI&:'(S EA=Z),CGWC?
MK]8B%R1[Q0:1L \LQP 8LKU"P2XI;+_S';&O9<7MV=.$4P9;@_H"RJQG[84G
M\F\1C"@01<TR;T(<-@WE*'W76^*YQU R?;TTC=&?=^LD+G*GMEXTVDJ+ 6"M
MXJ;B.Q'+JO^FR/KDQI$Q+WW)+" ^LH$.4.4E>L8^]J-F/_2YZDFNMGII*EF\
ML)6^2NHP]$YU[;]%Q=NH1#B0%K?Y%G%%5YOB@>K*/N^(:HAIQ^0/56]*%CW#
M,Q<88JY%4.Y!26%[EP.>OK,PC(DMF%H;E/V7E[>G&N.I'&+&%D@C(F1:LNX$
M9D[)H;$^]JD^L\<WX<D"*M)#T)_"Y;M1=!; P\*:)G"/;6DD!Y&PF((I05Y6
MH!+3I"PH#?S<#9E!E'SGMZ5X&4C$LJN=A%.I!<H]O<5*Q[ON5$R['ZC9:'KY
M-%*GM/)NX^DM"#1/R?M(BYL6_43]<GGNB=J(YUNK.W3VJ+@ B6BDI:1;1BPC
MC=B,T2PR7M-UQ6R!3"J6%%XNIJTN^S%'C+6:@KE?)^QC6:AQ68@ZY',4/Z<H
M>86]3=*&5/U!9+KA29M:,D DR.S)*WG!B-.=&Z9-=T&YQ<(,>9NB-1A0* ,*
M.:FHCS=\DHO0TAHSR0)G.6XP3JZ#9'M3-Y@U?Y\UBO93$ 7;O#T(M/F[Q657
MYQ^2E[/G1L=-\_@XX<M8<O6'I''RVI<F7WJUDXRNNNO/="M3\(T<^I\%$Y?X
MY J'\"[UI@KK$[P1!":&!P9WB^CK2N.K\'!@$--"V/ ,C@XMC4Z )R8&_6KR
M G>K,R]&0B%YB"F-RCCNYK<(W;E;U&*X'DUNN9R_C.?F47P%CAH):7AZ<2/&
MC=_%=)!U+OPCN)-!5'3!G Z5!^;HVH+ 5<@H(+L85</06T!N]NE4>R'FQEI&
M:&86)NO-..].!L@.9);F\Z=DV-1U9H7R^QL*P_^.XK?H$4]T'.$'":QK<@A.
M67F+\\]C&=.GF(NVJ +.]Q3#LXE9DM? 1_[Y'N\C7S"6E,G[=$">4S1EV>!<
M..#?,F:Y@]595F?QIH [S) \O:'P%7V*H^Q%=LD.)F?OUH5'@%[]Y5,@NUI;
MRR[!KJ%U/C)*VG;F(^5!JY:9+ Z3F[I%*_=5F@5;P)W%=]<Z#V^#=0?(Q[$D
M)P6Q%,2H.O_4-I;NE4V[3@;Q/=[068:Z0P!IZ\P+#%QJHG1!2ATK+8A/E\>G
MESM&JXP>379Y8*7EH1;"/5=KB/]DP:#XJ%]%6&1KC70V3]_T90)KP9]]19QS
M2S%[BBX:+"  F_7(@MNQ\LQ*'12Y21!_CM(=\H)U@'PY\*6T[*Q=?@HR>!!O
M\$7V2KQG />48+J#KN(EV#W%] *4#J0OA<G]TRJ>4-23H<4%H&=E>_!*F#;8
M!@@J;WF5W ;2_'*J&DLP$ZG4;HUB%CM<;(17)/H!T)0EGN1GP<].:R$RVH1I
MV8@[#A8 B'*3D+2L5;S59H;Z0K%:PH[+5J9S?=.6+HIE*T*;0H+031X"B?W9
M;I?$KQ+%W0 "BSM=-*00H!CR9!=+-:^=JUL->FM!(X:[62E3Z^LM1&NN0U:7
ME;;O^72^9UY(!,P[(1C^GBHBM$O-)?A)-F2TGL%B6@++<;XJ=U><IB*,9&?_
M*@4%JTQ2D'$6H+@*%.@9JAKF,Y;L\@PEA<@+ .3Q.L-SILCFU:&6M>FN&6 I
M?LYJ?0ENP,CO"F#3EXJ]FR+84'05P$NO2,UPTG6W1+?*"[@&F5:Z2.1U$^&#
MO26OZ/F>_=@C>6@O:A8#_'R$MG!;2^,2-3%_7>M;'&(K\G_)_'$8ZJ?X'B6P
M2M=Q0O1=Z?D>^"?%"V^&]J),BP\H0F\TOU@/"Z)8:U'#:3-MCK2,+D_Z82":
MD;]Z#H,-5:#UE(!:21@UKWA[GXX1?RB'AO_XY6*/+XB4FC3WX,7]R8U<IK-X
M"1*:(_(JVN#O_.O0K3^H@T@LC7EHO/<:=XW>9.S)3VVY_F024VM9PPRI,OF@
M3/?6I^:L5LG'K1N&W M7:H:LEK+M'=#&%>F4GIVJVK^P& P'2O%##P)CFD)?
MJ1_TGN99(X7QQR?<MIM).>@)&S(NX;7JGL"*R=-M54*YY#+? #IVD7=9$ESJ
ME7,79Q2V\7&'NUCB=SS ,*1I8_N2L3;@SX]/"5%C">Y'2N% 4<'P#JSB3_$H
M9))OB:::489X]*AM49.5!*^$:>L2$]A6UJ8 EB6YEQ$D:1:,J+OMU74,[YZ?
MW.353?SN?DGJ"O;$ Q(&>>UZA"]1B*TM!<TK_?",>&1: !$[2;-[P M@\!HW
M40&<CPOLZ7^5RL"AU$S#_J(DV9]%T3EXEH8*>UI[P65='QH10UUGFAO\&J'2
M>0)0L(C^L,Q\KKB^M55MJN>+2"#BX$(]=37!9WUK6QO>'<K:X@(*D)W.(0@#
M"!U>"!J+YA)$]"E0)PRU;C/5$M@* ,V8!(]VR9Y4>E<PS!_=R3+<R!(LU,1&
M>1&Z:=K-+ETK/R4\69U;HJHJSFVW/_O=JUL4 R%O;N3?0CZ-OV)^-?4#3XLU
MJ*ME?R^U>2PH/5"ZU%R.(T !LP5("F^@U>OJ -!2TYZ3)]KN\/E(]B(^O][T
MK*UF-]8+WK0$O8#_*4\L!<X6F#U8K0E >4+32E' ;^)J$M^[NJBP$53MGT:"
M;93>@HWQ1^7%HJJQ$ ^P&L?Q@.!JX#^"PD6F*NM-QMZCD#^GY.;+KEY)1*W.
M;T!:WO"+W,3U%L+-V]Y@=07C_$("]U*&ZE&.*M6 NHKA'I8>L?(N-<HLP"H1
M,^R254(]OR!OT@-*=S'U\>]O5>U$<2GB@QH/7E+X\$1+@Q B#YCUOJ9^C:9%
MT(EZ:?B@<W$#G"/; )(%;DF(/8&L2"PA$.YPV^5@A*YU-IHG-B6** WC7"UK
M3PG'\N<*7HBX5UZP(X(_^^H1IAY\>3_O?+S1;K80V)T$;DCSG,HT="9(V_.:
M:LFAK@UTT52: G/N,0Y;LI'>H3<"TM+JK]&IWA0!M06G2N4,AN,C47]VKF;Q
M1<(\'[#4A+=N26FD*&AZ*[3FO%:RB+HJAGOXU_@ENGIUH_3B)4#KJR^8?0(;
M"KX&\=6?R+O9J5Y;7X&&\V4;XD_1YB_?H.CT\^,WE>[C_1[GB5R;7$#>< OK
M+^%SD=@QB4-$]Q#>0F]O;]^3;00[Z,,//_SX#GY^1PA^\U\%(><?0,HAM/Z_
M_WQ7-KK,[F? Y=[:&$,E%YB H<AL6A4_& :G57(%8X;)VW2\LE$GIZWB[X1F
MG1UNUPDB*(E;=E)H^JN8#Y]EZ:"R['\]O2#'Y2&ICDM"49UXW38;6>R ]QE*
MZ&PP]QT'O_!.3)A8_DUMVDX<-\44$D+7=9Y;%N'$000\'K\"SHZA[#L[L,8X
M;@G1]?U7L0!A;2\*[3FL0>>B=2_21IW'*?=B-UZ'O\X#QRX0/W& O$/H.V4#
MSC]X$Y/?I-.,5+QVA!:F&DRKXN(\!N/GFJ9_B9-T17SJL'19:-H&KE^E)0>:
M<DA;<,"+UIRB.><?T*!#6ISV4<$BR!9]0G[@P:L8>92!&'E%$J+.EE%U,-EI
M+R(S@V!+13O_2>B\\P]*\!!60CQ%S9%,?3, ;A'@_E([WM %P$0<H.+\@]*9
M_$(;U^W*E/.^S_WP2IRBB_ #$!(]4))Y6&QX)9PKI',:,]8"CL,)R^L:\R#Q
M/TE+SA[3)PQ,V>17.BLM'"(9/.9 WEX"[T6< B=(,>M&FP4&\1DS;!G-B C,
M(K"1K,LUCI)/\M[9\HF?G[^;:4)5'%_9A1K35W3"X;UPA&XXT(^I+Y*&&8Q_
M034U Z>!$W$P68?2/7&*+RGI QN9>(\4(TDHIM140RG#G,Y\/P%53YQF;OA_
M@MU%[ ]=&TK0811/'$K3P40=H'H88Q%7P]* ^#YKN7.8"VO?06%>^CDNAJ6]
M-284-<R/37$_I@XEZ?R#_3N#)*$8X. L'R4NL_ ;47\;G*P3I^R?(W:07;,.
M[R+1V0@=<5@O3YRRGTY%2"==_8U-^)_HA$=$->:SDT=(5%A$ES8XOV1?N""L
MDL?\V>-_B?X(<3*]S%]TP\'\GM@11^@)80;G50@4?G^)"WK%"J#X!4J 264_
ML1QR(R<(4,N=LI43AU$_(:>-.@!4?K_^^?3N!D\%.:%?TX14+ OY=NLF>V>U
MIG<(8_"<;YF=[SOX(B<,TV6.IR%VJ&$YQ=^+JD%<O_!Z:DZF [X"DTH/S;B@
M_2B]3$E/X/1GT<P8&TE-3A1&5 AWTTITQD92Y=^;"S/UB2STSNQAJSQH+5E
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M.\4$3]D0IO4_']UW\1XX>_KD<.SN9?>ZJB2M3/CDK%0M*S41<<OK>,S\4Q4
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MWWV'?HXV010=].A%;Z?.XY[%]\G\6,->PSR\\544ZL*(?$KN@ ;4CH<R_Y
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MB[7:P='ZQ8R'60,*9GX-UASA^FF @?RJ!&(F2&RHQ.:HRWX6]5WWD*I_625
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M2DH9'/]56#FF37>O3/T7Z-(A;%5^F>2US_UMC-XS9)Y94.RB7)W*37A>9!-
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MSR2Q%DY 5:Y7A+FS>]HD<3HDJ%73O*='.4QO>W"0.CJOS,X[_HC ?'(;I(C
M00LX\^==EK=5K3(+]CT*24HTXNB=[&R>0?P7*><BQ.Z#X7..\RCQ8Q5QDH6Y
MJ@H"\\#\W*:8ATR)M+JV(DIZV2B07@K/V>R3D$"WK(JB^GH"210N%V58JMN
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MJMX ,X9;L9"2<;'\5]!=KR%$.CFT3>I'W@8.38T^C7*!2+E,EW(;^@8M>EK
MW(P%%]UL8*F$A2>SEF4^(20N/9;0OM('E4K'EBFYD%DBI4X"RNX4;.A;NQ-;
MV/=K+'"%^XA4:NUM\$<$MO=5NJSG79:W53UO6][0%%\6R>.^7JNSRULF)3)+
M) .9TT#B9) > HX.,A9XPZ2$2=7FK$]=M&^0T<AF1KC;%1'E3Q*DXV.4"KC5
M*VZF.E8CSCP&SN'<5\A-S\L.* 36LF![WW/YK1G ,[@6IQ%B .$0V]?AH#Y^
MW.A_Z<2-LY=(4M5K*',9*>L3-6PGE6@E80^R /CDDMS&Y<"*<YT( ,]I.#+\
M[ *WN:?0WJWLI.--\*,$1:#V&6/H_:1IZ (&WA^B!$D:=4=[( IOUCQQWF*S
M5/A-]5#DC[3Q&$:@]JFNNL<G\=]$?A,<^3(LA1'PVIFC?R$N-G'-J_FR$/L<
M*DPINLK6D I =0;PL9V?^"'K.'IT<O%K<3?$G&$A7GX$7R^K>B5NGA7MCP)7
MNDG%('((M9>/O/[A^!>7LC)D"%JOKR@<19I@B6?G'70*(#\P$::*H;1U#O2,
M5),.Q'Y>+9PT"9/ 2>IT R;2B(WRI$Y9HR!Y$.,T:(HR&VZ.)-5PB]5?&^2I
M5=HP"]QL11N7PM;(\J(#*\3DFE'Q'\^H.' EC#_<#1;+BZ0&ZO]&S!".;XZ7
MS'W7OJ7;2G1C2KLJGM3ZL8Q+C@"6$,W1C-$HWN54.7:Z/5^2CY@[<Y6Z<X5?
M%K\KQ=Z..4ABOZ0_#)Z,*P^<6PX;/<\(_-@LETKZ =DM P-U^INK0SSL<J<X
ML5B\5:>( ?Q[LX.\$R%0.WC7X?MPCX&A,,.'T2NRA@A=Q,<8?3\>/_P00G>
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M*U6+-@79,3:L\=%MIU,<#J)+3';'4RB&RWES^?PI]V,?:[0LN])D"CALY^P
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M_O$A%1K;X67;JO%GT@=FY1<F+N@V&KGU&%<;FL<G-2->ZH/+779=5BX@4.D
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MC-W]<*U;O$S2M9 HBF"BQKH8%]&B/XH5E6R<&0^K]*I_878CCY414VS</8=
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MN+ENZ",3"(?B*HF"1FG'KK;X<BH/17JV1-X]_"/N]\#?R7*9 A91Y+.2CR2
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M(_&65)DEFG,PW@=1L/2)@%?EO*ZNZ"\&0W/W]\)Y$+"[F2JO!!:C^CM7<YG
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MZZD(<(/%THC$[28H5DYM)["W** @0H/1K@M1-S1'0<ZAL:?S;9X!D#0]0+>
M#DJ?0G^T0%?MQU"P4H?>?[&3?^FY412]W5]!E9%DD3#A7O9;-A??KH=[HNI%
M!ZL]>0N58;UH0=)UBRR+/NX):^//)"_BE9LOS_U52'B4@N8QZ=?=N?S++96/
MY#4$ TB<J]*L56U07"%5K5YNQ;HGN9S&,U\6*,5<N5J':M25/89!0;["P*6)
M8E=:' X8QOTIE9,5(+CK%;*[DG17UJG4!3+:=D2QPHT8M@)<5=0^!7G5G$K5
MI[_[-6VZ$#I,*K9]4*QD$?7,:Q1SO)97K1U7W]K]*GTAZ2M)2X9KGT%%*Q0K
M4<%)=,K7F4[ ML \.W!P%*QJQID:[QIM8R0RSO6:;DDZP<]I\C5?P:)XL<9Q
MJVSJ_N0977?WI.T!Z^J 8Y.Q9)@O)%\E026)@8WQ[TD8YS_1OT &L,E5VW,(
M%&1_H:+&CJ-WW6SCP! BK6Z)@HA&\FSQ;'%_E61^  .PKZ*MUP H2*XY;8H2
M>,5!X]>''JW-NK/[RV;Q-5FLDFU&^?]$(&64D%C"X(?*<* +&LRJO4=P3W0C
M>PM,^B(1_X)JOS$]B3ED2BM=U#WZHMC("OP<<&B!D:("U"GD-V4@6[\14!"]
M7UZBV@"YSTCNM_A#FOB$!-D-_2=F.%U*8GK;:VMJC6)%U0XI0,&L(#1,LD.?
M_B@(EDJVJ<6>.Y,GU[XW"F+M;5.R9E46]&0^2(9I;S1G&6^WD3^-@LU3X$YS
M-(=!_5R]OXZ"V9(OA\NYYUMZ!E/ G-78\'3-49"CC89XSLARRRJ-]PJBJ+JA
M(*\(6>.ZLW+[UEJ@F+3\;(/_T&-Q]-).TJR(N1,*TLHSS[QKV1V8\S_IE6=#
M<^=VJ:O$YP&YL'/2#?A%(8GP$8)X(?-!:6[KU1'%BNUO";4![+K^1E(_S B+
MY][K=1GN\RC87<:-5A'?NB *35,49+ E>>D6"EZZ@U\:2_9((&.:_GL!;;;E
MH0<_:'?/M-- P?ZF-=\B++*CBWO5MQY^4FBQP',NIRNS2&PZH5BQSR2F^PH
MQ<Z#-=U8H+)"XH<V':A71Q0D*E2RJD#H;0#QY4MF4A5ARAP..JB'*S-=@1YG
M'M M"K^E9..%@:"X<)?PWRQUP_$G@F();M=T?JE(>$_BUSNH<,CG]S<2!3=)
M^JS.I+;JB(+$1S!6;XE84)8KUGWY=79"=OTUXR9*.;EPOFA+7NXW#(J5K8)#
MF%Y3/N=RX=K6:V[T/!XVHOL]<<=7,DEW+ U+X\E1MD*QHM*MDM*UV"29%[7N
M%XOCN\\X*!A0V7.E<_E&9/6&)^/XFI_EX&F+L):AON)^ZU/=.06SS17A_[V-
MK<$>]^GOGF!E]:?B2FHMO647%(= 5=A+'R=2;X>6 '@[;(F MNXWV,])^NLR
M27TJ!3$X'&W)=5U#%&MA*KTE%S!5WI.6?=VOU4\D?=,]]])O3B?J[X)?+G=T
M%IFH\_889K\^)O ,??%B3[PLJF>]7T\4VZX63P!.$7WFDZ(A"A+TY=GJI1A5
M5-GVQ4&HS])!@/\@$H;FZ$1]:Q3$=(4L2R%;F0 TM"@U>?BH[N_(9BJ7I-Q*
M7C'+/#!39Q3[H$1PLX-7-C1'04X;;]^(BZUM[7X;5MIW!4$5!_/E,O3)S3:-
M0PAN[M3<._NZ)[1(3Q+&DZ(8GH8T8VL46[  6 >]F/ZQ@H6- ^%YDR%B+5'-
M#QS3_2K78[P?1('3X!F*",HQ::T%M^WHGL2+-/$"\*G2XY7KCJ:J$9IM2[<3
M_ ?8^D:E,:KM,[$SA,@J]>^&H/<#QD/!D!* 26\?J[7 ,6F>,,@S" O9<V=A
M"K7JB()$?9'.O=![<!!70Z2I5V433]QMS"*ULC9&MUTW]^15T67/<<I@!4C*
MU ,0B]GM?@NQMC%AMJ&?PWS5]#.UK;$'#^F>+>I0 U%VCQ%7PH((=R,W+U&5
M6?([6D8P]!T6Q8D?$!''%,?U2#DFBI#O%5$V^"Q0,/\A%>BBUJ'+YA[N#YPU
M+"="Y,TZS#27C>6)JWY'L8V:\H4E<*9%-Q3DE:#V"^*OXO!?6\)//1QI.NTO
M24 B?2R6?6\4Q(+,WB77U_]!EO#9*]-VHT)Q#4KK]3>?Y=) ^@8O,Z!3+J:;
M 0JF-^,LC9GQFK8H"&FA58,U4?R;$%H; #8"N"93O\ ZC^D8WT'!0)OJ&TPU
MA<##Q(<X;]%.[80Y9#P4#!$U>FKQU/H*6_K6*(@IC0H2%G214FRV97?W0T'@
M[<-<_Q*6/Z*8:AG:PW?\79(I#Y"B&8KI"PV8!28PW:)X#[3JC:JQ>X&=7M_A
M:TQO\N1A256(5&-:53=S/_V_D^4R#4EV%_G@X\Y*91QB[^E_ ZHIU?Y=0]^>
MX^#8B@K'L*PC%VX=IC(61GZPU575HJIDW_W\T -]#@4[[TB>@U.$5\<PU5EM
MMT.BOSZM2!09\;CD%BBX+NH@/:3)DM"[)HF]"(H>FDI?&GN@(&H(D/^V_FIQ
M1B?Y,)+-3F7E(C_(Y]4##98;36,4NT6LE2GNJ=;"_>L+\UG3+1&4X:=Z\4'9
M$ 7?I3@B1?JNP0UKU1$%B;HB  Q2)9LOI7]3$=JC.Y)+0;P"I6T3-+AMIKX3
MU&U1K-L]R2N]IPSH7"12O)L(L=+B ?8< @79AZ:("Z</$&J9(JXO*SKM-%"P
MWYBC<K4E +AWDVS5Z""6?=T_7O7<(N ^./D%+CU8Z3JJ5_?L[YY@./$ADY0?
M&^6X%#^CV(C:P!)+#U>?_B@(?MJ^9(1*VG%^_=:5**MKBX(0$?8 P$?%%0<1
M(I?;+*=/46J?_FTY @JBVVXOU<R-E2-Z#N'^4GGR0Z%. 1K?-A*1LPQDH2/<
MV+ZK4S*S-"]<Y9])\IIZFQ75':.V$\38T+E<7"!<5?46;^B_M$1B33/W&^V!
MGOD4N+K6;*=F _=35N-=5I"5!?PK.%+!QI)$R>N.5<1)((FS ^BRD?8US1=1
MW+.*" 5*P].*JF\@ADG0JY;Q#9K>[G>0C?NXC$)5QZI*2;*M[3+L\#CV1H$6
M6Z4(IB&E9A.1ZI^>(%:0ZFG9\R8 WWN0; JH;>6..7!,!/LH"',O:\;GZM*
M#(W=DU)6/2[+2TG:)<M<>2)Y'G'GG1Z%>Y]14&SP>@2HMM*EHIG[M;OECPI]
MA2 8[#Q-5?J-N26*-;CT-O2(1$Q(#5C"'^"&@ADQN-CF]TG^#Y(_>*$:?-BR
M+PI">85BV:93A^E3FLTZ.[G?B%(AC7LJ,$$=#9[O1I<"[H4W8E>%H[,SBE6\
M:%>5T$$A:)JB((.*)]S7?NFEZ4[$\>NK:QN:.U?&+B$=FBKXETG0J@TJ_X:"
M[Y+X;W#'MUMAFWSE% _^N>4B?@<ABA[N[ZXBOB;C.>=I=D.W-/AO(..3&U(
M7;DCQ]NJMWMB]TX,HG^F'XBN"C@DL&1$N[MP'>;M*V/D3Z$X"")<1D9+%;8V
MC4&A5T?W.T5,LS <%G,4=Y'):&+=TSV1QG14>J(SHMO=UCW=$RE!(PK%6\9
M52>.=?CJ#A_2/5NX4YEA(&;GKU0G??5R4NJQYT' I#4OJIGN%%[+/49!0+R?
M)_1!DD3OQ5<ZY=W#]B4*?;I_"<2M:=Z\/IU1W-4V=KGS_(; ^D0L7 7P:&J-
M53?Y ,.ZWPGUW.OJ=;[^1O=PQL(5T_45R?PTW%@D;W</@&)':& 0>6(!/:MO
M5(*C<V5*-OUS'K[(@&]*]_%!(Z)@RCQ]]>+PWZ6;HZP#RCP:],&+<_97*3RO
MS.0QNM8'&=BYDLGRR1Y62:S)96[^CF)-50GN4G9_MZFSU04%6>?T>0W": NW
M;W6*KK]!7BP)>)##>K,MME4SR?3.5(!PJ+%1,.KSUH/B0 2LH@%9QV6@-LCE
M/WMP7;-2D@+W4<6/GD.X?])4!D5=$DT/FZ1Y"!2K7<F;8/*^C85Q7+G+U4U1
MD*%PN^]=O.26OBWQ*[RVH]=)D3[E_A ($&YV>S/%#&J8M,U7JE8H]L 56=*%
M"9B3(WS9,H@)>MC$*4R_>+F_*@)^B]])ZK.D8O:C:K4/'M3]NM:U:VYCN-JV
MPT\U[=P3<._EK!A)Z1J) Y8?-5_*HJ#RA=ZG/XK-7.I\ ELHW^D<1NJ6N(BP
MJ5:B:8N"$/EXPZ[A0<U*Y[*RI?LSI' K N2'J&L/H"$\.Z_*(VHBCQPPC'OR
M%;$DSQOZ>YR+ZZY]&W;U0+$QFQ#S=6!Y>H>G.8@EL CLRE/*=3W'0$%X94]N
M(>'4):T^Z?2]AD+!AGH*3&DY-WB)S3U0$-41\&C 5['IB(3$YJ.MA_31M45!
MB&2;5%F!N'GS><.L>,*@J7DV^PZ#@OQ'DGN@'Q0F'?W>5+=$0<2<<O0\BA(6
M7L'=4WHZM(U1D%+6\4J$0*)-0%/:,:U[NY=HNDJUF?SM/?HZMZ$7Z3!,I RY
MM072Q)NV=%T[]RNEQBHN7;^2K-RJ][Y/?Q3G\(H>'C\OJS?PXH$D"X.M%PFG
M/_NWH%6'<+\14!#-PVXU E8C WOQ-5&&OO4;POWF[E >^)79*NW7%D\/'@S%
M#F@C]NC%.EU;]VM:\U=4%PXS"!:UCS^U%L^J%XI5JA2^ QUW%K5EA_@""J8Q
MS8H$&4R9+S65B93V!'5+%$1T1IAF'3#W!9A]=AOS: T3V+UR9TPZ Q1,+P/]
MS AHS+;T'"<O&4G?8-NS$G/UV*@[DQ=^C.^@8* %UC,8/-(W]D:R8%HORMI1
MPQK_UB!CHV#49<+R?[BD#.51>?H)_$EC=- U=Z[VG&_I3)+T)DS7MS4G;.M'
MY] ,7\(X7&\5H "M'Y%L$D.92VTC%%,O TKH>:2WN^8MB:+$%^)$%9C WPJP
MX6?&2W3@3R 19HM*2@*>HJK7HLM$L>CDGC1%T+@L>Q50$Q8YV)8#H#@$0\;?
MB&(:$A#%V!$_[2^ZWT=LVG(I=X.[WJJ#\R>ITK_D(IH5L$C[7PFY]]:D&6-Q
MZ%@H#LS>:75%3G6)I\JRLA8K+Q:ZR'W"Z6WJ()\AP!-P-TJ1?"]5:()YH5@@
MA3D>"()RN-RVQ>\5C6_0IBL*,NM6398 -5\^9_S6%&$&; L(O:/;>]T]!@K"
M-8&S>NG3V,&Y:L)#?'XF4?3?<?(U?J(KD<3T(00?K0;T6],8R>H4F>79(BG,
M *0&VKM(X-FFHM%;&)#@8D<W7"#YS*K:U$;H\!&^@X*!?/YE^LV=4 VZ AHT
M'5"09.N&N:<2S^(KB=[(ER3.5\HK>M^Q4#""O2;\#:G>%.7%K&J(0+3=QZ-D
M#IL;<EP4:RP0,_7GM=; _9I6 GD1GB%'9EQG>;@&K'QZ>2ZWT5VX[(*1/G \
M]PS1!F\TI<,6Z=8]W1-Y$28/]*#E.;$$T>OJ@$2.DBR-QEQ+NQXH+I2V4J)'
M,*EVH-E/<>B8*!BC#2>K[A8I[7V^A#QXD11/;YSKF&J[;5")P0=W?];9*A:B
MD0Y2HMT&Q1J+S"()J939QBPR8.QZ(K"MD=A+P^0YSC;$#Y<A"31(W+J&SDE8
MA#D\][?TRGQC 64 [<Y*[(#U:!5N%@F_:M6$]>SN_CRI,.VEF$(>G=.,9>G7
M$\796]#1P2/%ZA94=]M=J*ZA;&B.@ASIH=<:49MMD$R\W"-O1(YMX57N?,W/
M4B2KV4DYY/CN3V<9R5LB(6N\DKJ&.-:<.[8:N.ZEH;VJ]Z)<4-O.[E=+ /7+
M .QQ\$A>M_3Z3]+=^6:3)F\JXV[_WCC657.8>%(UP/%LTTVBMM;;]D5"J++T
M CP2>M-(9R<4I&F,C]T.%AQE;EH!?A<[$=?'ZJ2DK :3KTV0M^B&@CPI:+BE
MVO;)8NWJC8+85MQAM?&2+),!H^W"%O7=49#+2KOEA8Q2WAHZ "5#<_<O( ]8
M)VEI8(#B+<DRI]S659_M[H)BE1KA AR4;;Z\@OA]$EA!H?4< @793^$KA^B"
M8C(UXP/<'<9+QZHG#B++^U&X,\IJL[<QO2K6[-V^V(D?+:_:7D.A8,,C"0A9
MPWN@3;DVY3!;=D9"JK)<4B6&7HIR&(OD@:2P<#=)RLR*V<4.)#B=0#'(P"A8
MI/)-/Y*8?.7%<&W=V5(7M&2I7.Z'N.M1$*I3L 2Z=!S,7Z+PE=LE^RAHJOY.
M"?9WP2^7.WJS9-RCOH,DC2]>[ G+SBI,>7'TZ_B5_EMP$WFUYWF?_BA66"-/
MM 0)4^11WS%0$*XL8ZU4[U0-W4O)QC+<2NMFCVY(?-=/:R^*BNAXM;.ZU@3%
MQC+(;,IEZ=,/\QTIH)%(1H41T)FS#(C@V0L[7OB7-:9_7*Q2XN5JT7^\K[@_
MLQIK'OC*BU*MM=Q2C:[;?Q <!P/D]U4202TB'KYVG^0<O/AI0V=;02\] D7*
MRG-]QT!!^//3(F6&02E>3Z\$Z5N[W\!UA,("=8%5T^05 /6Y8/9=4:S9%4G#
M-R:V=B8X*QJB((&JD7FZ]7-6^T$D61M?(&,']YOO;U[ZYJ6!97B>L36*]>'9
MX#>>SV0PG3&@W<K]2H#YF- F#*)M>1.F6?X J"P",NDV+NOQT 8[_K]ZR^V>
M0[EG [VWTMUY'%] -'JD<\DJ6Z'8@,JKRZ3H&3NX7P_QQ-P04L4- :8CLR(+
M#'55*6++?BC63$YE9"%A/-K?E%+;LRL*,N])KDI5*N':[%*B^H^"@OB]$U=%
M>JID<AD</FB83Z-@L_ H04$"EEQO4P6SBA02L'#&$S?L%U P30IV8([QR\C+
M,HO(B'IC]V]%+<RT*21RRV6AHRAD%NN^*-:,94("6@24 _L[E>ZS(/3-*+P=
M75"05>XN5=2-/J3*HAL*\EHA*"6@(\#C? 4KKE7D2KL;"O(69+VA1RC=R05_
M.H(?NOJ@((R7%J:O9TI6$/%=%..$P"$JD,R7K 9)RDMQ\EH>+'PJ>?",R:_[
M#XF"+>6Q8W!XV1TXMG_47T"&YBC(J3MP&[+.(X%;I/@1S%M*8V;?,5 0_K1]
MR=AEF5^_,:P!8R2+KK%[ :!=BT-"]V@]^<;6[HFY3%*X&'/23 O76EV,[=T3
M5(6L:RAH-D#M&4L$C-4\Y8&74+GRD62;A"<$]0PFL!D.Q5714'\,16/4+5$0
M@0%%ZI$J'#<\W'A0I7V<*;J_/0J=#$*;5;4-))%1RF^#0I.BMB(EL77C##$H
MBAU=O&7S)?TOFVVF!O]2-D1!PN4*MC;+T2^"@ND$_7##C"SBGYY@-2!"_WD3
MT*UZNP:8C33THFM*C]I@.,2X*!@D&90L4^3,/=R?:>[C3R)%+?M[\I7A?;6C
MG6PZN2>M#BK!53N!+Z>R;MOV0;$1GU943@;MA:DQS9J/^E;N5Z5>KK8[+J>C
MO7N"_IZLXNLW+\XN5R%97G^CPB6X\NCM3E^V5$.53:<F:?_?'RK*[NB?I%_8
M#YMZ5=Q?Q3=K9,+'\V^_I]N:$OG#'S_]\..G/^3>MR1.UKL_,'*IQ$'*JDS%
M?P&7A,4%2M%S)4T J_!?OVE^_3<USA-(TP](\!O%2B7U16(8U4G)LE5*EGSZ
M&9T_6R(JO__^-7G[0T!"1@7\X3OXP^^_9<'_ T&,EPF4.VL<<L8X'N18_UVU
M?4:85%GJBHZHF%/MYXFF=$X_&#!+K:0K27.J_SXQG_BS<AT'(!$;&%9O-_$D
M;^A;[D50U^F&_DMFF&:SI9.)<E[9355N.]%D%ZD'@O[3;OV21(H)UG^?:%+\
MYGLDKR'<%Y &OU9M1V6S2:=X22"B(KJE%^VW_R8[[1R;[2::I# _5.= ?[2U
M32?EYTT8D?22?O8U2?7<K+>:=L$M0.C:JV_J-.GT'[8O4>C?1(FG>J/;;2:=
MW/6:I!#N_CE-ON8KL !YL7X3J%M/-.%;?YF*VC+G>4XR+H1IGG1#X\E?)+H+
MU_EUFB;I99)"W4C]M"TZ3;H]E#DTK6U1;S7I!#N OEM3U;6?]D+C]WZ9K /Q
M$DI)Q=A\TBG_E$1;JO:D_!W0S[79;M))WL8Y 56'JICT&?4:+H/67#7-ISU@
M*[HANZ[=6J.)IB>\>KM//[PP1$'%Y%I-)I[:]3>?65PUDJJRV>22%<]G-8I5
MHLG$1\477MP0I"0JUUV"@3JE<E.@%_O-O28E8.%]*XH;<8#^#D;KVD\ZZ?,@
MH))H)OYS1]_+3]H)J]JZF.PE_>,\7= GLVNJ4DL7$V7[<9ZR>&TIO$TWVV9S
M%U-^2*A@&OV?<&,\=<K&4VFS\/V4>)H)UGZ>:$HLJO1A184W[9%O-9E8YC^/
MXZT7<8'-(.77FDUMG@6XT9!G<W1,L]5TXJEFU;,#:1B/X%B&K*]6\)AB[MU]
MI[)!<V54(ZO(OTX[H7H-U_:4Q._33JHHNJ.?5MEBVHG--V$,")J&G:=KJ9BH
M[$P:Q(FW81&[W_FK,"J7M(+%4+J+"D",NMLF20.2_M=O_OC7WW__F]DF#1,0
MI/_K-S_\9K;-Z$22#2\ !K^),(\[S@'M%-G\<HA*8RVQLZ/A,A+\^-/WP_*#
M3N E.1*.:/Q5!6<^G>I.T;K("L[\\,&9ED^NX,V/I\J;A@NPX,<?3Y4?:N]C
MP98_G39;6A[/@B]_/E6^Z)VL!6O^XU19HW3J%ESYRVESQ>Q)+IATLD*OPE\M
M>/+G@07?8^.)QDU><.=DA5^33[Y@SH?\:X@ *)@TL" <'0-_E"$&!4-.7!+6
MQC44_#EUD5@30E&PYV0E8TVX1L&7$Q>+=1$B!7M.7#ZN1Z,43#E9>;@= R-8
M\A\G*PZK8V\*MIRL'-R.]RE8<K+2KU6<4<&ED[4#=P0S%?PY<6E8&3=5\.;$
M)6%%F%;!F1,7@G5Q805[3EP65L>@%<PY64FX'O%6L.-D9>!VM)U@R5].5@96
M1_D5;#E9&5@?65BPYF1EX1Z1C 6O3E8BK@5*%MP86/X]"O-X(T"S8,7 XNXQ
ML:(*"RV8,;"$>TS,:(>B%DR91*X5,"U-/)01T5J8'"\*F&9)% ;L$O4B "5^
M6A$BP9!-CM6R]+(7QC:!2<2CB$F49\6_5.'$)6PA@P(5)F@-BHNY[2"QS_M,
M'>HB )0=_0^@ +YY$3QNYSDK;1[&KPS_2T.*75]GI$G02W9+8^C@C @S=F9S
M;ZD;8U@!*,3>JMEFOQ[F[LX([$T21B+JA;5-!U[5TB'OQ2,"Y:)8(1>JW0I(
MW,Y5L.CJ[LAS8&F;9^3@R<*#_5WQ5+-9,+2W\S<OC. *N4G2)WJM7Y&7O *'
M!G"U!E[TS=M]J+Z;#A]O:-IX]14!DEB67A%?4U3YJQ%BW=G9]M&4%+]/8M_X
M>'3W<R>D5,&>1GFDV<SAE9I0;N:[!RK2YF)[;^#"N2<Z]AN[N'P;-EY8[/=B
MN]=D6/U;T=G3&5G* G9F>HQ=G!%21-O1K?]"7S)XP#1U@>TO@L/&=/=L!D'(
MU>('NN]NXTMO$^9>$Y2OJ[6SZ;.BJZ$/Q?BH/M6Y2-KFCL66#@4%Q_$O*CG^
M'.:KRVV6)^NJ]-K.3(%55YR$=>XIV]XNE>'M>LLJ5MJ40M)KR;U&02+)/4+E
MA?GRF3ZF<(JLI+AF'R2D6)ZUCDZXI(?.T]75R^'+DWOTP0^NO13J3&72^;@B
MR] /]6]09T=W&ZZ2-KLU'V5;#%8S\_G )(@VRY?:,1W926A;YZS->*[E+J/
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MX6*(=?O+QSD98-7,<!N"U7_]."+#:-5Z2) BNO2])Y--F,)G_7 7O)\@M'?
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MG:8N5@86X1,7E;A&*!.+>-!$##\IK601+YL('.!1VM!TCYQ,:F7OE,-"KY6
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M\%DTCL9,;6Z!-+I*RSB*DPH5Q#CEYMY^KX.%ZD=J=_NJ-3D-ER*1^ZCJ0Q:
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M<7XPH)OFO#"OLF%G!<@]%&JA!AT'2?VZLD)0SH8V6^C^*BB@_ISM]B M&G/
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M$?$..LQ+?6R95IE%8"QAE>YY[&A6H$6 QK&!=8%22\/+0)=GHF/$\"GDQ8O
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MTW*;1??I)Z0=!,$JBN)Z<??I)LMW^'.S5.#N@CC'UH^KP_&/O\:0\^?A]O
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MX9OH!=)<SMI8$ROH(U#U1*!R;,9.A[;(A:)2[-=.(R1E ^\Z,RF69M=/(]/
MWG?VGIFSG28DBFV\9> #^[334,PSQMLZ^.@&]UZ0+,O"[31.1"-Y>]YZ1]%I
M&&R*I'0;X<4'NENW(UH#7-DF>:?QE=,;B/X!IX-_><)>WQ'A-!26Q$'[&/Z1
M<="BWB@=.%N4CR+'\23]8<N((>?YSGK6 8)NTZ+T5V>-)_IY9$<?6@31:14
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MZ-%Y&2<"H:-B0#OVMCH>AXXMK>FTEK X95O">K]KTR=Y=$AIJ;PB=7U$GY.
M<0D16JD^E1E*$X.2QBF61I[#RHZA> VO01I<Q7 24*K(DNR#82N@-=5W-%]
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M]\5J!!HN,;3ID#B)(PGVM %PXC,8Z[3W"@9O%P3&,,BZ4,!!&;\G@*3:U><
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M8 QD4J%=R@$W:_U4GJ]%M7E?.KZWJMI@59WB\-:E<@URCV8";H#\$A=_W.4
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MX%<9S_C)]#<7?7DL:O <Q-%]>AWL8Z@'LI]N9_8Q]XXN@%)##AEE(T0$>7Y
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MTHEPF;DT@CNRBZL=]83*CV3\!F]L3*R88J$N1O5F]/](E/^$!P).\)1MA7Z
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MW'X+Q=__$D-RV._!=1SDP0XD24"?";6MZA>R\^ S2&]W07I@/(%]UDCQ+-Y
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MKJHSL9 !O5 2=COF&<;C[#JYQ(^0;<")1VM4\*7*T1MR5T$1%U_3[+T .2X
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MHHS>Q+5RZI254\6>><>3WR_--Q4XND%C15JM0ND1IZ /\D5#QLFLH7.J,!<
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M]^Y%Z:;F-%L5B&D<_K^0Q\].'6]U]]W::WEQ^[[MY9:S6_W<H+$Z==4NGD7
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M/HY +WMGAX,_[=LZ>_J^H7(EED\@8V,"05PWM,=QM QY8F9\668ED($OR\#
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M4@\1* ?E/C.0$6#3;*2*#7$<;\,8J2B:Q%%D*+DH/U3%46B->:@TY&62^DQ
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M_EA[GO^<W*XXJW%;-JRZ1C$1KT375#')KB_Q*@YHOZ[H'T2>38/05_J<5+,
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MA*FT)5\IQ\*3I_Z1[..[#R].;_8AVMU]0WY.9:?-;A?Z"+?/3F\LR*-\B,O
MAM>OR>L^R5./R/STEF4(Q329ICBJKB?(:!)(P&\23*W<&2JLW"_DS#!7%%,,
M PI<)4">>2=Y78B8]9R<O(C P8SP]'VA7=G[<J?F-##,5_T^'XY1<B*;+B]E
M>IT0]6&SNPTQ\@G7I5'<5-C.(RH@=1_J89-!DL;Y9%\3QGT;[IJ6&TAC(!3I
M5.OIK:T:O7>W]PO,@V.T1Y,-9&*$:A1(T*X^O)!-O4_PBQ>A6_26G3EMZ2MI
M,M_[CZ?PRO?S0\ZBIEA"]I<8H\+<2F,2KQ&1'JL:E*4+8N*O0+D-2E[XN6;A
MG:O0^SM(:GG*Z>8VNT+(*$QWY$A+G;JTU96- :JRC*698<!,>)*IM/O2YS!&
M=(,UU>N.;L&945'==@ $1[9DC\_F6,HEGS"Y'U3<;)/Q@(D@Z?R*<)K-K@H<
MO4;D2*[S,*J-2.+?N^ 0JO7FX$0RE1%[1$&Z._0" C@_@#P-<RM%H>H2_E*:
M*YJ<:*S5(+K4.D8]5'-6\ER^AS%K"4<N(6V&5TLM)E.:,+_3/[&?;4-=/I[U
M69X32GOA(%I#P89\U,_DV8A= <;]"8R.J.,J[6=^U&_F0TP6(-1)4T2Z)]C2
MH(>NX!"B!HG2-SG&K*S+!>)XO88SPO8C.7%RL^D?'^)CGFUQ\E;2 Y4T]R%A
M[WVMU'06R"=3KWB ('R&.]:94Y=*W:_-("J=D0-D\R#[SSWY'?OY&Y/PISKC
MGFGL/LECVEO,R)XFGP22N,N\@<I+5R5%E RJ5;ZIE6B@,P$*F:L?@NI)NT7%
M_U>X=!L.!+-I#KV-(FOYYNO9Y2D? P98)9MCI],PEZ3;A$!SZDF\ZG%@Q5UJ
M]48$&X5@^T(;403;/:'1S>YS0;K_\.*<G%##[/#ZE0P^;>)^?-WE2X%DAB\H
MRXJ_U0)MVZA6:_OJ@>XPOR<O(S+:9E?W)HT#VH\SI6'^*"5#J^R]MD7.>!HX
MTQP_+;8AJEV?SD.JV-FOS&569/V440#D:&F=I7.T[>CKMNPCY"^VN8FB,IE
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M1UQY,'>1IWWO[=)3(/MI9#@,:Z*1-82/ 'MH;D9M1F5?S2RX)@.(I\-FB3L
M^Q)B,86OTC$HFH"-7KK'35K$M$MY7'A+6EM];'!8[I&IG8[^,ZC>T?;U[MGI
M:U6[AQNJW3@- U:[,O>E\DN!P4XJ[ D_;,_Z517<?^K!MTOM?JA+7CJ/*TH7
MQ6XF_E'(3!BQDPEZ':3;X)EP.W!EC( (YN-,1E,0[7^'\Q>$LT*!_PJ2"'8.
MJUN2[OA[?<;I.GV^C88TVH74@2K"F98B1G,J;PZ^#^AL> 8<(=;95GBX^@<5
M9,5_HB' 9*8B$1EY8:[>AUW^U9'N?!$;^N>7JC:GE(1]STA>N!4O3(1"W5V)
M*Y#I-RFO$4X>'#>%T_? S?N*<CD@\0Y2"@6X"F>@LF-0G1](9<-@<< 62^C-
MA4 5IUAW"#T.O _=V IGO(K>'R@R.$XP/O@)+*SHV:_=N8_%Z@U!"2H]7ECT
M&Q''?>^WF40;#58*Q7,FYF IQ4M]3_-RTP0>5ZZF.<!Z= %&&.D"$/VX$!*V
M998(^"8,R<JBX1B+(])&Q^_I>)W(?ZT)I/73'?6/7E:J9(M:7:>1.G]Z6XK]
M:-.X<Q"#$0S>-&EP%K<^*AY_$2PI]ASXX_:L7RTN18-OEUK_4E?@"QTD##S<
MQAXON(DS9ZC&0>G^W^/3XQX,E)324@19#Z\C\8O.5AC"'B$7MNZ9EZJ1/)T@
MB_!"\.UB1XU]0<="/]@XVZH8_XX.(]L!,HUD"*KD6L*4R06,<+MI)X;'"ELH
M!)\%K0+'E16)(L6"?\S121,[G3_D*;1I0Y491+WJ;U-\R_#'_<[7 KSU UV;
M@&.%AWU7D1!.Q0.)DPC,S) 6'*9;S!,K-T@"F9()(W_[1V<R<4LE!OT3+)5H
ME%0BB=I20]$RW5I_@;.LID2U%B!93W4ME]4O8&GY8W[?J$H.@@D8=!=!? .F
M8U?\\BSJJ"M^63Q-#*BS%DMK\5KJ8/7R8B:C2"3;L1\?9SVV0S/^1,HJS59"
MZSMK@)!J;Z7QP7EOUX(M<PX83X!5GX):2#CF ^:FF_K&$ J:L;N; 7\+$V_3
M>]G4Y?DV\ ':,&U:OMV'#KS>%,;QAI&.($F*(/8E>-$)6K#^.$T*Y?N3-/-%
M$,[\,(A%>]:O!MRBP2,\EP</3B ,OE5'ROM+FGFXD!XN)(8B*)!A4PIW(+DX
M=*TS"K#]IU+'G>%ZC,V7D0<*G?!:V!?IT8NDQ(*#8X#C@M%L_BW]PH8^CBG,
M$A+B5@_.46R@Z<R#$W.]"R+@>TT(4[:DC+4,"[AP==I.8OR^H/ES%=Z!X!B<
M;%-R;'L;[<G].DKBC4ZXSV&D'NPO*>"=.X@(]^7,19X1D)WS%P*$QAB$]TQ$
M/2\2"*<&F0#_QA#77 2J0 M%9Z@XK@)V"L(]0!VZ$2^^8D_"Z.Q0,C$/+.RO
MO(T9N09S$^ 0_\'[AH &,B)\ L$1#/R  >$::ZH3?JJ:\T\IEECN2GW'I+X1
M<?_Q<73PE \_BY)^=-_T\EF6%M-9=8X6-$'YJF3-4=4XS^8O[2F=%D$6P+:P
MN3&\WSPM8,RP.GC$=5*JX:CW'/A(>L"V3O_ILAG#T9,XJ*]7QY]LFLV =?+3
MQ*CVYJ1&>]:O9B;C#@&I\9;569N4^QU)#;B,X5M*#]]*)10(TRQ%W!<?6\QS
M'(XXSP%C!TO!G'44B>82%E=S>/:LID3=G 4CKE+&7T4-130P0OHSHJJ$+XSP
MJJ*SG=N%L!MA3<"ZB 0B[BA3CB(?Y<@,7CFE^P-E)#.)PSBXT7"&\&N2WL0B
MFHH2/T>)=B--*R(7AL*:B* *)(#?!048('L$%YN@BH+QQ>G-/N*WK#S&%=8X
M#$*ZHPWR5T2.? )-!M->O;Q'7KJD2T(T<<8"+A+..H/4!-&;*9RZCJ*4:.]>
MB?[+!+[RIE>*GU7?/<Z(U5J6+[V]P\$^ QB<NB:X!D2O1?G75JB#E>V8O#[=
M4%[C8<J7?G #EA?*:WTB_3SUX65FZ34X;&E[UJ\6[J?!>U<T^';)Z\^E9#/K
M6,L>6A@G)SQ[SN&DPU@*@5(&H%%&)EE4*U/DU^CQ:_3VZF*:+4GZH3$F7>.8
MX&7Z6@*&\3/V+[8M!8[Z)R>GWU=3FD\L$BC'X!Y DD-M<K\.^T?G)\.3D\'I
MX'@X.#T\V99,"/8WD D!QFG\=,%84S3?S!^T0="D2_U%D;7$6[T"?4S#V]V4
MP\\\?I)B;1)A)>P!_=XB"V=HOPQ/!F0^JEFP6E)18F$0 8]0RSP-OU9?S3O^
MYC-^4TMNN"O! H_ ]6!HB5N1A1(>O\@0EHD8'1I Z8A214&<*A1R_*-R:/9Y
M*/7P01\#%07_\/X:IV.X^C.(+A"6?P^RK\):KZYQU& 4U^TENJU>$]XU2V-F
M56:UZ[OT,TVQG=N4=LRU()L:[6_8@\+L'(Q3/=Q]H2"J$^#"F^+KC,@D#XPA
MK2Z\T?'W9H=45L@93)K<;>V;FY/89H4,JC4-9>F<K&PC4Q/+BCWBXV >2(!I
M0I^0\T$GA#9NC#E#>$P<,ZR,ILE;NC0ER!B@49A2$U@U!7?!M6&/ M[A+7@5
M)_M\L>)K+'J>!;+2E2U@LV"%T9+&9B:$15_Z1:PNG25A*+(#"IH]:-&V[K)\
M V,%_9?7::N,-[%5QF2KL%V23ORS@0_S]V$+80@:]II/ZL<OVF.KT%AQ#Y^Q
M%BW'JE5ED6#L>V>UQ*?/O[;8D&$M;<>XXE/=J?I!C&:Y:(S@<YC*B%^9D.CR
M]H[VM?"M"%W]D :91L/0.N9!FJHJ=IUY-0K>AXC5<@C/+DZ'_?-.H&Y/H(:;
M"-20/;Z*PP>;FS[,5*$_N9$M$:@K/H,QBU:/N'.>\ =$ZT0_=SAH3'RF3LK%
MG%SHV'@ZXE2B 'Z) P[[RMP6Y,%10,J;E4(\38.RO"\5O:V\<WLQJJ^U?JL1
M;7#:/S^Y$VSP>,*_>@SLO-6( U!C6/&(WD;*.@TD4]+;6:@BRH16VC^F@-7@
M0$M"+8$,"TEH0A:.ZTLBOP\2CUFYKC5F!_.0R(P /\LM6U,I60USE^52L*+9
M^5Y+3^UEUI]9CJY7^6WM2Y;P1+Z0QMM&&-QAK)QNPUAY.LOD27)7AZ=G@]'Y
M<'0V.CT_/QV=;,E4.=LP=S46B8"=KGP?:[@3!3:*D/-QD2EZP:V%&;S5X[[T
MWO.XO4_NN!]@>7=59;N@\;NJLJZJ[&7MY:<. #Q5C=GK# %LFO]%S@'"ZHV%
M;[#@E/4E@*M<($5N6T( %?8Z![?NC!4#<N15&'L!(:G3+)@K8P<;8!WG4#"C
MDB/P=I5)9PT3@+5IK?-BR>]40#DH8K4)5$^S^51B$?03ND7/C4;@+V,YE[EF
MC:DPT/4T"DW#.5:Y[7 P<#&"D;,@^<KFMTB*[(4$]E[QL=XT52(3O]R\AJBS
M1.<J'QD46W*L/SR0<L.0/M:8'GL5R!2&ZO*84>P5#X$<68)6(GJ374^^SP(3
M^%Z4A@7^#J/N;*DCK):XK@A^B@_1F-D[2"Z9[BD3&@BV N1'B&@8%\216$^.
M.B.S(R!3C6>39\&U(/C#6M:Q^QF]F.K*E._0 =.5#KQ&66W1)BX_IAT5+AS+
M) :F*JHY+9S<]&H4MDPZ.V2661$+=>'M!5R&4L)<[:.LG)\08>6:8<)&T*R3
MM;H@'@VR@@5</4N!C<?=7)=\I!K7Z]R^Y^V-]]=?:)=B'D1,3=9$G'TX-/*\
M.O0J?K?Z';)G$Z3;F8[GS.$F*#>O+J8)>8GO?^7EDE5?8BS_4<B(V6>P]NPV
MA&E,A:W-TNRCK'>?!5-,/9TZ5/&65,WYAI&93,"<D:N5*2LS,0TRE&\^;0B?
M.5#;LW[U9E+NX+U/9O#>S[2;?RX)7-L%.;Y23*+(DK0A3^UH151J1#F8(KKN
MO;8BO8]I<O"95"I/O@?:(IE@:!A+.@EA#'+CBA@G23"4\=T[&/MW%\Z X]["
MXK1IESA@B/^AFA:]V=E,T94N:*TX8MX$^YVY]D ;) =H.XI<&OFO];_=$W1+
M W%1J[")DHR:<@ !IU =K=QD554(E*N<S&QM-)$X$XYT438C<8NIP.+"<[/0
M( @TULS%O$:3(J.)U=;*(7_.O0*["E4KCZK$W05K8RQHC9%0%&MU!*C5R2HK
M^1+M.K .E,#:UW)AW5= FAWLU$R*G+E :*',R6?>;'$MTT(9)S'S*EH9/>2E
MK=*D =-'+H:7^+89-5/)VVQ#8-B\#?%W<YT$V-RL*V*T+4V:B6T*^(L-ZE[)
MC9OBHC@,>&E6.OG:_OL&A4U/AF1YG4;(<+"1%3+P_3RX%5C4!(]%DHFY0I2@
MNV' ,FG/ M:P+3CVEAD8<&!I&?$L5LZ=2S5DRNF=U&]5FV2FOI/_F!#XWHEN
M.06?[(YK-DUZFXZ?Z=2)-M:$HO^)O2&<TM 5@N\HA5NB>.9" Y0P2VY^0:6>
M*$<J$[7Q!G0 05LEB3":2R9R#@NN3$G\+7A'@6EJT3/],DJ%, ^^"I9O<2#G
MH#<"A E6@WB94S#FNOW5F\,"2ZI[(!]?PP7+07>UG+LF\#9K83?T?52[F?"M
M_8)!/U#<L!3:$X-?M&<!:UDV&KMKN'VHC+WGO4<;)RSA)%<(M&,SK4UB\DO-
M_B2#B7&#/^F HK(NTC8L*;33P @O- 4(GOU8Y"Z\YP[GC'(.E.[ $$\EFW$?
M48E.9H"8 .-7:)L3>\78!X/<JX8"%&$@=<L%[@OC=*+1/6;P-T%,OY3P="FB
M_3O=2U<RSDI5 ]:PQFM7]5'?>W\;B@7/I\-B=EC,1S$_O70PII-\P+/U$ZB:
M(G=L#.-CK\JT7HU29)I>8T,+F^[@O_$>8**!<TN9!)8H2$[9>Q!\$(:7QH7K
MYD9VA#8>,!=!0@VPF!ZSY\812*Q<P])'./C5!Z'XTE-%OSB=]!SYPC*)8_\W
M 05%$FX>@K*DUQ1ZN%N"5CQRQN" D)S)Q=WQM%V,I9F=U"957:L=K6U:V*9N
M7GV>)C<BB+G^MY)DZV'F0V?PZ")^D]SJS*!D*<@5SE)=FEQ2U]1>+JBON;0I
M,KJQPDH#5+.4(/N]@/T9R=#M S !!0PZDS5RCJ"'$+8>/--IQW/O-#P;IW>/
MOMFC[*8XNM;YC:;W*4]1K10";C%/(SF15(84+ZEGGVTIAWY/5G"BB5L9Z=PJ
ME?$NR2W#5K%%/DLSV %1Q:BX%K4(VAT@X XWN0O:N<--=KC)E[67=R#<LIM<
M_-N)MVS6"GGD^X9$#D,KZ<0O+3W?5P(,"30XV[. M3!%.794H._MV"^]SV;L
MGBE5:%>$I;EQHTE<!HG--0>PCF#8&3//PB7[WGNFY,-K:NV&T72QY(!L@Y4&
M?,5$UZS[MAVR0;TP:(L94/'N)L?&%(.4N,,H29)BDV++<8B_<&!0E; S5X'W
MUN*GGIVHZ^DHU5\GIG-3J+8+X(2-:P62X-[LO'-;$EE8?\@:W60^+<4"MK]Q
M%/2)T8U.V;E'^U_.YR)"NIR8P)0Z#D%TFY64RPH6-!3RF@.7U(85Q*"%P.66
MY)-'%Y!7J#MO[*0#?A6&&1)(. "F-@EUZXMOO27$O40^3P$:[ #JCP:H8]W)
M6B%&5A5(@Y8(,],N8;T0(\D%)D(L F6(LTHJ7H.RT;; JH2K <2W+-/P[@WR
MH%;GK;L3(VAJ%3.%']2&3<L#*T 1(AWUY?EAK$90]+6N!8I$$@*:^E!CZ^-8
M9,;PBG1O3L?,+MMAV]_BIR5 .1.JB!F@7;FN1IY/Z.XB S]>-(2;GU\$=0*H
M)=PW+].:*MV/K1E41M+<)4J,/[/*9T4 9.Z^0:'DB-/62UL$$X#,6 3Z> >5
M/)#N6X_.F, AT5DG86<1GK73OK, Y,_E&K0;3<PN.'-N*LT[5NZGO8@AGHBG
M0G<9O[P586$E.H*),W&-R0KX:-\0V"MYBTKSQ/#7ZT!_7@U=K,#<4>&@BE"S
ME"C;N+TR74U]$NJI1R3,#F<&1::3F;NZ93[I4_')F4TKMXS)%X/TZCGYJ6IQ
MFML B,OD!+>\X*(GT-^@@$M9!T]V,>DD#Q1=#'=/2%)HD61LK ;1M;9Z\,+#
MYDC6G)HT-<3);T2,.WXXLNRH9HO2$+"/H?=9MR"W.[K!TNEI,X?OSPUX3)>.
M)EK!:X3>KS[>;'[F@W6?Q6-RCM)#^YP7BCIR:5CF(D,<?VAJ,.EIRNG69&4R
M+JHY_(SY3"+;X\BMN@MQ+L%4H($&C^+9_X(\KR<X[B_X.KP/%+3\].'S%9]W
M7>S,R4\$&.S!!H]9_J 6V\6C_.[GMY^N6GIVU]8*:F.B^708&F*:&58HS&4Q
MM_WMJ1(^8P+DBOY></.2C$M&A%/V/M&MR32\-BMW4B06F'S&LP%#D(QM YD1
M2R)EGGA[5_M-I[5:8]EX,/?>[I=?XM,-UW3C+F;$3.#2*)N*C/),H;T5XJG2
M+%=[[YH? 3O.?0BM8X^@>ZK2<<* J7FA2[I#.&MD:,GRC#N_1C5,$E>6^C6S
MZ)12GS@H( )I8L#Z$_J,!;ZSB%9L>'YV0ES9!@2PLT88SJBEIY"(T6 I<%/]
MDJ4Y@Q48*CJ9H"BG38!ID2L$0AFPR;\S N0=YTLB[WU4A*;<$1X42M@@;'7"
MCJI(TIVUB\JDUB\LNMII%5WB^^A0J:\5E?I4$:;!D_1'?,4QIFB3&%-$+"P8
M9J( JX].L^^SL\O1)ZIUW)2Y<-L[5+K!8&ZF9SO+@5;ANDSXZUU*[)O>+^QJ
M-'7!NQ<)6VW)5XO?K&30T:PPH5[CRG![/E9;M<9\CW3_:B1-MJ+*M9KPXB97
MVUA98&86MI_?BNJYQ\7<:;_RB5S*2W8G']:#=K5=M+[(]#2AZ$%]4]H-J,B_
ML=6(#9&H>[T$&NY&[B^;[,9]Z#RME^-I=<2N+\-0ZP#*'4#Y9>WESO5X'M<#
MLQ%4MK^\F,D(=.9VG)''N2+M<"[^6-@18W+?(ORUNWG!=Q_>M2G@M2F@O(L=
MWM7?@Y)NU_LE@,,V2C2I<_05BT2W!%NDF5M*"RZVJ<JO=92FRV8BMJ5Y>WDZ
MU47[UJG[\*[1T]WA U/.ITWO>Z>.CJD@:=,".AQX'U#5D%))-5ZE,.C#$HP8
MV5-41SCR8=,4P(B(HK-313LVG39VH&M'#'QS[MQ'FN\&VQV7J"ZB-D-/="+D
MFEZ%JS$V#B]%X )@R_<[G'/K?QNL%YA=B,%:C?$9%5J">ZSC3I&N5;R2-\-X
M5*AID_=PELQ32W4S+HJ3!DR_W*^Y_I:XJ?$!88!0-B].8:R9\=]7,$C5!S_B
MS="PUKZ)?1-$D&M#;N7L&0V+@8,U2PO36/W"7<!>;5&D0K9@BDG='8I[LOGW
MO;^8%D[7J8P,66.4%N.<@#TP)PXATXTXQ%(!+=-F6U4=M"#KM J%6*K,B;A,
MV'<<CUZD V]X'!ONK$-G]G7<&6-R8-5WZ#@K!(AT,5YR4+7AV8Q5)A8T<8?B
M?/Y^QOWA5ORT.WRR)M_W!>2"Q":Y(.$C)Z%O0.A8/XH@=(>\JR6.VE_NA,JO
M*SW<J-7A<-@_^X/L.J=G[8H"-%D>.V8'8]*MC>8;\?PHSIAQPP6I9G"ARAD&
MJ!-8E,M0C7WG:S0\P61"GG^=4:1G.5!0!7,J!M0+W0JU0@B;##1&IC"WAF$-
M^B>HO"C-5!G*P!J@B#O3"#T>5LB4D".%J!DI;7L%PZ!<Q#EQ3B+]D"J[0B %
MFVESH\M_3/7+'(MJD"AX%F3SVGQU*LWD->=2*:W]T1@,O(D 4XI6!8TPJC"0
M*A*XW,1_=)W&UZA8Y\C3YN4@&V1>8#PF0C4)2M^^"+K)) N*R.3#Z*&30,9%
MQHUZ.%/'GP=*$\#HUAF<(E.+--%A,^JGD6HF*-L: ZNDU22H,.+8U#&ML'F@
MX1M6%G'LW.;W(IH:9&_E[7/2L%K I:VM6B4%O)PI[ A3L5W/8T<"@UQC\A$*
M9U@R<<<1B1P^OV3G@M9E"IM->8F8@DQCQP)-*;!P\<4@Y7L1YDQ-I0H,[AN;
M[ZX]O_G6:MQ1N%G,<.W> U,HKG%2:T"V^>"!'(5EAY0&NJ[*;5SJI2H:G"G+
M585C,4&Z?&+D+C@4^"8UN]#L!-CN>#2QI.7Q^*27DB5XK7"L;]6P>;ODMYT5
M U9,W:MNKT5CHZ7O$-@ TO<+>(:*U9O]I8.QTIIL?8/Z"^^*6\(1MHCX8G&A
MM0P$PV7*S0%,$45>/H\^!F'.IK]E?RM_H%SA'"!!@B@M'G1\+%?_!%8Y#;\Z
M!84U_!>6[Q(XI<BNY36'V\#MR&Q&B*]R=!:'Z6#*Y3/0MZ;ZKS&&LI$[%U49
M?EA1ZB4>A%QW-_(=$D<>#Y;IYY -,C8,?-3HB&TUC(3@]Z">BP556M,OE%$D
M]#.R8\*<:QUQ[4.1@8G$8":[7K2B$Z:K73N%QO&#MA(Y\^JRA17@LI<LF5FU
M2U.5*L_[#2O@,!JUNM6TH8?#Q]:!$0UN8OC.J[8"]IL*M:$P-L0T0K/WZ0VF
MC1_>L&%,4#[<D P7Y/A2"?V[BI!17<&ZY&FV;^K&5P=9!CE!_]/SB<K=1MRH
MWA5W?#&?5Y; G=):S?XHYW7THHEA7X30UQ#5%LM^"B(RM'(L8'L08:X.]E>C
MO@/V0YQ:;;@"7)4:=P+R1,D,?&*.P5JR<);7S5%HP9)0/W8XTI#/ $8#)U A
MQG2#6[?@E&&,\[1%(<G=/V(.RKK5I\IMV,2X3,W:3-O8F04"24*,O>QQ<3C[
M^=K6VJ^!5K6:T2D/W7BW0LW&9T-'J8+2-8X0ZU(8D+0!L%<B'3U#><NF!L=$
M+K6BO^]F#A[\TML303CKM>G]>.OK7CH,["YXQQT&ML/ OJR]W)DD32C-G81N
MN>K\G>F(VB;UYR"0/J8YFB$V_,#60R:F*;6PP&H6A4RP+C[C+DM!QQYT!L74
M.]D,1-D5VP7_89%4X&&[(4^:@GY)Z!!=%<>!]MIG8VK76,3HHI.)@KP;PNW2
MI$>%(ZGTD Z\QE?4W_G=IHW'-NXU_0;0(&9[6.=-W3B.C<.@'3G%>4T"MI&1
M[+CYI57@265JD5)BDVK^2S+UF(-'K1K0=5.\?(:M.ZUEX1IO0[DUVPG9R3S"
MA^F"^06K\UM?F2@01X[Q-2J*,ZXY-6[7"=J&4976/PU%)P=WEP #DV/MC9Q@
M=!#SDW,1+==O(9U/36KBEG/OYB77K[:;J,P<$U+T5JJ\RM3P1_)%?\1X.#P_
M:ZWQH!/"#G:P5@'>=*)+%*-((ANO+G=@W_M0S?##R1?J#M&A55[M-KW*KUDT
MEF%D2D740LEW])79-A#OY(EQ>-\\M/QD4+S))E"\"5-_VI8-OBZY5GZ:^:$,
MS3<M.59?&BD%T/Y:"Y953J5R3^]V Y6ME+AO$\VWA3SXR7F[]FU-OIVL"JU&
M^/<J-A]CBUS-EF8]!#(3"7*OF5A#,U(8&37'YO#I&L)$-L@SRZ6 XU&7.U4R
M8B@3VF1K]'9J!6?I#4J!=BT@)ZY8=Y.L.4 ^C0,Z0964%\/18(7"( 8; (DZ
MD*U#)Z9T[VV%A9I1]2>]-6PKCQ"-MNU>SIPW8NDAHP8Z,D$)S$ @F?X<TPB1
M:7_N-FVQ;I=#F:,;4Z) ^*QK58\&YU>-C#GFN$]E4F-IH05LF'Z-O3U8D05Z
MD:5"V*"B9S'FKIXP?+#PHK8WE (T+"5XFYZ3&C2?\W1*"E>SE&&0@P%>+.QR
MZ0N>S=KJ6MELUP*;;F*!32TQ%H6?A,JQ'@+>-X:T'-*LEBA^?<[,6/&,Z+%:
M7+'MH/ 8VJLF6JN](4A($6![V;W1/F)[ F80@+\/]RNL5XABDE&)7E^#?H +
MCVH7YK8S1(TYZT&$7YB1/-Z_J]U"V=%G+?.5MY:.:USD=_:\6$>Q517YIA"U
MVG.WTF:+*MM,P[-Z7!:NP968FB?B;L@0"<%.;*7O+[$$V2>#1.-6IK52V([=
ML8,36S>*!BZ)1NOB #PG[&YH$I[T,_SLB5N3GPU:C4"S5&JF>M.A!S?FU'"T
M%W)%+A;FKG3WWJN8>_NE3\7EF)')GJ23"78)0/@B5A<0MYIRY0,;8WH@\!\N
M06&A9YHQ_Y9F,"_O*L)UM-TK/@D0&Y+,P(\8(9>:>63OMZM/'_>9IV1T[OW:
M_]Q_A_F0X<GII3<:#H8>#$B)?_1=4F7V#&F,)9T*<Z COQG51TR"D/2%AV4.
M9'UBA892X'(N89Y,EGXS8S8'-$2#>3 5;!H[7/>Z]9G%]M[@C\I\4I5&FN+=
M"ZL=;$'[?F?6[:A9-]O$K)OY?IZRZ48.E5]N$F[W1>?/'[=$P'RI.'^N6XBG
MO!XC-O%A-J3@@TF6SC74'$ZU]H[&:9!%X/C-QX+:55!,V@6DI7&T:A8:&V5"
M+5-T!1?"^1$4+B,99*8\SM8L*H8Z/\!]J_8IY2[T/#ENRL+=PZ(T+-A[KE:G
M4;4>B ;=XAWYF9A$0/>ZE]AT+'/)-+BK/2/WC<FY_?)VW29Y5\O;GZ1A\N'I
MV6!T/AR=C4[/ST]')]MJF'RX4</D0Y &"%2<HF]G0^RPB7W%VML_&IP'FY:]
M/WW#9!H['J@*084;R'EVS@;02)V6:T$?WEI6V3?.HE%_Y"RV1,O]$<=63@R#
M,)'(W$6@;-MQVU ?*C$.F!I6X5Y3.1L%0'MLU**" [UD#'!#RFQX *NEP,PU
M76ASE1J E6Q!I)R5R*ZIX5W)M;2'T05=X*W*^N1]#KC6.:"]O9/'T!>;H"?H
MQR"R(5RMI1,X4&6E/P;!JW<4MPN9627.\^$1'%08N'4"B3F=X-]D!C ? H:-
M+N%&H5CD3/14L7 0^:57EE8D2BF\8NLX\.5Q;#N@^KE*L*0YK/T%+84BL\ P
M_*7US?HH(P^&>^-];Z\L&C3D[C'(U]P!EE'X28>R.N;DEQ$$Z5#C'6K\9>WE
MSKSKF).?V8!3P40@"<N8:O--+U.YJFC!N-G?.]\G^&O/:RRS=I"Y'&FP?KZ#
MCBV;<.Y?$B60C8)R1;Z3(6=; TOK1#Q!\Z\,F#K1V@=9"<'^WO'^I6%7Y*!C
M4R26L<D9A1W=W@S,[N.P1]>S[K86/A+>WB[B<MW9M GK458W? ,.PTY>;L\=
M'F_B#H_O)3;T,>C;%G?X;GI#SN5FZ 0A5I+0WT94U,*LI1]<>K74USPSEJ2W
MF&6!LK4P8\&N%F6\"<%.PLKUF)O]5WO_O2H+3$V$>L.]V;Z1<@TBU\ 6ITRV
MPA%;(SD7"$.8+_AWN%H!/27GHNC]DDL?5^$.%[]6B$TU1+"99(1]BM;K(T8\
M!=[J#;7S_P 5$N_)YY= 7=YINR(HW$0$A;Z/%>\FR.PC8M:G?5,512T10>]A
MK#;52NC>Q@"7E1HYK*F%"VD9(>P-S,&DO<-<TR6#D]/;S5R@FI\FE3Z$E:<U
MWK0^A&_ 7=P=N5:TMDQ2W=F2$[L<^B:)[F.NU&]-#<4'AY:<SU652?R:TY:Q
MU&"["J\D@3PT=2?F4N-83$54?J2Y+LN^?=I7:3YHE#<%Y<8HN9[F5Q>WH/!R
M4ON]>UV99T^F#ONG72YU.[G4HXURJ4>^39J.S@;3]BQ4LX<*8_SKZ\B-OE"*
M^^"1N[0=4O[!J<[2P6E(>M9K0C#<5#(]+5PP0!GM,EA%3"TVIRM=&')0^3C+
M$&A=845VM9/NP-K<F.SP:*="6.WLIP6+N$_T")54*'V.EFXX*TICESZ]I\@'
MQ5\EW,B-NN !U>PSW'L*TP(C@)/38U$/:(K;D/H"!;>>G&/,@CQG:PN<GY^[
MSW$:D]3:CSB0U^KV3@3R5^"94"GO=;"3'*H0RD/;FV5"'YOQO96C+S\AU*':
MG[$XN-W,!Q6\J'.$G>/+2F'=R;VT&J3GZ6K.G@%1(MN_M*0%:0*> W$4$#J'
M"Y&#K\PWC(ZZQL005W*)T=8@]9Y&BZ- BM.0:'^H^Q$,42-,'R9V5D;GT#1K
MSJ)0R 7#=!(>YP'>#PPOB?3%//<I!1M4;OJ9P\=6IS:IT=X*H0?K9TVAC#.I
M"R][/XU@A4$XH*)U+Z167$FD229\R=%'>G!M$3B( J^#\/C8N&'E]?&;2VJL
MD80SN. :2O<B1.$$RD:+8.%T"Y'JS3+<,/#"PEF6)G &IM3RG#O=T1!M0S7W
M;AYQ-MO.<O0>"-=T%^EEN28YG,RIR$I6E7+3F'JOLBZT\EP.-&F%=*F+6WO8
MURT4L=-!HJ$C'P;>W6YE:Q:$/6A>%%Z&M-JN#?2NAD8STHK8OW4#M#W9%WTV
ML&KM-.>IRFEG)SF<0KH'C*URL9FZ4;<T_?U+?;1D%M5>KXUSFWWZAU^QB3X\
MX]LUCZR\6&9NN4FI  5YBJMMYC"%:U90CU(%<Z$KBC&>R[]<65&4*"@N#V!G
M!"Q/-FG5\7B%U&ZU_&3]O+?K4H_ZQX>OTZ<>[Z1/_6M"Q&<-;7J<OJ7DSSIT
M;PSGK>I+'=",7+UN,WA'-;H3ASF.>@KP/:@S HC?=)K +-%YC\1"4!&EMRC&
M8.L8\T?7O5$C@)C^HD*5O9UTFJ]X3D$K_6945V @UEZVF_$.XT+):[8YQY*M
M-@-:7ME3$PZPVQ0]=QMU$_9S-G;9F(E#F]RV^XM2RY7-U3/%YF89R1:<HYGF
M(*! =-H,."'1%Z!D;N4\L$GQD)?%M:M+NQEOF2$K?Z5^JN<"JXA 8(%.],HM
M'7.=!MTAH%^&9NX0T!T"^F7MY<[6[)#/S[0#RY"ZXI@ZZMG52,V7AF0)&R"3
M IZB9@[=C+4 R*F52%ZM^T3AE641=* :;0:'.UE70G,O3;)H4S8IZH&B1GNW
M.FIC+@5L_(2IRN]]ODQT9 #6*Q&F.Q:U[5E6+2-:T/F">[FM6D=/A2:H G6/
MGR@YNSV(SI/ "$9'AZ/#T>CLY/#T]&@XW)8O.3S>"$9PC*B=2,P3RT/B5T [
M#..1[5G .HJG,O;^IB2-3S*XU?-LEGII/1UB?^"^1-F<"<4UO*B(8Q0F.BMG
MT\E&=L"M1:;98RA0]R%QFR4:+^KM\N _@QM5BD<M%*<! @'I9^2=<(=@TY/7
M5-V:!H^JH##D KGM!9J2\ <( CE7V/(95@7#KJ9[,GZ'XJI'30$3=-*<8D_7
MO8(SG"7"X2Z="*' ?XQ3I8A_!@4PD]'H; +Y[0B$YJ[(I2.ENT@'.FK)U:]E
M#^FTI!.K-2[NU1.L916JTO!MS2.MG%H;C8)^%D'92<DM2LF3C:3D"17XRU H
MW\?2_O(OK?/A7W .VK. *R@8'&V[I"-VI-7+V#.F4RE.^-0:AKYYD6@)7P/6
M&-NE 2.M"B3AD81DGKCA0Y(J<$ZXE2A\4;9U582X61]>Q/:C"0&@P0C+I,@L
MH0"/)1-3..ET7XPULH 6& F2<0_)?W*095A9@30 ..L<S%&;&+5,.CW#*Z;S
M-R!)0%1'46;BK@1/G<B8QV\FUD B9-DH0^P&5V]KCW2\9$:BQ4J412ATL9U]
M0ZO84DJ_FTDQ\=X351"&\7YFMB-B3'R:UQG$*EU]I^9M"5Q>O629G3Q_:E:M
M82GL,KA+5KOJ<2O0XU>@29!LUE*_WTY9[)JR.-U(69SZ/NUTOX9^5[X@NM@(
M*6[3UK(<_8QC;Y.BJ#K&V&M(KR/#6VH" [<U980UY@3+V.!S+6WV4F0R06&$
M0A,>@#2XTR CTY2N& ?A5VSG3:R*$9FP(.C1K'2,V)P2'/!-KHD<C?#!A+2F
M?C$DCSW#$QX:.ML89$6BC"I:9!([FZ?95^=A^Y33!LGW>SIVLP D6U6!2XF4
MYO_EJ ,P8^<XI:AFX!H;GXN\<]17XH8NQZKN0BE:&'N;6;#*1M<'-Z)#]W7H
MOHKN&9T_,1EMR]NA,U4B2X,J((VBC5RV&I(%B12-V;P$IKE!QFIC8FL-H9R*
M[=DU%AX\!^,"/:X7$AJV%R!@)\C%(RBKV7UETX?+?L&,2:S)TVQ16T^8!:SN
M'I=IZML@I": >F36]-%UTYSK+65K.!/A5T6\52IU."2K5<"]$B?-3T(9ITPG
MQ,IS8>7@(_A?#/(\-HT'_ZD7.64!JRW 7Q.)S_J,P$?%])<PLB2] 8-ZJM>4
M\ L:0559#HH)L.0OH?]E0P2-*72""M3W&2.P<7"#*T"=Y"9"YKIZC,UB)6$_
M8JN&%&0]O/@H73CK\99(1%.R;DG*ZU$2NE+7;5-<A%C9\&WC?W>WWYQ>*N\7
M6HTV62.6VN*RW)M.]A\&[O*IDNE/2 <O72 .%3R??,FU_JB'>;-79\LD>V;S
MZXVH,:1\3PUKX/ <H8HYH$:GV>F^:=R7ZOT90$'P@NM41B9D%J7%.->L>V$3
MA3\-&OS>!>]FEPK."4I6GU5M^EGRYDYQ43*"#Y9T"D[7 4L:8 _6!H ^30:R
ML0H:<++044$A69[&T&<N6SC%/F;B?491JDT-^VUOU/]GA^?A\#3(4_W_#8"1
M+]&8Z:;;3;>;;C?=;KK==+OI=M/MIMM-=U>G.WBV.J(.8KX+>[2#F'<0\Y>U
ME]LH=5^9DNFFVTVWFVXWW6ZZW72[Z7;3[:;;3;>;;C?=;KK==+OI=M/]P],]
MY,89KVK.CWO%=732T4DC.JD=^*/S;L-W2/'G0(K#]</S%E%XU,H<585HDMD1
M=?&)%XS3:^)HKB",B=Z0X)X:V4N-5PQ15LD4;JC!&UBS-J$_?(D;<?UTA\/^
MT<L_?$='_9/1Z9VG;YM+\*T.V7^);.GE61$3L4*F>MM9FPT Q"U=H+?OK_[N
M??GW]Y^N?GG_ZY</[SY['SZ^6RLD'KE*P_[9'Y'?Q_WAZ4EKY??;Y86W:=W\
M-ZF=>*/>>']+9XGW_CI(U/]I4^V$,ZXM":_^<,L6U+=:FC45Y9T:[Z;[BJ<[
M'%";L1<XY\=Y2"]!PEV%NC&XK6J++KH#T$VW<M[[IR]$GZ,5]CD+P-3Q_J/O
MO8>+E\\<'3P_/*X8U7\(ZMB\/%>9#.)'+,IP] ;^?S ZVJ0YPTN-E3W)ZQ^!
MZ7SXU*]_\Q7Y*<A%!S+?[4W\/"#S']Z,TVCYX[_\\&:6S^,?_Q=02P,$%
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MTLC=G^K0%GC',O.=Y,7)SSR8[(433#>2"0^P*(M0\83<="9Y5_3\C$>8B>E
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MF".4?W![(>.E3;B!:1 [S6S=Y+U<S31%L@@3CX#F)DVDA@L*-86^& !5(N!
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M?6MSVT:6]N?=7X$W4[-E55$,J1LE.9,J)W%FO#OC>"//[GY+-8&FV#$((&A
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M'$E4+H+EJ;4IVNCT16%4'5M3/?<FJ)*[-+Y#%69Y\_M+&@];_*#J)"AGR2=
M@]5>D$[:]7\Z2OR C]ZX86;B$Y'!K$)TXXB)Y-W % T8RH6WOXR,EE=BWEX
M?R^(M(B<:^NPB\LX <GXHSPC");C'4X3QHXG/UG>G3E,PPZM\H"PW6&8EDG1
MO[_*V#!*S]=FWWZM43H8G766\?TO<!QVY1-$2CL52IKM'M$Q#4^6#B\G#YI_
M@"UVK.^M4X66\:2W]AGRS1%JGP(=3(YXO'E4I4%XKZQE1#0(R,<(%:0GLL*
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MM"9?1P2V#%'ZDL%"C<ICB>49^\'/%!FD>GRVUZDGK;A\E/;*1]F@. _-N.*
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M;FY+6TS(.JLRC/C:_<3L&;>)#B )E*KNZ&1JM>02UH",#$IS9]?0E]+\5B1
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MKBFY?D*Q.6*Q388/=];D-M75RN/S>G,+L,LE4#6YU^'''..=J<F>,B_H;61
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M1=UC:-I\2I(@J9@M93VU "*4;H"N_]F_Z0<3&1$8 2T\*F^#%6LH)VQ5$,.
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M*-9WWX[3:/']OW_W[;28Q=__?U!+ P04    " #,.UE:N"LVH54#   5$
M#P   &)E86TM97@R,U\Q+FAT;>U846_;-A!^[Z^X-4">0ENVDMB5M !-XA3&
M4B=P7&ROE'2RN$JD0%*QU5^_HR1WF8NF'; ,!5P#ED@=CW??QX/.GZ/<EL7%
M*XARY"G=(;+"%G@Q^X.-_<$H&G936C#L5T2Q2ALPMBGPU]<53U,AU\&TVH8E
MUVLA UY;]8LH*Z4MES9\W6Z:BL<]%V95%7B#,R'#3TS(%+<!\\-22):C6.<V
M&)&E4D98H62@L>!6/&(8JRTSXI.+&2N=HF;TA()$U6[_3$GKEF P\BK;9]5%
M"UM;QDM1-,%*E&A@@1M8JI++W<)86:M*6FMQ:QDOQ%H&!68.2.3<=V$VN;#(
M3,43#"J-;*-Y%>[%?BY<:_N(6CHH4DELL6]$:O,@$Y8E9,>6O^.CT;D71D/G
M<1$-*_H2G2VM+PE:NU/81YVH0NG@R&L_X=<YV'1G&*LB?1E29MM<Q,)"5Z2?
MJ7EI4A**COH'JH7O!#P:?R.%?XWYAZF$J[O%PVRQ@KL;F"^N9_<SNM!T.7LW
M?UC-EK-KN/]P>3N_@K=75W<?%JOYXAW<S)?O?U;-__O"_-Z"^:_!_XY $T,3
ML ILCB!DHC3U)^Y:"\0-:,Q0HTR<"9:X%L;VQ@?++9;.=Z$&X/L^&T\FI^,)
MD.U&Z1(>F ]<IE_W,KV;?WXV'9]TX[-3?S+MQ^>^=S[IQQ//F[PY:??K0_G3
M\9-04U 9J%I3PJZ]&D@I3@HW&.N:ZP;&9R<P]MRUZY=RO8.<"<EE(GA!I]'G
M9MQFE\A+6.5([&-M16)@+I-!EX+SPRS#Q#5>B>89A^.C[=@;O0D-$4B5+BF.
M.P"M"E"/J)^$[S)WF?&J0J[=B$BWN3#P5LJ:EBS;)9]ACSSV&V1*M_DTY )(
MOQ92N,8$RY@V]T<MZM/!@18X'"CNH1E2$11*6(MPS,LJA)6J$ZJ2V]O[ ^7D
M4&OA4AFKY F\Y\;P)*\-6FL.E(LOVL$>#TZ+)041Y;38&EFOHUQJM#>!>"+6
MGDBSK, M2X5V_8 4&:&K2QFFPE0%;P)G#7?2;L=0J^[V)-V?M;$B:W;YMHZ,
MWN@_M=XS6N]OQ9?K75(]!B$+(2DYR[5MM7?X3P-1VSWNSEHC_\AX1DTZX,6&
M-Z85Z-'0B?J+5R3RW=\!?P%02P,$%     @ S#M96LY>^^K#"0  1'8   \
M  !B96%M+65X,S%?,2YH=&WM76US&CD2_KY5^Q^TF\HNJ6(P8./$P*6*V.36
M>UMVRB%5N8]B1N/112/-2AHP^^NO6QHPQB0A,79P(E?Y!4U+:K6DYU&W-'(_
ML[EX^1/I9XPF\)OT+;>"O1R^C_9;C59_SW\$@;U*HC]6R8P8.Q/L7[\6-$FX
MO.R^**YZ.=677'9I:=4O/"^4ME3:WJ^NT(1/5K)$5A7=9J/#9>^?B,N$776C
M_5[.990Q?IG9;@N>%,IPRY7L:B:HY1/6&ZNKR/!_L,ZQT@G3$:1 )?UB7GZJ
MI$41UFTU"UMIY6OKN6<IS;F8=4<\9X:<L2FY4#F5<\&QLE;E(&O9E8VHX)>R
M*UB*#>EC]GDUTXQ;%IF"QJQ;:!9--2UZ2W6WH>Y/5>>>?6!:8E.DDLRU?<H3
MFW53;J,8GC-GO]^>M Z;O?X>YGC9WRO@&\SIS'J?C=;8"ZNMCI50NONDZ;YZ
M'[?!U/?A6(FDMZ+;=HPRO,KXF%OB!^G"-!L:Y;.]\PF[Q*  TSMKF./AQ>CT
M]>GQ8'1Z?D;>O+MX^VYP-B*C\Y_[8_WRXMU?P[>DM4^CUD&-/B.#LQ/2ZB35
MIW=G)\,+,OIC2-X.C]]=G(Y.07CX_OB/P=F_AV1P/"+GKTGK:/^@[@H;O"6#
MD_,WH^')<CV8U]6]WVRCO"MN</%J<#9\&YV__VOXWWE)[6:S_?/#=MZZF;QI
MUVV[IT[KY$^523*<4&GJ)&;:\G1&;$9M=VZ57="3K'21I6/!YDI5MD:[ IHW
M#PZ?]BI<1M6P;+ _9H@$G:G2.GKH^6J.CAK-A3BT3M#"L*YA!=74,L\<4)V>
MUS7A!N:\X';6G4M70B"5+(#9E7W0Z!P\76:+JCUSNMBSR4=R'G4:OA6?RPI_
MZ%45Y]R%UE_;0U-H;336C'[HNI\1)JQIQ4V6;#;WD0VKM+FQ7>($ATU,137
M07XA-Y\ *]D=L"]2-Z/.PV\SY38:GZW&#6Y<T['!F)N#$LGHA!'-)IQ-60)H
MQ T92%E202X8+NJ(DN2UTCEI-:/_$)625XSF9)0QJ(B58#Y#3F7<Z-T%PKX8
MEVY-2OB-J'/OJZ0=6QH&? [XO&N0T@[XO#UCOJ(&4!D@.)^1#U)-!4LN6=W#
MM/;XG"C05BI+,!?EDE Y(Z6TND14@)F;0U$(W)3D\$ES@/:4QI"DB<K!I[+*
MR]T2D"QFQE ]0Y&<?F!0[U*9!M(24 :J%&AVK ,%8J[C,@<Q"=E!$X 3 F:(
M,V)*_'&=?\HTJPK!!N3<"$:Q'\F4VPP:: H6.P6QW )44PDT$X8%&&4\6S9#
M+[!#8(? #CL/:/N!'1Z '1A)N03\12B_QMLZ4 .(PV.]])S+%);W%..N\'<L
MR@3*!$Q? M<Z\ '78D9 1X-L@BPCQ#5=5$AM5JH&31,7T*VC1"E  #A" 9"[
MZHS3)Z8F(ZE04S,G$,TNN;&:0D44$[W>H&5]B0?,7)E;V@8J"%00J&#WT>L@
M4,'VC#FZ@9N_FPKFJR@S+JE5FG+X6#//')R>$JJ9 VX 8H[(  !+F,%)STV&
M.5 L!X\"O0K\G' 3"V5*R(<5:R4\@A=:Q2R!9$-J -@) P;PJ#R\BC,J+QD9
MP#+^HA0@X38C.C7FM7";$?C)?^2XUR(]<V#Y!-?Z2X3B 1YUV;BB]$9%*52$
M[5RE&9# 0%@W4,?CI8Y.XW C_-\FZ;PX:KP(G'.O,'E'8%RSG1Z8YBX&K=%G
MP9I;L^8),U /D)B+C7V>8>L8MHMI:3;/@O&S,0.VK&KR$3E5 A"5X$LAQ**'
M!E),NG)P2_K:MUOV#_VY'*#?*B1W3:'URG?$AQS\/-#%*,$3:IVB8\,33C7'
M!G ?.'0>J\222H/!/+=@,2[RY_PY91@H9,%_Q$Q $#!22D'1#85F.26N@X*0
MPX<8ER.C\->8H2#T"^1G2? , [T'>M\M- WTOEN$5!L'>K\O>M_8O;W%\IL[
MQAN3/2P0)CQ!#J=&2<< U #_X[8=$CO5R9QD@?8Y]3B-,=IUU>*2P_&Q]F"/
MJX4;HDO;?B[0<%4UJ"AU 51O7$PYC@$"G0)N _"22::I ,:')ZS I02*E-)Z
M5H<E!R_ UP^\'G@]\/INP6C@]=UBHEH<>'U[UAQ.J"B=;XNDQ]*4Q?B^BF1F
MS2[F[V83+]U_7+^EZ0@<,H*';?S&Z1@0^N-U;Q)'H MIAKO"Z>?/V)#Q?+_9
MK4F8MP'HT\/" P<'#@X<O%.0%SAXMUBCE@0.WJ)O[4GN-EGB =AJ.]@]6>'B
M+_"E,1"NXKC42(9+4><;Y>7*6$C!%P6A% -]0OXNJ89*2.V6< I,#I[MBERE
M9@S\ZD[JXB%>]PZ&U^69UR2C9A&61Y_8,3]+7+# M;YRY&=$\ ],5,=V5^3K
M=S!(X/E'SO/A=-4/@XZ=<+KJFYZN<N_5)7.*JE_[3NC*+5/&M1N%T/\%(>);
M>["@%RT3;I4VBWBL2X#"\IQ;R]A:YW2LJ'8>8,)!)Y>]!I0"OJ!!7Q-^XP[P
MG/O8WR4'E1W;E3)V!WF?/=J#4]M[;WHM*^!%&+&@QN!TNV31318 79=NREBZ
M%R,5["KRO8'78<!8+G/9@]%4 %]T\>GM&8A7:ZS<I_&_TN#XG"OI,D;@[3_B
MBS9>W/<]&]>W;61ZA<ZY%%R";A86;9ZQ;SX R_IDW]6.R&@*\[E+Q93.3"]<
MCG*/EZ,\B@58"+1\EXN-$&C9K?5:.*.X36L.A"!XG(##$A=/R^.Y^Y@S6)!6
MVQ:+LX)30 #<A_#;^6XGPAU$<.\:SU_[^J)E;G6LS[^KL":^01/(:-@BO+%F
M25P=7 !A6$\!.M7]-H@Q=6+*' P+_>&:486/UKX:%T(?CSST$9CWNP2ZP+R[
MQ17A^.!6F5?.2*II"9PUS9B+.0&3NKLR*LJM^ZT!+B=*3!CN#TAP/OV5'[H*
M4[&\$&K&X.DT4SXP16\0.A#P';=*U@8;U\%:@+( 9<&$/Z()PT+YXPMEMP;>
M>)G<:C8_N4ZN2O:#R>6[VZ;AT=>M?O<;G?;7Y6Q]Y4+]L'&PF^MM-RPQL"NM
M'V1WP(M#D%R$>ZO4YYT"QCB^;T>>I.YK TA95BIJ-]K/GS^]J1>DM2'M@>;F
M=L^&P#SHDM=LK$N\OZS=J9-VL]UY8&C?6E<]QBYX-5N[*1BFR@YS]#><"]6@
M^S[GPI[96[K\>U-?Z7L- ?WP<R$8,!@P&/#N_TQC(_L&W/WQ1KUO1+!A&(1A
M$'Y;]#W..$O)\(K%)9Y9(^?^G&R XC +@@W#( R#\.&@N/;&7YA"!6$+/*[>
M6UB[:?\ .S8NPK?;FS:[,Y'"&POA]/NW>&6AOX?_ _;E3_T]]]]C_P]02P,$
M%     @ S#M96@D.;S6I"0  >7D   \   !B96%M+65X,S%?,BYH=&WM76U3
M&SD2_KY5^Q]TF]I;4F6#S=L%VY<J!YQ;ZK8@!4Y5[J,\TX-UT4BSDL;&^^NO
M6QH;VYC@!)/ (:H2\$Q+:K4TS]/=TLB=H<OEVY]89P@\Q=^LXX23\+;WJ;[7
MW-[M[(2/*+!3270&.ITPZR82_OE+P=-4J*O6F^*ZG7-S)52+ET[_3>2%-HXK
MU_[%5YJ*T5*1NM-%J[%](%3[K[I0*5RWZGOM7*CZ$,35T%7W"FV%$UJU#$CN
MQ C: WU=M^(O:G6@30JFCE>PF4XQ;2'3RI$(M)J-PE5ZA?;:_E[&<R$GK;[(
MP;(S&+,+G7,U%1QHYW2.L@ZN79U+<:5:$C+J2H>*3YL9#X6#NBUX JW"0'UL
M>-%>:OM+S?E[G\$HZHK2"GSOQR)UPU8F7#W!^^ M^/=7S<-&N[-#)=YV=@K\
MAP;UAGW,3AL:A^5>)UIJTWK5\#_MNVTP#J,XT#)]'*/TKH=B(!P+TW1FFC6-
MTMR]1Y$OV"5!!< \6<,<]R[ZI^]/C[O]T_,S]N'CQ>7'[EF?]<]_[@S,VXN/
M?_0N67./UYO[6_PUZYZ=L.9!6GWZ>';2NV#]WWOLLG?\\>*T?XK"O4_'OW?/
M_M5CW>,^.W_/FD=[^S5?6?>2=4_./_1[)_/M4%G?]EYCE^1]==V+=]VSWF7]
M_-,?O?],:]IM-&9C]R1M^3/[OE-K%<ZL:XQ-]_VTQBX-'W'%>EAP4F,)&">R
M"7-#[EH/&;9-:[H\2(X/)$R5JJQ-ED5.:>P?_MJN>(-4H[IQ!*A 7?*)+ITG
ML'9HYNAHNS$3Q]Y)7EAH62BXX0X"MV%S9MK62%C$)"G<I#65KH10*IT1AZ][
M?_M@_]=Y-JOZ,Z6S'9?>4?+H8#OTXKZB^(=95K%B5V_],7:L/C# /[?\_W6Z
ML'K<;O=BD<<;C3UBZ^K:U-C^XHBF3<)E-<51?B8W?026BIO* 0A7UZ/VPQ_S
MT*TU/YO;"]R]8F"C,=>')3;D(V &1@+&D"(:"<NZ2I5<L@L@MY-IQ=YKD[-F
MH_YOIC/V#GC.^D/ AJ!$\UEVJI+M]D,@[*MQZ=9#B;\)=1[=B_L6U_4^!GN
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MB^Q/2W9$Z]RD4XI%TA<\H#3E9U<U2PZ'9V,3H)Y\A071N24_GV2XKCI4E*9
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MP]WU2SY/>]7HJ0WP(VZ]B)N<GMV0?9]-3IT=^N+DMS]U=OQ7+O\/4$L#!!0
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M20Q5 >%SLM3N:=QOV7-')R_Z+7=BZ6]02P,$%     @ S#M96O3K,/:I!0
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M*N#,V+P6/O=S,*%YO+\]\=2N'W<\]_CDJ'WJM8[;QUYG/YCBUMX92Z!?_"\
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M#,8X+[T_[_?G<\[WG,?CG-^_O^^+'M5]7Z_[OI[7];PV8__+_BQP^)*!L0%
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M%Y!4(IP@'T#[@^S_#MB#_T_(_@'V;UQX@).!#G0> S<  _:JR-S[0-RW\;T
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M6#+MZ+*P8DP8'_7B^.U[8F$(B(.7RLOQE2N](E$I?<Z0"EU.9-^YZ7I,M -
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M)*#C5& \639CBF6_X;$9@<*IGGZ3DJHV7-\*./B"!/K4.2^M'=U)&1A@5DW
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MM[(JU'4NZ?X5%GM]?PQOF (2,=OWH*$H05.W .EOEFK._M534(;19T%26L[
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M_5)+-%QU?(VZ218H(B: \X)B@D)T1L&/7XN'324F/'H;/EF<$R/[ULTH?GS
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MADNY@:@$D@ETZ+]JCKL#)4BH[L^&72 "[X5)BW$ "Q%8>"KP."HY;%FE"AU
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M&0A[MY8(%.7DYYXIA(!V6$\?^O!K#8#Q !%8%'$@G+@@+TD\^RU"!DD<*V!
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M1Q%,NPT5E6J9:S<,2=ZX/S.#XJ\)DQ2BTK@FW_3X$,KWT.Q3F@!$Z:1>',Z
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M5LY%]=%$1ZU_T:1;RDAU]3F>0@W&M8_N*1NW74W>W01]O3RVFEYP* O7))P
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M.N"*#3K.F2\CZ+Y]9#-T]?7Y-#IWMY[N*KO=[4CV6QL'L]%F4^ RLQ?>8([
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M[S]\FT]WM/N%YMY6]$YST^PH5;16S*^%)V]TO@!O?D 3/^TC=O%#HD-4D2G
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MK;XK@I-@>O.U46_AQ^\I95 +A72/@+.*"[NY"[LE7>1O%( 9O*1+,"/3SU,
M>@.BD\<+R+8@L9 "G/1"A'FL7Y@&@8\28JBLTYC*.B'[O+Z]Z]J]ZS9QI*O5
M;3('+"03:D];BVZ)^\.;8)>S2^!2 GIK!4(\0P$$8_<;/U U*J5*Z4,,H[(^
M<"0:;Z9(_#58NTXX0WZ.8$?,EGC@<R=NUC&MP3U(!ZF_-IWLFD-YN*I[N*XA
ML)FH"XC^.!R2Q-Y+9D.TJL!O4$DZZ->6*ADDL=WXC=!#$ \%4,^GN@CT3Z7-
MC(FXC(EZT!_$ N&_89C12]J_%%Z@*JR6IY)#[NR@ 'T?$;,RI%B5?P#32>::
MQ'$>G2;_#B4&J_U';?_6[F_M_N_6;NB<VUH?4;"/%$'R7N=[??00F69W](9\
M44_V$Q'4;O4ZC&M0F ]!?]A'IOM^*..* 1KH/KJJ"\1 O=$L.HGRG^TZ1H1H
M[4MYW55>QRL_.%M;PM!2I!9E!KZ![Q3L1+@/(L6-#,,FH7)56^I)[R(E%IE6
M9O\[']P<[X.;CQ$8,8<4H-\4ZDPL)VM)(*F.+Z=HI3_M)-O((VXQH:GA5.7B
M?ZP]%QQ9^HFJR']\<;/M8B?E'%5O5D4!2D+J#<2<Y-N7-N==[RJ,0)%O:!(#
MD_,"A;4B&'.)0: #O&L:)VM>GD3Z(E-;ER>UOX]C1LP>-T9@'U))]'4$]:)Q
M1>MIDWWDPC_?6J(&,AF<1S0D#6I-[.6<38\O<4O_EWNY9(Y'D&U: BWYS$R0
MLMT5'3/Y7D1+;Q0YB"Q K4W_[Q3@C(+,P7%B*-4D-J_S"=PV+DS[BQQ<)?[R
MZ8W:O\Y>^KM.Z?I&YZHUAB0YAEYBPC&1.!M!^')[*J3@%V"\[3;-P!I;EM$/
M?P8SQ7]Y5_N?7@">AE_&A/&;:MO*PG9*//Y)A#BB12FB']0&(LKX ;U$_T-U
M(@);W09AA97U'=[::N.7\#YTG-Z9G)(SO" LA65LNUMXE3DJ.$6D B4 %QD(
M%%K) J&&U(?Y]L)V3@Q5K$8]@W^\$'^LJ+;S2MT5[9NME]K_1=A_5K6?5D<0
M<.!:%(Q]M>9IW??G^JWG_?QY6)CQYS!RWB8:Y"YGLU7*<$EZZ2-=?>XN%\N5
MN3-;:?6TB'7B+_E(-WD_XA\>&+WZ%P@-F?U_]+3_]0:"^]?RN7]NI@GO3(W4
M7(9[*,!?F(H\^__>YXJW7.(DXLB-7HB_J-%E-'_G5CY=!2)+XJ_:E8%80$#O
M)>M#_U'YOX F.B.5[='J6-9.[U\*=LDZ7>'GLQ*W/S/KY1!<O#23L?7HGYK8
MH.%?V-___,.!M;R?C9-;?]K@3CYXFF56;UA6B_ZGF^!_LH/EZ:AD/I&O"G_1
MM#D=YK5URV*2_PHBS;$GN7GC6E__RLC>K5TS''B4Z_CGM?O=A_?#LL)?2+M4
M?_;>TPRQ\3_OJVPBQ)7U7SWZ4T"D6_^[ZM[_&IODR"/QY[U!U.>_ ?F?!.16
M854M\L],\6S7\H<2IS]M8_]W/J-&,: V,%'&%6@A.)&BS7[_A-BB;=8D!F)(
M'AEZ7\,\9;4?DRT-^ZKSQI?O4^VR)>M%62\J9]3M=\7\9*NA!C(QI)5&\V'$
M#PGO?VPYX0?4OMTJM$*,:MB\MC;C>HOHLITDU]&OBS^X=Y/-/E+\%H-AI%C.
M<>J_8D#[KTVQKFB)O0OZKYNS"!>FN G$&A8_7KG:K5)LN;*RP7A5;U!*AW4E
MM;Q&Q^X&S*CGB3D>$*T2.XYJ/X\\"9DPQID%[;#%=4(8UK</U6YT;*P,'&H.
M6QE5EZ><YO:XN+:O-^]!;_* RVC*EWT SG%43)(A6,V^@]6M&@X^]2G]ONX=
M\&1X0[5O[;<L&J4MGN,Q:0)S\8R 7Y58^[/IZG5'/&X/QX<,LR>DA,\(-)R^
M7[Y% 6!KRPOB3CE/7ML]WQ#8+H!I[R*)'G-H%E=NTZ0Y"),MQL533ZU-]^FI
M+IQ2<BNOA#C+EFPB)TKL>'^IED0/''3H!)<@;*=VYQ%76T=C\L=1N4]/=O1=
M'.<R>0\=:WOFR%/'B]=7N7-42C[OBF)N&,42JD*/8NY[L6?V#O;-%S>448!"
M,P8:GOT)G5:?7L#OH5C[$VK$3I8CFLVY1WE^@!G;#.YTJUSK+=I\M'_Y%B#,
M=X?^#?/CZ[.C%Y"!$Q2 \6D80>@RK%P;/42ZZNCM[^5X8CRYO4;$Y,[E>9U6
MJ*C+:B2P S>,)$ 8 C$0AAUP&#\+P;04%R/:6DKL:)>!0DL61'2"._!CO.)7
M)JR#:OG<\D;1;HCP+&[".Z+/8<<,?^5(^I3-4;K>V^3GG0LOZ0[?,MA]MG^L
M"?@I4'%%AR'<-L,#Y?MW>O5N$TI"/>]C"SV]/WY[^'/D&VMF6=6L^LW0<%[6
M)I'<?@KP*#N,+(R?01:9$^=:MUSJ& Q[/_3MQJ#MS>P_+D@ 7\U#V%B2.FBZ
M<IANMY\O\<"FMO<QDASQ^\.J,L7FJZ9G)&X,6*G?OG/EE;>2X_V$5N 9^\!=
MFL@KFFR ?;2A)G ^E\WP^BFQ7VN 1%[1<FLER1QZPAPK$9PRD1YR:/KE.M!+
M:?BU?!OK&7>HJY6S0Z+/;Y/9KVKOYGJJ& 2*'9^ZHB61-*BN1-2S(!K-7*L<
MW1XG74SI@TV\^T*.31"Y6:HTYSY"JQK-NUTD$P.J0$>0.6!N3RVK@A4:/[A0
M (\!21F/]D^NIRU8K'I:H3<&+H8WSP=QR=$L*^6R=XR3 O"O4(P#E5_@&GG2
MV46V,;(36*=IMCW_<08QSZW+3ST'B71*P!"8$>%B< Q^G\"XD(3-9G<^F,FU
M?Z^;4Y4A]?F*T6HV*KA&,HUKLQ?P_2]E68-__8&)U![>@W5W8%A(9F]),O@[
M:3A_R#'KXO#2#Z[IG;MPHQFV<_+%-2RUOB:.4[V5-Q6N%:\:3!HW^\D$P14+
MB0/[@: 5_HO![[G5:VZ;C>2#'F3T,SQG (_P7CK!.]M/6X*+-LL@EN^BB ZS
M'BP4X('KC +^*"M_U]!_UZ>6848C^JOPG&#WE9#F.COO3U<#IQ!T=OC>K,\S
MZOC-7?>W<O%6=T0E19P)"\S M^$IV;&)JR-!:E9L]@V'G>!*2&MV>%U6DE,)
ML5MCT%V^)K>FS$):@_6W'R=2!2\XV%\_VW9IIP34C*F.B" +P\:W;4[I"[\O
M)\"S..LX4Q>XA.\%YVW-VCS7L4A^I1W_.+\\^BYMPR]YG;,K*4"K#,N*7WMF
M7 Q)S<LS9[+7U^^C5YOGS6SYYJ65URJ1').QGF9DCL!!6QKB>/&T"XJ5\# &
M"1EKJ6;5<%%?,,_("SW\DJ4HK07+.;O*9E\#?@&JV&RE.K$LV4H\!7C18//.
M^:!]5DO/+6VWK+!J2-I/ZSS^3#PCE>J=0KM5$N<.]6"3S752[U-%(F:#XJTA
M :7D4<\G-U(FF5+8?LN/W, D=C<U]P+^#__#;O_)F._ZW3W&2S.11-Y'QJ.A
M8*)8UD>\5^<6S*!%P4?6E4/\_<'N\NTHGL]=,6PLWZXD^CD5^.$WB7XR[1[[
MRSD48):3 CC:5.#9G?@?!/JFP]XFS'K*M@R]>O-N;9VG\" ['[/7"]KK#72F
M@O0]4 +1IT]+ 0#TH3@8NX1F1R^^I[K<(,A1,F07ZM!'5;4U'H&@ #14OQV8
MBL#((3#R^[D4@$F36$P!U.1 )"K57_LUA>,=R90"9*4SD6D0N_<0#T>8B-'7
M:*G<&@\BBB[['FUI'VU!TL'X;4@D9FN0&@8TR9"_QOU!;.U=J-W?1?Y=Y-]%
M_A]?)!.1485]/Y^6Q"Z*R_/*O>I\3ORSL'XVX_I>X1IDK'JW+&ZW "\_W-Z>
MYQ=8F]OU&3/9,1Z=PF7!>I2R&-HE$/FUBKY8;$O/8:I+]<;7JW#MX<=EKOYY
MP\@E?RUJEVAV8>_///R_WZ3-)):B<;G_F#75*Y..QF'VN63 &')(>>&-!VR&
MFB<R3U%!N6"5_?O^$B9='RN]* "K7MS!DO;JW8);0&4N8UTE^G!G"!9JK"P=
M]@S&=J4R;+YYLX+5&I5 ?=$-L;>:1[!YE9X:[GT&9F+ILOXCAD;I9&2\V$J)
MD\47PZ3P79^=JHBO*'8J-"]A[S:O]WNOZ[74G7'VF\E)]^MT+(Q QV092"K&
MFPD]8(V[;;I;<.A$[#8D)N-ZF6[VPR_VPVP/UZ#2!<51UT2ZNBZ8!\)VD%QX
MS)K!W";QAESC65!$G4@H[HS;_!MB^:&+)8Y9>.:\UIM$SOG5R0*_5?FX\=!V
M2X]V-(^K&89^&PRR7%5L<9,H[+67\/WM]/'[.D+NC[("W 9VG\+C.IT7K+5P
MN89W1H?'=X>A :0BO]1UQ4,72. W%#<^HRK"[9,;]Q3$!549\J/,\GKD>POV
M()57'$UJ2KT:AS?(TX5XIS;4"3TU:3X]3<)376^I[Z\*F^E@S8[6=EB(:OJ<
M-/@!B!?N1XPJ<LL2J4$ X^WYVF]=?!3.:< 9TV[K<PG=UW!7:A9<MDX[B@J\
M2$1J]F_S>1@$%\.EWJ],..;O-\2D:P84/YST2MAB /T_[+UW6%/=MC>Z$!00
M(4H5$()TI4KOP0*(B $+2(V(]";2 @0B(KU$0$%0FH" ](ZT2.\B-71($%!J
M(A*BA.3+N_<Y[SY[G_?<^]WON\]W_[CGC_E,ULQ<8XXQYEB_.09SKC5TCQMK
M^"JM.6_U.,X;#IN.%HKQ6J48A\S9;OH--6=-+D/G;D,%0S%\:9W--K(+M:TZ
MZA#< _%?B]?T'/F#'BB>>>%VAYA_5(BXC.?>'!I'B#>]3W%ZY+7KQ]\\6=L
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MI,SW&SS<0;8I^?-NG=CY8U^Y4HUO&23MBLT-W2S:/48_$"/JB6LU6,[N0/'
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M&.1R@7^0#@IKY(_?3LB.T;I[4,; 0Q&I#3>R"C8[>2!\**Z2,$AWEMZ'_0G
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M=(>YH!OETU8&UHKN>KN=(SS/8I0' \/;!9KX?(^-D690_H1W_4_M"UWA^I$
M82%Y8[_)_2N#3?-%>75I:I:N$SY=GM$(152#Q@MDE)-/#UQDC [83\+L"J'3
MGN  UA_#=G'2%<G3=>H"SOI"D)Y$B%W(D2;E:*=;AO4)]H3L>F;/WIO01)S9
M"]M.-G]&3C!LOHAZII3);.41=JR #MQTTQ=V9!E15S1**_8?OY?U2!! O[HR
M?/H]H>N/\)9"UPG/*U2-.BFQ"P5CN*K,DJ=-G9TFLZ\T[5KZD<]MTDE:5;WK
M9GJYJ2:MQ6II]CV2?AQF]7)B5>EGG^='\3EMOG36\@9OQ$!FKI>C1VYJH<OE
M2W-CZ$L*[,39I,,&RH(.Z68QO@'2S^HOKXQZ?M.&^<TA6_LO_/.DB,X3738A
M[#H=K]CR:Y+Q<5YD\:+@[B>W;!\HZ HYE90/.#&E5NMX*QC[;7 5RP%R3$_F
MULIZ)6R(C'CQ[MEM:[OCO]O6OP\:DKMQO9??P5T1,#*R[-7ZY]/F.CY9\=L?
M7A/<]WYA\<(=O2_2N$Y[^^62(WQ)OK/0589E*1;=IPW872HD\C[M3LD0BI<X
MQR*:I3*4:_##/6%^>.CRCRG42MCM1DGH.CQ]OI-3P5?-J4XCF&]N(#,)+4I4
MZ)</5M<B\=1SK;=7M8IV):&JQ,1)DFFIO1W"%;9))XO=S.IX(H#0U_M]W1X]
M(D4!E%HET:I/^R/&%;-J1(YL5BAB-F5*E2QF)2"K,2(>TW,L'Z@VD:K>#4'Q
MS4HG<RA)N9W, Q;ZJIUOS]:S/GBQ789S7W6Q?S]J_'P_5X=R>8<!UC^N<;)X
M5SKF#!EEJE^KI7@U(CU5W=A@O6@%=Z?%I&T-Z3FL_ +3^&R(I3O+!NY[A\:/
M6K"4;B^$3A:W/**UB,Q5X<\$W,5V$)4^9[OWXV4ZY\VNVL2X2/Q6R:H=2BA^
M\"$V0 )]6;99DX]ZBAQ"P'0(EVGRDF)+"- AA4O,PVW2(K;M6'/IVPZF\O?\
M;)T/WC!Y/OF]?M_)30T' )B>T=+[L1OZ#-=I:Z%2.WO4:SDJ]^5F7WP@[K=7
M^?1^59BU_GEOSB3[L,XZ_LI][(DA!>?/C.FR7-L9G_"RV.]MR^>H$P0_I:XI
M-693L<18X$G'B-G\NU&.2@7%<ZP;"7FAZX"!Y VP.+YU2GPV<3>,\@NC+O3'
M"DGD_3-L1X'-[9![6]P.;)L>/<AK=$2$^X-Q6  @G8*2[VM.M_*Z$^>[I=I*
M3T0F\T,L\Q_I!>><-5)^.IQP'04(H#+89,5$BT8?*,S'JI^,\S KJ__XZ<.>
M"-B!Q6WJ+^8,'6K:P,W\%,5\1& /-URODP[<R:R"D_?85EDZ])M3^3 U$5>3
M/LT+^ A%B,HCKN.NN+W?+3UD/R/D?M9;+_->^7AFXQ2X.<GLIGU+=''X##R>
M[%ZFOD=>/BF@JE\B23$F/CQ\=@1C ".2,>V98, DE/.3%#I 4L140"ZPP2_*
MEO)"!Z!).E#9-BVO[48'4CZBAB+[O#"D=5GXQ8VX;M@4_ F6C(:/M=$!;?=R
MS#R-#I"CX 0B'<A&TOA[-]&!WGDZT.^P$!F/G17FH$Y1F<!M^Z%CV2%>2@*H
M.P/-9ES^M"@Z\"6#C  A8=")3)>J"9MSH /Q100X!:)1#3#[9HS A#/X6.0U
M3"7+6^CJ'9@KF-?@+R0Q[AQ1 =9A9LS14G0 T\NPV6>K /B'B\K3M40N\K5V
M)&T#8@*[ &M>*V>-)92HM>]U%^_Z@9X^T'GY-V%9J$'=H4&@Q1=_(2@!A'%1
ME.C >TLB#C($!I3$/[PJ30>,GO<VR+^"]S.=Q\QPPPOAG_ZZS6$C^X47!LFL
MU(,7,T%?J7E=*G9XK9@E%[1 +O#ZY@+P_)<DAL5BP"7<NU=PQY)W4C#4K;0$
M],%%75]P!QEIU7+O$D5$\-JQ@1:CYQ:B1$[9C\KF4^($I,"(%1-)+C@WP:K+
MKC O4K7[E*7%2[UM(9RF]X-O<B-;8:]P_*<]!OHR;\ZFE6^=-FMRO#2TS5I>
MXN@[I\Y0A\&"P&W!EK721T<L&]ZB=8B+.$Y5DSC3>OX]N4>',[72XP-D/R-J
MR__O?8%+@W'B/PGI*/KUWS"][3QRK"O=O_Z%5&[</C;I>-]C829JLWHU-$7Q
MV2>W#VH,=]RK3E,NO@GF&!Z_<X4.+&R"DJS$4BS]B5;ZL+N ^^;/%MTZ[X^\
MI+RMV.!C6C]<H?H(-@F=$NY8[4(QH=7;E%+&Z[JBM&_.!P*C>^]N'J<Z8:MO
M5[W<*5KW.^G^DP2.3K/9?9K,5%9BYE@;L:>F#.1H-M<E@E'G'!RTPS]Q1SJ/
M^U;&GKPSVE/@10<^ZA/VX!+TALANK3WUO57I PNB$X.F6+/J4V,QU*OW?)#V
MY)H^]W$*R;FFSP]'"JO$\6J*C+9JRC0J.9YJ)I"S+2S(Y_).BDFG2^C([ZF[
M\6Z:=7-!L-/IX&3*);15'AE#B);?2AXHQW,K8K ]ZUKE.Q%-.3,YN/(LN1O'
MDDX*!84 Z+Q>WRUB'E7>S"(XH?HNV_39MDPJTXR(\J;/8'>!F;FS7DYWI\5$
M1"K2$J?C[4J<!S>%4Q3)J/X8[.UB>)P=DGBOZ^CB(#X\'2'?D;]7'G[_O*S$
MN1<-S)Y5%W3IP(9"6@RXQ<Y*LC"R7-4L,IGL5VZY9V$B<_"$7+K-Y0;VG9\Z
M+P5][-<HC6TA8EYA F#$)V@](J(*WBFPE2^*=:S%TYV?-IO=56;3WR^709+<
M>J@ &W+,(CG)&0:C X[0!D'&]U'N:C*36E^X9PQG>2CKDW1B7##Q6HG=VT/!
MG3NM;_7.LZL8;>^]7J\VNSM?2*5#R;(PMHF 'LE%=/>?(R1U.JJY6!R;RX+;
MH84)X_ RD*]I)F:GL:B\06YP:Y.2=]D.;;9K/'H'#%4D6N.\$Z*H<:1\*E]T
M__P85)/E6"B5/8+DQUE4]2S2_A!/AR=)Q9JPV),)>9OE(VK03&[$$Q,'1*[9
M(X/@1$-<,#(+Q XT<-K#N-5E29N/0Z=0;]:[5]*=*XX$<(W=J>LR+.;1>58K
M<2ES2F"A<&M?)%?_Z4PH2$U>I;X2"DIVE<Z5,W$<*2S)R;<8[1@:J:?./)TO
MK,I[R%M25RDP+.(HFQ/,;RH8<19QIFLN\QV\0W NDSQ+1):!_(T2Y&S;-/+\
M"2*M+2CCV0R<I4J"V.%I?Y9',>O97@N=VFVV*B$+K_K8IN4WH#W)X11ML+'#
M'*O4L,5N+NTI=4-A*RK'[ 7+V_$-8=I*6>)P#HF0.YN##PJKLK<T$SJR3D\<
MK7Z X7(R\<^+.9+B8),QB8JT=(6?O1)CTVS5'%?\HC"_.+O D(38X'MD$&EZ
MIDRL_YG"^&B-TH(:47PNGQPW "67$MFE#[/% T[@2/8'!2S(]9_G1O6"3[CJ
M;=4U0K$=*3/F8]N<%:J#2+KH(0RR,9,&YK):U'FM"2C>+YKK(T^0D5[]=4?-
MW[?.>[<D#5@\W,;I<SQR\[7V=2="PFZ<K/4?32M*$YD]P"H2G1,?4502J3_L
MB,[P24(--T>Y>OA3>:,'JG,IQ\ J#!?:I1^1E5>2:5?J.&U1,U@CD29>?4*>
M.-'^R$VRI+3XZ/W!8Y<>Y1^KJ>Y_/EW1&L,6795#,WEN7@\GFNA%-!#@UR82
M,9*;D;=C8:%V)_,2]>:>;[(9*[X>5J,TXWJ6JD5VC:.>)%Z*(TSRV+E=K0]\
M6O6I^V37DR^?3]]HN'P(\%79L/YW[4/UZ&PZP R0$U*H,N2%QPZQH@7YR-\\
MO*"><7M6UO6!9TAUYUCH_A!XH<4V,;)F.);$.A=)+B+"*E6QMV81?!Z8RE-/
M\ E?V@IMXCL.Y/H?>EF"%W">T+ZHS[9>R%WD$X!0FK3:3+L!\E'A[Y4Z197+
M+R_X2&1O]4G86?5A7J'+0GX';+^N[8FR(?M[&FDI).S89!_^=ACR3?H7@:MA
M]E</-E[Z1]4#_7-9GFD""M6PS^R:_SRHTF?(6CV?38XF)(^?Z:]%\HQNE0^:
MA9'UJ$*.<\,Y,_FT9KGW9AX?PO4B<0_<M@U$V='PFI+H'8'(#^K6;GA'1\'C
M'ZZ,RPP=VI0XLN^5RV:[PB#.6G696Z<.[8%=.E+E;=2'^X@A8"K:0@WD*[AU
M-:IF,Y+4IRT13DI5=7F3.\P]1;+WH;:=FWGUA5G^)N-W\+=BF=LRE425RQ;1
M+E;:3NO\;$/[.S9.P-L2#5_7B>A+D3:V.'.J.AV$J:%=6M0]'Y^D:N:2(K'J
M2@,;<Q&_D=TM\O-R<RWD#K<B<WVFSVZ7W1GWVM1-+;NLWK[*?]R:I/4'V;:/
M#@2T:6XG=L\%DIBLHG4"R^O./7]R/[BYYE+YD-M<Z/Z;BIU^W4G/!2\A\![*
M<\)DB[Y=/ ;*Y7FD6OZZ] _&=2Y*E?=RTR+S_V$G&J KS&.FM%WCJ:/XG!09
M&><!#E2V]O"^L#3NU[]SV]8]-UC_FIDG3_>#"N'7F]A?7XNIB34 T"%P*I]:
MOW\Y%^ 14FR@U-T6&*V=@T,TN2(XY%($3;IK+K69N91M]YMZHSXHOELDYN$!
MB=9W^#Q$-9S#0:ZOJ*HDMX DF9Y@=U7W#EHWKG-X?JNUE=X.Q.=3VK*RM[C#
M>$7C'OH^"D'J>VC-<9--^KR53;-?$.]&GQK=ZF6GS&W9H-0A%[U_&K4E_*.V
MP)AHR#APS8M-D>NC!0'EKRZ:<<&0;-;17U-9BI@+Z^XR<'%QWJYRTW-*)02=
M[1M]PE%C[T$Q%PJ;7=3G.Y0_?!I;8W>TR5&U4RU&58\*?W%L[:U#/%]_/0$9
M?GH/DS40>UEV1(90NAFL SEH.)UG:*E$CCT&5\^]_'!>F:=!;BRER$Q/3.=L
M77[0D%0)XRBW_ 6.GQ[K1,>+W=U<M)474W]+H';Z&/_N.3Z;>8#L3E%#JQ$%
MPJR]"12U$[MS:"P&;!V?95M##XQM-0O_H-FOXGRBU"4V.6"2"K6V';-T@.;U
M!IJSHA:\YJP*+%!DB?14=O4JHDWBQP:5=B=R(VNCY@9B_LU28?3.IADYT1P*
M<E-[Q\[P*%JBNJ3 @ND_;L9T9E]SUI,L@&^@"I-EB9-'H:NOF!&K@GPVM9S[
M<"5=5<,(W>G5RB.KMH=63P>*,26A"F.R_:),E:<BQQ8H.ZEPLG6_W.$I2H7/
M?A3':.Q&/,Y%V%.SS4&N)U)\,4[R1':+D#^Q[5 ?OGW(C$SIPP5%[<$2 \L*
M!^=>#*3[U/=6%T8D\0EN/8>SVW[.]$1=]9D#,OQ^1\:DF28R.<%W/LS$G-+]
M7DC.]DODNY?GK<1Y/FNWB(99H]B/ +X^1M<CI(24D'WXL=0^S#75NX/S?C,/
MXSZ@XH);+3IKVS,S;A5C1OI.2KJ=N^6EDR@]DU'TZA1_VRTJ5\*P>R0VQ<HN
M[_>.!NB(<76X2<GL'N7%!E I??FH;.CYF.LA'3@7 [7A_LGQO:(?WO">(E>,
M.^_&YM?>R1EU,]\V<YII^DK?HKD?^ [.HREM#V>[(L].AE=%H6[-I L2:CU2
MSQ4TF2TZ/.Q8'*U%Q/CMN'+PQ&SU7N0)]%F:'RA O4H*= "EB<^4.W(:Y=+K
M*MT5+)3&9.>M'_QC1,*H@2/VP+"E#8XH57[U6)K28$:@@Z-&=5"L&$I6VK=,
M(:M+6NWPW9HM0D/I /HD27_N.CF$8NSS#LZ;ZX#@N>##_YZJTJ<O'-B]*V>P
M &P-G4=0_IBPL>%@&S\;X@ANTVLXBI>O;H!YF"!:TM&\-MMM2$I)$<E[ I]T
M]HR&=NX)=)1_R)%3']]_L!(E?B_P56:B^GG*>K0XB981@TKSV%_?WVO0O.-]
MPIU+DG<ELP-IQ_?=NKSS^$C1/+\&AQTY?VX_V6G B_6&(?'3I5.@AI%MP.<+
ME[:_/"+ '*%B5%'=8RR#3ES/JO*8*U93 /P XX;;1:?+5L0*,7[/VF/GPU?0
MYJKAC.)2M%D<1^W,T_>42U;)/U&<V6LMH7#FR)8,+4)F3:8@IGRR#9K_''JV
M/F\KE?:H?]LZ76EF-S>NV;Z]L3_6-L=\F]H1DXM>]2QZV]I:-+?1;I;R>426
M%^X)=")L5FRFPME;Y_11ZJU3NTU$FW6F=$:F).[6^MNP.Q_34W(Y20LJ%1HM
M%<$WV1!C;KJIWFK)'4TJ4F<1&N\_\<]021T6R2/OCV]Y2]3,63>%#X([3-X5
MZ-G56BSNX"V91 <V"F1Z)]MW#/G-R'IK'2_5]A-*3W)@N7=6<?KHL3-OF'6
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MZFO%8,&<Q]XBKW:*XATH>^11"T] YE'(G%""2A9U.%]V^6)'.9F1.<EY9.Z
M$.:\_"UH4;'WU6@-;=U2Q@:!;Z'8W+M40Z#72YZ2;1P,\Z3*['AD-&[[-:)Q
MN'9K0C#\TZ.5^J?,&*S]:;PXIN54ACQUB5E7_UO<<:U97TI^S&H*9(+O,00U
M#"C5H6E@I9I 80UNP:PB3$HGCS_%*/QK_C]1&/QS$9^78@9JO=  _SOD,Y<^
MS-< X</\3.'O,=+-2Z4V,/K(@;T,@TJ!>BLUT01/N _^B''"_U28&X=8Z[(C
MX40HJ"&OK3(4;"W)_8/Q7!A4CP:QUM?A6<GEQ']K60T9U1\L]:-=X&M,-RFM
M(?U=! IRGB_N6UMEG%/T()_G_M1>;NCLHMCCWBUMN0FE[RFR-92^WSN+]%J2
M;%'5EH3.XZ#M4FY)4?>U5<"@@>![3NJNH5CV2%>)=21/PY<Z"M=8+K$2FM94
MB,K+L!'D\QA&]T)_[U[OC/ZV"\\&&?V]*)GF.XMU-%G +:<B(R'@/WGP9Y+[
M@P0^KV_6NK'T#L29)=-\RR'I7]!DBU?;"T;=AZ_@6ESQ"L->/U$L/Z^R5Q\6
MZL#%F%7F0JTU\-@-EBA.[14;PPD1I5N60D/Y>[#\3)FXP=1E''9C)?(A-V3Z
MP2$W<"R[ ?LSH:C8\%A/CM??C)?"'@UMX9J4%1O(_Y68:26-[-*M:UIQ$8Y8
MBX2&L4=DX14/_4QQ/W?V^O25OQF=[5L>H[NEYUK@#[^/9;EKQK*?\L9-9Y<R
M=E750/Y[VZ4/?#!6O,89OZ*1,UB+9S^^-$HI(Q;7,^)8"8J/R1_P\5HVUY84
M&>E^&QMVT2)]MEQ?/?W9^<]!XB&3CWZ/.8<21NE8FN'$/Q(0T(#Z#LHX->*!
MQ0O?+,>X#\N7&++X=],=_UZ=&)./%=D6XCA9!EOV*RQKLF(?YM,/&SB_M^8*
M*$?ET/N@C'3OPU%Y.K_FZ#<*=J7,?M,""H&A']747:MX"Q_MFPH8 J3UZO"-
M@A,B-;>LKGY1$RD)RYTX0%.$V!K31Q/@4-9[GMVL2#'MY,A])LN^E[/ U! 8
MDKK>DVFD;>LV+\VX)?Q$9M_=B6CG74,%*3YU,.HT%ES@,S+A251[C9B0']2]
MA^M"O@V0N<.U PZ]-&I P4+I0!&B$.,7("TC>3&"E(7K3D9,-/-LF!+^9$5+
MB?<]HGX3[ >/>VZB55%3XG. *5Y*X(+1)ZEYP2E(W ^+U[BVPPOPX6*',4X8
M&>G'P,&'T*7' ]?;0J*T^8"LPS>ARU+?'[Y!-L],XC-D>F<O/)$Y>&QOAN8(
M>-S(^)5-V1>XS'ZN0PM&VH9LO]D^IJ926!\S^/X6OQ XA7T;L]N!UC(\K,V_
MFZ4RD/:^K2EQ>:O6NCA!^!6?XY-RF$)\.)_1-JZE)V*GZ( KA"05F&JCI"T8
M#6;.FR^!S@6A79X0LR70/US[F*D6"8$RU@E@[8:%\QFNW[>'!(D.#W&:UX64
M6 >+P'<CW\:F%'&]A4-7;XQ5:H!>W]-YR1"@#:A7%T!/C"4<L P@ANL?M,$@
MKM@EGI )OLK\BD8;6);Y%8[10=8EUMBO.ABN6T*;L+QS'<>[HXANJ]APKON,
MBP*D@:G()97DEU5*6E))?UFE74LJ&7]3Z2V#B>ZWG=Q[?$9 T[,'3-ZBPAG+
M&ZD_;&;B&8"N-EKX2[S^<Q3_\<YUF>L%H+@R%O:HP*0A*)\ABD&.!QTPA]&F
M=C$7G\>T)-.F(5O'+H6ALT6U[F(.'2B] +'-JJ$#ZM"AN50;=AX+>D*OT $0
M^[$7=*#A !V8##'P\H :M!ENOH[/$-B&A4,,Q'I^_\9QHW@#E#W^^4&P63MH
MZWMM8/W&:2@/DKTCX M#D'CI'V2PM*ICTI;R[R"[P(LAVFG,_.MDVLJE3 YB
M\)8E#-@5!)"8[]PHNS'3]7#*)RA45O :.8AA6I:1L]+^]%+-VF\%X"!K.]3%
M8IWH0.\.[ I"*,KF3M"!H4<0LH1?8X!\0V__/U!+ P04    " #,.UE:G9R#
M;ZW@!P!<TPH $0   &EM9S0S.3@S,C8Q7S$N:G!G[+MI5%-9URX:144$# J"
M@A 5$)4F-B!*%Q4!$3& "@)"5$0Z,64)$B4F"M(+E%I""051&@%I(I 0^@@A
M4!:%"*&1T*3!CB:PMT+8DNYNOWO&N7_>=XS[G>_G>3/&W /67JRUYUIS/O-Y
M5C:*#PH^0N.DLZLS8L7*%2M.KCB)0"A&$8Z(%?_#S\]!_J=CK%"\06Q8J_IA
MO:/2BAV(E1M6*&U8H>A H!"(%:O_WPZ(__59L5)IU>HURFM5UJG"'>@:B)4K
ME)16KE):O7K5*OCN7?@^8M6&U1NW[SNZ1M/SDO*.&UK[[S]ZL=;P6'7;)J\^
MP.C Y5_C5-9IZVS>HFN\TV37[CV65@>M#QVV<3SNY.QRPO7DF;/GO'W.^_H%
M70F^&A(:%GXS*OI6#.'VG?@'"8E)R2FICY_\_C0K^X]G.06%1<4O2TK+7M74
MTNAUC/J&QG96![NSZZ^W?_=S!@:'AC^,< 7"R8^?/G_Y.C4-?ON^L"A>@GXL
M__1K!4+I?[O^+_W: /NU<M4JI57*/_U:L3+F9X<-JU9OW[=FXU%/Y4LW-'?L
MO[]6Z]BC%]5M*H8'O(!-EW_M6Z=M9"DP!G^Z]E^>_?]S+.[_R+/_[=C_YQ<7
MH::T MX\I0T(#$(NWU60BOB/_<?^8_^Q_]A_[#_V'_NW1GW&#$6.NHB/RWY_
M49,KSI:];%TE71OI7ABPIUM8PD:O@4S/#3XL$MF<3J^:%M^I*WUQ[M.C6;.J
MC9L-LVX_VY[JJO.)N4*!: O'\)]@-M+_(EH+,- NW&R9!?TF,2<R+[\%Q+,"
MU726OB5],Z?-4+:,$T@<S\>?)K]%DM@W?F'X[#\:<;U_;&R4O4MY2K3)Y=3
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MV\8FN,3=MB!:O0K_I>B V2.:5^V#1U>./6S[G7(2IM+?D*D*! W]!GU/@?B
M 9I)AX@HZ( "H>(C+I'"^0W0Y<806L"3&E$^D$=XHV2X4_:,'T;<)<:(.Q_)
MRF04<28<7B)W6Q$).UK9S($UFBJ@.LD4STMW*1 9*&7Y?ICEHV6Y\*#6TCV4
M%)(JE (3XGEQ[Z@"4:U ,,@"C2%ZYFRF"#?;@I582QSA\:[+WS$EZ%RQ6Z:9
MTO#7 IBZ445Z$GNB2GU?I(.U- 8Z %R?Z?AM8HQP:U1(92-7$>WJARL7ANO2
M/"E.26SNYT<[R]93C#_]&5/SH6(J?,G[K:TSIV.KTD@H=1_D#];RA[OT#3U
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MB?LR">]WJ;P]7QGX)G^' CQZ5Q'N]#J"N'2B[PW)8>*O3,YLQ^Y)?6?,NNE
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M=CHGS>WZ"OE'5 VL[+<#M>(6&86TD=3_4W(-@$@6^F'KNGZ["$'L6 ?:?,?
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M?$&6XV!)O,N1JD87?8 Z)0+<O6@%8C,7"O\>F"J_JSM\GN)2VY#Z]Z17O-O
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M[RLC@3KR+$Z:()"F,U? @$Q#7=8*A[?!?H)^@9XS7D(88\/^ -@&@,FJ3-3
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MFZX)GM6C35M"TUTTA/C'8<]VC[4M-=+;.SZ6QYH9 >HN89%:JL1XO0X3(9'
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MS9'.!R]CAW-Y&5_6F0QV?-DG2!3 &+2C6M19W-[/H'IB6M]"@NE?QRFT6+P
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M0]8?U,$PM;DD:(@!5:U_]X@2L[E!]$V]^WK+E?E$YRT7"U^=I"-4Q1@6@\9
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MFAR5>WZZOU?1(9LL.G7"!"AD(;I414Z/@"J +3EC@1#0&%"LJ!H*I"1N9MA
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M^1\O''Y/G&QY?<VIY\_]/@YW5J7O/H7>%4@&\/ J)V1I)JKY&8LHPWA%@JH
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M3' ]@'(96:!T@BWJ!7U\XV>]/*<G]#+9$@%WQ'P;E,&;[J ;>Z3T]$MG-,K
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MA:3EXJ)ID[3!ET^&V^F9KWQR/%O;$*NL)>R'X1.< 'IS@_$FK#TZ(D2U_+N
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M.<V?MMW<F[MA<-X3C1C97' OXQI>#Q^!A4S'I\D@82PO,;8SF:';N$S$-9A
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MSN^SNX)+;]Q5%C(:0EW"CWMVSZ[]273A.MF!@7GWT2PF==]\ DK9V[[S@&<
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M/9^<$J'J?F&LN%.==J#GQ\>$+,( S;Y<0&T_*M2TA;2*D\E'I$J'R/M8F34
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ML:[9/'JZXO8&9<$*S\2?-*=#&A^<S/1_N2&);!SW"8C^<&LM.Q[SX!<4Q"Y
MX\3H)33&(.9Y\MD.]M YN7X>?PL]H'<>ET#)+O'J]W60M22$UQP5=Z0&"@GY
M1<3RVN=V;]_^MK-;=! RR8O>G!.4P[/]<5GV"<%HPSS.!!NRC&= KY\@%H^8
M?P"0-HXZ52>1K=&5IIB57I_'W4]CO"3 SB_G<5_2 I&M#O]>IOQ6K;U+ LD8
M%?ZD%@R-Y^)04T"&Q=+Z*<1"JF9I+PMD-Z6/!9-2C0,]'KXD9V41&IK:YW%7
MV-Q$<39WV*J/*\WC6\'!I<A&L%#8]ET8+\CCQE'0V[DST;_3:CW5-82RC'9&
M;A?#V^W][U8@8MJBOJF]ICOE#_  %1MTZ*(L:HV^3]/?#9/ S4+4EUL7?$!-
ML!D/YB#!4/YEJZ;"G).29&86XB)/)R)>[.0$!<7B-6N-Y:\10%+2O@5'T-4@
MFJ-XH7<,Y.0D/?>C"DO6O)HAX2?FMI09OHF;X^=4#Y$KXYNC9UJ0AB'IZS>B
MN'-&]'JA2ZD\_S3F>/\8:PYC!O,["3Q$R2)QFWK<F=*%F):Z*K BFM#("E;>
M]-1EMAGBE7"?,E;R#7RZ^<5 SZ7DKN;"(QG''[RAG4ITUYQZJ\1'U3AI;U\P
M%A3-X\8)NL5=2*PRA_!J,VV1IT R+&^ZRK! >YNIPD3W=L$*Q%GYG":#G'KR
M6PT<41,!=',HX[U:<H3OL./>41@=NMMR^WA>Y[V_HRP'>)VFZ0.8=5_35^D(
MMA<VU8WT'3HYA?$CFKL:#X\IW/5I4G4Q1M[G<09PYM[>I)B^&>E2N%!1F3MS
M1S^L[H+GD[>3,\%NZD'U4(G'^8RD#;E[]J-5TOJ8;"PX+43_E#:0,GU#RR-B
M(]>!K$DM&".T=WKE?O/ ;*!X&L\DVO;R[JR'3.]839#[$]T2W2SM!J*S.AIP
M!G.+=>M18X!L% M(5,3"1XWQN8S?1!"@/J6]P7"A1\.GI VS'=2E[E=;[2K'
M"KVWB:>#.-;$FG*#,S-!>Q@#)PH'\[V_^&PO\:L>VCJ/"]"MPV(J*_.X()HC
M,5?KMBBC=H"9ZMOP?@4GDV)NK;X$-RC.@]2KB:H:WJ6[">?YIL'.A[\Y&A'1
MI0X?K6LY8OOWF^_-SAQ^*IK>@9%^-%( 'A/ JZQ5;Q]@\QPLB'//(=0U3;(A
M@E+_*;4@<C4/EM]+X"_HF[X]?0??)36M$?#XSK038Z?Z3R\J?\OIO F%<**C
M%]6W)\I5"3MW.35%S?BCQM_J@CK:QZYGJ73EF-5U6B[C*[A%A@E&%U :!!\&
M779"JIJK7G/E4YVNWT60%5Y7N7^<YK@;<XL69\DC;#MNS1[X[MY[<8_W3'/G
M]VL"T(\/,&Z#N:M,P1H:55)49&QF"K3EJ#XJ(IG0 Z HA2B/Q[D4:F\#.F>M
MSE!&#*X&I3W2[)(UXI,-N>\5@U81FW?T>KH>&*5_"!G\^]2^O[YB#V.B&3D.
MR-L)NNLK@4TJW?&Y=/P\KI +"#-(LGK*-(LJT<.^:0XS6O<$;<D#+%AFS>.8
M_R82'+.7<O51@VD2&BG6';1:G(>V XV$21^Y=/AOL9JK92/IX-=*10A/L^4-
MS<S=+NRUA)0C!^^P>I8C@6M^W<#A[,J[3[K"]6SYO#1Z;WGB8^+[8>VU5_^N
M"R\"7 3@>>?):,U^%*,O=9632AEAB"QCYQ.WPCT=;.X;HCMDS41,$^*2'\39
MKZ!D <NXIP;/]'[Z],SJK_BB"O;)L),IGS\J;#<&X<=S,?1:!LCZ2/":4=4K
MC3EC@,2SQL)Z_-10L2+TJ=2(UJ-FO$*^D>=3N]7>Z>6W>)QA9/?+Y#!NE7-#
M/S6BMJROIK(E.BG@T[T3RW]>@$X]P%08:@O(> (PKE- 0%?3Q.I'V.C%C="\
MVAF^T,WW=0I1#J5^-L]S">(J$UG"3?N?W-C7GRS*)*Z];EX*.QR"C*<;WE!H
MMEWD<MH*3]O;' _ @A88_.VT@U9W!$A1JN3 CF3$2D]]#K*O.U[%:)<V%F0^
M&&O\J8*C(&>Q#?A?T[>#]6,36S=5(;MA'\P"%D>&Y=24W1[$FY$7?)+]OJHT
MVU]"QU1/A@UFW%'8ZQ)6V/D$8L@=U^9PF%_T7!.$22&N<R9/<.FHXWG1RGWY
MWTUT ?;XC%4#JLG39:&TI+B9.\$J65 $L>/CNYH:+"K$-&,NB 72C!5 NRZX
M +*B$:=7@GAW24HGNA(>TYP("]O+-V8*?Y2R+PL6%%15O*@8[Z-YSN1%D Y#
MG((SU1PJ=XB>7#/F[5E[L_)M4(Q<8#P4\05=W0\\&M>)R^<"U*@&L[GSV)?<
M8;S"(D,(:=A9&?-4^EJH=.X49!']H,J,&;P^;528>NH&,4=AY$J2.PM5)FHE
M^98RM.FVLFF V[:S8R?8O4M=?]'P8H]V%\;R_L3XW=>D=G8NI4&,F%6IW>%O
M($Z[MUC(SF7@X*@'']!-(/G*O6R[!*'D-_XVZ%29W:U2"_-C.V_XY:O*_S!]
ML>K3J/]OU_5'YW&(G9Y,, PH19,$N6C(1^T(+X!\E)$UT(0BI)#4G3?%' SY
M/$RCRD.%VT[3PQ8SJ]X<BQQ3&'%6T!!X4]KRLJ* EEZZBR(\_%>;%9\IO5D8
M$IT5@(D49)E W:.[#[5HU4L@CC(<HXZ!Q.W4!;J\27@D5(EG!D.&/<$%>"OZ
M<6BE*4P0;FG<TBC)DA6CIOGZG?8N4,;('W?'FC_FR7\O]?>])DI$"P[IG.GF
M*&*%J:)1;=LT"UXK57ER&#VD^L!.5A[04(AQZ95D")"/7J$OB+K_)C;U&_BV
M&:VRBV]@]7G\5GT<&\R&1^9QG47VA95?3N?(6R(,QU8<^.!O/5>*<9;14<T>
M%*-5X"&IA(4:-VA_%42Q;!G=6*..VH?SN&C!,+Z=8=P(>J*W*TDYOL$:/YJ#
MG-KU@4& YSKM3@2YPX&(2SDVFP(#B7NCTS]>1+.,"QMZ1^9&XDBW"?"/@;HB
M3-=4FNV C.T_CWNG AH&L ';* !E+'A#H=9A6'T1LV\B<Q[W7$+Z#VC&0T6'
M]NG_Q:X+O.P;#&K4'MKKOGK*8)O/0OXW8.#D,]"ZPWX#B-Y[4)2=I: :8Q!=
MD<^)%3^S_2/G0OGXK="0T.^N>V\ MX;^H$>H^(!1IUP6[%.FNY48@[Z)_%J;
MZ28X*1@:5ECWI '9S>XJ)ZKR=[IQ=-3YDN7%7852O?O@/ZFWVP3UWS36EMB)
M;?J>FRVV2?S[4W%H2MS_3M0$3 1@4B"R+%#!4@4HIY8PW@H>%W8D^BNLNP&S
MX J:OOHZ3)8]3R>ZGNM^_'JL6]Q.6C'=DM92M83JF6]+[E,AQLI?#URHG9K^
M!=Q;E7 J<S?D.2.>M<3HQ9U1Q/8L:(X:6>N2%FLY)\'0;NIKJIK9!T1))6'3
M(D/Z#T6CW_;5<J>RB1OK/Y>!UMUY:;:)IR[<,C8;?T\UIOT3=J\573(XY7F[
M9B;"O\-FT25- VKR 9LB!F,(TW+65P0_/.<,N:O/PUG0B%1>FZ?9$PY_I.B%
M'7E;F;T&BIY].N:[S;Z"2IV\FEA5R4SNYG[JO)1=?*ZU8N"MM@JS0Z71?^*Z
M9?^1Y%(F9["WNNK^'[ENWS"ZQ!)T5LSJUOBQ(,MBZ",70),V4* 07?*@Y&U!
MW4'G''F&<<KVXG!8 X5V2KY/@<)%YPP]U9DU<4?OVSK_F$B]>VI]YR.T0^=\
MA0!B'8XN46']\-:683&\&F@D=XLN">J8W>0<P)">IB0O&K<W@439TR_6I)MW
M6AT%.LA,B9VJF^W:S:%N[J%6Q:5F7<Z27\U11>,L%[#FKF 1XB;F<[N 3)*%
M((8#.X5.4L H)24CF<,D62 +P)[]KY!H&=LT8*FWF,G;1L>DX6X?UYUKUSS)
M6I-F.QSTLT/1CG=_,[<YX@<,,73\!4B4OA;+!"J-YAOZ >TOJ-^8ES=3.)4S
MYW&>]3 N.$$_ATY0^&T9MSO8,;(5S-*^Y?WCG9*#N-1(AL:+3O>%'QN*J-X\
MYMU64GHOWOO6G10T@M)$16QFL)<.TOZ,1"E2X.-@3)CV,6H4%G0V10[D"!I4
M]R/70)%EY1[BQ;T]G82%-5/.\,,*N-9H:VGAX3IPE-E*D=\LD;M. U8)9@8A
MA!DAYGR=YRFP,PFQK*61Y)07_R4(*QJ#UQM)X9W1VE])<7&K(LQL!W(E4ZAI
M([@M/^D!;TG(5F?-,FZ!VNG;-^3E>C.5J,$8YGF5V+]^2XJ?6DE+.*2]C^BG
M:Y8CN/ )(Y$5K4QQN>@T8.V9N.P[PKY>7WVP8.3];&=(Y)HBN\<!:=":OO9F
MD]_<"/L"Q;4;"#M:YW&A16OUNDDQU(L$(R :N"0P(L60,TKL\CH$1D03>',@
MZ)7I<2BZB#;=]O6;W;-SY;("YP%/[9F96I[ ="+40-U&C>Q/=HV<*?FH3J'^
M0_K?ZQK=HXB-NV81^AIX/,4$J#X429\:@&:?YK%RCHHGA\_*OFU-CHF*19V9
M'>=)*Z.@E44_U//;S-Q^1K]^.3CUUS<WO6\V/M444]6!NH5R3*RUOR* .PBY
M&(EBM:[6G$<[* 8\_!7*"F3/EMLR@B1(3LITG89Y(AMA5*4M92$2TZOZ^+%Z
M=>N@1R*)W 1Z%1S?\[Y%T'NPW;NFILC8ME,LIC@ [4V$!219'0!^3Y6HR8OH
MI[39\[C8="^UG[:<_3U8V6U0FY3O/;$7CE(:N7N3%M!CF^H:!V-N__#*K?84
M*"X(*'(1R?+/? XKDA[N]UU]]PAAVA^SEZONL(] K:>M!\Z0X10!LHD\.0OI
M*7N0]1@A2,##1PA@QM#KM_.X#A=,(#4AFT.1K]D2=J*@_I-NC4EN!CF_IG.\
M +7?>VWQ0> E"8QC3X9J#C,ZI?5-J@"92-(B _+YB^'*;A+7A*4 EL:6>/$:
MN&V#7". Z6UR<TO5R5LI30\&Z\:W]$DV^Y1=J-MHN'TA9C*_[%O,J+D_EHK>
M?/CAZ/L[4=6QS8/LM/L3-KL?)BQ"BQ_%I>9S;Z5FWWGP^JUCH_B6U^"-X,24
MA+,K?SX6_MQQ4UGW9"7R$) ]E(*)UBH1&*3NA^M*T4Y*@W4GNX!=+\Z=PGSJ
MLLULQL&] U$@E8D<3DX[2^IXD1JD/2!1^U'DZLI%:F:4ZZO?GPRTKK/.YDVT
M5/('SI1F:H]B//]="FKLH[TJB">]+L,B9EFKGB:$;@Y5/IU:#G/4Q<5=J!TX
MC\M7);HF&U.$KB!'_O%J\XM[82.196%W#@;U;\CTN(*FWR\[A8O2[O__0-GO
M_W[^?_Z$9J#] JY[!G!2.B14,E7ND-5^0B9Q,;(18G76G%G@/?PF_AH<'M#2
M7XV0*O\86^4MR/%<?GK:V,9T)>O<H_&0\U"/X_5'7I_>85']^WE<YG74&VC?
M*3B=;Z3>KZTE+D2<X17NF"#*9#C!+(UO KJ !ZGOD%C) @-*1$2\S:['L+C+
M?E7NYST#=">YE##A3:RJK'G$$V>X)UIR%FE;=B[09K[ZGUX9841BV'ER'G>&
M=84"!DMAY\+NJ6$C><QE^@HE9R5]8S]J\7K,?CE\L5D)']S'ZI%:(:;@[('T
M +I/56S1[VE^FSMG4QI)I_KO[D^GGHXQ#__R^(\%<UD!@#%[$<8K6BG@V4*5
M)5C9P5Y)U,>^:A7#'/D>)BN+C53D#ONM(/\2%/(Y$#(NN/UPW,9UIONV0.D1
MFO*5]' OSVCQCM-."<5A#ODK56^M,):BOTM7!SA*2^WP;D(LI.B2+TKWR\"2
MUG".__T )6OI!\"*;WZLNR [O(5J' 1%"KN(1E!EWH8-JF3C/;X$]ZNMJY.!
M^%5Q,W;V?=Z_/"6\Z;)44!H %1XL5-?#UJ!070!;*G[UC0;9BJFL:B1<]H*Q
M_'[CK33;G#7<UKX9EQ47G_3.O-4/X?9[$$QC9W><F4Y/^;X_J8477KSG4%KB
M_XN5?-9EI]^O;2')N*0&LHH@G\?A@'8_@>RW$6MM-:HOI3N"XEQ/3D[18*'2
M:+C-1T$L4P"V<9*IS-Y$/07I<O5EF\A+97#HX6^EWU^7$5L<_/ZIX^[? 4?H
MBH:U/_MW^^'&=I"3J[O!!CN-/F5=8MA#_+JTNS1R"-1]$SK1*XX83)I8_6!D
M;- U!LJ=*5%(NFZ]W_XAUV%5MG,N#OVREJ,0[L;B>R?0+B*N[O6H 0*PG];3
MO?N3$L\%UPUZW-DYO!TN&IR=.U698*G*FEPJM3U<9%L5IBCY^O">/18_XRTU
MNP J:SA*7HB8YBD$JBG-/L:+$F/81?,#?0,< ;%Z).+)+U42N&BXO3E9E.%+
M5?@YMV^,O]73E5J88]73R5_V^&7KCI1_:'?W?HJ_.M@KV75@9!5>(G'Y-(LN
M&=(DT769G:\![;[\)>AKB@7B(!-]!2L5C$KH:$\HV".<$9MW%-$9"^ F)<!L
M3AA[KG -#Q\0CL25+.>V\35[R[V+)_)NX+*E?V:3^M?_>^#K?_K4NBC(G00C
MNA.<K)S*Y7L+"H- LM!]$:U*@;^:O'4#QW/=])01;?-. 42X0I7W<>$SU*EW
MW-ZDX>=7)JL31UN;:9U6+Y][7,D'G1&SYZAA(BA"#9M 'T6*RAQ,>1KI#A*$
MU,6,E\1O8"?Y#F7+G8UP99<$P#P/G.@*["ZJR"]K>\?*VEM%*GA?SP/'$QBK
MBT9$04V"Y@&SB?W%07TXTO=K.4*"[DZ2L^;LOYDZNQB]E,><3OR0"[I,\%HC
M#\Q$]M?2MVHK!/)P)+)W'B??-C"-:<+K8ZDQB'/SVTFVT0R@,O -4QSZY&'[
M[<<*M*/K=^,8H&76^]^32O_UU,9T-[_MR:;;*J1F1_V-N\1,9#,GX?S+8U2-
MK]AF[\T48.GF+^25)=]?#W\4]*Z9V)U84).!\XYW^2+!P"M5@%&HE8#L,<$8
MB"/;TL]@M+M,CFF%=LI*6+]#LJBRXPD2>2NUAIWG89P6TO9D .NF&^2>L\9K
M2U_<QJX$];K$$Z9[W(M7LNH*YYS^W:[^?SXNGZCJ=-T^,&*HK13(R@5<+\0\
M04ZX3(][0*M2'X5CE&0K.@5^R E<G"FG(<DRT95Y')YA'T_ ^]J5_E5H([Y2
MVM ,U4Q*FO*F"BY5!EPHK:G(C%($>QT(_JE?;^9Z+IH&R*H$8.A4ON Q09??
M:*%(>X-ABVR&0Y7NBQG#@!GB(F,3X!O=8XI!B'1Y6INF]!**LIN\&/A$_<ZB
MW;\T_3P6N9$ON#AQ]/Q#O#JKIO2Z<^/GNX5S9O_W%P%'4:-9#"X"X3;L*ZYK
M"Q@VZ"OI(CZ![@7?4+!MT%[4!'8"2NG[R.;\2W%W:3?DU&Z*W=OXP:B.HEEF
MLFGUC@?(EMYJU5_B^J'TW'G</K.CK>\EL3C2V0><'G?X:PIBR6DG@*'N0YY$
M5[?BNS2"4B2\<Y+FKLZ"R:5OW[Z(DA/,WAA5"8QI-X0YCXX=FS"GF?<TKS1^
M2#O_"4THY UPYW$6M)#@P(-M(.]CZ5F-[?9%EHCROZZ4-Q#L=/1O^3R.2L&H
M\G*B%>($7RA'GZ%K0),<V?!4]BNXRQ-O.@PW=)&63]L.M>ZE[U<D,MZ\2*2"
MRJ BL6:]G=_"60FSJ'YW8B_^@^*BH8MN)#*X0/M+PDK!<=%PCT(PV:?9HEM_
M,N1OH:_6%DU3LZ]A7N0+[80_)<9\"Q7F?IP>9IM^D.SER05F<42;5S5<#=42
M#FUO) W;1):?Q;/N0@NM72]0J5IVG/82W1EFRP3Y B/^2OI)^&Q5#P<APAP9
MQ0 )!'<WF4T&AW<P/%]6TP/E6O_G;[K7-/?R;,-*K)SD*;%LDZMK]5ZNY?C!
M#5"X?/2I()M(@E] "5U'J1G$%70WL*!-R;&#FT+C! T(20X8QXEM:NL>DNVX
MH=:%P8ON<"M&NCLD$_O[W;[?XIU>/J#JM/H$6*>0L*")6 I10R,EV?8(-K3+
M =GMGV&IC)/)RYE>P?\&B0=1@2*\9>+YUIH9=[?/A^OA++!%KG^1OB>],B(L
M O\5!6Y1F+38WT@S_O37=4JXYZ_ZL\8!P-)F$;)2E\KM!3:F%Z0T:A<%#"'
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MSM\DV"5%=5LI@)U[$//GZ@+M8[X-+;PCTA/J:;^S63ZCSI*S[-P>CU@,.$)
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M[N>^?_.4^.@8YT?1UQ[C^H$,%*1?"<&@/LC6NED$F*,'/H>^]:<:L]K=3>E
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M.(=/& "XQR3@\M$F8+: 8^QN(=1UH+L"85;AGO''2*G+I$50B$. 6"^GS<G
MI?.O8M?>EIOA8[[2JC3;&34&-I(B 4;HR=X'QM9#16H,>E_'GN>@!/?A9,MF
M->8" Q6;(3))% ;)(NP$N(=CJ.]LD57Y8C5FW \EPN"W(Y"7O*JO7>#+S 3"
MU9CDH"\IDL 8<F;;^F:4O&&3R%BG.+(IU.PU$CZ\OLXB_V.E649,*_% __;Z
M.8/0R<-A12$'.<DX/:*HB@A>U9(]$/5@!2Z*/>@Y'6+TN>)GQRJ 3F]1,SDS
M%-]<)__40=(^4W>PBZH;1=B)1N:5<QU!\5_NW5#5%T.\@U 81=QGD'$H'%2-
M5MS?DO$<CD.7ZD^:L!/9HMFW$.4 M5\>B7%KX'T@/ 2I,5U38/.AMN'ME6WV
M-$XGX@%%BO)MVG^NK'"Y0I*XU/2S6SR>"!U8P-.( 4@!!>X/"'B9,/,EWP[1
MU<RJ?M%?U^IR8( H>H_+LG#.*#H=.!5T\%Y)%-GXF@I_9/"[DB;;[CCAW#XD
M.N"<[6SJ_'LG)3R<8OR_AXIZ.XHCGF.(!P#1[SCP3*8EHK-!*DP#:L)E^J!+
M!Z>&*/L![N3Y#[=MH>O)'8/NN#K7%W^^V9F561$UJ?N@8\T[J(#GU_^E/F1#
MRV$1>\V44. :7? LK#RBB9]>QY2YR6P7OG#>?N*A?CJ/%90CNE-*711;O#5M
MS9;?U[2U/]]C9=,IU&HS@*\.?Y_3@1:"046)V-[[E-R%1S6%3\J[,_#P&M&W
ML/ RV%;^H2P9WML(GGDG@'Q>-^"=A&,CHD35FJ<8MHB)Z*.<]X]_T<-'$6=_
M@5!V61G_]/_>)K3$JS';WJ!W<QAXQY6CTC-(>?PQMHX808+V#$E(L^A'*W"J
M!N(YDB'2TQ3;Y0?>C0Q=HKH':X'A1^43_"XFDV5-/Q$/OJ:%<T-M6GPX)A&"
MBVE;,B7LM5$Y_%RM! >GC+1K'C9'!JY->)\:/E?3#.*8+$U"Z9Y8A3,XQ!A2
M8^K)L&&1@@ZR9HNH,:4^$MV0#?4R4D>H$:A"7@CB$VEEG01]51'!AH+#QF0>
MG#DYY!@([Y/.)8TVK6I#^GRH>J?/"/^L0FF:PAHBH\:?2@9OX&5C$OOK[>V+
MGT3\1,8V^#@H'*^\_Z&B9=\5$3D!T+7A5!O:5)@I%DD=$V<\KWYMV?%F1]KH
MR8<J!HK(UUK=@C4%K8P)P<'*\)6%I5'D:H[,)3P^[+>$0P[199"=]$+V-F-%
MF/O.WS^_=MW95([1(8+'..-L,14VSE#LAWR5(?3-U9Q^1USJJ,7#AF91ZT7%
MWVI,* 1(F7K3C3>U[KJ;5TR<OI,\'6)[NCHWQ.ZD<X,^F_;;MP-RPZDFNFN+
M_SW&$DW#>O#71MEA*7/<KQ/] LW0%?9LAI@S;B;MX]G[!0X2[.C'H#1"(;$]
M&GL:K)=&,G8,7LN+QW?C=+]GZ&/;!3U>8IFW)(=)V 8%M[,E(P!VRM6A6;_K
MX?/I@EUJS,IRVEP'$4L4)6BVJSNP6%\[6J*XKYLHX'2VF5F?G,B+#^#A:JE<
MH>%4Y(J*VT5_ I2]6TS_*=F2':!7]L\E$<!](-1W_QFXP!RW4R2\:JAI@PJE
M0L'-(7%9JOMAS1;8GI8=(A11L?*&1]%7KKH=WNX?,+D!JI3X_"AP/CB"ET3B
M<\5UXS88+316!PBAGQIAX__54M$90\07*;"IEL*P'UE*/Z1ZTF('JH!P').,
MF8NNGTLD.(\@5G D%"Y%=1&U\T$PW0=Z]N3=3 YA+3A:5E$L<,F,KH_3?>8X
M8T\2M]TKG>Z/4I"'6+"EIATOUQ#X)?N<28!XH</PGT.8)7*.Y/:F!Z\QOQT6
MZ8B(HD^<1 2K>1R[/%!5B7?W+9E:N-G7[@6=E\>)D4I:.M_:7!Z;0MA*(QUL
M'JY[M?:VB0)U-4-:-[=FAQZ9)/?ZOG5YC?=&NIER.^PKQZ%!$MK5-M<]:?!R
MY!+=MPSA 75MF451N5:=(P75A9.T/DEL)VN%;6I=SXQ9^C=2*S@-)<WWQ!\1
MG"X;*AX:5>PY%[$\?8E9YQRT.T4QH'K*B1*F$VNHL,$WA2$:D66W\=SX(PL'
MY-VR57*?0$X#M._*L\")R2GJTT /UEU4P@;S)K%-(]?RSPG;K6WDU$Z9\S?)
M4=?X#\*D%O?L[&=7;SPL!+BH)#A!>F<FC>51D\A@"/N=#7KOYWC8],;?:$ [
MI^[3[*>8*Q+BDJ"H%T+ORTT-U=%4^2Z),'D^WU70=6@>,(T0N&0Y4E.M+0?7
M4E[ 'IQTB="+U"F$UI?!QLL0G<U* T:''^V\0O,,QX%^3%758H0>@'T7CJMB
M#"!K6N7U)8V9\^6D%S0GNMLGZ*HX('U]''XI3UPV:%]!#GGEXWM$&MR2)7@;
M[2^[L!B'Z.0KPP#N68[H&;&Z.XMX@6D-<#F<.ARO#SJ$(B]I+422A.6S._K6
M1JDQ6+J?B&7T+JH[>.":I@OAXG:C20K!G+ %='I?=*HZV\JH4U!]>-.;QC^7
M*7'H":; YU45;5A&-WD-P8/1;HV!R'*AA,^3F0HE5CD\\KI@B!4TQ-A"=QV2
M;1FF^X6+S&%]2<C2Q6]=&85-$+/]>O_[J!?0T\@'M/"C0Y]&YF5;/@K_Q4(;
MRF!3;#L9#&"/ ?[0[><1J!Z/5WK!V^1&M  IIQU8'3I)*OE<^?Q-7)R(; D%
M>01]5091ET/C7O6ODO_V/?8QKAQG#,5U"BS[8JDE05%!S$K4H WJF%D%&I5R
MDM%)T-.,X)"BS-><@:/;M4#A$M8R^M'!>@^CKJ;5+'"HJ^TGT"Q!.O*]]:S-
M</2&-M VA;[KV><WKC^U)<65^EPF]&YR@FT!;GN!F1J3HIDE[$/83F,AJV;D
M7_!WOB%"<BT[RTR1#-F(P@W(=,<APM;IN3):^\!&'Y<AND<A_<2PXUA+C,BF
M=#*8ULAU?6]M^\ K@]>VEM6NSUBBVD??A)[H1V0 U^@-F_1U "\XL!%'C..R
M<(PWK.6?DH (DJ!'LMQZSZBLXII0;SK F>'!IR]QN4,/>4R[KN@ACRX/Q4">
MU%C3TDD\WQ[?<E7QREV[\6HD<7@S V7_W!9A-3#;K=P(<'<A*Z:%M3GIL)O\
MW((B'2RX+2^2]'6'F(X4YDB(6?5YINDS!TCUG:O+2R! ?/33<>C&$YJ?7R*)
MTT^]ELF8.3/H*%P[P_@ID//;5LR3]/__]?^__K]YL=^P(0<M61,+1"4%M"5
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M^6^C7/TE.XB:QB)%1W4-;*=2MX\*1A>W^H]^^?A^??*-$Z\)J#A*N*/&O$E
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M=7@N\Y2D9A&6[LV+'GDNP6H+BH?IM[UR;%1[)ML<A:K<\-E'><&/AKT'<%K
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MS*5?^YZ'>2S/*Q_+"<XD'LK:7/X.R2R&;NRG4:_T $UU@#%77"ZJ2DI B,@
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M1_&0!XU?*^@NAH; BC9C7U51]SL]UOUO%,,ZTI-O>C67LZ/.,0W_2[OA?38
MDK&)ZL*XN&CT;U_26;90IY&%_GW6W^  Y'F?L0>-2PGC7^0,"RWP4^HI%$]
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M,'3!-M[)6X/?K3BWCU> 1Q(*_$1$??]A-QU_5YM],XY+$GQ#=3!,%V8G"SQ
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MFPG)*=Q02GRTW4.#IG66]ZPJZN^96#M;'3_6X$68-QZMRH8ML$IO^GX@C)S
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ML2/-!O:0#OA1<]G^I]>'Q\BJ1S==_#3ROJO.LW(.MVTG:FEL^>;1P<:2OH<
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MH(L?9,6INU+M"_@KK&[3E]B7>_4D7[_+.%O<D'NT*>6*.M'QTWVD!K-^ IL
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M$<$8?48'>3YLLM=P2SX9KG=%>QP*<BJ!MD -?FAC&P]/=E:R2AD;GFOZ"-M
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M?=XDYX+H*VMT$$NTN:0]"AL6ED8&]+&7@V<I-@%/.\J91\%CG^J9>K\QCH4
M*E1H'C8U%HQKZWMKWZ7=_<1.JY3HJD.4OP-T3)/C*/Y'0^$90NZ3>)";A=B
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M$/ G1C&";[A%"M"O8F7LQY#C)IBVM;N)::\<U86Q)&T$RVF*_7-5K<. ?N\
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MX!CHB%K9\5QHI0XYT"<,KV5%M-FU?M/-/C#BTKW2/$UC'K*C6QAQJBX?O[-
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M5OD%0KU[^\;[\'>8:8LIP#&:A9F^.J33^<@SFK70!JQ2 WDDJ]JDZ(,7,0T
ME\BN<,36UD$AA3)TK*^FQL?YZ]D7!3IUT&>:_BM O$]T@@+[\M4#][!5&[#)
M5G.,5ZXI>1QSQ+4_N2M"!<A$%U*W7]4R7(;%K:OZ/\T,OS4)A@C9R8 I$@#Q
M+Q3<2ZEE%6[IPQ=,$^W@S4UF6,+,DQP0'6FN!S_,?MB&)<!S.!?C!NC:.1SB
MM VC1RJF&(#7<"4\A4"WT' 9=8 5>'LDQ%"3_#2EG;:(34U)<ZMMKQ_PF;)'
M-@_^U/-7N0OX]NT8RUVEO,@^IC$$2N/6]:LA^YRFD-!5G;O[A&Z&-RRJY $<
MV-:Z'"QKOJ<Q_Y^R#25T"_V9M:R&@WVD4$UMG+/][N;>P_W8Y]#HF/QPJ<N*
M/M?FF*?Q!_NJKN_I;UI>QYQR*])H@DY>S,5Y&(O'M<ESNC&B- 8L1=V#P0^R
M*XC/(]"E; G!4MGFLH(ZCVKLM>6+.B7D+R6O9Y 2K'?X_+:F9^>:&W_Y?'_L
M@>MDF#!0?QZ#H#G<=Q1X<Q6ZJ!8BZF(-53-$!: CPPPMSQ+M4C9;\(%T[12.
MO1Z<S4Y^@CFBP^$GM*4L[M8^MK^Z.J3>_@(I.0U#+DOVLJM;OAS/U_A3ER84
M%RNV%>2I676BWH>Y.#3"F*(J3#3R"8SK+WS,D3] 2"!1&C*EP&M\)U;J?= N
M\D*PBLLF:!B!'>6.$%,JSVBQYY(.U<1^_!)7=JH6!O:"A/.UPE,:1_J3SF\R
MN3F-C%5M?XM/I5CR4S#?H &'\H-TZS$+B6+[];.9ZB=*<^0GPUUV4 WGE<BR
M<3(^E!<Z.)WN$9?;BUF[&>(#F$]L^I+?> "P:#3'2_EWXK;.&XV>NDS:AK_V
M/MB[ =CFO><KVH=W&(HZP2%0WG]TW60UVWBQ,1.QAO=#Q'9:@VS2\^ZH"P5^
M*5J"+- P[4:+S[I\GP+'ZO<F.%RKXGIW?DZN:Z32H6%J%KPJCB60EN[2%?T^
M_3R4_V5A]Q:"S!ZQ'T1-??2'N_31QJK;%U\"8@]&$]Z2TT<SK4%\?=L)62.V
M!2_F<.VM7GG/4K>]O*969G/,N_E>!RC914DTO!*U32EL71[Y[Q=>'MLY\>80
M3-\^\(F?/!S5>@:4(R[;H'EJN_,D@OX$(":B'FPRK*WXP;OLP+"$LVZ _=7-
M\9&U@L:<3T>8\Y!(T"G.$P:<!!LJSR1B4)1MK[-[V.X1%^>_/DA_]]9YRLLY
MG%8DE</KY(ASD):9P?N*[:E?"5_5.1E+4;$(FC5ED(E,:<.FS^%,USRNHB6E
M)I?-<D^R@RB%2*BZ,.M+?#O!.L%A#;].K.)G4BS87A4A \(=@ZW^@R>].QD4
MJ<)D.A 3\P)D/E=,PS!HTE[_/7L12,M)[G)5"R13KS^KN1+: E;*[GYVA(8*
M_TAVX/3P&LKS*B*'AT:;!U,KJ[VNJ)GX];.#5L/^>3&.U>/GKP1Y\*<IF*/_
MP4-LB*C%4L,]D:J,\.##L\+7,M1)BWF\UAY9&T#IT!' AQ3U(?8V8PUX4U]D
M#<6&G0@Y=LWA+E'0Y109X;5R2 G^!AR9P'Y3=4 ?KTO19>EI38:LP0EB#@6D
M\6$O[J1,38'W*4$J'W;E=3"'QCO(?A>FPZ"&]M*40L[:(3C.L:.U\>J!5Z1X
MK3Q#^35J!MN$1=W8I"M?"><E:\RM7]!C5,W'D>$WB:*WQMW-(4 L%($_\HU7
M6[[E$)!@>%R_FUZ:DB\ZB5?L_<9>0ZXX5N.;6\M9#J]/XFLVD^;1M6O_*G%9
M#V%9U0X=NA:^ITDXZ>6='T/K$5(J$WK'BHW7:"]5295%A,8("3&7!AZ8@OU"
MU)1+PE!P6/8*E5% ZN,3OR/;-(0%\-7=H'VN&VR:6NX/_?I+W%C+"3)AT*0
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M^M>.JY[-?+72,BK)8??-I:>#G"#/_MNM^R 9*<TMWWG+9OS0E.X"O%(?AA#
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MNV/&SAKD9W[,-U,$ H*35Z=%\6/V-^>-[;7Z0I;]J*XD&VAV4*'(0H,.$6'
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M:STS[50,5B#YX@>[+6%"1JWYIPHKO4_9Q'0849)XPRL@%:K%FU$MH)SU*0@
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MF9A%=G_4F.WPP*< X?B!('?HP]UZS^3C3X)> 4N.4@D%S_QGDR>^KI@!?H8
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MN_$)>%$O *\;:9W20]I5J#KZA(G<![;R@X_=0X8P.N_A56!UB[$LV3%%X9D
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MLXQM3[7N_YI@*S5*K@Q86OLN9$./W10:[F\[L\?F&"=3\G[BW@-9=]-=%/#
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M<6LSO;I<O.S+G0B7)VJ"HX0\(^&)WE-4M]CSF&\3"G=UI/Q%A6KV5F>L?W#
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M:D4M(#3?=G5?#B[+/NCYA <Q'^T^O)K=0H^[@>PGZ9:1>>)A$;390B0(/.E
M252<RY(M8%\^:5LFBW#,GWBC5.1&-Q!T1P[FI#]P,J6G&.5UID]NL=M<Z/4>
MS&U.M!&LV+Z@@_ZP('LJIR0LO#22G5.?6O @<%!TB/3FK4="6%)8@MZ1P.'#
M0T&<WXX(WS99Q@:]W;ZZQ7'/M9WCEQ__9/M?X,#/=_RS, ?J%XN@U6G-) UZ
M4R <B<;7[3U3K#2?8JA00:^#MA<A+Q5T#,>IY# EM*UBS'WIZP^0Z!AH@C7T
MGD?A?NCA.]?OORB2<)F/\Y/.?6)G669NCIF@AZ$.T>VKE-",3\$MFZ1P7,$$
M21J_,_,V[N)AZ^3M$$/,TH%DGJEG0[^$Y=DZ"(2G2L/,JEJ4I99>\SCTU7J<
M_:@^6D)=":V[=X02+>YOYJ6J,5K4S0D48?;P!:#]&;(,L,B(?>!R*7$LVZ:Y
M/N1&J)/LP:)^^Y]Z[,\7_2EM7)6)L1%P_)4.:)#=#";E"O"FM$[1?.HQF7R3
M9_X>L"V39@#I"RSP%3F[,ZRJ0+NR.T-C!ZM^M$YL2C3=M$<:/1AQ1\/3[)<V
M,[^=5SWTUI_V,'GH:19Q=]^/73_MW['7\,!/!_9B,!B;>2TA2P'FE1H?G@YE
ML!DQ!QEI^/XPY(*T3-\77))Q+O_PIJ&1P,;:]]E_R1."JW^215?)%F_]]. .
M=@,4!OB(VYJ"761>D#.0)4EK#EXCA]L;\9+<\]1UXBTNHT1[[X2WARD!WMUE
MQ?1-A\.&+'</'[_FGN"J/S+YSRW/BVOIA"VN*X\X\QEO!A4T%2-.9_?@&+.&
MW1+$PT%]W</A>&<^]D).G_%OD7DWZG5*8\JHN\#PB[4%FPZ_T2JG:IVK W?U
M?7U.GKF*,M>_:'_R@.<DP(L\(%,&[49>@IURG(JEW$<1)?&N.HJ VL(>-482
M3!:9)1 :H,UWX<U??W[2>8-N-7T]O2 6CJ$W15.WEM&;@@EB&7,1TG9;XW5Y
M+4Z38B/U;*:_*?3B=A__JL943'8N'G.@)"LR0/_ \\>NC#59K 6Q+0X/=W/C
M>D9"-*KM*Y=NC]:<2:'$\H7X2]0M=RG^_,"8NFQ)Y^(((2FM1F=5QZ[#(X%V
M6:$:^461=0]>O,CIV[3I5>"SQR\.KOW=R/+X^9-=_T$7 (?1F]XQ*["P'7W
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M)"&""%D9MLEU444XC Z).T%\C[2 :H<*F66$$R0,E?R*NWDDSRGWU@.H4Y&
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M/]$^)SO#>CZ*+5V.2M)BVG,<%K&G<(7#O63$BM9C$E( #K;4%ZD>MK #DO>
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M=6FN'?7/7;N6JS'F.- /#[EDBN,G5A#3D;F9Z)LI:%YQA2/JS'*;*T#<P8Q
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M$.66FB]I>Z%[A;"SZB*B/^(GO).*9EXK*E?6>\T]+#KZ[-@#:JH T*ML2[Y
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MKB?\\/F>N-[)\N</!$O!L3/AIQ]Z''L06=$2<SH:>=G]9KN8N2APS(.?C1B
M?"OKR.&:F N6&KLS Z+S[M_8DI?TV+9 M/2S3>Z1X=_:/NZY\:K<V?[I<MP;
M%FSJC6AEN?$9D+4'C]%7K""PY=5\K@7""\A)1H'WHHZZL,?0!:74C9]EQ]M(
MMW\'ATET!DF[VMU72 8]^+G<*W64TE&A:W:>1&49QS6@4GA"QZ*:H*$D_!<1
MF@:0N;94!&LTZ6SDBO/H;JCAST),19A\%4M>+3G%-*=9@&3!!6:Z(,D&BDZ4
M8T/DA-J'D6J,41VV!#H)&'JQ4+[&D%*,1MM'G@[UMY4,N#*O4/P:6PNK'L4A
M]UVE(6M4MU$,AUT&<5JD9EG<\,G+A'5R19Y-:S%5UC1'$Z58LS[O53MN]%-S
M?-_%3I?X+S.J%]=GY=F==ID'SY5+Y7'G=A RN%I/Z"Y PTZ",^0<#-JRFK&I
MN90&5G^OCWP5,_[^*,<!BGP\-FO&H)V7.SEN^';LCOL:J26YD3.ODZ;]I%)#
M2>_=(]]8=+3UWON1>&'U!S?8V$^"G<"B9D!]X?*D$'V4A[LK"!R6L\9%,B8C
MGPBU@2V!7B?+P?#,2N!:+NK+B NL5R/?8VK>Q$QRIQ3X0S*!T"_9T;7$HJ5O
M*I.H!_6T>'>/EWX.S51M"[WV?>BUU86>!>FFWQ=D';:YYK+OT;*(NVNM5R]^
M?'?M0PP&8W))RM*BD@0!MJ*4NA@)H <)>#EC: ;^0>Z;_@!*W5'O\R0O=JHT
M1/BE^<.YVK+^NZ?9_:=3EE\$;C%A8Y*B%YH;N;8-&03*>QN(_=L5L7+RY;/$
MU'RK[CJ\9!#KUZ-YM0BL(VR5;[Q$;")F<8VF54:[.J<H"R&C'9U3#$W_8(>L
M"S8^BXS977&6"?Q9<JI$C=F/ZT?9HR@%"">C\'LA$#ZYL.X+1!13&BFI@):[
MH^N[IO>(%10CL;1I$&YM$K4YQ7YV49D/13_8\$?KEE>M*Z]ZLR=3R LX2V@F
MG64NC"1 B_,=S;8C5O2FM@-92M5LS-?H++O_=65.8E-.\MD[:X7A7\.R@SMV
MM'[TLAD^\XS _/O/  &R*1,OXN)1\[6@2RS/171QUK$+L8:<)9-9%S3'!\-=
MBWCO_?OI;:(*]YJW]7*9?\>T17R*T3'I5F]/2"!EZ88(7-8-MDJSS(7"CY%.
MCA^8*C0LBA^1V4W5X_:H!2!5B1H31:K:'L:"-T >K+E=HDCA\INPK_QT-4AL
MS/3P2M(^QI3BT]U=JB.N_R'E!^]^YFFS%LAD01N8"H\7<DI3F[!7H9 G_MXK
MAW#;.HGAK-2 M_?+A]B36>Z)9\)DZ**;?>*6LS!C+!>7ZL*8W^=S[D3VYQBB
MU*K(F+$L?H/JOH9*S]'1T<$QYHF#8^GXDU.EDLJ*BLJ4+=&!WMX1/18)T='4
MPRLN#VGMMT[Y[KI-ALNAG8?W+<Q8?7?^O[MPL[C0IJ^(UD8N6W39=1):K3G.
M$#>X3?B O;S&85DXCZ4[,H(F$:&9A)OJL)&A/[+1]'IZ'/DJ$3N5N2.C6?C]
MAV[W!/' >DG)P00I%@L1/;NXY;M7:T!/47\((8KK2I7>5#*/#.XE"95-$_@)
M$['E(F]<OTQ*29O4KH<&Q3C=OLI4E,Q/EC$3AYLHF$\]Y83;#_=\G!2$+.[,
M39"[9=1M*AG-7XUTCL$?B>*/:@QD/9RNQIS 9H!H* L@'M-U\P,]+L6Z)Q10
M.V792>#8A/FN0E!#MJVW%%]'E/<VX.\[.$<0].1 !M*T\7E,P#PQ*]W/-S?Y
M2O%.>6)]:C+Q 05:CH5-;S8R05]L__,(ICYE*D9#T0KA[D?F4@24A<(GYF=#
M7#J^FMZY3_L)/)EG+M &>S-C%YQ#UG140CW$!=0>KZGTF!@7R]"&G-Q7FE,:
M?WG;SG_DOYW\G?O.:H)S+Y)9]#Y-'FZ!&A/&Z(OGU=QF'(!*9):ABDM03F3L
MAU6,!JY>S&=W6W!F+V?ALXVWI10SZ"9_MN[TX_7!WI*F)V7R\9UY,[V([F?5
M+V3%.A3.[*'_$8+IGA*-BZQHN\%,Y)W(4'9#(R91C=$.;^[); Z@,Q\/E)?P
M2JA^+W-"=$#"/8L/'8!.^;-7RP%=(KAO2PD#<IB$E\F+Z6VY)[Y 21+Z=>4/
MD+W"M]K;(_I2*.BG^)FYKYL;L76[S_,K5YY7W9C9!4EDED[4_"V1!5VESWY>
M06%7S^8*A0/_>H4=V! 9'KE@8U5V]E,!)28ZAF+>M+"^SF#MS@7Z.]*-U_$S
MEYU^7+#V\46,W5^]H?8_*1IY<D92G;T<VQAB!YI=J]M2"-4VA+B"R#,)R8SJ
MQ]]H.EN6)"7I4I-(SSO8K3K^G4ZR[-Y]'=/!&S]_;)Y]*W5+^2@\?_RZ_[(,
M-<:! :TACY.4WJB_L@'P0%L*EUT\?JDDVDM)H.8U"9GI' RU\$"TZN".S5L;
MC&@_J&XAZ[__W;MD0% 0]#[2MY,<LNJ>5(W1:"FFUN[JFJ!1)*HH0!=X/$AC
M*,_0F\@+4'8FJL#QN?VA,D6**VD![<>.VZ=<\SQC&.GN&C(+XVS28G@'&#SQ
MYJ!3GI2K/;JWNLK(."%0>9+SCIV9H-+PZZX<>*GGAFC/]=F8!]FA5[SJ5XX5
MTL5=0#F@@S4< $Y09U[F!"37SZ0AQC2?CHG2P":N'FW?4<_O1)]ZS?8%1P;<
M[._?*24OB=ILEO$DYE@GNW8'+L[OFS>]F5D9/K%?C5E4@W[_P[084$.15='#
MGGMMV"3,3B^@1;2?_9XB2.&LA2VY7?A0Z+QR#[RRLL9QX61:G>."W*(/68S?
M9HS.T]TAK[+@D8 O[Z,V:\[FT39#Z6)*9OY\D-*$2PE9TUY' ;]*S5(J*=]1
M[9L0J[IK:LP.N5T*;=NQ1<6%T9O#W@,./3D];OIM2U>L_.'CIL)KAZA=&A7_
M!L[VC_PWDK]MYU76+US*I#">I+I*/,X09BJ*N#=:PR$[T$\0X@).L+_MCRRA
M?AS8];P".B\9\2ZYJ\9<R1'$<Y:!<$)[;VM7Y\_K_F"RHJ%Q% &_)4;)P!+%
M?&BKTB%"R.BOVZ[TA4^F'I+KYNYY.42SA["+F-+!6.UC5Q]9A?/K 8EM=]W-
M9\F=/O59*[+WV;(Q\$WT+NN(82IO:?5$G/(P\A[Y/O!..&(\<[&4OHP:'=@M
M],Z\0Y(R!8G')P/EX6GB^G,;@J)FW9)HN,>10MY>+RK!EK?FZ\J;-/(G-8;\
M5@";=RO7X/I3$>UYX): ;I>OQV1X(1 L]YO8)+VT<EM8#%%PH \")"4>F^;[
MGV+1#:G$E[GC!D^/W*WIF81_I6ST1L%WP87_\H"/OT)@!Q0J?$6#KI6[+1K1
M3ZA^_3S%7=P?D8N;B 9/=OK*W<:'90.3%7T/"A-7>A&JP<RFW(K'E?3%4$KV
M+X$>\:=79S9R[*O?P?N*QAU=ZYV/(/Z N(\(.> SU9A01E8.$_1L&[@P[ >2
M+L<QTV;1WXRS. 128]HZIHD7N;BPWC(7%2!.3;_;]8=W(350JIGI^T7D60TX
MNCO+#WP./!\C;!&89Q?=4V,*8P ](A@G@@U6T@Z"9;6HNCM5V;25/"F3I[+2
M80H[&^B6E6?B9*)4!%=^N4,@H]\.C^*$0A42SJUP2IBLTS@VCI*J\.787!\?
M!@GW9T'-&<N=P%H<>"H>-FTBBN\RYQ]4[%45T'RKB54>XW))PN'JGNF\E\)B
M@2@IUY_=4<G%I1<#Q/WRX:0W0B"58UMRNVSZX,9D6=+I^#-2K/ZV N#PU%^^
MO_R/_/>1OVL[.[]OB4##'W2"W ,V)B,Z/+!:80F%/TJLPJ5\I>FHKL-.#BU#
M(]EJC"'B!"7ME?LQW'<Z[&PWE.VJA5(+J>'\UH_;%E:2L5K/J9S7[L,J5_H*
MZB2/K$.;)V.D<URXP?8-(KTZG)1B"54<^JGHK$B7ZK&S7KZHEMZ0[VH?7C0R
MX[=D:;OGU0]=)QA?G>9F"[DOE)*AU3FP6::4.]$DMR/=4.!3#6E456F=Y\P]
M5F4?P18^+C<ME! UJ#]YMI2OJ3Q/MQX;L@7Y$4\;3C*Q-DKKQFQ?<)_F; 1M
M"XA+(9C 1!#/PRX8&;E/=98(DNJ<Q42MD?T37Z;:EE"W[WP&*I**'_"S-OI'
M!L05E8]GF9W:'K6Z\5KSOT$>_U^1ATZE,:S2,@=6C+BVHO9R=&"M]\/0YU4U
M5<^S"O*'I-J'I?G:TOB,B+!=USS[KW??2G-N_P'W86#N1 V:6D[3PM&K/ETD
M6@*(T2#^]$H-XQ*"@0324_G.D/>C3XJOI/LT+/1LI5]-:@8R'\H>VNCIA"RC
M"K;?#"'H=[AJ9@SP<5BGNOUB'7X=BB<.S!SL!KA<R)8%&R>)U1C8Q$:Q$\1/
M.(/EWHFXP.?[)92KQ"5#W_!QC"LBT[-Y6[QHWN*)73\\>QWWX(]JWYJ9*Z[5
MET6((59K5+CQD2,[&>Z=#6%.A4]$*NWAI2J4<H0S,H@59@+1$H&4D8(S@=W.
MW!WS;?FP\_&GF7LW)G^4AZ=0BE+$D00',+N:<DR*TXTJ6)I\[5EQ@+>+V<:A
MQ$K11P_E]W"(ZB%7W*W&0/;Q&8@A+30S2)XZ/B+;DF6W&\H+OQ_02BF@G5/=
MF0[V56,0?=PU+G9J+"_U*2G-:L%U]I:\:(WXE37TVG"YAL3G(SLFID0TMOXB
M4++5A <[0[?$^*M<K+N1/%1"R9@"EL'?0PQ)HE%SOJ8\Y=+/3E,40RJ9[ZL?
ME;OQ63&);5DZ>2KVV&\KVYM.:SAO.[/$S>#U/^>$_Y'_4_(WS5#S8 6*>M\Q
MV?;(&S+HP1":=GIW 15U@4K/42L350[L(#UC]#X0]GY1UT6W\3\?F>YDPX$V
M2<AI"L-=96FZ0O>/GH<GAF%HCH6H,6%Q$%DY'PY7/8J+V7I4KCGA(W\<;+&M
M?OV-7N82@H8P! K<E;TI:/X+Z+J4F*'(,>#]]CZR)\NF+LTFZ:L'@HU0/2B6
M8YO)?6V*=>]BB^ZX&XDI)LB[D/6=IUK>ZPS&2_>^L..UI69W\HPXKELM?$"S
M:W:7!UZ;K>ILUO?^NC-N$5!%@5;EC MPXY'*><@K487]$4'Q&$Z;LQ RVR7_
MW6"UYY_0S<>1^Z$<:?+HJJ[5-4Q^,*7)_!>_13N5(;;G5^K:8!)Y_P:[H?_K
M6[^I9# $#ZTTN\(5/^&6!P^GTK;&W(]@LOT:TERY9D@K?0MG77\3@7TF4F=,
MM-B=],A3\[J8D?YL1)B8U?WG-<V4.I]BB-)T-,A_9/.#FT_H4C1_#2]58Q9Q
M40<AHPZQ%/ZIFRB^@:OZ,%0A9BR DJ1[JR6XRQ60ZF3')#(?>7<@.N<")9VN
M0\UV]+F1:,3#&=!\;PQ$;MQC4PWV-@6F]WA3*J"O?MTNC*DS+ D/T9OK6+*2
MF4%8VLL5/\*5"Y*+R!D MC(ZD"EL:2 LJ[0>%A#F@1_N^_80ETWE!7[?U )Q
M)6]O1<>$RK[B?G,EI0KC<M*=CYT19_F2]54B5-<_4%U/S?7R3Z4M(/>'*Y+E
M!X+H_=R*XN0GA7E^W9^[V40&4[-2P&Z?8J;O?^V<E[6]&3&.K&S3HQW\NJ1W
M\ZT//2B+.7/&+2,N;ZN6QNS=OQIV_"/_/>1ONM>%AG5DL:9R=P!=P'QF-G%8
MN3<H:-M"40/C$E,?#I=4/C]QA 6?CI8H6\BILVLB361^O76GXR43AM8CUMIQ
M"QRNO3@P#_EYR,X&6?Q5C=$D>\SM8%S)D\1>4H;T?_JX+C/N7@A-7Y5^=M(Y
M\-!//VZ7J#%I/2*MZ4CI[7[;_*^"QZ':Y^.--52[H^&/@/@/<G_Y9+,:4\F:
M2%>&0[E+V?/ 7@DW%5D"11_NF@GV2I3AKW)64I9" M^J%SFTK">1YEA>GHZ]
M\L$ONT_!YZV-EM?^6CSK_-='Z_^B+##SK>KMZ37UJP*#^P<;7$L'B[K6OP\,
M#@S:U4ZBG%[P6$Y:(-_2Y+*AT&/EJ5>C?_!Q7Z;18#@W\783P05HT%1C**(4
M -PWV4>(\7XIPM#"Y1M(2VEV7941=DQ/:(4\P'/2%6\"+Y!OK=R;/</4A4,+
MJIXCV Y7LXQ>E(#$TDAB"WX=P:B^VY4\;<"Z0XPF]9/%;1,LI3MMO^HW#@$Z
M232FK8-8DMH[F@%5Y+6.?A[U2W(NF&6Z.R<ZN&EXR<.OL&L3L/KH+Z;_QB$N
M:W.'_]T755\G'F"^%2/:?BA?LH.VH]<]JNON6.5NFG-"L!D_.11D-3-25GVC
MN)*3<:8N+?;^=1Z2P*HM=K7ML<EOS">37%^O2%4F-.;FYR2XFP;\UC553YQ*
MX?YQ4(QKP@OS$-T U S54)X$:$ICMUG0WR(;\G9W(M8!(Z;E_1',2NRXZ''4
M; :$DY$N5;;4/N@L16RHBP\^?A\P4AYE6'53FH"UA/$UO9V[>UC3KXE=A1)\
M$R.5:,E92C63V37BS#X-$:!0.9YG3KI*P\IPV/>J$B^Y9FI<[9%)!WSI[X]]
M='[[\TO9>)FTFMO)LG[>.:T3&#@6G4F]N%7OKS[B\8_\_86;AX-LBN'?>Z]Q
MQZ] >6J,KR9O,7*SY-LSU.\W Z];J6/(*U(Z=_HH;=U=[,CFOUK??^E\'8#<
M\Q1WU9AD+Y0Z]8#8\;&BJ%T#?"([54#$CN26Y5>X^P @3\Q?#WO*=[Q<H0(K
MH"M<32EUI=5!#]H79TJ&"S!6P'U3@>@-0FPI22A %DN46^E\HEXLP)Y$]&E$
M*!SD>K]SVY)&WT3OI*_NA'?&Z1L4;E!CHJEN!R [G5WI*^]-])<W=:Q^27Q$
MA%P]%$=Q%4S88$8\DSYM21PG.*B*X4B92.C,MS[2.T'LYRSGLD$\#[1;7;XU
M:Y('8*@'^;Z_Q$8<S>&;,;XS#-K; 7B:?!!I(,;4>#&Q@7*%J $OOTS4ABV@
M8V)\,GWI-L-&,YX:@ZVS+Z*2/*P.&#YCCJNLW_]ZX,??+Y(.CKK\U8SP?XM-
M0O5HZ'Z)^MQ.&A&]LNFO9U,ORGPL>,1*9N-S-L,4:24;34JT:MPRBME71O/G
MR1W'5_>&2H;YOTTI=>WXT>;O+<T.5H)JS-68<5=[EJY'$0KKK;A@+!8V$4DU
M82,/Q4TY'C9D*KXEADI$C3[QTA26F+F$R-=._IU;/C.Q>/9]34BII#3JHS2<
MW<$Q@W?V_L8K#;%]P[$">Z_:/I57&@50 7Z^2^^ :NT8-(#RUOMJC#BE5!D(
MNZ/\YJZHG)N4W#:Q"<SD+84&Q8!>7T44TXIC1/VY;=W8+)T9<558W41,V1RD
MYW#=.H;<3%AP"78S%J842R@+(ZHQN'Y;$S@<:"AE@D%RI2]5<_M<UQQZ=PC>
MGQM)228L70<OD@^GX0^1X7/084G>_%:)S^XO'X-G64VDE #71Y&V+5$A&T#=
MM-ZRPKJ>.D?I1/1!Y$W$OP$6_$?^SO)W)"#S-SW(&%H3GG]$?%EK*/+![9[O
M[V6XXE>6O_IPX'O93J?/XR;&IL<QJ[@M#$3;>YD: QYF0)LU^;C*[M&LA)<A
M2Z%A>:VB[II_Z/F\O5 \F#]*P2)OE7O26KC;Y*;WP.VDP/0=-C&/LA>FB <:
MB?5DR#%UPDV-69*.IJ-2517'-2!J_4B^#1NR8\$$<&M[3LN+5 'WNX\5D+=8
M.4AP/9LM_>K12XL,9VD5O#\@VOV\YG<=[X14TH<69$F&ZC:A18(?("M>=5=^
MZF=S]:D6BBC0ZF%[3/X07B]R3$Z4%N7N>9U3W64KQS=\V\T?+8BQK?MP3O^W
MB\3ZC'^#ALG_VUT:6P6(G@\:_3:AX$/[FWP8S?*7G]%?@M&$>="QA[!7.RU&
M;LZ3C'H7#R&M.*N5O4>[SI+2K9::KC[H 9V6M1E]M])S1W011!3D$/LB;-[1
M_"7U9GL0UMSX<";HCY\'- 0 )[<D3%P8W@4*)J+!A+T=+D2AO:2TT"/2Y,.?
M#WMRR4W<!7T5YV] .H*? UK=LZ]KVX+D])1"B?=,[EL\-IINK<J'DL&9!IPI
M35NJQJ00#6'[ JI,,L. -Y5 'LWY6+GME<WY25*R;G2/<V1-<U;)D2#[G6?"
M@+#3+D:[7J[S>W_UQMH:->97-6;B&V@G\X MYLZ$70#]^*1^.^F:KCJ3DD\M
M\E3QQ[RRH<%!;AI!BUK"SQ6DU@6".C*?JY38H>6==^O!ST62;Z[4L*_3/H2!
M1JZ^2QX3"WUL7@E^TIQ]U4YNF.#"N*5@:ZG8C0SN95EZG#V6]EY 47I1Z='4
MSXO7W%Z>2TKZR<O!?M6'#*_ER7_^\*1]%_]N'F*3":&4RG-BKI-:NJ6D#3EK
M/$\UM)_<Z$X$:7Z-)[-MF8BV1&[X_9*T53=P0CO>P99E.R]>ER8CA@/W.ZS#
M;MCE+[Q^<5?N.F^6PD9I2.\E+T$I)+X_4"R8. W2V_@!%)XHB[[T1>]4L$U3
M5?8Y@FV[T]2=>#^0E39E&2O:R^F:FIS0U>'/+JHH;",P'X;T!;-SA.-E)]GY
M=LMQ!]O_>LSRC_R;BE\N?!02@"4* (J1METE6M"70R0)I5&-F3_R\QC!4=Z6
MQ<[;JLD3VEXY]:PP2!3RVGQK]X<WO_2-Y,8]9>[O9MOG^3CO8==V.4V4%DT]
M1O2Y8@B;+C)V 5* I[A&R[7*@T\AHJS-#+X@%UPMC8F]<[9-'_I_V'O3J*:R
MK6TTM@B(D5Y!B(J BIA2.DLPVPZ10HR*B$)!M% A1(B6(!%BHB)]$T6%$DJB
M B(B1*13F@1(@+(00X\$(5TI/>RHA"U)=K[-N??GN7=\WQWO^]8Y=QS&F Q^
MA)W5S6<^SUYKS3DM[GT LMQ!>]^ZVMU4V+P#7@N]'_?PR P.^]0;]CE.'W?G
M<_."6?8=-4KC,KW!>1H(\XP6Q15(_$*=Y#LJH*N&:E0\<&&=F)52QG^A/!7J
MYEIYM\&'N:RE,5]VY;[8M;RZ=QAOAM<^]<"^E>SXWL9YNG*?:K\2"^6# ](@
M1!EH47V@/5*6%O401)0^W&Q+;H!W@@?>%$!W&X<L.O/3#[I^OO]B]/+'?O\\
MGQ]^/C6XX=<'%Z:+2RZ$2>.F!)1 -<J.U>\,:V[ZQ]V8UP!Y6A]NP90)D[>X
M[ ,Y31CP %93>18Z)V,=EITHEC@+5]#Z(J,XC:LBZ(E#6TJ['"2IST=@ASZE
MAUB(45K51/N9:1S*/@7ZLQ\\#A$$/+SVE$X4@JXLR!+?I$9!&P@3?)F;:"E+
M<?P#W!5%3ZH] _#P<7-6C\$!;RA(S(@=LF2W"P_+EJ82HZUYF(0YA"ESC,9.
MF"PMH\MU;+C"_IVW? >5)B<*Z<4_?UR)?L0))4!;?)3Z)%AS4K)*J:_PH77G
MK(#H,J-KVVU]L7&^5LE2()&N&UA64Y[^]:=L'Y#.Q>I G)-@<>4;K2#7;BJ!
M+%99'_%Q?]R->^<;\0W]@0MK754LH3?L?2)#*[<-3]J*R"G5F;%K;W[ET8PJ
MRF5N,2Z1><0JJPWQ)VNA:)DI%UXI^S,8[]+1KT:%L>*SW?SD,#_Z$_M$%>9M
MU019C5J:2PV!8A57J!=4C^BB,G,[*%3AH01D]P*L9*)DT7 3*\F7JD89X;#0
M .]*W]=!"O>XN3GD)Q5J0X%<W_W5#9YH;I\@I++0*K9@-*N&$GD@I\M+N1'B
M@LGU0O#P-/3C/F2IXR%+5E*MZXO@H66J@OE$MRL@+^X01G:.GQH6[N\FV0RY
M'8;>@MN_-K%I!=$2S')!/^5N4\XRV<&^J0@=GP/M83.ABYJJ4S^S'H=4YSW"
MC&,VW.&N26]=[VIPL--C2TKAFDM/,JYNN++NJ.Z>\^?7>>_9<%V3U00D8,!+
M9*5NM#B3-RZ\E;-)55V[P#K9ONVPXD#W--5&Q$H>V@4ZQ!46?+R6$7V*;44Q
M%@\GP.8_Y42]3[X6)(E^Z.!9FQ/QE]^D<CH!$$VA!6I4,Z<,46VCM#7*'_NV
M*@$)6<"7#"6"0$!W^7@,L7 /^!RK0\ENYNB&%F\U]#V>S-LD'M1H\.5=LO>\
M+%:C#,?DQ1O3@M+PS1AH@['2U%^Q#AY EG*Y*H]F2V0[UJB*.,'%:*DC!_1J
M]HU,G9E$>T 'X>4RMV080W4LQ2\C]AV%?)H<<>O[7%:Q-\JVY&SJJBAJ?6C,
M.TJ,<N7'3TTT=5ZGTS#+<1N5/T)]B !MI!O"NA0I C=Z-!-HVJVJ3VDF92XE
M.>+6@OR$;]%/Q@WE]XN(77CB99/6-95]RUY=[<V\C?BCFTY/;7O+U^G)&,4U
M6@OAI76,/<,<[E.C,%1=T(T[M+[N=9?2P3C!]$2/TE.27+/QA 0&M"F8QJB@
M!!>RY&S7+^E+>ZS;:W<]\QN-FVHB?ZJ,'G=@0D&(4D5\^@+:E$@P4Z.(P@]N
MO)V?9OA<C@$5>U>> IK'%OHS2Z' %EA#YG.+JBE-OJ;U_I"+4\X.<#HUW';?
MJ5C@2B!TB7S1(BDP?!:S!.+OGM^ DZE1#6T!:R&LK(@'6]P5!4,R6:0X-K8R
ML3#9W1[;WRKW[JBE%YZ"HKD^VHM2E\"65=>GK-B<\JJL,3Y/J#NSZ^S!K^O>
M[$9_,U&E<$2E .C)@#8:)S'K@5?QDT=%_ 0U2M>BDQ51"@X?;U=> H4M5;[G
M?UL4DAF%OP5;0WX-U7T):SMS@>#NI^#,TR*=^P5S%[Y8,J?'OS5R6K'P"D>D
MD<%*&^3W%KA'6)K90O^P4-K,6>JR2Z;'Y>7\ )YC*JUHZV5AN>"XU*D>HP=A
MC[SNJ[63T V'QF +(]]41AK5C)85\.;YN%;6_;323W^&%_&Z;('.9+DC-(N>
MQ"LVS%=MRCO1VXN5#8NL&\G)D=7G\FZ>M _U:1E:VJ[T>#$2(L[&/AX3I$[=
MV3[UR]U3!V^EY[5K=![_=TVO2M<3@E$(8T74SK+(B5S%)OBMX'#N&E]FLQJ5
M$K .JI!D^UV]?(5J!N*YI2-S$6FY6F^^E ^2FH3ZWR8/OWV:8#I_[M1#?NK2
M&4J\O ;6:5<]P$]4(2$G2I56:T=_^I0I8271EM6HGE!/PT?BQN;4*.G3P@BI
M<+G[,]>* &>5G9A=("*OX*\1_;S7?G]<A+M%<-<_LFZFNG@4(P/J2A>)^'&$
M4O+-DI*P%P@8*9QH+5%;JDFFV2==W&5V :]D+0R7_:6WPJN8W%F.T=D.ZKZ(
M[<N*SX 6[K\V]O+>$D;[Q0R=$9H.*(RO72=^N%/H!@IC[7=9<VGFG:$&^269
MCT>N&,T%W"WPV[2AN"XUMKBN?+.[S9J?-'>TH<+^;O+S7T*@OK^@-XQF' TA
M@$?Q'X8/_U[=0%=L#I9[V9_5-+)AI1'TU]Y^O.[ZQ72]O)N+3M]V,X3OS< 7
MF.!5H3*/(4<<KNPT. NSF(D&"[Y[2 @W<I#5$D-!U-<S(_9R59D:=8YU$U-)
MKM?.W>E:0#T-;1.A$W(60]]![5/=TC0@ =#2X-5I-QD1T/ 6Z-SD$Z<K&9G)
M5\5"P]'9H15],V:D!A-!2)9P;C>B_DKCE;I8>1UD"H[+4U1,SFD&9$UGL/65
M1]O7]BEM)6: ?(?JX;'=*5_\0G8ZEIV>SXW=\P3*Y KRC+,PB>$Z>]9WA^_Z
MM5%QB!WGG$TTB,+,E^G1O ;:P%IEBJWC0A3;=L^*&U(SZTFV!;1.%M=Z.&Z6
M)UQ&6Y^]1Z>DXI<7\B\A.<:]&3;7;%IHNNE30UT\P4K"9JFG;&FF>)#NJD;A
M.)"5VWQEC2)D%$(!,CV!64J>9(DYNMB)81;ESS];I3XW)GQG_;IJ<63>"=HJ
MU3/:DI_:W51U>6-1:ZY$9A679)-"G1@NZ\*J'0L+^BG#C7.N3Q,6*+CS&Z,P
M$F=*K2?FR\K6M>/6TOC,TKZ)4M"ZY2ZM6XW25.YR2F7KT/AT3=PJ2K7_HJ,@
MO<GYX;Y]=WDYFF!:_(NWN<*/HW)CX^K @&R;PHD+GW(T-U3&WI6;PCJ9B#9=
M S<"<JPR5(WJS8*Z"#D$,!++J#64><'+2L$:B0^7;C!"<P(U& BUNTZS!8-2
M7!R>#8PA3,,IK@+ALW0C!UM3OXX9&[?TH5E\]X6P=6\J<ZPWR_ZPBUN,;A="
MC@3XR&7%,C7J T>&@( O2>J)HDW_W>O_/_:O:S[#\4H#(:R9K\ A8'\<.)_J
M);\$?3<JSBM^6HI.8:]6'@1K]F"2V<;4?2^[*LSL#LL.IU2M>U%!6OW"P4]E
MPPM8U>-=WD9WJ\VRG:.5DG))66XCU^BK,6 D>J)'01GCH-DKX ^$5U@>1V".
MCF-J*9U+*/KRVQ !)$F,>8-6K0?;?4Z9;P/IS21$45*<3L;\U&U?MV)607:7
M#2=;=JW(?=3/%25/[I5X:KCGS.Y&P2?8EDA;L711'A,\Q($V13:C^Z6PIDJ6
MW*)&Z>-<8#X"F86J/!;;@L;/BAUN!$S&U"A4";EV&^+"BXW96AS9SU^A'+]0
M-R^$8,KGZX[9>,N^4-)VG,G@'^H[T7G2EE/&@AQ]8.T@60RL%0,.2X0-&,&#
M\% "@HJ(/M4<SY6$Q>2>I/R*22:LJ/5PF+J=)4QT ?)^L_=T;L&9]7V3$5D_
M0R3W]MH?GX_.?8YUR$D\0P]][A&MC*7.5_E)A2TH&G*EK$II$"EQJI]T:J%C
MJ'L0U/E6JKJ]Y5L16K>.$5.[3T9VZZ69?QP5KJKU6MZK@["_R..,AKLDG 5X
MF&';]FFH.'SN1":+&'5M3#@*M*M12I/[R$,*58_9*Y7:*B2 AP@969$I;!0E
M6]X,16LT,F\Z6N!K0!^>&J4#+?W<Y]/G *3NO/8[^5RT>,>,<.5XUI(6+L7R
M56?%R:Z&7Z$,P>+V"(8.@8"B'YZO2(;_,-XBK!J><)7%RP]"EV5)P'6$OS0-
M,.(KJS"&*^(+*6G#W"S,+;8EQ:VE^IWC3MQ]%N67+U/C_F5@&41]/BZX0"(]
M_[F\;/LB ^9P]%.*AV1::3)?-LL=7/I8%B@>KE>C!./UF)5*_3/%(QA#NMB@
MIA->RP4+3G;/X+4@Z1'(S:J@6,B\13 J3Q1UAZM^Z1VM]<Q'0E"FD<!F_!*1
M;?FFNK,N7DY#F.IK9*$< 40WD:8?0:<1=.BBPJ-P)[."$UOK_\2?\K,?(NY;
MI*JHKF.E8%]"Q"XWY-M7T\]S])3N=_W BND;#OQ)VX#68QWVI%U:1E6]Z:VG
M[NZ1 3%A+HY"1UHOL)I#PD ["V M3[!FK^HA#36.T<&M4@+@$ ,<.%1;JR D
M?\/' #HS:/T DOD/4(NLIKG2Y$IF;C\AQ,<XO>V<N,BZTOC.R!PFQN6'H;4R
M@SZ3DI(%"CH2BIY"K$.()IA(1>93*IN]13[?XX*6 @G"E2X^3T+N6/).^,8]
MD)#C E;VUMI%;]C^?-7GVLZM85MM]20.K].LJX\4*3ZQ1C#_QXDM&=D(X^-
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M$VT&98;D%MXIIJT? S1^3S04Z;IOG='[;=4U)J(82FGO-.1AR#-<J#J]%;;
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M<XO.)0ERF'J-8>2MDZ%6%:]?HU3U3VK5*#&AB1S'7(,P%+R$WR T@WPD05S
MC/C#>,Y*&?]F11%F)13$V_GSQ$B5;UA1@>>N\J'CLC92Y-*9UZ5U56]*Z^*T
M6XDBQC!GP/0?A\/_%WEO&M5$UK:-1E$0$2*BH"!$!41%2*L,BD!:40%I3"L*
M D)41 @1\]B"! DIE5G$M-J*0D,:$:(R1&12",00 H_2=&06$#*URA2I:B%4
M0Z4XQ?.>7V>][_J^[YSOK.<]Z_PH6 RKLFOO>U_W=>VZ!T!(XIL5,KZIA?"<
M3'(C2"?#?O("<X?!:XO7/ 9'[.P2_7)HC"JG+X:=O2";VQB\G=L9G'<X$2^J
M!:E_A8Z^#_5>,7L_.0!'.'N4\I!004&,(U!=+@9,.M % 9X43A]@-S6ZP-G&
MN7$E[-3&#>#D;=8ZQM<9<I?(^^FID5!S^)$<T V!R]U<^EF#SYPQ3EYKXEO1
M/C07_.:N"XOS'W%(_VG1=<"[YS\MTOZCSE3>OZU?=R8'_ =7=0@X)X&MG%5L
M91;)SX6>V;B1Z4[ N:XX\XL'X-X ]:)2^1]<I^P=PK2C[YEKRN!:\0NRF;6X
MCG$U4&5^L?"&('(<7HM1FH^"*+;E(<TMX&PTX>C>:;-YG#':35A959VWNJ@Q
M5W^F29(<1UYLG.-5SA7 ?Z04&W[_<O3]PX._/_8[OV@< ,^U3C3,XY9))J;G
M0E@?7%HX+^<4K<V3>H@>&-+S>W!$IHBD&V.ID!J'CI:''9NEIS,](4NOKHN?
MC'S6U[&O_6Z[GAAAZZMI"?B$3?]>=0"I@H>AM?H[F)#(-=\EOC*/TZFBIW-6
MEEE?$R5&0T;*U3.4-<SPXBCK:W=I H/Q4.(KL*[-QI9:,"!<Z[7QIH/F_V<A
MR0)G0%9$ @]+^@GH\EPP'EW+Z@S5TVJNLZ[^QB3"'?*3$U63-Z6ZTPD]?M;2
M%/X^M[)W0R/9E0>U:.B*OHW=3#O%TANZ/(<_>RY@SM97LVDA1F67PEE(AVWI
MB"EO+N @9"F?2;>"V!-_*Q.C])VZ6NM8V:510"5%M4X^://J]0L0$+.797[F
MO"&L*BVUYB?LU<L[TBK.62.B!5 ,^!$*HH$YV:^;](H#6_4AZVWFC+ M=:Q*
M0WCSX"H?J)Q4^5]0F HF5)#-J:[.\>;L<3V?N,L@I>5(W95<B.QS\'9\[@\U
M+SN8"=S!P9#AJ$:]JLZ-22<;--481Y+*9S"*O(2!.6(Q90G#3^$IDJP=O1<Y
M; MZWG;0WR6V6 ,9W[]4U7:F="2HO?IS[M/@7=N\*CX._M,R9_=G]KF*0AZ8
MA&')J87(L^DLVX!N020=MDJM=^<\_2 59)0#X>1UC+=599Z'NU7E[9J\UC?X
M3!>5ZE75@W?R:,X1D-/<<+639E*3/X\CP]E6@OYA\UM:M9A34 /"!)*L>!Y7
MB4=6_\X24E[XUB0]QAR9FUR:/' ENRB2HE,ER2*L:=S)]('K?QME675-)1(.
M]DYQC!QR YI-":E\HIRB"U^@U=VNM"B\?.GIF'1@X'QV(;+HO\CI%"SY3<,E
M14GZ1>CR;%!/C0F\&QF1%#/70&A2?0SNGW-E<##Y[VX7]'&$8AHKT&.N[.%;
M/QMQ<><"B@2?X(;@$]VN^$)J!YP@SIG*EH+WJ-]&@S[.?N9&)%H\<Y[-044
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MOMB\@"9T0S9JR#,8'!_8_]'S-X^B]F>,-#%]:7EE9+YQ=]6@X*N>V@N[[1I
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MZ/ ;7EE@,_[SQGK(\UHUR01VUWE@&P$MXQ.C":,-__;,N?^M5\!G;LLDO!U
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M#X7*/A5-2:H(]08EPCX2F,0X_]?EE9! 3%SIE8,74;0/57AET[7K%1H/G\S
M_+?AKSJ9SL;5Y56'!@^_.C>/LPJF?+!4BQ8JU)X5#&)>&\\;DL*5HOPEFL<.
MF4!&77D1];)S!KIQG+(J5M\G!!9 >WUS5A543:8-VT%T$6,:HH<[_MJ+[NES
M7-W09<=?5#(HF3V*F3\9PZ\W:#<'#$ETQC;$G DC0C;&T%.DEI6?E#(/P'[R
MK;&#Y!7PC/H^G*;("WX#Z$V;;^H2[_PXED-*<A"DU%Z-NQ43G$<_T7VVPP[=
M#O\:%?255QSI%*01D],H+TF(^3HNHB70I++,$0--N:O^W.[1J\Y9[N91P+)2
M9"^HE+-%6?1]D']1V5CCGJYJO.&8GCQO5VM.1.9DK/F%<=-/D@S'.6!-T!C]
M]$!Q$3?JQ^ CBS28_.0+P&.&V!-LQ)[@)Z8#1+_EV%'">D]8G%+[AC.PZ&+Y
MDKK&$@5'EWHE3$0PI!^X96^OTRQ=^K809A_M1M(OG(=^@XKOGWGMX'T%5?ZO
MYHT ]P#$L*\%J"8AAAC[#0!]U Q-62S''&VS,(?O*P!=AH[Z#AP>K]#'AX(V
MF564FZ%:O7)X8RDLY#LKW(+?N+1D8\S(%/XBJLNKO5T:F]LF2&TC9:J^U%4]
MD+98F+]&Q8!,SH,W]JG\L*>,AT@3TC)DB:80M6"Z@H(F-TMQD/--EC%":82^
MYLE&I^T2_"H:,A4V:6;"4 LH.8B=23F2,J4W:!=VH&N-@XI$GC-)MPPN&3^]
M2*/%J%27:QX@2^S)MP$J^9K["F/:A9DT,6<M:@['!%DK6\T+/^:%-5\YN[3N
M[LF[_44?;.(M3V;N>NHN+H0Y(M8F\&O>0B=2.,VCS]6Z9-1I5GU/D47P?]&-
M['T>&7"E)(%61AT8NM\\&_[UWN5S;7'TIX.GVB(<2^R:+SL<V#./VS.I!PA_
MEE8?[,>4>_*@6JKA\%VMG$D#-DU2/,N2T3R0;*2YU:\?1-%*Y/_1=L'^P!=?
MXQO4 <NKT<I@GBI K;^0V0I[JG<N?&<045V) I]A80-+Y.8V\B\88X#;6@->
M^,@T/LU.P-IIR;KQQIUIHIP3Q65E;V4-FSJ02\^IC6N[5-5E1\:]7][H520>
MGCE&RWU]S56*N=T;WP"A.=_QZ5A=Z$+X^W)-7GA]!_=U38.+\TTBT^=\YX"Q
MD3[I&/CY_O/1@:;PM1Y.=V(3]3O>U-P]^PZ?.&>',0Y, \@> 34<<3 )(R"5
M1%4L^$T!B//(7CW3[99O7E#SG<'RVG+J[-+"*-,.$&'M!GFII_LF8QIVVN:%
MSASNX#;VG.XH=70[,Y'ZJ&C,Y(KTCX4@\DV"<Q35/EO6@*#J4@=KV(JV2"9-
M]7EN3E2993WL:;\7I/>-.G?GF;EAF;AU-D!]E*U9)? 4R'Z5@K3)"6?,C7[2
M/'4ES 7!S@J.2@^*4\2)$D@KQ>!7D<*_5F9+UV'0_:" U&G.LG'WC:\Z70DR
M,G[,9;B"D%8]=%AT*%AUCFI*&QZ*6C4:,/MKD._7NXMF0^:8@#!H'G>:!V^.
M&5[2);B STJ2SZ0W6@]&!:7=X%L^9NQJ04G0$5[AR#<1]1FMDNJN Z+UF[,>
M!P^3S7]Q>5"_^1']6:A=>_$O?7W&)M  >HI& N-,$,/,'_AS=MEB0A9K4]([
M;U)5#'"-Y7Q#DO!U2%NRTK,@RN+"26T/-6'#)&4;==EIP96%HUA EDYY,8FL
MB6O&R!1R:>[(Z#QNM8/$#+%]'TM9S@#$G.6N=)K<SG\>UU177( ATE[>OE)&
M@CCH4 %WM(Y?._ @>[M+>'X1[?+SJ"U]WX(^ZL4@7SH$,HD$MOPC.S*:%\,9
M"&[V6Y=_]"F-M-XUL]KSN-Y%(Q%J^+[4]>&[2DLSRW\$>:XB;TKOP9$8J#8Z
M**T,4!G-65))M401/OW',:#R/!?S2&+IJG+7RT#16-VY.GPJ:I%WA9"NU6RZ
M7IT6T#5-7CH,AS4'76PH+GORS3.A<,CN3D-*&?<5&L4,P0CB,T"XLRKCJ\K5
M&L2K^Z'D!SE/>JE/3S&,9-S4*C>?(\D?-_1,O?V*NE+&B_=R;P\$^]@%BW(.
M]E>_BB<>:QG3"K>9^C;GRGI+JI1,\.9VPV2U#VP-]AT"!6_PVO#E4V#-(U ]
MZR-=3>V;)=_D34<'B)\I]G)6GQJ;0:TYXISRAK(Q=TM.\.O&:'_EB89 8>W/
MWW/NJTG@!0&R\@NY9S+V%>D, ?\VGM7GZ^HL-0.HF.'?&CYE]_OC-M%L=DMN
M@X[O\3O[!XKSB@>*LE[3?*QKJ\\G7V/8($:%J$&J)@/;/864ZHCKI',D+62#
MIJ!Q#>:+\KB,&F QC6!8Q5GT$?8[V8.8R1.#6^HX:5]YS(U*^LHQ4U^5) 4A
M\:),8X<^YSBT968Y4%\.!P]+3QZ\/"H  R7P;C.Y#6*H;!4L8ZUAL-5,. 52
M*G3$@,X88658[7ODZ!.&5M-5G>3MT_52_<$VYYN.;F;-76.-&_B]#H.?7-8\
M2*[X,/I># #/O^_K-:ZEQ+#>24$O KR9-^$#K6=2- ])YRBI'+W&+0>+HTS=
MV.P-'#%K.^24Q1WKE827>,B'_%I9EM#!UE3.\1</$IV/O7YOYELGZ+*_.#7X
MNKBB_G5M]@AOP%EMK[D+T$9<[714GG/.R%H8R5^6[9<K[&3ZPXERP;J/<$CU
MDRK?< >S]JBFL4F?)']CTX2H*[V7Q71@,X?;%K?ZY8<!UPT$L74?0G"\D.VL
M&XYM_C?YBO:(1]$V=9JJL*K7^?WGSBSI,[[#>N?<$22QVF=!8_ N*F\<BKP[
M)C]^>![7FSV!H=A2XXZ%_%5XLR %6Y3'^<:PK7(2'\Q(DY/%F @'"X]])AHR
M.L=#X(//X,'O>[$U,3]KY^Q= ]$1JZOSN.N\"01?[EDXZAE2U1V3F]M \&K(
M&3]<.?0"PUGL4X3;'083]M(H\.;6"9.7+5LVUN:,JP_"2X'$S-@3-[T7\F1P
MI\9,XBRC*H>&/DIB'1X]H.;[1Y"N,"Z+6.;@E>N%#+\F%X-,.5T/CO.M[."3
MY (#ZA47B^L%5%.F;O29HL@!]T=+R_.*J35.':WTB+#PZ*5E5<ON>*PZ]/PW
M+63(%9.].C6LCR9Q=84,(S5)<Y^_*\PJSOM)$$/T(URO#!YRE]]2=$S[#!%:
M./B"GK#:]E=U-_J.=%B,B$GWW;+S;PQ."=!EE[&[; :$'H"LF%#+N4$Z3[D%
M5.I@NL=&.(\SA ,4VL^4I P"CJ\'98IRV$T9R"Z9*JRYT0*34;& &9,"9\NY
MX'!]^:B3^U+3<^H@^\++I3#/ZW57;&!QI8M3B>;1260C[%L<&A+E0F_"&.U5
M5D%BB2]O6/H!MA7Y9V?GJ)KOM+E7Q\;2BSW=6LI<*PY:#=SZ8^:N]^J+WW9M
MNC/RRR*$"PC%0 V &(^K(^#K<^ZP!ZI[&4Q0.%6#DE8+_=Z+"!4B8SQ^8HB@
MLE/N@_:Y'G0LM=#JCK'S?#./6U5%63:J'EY7TSF=N/SSMZ8[(8SRR>"^LHE)
M3($GGX^T$UPG90%5.@M5MO5VS>UCZ,@H+?ITC"FH@J%YW)L9BJ&#9#%B60O:
M)//-G\'VT\?L?!07 #"906I"EX(S*5]+E6!6%6OSJYZI0=V8/]]'.]0_*DLI
M:LB9QW'IB,D,NMR% _K281NBF)+AOJ8W^P<8@BZ=@\WF7)\8+>DN96U@]/W0
M;7(4&GK^C'J6DAJZLKH/H='BK8RH*D6TL\C4&A66"P4P!K])@?,XZB1LG3:A
M^P2YJGDFN" =X+T1X$E404:V#U@HGTEVY"UG_@ 95\L$2;,7ZB+2D:.\]N>,
MB#>SZFR+ HC4HEN\SXVGOE7;>Y4LTKC+\ZT@_:$&'!#,J?R"&'U1TEOG<? &
M_ V2+$]02TICZLNDMP>PN2TJ8UK4=Y7&:!;/B#C+$0]YHD_P/"[U7!^Q%-&S
M"EHSF8&N&74A-KDEB*/EX\]^ZT;"Y4.161Y'G2^'# $/@3=X>#.WE92%*9,?
M,7DB>^B^'9H4<:Y1UD]-9@"&+-.]R+D>?C!5MM#CU:ESUM?G4 >/3Y33C7SB
MGL$#@TV0S0W>'WEGBN!VSS19=0_2[N.1.JDY""BLB/"F  U!()K'(<[2]:2_
M^_H6.H?I;&1U"EX$M) &/60FR.H 5/?1W E&F%AJ5@P8\,2#Y*6,N-9&8\@D
MM=$:65?7,4U,XIB67F2>D0UI=\[CCG(.5;P$BXM[9W8Z_2K%(QN=/Y0;E "7
MUNI,T3%06FB@2VG<" AW"6C2Y>B'>=Q:@!:BUYIO!1)37,/E&AUY6A-Y.2/)
M$VRIO:R<7$:!_?RS6QIM(?LB:GQ99-#VH++>@B>,JP3=H$S!RE'4 C)O*0K;
M_+-#";N;N% Z9*6>>B&ZJQ8)A ,AKG+R%FL/TP7Z(B)IM8/O0B)DM1FN)H4?
MX=HW.V@YTILQ;GHGV:VLQ?!U;E"[G+<*SF[.>7#_&;4NEM\I4IB'2OQN:X"7
MQ9VLA137T^C'X578]RQ4Q%E$HA%7Z)G9^;6B1C=;%>34"^>VY^O!K^7Q9M_#
M]^5'5Y?/'#WY 7[<,CLI>AF:_C66I"L=,>W(.M,MMYL9P@'$QG]5Y1;(LE #
M0[8APT.=#)>'M7Q>>.T;0CFRZ^S>XYI)9-N0F?SYK6I^)\?ZK.:3YL/:C.UA
ME6BF^PK$ /:9<T4V@9YOZ#?0)>]1 K(!OB1_Y6HMDRR.A,CV[,*1E?%%I6U1
MNX:E47ZAOI<NQS\?<ZD>0KFE&+[6/2B+3P#B8R\32XY^;V$FP_>GJ:/@H\Q9
M;I.T_XN,+@HYXL-MO'<4U&FBXV"769]^BP%OHL6DJ$X[[Q\S9.O[N0TBK_"(
MJIKS/[T_X/?QZ;__O<1_>:&8-<A4G'Y /07IB"3)A&IL5R9 MNIT<II@.=.M
M##93WX9]P3"%2?/0ML$CH&+L2TOH*KCCDHR@/::>]>=R&5?^=BRS;45MHEU\
M@P]64)9$!?!LTF)LQS%5-(\+_^5'G;\=%AI()66AEI@21*!:9'6<POF-RKD5
M(/PKAVFJ0O/S]JD2O&$#.XGO =$]>UD6'T>E:_E^*WKUGP7"<<?9PGLT=TOP
M"-NN_=-P6<RL?S:/>C5Q3#I*:L2(%F4B&MJ+Z@KF;-"/&!+XXP<)PM -<%@!
M7"AK*5-(EL):@>_G<7)S2#PI)"77&3= "2VA>RTLZIPB/"O@E 3C["+$O8,W
M434X!S.=[7GZ.2.F,VE$1\)(A!  /7DIP\L6#ML94G3YO6)&YIL=08Q*V5)!
MDQU)G?@"QLM5]H.B?/?,$)!506K5(V4XH;:,(BBEV\*DOJOH+_?U'VB'['Z2
M2\4OK7;N2YC320P+?];_<73V?EYYP9GX%0]F'CCW0B']0\'OBL)O?!Z(N;M.
M?L<[<--]<W/O%4_6_Z@#7V5U [649O+@975/'T9!V ,B;TIF@/L62'V/-TY8
M+DFO9NO#0834 8.G]R(Y2_A[2T:O3W/T8 +Y_2:+=<'MZX4*W=.ONF-GN@5R
MV^Y)Q]>D8AX.$'XAF:&K89LF@3[+%!"Z"L(G%R$DT"F%RP@3#J\ .9G,RP4,
MNLB=T&EWM\NW8RK$DEQYXUU3TQ\##C?-$AAW5B_VVOY[J\84FUL_INT\[C$5
M\R;SN&52 ^"O&C9\7+I\'C>2PR1A^L)9Q$'*?L._X<"[==0&"^U<EI[$YM07
M/D]/"ET=$H=M\(1$L$O-@2_+?'=^77N1&7#).<G1?%<K@*^BE1V*W)3_UTQ3
MJ%.OH]WB/^(M7_7R/>1Y.H<S.A4:#V 3X04165^Q8 2\A4*5D 0QRFWF5#IG
M.))N WJ?88E,DF2QMY?O@PTNB&E?#V>6,[)#NDO=K6%\ %@U;,UI)JQHM&3D
M-L_^;GI,&NA;NL^.D\R3I*3>BC7C36^ZO5M^>_?CK$TWK4XJ;CHNI,;O?W+I
M\;6GZ;]M>W[M^6\X'"[@9[A0'0]K*8&UHQQ#5RKH+)O)1#=$<EU(MYE'08D0
MXW^W8NX]O!TC,8H:L!ZN/GUYA8U3;<5ZL0GR[0<<8$("(_"(T2Z%0-C@K"0C
MJSV4$3=B!8O$$%NNO@<FJ&.[7'W.Q!;1W+? X<]I.40V,Q[:ZE#??9/!WZJ(
MIH@H^*G)Q6.=!]B\X$C4NGNB>R0 DW$EZ(\+M7P:]=$. /R>"-OW\)#5:2*"
MSC3=E-7.V@W/XY38P*3ZCA_.)Y"T,9(%?RF \_%9%"TZG[PTM9HF8YM2C5DN
MT%>VW#8QCES'1_]9^9X943PZ("[+^XCIS#'M]#N/6TV?;]KV>-.6XP=^7'/B
MQ/?+G^.6+\S*BN4MF"MD[E'JF\Z)&NU -$/!QH]=6NMHI]<<="*UMC!JI=$]
M??6C9X-#@2'-Y,U[9'=T5=\3/BU4/-?35)$BZ;"+I5JE><C28[VC5 (9"%XN
M3;.PZ$:(\G:C@%Z=6\%-_HUND/MU9S'I-FF-Z\''(W57[LBD2ZC&IN2DTO)H
MB'66+7HA/O,TJG$#Y)XGAP7=?C*"4+J")2$L1E<P%X'>#^&]LK0F3II@&;)M
M9H/>(]>]H+(IR#-IBGKQA23W697&8CCX 7%C_/"AB"O6M[-%]"1@&4N?>FR$
MI(.N09QAOP*)39Y3%CCX!ET+.MUW$'SK#=G;-!N:'6'%4?&M&\8[_\_7__\?
M:2RI!2]LXJ2V>5R4$KR'ZBK!>O7ICNJ-- 5IH$_IECG^8-./O$20*SMU%;C-
M]%H2I3C%;<XCR[YI;SL=N?0C_5O5V4:,-B6=P-!_QYP#(-SHCH>YQ[N.<)2D
M@5PQ:X?FB:O/%T_T;@Q[U<<!F"1__F1B"9L;BNP  Y(1WXB+.Y8VM&;$ZEIZ
MV+4W=V$:#OPIHIF\!A!Z ;)ZZ0K2&5Y*SG5!+1R1 /JI#X /:S=_\<Y4I(DY
M*ZF-F^$T1>"/=7\3"Z(L7#M=MRH>%=%H"5Z-IFU6Q;NCP_G9FETL8V0WR!-*
M4RD&C8:,56^HH<O@0!EY&?;;BP^6G2F& ]Z@A"YDEWP<)SQN&/&$>N6*+.7'
M _'+=58O&NKX;U"E_=]1;?U_8_<1)O&_:ATRA][$P5K_U5\[_O=U\>C^4>OH
M*H>3RA,'#AX_<'!Y^LW%SY\_773B^W_%L"RZ?N1_F"SV/W_9_BG A(YZC>:N
M@$Y)_0NQU92Y:\.62D)*A_WMS%C>!S=>)M\L(=ZTU;U,1C2GKAI%=X#NO$U6
M5*<">2+=)_^OI4YQ+6,MWF5/9CL7WM?MH<!;*(BI]=P/K/;AC:\U!8#L%ZD)
MWQ<ZU-KDD@17[H=]>' ./FT>5Y5]W;YT,ZV-QDXEK*IZQ-\KYYF'4K>\))]]
M*0&_M1S=;MSKXN"^H\]^=9N8]48*QO)4@CD\0TPZ3X>W\9HH!";M/6+X=)^<
M8\C@A+XGR"=5<6!/](&CWCHWI^A&^^0:@N)6KW^)F;7@5AC(SG+<:I-]K-=]
MX[@!M!]C9I1\2FT?LDJ@-L?\_ /&=D: N@S>6@"7A'1-G'\)LL4<_#+$%LI]
MLS_D:UH38.CP@52M[%*^OI1 3*D6EC-LCO%OZE;S5HR=7W;C6ARI@H2L)JD7
MHN;2F'O9"O+$?:BUB;(Z9BZ!%LCTE4?:$P[!;)EMR9TJZK ;'%]:E)WI2MS]
M*K"LC$>?$CZF^=+M^M)BH\-\OY/ZJ(N 1S:JBGF<]N__<4[Z$#!DJS!RL$0,
M<R%+I2"9:73I4ME(D$0XKO(0$JHYHK8E[C%J%\X-OG/L<N1HYX"A=A[FT0TV
M=T\B)PP;3%N;A@@'OQU%J[#Q70"$BD8WT*FPB+F@ATJ8.P30ZJ 3(^ 0IOXM
MP4K1=Y&4E0YF;5O_K.!G*[ !1';Y=L8^FN YZU\^ 5_)-^ZIJ@]>5U +1RNB
MSWONQ $%;FMDA,H(U8FY/:P/P(HIR2U*);Z%L@BY %]Z_O<E;CI?OTST=!YW
MGN)J^+$F4Q&R:9]VO9RP*GB? QF0L]=0<YS38R9W&,_C?JBYHA<ZC_MOD.OY
M/Y4/>I>9  ^!W]0T>"L4H+X&5Y;9I*%F3#/0) /=!'>=H-M]3MH'EM^_7!*Z
M[PS=ZDYB?8 @.+QK*L3>QL2EO"PVO'C =BAD_ZU%,"9&EKIA/BD9"*/#UFR5
M"<:H+L"M<DDZZ@:E-9O;'H: 9KW)5##264U9RB+0<GI:,IXP[HG]ZU)+(H"2
ML;JD#U$#S1:&'6<2*:AA^W=C+W<ZE<D'?2-F//;W.="-1G*<,YA[GI^DY5M
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MHE^/U00TU0YPFZ2+X6 ?./8R;\3EE]G02OK"J6MZZ![P-C>!&Q0R$"+2?EW
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MRYJQ5A%#.K,^+'68_*VV#OM]<*W\-3IJU1URBN;V7/,[MNB-=9SJU@DB.*(
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M:\UAV"7Y[P8\8S?:"&/(2&,C'#:/T_(1_:*ZBP&LU%38K83*M()]'KZ.\\
MC!G#Z:L#AP ;_'QPUFG(\ 6<53H8W+ZN=1_8<,?X[672\[^MV]QU&!=A!^5>
M6-,++@7-Y)S+[EL9._K?U-X8IJ4.67<R0F7U+Y9O>EYM6I)R*3%J<=&9UVMZ
M8MIR68>Z+R2+*>*!$ZWK?,9B_CN.Z.G$R6/0=@ILK22B7805B+5.2FN&NP%#
M VZ$M@M_CGSRU\42S(SQLNDT_I$B85F0R$:_X]2&HN*@X@];VY?='*A.N]GR
MSRI<8J\1^A/G:4<K .\4H%JW'S).0K2)2THRLY=@\A&^6 Y? #(VW6-VS^.6
MH9J?"TQZW-<2] ?A"Y+]H" 378O8O%G]I(>5PO@QJEJR\//T@_"G$>,TV\=W
MC%HXAO.XGP$A'FC\C,$_9Q1#L_ 3SCN,6MX/O$SJFLJ8Q]F3X5/3L!L!95'$
M:CQD;*#<"7SS\:\ &G]0I]P!H)^M-JI]K!@S>#<@2B*VE/.:J3Y]\'=P>M@)
MVP:90SLZF;:"9-<DD"4KS>*'T4@I2$380SA/VVV/#X1/3KT=?U&&-SH!4X.Z
M:=.^36-DB[OQYQ:@UV/^4^I%*-?5'AV ;;D3G9AI,=XT+/>&,IL*=L*EPQU9
MS@U/"HQA*M@'Z(JX[^ ]V(!/4@SAD1-UD&YIZ;N(.H_\U^6E$8&V53EUT(8J
M-U$E^W;8 VI==LX"Y58/^LC$+#0B*YW< [K(R)-Z8/0)"TOX%)3[:H@ 7Y&^
M#"@Z;O>@D[_GE-&$7T+ES;;M$7E3M[:W/X"3O?(\7W3.U)OO\:D?B [;Q@[]
M+["*]3!9S$*UUBAU4%&\GW/8Y!'E4881O(8[5K<#TKTE(YC" SZUT&ONO9J)
MNDAJ OF*S8.74';9@[\>[HX-LR@Z5?@^T#LZ+$G_IX[0N#4XI5T&&H5:8>OS
ME@-Z<%BY;:<*&;'P;8AYK,['YP6Z@K$4_MWF_.]#ZQ]\=9C'-2>9R 9+"JF1
MUV>YT??;'WE$AVG7_M'/P]-HI#'"I%J&3A<.56[!/L^9N1IH].(3[HT1"*@Q
M/5Z*;=N&+73M?>"!0E6.1#^&F&Y28/($-'IO.OCZSB,2B^_RD'0])MB_V7TU
MY\=>.]?ML@>]L>GVMIY).T9O769>[:1\N@T14/Q!+$A>A?M4,>PKI&>LB4:I
M8\^#(*H9H"]F'(>%<H[#Q]LW[-]5LTT9.[JMZF*^K-4FI7!OUYYP'D@M(#S#
MR!;0^ );]4-<V'IZ<F!XFCVI9"+&_$[W'SZCVIW(;E H_U0,NAR!U^,1FZ4U
MX[8;R"RF06*YVV:A?''FI7N/Z^6VIU'MI+ C8$XQ1L$B$WJ,A]9WV8,+5$']
MM^'6X=)&(BMPZ+:,FT9:@1K!)LT)4X5G'WPN($#L9N)2>FA0GT.P]SU?EY^Z
MJBMI_D\%/0XZNZ<J<_Y^W;7T\84\N<;5G<LZ4U%[0/J" .YCPW:<R79E(MS=
MS*FBM6).\>V R,((-.<*IS4'F9WBTB: )=$6MS8E "R$>@]FR0KRRU1%)_IJ
M:(8><I+1$"P@@X*TQS7Y!LU^SFZB+X]O1!6^9<8C!&Q!-@C.2_3&')T$U2:3
M64IG9&=U?3VOOI<C2\V$M@\3TTZFQD=,'Y 8?A8LKAZMB5E_]';O8YNACY]N
MTTJSUR7>PW_35ST41%(N2YZR,"INBG8*JGG-MBXR-A9"6&#$%_B6*# EFUO^
MUZJYEM*(^Y_%(;<+Z8GD7OYN+M6YH1((*QT5>Z872R3OVQUG+N\V_.J!]"(!
M:@>/N8_;!9HF?A)=OI[2CW&^9_G?M4XAJ^ (&4&3?DYV__>U+X>*(;S<*A7Q
M"M-H#BKEA3/, 7='K^BHR(DARO3(I(OR!V2Q"H-4H9G<MVQ%)F4EL@OV!V3D
M'^@)7YMOT0OD;?(S>0)A2>=CQLYA$92PVYIC6E)^/RA2G%T8?_;2J8H3)R(=
MZUKN ,5C3GT&J,VH (SB(F8CRLW'!R(%JQ"SXDC?*/WWN^5$,4U1 =&N50:X
MWCGMM'UTSBF[P1AV5VS2R/_V("3<WSAS<[#WLD.JFVO.+X"3L#V"\>GD&Y.
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M\%.6<?FR\)R^N=]"@*_J?.X-D-/$3BD'WAC6U,$6@(=(675639)D4E7*=<#
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MLEKSR4NH7 W(?1@87_G4)V 189=,6>L$%SIR!,;>U3!1W11$<-_-M@ K^)9
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M+/[ -.^M.;ZV9V+B?H^T*]9\OZ0]NV]L<M7"F2#4,A/VQX#H)'QE'I=N+NM
M8PR!YHN UCQNU%RPG 19\G?.XUY?%91+X)AI1+\-O5&JQ %R,_2U )D*G\>Q
M#OPKL7#4%'BBB:X1J!,(7W^Z3%H G.3"+D)%@JJ*%"E(YCR39,SCS@C2)8MH
MJ#.]>R],E0*K6B%+(: ?DPA8T!\IW(A-=6'I]@_Y1&FEEV]7;&5(8O":V"R'
MF1?GN=Q*TW$?7]?!,6.@OQWX?612"-)D^%<4V"5>X0^'@=ME%"%P%7->]H"8
M@RY]%_^ 08+)4F 9PQGTO!U?06RR)?N]Z&9LDJJ(7F_.7W#PW3\V<K#G7,V3
M#)^!\?2IJ<"@]#,W!-W9_R9-L+ER9B;G3ECTPTC_G+JDE#^VG0BA4$YX1(11
M:?HY.8EW[PSM.)GJH/$@QW^OQZ(JW'9*OL",).4*0)^.=](.31%WH$-QZDVL
MSZ&=]>!0)D01NKM"*0]Y,K17*F#U%VR"SKXX-[CJAZB5.CU/?8V>Y.W;L!>G
M6G5?D(//$H!T)T3?4O;K<Y9,-#UII/0<9#O8C,!GP3C:TL_/_LY8=C@DA'&Q
MGVE(-<[YY:GX+$\M!6FQU'%15,=PJ[KAF_O"EEE*Y#/57<%)KM;GH)4IN>D-
M3LBI7L1?\=O.)?TAFB AQ76E8@/EMV<B"'\0?[-P^-4YS$_^&&F-U,WCL#U.
M 7]IG918"Y76=,V6A'.WRD)2Z*0S^+>OE2USQZK):\[6T$Q@B9!B&INDW_2^
M3;N]C)0Q$9:ZY.#0&.?LS>F.VX#T+@6,RYU\T! F(AJC_0E.*0X;>TMKX39E
M: 1E&6.]06;3GU8P.10ZW'V8]US'INH[Q'#^>R"PU># #Q&U7W! 26YVPV:$
M" >'JDJA[7*ORPWF$?<W_#%FX0RQ6'S+T ^%)[\F<9M-LSFTCVO\=*SN/-U?
MNZ^Q561AAVTY/M!HS=?M$LE)\,;6B2,:O?Q98UX@\X[2AV$)&9='7(PL+KWZ
MU1L<R9B)VO_ZJ/C@^O8*WW7"/Z^[OLT67..JA8ES*>!APJJ0?-HP>=)-N9F^
M.=B3O$T116H&3!HVTZNWK91&.&R<:C"#??85G-MG:S$P@=HVX*GN5CE]B:'A
MDE_HV]%E/[\YG;VR80WV:?L<$K^?"+*?BT\FG1VP7>MR^MD+?JHY]00\75GS
M.<\\,^KG.9TKM;^YM%'CKGGB2$635%17K;5M_=DIXFR2$F!L+ B[8K?P<X,%
M7"SWV6W&O_'H);;[& L?'6_=$?[[R_+WE?^$A][<Y[>S,/X[6=&A5O@D2;,!
M_7E<:(=8*&N](KB _P%.;L$V]3EN=L-2D)E,DY*OU\Z:2C(8_F"]R-F$]2W-
MCHB:B=\V.A:74\0!'@X?>VLJR-M>BIJWE/\IP'W&4-V9W(G=&C=;N6B_I":D
M]&'Z.MO8HM%YW))J%TL]R[\]GKP$_=/" I:?\=[4<^?,.J/4U5L8F0H,<R4[
M Z<D5R15E$EMB"N<QU7/3@:58\Y"$]5D!,#%A:.!_V"?<N!&V=@\#H]H<.$J
MW^Z90V?!OJYOHSQ>W5[C_J:N,?%G<1OQW=2:W#,9"T )8JJII*.MA*>/[RCC
MPH$:_TDSD">U*(1\ E5_/';%N5O1,PC+ N <PN)1P)S2W!48F?MGW@GM!_,X
M6GAGNV*\[8C-7/[MFB<%\IBT>1Q TIG'15'>#@QO2F.L5E4"YR@9)8SO"V6"
M5DY*P<[MIQX?_+Y':+&YU_4?AWQQ_AUAX'ON\?7:Z D W"6!U["%7-BF%'/.
M5&WU"203XKX:/*( !+##*=E?F%,;U&X)9-8RK8(0W^>"NT%/>VNB]*4Z6^A:
M8I<=%;'61S;UA%UZT*Q7A#Y$#F+3M9H4GK3I KZ1-M F%;"#CV55 (;N>O1A
MV=H_T9^6E5UT2G'U@2I>-20&[^UJU6C\<NJJ=$_#)Q_J+ORW,]RO9U17@(_1
MM.LD=?XN>!"O.L)916UB(_K6J"Y;721Z+U=Q'F*W$I;337:YG*Y5MX.-^ 2Q
MKY0N/UO9Z:Y!+VJV,.N/?7M'WY/G[:Y'$>'^V:Y]Z<+I5.!/TKM$5&NK<C^S
MD0 >^TM HXGQLIPRB*2X"WHU$Z\?1GZ!:9!G'Y <8M7'B(>TFYA;X$N05G=S
M;6#8-3EM ?RX:;A9?/M#+0"FK+!7G7X3-!CN:6F#6Z@JVLC]&*;8@CU\/2"]
M0ZK.:LF5L=E;D=VJ3.02,_2R0*1M!'&; J9+SAZ?M&%NADW[Y/*F]6TU+>7#
MDD5T30_>4;,9_=?EE&Z:D)T^C]-IV$K?LQ].!F_)\5?=-\+XD,R.3E<JB!$M
MDRQ7JXH]*:$;[LB).I*Q0(\ON+& 2NYZ[><76CQP\?;_PQE8QZ:F)FUL+]"F
MIZ(F*LY7?JKG\^OS7*A!/C[A8FKFW;OI=]9<'5IRZ&->1+!EAGU8W+'#NS0R
MK#^R-=#WDJ>T9O9U/6:'0!<S(M([8:MD5<G3WM@5#?JP];"_4&#$V)T8I3OD
MTWX&KQT>LD;0B_86']_C7OSP>%+NI"+O6$U?F=NS"$7W^];O:K',W[%UGD*T
MU+>008@U.'L=-:#/#K-%@NL)\6D.V&:#39K$C^](I_%OZ:%")\>Z6+1&SC6/
M5"2\ZO8=JDS22+U5&CZT$C*??,7K><SM]KDZU#QVDO \[W%Y27A@2''E>&!*
MSHVB<(5)WN/*1V/^!]]%B,_=*1WX*QYX2!EZSX]3Y/CY/6F+CHUUO2&D+3KL
M8_W($EO<C61VGLFD&;;S78'&$,SLDHXH$EYLI6O*!$WL='^2QF.&ETY/()[E
MKL4PZII))%YSMNUZ[WW>WC=L>%:4%.I3UY AEP>X.E0P#D&Z58HDLA=X7>'5
M+Y 6<L"XV<E8)159" N5]HBSBL,T9+8+=!H<X=/*5PVVD 8[DQ$!$>3MW"LS
M=TZ2]>F)'M"E>=PUS:;:9%'"9@K]2+-_+D5W.F]8Z#STE%HB+(X\(H[L(W6Q
M$#,,O"X:AKCJYM^+KL&WH".[@_VEI9/QR@1Z:.O06K"C&;^"?DK>QS2CTPYT
M(O[2CG=% ;Y:7QQ>",#VRM[)_A:5;5BJ@=S7I=6/5INTT[YLGV8C!0SK1PP?
MX77HY.%<Q,!*P8+L+;1[W/6#8?8P\=4GZ",28AYL\"/G1.8!6 +6?9SYZ_SJ
M+CO&]F&7<:)%1)W-BYZPYQ"Y.;/^=JID[Q*..%=($K<J N#N8=IRQ![>B<4[
M'%P%F34%)D8.;08UA:3K'%W^I6':LE&?6)W,2.8:D)O"]WHT7F=7P.,Y*J(2
MRXX'!6F7R7C;+CV[[P1_PT+7(4#Z&P$\2("MG-*0]</SN 'V@>Z9=A]%)F3%
MCLTD9R00FW>Z;^*8T =\7S[I8X1>'"88GE@[UB:?_(6F[R4GN#3OC0Q99Q!9
M=RTZ^'W$G. =4$.#G2BHC@(.4]K#55(3Q,A=J&A[ <,%3K!3M)QTC:D+F@A;
M8$!F[BZ4]U_EVMM&N:^FFI9>=SU23N<<>?--13O8=8&Q-H]X#<,K*Z#'V=UC
M_@GY?7_4&E\F/!. 1XDP,6S"4BU7#M%2&U8PDCCR4C9S&[VJ:2M]W!<^ @8U
M.9/3^'M*Z1B /=H3XVM&@>R>RJ<-Z81&\?KLIX\^BWL<<P#PQA#]VD#X;.[(
M;L>J47(9L&,>MX(DA2FZC38*  =(.>*^,LT_/@TT RO<G8]_/IP9<]HR #'!
M0-Z0I6=>S)K!(NA+<=&:K,/?O#^)5(?1]P30<QJV\D(,J7*O*TQ;+(Y639 ,
M^ "H%)8VBIW2;-Q7,WSAI$N ;%$/=^8N91D]@\RRV +^D:>X53)N^KBT;-0G
MR7)PE&>:4VR>_]XQ+VNFIF6Z$8 M,7@N420YWD(VJZZ2S@Z:'7V2&&'CZLUE
MK <%;.14J&W)3]O>T;OEYKD9_( (._FZ')^D<T[/<W:<?1YQ)M5DUS);*P5?
M58AM20F\K@L5DYXY-7IV A$ !MV?B69%@JN414S+O^LR/"#,0PG[G?(V7)[=
M3M >@ M>*\:,^6#PI 2QC+/86OT<5/5^^5P;R/\K"EEQ(@( Z;S)_&C K%6M
MX0M>'>,Y^;IQ%1R6X-1+YRW]<N^H2K5 T&+Q:V'[VHVGO$-K.+X2K4MBZOY*
MM'"YT(A_:/>B0XV+]!YL$6K97-QC&*F_XW[6#P\NMF3HZ1ENWJAU#Z?AO8OP
MIQ=BAL&>1>7_$M)N(5631>3L>1QO9%*SC R.8[A8>YIA:=5H'C^<_0(:;PZQ
M@=HE:=5N8=[0XYHDQZ+'=!_A8?KAKM:@6EZ?/5<OLF!-[SI(8^K..N.YH[/Q
M!BIU7KKZCN],PV*@\1#FHV^K*AE[E#\A1V"GQ^/N6F!K,A(K,]=L2M"\_JW]
M9]CQ[V#KW;U\AX?4A(8\5/>W4<J9VM[JKZ7C<TFJ]J)(/W!TEM?_Y?T\[H#A
M0<TO=\!D=!F&I*YZ(ZXW7X_(->9QDR[0F'S3M=G:$!)<7PQ3?N1_#ST28<1M
MPFLP=O3;VI!S7IN@^@'3P@XGY*?KS+UQ\[CN#E;#"L05+!4&XZ42%F(B>^DB
M(Z<B!B4,ITYWBY);$:1K%8R%19]_IE-]P:N?<P]UA#JQ)AFD*-WLNJA_C@1Y
ME]ZKO;/N^A.W7N9AYN"_.L+!&T:P_S</^DE5"(1S=081<O>:.[>D7DU"DV9!
MEHG3C=9/HM)(B^6@JFV OI;:HZ-NRIZ>UWK5WKK$:V_O;%;U@CDC4"(%&BG)
M<=RS($NFV32=XG?88QT^ E17(EY#=")!'YOH-LR40KV[Y.$/"E:4W-R68G&\
MZ,:5F,,.S'78%(>"U*8$%KN!B'B"A";N#Z,[T%ZHM)EC @.OA@RZG=;=Y"I8
M:0CYX6B"6\%G6=YNQ=T_O]S8-_PQ"\-V+FRQ$L4;J*H$X22]#K6L$$^Y\RW#
ME*P_U,"2$4S@TKWSN)1)Y1XX57YR'G?Z!2BX;&-SH6$5'!V0[Z,)JOJ2H<3%
M>K:/N3EGV9\D*1*0ALUM)JKUU[ U.8O#(S<3C!CKNV8V4'_GGU*>HX\TBT>:
MJ<';O@3/FL9?:5@4X5M.;=!*[3N\S%T/LN4TF1L/#:Z(^#M]U98_%ZB.,OLQ
MJD1!].,5U-Q#;YBF]%:YYF3\,-4A1Z,;_0$."KLR66,H^2@L0\CPE5@97C<D
MXMEF:T>N=$7#ZKT%,?MSOOS)VT1#Y S, ))%)&D1J=HI_8AL>L)):8LXPBX7
M'[]_R655]GM"7I-.T#/%,;]]B[.T1M&5X)F;KY<^YQP 4D+6Y&Q:M$7XT/5@
MQ_KI::>)B_.XQ>I;6?L&7,G=QVAG':]9,.#4:ERX[@6K):&XHZGC6EO,C7L^
M6219O[#=CZ"WSQAP]+9!CD%$45UPTXHU=P]8KRH9GO."=90VS';2LWX6.85T
M;OHR1;-!@YXDS[:NQ.Q2*-""5SJ0K",,QK?#B3Y/ZONFSYP)N."@$Y(X,%[V
MU:V]N6K[OEVD]AAD*?9D+P!IL0NG)1ZHG68QK!YOS#U6"\WCLKX1W^:^VO9V
M\$)S_SQNV7 /4RMHW-%JS?UG7<C2BGU/_[PU\#8S^A/;#U:W"#T!-'KPXZ,M
M7D =BGQ5;L.JALIU\8&_=LUP,@ 3UPC:NEO/@FLKEPTM!B]<B64\>?@\[1U]
MX'#J".-B>V(D>HJMVOKY'OY+#;9-6X#&&E,RHA^DL'HCB+3&#.P0#,E?>@T3
MKC*-)?!^PM4XB0[?C4;(_$98,7YX+"[O+G((ZBMV&?V%'F S[%UY,MC#3CQ:
MU)VW-9+Y"OO P]AT/Y+@2-)"P1/-B:_*4'J;H@(6@M/- E-[B84DDJD#=EQ%
MC!Z%)UC#)#DO&[4(\CH%//J'-ZM]Z:S,+,HS^N=[K;&77 ^A8SO: 1]L[\:0
M)]C*76HE3] G./25H(HBS +DDF8"#HF&0Z%S7V6SR1./'=BF<')3WN+\8:(.
ME2K%^%> ",.'Z;$OW;"H\:@VI41D5WJI^/@8K31H**11XW8'U*G<Q.PG@3&2
MB6-*$N*J^ET0)L"^1?$:+&V<3JD5JTJ3[77(Z%+.,,50$O&&?E>4,)L5&_N\
MG^\!D@[UQ2Z\*"?H1_:']_-NV>L=R'GR&^_JBC<+9^I;*& HY^JG9ST4V2QB
MZ"\RO5"D2/_4%86<53I&. _>J/FG98#<0[,G7V\@_''BY,"#N9<UZ==7?,IQ
M6Y9^> 6P7D"EP?96J):9<CNR%>9 I4+*"M(YXO5YG"YJ2#<1 7H,KZ@'\-U6
MYE(XV2J5;W1_S,(2TA!Q4OF'I!388T/>@$?W!;N3-90T3_G8&>KQTQ'+-@#W
M!+)Q"4@W49EIJFL",KA]@N^-_@80$=7:B>'8\T@0'(W!HA3WG6H>=3[8IY%B
MP#>0<UD-6[HKYW'2W(+UW1<<\-KT[A\%H"3-YE[/>?>%C4FG'/INE04W&DW^
M 0X&\C/=^$_;37?@D.WJ*VM4PJEM10R(K0(]4B3P3KMQ[L"+4FYJC"!58H*M
M%[*I%X,)#CQ0\;)R@)[KI3['4&T.7CO;V$6MXU[+F1)53YO0J8=[<SU?[+-Z
MGOWW(;RB49T*,<)Y-H]K[I@ --$AC@;CD-*17D*K"AQ$CL-^>1P1+3G>H,"N
MQI?2U/G*?3.\H2-Z\\!HGCL'BHPJ6\=SKE[]2%> +D-5UX!([CL7:?_D4WF'
MN$A*;"9<B2.9,X) __T@,1G= GOY@Z2LFG)\:AU9%,[W+QMC+H2.97/DYL0?
M"RB$43_G\W-]=\+KA+O+7E9L>]=HWCR/*R;QPA S-RR"<U6\%I[\N+LNX1U+
M/O7([H(F]O:[>Z-#N-3QH[_]M:,>(@H-3B6"5<T_C,UYUO5-WP<+V/+!D][.
MO,PHJQMV]W&J+%4!*9+XKEM1 ^KP1/AWF"$*:=D6"U]L:;5*8ZZB<_=#ZTS/
M?@#3^_=#&L59PC'WE?VGTSZ-[X)T"G(K [:$3TVLOA'@Q??_'LOLHH T#F),
M0Y= D)92<4-UF;D!5@[[)R/V58-6ZJ$%SH: I2V^)&%M[MH1I9.<\FI?K*V/
M'W0@\Y<G%>+:9-DEU(Y^0/[WI@>0C7'<62GW#44=5"U(\L&%0=WNND#C,:;)
M)?#=('!2PNP"-!&;.:<,>[<?^TZ%Q9(PW&4\:I0_OB?&[DR_ R5UZ;VAT4-B
M;5L76<C32^O8*S3GEAP*L04U%==A ^51QO8W#5O1UX"QJPZ4*\M-D^.+8<&K
MP)F<^I+O\AT?GG?-V/-N3>89"TJ_E^ER9>V_]!_HKPYZJ0BLO7LV?M6O5M5O
M%G@8'OS_]8O2SD;TNM$#U%:*XD=UU]WRA;(4P+L7P3Q<HSGIPR=^[#SNC%6S
M9.Z)^XJ#FM_R_U.^V @-)?!F)V<QD,E7<4G2&D%UZ\0>Y3(,&9M61T4W 2O=
MK1DV\'IPNTQ3!"Q#M,$W(+O1S3JP)S9SH)U&@:RN\%T>4OL#"2D.T\;CSJW7
M&>2+91)*ASN[L,W\>@*>-;F+U%WP7R]S._1?ZWF%_8E/G35RE[F=.0" %TL1
M_4Q%/DRXQ\3FHYH[J2TCF5+',1B7EF<E)*=3+/@:REVP9:O[@ELB'M.L9S6D
M>UM&,V/X@KD*9F5\$=791C';;QJ??OY0T)&NN^0_1N=^G\<%;/YO2EE&=V'^
M%!(,1+AKHJ\:%JEN,!P>+7&]J#P-HP1XWZ3T^;OH*) B'51DRM4)5%<-1@;R
MHUO[";KVF1<W94N.=)V&CI6$';<[33@$-)8)GI[@/&,C^N6O!'H,GP=V'(B@
M$$*.A<H]XS?)"WP]\;@QQ[B"5?#.!W]MW;MM--YB2:<<OE+BN>>[ <.CA_7[
M3RF6J#<@?>B^'H,>TA<<\** )3A+8]6)IHK \B:*(>*BM*13CW:=,W&<LQ(2
MDO-RJKAH%T6ONF,3YT"#XUP%P81_J&CLQO*\J>0'\.&>H;\6Q9$)<YGTH":4
M 'JENNZ4"I9&."9HIC#6W/N,FH"O4TH]3W5_H^ _FR8UW"Z*<-RJWV+MYG*@
MNK:J]GJ58:KAB3_.77;ZGT\F?R$Q@ 5-S*7=17VN87*V+NRU+V>NXZ?,8Y [
MK^2S:4Q>3A'Q1NEHIR22YYC3D92T<_D[L4V)?.S(QT8S@>&"SG^W3/08<7HB
MIMQL\,C1E]7=,>V.79_F<8=Z:%.GJIX^>5J5,F4W3;LP9>&2&.031/]0\.G3
M)<O4):&7SL9ZG".D$58"T@\<>*VD<2?M? UW(+Z1Z=QG(]XWW(7JT/?(R2*8
M^R$U[NK>9Q#I,H-0":]X?.ACMGQ<Y%>;NWQS6]3%;>V:>0N4MSV8RYFO".#%
M,,1 B&KM4?J2E9L8/]"RG9V:[W)TJ$-68'8A1)+UW9*QER*[:T"^B3,KS<;5
M&GA [VB>:V\H+_GLEVNQ]N: :$XSY=3SKON_!9P8C#S84>H%X1&3:527 &.F
ML.@W>!0<4"3 1.56.EF^N&98<"V.8[0.KH2N*D6_TC4*YG&BAM78#N:EVA.U
M3H0[,=?VV._@.\X.K:MS)W:_+AA:\Z90N>#PN7H<R@WG?EW P_#O78%41A0G
MR*U4^:@N'+@F?H=CK:"*-1$_3$GO;%>^*U(Z") -)H*5%\[M66?0%->QO@5>
MOWLC_4/K;*8L4:TG9#*IAPWN]ZO*HU5OYG'GN/#&:1'PSO*H,71"W%$4P=%I
M<(.3&WE/PN/[XTP6!M:#?@_ZOXS.W1[BQ.M6Q8*S02]SNL;:CMS==?/US_CN
MO.\<Q=^J,G05VBQX)FDEB+GREZ\R&TF+^ LJZ"US?UVPK*Z'+"JU6D_)R!JC
MV_^IU*(V[(3.*M*E*LW7E/4U61>:?_);.R48.:26J(* QC8"@7A!,DQI:?\E
MP&'I Q_E-$:M*.G\N%RJ(4?<V8&YW26H %K[B7ZVYU6X_CZ+XS-;[(JO+KG,
M)[ (M?T3VDJUR@EI'A=1SX:M9M.96^C;AS5;)-?C.%HE&%40$M^IK\?T7/WO
M10[909_J:8\0&_C2,,P(4K=,$X"_(CZY!U]V\H^51A1Y]MNKW"6B$-.>;]-Z
MY*2*D('C.*9:]W,M<R7S;Q)X&#] 4+Q1U9&D3S W2'M%205T&<&%R,GC-LQM
MR$F0(-26I'%6N3M]#GQ]YR*QZ:55"[JZJL>!2GHW\JKN0UY':@7?+0R(E7(-
M*0R3I#7+<HP5,Y\Q8NF$&&;*)(C^=E3+5IT[1($ET,@K\?3$_T/>FT8UD79M
MHW%$1(P(@H(01U"95"9EBHJ(-&)4% 2$M -"B)"V$8D04HHRB1"'%EIHB(B(
MRA 9(U,B$* 5D1DD")F<&")5"K$DE>(KGO6>L]:WUOM^?\Y9Z_PX/V#!C]QU
M#WOOZ[I2^]Z;!@''(4*<#3&-N;H_,0G5]H?')?&?*XF-Y-09X_Q'SA4O8#>I
M6N+'/L<=SPQV>?::2T7J'^#G_EL8>I?3@6=L/;ZX9Q;W_A&P%&TS6@&Q$!WV
M*W:Y&L9^V?.L"8N9G<P5 ^9,(SJ/E 3H3$[CM>$?9(@5OQFR:V8GZG?<N* G
M<#;KOU1K8.[A!AVW3[Q>Y_1P<X'"IKU^>KCC8R*BZX]J%M1@]/4\\W7.&M4+
M="FS.YHE]P1;B 9?1_1@]E8X,A\^3%P4XKS#*TC<8308*B2D(J<+QHWT>="Q
M0=CEZ.VL8&Z_HZ<$**OLM8M*#9F'LH68:5W/,82M .7^<8)V'9X";O2$,7&Z
MJH1GP=(:C2+B^1)_BR3'@SEV59!KOF#FQ,^$;];&GMYMQTNK7V(NDK[F0HZ8
MM 1HGGN'_I4%KS]1]\/_M3)"T+W7[';M7J4M.L ]8B7XM+H) X_%5&I2RM8=
M'32S%X?^OKO5R-;;$4"TLKQ5Z43Q4Q&XEWA=5%Y2\/"#.RAM$Q]5I<[B0O#S
M3\(W9X@KX"C,NO!33@X'!FQ, RCGTB<]>NL\:$1,!] ]>S_L?>P'%[B6TS=Y
M:*0L@CG_?=6E><I<I0YF9:<!<98(/$HPF.M&,A&C//R5J,M<1_=H*FBNZ;@>
M7J<!G944),WB)&O29GH\:P:LLTVEHJMU:E%2)[O#_%[K\8# +TUWQDJ_?A_S
M"^G3_+O7["V("@'P9 =LC F+MM8:?..D4*EXV,G48;A")HFGH? 'XC;2/,0/
MSI N0>PBKD2=#BJBZD<UDG#P=]IRWS$[O]@I/W\X^=*3/N?62.,<[@[_-Z/?
M^8BV":HI5=T@BN\3]1$7Y5YD$60BUX"TI<QJ<1A)\BFG%.II=5X$&1;$USF4
MA-H?SB_!:XZ2\:@>LK/4T\WGWOZ>XI)(PU#ST,\C+0XI 39%9WD\Y2$"Z$6
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M[)8%_(8W:%N<FD]EJI75@XJ"*\%298KY2JN"O;O[K8=UT=:C+RH^.L\QGU!
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MJBZ>R5>>58^9M-K*=U11WF[X9A:G+:ID(P9SA1_\YEX_(WONS5W/C*,RR-!
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MVKGV9A?+-\-=2O>QG^GZ.:FGKZBS2;W!?(C59)DX,Q7A'G9%DGRR51^]S6P
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M[>L\>$;3Y$CJ6\(YB"2H325[P*=SVZB7RAJ**-XYV_KK O)LZL8C)5Z[XD:
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M604#CE+Z,#M$JX'SDRGVKB65X$^9&R:5M> %@JH,[]+A+&IL%"E]I,._I_N
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MX\@!PYZQ)GNIM&,]]T(M^3DC .X$ 1DQJ8:_B1$+<\%!F4"H-J\,,I^V8 1
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MN50?=A5?*RQ=P[W)-T0\>\J[/U]HCBTM;?FG76!2[#AC=N=]U!./-2V=TD\
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MD!9Y>5"4_^I1893NOW.(*57%U%QG;%NL'0Q&3.I@7#M'DS?H#CE?;\@@W%K
M&3D25B''X%[HE#]<JCX,?Z3T7L[P3;ZVA;*&M 7^>JR.+:\O/@:.]*$$'\O/
MRHZ\!5RF@VUB.;NMZ<+M.3_@R0"&6<NPQTQ*%\@*@*>DK,>\5$<BBV"QJ);]
M^:[0AL+Q(,IJQC$HD[/2+00R]>MY^.)*@JT6S63"I81D^>1TQF23!9^S_M,<
M)ZKP!_QLWO](%KCQ\5%GJ;$ $$L+#PNG.8[\\\_[[N% 26#0H=[@X/?OC_ZY
MR@0\P-[1>V1L_8EBUZ>/[^!VG*!P1A>C=!;;1CHP"9B3%4IUW4ZKKZ"O3,@&
MB"\W@!YV%+S':6<OG<AK=OE<'F^1S2F?^.63"[^LT/3.Y\^1#](I1EXE075_
M/'B]1.N)0/:8#)[D)@/@$6#(-4!3P=\..XL7<*MM\\7SVD+V<KI1:\J;WN.0
M/QLY%58]'FAW_]&$)#61W-:T[!K <BQP#X#6]#<^5/DU'M)S/3P0EU!-]FK!
M:2P?"CH[E/Z(I5 =!K^9JN<.<51.L"Y8ISX4_J1W6.&?1MK H$,V/K$;;O:-
M5<AS89M2BR-G+!UYO&=O9^FKWFQ2[QTX-#V^%-7[9[$M;S&'!TS.0AA90(PW
MR[H0FWP.GG'@;7W73=092)9,MYG"^?)JSP//7D#D(<2V^H^*QU%\P_X-O3&3
M"*5X:'@LL$HR\B';JJF/L>=1$P[89Y937O:IT=2EK/;1NS&7\%^9<1^**T*&
MWP4$>CPCYL?&QVWQ SV?WXM_M<GNP](]&_S_'." QX%WKB?@4CEP8SYBJDB]
M(UJZ%J$^MDN3^R9+R!U=R1(!V[$S.KBZYG:8/-%9;!HH',_]8M-:.C85F7NM
MNN_GP+&W(\'M$!%R53.!UB<4T'\!-YRDDFB*2-OH'-4SV%PA36*ZP!U*@05C
M=S^Z PF$.^+BY< 2:M[4[-Q-9&,9XMB#KJ/?]0);II,0Y\=!L)\>X6!+ SA2
MS;]]N>EBA<JKVF_B$^==.;JJHQO502)@+XBGNJ5Y1D2HQ+:N5#X>3L,+%^_(
M=#Z",7SN([IU4&^S=^E0%^0NLG3KCTOPMNGT]TW1Q9!/\,U84XG?ZC\D%QO"
M@%B]@=^7:!:#ZKP!607PM&-1_GQD,7>C?<Y,MQ>]"%61QK"0^2Y'=H(-@O3F
M6"71("@JWJQ34W.76KD8)M:9S"\H&W84?RA6T(P_F?WL,-!8._+J:CR-9OTE
M7^V+C3Q%UJMQTU7Z+%7MT[#Y6\O9CEG:03W-:R"\DI?I9BZ?LF]MZO_G]P$)
M,<.1P!I=Y9NZ5,P9,MWM^<A+?E<9HB51'38<"+FP[XN1AHH-=P@(ZWI7I^)K
M"MP\PM0_(R:]) ?&MS Q7$',^BFJE\YN#]4=F+&1+H># OA]#7K:F-WC$5_9
M])HQW[B'5K,%LZ6\5-N9SI,FZ7O])..N= 87^AD^!8X2))ZJ3)#<)M4=H9O+
M/A1 +$79/7G![L4^X-^&;)9WM64M%5MN] :F" :PH#VPJ8MP"UGZ,'COA]*J
MB?G^=N[5LBC#KOBK0&6PZ>]+9Z91G83_^NQ1R9&T=7"'ZO7BVU785!'Z7!FC
M*V)N!\O3R9%[R9@<QQA9M+=BVG!X[-H"+JO^!7$M(P;B)-\]#6VM/JO0(WT4
M33_P37CL4TK]*AF_LX"+F# =F*,0&8D0!S$&5&<UO!)-*3FRDIA)UA+$L)<B
MIWO=0A=PAHPXF0U!;X('&#&T+G^*81SFQ[,V@=9L94N23^WS?D>'.L@Z!=T<
ME?MT/._UZ+>]#,^K<14+N"KRI/"_G=L(G&,/*>6FDZ_ 7-6X)MEM,S@AF[XY
M0]:*_,E;?8K9=2WD _=2V/GRT]"QYF[Z!XGK LZ$WN'GPDIGG*@\G/(Q8+#!
MQ_O4LZM6SVYW_44!3[/99-"3#'_+GB1"4M4Y2(H8QZ(ZXTV"5(9]7 VR'3JX
M@&N@O+2-/0G'0QSASJY$<+H],+SQGC+17;1:UX=V,4M!KU]K>JH?P5?3*X47
M%G!G![AAORS]%UN5F\[H* ?\N6-*J0YBOI&NF9E.HQ@P[9E_;H.$!T#IE*Y"
M8("080LY^<85CO[&@?H$0<:\[6Q'"K).?OB"&ZV,;O.&#];<E_^FA.)2*A_1
MXV:&=Y7"M\2/@6,<\"?N)"8!EA]>?+D:P4DJQ##]YCDD$-*^[JC15ARJ?(2<
M!SE)Z,Y.T$8<NA?L_)"VC&22-]Q1.SZZ/B71M*VIA5],JI.["E:_"YHX-6'F
M5V;K:,/!#Y<0Q!V(63\V]'[0%#'BJ5K@3C!>E0^_D&,$$!/]'63<N$\US KL
M>U,NX^HQ+L!AUWA,/6@-O_9A([?<,TQ!T V&E6VY9BG9=8%PGFJZ]>1>1-5T
M['??.<]*H%4L #U\3.9]2%]5"!SD .VXT!.%4<A:;L#M[3O2-_?-D%E-V?GV
MRW_8<OCBB/RG[J,5VY_B\(IJ@>R]+_S=G().A(P4?2 OU>IPG!B^J[X(LT2?
M:X,._S+<Q;4P]8<>CAML\6OL#:HN'J\3?S-L?7M]]]I-Z)! =DOP!)@*P<!V
M4I-R;K'GQ@5"EH36SDXS8OA!K.S+*R[CC>#B]M"U\!E9". )5N?<!P>%Z!8H
M);>8ZI+5;/8Y2T%>%ZVC?S_LX;L)TFZ,)?YVL;@Q/Z"?F:&Y \BJ*. QP3"W
M?5X@]!WR5%5B)A.O,$DKZE($32^/4J';P*ZTOT%-J;BA6E5;%LEW!N=2:+.=
MY&.%JC=[CWT\F'2<?=3Y2ADR;"O"]+;[IZ7()]*B)[R_@.-11%U9F"VCF\8X
MC;Q)C=+'M8.RVBU$,4%<@YP",HXCAP>KF]UK0L>?C).<?>Q;25MZ!?*M]^U8
MJN8<E]&B*,=W=X*NGK0^'#9_%]69P CR+<95S:_ !?805U4 L]4Q])4QYC*"
MF*#%"&H&Y]K(6G#[H&CTVSZ&4>69B5]@*\<IYMR1^B<@+]VZ(7&I.+<G("18
M2O>;^[XWK,<PQ/M-'=I'CL1+R#+B9 4X?!)N51]F!(.FK924:Z='R@KBE<14
MYJ8GX.=?YFL>;(TA>_3^W7)O:__LB$=,3="QMS._T>(29AN?4;VWY>@<8=B7
M8-/^22#[I:D_\UHRYE/\52=3= (] F9IZ?-:-QBK3CI<".]U'*J?.K)F1TG[
MU\!#=P_Y!9Q1A/^\Y.L@8GH*7?'G5<R ?X%]0?++>><I_%505T18BL0I*"91
M7T;A \H.IBX4PLFH#R%[]CT8='.-4M!6!@NYD<HC#?E"%^1:<L_80"YJU?-W
M;WA(PE0CX747LF\,.H7>L0(70YA7=X@ 9&Y"O>GM8HX@!3Q"-FAU%+,0X[LJ
M<UZVSD&[IH]3GF"8T+[N5_U53J-;H.R[L;$F/4L*1[?]@/_M]4V/<,N"<J#U
MT&*=F#SQ/7YI"3I*J"VL* \INM-[O%<0C;_IW.A_(N7'W4$C071%P-9]XW\$
M[EGG;F/W\PH<8==B^YK%2AL#!/"P=&CEA.H\2^G$A;H"(6LQV8CQ Q21R75S
M0_6[;9O=%0">[BX\&6F)!^]B)V6J&$XXVLM85_;"YU)5L)1ZK7. 6_W>L[P#
MH!6/"3HCQ!QXM[-PU!7F0+KMHXM.!?M6&VH. 9F(ER+15,C?H;FG@),5,8;"
MD/Z:V>\N=\9W[$1[F'J^)N-7;GX2QBOPL$>]:;^5WXM<'UZ.?R#:,\.5T%0Q
M@T193[VOQ$C&K*T8N2HXWUO/S;#\IH_XF9'ZX_/\/^KJ!S\\R_^3EW+FGR]*
MFMW:DGM@ZNN]L9Z##A2#(;O2!U2ST.?E#G<.\.9)15$50PZU!E9I%ZO*"I=N
M^?'&)AW=C1MV+GNK#0'JU4#K[WR#Q:9-5,)UH+XK<P%'DQHB@;6P-N39"IC6
M TOH0:K8)/F:SRV*+E;AIE[&&;EWHGM[+X,.W[,JO.[8N?7UQ(!)J%F0)NBH
MVB.YK+K$BSP<IJG'UN+-XLJC9D!KV']%OBE9I%VP4,9*(ZV@"T5,*S W@^$H
M5Q/6CLU=L=S=4S]B+S;;RI/O]0P $=/J*Y<MM":.]A<-V%Z<2=MQL>CPYY@&
M[V>5JIOI.-1@ :?0]DT&9FX34PEP-FG] NZC@-)GC1C24)WXQ?BF;6J[$;23
MLM+MDI*<YJ7P32-MA'E*P7JXWT%M+C6 E2(7T^1F&[=YOQNE6D_ T;0(.7<9
M'.%3WU/\HN^S68)K]8&OIYH*9W,(O8N== A0![*N"'.&(FA0)$BU=,/4]]0]
MN9YI>Z%5/\.GE*[[$G6#'<.+X-T^M.--?5R'O9LPXD'^AG&V*I1^K9U:3'T0
M-![O;U:=DK_*9#ZGKGK$1NHU0YG,Q9P+9MIVY!]]LZ0K,9^@-\KL =8T)X*4
M]CQGD>]2;CLAW=*HSXU,4])TQY]01PT@K>)BAAL< 8[:'E*VY8T4I%26#'5N
M'XL=>1=D$2WTN^5M+.BI9BP>:6W-0SO@1\&["!5/4S(S_&C'8C-90MU',7D]
M?""H\J"@$; 8"UW=C[\><W''WS9K7IN.VM\]\#1OVYFSD9_7'GUE\@5'?F.#
MZLL7BSA&21MRIZ:+T5>%.,'3/KX)*C0)M0*MT(K(#;]1*99N47:L."BU(V&M
MD2,G*5?(-((OSS.43I884\HLR_J'U[<A'.F!;8N9@YS5#&()K%9%8,/N@,D*
MEK# W+-[4CNSV5YM@O9RZG-9<?5O=WS@ 09POAC=##F+;+6^A@R4-7!.0QYO
M,->^0G7CZB-AG"5'KC$_L+^H]2.G-@(QY*(K$[!9;^E%:.J#S#\)W\21V4ZA
MQO#]V#*Z4F$B@'QEK.0/=Q6)4]7L+,?E M\LP6J&=;PBZURDXP@YN)\8,SE+
M7R8I;<Z=TXW[^;&T.8?R)!>QC"\_(XF:!](%5*JNKF[DCJH+%P2R!Y2ZF.J"
M>P557LL;2DOK"?4E/PT/![6EK3(XD&:\:Y.GV?9O<4NAI?^U!TX2JL\P5L+[
MU6Z,( V+J87^*3 G_]@)B +];\9QACKDG=,O.[\!,!#YG@]]% K2R<L:_)OO
MO!+EAFY-.@J]*5"Z6ISOGXPK4N3;<)=W$MD-^-61"[C%AF%:+[ S=G@!)W\!
MR I"+> (94N"^A2FCR>IFF306Z$];,>8HH@H^$V]90NX9"NENGK:2B25\(UZ
M:A"C"NE(ER-:J6"S^!L'N$> Z.%I=)N RH$QXT76GX4>!@'IE,;RMLX$A66Q
MO,#R0T]7AP CQ1?8[Z0!D%Y96GF'U623!R<UKDNR9G9XV/R'\,+A [RFIJR+
M5N?KGCK;HU^YF,4=)SE%<NHZ$&.*6&I(LF;V 1@HG*=<]Y-^@U#DTYE)JNOP
M"QGV>&844?( <8?Y2TMS, B6^G?79P6U7[/.OJPABIX>Y>T:&6,:]B*G8XQO
MQ%78UKPD]X^F(TPX&=OS>6R9G1B[STA% 'B<?3WP%Y[?56WAB#\%;IPT"+FS
MP3>91(#R1W:9G(KQ#K_WON6!1QAPSHZY9O'+VHM%!M8B)E^)*:@U$@,_J]WS
M_5WY]$M?L[&*GQ[NNWG84QP'AVTJWO;U^K-L';<G^_<[;=I Z U9@YQ@8)B4
M])Y\3K/3:P&WDJWZ3E..7'0_M(FPNF$ZF:SK7A3D;G.88:^@9)*"-N^%L[X_
MLB6(>B@B57HT#YA9#-I_I>$SUBTF^6BR^*;H.Y(6:)K.7#M&,/C,""D)I1/$
M@TY-.45%U%%M*)0KU_MYM"OT28I$*+KFT)3-=FR_5RV1G''LK*K40PM*QQL'
MY\,?:$N-3U!>3B-K>A>3<)(*R5&8GIU6OLE5DQGN<"=Y\D;EQ"_!B!DMF=,0
M?XNYA&'^!(Z(+QWBWRNBY[Y\RS@)^J;&<=9&\GYY'T6R:1IDV-2,-^6T6(P^
M+_.Q3H[3VSVVC]PD78]XP7&@X##-@.$-S=WD6T9NWV);#7\4!YK>JD\VF/SJ
M'1VH03GGEX5>8)ZU/^LF&LF:X'0NX#(H8# %WN+?NIE>N&?Q/3SZ>M#9+,''
M8I8E%*2:<-;%>7M-?3 9-+D[1M8^!XV66\PV_RW>FQ2H^T?>GH._$._:=<G5
MK60P H^L<56@-0Q_]0%F]P*NCG*3YK@MI,%[)%:!%U,R":O-O,@])853MLW+
M8QZ,IMG91:SZJ%CZ>LX[SL;SGS^-YP@EA)5D64?7K;QK0N<.PO"<PCDC9&YO
M>P%8+,M-85I4-WX*TZ7I-R@6<.N1X\[\[Q5GS* 9<SS)-'MUV$7(X2N.F?-?
MB4"^0)8MT,_Z"W86">H].\I8F[3@,Z#KB>Z-S;0]1:>,&+1!IOXKXX1OWM<%
M[S?.N/!RA^]ELS[F1?H$BD^!B>43?K\P'!:+QR+'(1HK=-R8W\^(@Z;;./JS
ME=2M>1[/GM6_=<"G2(UWT"X^Y*WVUOM]U.I)RM7"PY;S(YN"[@N\F<9 :Q$'
M/#3-.F^$/:T6^A9SQM7#'6(@6S*0;?=S]Y.O KEG%%GKR-2*/P013O^>*;%]
M?LO'=&PQ%P_>Q$4,8V4^G9A3%7)@Z[G)#JV*TE<6[;G5]"YYS5WH%*773OXL
M95Q7XTJ!'[E%5;T;=^IM-9>,._&Z*4&XL>6B2Z^V?Z?]2;L-2&WR;,<G<_1(
MMG2F,*!GAI!.QB/FD.G!7C?WR#RFH#S*T@G\G*\(<1(&/TE/^&VR(<-U[S'S
MQ&,]KOFW&ENRZ2>OGEZ6-11-K7#*?U3#MOH]\$7 2,T]N^+U/6/0^*'1_6%6
M,W[3%J+&J,OGJ(]D=_84XB:,*N^=O8Q[L/WZXP?+C^-P2Z[CUN.T<?JXT@?X
MKRXP1FN689PSJ440.9U*<GP*WX7(*C8J!(RIUQ(_E)M.#<FX+(&6XZ&0 _0W
ME7)R2J$>+"@J(:WC/QFX>-$AK0I=%Z78N^+/AU[4B*OA&A;>>9%J<P1@ "&3
MUTU/4L9/+5?OCLRM>NKV%3D ]T(LA6^&\@Y]:"C,Q;>-:S 6>S%OK2$T+/Y)
M?L;J5NC:S#"-2R3V9(V]F.EQ,GWEFM#ID$6 8'SW%-K+3ZL,_G3-DJ4FT^\&
M=3=0#%[>:4PKB;;<W,??#I^?\.QI< HX=7+P+/B!&UM\WZ)ZQB+\G"7M:SXV
MR0\:%A!.3N?P?-. <V1X6WG[8F9);7S:#H;[8\2MQ\TCW#3I@D,648E/B?MS
M)LM?7BZR#6KW<Y90;G6E!NZI1FR4UE=G5E<'#$?%GP@1*V)VHUV:PHE_'V-/
M]PYH?49>@C'HQX$8JR.0UM$;_S?FWCRHB>UK&XVBHB*$25 0HJ*B!P$'AB.$
MM!.B(D8<0$"(RD$F0U1  H2T@,P"1SF"PH&(@* ,$1FB"(D0AN-!9"82A$PJ
MLW040DN2YH;?>V_5][ZWOJI;]X];]X^F4J$JO7OOM==ZGMYK/:M7<EM>:5J=
MXFFVB&KK*' LD]G!C<5CDIN#8^Z$%AKZDQ/QN4>@S86B!N;]0LHQ:!)?/KZP
M]5E.A1]N?V5/_0'OIZCPL*D6A;7&*R9T+\LW/050H5J-4([(7^ LR>F"A.19
MP& ,V0C'B7CQMUGK0M/5X4"W6DZ]97CIF.%JV%Z0KL6[Z#]?ZZ+5402D?>FI
MB5WW<J*6D>WSN2Z4>E?QHT207PXJ+^%^PBM"6KU#I%"N(Y(\@5,4@4:=#$K\
M8&=2I&^8L,&W-3LW]^/]9[(C?;,8NZ!IJKX,UW?-*;*9^Y7+_40X46PO<++Y
M@5>?= \M53@#!*.8$ANP<1#S2D+SAWSYZ+;T9 :H8N%8,ANUAJF.C$1<BX:&
M''J>OM)H"1/0T93C8AY[$:4)@X?BMB3WV-DZ0;<?1V[Z=L"H^V[ _*XYY:ES
M2UT:J;TL?>9>-VH7 ;J(YNZ5V0>&EXS7S2<C&V!7A57A3"F^<*XE/?./+IPQ
MY0;'T 14^73\98M/B2=L[BK^QBCQ)]I5I KQ:WA1&1=K45.*)^]DP3NF#/?+
M:>#U&6Z6) V.\A;2[@(UI/A>R67(-Z[>Y^I\!*&9%L_U1$JCQ*P+S*JZE:&
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M:T>/B/&Z!WN<^-W2S@;YT;."T1>2&NS973&]O6<NL/T "L@DI"NX:Z3U5*P
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M+@LZ8PX[8%<J.(#V(HJ]C=KMWC98QA*<DQ$'0J2$M7"*!RT@*D5 ;S4W<8+
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MKZ9S$"_L<^],EAWP6;^(2F6BR3WO8%N1;O3TM6R3D 8.=F/XS1N6!NJ?\<0
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MSP+ZC.W=7(T4@M?QW'9DC>H3F34'5%#_H3!)C#PIU'S9T6SJ0[I,#>X6:PG
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M9^_8H:4C)]Q_7MYR=Y_=UZV7:_?J3:<\Y;6T\B0+B?GAY(FCIL!M"V?5DQE
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M',6!5=7SN!,+'\"?DH/;X%U<Q5=5+G!N2D1 -7\J@Q!=^)H,;\0\W!Y&4!]
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MPU+/6(W8.F-8K8&L@^RX5)++C6>J2_VT&N965>W/]G5?N'ZBLYN2>)[]-3F
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M>?-"Z:F5L6+N<AJC[0()%$4%K9@,U#[=>2LU*%U/K[JN\$ZAOS"_^(UHH4M
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M$C,",4"%';Q7CF_1T&J]T(ELH5^J%I2_#DI9/$C1Q\9MDQNE2\)2UAR7ADT
MK:'!,>5#Z[F5H*H:"O$*\)QXH;PCGL? 1LW*J[3S_--=!%.D!?=^-FFZ;9_P
M2Z,Z*=H=%?"1BTQ-7Z8-&83Y5K3YR(R8U[0&;^4F'/*T.73H-M6FX<9&[89E
MZ6/&]43(CJK R6,R7[,G-BCQC';1DN"!X(IP&X%DJ$C,33'"==OGXZ^E7^DV
MAJR*^KYZ_'NXT@7,:Z[]]N[>J^KWS[>_NH_C42=&I"B=U6LPH&*!!DL@T-F[
M1<MXG"HC:7FAB!N2-!4;?P,D9,F*M0^SLXFQ=9:/2\PK6%%UNSJ"\!K^V:M+
M(\]RP*%GMUC6,1-!/MT518Y<01>R\ND\9N=7-&KH:.I]Q/B$F\OA+"%_1_^K
MM@-H.#>/N4J$=K.;F/TATGG,..H%B3;63?A8QFKH,?A+ILN6.]4C1B!=.!S%
M= =9<0RMRY3S/[)-Y*>%+]J#/4G2)D'$G,?%,L^[;0$N)(*X8.X<T&!JG#:&
MK%PX%B&K8H9DW58N1_ZQ:*N9NE?&X#.QVU)#E!Y]PR++1;-/_^]\]/\+/\!^
M(NA ^GV090CTKY1;(V^Q,3HJ8]=?WNB8@N8QJ1ER@>H14QL8K8>N'L9U!O__
M>GT'RPZ/9M-?GS>N/6+09MEET[IN[XF\_]+<-KYQV.B;-S@8\3+BW\-+!2UD
M-@Y>9Z XC:Y?$'U+-?19>9GNUL$P^K&&_2?-E7?N74_=9KI#;_$U1Z)D(Q0L
M3K2V$20$WZ04/QGU\+W6$;0ST+L;)A7]"-UWQ>_L/";+=>(;&DL+213E+PUA
M=7M8XX[*)?!N* 54BH&')=2WIG4KX'UU^V!'J%#2G&WB"#LJ3]!/E%>]:X</
MB4UHQ@EC'N _/>6DZ&PCIWF,<4O&/"8I[UVG51^&R)C'B%$P!N_B&H#^2$2+
MV3^+K.S'1RV\-$]Y9Z:(E^*24T]5"^I)47-QOP)N$O32.H]0Y;DM^G=VI2W)
M\S+F>>X;F3"N%=#)V_-9$AWX,&KG': !0Z3.8R SM>:3\YA  -K%0AE)PL(F
M>'4(^<YK2B?L@R)-4Y%VP'!Z W_ <@ 77:<O,".?AGS C^6_(VAWFN8J8_TE
MF1KZLM,I$M9]^(CD=]W JWG,$2)X@@M9A2D8J@1 H@O-8Y2!+-1<"E^8UE9L
M5:S6\,2ML@A4$U?F/]Z6-O'*M[KYE;$T):G\H] QM<7(K.L/$'D<:CH,%D29
MSB3I=K7HS6,$&AAZFW('HY58YCIN!0+'(1VE*;P=Y#828VWV?_S6-6U V=X#
M.[X-SS;P3]&F"9KFHM(96^0%":R<B/4LV^/2 -*%GAL1ZF%65<DMG9U";+[O
MR_NK3%($=9NA)8W"X5C.7BFP$2+RLK?+@^O+069LQ92V;_6)*FE8F:6+=( G
M/),31@6*KVSX'K-H32;UCG&6Z;D)T9;"\9V8EW4+?<'NTU(5KT%@G*P\26,J
MMH*]F6CH"UG'(.]B,ET'1 K\"T8UAVAO]K.UV@HH[F4EJ<6T1.<.CTL]MB8O
M1E]Z6GC)K=)2<T=U!7=#NCR<D& V#CQ#AFS*D%4/0FP8[3;#$]LEK,5^;*V&
M-QY(!]?@%F,QO*<\S7'#MA!(73)XX73W:O.7]HI:-?'@8&EEDK?VK2>]NPX3
MV_T5\:AY*%ML.,B]/E(R3O3%#S@H[D$AK+[RQ'OB@90X(2Z.L6G@?_;W8DBQ
M#"TF6?[/I1M[I^8Q4;2<S+4Q%FMCX<^VQU$/MU:EEU.A ZVM1/ "RV" UJ6(
M4CV#+91'()G4^(%K?1W.'Z=#XSF#_,9:CWHF)C@<;P\5W18[U>KB-* 4$KB<
M:TK8E.+475YL??AQ@&4K)Z&SAQO ]<%"^_2:+A0G%R@]&5_=S?\W]@V@0,:*
M/Z'@\)*W5;N[5+'2E*8!UII,P'1Y KZ<CJOZ=3KQT&^"(YOY*Q911^%V^<_+
M0,/.(%1(E0O&\XA-W"3@/7R>XK41^GQ;'@.LH=5X@<9-38)M5>W!6%W<4LBU
M/C0$WBV*J_Q+2 OL*TE<]6-H2]>K3BOG>Y,<;\F'%6HC@F8 (ACNM6+6BR#C
M,NV?%=RX.A.D?='AW]<UU@UI@+&\Y<;#>VV^9!\B/[T>-W"C]Z)2A*PP02%@
M'=(K B_Q!Y:T F6B%FQ_F(0:C1C]X*X*YL;=%6D1U(7THP]LEX3GCKJOR2H8
M(6L&<LC2%)T1F^B"Q._=P>K.JV0D=/;]$+L3O>NW=E6$7>RFW@+2%]IAP^MR
MD95V<A*R,A$LD.#'=RF7TK54:+KP9R82MKSK B@31P?$DXF%4(V$&&6K9I15
MXK>?N)IQ"$H\T\/Q+/0EK[?UOEU@GS<T4F<2V^2"J(&"!!@O&]3_&!QN%. P
M3(2V#T^4H3,*;1+!Z]0:1-J,3814N;TDI EXP-@XCXGN%Y,CLFW!E.1DKIB8
M:+2\D[&)1G6(0 ;<4WBAI.:4J#JB)\Y)?B;I[6"_R->]Y8$,6.5 LZP-" X3
M8WOYT*&C?"?0&-8M4EC*18URG?3F-@<QM1ZKY\?MOU-;.].:R+%2'H&=.N$E
MQ8-7CKI[A'LYV:F=[OPC:_%G(^8+RIG'\.N?@#L7)(MT4*=VY1@JMT+X!1GF
M3/':VEVWTT'NXXS:R<;SN*NA"RV 3@!A0WYDL5TIZ!-C2\X?VY^1];0UH24)
M&\]]%Y3DT/RG4!77QS.*-8XWWXP0B>(THAK1EP\=N("H7WT+-#@R[*#SGFJ*
MNY"F'!4:VIPSCS(3F<M]W]/WZNIQRZ;&NR1.1=,GX2.A.SJF#<.D%@TWEE4@
M\6J)=/OB =]J=O*T@9V#RL2C-5N-I-LLUI,SH_5:+[@Y%=J+\^6ZC^K,TL]$
M'/B>C>#7&#2\=;RQVL+>E.UX\X_D@]Z/_U/?\F01<D,$_@TT_)>-:H.$V'$1
M>%:=R*9S4>4>95^/+.U7D*91)&O<8TG& CY3/ZVGD(^5RL"IRDGF!,[W[WE,
M\D?BV";<;V_!W#J&<*$C/+&/AZSL$?-7TV85GZ"Q%W0]$(6;BK V]8;2H1]>
M^^0I<;!K(>61D/^F%=63RV!;4)3(\7XC].WPT[\SEI&7'6W^-">)=!H1U+U'
M.M[_0ET>V8DNA8P(.N(6%__+6-5%]*,FN>Y^8O8\>RE$S(& T]FR?YZ)K5W)
M.G6;Z+;= :8/1];I6:_](1#\:2KUM1QK,'B!00+F,;+WI+E_U)#+TURPDPC>
MVX:K0H<9HIC'4(UG/;B2I[8:MYGX__C,><RJ4!+Q #_KN^/W<-54S6UD87N:
M.(L)GDMYP 4O8/OM'57%=8M'"(<Z8>,[;Z&RQH5&GK8W7E'::;.-R%[0XYBP
M-6;J%H=8-"8DY-X)\0YY-6:S;HY0&F:4^VHLP^E,->/UK/!2K'R9G(M@;ZA*
ML FV%PI@=54BLHBF?J*T=\;)< TV:8[=Q,=!+WM;.B</^=^0GV&B!%@+-JZH
MZ&ULN"O,S_(AIEX-N6/X,,35VSEMZ@(&B22*!XD+^T ]R G5/A.;"X &-XZ!
M7.\DF!Z]?:%7'DX+]H..2_B1(JU@.\9/LA8W:3I3XQ!O:#UX:\@4C'[Z,'19
MGWP'^Z67XYH\6L;=QU(#Y75.US1SI)(;B8.VD6"]&D3=7_D70T1<C.C33ZDR
M;+=*<?T%K<*6W%<PBC=8)0$^ KK&((:T\W9;E&>9THU$[9F4M6-IH<=;8R=?
M=C5>IJ6X=+^U=3;\!'D[OR-K^8=:J=AC+'BCVTN@(8!^7(+K%RR\:W8<I"E$
MC:')13(/G! #;Q#0-20I"1^+/3]+=C(VG+8](DVR/X5J!O$_+X'U@)\7#7_^
M';N\QC>00[$9*1W1&KA_+Q;>V+I0L!=:*#,G!EOKF=&$=:H49"6C UA)I)@=
M:KDKT@D&A'<:&-ODLPWAYUMYZ=5;F-%_TNX<ZX6M\[Y"[ M=DR6<P[^@]//=
M9K?&_RBM*05[WUWEIO'@3T1?8@).O0X/35V2\WGD_ME&9AE=_YNJ;6*6QXT9
MPLL+XA@;*/G!R<YU.IW(5C^"J3PY8EN-?TW\A+%\J/BE!\^LA/GB1[5&TA.>
M]?1O:UAS#%G#4[TR^Q:+PGL321@H.MH;PDD#-J#>ER-TR7L9GO&[#>ZPCBPG
M)A/V9CJ6>=0X70K8SK&^MHDY?L+,[@\VQ8Q;SH1V6,-:@B;<4O1GV5Z+5<^Y
MXA>WX6VJ7 +A> XT>TR.;?)GK1[!:<Z(5M'L6T+32H/14%PTPM5"-M$\.>>D
M]VQ7%OAK>U#F\O-NW2JOB=4WBDHG;.PHSTR\C_U%0Y>&L7#<601>($'&\>T<
M*S3$99[\%ER$< ^[@G1_'E.^LKMN*Z3%/W7?U#$?<KCTH7N<$P+^%/8NV=4U
MC2X%5'8"G X)9-LD/WCSQB $>0DO0>.\D;ZMNN,:<1UWH7B"9CE>\[C.VSOX
M^XR#-)_F#+-QZ4:OP6/(%A ;,57^(5M,K7A'FPE)V&!;&+PK&[<?T"V;QT1N
MY%P-EGK>#B9".Z=B+9DKS8M> XUV83[*?7[9V^1F0P^-]G=M$U@J4Y*-=+M,
M@]T>?T\YF]QZJ;OX*LW[ SM#[&E76R! B2H@_F<>TR<X_:YW"U2DO(YT(E;=
M)9:_<]I9MHLDW.AYS.KQZ>*S7XR&E.>Z8/N7L&NF6UFRSD_CKA?=091 ]8^F
MH4E%ZWLWK<FU1XWJ1P<TBRW :B&?F)4[4C>6'@V^VS[.6 5%C_OX+B$9/4^?
MQ^C:[JE^>^[K]YTWJU(=[HF;>0W4S<H]10M8:5>@6-U5K Z;J5(!?]9ZT;UE
MT>P4@5C \["_\_Y''*HR&=OIKO\[?-UIN_7B^G^TI*-'_-I\UH6(LKDHI(K_
M(2;IWZJ.%HQW*8/H>/G?6O=^CKCKM1)CC$P@BEG!OZ*;I=VVKF)#5^DGO_6'
MLQE% >(VBSL6]T+W11L@YA]0^_<2Q6_7^N\9N4UW5L6Q3*_[7H(=J/([TI\_
M>J67/G/:/1%^9=WF&Y7$;8T:RT-N;F"["58?)G[ 1Z")R)/4=T$J&E^4CXCT
M14W 2GA=AQ5Q!6S?:UJG0?=#1<RO>I'V#$F7;L.5+X^_)Z:N<2-#D1_ESK/Q
MP>@Z?"R@$<^V>]<Z7[52US9[FOPJ(SGU*DR +Z-F_4L4%R+[TUTKH3NH RK.
M0/A77Z^0-=;(CD(!,O(&J,;I739MJ-G*T+N5J57!5??7SXO2_)\1@EWT0Z&7
M9-?$?]GDS+DK.@OK+VQJY/J%>RD^<GW) ZX*  (*5B;Z[87U09\F\D,]5F#Z
MX16W"N2US/J^K1G?_[$P>#;QS<D@?Z7"^>@VO/'D5 , 6?Q"5AJ"8XT?\^BG
MNQAV2#MA1_KGM-GF[/U0U1N:Z?$#A]_S7OH25Q;;JGM?S:_![CL4?HVJ.;I7
MZU)%?#H& Z295D<1-@N"PWV:0[-@5_TJN6Y9") _LM]U5H^QI;J\V\J0L,L4
M=[Z]V.R6%573*BN[*)QZB!";-SCD5ZE/8-^^2LWQVV!:R;R>U!N6R@CT<2O.
MZ-U>[G0\X>L R1#D4/*JTFY6)X>Y=$D2AG8&?$_^^6WR>D37= JRZI=R+WVM
M*IDHSL=5Q([S0:Q7MQ4I0J1>MT,X0M"[AX:SE3.IL3>4&P/;29VI]?S@DJ&2
M'*DZ-V;N2\4;R# XP.'\KXI9<'14S_J[TT=SD[DUT&WE!31'9-:M (<BKP+*
MY4COT#[!A.W!EQ3WJ7@X4*0U$W"AR3TK.IIC$QMGI;$%+YR!M^:.SK6-W_'3
M?VBDW1F49:2>&!\05.01L.^0OV\],=F_B+IJ1\HZA;L@+M!*08N:NR&(L1QP
M-CKP:8G%\9+CTH&!_FSK3\T&4.BR9YB0)XM/>W< /M1$&Z ^)5FT K$8Y6(Y
M5G)49)+E2WB$ USHAFS_,_IFV1AYS6C:W-]#6O*C Z_>MTDF@C?9W"V[57J2
M[4Z?U>T\(?\T"E0D&2"K,E$I\!#>WT$ML44S\M(JN4]"\"$-@F-0\=86<EG!
M UO?N>*9@LQ@;V]"L=Q"YI/P9)!JGC P2!Y2?^ZQ?R"N1!QSZ +<A&H)A@WR
M!<4E[O\=RBYHX2?AUE@.J[+0U"A<;E\(;77G&.WLI*OET";-@$:&>N^,QZ![
M<YY\/Q.\XR:WCJ53PNQZL]G5_QFM>9S6@S=_LF<1$D,&C_$A8Q]8BZI@JN+J
MEC"$O0!X"O]@'K."?D/N)6J>RQ-%U)GT0[F*Z,ZW>#I1QM6&O'#:D/F8XGZW
MK;<)S;4I/M=!"JC]:UECG]M/%KJ-6 RZCZ3I-P]/%XE%BZ&MDB_15 DUMFX-
MR'I@:W'S7T6V(4B-+4]1_^%2\G'C+<7<B7@?[X+ZMHWGMEJZC)XZKO_DTKHU
M3X:&AKX,J3N=W%Q141%C$N;O3WNB'A9&T[P6LV)SO,N!JS%6EZ4)5A>3=,ZM
MVXEQ/HRK3X=U[B K%LY(+D6$9#9K8IF4NAAI7^*E2J/[R#8$DR-=YF(GCDMQ
M&'@O2.(51NT?V@B:<E?<,L^OZ;02J5/>V['C*PQ-&D(JO7;V7.NAG[(*<#K?
M.YR$^$(.Z!H>0WKU1?W\5NJ CR(,\BLI$9@LE,C3K+-R"J1W:V[!)Y+J:27K
MZSV_$X(<U_UXUR30K*HB34>]O$]\"$0!X WLN)ZD;!F_A2F,5;R"BNXM*:M@
M13KP\%%U.,[2W6]=*ZT9:Z&GK/7IYL/C1KNZON^[Y_!%LW7;':2(OA[--3Y<
M<2)QF;MPLE5AU8YL'7.96.+X%O:1SS9QX\?N!M3O362JTQ*;WT-J_H3?QD[4
M%1YY'8^:_WH_T$I=3>1</*L6 >-43X&;V/[)]2^@E<J#]!60\;J=\A;F2H8F
MM$32VY.&WW*.N8(&G+QI<?3T!0NMKLTFN_X\$S[Z_V>19-93^FWE2J2)J,UQ
MPB<1MB$MJ-NRFO#K^:^3KE%U:3)4\3M(^5IM12O<O_H]&:N>C;+2..]\S*.F
M'N_UX^MO\XY[->L+Y]XD8+[!!N*49?!!\'LFRF5CZ]:"W >VVW./FDVGJ-.L
M#W?2]TK:=@\>7JQA?:S#S#3H\_K#F!7% =<.8Q;1=+H7^M'_/_SY:P^="!JR
M$GWD*G8$?2M55E-L5Y[)U&^0U.KC=+]22#NSIC_"CH9/QBPH$P>TK?Y.+[[5
M^6#SPP_+JT=WOL#R 6BW&JS-KR>#%_']:@O32&K"XVBMDN1T:3BUL6YW)SU
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M_N'DN&4M&C@% 6%4,3.V\PWD=*I*_BZF<1YSN/HIWM9K+. >OJ\)%:-O9IN
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M(>>MT^U"3\J^02_1Q[N+^F TG48^Y2Z@D2'=7X*/-=)6O9L(PAM PTUI1NO
M+TER=8E:*WX115#=4G2;ZI/7>D]&UH2MRZ"P'(]1O?2]PB-WI%C=D=NF\QC3
MB16T#%*O2*BF2(&PRMUTRQ["7J1C'J-+UP#)DN2D$.\",HW?.C>3'?D*\/-[
M8NE^\_'-67/C'JNLX[+T<1O"LV7?"^Z^^^I(]=]V]]<^X$#V<M0\ E'\-V$I
ME"?&QO=F[U256/71ETCML$T\R7 <8DJWK0'U$@.G#9VMG,*(NF:Q#5D6+4]&
MTN\<7ZH?S8J%*9+A[-YE"0=S*(%>@( ([1Z&M:;$P[!.D>)F%_'FU$.&A5S
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MQ7_O=5^T'I;*DA2%M&"Y,YTGU)H7)A)J O,*R7Z*)<S-"KQ3H+(;OPNZ!@/
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M*_M$-ZC7[75KR&I+FF\%06Q:K[W)\NNA>Z?5]+)+49SN0&W!RUV?3U'<E7O
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MIWI@QMK. G72G".W9(N+7_=9F\N3TC 6_PXH"@'1MUG8S'RJ1^Y&\U;DTK?
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MV6+C\(A5K:,F,*.0RI5>9EYWMG@:G^ +SF8Z8PG)2NU)/;^!+UT/G!V_ILL
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M57_VG.G;EW/P3/=MY.*VI[N]B_8)^.NM"#NB=@/^7=J+O)^ !O@@LB>UYKV
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MY+VB;P0Q":?)N8;1U=>Y^GAK:K/$4ETF^/=;R>%=$/EIP*Z&F)@8S\JT%;:
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M16+G+$J\_IIBFI=YW]RHK[CX9-^4S5F[NHM.-K[3DOR[H0ZYN:,.6YPSC/N
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M#7X^JJ6*"3\(^P3*55BI'Q+(W/XLSUYGTPN2&NZ2D,RJ!J$!E&EJ.I:]]7M
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M&P76+Y)C;^"-^VFX7OP&>HL['Y.9S@Q_ F$;YSKNS]318V1_:$ 9]4-;09H
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M?6IV-ECM4AB1C/H.) @7P$M4)IUY[72TRAJB@ 6N.<3MX:;BJJNJ+:+PC:'
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M#@OM2#J\I[[N"NO/8%/68].L#27C>3;DF$N+9E%1'3NP[_I4&"RLW]X.B%B
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MN"SNU39;Z-SW'2,A0-OT8%UW<*+)Q+P.G'.T^->>,BX+0Y="U1-\@@E^*33
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MPAW[I[Y;*@H*/9^,'B9&QUZ(LK@2BW [S7@$E)[2B'-.N'!W!E!!N**RG!N
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M6-X]U6H\T/@7U,8W.?LU065?V$PRAM]AP= JE8&5XF(OC2!A&D/+)$S9'Q(
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MC<+;P/7J:&2AF28Z0WR!90,?@'KK/\%/MZTC+G!!UA@%B E2D\'T(M+/-:P
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M'>H&SG2RS?LC+2GA_.MK!&TQ41>B'/L^MZY/>WWE+U3XKY8[_N:I[Y\5?PP
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M:I@Q]E,@6(-Y'$8>KL<AW\.0U@\3/%(H+P J*.H56@\X3[-"E\,B0IN:^N?
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M59!G8=QC'/F-5\H4;O-8/!<,YL .=HA)B688I(SV88/&=(W[IU+FL7P)\7S
M:I#]#9:9HY7<A4/<>;7'RFB9?L(F1AS%G&2[THA7>:_X6.2G=]CL,N_RPXL\
M%.D!]69#J*'DQVW!NU M<$8FM=NM^QE#<FF ADL;6?N8;83,Q$(AP"M[]75E
MQ]$N]ZWRNH!C8 'WU#?AE=6 ">W<D&MHIL?/CF7.AJ=D[U]67R4]S!6F"^'-
M8YI2N!?L10V6::E O0_ X$B)FIOP9X6_$3S0+%@*:I%OX1K56)I58Z&(?!7
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M3.O=W8C,V+"/<+RKUN-$Z=$A0X6:]O4:-($LM$2-'^FNDQ8CR[%)W6"WV[I
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M1PTEPGDJ3I+0I!>K.D6\Q.\4CL[^ALVY!*/(2YI-@[2B$=?FY/%M;E[\3X8
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ML9#4!I1$2G\*"KQVL>;#;5')A8(1:6O2B<[2B@AW-]Y58"\F_,]8^O!'; ;
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MR3U[6<X(I]5Z5^YA! Q56!$E/$N*+7I,ZL0W+L]F>I<B/@&]7Z*C8VNE;RJ
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M/0B7'<HO.]%>ONG6/:0PJ,>QX\#:P(%W-._HM4'^.\#/]O^7@^,#OL[@+K
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MR.80-'1+%1CIFE:=0*E*C@Z[%QY"@H1IT05?)1:Z#TTYG-)(:YO^/VG)I6K
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M8;T3UD-->K"E"=K5B+PM7J:72CW/&^ WR[XTJ-XUFBB]0%$O,Q2V:]OUE&;
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M.5O:6/@M%1P0UV,2YL)8P%H)/X-V.OU$I_O:4CC.'P=34:-![=@7EBD<J-X
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M7$,S'!B#F"?\DSM.]5243ZDG8CW?1S?0[T0^Z=\\AQO=2VLM;N?I DW/:6!
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M&PNNBI:QM_4WEOS]EXG<I8FV)"PY..@ M2WSU,$'5]8A&1C.!9+,S["["&"
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M88G&)Q)"NH";=C"0=DNH/HAL2YA ^(8)S NXI/]Q_/OGGSER#$@V$_#O5<0
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M;6KT'Z:4X0<3V!H:OOP]L5*),(;LZRE8.!\+;\6"&":;/-="]5XZ@"9,R3A
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MP[+&\ 1"47L]P2+L,I#OAW;TLC@!)=@M)7RM)A2(I:"$0W]@%V3!WM+LUJ3
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MQERIR[-%;$L8I^&0EL\]18.E<@W47J869#!)?SWVB5E4HF(;(J(#/0TDSZ+
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ML/XKGP9+Q@\U" LLZZ<W"7VA@8;[TTDU-PIKV4V6\>4-EE\9Y2Y/'S29-PY
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M2!$!$3$BF[(D0EBL5B.[!"$+M@B"F5$(4S(9[N'WO^\7]SF_\[Q[7CSG/"^
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MF;&8'6$D2);5:/4HNF #Q+T69TAN"S.#-V0F&!46L;ABSNKNBIHDXK$NYN2
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MH2-_)</&KF<5;,@5:VGMKQ7:/8//+?_BV-3?4GRXF/5^QO6G\>" 6RO[_09
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M4VZQEBO(A_A!_$-QC[D_9 RH(IKB:_9;GC?YA?@5%WO)6T5_XW2X')AXX>X
MCLNU!9^T^SZA>.K(NP3OSJG[_K-!J 0T:4S4>&#SB]CDYW0=.J>#OYRZ+6*$
MED6NFB.T\5*&31OA#86POSRLZ+CB$]V$-=(2;,X[\X@>/;NO(BGR7AMK9L;Y
M8EA1O&%#<\19&"QJ(YC]U^:N@6HW^DL7U'I4XXJ]I5?732S0N+-VJ,\B9O"M
MD3G"-4?Z(+$%L^VC;H)H"EZ6<#-RRQL:$C73LZ2'L=4]4Y1O/EY4EQTO;'X0
M(PW(<ZZ(9YA=#9PMX)^<,3AS(7;E)1.<V_+ +SAF3.:[CZ,1>+6R52SBS!'
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MW%M=X1P;/-YGMT0PO<O]]6=SY1?I3H+[?-MISW'AADY WLD;S/&'KKF?KF-
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MP3K=*]BWR.!WR*1&GT7QZJYF+J;!D1Z=G"V<5V1]H1&ZI;9W.C3$_Y:B/5W
MXGLBR7!B6T)@??:#O1</U"E?,_W['DTUN;4*UT&"Y#B$PJ8NT"X&F[W=+5$F
M,B\D;B%<^>CD:L48:@O7*2@3=9KUZ#:<DU(_Q\^O.)8DD?P@8H?D\K!IY>-;
MK6&&?=3O%/D_BN^.N?Y(DAZH*1-O_R6B(7OTC1,$HBM&'7VA#DS?CI"]@\JA
M:O-.WC0>C[B^"=T%WUY]>T3WHM>.P3<WW#8>M=2[K;?M*7U<HA[7ILX1%.6
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M6*.'D92'+('B;UX',XV^,HYFQ2*V!%<5M]^&I+N(8OI"X3H6<[XEV*5)ML"
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MW,TX-X0:=4NT-8+@?<YUTJ?HAO "[7HP&Z8=9!T9*!J,[1A\>Z_8LWB\Z>.
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M1%)]8)9R,YSL83 2$7"%1S5^>*XT'-6LK!A"M3\DU&AA[MG)$I0&9K1&??I
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M%H^K,Q70L83#8#"&))8"L*6Z0->J4-5?1/PSAE$].)2I]$=[3,OK2A$;3D?
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M?K =Q)R2:I?=_AK9E/1+W> <C>5+S8AXLU*8GYNRZH/]*ZJMNAS;ZH4/\',
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MZ9PM>(6K^OXJ%X?=3$.;9&[U*O8->HLCWQ"X#MZ,L*XIE-6 FK!7QR1:-YU
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MJ4GQ-M_\+Z/J]P<,ILWN/JY3_K]PJ./_7T![ ^0I\>I[R I:T%)O$4G%Y#]
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MLFN;;6#"Y1_[:K#8L+O!4(9W[6O0\"^3J++;]:5^-D-,X943^S0,_J\#]Y<
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M47^GGKW5["&ND/U?-J '[P<'Y:B[$H<RI#FIG-WT;H8!NK[QTMBD;_0C"QS
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M!A0P@9F#X*GY=AR&Y@J5<TP@N8QA-A0(L8*@MF+R&+?Z:A/E17BP4]Z)C)/
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MO=UMWO;7KI*/)'@]#UDSK#I&YW%?DB;%*B*,UK")<43)([(>S:80=NEQ.94
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M'XCW]7&V4.D="I.DMZP7[WD2;M+%@/=0GBP?]GC<*;7SGB!!WXI1U7X(7>)
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M5/E _8CX\]+. 8$7Q%+9T*PIF6)V;:4*3W66DEOP*;*W,]Y9,S)L6T52\ Y
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M%Y. 1K'L\VWZ>MBL/R;(*#(O\'<7&QG3!!5'>&%Y=-G/F;)>EU-2@4Y$L,Z
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M>T&45Z\CRL[-8RY0\:UN^27E,?6NL'U7SL@>Z'2R6KG_R*G>+\2:!*Q.R,0
M/^+$IP!)D, I(G\?8$IP1==U%V!@ \TJ)$,*-4:;"<1@(3M&+F'UA&L@I85H
M@KP+->^KQ2T*/!+N4>?G1U_=YV$C(V>/;%41\F*?!TJB(EH*0['@;(;+D:FR
M!K -!<LMWK&'@#O\<_C<4GL(G>FE$1-$$P^CY)0G4,,A;3$_ML3FYP%GX8[H
M0*MY3!X00V8@2WT 4M%R[YB4^ZQLG'\-;Q]!<#G<2K'RY2H"-(]).XGH4@UE
MJ*8M5@,J489SB9ND#5>#SZ'_1/.%2MB!/^)")L7J>ZJP-F Y=X]1YR!^F^ ^
M9-$4:M'SJ'=)JEAXTN>"?/=&;E^"WE\Z/SYJ^8"4Q=1!.6N9!#Q-A%Q%K1(C
M&EZ%DWFU\-/F,1POX3QF$2T9TE5E"A,)ZZ!B,+&M%^DG5CO7)9WA1TY<G'[A
MDA4_J<FS.%ESU_:6 ]NAMF3G/M%%%ROSCCG&_ZC9,+F*-14DPPT%G=%6$7]E
MZR)#8C(J)_,*0XV@F"?4#@'1 (XR$^+-6LO\/[Q56.W YQ!P(N5,PUO'T8S!
MD4B[J&=WKY]F;7VJ)Q?!EF:@CFPV%9 VX$#*-+HS.DV.]7"OJA3JU]!V*26+
M,Z!OQ1W91+[.7(C4]A-O))3\.K*V^U(M-9Z?ZUJ$&;AD'C3<:'&@N^;>)HUU
MVKG5(:+_ZW'^O^MQH&^:RZC]V_@8X )%'.2GS04ND(>$:M0LJ1E(?ZG)ZX97
MJE$A<:A\[YO^FB[=&/.P%TFB=!<CRB_=W!"Y54R;->YV4"3WX!.(U#2'W)5U
MO WO=M$"1U6.&8\>B.EGT<8?\U?!)' 26<;64"&%U[>$$"\9"17@/U.GFY,.
MO*^%R>(Y[%0U&-12H/XI,",@''VX;X^R8_#@-B^';\=4+^(^?CAB^Q)MJ9BH
M#V]VG7+5'*(/N#7OEY,9?.MY3#3?,A)G3-@8?90"^UZ5+82"PP3F7^ZB([S;
M[/)W#(KGBC;K'7WB/21UK21K:I2_\PAK*/>W%=-R(FS%T3C1K*#3<JO]"KVI
M/(TOS5+[E+M&A6WF&:D84W$J8%^:C--JCU]!?20L72\BRL(CZU'VK0GR\6X6
MNWS)"[\_47^E]@E$;KV,NHG3,VY+ZIT?':=,ZGCS?$@^O;5;%9%W3E35\ [_
M)X/:\V7$/3TO!PQ8<MT_7W])OCU4BV+.( $#[QD@_CH]E*8N+3S2Z\ASA+#J
M/WN198/4K$UGQ*7EX*@\0DC.1ESZ8=<XC\@M_7>\5:Y"*Q/_;H<OI8=K(MFT
M@ 26MN1[[.%0(,)ZU3SFEI^0J,:/2>8NU=U?#F2/[*Z!PL%AN5E+L<8B[V2[
M;/HZ'*#([=S5<UC6T!?K88N:ZGMK7DVOSG(_L]\&/;D[?ED>M2GGW:XT\EL@
MARA5X89^&99VH3R3YJJ]2W>%ST!O5=:][?2- X0E4%P+SSQ9DH[HH5(I 8OE
M9Q/64]N]>Q-F7C:H=.OR7D",P^_CYS'+H\UVT:UZ>P-4C@/7GTR(C=3EV@/T
M ?+7&%P-7UL\CVDC:_U";=B?2,CR2LA".FU$;R+7F"D7UUO_0;>!3VE9M9)%
MH5")X^G:1^"LC"'LRO3C68(?..\\!E]4<$\K2!;1GWL^O-A)>!#K*2CR/QMT
M%CN,-0<$T?.8\\0T,GB,D<H'3Z#\Q\XC#L0WX7#<-674<EEB,]9D/.E2M>I1
MVUS^FW.)SR% 2#<&IS-=0O8?'0A76>?%4N0^-J'H^F>O$%/]SO2X3)M&$TQS
M/E,=B8Z7^-+Q&,:R,7-2&SN7#QY&7>9LLV1()ZCP2.$Q;5DM/],7:';=DONB
M*\::R:YQJTN732\Y4D86 A%.MRZ'J7Y12X+O?G%T3LX=SO4[ Z,0F:JA454'
M9V%+H@9+74H>2I:SE+7@-[4/M%V&RPHUT=Y$S"+-V_C/:8=5E0]L6RC9;B-O
MT%6_?*QTM>K) "N,HI=!6#<"C:SEXLO'74-70:1=Q4^'#H93G@7C^L@F@* )
MJ./G>>QA4XFM*".,M857LUJ0U:ICC&?4Y)922Q'/' [MC_=)WC?@N.5E?WP*
M^6BC]NZ%ZC[GCX?:Y,G>P^Y/PU,_CP1LO+O.ZCH&R?+8K F@O^/7D*=BRI$!
MYK+OC88*_I1*3KP1ZJEJ;0@,="BPW@Z.9M2$7*4%2)5A!U16?Y+./7LQ1ZB2
MD8PA2DO]^9WCXC_]Q*'59S/L9.R_*8.H_N5KS(, P7IB) /:FCG5KEDY#E1[
M-9&NA3I#F4Z-&C>:(SC;S,_TD5-642D^4))8E#452\"-)9FEK>]WZ2"91-;=
MGG"M3R9WFF9:)L:]77TF%_<)@"UJI40Q1\J<(J)2/@^R4TG49[5/B>'SF!NF
M8M<<Q)'^+A2K?8BLI1T%+4WGR"V4#/+:&<9:"&@N8K40#:D)M(/)LHJ=39(5
M9JT[QK?XC\SZUJ#RU?&22T!X_0^S_WFY;704K+R)4_=IM'E,KVO3-HPVOP\E
M 1.D-/IN$!">TN;/8\ZQQ4+U$#0LIV06X5N8.< RNFZD:^G65Y!>64PV<#E6
M-HV#% +$3,7EA.(SFO^.=ATPQZ5]F?%QTBMM]U=9%U>.BS,8L6HVO(J#&'[2
M.*,/)?%LH6_JA%J(K**H+RP4^(CT&[$5T?7A"U4O\R=/O:])V2?\1;5\Q$QT
ML52<7.'7+!*7%95N "79'IXRTLH@L<3KZ7C1E0J6_R0GD'@/;?(%<0EW'5B(
M+.-K=D+%PCG3NRR(K2A@J^+DG):2W]L^AC6J#C7B6_D6U)W"PL G'3K.7\<D
M6-H&&1:[?QUEHV[/OY$V9UZ7?(+_JWU&V_.0JH-@7;777!A+Q^M*K?KH=O2.
M)$X6LOY#U&\'HT<<!SY#VS6_4DU#O(/\WV_6#D-! L+J'EB3?OLT8V_O9J^
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M<)#WG%_=*LDJ%DBL:4YT@R"(.Z[C!61W1,0CMK'&"6T\<ZL7L^0AY.2ZS >
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M_KK!Z"/7['AV[*AQL-!2I:^TS9\8.&?Y_.WGX9#]1IW<OR3+55[.X>?S_#'
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M5!. TCN//WOE]0S(<A=1FGY4>^4CW^64&3EAZ<D655U93?.@C=,MVVQJJ&Y
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M_PYN/4LVK$!_]N1L6EI!(RKE&OCSYM9 #GOJS)C9;42Q^:6D3@ZB[SL%N_[
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M+3%UTNH)0.ZRN2"^A#T*94HH\,9'I&+[1R&]OPG@-("LTCX'8+.XHCR5-V0
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M\;^6G!OZQ:WRV6N)R<L0^73.AA7_ZOQ77*B7T#3PG#4Q+-^)_/N1UH71@OW
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MK-B[4D>B?E&&,@S)G,$V"F<GQ -9P=R5\&[%+AC]FN-(B,2'CE,WC]&<*.A
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MKDN>4KK,I\5$=I!C--:V>1&EM2( \$QOBP',+CEVM?S3//R6Q%W3B-8CEGJ
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ME[1" %PO%CV;O7X0ONC63GX^Z<U-3Y U]K'T(TC%J5-S8HNP[\^0>;V(BB%
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M0"D:332[TS8CQYKV5D22:':M?,FMPW4ETM@\Z@[1#L=PL@[%/YBY[_]KRW"
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MKY0Y@UURSI+75_V-;32167B45<$G06Y:6V2,A*4WW9)<>(LNW48U KU[5"N
M3_F)3FZ*(-^Q[=08,7W-YTGKPH\6OO]H'TSX.2CXG^U.Y-K$6)3R%$NBJ5KM
M[,I#2)4)F^3S52L_I8*$'J$.]@1YW$$L*^IF"#QW0I<>!MR;%AJXS[AJ4;#=
MX?W?OT:$3X;&L\<NSO$649GT-3X>R4JO;_N!TW-K*=R]#2/)CF^LVU7":N@V
M$)+CLQT)Y5<$2-JP<9=(TG89NXN9CHP/=YPSL >R S6[V<%>Y/0FI@&EQ!]:
M6QM(PF:[5N0,[$^=RV$NIUX %H*>/&W)2<U+.0(4W!)((P8__+[B\\!$GTH[
M2OF[5,FDBUV6JF)!#MWT^D64K!W(^.0/$CI8ZSXOHBQ5S@'HZTWO'(\WE<X$
M@%%-2$C646[[N%8-Q+@\O'07:NW<0HE:1/GS0PYF?,0S=786[\'>)S01.NF0
MDW\/ ;(9N$9;374%,SOIB$#NV ='BPAJ%(R4S\-CL]B3^L.SC0I'T@PYV]<.
MBI6Z:D%[)<.!4+9T(F'KOB9TY93*?!!VFW0!_?@9R3*7F9]?N\0HHE6KCRLH
M\+;_>F7V+*+68N.Y65L_A[!+-8#1]UCMME4UI)F[$=1CT,.'N^S85S@64YYZ
M@OCP--SC&6VM:7;XZ5N/</<H\7P\Z-Q_>_@<:?R^*A8K:A8"800!0._07BJ8
M*B"+32ZW12KT87\EETHM]FT6:#+<,4:47C&]HZX,6N 5ZP+L;D>T%G7;J!O6
MB!KYVLU5D_*_VGNSJ";N__\_BHJ*& 0! 2&NH")$*X'*DE11$1&C4*42(;54
M62*F%I$((:,BNY J%2I\("H"(F*4M4)," GPL501V20(V5J536:LA)%,AM^D
MWW/^5_^KWSF_\[OXY>+!!8>3#/-^+<_G+.\7?__ 9Y'IJ*S\IJ(Z0)IX^M:6
ML9S81[)+R2O (=2T'#ODM9R7]-JNRQ, ,X!@"O/5]?*4\SJJ2MY!R:;7\Z1=
M5Z,KV;OZSO/J6,W!8'_1/?9Q&%!T,DW?P%GV9YFFQ1&^_?%+ML8:P=G?#IQ=
M+[B)ZO<RC6'[*IGZG5))F#/8HI^!BG82ZM:QV;H4-_G5DO7P(%@4]A@J+X*,
M)-9-75>%ZQ$S\./E:DQE<>R+!>OOQUP8L8>?J_ +6'(I:EU7VP"]F$JI,]'>
M,_O0%%;/^\"=Z,(4-"8=Q.N0[:"DE6XCBGH6H<)/YJE\&.+0$*G<'HF&\R!U
M&]D>CE4-3OO,ETL+*[AN[3"S&MZ8UQ*RHM/Q65F7BFO-*OOK5:$->Q=__"?2
MG_]P@@ Q3G!2NWF, OXL1U8ZH:LZ=X.-::+3)KQ!NJKC$L=X%%VZOQI9FWR7
MA5=53!27AK-26O\NOQCO8M$F2[\B\%5->@1'NS*GBWQ.DIH'\AE53UN,W]#!
M V$AU%<BQ7L =CW66'6BNJ2@%-D&G:VJ#&OR7Q<Z.@M(*5<:$PI<5F_>\/(Q
M3;+AX76_#==6/EB_?2DGY-]7"_XKHR"K)5I_M)\"'NF"-SL\PZ(_@U*;(,%G
M>U 644[3![/]H*Y,Q$+1A8_F#;Z":^CXL1 'B][SSQ+V]'AO5O#-6$N3=R&6
M*E.34&@@-UZ'G>Z-_=Y%JR9(0!F@*$!MGD!\9/4S;-&4X-GR3QWE<*-BBNN]
MX[Z_46SQUOBIU8CMZT<C5@LL;\9^_"MJ:/WR>?\=IXG *#_IL+/"[Q)PE@ [
M.K73J@@XM(]G)&)0L//:1UXU/N-NR\P@5=MJQ1QC^*3J%K+]S*>RCJQ89*V*
M>/7G%X_DT95)"W/S5+RE8^O^_OPBO/6;>>.452+%)8H%Y21_*$ES5%>#B=5M
M;6 "M0=A,N]@'U\[DTO> 9>A5BR^,F)D]#5CO@G?00YW2@L?%:O"' #SZ$)1
MVMDI$J0</@/3VT3X6&]25=2Y R7Z9\$Q:W<S%>O.ET0:"APPAPMYETU_+ )#
M"/#6<OW+"%T0=8(/ LH!\0N*YJ&N'(@A9LF85]@DK5<TW4*D#&?5$!;'= ]'
M>0+7Y,&U($5ZL0XK5L2,1&ZJMX=RW"=$\M,0ZQ:AS>F@T)P5=SB_!Z*@RS=#
MN9D@ 37!OG !05<JW#JR2S&54F(%IU9PK5A849WTDY388QVX Y\^R[\V-55O
M66M3 PJS5<^(M-Y;:[4'HJ\-N#!6;5ELK#D"1:+^=*E(ZX1^-8?KC0OB_VV"
M+L,<_Z_']6/J:^=P<,4<[N&X=LO YWCMSYQ> I:8I[K>3*EYDT80HX-C \Y(
M=$9*PK7XP!V'GPV<'_\6RJ^XSPHY3+8"15<WWC@=!DC#W7J=GKQF$\M' Y+B
MJN@Q5I71R_[XPG]O_?__3:^,T[",K YB?7+Q0TW:B*V==%,Y^U"V)L>?O'J0
M]8=&&PBFON>: [)=@K4,5;5?P)/>:6>\Z5O6I>AN1D'3A:+[]-!1;KQ/6<ZP
M]-S0\[$Y7 T!L4L"N=)"0CM!EH<NGP?Y5$SNT'[+#H3S5+3QR;BCNC+R>MA/
M24U!+&(>O[C]O!PN$J..</"#%TFLV.GQH3#;3YJ.UI(5(*N;[767Y>OGZ3(L
M%<T#Q)@%BN+9H,\I-5W(ZD[M >3KU[?[R6N057 *G_6^1=.8;WRT9PUT]N8<
MSG0UVZMJ//&'%V=DZ>EUIJ$!@0G28XRX,P.>#D7W]S2:69M7Q&-K^CV6IYLY
M+S#QP!],VJ=_XQ,0[\>^A2DSUHCAOZ&(CCF<>5TLHS5$;E,?Z+$;9L0J^#9C
MG@LKKK)WN?^6HPX(9 8]J:F#4M-R[K&*6D>L7R%XE6A)M)  EA67"3R+8>,_
M*98<&TX;  ;086('8CX+P!NL)RV4.7XMHCIZ.P];@05 E/P*IME\L&H@$1J]
MYFQ@AX,)K7)S%E4JJR-O@<A-LR'9[+5J/KQ?L%-)SYA]GQ&?;-1>8MH W<R1
M?0E=[4G'Q(FXA_XX9*)8R1^J0I?<@>A[X& -D8 . W5HK9(IJ\#Z[-5Q56 7
MXN)C(O'LF&A3A)EW:%VGVCULB5?(;4JZV;@M729</3IB)GBJC1QZ]-&59)=$
M^R\Y CLS!6PG[.=IM(, GL#:<L)$IW8>>R>(EXP*YV,%KK8Q0Q1]4B&R&"]Q
M$S9 D1ESN.BNJR$.=B"0BYQ34RQ8%=)&X3:0E\[>?#]F0+:O6;5D2-)/WO;X
MJ[*REW< 6[02$ \FY"<Z36++O& [M*\V/K8,CI/(ZQMSITC#<8=+G -W[*]-
M[R#4-)22^N]<]+IGE?_J371AZMN>/T=7'M,DF/]W[/J3V_@*D>()W9QL"8@%
M/'"_3XBR K%(:.E!E@R0O9!8@BG9)B!23;%G?9I1=F0*U[+B0B&JE)?5X-G1
M1K1D=4J#8BYPS. D]U3EAY[C26'&;<*UX,=F1ODS(0_ ?/,:]#D!W$> /2 @
M<AA_7"< 8N9PEPGUQ$D "I$T<+Z"WT/9[9B^^KHN,'(_%O.= 6$,:5-"J@OB
M!)5*?@KWN\WXV:<1V<#QKH/H66S_I%C@/L/CR6B35&A7-T. O0L4A&SA5OT>
M*60\P@3=LY-5+]9K$G1W/A-6PG,XK>OIWWO.\]+H9@A!15S<J3;=[76\-*G8
M?:B]EDUYA0Z>6A\8R53=8OI*OF]LO("6::T!L8E(\98Z5*%A8,XRD&VJN^X&
M6+"\5'ZIYY/#/_4$ZA[,X1A)DW[B\"V\P-K?(0_)E-50**<[Q+24)1$WE4EE
MKJ)[8=M*1L;D+S,K:GZO;_J/$>9<U_$[KNI?FL:.E4[6SXFPY:SF]+J+ZM]/
M>$"^RLFI-OZ;]^W;V0%@E[0 #GL8);1Z!F?R8=O.4+!ZN"M-0<MQZ.J015X[
M'V8T<<$Z="I%X*..I4A0NR+IR*::/"G9 C%/1Y?KV^D+=*BI<9*FDMMBC9XZ
M!3MY9)R&0\!&!?,J<OP!''( 4_* :LJ*19#87IWQC-B;?-):FHJ9:A.5$U>P
MMW1D=,1]#6N].#^QCY?^>7S_0[),OZ6H?A!N"L"Q!\21'X'31-CI_40PM/L?
MS5W,LQ'5759A:%_)?*P2I*O\6JCI'A5B"Q91997S4)0#1 -FLIB<!02STW#
M_1- JQ#R*>9+7>+/[U?6%U";!^JXQ2+%"&45#&B68E_U#!#3*8HB3!/7.].-
MV(?@>BCE #2':TE112N[53"WE.7<QK.,K[(+6_1/"(M(&F9T\)8)B?!Z%>&J
M6T9H4F<7?C1\BS!WYX:ZIA;C%W+P'!,Q:U90$8MQS7JH8G([EC>0 $X'=R@=
MJU5 JA"G>TB)W$S>#,]T$):QDY7._%5O.L&ACL=\:2#05N*4U\;!P_PYW.(7
M3;(Q\IK>,_D=TL:$PL7@6"CC&,<1[1 I\D2?LHFP(T_WF_$$4]\SP'<B_3S0
MCUVR*F5D*QW>2,D1G1YF2IL"V#3= T$\R/L&I%Q6"6H*I%PE/TVTTGLSE-3&
M^;KH ..JL %\=&,.A_\\M>SM>/2"QW,X)JMTW^O>[<TE 4P9'MXPA=SM1)=@
MO>GT/*W='&[<$]EY&R\:A]U!I@1OH7\J2 Y^QQQRDM#K>+D"H!3[#4FD*!IQ
MX2E%J>1%+.-V&;:VO(R2[0T0_QIBH72).[9M(LO>3W4.Q$N9MK"H31;V'X=M
MK]A.T4I"VJP[OV+K+_ -_)2C*)T*>Q1T)!I/V&!B(PY;KF9 [,&AC.P%U2IJ
MF_R:AF*&XG:I3<;MMR'[NC$9-)65^*@X^DZ,Q\!B=-T &P!%JL;+Y+6P[_ZZ
MZ'@3.7Z4["QP5[W[0[,8Y]D%._,0,V--DNXR]K\QK;#CWDM1W @1K11%T&6^
M&J\>NJJLKS&%LQT)A YEJ^GI3;%]-UBZR&?P+17/EL4]V%='-+7W#0]PCHT7
MK%=56W6&@4 FXES5]F@P?)3 X/3,X1IR!O3JU_1'>$ ;-M9T-#]=!63):RB9
MZZ"7>>6_>\962"GSV'[,M!%*\E?K#N87[IW#7?,F/!PK=+DVN;&MA)M\<D'/
M"4^[3(X 2XELX PE5523@.6?AO\:8:ABMW1UT.L26IFVZ$M@"7OE0+^SBFK+
MF,-9N5UD6ZCLBNT._'[+U;6N:R$<3.\3'%4%'MCTI^VIG*O;;NVKK(RV:N3]
M(C=%Y\/O-5CC37$GK\7R:%]>TFV62"JJQ;=1LCT2'4J9\9')91]$UAS2&&#&
MMC']NWCBI[>#PV]9Z\/!OW7#]QY+-0,)>:T?PFS>&KT7P6OQ6 )H$O7;?J$M
MV+I1&'J570_Y:K(;^L[3K=A;=+\)\1[2+EO$&XX#?17IK3QKF*MLJ[/=5PQJ
M@\#RFI$- X($I=P*+ID]W]^>6BEVY5:.)1ZKJ):/%^9H*1'<P3D<NKIJ#F?L
MS?;6716=UOO7ES.: %TC>=YX^#8A'*?*2?R'QL3+]H):U1PN2^#&+/&/?5@O
M7P'[JB@MD\<Z)2-;G]6BPT_@)'5@A&_AN]FQJ2--O7.XVU-89&,B[\I&CGC>
M-T:H&3[##X?[2KZ:LZG6P:O67#J]X<9%TA<C+=9A_OB+!QXD:-U,_>9PAYE#
M#9<HM3)T*Z#XAVL)5[0 "T6*_Z [09?!'B16T25KID/T%'Y;=3%4 U&QCEO&
M<'!HMO*\:NUNG39TK+;NMU Y[<3QMRL_G?T^WYHUI#W$QXX<Q6_,W2E<J4^J
M._EN^9L!QHN@G3]</ZJ^X0&.Y/)79[14E59N^:.E:O.:*TM6SOOL,H/85FM7
MP%.:,*BA6GMDG&<EQ.RC^!OA6IA ARJD\B%"./P,,IU^!T\^_-#8U%#Z,)JS
MC"O%@W.X8)!S4Q6MKJM[#'FDUD]&' ;1HF5Q#+/A0Z>RH0#4=$1WZ2Q69^HH
MM4,49&6$VKJ=>&T.]X0_X:3:)#1!7_!J31NE!'/83_R)54OO^0L294WS,"$H
ML?:D7HNWHRQFQ4F%MN# Y6HWN<6;,4^K=)8WI2+&TR^UKBH9'SR'V\/%TO"_
M52JFUGJ:I_,X,?!)?U_P,/"'!R6:KO7!XGH.-Y8&&WU#6#TJKP&NB!29F,&<
MPTWL )D:)\@C%W'2[D2'Z,N4#3 73#@![:M0Y;@ZQ_[,S"K!,_'/*\=KA\=D
M[S+OPD6M^CU*E44ZSAPN"'+-KFZHKY!4/;\[;&>#ZK?5@9&SNKMSN%@L=D,F
M,*FUP$I7(EPW+C=FSX.&?'LX6U L5LR\US\,'VU"FQ6T#.%:AN?,E:F(^L)V
M+_ERV$M)E0 K66/4I6/6/W\0F0E"5/A%HZ'W+F0J8=D_1'0IYCJ=]P%B<\K$
M-]B91Q]VY4R_YX%!<BO]6 $J ?:,T.!U34+W)0(7[78$@/?Q3.)Y686"!A .
MD*!.S:"'E'HY<6S,]ME?E;'*80^EKBL;-6>];T\8<#2A41:/A\S^<K,W9M$;
MHRE^%@!&Z:^;1X;#*Y(4A)22I7 IF*#.+U;^Q16+ZNH(-D)'5D7[3_# P9RS
M;DQSN%8L>Y_I!-/NAX;%_$1KS*B;6@);B']^7O'\0HG-,["]5.-RX#EVG&<\
M)B>UONAKR@)*-&:*-,W0\BHU5^:!+E%#9WN4'IE8[4T/*Y*&;X0BKT[K0CJ:
MW#,C5(%G9RZ4J@(3Q.&.<+2::?I<E?W\5',?XD5(I07=2 [U&M?.X3XTJPHZ
M\%=Y"S'=5ZN6M^$S'*Q 0#RU #Z@[B"O@U.J&%:'X9@!B=E@]83G36&YH_OL
MI5[5C1$7<Q/CWW_OGR)N/7/^-[[K5.S)@B]+L.IVT VP0<[ ;5A)TA>GK!BR
M79]@)ZC6-.K*3SZ%6?&TD/J\([WO('D[-9N\L_&:='G1!:%=MJHQQ:WRX_G!
MCY/!W^8=?>)_?:+L& [1#^/1/ZA$JNN"MR1,GL,^=2WLK]W##H!O,K1FR'Q=
M6;P\*WPG;*P@6(RPG*EP)]2A\LA%-\)QRNFI:_7/M@S'VW7AX1VMHN7(R9]B
MJYFQ\3D[ONW]_-S-U-<O^QAD$L/!3L-"O2#Z$=%OAKZ<5:0AZD4_(/[J(YL!
M>H5A@3-I4PY;2RG+/@K7L>3M#H0^)C=MNHL0?62($>X\0.):\Y:R\G:#E&S$
M&B*TROI%CZ+)CJ_JM;0C"^\MN2^YCV):47SO$M"*A?.57O=%:BV===BJY;F)
MBB);=M^I$E=KYCE?FEO>1(!] /3(4RT)&)S2>_UO/3K&<+-QZ/+;NANBTU.Y
M!#  ?XU0/\,EKW[.9\?K"@76B@1XH;I2<%R=XT"?-\BFP>-@R#=0W5<P]C,P
M_0H[P+'Q]LLS)V#1-]#:UV^*<JQH=K<;2<\!L;W^)79YC?'$-)9XC&R-$*:
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M$^[#0I;QOY>_-@=B_W0<,#'UUQRN/TN7<]]H%H)$[;P4WK)IDT GE5\;+PW
M3].TV^^_&2WQ@-ZG"C;?#Q]]=S$V=;JLY-F#-R?>#A;]YM1HO:T=O AV8K7_
M*X\C>;<YK^9P.(3F6L%4$G)X2Q!Z0FE4$S=C.@"_A+T;Y&61G.V-]^><ZB-=
M_#QL?*R7.$!]['=M.,PD;N6^[Z[_YOVDBO,]MIX!%,55^A,B8DE7-5Y"MW-Z
MFO@==G@KQ!-.Y)EZ4PBM<@<6T%KH"Y_S]G_$ND>^$UD%$]HLWH[199PUHN X
MR[\%]%-64'(1.W9KB9?6#A WBAY[3*Q0<S/U QPCN6;HJ\@.BCG'" F$C0 /
M*25CQ &RRHQ4TC,UA6<\VR:K\W,4>%/ZKH>TP'O?^4>P"[-=FC([!LLNKBC%
MH;&4']QU-T4*!5Z6KKFI>XK%W&-Z?62J]UKM3K8'7 2 _VCVZ=(%2=I#4:(%
M;CYV$H_\;>/F(S''?H$'6DLV9'4> )]-776IGS*'C0Z_FB9DT,W*^J=(S!5[
M2^'379($>V-D98\B86(S%BD)_61S0!Q(4630ZPM:]2^IS+10+-DV2F8N4!-R
MB1(SZ:'&IW"(R-8!_L='TYL^NCGS'>"ACH+0A>_XIRH^.&P#IS6E#V!.Y\'^
M"?91Y1[PM$AIQR@.EH@4PTS,J2#F'9K_]/\[/S /77I2^[6,#HAW"7%(S("J
M!]FNXF'QNIILS4JGP7'ET:% &N*GI)JRF,H*K%PO8@%M'G.X9>QX)=UBK&1]
M[YDZ1O7>.LIJ5J*.9$_=D[;S_%0O#]Y2@%B(4--4_?TQQ /TR"%[H:TCCA#6
M%C?"#_"FL(6B0X*7 9IB(5RF<EYY92R9V6XE(V0 ,?;S%[,)RAYF[,G*\03K
M<RWQU?2]W=6"\>%=*W#>?'3Y6QBKM&:B'S WU#7I!9;3<ERIJ]G!KSG>;/=;
MJB=]C^K>0QZME&7L7>#Y:A-)0GE,@E5.4H77GOZ98QXU^X[<*1S9G3.[5D&$
M201TB4X-7'F1I(T8(ZRF1.&'**KP;.-,(8G3.\MOESL,P374[$3=90%TND(9
MN-1^'W'A<)2[YV3OJZASK/>MJ$O?N]>?QQ?VD;PR_VKZBG,!$'=SEF$%0_XF
M!5W<J""DT9<+@D',YJ6@+BP[B<-\.$#=W#GLUPXL8UN7LK> 9S%?ELYQ%?0*
MJ&K&$&\%3-QWI4L2.G0"EK11=:7E;^] RVMNQU@3AD_A #L>&(U5VFP 'T^%
MMQ@C%@DJZUP2UHOQNA0@:MA# BPC)8U..68'AD6T$VPY#O",?[?+%/_LRQ2E
MEXZI>%>@TEE++BQX<YP1O@F*_[)N*KB$QK_.^3]Y">$V5G6B@+\WB\!S!;IB
M!)CMIC<$7DQ'[#K4!#PJIH,A?-CY/6(!J/O+& IFIMQ*N"TZG *;L0.]/;WI
M*SXS%[)J58_J(QBW1V*F%KYKKF;]HRQHTS]3[0NF73>A7KRHU#FWA71W;,@O
M^ [WI1E=[H+](]9L3&5<2>9(.6ZZ<HJBQ(-GABYB;^@34,'&%D)]^L3?3FT4
M!UBMY'(%&^/5=C8<.Y;&4G_EI5;ZB<47S^$LYW!*FT9:F)_4-N?&&SC_XS^[
M'.P# F.ZI/(W,XAY GKDE'X:S!RN%J?#$F:ZF+-Z +,(B/V@]BA[J[XI+ZB
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M)FKX<')EC*SB\E]]CG \Y"&V_8R:P<7@;%BL2VF_A61D39;))'DFL+?_Y>L
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MW'NS.S\N;@ZW>.9:?.17;:KL'SVS!M]^^6%3N(S9,_9__;Z) 0,&#!@P8,"
M 0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"
M 0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"  0,&#!@P8,"
M 0,&#!@P\+^+T=S@_P)02P$"% ,4    " #,.UE:U1S?IMTP!@ :[$0 $0
M            @ $     8F5A;2TR,#(T,3(S,2YH=&U02P$"% ,4    " #,
M.UE:8.(RSZI1 @ 2#B0 $0              @ $,,08 8F5A;2TR,#(T,3(S
M,2YX<V102P$"% ,4    " #,.UE:[_(_GR@R  "EH@$ $
M@ 'E@@@ 8F5A;2UE>#$P7S$X+FAT;5!+ 0(4 Q0    ( ,P[65IS^+8(%QL
M -P6 0 0              "  3NU" !B96%M+65X,3!?-#(N:'1M4$L! A0#
M%     @ S#M96ITQTP17-0  ZZ<!  \              ( !@- ( &)E86TM
M97@Q.5\Q+FAT;5!+ 0(4 Q0    ( ,P[65JX*S:A50,  !40   /
M      "  00&"0!B96%M+65X,C-?,2YH=&U02P$"% ,4    " #,.UE:SE[[
MZL,)  !$=@  #P              @ &&"0D 8F5A;2UE>#,Q7S$N:'1M4$L!
M A0#%     @ S#M96@D.;S6I"0  >7D   \              ( !=A,) &)E
M86TM97@S,5\R+FAT;5!+ 0(4 Q0    ( ,P[65K!U$+;-@4  +@D   /
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-  P Y@(  #D[$@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>beam-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:beam="http://beamtx.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="beam-20241231.xsd" xlink:type="simple"/>
    <context id="C_800475ef-859c-4969-8401-92e0526a5add">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_80db0869-90aa-4f87-a32a-529c3993d14c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_81012567-268b-4289-94b6-e8719b8246c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_813182af-346c-4681-a9ad-91dbab4005fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_814c73a2-13c5-4097-a2c8-bac30dd2d509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_817c79ea-b465-4bb1-8354-36977c68b051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_81c512a2-b46f-4d8c-9387-3f1e58834fa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_82c07a0b-8c7a-44a6-b246-a5568dfbfc60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_82d42227-3e5c-4f52-9372-708bac5614fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_82e2a9c0-7247-45b0-b901-8dec8be826ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8344d4f6-8b07-419a-b031-0646b3b208b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_836d03ea-dc4b-4efb-b811-4ce1b53f71f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_846e5021-b00e-430e-b479-dfc4350907cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_85f101d5-687c-4b48-a5aa-3771ed3f1761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_87adf2d6-df78-4402-8dd8-a6be3d79324e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87b2a2c4-113b-4df3-b4a2-5e89a5c1ea98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_886c80e8-4054-44c9-a88c-53a8d43b6e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a19511f-2844-4f6d-b5ed-8ff465336cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b3ff14f-8fb9-421a-a317-71af6ec52baa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">beam:CommencementOfFirstPhaseOfLeaseInOctoberTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f22ed6f-66b3-48a8-b7b5-ae4b554749dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f838b8f-003d-4c56-9981-96bf4aa3558f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_8fffa0c5-ef26-4f15-a702-c749a8609fd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9064c4c3-29b7-480d-8518-b5181173d660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_91314f01-9991-4b7a-bf23-848ddb837575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_93ba963b-981f-49c9-a3d3-fb183f09f550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_93edf44d-3df4-4991-a2e7-7db1fdea70fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_943bbfdd-15ab-44cf-894a-0a745768d5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_946d0d92-ab51-4d13-aa91-deb5bafa88d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_946fe569-b5da-4993-a5e7-d60b0d8a7441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_95f6702d-f704-4654-9cb9-17cb2a30898f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beam:AssignedToCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">beam:UponParticipationElectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_968b0854-5a99-4bae-a667-e1e1a12f2c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_96d19294-dd72-40a8-a259-c7e1d6e2f357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_979dd123-9531-40b9-b541-eec96ea77e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_97a94644-ff61-46cd-95e9-1614d5a9b854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98297106-5ba9-49e4-9046-f4505117edac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_987488ec-2b63-4e33-9f1f-663eb101d201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_98e22f9d-79ae-43bd-8044-17f44f41029a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98e29b92-f652-4c61-b122-e4d83608d91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9943b4f2-89ba-4814-ad32-f267e31916f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_99cb6cd9-808d-43eb-9961-10066106286f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a16ff51-e500-41df-8c2c-d24921af54f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b047b26-6d29-4529-a19f-49dec29b0738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9b3ddcbc-bcaa-4620-bd37-18182d7ee2a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9bd424a3-b990-4948-a990-a2d46eaf923c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:ProductDevelopmentAndRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c33e7b3-8a93-4aa9-a157-7bb70a697ac5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9d139695-ac25-4472-b259-92e6538cbf05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e0b9b06-588c-4f43-8b01-cd02f7537d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:SuccessPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9e71c9b4-c135-4fae-b90c-ed325df0b8f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e824cf6-96ad-482c-938b-89bcefc2519a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9eb93719-d476-49d6-a58e-2223125d2c02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9f2e893f-35a5-44f6-bf6e-ed53809acd18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2025-02-18</instant>
        </period>
    </context>
    <context id="C_a1582983-8e90-4aba-91dc-4e54d1f21245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a2d5f9fc-a682-42df-9b5c-99526ad1bc2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a3572b5b-a007-4ae4-b166-33e00788180a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a46bf662-b041-4823-abd8-67f3900593df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_a4d1b346-89bb-46d5-943f-3575e89e7f76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a65535bf-d336-4fc3-a256-1c5e23cda5be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a6a0e0af-be42-49df-9199-a22238777a85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a88c5e15-481f-445a-947c-2cb1d21faaee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_a9e94ca6-e934-4ab8-aeb5-8d4b40f267a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa7b8d00-54cd-467a-afdf-694a607825bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ab0bc947-ab71-4f35-bc58-9f7f62090216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ab2d17df-4178-483f-b1be-0b511648abbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ab6a3226-270a-448c-aa4a-011574bd549f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ad3ad482-636a-4574-9008-c4bfd3d86594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ad5b92a4-0e86-485f-829d-78650bd85771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ae43c909-7d70-442f-bc98-6a2f16383942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_af7898ba-b7e3-42e1-92b5-062444fe5f45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">beam:ScientificConsultingAndOtherExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:FounderShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b047b3c6-6f6d-40d7-952c-100389cfdae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b0b3e437-b9b5-409d-a425-2ab1467d81a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b17f1931-4673-4c3e-986b-af325cf85498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1a1acf3-c64f-4967-b7e4-958c7a788e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b377391a-9d98-4bd0-8cd9-4b1adecb8106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3cae63a-1abc-4394-a9ad-0e685d5f41a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b519bc91-9533-4dcb-a39c-d95a0025a438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b772f99d-0bbb-4fb9-9d12-6cd094a0084e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b83b237b-6d18-4327-8bbc-c9cdb6104ded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b942b8ee-cafd-4a43-b778-957590c7d5a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b9f60852-435f-4678-a85f-62bd679a4179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ba54c365-7b5b-490a-a13d-b7f791f97e43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc22551d-700b-4bc6-97af-b994c3ba0a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc54d5fa-e469-4984-8576-7bcd6d681ec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bcb6c93c-f14e-4acc-a009-3920a219ed08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bef248b2-037e-41dd-b7a6-9d8e777e673c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf27e455-b39d-4609-980a-18b8f5630e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfa4765e-7ba8-440e-948f-ab1010661413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c0afc77b-a8b0-40be-ba4a-78a824b97e4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c2169fb1-18be-4514-9888-865d6522b536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c2e860ef-951c-4824-addf-069a1f368442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_c448f064-efee-4973-8a00-ca00db426a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_c4d3bfe7-33e4-4541-9d0a-0c3653425814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c6a74e2e-8d45-4ca0-9483-c5961f7d2166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c6e8ae6e-253b-496d-b53a-66bdfb253362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c8171dae-98d5-431f-8a83-4520d464b7e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ca386094-8a4e-4c31-bbb9-c0a598866d8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cad5e1f8-39af-4380-a00d-766ccfd05763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cc9a65a2-a296-4a7c-ad5a-f2a43865bbed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_ccd6d443-83ef-4b86-af01-1073799931eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce201eb2-a040-4b8c-828b-f421220ff5bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ceb22f03-41f2-470f-b6af-1fe085c96885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf066df4-fc9e-41d6-925d-5f1920357b78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cf2ed59c-a2d6-4c18-ba5c-2809399c54d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cf6c0d45-c719-46d3-96bf-bf86ff65ea9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf84f853-64e7-4f6f-a1df-e90a15485b3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_cfa419f9-1c34-4353-b182-40b224d5ecee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cfbe57c7-0589-40d9-95a3-4e571ea9c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2b86f6d-7df8-4851-bf8a-c817cab8b129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d2eb4314-6249-4e88-ab61-d2f3989cba46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d318bed9-9799-44fd-bb35-943b44e05e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d4874037-4abb-4593-9198-ea79ea979323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_d499c8ac-d8df-400b-8755-7d20c1c148c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d5f96b32-a698-4369-8181-0a106fbfb45a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d654daf4-dddc-4c8c-bf67-b1fb10abf6ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d81129aa-e4b3-4b3a-b639-c6b46fd97eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d996319a-4fd9-4406-ad76-885120f0800c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d99e5c1a-0015-40a1-bf03-09c293ead256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d9c08767-4f6e-47cc-be86-e673973ca8ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_db09f235-a08f-4af4-a99c-599807b457f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:OtherPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_db910110-c7b9-47bd-9b00-ef30f2e39bbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beam:FormerStockholdersAndOptionholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">beam:GuideTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-23</instant>
        </period>
    </context>
    <context id="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_dc200094-3ff1-4578-a977-4d4a2356f15b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dd66f54e-6ff6-4a57-b80d-1a794bfab97f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_de039678-b07d-4465-a92c-33cf16c0096f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e09975e5-fe39-42ca-9dd2-53a5844a5478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e09cf5f9-77a3-4eb4-b400-584b976cf70e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e0cca600-4621-432f-b776-908bc8bb5ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e0ec3d1c-7bc1-435c-aba5-b5b2222df11e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e1810127-cbd6-4854-8acf-9b9986eb6b42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1d74f31-840b-44fe-a432-c3e0d8792431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">beam:ResearchPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-07-19</endDate>
        </period>
    </context>
    <context id="C_e23b6999-779a-4b5c-abb4-d337cb7a4896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e2c7432a-a6e2-4466-b4d0-b448e1cd2b34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e2d79338-1ac4-4b79-83d8-f195b051536a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_e2e2c4ed-f4d9-44d7-bdf2-3812900f3384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e38cf897-c702-4909-b484-fcd5d6b3590c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e3e53934-eb8b-4bda-9434-0a170bb66af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_e41e2e9a-3d40-4c73-9a6a-0d57206be6a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5221100-f194-45c9-83f5-e78d6eb47872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e52f1520-daf9-498e-8105-a8484d3187d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e5a0c25d-1ed8-41b2-b186-af6d43e40731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e64b5f77-b749-4105-a5c5-6201bccd7330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e708f03e-b5c8-4b4c-851b-c790a40ee844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e772a7bb-81e7-41e0-b75e-c792428e3114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e772ddd5-a271-42f1-b38d-0e1d6248021c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e78edfaa-86d2-4b56-8b7f-1698cc8559cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e86d3ec5-e144-44e9-8637-dc263422e9d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_e8a4929a-82aa-4502-9781-741961c7ae2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e8dda33f-8c82-42ac-b988-c7074b08349c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e9cd4ea8-3457-4c9a-9f89-0bc504f1aa04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ea4d3092-a838-4e9e-9f43-dfd61bbd3ac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eaa2ddbc-9a2b-4667-a992-ede8aed104d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_eb90fc29-55a2-424a-aaa9-70b942a8d848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ebd07b65-49d7-49db-9728-c7dfc9f5943d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eda2e163-7061-4ef9-bdb3-990396f121b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_ede17f6b-07f6-4cb0-8a64-18644baafbc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandSeventeenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_ee6bd22e-01c2-4e00-93f7-c74415f012a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee6f8e30-6665-4a51-9ae1-dad612ace074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee767960-3dae-4bd8-8d2c-8f119f919035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eecadce7-cffa-42a7-a808-35c5ac47a667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_ef0903ad-79ab-4cc9-8a92-a1067bb62252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ef90c8a2-4431-4529-a22a-71ad29ed2842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_f0410223-d81d-47a5-95ac-2348253d72de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f086de51-1e25-47ba-abfb-108a2b30d5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f0a9d4a5-df6e-4595-9abe-cec53ac89acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f1109e54-6e94-4d48-a4a5-64a3507c850d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f14e16da-1c53-4541-9a52-16820f10bad3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f24310ad-daa3-4d84-88fe-4f5f29e1c62b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f2642d59-f792-41fa-8608-056dec1837ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f3b3e1c3-33ab-45c8-9774-7e07c887e615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f4879e76-4b06-44ba-bf62-86e70abf1d54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f4b1ef06-ec54-4fed-af05-d4a7050c16b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f605087d-584c-49ce-a137-7ec63bdd3243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f6e9e1b7-0f7e-4ca5-8405-404a9168b722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f70341dc-ca94-4cc2-9501-827588f59d28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f74446ed-1db8-4037-8b3c-5b97e15acbc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2024-07-19</instant>
        </period>
    </context>
    <context id="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f791e745-de9c-42ed-8a7a-14e39c2a105f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f7d01556-0db0-4405-b94b-9d3f9b6e51a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f8810dbf-4f3c-4f86-9ff9-d0d332a94fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f89f6da8-621e-4376-b358-73a07809ea70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f8bffd7e-bec1-4a21-84c9-e2e5a56dbf98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f91cd450-b36e-4a10-b341-9cb4a003d5a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb510e5f-fbb4-4322-a22a-8b7179089277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fb6723fb-3691-4707-acfb-4ac88805b04b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fc0f5107-4297-4f5b-b705-3f7c3b7a3888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fd96341a-93d5-40cd-b881-5aa499e5c784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff00880d-6565-4225-b41c-28e680e96f39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_01b2a6c8-36f9-4f72-bd42-832c0a6e6c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0246c702-b123-4f5d-b939-4edd1eea0949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-10</startDate>
            <endDate>2021-06-10</endDate>
        </period>
    </context>
    <context id="C_033b016b-6895-4539-b361-157a3608f06c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0345315c-39e6-4913-8fb3-95c4a3fb15d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_03458b68-88f0-4f4c-835b-84b7c3df3693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_034a8b22-6f57-47e9-bcaf-d420a86c3ac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:ProductDevelopmentAndRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0515efd6-8f8f-400e-9505-a0e0559e9790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_051ea08a-43d3-423d-856c-04c479177819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_07957533-1268-4b9e-a1dc-14b0a90775cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_083cb9d5-4b38-4882-b265-50928e148535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0a6ecb33-4df6-4c5e-a4a2-fb3d9efdf7cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0b1904af-7fc2-4128-b51e-282e6a1495b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b791370-9688-483b-9d3b-52cc2807c2c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0bc8b385-01b6-4b97-b455-c669606db4c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0c39d71b-489e-44e9-a246-f57bf060b04f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0dda2cef-a73d-4c05-8098-6cd82221208a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0e6053bb-b35e-475a-bcae-f92658e7661a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e6c1574-d290-4081-9ab2-1ea6ba4e8324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0ee731d4-613b-4c17-be22-2735e8f23bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0faad1e3-a733-4640-bd7e-1ccdf04dcbda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1032047d-f16a-438d-95bb-df888c1ca808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_10b0f522-be77-400a-bec4-a92278231be3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12936f08-d240-4e4b-9e13-6dc84a43dbce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1320b092-7bb5-4608-a1f8-382e3ea5a98a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_13901643-aa76-4301-bdf7-ba774fec2028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_13e504bd-d42c-4cb7-9480-fe49e29deb03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_141a0bab-6778-428c-9b18-6212d89a1a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_149701ae-170a-49a0-bd98-e2e011d76e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_15adaf12-5523-4f2f-ab23-7a53126734cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_17281164-6360-4131-bbca-c983bf53650c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:PrimeMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_17ab1823-a6d7-4de6-8f1b-d8443d01ce0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_18b725ca-8307-4b02-bf86-cd5bacd75fe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1915376c-4402-4696-8764-c838f2eb80a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_199c64fb-9ab2-4c44-aa73-4ccf1cc07ee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_19c18905-de30-4069-8f57-7d6b0794deab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1a4862fd-f679-425c-8077-3914a663d90a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">beam:CommencementOfSecondPhaseOfLeaseInJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_1ab7b8fc-388e-483b-a455-4d344bf26d3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1bb5d16d-4da2-4d42-b325-fdfab05f797f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1df55ac6-9859-4cab-9d1d-717a8ccaca01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1e89bb30-0a11-458c-b317-6b5ebf170463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">beam:AmySimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1f14ed46-687f-4e31-ac5e-c38d1b43d86f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1f91b334-6d1a-442e-9b9d-4fc20bb74482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_2003a022-90cd-4bc2-bf5e-3e183c02ed3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21a59809-dfb3-4b7d-8868-958dd1e18924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_21ed1982-a773-41b3-9848-3a746c980eb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_22bf2ac7-5934-477b-9c81-096c75b0a449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_231917f7-78a3-4fef-87ae-dc90b41b4c08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2319aab4-a1e3-430e-8e4d-7cceabb77d5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_23ce121e-638f-43db-86dc-7ed74a544114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_23df4ae1-062b-4bd7-b3e6-9c50a1bd7d4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_23fc252d-db0b-4f39-ab2b-7b17b577a703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_244af9b5-ee40-4af4-8025-4f3676ba9ad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_257027f1-7dcd-416a-869c-74ce3e11938f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_25de5467-3e1a-4a4d-82d0-cb68b684e458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26e65229-9380-4e02-a80b-356c8953d6fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">beam:AmySimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2c909485-c763-4bfd-87a0-49786aefa4fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e4a2701-d32c-4f02-930f-f0d27e58173d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2f5b4752-7d3c-4f25-abd8-17c95208595a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3019e88f-46c3-46a0-aaa1-f470bb587e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_30808f53-fe50-4e76-b73c-7f5690993b05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:EditasLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_30db48d9-fd35-4524-9f25-e5f0967f30bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:SanaBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_30e95c96-73e5-48eb-9598-acd156ccfd5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beam:FromTwoThousandSeventeenPlanSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_3112c485-fa21-4803-9cf3-c428e7cc148a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31375b14-847b-4dfc-8fc0-3d961e512723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_324afbe2-466a-44bf-954d-9a90de220b99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3323b4d1-71fb-4439-a445-cda91d3bdbde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_33491d05-f4b0-41eb-b082-0966c1c67aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:JeffriesLlcSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_34071179-b962-4e08-81ba-677a509604da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_349daa7a-ee95-4e81-a366-8d8ce431c2f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3565eb40-7e5d-4491-b679-204f6e71151e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_36b8ac53-6fab-4279-8285-1a0366571ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">beam:ExploitationLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_383b09a9-52f2-47a2-9a87-2d0c4207c081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_388bb271-1237-4e73-bb59-50ed985c9182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_389b0c5f-dbe8-49a8-ab15-9087170a4b41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beam:VerveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3ab34109-c504-4c2d-b824-f10aa01d2eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3ac29eac-6794-4f6c-aaeb-4e2937541c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_3af7bef2-d1fd-4b29-805f-7afc562dc297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3b9e7d95-7542-4a96-be2f-5ddf5efc044b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3fe5e002-e81f-4070-850c-d91b8489178b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">beam:NonCashStockBasedCompensationExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_40bf49b4-00ca-4786-9c26-7a8dce5bfd9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4199c4a6-3fa7-41c4-9f65-6bba20a54792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4229e173-9015-4f39-94ef-b11fa932f35a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_43329f90-70ad-4d83-9eb9-e3326b1f696b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:SalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-07-19</endDate>
        </period>
    </context>
    <context id="C_43ad7076-7bc9-411a-b3ab-a6ecbc89e42b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_43ded48b-9f05-4004-ac86-baa2f80a25b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4560ba19-2a2b-4005-ab3c-d11d72951668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46319399-2d12-411d-8c34-596d176648f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_46b2d578-5aad-4081-994e-51251d5c3c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4768fad0-596a-43bc-a633-4ba916d5e2bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:ApellisPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_480875b2-e64b-432b-b458-b70c8350f511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_48270b1e-53eb-4dbc-9160-a5e56e9c41e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_48e046f4-2f13-45b1-996e-dc68dffe5446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4b443d77-d326-4c74-b2e0-a91039c22fd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4c1fa6f3-850d-46e4-b180-0fdb4f170121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4caac963-d273-445d-aea2-8c8e7d840dbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4d433f10-5951-4793-a073-4cde03a41826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:OtherPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4e0928f3-a41c-46c8-adbf-38ad87f13f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f1eba65-fbc3-49e1-9877-736765296cdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4f5d5cc2-830f-4657-be05-fa7964276c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_50e72256-3be3-432c-b4b0-8c3fd8054073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_51719419-8be3-40d6-b822-aac6d564e3b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_525cf13e-fad6-4e2f-9c9e-48ad51403c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52f693f7-a425-4188-9db1-a96f66ed8a57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53ff89ee-a53c-493c-897d-5a1e22a591f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_55e6ef57-9f81-41ee-995e-bf71d1163777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_55ec542c-c4d2-4393-9e6b-a19e465465aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_56abebc6-1481-4c6b-a7b2-1ce074ebc051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5770c0c0-0283-4886-822d-4ead5360cae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:ExternalGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5857fee8-666a-476e-977c-4c0b45614d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_586c5528-76ab-4467-958c-e7217226efd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:VerveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_5a05ec5d-cf56-49cb-b84e-2b325f31bc00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beam:AssignedToPfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">beam:UponParticipationElectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5bc0c4e6-20ab-442d-9c3e-39c7a8ea82c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5bf0ef81-7ab5-4b17-86bb-38c4a75f4dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ca56256-2128-4152-ba15-ce38a36b87a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">beam:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d64756d-a5a5-4436-8aa5-135287bdbf64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">beam:CorporateEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5d6e5236-b729-4f30-be75-4efef352181c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f5bdd0f-e177-4378-a5c9-df51ce96de8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_5faf1e6f-7db9-44a9-9e75-3c1cdc11b9ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beam:FormerStockholdersAndOptionholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">beam:GuideTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-23</instant>
        </period>
    </context>
    <context id="C_6026a8e0-6d93-4439-a24e-e03c582cd8c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_610ac957-5c8d-4898-bdab-ead2ab364037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_614fab24-9c40-4e21-a14b-7243d9e14888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">beam:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_623147d8-2cfc-43d4-ad7a-4b423fda8bc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6268b7c6-50cc-4b67-b26d-5fcdb3082e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-10</startDate>
            <endDate>2021-06-10</endDate>
        </period>
    </context>
    <context id="C_640fc477-4635-473c-bec3-329a0998059a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:SuccessPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_64b520ff-9453-43d5-8018-62b50616536e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_66014777-6584-477d-9aa8-ffa7abbe1249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6605f422-e078-49c1-bb32-3b2f67d8c39b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_66656a01-1fea-46c0-875c-123162651c9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6694c047-b444-4cf8-931a-d5e47d7fa960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_683f1b33-2bd8-4061-9079-5d7ad5b7fa98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ac8ef0e-3351-4f21-bad5-60d55bade8c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ae048e6-a4cd-4f07-9ad4-aadfd8ecf040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6c230fe6-3e37-42ee-94d5-d6260b72323d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">beam:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6e43c27e-aca0-44b5-b3bb-27130f064fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ef5f0dc-2479-4c31-82d9-09b202c6d219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_7171d6c3-3dec-4790-a576-1812c763d4fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">beam:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_72946174-54ef-42ee-b20d-174ccb0133a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_75673cb0-aa17-46e5-a5b8-9bf245874d0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-07-19</endDate>
        </period>
    </context>
    <context id="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beam:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ac0159f-2dc4-4afb-bc22-e46e6ac8813f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7b3060c0-eaf2-45d0-a198-e1f21e52d13b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7bde4f21-b869-4f23-b886-c0c6dfff5351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">beam:OrbitalTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_7d2ef810-7ee1-4ead-9635-e33269a8e377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7d97cc6a-a7a9-4cdc-bdd8-2d91dd596f4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">beam:ContingentConsiderationOfTechnologyLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e7cb18e-69e1-417d-807d-8ec7e9b03e54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7e896a77-237e-4692-a24d-3c3b46d3a2db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">beam:SuccessPaymentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">beam:MeasurementInputFairValueOfCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ed33382-7533-4a0f-94fc-b6c4d06ac455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7fbcfe71-e126-4c16-a2f8-6d4074f3e339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">beam:PerProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7ff6fe20-72a4-4903-950c-bd6bf0d3b3c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ff8794b-8499-4caa-8e54-fbac240792c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ffb90b6-e3c3-4094-a911-c196df383847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001745999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">beam:LillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Option">
        <measure>beam:Option</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Positions">
        <measure>beam:Positions</measure>
    </unit>
    <unit id="U_Segment">
        <measure>beam:Segment</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Founder">
        <measure>beam:Founder</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4b150673-d530-4e27-b32e-c308166d6f5f">0001745999</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_44bbdf39-75b0-4e2d-91b6-bc6f8fafd314">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_ec6c3e71-0f51-488b-b6fd-efcdd79ede09">FY</dei:DocumentFiscalPeriodFocus>
    <ecd:TrdArrDuration
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_662b40b3-87ec-4a96-b46f-86be6e3fcabb">P419D</ecd:TrdArrDuration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      id="F_e956a4ad-eb1c-418b-a3ab-90753a35728e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      id="F_551a0859-97e0-4c44-b2cf-761c527698d6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      id="F_42995f5e-5cf3-4580-bb7b-2701972eab60"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      id="F_7662523a-3bfe-403c-87db-b8b2c549a337"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0794c34f-35e0-41b4-bece-9a3a0619ac97">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      id="F_28208d39-9753-4125-b201-de2b195f562d">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      id="F_4ef95e1d-df40-47c3-9777-21876464c49e">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_b9f60852-435f-4678-a85f-62bd679a4179"
      id="F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      id="F_f812e6fe-6a44-4c16-bfa9-574585f77a74">http://fasb.org/us-gaap/2024#OperatingExpenses</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_b17f1931-4673-4c3e-986b-af325cf85498"
      id="F_f65e9bb1-b2e1-469e-be73-4e76142cee9f">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      id="F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      id="F_892f3c97-c2f0-430b-9466-4813ae1bf322"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_3745d23f-5fb4-4f44-b19b-06bb7321b4f1">http://beamtx.com/20241231#JohnEvansChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_c09ed080-95c6-42cb-9d05-3689f0ee40cc"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_db2bac11-48f9-4a6a-b941-8a8d70caf457"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_2bf1014e-0ccd-404d-af29-1b34384a4999">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_dc0c8dc2-d2f4-4592-a141-e5bc70eda85c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_af5f6e3b-5fcc-44c7-8a18-95bc8aa01905">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_1a331820-0ed8-4009-912b-83e88eed5749">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_dcd4091d-2ee6-438f-b93a-6b83815b6882">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_e0c4486f-1a08-43b3-83ba-0a3e0968f615">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_fb595051-7e28-4082-9764-32fd53d11e9d">001-39208</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d2249088-7d96-4298-ab5d-cecdef2c7175">Beam Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c1be5f43-9637-416a-888d-c7cdc0913e6e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5c5fb062-c857-472e-a850-274cce8e8f82">81-5238376</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_dd1594c9-8705-4036-a9c4-3c1497b7f7d5">238 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0c94fcdc-f249-4e26-9196-4d11b4cb24ae">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_1cc19067-329e-4c07-8d08-9d0fde1c4b5d">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5dbe5a2d-7142-42bf-be11-1488ca9df89b">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d0f13101-8a61-4af1-9689-ebfc71c73264">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4383e8f0-c008-4f3d-9fa1-88081209b664">327-8775 </dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_f9cd247e-055e-49c5-a1dd-8e4815e51956">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_58797ef7-100d-4ff6-9256-32dd64af3b99">BEAM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_db5cc30b-8ff7-4d24-91a9-5a11f29f98b0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9c694744-4e82-48ab-ab6f-122ae9594188">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_008ce1bb-5ffe-466b-b8bf-1abf42f52cd4">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_2961eba2-08be-4739-93c1-14c106786635">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5e5475a9-5e97-4b26-a332-40ab8a3b8b3d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_197e4bc3-dbce-41e2-b3b7-56c3534f5392">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d6dc1941-ff23-4c05-9275-df4e2787bcab">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_7d8f11b2-2d21-41b6-8aa1-8404c856f977">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c0733452-49a2-4c17-b1e6-7999f409b7b3">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9f4f43ad-3593-41bf-bcdb-b0669a3fe98d">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_a5ce4298-aef2-4dcc-baa2-c685638e0348">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_5f5bdd0f-e177-4378-a5c9-df51ce96de8d"
      decimals="-7"
      id="F_880c4ec0-a841-4ab9-a922-c44b20b165ad"
      unitRef="U_USD">1910000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9f2e893f-35a5-44f6-bf6e-ed53809acd18"
      decimals="INF"
      id="F_4f10a84d-89a4-4dc2-a854-195b1eff52a7"
      unitRef="U_shares">83688295</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4b953154-a017-4a67-bc4f-cead06c830cd">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Registrant incorporates by reference into Part III (Items 10, 11, 12, 13 and 14) of this Annual Report on Form 10-K portions of the Registrant&#x2019;s definitive Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_6d1e348d-9173-4aaf-9d04-f86b3ea67cf6">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have certain processes for assessing, identifying and managing cybersecurity risks, which are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;built&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program/information technology function and are designed to help protect our information assets and operations from internal and external cyber threats&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and enhance our practices. We engage certain external parties, including consultants, independent privacy assessors, computer security firms and risk management, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. We consider the internal risk &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;oversight&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; programs of third-party service providers before &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engaging&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; them in order to help protect our company from any related vulnerabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on an assessment using these processes, we do not believe that there are currently any risks from known cybersecurity threats that are reasonably likely to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affect&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; our company or our business strategy, results of operations or financial condition. For additional information, please see the risk factor titled &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.&#x201d; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;under Item 1A., &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk factors&#x2014;General risk factors, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President of Information Security&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, IS&#x2019;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_cb1990c6-962e-41c2-97e8-4e3521f28aae">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have certain processes for assessing, identifying and managing cybersecurity risks, which are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;built&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program/information technology function and are designed to help protect our information assets and operations from internal and external cyber threats&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_51daa59f-1973-4980-a05c-eba86256dc3e">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_68b1c07a-a225-49f9-961f-c400f5d959ce">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_12856b45-07ac-4900-8750-2481f0847104">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4c7acb74-b32f-42ca-abad-00b5eb744940">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_e5446588-ed38-4665-bd76-e3e60d00927e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_6bd386b1-2c59-4378-8b6a-a1e940470a34">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our board of directors provides direct oversight over cybersecurity risk, and provides updates to the board of directors regarding such oversight.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c647664f-b69f-421c-aa96-4553891e8eda">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee receives updates quarterly from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_444e78b5-3c42-4df6-a59b-e5b95a4d306a">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0fe47729-942b-451b-b2a7-e3526c58ff4b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President of Information Security&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, IS&#x2019;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0cadbfb1-3016-4d18-b02c-3047e1dd7536">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Vice President of Information Security&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the VP, IS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees and third-party service providers to address cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d96ade00-0b44-4736-93bf-d5b6372b5ed1">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9febebb2-0e2c-47a1-8301-e9246f76baee">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, IS&#x2019;s cybersecurity training includes 25 years of experience building and maintaining cybersecurity programs, and he obtained his certified information systems security professional, or CISSP, certification from the International Information System Security Certification Consortium, or ISC2, and his Cybersecurity and Infrastructure Security Agency, or CISA, certification from ISACA.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5ed948e5-23af-4c3a-9d56-dc35e6d6a310">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educate employees on the importance of reporting all incidents immediately.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_13e504bd-d42c-4cb7-9480-fe49e29deb03"
      id="F_934830b7-5d2f-4bbf-b483-060e4eb77ef0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Director and Officer Trading Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table describes for the quarterly period ended December 31, 2024 each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a &#x201c;Rule 10b5-1 trading arrangement,&#x201d; or (2) a &#x201c;non-Rule 10b5-1 trading arrangement&#x201d; (as defined in Item 408(c) of Regulation S-K):&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:1.204%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:10.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:11.998%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:25.295%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:12.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:26.875%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(Title)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action Taken &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(Date of Action)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nature of Trading Arrangement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Duration of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Number of Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amy Simon&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chief Medical Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;November 7, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_662b40b3-87ec-4a96-b46f-86be6e3fcabb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204,956&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_ea2f458a-6690-4c11-a365-e99f8875a3b3">Amy Simon</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_4f21b7c3-6c16-4160-b117-cc10b57f19e2">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_c4deaf70-8e35-4799-8c79-c8e9e5e2fb6d">November 7, 2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_64ea169c-6037-425e-9b93-0ceadf8bc389">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate
      contextRef="C_2816b8cb-0c9b-4de8-a4b2-7b9dd6b87d8f"
      id="F_69fe99c8-160a-4a2e-af0c-aa487cf6b9be">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_1e89bb30-0a11-458c-b317-6b5ebf170463"
      decimals="INF"
      id="F_41427ba0-0518-415b-bdc6-7c2b7d24129b"
      unitRef="U_shares">204956</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorFirmId
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_7e4cfc03-d7f9-4b1d-95e2-539397469fdf">34</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d39d7afa-dcde-474b-bf6f-0f267f6daab1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Beam Therapeutics Inc. and subsidiaries (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and other comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control &#x2014; Integrated Framework (2013)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2025, expressed an unqualified opinion on the Company's internal control over financial reporting.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_a1fe2d09-dade-4069-9c68-94ef81762473">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_cb300023-04d4-4646-b0dd-c7ad73d35713">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_b3190044-c871-4054-9fe7-2bbbe980ccae"
      unitRef="U_USD">281967000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_983b3200-bba3-4b02-8884-235486765a52"
      unitRef="U_USD">435895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_7f57c6bf-9d2a-46ba-832d-5100ccacb22d"
      unitRef="U_USD">568773000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_d075d208-1bcb-45be-ad14-9937f2d0ef45"
      unitRef="U_USD">753981000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_457488d9-3d21-4bbe-ae43-5dc8d4c5952b"
      unitRef="U_USD">27409000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_38fe91a6-82a5-4a00-bc3d-5293be6aab4d"
      unitRef="U_USD">21167000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_b7ae7aae-4986-41fd-839d-b0d363f0f18c"
      unitRef="U_USD">878149000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_0e2e24bf-879f-4319-90c4-f1a5ffc9e02d"
      unitRef="U_USD">1211043000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_745ecb83-88bf-4b19-883a-d198c91479d3"
      unitRef="U_USD">111412000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_0a6e7e23-c59b-4d0d-aad7-de6bb6ddd414"
      unitRef="U_USD">124960000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_906f61c5-9fb6-4046-a70f-66291e9c78f8"
      unitRef="U_USD">8144000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_59cb8b4c-dd91-4ae3-ab2f-dfbb6b74a7b6"
      unitRef="U_USD">8719000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_dad4d5da-f7b7-40aa-a47f-7513ba68d7d8"
      unitRef="U_USD">104865000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_68441e87-c67c-4ba3-b119-b6fc1148e602"
      unitRef="U_USD">112846000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_23b8732c-26a6-40cf-b5aa-3ea04ff1fa61"
      unitRef="U_USD">1254000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_bc611d42-9a1d-4bde-9636-c7fda1228fd4"
      unitRef="U_USD">2146000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_bcd78204-2dd7-412d-9883-7a0f754e953c"
      unitRef="U_USD">1103824000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_9a7f4d83-f9ce-4148-b139-ae9edffbab31"
      unitRef="U_USD">1459714000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_072cc25b-a603-45ca-afd9-2d3d8812e506"
      unitRef="U_USD">3871000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_36cf8b8f-a35e-4ff7-a042-ef985e92f2f7"
      unitRef="U_USD">1617000</us-gaap:AccountsPayableCurrent>
    <beam:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_d426e272-c409-4548-b984-7d40c1e10921"
      unitRef="U_USD">47468000</beam:AccruedExpensesAndOtherCurrentLiabilities>
    <beam:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_8bb975ab-43f4-4a99-90d4-42739d76576c"
      unitRef="U_USD">111664000</beam:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_029a9c1d-ac0d-49cc-aba9-e149a148fcd1"
      unitRef="U_USD">8400000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_4445a20f-fecc-4162-ad71-0c7a24738a33"
      unitRef="U_USD">10800000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_34a4970f-c7a0-4f2e-8bef-6d4d8ab2ea02"
      unitRef="U_USD">108858000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_99951552-0f02-4aea-976d-3e45303af05b"
      unitRef="U_USD">68706000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_858c36ba-1f4f-41aa-b64d-b14205cf9de5"
      unitRef="U_USD">13469000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_7e1b7913-f5c8-4dc0-93a8-bd84cf2dcb19"
      unitRef="U_USD">12778000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_5707329b-fbea-4fec-a7bd-2b9f1df357f7"
      unitRef="U_USD">182066000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_19992275-94e6-4896-8b95-55a9cf677ac3"
      unitRef="U_USD">205565000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_2d998ec2-e5ed-49ac-8e51-865926c0fc69"
      unitRef="U_USD">147956000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_ae7711ae-eeb7-4772-bf5c-c3af070c04e3"
      unitRef="U_USD">159911000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_2d87dade-a2a4-4906-8841-286c5749e6b8"
      unitRef="U_USD">1131000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_3147f957-b2d5-4fbe-8b07-e9648663c891"
      unitRef="U_USD">2723000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_9ecfd229-dc6e-4d93-986b-aef7e817f38d"
      unitRef="U_USD">33218000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_454735c0-ddc4-4e09-b735-bb232f2ea497"
      unitRef="U_USD">109888000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_52350987-1d5e-4c4b-99a7-e200daecb66b"
      unitRef="U_USD">5404000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_0af5c29f-0b7b-46fe-bcf4-064396a3204d"
      unitRef="U_USD">504000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_e3e9a5fb-8c97-44d9-bd77-c24df5c9ae04"
      unitRef="U_USD">298000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_dc13ace6-ee40-4fbe-958b-b11fe9d69d3a"
      unitRef="U_USD">370279000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_5e107c2e-2f03-46b4-8005-20f0e16bf753"
      unitRef="U_USD">478385000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_1d27ce24-ef5c-41cd-9fc2-ddce126e87ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_d19e0f68-a22e-4161-b6c0-01f6a09bbdf8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_c095feb8-171f-43e9-b4d3-f67d803d89c3"
      unitRef="U_shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_4a84875f-ec5e-4e82-a48f-c5483d358b73"
      unitRef="U_shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_a250ec6c-b9a5-416f-bc27-852cb6f65a6d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_8e727fc7-337d-4655-9659-58f339b8d690"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_6a55958f-6d98-441d-921a-dd622fa25efd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_cbcc3f97-9f6a-49e8-88a4-0fef08154a9a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_4aeca014-c41f-49fe-8200-0789230663b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_4c8e3247-5e00-44a6-9a2b-177fe79df242"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_de534136-153b-4cca-97ff-271b31889631"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_6b351155-10d4-4597-ae43-c3eb0e4bfdbb"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_a51be6ef-77f7-47f8-b8e9-521e01ab614d"
      unitRef="U_shares">83633069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_7ae8805f-2e93-479f-b48a-443f3e4055d3"
      unitRef="U_shares">83633069</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_c119b8b0-bb6e-4d9d-93c0-c41858c03d0e"
      unitRef="U_shares">81632496</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_08d1f565-aa4b-48d1-b901-3d680d7e3a72"
      unitRef="U_shares">81632496</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_9e0b69a4-4faa-4e17-a333-2156adc6d07f"
      unitRef="U_USD">836000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_34ed52d6-4f82-43a5-86e9-acb37c0615ae"
      unitRef="U_USD">816000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_aff48176-acf1-4588-8def-a9506cd59e4e"
      unitRef="U_USD">2298661000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_8ea465c3-6546-4474-a7c5-a3ebd309395a"
      unitRef="U_USD">2169798000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_49b8045f-cc59-4b53-8a74-24405b7cf625"
      unitRef="U_USD">679000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_8e54eded-2aee-4cf2-b91b-9082878df4a9"
      unitRef="U_USD">604000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_b91bac6c-c558-4d25-bf2b-a50c3b138c0e"
      unitRef="U_USD">-1566631000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_0bc204c4-e500-44c3-9372-d2c7239aa206"
      unitRef="U_USD">-1189889000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_623756a6-1225-4cf5-b193-ff4e633c4950"
      unitRef="U_USD">733545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_70a593ab-b134-4f58-93d4-4cd18a577a07"
      unitRef="U_USD">981329000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_f1e681f8-6dc4-411c-bdf7-c9244a9246ba"
      unitRef="U_USD">1103824000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_82a776b7-4496-4b0c-bb4e-5f2ad811697e"
      unitRef="U_USD">1459714000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_961ac718-c840-4279-9338-017f28f3c5e5"
      unitRef="U_USD">63518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_bacf522a-248d-42c6-a2e6-e93c2bb9e817"
      unitRef="U_USD">377709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_77bf99ca-a453-41df-94a2-956577c20eae"
      unitRef="U_USD">60920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_5a1aac89-c9ab-4c80-bbfe-c62d0a6570be"
      unitRef="U_USD">367561000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_6e683d93-0856-4242-bb78-500ee4ebcb22"
      unitRef="U_USD">437381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_88eeaa9d-ad7a-4c90-a40f-c127a02c8dd0"
      unitRef="U_USD">311594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_5e42be19-0dd5-4e95-902e-54725446eced"
      unitRef="U_USD">111525000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_37f8430a-09f4-4554-a44c-67f54c6412ed"
      unitRef="U_USD">116813000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3e82f064-ee60-4120-ab0c-f31b403be799"
      unitRef="U_USD">87805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_723e3b9c-dbea-477b-8441-64214d07816d"
      unitRef="U_USD">479086000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_b7e11d28-9d28-429f-a25c-79973e36c685"
      unitRef="U_USD">554194000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_7034d78a-e419-4b08-9499-e6b8d0e949c6"
      unitRef="U_USD">399399000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_1cadaf4f-7f24-43a2-9b78-32f625b76426"
      unitRef="U_USD">-415568000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_f64d9041-66c0-4652-962a-0e692f031027"
      unitRef="U_USD">-176485000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_fcae2e62-2052-4a62-8b8b-031281350092"
      unitRef="U_USD">-338479000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_6579c0c4-2f33-4e4e-9b88-ef0f46992a7a"
      unitRef="U_USD">2272000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_80236f0f-c606-4b8f-baae-d746266b8810"
      unitRef="U_USD">7500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_f0f4dbe3-f6fe-4b12-8286-b97215368bb0"
      unitRef="U_USD">23900000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b0da24ee-2914-4baa-91b6-1e747cc80286"
      unitRef="U_USD">-14093000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_31aa552f-4d9c-43dd-98ec-9d9eaad56c3d"
      unitRef="U_USD">-18592000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_fe425b4f-69b1-49e8-8af9-23507d0148b6"
      unitRef="U_USD">20200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <beam:ChangeInFairValueOfContingentConsiderationLiabilities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_8b1a30b8-0039-4a4e-9c5c-804359287ea6"
      unitRef="U_USD">-1592000</beam:ChangeInFairValueOfContingentConsiderationLiabilities>
    <beam:ChangeInFairValueOfContingentConsiderationLiabilities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_e0a05193-ee1e-4313-8805-82d40e736b63"
      unitRef="U_USD">-9740000</beam:ChangeInFairValueOfContingentConsiderationLiabilities>
    <beam:ChangeInFairValueOfContingentConsiderationLiabilities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_e0a3f848-ec6f-40d1-91b5-6fccc03d1c36"
      unitRef="U_USD">-18904000</beam:ChangeInFairValueOfContingentConsiderationLiabilities>
    <beam:InterestAndOtherIncomeExpenseNet
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_0e87161b-a921-4f2f-9142-03be6ce6b4c8"
      unitRef="U_USD">49094000</beam:InterestAndOtherIncomeExpenseNet>
    <beam:InterestAndOtherIncomeExpenseNet
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_f48814ed-44cd-4068-a47b-dcd1d9fd6e69"
      unitRef="U_USD">46676000</beam:InterestAndOtherIncomeExpenseNet>
    <beam:InterestAndOtherIncomeExpenseNet
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_1a560a27-bc39-4421-8795-7a28e1f17283"
      unitRef="U_USD">15297000</beam:InterestAndOtherIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_dc517c7b-6382-45cf-84ec-942daa134baf"
      unitRef="U_USD">38865000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_03e247eb-f677-43e8-9436-a1de4c1553dc"
      unitRef="U_USD">45324000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_0ec71f5b-a195-4de3-aba3-7187aba26a4e"
      unitRef="U_USD">78301000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_1ef119d3-0491-47be-a1f0-430190dcc2fe"
      unitRef="U_USD">-376703000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_6b9c22b9-8f5b-426d-9816-54aec8068f4f"
      unitRef="U_USD">-131161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_97a41643-8955-4f40-96e8-3de1a419d43c"
      unitRef="U_USD">-260178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_bd0afcf0-da0d-455f-8154-8d4c14d6d440"
      unitRef="U_USD">39000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_f7d2ce4c-d603-421b-bb0f-0cb49d001d02"
      unitRef="U_USD">1366000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_87b00bd4-4f16-422b-88c7-e9cdbcc6e71a"
      unitRef="U_USD">3410000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_840629ee-93f0-4d88-93ca-c568f04cbd07"
      unitRef="U_USD">-25500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_e5361321-3d04-4cd7-9dbf-ee220c5ee4ff"
      unitRef="U_USD">-376742000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_1a6969d3-7abe-44b4-8b0e-8c893c3df78e"
      unitRef="U_USD">-132527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_bca6614c-5e03-443c-a710-645d17124fb9"
      unitRef="U_USD">-289088000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_e3520d28-7eb7-4102-bd7f-4d96aa7e0fe8"
      unitRef="U_USD">75000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_46663c03-af6e-4b91-9a81-9647116f157c"
      unitRef="U_USD">3034000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_faf29475-8bcb-4ace-be4d-03aa01b3a7c5"
      unitRef="U_USD">-2380000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a509a4e6-be84-4bfb-a61c-2dc4e9550bab"
      unitRef="U_USD">-376667000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_c5912831-d824-47de-9d37-b6e9bbccbda9"
      unitRef="U_USD">-129493000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_8986824f-b4a2-46e3-987e-18e310d584b7"
      unitRef="U_USD">-291468000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_9e0d8ac5-ade0-4f80-ad2b-e97cf4a1a8a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_81268497-ff0b-4096-b9f7-2e2b24428a75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_82ba624c-9082-44c3-92c1-c006e374dfc1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_f0ca9f84-1cce-4c5e-ac1c-470f11fae04f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_dcd2b855-274c-4196-8dec-9b83e4f9c135"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_8b845a68-2252-4117-a377-48f156d75fd7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="0"
      id="F_d5ceee0f-b1d7-4c30-bc7d-dcee61107851"
      unitRef="U_shares">82313008</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="0"
      id="F_444b29c3-5128-426a-a691-b64ba6acff09"
      unitRef="U_shares">82313008</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="0"
      id="F_a0d51ef6-168f-458d-89f4-5ec4c949dfe6"
      unitRef="U_shares">77151771</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="0"
      id="F_1aaee27a-0e87-48e0-934d-6bfa04812cda"
      unitRef="U_shares">77151771</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="0"
      id="F_67c87a79-068a-40d3-97f0-5a8e4185a913"
      unitRef="U_shares">70015305</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="0"
      id="F_67983ac9-cecb-4cd0-bb0b-03370028a423"
      unitRef="U_shares">70015305</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c"
      decimals="INF"
      id="F_7d101455-4d70-409d-b40e-ba3dd314685d"
      unitRef="U_shares">68389425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e0f02907-15be-4104-9c45-7a31cf8d4f8c"
      decimals="-3"
      id="F_9d5f5c16-4dfd-416b-868a-44210e5fae29"
      unitRef="U_USD">684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b83b237b-6d18-4327-8bbc-c9cdb6104ded"
      decimals="-3"
      id="F_0940c46a-d0d7-40af-b02f-af266c51d6c6"
      unitRef="U_USD">1594378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_199c64fb-9ab2-4c44-aa73-4ccf1cc07ee0"
      decimals="-3"
      id="F_4bb607ed-b1d8-47e8-b89d-580956ebda20"
      unitRef="U_USD">-50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b047b3c6-6f6d-40d7-952c-100389cfdae9"
      decimals="-3"
      id="F_5ef846c3-95da-4885-b0cc-e62acd966129"
      unitRef="U_USD">-768274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5"
      decimals="-3"
      id="F_ad3f971b-7274-42b2-99f8-349482d9a36b"
      unitRef="U_USD">826738000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"
      decimals="INF"
      id="F_e53149ca-698e-4d55-8759-398d6169809b"
      unitRef="U_shares">70073</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b"
      decimals="-3"
      id="F_64cb7b49-4e19-485a-8a65-d992a33baba6"
      unitRef="U_USD">3075000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3b60e156-c9cd-49ba-b3aa-6379b3e8939c"
      unitRef="U_USD">3075000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <beam:StockIssuanceCosts
      contextRef="C_5ca56256-2128-4152-ba15-ce38a36b87a3"
      decimals="-5"
      id="F_b26067aa-5ec7-49be-8ada-95845bdf4a05"
      unitRef="U_USD">2700000</beam:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ab6a3226-270a-448c-aa4a-011574bd549f"
      decimals="INF"
      id="F_2ae85f23-68f3-4dcc-8af1-8b5d10eb4ea8"
      unitRef="U_shares">1909103</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ab6a3226-270a-448c-aa4a-011574bd549f"
      decimals="-3"
      id="F_3e4cfece-c585-4d3e-92b6-b4aff804f4ee"
      unitRef="U_USD">19000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b519bc91-9533-4dcb-a39c-d95a0025a438"
      decimals="-3"
      id="F_25861e7e-abfa-4be6-8199-2f2755872a3d"
      unitRef="U_USD">108057000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5ca56256-2128-4152-ba15-ce38a36b87a3"
      decimals="-3"
      id="F_95752352-6c51-4195-90cc-c0a360d63b3a"
      unitRef="U_USD">108076000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"
      decimals="INF"
      id="F_7ceaa00d-a100-40a0-bd40-4eeb2ea20b56"
      unitRef="U_shares">424303</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"
      decimals="-3"
      id="F_46b45046-870e-42bb-b0fc-01dfa035d6c9"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b"
      decimals="-3"
      id="F_9b6948ff-9022-47d4-b420-ad1c4645d9c2"
      unitRef="U_USD">-4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b"
      decimals="-3"
      id="F_ba1cc0d6-b9b7-4e31-a483-5f96184a1b47"
      unitRef="U_USD">84321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3e93485d-96e5-41b2-b10e-9760dc317d61"
      unitRef="U_USD">84321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"
      decimals="INF"
      id="F_29f24555-5cd8-425d-b69e-f07b45b5cfd0"
      unitRef="U_shares">484435</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a815aae5-8ebd-4ab9-ae8b-93e0ffc52dc9"
      decimals="-3"
      id="F_026fc019-f45d-4392-a5f4-151282fe996f"
      unitRef="U_USD">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5cecab40-29ff-479f-b5f3-b12b245ffb7b"
      decimals="-3"
      id="F_e9cc4b1a-57d8-4378-bbcc-ac0d41751779"
      unitRef="U_USD">2727000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_c4ed3326-b2b6-42f5-8016-5bbb81ae0c09"
      unitRef="U_USD">2732000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_480875b2-e64b-432b-b458-b70c8350f511"
      decimals="-3"
      id="F_3f520c86-f0b6-410f-922b-a6a0757a4164"
      unitRef="U_USD">-2380000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_38c66c3c-a080-4eac-9d74-97d87ae1a04b"
      unitRef="U_USD">-2380000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_17ab1823-a6d7-4de6-8f1b-d8443d01ce0c"
      decimals="-3"
      id="F_be01af30-4d0c-4c63-a700-0ce6a164b3a4"
      unitRef="U_USD">-289088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_239ac0ca-056a-41db-8bf3-c7961b8063cc"
      unitRef="U_USD">-289088000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_9a16ff51-e500-41df-8c2c-d24921af54f7"
      decimals="INF"
      id="F_a9d7b88c-0346-4949-a073-8ba75ee4c1e1"
      unitRef="U_shares">71277339</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9a16ff51-e500-41df-8c2c-d24921af54f7"
      decimals="-3"
      id="F_8a20c98e-1c71-4f2b-9bdd-756a62f9a092"
      unitRef="U_USD">712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_525cf13e-fad6-4e2f-9c9e-48ad51403c66"
      decimals="-3"
      id="F_792cd3ef-bbbf-4c6b-8f75-8cc4a547e578"
      unitRef="U_USD">1792554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1a1acf3-c64f-4967-b7e4-958c7a788e9e"
      decimals="-3"
      id="F_629b21a0-5274-4ba3-94a9-3a83ce6dac98"
      unitRef="U_USD">-2430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fb510e5f-fbb4-4322-a22a-8b7179089277"
      decimals="-3"
      id="F_4fb12656-7601-47c0-b466-b0ad7f2e246f"
      unitRef="U_USD">-1057362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_a949ba63-5b2b-4f64-8e2d-899179293534"
      unitRef="U_USD">733474000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="INF"
      id="F_f571d8ec-f734-4435-be34-defa5edbc3d5"
      unitRef="U_shares">130403</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="-3"
      id="F_85852a52-9ad8-4ef8-aa28-896a06365a6f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78"
      decimals="-3"
      id="F_5b9ef523-c499-4761-80a9-b6557e2527d2"
      unitRef="U_USD">3031000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_bb947d60-6f6b-437b-8f0b-16ef8f500b84"
      unitRef="U_USD">3032000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <beam:StockIssuanceCosts
      contextRef="C_c8171dae-98d5-431f-8a83-4520d464b7e9"
      decimals="-5"
      id="F_e48c32e1-6287-4a84-b725-90a2ca9a827c"
      unitRef="U_USD">6100000</beam:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f1109e54-6e94-4d48-a4a5-64a3507c850d"
      decimals="INF"
      id="F_1ce4ecea-790c-420b-9fdf-693ce8399f3e"
      unitRef="U_shares">6952703</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f1109e54-6e94-4d48-a4a5-64a3507c850d"
      decimals="-3"
      id="F_5aaf8c17-633d-480a-bf11-02a9a9e688a1"
      unitRef="U_USD">70000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_97a94644-ff61-46cd-95e9-1614d5a9b854"
      decimals="-3"
      id="F_03055012-9f22-4753-bd0f-bc9312c71ce1"
      unitRef="U_USD">235868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c8171dae-98d5-431f-8a83-4520d464b7e9"
      decimals="-3"
      id="F_3e2b12bb-0d5f-4034-990a-404aba9b5e9b"
      unitRef="U_USD">235938000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="INF"
      id="F_809ecd34-63af-4ab4-938d-7ce65a6e28f0"
      unitRef="U_shares">2004811</beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement>
    <beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="-3"
      id="F_86c3e265-03cb-4809-a1c0-10d12c54f2e5"
      unitRef="U_USD">20000</beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1>
    <beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1
      contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78"
      decimals="-3"
      id="F_038ddae6-06ab-4664-b24c-b75197d2c5ba"
      unitRef="U_USD">33580000</beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1>
    <beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_bf820045-b4d0-4d3b-9aca-97e6a1cd8e41"
      unitRef="U_USD">33600000</beam:IssuanceOfUnregisteredCommonSharesInConnectionWithLicenseAgreement1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="INF"
      id="F_70b2625f-5981-4839-9e8f-5bf0b2c7a9ae"
      unitRef="U_shares">469531</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="-3"
      id="F_ce5e818d-843c-4fc0-90bf-951b19f3934f"
      unitRef="U_USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78"
      decimals="-3"
      id="F_b1996443-fb7d-4f01-94f1-b254aa4d700d"
      unitRef="U_USD">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78"
      decimals="-3"
      id="F_637e2bd5-f4f0-4a4c-9cb3-3cf2ee028c8c"
      unitRef="U_USD">98647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_114e6b40-47e5-4ea7-8e8d-7bbf3067afca"
      unitRef="U_USD">98647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="INF"
      id="F_9b99294a-82cd-40bf-9067-e9af374887a8"
      unitRef="U_shares">797709</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7d2ef810-7ee1-4ead-9635-e33269a8e377"
      decimals="-3"
      id="F_00b010a2-f9d8-4275-a556-af3df1045a38"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cf066df4-fc9e-41d6-925d-5f1920357b78"
      decimals="-3"
      id="F_70777f3f-e18c-4641-bbc5-a8ca9b6b81aa"
      unitRef="U_USD">6123000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_e1aec229-43b5-4dbe-876d-f6f3da854cc5"
      unitRef="U_USD">6131000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_ca386094-8a4e-4c31-bbb9-c0a598866d8d"
      decimals="-3"
      id="F_eb211d9d-c04d-4380-a0b0-20c97dc3eebc"
      unitRef="U_USD">3034000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_161392e1-523a-4da6-836f-c891dd6c78c2"
      unitRef="U_USD">3034000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_98e22f9d-79ae-43bd-8044-17f44f41029a"
      decimals="-3"
      id="F_3958dbba-d569-47b4-99ca-fe686f1dc1d1"
      unitRef="U_USD">-132527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_599791b1-780a-4dea-9ee2-a2179dcd8f03"
      unitRef="U_USD">-132527000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf"
      decimals="INF"
      id="F_f68c79d2-cfb0-49e5-8563-0ccbe8345b9f"
      unitRef="U_shares">81632496</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8e88346f-34ad-4bc8-bbcb-dc8a9570f8bf"
      decimals="-3"
      id="F_74339fc7-cab2-4d0a-a9d3-fea6198c1589"
      unitRef="U_USD">816000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e8a4929a-82aa-4502-9781-741961c7ae2b"
      decimals="-3"
      id="F_77c51b4c-41b3-4502-bdfe-04a5b5f798e0"
      unitRef="U_USD">2169798000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee767960-3dae-4bd8-8d2c-8f119f919035"
      decimals="-3"
      id="F_2ecaf290-868a-4d3d-bb65-70c4a9b9b9cf"
      unitRef="U_USD">604000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2c909485-c763-4bfd-87a0-49786aefa4fe"
      decimals="-3"
      id="F_6774fb82-83cb-4f42-9178-f4e2a341a25b"
      unitRef="U_USD">-1189889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_e08e29b5-9bdd-4ee1-a6e5-bfaea48dadb0"
      unitRef="U_USD">981329000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="INF"
      id="F_c44dcb3b-bd2f-4112-b8a8-22b23980e9d2"
      unitRef="U_shares">135187</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="-3"
      id="F_b7e53d9e-0073-44cc-8976-a7c18f0da797"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848"
      decimals="-3"
      id="F_8d38a5cc-f1c1-4dd2-bc22-d1c992b89420"
      unitRef="U_USD">2620000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_face1c7e-b876-4b72-8805-f171a1e83b7b"
      unitRef="U_USD">2621000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="INF"
      id="F_0b74d103-c84b-4023-bd7e-7510d0a091fe"
      unitRef="U_shares">1302037</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="-3"
      id="F_4b92b659-d5d3-40c5-b041-b898743a8b50"
      unitRef="U_USD">13000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848"
      decimals="-3"
      id="F_68ba73b6-1954-42db-8ce8-2e3ac06e716d"
      unitRef="U_USD">-13000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848"
      decimals="-3"
      id="F_5c9d838e-a33a-4820-bf69-bcb3ebc280cd"
      unitRef="U_USD">120662000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_616144af-a07b-4890-9324-33c8780f2527"
      unitRef="U_USD">120662000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="INF"
      id="F_0e2f5e7f-9186-46f9-a410-9c4223a8af56"
      unitRef="U_shares">563349</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_12936f08-d240-4e4b-9e13-6dc84a43dbce"
      decimals="-3"
      id="F_f1ab480f-dfaa-432a-a389-0d3706d3d318"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_eb90fc29-55a2-424a-aaa9-70b942a8d848"
      decimals="-3"
      id="F_dbe31ff9-7e8c-40f9-b163-2c9ae31ce4c9"
      unitRef="U_USD">5594000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_22d1abc2-54c9-49e0-97e6-4c1ad0e1b453"
      unitRef="U_USD">5600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_22bf2ac7-5934-477b-9c81-096c75b0a449"
      decimals="-3"
      id="F_9eb01451-ad6e-44df-92e0-4dbab3ae7d4b"
      unitRef="U_USD">75000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a48f6c17-b42e-4eb3-81a5-9c2008fd4223"
      unitRef="U_USD">75000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_d5f96b32-a698-4369-8181-0a106fbfb45a"
      decimals="-3"
      id="F_feb2a95c-0cb1-4915-9b18-70699776c6bd"
      unitRef="U_USD">-376742000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_33ec005e-5503-4257-b02c-f0ec07b308c4"
      unitRef="U_USD">-376742000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce"
      decimals="INF"
      id="F_b16f9555-0f93-4516-b4c7-0f27b16fd809"
      unitRef="U_shares">83633069</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_225833f5-a4b4-4ee3-bc7f-ad38dd5047ce"
      decimals="-3"
      id="F_9f38da1f-4871-47a7-b587-57ed79caca75"
      unitRef="U_USD">836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_257027f1-7dcd-416a-869c-74ce3e11938f"
      decimals="-3"
      id="F_a9b9ab1c-e21e-46a2-83a9-35fe57a84daa"
      unitRef="U_USD">2298661000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ff6fe20-72a4-4903-950c-bd6bf0d3b3c2"
      decimals="-3"
      id="F_6818badc-3f40-44eb-9cfb-81be1fcd2065"
      unitRef="U_USD">679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_979dd123-9531-40b9-b541-eec96ea77e9a"
      decimals="-3"
      id="F_95503965-c683-4ea6-a411-044912018a7c"
      unitRef="U_USD">-1566631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_edf5e0aa-ab32-43bb-89c7-dbc0d1dd5c6e"
      unitRef="U_USD">733545000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a8f653c1-37d7-480b-bdd2-9c7384c62ce9"
      unitRef="U_USD">-376742000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_88fd84c4-588d-4cab-8628-786d4ece7b27"
      unitRef="U_USD">-132527000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_af69aac9-b112-45e7-9177-dce2c818ced2"
      unitRef="U_USD">-289088000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_8a960eb2-3c21-4138-8a46-2bc0d6c837d4"
      unitRef="U_USD">-25500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_3c5fa620-6da6-4e8b-81cc-d0b0173ced9e"
      unitRef="U_USD">21925000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_4b8010fd-a05a-4354-bacc-96dd60e8af31"
      unitRef="U_USD">20012000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_38cb048e-86b8-4517-b2c6-ffa25f072cb8"
      unitRef="U_USD">14147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b95c1c2b-32a5-4806-89b1-1afaec657c7b"
      unitRef="U_USD">22765000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_33383bab-6a7a-4876-8b69-73cef1515677"
      unitRef="U_USD">29743000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_f536564a-dc4d-4389-812a-1fcd11f8ced1"
      unitRef="U_USD">9410000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_4667892b-a103-4336-a31a-61007d71344b"
      unitRef="U_USD">120662000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_e9d8ad0a-1b23-4027-aad1-bbb8edb561f4"
      unitRef="U_USD">98647000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_0f2c4b10-aa3e-4707-b775-54ab38b731ae"
      unitRef="U_USD">84321000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_8ed95c36-fa96-4d12-8d79-53bccffcce23"
      unitRef="U_USD">9668000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_24fc3a21-d4c6-45a2-80ae-80f05ed0911c"
      unitRef="U_USD">9519000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_4d35a37f-51d3-4e98-84c2-17f37f235ed5"
      unitRef="U_USD">8430000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_c3c7ac4b-8874-4fe5-b79b-389c44fc0a28"
      unitRef="U_USD">2272000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_f910c749-38dc-48c8-9166-dbb06c2474a3"
      unitRef="U_USD">7500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_cc8c0e99-6a7d-4839-a7db-b06c3f1bbdf5"
      unitRef="U_USD">23900000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_bfe034a7-b7b8-4fab-b31c-beddfbe25808"
      unitRef="U_USD">-1592000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_b3ef6402-6bef-472b-adfa-1e58c19551dc"
      unitRef="U_USD">-9740000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_4c66c964-1b4d-4d95-99af-2fc70966f44b"
      unitRef="U_USD">-18904000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_451b7f38-40df-4306-9f5d-dc0bbd3ef470"
      unitRef="U_USD">-14093000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_acc80e2c-4476-4699-9172-96f4ccaa035f"
      unitRef="U_USD">-18592000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_bd0024d7-4da4-472a-bae4-bab288094662"
      unitRef="U_USD">20200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_5beee07d-2d0c-4e86-b27c-b317c002bfa9"
      unitRef="U_USD">-3000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_21ee41d8-fc09-4659-b690-f16896b7cd93"
      unitRef="U_USD">5349000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_6d843f73-3f0d-4cf6-8d95-50898ac0eaf1"
      unitRef="U_USD">6473000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_ee035c98-070b-4350-a1fc-eabac2dff584"
      unitRef="U_USD">7753000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_fb66d75f-cec7-438f-ae60-f772daee6608"
      unitRef="U_USD">1807000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_4d995141-83a9-40aa-9de4-e58da44028c7"
      unitRef="U_USD">-7578000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3c1bce13-5a76-4a50-badd-acc66eb620ef"
      unitRef="U_USD">2373000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_4b48fdca-7572-486e-af77-63be0175eb9d"
      unitRef="U_USD">-57685000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_8cfaa52a-d2b9-4c84-8d7b-d771eaabb308"
      unitRef="U_USD">67663000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_883481fb-387e-4bf7-a6be-86a1906ec7f5"
      unitRef="U_USD">-16933000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_58b09a55-0b8a-4ca2-8502-0f96e2a27a65"
      unitRef="U_USD">-12951000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_5386273a-2462-4919-9b6d-ea91bf64e9a1"
      unitRef="U_USD">-10168000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_e989f411-daeb-475a-ab8a-438ec8b51d44"
      unitRef="U_USD">12430000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <beam:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_2a410e70-d242-4634-b73a-03b15dea75e2"
      unitRef="U_USD">146000</beam:IncreaseDecreaseInCollaborationReceivable>
    <beam:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_73346e14-a237-42dd-8e1c-35c2f8576610"
      unitRef="U_USD">-300000000</beam:IncreaseDecreaseInCollaborationReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_d1fcd7d5-96b6-425a-95c0-da7be67227d1"
      unitRef="U_USD">-36518000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_b333598c-116d-4183-9b71-9d45beb80361"
      unitRef="U_USD">-159559000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_d6446095-ff4f-4110-b4f5-897d714b01b3"
      unitRef="U_USD">-35920000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b9f1a2c9-de15-4567-ab13-fa109c1a577a"
      unitRef="U_USD">473000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_a7b56459-cbb8-450d-9e01-0ab387ea59b0"
      unitRef="U_USD">-194000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_d3cca716-6a70-4f01-9ba8-4aeac1e38f9b"
      unitRef="U_USD">-2569000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_76133740-3090-4b06-ae7d-9ec3c83b3cc8"
      unitRef="U_USD">-347246000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_ba392b6b-354f-4bc2-aecf-11d751c5c215"
      unitRef="U_USD">-149195000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_1b32d310-2412-4715-bc54-7cda3ac7ccb7"
      unitRef="U_USD">22527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_da7fdcdc-71a6-4281-a69a-287d4db49979"
      unitRef="U_USD">8946000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_95ae018a-cc5d-4868-a853-a8c85efda665"
      unitRef="U_USD">33732000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_ad197a26-c5a1-400f-ba00-7fbd38d701ee"
      unitRef="U_USD">48951000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b98e9cfb-0ff8-4c43-8389-200a1b67c854"
      unitRef="U_USD">486439000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_e90ae732-e545-45d5-aa3e-6b92ba75fe50"
      unitRef="U_USD">984338000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_2ac33bc9-8ee1-48f8-b762-5d64de94c389"
      unitRef="U_USD">1616999000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b34c6db3-12b0-45d9-91bb-7a3124f05efe"
      unitRef="U_USD">680392000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_b9fdfbb5-9eef-4e10-85cc-b0b5f8529cf3"
      unitRef="U_USD">1089910000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_17963743-86f9-4c18-84c5-f76e187f30eb"
      unitRef="U_USD">1204614000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_4af9f77b-1f1d-47e1-9bae-5b2f7ee41a08"
      unitRef="U_USD">185007000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_3632afd8-0fc7-4def-9b96-58d9d029a071"
      unitRef="U_USD">71840000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_62c228cf-387c-403d-90c2-bf18bb8e6600"
      unitRef="U_USD">-461336000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_70e8cdc4-1eeb-43d8-bb41-52c7bd7bb993"
      unitRef="U_USD">236568000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_948106ae-0e66-4b4a-962c-ca71600a15e7"
      unitRef="U_USD">108258000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b9dfc6aa-a677-4c83-9f49-f7f93f04a97f"
      unitRef="U_USD">2621000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_69438cd3-a782-4f4a-9897-e436bdd8135d"
      unitRef="U_USD">3032000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_4c1bb1d1-fec5-48fa-9d0c-20a0a07feaae"
      unitRef="U_USD">3075000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_152fd852-10f9-46ef-9b9c-51acf01618cf"
      unitRef="U_USD">631000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_7e2e8fa0-daf0-41c3-abe9-fdd8c38d8700"
      unitRef="U_USD">188000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a2e64b8c-c7d9-4592-a50a-7dbf160fd203"
      unitRef="U_USD">485000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_9f3c7e3c-b05e-4ea6-a6db-d1a1aefe50ac"
      unitRef="U_USD">2252000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_fd60e5b2-219b-4a24-82d5-4af72943376b"
      unitRef="U_USD">2287000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_3f0c7efc-d23a-48eb-934b-769426064bdd"
      unitRef="U_USD">5600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_a04a9c03-c01e-4da5-98ee-ad282692475a"
      unitRef="U_USD">6131000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_915443cb-f40a-42aa-9f09-0435ef873064"
      unitRef="U_USD">2732000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_1be4de33-9614-45a3-a3c1-a10015951f8d"
      unitRef="U_USD">33600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_e1c138c4-9133-431c-8dc7-0bacb7242444"
      unitRef="U_USD">7736000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_695fc62d-d00f-4f2f-ac3e-32833a4ad905"
      unitRef="U_USD">276448000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_536298cf-c295-4411-8bdc-1b21b95f5bcf"
      unitRef="U_USD">111590000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_533d6691-d55b-4f5b-a9c1-f9867ba70980"
      unitRef="U_USD">-154503000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_fc020acd-f8fc-4ebc-81ce-9c52f70b67fe"
      unitRef="U_USD">199093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_7ee3e085-041b-4c7c-9e22-d6a73293b0cc"
      unitRef="U_USD">-327219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_c58cc8fd-8f1a-4414-af30-5cd553e2a1e2"
      unitRef="U_USD">444614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_e8fd6899-b205-4199-bb45-bb6fe67155bc"
      unitRef="U_USD">245521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4e5fa514-5d36-4c98-a0ea-15f5fd9278c5"
      decimals="-3"
      id="F_8b8b2b64-c70c-4a35-a40b-4eaea54303c9"
      unitRef="U_USD">572740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_c480c97d-92f8-4801-a431-b6ac5ef5f488"
      unitRef="U_USD">290111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_ae9b2fc8-2239-4805-8c44-f9239a1ddfc1"
      unitRef="U_USD">444614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_ff21952d-6640-4dbc-9ffb-2841ba0d69ae"
      unitRef="U_USD">245521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_0eb49d16-1631-442b-8007-fe16cf19c447"
      unitRef="U_USD">32000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_9815babd-9d19-4773-836d-95d9b1ec6345"
      unitRef="U_USD">160000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_9a9c5fe0-ec34-4bc5-9ccd-9ba2e441f25a"
      unitRef="U_USD">376000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_b0f8cab1-50df-4f2d-9d5a-d3baed1e1348"
      unitRef="U_USD">834000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_cfb26d5e-c3c8-4938-bc18-ac16a0a3d2b2"
      unitRef="U_USD">1403000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_eee55a93-bec5-4481-8928-ee2d3fd0028b"
      unitRef="U_USD">5783000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_cc188687-4604-4afc-aa60-a4423cc11923"
      unitRef="U_USD">-1626000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_4a1dca42-ee84-49e9-a1c5-75e76e69d866"
      unitRef="U_USD">3852000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_ce4c86b4-93fc-4e41-a68a-081f1ceaf712"
      unitRef="U_USD">41050000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <us-gaap:ContributionOfProperty
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3bae97d6-a610-4fd1-80d8-04cd194549f5"
      unitRef="U_USD">25500000</us-gaap:ContributionOfProperty>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d5a5c839-f660-49d1-ba55-4668b9423e02">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nature of the business and basis of presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Beam Therapeutics Inc., which we refer to herein as the &#x201c;Company&#x201d; or &#x201c;Beam,&#x201d; is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam&#x2019;s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and capital resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, research and development costs including preclinical studies and IND-enabling studies, organizing and staffing the Company, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company has established internal manufacturing capabilities. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into an at the market sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. The Company agreed to pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares sold under the Sales Agreement during the year ended December 31, 2024. As of December 31, 2024, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,769,001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock under the Sales Agreement at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;864.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting commissions and offering expenses payable by it.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has incurred substantial losses and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion as of December 31, 2024. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects that its cash, cash equivalents, and marketable securities as of December 31, 2024 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;850.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <beam:StockIssuanceProgramAuthorizedAmount
      contextRef="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2"
      decimals="INF"
      id="F_d3f384d7-7dbe-43c5-931d-383a8583e33b"
      unitRef="U_USD">1100000000</beam:StockIssuanceProgramAuthorizedAmount>
    <beam:CommissionRate
      contextRef="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a"
      decimals="3"
      id="F_33459cfd-a5ff-4b7e-8484-7df53a449ceb"
      unitRef="U_pure">0.03</beam:CommissionRate>
    <beam:StockSoldDuringPeriodSharesNewIssues
      contextRef="C_33491d05-f4b0-41eb-b082-0966c1c67aa3"
      decimals="INF"
      id="F_5e5a0644-e50f-42d2-b6fb-0a7ecb2214f8"
      unitRef="U_shares">0</beam:StockSoldDuringPeriodSharesNewIssues>
    <beam:StockSoldDuringPeriodSharesNewIssues
      contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028"
      decimals="INF"
      id="F_8aa358fc-8cb0-4a0f-984e-ebf578276e44"
      unitRef="U_shares">13769001</beam:StockSoldDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_9e824cf6-96ad-482c-938b-89bcefc2519a"
      decimals="2"
      id="F_c9d8bfd4-3531-4559-b0b5-4a41013add54"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">62.75</us-gaap:SaleOfStockPricePerShare>
    <beam:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028"
      decimals="-5"
      id="F_bbc82e1c-70d6-41f1-9dc4-4973246faa15"
      unitRef="U_USD">864000000</beam:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-8"
      id="F_3cbe76bd-7ef2-49d2-9865-73c14d522ae4"
      unitRef="U_USD">-1600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-5"
      id="F_56f7a7a3-ffef-46ec-acc5-6cac5fafd596"
      unitRef="U_USD">850700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0f0d67ee-8d21-487d-a0cc-cee56deeb9c3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. S&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ummary of significant accounting policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or the FASB.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and other derivative liabilities, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents consist of checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company&#x2019;s leases of its facilities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#x2019;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies marketable debt securities as available-for-sale and includes such securities within marketable securities in the Company&#x2019;s consolidated balance sheets. Available-for-sale securities consist of commercial paper, high-grade corporate notes, U.S. Treasury securities and government securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expensed over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in interest and other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies investments in equity securities that have a readily determinable fair value as marketable securities in the Company's consolidated balance sheets. The Company&#x2019;s marketable securities are stated at fair value. Typically, the fair value of these securities is based on a quoted price for an identical equity security. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records changes in the fair value of its equity securities in other income (expense), net in its consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. For the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had not experienced any losses related to these indemnification obligations, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity issuance costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes incremental legal, professional, accounting and other third-party fees that were directly associated with its stock offerings as other non-current assets until the offerings are consummated. Upon consummation, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in-capital generated as a result of the offerings.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no changes to the valuation methods utilized during the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates transfers between levels at the end of each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in interest and other income (expense). Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (or asset groups) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to a license agreement between the President and Fellows of Harvard College, or Harvard, and the Company, or the Harvard License Agreement, and a license agreement with The Broad Institute, Inc., or Broad Institute, and the Company, or the Broad License Agreement, (see Note 9), the Company is required to make success payments to Harvard and Broad Institute based the achievement of specified multiples of the initial weighted average value of the Company&#x2019;s redeemable convertible Series A-1 Preferred Stock and the Company&#x2019;s redeemable convertible Series A-2 Preferred Stock, or together the Series A Preferred, at specified valuation dates, payable in cash or Company common stock. Subsequent to the IPO, the amount of the success payments is based on the market value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of Beam&#x2019;s common stock. Pursuant to a settlement agreement between a research institution and the Company, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty through 2038. Any amounts due must be settled in cash.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The success and settlement payments are accounted for as derivatives under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The liabilities are recorded at fair value at each balance sheet date with all changes in value recognized in other income (expense), in the consolidated statement of operations and other comprehensive loss. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations. To determine the estimated fair value of the success payments, the Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Series A Preferred, prior to the IPO, and the value of the Company&#x2019;s common stock, subsequent to the IPO.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases and rent expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for leases using a right-of-use, or ROU, model, which recognizes that, at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to pay fees for operating expenses in addition to monthly base rent for certain operating leases (non-lease components). The Company has elected the practical expedient which allows non-lease components to be combined with lease components for all current asset classes. Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements are not unique and are retained by the lessor at the end of the lease. However, in the case of a space designed to be suitable for the Company&#x2019;s specific real estate needs and if the Company is responsible for cost overruns, the Company is the accounting owner of the leasehold improvements and costs associated are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s real estate operating leases provide for scheduled annual rent increases throughout the lease terms. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full terms of the lease. Tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the ROU asset related to that lease at lease commencement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may be required to make milestone payments to the former stockholders and optionholders of Guide Therapeutics, Inc., or Guide, in the form of its common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value is determined based on probability adjusted discounted cash flow model that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success or in the probabili&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ties as to the periods in which milestones would be achieved would result in a significantly higher or lower fair value measurement. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. The Company only applies the five-step model to contracts when it determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Note 10.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Note 10.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, (ii) the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property, or IP: If the license to the Company&#x2019;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Notes 9 and 10.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore consideration included in the transaction price is constrained. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract balances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as an account or other receivable. A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities, or deferred revenue, primarily relate to contracts where the Company has received payment, but it has not yet satisfied or fully satisfied the related performance obligations. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its obligations under these arrangements. Upfront payment contract liabilities resulting from the Company&#x2019;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The changes in the total deferred revenue for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;338,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions to deferred revenue from license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amounts recognized in revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting, and other contracted services. The cost of obtaining licenses for certain technology or IP is recorded to research and development expense when incurred if the licensed technology or IP has not yet reached technological feasibility and has no alternative future use. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options, restricted stock awards and restricted stock units. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and other comprehensive loss based on their fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards and restricted stock units.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation awards are subject to either service- or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The Company bases its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus, weighted with its own volatility for the period in which its stock has been publicly traded. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees and non-employees, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred. Due to the uncertainty about the recovery of the expenditure, amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Variable interest entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii) the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in stockholders&#x2019; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in equity that are excluded from net loss. The Company&#x2019;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For purposes of the dilutive net loss per share calculation, stock options and stock units for which the performance and market vesting conditions have been deemed probable, potential dilutive securities, unvested restricted stock, and common stock options are considered to be common stock equivalents, while stock options and stock units with performance- or market-based vesting conditions that were not deemed probable of meeting the applicable vesting conditions are not considered to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders was the same as basic net loss per share attributable to common stockholders, since dilutive common shares were not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity method of accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship.
&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the equity method of accounting, the Company&#x2019;s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company&#x2019;s proportionate share of the investee&#x2019;s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset&#x2019;s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&amp;amp;D, that has no alternative future use. To the extent a basis difference relates to IPR&amp;amp;D and the investee is not a business as defined in ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or ASC 805, the Company immediately expenses such basis difference related to IPR&amp;amp;D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee&#x2019;s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company&#x2019;s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company&#x2019;s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding or commits to guarantee investee liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee&#x2019;s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company accounted for its investment in Orbital under the equity method of accounting. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; carrying value related to this investment as of December 31, 2024 or 2023. Refer to Note 10 for further details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment and geographic information&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment operating exclusively in the United States&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;, Segment Reporting (Topic 280). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements. The Company&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the ASU as of and for the period ended &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the required disclosures are included in Note 17, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Data&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently announced accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The amendments in this update expand income tax disclosure requirements, including additional information pertaining to the rate reconciliation, income taxes paid, and other disclosures. This update is effective for annual periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_143c74b4-f470-4713-b5d8-465636728484">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or the FASB.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_01b5cfee-b2d9-44d0-8b57-9762dc2bb135">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_74eb44aa-6202-47e3-a65a-e87647f71c80">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and other derivative liabilities, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_90684386-3502-4c4e-9068-932662bccc70">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents consist of checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company&#x2019;s leases of its facilities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#x2019;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5b345ca2-a9ec-44c5-acdd-569a4a978fee">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles cash, cash equivalents, and restricted cash reported within the Company&#x2019;s consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_b5259621-683d-4b6d-9d64-ed92ab6233c9"
      unitRef="U_USD">281967000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_9fb63812-e1a8-4551-bda1-ccf0a11ec929"
      unitRef="U_USD">435895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_0eca6e81-bd62-40a2-a85a-b7c529a70d6f"
      unitRef="U_USD">232767000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_dced7681-18c6-43d0-8a32-6a7725af6ca0"
      unitRef="U_USD">8144000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_7c961afd-5f5a-4276-a14f-9b431a9d5e7a"
      unitRef="U_USD">8719000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_7fa0db00-a2dc-42f1-92cd-9eb5bbfa4ef2"
      unitRef="U_USD">12754000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_21dcaccc-dda8-428a-bdc0-585497577f2c"
      unitRef="U_USD">290111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_e72bd56b-1172-4637-8b51-edefc3309eab"
      unitRef="U_USD">444614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_d515b1d4-e881-40ae-9869-ac284a814d3d"
      unitRef="U_USD">245521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_1ad5b6e5-6b55-491d-8a1e-f4f71903af71">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies marketable debt securities as available-for-sale and includes such securities within marketable securities in the Company&#x2019;s consolidated balance sheets. Available-for-sale securities consist of commercial paper, high-grade corporate notes, U.S. Treasury securities and government securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expensed over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in interest and other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_24f45953-875e-4d47-af8b-a95c8ba071fc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies investments in equity securities that have a readily determinable fair value as marketable securities in the Company's consolidated balance sheets. The Company&#x2019;s marketable securities are stated at fair value. Typically, the fair value of these securities is based on a quoted price for an identical equity security. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records changes in the fair value of its equity securities in other income (expense), net in its consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity method of accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship.
&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the equity method of accounting, the Company&#x2019;s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company&#x2019;s proportionate share of the investee&#x2019;s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset&#x2019;s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&amp;amp;D, that has no alternative future use. To the extent a basis difference relates to IPR&amp;amp;D and the investee is not a business as defined in ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or ASC 805, the Company immediately expenses such basis difference related to IPR&amp;amp;D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee&#x2019;s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company&#x2019;s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company&#x2019;s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding or commits to guarantee investee liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee&#x2019;s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company accounted for its investment in Orbital under the equity method of accounting. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; carrying value related to this investment as of December 31, 2024 or 2023. Refer to Note 10 for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4f913852-72b7-44ec-97dd-a8646aee0cd7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9b191257-0882-4c3a-9f66-97922a3f835c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. For the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had not experienced any losses related to these indemnification obligations, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_ae6b5c2f-3ddb-4b5f-afe3-50bf1e181241"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_757b5fe1-729f-467b-8447-f1e639e0a4d7"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="INF"
      id="F_020b2356-9198-4d8d-934c-c7f54970f48c"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <beam:EquityIssuanceCostsPoliciesPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_b6c0ed05-d40c-4eaf-8b34-a0f553394016">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity issuance costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes incremental legal, professional, accounting and other third-party fees that were directly associated with its stock offerings as other non-current assets until the offerings are consummated. Upon consummation, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in-capital generated as a result of the offerings.&lt;/span&gt;&lt;/p&gt;</beam:EquityIssuanceCostsPoliciesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_56f5b2ff-4a18-4462-a029-5c50eddd5965">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no changes to the valuation methods utilized during the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates transfers between levels at the end of each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_96c9c6b5-a745-4eb3-add5-69dc87ea9637">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in interest and other income (expense). Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <beam:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_520090f1-3535-43a2-a149-2142223fbd62">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_360eabeb-5bbc-4b75-86fd-e7d0c0e6ea7d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</beam:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_18b725ca-8307-4b02-bf86-cd5bacd75fe4"
      id="F_070bca50-cb9e-4ea4-8355-cb4b386540fa">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_eaa2ddbc-9a2b-4667-a992-ede8aed104d7"
      id="F_5e4df37f-ead9-4737-9ce0-22e7d8b624ba">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_182da381-d124-4db0-a7e9-0d23075637d0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets (or asset groups) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_32262e62-3b5c-484c-b40a-4d6d0c3cd40e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="INF"
      id="F_658d13e1-b15c-4c89-a181-f0ffacce5ea0"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="INF"
      id="F_34b64850-9cee-4a39-82a2-fbb623997f14"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_3d8b0ccd-6aa6-43c8-944e-30c3ba42f8ed">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to a license agreement between the President and Fellows of Harvard College, or Harvard, and the Company, or the Harvard License Agreement, and a license agreement with The Broad Institute, Inc., or Broad Institute, and the Company, or the Broad License Agreement, (see Note 9), the Company is required to make success payments to Harvard and Broad Institute based the achievement of specified multiples of the initial weighted average value of the Company&#x2019;s redeemable convertible Series A-1 Preferred Stock and the Company&#x2019;s redeemable convertible Series A-2 Preferred Stock, or together the Series A Preferred, at specified valuation dates, payable in cash or Company common stock. Subsequent to the IPO, the amount of the success payments is based on the market value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of Beam&#x2019;s common stock. Pursuant to a settlement agreement between a research institution and the Company, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty through 2038. Any amounts due must be settled in cash.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The success and settlement payments are accounted for as derivatives under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The liabilities are recorded at fair value at each balance sheet date with all changes in value recognized in other income (expense), in the consolidated statement of operations and other comprehensive loss. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations. To determine the estimated fair value of the success payments, the Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Series A Preferred, prior to the IPO, and the value of the Company&#x2019;s common stock, subsequent to the IPO.&lt;/span&gt;</us-gaap:DerivativesPolicyTextBlock>
    <beam:PercentageOfRoyaltyPayments
      contextRef="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e"
      decimals="2"
      id="F_381c458d-13fa-4050-93ef-5022a3c15063"
      unitRef="U_pure">0.01</beam:PercentageOfRoyaltyPayments>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_271abee7-db84-4047-979b-794117265d55">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases and rent expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for leases using a right-of-use, or ROU, model, which recognizes that, at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to pay fees for operating expenses in addition to monthly base rent for certain operating leases (non-lease components). The Company has elected the practical expedient which allows non-lease components to be combined with lease components for all current asset classes. Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements are not unique and are retained by the lessor at the end of the lease. However, in the case of a space designed to be suitable for the Company&#x2019;s specific real estate needs and if the Company is responsible for cost overruns, the Company is the accounting owner of the leasehold improvements and costs associated are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s real estate operating leases provide for scheduled annual rent increases throughout the lease terms. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full terms of the lease. Tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the ROU asset related to that lease at lease commencement.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <beam:AssetAcquisitionsPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_47950677-72bb-49d4-bf45-89ddad81adcb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.&lt;/span&gt;&lt;/p&gt;</beam:AssetAcquisitionsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_fea7a073-3083-4293-a6f0-c33c68cc9a50">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may be required to make milestone payments to the former stockholders and optionholders of Guide Therapeutics, Inc., or Guide, in the form of its common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value is determined based on probability adjusted discounted cash flow model that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success or in the probabili&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ties as to the periods in which milestones would be achieved would result in a significantly higher or lower fair value measurement. The Company will continue to adjust the liabilities for changes in fair value until the earlier of the achievement or expiration of the obligations.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_72812e94-f23c-422d-8c30-1cc722f90adc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. To achieve this core principle, the Company applies the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. The Company only applies the five-step model to contracts when it determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Note 10.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. Determining the standalone selling price requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Note 10.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, (ii) the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property, or IP: If the license to the Company&#x2019;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#x2019;s license and collaboration agreements in Notes 9 and 10.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Milestone payments: At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore consideration included in the transaction price is constrained. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commercial Milestone Payments and Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_4204a2d4-28e8-4e54-a707-2941c6a485e5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract balances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as an account or other receivable. A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities, or deferred revenue, primarily relate to contracts where the Company has received payment, but it has not yet satisfied or fully satisfied the related performance obligations. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its obligations under these arrangements. Upfront payment contract liabilities resulting from the Company&#x2019;s license agreements do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The changes in the total deferred revenue for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;338,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions to deferred revenue from license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amounts recognized in revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_27443c21-39f5-40cb-8dd2-41b80c477e7e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The changes in the total deferred revenue for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;338,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions to deferred revenue from license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amounts recognized in revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_8e9711b0-6752-4af4-af46-25f624ff70d9"
      unitRef="U_USD">178594000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_23c34874-bdc1-42e6-b9e3-2958be00d4e1"
      decimals="-3"
      id="F_58726e61-648b-4bde-a62b-8064c59fdbd9"
      unitRef="U_USD">338153000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_4cba1d80-8fa7-4756-8856-c595d9e5f34e"
      unitRef="U_USD">36518000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_cc37a3ee-afbc-4dc2-83b5-333630320c3b"
      unitRef="U_USD">159559000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_f12a2066-e608-4024-a6c7-5d33f6bf0bab"
      unitRef="U_USD">142076000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_5c6dc34a-0009-46b8-9f38-fdfbba340242"
      unitRef="U_USD">178594000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_10e8d96d-528e-4384-9c47-5b4b478c6e45">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting, and other contracted services. The cost of obtaining licenses for certain technology or IP is recorded to research and development expense when incurred if the licensed technology or IP has not yet reached technological feasibility and has no alternative future use. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9dc01c3b-f851-4341-8b5d-7fe400204fc4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options, restricted stock awards and restricted stock units. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and other comprehensive loss based on their fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards and restricted stock units.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation awards are subject to either service- or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The Company bases its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus, weighted with its own volatility for the period in which its stock has been publicly traded. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees and non-employees, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_e3300ec2-5570-45e9-b51b-d44d53ac7bac"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_fa0904e3-abdb-4651-903c-afbcb6275f73">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred. Due to the uncertainty about the recovery of the expenditure, amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_f93b0390-d9c4-4ad2-99b4-e845e1ae306d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Variable interest entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii) the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_dc2969d4-b7a9-49cb-9875-e58a76931263">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_b33c5d5c-594c-4298-aa3e-e10689e4841b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in stockholders&#x2019; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in equity that are excluded from net loss. The Company&#x2019;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_fed40b4d-4b22-4017-ba5a-3215b87b3402">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For purposes of the dilutive net loss per share calculation, stock options and stock units for which the performance and market vesting conditions have been deemed probable, potential dilutive securities, unvested restricted stock, and common stock options are considered to be common stock equivalents, while stock options and stock units with performance- or market-based vesting conditions that were not deemed probable of meeting the applicable vesting conditions are not considered to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders was the same as basic net loss per share attributable to common stockholders, since dilutive common shares were not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_59411752-48c5-4e82-a539-98f7e64606ba"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_368bd464-a034-4238-90eb-ee8006040c63"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestments>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_79746371-c640-4857-ab8f-c65fe91fd1c1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment and geographic information&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment operating exclusively in the United States&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_307ef690-66e9-4f4c-8a4e-fc475bc7a86e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_b0417dd4-76c0-4c9c-8f48-bb23fab3561d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;, Segment Reporting (Topic 280). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of this standard did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements. The Company&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the ASU as of and for the period ended &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the required disclosures are included in Note 17, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Data&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently announced accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The amendments in this update expand income tax disclosure requirements, including additional information pertaining to the rate reconciliation, income taxes paid, and other disclosures. This update is effective for annual periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a"
      id="F_55001df2-3c8f-45ae-9f55-faa5b227ab0f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a"
      id="F_c4bffbd2-0519-4a5c-bbe0-17a6f558be8f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_a3572b5b-a007-4ae4-b166-33e00788180a"
      id="F_45326ddc-918f-40ab-a332-a91274f03709">2024-12-31</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_db75f5f0-3325-498e-bd0a-b5220ed2ad35">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. P&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;roperty and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes depreciation expense incurred (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_5bd02a4d-073b-44ef-8d2b-94a3c143a9b6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b9f60852-435f-4678-a85f-62bd679a4179"
      decimals="-3"
      id="F_4c660713-95be-4d2e-a201-20b66c683172"
      unitRef="U_USD">101195000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_23fc252d-db0b-4f39-ab2b-7b17b577a703"
      decimals="-3"
      id="F_a9e47516-4a30-4952-833c-f526ce1eea92"
      unitRef="U_USD">100186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_324afbe2-466a-44bf-954d-9a90de220b99"
      decimals="-3"
      id="F_adce0743-4d1d-4b1f-8d25-c795145cb904"
      unitRef="U_USD">71788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5d6e5236-b729-4f30-be75-4efef352181c"
      decimals="-3"
      id="F_d67e6046-2758-468f-a992-9fe899dcf6e8"
      unitRef="U_USD">61674000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9e71c9b4-c135-4fae-b90c-ed325df0b8f3"
      decimals="-3"
      id="F_62e1ae65-43f2-4216-bac5-6b0db9c3a534"
      unitRef="U_USD">4836000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c6e8ae6e-253b-496d-b53a-66bdfb253362"
      decimals="-3"
      id="F_0878cb4d-1467-460c-a4b4-b3558855b4a8"
      unitRef="U_USD">4836000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_817c79ea-b465-4bb1-8354-36977c68b051"
      decimals="-3"
      id="F_c2f6690f-4c76-4e31-ae84-edc0e716e2d7"
      unitRef="U_USD">3170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f91cd450-b36e-4a10-b341-9cb4a003d5a8"
      decimals="-3"
      id="F_3a13f1bd-6a76-4412-a098-eb59602737d3"
      unitRef="U_USD">3163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_91314f01-9991-4b7a-bf23-848ddb837575"
      decimals="-3"
      id="F_3efa2620-1d33-43b8-ab80-c3f0bffa1cd4"
      unitRef="U_USD">2530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_23ce121e-638f-43db-86dc-7ed74a544114"
      decimals="-3"
      id="F_c7acebb5-c079-4b3f-9d80-5a8e6ab44ed6"
      unitRef="U_USD">5283000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_a029634e-9865-4662-be84-75d04e3df5bb"
      unitRef="U_USD">183519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_70df8d28-97c1-4b55-be1f-d2bfe55b5a62"
      unitRef="U_USD">175142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_df468e8a-af15-4870-99cb-adeea3fffb9a"
      unitRef="U_USD">72107000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_76556bed-923f-4ac8-84de-acb1149a2bda"
      unitRef="U_USD">50182000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_80508325-e0cd-409b-8bdf-4e6ba0dd81b2"
      unitRef="U_USD">111412000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_cefdf11c-bb46-4d2f-a96d-eed55a870f94"
      unitRef="U_USD">124960000</us-gaap:PropertyPlantAndEquipmentNet>
    <beam:SummaryOfDepreciationExpenseIncurredTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c408378f-3003-42de-913e-8213f66cba25">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes depreciation expense incurred (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</beam:SummaryOfDepreciationExpenseIncurredTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_1f6dbb18-c661-48e3-b256-743abde1d797"
      unitRef="U_USD">21925000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_d9af18aa-f7e4-4a64-b6ec-196f51d06bcb"
      unitRef="U_USD">20012000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3e5359b7-a3d5-4f9d-903c-68eec6111542"
      unitRef="U_USD">14097000</us-gaap:Depreciation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_accf629a-3000-48fb-ae43-47b15da39245">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;air value of financial instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments that are measured at fair value on a recurring basis consist of cash equivalents, marketable securities, equity securities of Verve Therapeutics, Inc., or Verve, and Prime Medicine, Inc., or Prime, contingent consideration liabilities related to the Agreement and Plan of Merger, dated February 23, 2021, between the Company and Guide, or the Guide Merger Agreement, success payment derivative liabilities pursuant to the Harvard and Broad License Agreements and settlement payment derivative liabilities associated with a settlement agreement with a research institution.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;850,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;850,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative settlement liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy at December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;457,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2013; Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Commercial paper and corporate notes are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through using models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Marketable securities, excluding corporate equity securities, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024 and 2023, the Company held an investment in Verve consisting of shares of Verve&#x2019;s common stock. As of December 31, 2024, the Company owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;546,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Verve's common stock, the value of which is included in marketable securities in the consolidated balance sheet. The Company recorded the investment at fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other expense during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively, associated with changes in the fair value of Verve's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2022, Prime completed an initial public offering of its common stock. As of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,608,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Prime's common stock valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other expense during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively, associated with changes in the fair value of Prime's common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Success Payment Liability&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; As discussed further in Note 9, the Company is required to make payments to Harvard and Broad Institute based upon the achievement of specified multiples of the initial weighted average value of the Company&#x2019;s Series A Preferred or, subsequent to the IPO, the market value of the Company's common stock, at specified valuation dates. The Company&#x2019;s liability for the share-based success payments under the Harvard and Broad License Agreements are carried at fair value. To determine the estimated fair value of the success payment liability, the Company uses a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.822000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The computation of expected volatility was estimated using the Company's historical volatility along with available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the estimated number, timing, and probability of valuation measurement dates in the calculation of the success payment liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Under the Guide Merger Agreement, Guide&#x2019;s former stockholders and optionholders are eligible to receive up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in technology milestone payments and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in product milestone payments, payable in the Company&#x2019;s common stock valued using the volume-weighted average price of the Company&#x2019;s stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is achieved. As these milestones are payable with a variable number of shares of the Company&#x2019;s common stock, the milestone payments result in liability classification under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs based on timing of achievement that were unobservable in the market. These contingent consideration liabilities are classified within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Technology Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Product Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of Achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Projected Year of Achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Technology Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Product Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derivative settlement liability&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; On July 19, 2024, the Company entered into a settlement agreement with a research institution pursuant to which, in exchange for a release of claims in its favor, the Company agreed, among other things, to pay the research institution an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and to make additional payments contingent upon the development and commercialization of BEAM-102 and BEAM-302. These contingent payments consist of certain development, regulatory, and sales-based milestone payments, as well as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty through 2038. Any amounts due must be settled in cash. The maximum amount of development and regulatory milestone payments under the settlement agreement is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and the maximum amount of sales milestone payments is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, per program. The Company paid the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment during the 12 months ended December 31, 2024. There was no material charge related to this settlement in the year ended December 31, 2024 as the settlement value was substantially accrued in prior periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contingent settlement payments are accounted for as a derivative under Accounting Standards Codification 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as the potential payments meet the definition of a derivative and are not subject to any scope exceptions. The derivative liability is recorded at fair value on the Company's balance sheet with changes in value recognized in interest and other income (expense) in the consolidated statement of operations and other comprehensive loss. To determine the estimated fair value of the liability, the Company applied a probability-based model, which utilized inputs based on the potential achievement and related timing of certain development, regulatory and sales-based milestones that were unobservable in the market. This derivative liability is classified within Level 3 of the fair value hierarchy above.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following assumptions were incorporated in the calculation of the fair value of the derivative settlement liability:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.315%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.424000000000003%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of achievement of settlement payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Projected Year of achievement of settlement payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in fair value of the derivative liability based on level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.914%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.485%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial recognition of derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0e2e6776-6eac-47b2-a9b3-c37568cf00d8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;850,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;850,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative settlement liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy at December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;457,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Success payment liability &#x2013; Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contingent consideration liability &#x2013; Product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bc54d5fa-e469-4984-8576-7bcd6d681ec9"
      decimals="-3"
      id="F_631c7295-1e61-4671-9146-5a86c9a4413e"
      unitRef="U_USD">281786000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2f5b4752-7d3c-4f25-abd8-17c95208595a"
      decimals="-3"
      id="F_60039823-cfab-4620-bff2-147440fe9bb6"
      unitRef="U_USD">281786000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6e43c27e-aca0-44b5-b3bb-27130f064fd6"
      decimals="-3"
      id="F_3d762b7d-341b-4201-90b5-95fdc76cbcde"
      unitRef="U_USD">281786000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0ee731d4-613b-4c17-be22-2735e8f23bcf"
      decimals="-3"
      id="F_2825c44d-0543-49b9-ac08-596f7a9bcc79"
      unitRef="U_USD">181296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_55ec542c-c4d2-4393-9e6b-a19e465465aa"
      decimals="-3"
      id="F_c3125b5d-1bfe-46da-9ad7-366854b47d03"
      unitRef="U_USD">181296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9c33e7b3-8a93-4aa9-a157-7bb70a697ac5"
      decimals="-3"
      id="F_f86804dc-27a2-45c6-bd62-2f8e5787c4d5"
      unitRef="U_USD">181296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bc22551d-700b-4bc6-97af-b994c3ba0a2e"
      decimals="-3"
      id="F_53e2bf16-7d89-4ea2-b01a-53ecb5835b24"
      unitRef="U_USD">100165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_683f1b33-2bd8-4061-9079-5d7ad5b7fa98"
      decimals="-3"
      id="F_ce57ec33-4eb8-4652-97b1-a7f7142284bc"
      unitRef="U_USD">100165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6ae048e6-a4cd-4f07-9ad4-aadfd8ecf040"
      decimals="-3"
      id="F_dad72acd-3940-4961-a222-462cd6fff76f"
      unitRef="U_USD">100165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_383b09a9-52f2-47a2-9a87-2d0c4207c081"
      decimals="-3"
      id="F_1e139d71-8bc7-4771-972f-672ecbfde862"
      unitRef="U_USD">164770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad3ad482-636a-4574-9008-c4bfd3d86594"
      decimals="-3"
      id="F_fd6182df-277a-4fc2-8899-248dc942354e"
      unitRef="U_USD">164770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d2eb4314-6249-4e88-ab61-d2f3989cba46"
      decimals="-3"
      id="F_ee0c7829-1991-4d08-9eae-c54b9492cbdd"
      unitRef="U_USD">164770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3b9e7d95-7542-4a96-be2f-5ddf5efc044b"
      decimals="-3"
      id="F_b1b5d48a-7a15-482f-a219-11567ec70655"
      unitRef="U_USD">114761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2e4a2701-d32c-4f02-930f-f0d27e58173d"
      decimals="-3"
      id="F_2237745b-0766-4d08-8de4-f0ab7a6b9cc4"
      unitRef="U_USD">114761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e5a0c25d-1ed8-41b2-b186-af6d43e40731"
      decimals="-3"
      id="F_9a6beb34-8c6d-4655-9e87-e76073f6a528"
      unitRef="U_USD">114761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_5d64756d-a5a5-4436-8aa5-135287bdbf64"
      decimals="-3"
      id="F_8285e87e-1bbb-4651-a3e0-154ac9d4d2a7"
      unitRef="U_USD">7781000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_cf2ed59c-a2d6-4c18-ba5c-2809399c54d4"
      decimals="-3"
      id="F_7e803b05-0d53-4d08-8b9f-2d14929dbff1"
      unitRef="U_USD">7781000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_01b2a6c8-36f9-4f72-bd42-832c0a6e6c71"
      decimals="-3"
      id="F_66db8d5e-0c31-4e6e-ab0b-6b15d1eba612"
      unitRef="U_USD">7781000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808"
      decimals="-3"
      id="F_b0b44ee6-1370-4614-b8b1-44298002532a"
      unitRef="U_USD">850559000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd"
      decimals="-3"
      id="F_9bb5b434-99f3-46a2-a3de-4c76eeda8c91"
      unitRef="U_USD">850559000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_81c512a2-b46f-4d8c-9387-3f1e58834fa0"
      decimals="-3"
      id="F_534b2b6c-e292-4843-a68f-61053313425b"
      unitRef="U_USD">289567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bf27e455-b39d-4609-980a-18b8f5630e5f"
      decimals="-3"
      id="F_177e127e-3a44-4f09-853f-0aa894521442"
      unitRef="U_USD">560992000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_3019e88f-46c3-46a0-aaa1-f470bb587e9d"
      decimals="-3"
      id="F_c191ff8e-7cdd-47db-8d93-601e1368c3c8"
      unitRef="U_USD">3900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_66656a01-1fea-46c0-875c-123162651c9f"
      decimals="-3"
      id="F_dc774359-4b60-4f03-8f02-00a5e70414af"
      unitRef="U_USD">3900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_7e896a77-237e-4692-a24d-3c3b46d3a2db"
      decimals="-3"
      id="F_d4a4d623-4355-4779-835f-f6242c8adf9e"
      unitRef="U_USD">3900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_0e6c1574-d290-4081-9ab2-1ea6ba4e8324"
      decimals="-3"
      id="F_3aaea7d2-00f4-4aee-93b0-ec59fbd3307a"
      unitRef="U_USD">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_943bbfdd-15ab-44cf-894a-0a745768d5a3"
      decimals="-3"
      id="F_e4a76e7b-66ec-4a62-af4e-8091959ae03b"
      unitRef="U_USD">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_3112c485-fa21-4803-9cf3-c428e7cc148a"
      decimals="-3"
      id="F_6430b689-fe3a-4518-80c6-c44cc4a7f5a7"
      unitRef="U_USD">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808"
      decimals="-3"
      id="F_9ee26cac-e4b4-435b-96c0-54b0a5d773c6"
      unitRef="U_USD">5404000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd"
      decimals="-3"
      id="F_0ca37b7a-6d79-4458-8822-6b76c94fd878"
      unitRef="U_USD">5404000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b"
      decimals="-3"
      id="F_43bedee6-53e7-4e9a-a208-354915cbc11c"
      unitRef="U_USD">5404000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_033b016b-6895-4539-b361-157a3608f06c"
      decimals="-3"
      id="F_a9aa96b9-946c-4978-b22e-03b1d880d6d3"
      unitRef="U_USD">496000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_e09cf5f9-77a3-4eb4-b400-584b976cf70e"
      decimals="-3"
      id="F_7519ebeb-1da1-4bf6-ad04-610231404dcf"
      unitRef="U_USD">496000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_7d97cc6a-a7a9-4cdc-bdd8-2d91dd596f4a"
      decimals="-3"
      id="F_17e87756-98b7-428b-a3d0-9e597e54b426"
      unitRef="U_USD">496000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_5857fee8-666a-476e-977c-4c0b45614d60"
      decimals="-3"
      id="F_9cfa3a22-a0d6-4681-9a11-ee8aa6934b48"
      unitRef="U_USD">635000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_4c1fa6f3-850d-46e4-b180-0fdb4f170121"
      decimals="-3"
      id="F_513173db-dd21-480b-a6c9-3357e85b4a39"
      unitRef="U_USD">635000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_d499c8ac-d8df-400b-8755-7d20c1c148c7"
      decimals="-3"
      id="F_4893eee0-e84a-4067-973f-632dd4ef27c7"
      unitRef="U_USD">635000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1032047d-f16a-438d-95bb-df888c1ca808"
      decimals="-3"
      id="F_07aff6af-b15b-4dd6-8fc4-c3d8ed41e25b"
      unitRef="U_USD">14935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_f4f4b14f-4170-409c-aaa4-52227cbb19fd"
      decimals="-3"
      id="F_3f37c32e-e32a-4213-b506-4bf11a72d493"
      unitRef="U_USD">14935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_30dc2945-1fee-4b5f-b9fd-8aeb1c465c7b"
      decimals="-3"
      id="F_80ae78d3-e6d5-472c-812c-33bc52faef2a"
      unitRef="U_USD">14935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_40bf49b4-00ca-4786-9c26-7a8dce5bfd9c"
      decimals="-3"
      id="F_dd3bfdb3-6d3d-490b-8533-a2aa1fdabcac"
      unitRef="U_USD">435689000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_82d42227-3e5c-4f52-9372-708bac5614fc"
      decimals="-3"
      id="F_3642f5ac-672f-4b06-b39b-d5c65684a49e"
      unitRef="U_USD">435689000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d9c08767-4f6e-47cc-be86-e673973ca8ad"
      decimals="-3"
      id="F_79efed45-0f0e-40e2-ae0d-1fae257a75c3"
      unitRef="U_USD">435689000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_43ded48b-9f05-4004-ac86-baa2f80a25b5"
      decimals="-3"
      id="F_8faca5b4-6cbd-40c5-ae6b-826a8091313d"
      unitRef="U_USD">285289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_52f693f7-a425-4188-9db1-a96f66ed8a57"
      decimals="-3"
      id="F_f035788f-ef96-4613-8df6-5d5a1eabc7a2"
      unitRef="U_USD">285289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_87adf2d6-df78-4402-8dd8-a6be3d79324e"
      decimals="-3"
      id="F_0854ce59-5ddf-4709-85f7-19c2a488a16c"
      unitRef="U_USD">285289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_98e29b92-f652-4c61-b122-e4d83608d91b"
      decimals="-3"
      id="F_5aee8765-82dd-49d0-b115-82493c01282a"
      unitRef="U_USD">23525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e2e2c4ed-f4d9-44d7-bdf2-3812900f3384"
      decimals="-3"
      id="F_3f8ac8c0-5ced-43d4-aa4b-c3c5a6a1180e"
      unitRef="U_USD">23525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f8810dbf-4f3c-4f86-9ff9-d0d332a94fe0"
      decimals="-3"
      id="F_7b2a2137-a88b-46f5-8b29-f4d8ad0f8b1c"
      unitRef="U_USD">23525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8f22ed6f-66b3-48a8-b7b5-ae4b554749dd"
      decimals="-3"
      id="F_e98fcc87-8d8b-480b-8210-44001ca9d87e"
      unitRef="U_USD">152147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_244af9b5-ee40-4af4-8025-4f3676ba9ad1"
      decimals="-3"
      id="F_23126ebf-c494-41d0-88d2-9cd3216ecfb2"
      unitRef="U_USD">152147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_85f101d5-687c-4b48-a5aa-3771ed3f1761"
      decimals="-3"
      id="F_a6c7a797-aeb3-4c52-ad9e-e9447344c3a2"
      unitRef="U_USD">152147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0345315c-39e6-4913-8fb3-95c4a3fb15d2"
      decimals="-3"
      id="F_6ef896a4-10b0-41b7-9f0b-0039585f663c"
      unitRef="U_USD">271145000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c6a74e2e-8d45-4ca0-9483-c5961f7d2166"
      decimals="-3"
      id="F_9e79305b-2f7e-465c-b41e-78f894c42636"
      unitRef="U_USD">271145000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0faad1e3-a733-4640-bd7e-1ccdf04dcbda"
      decimals="-3"
      id="F_75b6172a-0bad-4193-b163-7713a0be197c"
      unitRef="U_USD">271145000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_e64b5f77-b749-4105-a5c5-6201bccd7330"
      decimals="-3"
      id="F_50d09261-1970-4f7a-9c03-5525bea66026"
      unitRef="U_USD">21875000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_98297106-5ba9-49e4-9046-f4505117edac"
      decimals="-3"
      id="F_caa621e8-250a-4df2-afe5-da6ad55fa9dd"
      unitRef="U_USD">21875000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_bef248b2-037e-41dd-b7a6-9d8e777e673c"
      decimals="-3"
      id="F_8b6b0f6a-b141-4dc9-b1ed-0c7b0f35b33d"
      unitRef="U_USD">21875000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4"
      decimals="-3"
      id="F_5afb03e6-7304-4ac1-a0fa-7195ece77fdd"
      unitRef="U_USD">1189670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fd96341a-93d5-40cd-b881-5aa499e5c784"
      decimals="-3"
      id="F_d9a5c04c-6bad-4c88-9d66-cea880807cfa"
      unitRef="U_USD">1189670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4199c4a6-3fa7-41c4-9f65-6bba20a54792"
      decimals="-3"
      id="F_c7e935ad-1789-4d31-93dd-0cff3db0f824"
      unitRef="U_USD">457564000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_388bb271-1237-4e73-bb59-50ed985c9182"
      decimals="-3"
      id="F_cab34cb7-ff54-4df0-a018-100597f1710c"
      unitRef="U_USD">732106000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_5bf0ef81-7ab5-4b17-86bb-38c4a75f4dea"
      decimals="-3"
      id="F_6524a8ae-ba3f-4029-8c93-f1a5cecbdc9f"
      unitRef="U_USD">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_25de5467-3e1a-4a4d-82d0-cb68b684e458"
      decimals="-3"
      id="F_a819a237-faa4-453c-a798-a9eb587c6b91"
      unitRef="U_USD">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_e38cf897-c702-4909-b484-fcd5d6b3590c"
      decimals="-3"
      id="F_35a784c7-c80e-4db5-80f9-d3d0923fdb1a"
      unitRef="U_USD">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_cad5e1f8-39af-4380-a00d-766ccfd05763"
      decimals="-3"
      id="F_9e0ee0f7-c19e-47a0-8661-b3bbc1ac47f6"
      unitRef="U_USD">5600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_2319aab4-a1e3-430e-8e4d-7cceabb77d5e"
      decimals="-3"
      id="F_f8011ed7-f118-4f68-b210-632bae220fd3"
      unitRef="U_USD">5600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_e41e2e9a-3d40-4c73-9a6a-0d57206be6a7"
      decimals="-3"
      id="F_4f43ca85-a158-49d1-bc81-4f6ba3506edb"
      unitRef="U_USD">5600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_9064c4c3-29b7-480d-8518-b5181173d660"
      decimals="-3"
      id="F_4b2a0396-3b1d-446b-9b45-9f621ebbdb7d"
      unitRef="U_USD">1371000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_c2169fb1-18be-4514-9888-865d6522b536"
      decimals="-3"
      id="F_c1cb0b5c-66d7-4e51-87f9-741f51d267d3"
      unitRef="U_USD">1371000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_8344d4f6-8b07-419a-b031-0646b3b208b4"
      decimals="-3"
      id="F_43d2eabe-bdbb-450f-8ac0-4bc14634e332"
      unitRef="U_USD">1371000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_fc0f5107-4297-4f5b-b705-3f7c3b7a3888"
      decimals="-3"
      id="F_e604c95f-60a2-41a5-86f4-ffcda4910201"
      unitRef="U_USD">1352000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_cfa419f9-1c34-4353-b182-40b224d5ecee"
      decimals="-3"
      id="F_3baebd44-13a3-47f0-b7e6-fd601a175b51"
      unitRef="U_USD">1352000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_e09975e5-fe39-42ca-9dd2-53a5844a5478"
      decimals="-3"
      id="F_9bbc38c6-b134-44ad-8628-97187e98651b"
      unitRef="U_USD">1352000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_47f52854-8275-4ccd-9bfd-c33a0210e0d4"
      decimals="-3"
      id="F_31999806-d7bf-4c5c-a23d-06ee88b6c0d9"
      unitRef="U_USD">13523000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_fd96341a-93d5-40cd-b881-5aa499e5c784"
      decimals="-3"
      id="F_5169c164-9f9c-4a7e-92c5-9e42083a1983"
      unitRef="U_USD">13523000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_814c73a2-13c5-4097-a2c8-bac30dd2d509"
      decimals="-3"
      id="F_4243f6fb-e107-4895-8571-c564b56777d2"
      unitRef="U_USD">13523000</us-gaap:LiabilitiesFairValueDisclosure>
    <beam:EquitySharesHeld
      contextRef="C_36b8ac53-6fab-4279-8285-1a0366571ae4"
      decimals="INF"
      id="F_873ba82d-5c8f-402c-aeff-20655bcabb5f"
      unitRef="U_shares">546970</beam:EquitySharesHeld>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_e9cd4ea8-3457-4c9a-9f89-0bc504f1aa04"
      decimals="-5"
      id="F_912a1912-7477-4346-97ea-fc3058299704"
      unitRef="U_USD">3100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_ef90c8a2-4431-4529-a22a-71ad29ed2842"
      decimals="-5"
      id="F_71c393b3-b39a-476f-90ab-7e0a24bd9157"
      unitRef="U_USD">7600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_ea4d3092-a838-4e9e-9f43-dfd61bbd3ac8"
      decimals="-5"
      id="F_cf70edb4-41fe-44f1-b0bc-9c990d9892cd"
      unitRef="U_USD">-4500000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_389b0c5f-dbe8-49a8-ab15-9087170a4b41"
      decimals="-5"
      id="F_a700ed9e-9a6f-47e6-93df-2b6e4fb7a8c8"
      unitRef="U_USD">-3000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <beam:EquitySharesHeld
      contextRef="C_ee6bd22e-01c2-4e00-93f7-c74415f012a3"
      decimals="INF"
      id="F_77a70a11-e2fd-41b3-8b65-fda17fe06ec4"
      unitRef="U_shares">1608337</beam:EquitySharesHeld>
    <beam:EquitySharesHeld
      contextRef="C_d81129aa-e4b3-4b3a-b639-c6b46fd97eeb"
      decimals="INF"
      id="F_3f0291cd-f583-4bfb-980e-c442bec03249"
      unitRef="U_shares">1608337</beam:EquitySharesHeld>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_07957533-1268-4b9e-a1dc-14b0a90775cc"
      decimals="-5"
      id="F_46790ac3-87a0-4d90-bbde-da83e60299f6"
      unitRef="U_USD">4700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_f3b3e1c3-33ab-45c8-9774-7e07c887e615"
      decimals="-5"
      id="F_5959b9bf-41aa-4214-bd23-9c5a1d5f5547"
      unitRef="U_USD">14200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_946fe569-b5da-4993-a5e7-d60b0d8a7441"
      decimals="-5"
      id="F_95165160-0997-4e99-b6af-832e5dd31c81"
      unitRef="U_USD">-9600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_17281164-6360-4131-bbca-c983bf53650c"
      decimals="-5"
      id="F_c9566283-1040-4098-a5a2-7ae73f9f0618"
      unitRef="U_USD">-15600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_9634d241-0955-4143-9459-520985fd6173">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a962cc09-2a8c-4490-81ec-7cda2c31aa57"
      unitRef="U_USD">-14093000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_7040ce9c-8e58-4f48-99d8-ecf5f2e78538"
      unitRef="U_USD">-18592000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_f5ea164c-7ed5-479c-a734-f44a0183e8e4"
      unitRef="U_USD">20200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e"
      id="F_c72767de-daff-40f7-b28b-5fd4b7b71dfa">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.822000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_7e8d88d5-e635-4ad6-85a1-6c2a328dfa18"
      decimals="2"
      id="F_1fccbfc9-232c-47f3-a38b-7dbd50a63cc7"
      unitRef="U_pure">24.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_ab0bc947-ab71-4f35-bc58-9f7f62090216"
      decimals="2"
      id="F_24e761ec-4801-450c-972d-509d532d4a91"
      unitRef="U_pure">27.22</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_f14e16da-1c53-4541-9a52-16820f10bad3"
      decimals="2"
      id="F_ec30e141-956c-4d59-90d2-10477fd0b265"
      unitRef="U_pure">24.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_6026a8e0-6d93-4439-a24e-e03c582cd8c8"
      decimals="2"
      id="F_f5b7654b-a101-450d-9e72-9b7e9c5092d2"
      unitRef="U_pure">27.22</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_e23b6999-779a-4b5c-abb4-d337cb7a4896"
      decimals="2"
      id="F_6fed7c7f-48c7-4a13-af10-e505a99937c7"
      unitRef="U_pure">0.78</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_21a59809-dfb3-4b7d-8868-958dd1e18924"
      decimals="2"
      id="F_34680c88-284d-4bf6-8d97-c1dc6538d8bf"
      unitRef="U_pure">0.80</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_e0cca600-4621-432f-b776-908bc8bb5ba7"
      decimals="2"
      id="F_e636aed5-d543-4144-9313-251c6af9ed04"
      unitRef="U_pure">0.81</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_d996319a-4fd9-4406-ad76-885120f0800c"
      decimals="2"
      id="F_5f73c06a-72c4-46dc-b31a-de27bb338c2d"
      unitRef="U_pure">0.79</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_0a6ecb33-4df6-4c5e-a4a2-fb3d9efdf7cd"
      id="F_0dc6370f-1553-4618-baea-65cf3ae31dd5">P0Y10D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_813182af-346c-4681-a9ad-91dbab4005fb"
      id="F_73b4f1be-921d-4fbf-914a-1deafbe6fde6">P4Y5M26D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_0e6053bb-b35e-475a-bcae-f92658e7661a"
      id="F_9548a7bb-f314-489e-8b4f-523742f7bbfd">P0Y21D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_f791e745-de9c-42ed-8a7a-14e39c2a105f"
      id="F_9cd1856e-b4fa-4b65-b32b-11d5534b3738">P5Y5M26D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_ff00880d-6565-4225-b41c-28e680e96f39"
      id="F_8c602cae-8583-4496-9442-a8bd1f364ef0">P0Y10D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_de039678-b07d-4465-a92c-33cf16c0096f"
      id="F_592f57f1-7527-4277-96b9-04cd41bcae0f">P5Y4M9D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_f6e9e1b7-0f7e-4ca5-8405-404a9168b722"
      id="F_8362fca3-d290-471c-b1e2-e043140b9e3f">P0Y21D</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_6ac8ef0e-3351-4f21-bad5-60d55bade8c9"
      id="F_057755be-9831-458b-bf78-ce8a107a0af3">P6Y4M9D</us-gaap:DerivativeTermOfContract>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e"
      id="F_5e0746fa-cd60-42bc-b646-6e4528b97a30">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Harvard&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Broad Institute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_b942b8ee-cafd-4a43-b778-957590c7d5a6"
      decimals="-3"
      id="F_1d30ec21-34d7-4c96-88a1-ef1147cf04da"
      unitRef="U_USD">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_e1810127-cbd6-4854-8acf-9b9986eb6b42"
      decimals="-3"
      id="F_2f0a3a9c-0d96-4a74-b2d4-609b63c1fb8b"
      unitRef="U_USD">9300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f7d01556-0db0-4405-b94b-9d3f9b6e51a6"
      decimals="-3"
      id="F_f1a038e0-6d56-4412-9ef1-253a79b16a68"
      unitRef="U_USD">18300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_46319399-2d12-411d-8c34-596d176648f2"
      decimals="-3"
      id="F_9e912f13-934b-4d8a-ab3e-f0978aad4858"
      unitRef="U_USD">-3800000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_3ab34109-c504-4c2d-b824-f10aa01d2eaa"
      decimals="-3"
      id="F_10f49dd5-d985-481c-8a24-dc0c66c099c3"
      unitRef="U_USD">-3700000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_c0afc77b-a8b0-40be-ba4a-78a824b97e4b"
      decimals="-3"
      id="F_4a2ced5d-569e-4641-8dd5-46fce53e573d"
      unitRef="U_USD">-7500000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_96d19294-dd72-40a8-a259-c7e1d6e2f357"
      decimals="-3"
      id="F_11da0d95-3536-45bd-a409-9978f38a4afb"
      unitRef="U_USD">5200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_7b3060c0-eaf2-45d0-a198-e1f21e52d13b"
      decimals="-3"
      id="F_c6327444-0ffb-421a-90ea-fdd8812521a8"
      unitRef="U_USD">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0bc8b385-01b6-4b97-b455-c669606db4c9"
      decimals="-3"
      id="F_210f6138-6064-4291-b66c-6e4a56b75eee"
      unitRef="U_USD">10800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_53ff89ee-a53c-493c-897d-5a1e22a591f0"
      decimals="-3"
      id="F_483feeca-2f4b-40b2-b8bf-4262f6020958"
      unitRef="U_USD">-1300000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0c39d71b-489e-44e9-a246-f57bf060b04f"
      decimals="-3"
      id="F_f2ecdb94-f6a0-41d0-b0c7-d4730a0aa0f5"
      unitRef="U_USD">-1100000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_fe0fe99f-d377-4022-9d8f-64f7a6020f3e"
      decimals="-3"
      id="F_7175d282-9c6b-4c41-8d1f-d78f96b45d4f"
      unitRef="U_USD">-2400000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1df55ac6-9859-4cab-9d1d-717a8ccaca01"
      decimals="-3"
      id="F_3e030dc9-a5b6-4f39-a4ae-bb0a93a51ee3"
      unitRef="U_USD">3900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_b377391a-9d98-4bd0-8cd9-4b1adecb8106"
      decimals="-3"
      id="F_fa0fff2f-5c86-438b-971a-c24eafce30c3"
      unitRef="U_USD">4500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_4e0928f3-a41c-46c8-adbf-38ad87f13f70"
      decimals="-3"
      id="F_b68cf35a-b807-4925-a1ef-a638c8eb6155"
      unitRef="U_USD">8400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <beam:PotentialMilestonePayableInFormOfCommonStock
      contextRef="C_db910110-c7b9-47bd-9b00-ef30f2e39bbb"
      decimals="-5"
      id="F_2926ebbe-68f5-4f1e-98bd-2589aa68ef75"
      unitRef="U_USD">100000000</beam:PotentialMilestonePayableInFormOfCommonStock>
    <beam:PotentialMilestonePayableInFormOfCommonStock
      contextRef="C_5faf1e6f-7db9-44a9-9e75-3c1cdc11b9ce"
      decimals="-5"
      id="F_340c7990-e990-4d9d-b107-2f7a7a96c555"
      unitRef="U_USD">220000000</beam:PotentialMilestonePayableInFormOfCommonStock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939"
      id="F_41979b49-4a5c-48db-9134-37fe5f64e078">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Technology Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Product Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of Achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Projected Year of Achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_cfbe57c7-0589-40d9-95a3-4e571ea9c241"
      decimals="4"
      id="F_a79768a9-40a2-45cf-b113-ca7b0ae4c491"
      unitRef="U_pure">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_3323b4d1-71fb-4439-a445-cda91d3bdbde"
      decimals="4"
      id="F_a19b2256-fe4b-4bbe-a5d6-837d7f743182"
      unitRef="U_pure">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_21ed1982-a773-41b3-9848-3a746c980eb5"
      decimals="4"
      id="F_7e6375d8-8608-4b1d-8af4-2482d1ba3779"
      unitRef="U_pure">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_1320b092-7bb5-4608-a1f8-382e3ea5a98a"
      decimals="4"
      id="F_9b7bb58e-9ac0-4990-a2f2-30053535e7bc"
      unitRef="U_pure">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_e78edfaa-86d2-4b56-8b7f-1698cc8559cd"
      decimals="2"
      id="F_ff457a60-22d1-48e9-8112-a73142a111d7"
      unitRef="U_pure">0.02</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_ba54c365-7b5b-490a-a13d-b7f791f97e43"
      decimals="2"
      id="F_fec6dded-edf4-438e-828c-fc796225bf8d"
      unitRef="U_pure">0.02</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_d654daf4-dddc-4c8c-bf67-b1fb10abf6ab"
      decimals="2"
      id="F_8aaeb374-d5f0-4525-9a78-9f0c66645cdb"
      unitRef="U_pure">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_e8dda33f-8c82-42ac-b988-c7074b08349c"
      decimals="2"
      id="F_6dafd800-235e-4347-9240-c5677e4b3bc9"
      unitRef="U_pure">0.01</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_bfa4765e-7ba8-440e-948f-ab1010661413"
      decimals="2"
      id="F_2c780dd5-56cf-4d05-b6a9-7f6b6580ca0f"
      unitRef="U_pure">0.02</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_81012567-268b-4289-94b6-e8719b8246c6"
      decimals="2"
      id="F_6d6da8f2-132c-494d-9f87-02c6b3e92314"
      unitRef="U_pure">0.01</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_836d03ea-dc4b-4efb-b811-4ce1b53f71f4"
      decimals="2"
      id="F_89b8b94f-c547-42ed-a833-7a1985d9bd07"
      unitRef="U_pure">0.02</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821"
      id="F_287ed916-f38a-44f0-8c55-bb6415f4a6fd">2026</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7"
      id="F_61f82e88-4fb1-4ed8-a6cc-32684bc1bfa0">2025</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_23df4ae1-062b-4bd7-b3e6-9c50a1bd7d4f"
      id="F_f3ac817b-7931-4cde-8366-ca0d5afc983f">2028</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_886c80e8-4054-44c9-a88c-53a8d43b6e0e"
      id="F_14e0f7c1-b3d9-4c10-915b-f30e9a1ea775">2034</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_46b2d578-5aad-4081-994e-51251d5c3c82"
      id="F_9dde4dd0-e2f3-4473-a431-2295841f9857">2025</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear
      contextRef="C_b0b3e437-b9b5-409d-a425-2ab1467d81a1"
      id="F_115f282b-5c8c-4f47-ae0b-38add186326b">2031</beam:BusinessCombinationContingentConsiderationLiabilityExpectedAchievementYear>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939"
      id="F_45bf9145-6c94-499c-b418-86b222304e11">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Technology Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Product Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1ab7b8fc-388e-483b-a455-4d344bf26d3f"
      decimals="-3"
      id="F_8587bb22-7d34-4431-9cdc-78032b6e131e"
      unitRef="U_USD">6025000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a1582983-8e90-4aba-91dc-4e54d1f21245"
      decimals="-3"
      id="F_6f46c7d6-87c8-4a35-bec0-dda4dd26e6a5"
      unitRef="U_USD">6438000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d2b86f6d-7df8-4851-bf8a-c817cab8b129"
      decimals="-3"
      id="F_d57b3f66-e189-465e-9adf-b61de4bdf410"
      unitRef="U_USD">12463000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_bb4c3f17-3a94-45f5-bab7-e4625eb997c7"
      decimals="-3"
      id="F_ef829fbd-4ea5-4626-a117-8fa43e421bf0"
      unitRef="U_USD">-4654000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_64b520ff-9453-43d5-8018-62b50616536e"
      decimals="-3"
      id="F_6e11b751-39a9-4968-936e-90348d4f70cd"
      unitRef="U_USD">-5086000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_82e2a9c0-7247-45b0-b901-8dec8be826ad"
      decimals="-3"
      id="F_f87d4701-60a2-4f66-b183-490095437e0d"
      unitRef="U_USD">-9740000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f4879e76-4b06-44ba-bf62-86e70abf1d54"
      decimals="-3"
      id="F_7a9d622e-35cd-4a40-836c-13eba805bbf4"
      unitRef="U_USD">1371000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_8b3ff14f-8fb9-421a-a317-71af6ec52baa"
      decimals="-3"
      id="F_8f7a5498-fd7a-4729-b6bd-8f4853981328"
      unitRef="U_USD">1352000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_9b047b26-6d29-4529-a19f-49dec29b0738"
      decimals="-3"
      id="F_809ee891-bbf4-454c-a24e-de73926599e2"
      unitRef="U_USD">2723000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_ed503adf-3b7f-4089-9aaf-1cdaa5e74821"
      decimals="-3"
      id="F_de6a068a-bbf1-4aec-837d-64c4dfbd8859"
      unitRef="U_USD">-875000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_55e6ef57-9f81-41ee-995e-bf71d1163777"
      decimals="-3"
      id="F_b74d03e2-68c0-487d-9839-b4691d922711"
      unitRef="U_USD">-717000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_3c8e1fae-ab75-4606-a07b-ce821c7a4939"
      decimals="-3"
      id="F_9bb4b732-2e64-49d8-8d75-5d6c0cfcc7de"
      unitRef="U_USD">-1592000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_bcb6c93c-f14e-4acc-a009-3920a219ed08"
      decimals="-3"
      id="F_e67fea48-a79a-4e03-a2a8-31a72a60e1ec"
      unitRef="U_USD">496000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_946d0d92-ab51-4d13-aa91-deb5bafa88d2"
      decimals="-3"
      id="F_e976e0bb-8ffa-4219-a1ef-bce9a8f295df"
      unitRef="U_USD">635000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_ee6f8e30-6665-4a51-9ae1-dad612ace074"
      decimals="-3"
      id="F_ba941b04-48be-4baf-8ead-2f3685ac6f25"
      unitRef="U_USD">1131000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <beam:SettlementAgreementUpfrontPayment
      contextRef="C_f74446ed-1db8-4037-8b3c-5b97e15acbc4"
      decimals="-5"
      id="F_f0b807dc-7b74-4a17-8b9a-bc506a006b12"
      unitRef="U_USD">15000000</beam:SettlementAgreementUpfrontPayment>
    <beam:PercentageOfRoyaltyPayments
      contextRef="C_e1dc78b3-e0f0-4747-bbd1-31a2907ab93e"
      decimals="2"
      id="F_4d69546d-d544-4a01-9e58-f8f98f2df09d"
      unitRef="U_pure">0.01</beam:PercentageOfRoyaltyPayments>
    <beam:PotentialMilestonePaymentsDueUnderSettlementAgreement
      contextRef="C_75673cb0-aa17-46e5-a5b8-9bf245874d0a"
      decimals="-5"
      id="F_a97142b3-0f46-4fa3-abc2-d9a612e0ebe3"
      unitRef="U_USD">15000000</beam:PotentialMilestonePaymentsDueUnderSettlementAgreement>
    <beam:PotentialMilestonePaymentsDueUnderSettlementAgreement
      contextRef="C_43329f90-70ad-4d83-9eb9-e3326b1f696b"
      decimals="-6"
      id="F_7dd3f5c1-9dd7-4140-955a-267dd5cce00a"
      unitRef="U_USD">35000000</beam:PotentialMilestonePaymentsDueUnderSettlementAgreement>
    <beam:SettlementAgreementUpfrontPaymentPaid
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-5"
      id="F_06ed405b-c6c8-43a7-b443-7b8e428aadac"
      unitRef="U_USD">15000000</beam:SettlementAgreementUpfrontPaymentPaid>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b"
      id="F_82e0e483-e3f0-4fe1-85f3-8575095c38df">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following assumptions were incorporated in the calculation of the fair value of the derivative settlement liability:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.315%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.424000000000003%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of achievement of settlement payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Projected Year of achievement of settlement payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_19c18905-de30-4069-8f57-7d6b0794deab"
      decimals="4"
      id="F_b1718e12-0b40-4816-a6aa-ad4526c6003b"
      unitRef="U_pure">0.10</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_b3cae63a-1abc-4394-a9ad-0e685d5f41a5"
      decimals="2"
      id="F_b2f89820-e15b-484c-99b9-2232e27b1f3e"
      unitRef="U_pure">0.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_7171d6c3-3dec-4790-a576-1812c763d4fd"
      decimals="2"
      id="F_0c085fb5-5bb4-4dd2-86d9-f8e7d81cfac7"
      unitRef="U_pure">0.44</us-gaap:DerivativeLiabilityMeasurementInput>
    <beam:SettlementPaymentsExpectedAchievementYear
      contextRef="C_1e36b9f2-d92e-48f5-9eb9-a90bf6dcb357"
      id="F_dee9feb2-3e38-4d6a-a57d-9174c322556f">2027</beam:SettlementPaymentsExpectedAchievementYear>
    <beam:SettlementPaymentsExpectedAchievementYear
      contextRef="C_31375b14-847b-4dfc-8fc0-3d961e512723"
      id="F_aa8b2a6e-4e03-4cd9-9b5c-ffe134a45be5">2038</beam:SettlementPaymentsExpectedAchievementYear>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b"
      id="F_8b087009-b359-4abe-a6a4-88a05df0aa62">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in fair value of the derivative liability based on level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.914%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.485%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial recognition of derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b"
      decimals="-3"
      id="F_c51422c0-52c8-4855-8466-ceed06b3e021"
      unitRef="U_USD">5276000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_6605f422-e078-49c1-bb32-3b2f67d8c39b"
      decimals="-3"
      id="F_2101e174-80c4-4d48-b3e1-3d0cfb17374a"
      unitRef="U_USD">128000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_34071179-b962-4e08-81ba-677a509604da"
      decimals="-3"
      id="F_1dedd18b-4af8-434e-9796-7e2de71a0610"
      unitRef="U_USD">5404000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_da562aee-863e-470f-8387-20592346a01a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities held at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities held at December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. At December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the balance in accumulated other comprehensive (loss) income was comprised solely of activity related to marketable securities. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; realized gains or losses recognized on the sale or maturity of marketable securities for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022 and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive (loss) income for the same periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;less than one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_e001b8e4-efc0-409b-bca4-b2ef1b126bbd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities held at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s marketable securities held at December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7"
      decimals="-3"
      id="F_ebf9482e-9b8f-4889-bfec-bf35c0391aa7"
      unitRef="U_USD">181095000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7"
      decimals="-3"
      id="F_d8df929e-3df1-4354-9fd5-c9db73c75367"
      unitRef="U_USD">210000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7"
      decimals="-3"
      id="F_bfeb64d4-67d5-4a0f-b75f-db3e7e0bbcf6"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4b443d77-d326-4c74-b2e0-a91039c22fd7"
      decimals="-3"
      id="F_07583d01-1d83-48f1-8b8a-ebfb8d142a58"
      unitRef="U_USD">181296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114"
      decimals="-3"
      id="F_df5b7273-59a8-4889-a7b8-fd5ab672f535"
      unitRef="U_USD">100175000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114"
      decimals="-3"
      id="F_007ec9e0-c081-4715-8e53-071218221084"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114"
      decimals="-3"
      id="F_b005122a-3530-4500-aead-e5a60569573a"
      unitRef="U_USD">113000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e772a7bb-81e7-41e0-b75e-c792428e3114"
      decimals="-3"
      id="F_e1c1b362-3561-40ed-ae87-80758cd84ec6"
      unitRef="U_USD">100165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3"
      decimals="-3"
      id="F_d8e32f43-b24c-4ff3-8876-d0da16e1e5df"
      unitRef="U_USD">164491000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3"
      decimals="-3"
      id="F_bbc2a2b6-4f2a-4d3b-a5f3-807367f9f96e"
      unitRef="U_USD">289000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3"
      decimals="-3"
      id="F_628dfec0-68d0-4e7b-845d-aead31417928"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e72082c3-2fc5-4e8e-9517-6c5a9e814df3"
      decimals="-3"
      id="F_630ff11f-e1b1-4519-86be-e896db0573ea"
      unitRef="U_USD">164770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd"
      decimals="-3"
      id="F_aaf21111-08ec-429b-b355-8d81dfe4cf2b"
      unitRef="U_USD">114552000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd"
      decimals="-3"
      id="F_fbf20026-a85b-4643-9ced-cfb29d550ea7"
      unitRef="U_USD">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd"
      decimals="-3"
      id="F_c04eaab5-9f2c-4344-b1bf-0b2e1633d68e"
      unitRef="U_USD">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ab2d17df-4178-483f-b1be-0b511648abbd"
      decimals="-3"
      id="F_b053b573-4dfe-49fe-9a8b-9bdc6e0a5ddb"
      unitRef="U_USD">114761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_ccd6d443-83ef-4b86-af01-1073799931eb"
      decimals="-3"
      id="F_bd895f93-37e6-4661-b3fc-b3f3affd1197"
      unitRef="U_USD">7781000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_ccd6d443-83ef-4b86-af01-1073799931eb"
      decimals="-3"
      id="F_9e08c67d-8929-4b86-aa71-0834e105f068"
      unitRef="U_USD">7781000</us-gaap:EquitySecuritiesFvNi>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_28cbe42b-88c4-477c-a877-8d74ef4c5023"
      unitRef="U_USD">568094000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_eed5524c-0619-41ac-a124-141bed51d61e"
      unitRef="U_USD">837000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_afe16590-b229-481d-8ed2-c7dc51f992df"
      unitRef="U_USD">158000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_cc5ae2b8-62b0-46f3-bd22-b1cdd329d822"
      unitRef="U_USD">568773000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a"
      decimals="-3"
      id="F_46c54763-4b83-4897-a0d1-11f0f3e64fe0"
      unitRef="U_USD">285054000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a"
      decimals="-3"
      id="F_bdc3c38a-9ac0-4bd0-849d-2e5bf2e2f271"
      unitRef="U_USD">250000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a"
      decimals="-3"
      id="F_a5259b11-a921-4a29-a545-a17ceaf748a9"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0dda2cef-a73d-4c05-8098-6cd82221208a"
      decimals="-3"
      id="F_d9908d9b-2c38-49a8-bbc7-8fd591c2ac69"
      unitRef="U_USD">285289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073"
      decimals="-3"
      id="F_cfc64b24-9367-4ec4-82a3-293467a71153"
      unitRef="U_USD">23462000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073"
      decimals="-3"
      id="F_7c5ee0b7-3dd5-49dc-8026-fe21221a5dd5"
      unitRef="U_USD">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_50e72256-3be3-432c-b4b0-8c3fd8054073"
      decimals="-3"
      id="F_7e9b5393-6689-406b-acc0-f7893a43e27e"
      unitRef="U_USD">23525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_10b0f522-be77-400a-bec4-a92278231be3"
      decimals="-3"
      id="F_2867f94e-6804-47b4-9ab2-d67570ddcaad"
      unitRef="U_USD">151805000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_10b0f522-be77-400a-bec4-a92278231be3"
      decimals="-3"
      id="F_8eadc572-e3dc-4416-9e07-a894ef2edfd8"
      unitRef="U_USD">436000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_10b0f522-be77-400a-bec4-a92278231be3"
      decimals="-3"
      id="F_d59a3642-c891-4d69-867a-1ea868641ab5"
      unitRef="U_USD">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_10b0f522-be77-400a-bec4-a92278231be3"
      decimals="-3"
      id="F_651617f4-65f3-40d6-b0ca-664e969114cb"
      unitRef="U_USD">152147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729"
      decimals="-3"
      id="F_c02ffb35-6fd2-40fc-9c65-bc14271db73e"
      unitRef="U_USD">271181000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729"
      decimals="-3"
      id="F_7ce4fc58-5f49-4a73-9995-20f77e86dd39"
      unitRef="U_USD">328000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729"
      decimals="-3"
      id="F_ed98a4c9-327b-4fd8-92a0-4b556f479b55"
      unitRef="U_USD">364000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bc1f0ce2-9ca4-4af1-9b36-842ad1c62729"
      decimals="-3"
      id="F_890f347e-0a7d-434e-ad1a-5fa2690963eb"
      unitRef="U_USD">271145000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_f70341dc-ca94-4cc2-9501-827588f59d28"
      decimals="-3"
      id="F_44cee08b-45b0-412c-ad75-b26b52fc60e9"
      unitRef="U_USD">21875000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_f70341dc-ca94-4cc2-9501-827588f59d28"
      decimals="-3"
      id="F_ee457d59-a644-4390-a652-f1e2d164f41f"
      unitRef="U_USD">21875000</us-gaap:EquitySecuritiesFvNi>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_96ec037f-6485-4db0-846d-0bdb8812ff16"
      unitRef="U_USD">753377000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_5a00ef8c-14d6-4249-af0a-8d137048ccff"
      unitRef="U_USD">1077000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_1557db56-e7fb-48b2-b4f8-3ae9cdcc2bd9"
      unitRef="U_USD">473000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes>
    <beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_c2b44c20-e327-4f33-8da0-39fedf926932"
      unitRef="U_USD">753981000</beam:AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_7983b412-cc05-4148-a38c-af03529b3cb4"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="INF"
      id="F_507e26a5-9682-41c1-9b53-1e36b0f97a36"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="INF"
      id="F_c5ba7dce-9e31-4649-a8b1-564e8d42121a"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <beam:DebtSecuritiesAvailableForSaleMaturityPeriod
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_05e202a7-f103-4a04-96f1-46a7c74a9b5d">less than one year</beam:DebtSecuritiesAvailableForSaleMaturityPeriod>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_feca2c7b-1271-48a2-b4a3-f6bcfeb96cc9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contingent obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Process development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_24060028-e254-44ea-8ea7-4b86d490938f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contingent obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Process development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <beam:AccruedContingentObligationLicenseAgreementCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_baf711e7-1e1a-4dee-b3b0-255c048cf152"
      unitRef="U_USD">0</beam:AccruedContingentObligationLicenseAgreementCurrent>
    <beam:AccruedContingentObligationLicenseAgreementCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_97513116-5d03-4f7d-a39d-7bc4649d2a60"
      unitRef="U_USD">43280000</beam:AccruedContingentObligationLicenseAgreementCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_17fe8262-50d4-4a39-a6d0-2e37735daa77"
      unitRef="U_USD">21572000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_0a6d31ef-279b-40ee-8120-634f257857f2"
      unitRef="U_USD">21774000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <beam:AccruedResearchCosts
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_aff067f1-0516-4a21-a5d7-63141d37c282"
      unitRef="U_USD">11179000</beam:AccruedResearchCosts>
    <beam:AccruedResearchCosts
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_a01df4c2-3510-47f5-b960-1245bf1e7fd1"
      unitRef="U_USD">9804000</beam:AccruedResearchCosts>
    <beam:AccruedProcessDevelopmentAndManufacturingCosts
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_b66ba54f-ace1-4b97-86e0-b37fae154aef"
      unitRef="U_USD">3525000</beam:AccruedProcessDevelopmentAndManufacturingCosts>
    <beam:AccruedProcessDevelopmentAndManufacturingCosts
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_73d93495-870f-44ef-9436-ac3b54365ec9"
      unitRef="U_USD">4697000</beam:AccruedProcessDevelopmentAndManufacturingCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_0a751167-83de-4dbe-a5b5-b6a77f62be99"
      unitRef="U_USD">3381000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_302c369b-a3f8-423f-967c-37c8617c46f6"
      unitRef="U_USD">3468000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_7b3a1cb4-deae-4181-87b0-b8ace47755a0"
      unitRef="U_USD">7811000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_e1ad57fa-b44f-4663-a525-f6f3cdae0dbc"
      unitRef="U_USD">28641000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_9202d1ca-fcda-4a64-8304-5d57d8b213cc"
      unitRef="U_USD">47468000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_60608c01-505f-464e-8d71-f3e962e42683"
      unitRef="U_USD">111664000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_584240fa-7f86-4a1e-86f5-af0f1151fcab">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s operating leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A February 2018 lease for office and laboratory space as amended, which commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and terminates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The lease is subject to fixed-rate rent escalations and provided for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in tenant improvements allowances and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a term &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extension option.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An October 2018 lease for laboratory space as amended, which commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and terminates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amended lease is subject to fixed-rate rent escalations and provides an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; periods through December 31, 2029.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An April 2019 lease for office and laboratory space that was built over the course of 2020 and 2021. Pursuant to the terms of the original lease agreement, the first phase of the lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (rent payments for the first phase began in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and the second phase of the lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (rent payments for the second phase began in&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; February 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The lease is subject to fixed-rate rent escalations and provides for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in tenant improvements and the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; terms of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; each&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company determined that it is the accounting owner of all tenant improvements. In August 2021, the Company executed an amendment to this lease to occupy additional space. The term of this lease runs concurrent with the term of the April 2019 lease through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An August 2020 lease for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square foot manufacturing facility in Research Triangle Park, North Carolina. Construction of the manufacturing facility began in 2020 and the Company began making rent payments in the fourth quarter of 2022. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease will terminate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the rent commencement date, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The lease is subject to fixed-rate rent escalations and provides for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in tenant improvements and the option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; terms of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; each, which were not reasonably certain of exercise as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes operating lease costs as well as sublease income (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the lease term and discount rate for operating leases:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the lease costs included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.022%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.364%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.945%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.945%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the future maturity of the Company&#x2019;s operating leases for each of the next five years and total thereafter were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <beam:OperatingLeaseCommencementMonthAndYear
      contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"
      id="F_4e1cefa4-a730-433f-ab22-b459c98de3e9">2018-03</beam:OperatingLeaseCommencementMonthAndYear>
    <beam:OperatingLeaseTerminationMonthAndYear
      contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"
      id="F_e684ece9-4c2c-4112-adfc-e136e150b755">2029-09</beam:OperatingLeaseTerminationMonthAndYear>
    <beam:LeaseholdImprovementsLandlordAllowance
      contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"
      decimals="-5"
      id="F_378596f9-1aa8-4387-b523-e75140fc4258"
      unitRef="U_USD">6100000</beam:LeaseholdImprovementsLandlordAllowance>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"
      id="F_4e8d81ab-4a76-40a6-b78d-72b566e5aa25">a term extension option.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_ccb1a659-fef4-488d-b02f-e973d39dbbf9"
      id="F_9093d581-eae3-487e-b39a-6beb9e3a5626">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <beam:OperatingLeaseCommencementMonthAndYear
      contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"
      id="F_a7fb3834-37df-4db2-bca4-1ffccd3fe134">2019-04</beam:OperatingLeaseCommencementMonthAndYear>
    <beam:OperatingLeaseTerminationMonthAndYear
      contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"
      id="F_2958ea3f-bad7-405f-a91b-ead7d0f1ef3d">2025-12</beam:OperatingLeaseTerminationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"
      id="F_9f5e31ee-2195-491c-a4d2-acab1833c1bd">The amended lease is subject to fixed-rate rent escalations and provides an option to extend the lease for two additional two-year periods through December 31, 2029.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"
      id="F_14d8c624-0e0b-48e2-be40-6f25c4353754">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <beam:NumberOfOperatingLeaseRenewalOptions
      contextRef="C_725a8a31-e6f4-4206-af9d-3b6798ac1c4c"
      decimals="INF"
      id="F_b2a8be18-4ea7-4cab-857b-8ad31785df68"
      unitRef="U_Option">2</beam:NumberOfOperatingLeaseRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_87b2a2c4-113b-4df3-b4a2-5e89a5c1ea98"
      id="F_1b7cb419-7945-4808-8a40-04cffa0dccf8">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <beam:OperatingLeaseCommencementMonthAndYear
      contextRef="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24"
      id="F_c985ce5b-af67-4704-8b5d-0486f0cd9051">2020-10</beam:OperatingLeaseCommencementMonthAndYear>
    <beam:OperatingLeaseRentPaymentsBeginMonthAndYear
      contextRef="C_8cc83ba0-2581-4023-b62e-af3dcdfc8e24"
      id="F_7411e56f-9dbd-4097-bfc2-63ca8a96abed">2021-08</beam:OperatingLeaseRentPaymentsBeginMonthAndYear>
    <beam:OperatingLeaseCommencementMonthAndYear
      contextRef="C_1a4862fd-f679-425c-8077-3914a663d90a"
      id="F_0eadf4c7-0270-4904-a876-e11bc2c10e39">2021-01</beam:OperatingLeaseCommencementMonthAndYear>
    <beam:OperatingLeaseRentPaymentsBeginMonthAndYear
      contextRef="C_1a4862fd-f679-425c-8077-3914a663d90a"
      id="F_2d04855a-bbdf-4a97-82b6-4e12961b7453">2022-02</beam:OperatingLeaseRentPaymentsBeginMonthAndYear>
    <beam:LeaseholdImprovementsLandlordAllowance
      contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2"
      decimals="-5"
      id="F_4a4f6fcc-3784-4a9b-9031-57d60590a20c"
      unitRef="U_USD">23400000</beam:LeaseholdImprovementsLandlordAllowance>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2"
      id="F_01c2769a-5211-402c-b45a-a7df1249cc50">option to extend the lease for two terms of five years each</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2"
      id="F_e6c4443c-ff8b-4fa7-a7fb-c8c4c13346cc">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <beam:NumberOfOperatingLeaseRenewalOptions
      contextRef="C_eda2e163-7061-4ef9-bdb3-990396f121b2"
      decimals="INF"
      id="F_456f9cc1-3530-4b4f-b182-cd8800f34326"
      unitRef="U_Option">2</beam:NumberOfOperatingLeaseRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_d4874037-4abb-4593-9198-ea79ea979323"
      id="F_912aca97-d565-4e5c-ac87-8859c105eafe">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <beam:OperatingLeaseTerminationMonthAndYear
      contextRef="C_987488ec-2b63-4e33-9f1f-663eb101d201"
      id="F_12d817fe-be8c-465d-ba2d-3e7c930cc4cb">2034-02</beam:OperatingLeaseTerminationMonthAndYear>
    <beam:AreaOfFacilityBeingBuilt
      contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c"
      decimals="INF"
      id="F_f63f1e3b-d4b1-400a-b5db-35cb865ef7f8"
      unitRef="U_sqft">100000</beam:AreaOfFacilityBeingBuilt>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a"
      id="F_cf7e467c-2b1b-49d5-a8fb-cbea71ef7e96">The lease will terminate 15 years from the rent commencement date, December 2022. The lease is subject to fixed-rate rent escalations and provides for $20.0 million in tenant improvements and the option to extend the lease for two terms of five years each, which were not reasonably certain of exercise as of December 31, 2024. </us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c"
      id="F_417d6d67-4fe4-427a-9df0-95c26f9da074">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <beam:OperatingLeaseCommencementMonthAndYear
      contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a"
      id="F_cd85310e-a156-4c07-9ce3-f99ec54d1ec3">2022-12</beam:OperatingLeaseCommencementMonthAndYear>
    <beam:LeaseholdImprovementsLandlordAllowance
      contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a"
      decimals="-5"
      id="F_411e634a-98ea-4ae1-be1c-78e295b9b4e5"
      unitRef="U_USD">20000000</beam:LeaseholdImprovementsLandlordAllowance>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a"
      id="F_4edcd284-e886-451c-b371-8d2459f36e79">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <beam:NumberOfOperatingLeaseRenewalOptions
      contextRef="C_4229e173-9015-4f39-94ef-b11fa932f35a"
      decimals="INF"
      id="F_beb33461-75bd-4551-9d3c-eee0ea5cac3d"
      unitRef="U_Option">2</beam:NumberOfOperatingLeaseRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_dc035efa-c918-4bd6-b0c6-3e522bb69c7c"
      id="F_f465d438-ee3e-4b3a-a646-335e810554fb">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_2e871320-68e7-4540-b5b3-932b9eea7914">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes operating lease costs as well as sublease income (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_e1c35aad-d159-43bb-bff8-0e6e3cfb531a"
      unitRef="U_USD">21649000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_c7441608-080d-4a38-b833-0970eda04d5f"
      unitRef="U_USD">22063000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_ebbb10e4-6a9c-4148-9235-143b419dfec8"
      unitRef="U_USD">19536000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_3903f3c6-aaff-4c49-9e0d-2d2df7292310"
      unitRef="U_USD">6295000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_fc5e6cdf-e577-4757-9bf8-c10e5c283401"
      unitRef="U_USD">5777000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_dff7f3ab-f20e-4ed8-b232-6ce1b1917f15"
      unitRef="U_USD">4364000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_bd461b65-c74d-4097-ad10-3a97c23bdb9c"
      unitRef="U_USD">9000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_7b6cf1a3-778f-43d1-8448-74fcd773d50e"
      unitRef="U_USD">9000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_d7dcc5e9-c977-47db-9f52-281df1cd66d5"
      unitRef="U_USD">307000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_07b96090-c7de-426c-be22-6ab6258738e7"
      unitRef="U_USD">1319000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_15900a62-ab62-4667-b65e-63be1f50d08c"
      unitRef="U_USD">36944000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_883b362e-9dfa-4b92-921c-375110484962"
      unitRef="U_USD">36840000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_a755a876-d64a-4394-80d3-ac1d1d09db58"
      unitRef="U_USD">22888000</us-gaap:LeaseCost>
    <beam:OperatingLeaseTermAndDiscountRateTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_1b75d439-65c4-4166-b24b-c6e2a6bfacfb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the lease term and discount rate for operating leases:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</beam:OperatingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      id="F_8f129c96-f203-45f1-aa65-ae6a00137dcd">P9Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      id="F_bb26a70f-3018-4e65-984f-1082c42a610d">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="3"
      id="F_178516e1-080e-48bd-ad82-bcae3a09a441"
      unitRef="U_pure">0.073</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="3"
      id="F_44aba235-c038-43b3-a941-5145706a94f3"
      unitRef="U_pure">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <beam:LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_21221d7c-2e9c-45d9-80f6-1df2b5fe7db8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the lease costs included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.022%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.364%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.945%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.945%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</beam:LeaseCostsIncludedInMeasurementOfLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_1d914231-2534-4acb-885f-69e9a35506bd"
      unitRef="U_USD">24981000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_22ddfbb2-c9b0-426a-8134-551d2538ce34"
      unitRef="U_USD">22603000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_65393177-986e-45f5-93f2-f92f0758d135"
      unitRef="U_USD">19052000</us-gaap:OperatingLeasePayments>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_741de03d-28ec-4a36-b218-a5255f7966ea"
      unitRef="U_USD">-1626000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_0507bc04-4386-4070-99de-d336324745cc"
      unitRef="U_USD">3852000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <beam:OperatingLeaseLiabilitiesIncreaseDecrease
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3857ef1e-a49f-443e-8206-32119712abdb"
      unitRef="U_USD">41050000</beam:OperatingLeaseLiabilitiesIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_73778de1-a96f-4595-8906-b76d4642db9c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the future maturity of the Company&#x2019;s operating leases for each of the next five years and total thereafter were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_13dba810-fcd5-4d81-926a-0f1a6671eb72"
      unitRef="U_USD">24360000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_f32b9c85-de02-487b-a384-022fa3ef32b4"
      unitRef="U_USD">22526000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_2522fbc9-281a-483f-982a-150234e89d36"
      unitRef="U_USD">23157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_dca92ab7-610a-4588-ba63-68f28a13abc8"
      unitRef="U_USD">23374000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_db7efb20-6723-489d-8c71-272b3a4799b2"
      unitRef="U_USD">22147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_a80ab5f2-28cb-44e1-af40-0eb460230fd3"
      unitRef="U_USD">112167000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_c44f1bcd-3424-429a-98e6-8306d397c018"
      unitRef="U_USD">227731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_c8d52e58-0f85-4e5e-b382-2ee793ca5519"
      unitRef="U_USD">66306000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_f8081411-417d-4451-bec4-f346dd17d9b2"
      unitRef="U_USD">161425000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_73b1f2ea-d5e5-4071-8277-4e99cdfd1b66">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Strategic restructuring&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Company announced updated portfolio priorities and strategic plans to restructure the Company to streamline its business operations. In connection with this portfolio prioritization and strategic restructuring, the Company reduced its employee headcount by approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; positions, or about &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of its workforce. During the year ended December 31, 2023, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f812e6fe-6a44-4c16-bfa9-574585f77a74;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;restructuring charges&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the consolidated statement of operations related to these actions. These charges included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of one-time termination benefits and contractual termination benefits for severance, healthcare, and related benefits and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of non-cash stock-based compensation expense. The workforce reductions were substantially completed as of December 31, 2023, however the severance and other costs are paid over time.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the restructuring liability activity for the Company's workforce reductions for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 as recorded in accrued expenses and other current liabilities in the consolidated balance sheet are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expenses incurred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_26e65229-9380-4e02-a80b-356c8953d6fd"
      decimals="0"
      id="F_d3696d7d-52a7-4d09-82f2-e09d990045ea"
      unitRef="U_Positions">100</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_26e65229-9380-4e02-a80b-356c8953d6fd"
      decimals="2"
      id="F_e94cbfbc-4809-4ade-a21a-9028c449e40c"
      unitRef="U_pure">0.20</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="C_614fab24-9c40-4e21-a14b-7243d9e14888"
      decimals="-5"
      id="F_d818483f-4518-4f68-afff-f6d4f5109094"
      unitRef="U_USD">6700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_f2642d59-f792-41fa-8608-056dec1837ab"
      decimals="-5"
      id="F_bedb59b7-8570-4c63-b16c-9a14d1e46fad"
      unitRef="U_USD">6500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_3fe5e002-e81f-4070-850c-d91b8489178b"
      decimals="-5"
      id="F_9a70f16e-c4c6-4d58-b634-be7443bf53f7"
      unitRef="U_USD">200000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_900f0b83-4a55-4f9a-954e-0d5dfc19095d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the restructuring liability activity for the Company's workforce reductions for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 as recorded in accrued expenses and other current liabilities in the consolidated balance sheet are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expenses incurred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued restructuring balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_4190209f-b042-4e08-9431-46b646d97728"
      unitRef="U_USD">6494000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_27c3c261-65e9-4bbb-9268-6ac49eee46ed"
      unitRef="U_USD">1999000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_53e4dbca-d936-401d-8819-b8b3d3ea2459"
      unitRef="U_USD">4495000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_55593b1b-ac5c-40d5-8534-b9eb087af798"
      unitRef="U_USD">4495000</us-gaap:PaymentsForRestructuring>
    <beam:LicenseAgreementDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_f01c75ab-cbd1-49db-a0a7-9bc202ff622e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License&lt;/span&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has various license agreements related to technology used in its research and development activities. The license agreements may include up-front payments, option fees, ongoing maintenance fees, sublicense fees, royalty-based payments, milestone payments, success-based payments, and other payments. Option fees, when applicable, are recognized when exercised, maintenance fees, sublicense fees, and other payments are recorded as incurred based on the estimated amounts due or that will ultimately be paid. Contingent payments that are not required to be accounted for as a derivative are recognized as incurred. As the success-based payments due under the Company&#x2019;s license arrangements are derivatives, the change in the fair value of the success-based payments are recognized in a separate line item in the statement of operations and comprehensive loss, as discussed further below. The total contingent obligations and non-royalty sublicense fees included in research and development expenses in the statement of operations and comprehensive loss were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The value attributable to sublicenses and the related sublicense fees due under the Company&#x2019;s license agreements may require estimates and other judgments related to contractual requirements, which creates uncertainty over the ultimate amount that would be paid under these arrangements. Contractual amounts due are accrued and if a contingency exists related to the interpretation of the amounts due under the license agreement, the Company recognizes a liability for the amount that is probable and estimable. When no amount within the range of potential payments is a better estimate than any other amount, however, the minimum amount in the range is accrued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Harvard license agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2017, the Company entered into the Harvard License Agreement for certain base editing technology pursuant to which the Company received an exclusive, worldwide, sublicensable, royalty-bearing license under specified patent rights to develop and commercialize licensed products and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product, unless terminated earlier by either party under certain provisions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Partial consideration for the rights granted under the Harvard License Agreement include success payments, which are further described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Success Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Under the Harvard License Agreement, Harvard is entitled to receive success payments, in cash or shares of Company stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Company&#x2019;s Series A Preferred at specified valuation dates. The success payments range from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to a maximum of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and have valuation multiples that range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the initial weighted average value of the Series A Preferred. Subsequent to the Company&#x2019;s February 2020 IPO, the amount of success payments is based on the market value of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company&#x2019;s IPO.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company elected to make the payment in shares of the Company&#x2019;s common stock and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,825&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to settle this liability on June 10, 2021. The Company may owe Harvard success payments of up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s success payment liability for Harvard (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Harvard success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.812%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Harvard success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#x2019;s licensed products at such time. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. Upon determination that a Harvard Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company will monitor the Harvard Product Milestone payments for this arrangement on an ongoing basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent products are commercialized under the Harvard License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Broad license agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2018, the Broad License Agreement was entered into with Broad Institute for certain RNA base editing technology including an RNA editor platform. Under the Broad License Agreement, Broad Institute granted exclusive and non-exclusive worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed product and a nonexclusive, worldwide, sublicensable, royalty-bearing license under certain patent rights to research and develop licensed products. Under the agreement the Company shall use commercially reasonable efforts to develop licensed products in accordance with the development plan, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The license term extends until the later of the expiration of (i) the last to expire licensed patent covering a licensed product, (ii) the period of regulatory exclusivity associated with a licensed product or (iii) a certain period after the first commercial sale of a licensed product unless terminated earlier by either party under certain provisions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additional consideration under the Broad License Agreement included Success Payments, which are further described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Success Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; Under the Broad License Agreement, Broad Institute is entitled to receive success payments, in cash or shares of Company common stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Series A Preferred at specified valuation dates. The success payments range from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to a maximum of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and have valuation multiples that range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the initial weighted average value of the Series A Preferred. Subsequent to the February 2020 IPO, the amount of success payments is based on the market value of the Company&#x2019;s common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company&#x2019;s IPO.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company elected to make the payment in shares of the Company&#x2019;s common stock and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,825&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to settle this liability on June 10, 2021. The Company may owe Broad Institute success payments of up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; success payments were due to Broad Institute.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s success payment liability for Broad Institute (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Broad Institute success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Broad Institute success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#x2019;s licensed products at such time.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs will be expensed as incurred. Upon determination that a Broad Product Milestone is probable to occur, the amount due will be recorded as research and development expense. The Company monitors the Broad Product Milestone payments for this arrangement on an ongoing basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent products are commercialized under the Broad License Agreement, the Company will accrue royalty expense and sublicense nonroyalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Editas license agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. More specifically, Editas granted to the Company a worldwide, exclusive, sublicensable, license (subject to certain exceptions and conditions) under certain intellectual property controlled by Editas for the use of base editing therapies for the treatment of any field of human diseases and conditions, subject to certain exceptions, or the Beam Field, and the licenses granted or to be granted under the Editas License Agreement, or the Editas Development and Commercialization License. Additionally, Editas granted to the Company a royalty-free, non-exclusive license under certain intellectual property owned or controlled by Editas to perform research activities in the Beam Field, or the Editas Research License. Editas provided the Company with an exclusive option to obtain an Editas Development and Commercialization License to three additional groups of intellectual property owned or controlled by Editas, on a group by group basis, during the specified option period, subject to certain exceptions. Pursuant to the Editas License Agreement, the Company will use commercially reasonable efforts to develop a product that includes the rights licensed to the Company within a specified period of time and to commercialize any such products that have received regulatory approval in certain specified countries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additional consideration will be due to Editas if the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company elects to exercise its option to obtain an Editas Development and Commercialization License to any of the three categories of intellectual property underlying the Editas Research License, for a fee ranging from a mid-teen million dollar amount to a low to mid-eight digit dollar amount per group, depending on the timing of the option exercise. Additionally, the Company is required to reimburse Editas for certain payments Editas may be obligated to make under existing Editas license agreements related to the intellectual property being licensed to the Company, including (i) development, regulatory and commercial milestone payments and certain sublicense income payments due as a result of the Editas License Agreement and (ii) a percentage of the annual maintenance fees and patent fees due to certain of the Editas&#x2019; licensors. In addition, to the extent any products are commercialized under an Editas Development and Commercialization License, the Company would be required to make royalty payments equivalent to the royalties that would be due from Editas to any applicable licensors of Editas related to the sales of such licensed products, plus an additional tiered low- to mid-single digit royalty, depending on whether such licensed product is covered by an Editas-owned patent.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The license rights and option rights granted by Editas to the Company are subject to the terms and conditions of the underlying license agreements that Editas is a party to and under which Editas licensed rights or option rights to the Company and the termination of such in-licenses, as applicable. Unless earlier terminated by either party pursuant to the terms of the agreement, the Editas License Agreement will continue in full force and effect and will expire on a licensed product-by licensed product and country-by-country basis upon the later of (i) the last-to-expire royalty term under any applicable institutional license to Editas and (ii) the date at which such product is no longer covered by a valid claim of a licensed Editas-owned patent in such country. The Company has the right, at its sole discretion, at any time to terminate the Editas License Agreement in its entirety or on a group-by-group of intellectual property basis, upon ninety days written notice to Editas. Upon termination of the Editas License Agreement, all rights and licenses granted by Editas to the Company (including the rights to exercise options and obtain such licenses) will immediately terminate and patents within a group of patents will no longer be deemed licensed patents. Expiration or termination of the Editas License Agreement for any reason does not release either party of any obligation or liability which had accrued, or which is attributable to a period prior to such expiration or termination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The option exercise fees under the agreement will be recorded as research and development expense, if and when the Company exercises such options. To date, no options have been exercised. The annual maintenance fees are recorded as an expense on an annual basis based on the stated amount for the applicable year. Annual patent costs are expensed as incurred. In addition, the Company is required to make certain development, regulatory and commercial milestone payments to Editas upon the achievement of specified milestones. To the extent applicable, sublicense income payments will be accrued for the amount the Company is obligated to pay under each applicable in-license as amounts are due to Editas. Lastly, to the extent products are commercialized under the Editas License agreement, the Company will accrue royalty expense for the amount it is obligated to pay, with adjustments as sales are made.&lt;/span&gt;&lt;/p&gt;</beam:LicenseAgreementDisclosureTextBlock>
    <beam:ContingentObligationAndNonRoyaltySublicenseFees
      contextRef="C_66014777-6584-477d-9aa8-ffa7abbe1249"
      decimals="-5"
      id="F_22116ff7-3537-42eb-8a63-1589c5a26807"
      unitRef="U_USD">3200000</beam:ContingentObligationAndNonRoyaltySublicenseFees>
    <beam:ContingentObligationAndNonRoyaltySublicenseFees
      contextRef="C_7ff8794b-8499-4caa-8e54-fbac240792c1"
      decimals="-5"
      id="F_1bf1db8a-67f7-4790-af8e-ef8552fb11c1"
      unitRef="U_USD">43500000</beam:ContingentObligationAndNonRoyaltySublicenseFees>
    <beam:ContingentObligationAndNonRoyaltySublicenseFees
      contextRef="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589"
      decimals="-5"
      id="F_5b53dcd7-088a-466f-98b8-7a6a310bdeaa"
      unitRef="U_USD">2700000</beam:ContingentObligationAndNonRoyaltySublicenseFees>
    <beam:SuccessPayments
      contextRef="C_5bc0c4e6-20ab-442d-9c3e-39c7a8ea82c0"
      decimals="-5"
      id="F_bc167149-9a1e-4f54-8edb-193dc9a060c6"
      unitRef="U_USD">5000000</beam:SuccessPayments>
    <beam:SuccessPayments
      contextRef="C_231917f7-78a3-4fef-87ae-dc90b41b4c08"
      decimals="-5"
      id="F_3aaa6863-9d0d-455b-ae5a-40511444cf81"
      unitRef="U_USD">105000000</beam:SuccessPayments>
    <beam:SuccessPaymentsValuationMultiples
      contextRef="C_846e5021-b00e-430e-b479-dfc4350907cb"
      decimals="0"
      id="F_418931c5-dc4b-47c7-b01e-22d7a44e996e"
      unitRef="U_pure">5</beam:SuccessPaymentsValuationMultiples>
    <beam:SuccessPaymentsValuationMultiples
      contextRef="C_e0ec3d1c-7bc1-435c-aba5-b5b2222df11e"
      decimals="0"
      id="F_3f816deb-e68e-49ef-bcca-6447d57cd902"
      unitRef="U_pure">40</beam:SuccessPaymentsValuationMultiples>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_9e0b9b06-588c-4f43-8b01-cd02f7537d2d"
      id="F_b2824e27-149b-4af0-aa0f-be2160a76457">The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company&#x2019;s IPO.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:SuccessPaymentAmountDue
      contextRef="C_8f838b8f-003d-4c56-9981-96bf4aa3558f"
      decimals="-5"
      id="F_1e86c1cd-7818-49a6-9452-514a5d897868"
      unitRef="U_USD">15000000</beam:SuccessPaymentAmountDue>
    <beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability
      contextRef="C_0246c702-b123-4f5d-b939-4edd1eea0949"
      decimals="INF"
      id="F_749b63d4-d745-4c56-9211-42a0c56e1810"
      unitRef="U_shares">174825</beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability>
    <beam:AdditionalSuccessPaymentAmountDue
      contextRef="C_a2d5f9fc-a682-42df-9b5c-99526ad1bc2b"
      decimals="INF"
      id="F_9de3fe6c-b507-42bb-b9b9-4222311c6dc6"
      unitRef="U_USD">90000000</beam:AdditionalSuccessPaymentAmountDue>
    <beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_66e685d3-a9b9-4187-8972-eaa886477f09">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s success payment liability for Harvard (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Harvard success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s success payment liability for Broad Institute (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Broad Institute success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</beam:ScheduleOfSuccessPaymentLiabilityTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_800475ef-859c-4969-8401-92e0526a5add"
      decimals="-3"
      id="F_e569513d-4514-4986-b742-af332cb833fd"
      unitRef="U_USD">3900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_80db0869-90aa-4f87-a32a-529c3993d14c"
      decimals="-3"
      id="F_f7873a95-9262-4d95-b394-774172401882"
      unitRef="U_USD">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <beam:ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_925825da-a970-4a7a-b3b2-bae9c46b9761">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.812%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Harvard success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Broad Institute success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</beam:ScheduleOfChangeInFairValueOfSuccessPaymentLiabilityTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_623147d8-2cfc-43d4-ad7a-4b423fda8bc2"
      decimals="-3"
      id="F_eaf0efb9-f464-44db-8296-8eefda9cdb41"
      unitRef="U_USD">1300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_c4d3bfe7-33e4-4541-9d0a-0c3653425814"
      decimals="-3"
      id="F_ab643287-d8ed-46e2-80be-a789ac690803"
      unitRef="U_USD">3800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_a9e94ca6-e934-4ab8-aeb5-8d4b40f267a6"
      decimals="-3"
      id="F_11c534bd-a147-4c47-b00b-ba9c4ab25e33"
      unitRef="U_USD">12000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_db09f235-a08f-4af4-a99c-599807b457f1"
      id="F_f56f40ab-389d-49ed-a986-5ff89f684844">The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#x2019;s licensed products at such time. </us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:AggregateMilestoneAmount
      contextRef="C_034a8b22-6f57-47e9-bcaf-d420a86c3ac8"
      decimals="-5"
      id="F_83d428f2-fe27-4a37-9c35-112722125b3c"
      unitRef="U_USD">75900000</beam:AggregateMilestoneAmount>
    <beam:SuccessPayments
      contextRef="C_f24310ad-daa3-4d84-88fe-4f5f29e1c62b"
      decimals="-5"
      id="F_50b22abb-5722-4d90-bd66-6c6fdf8216e5"
      unitRef="U_USD">5000000</beam:SuccessPayments>
    <beam:SuccessPayments
      contextRef="C_9b3ddcbc-bcaa-4620-bd37-18182d7ee2a9"
      decimals="-5"
      id="F_7427b8a7-abb8-4bf4-bbb2-d0c2bdddbb11"
      unitRef="U_USD">105000000</beam:SuccessPayments>
    <beam:SuccessPaymentsValuationMultiples
      contextRef="C_083cb9d5-4b38-4882-b265-50928e148535"
      decimals="0"
      id="F_238f1621-ccca-4ec6-8682-7fba5017f5a4"
      unitRef="U_pure">5</beam:SuccessPaymentsValuationMultiples>
    <beam:SuccessPaymentsValuationMultiples
      contextRef="C_c2e860ef-951c-4824-addf-069a1f368442"
      decimals="0"
      id="F_a754a0e8-b27d-4130-ba92-0aed7c8cc38c"
      unitRef="U_pure">40</beam:SuccessPaymentsValuationMultiples>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_640fc477-4635-473c-bec3-329a0998059a"
      id="F_3be84881-6bd2-4ef8-a6db-03750e19cb26">The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company&#x2019;s IPO.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:SuccessPaymentAmountDue
      contextRef="C_1f91b334-6d1a-442e-9b9d-4fc20bb74482"
      decimals="-5"
      id="F_78ea51a7-e574-4259-9ea6-c43b738a4f03"
      unitRef="U_USD">15000000</beam:SuccessPaymentAmountDue>
    <beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability
      contextRef="C_6268b7c6-50cc-4b67-b26d-5fcdb3082e86"
      decimals="INF"
      id="F_392c996e-754b-4de8-b95c-f964b4263cc3"
      unitRef="U_shares">174825</beam:StockIssuedDuringPeriodSharesSuccessPaymentLiability>
    <beam:AdditionalSuccessPaymentAmountDue
      contextRef="C_a65535bf-d336-4fc3-a256-1c5e23cda5be"
      decimals="INF"
      id="F_9cdcb029-bf4d-4908-9e37-72d11cfcf449"
      unitRef="U_USD">90000000</beam:AdditionalSuccessPaymentAmountDue>
    <beam:SuccessPaymentAmountDue
      contextRef="C_ad5b92a4-0e86-485f-829d-78650bd85771"
      decimals="-3"
      id="F_ec991800-09be-464f-9a52-8f4c479809b1"
      unitRef="U_USD">0</beam:SuccessPaymentAmountDue>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_ad5b92a4-0e86-485f-829d-78650bd85771"
      decimals="-3"
      id="F_f705040d-0314-499f-9ee0-d01f59f4b107"
      unitRef="U_USD">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_e5221100-f194-45c9-83f5-e78d6eb47872"
      decimals="-3"
      id="F_212f386b-78cd-47ee-a4de-ac474be3377f"
      unitRef="U_USD">5600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_2003a022-90cd-4bc2-bf5e-3e183c02ed3c"
      decimals="-3"
      id="F_b239a07b-4832-434b-bf68-2e70fb29d395"
      unitRef="U_USD">1100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_ebd07b65-49d7-49db-9728-c7dfc9f5943d"
      decimals="-3"
      id="F_f39d97f2-fe33-4810-9e27-5f523672c68d"
      unitRef="U_USD">3700000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_ce201eb2-a040-4b8c-828b-f421220ff5bf"
      decimals="-3"
      id="F_1674553c-24d2-4438-b21b-f9d8ed429173"
      unitRef="U_USD">11900000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_4d433f10-5951-4793-a073-4cde03a41826"
      id="F_b51c2b93-630f-4e49-91c6-e116fa65a9f4">The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company&#x2019;s licensed products at such time.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:AggregateMilestoneAmount
      contextRef="C_9bd424a3-b990-4948-a990-a2d46eaf923c"
      decimals="-5"
      id="F_c04c0a93-3589-4a15-921f-edabe325f7eb"
      unitRef="U_USD">75900000</beam:AggregateMilestoneAmount>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_30808f53-fe50-4e76-b73c-7f5690993b05"
      id="F_71ff642b-c949-4500-9645-e8fb28ae6888">In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. More specifically, Editas granted to the Company a worldwide, exclusive, sublicensable, license (subject to certain exceptions and conditions) under certain intellectual property controlled by Editas for the use of base editing therapies for the treatment of any field of human diseases and conditions, subject to certain exceptions, or the Beam Field, and the licenses granted or to be granted under the Editas License Agreement, or the Editas Development and Commercialization License. Additionally, Editas granted to the Company a royalty-free, non-exclusive license under certain intellectual property owned or controlled by Editas to perform research activities in the Beam Field, or the Editas Research License. Editas provided the Company with an exclusive option to obtain an Editas Development and Commercialization License to three additional groups of intellectual property owned or controlled by Editas, on a group by group basis, during the specified option period, subject to certain exceptions. Pursuant to the Editas License Agreement, the Company will use commercially reasonable efforts to develop a product that includes the rights licensed to the Company within a specified period of time and to commercialize any such products that have received regulatory approval in certain specified countries.Additional consideration will be due to Editas if the Company elects to exercise its option to obtain an Editas Development and Commercialization License to any of the three categories of intellectual property underlying the Editas Research License, for a fee ranging from a mid-teen million dollar amount to a low to mid-eight digit dollar amount per group, depending on the timing of the option exercise. Additionally, the Company is required to reimburse Editas for certain payments Editas may be obligated to make under existing Editas license agreements related to the intellectual property being licensed to the Company, including (i) development, regulatory and commercial milestone payments and certain sublicense income payments due as a result of the Editas License Agreement and (ii) a percentage of the annual maintenance fees and patent fees due to certain of the Editas&#x2019; licensors. In addition, to the extent any products are commercialized under an Editas Development and Commercialization License, the Company would be required to make royalty payments equivalent to the royalties that would be due from Editas to any applicable licensors of Editas related to the sales of such licensed products, plus an additional tiered low- to mid-single digit royalty, depending on whether such licensed product is covered by an Editas-owned patent.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_7fe69c21-0377-473f-b7f0-71caf1e83316">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Collaboration and license agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company&#x2019;s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company&#x2019;s opt-in rights to co-develop and co-commercialize Verve&#x2019;s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million nonrefundable upfront payment and is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; If &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lilly does not opt-in to co-develop and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;co-commercialize &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a licensed product, Lilly is obligated to pay the Company a percentage of any royalties received from Verve for sales of such product, subject to certain caps on a licensed product-by-licensed product basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the effective date of the Lilly Agreement, Lilly has the right to request the Company to perform any critical research and development services, if Lilly reasonably determines that the Company is uniquely able to provide such services and other conditions are met, including that no other third parties can provide such services. The parties will negotiate an agreement governing the Company&#x2019;s performance of such activity, if any, and the Company will be compensated for any services at approximately cost plus a margin. The Company has not been requested to perform any services and believes it is remote that Beam would be requested to provide any services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Lilly Agreement, the Company and Lilly entered into a Stock Purchase Agreement providing for the sale and issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004,811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to Lilly for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company received the consideration under the Stock Purchase Agreement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in October and the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in November 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Lilly Agreement and Stock Purchase Agreement were negotiated at the same time as a package and have been accounted for as one combined contract. The Company accounts for the component of the arrangement to transfer common stock to Lilly under ASC 505, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the revenue component under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company first applied the guidance in ASC 505 to measure the fair value of the common stock issued and allocated the remaining consideration to the ASC 606 component of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The overall ASC 606 transaction price as of the inception of the contract was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is comprised of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the residual value of the proceeds received in excess of the fair value of the common stock sold to Lilly of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The fair value of the common stock issued to Lilly was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, as determined by management with the assistance of a third-party valuation specialist. There is no variable consideration included in the transaction price at inception. The Company will re-evaluate the transaction price at each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that the collaboration rights and licenses to intellectual property have the same pattern and timing of transfer and are transferred as of the effective date of the Lilly Agreement. Lilly&#x2019;s right to request research and development services represents an optional purchase in the agreement that does not constitute a material right. All other items promised to Lilly are immaterial in the context of the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized revenue for the performance obligation at a point-in-time in October 2023 as all requirements related to the performance obligation have been completed. Any consideration received related to Lilly&#x2019;s optional purchase of the Company&#x2019;s research and development services will be accounted for as a separate contract if and when the option is exercised in accordance with ASC 606. During the year ended December 31, 2024 the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue related to the achievement of certain clinical, regulatory and alliance events. During the year ended 2023 the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue related to the Lilly Agreement. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred revenue related to the Lilly Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Orbital&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2022, the Company entered into a License and Research Collaboration Agreement, or the Orbital Agreement, with Orbital Therapeutics, Inc., or Orbital. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ribonucleic acid, or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In exchange for the licenses and services provided by the Company under the Orbital Agreement, the Company received a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by Orbital, and research and development support services as outlined in a research plan. Orbital also granted the Company an exploitation license to certain RNA technology and nonviral delivery technology controlled by Orbital. The exploitation license is exclusive in the fields of gene editing and conditioning and nonexclusive in all other fields other than vaccines and certain protein therapeutics. The Company also received &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Orbital&#x2019;s common stock at closing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The research plan has a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and can be extended for unspecified periods upon mutual agreement between the Company and Orbital. The exploitation licenses are exclusive for an initial research term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which may be extended for up to two successive one-year periods&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; by mutual agreement between the Company and Orbital. Either party may terminate the licenses granted to it under the Orbital Agreement for convenience on a product-by-product basis at any time by providing 90 days&#x2019; prior written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the consideration received under the Orbital Agreement under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, which represents the fair value of the Company&#x2019;s equity interest in Orbital&#x2019;s common stock at inception. There is no variable consideration included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that the research and exploitation licenses are not distinct from the other promises in the Orbital Agreement, and as such the Company determined that the licenses combined with the research and development services, know-how transfers, committee participation and materials transfer represent a performance obligation. The Company recognizes revenue associated with the Orbital performance obligation over time as it is satisfied during the term of the agreement, which is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue during the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue during the year ended December 31, 2022. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of current deferred revenue related to the Orbital Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Beam does not have a controlling financial interest in Orbital as Beam does not have the power to direct the activities of Orbital. The Company has significant influence over Orbital through its noncontrolling representation on Orbital&#x2019;s board of directors and the Company&#x2019;s equity interest in Orbital. Accordingly, the Company does not consolidate the financial statements of Orbital and accounts for its investment using the equity method of accounting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of the closing date in September 2022, the fair value of the Company&#x2019;s investment in Orbital was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The fair value of the Orbital common stock was determined by management with the assistance of a third-party valuation specialist. In determining the fair value of the Company&#x2019;s investment, the valuation specialist used an option pricing model backsolve approach based on Orbital's most recent funding of preferred stock. The valuation requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are level 3 inputs, include the anticipated holding period to an exit and liquidity event, the volatility of market participants (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%) and the discount for lack of marketability (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%). At the date of the investment, a basis difference was identified as the carrying value of the Company&#x2019;s investment in Orbital exceeded the Company&#x2019;s proportionate share of the underlying net assets in Orbital. The Company concluded that the basis difference was primarily attributable to Orbital&#x2019;s IPR&amp;amp;D assets. As Orbital did not meet the definition of a business due to substantially all of the estimated fair value of the gross assets being concentrated in the group of similar IPR&amp;amp;D assets, the basis difference attributable to the IPR&amp;amp;D with no alternative future use was immediately expensed as of the date of the investment. The Company&#x2019;s proportionate share of the basis difference exceeded its carrying value of the equity method investment in Orbital and the equity investment balance was reduced to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. There is no commitment for the Company to provide financial support to Orbital. The Company recognized a loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in association with the basis difference charge in the Company&#x2019;s consolidated statements of operations for the year ended December 31, 2022 and did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize a gain or loss from the equity method investment for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pfizer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company&#x2019;s base editing technology to develop &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%/&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of the Pfizer Agreement, the Company was entitled to receive a nonrefundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in consideration for the rights granted to Pfizer under the collaboration. Should Pfizer exercise its Opt-In Right for any of the three programs, the Company would be eligible to receive development, regulatory, and commercial milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per program, for potential total consideration of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion, plus royalty payments on global net sales for each licensed program, if any. If Pfizer does not exercise its Opt-In Right for a program, the Company&#x2019;s rights in such program revert to the Company and the Company will be required to pay Pfizer earn-out payments equal to a low single digit percentage of net sales earned on such program for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period, if any. As the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront fee was not received by the Company as of December 31, 2021, the Company recorded a collaboration receivable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million with a corresponding deferred revenue liability. The Company received the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment in January 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the collaboration term, Pfizer has a one-time option to substitute a disease that is the subject of a specific program with one pre-defined substitute disease. The collaboration has an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and may be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extended for an additional year on a program-by-program basis&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Pfizer may terminate the Pfizer Agreement for convenience on any or all of the programs by providing 90 days&#x2019; prior written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the Pfizer Agreement under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The overall transaction price as of the inception of the contract was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is comprised entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has concluded that the licenses to its base editing technology, including the exclusive development and commercialization rights, are not capable of being distinct from the other performance obligations, and as such the Company has determined that the licenses combined with the other research and development services represent performance obligations and no up-front revenue was recognized for the licenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The selling price of each performance obligation was determined based on the Company&#x2019;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Pfizer Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue for each performance obligation as it is satisfied during the term of the agreement using an input method. The Company allocated the transaction price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to each of the three performance obligations, which includes each of the three base editing programs combined with the research and development services, licenses, and exclusive development and commercialization rights. Revenue is recognized using an input method based on the actual costs incurred as a percentage of total estimated costs tow&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#x2019;s performance in transferring control of the goods and services promised to Pfizer and represents the Company&#x2019;s best estimate of the period of the obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue under the Pfizer Agreement, during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of current and long-term deferred revenue, respectively, related to the Pfizer Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sana Biotechnology&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2021, the Company entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, under which the Company granted Sana a license for non-exclusive rights to its CRISPR Cas12b nuclease system for the development and commercialization of certain engineered cellular therapy programs. In addition to the license, the Company performed an initial technology transfer following the effective date of the Sana Agreement providing Sana with certain know-how, as required under the Sana Agreement. This technology transfer occurred in 2021. Following the license transfer and completion of the initial technology transfer, Sana is responsible, at its sole expense, for the development and commercialization of therapeutic products which must contain either specified CAR antigen targets or pluripotent stem cell, or PSC, product types.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As consideration for the license, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from Sana in October 2021. In addition, the Company may be eligible to receive development, regulatory, and commercial milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from Sana on any product candidate or product. The Company will also be entitled to receive royalties equal to a low single digit percentage of net sales on any product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days&#x2019; prior written notice or upon 180 days&#x2019; prior written notice after first commercial sale.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the Sana Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is composed entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has identified a single performance obligation, which includes (i) the non-exclusive license granted to Sana under the Company&#x2019;s patent rights and know-how and (ii) the initial technology transfer following the effective date, which occurred in 2021. The Company further concluded that the Option Rights, Replacement Right, and Genetic Target Nomination Rights did not grant Sana a material right. As the Company only identified one performance obligation, no allocation of the transaction price is required.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue under the Sana Agreement during the year ended December 31, 2024 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue under the Sana Agreement during the year ended December 31, 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;revenue under the Sana Agreement for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Apellis Pharmaceuticals&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company&#x2019;s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the collaboration, the Company is eligible to receive a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in upfront and near-term milestones from Apellis, which is comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million received upon signing and an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment on June 30, 2022, the one-year anniversary of the effective date of the Apellis Agreement, or the First Anniversary Payment. Following any exercise of an Opt-In Right for any of the six programs, the Company will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and may be extended up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on a per year and program-by-program basis. During the collaboration term, Apellis may, subject to certain limitations, substitute a specific complement gene and/or organ for any of the initial base editing programs. Apellis may terminate the Apellis Agreement for convenience on any or all of the programs by providing prior written notice. The Company received the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment from Apellis in July 2021 and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million First Anniversary Payment in June 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the Apellis Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The overall transaction price as of the inception of the contract was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is composed of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the First Anniversary Payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation were material promises that were both capable of being distinct and were distinct within the context of the Apellis Agreement and represented separate performance obligations. Therefore, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any upfront revenue related to the license. The Company further concluded that the Opt-In Rights and option to extend the collaboration term did not grant Apellis a material right. The Company determined that the term of the contract is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as this is the period during which both parties have enforceable rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The selling price of each performance obligation was determined based on the Company&#x2019;s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Apellis Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue for each performance obligation as it is satisfied over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term using an input method. The Company allocated the transaction price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to each of the six performance obligations, which includes each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation, and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is being recognized using an input method based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the entity&#x2019;s performance in transferring control of the goods and services promised to Apellis and represents the Company&#x2019;s best estimate of the period of the obligation. For the years ended December 31, 2024, 2023, and 2022, the Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue, respectively, related to the Apellis Agreement. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, there is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of current and long-term deferred revenue, respectively, related to the Apellis Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Verve&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Verve Agreement, Verve issued the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock as partial consideration for the licenses granted, having a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The fair value of the Verve common stock was determined by management with the assistance of a third-party valuation specialist. In addition, to the extent certain clinical, regulatory, and commercial milestones were met with respect to licensed products, Verve was required to pay to the Company certain amounts, as defined in the agreement. Lastly, to the extent there were sales of a licensed product, Verve was obligated to pay the Company royalties, as defined in the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also purchased shares of Verve's Series A preferred stock during the year ended December 31, 2020. During June 2021, Verve completed an initial public offering of its common stock. In connection with Verve&#x2019;s initial public offering, Verve effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2592&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse stock split and also converted all shares of its preferred stock into shares of common stock. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the Company owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;546,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Verve's common stock valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management determined that the performance obligations associated with the Verve Agreement were the combined licenses and improvements related to the licensed technology. All other items promised to Verve were immaterial in the context of the agreement. The fair value of the shares issued by Verve to the Company were considered a fixed upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the form of non-cash consideration.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Company, Verve, and Lilly entered into a Side Letter Agreement whereby the Company agreed to delegate to Lilly certain rights and obligations existing under the Verve Agreement, including the Company&#x2019;s rights and obligations to co-develop and co-commercialize opt-in products, the financial rights to milestone and royalty payments, and the right to participate on certain joint decision-making committees. The Company determined that the transfer and delegation of rights represents a modification of the Verve Agreement to be accounted for as if it were part of the existing contract in accordance with ASC 606. Prior to the modification, the Company determined that its performance obligations associated with the Verve Agreement at contract inception and subsequent modifications were not distinct and represented a single performance obligation, and that the obligation would be completed over the performance period of the agreement. Accordingly, the upfront payment was being recognized as revenue using a time-based proportional performance model over the contract term (April 2019 through 2038) of the collaboration, as license revenue. The milestone payments and royalties were considered variable consideration and were constrained up until the modification date as no milestones or royalties were achieved. Subsequent to the modification, management concluded that the Company does not have material ongoing obligations to Verve in the arrangement and that the remaining revenue under the agreement should be recognized at a point-in-time upon modification. Therefore, the Company recognized the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of unrecognized revenue in October 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any revenue under the Verve Agreement during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remaining deferred revenue related to the Verve Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024. For each of the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of license revenue, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3"
      id="F_81a439d5-0b63-4b1e-84bf-6a26e8afd1ef">In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company&#x2019;s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company&#x2019;s opt-in rights to co-develop and co-commercialize Verve&#x2019;s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:CollaborationAgreementUpfrontPaymentReceived
      contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1"
      decimals="-5"
      id="F_21541175-e9cd-44fb-a325-0869236a66c4"
      unitRef="U_USD">200000000</beam:CollaborationAgreementUpfrontPaymentReceived>
    <beam:PotentialAdditionalProceedsFromTransferAgreement
      contextRef="C_a46bf662-b041-4823-abd8-67f3900593df"
      decimals="INF"
      id="F_1210aa96-0016-4539-82a3-ccf7f58dd359"
      unitRef="U_USD">350000000</beam:PotentialAdditionalProceedsFromTransferAgreement>
    <beam:CollaborationAgreementTermOfContract
      contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3"
      id="F_1ac88af3-6c92-40c3-bc02-a4d47078bba7">P6Y</beam:CollaborationAgreementTermOfContract>
    <beam:StockPurchaseAgreementShares
      contextRef="C_051ea08a-43d3-423d-856c-04c479177819"
      decimals="INF"
      id="F_d15ebeb1-a3d8-4334-8c36-832c0ccd542e"
      unitRef="U_shares">2004811</beam:StockPurchaseAgreementShares>
    <beam:StockPurchaseAgreementAggregatePurchasePrice
      contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3"
      decimals="-5"
      id="F_775089ec-7863-4bb8-a29c-3f77d1184db5"
      unitRef="U_USD">50000000</beam:StockPurchaseAgreementAggregatePurchasePrice>
    <beam:StockPurchaseAgreementAmountReceived
      contextRef="C_e3e53934-eb8b-4bda-9434-0a170bb66af3"
      decimals="-5"
      id="F_87e79215-0d92-4b1b-9a19-d22f105f8c06"
      unitRef="U_USD">50000000</beam:StockPurchaseAgreementAmountReceived>
    <beam:CollaborationAgreementUpfrontPaymentReceived
      contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1"
      decimals="-5"
      id="F_3a03673f-858e-417e-9447-d930ed56feed"
      unitRef="U_USD">200000000</beam:CollaborationAgreementUpfrontPaymentReceived>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_051ea08a-43d3-423d-856c-04c479177819"
      decimals="-5"
      id="F_d81b84c2-c89e-49cb-8052-d704aaa47e37"
      unitRef="U_USD">216400000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementUpfrontPaymentReceived
      contextRef="C_f030aa3a-70e6-4f47-97dd-f2ba88a2b9f1"
      decimals="-5"
      id="F_051a805a-35be-4277-a79a-16ac0dbc82c6"
      unitRef="U_USD">200000000</beam:CollaborationAgreementUpfrontPaymentReceived>
    <beam:CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue
      contextRef="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7"
      decimals="-5"
      id="F_50041fb5-373c-4211-82eb-6212b9aeb117"
      unitRef="U_USD">16400000</beam:CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue>
    <beam:CollaborationLicenseAgreementFairValueOfSharesIssued
      contextRef="C_64d5eaf7-162a-41b8-9efc-10ce22ae1df7"
      decimals="-5"
      id="F_dbfa2801-cd67-4e0f-af06-69b9f413876d"
      unitRef="U_USD">33600000</beam:CollaborationLicenseAgreementFairValueOfSharesIssued>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_7ffb90b6-e3c3-4094-a911-c196df383847"
      decimals="-5"
      id="F_c58acf01-c610-4966-8ccd-f01ab7ca2e9c"
      unitRef="U_USD">25000000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_dd66f54e-6ff6-4a57-b80d-1a794bfab97f"
      decimals="-5"
      id="F_b418873a-f422-4cb3-90bb-ee20b40c790b"
      unitRef="U_USD">216400000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7ed33382-7533-4a0f-94fc-b6c4d06ac455"
      decimals="-6"
      id="F_3e0238d6-921e-48c0-a672-7f9420d45f28"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31"
      id="F_ecae1b94-ca05-4fcc-bf82-d01b05198b73">Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:CollaborationCommonSharesReceived
      contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960"
      decimals="-6"
      id="F_e9783e5a-1972-448c-92ca-cd86bab3c753"
      unitRef="U_shares">75000000</beam:CollaborationCommonSharesReceived>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_e1d74f31-840b-44fe-a432-c3e0d8792431"
      id="F_004ddb36-d5c6-493b-9cfc-e202727bef3f">P3Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a"
      id="F_fc4a86fd-ac54-490b-b200-05073dc0bf3d">P3Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationArrangementExtensionTermDescription
      contextRef="C_37c60d38-5fe6-4179-a60d-360ee5ccee7a"
      id="F_9a52ca89-d889-40e8-91bb-0d5d14504c79">which may be extended for up to two successive one-year periods</beam:CollaborationArrangementExtensionTermDescription>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960"
      decimals="-5"
      id="F_434235fd-d29f-44aa-a5cf-18a9f762d7ee"
      unitRef="U_USD">25500000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition
      contextRef="C_6f489ee0-30c4-44dd-9bd9-4858a5024d31"
      id="F_8e714273-5b6a-4cf8-9ce8-a5e1c5a4bc5c">P3Y</beam:CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce"
      decimals="-5"
      id="F_a9eb9ca1-4c77-457c-8816-a8483d1b824a"
      unitRef="U_USD">8500000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8"
      decimals="-5"
      id="F_f97b3dd2-ee3c-4873-849d-814663524706"
      unitRef="U_USD">8500000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_d318bed9-9799-44fd-bb35-943b44e05e86"
      decimals="-5"
      id="F_3f9e9713-d268-4838-a609-2e76d7937fb6"
      unitRef="U_USD">2100000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_72946174-54ef-42ee-b20d-174ccb0133a1"
      decimals="-5"
      id="F_b4e1fbf0-4bba-4507-ba0b-18288f05addb"
      unitRef="U_USD">6400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960"
      decimals="-5"
      id="F_655dc6ec-6627-4211-b023-1f21e111da98"
      unitRef="U_USD">25500000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_eecadce7-cffa-42a7-a808-35c5ac47a667"
      decimals="2"
      id="F_2d5bf57e-5ba8-4598-8001-f61156343b0c"
      unitRef="U_pure">0.68</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_7bde4f21-b869-4f23-b886-c0c6dfff5351"
      decimals="2"
      id="F_23f4ebd6-7df7-4015-b40e-e2eb93a53ecd"
      unitRef="U_pure">0.43</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:EquityMethodInvestments
      contextRef="C_6694c047-b444-4cf8-931a-d5e47d7fa960"
      decimals="0"
      id="F_2b636dbd-2827-4f13-9e7d-514b0dffb59d"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_d318bed9-9799-44fd-bb35-943b44e05e86"
      decimals="-5"
      id="F_12ce6cf4-132a-4e17-8827-f628edb84384"
      unitRef="U_USD">-25500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_f76dcec0-a867-4eb7-bad1-ace9f634f5ce"
      decimals="-6"
      id="F_9c5b1885-4bb3-4c2c-b1d4-9ce96e66fbd9"
      unitRef="U_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_410fb12e-9165-4bbd-99f4-e2dc19f85ae8"
      decimals="-6"
      id="F_68dfefa6-9e13-43f3-b86f-ca60532bb924"
      unitRef="U_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535"
      id="F_6684cdcb-13a9-4624-997a-01a0445f5893">In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company&#x2019;s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage
      contextRef="C_5a05ec5d-cf56-49cb-b84e-2b325f31bc00"
      decimals="2"
      id="F_5066bd77-9fe7-4528-ad59-1e9ae1804d32"
      unitRef="U_pure">0.65</beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage>
    <beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage
      contextRef="C_95f6702d-f704-4654-9cb9-17cb2a30898f"
      decimals="2"
      id="F_5d95b8fe-67da-41d0-a967-4b547481f154"
      unitRef="U_pure">0.35</beam:NetProfitsAndDevelopmentAndCommercializationCostsPercentage>
    <beam:NonrefundableUpfrontPaymentReceivable
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-5"
      id="F_6a3ae732-cbdd-42c4-bc41-da88d7b16df9"
      unitRef="U_USD">300000000</beam:NonrefundableUpfrontPaymentReceivable>
    <beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable
      contextRef="C_7fbcfe71-e126-4c16-a2f8-6d4074f3e339"
      decimals="-5"
      id="F_def5a21a-d980-4ddf-b2d6-7980ba99a8e9"
      unitRef="U_USD">350000000</beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable>
    <beam:PotentialConsideration
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-7"
      id="F_b8646665-de8c-4573-a0df-b0a4b97bef46"
      unitRef="U_USD">1350000000</beam:PotentialConsideration>
    <beam:EarnoutPaymentPeriod
      contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535"
      id="F_50d314d6-7ce5-4cc8-89c8-3d0ef38711ad">P10Y</beam:EarnoutPaymentPeriod>
    <beam:NonrefundableUpfrontPaymentReceivable
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-5"
      id="F_61680f51-eb9a-4160-83f2-ef04fe0e2283"
      unitRef="U_USD">300000000</beam:NonrefundableUpfrontPaymentReceivable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-5"
      id="F_12f65313-bc4b-4afc-a1c2-1e35e1e7e83f"
      unitRef="U_USD">300000000</us-gaap:ContractWithCustomerLiability>
    <beam:CollaborationAgreementUpfrontPaymentReceived
      contextRef="C_cf84f853-64e7-4f6f-a1df-e90a15485b3b"
      decimals="-5"
      id="F_8ffb5126-55fc-466b-a5f3-e4f40ae004a1"
      unitRef="U_USD">300000000</beam:CollaborationAgreementUpfrontPaymentReceived>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535"
      id="F_2a57eea9-f01d-4933-9a6b-dc5a203b16dc">P4Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationArrangementExtensionTermDescription
      contextRef="C_dd5f2a41-8fcd-4c26-82a5-3cef30f3c535"
      id="F_572f0470-4144-4d2d-babe-7de7b8850457">extended for an additional year on a program-by-program basis</beam:CollaborationArrangementExtensionTermDescription>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-5"
      id="F_bb0c2076-2e19-4a49-923d-d6e0b9e0a3f1"
      unitRef="U_USD">300000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_4f5d5cc2-830f-4657-be05-fa7964276c44"
      decimals="-5"
      id="F_97462d0f-5b47-439f-b7b3-45175f9a0bb5"
      unitRef="U_USD">300000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_e708f03e-b5c8-4b4c-851b-c790a40ee844"
      decimals="-5"
      id="F_4adc3d2f-5a5f-4cb1-b932-b69d83f030f5"
      unitRef="U_USD">8400000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_51719419-8be3-40d6-b822-aac6d564e3b7"
      decimals="-5"
      id="F_15444090-60a8-4c54-b712-634076bd32fc"
      unitRef="U_USD">134300000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_4f1eba65-fbc3-49e1-9877-736765296cdd"
      decimals="-5"
      id="F_3eb1ab69-ab35-4abe-8515-21d58c3456b0"
      unitRef="U_USD">48200000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb"
      decimals="-5"
      id="F_90ddf72f-3eac-43d7-90b3-de0c5164973b"
      unitRef="U_USD">88500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_9d8bebc6-7cd1-4d37-90f4-c3cb6fb1afeb"
      decimals="-5"
      id="F_a2448249-eadb-49b3-b8ec-c391b1d9ac3d"
      unitRef="U_USD">20600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <beam:LicenseAgreementUpfrontPaymentReceived
      contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee"
      decimals="-5"
      id="F_5a2b50bf-924d-4c53-9c5c-5203f0fb7b0b"
      unitRef="U_USD">50000000</beam:LicenseAgreementUpfrontPaymentReceived>
    <beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable
      contextRef="C_e2d79338-1ac4-4b79-83d8-f195b051536a"
      decimals="INF"
      id="F_697302bd-fd5c-47f2-8e5a-1b81b34539c7"
      unitRef="U_USD">65000000</beam:DevelopmentRegulatoryAndCommercialMilestonesReceivable>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_e86d3ec5-e144-44e9-8637-dc263422e9d7"
      id="F_a58a2c12-8f84-4092-af20-c834d3bdf1bd">For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $15.0 million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $30.0 million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days&#x2019; prior written notice or upon 180 days&#x2019; prior written notice after first commercial sale.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:AdditionalFeePerAdditionalOptionRight
      contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee"
      decimals="-5"
      id="F_7125e19e-4f6b-4b74-88f6-e1a8df88d61b"
      unitRef="U_USD">15000000</beam:AdditionalFeePerAdditionalOptionRight>
    <beam:OptionRightsAggregatePotentialAdditionalConsideration
      contextRef="C_a88c5e15-481f-445a-947c-2cb1d21faaee"
      decimals="-5"
      id="F_0c65892e-0c5d-420a-9b68-88b025d5b1df"
      unitRef="U_USD">30000000</beam:OptionRightsAggregatePotentialAdditionalConsideration>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_c448f064-efee-4973-8a00-ca00db426a3e"
      decimals="-5"
      id="F_b714876e-4554-4e4f-94ed-39ca11a16e0a"
      unitRef="U_USD">50000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_1f14ed46-687f-4e31-ac5e-c38d1b43d86f"
      decimals="-5"
      id="F_16be20aa-e5f3-47a8-9684-b8d08d3bca66"
      unitRef="U_USD">2000000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_30db48d9-fd35-4524-9f25-e5f0967f30bf"
      decimals="-5"
      id="F_35554741-0691-4044-a649-566481c90ab0"
      unitRef="U_USD">1800000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_82c07a0b-8c7a-44a6-b246-a5568dfbfc60"
      decimals="-6"
      id="F_ab4ee96c-793c-408c-9c6f-8c517e565aff"
      unitRef="U_USD">0</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"
      id="F_4e996f6a-d4e1-40b2-9f3f-94785260743d">In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company&#x2019;s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.</us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_84c43dfe-ef3d-41ec-9d55-eff61a072fe3"
      unitRef="U_USD">75000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:UpfrontFeeReceivableUponSigningContract
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_8e74ba0c-052e-44e3-959a-90ada1836bd5"
      unitRef="U_USD">50000000</beam:UpfrontFeeReceivableUponSigningContract>
    <beam:CollaborationAgreementFirstAnniversaryAmountReceivable
      contextRef="C_cc9a65a2-a296-4a7c-ad5a-f2a43865bbed"
      decimals="-5"
      id="F_4c907d31-6c86-4ec8-83f8-56eaf06cc2e1"
      unitRef="U_USD">25000000</beam:CollaborationAgreementFirstAnniversaryAmountReceivable>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"
      id="F_a00a1180-17fc-4499-99b1-723cb27d6bfb">P5Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationArrangementExtensionTerm
      contextRef="C_dc200094-3ff1-4578-a977-4d4a2356f15b"
      id="F_7ec338ed-ac29-4c6b-8b93-1aff6d470515">P2Y</beam:CollaborationArrangementExtensionTerm>
    <beam:UpfrontPaymentReceivedUnderTermOfAgreement
      contextRef="C_4768fad0-596a-43bc-a633-4ba916d5e2bd"
      decimals="-5"
      id="F_9d7f792c-4e76-4d1c-8a76-6536fc26e402"
      unitRef="U_USD">50000000</beam:UpfrontPaymentReceivedUnderTermOfAgreement>
    <beam:CollaborationAgreementFirstAnniversaryPaymentReceived
      contextRef="C_43ad7076-7bc9-411a-b3ab-a6ecbc89e42b"
      decimals="-5"
      id="F_cc796b5c-f7d5-4cef-8df6-07f010f7a525"
      unitRef="U_USD">25000000</beam:CollaborationAgreementFirstAnniversaryPaymentReceived>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_cc01ea83-f9bc-459e-bcfa-c5a99afc35a5"
      unitRef="U_USD">75000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:UpfrontFeeReceivableUponSigningContract
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_75d03eb5-a818-4cfa-af2f-e4f32f4deed0"
      unitRef="U_USD">50000000</beam:UpfrontFeeReceivableUponSigningContract>
    <beam:CollaborationAgreementFirstAnniversaryAmountReceivable
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_af17ae79-8c52-44b2-a5ce-9cbe9d12e920"
      unitRef="U_USD">25000000</beam:CollaborationAgreementFirstAnniversaryAmountReceivable>
    <beam:UpfrontRevenueRecognized
      contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"
      decimals="INF"
      id="F_145cff8d-bb17-45a4-b29e-d9b9b5b345e3"
      unitRef="U_USD">0</beam:UpfrontRevenueRecognized>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"
      id="F_aa0b56df-0ba9-4916-8853-02364bc76394">P5Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationArrangementInitialTerm
      contextRef="C_24b472bb-cf24-44c4-b30d-0f39871bf9cf"
      id="F_adf25162-2fd1-4793-97a3-ec3d87f3c0c5">P5Y</beam:CollaborationArrangementInitialTerm>
    <beam:CollaborationAgreementAggregateTransactionPrice
      contextRef="C_2fc1c152-311d-499f-b1d0-6fb0cf223f36"
      decimals="-5"
      id="F_389068cb-37ce-4f03-aa7d-e759417d2bca"
      unitRef="U_USD">75000000</beam:CollaborationAgreementAggregateTransactionPrice>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_141a0bab-6778-428c-9b18-6212d89a1a93"
      decimals="-5"
      id="F_75f9594d-6c1f-4603-8611-f7e22de6eb8f"
      unitRef="U_USD">19700000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_fb6723fb-3691-4707-acfb-4ac88805b04b"
      decimals="-5"
      id="F_0b46372b-6802-44d2-a9d5-b6aeaab39db1"
      unitRef="U_USD">16400000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_8fffa0c5-ef26-4f15-a702-c749a8609fd3"
      decimals="-5"
      id="F_b3c8818e-ecd2-4fc7-9ac1-df214717dac9"
      unitRef="U_USD">10600000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_a6a0e0af-be42-49df-9199-a22238777a85"
      decimals="-5"
      id="F_191991e1-356e-4bbb-8f3e-7f5097341b56"
      unitRef="U_USD">14000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_a6a0e0af-be42-49df-9199-a22238777a85"
      decimals="-5"
      id="F_2b9cf6ea-66fc-4e8f-8bb0-8cb2b913c5fb"
      unitRef="U_USD">12600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:CollaborativeArrangementNatureAndPurpose
      contextRef="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a"
      id="F_f77ad769-c099-4f4d-b792-b87affc2b5ec">In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. </us-gaap:CollaborativeArrangementNatureAndPurpose>
    <beam:CollaborationLicenseAgreementSharesReceived
      contextRef="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648"
      decimals="-5"
      id="F_8d23922f-402a-4a7e-a9fd-76d5ecf5ae20"
      unitRef="U_shares">2600000</beam:CollaborationLicenseAgreementSharesReceived>
    <beam:CollaborationLicenseAgreementFairValueOfSharesReceived
      contextRef="C_c3c7a7ad-6a77-401e-9cc4-444ebeb5c648"
      decimals="-5"
      id="F_d0de72f5-505f-429b-8a4f-0a8bbe324b42"
      unitRef="U_USD">500000</beam:CollaborationLicenseAgreementFairValueOfSharesReceived>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0"
      id="F_7e80aeb3-65b2-4d2e-b8e0-df0d100d33d0">one-for-9.2592</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_964b2569-eb9e-4fb8-8f77-4282b5860ac0"
      decimals="4"
      id="F_74c8208e-8624-496d-85f8-c1dcf54d59d8"
      unitRef="U_pure">9.2592</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <beam:EquitySharesHeld
      contextRef="C_36b8ac53-6fab-4279-8285-1a0366571ae4"
      decimals="INF"
      id="F_89e43b90-38d0-487a-b27c-e605d0959c23"
      unitRef="U_shares">546970</beam:EquitySharesHeld>
    <beam:EquitySharesValueHeld
      contextRef="C_9eb93719-d476-49d6-a58e-2223125d2c02"
      decimals="-5"
      id="F_2e103987-f4d5-4d45-a755-95e86a345c20"
      unitRef="U_USD">3100000</beam:EquitySharesValueHeld>
    <beam:UpfrontPaymentFairValueSharesReceived
      contextRef="C_eb77fec1-6325-48a0-89e4-aaabf47cbc3a"
      decimals="-5"
      id="F_c056dc97-1e48-4ad9-a03e-2265a5086079"
      unitRef="U_USD">500000</beam:UpfrontPaymentFairValueSharesReceived>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_586c5528-76ab-4467-958c-e7217226efd0"
      decimals="-5"
      id="F_7dd32912-3553-4822-88e2-3fc6422bac00"
      unitRef="U_USD">300000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_48e046f4-2f13-45b1-996e-dc68dffe5446"
      decimals="-6"
      id="F_1f2090fa-3819-46ab-a278-342371e94e0a"
      unitRef="U_USD">0</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_9eb93719-d476-49d6-a58e-2223125d2c02"
      decimals="-6"
      id="F_ecc61200-820d-4007-95fb-6d1ddf4949f0"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_0b1904af-7fc2-4128-b51e-282e6a1495b8"
      decimals="-5"
      id="F_a49b0d36-8b88-4ca2-9153-c798a0c8b70e"
      unitRef="U_USD">400000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <beam:CollaborationAgreementPerformanceObligationRevenueRecognized
      contextRef="C_e2c7432a-a6e2-4466-b4d0-b448e1cd2b34"
      decimals="-5"
      id="F_65ca81fa-6007-4a86-8a94-867f85d4f9cb"
      unitRef="U_USD">100000</beam:CollaborationAgreementPerformanceObligationRevenueRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_2288cdd3-ed2c-4839-b0f4-3e8a78716f43">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into the Sales Agreement with Jefferies pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of its common stock having aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. The Company agreed to pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. As of December 31, 2024, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,769,001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock under the Sales Agreement at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;864.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting commissions and offering expenses payable by it.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of the Company&#x2019;s common stock are entitled to one vote for each share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The holders of the Company&#x2019;s common stock shall be entitled to receive ratably dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <beam:StockIssuanceProgramAuthorizedAmount
      contextRef="C_e52777dd-4d29-43df-9dc4-542e20ab7fa2"
      decimals="INF"
      id="F_43a85743-a1e1-46f9-ac15-625e8b91aef7"
      unitRef="U_USD">1100000000</beam:StockIssuanceProgramAuthorizedAmount>
    <beam:CommissionRate
      contextRef="C_28b27276-6ff0-45b2-8e23-dcf9ee251c3a"
      decimals="3"
      id="F_76b1c415-ed06-4d10-89e7-f6e202ab1274"
      unitRef="U_pure">0.03</beam:CommissionRate>
    <beam:StockSoldDuringPeriodSharesNewIssues
      contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028"
      decimals="INF"
      id="F_5a09ea0c-cbc8-4607-bc94-04f1cf5d2387"
      unitRef="U_shares">13769001</beam:StockSoldDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_9e824cf6-96ad-482c-938b-89bcefc2519a"
      decimals="INF"
      id="F_3d527635-b4de-4964-83a8-1d66ed05b366"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">62.75</us-gaap:SaleOfStockPricePerShare>
    <beam:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_13901643-aa76-4301-bdf7-ba774fec2028"
      decimals="-5"
      id="F_7c7e09b1-5a77-46b8-9c87-2a05323fa992"
      unitRef="U_USD">864000000</beam:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_7720f00f-8bef-4150-8891-7b2f85a9efbe">The holders of the Company&#x2019;s common stock are entitled to one vote for each share of common stock.</us-gaap:CommonStockVotingRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_153cf094-54d8-41a9-bdf8-9a9b4ba0d8b4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Stock option and grant plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2017 stock option and grant plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2017, the Company&#x2019;s board of directors adopted the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan, or the 2017 Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options, restricted stock or other awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2017 Plan is administered by the board of directors. Stock options awarded under the 2017 Plan expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after the grant date. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2017 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 incentive plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2019, the Company&#x2019;s board of directors adopted the Beam Therapeutics Inc. 2019 Equity Incentive Plan, or the 2019 Plan, and, following the IPO, all equity-based awards are granted under the 2019 Plan. The 2019 Plan provides for the grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2019 Plan was initially &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,700,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, or the Share Pool, plus the number of shares of the Company&#x2019;s common stock underlying awards under the 2017 Plan, not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,639,818&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, that become available again for grant under the 2017 Plan in accordance with its terms. The Share Pool will automatically increase on January 1st of each year from 2021 to 2029 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percent of the number of shares of the Company&#x2019;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#x2019;s board of directors on or prior to such date for such year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,773,507&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares reserved and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,591,110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations and other comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted were:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of option activity under the Company&#x2019;s equity award plans:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.844000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value (1)&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,276,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,678,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;563,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;785,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,605,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,896,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing price of the common stock for the options that were in the money as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has granted stock options to certain employees to purchase shares of common stock that contain certain performance-based vesting criteria, primarily related to the achievement of certain development milestones related to editing applications, and the closing price of the Company&#x2019;s common stock following an IPO. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. The expense related to performance-based options was immaterial for the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The aggregate intrinsic value of stock options exercised during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The weighted-average exercise price of stock options exercised for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued shares of restricted common stock during the years ended December 31, 2024, 2023 and 2022, which consisted only of restricted stock units. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted common stock issued generally vests over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f65e9bb1-b2e1-469e-be73-4e76142cee9f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Generally, if the holders of restricted stock units cease to have a business relationship with the Company, any unvested restricted stock units will be cancelled.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,233,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,302,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,576,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate fair value of restricted shares that vested during the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, there was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2020, the Company&#x2019;s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company&#x2019;s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and at a purchase price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;
The Company used the Black-Scholes option valuation model to estimate the fair value of the purchase right under the ESPP on the date of grant. The expected volatility is based on the historical volatility of the Company's common stock for a period of years corresponding with the expected life of the option. The risk-free interest rate is based on the U.S. Treasury yield curve at the time of grant for securities with a maturity period similar to the expected life of the option. The expected life is based on the term of the purchase period for the grants made under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the straight-line attribution approach to record the expense over the offering period. Stock-based compensation expense related to the ESPP for the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,187&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,073&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares under the ESPP during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022 respectively. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,928,706&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance under the ESPP.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_ede17f6b-07f6-4cb0-8a64-18644baafbc3"
      id="F_960baca5-4eab-4eb8-ab3b-7358975ef94f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_3ac29eac-6794-4f6c-aaeb-4e2937541c74"
      decimals="INF"
      id="F_70dd9a9d-8ba5-4ea3-8cc1-af3799de2ca5"
      unitRef="U_shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_30e95c96-73e5-48eb-9598-acd156ccfd5e"
      decimals="INF"
      id="F_bc2966f4-0eec-4b1b-bec6-3316d4b7e72d"
      unitRef="U_shares">5639818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_0515efd6-8f8f-400e-9505-a0e0559e9790"
      decimals="INF"
      id="F_286ccb63-4a74-46f3-801f-1807d51b0586"
      unitRef="U_pure">0.04</beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_aa7b8d00-54cd-467a-afdf-694a607825bb"
      decimals="INF"
      id="F_8fe49dd5-2e03-42de-af30-f066cbd8ebc8"
      unitRef="U_shares">13773507</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_aa7b8d00-54cd-467a-afdf-694a607825bb"
      decimals="INF"
      id="F_9467e893-3683-46e4-bc1a-a7da1e61ccf8"
      unitRef="U_shares">1591110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_3b9cef1b-62aa-4005-b3a2-1069a588201e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations and other comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_66014777-6584-477d-9aa8-ffa7abbe1249"
      decimals="-3"
      id="F_27410327-f8ef-4072-b55a-8dec57c60b92"
      unitRef="U_USD">73523000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7ff8794b-8499-4caa-8e54-fbac240792c1"
      decimals="-3"
      id="F_bb473ad5-586c-4a90-8138-e64df73c937e"
      unitRef="U_USD">57812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9b230fb2-b8f0-4f54-b0e0-e574c073d589"
      decimals="-3"
      id="F_09f1c98c-1112-4287-9500-0aaa2a40c0f5"
      unitRef="U_USD">52004000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7e7cb18e-69e1-417d-807d-8ec7e9b03e54"
      decimals="-3"
      id="F_1e3ed433-5284-4eee-9cdf-4bfb4198f672"
      unitRef="U_USD">47139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b772f99d-0bbb-4fb9-9d12-6cd094a0084e"
      decimals="-3"
      id="F_0397eb79-22a0-44aa-891b-2000a3cee6e4"
      unitRef="U_USD">40835000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_349daa7a-ee95-4e81-a366-8d8ce431c2f7"
      decimals="-3"
      id="F_2fffb305-074f-4640-a46d-6bef80f8833a"
      unitRef="U_USD">32317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_5bdd3cd1-b3b5-466a-9f70-86d6c63a4ab1"
      unitRef="U_USD">120662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_9074c583-8071-4447-a334-c7ac38f0d3e3"
      unitRef="U_USD">98647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_8247e627-e21e-4a1a-8818-9ebe46d65554"
      unitRef="U_USD">84321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d9930b4a-669a-4b8d-a8fc-cc4fce70837e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted were:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_2877ca76-fa4d-4e38-9908-2f3dc7798ecd"
      unitRef="U_pure">0.762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_4226de45-9d44-44ac-8eac-15135c7729b1"
      unitRef="U_pure">0.785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_5da5a547-f7bd-4a0b-bd12-50011e20c210"
      unitRef="U_pure">0.763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_d32e4086-7036-40bb-8e89-76b971a9f61f"
      unitRef="U_pure">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_c8f8f710-f0f6-4b53-8b8f-6d7c18985a78"
      unitRef="U_pure">0.748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_6ac4fd5d-d886-4453-97fd-75f091b9231c"
      unitRef="U_pure">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="4"
      id="F_bc63bb90-f95d-44b7-86ca-0b3587d4fa79"
      unitRef="U_pure">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="4"
      id="F_59c89284-6c49-4073-8f28-382fb36f3eb8"
      unitRef="U_pure">0.0373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="4"
      id="F_0f705649-66d5-478c-91e2-0222a92b93d2"
      unitRef="U_pure">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="4"
      id="F_3ad8fa37-6837-4e80-8a41-0def6d60ffa4"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="4"
      id="F_cf705813-567e-4dbb-a427-0d63d9cc7dc2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="4"
      id="F_be696168-e3e6-47cb-a0e4-d5e4a85050b2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_69c3575c-e1e1-4eaa-b7db-0124cc38569f">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      id="F_bd8ab6d9-5383-4132-8c7b-cae0ece7cf00">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      id="F_f052b868-c772-4acd-a2dc-5fa8cce184f8">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_23ede3c0-01e5-4298-9849-34561f48de57">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of option activity under the Company&#x2019;s equity award plans:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.844000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value (1)&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,276,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,678,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;563,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;785,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,605,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,896,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing price of the common stock for the options that were in the money as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="INF"
      id="F_2cecf07c-76c9-483a-8621-c54f9aa73d73"
      unitRef="U_shares">8276033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="2"
      id="F_cd1db932-ca16-48d7-abde-ea665e8c2c94"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      id="F_c5ea3182-6a08-475e-b078-4c0d3a994820">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_baa9a2cc-7982-4f4b-ba2c-d52f595678c8"
      unitRef="U_USD">51653000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_646e21d6-3f6c-4a35-8db0-6eaf4b7bdbc5"
      unitRef="U_shares">2678145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_83e6e4b2-4014-4eba-bfea-7caacff8088c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_acfe3e39-0c7c-4a11-b8cf-2ebe43de2da1"
      unitRef="U_shares">563349</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_5df6c86f-3469-4449-8ceb-1b78225b284f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_07badd3f-cf68-4964-ba06-22ff9359bd76"
      unitRef="U_shares">785287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_9209bb12-ed90-42a6-934b-e2831b50903f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">53.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_d01d0393-8554-4f84-a850-8d15c843f89e"
      unitRef="U_shares">9605542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="2"
      id="F_3963d3a3-895c-47d3-8f2f-32f916d3e877"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">38.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_37c78f52-55c2-401f-a299-9b4f97aa8ae8">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_c461051c-f398-4ec0-b745-ab993d057bf5"
      unitRef="U_USD">37182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="INF"
      id="F_ede65ae9-dd4c-4fcb-ac49-940fbcc352c0"
      unitRef="U_shares">5896483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="2"
      id="F_2b76be8b-9946-48ad-82fe-6c8ce9954ae2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">40.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_d8f19922-25d1-4bd8-b373-808dbd000c62">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_fab758f9-ef71-41da-9a39-1f2dfefec80f"
      unitRef="U_USD">36102000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_ead8b19a-c7ea-4db1-b9f7-6f802b25de10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_f59e5b8f-0305-4301-8507-9962892998b8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_8d6e1962-3264-45b0-9106-66115e88c7e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">40.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-5"
      id="F_ef08292f-6931-449d-85a2-b176387a6f52"
      unitRef="U_USD">10700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-5"
      id="F_95dee046-e94f-4ab8-8d5b-328e8d7134fd"
      unitRef="U_USD">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-5"
      id="F_5ff8236c-9cf0-424a-aa49-b6fcb47836dc"
      unitRef="U_USD">23400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_01a15791-5d81-4625-8459-903231b02133"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_0e8a9c3b-0a2f-4df7-b90c-982e2b14df12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_c49cf9f3-b8c1-470f-855d-6ab358c360a8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_f8bffd7e-bec1-4a21-84c9-e2e5a56dbf98"
      decimals="-5"
      id="F_06a61528-b9e9-49eb-86e3-9e6dc49e145c"
      unitRef="U_USD">86800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f89f6da8-621e-4376-b358-73a07809ea70"
      id="F_3c9ed83b-21e7-412d-8dc0-f98276c95837">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_1bb5d16d-4da2-4d42-b325-fdfab05f797f"
      id="F_b9fa0e9e-64bc-4b40-9408-ad8c56db34f5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_263e61ce-df0d-4a76-b595-81ea928ebd01">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes the Company&#x2019;s restricted stock activity:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,233,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,302,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,576,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_610ac957-5c8d-4898-bdab-ead2ab364037"
      decimals="INF"
      id="F_2858c2ca-037e-46a5-bd80-e93a947f8264"
      unitRef="U_shares">2927152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_610ac957-5c8d-4898-bdab-ead2ab364037"
      decimals="2"
      id="F_8eb05e82-1bcc-4d7c-ba71-397bed2b5ee4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">40.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="INF"
      id="F_05e53c4f-ae9c-473e-9d4c-b04c8ec26ad7"
      unitRef="U_shares">1233688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="2"
      id="F_24e57df5-80b6-464f-a0b8-e7a730258ceb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="INF"
      id="F_bb7aa6c8-153f-429b-a365-a75426a734e3"
      unitRef="U_shares">1302037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="2"
      id="F_97b6e302-f51a-4ed7-b6dc-b54a62816e76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">39.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="INF"
      id="F_908ea98e-ecb8-4ed9-9b38-6e9099a8e42d"
      unitRef="U_shares">281948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="2"
      id="F_16ead2a5-61c0-4d01-b10f-525bd225b13d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">38.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2"
      decimals="INF"
      id="F_2681448a-4723-4b0a-8db9-9293509ba498"
      unitRef="U_shares">2576855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2"
      decimals="2"
      id="F_3bf94488-2a7b-4d1b-9d8e-5b315b09f9d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      decimals="-5"
      id="F_50ec8fde-5a38-4b93-96a8-2a11e08a9e70"
      unitRef="U_USD">35600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_ef0903ad-79ab-4cc9-8a92-a1067bb62252"
      decimals="-5"
      id="F_e0b4e330-34bf-47d9-a9d0-7754c020d44f"
      unitRef="U_USD">13800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_ceb22f03-41f2-470f-b6af-1fe085c96885"
      decimals="-5"
      id="F_5a120620-7835-40e4-a7c4-976bac71e523"
      unitRef="U_USD">53100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_9943b4f2-89ba-4814-ad32-f267e31916f2"
      decimals="-5"
      id="F_adbf76e8-83c1-4a22-8bd1-f8770713363d"
      unitRef="U_USD">68400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_87112419-0396-4bb6-9f5b-3a1ae9ccfb12"
      id="F_281f0e95-0513-4f95-b17a-2dc3e0014804">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e"
      id="F_f7a5a450-49d6-468f-8694-4ea4823f5cc3">In February 2020, the Company&#x2019;s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company&#x2019;s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount
      contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e"
      decimals="0"
      id="F_1db8fd3f-b093-4b02-a09c-f9f10695361f"
      unitRef="U_USD">25000</beam:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionYearlyLimitAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_3565eb40-7e5d-4491-b679-204f6e71151e"
      decimals="INF"
      id="F_868766e9-be88-4207-81af-afcfc1d61620"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0"
      decimals="-5"
      id="F_afbe6baa-794e-424f-8a4f-537ddf623084"
      unitRef="U_USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df"
      decimals="-5"
      id="F_379ca9b7-51ca-47b9-972a-697bb548b79f"
      unitRef="U_USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f"
      decimals="-5"
      id="F_4c74fba1-afc3-495d-b3db-0c794bb0158c"
      unitRef="U_USD">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_d84eb086-d87a-4ede-a00a-197a4f04b2d0"
      decimals="INF"
      id="F_28739a86-e1f5-4a1d-9765-ad971714648e"
      unitRef="U_shares">135187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_7a9b4b3c-4787-4fa2-805d-f682ee1503df"
      decimals="INF"
      id="F_0a1484e0-5dc0-474f-9093-5bee167e10ff"
      unitRef="U_shares">130403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_a22089ef-05f1-4e6f-8c98-02d9b7b0213f"
      decimals="INF"
      id="F_fc81d8d7-5c9e-4e33-b2cc-f768a7b4b68c"
      unitRef="U_shares">70073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_03458b68-88f0-4f4c-835b-84b7c3df3693"
      decimals="INF"
      id="F_31a633fe-7870-45f4-995a-c96fd697392d"
      unitRef="U_shares">2928706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_a66f09ba-ff94-4c8e-87e1-9f39f30f9702">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Net loss per share attributable to common stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As noted above, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.058%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.058%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,576,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,692,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,605,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,276,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,548,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,255,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,276,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,287,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,313,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,151,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,015,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_86e37b5d-9385-4263-8d44-e1f15289a302">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.058%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.058%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,576,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,692,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,605,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,276,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,548,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,255,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,276,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,287,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f4b1ef06-ec54-4fed-af05-d4a7050c16b7"
      decimals="0"
      id="F_ebba94cd-9894-483f-815e-670312511e31"
      unitRef="U_shares">2576855</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a4d1b346-89bb-46d5-943f-3575e89e7f76"
      decimals="0"
      id="F_a5fbd4dc-eeca-4856-970d-8a75874edd0c"
      unitRef="U_shares">2927152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf6c0d45-c719-46d3-96bf-bf86ff65ea9a"
      decimals="0"
      id="F_018ea452-8292-4474-acc4-4f867397af68"
      unitRef="U_shares">1692819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4caac963-d273-445d-aea2-8c8e7d840dbc"
      decimals="0"
      id="F_3e713d30-7cd9-42a1-ac6a-47737fb13c88"
      unitRef="U_shares">9605542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6ef5f0dc-2479-4c31-82d9-09b202c6d219"
      decimals="0"
      id="F_5d202bcd-0b6e-4d1b-9eb7-f48779ca752b"
      unitRef="U_shares">8276033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3af7bef2-d1fd-4b29-805f-7afc562dc297"
      decimals="0"
      id="F_74d95a38-3ca7-4694-80fa-748ef79bde05"
      unitRef="U_shares">7548392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e52f1520-daf9-498e-8105-a8484d3187d1"
      decimals="0"
      id="F_0c500c60-94e6-4042-93b6-ced937a01db8"
      unitRef="U_shares">73399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f0410223-d81d-47a5-95ac-2348253d72de"
      decimals="0"
      id="F_7dadcba9-b1cd-4b09-a8d4-d27578b77953"
      unitRef="U_shares">73415</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1915376c-4402-4696-8764-c838f2eb80a0"
      decimals="0"
      id="F_91ab8676-8b8a-4f27-87ee-4ca9078963c4"
      unitRef="U_shares">45906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="0"
      id="F_74d23dea-135f-4ea7-a225-48fe59015237"
      unitRef="U_shares">12255796</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="0"
      id="F_285ba502-9e3e-48a4-aa58-749261f4dc4a"
      unitRef="U_shares">11276600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="0"
      id="F_4f94031e-f500-4954-99f3-7085fd294e61"
      unitRef="U_shares">9287117</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_66a30d6d-73ce-43f0-8947-2c9f175c1b82">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,313,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,151,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,015,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_c85e7f0e-cdb3-443a-9380-3f310c74e586"
      unitRef="U_USD">-376742000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_502acaee-5bfa-424d-a1e1-959df59678a2"
      unitRef="U_USD">-132527000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_ae07bcc4-27a1-4b9e-b3af-4fa8ff519fbd"
      unitRef="U_USD">-289088000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="0"
      id="F_2ad258e0-5cd1-4abb-a23d-555d0921ce12"
      unitRef="U_shares">82313008</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="0"
      id="F_cfeb4f6b-ddd1-4bc5-a2cb-8a1a40657300"
      unitRef="U_shares">82313008</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="0"
      id="F_02c30249-1c15-4b98-b4d2-9071476ce4e2"
      unitRef="U_shares">77151771</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="0"
      id="F_7d021a90-68a6-4b4d-a527-54ea5687a1f4"
      unitRef="U_shares">77151771</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="0"
      id="F_5519ed4b-08b8-4544-8167-2b91769ecf6d"
      unitRef="U_shares">70015305</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="0"
      id="F_3da5226b-2f92-4e2c-89eb-e91363db4244"
      unitRef="U_shares">70015305</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_44bfa0df-7671-4738-a0f2-73077e14f60f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="2"
      id="F_dfa10d44-9b12-4021-9874-31ee5dc751b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_6c245c48-4c74-4485-957b-25fd2950909c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="2"
      id="F_ea8cf1af-afaa-434e-8398-870d77c04d52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_4cdf7c41-acf7-435c-96fd-bb8cc2f79b72"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="2"
      id="F_c1f75c64-3bee-4fe6-a1dc-a8ca8ec29ba7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c2c9a564-ccf4-45d5-b951-945b11a696da">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.045%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.045%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nondeductible/ nontaxable permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized Research&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;366,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_892f3c97-c2f0-430b-9466-4813ae1bf322;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024, 2023 and 2022, the Company recorded a current tax provision of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of income tax expense, respectively, which reflects that Company generated taxable income that was not fully offset by the use of net operating loss carryforwards and tax credits. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s deferred tax assets and has determined that it is not more likely than not that the Company will recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2024 and 2023. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2024 due to the increase in deferred tax assets, primarily due to increased capitalization of research and development expenditures in 2024. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, limit a corporation&#x2019;s ability to utilize tax attributes to the extent the corporation experiences an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change in ownership, measured by value, among 5% or greater shareholders over a rolling three-year testing period. To the extent a corporation experiences an ownership change, utilization of pre-ownership change tax attributes (e.g., net operating losses and general business tax credits) to offset post-ownership change taxable income or taxes, is subject to an annual limitation, generally calculated as the pre-ownership change equity value of the corporation, subject to certain prescribed adjustments, multiplied by the long-term tax exempt rate published monthly by the Internal Revenue Service. The Company completed a Section 382 study as of December 31, 2024, and determined that no historical ownership changes occurred since December 2021. The Company may experience ownership changes in the future as a result of shifts in stock ownership.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal net operating loss carryforwards compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2023. Additionally, as of December 31, 2024, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of Massachusetts tax credits that expire starting in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. As of December 31, 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of Massachusetts tax credits that expire starting in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, and 2023, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any interest or penalties for unrecognized tax benefits since its inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company filed income tax returns in the United States and the Commonwealth of Massachusetts in all tax years since inception. Tax years beginning in 2021 remain open to examination in these jurisdictions, as carryforward attributes generated in past years may be adjusted in a future period. The IRS has not made any assessments as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_25e10866-dcc0-43bf-a4f9-b50103ec41d0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.045%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.045%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nondeductible/ nontaxable permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_d2a6f2ab-0d2f-4df4-8b25-48867378df35"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_12f01cb4-44e4-41c6-bb43-137703300b38"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_e5874d93-a743-4dcc-bf5b-3ef5d5b77531"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_8e0221dc-7bee-4d12-ae9a-514af1a129f0"
      unitRef="U_pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_00d93f6d-a02a-485c-9f26-24b13510838a"
      unitRef="U_pure">0.133</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_4c4e072a-b4fe-4f9f-9715-656158fed621"
      unitRef="U_pure">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_0d869033-168a-4a95-a6eb-f77a0c0de65e"
      unitRef="U_pure">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_d5c2de65-2050-40f2-a680-8a0b428fc912"
      unitRef="U_pure">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_a20a1155-57b8-4953-9a38-b081c0863436"
      unitRef="U_pure">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_000e0275-6d28-412e-b443-2ca6fabf8964"
      unitRef="U_pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_3326e31b-39d0-45d0-8847-ebe57b121c93"
      unitRef="U_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_d90af441-d5b8-49c3-90ab-5e2a04fb3a49"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_2b06e858-652a-4f44-975b-42a635b141bd"
      unitRef="U_pure">-0.311</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_e6f5a0bb-2a59-4037-bc5e-c917fef04d8b"
      unitRef="U_pure">-0.509</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_6352d90c-00d6-47bb-a0ba-0bc7226b6d7f"
      unitRef="U_pure">-0.32</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="3"
      id="F_2b94db3f-68b5-4e2e-8ebf-453f5a548c7c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="3"
      id="F_78b2f28d-b1fe-4cc7-b5b0-29fe2ded498f"
      unitRef="U_pure">-0.011</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="3"
      id="F_d5194ef4-1c28-4fa5-9a35-6f3ac9486f98"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_6928f457-dd71-4b8c-bd53-8aa17d113b24">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized Research&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;366,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4e8cd0a9-ab91-4b0f-b52d-ae442ac55154;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_892f3c97-c2f0-430b-9466-4813ae1bf322;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_0c558f91-dc73-464d-831e-40bb3ab2e4e0"
      unitRef="U_USD">48954000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_00a2ada4-049d-40a5-b47d-ef522a6b76e5"
      unitRef="U_USD">3959000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_1af572ba-8887-4939-9322-a3978022a8f3"
      unitRef="U_USD">87554000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_1700d334-2305-46ea-a014-670243f6c631"
      unitRef="U_USD">56759000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_599b1826-4c9a-4ae4-aa34-aad9695c6f65"
      unitRef="U_USD">12868000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_dc4652a2-18a0-4e1b-90b7-201c698220f3"
      unitRef="U_USD">17386000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_0cac11c6-858d-4899-b796-77fb131a3197"
      unitRef="U_USD">38815000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_250f60d6-fdf8-42d3-9f11-23179184f741"
      unitRef="U_USD">48792000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_c1a4ab80-6be6-4f0b-bfa6-3c0d0b3325ed"
      unitRef="U_USD">3771000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_66bc2874-62fa-48ad-acd6-253b2850b558"
      unitRef="U_USD">2951000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_4e3b9e88-9c8a-419a-a7f7-9f0d0c655b71"
      unitRef="U_USD">21218000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_fdd52e91-16aa-4dec-9d8a-b27dd443b880"
      unitRef="U_USD">20587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <beam:DeferredTaxAssetsAmortization
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_0dec5f6f-18b8-4b0a-b2fe-c28c25c63406"
      unitRef="U_USD">30508000</beam:DeferredTaxAssetsAmortization>
    <beam:DeferredTaxAssetsAmortization
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_efc1c122-0df1-46bd-89bc-d306c65f92ce"
      unitRef="U_USD">30917000</beam:DeferredTaxAssetsAmortization>
    <beam:DeferredTaxAssetsCapitalizedResearch
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_85dd4bbc-6ea8-47b9-882b-7c34a9b2ab18"
      unitRef="U_USD">180954000</beam:DeferredTaxAssetsCapitalizedResearch>
    <beam:DeferredTaxAssetsCapitalizedResearch
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_3d54e0f7-ee51-4496-806c-a09f95c75474"
      unitRef="U_USD">137721000</beam:DeferredTaxAssetsCapitalizedResearch>
    <beam:DeferredTaxAssetsLeasingArrangements
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_d0ad3fce-ef1c-4cca-89f5-68fa520ea3cc"
      unitRef="U_USD">44096000</beam:DeferredTaxAssetsLeasingArrangements>
    <beam:DeferredTaxAssetsLeasingArrangements
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_03cc47a4-62c5-47ff-bf11-26d585c9aa38"
      unitRef="U_USD">47179000</beam:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_f500b97f-e96b-453b-8b47-0651ecff2523"
      unitRef="U_USD">468738000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_0f0a0121-e53c-44ef-9761-4b80f20068f5"
      unitRef="U_USD">366251000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_9777b390-7167-4d2e-89a0-5af012657f52"
      unitRef="U_USD">28649000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_4409ad30-61a5-451d-9e05-6029b6826b8f"
      unitRef="U_USD">30830000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_6eefd00a-8dd4-479a-9500-654aa4e13376"
      unitRef="U_USD">267000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_3446b6f7-e00a-42a6-9888-9bcf663beccb"
      unitRef="U_USD">649000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_20ebe273-256c-4dc0-9833-5cb9316e29e0"
      unitRef="U_USD">1563000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_7d2a75c0-4593-45ff-937b-aef62d20f09c"
      unitRef="U_USD">5415000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_709c7af7-b807-43f7-a868-61848d968ae3"
      unitRef="U_USD">438259000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_ecbfc290-af13-4e0d-a595-7dcf4dd96089"
      unitRef="U_USD">329357000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-5"
      id="F_6f7af6e3-de60-4bba-b6c3-39410ae7def0"
      unitRef="U_USD">100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-5"
      id="F_6a2c1cd2-7df4-48c5-b765-6e8f11302fca"
      unitRef="U_USD">1400000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-5"
      id="F_315e1c34-4503-4dc4-932e-8f3438b2b7ee"
      unitRef="U_USD">3400000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-5"
      id="F_34d182dd-e65d-4fad-b44d-eda92e556ad8"
      unitRef="U_USD">108900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-5"
      id="F_ac5a796b-ea98-41e8-83af-f202bb0aa746"
      unitRef="U_USD">75000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f086de51-1e25-47ba-abfb-108a2b30d5ee"
      decimals="-5"
      id="F_e3bf2a6a-ea32-49c0-a39a-bc7ead8b081f"
      unitRef="U_USD">181500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0"
      decimals="-5"
      id="F_90f98c1b-871d-4f96-a95d-caaf4650f8cd"
      unitRef="U_USD">16600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f086de51-1e25-47ba-abfb-108a2b30d5ee"
      decimals="-5"
      id="F_d37fc597-ccbd-432b-98c9-e847e5a25a8a"
      unitRef="U_USD">61700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ae43c909-7d70-442f-bc98-6a2f16383942"
      decimals="-5"
      id="F_11a74bab-ebec-48fb-aa4c-415c8e1db6be"
      unitRef="U_USD">32700000</us-gaap:TaxCreditCarryforwardAmount>
    <beam:TaxCreditsExpirationStartingYear
      contextRef="C_48270b1e-53eb-4dbc-9160-a5e56e9c41e4"
      id="F_8841821b-6326-40de-a23c-2573e69e2eb2">2043</beam:TaxCreditsExpirationStartingYear>
    <beam:TaxCreditsExpirationStartingYear
      contextRef="C_7ac0159f-2dc4-4afb-bc22-e46e6ac8813f"
      id="F_5a19acfb-1a4b-44b7-9119-cb58cac46c71">2038</beam:TaxCreditsExpirationStartingYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_968880b9-7cbc-400d-b3d6-d07c55ff30e0"
      decimals="-5"
      id="F_ba90ef04-9cf6-4532-b2d2-69a4541abfb4"
      unitRef="U_USD">41300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4560ba19-2a2b-4005-ab3c-d11d72951668"
      decimals="-5"
      id="F_b4a0d936-9418-42fd-95e1-cda7a6d8e4f7"
      unitRef="U_USD">19500000</us-gaap:TaxCreditCarryforwardAmount>
    <beam:TaxCreditsExpirationStartingYear
      contextRef="C_d99e5c1a-0015-40a1-bf03-09c293ead256"
      id="F_3a114b0c-e353-43d1-855b-0c2deb7dd590">2042</beam:TaxCreditsExpirationStartingYear>
    <beam:TaxCreditsExpirationStartingYear
      contextRef="C_93edf44d-3df4-4991-a2e7-7db1fdea70fc"
      id="F_4bbc7328-08d1-458e-9d80-981a66a0035a">2037</beam:TaxCreditsExpirationStartingYear>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_6bf4371d-f11f-4b07-a378-d85c1e344ff3"
      decimals="-3"
      id="F_5417ab5e-3ea1-475b-8f02-3b5a4bca8452"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_149701ae-170a-49a0-bd98-e2e011d76e53"
      decimals="-3"
      id="F_ab363a81-cbf1-4791-b6ad-5700d30db3f7"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_e49cbdfb-442f-4711-aae2-0c9b0a2fc4b4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_356e4b95-fb06-46f6-a8ac-699536edc790">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Related party transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Orbital&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in Note 10, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company&#x2019;s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Founders&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company made payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, to its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; founder shareholders for scientific consulting and other expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_8a19511f-2844-4f6d-b5ed-8ff465336cef"
      decimals="-5"
      id="F_038d932f-904a-4900-bf2e-6f436c195f75"
      unitRef="U_USD">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_9d139695-ac25-4472-b259-92e6538cbf05"
      decimals="-5"
      id="F_1237546b-23fb-46a4-8ded-71038f98964f"
      unitRef="U_USD">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_af7898ba-b7e3-42e1-92b5-062444fe5f45"
      decimals="-5"
      id="F_49a3f36e-58ce-40f6-b48a-c929553d8664"
      unitRef="U_USD">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <beam:NumberOfFounderShareholders
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_b6f5f3ca-749b-45eb-a290-99a932353e06"
      unitRef="U_Founder">3</beam:NumberOfFounderShareholders>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_8adb4747-6c5c-4507-ba48-eceef1efabc9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Employee benefits&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2018, the Company established a defined-contribution plan under Section &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;401(k)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Beginning January 1, 2020, the Company made matching contributions equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the employee&#x2019;s contributions, subject to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation. The Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <beam:DefinedContributionPlanName
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_0c3507cd-2b37-4cb4-8156-8c7647077d77">401(k)</beam:DefinedContributionPlanName>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_1a34df2e-9bdc-4764-b352-4c26350c20fc"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="INF"
      id="F_92f20b9c-84cd-4be7-899a-426b13af3c7d"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-5"
      id="F_adb51209-10dc-4a85-b5da-7b563dc9c713"
      unitRef="U_USD">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-5"
      id="F_042fe0f9-60a1-4816-959f-94acbc5c9829"
      unitRef="U_USD">2500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-5"
      id="F_9a6d2d43-314b-405b-93e2-2599f2187f18"
      unitRef="U_USD">2000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_c4cf81d7-7ea0-4bf5-8784-d5f9f4308bbd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;17. Segment Data&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3745d23f-5fb4-4f44-b19b-06bb7321b4f1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM is John Evans, its Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c09ed080-95c6-42cb-9d05-3689f0ee40cc;"&gt;&lt;span style="-sec-ix-hidden:F_db2bac11-48f9-4a6a-b941-8a8d70caf457;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment and the measure of segment profit or loss is consolidated net income (loss). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The internal reporting of significant segment expenses is based on the functional classification. External expenses include costs from external manufacturing, clinical and research organizations, supply chain and logistics costs, consultants, and other vendors. Employee related expenses include, employee salaries and benefits costs, employee meal, travel and entertainment spend, along with payroll related taxes and other similar items. These functional costs exclude stock-based compensation, facility and information technology costs, depreciation and amortization, and other segment items.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below provides information about the Company&#x2019;s segment, including significant expenses, other segment items, certain other segment expenses, and a reconciliation to net income (loss):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External research and development expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;155,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External general and administrative expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facility and information technology related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* Denotes significant segment expense&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Segment Items includes:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of derivative liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of non-controlling equity investments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of contingent consideration liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss from equity method investment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Milestone expense&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License and Sublicenses fees&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_32c24534-43d2-431f-8f5b-72d4616ecdda">The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      id="F_e2da578a-8b12-4aab-963d-11cdc0175806">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External research and development expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;155,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External general and administrative expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facility and information technology related expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* Denotes significant segment expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Segment Items includes:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of derivative liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of non-controlling equity investments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of contingent consideration liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss from equity method investment&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Milestone expense&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License and Sublicenses fees&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a72b10b2-b2f8-4e28-8e63-9a715782c3bd"
      unitRef="U_USD">63518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_543e414b-4242-448a-8238-c89b1403ad84"
      unitRef="U_USD">377709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_c0bf04fc-ebe0-4bc7-b865-7cecf0665825"
      unitRef="U_USD">60920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f0a9d4a5-df6e-4595-9abe-cec53ac89acc"
      decimals="-3"
      id="F_d0c81c6f-08c9-40db-867f-a3b16aaf2786"
      unitRef="U_USD">115189000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_56abebc6-1481-4c6b-a7b2-1ce074ebc051"
      decimals="-3"
      id="F_06b833a7-e4ab-467a-a8ab-38725ed73519"
      unitRef="U_USD">155063000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f605087d-584c-49ce-a137-7ec63bdd3243"
      decimals="-3"
      id="F_821126a7-ab43-4eae-b878-c546e9e97541"
      unitRef="U_USD">112380000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0b791370-9688-483b-9d3b-52cc2807c2c4"
      decimals="-3"
      id="F_f8a967fb-c695-41a7-93eb-add53e73c852"
      unitRef="U_USD">98796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_99cb6cd9-808d-43eb-9961-10066106286f"
      decimals="-3"
      id="F_e078c148-295f-48b3-88a3-b9294dc14f31"
      unitRef="U_USD">109878000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6c230fe6-3e37-42ee-94d5-d6260b72323d"
      decimals="-3"
      id="F_3e0d6daf-08c1-4855-9563-18d3bb3ede1e"
      unitRef="U_USD">89547000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_968b0854-5a99-4bae-a667-e1e1a12f2c18"
      decimals="-3"
      id="F_805f61e5-2eb7-493d-bb18-6240f3c86fa2"
      unitRef="U_USD">25115000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e772ddd5-a271-42f1-b38d-0e1d6248021c"
      decimals="-3"
      id="F_4737d07e-ba24-4731-a7f9-43491174d129"
      unitRef="U_USD">40016000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5770c0c0-0283-4886-822d-4ead5360cae3"
      decimals="-3"
      id="F_e73ee3e8-2c4a-48e5-8e6a-e875fc030bca"
      unitRef="U_USD">25885000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0b791370-9688-483b-9d3b-52cc2807c2c4"
      decimals="-3"
      id="F_7e7977d0-4a5b-471b-afd3-26597a4dcacc"
      unitRef="U_USD">34822000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_99cb6cd9-808d-43eb-9961-10066106286f"
      decimals="-3"
      id="F_2e332c60-f72e-44ec-8d09-b388c5f0f772"
      unitRef="U_USD">31305000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6c230fe6-3e37-42ee-94d5-d6260b72323d"
      decimals="-3"
      id="F_917adf4f-0dee-4fd1-8b5f-4ddd4b02c6ae"
      unitRef="U_USD">28105000</us-gaap:GeneralAndAdministrativeExpense>
    <beam:FacilityAndInformationTechnologyRelatedExpenses
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_a8124a67-5c45-47c3-8e04-493444fd0374"
      unitRef="U_USD">55911000</beam:FacilityAndInformationTechnologyRelatedExpenses>
    <beam:FacilityAndInformationTechnologyRelatedExpenses
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_bcbf703c-5828-40bd-8525-9b6d4fb8d54e"
      unitRef="U_USD">53804000</beam:FacilityAndInformationTechnologyRelatedExpenses>
    <beam:FacilityAndInformationTechnologyRelatedExpenses
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_774cc520-8326-4ffa-b7b3-53fcd6d6318a"
      unitRef="U_USD">41448000</beam:FacilityAndInformationTechnologyRelatedExpenses>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_d6d2dadf-fcc1-4623-9ca0-32616898d25e"
      unitRef="U_USD">21925000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_0b6d7555-eb05-438d-8e31-9bde124c96ef"
      unitRef="U_USD">20012000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_c5028870-1229-4a5e-be24-fc3078129e4f"
      unitRef="U_USD">14147000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_ce4c92d9-121c-48c7-b554-740932d2e6ec"
      unitRef="U_USD">120662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_b9f8721d-65c8-4733-81e6-c61aedb5f55f"
      unitRef="U_USD">98647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_b61b28f3-5868-4811-81ae-e327c53d6de7"
      unitRef="U_USD">84321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_3aeca39d-8e77-4e60-ae5a-1f8b0e5988ae"
      unitRef="U_USD">49094000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_1590116a-1b61-4ed4-9451-90f488cac8d7"
      unitRef="U_USD">46676000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_76aef40e-d49b-498e-8c65-7d8d4d0c6d4e"
      unitRef="U_USD">15297000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_761dfdc7-aeac-4bc2-a876-8943bf424e2f"
      unitRef="U_USD">39000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_4b4c357d-7605-4f66-8864-8d34f6bdfa99"
      unitRef="U_USD">1366000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_3f3eb217-223e-4761-9067-218832278eb0"
      unitRef="U_USD">3410000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_65bdfd14-acec-4493-b98e-5749a3b951f9"
      unitRef="U_USD">-16895000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_3bd9070b-aa56-4914-a319-6ba05e31c95d"
      unitRef="U_USD">-46821000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_d34385f7-ea13-4fca-8853-eb5d4152cdd0"
      unitRef="U_USD">33938000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ca3a0f9-f85f-4e45-8f66-1ea07adbdbcf"
      decimals="-3"
      id="F_7bb536e2-e4a0-48b2-8daf-be90607ffd66"
      unitRef="U_USD">-376742000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93ba963b-981f-49c9-a3d3-fb183f09f550"
      decimals="-3"
      id="F_86684973-264f-4779-b577-d68d2b724916"
      unitRef="U_USD">-132527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_15adaf12-5523-4f2f-ab23-7a53126734cb"
      decimals="-3"
      id="F_495a4a32-01ce-4520-a34b-43f2e3c1ce6e"
      unitRef="U_USD">-289088000</us-gaap:NetIncomeLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
